PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Best, A; Handoko, L; Schluter, E; Goringer, HU				Best, A; Handoko, L; Schluter, E; Goringer, HU			In vitro synthesized small interfering RNAs elicit RNA interference in African trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; MESSENGER-RNA; GENETIC INTERFERENCE; HUMAN DICER; C-ELEGANS; CAENORHABDITIS-ELEGANS; MAMMALIAN-CELLS; DISTINCT ROLES; BRUCEI; DROSOPHILA	RNA interference (RNAi) describes an epigenetic gene silencing reaction by which gene-specific doublestranded RNA acts as a trigger to induce the ribonucleolytic degradation of homologous transcripts. RNAi in African trypanosomes has been shown to be involved in regulating the transcript abundance of retroposons, and the process currently represents the method of choice in gene function studies of the parasite. However, little is known concerning the mechanistic and structural aspects of the processing reaction. This is in part due to the absence of a trypanosome-specific RNAi in vitro system. Here we demonstrate that both the Dicer and the RNA-induced silencing complex steps of the RNAi reaction pathway can be monitored in vitro using cell-free trypanosome extracts. The two in vitro activities and the generated small interfering RNAs (siRNAs) are characterized by features known from other organisms, and we demonstrate that chemically as well as enzymatically synthesized siRNAs are functional in the parasite. Thus, the transfection of synthetic siRNAs can be used to rapidly monitor gene knockdown phenotypes in Trypanosoma brucei, which should be helpful in genome-wide, RNAi-based screening experiments.	Tech Univ Darmstadt, Dept Genet & Microbiol, D-64287 Darmstadt, Germany	Technical University of Darmstadt	Goringer, HU (corresponding author), Tech Univ Darmstadt, Dept Genet & Microbiol, Schnittspahnstr 10, D-64287 Darmstadt, Germany.	goringer@hrzpub.tu-darmstadt.de	Handoko, Lusy/C-3645-2017	Handoko, Lusy/0000-0001-7989-4243				Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Blaszczyk J, 2001, STRUCTURE, V9, P1225, DOI 10.1016/S0969-2126(01)00685-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUN R, 1979, ACTA TROP, V36, P289; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; DaRocha WD, 2004, MOL BIOCHEM PARASIT, V133, P175, DOI 10.1016/j.molbiopara.2003.10.005; Djikeng A, 2001, RNA, V7, P1522; Durand-Dubief M, 2003, BMC BIOL, V1, DOI 10.1186/1741-7007-1-2; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Liang XH, 2003, P NATL ACAD SCI USA, V100, P7521, DOI 10.1073/pnas.1332001100; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Martens H, 2002, MOL BIOL CELL, V13, P445, DOI 10.1091/mbc.01-04-0211; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Motyka SA, 2004, CURR OPIN MICROBIOL, V7, P362, DOI 10.1016/j.mib.2004.06.004; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Nicholson Allen W., 2003, P149; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Robinson KA, 2003, MOL BIOCHEM PARASIT, V128, P217, DOI 10.1016/S0166-6851(03)00079-3; Schwarz DS, 2004, CURR BIOL, V14, P787, DOI 10.1016/j.cub.2004.03.008; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; Shi HF, 2004, EUKARYOT CELL, V3, P1445, DOI 10.1128/EC.3.6.1445-1453.2004; Shi HF, 2004, MOL CELL BIOL, V24, P420, DOI 10.1128/MCB.24.1.420-427.2004; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Terskikh A, 2000, SCIENCE, V290, P1585, DOI 10.1126/science.290.5496.1585; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Ullu E, 2004, CELL MICROBIOL, V6, P509, DOI 10.1111/j.1462-5822.2004.00399.x; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; Wheeler DB, 2004, NAT METHODS, V1, P127, DOI 10.1038/NMETH711; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang HD, 2004, CELL, V118, P57, DOI 10.1016/j.cell.2004.06.017; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582	60	11	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20573	20579		10.1074/jbc.M414534200	http://dx.doi.org/10.1074/jbc.M414534200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781462	hybrid			2022-12-25	WOS:000229242000052
J	Batsche, E; Desroches, J; Bilodeau, S; Gauthier, Y; Drouin, J				Batsche, E; Desroches, J; Bilodeau, S; Gauthier, Y; Drouin, J			Rb enhances p160/SRC coactivator-dependent activity of nuclear receptors and hormone responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; GLUCOCORTICOID-RECEPTOR; TRANSCRIPTIONAL REPRESSION; ADIPOCYTE DIFFERENTIATION; MEDIATES TRANSACTIVATION; ACTIVATION FUNCTIONS; GROWTH SUPPRESSION; SUBFAMILY	The retinoblastoma tumor suppressor protein (Rb) is best known as a repressor of genes involved in cell cycle progression. Rb has also been implicated in activation of transcription, in particular by nuclear receptors (NRs) and by differentiation-related transcription factors, but the relevance of this activity is unclear. We show that Rb and the related proteins p107 and p130 enhance the activity of NRs related to NGFI-B (Nur factors) through direct interactions with NGFI-B and SRC-2. Although recruitment of SRC/p160 coactivators to the NGFI-BAF1 domain is independent of Rb, its presence enhances SRC-dependent transcription. Rb potentiation of SRC coactivators is exerted on a subset ( Nur factors, hepatocyte nuclear factor-4 (HNF-4), SF-1, and ER) but not all NRs. The levels of Rb-related proteins modulate hormone responsiveness of the NGFI-B-dependent pituitary proopiomelanocortin gene and HNF-4-dependent transcription during enterocyte differentiation. Increased Rb expression upon cell differentiation may promote differentiated functions, at least in part, by potentiation of NR activity.	Inst Rech Clin Montreal, Mol Genet Lab, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Drouin, J (corresponding author), Inst Rech Clin Montreal, Mol Genet Lab, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada.	jacques.drouin@ircm.qc.ca		Batsche, Eric/0000-0002-5145-5270; Bilodeau, Steve/0000-0002-9799-3832; Drouin, Jacques/0000-0001-8226-5691				Abbondanza C, 2000, P NATL ACAD SCI USA, V97, P3130, DOI 10.1073/pnas.050015697; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BATSCHE E, 2005, J BIOL CHEM; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chang KH, 1997, P NATL ACAD SCI USA, V94, P9040, DOI 10.1073/pnas.94.17.9040; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chen SL, 2000, GENE DEV, V14, P1209; COPPOLA JA, 1990, ONCOGENE, V5, P1731; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Frost SJ, 1999, MOL ENDOCRINOL, V13, P1801, DOI 10.1210/me.13.11.1801; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, ONCOGENE, V7, P693; Hinton DR, 1998, CANCER LETT, V126, P209, DOI 10.1016/S0304-3835(98)00013-5; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Lu JM, 1998, J BIOL CHEM, V273, P31528, DOI 10.1074/jbc.273.47.31528; Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003; Maira M, 1999, MOL CELL BIOL, V19, P7549; Martens C, 2005, MOL ENDOCRINOL, V19, P885, DOI 10.1210/me.2004-0333; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Noe V, 1998, ONCOGENE, V16, P1931, DOI 10.1038/sj.onc.1201718; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Poulin G, 1997, MOL CELL BIOL, V17, P6673, DOI 10.1128/MCB.17.11.6673; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Sterner JM, 1996, CELL GROWTH DIFFER, V7, P53; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032	43	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19746	19756		10.1074/jbc.M413428200	http://dx.doi.org/10.1074/jbc.M413428200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767262	hybrid			2022-12-25	WOS:000229113700041
J	Singh, SV; Srivastava, SK; Choi, S; Lew, KL; Antosiewicz, J; Xiao, D; Zeng, Y; Watkins, SC; Johnson, CS; Trump, DL; Lee, YJ; Xiao, H; Herman-Antosiewicz, A				Singh, SV; Srivastava, SK; Choi, S; Lew, KL; Antosiewicz, J; Xiao, D; Zeng, Y; Watkins, SC; Johnson, CS; Trump, DL; Lee, YJ; Xiao, H; Herman-Antosiewicz, A			Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; OXIDATIVE STRESS; CYCLE ARREST; ISOTHIOCYANATE SULFORAPHANE; CHEMOPREVENTIVE AGENT; MEDIATED APOPTOSIS; EPITHELIAL-CELLS; IN-VIVO; BROCCOLI; INDUCTION	We have shown previously that sulforaphane (SFN), a constituent of many edible cruciferous vegetables including broccoli, suppresses growth of prostate cancer cells in culture as well as in vivo by causing apoptosis, but the sequence of events leading to cell death is poorly defined. Using PC-3 and DU145 human prostate cancer cells as a model, we now demonstrate, for the first time, that the initial signal for SFN-induced apoptosis is derived from reactive oxygen species (ROS). Exposure of PC-3 cells to growth-suppressive concentrations of SFN resulted in ROS generation, which was accompanied by disruption of mitochondrial membrane potential, cytosolic release of cytochrome c, and apoptosis. All these effects were significantly blocked on pretreatment with N-acetylcysteine and overexpression of catalase. The SFN-induced ROS generation was significantly attenuated on pretreatment with mitochondrial respiratory chain complex I inhibitors, including diphenyleneiodonium chloride and rotenone. SFN treatment also caused a rapid and significant depletion of GSH levels. Collectively, these observations indicate that SFN-induced ROS generation is probably mediated by a nonmitochondrial mechanism involving GSH depletion as well as a mitochondrial component. Ectopic expression of Bcl-xL, but not Bcl-2, in PC-3 cells offered significant protection against the cell death caused by SFN. In addition, SFN treatment resulted in an increase in the level of Fas, activation of caspase-8, and cleavage of Bid. Furthermore, SV40-immortalized mouse embryonic fibroblasts (MEFs) derived from Bid knock-out mice displayed significant resistance toward SFN-induced apoptosis compared with wild-type MEFs. In conclusion, the results of the present study indicate that SFN-induced apoptosis in prostate cancer cells is initiated by ROS generation and that both intrinsic and extrinsic caspase cascades contribute to the cell death caused by this highly promising cancer chemopreventive agent.	Univ Pittsburgh, Inst Canc, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Roswell Park Cancer Institute	Singh, SV (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Res Pavil Ste 2-32A,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	singhs@msx.upmc.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552; Herman-Antosiewicz, Anna/0000-0003-0526-2168	NCI NIH HHS [CA101753, CA076348] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101753, R01CA076348] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ambrosone CB, 2004, J NUTR, V134, P1134, DOI 10.1093/jn/134.5.1134; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barcelo S, 1996, CARCINOGENESIS, V17, P277, DOI 10.1093/carcin/17.2.277; Brooks JD, 2001, CANCER EPIDEM BIOMAR, V10, P949; Buccellato LJ, 2004, J BIOL CHEM, V279, P6753, DOI 10.1074/jbc.M310145200; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Choi S, 2005, CANCER RES, V65, P2035, DOI 10.1158/0008-5472.CAN-04-3616; Chung FL, 2000, CARCINOGENESIS, V21, P2287, DOI 10.1093/carcin/21.12.2287; Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61; Conaway CC, 2002, CURR DRUG METAB, V3, P233, DOI 10.2174/1389200023337496; Denning TL, 2002, FREE RADICAL BIO MED, V33, P1641, DOI 10.1016/S0891-5849(02)01141-3; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031-9422(00)00316-2; Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099; Fimognari C, 2002, CARCINOGENESIS, V23, P581, DOI 10.1093/carcin/23.4.581; Gamet-Payrastre L, 2000, CANCER RES, V60, P1426; Genova ML, 2004, ANN NY ACAD SCI, V1011, P86, DOI 10.1196/annals.1293.010; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hecht SS, 2000, DRUG METAB REV, V32, P395, DOI 10.1081/DMR-100102342; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hu R, 2004, J PHARMACOL EXP THER, V310, P263, DOI 10.1124/jpet.103.064261; Jackson SJT, 2004, CARCINOGENESIS, V25, P219, DOI 10.1093/carcin/bgg192; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOBLYAKOV V A, 1976, Biokhimiya, V41, P1497; KOLM RH, 1995, BIOCHEM J, V311, P453, DOI 10.1042/bj3110453; Leach JK, 2001, CANCER RES, V61, P3894; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li NY, 2003, FREE RADICAL BIO MED, V34, P465, DOI 10.1016/S0891-5849(02)01325-4; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Misiewicz I, 2003, ONCOL REP, V10, P2045; Murata M, 2000, FREE RADICAL BIO MED, V28, P797, DOI 10.1016/S0891-5849(00)00168-4; Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326; Narayanan PK, 1997, CANCER RES, V57, P3963; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Paolini M, 2004, CARCINOGENESIS, V25, P61, DOI 10.1093/carcin/bgg174; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Ricci JE, 2003, CELL DEATH DIFFER, V10, P488, DOI 10.1038/sj.cdd.4401225; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Singh AV, 2004, CARCINOGENESIS, V25, P83, DOI 10.1093/carcin/bgg178; Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhoeven DTH, 1996, CANCER EPIDEM BIOMAR, V5, P733; Wang LG, 2004, INT J ONCOL, V24, P187; WATKINS SC, 1987, J NEUROL SCI, V82, P181, DOI 10.1016/0022-510X(87)90017-7; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xiao D, 2004, ONCOGENE, V23, P5594, DOI 10.1038/sj.onc.1207747; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Ye LX, 2001, CARCINOGENESIS, V22, P1987, DOI 10.1093/carcin/22.12.1987; Zhang SMM, 2000, CANCER EPIDEM BIOMAR, V9, P477; ZHANG Y, 1994, P NATL ACAD SCI USA, V91, P2147; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	60	296	308	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19911	19924		10.1074/jbc.M412443200	http://dx.doi.org/10.1074/jbc.M412443200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15764812	hybrid			2022-12-25	WOS:000229113700061
J	Tsuneoka, M; Teye, K; Arima, N; Soejima, M; Otera, H; Ohashi, K; Koga, Y; Fujita, H; Shirouzu, K; Kimura, H; Koda, Y				Tsuneoka, M; Teye, K; Arima, N; Soejima, M; Otera, H; Ohashi, K; Koga, Y; Fujita, H; Shirouzu, K; Kimura, H; Koda, Y			A novel Myc-target gene, mimitin, that is involved in cell proliferation of esophageal squamous cell carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE-DECARBOXYLASE GENE; C-MYC; CHROMATIN IMMUNOPRECIPITATION; PROGNOSTIC-SIGNIFICANCE; HISTONE ACETYLATION; MYC/MAX/MAD NETWORK; EXPRESSION; PROTEIN; CANCER; GROWTH	Myc is a ubiquitous mediator of cell proliferation that transactivates the expression of various genes through E-box sites. Here we report a novel gene, mimitin (Myc-induced mitochondrial protein), that encodes a mitochondrial protein with a molecular mass of 20 kDa. We demonstrated that the transcription of mimitin is directly stimulated by c-Myc. To investigate the role of Mimitin, its expression was suppressed by the RNA interference (RNAi) technique. Whereas specific inhibition of mimitin expression did not affect cell proliferation in human cervical carcinoma, colon adenocarcinoma, and hepatocarcinoma cell lines, it did suppress cell proliferation in human glioblastoma, esophageal squamous cell carcinoma (ESCC), and embryonic lung fibroblastic cells, with the greatest suppression efficiency in ESCC cells. To investigate whether mimitin is related to tumorigenesis in ESCC in vivo, the expression of Mimitin protein in ESCC tissues was studied. Mimitin was highly expressed in 80% (28 of 35) of ESCC tumors, suggesting that high expression of Mimitin is a characteristic feature of ESCC. The expression level of Mimitin was found to be correlated with that of c-Myc and cell proliferation, but not with the histopathological grade, stage of cancer, or age of patients. Taken together, these results suggest that the novel gene mimitin is a direct transcriptional target of c-Myc, and is involved in Myc-dependent cell proliferation at least in ESCC cells.	Kurume Univ, Sch Med, Div Human Genet, Dept Forens Med, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Sch Med, Dept Pediat & Child Hlth, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Sch Med, Dept Surg, Kurume, Fukuoka 8300011, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan; Chiba Univ, Grad Sch Sci & Technol, Chiba 2638522, Japan; Chiba Inst Sci, Choshi 2880025, Japan	Kurume University; Kurume University; Kurume University; Kurume University; Kyushu University; Chiba University	Tsuneoka, M (corresponding author), Kurume Univ, Sch Med, Div Human Genet, Dept Forens Med, Kurume, Fukuoka 8300011, Japan.	tsuneoka@med.kurume-u.ac.jp	Koda, Yoshiro/AAY-6902-2020	Koda, Yoshiro/0000-0003-1368-0116				Albertsson M, 2002, ACTA ONCOL, V41, P118, DOI 10.1080/028418602753669472; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; Coggi G, 1997, CANCER, V79, P425, DOI 10.1002/(SICI)1097-0142(19970201)79:3<425::AID-CNCR1>3.0.CO;2-H; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEMETER J, 1995, P NATL ACAD SCI USA, V92, P1436, DOI 10.1073/pnas.92.5.1436; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; GERDES J, 1984, J IMMUNOL, V133, P1710; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HICKSTEIN DD, 1989, J BIOL CHEM, V264, P21812; HOZUMI M, 1983, ADV CANCER RES, V38, P121, DOI 10.1016/S0065-230X(08)60189-X; Ikeda G, 1999, CANCER, V86, P1396, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1396::AID-CNCR3>3.0.CO;2-H; KANDA Y, 1994, INT J CANCER, V58, P291, DOI 10.1002/ijc.2910580224; Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004; Koda Y, 1997, J BIOL CHEM, V272, P7501, DOI 10.1074/jbc.272.11.7501; Koda Y, 1997, EUR J BIOCHEM, V246, P750, DOI 10.1111/j.1432-1033.1997.t01-1-00750.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Mandard AM, 2000, MUTAT RES-REV MUTAT, V462, P335, DOI 10.1016/S1383-5742(00)00019-3; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEKADA E, 1982, BIOCHEM BIOPH RES CO, V109, P792, DOI 10.1016/0006-291X(82)92009-5; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; Morrish F, 2003, GENE DEV, V17, P240, DOI 10.1101/gad.1032503; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; NISHIHIRA T, 1994, ATLAS HUMAN TUMOR CE; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Pendeville H, 2001, MOL CELL BIOL, V21, P6549, DOI 10.1128/MCB.21.19.6549-6558.2001; PORSCHEN R, 1994, CANCER RES, V54, P587; Saeki K, 2000, J BIOL CHEM, V275, P31996, DOI 10.1074/jbc.M004794200; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SCHWARTZ B, 1995, BIOCHEM J, V312, P83, DOI 10.1042/bj3120083; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Skehel JM, 1998, FEBS LETT, V438, P301, DOI 10.1016/S0014-5793(98)01317-9; Sobin LH., 2002, UICC INT UNION CANC; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; Teye K, 2004, AM J PATHOL, V164, P205, DOI 10.1016/S0002-9440(10)63111-2; Triepels R, 2000, HUM GENET, V106, P385, DOI 10.1007/s004390000278; TSUNEOKA M, 1992, J BIOL CHEM, V267, P9107; Tsuneoka M, 2004, CLIN CANCER RES, V10, P7347, DOI 10.1158/1078-0432.CCR-03-0543; Tsuneoka M, 1997, ONCOGENE, V14, P2301, DOI 10.1038/sj.onc.1201067; Tsuneoka M, 2000, ONCOGENE, V19, P115, DOI 10.1038/sj.onc.1203232; Tsuneoka M, 2002, J BIOL CHEM, V277, P35450, DOI 10.1074/jbc.M204458200; WANG DY, 1994, CANCER-AM CANCER SOC, V74, P3089, DOI 10.1002/1097-0142(19941215)74:12<3089::AID-CNCR2820741205>3.0.CO;2-N; Wonsey DR, 2002, P NATL ACAD SCI USA, V99, P6649, DOI 10.1073/pnas.102523299; YANO H, 1988, ACTA PATHOL JAPON, V38, P953; YOSHIDA K, 1995, CANCER, V75, P1467, DOI 10.1002/1097-0142(19950315)75:6+<1467::AID-CNCR2820751514>3.0.CO;2-Y; YOUSSEF EM, 1995, CANCER, V76, P358, DOI 10.1002/1097-0142(19950801)76:3<358::AID-CNCR2820760303>3.0.CO;2-C	59	27	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19977	19985		10.1074/jbc.M501231200	http://dx.doi.org/10.1074/jbc.M501231200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774466	hybrid			2022-12-25	WOS:000229113700067
J	Smith, EM; Finn, SG; Tee, AR; Browne, G; Proud, CG				Smith, EM; Finn, SG; Tee, AR; Browne, G; Proud, CG			The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; 4E-BINDING PROTEIN-1; ELONGATION-FACTOR-2 KINASE; PHOSPHORYLATION SITE; GENE-PRODUCTS; MTOR; BINDING; TRANSLATION; ACTIVATION; RHEB	Amino acids positively regulate signaling through the mammalian target of rapamycin ( mTOR). Recent work demonstrated the importance of the tuberous sclerosis protein TSC2 for regulation of mTOR by insulin. TSC2 contains a GTPase-activator domain that promotes hydrolysis of GTP bound to Rheb, which positively regulates mTOR signaling. Some studies have suggested that TSC2 also mediates the control of mTOR by amino acids. In cells lacking TSC2, amino acid withdrawal still results in dephosphorylation of S6K1, ribosomal protein S6, the eukaryotic initiation factor 4E-binding protein, and elongation factor-2 kinase. The effects of amino acid withdrawal are diminished by inhibiting protein synthesis or adding back amino acids. These studies demonstrate that amino acid signaling to mTOR occurs independently of TSC2 and involves additional unidentified inputs. Although TSC2 is not required for amino acid control of mTOR, amino acid withdrawal does decrease the proportion of Rheb in the active GTP-bound state. Here we also show that Rheb and mTOR form stable complexes, which are not, however, disrupted by amino acid withdrawal. Mutants of Rheb that cannot bind GTP or GDP can interact with mTOR complexes. We also show that the effects of hydrogen peroxide and sorbitol, cell stresses that impair mTOR signaling, are independent of TSC2. Finally, we show that the ability of energy depletion (which impairs mTOR signaling in TSC2(+/+) cells) to increase the phosphorylation of eukaryotic elongation factor 2 is also independent of TSC2. This likely involves the phosphorylation of the elongation factor-2 kinase by the AMP-activated protein kinase.	Univ Dundee, Sch Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland	University of Dundee	Proud, CG (corresponding author), Univ British Columbia, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z4, Canada.	cgpr@interchange.ubc.ca		Tee, Andrew/0000-0002-5577-4631; Proud, Christopher/0000-0003-0704-6442; Smith, Ewan/0000-0002-3992-3748				AMONS R, 1990, BIOCHIM BIOPHYS ACTA, V1037, P401, DOI 10.1016/0167-4838(90)90043-F; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; BEUGNET A, 2002, BIOCHEM J, V372, P566; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Browne GJ, 2004, MOL CELL BIOL, V24, P2986, DOI 10.1128/MCB.24.7.2986-2997.2004; Browne GJ, 2004, J BIOL CHEM, V279, P12220, DOI 10.1074/jbc.M309773200; Browne GJ, 2002, EUR J BIOCHEM, V269, P5360, DOI 10.1046/j.1432-1033.2002.03290.x; Christie GR, 2002, J BIOL CHEM, V277, P9952, DOI 10.1074/jbc.M107694200; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Fattori R, 2003, LANCET, V361, P247, DOI 10.1016/S0140-6736(03)12275-1; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gingras AC, 2001, PROG MOLEC, V27, P143; GLEESON M, 1986, CLIN CHIM ACTA, V156, P97, DOI 10.1016/0009-8981(86)90184-1; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Henin N, 1996, BBA-GEN SUBJECTS, V1290, P197, DOI 10.1016/0304-4165(96)00021-9; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Houghton PJ, 2003, CURR TOP MICROBIOL, V279, P339; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kimball SR, 2002, CURR OPIN CLIN NUTR, V5, P63, DOI 10.1097/00075197-200201000-00012; Knebel A, 2002, BIOCHEM J, V367, P525, DOI 10.1042/BJ20020916; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Martin ME, 2000, BIOCHEM J, V351, P327, DOI 10.1042/0264-6021:3510327; McLeod LE, 2002, FEBS LETT, V531, P448, DOI 10.1016/S0014-5793(02)03582-2; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Patel J, 2002, EUR J BIOCHEM, V269, P3076, DOI 10.1046/j.1432-1033.2002.02992.x; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; PRICE NT, 1989, BIOCHIM BIOPHYS ACTA, V1008, P177, DOI 10.1016/0167-4781(80)90005-6; Proud CG, 2003, CURR TOP MICROBIOL, V279, P215; Proud CG, 2004, DNA REPAIR, V3, P927, DOI 10.1016/j.dnarep.2004.03.012; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; SAKAIDA I, 1990, MOL PHARMACOL, V37, P435; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Tabancay AP, 2003, J BIOL CHEM, V278, P39921, DOI 10.1074/jbc.M306553200; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Tinton SA, 1999, FEBS LETT, V446, P55, DOI 10.1016/S0014-5793(99)00185-4; Vary TC, 2000, AM J PHYSIOL-ENDOC M, V279, pE1178, DOI 10.1152/ajpendo.2000.279.5.E1178; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Wang XM, 1997, BIOCHEM BIOPH RES CO, V238, P207, DOI 10.1006/bbrc.1997.7273; Wang XM, 2003, MOL CELL BIOL, V23, P1546, DOI 10.1128/MCB.23.5.1546-1557.2003; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhu JL, 1999, GASTROENTEROLOGY, V117, P1198, DOI 10.1016/S0016-5085(99)70406-3	57	291	311	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18717	18727		10.1074/jbc.M414499200	http://dx.doi.org/10.1074/jbc.M414499200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15772076	hybrid			2022-12-25	WOS:000228932300023
J	Fedele, M; Pentimalli, F; Baldassarre, G; Battista, S; Klein-Szanto, AJP; Kenyon, L; Visone, R; De Martino, I; Ciarmiello, A; Arra, C; Viglietto, G; Croce, CM; Fusco, A				Fedele, M; Pentimalli, F; Baldassarre, G; Battista, S; Klein-Szanto, AJP; Kenyon, L; Visone, R; De Martino, I; Ciarmiello, A; Arra, C; Viglietto, G; Croce, CM; Fusco, A			Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell	ONCOGENE			English	Article						high-mobility group proteins; pituitary adenomas; NK1.1; IL-2; IL-15; lymphomas	EXPRESS HIGH-LEVELS; GROUP PROTEIN I(Y); HMGI(Y) PROTEINS; NEOPLASTIC TRANSFORMATION; C GENE; PHENOTYPE; REARRANGEMENTS; ACTIVATION; CARCINOMA; LIPOMAS	Overexpression of HMGA1 proteins is a constant feature of human carcinomas. Moreover, rearrangements of this gene have been detected in several human benign tumors of mesenchymal origin. To de. ne the role of these proteins in cell transformation in vivo, we have generated transgenic mice overexpressing ubiquitously the HMGA1 gene. These mice developed mixed growth hormone/prolactin cell pituitary adenomas and natural killer (NK)-T/NK cell lymphomas. The HMGA1-induced expression of IL-2 and IL-15 proteins and their receptors may account for the onset of these lymphomas. At odds with mice overexpressing a wild-type or a truncated HMGA2 protein, adrenal medullar hyperplasia and pancreatic islet cell hyperplasia frequently occurred and no increase in body size and weight was observed in HMGA1 mice. Taken together, these data indicate an oncogenic role of the HMGA1 gene also in vivo.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Thomas Jefferson Univ Hosp, Dept Pathol, Philadelphia, PA 19107 USA; Ist Tumori Napoli Fdn G Pascale, I-80131 Naples, Italy; NOGEC, CEINGE, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Jefferson University; Fox Chase Cancer Center; Jefferson University; CEINGE Biotecnologie Avanzate	Fusco, A (corresponding author), Univ Naples, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Pentimalli, Francesca/K-4936-2014; Battista, Sabrina/AAY-2981-2020; Baldassarre, Gustavo/K-1350-2016; Young, Richard A/F-6495-2012; Fedele, Monica/C-1417-2015; Viglietto, Giuseppe/AAC-2852-2019; visone, rosa/K-7910-2016	Pentimalli, Francesca/0000-0003-4740-6801; Battista, Sabrina/0000-0001-5899-9759; Baldassarre, Gustavo/0000-0002-9750-8825; Young, Richard A/0000-0001-8855-8647; Fedele, Monica/0000-0002-9171-1312; Viglietto, Giuseppe/0000-0003-2327-7515; Ciarmiello, Andrea/0000-0002-6579-656X; VISONE, Rosa/0000-0002-4993-0220; Arra, Claudio/0000-0003-3162-2091; Kenyon, Lawrence/0000-0002-3719-9565; Fusco, Alfredo/0000-0003-3332-5197				Abe N, 1999, CANCER RES, V59, P1169; Abe N, 2000, CANCER RES, V60, P3117; Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; Arlotta P, 2000, J BIOL CHEM, V275, P14394, DOI 10.1074/jbc.M000564200; ASHAR HR, 1995, CELL, V82, P57; Azimi N, 2000, J VIROL, V74, P7338, DOI 10.1128/JVI.74.16.7338-7348.2000; Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Bandiera A, 1998, CANCER RES, V58, P426; Battista S, 1999, CANCER RES, V59, P4793; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Berlingieri MT, 2002, ONCOGENE, V21, P2971, DOI 10.1038/sj.onc.1205368; Brunetti A, 2001, FASEB J, V15, P492, DOI 10.1096/fj.00-0190com; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Di Noto R, 2001, LEUKEMIA, V15, P1641; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Fedele M, 2002, ONCOGENE, V21, P3190, DOI 10.1038/sj.onc.1205428; Fedele M, 1996, CANCER RES, V56, P1896; Fehniger TA, 2001, J EXP MED, V193, P219, DOI 10.1084/jem.193.2.219; Finelli P, 2002, CANCER RES, V62, P2398; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; HOGAN B, 1983, NATURE, V306, P313, DOI 10.1038/306313a0; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Melillo RM, 2001, MOL CELL BIOL, V21, P2485, DOI 10.1128/MCB.21.7.2485-2495.2001; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; TAMIMI Y, 1993, CANCER RES, V53, P5512; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Tkachenko A, 1997, CANCER RES, V57, P2276; Wood LJ, 2000, CANCER RES, V60, P4256; Xiao S, 1997, AM J PATHOL, V150, P901; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	37	121	123	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3427	3435		10.1038/sj.onc.1208501	http://dx.doi.org/10.1038/sj.onc.1208501			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735694				2022-12-25	WOS:000229038800005
J	Miura, S; Karnik, SS; Saku, K				Miura, S; Karnik, SS; Saku, K			Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; V2 VASOPRESSIN RECEPTORS; ENDOTHELIAL-CELLS; ACTIVATION; OLIGOMERIZATION; DIMERIZATION; INACTIVATION; APOPTOSIS; AT(1)	Members of the G-protein-coupled receptor superfamily (GPCRs) undergo homo- and/or hetero-oligomerization to induce cell signaling. Although some of these show constitutive activation, it is not clear how such GPCRs undergo homo- oligomerization with transmembrane helix movement. We previously reported that angiotensin II (Ang II) type 2 (AT(2)) receptor, a GPCR, showed constitutive activation and induced apoptosis independent of its ligand, Ang II. In the present study, we analyzed the translocation and oligomerization of the AT(2) receptor with transmembrane movement when the receptor induces cell signaling. Constitutively active homo- oligomerization, which was due to disulfide bonding between Cys(35) in one AT(2) receptor and Cys(290) in another AT(2) receptor, was localized in the cell membrane without Ang II stimulation and induced apoptosis without changes in receptor conformation. These results provide the direct evidence that the constitutively active homo- oligomeric GPCRs by intermolecular interaction in two extracellular loops is translocated to the cell membrane and induces cell signaling independent of receptor conformation and ligand stimulation.	Fukuoka Univ, Sch Med, Dept Cardiol, Jonan Ku, Fukuoka 8100180, Japan; Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA	Fukuoka University; Cleveland Clinic Foundation	Miura, S (corresponding author), Fukuoka Univ, Sch Med, Dept Cardiol, Jonan Ku, 7-45-1 Nanakuma, Fukuoka 8100180, Japan.	miuras@cis.fukuoka-u.ac.jp	Karnik, Sadashiva/Y-2477-2019; Saku, Keijiro/HGB-6168-2022	Karnik, Sadashiva/0000-0003-0746-2753; 	NHLBI NIH HHS [HL57470, R01 HL064845, R01 HL057470, R01 HL083243, HL64845] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064845, R01HL057470] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Davies A, 2001, J MOL BIOL, V314, P455, DOI 10.1006/jmbi.2001.5167; Daviet L, 1999, J BIOL CHEM, V274, P17058, DOI 10.1074/jbc.274.24.17058; Feng YH, 2000, FEBS LETT, V484, P133, DOI 10.1016/S0014-5793(00)02141-4; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Hein L, 1997, MOL ENDOCRINOL, V11, P1266, DOI 10.1210/me.11.9.1266; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Karnik SS, 2003, TRENDS ENDOCRIN MET, V14, P431, DOI 10.1016/j.tem.2003.09.007; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Matsubara H, 1998, CIRC RES, V83, P1182, DOI 10.1161/01.RES.83.12.1182; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Miura S, 2003, J BIOL CHEM, V278, P3720, DOI 10.1074/jbc.M211338200; Miura S, 2002, J BIOL CHEM, V277, P24299, DOI 10.1074/jbc.M202743200; Miura S, 2003, HYPERTENS RES, V26, P937, DOI 10.1291/hypres.26.937; Miura SI, 2000, EMBO J, V19, P4026, DOI 10.1093/emboj/19.15.4026; Morisset S, 2000, NATURE, V408, P860, DOI 10.1038/35048583; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; Nouet S, 2004, J BIOL CHEM, V279, P28989, DOI 10.1074/jbc.M403880200; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; PUCELL AG, 1991, ENDOCRINOLOGY, V128, P1947, DOI 10.1210/endo-128-4-1947; Schulz A, 2000, J BIOL CHEM, V275, P2381, DOI 10.1074/jbc.275.4.2381; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	28	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18237	18244		10.1074/jbc.M500639200	http://dx.doi.org/10.1074/jbc.M500639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746093	hybrid			2022-12-25	WOS:000228807200082
J	Borra, MT; Smith, BC; Denu, JM				Borra, MT; Smith, BC; Denu, JM			Mechanism of human SIRT1 activation by resveratrol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I TRANSCRIPTION; SILENCING PROTEIN SIR2; NF-KAPPA-B; SACCHAROMYCES-CEREVISIAE; HISTONE/PROTEIN DEACETYLASES; ANTIOXIDANT ACTIVITY; LIFE-SPAN; NAD(+)-DEPENDENT DEACETYLASES; SUBSTRATE-SPECIFICITY; HISTONE DEACETYLASE	The NAD(+)-dependent protein deacetylase family, Sir2 (or sirtuins), is important for many cellular processes including gene silencing, regulation of p53, fatty acid metabolism, cell cycle regulation, and life span extension. Resveratrol, a polyphenol found in wines and thought to harbor major health benefits, was reported to be an activator of Sir2 enzymes in vivo and in vitro. In addition, resveratrol was shown to increase life span in three model organisms through a Sir2-dependent pathway. Here, we investigated the molecular basis for Sir2 activation by resveratrol. Among the three enzymes tested ( yeast Sir2, human SIRT1, and human SIRT2), only SIRT1 exhibited significant enzyme activation (similar to 8-fold) using the commercially available Fluor de Lys kit (BioMol). To examine the requirements for resveratrol activation of SIRT1, we synthesized three p53 acetylpeptide substrates either lacking a fluorophore or containing a 7-amino-4-methylcoumarin (p53-AMC) or rhodamine 110 (p53-R110). Although SIRT1 activation was independent of the acetylpeptide sequence, resveratrol activation was completely dependent on the presence of a covalently attached fluorophore. Substrate competition studies indicated that the fluorophore decreased the binding affinity of the peptide, and, in the presence of resveratrol, fluorophore-containing substrates bound more tightly to SIRT1. Using available crystal structures, a model of SIRT1 bound to p53-AMC peptide was constructed. Without resveratrol, the coumarin of p53-AMC peptide is solvent-exposed and makes no significant contacts with SIRT1. We propose that binding of resveratrol to SIRT1 promotes a conformational change that better accommodates the attached coumarin group.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Denu, JM (corresponding author), Univ Wisconsin, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.	jmdenu@wisc.edu	Smith, Brian C/D-9949-2013	Smith, Brian C/0000-0001-6330-2768	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM066366, T32GM008349, R01GM065386] Funding Source: NIH RePORTER; NIGMS NIH HHS [F31 GM066366, NIH 5 T32 GM08349, R01 GM65386] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal BB, 2004, ANTICANCER RES, V24, P2783; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Avalos JL, 2002, MOL CELL, V10, P523, DOI 10.1016/S1097-2765(02)00628-7; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Blander G, 2005, J BIOL CHEM, V280, P9780, DOI 10.1074/jbc.M414080200; Borra MT, 2004, METHOD ENZYMOL, V376, P171; Borra MT, 2004, BIOCHEMISTRY-US, V43, P9877, DOI 10.1021/bi049592e; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; Burkitt MJ, 2000, ARCH BIOCHEM BIOPHYS, V381, P253, DOI 10.1006/abbi.2000.1973; COPELAND RA, 2000, ENZYMES PRACTICAL IN, P276; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Fang JG, 2002, CHEM-EUR J, V8, P4191, DOI 10.1002/1521-3765(20020916)8:18<4191::AID-CHEM4191>3.0.CO;2-S; Fremont L, 1999, LIFE SCI, V64, P2511, DOI 10.1016/S0024-3205(99)00209-X; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Gescher AJ, 2003, CANCER EPIDEM BIOMAR, V12, P953; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Granados-Soto V, 2003, DRUG NEWS PERSPECT, V16, P299, DOI 10.1358/dnp.2003.16.5.829318; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hirao M, 2003, J BIOL CHEM, V278, P52773, DOI 10.1074/jbc.M308966200; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jackson AD, 2002, J BIOL CHEM, V277, P18535, DOI 10.1074/jbc.M200671200; Jackson MD, 2003, J BIOL CHEM, V278, P50985, DOI 10.1074/jbc.M306552200; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kundu JK, 2004, MUTAT RES-FUND MOL M, V555, P65, DOI 10.1016/j.mrfmmm.2004.05.019; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Marcotte PA, 2004, ANAL BIOCHEM, V332, P90, DOI 10.1016/j.ab.2004.05.039; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Murcia MA, 2001, J FOOD PROTECT, V64, P379, DOI 10.4315/0362-028X-64.3.379; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; Olas B, 2001, CELL BIOL TOXICOL, V17, P117, DOI 10.1023/A:1010962222305; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Pinto MC, 1999, J AGR FOOD CHEM, V47, P4842, DOI 10.1021/jf990448n; Posakony J, 2004, J MED CHEM, V47, P2635, DOI 10.1021/jm030473r; Ray PS, 1999, FREE RADICAL BIO MED, V27, P160, DOI 10.1016/S0891-5849(99)00063-5; RINE J, 1987, GENETICS, V116, P9; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P9249, DOI 10.1021/bi034959l; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Schmidt MT, 2004, J BIOL CHEM, V279, P40122, DOI 10.1074/jbc.M407484200; Schultz J, 2004, J NATL CANCER I, V96, P1497, DOI 10.1093/jnci/96.20.1497; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Shou WY, 2001, MOL CELL, V8, P45, DOI 10.1016/S1097-2765(01)00291-X; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Stojanovic S, 2001, ARCH BIOCHEM BIOPHYS, V391, P79, DOI 10.1006/abbi.2001.2388; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wegener D, 2003, CHEM BIOL, V10, P61, DOI 10.1016/S1074-5521(02)00305-8; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	67	822	876	1	145	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17187	17195		10.1074/jbc.M501250200	http://dx.doi.org/10.1074/jbc.M501250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15749705	hybrid			2022-12-25	WOS:000228615500080
J	Bugaj, V; Alexeenko, V; Zubov, A; Glushankova, L; Nikolaev, A; Wang, ZN; Kaznacheyeva, E; Bezprozvanny, I; Mozhayeva, GN				Bugaj, V; Alexeenko, V; Zubov, A; Glushankova, L; Nikolaev, A; Wang, ZN; Kaznacheyeva, E; Bezprozvanny, I; Mozhayeva, GN			Functional properties of endogenous receptor- and store-operated calcium influx channels in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA A431 CELLS; PLASMA-MEMBRANE; CATION CHANNELS; CA2+ CHANNELS; TRP; DEPLETION; ACTIVATION; CURRENTS; ENTRY; PROTEIN	Activation of phospholipase C (PLC)-mediated signaling pathways in non-excitable cells causes the release of calcium (Ca2+) from inositol 1,4,5-trisphosphate (InsP(3))sensitive intracellular Ca-2+ stores and activation of Ca2+ influx via plasma membrane Ca2+ channels. The properties and molecular identity of plasma membrane Ca2+ influx channels in non-excitable cells is a focus of intense investigation. In the previous studies we used patch clamp electrophysiology to describe the properties of Ca2+ influx channels in human carcinoma A431 cell lines. Now we extend our studies to human embryonic kidney HEK293 cells. By using a combination of Ca2+ imaging and whole cell and single channel patch clamp recordings we discovered that: 1) HEK293 cells contain four types of plasma membrane Ca2+ influx channels: I-CRAC, I-min, I-max, and I-NS; 2) I-CRAC channels are highly Ca2+- selective (P-Ca/Cs > 1000) and I-CRAC single channel conductance is too small for single channel analysis; 3) Imin channels in HEK293 cells display functional properties identical to Imin channels in A431 cells, with single channel conductance of 1.2 pS for divalent cations, 10 pS for monovalent cations, and divalent cation selectivity P-Ba/K = 20; 4) I-min channels in HEK293 cells are activated by InsP3 and inhibited by phosphatidylinositol 4,5-bisphosphate, but store-independent; 5) when compared with Imin, Imax channels have higher conductance for divalent ( 17 pS) and monovalent ( 33 pS) cations, but less selective for divalent cations (P-Ba/K = 4), 6) I-max channels in HEK293 cells can be activated by InsP(3) or by Ca2+ store depletion; 7) INS channels are non-selective (P-Ba/K = 0.4) and display a single channel conductance of 5 pS; and 8) INS channels are not gated by InsP(3) but activated by depletion of intracellular Ca2+ stores. Our findings provide novel information about endogenous Ca2+ channels supporting receptor-operated and store-operated Ca2+ influx pathways in HEK293 cells.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Bezprozvanny, I (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, K4-112,5323 Harry Hines Blvd, Dallas, TX 75235 USA.	Ilya.Bezprozvanny@UTSouthwestern.edu; gnmozh@mail.cytspb.rssi.ru	Glushankova, Lyubov/AAE-9361-2021; Kaznacheyeva, Elena V/I-7260-2017	Glushankova, Lyubov/0000-0002-9995-1214; Kaznacheyeva, Elena V/0000-0003-1273-1188	NINDS NIH HHS [NS38082] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038082] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALMERS W, 1984, J PHYSIOL-LONDON, V353, P565, DOI 10.1113/jphysiol.1984.sp015351; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Clapham DE, 1996, NEURON, V16, P1069, DOI 10.1016/S0896-6273(00)80132-4; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; Gusev K, 2003, J GEN PHYSIOL, V122, P81, DOI 10.1085/jgp.200308815; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HILLE B, 2001, IONIC CHANNELS EXCIT, P448; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Kaznacheyeva E, 2000, J BIOL CHEM, V275, P4561, DOI 10.1074/jbc.275.7.4561; Kaznacheyeva E, 2001, P NATL ACAD SCI USA, V98, P148, DOI 10.1073/pnas.98.1.148; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov KI, 1999, PFLUG ARCH EUR J PHY, V437, P305, DOI 10.1007/s004240050784; Kiselyov KI, 1997, FEBS LETT, V407, P309, DOI 10.1016/S0014-5793(97)00366-9; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Ma R, 2003, J BIOL CHEM, V278, P52763, DOI 10.1074/jbc.M309610200; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; MOZHAYEVA GN, 1990, FEBS LETT, V277, P233, DOI 10.1016/0014-5793(90)80853-B; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; PREMACK BA, 1994, J IMMUNOL, V152, P5226; Putney JW, 2001, J CELL SCI, V114, P2223; Schaefer M, 2002, J BIOL CHEM, V277, P3752, DOI 10.1074/jbc.M109850200; Shalabi A, 2004, J BIOL CHEM, V279, P1040, DOI 10.1074/jbc.M308234200; Shi J, 2004, J PHYSIOL-LONDON, V561, P415, DOI 10.1113/jphysiol.2004.075051; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Suzuki M, 2000, BIOCHEM BIOPH RES CO, V274, P344, DOI 10.1006/bbrc.2000.3135; Uchiyama T, 2002, J BIOL CHEM, V277, P8106, DOI 10.1074/jbc.M108337200; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Wu XY, 2002, J BIOL CHEM, V277, P13597, DOI 10.1074/jbc.M110881200; Yamada H, 2000, NEUROSCI LETT, V285, P111, DOI 10.1016/S0304-3940(00)01033-8; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3; Zubov AI, 1999, J BIOL CHEM, V274, P25983, DOI 10.1074/jbc.274.37.25983; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	45	49	51	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16790	16797		10.1074/jbc.M500192200	http://dx.doi.org/10.1074/jbc.M500192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15741171	hybrid			2022-12-25	WOS:000228615500031
J	Katabami, M; Donninger, H; Hommura, F; Leaner, VD; Kinoshita, I; Chick, JFB; Birrer, MJ				Katabami, M; Donninger, H; Hommura, F; Leaner, VD; Kinoshita, I; Chick, JFB; Birrer, MJ			Cyclin A is a c-Jun target gene and is necessary for c-Jun-induced anchorage-independent growth in RAT1a cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED TRANSCRIPTION; CELLULAR-TRANSFORMATION; EMBRYO FIBROBLASTS; DEPENDENT KINASE-2; PROTEIN-KINASE; RAT-1A CELLS; S-PHASE; EXPRESSION; PROGRESSION; INDUCTION	Overexpression of c-Jun enables Rat1a cells to grow in an anchorage-independent manner. We used an inducible c-Jun system under the regulation of doxycycline in Rat1a cells to identify potential c-Jun target genes necessary for c-Jun-induced anchorage-independent growth. Induction of c-Jun results in sustained expression of cyclin A in the nonadherent state with only minimal expression in the absence of c-Jun. The promoter activity of cyclin A2 was 4-fold higher in Rat1a cells in which c-Jun expression was induced compared with the control cells. Chromatin immunoprecipitation demonstrated that c-Jun bound directly to the cyclin A2 promoter. Mutation analysis of the cyclin A2 promoter mapped the c-Jun regulatory site to an ATF site at position - 80. c-Jun was able to bind to this site both in vitro and in vivo, and mutation of this site completely abolished promoter activity. Cyclin A1 was also elevated in c-Jun-overexpressing Rat1a cells; however, c-Jun did not regulate this gene directly, since it did not bind directly to the cyclin A1 promoter. Suppression of cyclin A expression via the introduction of a cyclin A antisense sequences significantly reduced the ability of c-Jun-overexpressing Rat1a cells to grow in an anchorage-independent fashion. Taken together, these results suggest that cyclin A is a target of c-Jun and is necessary but not sufficient for c-Jun-induced anchorage-independent growth. In addition, we demonstrated that the cytoplasmic oncogenes Ras and Src transcriptionally activated the cyclin A2 promoter via the ATF site at position - 80. Using a dominant negative c-Jun mutant, TAM67, we showed that this transcriptional activation of cyclin A2 requires c-Jun. Thus, our results suggest that c-Jun is a mediator of the aberrant cyclin A2 expression associated with Ras/Src-induced transformation.	NCI, Dept Cell & Canc Biol, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Birrer, MJ (corresponding author), NCI, Dept Cell & Canc Biol, NIH, 9610 Med Ctr Dr,Rm 300, Rockville, MD 20850 USA.	birrerm@bprb.nci.nih.gov	Donninger, Howard/I-9874-2019	Donninger, Howard/0000-0002-8589-1660				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Andrecht S, 2002, J BIOL CHEM, V277, P35961, DOI 10.1074/jbc.M202847200; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; Beier F, 2000, J BIOL CHEM, V275, P12948, DOI 10.1074/jbc.275.17.12948; Bindels EMJ, 2002, ONCOGENE, V21, P8158, DOI 10.1038/sj.onc.1206012; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; BROWN PH, 1993, ONCOGENE, V8, P877; Chang FM, 2001, ONCOGENE, V20, P4354, DOI 10.1038/sj.onc.1204564; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DIEDERICHS S, 2004, J BIOL CHEM; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; El-Ghobashy AA, 2004, GYNECOL ONCOL, V92, P628, DOI 10.1016/j.ygyno.2003.11.010; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; Faivre J, 2002, ONCOGENE, V21, P1493, DOI 10.1038/sj.onc.1205215; Feakins RM, 2003, HUM PATHOL, V34, P1276, DOI 10.1016/j.humpath.2003.07.005; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Haddad R, 2000, BIOCHEM BIOPH RES CO, V274, P188, DOI 10.1006/bbrc.2000.3124; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; Harwell RM, 2004, J BIOL CHEM, V279, P12695, DOI 10.1074/jbc.M313407200; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hommura F, 2004, MOL CANCER RES, V2, P305; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kang JS, 1996, MOL CELL BIOL, V16, P3370; Kinoshita I, 2003, ONCOGENE, V22, P2710, DOI 10.1038/sj.onc.1206371; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Leaner VD, 2003, ONCOGENE, V22, P5619, DOI 10.1038/sj.onc.1206644; Lele KA, 2004, BIOL REPROD, V71, P1340, DOI 10.1095/biolreprod.104.030387; Liao C, 2004, INT J CANCER, V108, P654, DOI 10.1002/ijc.11573; LIN PH, 1995, ONCOGENE, V10, P401; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Muller C, 1999, J BIOL CHEM, V274, P11220, DOI 10.1074/jbc.274.16.11220; Muller C, 1999, BLOOD, V94, P4255, DOI 10.1182/blood.V94.12.4255.424k32_4255_4262; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Muller-Tidow C, 2003, CANCER LETT, V190, P89, DOI 10.1016/S0304-3835(02)00582-7; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; RAPP UR, 1994, ONCOGENE, V9, P3493; Ravnik SE, 1996, DEV BIOL, V173, P69, DOI 10.1006/dbio.1996.0007; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schulze A, 1998, J VIROL, V72, P2323, DOI 10.1128/JVI.72.3.2323-2334.1998; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SOPRANO KJ, 1992, ANN NY ACAD SCI, V660, P231, DOI 10.1111/j.1749-6632.1992.tb21075.x; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Sunters A, 2004, J BIOL CHEM, V279, P9882, DOI 10.1074/jbc.M310184200; Sweeney C, 1996, DEVELOPMENT, V122, P53; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; TAVOLONI N, 1994, J CELL BIOL, V126, P475, DOI 10.1083/jcb.126.2.475; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wu YZ, 2003, ONCOGENE, V22, P8891, DOI 10.1038/sj.onc.1206898; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; Yang R, 1997, CANCER RES, V57, P913; Yang R, 1999, BLOOD, V93, P2067	72	31	34	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16728	16738		10.1074/jbc.M413892200	http://dx.doi.org/10.1074/jbc.M413892200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15737994	hybrid			2022-12-25	WOS:000228615500024
J	Kuznetsov, NV; Andersson, P; Gradin, K; von Stein, P; Dieckmann, A; Pettersson, S; Hanberg, A; Poellinger, L				Kuznetsov, NV; Andersson, P; Gradin, K; von Stein, P; Dieckmann, A; Pettersson, S; Hanberg, A; Poellinger, L			The dioxin/aryl hydrocarbon receptor mediates downregulation of osteopontin gene expression in a mouse model of gastric tumourigenesis	ONCOGENE			English	Article						osteopontin; dioxin/aryl hydrocarbon receptor; gastric cancer; gene expression profiling; suppression subtractive hybridization	IMMUNOGLOBULIN-M; INFLUENZA-VIRUS; AH RECEPTOR; IDENTIFICATION; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; INHIBITION; INDUCTION; AP-1; TRANSCRIPTION; PROGRESSION	The dioxin/aryl hydrocarbon receptor functions as a ligand-activated transcription factor regulating transcription of a battery of genes encoding primarily drug-metabolizing enzymes. Expression of a constitutively active mutant of the aryl hydrocarbon receptor (CA-AhR) in transgenic mice results in development of stomach tumours, correlating with increased mortality. We have used suppression subtractive hybridization techniques followed by macroarray analysis to elucidate which genes are differentially expressed during this process. In the glandular stomach of CA-AhR mice, we observed decreased mRNA expression of osteopontin (OPN), a noncollagenous protein of bone matrix that is also involved in several important functions including regulation of cytokine production, macrophage accumulation, cell motility and adhesion. Downregulated expression of OPN during tumour development was confirmed by RT-PCR and RNA blot analysis. Immunohistochemical analysis showed that this decrease was confined to the corpus region, correlating with the restricted localization of the tumours. Decreased OPN mRNA expression was also observed in other organs of CA-AhR mice. Taken together, these results show that OPN is negatively regulated by the dioxin receptor, and that downregulation of its expression correlates with development of stomach tumours in mice expressing a constitutively active mutant of dioxin receptor.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; InDex Pharmaceut AB, S-17177 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Poellinger, L (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.	lorenz.poellinger@cmb.ki.se	Pettersson, Sven/F-9511-2015; Kuznetsov, Nikolay/AAB-2354-2021; Кузнецов, Николай Юрьевич/GZM-2865-2022; Kuznetsov, Nikolai V/I-7622-2013	Kuznetsov, Nikolay/0000-0002-0131-6387; Kuznetsov, Nikolai/0000-0003-3010-3927; Hanberg, Annika/0000-0001-7255-9856				Agrawal D, 2002, J NATL CANCER I, V94, P513; Andersson P, 2003, BIOCHEM BIOPH RES CO, V302, P336, DOI 10.1016/S0006-291X(03)00185-2; Andersson P, 2002, P NATL ACAD SCI USA, V99, P9990, DOI 10.1073/pnas.152706299; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Baumgarth N, 1999, P NATL ACAD SCI USA, V96, P2250, DOI 10.1073/pnas.96.5.2250; Baumgarth N, 2000, J EXP MED, V192, P271, DOI 10.1084/jem.192.2.271; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; Boes M, 1998, J EXP MED, V188, P2381, DOI 10.1084/jem.188.12.2381; BROWN LF, 1994, AM J PATHOL, V145, P610; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; Crawford HC, 1998, CANCER RES, V58, P5206; Denhardt D T, 1998, J Cell Biochem Suppl, V30-31, P92; Denhardt DT, 2003, CLIN EXP METASTAS, V20, P77, DOI 10.1023/A:1022550721404; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609; Frueh FW, 2001, TOXICOL LETT, V122, P189, DOI 10.1016/S0378-4274(01)00364-2; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Iizuka J, 1998, LAB INVEST, V78, P1523; KLEMAN MI, 1994, J BIOL CHEM, V269, P5137; Kolluri SK, 2001, CANCER RES, V61, P8534; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kurachi M, 2002, BIOCHEM BIOPH RES CO, V292, P368, DOI 10.1006/bbrc.2002.6669; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; McGuire J, 2001, J BIOL CHEM, V276, P41841, DOI 10.1074/jbc.M105607200; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; MIYAZAKI Y, 1990, J BIOL CHEM, V265, P14432; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Nemir M, 2000, J BIOL CHEM, V275, P969, DOI 10.1074/jbc.275.2.969; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; Ohbayashi T, 2001, FEBS LETT, V508, P341, DOI 10.1016/S0014-5793(01)03039-3; Oikawa K, 2002, BIOCHEM BIOPH RES CO, V290, P984, DOI 10.1006/bbrc.2001.6302; Paciorkowski N, 2000, J EXP MED, V191, P731, DOI 10.1084/jem.191.4.731; POHJANVIRTA R, 1994, PHARMACOL REV, V46, P483; Puga A, 2000, BIOCHEM PHARMACOL, V60, P1129, DOI 10.1016/S0006-2952(00)00403-2; QuHong, 1997, J HISTOCHEM CYTOCHEM, V45, P21; Renault MA, 2003, CIRC RES, V93, P674, DOI 10.1161/01.RES.0000094747.05021.62; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Rivera SP, 2002, MOL PHARMACOL, V61, P255, DOI 10.1124/mol.61.2.255; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Suh J, 2002, TOXICOL APPL PHARM, V181, P116, DOI 10.1006/taap.2002.9403; Svensson C, 2001, MOL PHARMACOL, V60, P135, DOI 10.1124/mol.60.1.135; Thomas RS, 2001, MOL PHARMACOL, V60, P1189, DOI 10.1124/mol.60.6.1189; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; von Stein OD, 2001, METH MOL B, V175, P263; Yumoto K, 2002, P NATL ACAD SCI USA, V99, P4556, DOI 10.1073/pnas.052523599	53	16	19	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3216	3222		10.1038/sj.onc.1208529	http://dx.doi.org/10.1038/sj.onc.1208529			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735673				2022-12-25	WOS:000228728100015
J	Elias, B; Laine, A; Ronai, Z				Elias, B; Laine, A; Ronai, Z			Phosphorylation of MdmX by CDK2/Cdc2(p34) is required for nuclear export of Mdm2	ONCOGENE			English	Article						CDK2; mdm2; MdmX; nuclear export; phosphorylation; stability	P53-BINDING PROTEIN; UBIQUITIN LIGASE; DNA-DAMAGE; P53; EXPRESSION; TRANSACTIVATION; OVEREXPRESSION; AMPLIFICATION; DEGRADATION; MECHANISMS	Mdm2 and MdmX function as cellular regulators of the p53 tumor suppressor protein. Intriguingly, the activities of these proteins are interdependent; MdmX stabilizes Mdm2, enabling its activities towards p53, but it also requires Mdm2 for its nuclear localization. Here we demonstrate that via its phosphorylation by CDK2/Cdc2(p34), MdmX regulates nuclear export of Mdm2. Cdc2(p34) phosphorylates MdmX on Ser 96 in vitro. Mutation within this site (MdmXS96A) impairs, whereas phosphomimic substitution (MdmXS96D) increases the cytoplasmic localization of MdmX, suggesting that CDK2/Cdc2p34 phosphorylation is required for export of MdmX from the nucleus. Consequently, cells that express MdmXS96A retain Mdm2 in their nuclei, suggesting that export of Mdm2 to the cytoplasm is MdmX-dependent. Similarly, treatment of cells with the pharmacologicalinhibitor of CDK2/Cdc2p34 or with a dominant-negative Cdc2 results in nuclear localization of MdmX and Mdm2 and decreases the level of Mdm2 expression. Since Cdc2p34 is active in nonstressed conditions, our finding provides a novel insight into the signaling cascade involved in the regulation of MdmX localization and for regulation of Mdm2 localization and stability.	Mt Sinai Sch Med, Ctr Canc, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), Mt Sinai Sch Med, Ctr Canc, Dept Oncol Sci, 1 Gustave Levy L Pl,Box 1130, New York, NY 10029 USA.	zeev.ronai@mssm.edu		RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA59908] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059908] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALARCONVARGAS D, 2003, ADV CANCER RES, V89, P1; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Finch RA, 2002, CANCER RES, V62, P3221; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Ghosh M, 2003, BIOCHEMISTRY-US, V42, P2291, DOI 10.1021/bi0271291; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Parant JM, 2001, GENE, V270, P277, DOI 10.1016/S0378-1119(01)00432-2; Ramos YFM, 2001, CANCER RES, V61, P1839; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Sabbatini P, 2002, DNA CELL BIOL, V21, P519, DOI 10.1089/104454902320219077; Shah OJ, 2003, J BIOL CHEM, V278, P16433, DOI 10.1074/jbc.M300435200; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200	27	15	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2574	2579		10.1038/sj.onc.1208488	http://dx.doi.org/10.1038/sj.onc.1208488			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735705				2022-12-25	WOS:000228180600015
J	Hastak, K; Agarwal, MK; Mukhtar, H; Agarwal, ML				Hastak, K; Agarwal, MK; Mukhtar, H; Agarwal, ML			Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate	FASEB JOURNAL			English	Article						siRNA; G1 arrest; caspase activation; chemoprevention	CELL-CYCLE ARREST; GROWTH ARREST; P53; INHIBITOR; EXPRESSION; P21(WAF1); INDUCTION; KINASE; DEATH; BCL-2	Treatment with epigallocatechin-3-gallate (EGCG), a polyphenolic compound of green tea, results in activation of p53 and induction of apoptosis in prostate cancer LnCaP cells. However, no direct evidence has delineated the role of p53 and p53-dependent pathways in EGCG-mediated apoptosis. To understand the mechanism of negative growth regulation of prostate cancer cells by EGCG we undertook a genetic approach and generated an isogenic pair of prostate carcinoma cells PC3 (p53(-/-)) by stably introducing a cDNA encoding wild-type p53. Treatment of the resultant cells, PC3-p53, with EGCG led to, as reported earlier in LnCaP cells, an increase in p53 protein, which exacerbated both G1 arrest and apoptosis. This response was accompanied by an increase in the levels of p21 and Bax. The cells lacking p53 continued to cycle and did not undergo apoptosis upon treatment with similar concentrations of EGCG, thus establishing the action of EGCG in a p53-dependent manner. This observation was revalidated in another prostate cancer LNCaP cells harboring wild-type p53. Inactivation of p53 using small interfering RNA (siRNA) rendered these cells resistant to EGCG-mediated apoptosis. Because p53 activation led to increase in p21 and Bax, we investigated whether these two proteins are important in this process. Ablation of p21 protein by siRNA prevented G1 arrest and apoptosis in PC3-p53 cells. The p53-dependent increase in Bax expression altered the Bax/Bcl-2 ratio and paralleled the activation of caspase 9 and 3 and cleavage of PARP. Transfection of cells with Bax siRNA abolished these effects and inhibited apoptosis but did not affect the accumulation of the cells in G1. In summary, using isogenic cell lines and siRNA, we have clearly demonstrated that EGCG activates growth arrest and apoptosis primarily via p53-dependent pathway that involves the function of both p21 and Bax such that down-regulation of either molecule confers a growth advantage to the cells.	Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Cleveland Clin, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44106 USA; Univ Wisconsin, Dept Dermatol, Madison, WI USA	Case Western Reserve University; Cleveland Clinic Foundation; University of Wisconsin System; University of Wisconsin Madison	Agarwal, ML (corresponding author), Case Western Reserve Univ, Dept Genet, 10900 Euclid Ave, Cleveland, OH 44106 USA.	munnaagarwal@hotmail.com			NATIONAL CANCER INSTITUTE [R01CA078809, R01CA098916] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA98916-02, R01 CA 78809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhami VM, 2003, J NUTR, V133, p2417S, DOI 10.1093/jn/133.7.2417S; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Chen TG, 2004, CANCER RES, V64, P7412, DOI 10.1158/0008-5472.CAN-04-2077; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Gartel AL, 2002, MOL CANCER THER, V1, P639; Grassilli E, 1999, CANCER RES, V59, P2451; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885; Gupta S, 2001, P NATL ACAD SCI USA, V98, P10350, DOI 10.1073/pnas.171326098; HALDAR S, 1994, CANCER RES, V54, P2095; Hastak K, 2003, ONCOGENE, V22, P4851, DOI 10.1038/sj.onc.1206708; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jin G, 1999, EUR J BIOCHEM, V263, P534, DOI 10.1046/j.1432-1327.1999.00533.x; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kobayashi N, 2000, CYTOKINE, V12, P1745, DOI 10.1006/cyto.2000.0782; Lu YP, 2002, P NATL ACAD SCI USA, V99, P12455, DOI 10.1073/pnas.182429899; MIYASHITA T, 1995, CELL, V80, P293; Mukhtar H, 1999, TOXICOL SCI, V52, P111, DOI 10.1093/toxsci/52.2.111; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Shin BA, 2001, CELL GROWTH DIFFER, V12, P243; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Weisburger JH, 1999, P SOC EXP BIOL MED, V220, P271, DOI 10.1046/j.1525-1373.1999.d01-46.x; Wu Q, 2002, J BIOL CHEM, V277, P36329, DOI 10.1074/jbc.M204962200; Yang CS, 2000, J NUTR, V130, p472S, DOI 10.1093/jn/130.2.472S; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	37	123	127	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					789	+		10.1096/fj.04-2226fje	http://dx.doi.org/10.1096/fj.04-2226fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15764647				2022-12-25	WOS:000227901300017
J	Gu, CK; Shim, S; Shin, J; Kim, J; Park, J; Han, K; Park, S				Gu, CK; Shim, S; Shin, J; Kim, J; Park, J; Han, K; Park, S			The EphA8 receptor induces sustained MAP kinase activation to promote neurite outgrowth in neuronal cells	ONCOGENE			English	Article						Eph; ephrin; EphA8; MAP kinase	TYROSINE KINASE; EPHRIN LIGANDS; PATHWAY; DIFFERENTIATION; IDENTIFICATION; MECHANISMS; RESIDUES; BINDING; FAMILY; DOMAIN	Recent studies in our laboratory demonstrate that ligand-mediated activation of the EphA8 receptor critically regulates cell adhesion and migration. In this report, we show that the EphA8 receptor induces neurite outgrowth in NG108-15 cells in the absence of ligand stimulation. Using various deletion mutants lacking specific intracytoplasmic regions, we confirm that the tyrosine kinase domain of EphA8 is important for inducing neurite outgrowth. However, the tyrosine kinase activity of EphA8 is not crucial for neurite outgrowth induction. Treatment with various inhibitors further reveals that the mitogen-activated protein kinase ( MAPK) signaling pathway is critical for neurite outgrowth induced by EphA8. Consistent with these results, EphA8 expression induced a sustained increase in the activity of MAPK, whereas ligand-mediated EphA8 activation had no further modulatory effects on MAP kinase activity. Additionally, activated MAPK relocalized from the cytoplasm to the nucleus in response to EphA8 transfection. These results collectively suggest that the EphA8 receptor is capable of inducing a sustained increase in MAPK activity, thereby promoting neurite outgrowth in neuronal cells.	Sookmyung Womens Univ, Dept Life Sci, Seoul 140742, South Korea; Sookmyung Womens Univ, Inst Nat Sci, Seoul 140742, South Korea; Hallym Univ, Dept Genet Engn, Chunchon 200702, South Korea	Sookmyung Women's University; Sookmyung Women's University; Hallym University	Park, S (corresponding author), Sookmyung Womens Univ, Dept Life Sci, 53-12 Chungpa Dong 2 Ka, Seoul 140742, South Korea.	scpark@sookmyung.ac.kr		Park, Soochul/0000-0002-7029-3414				Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Choi S, 1999, MOL CELLS, V9, P440; Choi S, 1999, ONCOGENE, V18, P5413, DOI 10.1038/sj.onc.1202917; Coulthard MG, 2002, INT J DEV BIOL, V46, P375; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Gendron L, 2003, J BIOL CHEM, V278, P3606, DOI 10.1074/jbc.M202446200; Gu C, 2003, FEBS LETT, V540, P65, DOI 10.1016/S0014-5793(03)00223-0; Gu C, 2001, MOL CELL BIOL, V21, P4579, DOI 10.1128/MCB.21.14.4579-4597.2001; Himanen JP, 2003, INT J BIOCHEM CELL B, V35, P130, DOI 10.1016/S1357-2725(02)00096-1; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Jeong J, 2000, DNA CELL BIOL, V19, P291, DOI 10.1089/10445490050021203; Klein R, 2001, CURR OPIN CELL BIOL, V13, P196, DOI 10.1016/S0955-0674(00)00197-6; Koo J, 2003, DEV DYNAM, V226, P596, DOI 10.1002/dvdy.10253; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; Mellitzer G, 2000, CURR OPIN NEUROBIOL, V10, P400, DOI 10.1016/S0959-4388(00)00095-7; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; NELSON P, 1976, P NATL ACAD SCI USA, V73, P123, DOI 10.1073/pnas.73.1.123; Park S, 1997, ONCOGENE, V14, P533, DOI 10.1038/sj.onc.1200857; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; Pratt RL, 2002, ONCOGENE, V21, P7690, DOI 10.1038/sj.onc.1205758; Schmucker D, 2001, CELL, V105, P701, DOI 10.1016/S0092-8674(01)00391-9; Tepass U, 2002, CURR OPIN GENET DEV, V12, P572, DOI 10.1016/S0959-437X(02)00342-8; Tong JF, 2003, J BIOL CHEM, V278, P6111, DOI 10.1074/jbc.M208972200; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; YAN MH, 1994, J BIOL CHEM, V269, P19067	28	37	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 16	2005	24	26					4243	4256		10.1038/sj.onc.1208584	http://dx.doi.org/10.1038/sj.onc.1208584			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15782114				2022-12-25	WOS:000229815300008
J	Clatworthy, AE; Valencia-Burton, MA; Haber, JE; Oettinger, MA				Clatworthy, AE; Valencia-Burton, MA; Haber, JE; Oettinger, MA			The MRE11-RAD50-XRS2 complex, in addition to other non-homologous end-joining factors, is required for V(D)J joining in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; DNA-LIGASE-IV; DOUBLE-STRAND BREAKS; TELANGIECTASIA-LIKE DISORDER; CLASS-SWITCH RECOMBINATION; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; RAG PROTEINS; CELL-CYCLE; IN-VIVO	Lymphoid cells of the vertebrate immune system rely on factors in the non-homologous end-joining (NHEJ) DNA repair pathway to form signal joints during V(D)J recombination. Unlike other end-joining reactions, signal joint formation is a specialized case of NHEJ that also requires the lymphoid-specific RAG proteins. Whether V(D) J recombination requires the Mre11-Rad50-Nbs1 complex remains an open question, as null mutations in any member of the complex are lethal in mammals. However, Saccharomyces cerevisiae strains carrying null mutations in components of the homologous Mre11p-Rad50p-Xrs2p (MRX) complex are viable. We therefore took advantage of a recently developed V(D) J recombination assay in yeast to assess the role of MRX in V(D) J joining. Here we confirmed that signal joint formation in yeast is dependent on the same NHEJ factors known to be required in mammalian cells. In addition, we showed an absolute requirement for the MRX complex in signal joining, suggesting that the Mre11-Rad50-Nbs1 complex may be required for signal joint formation in mammalian cells as well.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Rosensteil Ctr, Waltham, MA 02454 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Brandeis University; Brandeis University	Oettinger, MA (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, 50 Blossom St, Boston, MA 02114 USA.	oettinger@frodo.mgh.harvard.edu		Haber, James/0000-0002-1878-0610	NIGMS NIH HHS [GM48026, GM20056] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048026, R01GM020056, R37GM020056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Bender CF, 2002, GENE DEV, V16, P2237, DOI 10.1101/gad.1007902; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Brachmann CB, 1998, YEAST, V14, P115; Brendel M, 2003, MUTAT RES-REV MUTAT, V544, P179, DOI 10.1016/j.mrrev.2003.06.018; Cannon JP, 2004, IMMUNOL REV, V200, P12, DOI 10.1111/j.0105-2896.2004.00166.x; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; Clatworthy AE, 2003, MOL CELL, V12, P489, DOI 10.1016/S1097-2765(03)00305-8; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Demuth I, 2004, HUM MOL GENET, V13, P2385, DOI 10.1093/hmg/ddh278; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; Feldmann H, 1996, J BIOL CHEM, V271, P27765, DOI 10.1074/jbc.271.44.27765; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank-Vaillant M, 2001, GENE DEV, V15, P3005, DOI 10.1101/gad.206801; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, J BIOL CHEM, V273, P24708, DOI 10.1074/jbc.273.38.24708; Harfst E, 2000, MOL IMMUNOL, V37, P915, DOI 10.1016/S0161-5890(01)00008-6; Herrmann G, 1998, EMBO J, V17, P4188, DOI 10.1093/emboj/17.14.4188; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; Huang JR, 2002, NUCLEIC ACIDS RES, V30, P667, DOI 10.1093/nar/30.3.667; Huye LE, 2002, MOL CELL BIOL, V22, P3460, DOI 10.1128/MCB.22.10.3460-3473.2002; Jiang H, 2004, J BIOL CHEM, V279, P8478, DOI 10.1074/jbc.M311219200; Jones JM, 2001, P NATL ACAD SCI USA, V98, P12926, DOI 10.1073/pnas.221471198; Kegel A, 2001, CURR BIOL, V11, P1611, DOI 10.1016/S0960-9822(01)00488-2; Kracker S, 2005, P NATL ACAD SCI USA, V102, P1584, DOI 10.1073/pnas.0409191102; Lahdesmaki A, 2004, J BIOL CHEM, V279, P16479, DOI 10.1074/jbc.M312796200; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; Lee JH, 2003, J BIOL CHEM, V278, P45171, DOI 10.1074/jbc.M308705200; Lee SE, 2002, DNA REPAIR, V1, P27, DOI 10.1016/S1568-7864(01)00003-9; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MALONE RE, 1980, P NATL ACAD SCI-BIOL, V77, P503, DOI 10.1073/pnas.77.1.503; Manolis KG, 2001, EMBO J, V20, P210, DOI 10.1093/emboj/20.1.210; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Moreau S, 1999, MOL CELL BIOL, V19, P556; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Ooi SL, 2001, SCIENCE, V294, P2552, DOI 10.1126/science.1065672; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Qiu JX, 2001, MOL CELL, V7, P77, DOI 10.1016/S1097-2765(01)00156-3; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; Reina-San-Martin B, 2005, P NATL ACAD SCI USA, V102, P1590, DOI 10.1073/pnas.0406289102; Rooney S, 2004, IMMUNOL REV, V200, P115, DOI 10.1111/j.0105-2896.2004.00165.x; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; Schultz HY, 2001, MOL CELL, V7, P65, DOI 10.1016/S1097-2765(01)00155-1; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Theunissen JWF, 2003, MOL CELL, V12, P1511, DOI 10.1016/S1097-2765(03)00455-6; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Tsai CL, 2002, GENE DEV, V16, P1934, DOI 10.1101/gad.984502; Valencia M, 2001, NATURE, V414, P666, DOI 10.1038/414666a; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Yu JH, 2004, MOL CELL BIOL, V24, P1351, DOI 10.1128/MCB.24.3.1351-1364.2004; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	78	12	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20247	20252		10.1074/jbc.M500126200	http://dx.doi.org/10.1074/jbc.M500126200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15757898	hybrid			2022-12-25	WOS:000229242000012
J	Prakash, P; Pathak, N; Hasnain, SE				Prakash, P; Pathak, N; Hasnain, SE			pheA (Rv3838c) of Mycobacterium tuberculosis encodes an allosterically regulated monofunctional prephenate dehydratase that requires both catalytic and regulatory domains for optimum activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORISMATE MUTASE; ESCHERICHIA-COLI; DEHYDROGENASE; BIOSYNTHESIS; GROWTH; ACID; IDER	Prephenate dehydratase (PDT) is a key regulatory enzyme in L-phenylalanine biosynthesis. In Mycobacterium tuberculosis, expression of pheA, the gene encoding PDT, has been earlier reported to be iron-dependent ( 1, 2). We report that M. tuberculosis pheA is also regulated at the protein level by aromatic amino acids. All of the three aromatic amino acids (phenylalanine, tyrosine, and tryptophan) are potent allosteric activators of M. tuberculosis PDT. We also provide in vitro evidence that M. tuberculosis PDT does not possess any chorismate mutase activity, which suggests that, unlike many other enteric bacteria (where PDT exists as a fusion protein with chorismate mutase), M. tuberculosis PDT is a monofunctional and a non-fusion protein. Finally, the biochemical and biophysical properties of the catalytic and regulatory domains (ACT domain) of M. tuberculosis PDT were studied to observe that, in the absence of the ACT domain, the enzyme not only loses its regulatory activity but also its catalytic activity. These novel results provide evidence for a monofunctional prephenate dehydratase enzyme from a pathogenic bacterium that exhibits extensive allosteric activation by aromatic amino acids and is absolutely dependent upon the presence of catalytic as well as the regulatory domains for optimum enzyme activity.	Ctr DNA Fingerprinting & Diagnost, Mol & Cellular Biol Lab, Hyderabad 500076, Andhra Pradesh, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Hasnain, SE (corresponding author), Ctr DNA Fingerprinting & Diagnost, Mol & Cellular Biol Lab, Hyderabad 500076, Andhra Pradesh, India.	hasnain@cdfd.org.in	HASNAIN, SEYED/C-1492-2009	Hasnain, Seyed/0000-0002-2967-0791				Aravind L, 1999, J MOL BIOL, V287, P1023, DOI 10.1006/jmbi.1999.2653; Atkinson DE, 1977, CELLULAR ENERGY META, DOI DOI 10.1016/C2009-0-03136-5; Bange FC, 1996, INFECT IMMUN, V64, P1794, DOI 10.1128/IAI.64.5.1794-1799.1996; Chen SQ, 2003, EUR J BIOCHEM, V270, P757, DOI 10.1046/j.1432-1033.2003.03438.x; Chipman DM, 2001, CURR OPIN STRUC BIOL, V11, P694, DOI 10.1016/S0959-440X(01)00272-X; DAVIDSON BE, 1987, METHOD ENZYMOL, V142, P440; FISCHER R, 1987, METHOD ENZYMOL, V142, P507; FRIEDRICH B, 1976, J BACTERIOL, V126, P712, DOI 10.1128/JB.126.2.712-722.1976; GETHING MJH, 1977, EUR J BIOCHEM, V78, P111, DOI 10.1111/j.1432-1033.1977.tb11719.x; Gold B, 2001, MOL MICROBIOL, V42, P851, DOI 10.1046/j.1365-2958.2001.02684.x; GORCHAN BG, 2002, INFECT IMMUN, V7, P3080; Parish T, 2002, MICROBIOL-SGM, V148, P3069, DOI 10.1099/00221287-148-10-3069; PITTARD AJ, 1987, CELLULAR MOL BIOL, P368; Pohnert G, 1999, BIOCHEMISTRY-US, V38, P12212, DOI 10.1021/bi991134w; Prakash P, 2005, J BIOL CHEM, V280, P19641, DOI 10.1074/jbc.M413026200; Rodriguez GM, 2002, INFECT IMMUN, V70, P3371, DOI 10.1128/IAI.70.7.3371-3381.2002; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Wildermuth MC, 2001, NATURE, V414, P562, DOI 10.1038/35107108; Zhang S, 1998, J BIOL CHEM, V273, P6248, DOI 10.1074/jbc.273.11.6248	19	17	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20666	20671		10.1074/jbc.M502107200	http://dx.doi.org/10.1074/jbc.M502107200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15753077	hybrid			2022-12-25	WOS:000229242000064
J	Thompson, AJ; Price, KL; Reeves, DC; Chan, SL; Chau, PL; Lummis, SCR				Thompson, AJ; Price, KL; Reeves, DC; Chan, SL; Chau, PL; Lummis, SCR			Locating an antagonist in the 5-HT3 receptor binding site using modeling and radioligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; AGONIST-BINDING; EXTRACELLULAR DOMAIN; DIRECTED MUTAGENESIS; AUTOMATED DOCKING; GLYCINE RECEPTOR; RESIDUES; SUBUNIT; CELLS; GABA	We have used a homology model of the extracellular domain of the 5-HT3 receptor to dock granisetron, a 5-HT3 receptor antagonist, into the binding site using AUTODOCK. This yielded 13 alternative energetically favorable models. The models fell into 3 groups. In model type A the aromatic rings of granisetron were between Trp-90 and Phe-226 and its azabicyclic ring was between Trp-183 and Tyr-234, in model type B this orientation was reversed, and in model type C the aromatic rings were between Asp-229 and Ser-200 and the azabicyclic ring was between Phe-226 and Asn-128. Residues located no more than 5 angstrom from the docked granisetron were identified for each model; of 26 residues identified, 8 were found to be common to all models, with 18 others being represented in only a subset of the models. To identify which of the docking models best represents the ligand-receptor complex, we substituted each of these 26 residues with alanine and a residue with similar chemical properties. The mutant receptors were expressed in human embryonic kidney (HEK)293 cells and the affinity of granisetron determined using radioligand binding. Mutation of 2 residues (Trp-183 and Glu-129) ablated binding, whereas mutation of 14 other residues caused changes in the [H-3] granisetron binding affinity in one or both mutant receptors. The data showed that residues both in and close to the binding pocket can affect antagonist binding and overall were found to best support model B.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Albert Einstein Coll Med, Bronx, NY 10461 USA; Chem Comp Grp Inc, Montreal, PQ H3A 2R7, Canada; Inst Pasteur, Paris, France; MRC, Mol Biol Lab, Div Neurobiol, Cambridge CB2 2QH, England	University of Cambridge; Yeshiva University; Albert Einstein College of Medicine; Chemical Computing Group; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; MRC Laboratory Molecular Biology	Lummis, SCR (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	sl120@cam.ac.uk		Thompson, Andrew/0000-0002-7046-6792; Price, Kerry/0000-0002-5563-4567	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Beene DL, 2002, BIOCHEMISTRY-US, V41, P10262, DOI 10.1021/bi020266d; Boess FG, 1997, NEUROPHARMACOLOGY, V36, P637, DOI 10.1016/S0028-3908(97)00044-0; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; GILL CH, 1995, BRIT J PHARMACOL, V114, P1211, DOI 10.1111/j.1476-5381.1995.tb13335.x; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARGREAVES AC, 1994, MOL PHARMACOL, V46, P1120; Huang XQ, 2001, J MED CHEM, V44, P1883, DOI 10.1021/jm000557p; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699; LUMMIS SCR, 1993, EUR J PHARMACOL, V243, P7, DOI 10.1016/0014-2999(93)90160-J; Maksay G, 2003, J RECEPT SIG TRANSD, V23, P255, DOI 10.1081/RRS-120025568; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mu TW, 2003, J AM CHEM SOC, V125, P6850, DOI 10.1021/ja0348086; Newell JG, 2003, J BIOL CHEM, V278, P13166, DOI 10.1074/jbc.M211905200; Niemeyer MI, 1998, BRIT J PHARMACOL, V123, P661, DOI 10.1038/sj.bjp.0701657; Niesler B, 2003, GENE, V310, P101, DOI 10.1016/S0378-1119(03)00503-1; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Price KL, 2004, J BIOL CHEM, V279, P23294, DOI 10.1074/jbc.M314075200; Reeves DC, 2003, BIOPHYS J, V84, P2338, DOI 10.1016/S0006-3495(03)75039-5; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schapira Matthieu, 2002, BMC Structural Biology, V2, P1, DOI 10.1186/1472-6807-2-1; SCHMIEDEN V, 1993, SCIENCE, V262, P256, DOI 10.1126/science.8211147; Spier AD, 2000, J BIOL CHEM, V275, P5620, DOI 10.1074/jbc.275.8.5620; Spier AD, 1999, MOL BRAIN RES, V71, P369; Turchin A, 1999, BIOTECHNIQUES, V26, P672, DOI 10.2144/99264st02; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H; Venkataraman P, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-15; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Yan D, 1998, NEUROPHARMACOLOGY, V37, P251, DOI 10.1016/S0028-3908(98)00010-0; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	41	65	67	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20476	20482		10.1074/jbc.M413610200	http://dx.doi.org/10.1074/jbc.M413610200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781467	hybrid			2022-12-25	WOS:000229242000040
J	Xin, H; Xu, XL; Li, LY; Ning, HX; Rong, Y; Shang, Y; Wang, YY; Fu, XY; Chang, ZJ				Xin, H; Xu, XL; Li, LY; Ning, HX; Rong, Y; Shang, Y; Wang, YY; Fu, XY; Chang, ZJ			CHIP controls the sensitivity of transforming growth factor-beta signaling by modulating the basal level of Smad3 through ubiquitin-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; DEPENDENT DEGRADATION; TRANSCRIPTIONAL ACTIVATION; PROTEASOMAL DEGRADATION; INTERACTING PROTEIN; MAMMALIAN-CELLS; LIGASE COMPLEX; E3 LIGASE; C-JUN; TRANSDUCTION	Transforming growth factor-beta (TGF-beta) signaling is critical in a variety of biological processes such as cell proliferation, differentiation, and apoptosis. TGF-beta signaling is mediated by a group of proteins including TGF-beta receptors and Smads. It is known that different cells can exhibit different sensitivities to TGF-beta. Several molecular mechanisms, such as the differential expression of the receptor levels, have been suggested as contributing to these differences. Here, we report evidence for a novel mechanism of regulating TGF-beta sensitivity that depends on the role of CHIP ( carboxyl terminus of Hsc70-interacting protein) in regulating the basal level of Smad3 via the ubiquitin-dependent degradation pathway. First, using a luciferase assay we found that overexpression of CHIP inhibited TGF-beta signaling, whereas silencing CHIP expression by small interfering RNAs led to increased TGF-beta signaling sensitivity. Second, based on the results of cell proliferation assays and JunB expression, we found that TGF-beta signaling could be abolished by stably overexpressing CHIP. Third, in those cell lines with stably expressed CHIP, we observed that the Smad3 protein level was dramatically decreased. Finally, we demonstrated that CHIP served as a U-box dependent E3 ligase that can directly mediate ubiquitination and degradation of Smad3 and that this action of CHIP was independent of TGF-beta signaling. Taken together, these findings suggest that CHIP can modulate the sensitivity of the TGF-beta signaling by controlling the basal level of Smad3 through ubiquitin-mediated degradation.	Tsing Hua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China; Tsing Hua Univ, Inst Biomed, Beijing 100084, Peoples R China; Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA	Tsinghua University; Tsinghua University; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Xin, H (corresponding author), Tsing Hua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China.	zhijiec@mail.tsinghua.edu.cn	Chang, Zhijie/AAH-8109-2019	Chang, Zhijie/0000-0003-1567-3227				Bai RY, 2002, NAT CELL BIOL, V4, P181, DOI 10.1038/ncb753; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Cardozo CP, 2003, ARCH BIOCHEM BIOPHYS, V410, P134, DOI 10.1016/S0003-9861(02)00680-X; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim RH, 2000, GENE DEV, V14, P1605; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Li LY, 2004, MOL CELL BIOL, V24, P856, DOI 10.1128/MCB.24.2.856-864.2004; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lin Y, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-15; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Miyazono K, 2000, J CELL SCI, V113, P1101; Moustakas A, 2001, J CELL SCI, V114, P4359; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nourry C, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-20; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wang TW, 2003, FRONT BIOSCI, V8, pD1109, DOI 10.2741/1057; Wiederkehr T, 2002, CURR BIOL, V12, pR26, DOI 10.1016/S0960-9822(01)00644-3; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200; Zhu HJ, 1999, J BIOL CHEM, V274, P32258, DOI 10.1074/jbc.274.45.32258	50	77	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20842	20850		10.1074/jbc.M412275200	http://dx.doi.org/10.1074/jbc.M412275200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781469	hybrid			2022-12-25	WOS:000229242000082
J	Roper, JR; Guther, MLS; MacRae, JI; Prescott, AR; Hallyburton, I; Acosta-Serrano, A; Ferguson, MAJ				Roper, JR; Guther, MLS; MacRae, JI; Prescott, AR; Hallyburton, I; Acosta-Serrano, A; Ferguson, MAJ			The suppression of galactose metabolism in procylic form Trypanosoma brucei causes cessation of cell growth and alters procyclin glycoprotein structure and copy number	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; ACIDIC REPETITIVE PROTEIN; BLOOD-STREAM FORMS; POLY-N-ACETYLLACTOSAMINE; AFRICAN TRYPANOSOMES; TRANS-SIALIDASE; GLYCOSYLATION MUTANTS; ANTIGENIC VARIATION; MEMBRANE ANCHOR; LINKED GLYCANS	Galactose metabolism is essential in bloodstream form Trypanosoma brucei and is initiated by the enzyme UDP-Glc 4'-epimerase. Here, we show that the parasite epimerase is a homodimer that can interconvert UDPGlc and UDP-Gal but not UDP-GlcNAc and UDP-GalNAc. The epimerase was localized to the glycosomes by immunofluorescence microscopy and subcellular fractionation, suggesting a novel compartmentalization of galactose metabolism in this organism. The epimerase is encoded by the TbGALE gene and procyclic form T. brucei single-allele knockouts, and conditional (tetracycline-inducible) null mutants were constructed. Under non-permissive conditions, conditional null mutant cultures ceased growth after 8 days and resumed growth after 15 days. The resumption of growth coincided with constitutive re-expression epimerase mRNA. These data show that galactose metabolism is essential for cell growth in procyclic form T. brucei. The epimerase is required for glycoprotein galactosylation. The major procyclic form glycoproteins, the procyclins, were analyzed in TbGALE single-allele knockouts and in the conditional null mutant after removal of tetracycline. The procyclins contain glycosylphosphatidylinositol membrane anchors with large poly-N-acetyl-lactosamine side chains. The single allele knockouts exhibited 30% reduction in procyclin galactose content. This example of haploid insufficiency suggests that epimerase levels are close to limiting in this life cycle stage. Similar analyses of the conditional null mutant 9 days after the removal of tetracycline showed that the procyclins were virtually galactose-free and greatly reduced in size. The parasites compensated, ultimately unsuccessfully, by expressing 10-fold more procyclin. The implications of these data with respect to the relative roles of procyclin polypeptide and carbohydrate are discussed.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland	University of Dundee	Ferguson, MAJ (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.	m.a.j.ferguson@dundee.ac.uk	Ferguson, Michael A. J./F-7829-2010; Prescott, Alan/Y-5956-2018; Acosta-Serrano, Alvaro/L-5503-2015	Ferguson, Michael A. J./0000-0003-1321-8714; Prescott, Alan/0000-0002-0747-7317; Acosta-Serrano, Alvaro/0000-0002-2576-7959; Hallyburton, Irene/0000-0003-4883-5560; MacRae, James/0000-0002-1464-8583				Acosta-Serrano A, 2000, J MOL BIOL, V304, P633, DOI 10.1006/jmbi.2000.4246; Acosta-Serrano A, 2004, EUKARYOT CELL, V3, P255, DOI 10.1128/EC.3.2.255-263.2004; Acosta-Serrano A, 1999, J BIOL CHEM, V274, P29763, DOI 10.1074/jbc.274.42.29763; Acosta-Serrano A, 2001, P NATL ACAD SCI USA, V98, P1513, DOI 10.1073/pnas.041611698; Atrih A, 2005, J BIOL CHEM, V280, P865, DOI 10.1074/jbc.M411061200; BRICKMAN MJ, 1990, J PROTOZOOL, V37, P219, DOI 10.1111/j.1550-7408.1990.tb01131.x; BRUN R, 1979, ACTA TROP, V36, P289; Butikofer P, 1999, J CELL SCI, V112, P1785; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; DECARVALHO LCP, 1993, J EXP MED, V177, P465, DOI 10.1084/jem.177.2.465; ENGSTLER M, 1993, MOL BIOCHEM PARASIT, V61, P1, DOI 10.1016/0166-6851(93)90153-O; Ferguson M. A. J., 1993, GLYCOBIOLOGY, P349; FERGUSON MAJ, 1993, BIOCHEM J, V291, P51, DOI 10.1042/bj2910051; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; Hwa KY, 2000, MOL BIOCHEM PARASIT, V111, P173, DOI 10.1016/S0166-6851(00)00310-8; Lillico S, 2003, MOL BIOL CELL, V14, P1182, DOI 10.1091/mbc.E02-03-0167; MacRae JI, 2005, GLYCOBIOLOGY, V15, P131, DOI 10.1093/glycob/cwh149; Mehlert A, 1998, MOL BIOCHEM PARASIT, V91, P145, DOI 10.1016/S0166-6851(97)00187-4; Mehlert A, 1999, MOL BIOCHEM PARASIT, V98, P291, DOI 10.1016/S0166-6851(98)00168-6; Mehlert A, 1998, J MOL BIOL, V277, P379, DOI 10.1006/jmbi.1997.1600; Michels PAM, 2000, PARASITOL TODAY, V16, P482, DOI 10.1016/S0169-4758(00)01810-X; Montagna G, 2002, EUR J BIOCHEM, V269, P2941, DOI 10.1046/j.1432-1033.2002.02968.x; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; Nagamune K, 2004, J EXP MED, V199, P1445, DOI 10.1084/jem.20030635; Nolan DP, 1999, CURR BIOL, V9, P1169, DOI 10.1016/S0960-9822(00)80018-4; Parsons M, 2004, MOL MICROBIOL, V53, P717, DOI 10.1111/j.1365-2958.2004.04203.x; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; RODITI I, 1989, J CELL BIOL, V108, P737, DOI 10.1083/jcb.108.2.737; Roditi I, 1999, MOL BIOCHEM PARASIT, V103, P99, DOI 10.1016/S0166-6851(99)00124-3; Roper JR, 2003, MOL BIOCHEM PARASIT, V132, P47, DOI 10.1016/j.molbiopara.2003.07.002; Roper JR, 2002, P NATL ACAD SCI USA, V99, P5884, DOI 10.1073/pnas.092669999; Schlaeppi AC, 2003, J BIOL CHEM, V278, P49980, DOI 10.1074/jbc.M309548200; SCHNEIDER P, 1994, J BIOL CHEM, V269, P18332; Schuck P, 2004, BIOPHYS CHEM, V108, P187, DOI 10.1016/j.bpc.2003.10.016; Shaw MP, 2003, MOL BIOCHEM PARASIT, V126, P173, DOI 10.1016/S0166-6851(02)00243-8; SOMMER JM, 1994, ANNU REV MICROBIOL, V48, P105, DOI 10.1146/annurev.mi.48.100194.000541; STEIGER RF, 1980, EUR J BIOCHEM, V105, P163, DOI 10.1111/j.1432-1033.1980.tb04486.x; Tetaud E, 1997, BIOCHEM J, V325, P569, DOI 10.1042/bj3250569; Thoden JB, 2001, J BIOL CHEM, V276, P15131, DOI 10.1074/jbc.M100220200; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vanhamme L, 2001, TRENDS PARASITOL, V17, P338, DOI 10.1016/S1471-4922(01)01922-5; Vassella E, 2000, GENE DEV, V14, P615; Vassella E, 2004, MOL BIOL CELL, V15, P3986, DOI 10.1091/mbc.E04-04-0341; Vassella E, 2003, MOL BIOL CELL, V14, P1308, DOI 10.1091/mbc.E02-10-0694; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244	52	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19728	19736		10.1074/jbc.M502370200	http://dx.doi.org/10.1074/jbc.M502370200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767252	hybrid			2022-12-25	WOS:000229113700039
J	Nister, M; Tang, MJ; Zhang, XQ; Yin, CY; Beeche, M; Hu, XR; Enblad, G; van Dyke, T; Wahl, GM				Nister, M; Tang, MJ; Zhang, XQ; Yin, CY; Beeche, M; Hu, XR; Enblad, G; van Dyke, T; Wahl, GM			p53 must be competent for transcriptional regulation to suppress tumor formation	ONCOGENE			English	Article						p53; transactivation; DNA binding; apoptosis; tumor suppression	IN-VIVO; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; TRANSGENIC MICE; TERMINAL DOMAIN; EXCISION-REPAIR; MUTANT MICE; WILD-TYPE; ACTIVATION; DEFICIENT	In vitro studies suggest that effective tumor suppression by p53 requires multiple domains to execute transcription-dependent and transcription-independent functions. We generated a mutant p53 allele in mice, p53(W25QL26S) (p53(QS)), containing an inactive transactivation domain to evaluate the importance of transactivation for p53-mediated tumor suppression. Recently, we discovered that the allele also contains a valine substitution for alanine at codon 135, which borders the DNA-binding domain. We found that p53(QSval135) bound to chromatin albeit less well than p53(QSala135), but both were equally deficient in transcriptional regulation, apoptosis induction in mouse embryo fibroblasts (MEFs), and suppression of tumor formation by E1A, Ha-Ras transformed MEFs. p53(QSval135) mice and p53-null mice exhibited identical tumor development kinetics and spectra in spontaneous and oncogene-initiated tumorigenicity assays, when tested in a homo- and heterozygous configuration. The p53(QSval135) allele did not have dominant negative functions and behaved as a null allele. Taken together, these data indicate that effective tumor suppression requires the transcriptional regulation function of p53, and they suggest that transactivation independent functions of p53 are unlikely to contribute significantly to tumor suppression in vivo.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Karolinska Univ Hosp, Karolinska Inst, Dept Oncol Pathol, S-17176 Stockholm, Sweden; Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, S-75185 Uppsala, Sweden; Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; Uppsala Univ, Rudbeck Lab, Dept Oncol Radiol & Clin Immunol, S-75185 Uppsala, Sweden	Salk Institute; Karolinska Institutet; Karolinska University Hospital; Uppsala University; University of North Carolina; University of North Carolina Chapel Hill; Uppsala University	Wahl, GM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wahl@salk.edu			NCI NIH HHS [CA61449, CA046283] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061449, R01CA046283] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; Lu XD, 2001, MOL CELL BIOL, V21, P6017, DOI 10.1128/MCB.21.17.6017-6030.2001; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	53	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3563	3573		10.1038/sj.onc.1208354	http://dx.doi.org/10.1038/sj.onc.1208354			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15750633				2022-12-25	WOS:000229221800004
J	El Ghachi, M; Derbise, A; Bouhss, A; Mengin-Lecreulx, D				El Ghachi, M; Derbise, A; Bouhss, A; Mengin-Lecreulx, D			Identification of multiple genes encoding membrane proteins with undecaprenyl pyrophosphate phosphatase (UppP) activity in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACITRACIN ABC TRANSPORTER; BACILLUS-LICHENIFORMIS; BACA GENE; PEPTIDOGLYCAN SYNTHESIS; DIPHOSPHATE SYNTHASE; CYTOPLASMIC STEPS; RESISTANCE; PURIFICATION; SUBTILIS; SEQUENCE	The bacA gene product of Escherichia coli was recently purified to near homogeneity and identified as an undecaprenyl pyrophosphate phosphatase activity ( El Ghachi, M., Bouhss, A., Blanot, D., and Mengin-Lecreulx, D. ( 2004) J. Biol. Chem. 279, 30106-30113). The enzyme function is to synthesize the carrier lipid undecaprenyl phosphate that is essential for the biosynthesis of peptidoglycan and other cell wall components. The inactivation of the chromosomal bacA gene was not lethal but led to a significant, but not total, depletion of undecaprenyl pyrophosphate phosphatase activity in E. coli membranes, suggesting that other(s) protein( s) should exist and account for the residual activity and viability of the mutant strain. Here we report that inactivation of two additional genes, ybjG and pgpB, is required to abolish growth of the bacA mutant strain. Overexpression of either of these genes, or of a fourth identified one, yeiU, is shown to result in bacitracin resistance and increased levels of undecaprenyl pyrophosphate phosphatase activity, as previously observed for bacA. A thermosensitive conditional triple mutant Delta bacA,Delta ybjG,Delta pgpB in which the expression of bacA is impaired at 42 degrees C was constructed. This strain was shown to accumulate soluble peptidoglycan nucleotide precursors and to lyse when grown at the restrictive temperature, due to the depletion of the pool of undecaprenyl phosphate and consequent arrest of cell wall synthesis. This work provides evidence that two different classes of proteins exhibit undecaprenyl pyrophosphate phosphatase activity in E. coli and probably other bacterial species; they are the BacA enzyme and several members from a superfamily of phosphatases that, different from BacA, share in common a characteristic phosphatase sequence motif.	Univ Paris 11, CNRS, UMR 8619,Lab Enveloppes Bacteriennes & Antibiot, Inst Biochim Biophys Mol & Cellulaire, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Mengin-Lecreulx, D (corresponding author), Univ Paris 11, CNRS, UMR 8619,Lab Enveloppes Bacteriennes & Antibiot, Inst Biochim Biophys Mol & Cellulaire, Batiment 430, F-91405 Orsay, France.	dominique.mengin-lecreulx@ebp.u-psud.fr		MENGIN-LECREULX, Dominique/0000-0003-3205-0275				ALLEN CM, 1985, METHOD ENZYMOL, V110, P281; Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; Bernard R, 2003, FEMS MICROBIOL LETT, V228, P93, DOI 10.1016/S0378-1097(03)00738-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIN BD, 1993, J BACTERIOL, V175, P3784, DOI 10.1128/JB.175.12.3784-3789.1993; Cao M, 2002, J BACTERIOL, V184, P6123, DOI 10.1128/JB.184.22.6123-6129.2002; Chalker AF, 2000, MICROBIOL-SGM, V146, P1547, DOI 10.1099/00221287-146-7-1547; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; El Ghachi M, 2004, J BIOL CHEM, V279, P30106, DOI 10.1074/jbc.M401701200; FIEDLER W, 1988, J BIOL CHEM, V263, P14684; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; Fujihashi M, 2001, P NATL ACAD SCI USA, V98, P4337, DOI 10.1073/pnas.071514398; FUNK CR, 1992, J BACTERIOL, V174, P205, DOI 10.1128/jb.174.1.205-213.1992; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Harel YM, 1999, J BACTERIOL, V181, P6176, DOI 10.1128/JB.181.19.6176-6178.1999; ICHO T, 1983, J BACTERIOL, V153, P722, DOI 10.1128/JB.153.2.722-730.1983; Kato JI, 1999, J BACTERIOL, V181, P2733, DOI 10.1128/JB.181.9.2733-2738.1999; MENGINLECREULX D, 1982, J BACTERIOL, V151, P1109, DOI 10.1128/JB.151.3.1109-1117.1982; MENGINLECREULX D, 1983, J BACTERIOL, V154, P1284, DOI 10.1128/JB.154.3.1284-1290.1983; MENGINLECREULX D, 1985, J BACTERIOL, V163, P208, DOI 10.1128/JB.163.1.208-212.1985; MEYER W, 1992, EUR J BIOCHEM, V207, P741, DOI 10.1111/j.1432-1033.1992.tb17104.x; Miller J. H., 1972, EXPT MOL GENETICS, P431; Neuhaus FC, 2003, MICROBIOL MOL BIOL R, V67, P686, DOI 10.1128/MMBR.67.4.686-723.2003; Neuwald AF, 1997, PROTEIN SCI, V6, P1764, DOI 10.1002/pro.5560060817; Ohki R, 2003, J BACTERIOL, V185, P51, DOI 10.1128/JB.185.1.51-59.2003; PODLESEK Z, 1995, MOL MICROBIOL, V16, P969, DOI 10.1111/j.1365-2958.1995.tb02322.x; Podlesek Z, 2000, FEMS MICROBIOL LETT, V188, P103, DOI 10.1111/j.1574-6968.2000.tb09176.x; POLLOCK TJ, 1994, J BACTERIOL, V176, P6229, DOI 10.1128/jb.176.20.6229-6237.1994; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rick P, 1996, ESCHERICHIA COLI SAL, P104; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shimizu N, 1998, J BIOL CHEM, V273, P19476, DOI 10.1074/jbc.273.31.19476; SIEWERT G, 1967, P NATL ACAD SCI USA, V57, P767, DOI 10.1073/pnas.57.3.767; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; STONE KJ, 1971, P NATL ACAD SCI USA, V68, P3223, DOI 10.1073/pnas.68.12.3223; STORM DR, 1973, J BIOL CHEM, V248, P3940; Stukey J, 1997, PROTEIN SCI, V6, P469; TOSCANO WA, 1987, ANTIBIOTIC INHIBITOR, P101; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	42	111	116	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18689	18695		10.1074/jbc.M412277200	http://dx.doi.org/10.1074/jbc.M412277200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15778224	hybrid			2022-12-25	WOS:000228932300019
J	Sato, K; Crowley, PB; Dennison, C				Sato, K; Crowley, PB; Dennison, C			Transient homodimer interactions studied using the electron self-exchange reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE ANALYSIS; CYTOCHROME-F; PROTEIN COMPLEXES; PHOTOSYSTEM-I; DRYOPTERIS-CRASSIRHIZOMA; REDUCED PLASTOCYANIN; ANABAENA-VARIABILIS; COPPER PROTEINS; BINDING-SITE; ACIDIC PATCH	Transient homodimer protein interactions have been investigated by analyzing the influence of ionic strength (NaCl) on the electron self-exchange (the bimolecular reaction whereby the two oxidation states of a redox protein interconvert) rate constant (k(ese)) of four plastocyanins. The k(ese) values for the plastocyanins from spinach, Dryopteris crassirhizoma (a fern), and the green alga Ulva pertusa, which possess acidic patches of varying size and locations, increase 190-, 29-, and 21-fold, respectively, at elevated ionic strength (I = 2.03 M). In contrast, the k(ese) for the almost neutral cyanobacterial plastocyanin from Anabaena variabilis exhibits very little dependence on ionic strength. The temperature dependence of the k(ese) for spinach plastocyanin (I = 0.28 M) provides evidence for poor packing at the homodimer interface. Representative structures of the transient homodimers involved in electron self-exchange, which are consistent with fits of the ionic strength dependence of k(ese) to van Leeuwen theory, have been obtained from protein modeling and docking simulations. The Coulombic energy of the docked homodimers follows the order spinach > D. crassirhizoma > U. pertusa > A. variabilis, which matches that of the overall influence of ionic strength on k(ese). Analysis of the homodimer structures indicates that poor packing and high planarity are features of the interface that favor transient interactions. The physiologically relevant Mg2+ ion has a much more pronounced influence on the k(ese) of spinach plastocyanin, which along with the known properties of the thylakoid lumen suggests a biological role for electron self-exchange.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal; Univ Newcastle Upon Tyne, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Universidade Nova de Lisboa; Newcastle University - UK	Crowley, PB (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Av Da Republ,Apartado 127, P-2781901 Oeiras, Portugal.	crowley@itqb.unl.pt; christopher.dennison@ncl.ac.uk	Crowley, Peter B./A-7822-2013	Dennison, Christopher/0000-0001-8665-052X; Crowley, Peter/0000-0002-5365-0096				ANDREW SM, 1993, J AM CHEM SOC, V115, P5516, DOI 10.1021/ja00066a020; ARMSTRONG FA, 1985, FEBS LETT, V190, P242, DOI 10.1016/0014-5793(85)81292-8; Badsberg U, 1996, BIOCHEMISTRY-US, V35, P7021, DOI 10.1021/bi960621y; Bahadur RP, 2004, J MOL BIOL, V336, P943, DOI 10.1016/j.jmb.2003.12.073; Bond CS, 2001, J MOL BIOL, V306, P47, DOI 10.1006/jmbi.2000.4201; Bork P, 2004, CURR OPIN STRUC BIOL, V14, P292, DOI 10.1016/j.sbi.2004.05.003; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Carrell CJ, 2004, BIOCHEMISTRY-US, V43, P9372, DOI 10.1021/bi049634z; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; COLMAN PM, 1978, NATURE, V272, P319, DOI 10.1038/272319a0; Comeau SR, 2004, BIOINFORMATICS, V20, P45, DOI 10.1093/bioinformatics/btg371; Crowley PB, 2003, ACCOUNTS CHEM RES, V36, P723, DOI 10.1021/ar0200955; Crowley PB, 2004, BIOCHEM J, V378, P45, DOI 10.1042/BJ20031423; Crowley PB, 2001, J AM CHEM SOC, V123, P10444, DOI 10.1021/ja0112700; Crowley PB, 2004, PROTEINS, V55, P603, DOI 10.1002/prot.20043; De Rienzo F, 2000, PROTEIN SCI, V9, P1439, DOI 10.1110/ps.9.8.1439; DENNISON C, 1993, J CHEM SOC DALTON, P1959, DOI 10.1039/dt9930001959; Dennison C, 2002, BIOCHEMISTRY-US, V41, P552, DOI 10.1021/bi011514t; DIXON DW, 1990, J AM CHEM SOC, V112, P1082, DOI 10.1021/ja00159a030; Gavin AC, 2003, CURR OPIN CHEM BIOL, V7, P21, DOI 10.1016/S1367-5931(02)00007-8; Henrick K, 1998, TRENDS BIOCHEM SCI, V23, P358, DOI 10.1016/S0968-0004(98)01253-5; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; Illerhaus J, 2000, J BIOL CHEM, V275, P17590, DOI 10.1074/jbc.275.23.17590; Impagliazzo A, 2004, J AM CHEM SOC, V126, P5658, DOI 10.1021/ja049619h; Inoue T, 1999, BIOCHEMISTRY-US, V38, P13853, DOI 10.1021/bi990502t; Kanbi LD, 2002, J MOL BIOL, V320, P263, DOI 10.1016/S0022-2836(02)00443-6; Kieselbach T, 1998, J BIOL CHEM, V273, P6710, DOI 10.1074/jbc.273.12.6710; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Leigh R. A., 1986, Advances in Plant Nutrition, V2, P249; LOMMEN A, 1990, J BIOL CHEM, V265, P2768; Mandell JG, 2001, PROTEIN ENG, V14, P105, DOI 10.1093/protein/14.2.105; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MEDINA M, 1993, EUR J BIOCHEM, V213, P1133, DOI 10.1111/j.1432-1033.1993.tb17863.x; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; NAR H, 1991, J MOL BIOL, V221, P765, DOI 10.1016/0022-2836(91)80173-R; Nersissian AM, 2002, ADV PROTEIN CHEM, V60, P271; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nooren IMA, 2003, J MOL BIOL, V325, P991, DOI 10.1016/S0022-2836(02)01281-0; Sato K, 2004, J AM CHEM SOC, V126, P3028, DOI 10.1021/ja038188k; Sato K, 2003, J AM CHEM SOC, V125, P2101, DOI 10.1021/ja021005u; Schlarb-Ridley BG, 2002, BIOCHEMISTRY-US, V41, P3279, DOI 10.1021/bi0116588; Schottler MA, 2004, PLANT PHYSIOL, V136, P4265, DOI 10.1104/pp.104.052324; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; Scott WRP, 1999, J PHYS CHEM A, V103, P3596, DOI 10.1021/jp984217f; Shibata N, 1999, J BIOL CHEM, V274, P4225, DOI 10.1074/jbc.274.7.4225; SOLA M, 1989, J AM CHEM SOC, V111, P6627, DOI 10.1021/ja00199a023; Soriano GM, 1996, BIOCHEMISTRY-US, V35, P14590, DOI 10.1021/bi9616211; Sugawara H, 1999, J BIOCHEM-TOKYO, V125, P899, DOI 10.1093/oxfordjournals.jbchem.a022366; Thompson JD, 2000, NUCLEIC ACIDS RES, V28, P2919, DOI 10.1093/nar/28.15.2919; Ubbink M, 1998, STRUCTURE, V6, P323, DOI 10.1016/S0969-2126(98)00035-5; van Amsterdam IMC, 2002, NAT STRUCT BIOL, V9, P48, DOI 10.1038/nsb736; VANDEKAMP M, 1990, J AM CHEM SOC, V112, P907, DOI 10.1021/ja00158a082; VANLEEUWEN JW, 1983, BIOCHIM BIOPHYS ACTA, V743, P408, DOI 10.1016/0167-4838(83)90400-4; Xue YF, 1998, PROTEIN SCI, V7, P2099, DOI 10.1002/pro.5560071006	58	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19281	19288		10.1074/jbc.M500842200	http://dx.doi.org/10.1074/jbc.M500842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15743773	hybrid			2022-12-25	WOS:000228932300085
J	Lin, L; Ozaki, T; Takada, Y; Kageyama, H; Nakamura, Y; Hata, A; Zhang, JH; Simonds, WF; Nakagawara, A; Koseki, H				Lin, L; Ozaki, T; Takada, Y; Kageyama, H; Nakamura, Y; Hata, A; Zhang, JH; Simonds, WF; Nakagawara, A; Koseki, H			topors, a p53 and topoisomerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage	ONCOGENE			English	Article						topors; p53; tumor suppressor; DNA damage; cell cycle; apoptosis	TUMOR-SUPPRESSOR; SUMO-1 MODIFICATION; NUCLEAR-BODIES; GENE; EXPRESSION; SUMOYLATION; INTERACTS; LIGASE; CANCER; DEATH	The RING family zinc-finger protein topors (topoisomerase I-binding protein) binds not only topoisomerase I, but also p53 and the AAV-2 Rep78/68 proteins. topors maps to human chromosome 9p21, which contains candidate tumor suppressor genes implicated in small cell lung cancers. In this study, we isolated the murine counterpart of topors and investigated its impact on p53 function. The deduced amino-acid sequence of mouse topors exhibits extensive similarity to human topors. Overexpressed myc-tagged topors associates with and stabilizes p53, and enhances the p53-dependent transcriptional activities of p21(Waf1), MDM2 and Bax promoters and elevates endogenous p21(Waf1) mRNA levels. Overexpression of topors consequently results in the suppression of cell growth by cell cycle arrest and/or by the induction of apoptosis. Taken together, these studies identify topors as a positive regulator of p53. The expression of topors is induced by exposure to the genotoxic reagents cisplatin and camptothecin, a DNA topoisomerase I inhibitor. We therefore postulate that topors mediates p53-dependent cellular responses induced by DNA damage, suggesting its physiological role as a tumor suppressor.	RIKEN Yokohama Inst, RIKEN Res Ctr Allergy & Immunol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Chiba Univ, Grad Sch Med, Dept Mol Embryol, Chuo Ku, Chiba 2608670, Japan; NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Chiba Univ, Grad Sch Med, Dept Publ Hlth, Chuo Ku, Chiba 2608670, Japan	RIKEN; Chiba University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Chiba Cancer Center; Chiba University	Koseki, H (corresponding author), RIKEN Yokohama Inst, RIKEN Res Ctr Allergy & Immunol, Tsurumi Ku, 1-7-22 Suehiro, Yokohama, Kanagawa 2300045, Japan.	koseki@rcai.riken.jp	Koseki, Haruhiko/I-3825-2014	Koseki, Haruhiko/0000-0001-8424-5854	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043012, ZIADK043012] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Batchu RB, 1999, CANCER RES, V59, P3592; Chu D, 2001, J BIOL CHEM, V276, P14004, DOI 10.1074/jbc.M010262200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Engelhardt OG, 2001, EXP CELL RES, V271, P286, DOI 10.1006/excr.2001.5380; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; HARPER JW, 1993, CELL, V75, P805; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; Klibanov SA, 2001, J CELL SCI, V114, P1867; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mann KK, 2004, CANCER CELL, V5, P307, DOI 10.1016/S1535-6108(04)00089-3; Matthews JM, 2002, IUBMB LIFE, V54, P351, DOI 10.1080/15216540216035; MIYASHITA T, 1995, CELL, V80, P293; Oyanagi H, 2004, LUNG CANCER, V46, P21, DOI 10.1016/j.lungcan.2004.03.009; Rajendra R, 2004, J BIOL CHEM, V279, P36440, DOI 10.1074/jbc.C400300200; Rasheed ZA, 2002, EXP CELL RES, V277, P152, DOI 10.1006/excr.2002.5550; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saleem A, 2004, ONCOGENE, V23, P5293, DOI 10.1038/sj.onc.1207700; SCHLEHOFER JR, 1994, MUTAT RES, V305, P303, DOI 10.1016/0027-5107(94)90250-X; Secombe J, 2004, J BIOL CHEM, V279, P17126, DOI 10.1074/jbc.M310097200; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Weger S, 2003, EXP CELL RES, V290, P13, DOI 10.1016/S0014-4827(03)00292-1; Weger S, 2002, J GEN VIROL, V83, P511, DOI 10.1099/0022-1317-83-3-511; Yamaki M, 2002, GENE, V288, P103, DOI 10.1016/S0378-1119(02)00458-4; Zhou R, 1999, GENE, V235, P93, DOI 10.1016/S0378-1119(99)00203-6	33	42	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3385	3396		10.1038/sj.onc.1208554	http://dx.doi.org/10.1038/sj.onc.1208554			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735665				2022-12-25	WOS:000229038800001
J	Li, XD; Ikebe, R; Ikebe, M				Li, XD; Ikebe, R; Ikebe, M			Activation of myosin Va function by melanophilin, a specific docking partner of myosin Va	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCONVENTIONAL MYOSIN; MELANOSOME TRANSPORT; MOTOR-ACTIVITY; LINKS RAB27A; ACTIN; SLAC2-A/MELANOPHILIN; MUTATIONS; BINDING; PROTEIN; DOMAIN	It is known that melanophilin is a myosin Va-targeting molecule that links myosin Va and the cargo vesicles in cells. Here we found that melanophilin directly activates the actin-activated ATPase activity of myosin Va and thus its motor activity. The actin-activated ATPase activity of the melanocyte-type myosin Va having exon-F was significantly activated by melanophilin by 4-fold. Although Rab27a binds to myosin Va/melanophilin complex, it did not affect the melanophilin-induced activation of myosin Va. Deletion of the C-terminal actin binding domain and N-terminal Rab binding domain of melanophilin resulted in no change in the activation of the ATPase by melanophilin, indicating that the myosin Va binding domain (MBD) is sufficient for the activation of myosin Va. Among MBDs, the interaction of MBD-2 with exon-F of myosin Va is critical for the binding of myosin Va and melanophilin, whereas MBD-1 interacting with the globular tail of myosin Va plays a more significant role in the activation of myosin Va ATPase activity. This is the first demonstration that the binding of the cargo molecule directly activates myosin motor activity. The present finding raises the idea that myosin motors are switched upon their binding to the cargo molecules, thus avoiding the waste of ATP consumption.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	Mitsuo.Ikebe@umassmed.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048526, R01AR041653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006103] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR048526, AR41653] Funding Source: Medline; NIDCD NIH HHS [DC006103] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; Fukuda M, 2004, J CELL SCI, V117, P583, DOI 10.1242/jcs.00891; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; Huang JD, 1998, GENETICS, V148, P1963; Karcher RL, 2001, SCIENCE, V293, P1317, DOI 10.1126/science.1061086; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245-5255.2003; Langford GM, 2002, TRAFFIC, V3, P859, DOI 10.1034/j.1600-0854.2002.31202.x; Li XD, 2004, BIOCHEM BIOPH RES CO, V315, P538, DOI 10.1016/j.bbrc.2004.01.084; Maruta S, 1998, EUR J BIOCHEM, V256, P229, DOI 10.1046/j.1432-1327.1998.2560229.x; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SEPERACK PK, 1995, EMBO J, V14, P2326, DOI 10.1002/j.1460-2075.1995.tb07227.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wang F, 2004, J BIOL CHEM, V279, P2333, DOI 10.1074/jbc.C300488200; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; Wu XF, 2002, MOL BIOL CELL, V13, P1735, DOI 10.1091/mbc.01-12-0595; Wu XF, 1997, J CELL SCI, V110, P847; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760	32	77	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17815	17822		10.1074/jbc.M413295200	http://dx.doi.org/10.1074/jbc.M413295200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15760894	hybrid			2022-12-25	WOS:000228807200033
J	Lemaire, C; Godefroy, N; Costina-Parvu, I; Rincheval, V; Renaud, F; Trotot, P; Bouleau, S; Mignotte, B; Vayssiere, JL				Lemaire, C; Godefroy, N; Costina-Parvu, I; Rincheval, V; Renaud, F; Trotot, P; Bouleau, S; Mignotte, B; Vayssiere, JL			Caspase-9 can antagonize p53-induced apoptosis by generating a p76Rb truncated form of Rb	ONCOGENE			English	Article						apoptosis; caspase-9; fibroblasts; p53; Rb	RETINOBLASTOMA PROTEIN; MEDIATED CLEAVAGE; P53-DEPENDENT APOPTOSIS; CYTOCHROME-C; ACTIVATION; P53; INHIBITION; INDUCTION; CELLS; GROWTH	The tumor suppressor Rb ( retinoblastoma protein) is known to regulate p53-dependent apoptosis, but the mechanisms involved are unclear. In a rat fibroblast model, we previously observed that caspase inhibition potentiates p53-dependent apoptosis and prevents the Rb cleavage associated with p53 activation. These results suggested that a caspase(s) can antagonize p53-mediated apoptosis via the production of a protective Rb truncated form. Here, we identify caspase-9 as the caspase that interferes, upstream of the mitochondrion, with p53-induced apoptosis in both immortalized and primary fibroblasts. This caspase can be detected as a p38 processed form in living cells, in the absence of apoptosome formation and apoptotic signal. We also provide evidence that the involvement of caspase-9 in a premitochondrial protective pathway results from the previously undescribed cleavage of Rb, at a LExD site, into a p76(Rb) form, which antagonizes p53-induced apoptosis. These results establish that a truncated form of Rb can display an antiapoptotic activity, rather than just being a by-product of Rb degradation.	Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, FRE 2445, F-78035 Versailles, France; Ecole Prat Hautes Etud, Lab Genet Mol & Physiol, F-78035 Versailles, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Vayssiere, JL (corresponding author), Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, FRE 2445, 45 Ave Etatsunis, F-78035 Versailles, France.	vayssiere@genetique.uvsq.fr	Godefroy, Nelly/AAG-2052-2020; Mignotte, Bernard/A-3499-2009; Ferecatu, Ioana/AAW-5055-2021	Mignotte, Bernard/0000-0002-8512-8518; Ferecatu, Ioana/0000-0001-6842-9506; Lemaire, Christophe/0000-0001-6316-8781; Krejbich Trotot, Pascale/0000-0001-7329-1716				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; An B, 1996, CANCER RES, V56, P438; Angelastro JM, 2001, J BIOL CHEM, V276, P12190, DOI 10.1074/jbc.M009523200; Bitzer M, 2002, J BIOL CHEM, V277, P29817, DOI 10.1074/jbc.M111898200; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Bowen C, 1998, CANCER RES, V58, P3275; Chandler JM, 1997, BIOCHEM J, V322, P19, DOI 10.1042/bj3220019; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Cregan SP, 1999, J NEUROSCI, V19, P7860; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Fattman CL, 2001, ONCOGENE, V20, P2918, DOI 10.1038/sj.onc.1204414; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Forcet C, 2001, P NATL ACAD SCI USA, V98, P3416, DOI 10.1073/pnas.051378298; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Gao CF, 2001, EXP CELL RES, V265, P145; Godefroy N, 2004, CELL DEATH DIFFER, V11, P785, DOI 10.1038/sj.cdd.4401398; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Lemaire C, 1999, CELL DEATH DIFFER, V6, P813, DOI 10.1038/sj.cdd.4400556; Lopez-Hernandez FJ, 2004, CELL DEATH DIFFER, V11, P154, DOI 10.1038/sj.cdd.4401329; Macleod K, 1999, CURR OPIN GENET DEV, V9, P31, DOI 10.1016/S0959-437X(99)80005-7; MALCOMSON RDG, 1995, BRIT J CANCER, V72, P952, DOI 10.1038/bjc.1995.440; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rincheval V, 1999, FEBS LETT, V460, P203, DOI 10.1016/S0014-5793(99)01345-9; Ritter PM, 2000, EUR J CELL BIOL, V79, P358, DOI 10.1078/S0171-9335(04)70040-0; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Slinskey A, 1999, J VIROL, V73, P6791, DOI 10.1128/JVI.73.8.6791-6799.1999; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1999, CANCER RES, V59, P999; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426; ZHENG DQ, 1994, ONCOGENE, V9, P3345; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	58	16	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3297	3308		10.1038/sj.onc.1208493	http://dx.doi.org/10.1038/sj.onc.1208493			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735701				2022-12-25	WOS:000228881800008
J	Toyoshima, M; Shimura, T; Adiga, SK; Taga, M; Shiraishi, K; Inoue, M; Yuan, ZM; Niwa, O				Toyoshima, M; Shimura, T; Adiga, SK; Taga, M; Shiraishi, K; Inoue, M; Yuan, ZM; Niwa, O			Transcription-independent suppression of DNA synthesis by p53 in sperm-irradiated mouse zygotes	ONCOGENE			English	Article						p53; transcription independent; DNA-binding domain; S-phase checkpoint; X-rays; mouse zygotes	REPLICATION PROTEIN-A; BLOOMS-SYNDROME HELICASE; S-PHASE CHECKPOINT; WILD-TYPE P53; HOMOLOGOUS RECOMBINATION; HOLLIDAY JUNCTIONS; MUTANT P53; P53-DEPENDENT APOPTOSIS; XENOPUS-LAEVIS; HUMAN RAD51	Cell cycle arrest in response to DNA damage is important for the maintenance of genomic integrity in higher eukaryotes. We have previously reported the novel p53-dependent S-phase checkpoint operating in mouse zygotes fertilized with irradiated sperm. In the present study, we analysed the detail of the p53 function required for this S-phase checkpoint in mouse zygotes. The results indicate that ATM kinase is likely to be indispensable for the p53-dependent S-phase checkpoint since the suppression was abrogated by inhibitors such as caffeine and wortmannin. However, ATM phosphorylation site mutant proteins were still capable of suppressing DNA synthesis when microinjected into sperm-irradiated zygotes lacking the functional p53, suggesting that the target of the phosphorylation is not p53. In addition, the suppression was not affected by alpha-amanitin, and p53 protein mutated at the transcriptional activation domain was also functional in the suppression of DNA synthesis. However, p53 proteins mutated at the DNA-binding domain were devoid of the suppressing activity. Taken together, the transcription-independent function of p53 associated with the DNA-binding domain is involved in the S-phase checkpoint in collaboration with yet another unidentified target protein(s).	Kyoto Univ, Dept Late Effect Studies, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan; Kanazawa Med Univ, Med Res Inst, Kahoku, Ishikawa 9200293, Japan; Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Kyoto University; Kanazawa Medical University; Harvard University; Harvard T.H. Chan School of Public Health	Niwa, O (corresponding author), Kyoto Univ, Dept Late Effect Studies, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan.	oniwa@house.rbc.kyoto-u.ac.jp	Adiga, Satish Kumar/AAU-4386-2020	Adiga, Satish Kumar/0000-0002-2897-4697				Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Achanta G, 2001, CANCER RES, V61, P8723; Aguilera A, 2001, TRENDS GENET, V17, P318, DOI 10.1016/S0168-9525(01)02309-5; Amariglio F, 1997, ONCOGENE, V15, P2191, DOI 10.1038/sj.onc.1201395; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; Clute P, 1997, DEV BIOL, V185, P1, DOI 10.1006/dbio.1997.8540; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; Davies SL, 2004, MOL CELL BIOL, V24, P1279, DOI 10.1128/MCB.24.3.1279-1291.2004; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Kumari A, 2004, ONCOGENE, V23, P2324, DOI 10.1038/sj.onc.1207379; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Longhese MP, 2003, MUTAT RES-FUND MOL M, V532, P41, DOI 10.1016/j.mrfmmm.2003.08.009; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pichierri P, 2004, EMBO J, V23, P3154, DOI 10.1038/sj.emboj.7600277; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Shimura T, 2002, RADIAT RES, V158, P735, DOI 10.1667/0033-7587(2002)158[0735:TNSMOT]2.0.CO;2; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TSUKADA T, 1993, ONCOGENE, V8, P3313; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Yakovleva T, 2002, TRENDS BIOCHEM SCI, V27, P612, DOI 10.1016/S0968-0004(02)02209-0; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yarbrough WG, 2002, CANCER RES, V62, P1171; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou XY, 2002, CANCER RES, V62, P1598	52	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3229	3235		10.1038/sj.onc.1208514	http://dx.doi.org/10.1038/sj.onc.1208514			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735681	Green Submitted			2022-12-25	WOS:000228881800001
J	Matthess, Y; Kappel, S; Spankuch, B; Zimmer, B; Kaufmann, M; Strebhardt, K				Matthess, Y; Kappel, S; Spankuch, B; Zimmer, B; Kaufmann, M; Strebhardt, K			Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1	ONCOGENE			English	Article						RNA interference; H1 promoter; doxycycline; polo-like kinase 1	RNA-POLYMERASE-III; POLO-LIKE KINASE; MAMMARY-TUMOR VIRUS; CIS-ACTING ELEMENTS; SHORT HAIRPIN RNAS; GENE-EXPRESSION; DOWN-REGULATION; TRANSCRIPTION; CENTROSOME; ACTIVATION	RNA interference (RNAi) is a powerful tool for studying gene function. We developed an inducible genetic element for short interfering RNA-mediated gene silencing. This system uses a tetracycline (Tet)-responsive derivative of the H1 promoter and the Tet repressor (TetR) for conditional expression of short hairpin RNA (shRNA) in HeLa cells. Promoter constructs were generated, which contain the Tet operator (TetO) derived from a prokaryotic Tet resistance transposon upstream and/or downstream of the TATA box. To quantify the response of controllable transcription units for shRNA expression, we examined the functional activity of polo-like kinase 1 (PLK1), a key component of mitotic progression, that is overexpressed in many human tumors. Cotransfection of plasmids for the expression of TetR and shRNA/PLK1 under the control of an H1 promoter-variant carrying TetO upstream of the TATA box did not alter PLK1 expression and proliferation properties of HeLa cells in the absence of doxycycline. Addition of the antibiotic led to marked downregulation of endogenous PLK1 accompanied by strong inhibition of cellular proliferation. Our data indicate that an inducible transcription system for shRNAs based on the human H1 promoter could be a versatile tool for controlled gene silencing in vitro.	Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Strebhardt, K (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7,Haus 15, D-60590 Frankfurt, Germany.	strebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BRINSTER RL, 1982, NATURE, V296, P39, DOI 10.1038/296039a0; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Chong SS, 2001, J BIOL CHEM, V276, P20727, DOI 10.1074/jbc.M100088200; DANZEISER DA, 1993, MOL CELL BIOL, V13, P4670, DOI 10.1128/MCB.13.8.4670; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; DINGERMANN T, 1992, EMBO J, V11, P1487, DOI 10.1002/j.1460-2075.1992.tb05193.x; DINGERMANN T, 1992, MOL CELL BIOL, V12, P4038, DOI 10.1128/MCB.12.9.4038; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HANNON GJ, 1991, J BIOL CHEM, V266, P22796; HILLEN W, 1984, J MOL BIOL, V172, P185, DOI 10.1016/S0022-2836(84)80037-6; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; HYNES NE, 1981, P NATL ACAD SCI-BIOL, V78, P2038, DOI 10.1073/pnas.78.4.2038; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; LOBO SM, 1990, NUCLEIC ACIDS RES, V18, P2891, DOI 10.1093/nar/18.10.2891; Luukkonen BGM, 1998, RNA, V4, P231; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; Mittal V, 1996, MOL CELL BIOL, V16, P1955; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; Myslinski E, 2001, NUCLEIC ACIDS RES, V29, P2502, DOI 10.1093/nar/29.12.2502; Noonberg SB, 1996, J BIOL CHEM, V271, P10477, DOI 10.1074/jbc.271.18.10477; NOUER L, 1991, HEAT SHOCK RESPONSE, P167; Ohkawa J, 2000, HUM GENE THER, V11, P577, DOI 10.1089/10430340050015761; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; SPANKUCH B, 2004, IN PRESS CURR PHARM; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; STREBHARDT K, 2001, ENCY MOL MED, P2530; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Watanabe Y, 2003, NAT CELL BIOL, V5, P379, DOI 10.1038/ncb0503-379; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Yuan JP, 1997, AM J PATHOL, V150, P1165	44	46	55	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2973	2980		10.1038/sj.onc.1208472	http://dx.doi.org/10.1038/sj.onc.1208472			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735719				2022-12-25	WOS:000228649500006
J	Volanti, C; Hendrickx, N; Van Lint, J; Matroule, JY; Agostinis, P; Piette, J				Volanti, C; Hendrickx, N; Van Lint, J; Matroule, JY; Agostinis, P; Piette, J			Distinct transduction mechanisms of cyclooxygenase 2 gene activation in tumour cells after photodynamic therapy	ONCOGENE			English	Article						photodynamic therapy; COX-2; NF-kappa B; PI3K; PKC; T24 cells; HeLa cells; pyropheophorbide	NF-KAPPA-B; KINASE-C-ALPHA; RELA/P65 SUBUNIT; NITRIC-OXIDE; APOPTOSIS; AKT; PHOSPHORYLATION; EXPRESSION; PHOTOSENSITIZATION; PHARMACOKINETICS	Photodynamic therapy (PDT) is a minimally invasive treatment for cancer and several noncancerous proliferating cell diseases. PDT relies on the uptake of a photosensitizing compound by the pathologic tissue followed by a selective irradiation with visible light, which leads to oxidative stress-mediated cell death. However, some studies showed that PDT induces the release of proangiogenic factors, such as vascular endothelial growth factor, and/or cyclooxygenase-2 (COX-2), thereby promoting cancer cell regrowth following PDT. In this work, we focused on the molecular mechanisms regulating COX-2 expression after low-dose PDT in two cancer cell lines, namely HeLa and T24. We report that PDT induces COX-2 expression in these cells and this expression is mainly due to nuclear factor kappa B (NF-kappa B)-dependent transcription of cox-2 gene without any post-transcriptional regulation. However, the transduction mechanism leading to NF-kappa B activation and subsequent cox-2 gene transcription differs in both cell types. In T24, NF-kappa B activation occurs through a protein kinase C (PKC)alpha- and phosphoinositide-3-kinase (PI3K)-dependent I kappa B kinase (IKK) complex activation, whereas in HeLa cells, NF-kappa B activation is mediated by PKC- and PI3K-independent IKK complex activation.	Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Catholic Univ Louvain, Div Biochem, B-3000 Louvain, Belgium	University of Liege; Universite Catholique Louvain	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium.	jpiette@ulg.ac.be	Van Lint, Johan/P-9073-2019; Agostinis, Patrizia/AAO-2468-2020; Agostinis, Patrizia/ABI-1177-2020	Agostinis, Patrizia/0000-0003-1314-2115; Van Lint, Johan/0000-0002-0275-571X				BELLNIER DA, 1993, J PHOTOCH PHOTOBIO B, V20, P55, DOI 10.1016/1011-1344(93)80131-R; Bork PM, 1999, PLANTA MED, V65, P297, DOI 10.1055/s-1999-13989; Deane JA, 2004, ANNU REV IMMUNOL, V22, P563, DOI 10.1146/annurev.immunol.22.012703.104721; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dougherty TJ, 2002, J CLIN LASER MED SUR, V20, P3, DOI 10.1089/104454702753474931; Ferrario A, 2000, CANCER RES, V60, P4066; Ferrario A, 2002, CANCER RES, V62, P3956; FLATOW U, 1987, INT J CANCER, V40, P240, DOI 10.1002/ijc.2910400220; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Henderson BW, 1997, CANCER RES, V57, P4000; Hendrickx N, 2003, J BIOL CHEM, V278, P52231, DOI 10.1074/jbc.M307591200; Huang WC, 2003, J BIOL CHEM, V278, P9944, DOI 10.1074/jbc.M208521200; Jang BC, 2004, BIOCHEM BIOPH RES CO, V316, P398, DOI 10.1016/j.bbrc.2004.02.060; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Khan KMF, 2004, J BIOL CHEM, V279, P22039, DOI 10.1074/jbc.M312735200; Kim SJ, 2003, BIOCHEM BIOPH RES CO, V303, P206, DOI 10.1016/S0006-291X(03)00305-X; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Makowski M, 2003, CLIN CANCER RES, V9, P5417; Matroule JY, 2000, ANTIOXID REDOX SIGN, V2, P301, DOI 10.1089/ars.2000.2.2-301; Matroule JY, 1999, J BIOL CHEM, V274, P2988, DOI 10.1074/jbc.274.5.2988; Matroule JY, 2000, METHOD ENZYMOL, V319, P119; Morita I, 2002, PROSTAG OTH LIPID M, V68-9, P165, DOI 10.1016/S0090-6980(02)00029-1; Nemeth JF, 2001, BIOCHEMISTRY-US, V40, P3109, DOI 10.1021/bi002313c; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; Ozes ON, 1999, NATURE, V401, P82; Payne JT, 1996, LASER SURG MED, V18, P406, DOI 10.1002/(SICI)1096-9101(1996)18:4<406::AID-LSM10>3.3.CO;2-7; Piette J, 2003, BIOCHEM PHARMACOL, V66, P1651, DOI 10.1016/S0006-2952(03)00539-2; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Taher MM, 2002, IUBMB LIFE, V54, P357, DOI 10.1080/15216540216039; Tang QB, 2001, CANCER RES, V61, P4329; Trushin SA, 2003, MOL CELL BIOL, V23, P7068, DOI 10.1128/MCB.23.19.7068-7081.2003; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027	45	32	33	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2981	2991		10.1038/sj.onc.1208481	http://dx.doi.org/10.1038/sj.onc.1208481			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735712	Green Published			2022-12-25	WOS:000228649500007
J	Kim, SO; Kundu, JK; Shin, YK; Park, JH; Cho, MH; Kim, TY; Surh, YJ				Kim, SO; Kundu, JK; Shin, YK; Park, JH; Cho, MH; Kim, TY; Surh, YJ			[6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-kappa B in phorbol ester-stimulated mouse skin	ONCOGENE			English	Article						chemoprevention; cyclooxygenase-2; [6]-gingerol; p38 MAPK; NF-kappa B; mouse skin	SIGNAL-TRANSDUCTION PATHWAYS; NITRIC-OXIDE-SYNTHASE; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; CYCLOOXYGENASE-2 EXPRESSION; TRANSCRIPTIONAL ACTIVITY; MOLECULAR-MECHANISMS; CELL-TRANSFORMATION; BINDING PROTEIN; P65 SUBUNIT	[6]-Gingerol, a pungent ingredient of ginger (Zingiber officinale Roscoe, Zingiberaceae), has a wide array of pharmacologic effects. The present study was aimed at unraveling the molecular mechanisms underlying previously reported antitumor promoting effects of [6]- gingerol in mouse skin in vivo. One of the well-recognized molecular targets for chemoprevention is cyclooxygenase-2 (COX-2) that is abnormally upregulated in many premalignant and malignant tissues and cells. In our present study, topical application of [6]- gingerol inhibited COX-2 expression in mouse skin stimulated with a prototype tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). Since the transcription factor nuclear factor-kappaB (NF-KB) is known to regulate COX-2 induction, we attempted to determine the effect of [6]- gingerol on TPA-induced activation of NF-KB. Pretreatment with [6]-gingerol resulted in a decrease in both TPA-induced DNA binding and transcriptional activities of NF-KB through suppression of IKB alpha degradation and p65 nuclear translocation. Phosphorylation of both IKB alpha and p65 was substantially blocked by [6]-gingerol. In addition, [6]-gingerol inhibited TPA-stimulated interaction of phospho-p65-(Ser-536) with cAMP response element binding protein-binding protein, a transcriptional coactivator of NF-KB. Moreover, [6]-gingerol prevented TPA-induced phosphorylation and catalytic activity of p38 mitogen-activated protein ( MAP) kinase that regulates COX-2 expression in mouse skin. The p38 MAP kinase inhibitor SB203580 attenuated NF-KB activation and subsequent COX-2 induction in TPA-treated mouse skin. Taken together, our data suggest that [6]-gingerol inhibits TPA-induced COX-2 expression in mouse skin in vivo by blocking the p38 MAP kinase-NF-KB signaling pathway.	Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Seoul 151742, South Korea; Catholic Univ Korea, Coll Med, Seoul 150010, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Catholic University of Korea	Surh, YJ (corresponding author), Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea.	surh@plaza.snu.ac.kr	Shin, Young Kee/C-8929-2011; Kundu, Joydeb/E-6004-2010	Shin, Young Kee/0000-0003-0896-718X; 				Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Asano TK, 2004, DIS COLON RECTUM, V47, P665, DOI 10.1007/s10350-003-0111-9; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Bode A M, 2000, Lancet Oncol, V1, P181, DOI 10.1016/S1470-2045(00)00029-2; Bode AM, 2004, MUTAT RES-FUND MOL M, V555, P33, DOI 10.1016/j.mrfmmm.2004.05.018; Bode AM, 2001, CANCER RES, V61, P850; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chen NY, 2001, CANCER RES, V61, P3908; Chun KS, 2004, CARCINOGENESIS, V25, P713, DOI 10.1093/carcin/bgh076; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; Chun KS, 2003, CARCINOGENESIS, V24, P1515, DOI 10.1093/carcin/bgg107; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Grab LT, 2004, BBA-MOL CELL BIOL L, V1636, P29, DOI 10.1016/j.bbalip.2003.12.002; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Gupta S, 2004, CANCER RES, V64, P3334, DOI 10.1158/0008-5472.CAN-03-2422; Harnish DC, 2000, ENDOCRINOLOGY, V141, P3403, DOI 10.1210/en.141.9.3403; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Jiang X, 2003, BIOCHEM BIOPH RES CO, V301, P583, DOI 10.1016/S0006-291X(03)00011-1; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kismet K, 2004, CANCER DETECT PREV, V28, P127, DOI 10.1016/j.cdp.2003.12.005; Kundu JK, 2003, J NUTR, V133, p3805S, DOI 10.1093/jn/133.11.3805S; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lee MW, 2000, BIOL PHARM BULL, V23, P517, DOI 10.1248/bpb.23.517; Liao CH, 2004, MOL CARCINOGEN, V41, P140, DOI 10.1002/mc.20050; Lim JW, 2001, LAB INVEST, V81, P349, DOI 10.1038/labinvest.3780243; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Mohan S, 2003, ORAL ONCOL, V39, P537, DOI 10.1016/S1368-8375(03)00035-6; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Nakao S, 2000, MOL CELL BIOCHEM, V209, P113, DOI 10.1023/A:1007155525020; NEWALL CA, 1996, HERBAL MED GUIDE HLT, V4, P296; Nomura M, 2000, CARCINOGENESIS, V21, P1885, DOI 10.1093/carcin/21.10.1885; Park KK, 1998, CANCER LETT, V129, P139, DOI 10.1016/S0304-3835(98)00081-0; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Surh YJ, 2002, FOOD CHEM TOXICOL, V40, P1091, DOI 10.1016/S0278-6915(02)00037-6; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Surh YJ, 1999, MUTAT RES-FUND MOL M, V428, P305, DOI 10.1016/S1383-5742(99)00057-5; Takahashi N, 2002, EUR J BIOCHEM, V269, P4559, DOI 10.1046/j.1432-1033.2002.03157.x; Tiano HF, 2002, CANCER RES, V62, P3395; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wilms H, 2003, FASEB J, V17, P500, DOI 10.1096/fj.02-0314fje; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	60	209	225	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2558	2567		10.1038/sj.onc.1208446	http://dx.doi.org/10.1038/sj.onc.1208446			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735738				2022-12-25	WOS:000228180600013
J	Park, SY; Choi, GH; Choi, HI; Ryu, JW; Jung, CY; Lee, W				Park, SY; Choi, GH; Choi, HI; Ryu, JW; Jung, CY; Lee, W			Depletion of mitochondrial DNA causes impaired glucose utilization and insulin resistance in L6 GLUT4myc myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; DIABETES-MELLITUS; ETHIDIUM BROMIDE; RAT ADIPOCYTES; RECEPTOR SUBSTRATE-1; SIGNALING PATHWAYS; TRANSPORTER GLUT4; PLASMA-MEMBRANE; NIDDM SUBJECTS	Mitochondrial dysfunction contributes to a number of human diseases, such as hyperlipidemia, obesity, and diabetes. The mutation and reduction of mitochondrial DNA (mtDNA) have been suggested as factors in the pathogenesis of diabetes. To elucidate the association of cellular mtDNA content and insulin resistance, we produced L6 GLUT4myc myocytes depleted of mtDNA by long term treatment with ethidium bromide. L6 GLUT4myc cells cultured with 0.2 mu g/ml ethidium bromide (termed depleted cells) revealed a marked decrease in cellular mtDNA and ATP content, concomitant with a lack of mRNAs encoded by mtDNA. Interestingly, the mtDNA-depleted cells showed a drastic decrease in basal and insulin-stimulated glucose uptake, indicating that L6 GLUT4myc cells develop impaired glucose utilization and insulin resistance. The repletion of mtDNA normalized basal and insulin-stimulated glucose uptake. The mRNA level and expression of insulin receptor substrate (IRS)-1 associated with insulin signaling were decreased by 76 and 90% in the depleted cells, respectively. The plasma membrane (PM) GLUT4 in the basal state was decreased, and the insulin-stimulated GLUT4 translocation to the PM was drastically reduced by mtDNA depletion. Moreover, insulin-stimulated phosphorylation of IRS-1 and Akt2/protein kinase B were drastically reduced in the depleted cells. Those changes returned to control levels after mtDNA repletion. Taken together, our data suggest that PM GLUT4 content and insulin signal pathway intermediates are modulated by the alteration of cellular mtDNA content, and the reductions in the expression of IRS-1 and insulin-stimulated phosphorylation of IRS-1 and Akt2/protein kinase B are associated with insulin resistance in the mtDNA-depleted L6 GLUT4myc myocytes.	Dongguk Univ, Dept Biochem, Coll Med, Kyungju 780714, South Korea; SUNY Buffalo, Sch Med, Dept Physiol & Biophys, Vet Affairs Med Ctr,Biophys Lab, Buffalo, NY 14215 USA	Dongguk University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Lee, W (corresponding author), Dongguk Univ, Dept Biochem, Coll Med, Kyungju 780714, South Korea.	wanlee@mail.dongguk.ac.kr	Lee, Wan/B-6252-2013	Lee, Wan/0000-0002-5181-2135; Ryu, Jiwon/0000-0003-0251-7858				Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANTONETTI DA, 1995, J CLIN INVEST, V95, P1383, DOI 10.1172/JCI117790; Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Biswas G, 2003, J CELL BIOL, V161, P507, DOI 10.1083/jcb.200211104; Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; CHEN LB, 1989, METHOD CELL BIOL, V29, P103; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; Froguel P, 2001, RECENT PROG HORM RES, V56, P91, DOI 10.1210/rp.56.1.91; Gerbitz KD, 1996, DIABETES, V45, P113, DOI 10.2337/diabetes.45.2.113; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; Han JC, 2003, ARCH BIOCHEM BIOPHYS, V413, P213, DOI 10.1016/S0003-9861(03)00120-6; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; Hayakawa T, 1998, J BIOL CHEM, V273, P20300, DOI 10.1074/jbc.273.32.20300; HERZBERG NH, 1993, BIOCHIM BIOPHYS ACTA, V1181, P63, DOI 10.1016/0925-4439(93)90091-E; Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791; Holman GD, 2001, TRENDS CELL BIOL, V11, P173, DOI 10.1016/S0962-8924(01)01953-5; Huang C, 2002, DIABETES, V51, P2090, DOI 10.2337/diabetes.51.7.2090; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; KANAI F, 1993, J BIOL CHEM, V268, P14523; Kanzaki M, 2003, CURR BIOL, V13, pR574, DOI 10.1016/S0960-9822(03)00478-0; Kelley DE, 2001, DIABETES CARE, V24, P933, DOI 10.2337/diacare.24.5.933; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Khan AH, 2002, DIABETOLOGIA, V45, P1475, DOI 10.1007/s00125-002-0974-7; Khayat ZA, 2000, J CELL SCI, V113, P279; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HK, 1998, DIABETES RES CLIN PR, V42, P161, DOI 10.1016/S0168-8227(98)00110-7; Lee W, 2000, BIOCHEMISTRY-US, V39, P9358, DOI 10.1021/bi0007021; Lee W, 1999, J BIOL CHEM, V274, P37755, DOI 10.1074/jbc.274.53.37755; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; Li Y, 2004, J BIOL CHEM, V279, P45304, DOI 10.1074/jbc.C400186200; Malide D, 1997, J HISTOCHEM CYTOCHEM, V45, P1083, DOI 10.1177/002215549704500806; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Park KS, 2001, AM J PHYSIOL-ENDOC M, V280, pE1007, DOI 10.1152/ajpendo.2001.280.6.E1007; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Seidel-Rogol BL, 2002, NUCLEIC ACIDS RES, V30, P1929, DOI 10.1093/nar/30.9.1929; SERRADAS P, 1995, ENDOCRINOLOGY, V136, P5623, DOI 10.1210/en.136.12.5623; Simoneau JA, 1999, FASEB J, V13, P2051, DOI 10.1096/fasebj.13.14.2051; SIMONEAU JA, 1995, FASEB J, V9, P273, DOI 10.1096/fasebj.9.2.7781930; Simoneau JA, 1997, J APPL PHYSIOL, V83, P166, DOI 10.1152/jappl.1997.83.1.166; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, pE572, DOI 10.1152/ajpendo.1999.277.3.E572; Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Watson RT, 2001, RECENT PROG HORM RES, V56, P175, DOI 10.1210/rp.56.1.175; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952; Whitehead JP, 2000, CURR OPIN CELL BIOL, V12, P222, DOI 10.1016/S0955-0674(99)00079-4; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8; ZYLBER E, 1969, J MOL BIOL, V44, P195, DOI 10.1016/0022-2836(69)90414-8	66	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9855	9864		10.1074/jbc.M409399200	http://dx.doi.org/10.1074/jbc.M409399200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15764607	hybrid			2022-12-25	WOS:000227559600015
J	Kienitz, A; Vogel, C; Morales, I; Muller, R; Bastians, H				Kienitz, A; Vogel, C; Morales, I; Muller, R; Bastians, H			Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol	ONCOGENE			English	Article						cell cycle; mitosis; mad2; apoptosis; genomic instability	ANAPHASE-PROMOTING COMPLEX; MITOTIC CHECKPOINT; KINETOCHORE LOCALIZATION; CHROMOSOME INSTABILITY; ASSEMBLY CHECKPOINT; AURORA-B; PROTEIN; BUBR1; CELLS; INHIBITION	The mitotic spindle assembly checkpoint ensures proper chromosome segregation during mitosis by inhibiting the onset of anaphase until all kinetochores are attached to the mitotic spindle and tension across the kinetochores is generated. Here, we report that the stable partial downregulation of the spindle checkpoint gene MAD1, which is observed in human cancer, leads to a functional inactivation of the spindle checkpoint resulting in gross aneuploidy. Interestingly, although Mad1 is thought to act as a kinetochore based activator of Mad2 during checkpoint activation, we show that normal levels of Mad2, but not of Mad1, are required for preventing premature sister chromatid separation and for maintaining the timing of an undisturbed mitosis, suggesting a Mad1 independent function of Mad2 that operates independent of its checkpoint function. Most significantly, a partial repression of either MAD1 or MAD2 confers resistance to nocodazole, a drug that inhibits microtubule attachment. In contrast, sensitivity to clinically relevant drugs like taxol or monastrol that inhibit the generation of tension across kinetochores is not modulated by partial downregulation of MAD1, suggesting a functional bifurcation of spindle checkpoint dependent apoptotic pathways.	Univ Marburg, Inst Mol Biol & Tumor Res, D-35037 Marburg, Germany	Philipps University Marburg	Bastians, H (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res, Emil Mannkopff Str 2, D-35037 Marburg, Germany.	bastians@imt.uni-marburg.de	Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Campbell MS, 2001, J CELL SCI, V114, P953; Canman JC, 2002, CELL MOTIL CYTOSKEL, V52, P61, DOI 10.1002/cm.10032; Chen RH, 1999, MOL BIOL CELL, V10, P2607, DOI 10.1091/mbc.10.8.2607; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Duesberg P, 2000, CANCER GENET CYTOGEN, V119, P83, DOI 10.1016/S0165-4608(99)00236-8; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Gurtu V, 1997, ANAL BIOCHEM, V251, P98, DOI 10.1006/abio.1997.2220; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; Masuda A, 2003, AM J PATHOL, V163, P1109, DOI 10.1016/S0002-9440(10)63470-0; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Michel L, 2004, P NATL ACAD SCI USA, V101, P4459, DOI 10.1073/pnas.0306069101; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137; Shichiri M, 2002, CANCER RES, V62, P13; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Sironi L, 2001, EMBO J, V20, P6371, DOI 10.1093/emboj/20.22.6371; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 2004, CHROMOSOME RES, V12, P599, DOI 10.1023/B:CHRO.0000036610.78380.51; Vigneron S, 2004, MOL BIOL CELL, V15, P4584, DOI 10.1091/mbc.E04-01-0051; Vogel C, 2005, J BIOL CHEM, V280, P4025, DOI 10.1074/jbc.C400545200; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Wang XH, 2002, CANCER RES, V62, P1662; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	61	75	79	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4301	4310		10.1038/sj.onc.1208589	http://dx.doi.org/10.1038/sj.onc.1208589			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15782113				2022-12-25	WOS:000229815300013
J	Asensio, JL; Albert, A; Munoz-Espin, D; Gonzalez, C; Hermoso, J; Villar, L; Jimenez-Barbero, J; Salas, M; Meijer, WJJ				Asensio, JL; Albert, A; Munoz-Espin, D; Gonzalez, C; Hermoso, J; Villar, L; Jimenez-Barbero, J; Salas, M; Meijer, WJJ			Structure of the functional domain of phi 29 replication organizer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; PROTEIN P16.7; PHI-29 DNA; PROGRAM; CRYSTALLOGRAPHY; POLYMERASE; SEQUENCES; SUITE	The Bacillus subtilis phage phi 29-encoded membrane protein p16.7 is one of the few proteins involved in prokaryotic membrane-associated DNA replication that has been characterized at a functional and biochemical level. In this work we have determined both the solution and crystal structures of its dimeric functional domain, p16.7C. Although the secondary structure of p16.7C is remarkably similar to that of the DNA binding homeodomain, present in proteins belonging to a large family of eukaryotic transcription factors, the tertiary structures of p16.7C and homeodomains are fundamentally different. In fact, p16.7C defines a novel dimeric six-helical fold. We also show that p16.7C can form multimers in solution and that this feature is a key factor for efficient DNA binding. Moreover, a combination of NMR and x-ray approaches, combined with functional analyses of mutants, revealed that multimerization of p16.7C dimers is mediated by a large protein surface that is characterized by a striking self-complementarity. Finally, the structural analyses of the p16.7C dimer and oligomers provide important clues about how protein multimerization and DNA binding are coupled.	CSIC, Dept Quim Organ Biol, Inst Quim Organ Gen, E-28006 Madrid, Spain; CSIC, Grp Cristalog Macromol & Biol Estruct, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; CSIC, Grp RMN, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Inst Biol Mol Eladio Vinuela, E-28049 Madrid, Spain; CSIC, Ctr Invest Biol, Grp Biol Estruct Prot, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Organica General (IQOG); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Meijer, WJJ (corresponding author), CSIC, Dept Quim Organ Biol, Inst Quim Organ Gen, Plaza Murillo 2, E-28006 Madrid, Spain.	wmeijer@cbm.uam.es	Salas, Margarita/J-9873-2014; Gonzalez, Carlos/A-4734-2013; Albert, Armando/J-2373-2012; Hermoso, Juan/J-3433-2012; JIMENEZ-BARBERO, JESUS/D-4431-2014; Asensio, Juan L./J-1996-2015	Salas, Margarita/0000-0001-5939-3441; Gonzalez, Carlos/0000-0001-8796-1282; Albert, Armando/0000-0002-0026-6816; Hermoso, Juan/0000-0002-1862-8950; JIMENEZ-BARBERO, JESUS/0000-0001-5421-8513; Asensio, Juan L./0000-0001-7536-5221; Meijer, Wilfried/0000-0003-1842-0049	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [2R01-GM27242-24] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; FIRSHEIN W, 1989, ANNU REV MICROBIOL, V43, P89, DOI 10.1146/annurev.micro.43.1.89; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Johnson CS, 1999, PROG NUCL MAG RES SP, V34, P203, DOI 10.1016/S0079-6565(99)00003-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kalodimos CG, 2004, SCIENCE, V305, P386, DOI 10.1126/science.1097064; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; Meijer WJJ, 2000, EMBO J, V19, P4182, DOI 10.1093/emboj/19.15.4182; Meijer WJJ, 2001, MOL MICROBIOL, V39, P731, DOI 10.1046/j.1365-2958.2001.02260.x; Meijer WJJ, 2001, MICROBIOL MOL BIOL R, V65, P261, DOI 10.1128/MMBR.65.2.261-287.2001; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; MUNOZESPIN D, 2004, J BIOL CHEM, V1, P1; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neidigh JW, 2002, NAT STRUCT BIOL, V9, P425, DOI 10.1038/nsb798; Noirot-Gros MF, 2002, P NATL ACAD SCI USA, V99, P8342, DOI 10.1073/pnas.122040799; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SALAS M, 1996, DNA REPLICATION EUKA, P131; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santelli E, 2000, J MOL BIOL, V297, P437, DOI 10.1006/jmbi.2000.3568; Serna-Rico A, 2002, J BIOL CHEM, V277, P6733, DOI 10.1074/jbc.M109312200; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	38	9	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20730	20739		10.1074/jbc.M501687200	http://dx.doi.org/10.1074/jbc.M501687200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15772069	hybrid			2022-12-25	WOS:000229242000071
J	Brunet, E; Alberti, P; Perrouault, LC; Babu, R; Wengel, J; Giovannangeli, C				Brunet, E; Alberti, P; Perrouault, LC; Babu, R; Wengel, J; Giovannangeli, C			Exploring cellular activity of locked nucleic acid-modified triplex-forming oligonucleotides and defining its molecular basis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX FORMATION; ANTISENSE OLIGONUCLEOTIDES; TRANSCRIPTION ELONGATION; PHYSIOLOGICAL PH; RNA CLEAVAGE; IN-VITRO; DNA; INHIBITION; LNA; STABILITY	Triplex-forming oligonucleotides (TFOs), as DNA-binding molecules that recognize specific sequences, offer unique potential for the understanding of processes occurring on DNA and associated functions. They are also powerful DNA recognition elements for the positioning of ubiquitous molecules acting on DNA, such as anticancer drugs. A prerequisite for further development of DNA code-reading molecules including TFOs is their ability to form a complex in a cellular context: their binding affinities must be comparable to those of DNA-associated proteins. To reach this goal, chemically modified TFOs must be developed. In this work, we present triplex-forming properties ( kinetics and thermodynamics) and cellular activity of G-containing locked nucleic acid-modified TFOs (TFO/LNAs). In conditions simulating physiological ones, these TFO/LNAs strongly enhanced triplex stability compared with the non-modified TFO or with the pyrimidine TFO/LNA directed against the same oligopyrimidine oligopurine sequence, mainly by decreasing the dissociation rate constant and conferring an entropic gain. We provide evidence of their biological activity by a triplex-based mechanism, in vitro and in a cellular context, under conditions in which the parent phosphodiester oligonucleotide did not exhibit any inhibitory effect.	Museum Natl Hist Nat, USM 503, Biophys Lab, CNRS,UMR 5153,U565, F-75005 Paris, France; Univ So Denmark, Nucle Acid Ctr, Dept Chem, DK-5230 Odense, Denmark	Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); University of Southern Denmark	Giovannangeli, C (corresponding author), Museum Natl Hist Nat, USM 503, Biophys Lab, CNRS,UMR 5153,U565, 43 Rue Cuvier, F-75005 Paris, France.	giovanna@mnhn.fr	BRUNET, ERIKA/H-9297-2017; BRUNET, ERIKA/K-7154-2016; wengel, jesper/K-1177-2013	BRUNET, ERIKA/0000-0002-1726-4673; BRUNET, ERIKA/0000-0002-1726-4673; Alberti, Patrizia/0000-0002-5231-3768; Wengel, Jesper/0000-0001-9835-1009				Alberti P, 2002, NUCLEIC ACIDS RES, V30, P5407, DOI 10.1093/nar/gkf675; Arimondo PB, 2001, BIOCONJUGATE CHEM, V12, P501, DOI 10.1021/bc000162k; Besch R, 2004, CURR DRUG TARGETS, V5, P691, DOI 10.2174/1389450043345100; Brown PM, 1998, BIOCHEMISTRY-US, V37, P16139, DOI 10.1021/bi981768n; Buchini S, 2003, CURR OPIN CHEM BIOL, V7, P717, DOI 10.1016/j.cbpa.2003.10.007; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Crinelli R, 2004, NUCLEIC ACIDS RES, V32, P1874, DOI 10.1093/nar/gkh503; DIVIACCO S, 1992, GENE, V122, P313, DOI 10.1016/0378-1119(92)90220-J; Elayadi AN, 2002, BIOCHEMISTRY-US, V41, P9973, DOI 10.1021/bi025907j; Faria M, 2000, P NATL ACAD SCI USA, V97, P3862, DOI 10.1073/pnas.97.8.3862; Faria M, 2001, J MOL BIOL, V306, P15, DOI 10.1006/jmbi.2000.4386; Fluiter K, 2003, NUCLEIC ACIDS RES, V31, P953, DOI 10.1093/nar/gkg185; Francois JC, 2004, NUCL ACID M, V13, P223; Giovannangeli C, 1996, J MOL BIOL, V261, P386, DOI 10.1006/jmbi.1996.0471; Giovannangeli C, 1997, P NATL ACAD SCI USA, V94, P79, DOI 10.1073/pnas.94.1.79; GIOVANNANGELI C, 1992, P NATL ACAD SCI USA, V89, P8631, DOI 10.1073/pnas.89.18.8631; Hertoghs KML, 2003, NUCLEIC ACIDS RES, V31, P5817, DOI 10.1093/nar/gkg801; Kamiya M, 1996, J AM CHEM SOC, V118, P4532, DOI 10.1021/ja952287j; Koizumi M, 2003, NUCLEIC ACIDS RES, V31, P3267, DOI 10.1093/nar/gkg416; Koshkin AA, 1998, TETRAHEDRON LETT, V39, P4381, DOI 10.1016/S0040-4039(98)00706-0; Kurreck J, 2002, NUCLEIC ACIDS RES, V30, P1911, DOI 10.1093/nar/30.9.1911; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; Mills M, 1999, J MOL BIOL, V291, P1035, DOI 10.1006/jmbi.1999.3014; Nulf CJ, 2004, NUCLEIC ACIDS RES, V32, P3792, DOI 10.1093/nar/gkh706; Obika S, 2001, BIOORGAN MED CHEM, V9, P1001, DOI 10.1016/S0968-0896(00)00325-4; Obika S, 1998, TETRAHEDRON LETT, V39, P5401, DOI 10.1016/S0040-4039(98)01084-3; Parekh-Olmedo H, 2002, CHEM BIOL, V9, P1073, DOI 10.1016/S1074-5521(02)00236-3; Randazzo A, 2004, NUCLEIC ACIDS RES, V32, P3083, DOI 10.1093/nar/gkh629; Roberts RW, 1996, P NATL ACAD SCI USA, V93, P4320, DOI 10.1073/pnas.93.9.4320; ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808; Schmidt KS, 2004, NUCLEIC ACIDS RES, V32, P5757, DOI 10.1093/nar/gkh862; Seidman MM, 2003, J CLIN INVEST, V112, P487, DOI 10.1172/JCI200319552; Sorensen JJ, 2004, NUCLEIC ACIDS RES, V32, P6078, DOI 10.1093/nar/gkh942; Sun BW, 2004, BIOCHEMISTRY-US, V43, P4160, DOI 10.1021/bi036064e; Torigoe H, 2001, J BIOL CHEM, V276, P2354, DOI 10.1074/jbc.M007783200; Vester B, 2002, J AM CHEM SOC, V124, P13682, DOI 10.1021/ja0276220; Wengel J, 2003, NUCLEOS NUCLEOT NUCL, V22, P601, DOI 10.1081/NCN-120021963; Whitehouse I, 2003, MOL CELL BIOL, V23, P1935, DOI 10.1128/MCB.23.6.1935-1945.2003	38	36	37	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20076	20085		10.1074/jbc.M500021200	http://dx.doi.org/10.1074/jbc.M500021200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15760901	hybrid			2022-12-25	WOS:000229113700078
J	Wei, CJ; Francis, R; Xu, X; Lo, CW				Wei, CJ; Francis, R; Xu, X; Lo, CW			Connexin43 associated with an N-cadherin-containing multiprotein complex is required for gap junction formation in NIH3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTES; PLASMA-MEMBRANE; INTERCELLULAR COMMUNICATION; PROTEIN CONNEXIN-43; RAT CARDIOMYOCYTES; MEDIATED ADHESION; CATENIN COMPLEXES; CHANNEL PROTEIN; PHOSPHORYLATION; EXPRESSION	Previous studies have indicated an intimate linkage between gap junction and adherens junction formation. It was suggested this could reflect the close membrane-membrane apposition required for junction formation. In NIH3T3 cells, we observed the colocalization of connexin43 (Cx43 alpha 1) gap junction protein with N-cadherin, p120, and other N-cadherin-associated proteins at regions of cell-cell contact. We also found that Cx43 alpha 1, N-cadherin, and N-cadherin-associated proteins were coimmunoprecipitated by antibodies to either Cx43 alpha 1, N-cadherin, or various N-cadherin-associated proteins. These findings suggest that Cx43 alpha 1 and N-cadherin are coassembled in a multiprotein complex containing various N-cadherin-associated proteins. Studies using siRNA knockdown indicated that cell surface expression of Cx43 alpha 1 required N-cadherin, and conversely, N-cadherin cell surface expression required Cx43 alpha 1. Pulse-chase labeling and cell surface biotinylation experiments indicated that in the absence of N-cadherin, Cx43 alpha 1 cell surface trafficking is blocked. Surprisingly, siRNA knockdown of p120, an N-cadherin-associated protein known to modulate cell surface turnover of N-cadherin, reduced N-cadherin cell surface expression without altering Cx43 alpha 1 expression. These observations suggest that in contrast to the coregulated cell surface trafficking of Cx43 alpha 1 and N-cadherin, N-cadherin turnover at the cell surface may be regulated independently of Cx43 alpha 1. Functional studies showed gap junctional communication is reduced and cell motility inhibited with N-cadherin or Cx43 alpha 1 knockdown, consistent with the observed loss of both gap junction and cadherin contacts with either knockdown. Overall, these studies indicate that the intracellular coassembly of connexin and cadherin is required for gap junction and adherens junction formation, a process that likely underlies the intimate association between gap junction and adherens junction formation.	NHLBI, Dev Biol Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lo, CW (corresponding author), 50 South Dr,MSC 8019,Rm 4537, Bethesda, MD 20892 USA.	loc@nhlbi.nih.gov	Francis, Richard/P-2524-2015	Francis, Richard/0000-0002-4401-1946	NHLBI NIH HHS [Z01-HL005701] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005701, ZIAHL005701] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; Barker RJ, 2001, CELL COMMUN ADHES, V8, P205, DOI 10.3109/15419060109080724; Barker RJ, 2002, CIRC RES, V90, P317, DOI 10.1161/hh0302.104471; Bauer R, 2004, MOL BIOL CELL, V15, P2992, DOI 10.1091/mbc.E04-01-0056; Berthoud VA, 2004, CARDIOVASC RES, V62, P256, DOI 10.1016/j.cardiores.2003.12.021; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; Cooper CD, 2002, J BIOL CHEM, V277, P44962, DOI 10.1074/jbc.M209427200; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Frenzel EM, 1996, DEV BIOL, V179, P1, DOI 10.1006/dbio.1996.0237; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Giepmans BNG, 2001, CELL COMMUN ADHES, V8, P219, DOI 10.3109/15419060109080727; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Govindarajan R, 2002, J BIOL CHEM, V277, P50087, DOI 10.1074/jbc.M202652200; Gutstein DE, 2003, J CELL SCI, V116, P875, DOI 10.1242/jcs.00258; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hertig CM, 1996, J CELL SCI, V109, P1; Herve JC, 2004, EUR BIOPHYS J BIOPHY, V33, P201, DOI 10.1007/s00249-003-0381-0; Huang GY, 1998, J CELL BIOL, V143, P1725, DOI 10.1083/jcb.143.6.1725; Jordan K, 2001, J CELL SCI, V114, P763; KEANE RW, 1988, J CELL BIOL, V106, P1307, DOI 10.1083/jcb.106.4.1307; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Laing JG, 1998, CARDIOVASC RES, V38, P711, DOI 10.1016/S0008-6363(98)00060-1; LAIRD DW, 1991, BIOCHEM J, V273, P67, DOI 10.1042/bj2730067; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; LEE S, 1987, CELL, V51, P851, DOI 10.1016/0092-8674(87)90108-5; Li WEI, 2002, DEVELOPMENT, V129, P2031; Luo Y, 2003, J CELL SCI, V116, P1471, DOI 10.1242/jcs.00339; MEYER RA, 1992, J CELL BIOL, V119, P179, DOI 10.1083/jcb.119.1.179; MONIERGAVELLE F, 1995, J CELL SCI, V108, P3839; Musil LS, 2000, J BIOL CHEM, V275, P25207, DOI 10.1074/jbc.275.33.25207; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; PAUL DL, 1995, DEVELOPMENT, V121, P371; Postma FR, 1998, J CELL BIOL, V140, P1199, DOI 10.1083/jcb.140.5.1199; Sohl G, 2003, CELL COMMUN ADHES, V10, P173, DOI 10.1080/15419060390262877; Stites J, 1998, CELL MOTIL CYTOSKEL, V39, P31, DOI 10.1002/(SICI)1097-0169(1998)39:1<31::AID-CM4>3.0.CO;2-J; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Wahl JK, 2003, J BIOL CHEM, V278, P17269, DOI 10.1074/jbc.M211452200; Wang YJ, 1997, J CELL SCI, V110, P301; Wu JC, 2003, J CELL BIOCHEM, V88, P823, DOI 10.1002/jcb.10390; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Xu X, 2001, J CELL BIOL, V154, P217, DOI 10.1083/jcb.200105047; Yeager M, 1998, CURR OPIN STRUC BIOL, V8, P517, DOI 10.1016/S0959-440X(98)80131-0	48	167	175	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19925	19936		10.1074/jbc.M412921200	http://dx.doi.org/10.1074/jbc.M412921200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15741167	Green Submitted, hybrid			2022-12-25	WOS:000229113700062
J	Xie, Q; Lin, TX; Zhang, Y; Zheng, JP; Bonanno, JA				Xie, Q; Lin, TX; Zhang, Y; Zheng, JP; Bonanno, JA			Molecular cloning and characterization of a human AIF-like gene with ability to induce apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; CELL-DEATH; REGULATES APOPTOSIS; SERINE-PROTEASE; BINDING; IDENTIFICATION; MITOCHONDRIA; EXPRESSION; SEQUENCE; XIAP	In this study, we cloned and characterized a human gene homologous to the apoptosis-inducing factor (AIF), which is named AIF-like (AIFL). Human AIFL has 598 amino acids, with a characteristic Rieske domain and a pyridine nucleotide-disulfide oxidoreductase domain ( Pyr_redox). AIFL shares 35% homology with AIF, mainly in the Pyr_redox domain. Reverse transcriptase-PCR analysis showed the expression of AIFL mRNA in all tissues tested, i.e. brain, colon, heart, kidney, liver, lung, muscle, ovary, pancreas, placenta, small intestine, and testis. We developed antibodies against human AIFL using fusion proteins as antigens. The antibodies specifically recognized the antigen and heterologously expressed AIFL proteins. The expression of AIFL proteins in human tissues was also ubiquitous, demonstrated by immunohistochemistry in tissue array slides. Subcellular fractionation and immunofluorescence staining studies revealed that AIFL is predominantly localized to the mitochondria. Similar to AIF, overexpression of AIFL induced apoptosis, as shown by increased cytoplasmic nucleosomes and subdiploid cell populations in AIFL-transfected cells. The segment 1-190 containing the Rieske domain induced apoptosis, whereas the segment containing the Pyr_redox domain did not contribute to the pro-apoptotic function. The mitochondrial membrane potential of cells transfected with AIFL was significantly more depolarized than that of the control. AIFL transfection-induced cytochrome c release and cleavage of caspase 3. Furthermore, the pan-caspase inhibitor Z-VAD-fmk inhibited AIFL induced apoptosis. In summary, AIFL induces apoptosis in a caspase-dependent manner when heterologously expressed.	Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA; Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Urol Surg, Guangzhou 510120, Peoples R China	University of Southern California; Indiana University System; Indiana University Bloomington; Sun Yat Sen University	Zheng, JP (corresponding author), Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.	jianping@usc.edu; jbonanno@indiana.edu			NATIONAL EYE INSTITUTE [R01EY008834] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008834-13, R01 EY008834] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adams JM, 2002, CURR OPIN CELL BIOL, V14, P715, DOI 10.1016/S0955-0674(02)00381-2; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; Brdiczka D, 1998, BIOFACTORS, V8, P235, DOI 10.1002/biof.5520080311; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DARZYNKIEWICZ Z, 1999, APOPTOSIS PRACTICAL, P63; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Guda C, 2004, BIOINFORMATICS, V20, P1785, DOI 10.1093/bioinformatics/bth171; Guda C, 2004, NUCLEIC ACIDS RES, V32, pW372, DOI 10.1093/nar/gkh374; HANSEN TM, 2003, SCI STKE, V193, pPE31; Hatada S, 1997, GENE, V194, P297, DOI 10.1016/S0378-1119(97)00208-4; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Link TA, 1999, ADV INORG CHEM, V47, P83, DOI 10.1016/S0898-8838(08)60077-X; Lipton SA, 2002, CELL, V111, P147, DOI 10.1016/S0092-8674(02)01046-2; Liu MQ, 2000, J BIOL CHEM, V275, P29400, DOI 10.1074/jbc.M002173200; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Milon L, 2000, J BIOL CHEM, V275, P14264, DOI 10.1074/jbc.275.19.14264; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Ohiro Y, 2002, FEBS LETT, V524, P163, DOI 10.1016/S0014-5793(02)03049-1; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; RANALLI M, 2003, CELL PROLIFERATION A, P340; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Sun XC, 2000, AM J PHYSIOL-CELL PH, V279, pC1648, DOI 10.1152/ajpcell.2000.279.5.C1648; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Valgardsdottir R, 2004, EXP CELL RES, V299, P294, DOI 10.1016/j.yexcr.2004.05.019; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wu M, 2004, ONCOGENE, V23, P6815, DOI 10.1038/sj.onc.1207909; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhang JH, 1997, GENOME RES, V7, P649, DOI 10.1101/gr.7.6.649; Zheng JP, 1997, AM J PATHOL, V150, P2009; Zhu H, 2004, J BIOL CHEM, V279, P30316, DOI 10.1074/jbc.M402664200	66	49	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19673	19681		10.1074/jbc.M409517200	http://dx.doi.org/10.1074/jbc.M409517200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15764604	hybrid			2022-12-25	WOS:000229113700032
J	Bhatia, B; Tang, SH; Yang, PY; Doll, A; Aumueller, G; Newman, RA; Tang, DG				Bhatia, B; Tang, SH; Yang, PY; Doll, A; Aumueller, G; Newman, RA; Tang, DG			Cell-autonomous induction of functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) contributes to replicative senescence of human prostate progenitor cells	ONCOGENE			English	Article						15-lipoxygenase 2; replicative cell senescence; stem cells; prostate progenitor cells; cell cycle; gene regulation	OLIGODENDROCYTE PRECURSOR CELLS; EPITHELIAL STEM-CELLS; BASAL-CELLS; IN-VITRO; EXPRESSION; CULTURE; CANCER; 15S-LIPOXYGENASE; IDENTIFICATION; HYPERPLASIA	Normal human prostatic (NHP) epithelial cells undergo senescence in vitro and in vivo, but little is known about the tissue-specific molecular mechanisms. Here we first characterize young primary NHP cells as CK5(+)/CK18(+) intermediate basal cells that also express several other putative stem/progenitor cell markers including p63, CD44, alpha 2 beta 1, and hTERT. When cultured in serum- and androgen-free medium, NHP cells gradually lose the expression of these markers, slow down in proliferation, and enter senescence. Several pieces of evidence implicate 15-lipoxygenase 2 (15-LOX2), a molecule with a restricted tissue expression and most abundantly expressed in adult human prostate, in the replicative senescence of NHP cells. First, the 15-LOX2 promoter activity and the mRNA and protein levels of 15-LOX2 and its multiple splice variants are upregulated in serially passaged NHP cells, which precede replicative senescence and occur in a cell-autonomous manner. Second, all immortalized prostate epithelial cells and prostate cancer cells do not express 15-LOX2. Third, PCa cells stably transfected with 15-LOX2 or 15-LOX2sv-b, a splice variant that does not possess arachidonate-metabolizing activity, show a passage-related senescence-like phenotype. Fourth, infection of early-passage NHP cells with retroviral vectors encoding 15-LOX2 or 15-LOX2sv-b induces partial cell-cycle arrest and big and. at senescence-like phenotype. Finally, 15-LOX2 protein expression in human prostate correlates with age. Together, these data suggest that 15-LOX2 may represent an endogenous prostate senescence gene and its tumor-suppressing functions might be associated with its ability to induce cell senescence.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Marburg, Dept Anat & Cell Biol, D-3550 Marburg, Germany	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Philipps University Marburg	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, 1808 Pk Rd 1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020; Doll, Andreas/I-1449-2012	Tang, Dean/0000-0001-5029-1174; Doll, Andreas/0000-0001-8965-8682	NATIONAL CANCER INSTITUTE [P01CA106451, R01CA090297, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023374] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA106451, CA90297, CA16672] Funding Source: Medline; NIA NIH HHS [AG023374] Funding Source: Medline; NIEHS NIH HHS [P50 ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhatia B, 2003, J BIOL CHEM, V278, P25091, DOI 10.1074/jbc.M301920200; BONKHOFF H, 1994, PROSTATE, V24, P42; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Castro P, 2003, PROSTATE, V55, P30, DOI 10.1002/pros.10204; Choi J, 2000, UROLOGY, V56, P160, DOI 10.1016/S0090-4295(00)00538-0; Collins AT, 2001, J CELL SCI, V114, P3865; Cristofalo VJ, 1998, P NATL ACAD SCI USA, V95, P10614, DOI 10.1073/pnas.95.18.10614; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Garraway LA, 2003, PROSTATE, V55, P206, DOI 10.1002/pros.10244; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Hudson DL, 2000, LAB INVEST, V80, P1243, DOI 10.1038/labinvest.3780132; Jarrard DF, 1999, CANCER RES, V59, P2957; Kilty I, 1999, EUR J BIOCHEM, V266, P83, DOI 10.1046/j.1432-1327.1999.00818.x; Kinbara H, 1996, PROSTATE, V29, P107; Kuhn H, 1999, ADV EXP MED BIOL, V447, P5; Liu AY, 1997, P NATL ACAD SCI USA, V94, P10705, DOI 10.1073/pnas.94.20.10705; Raff M, 2003, ANNU REV CELL DEV BI, V19, P1, DOI 10.1146/annurev.cellbio.19.111301.143037; RICHARDSON GD, 2004, J CELL SCI      0629; Robinson EJ, 1998, PROSTATE, V37, P149, DOI 10.1002/(SICI)1097-0045(19981101)37:3<149::AID-PROS4>3.0.CO;2-E; Ruijter E, 1999, ENDOCR REV, V20, P22, DOI 10.1210/er.20.1.22; Sandhu C, 2000, CANCER RES, V60, P2616; Schalken JA, 2003, UROLOGY, V62, P11, DOI 10.1016/S0090-4295(03)00758-1; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schwarze SR, 2001, ONCOGENE, V20, P8184, DOI 10.1038/sj.onc.1205049; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shou JY, 2001, CANCER RES, V61, P7291; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Tang DG, 2000, J CELL BIOL, V148, P971, DOI 10.1083/jcb.148.5.971; Tang DG, 2001, SCIENCE, V291, P868, DOI 10.1126/science.1056780; Tang SH, 2004, ONCOGENE, V23, P6942, DOI 10.1038/sj.onc.1207913; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; Tran CP, 2002, MOL CANCER RES, V1, P113; Untergasser G, 2002, CANCER RES, V62, P6255; van Leenders G, 2000, LAB INVEST, V80, P1251, DOI 10.1038/labinvest.3780133; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5	37	45	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3583	3595		10.1038/sj.onc.1208406	http://dx.doi.org/10.1038/sj.onc.1208406			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15750631				2022-12-25	WOS:000229221800006
J	Barnich, N; Hisamatsu, T; Aguirre, JE; Xavier, R; Reinecker, HC; Podolsky, DK				Barnich, N; Hisamatsu, T; Aguirre, JE; Xavier, R; Reinecker, HC; Podolsky, DK			GRIM-19 interacts with nucleotide oligomerization domain 2 and serves as downstream effector of anti-bacterial function in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACID-ACTIVATED REGULATOR; CROHNS-DISEASE; INNATE IMMUNITY; NADPH OXIDASE; FAMILY-MEMBER; GENE-PRODUCT; IFN-BETA; NOD2; DEATH	Nucleotide oligomerization domain 2 (NOD2) functions as a mammalian cytosolic pathogen recognition molecule, and variants have been associated with risk for Crohn disease. We recently demonstrated that NOD2 functions as an anti-bacterial factor limiting survival of intracellular invasive bacteria. To gain further insight into the mechanism of NOD2 activation and signal transduction, we performed yeast two-hybrid screening. We demonstrate that GRIM-19, a protein with homology to the NADPH dehydrogenase complex, interacts with endogenous NOD2 in HT29 cells. GRIM-19 is required for NF-kappa B activation following NOD2-mediated recognition of bacterial muramyl dipeptide. GRIM-19 also controls pathogen invasion of intestinal epithelial cells. GRIM-19 expression is decreased in inflamed mucosa of patients with inflammatory bowel diseases. GRIM-19 may be a key component in NOD2-mediated innate mucosal responses and serve to regulate intestinal epithelial cell responses to microbes.	Massachusetts Gen Hosp, Gastrointestinal Unit, Dept Med, Ctr Inflammatory Bowel Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Podolsky, DK (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, Dept Med, Ctr Inflammatory Bowel Dis, 55 Fruit St, Boston, MA 02114 USA.	dpodolsky@partners.org		Barnich, Nicolas/0000-0001-9465-7844	NIDDK NIH HHS [DK07191, R01 DK060049, DK43351, DK60049] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007191, P30DK043351, R01DK060049] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; Athman R, 2004, CURR OPIN MICROBIOL, V7, P25, DOI 10.1016/j.mib.2003.12.013; Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CM, 2004, J BIOL CHEM, V279, P25876, DOI 10.1074/jbc.M400682200; Chidambaram NV, 2000, J INTERF CYTOK RES, V20, P661, DOI 10.1089/107999000414844; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Elson CO, 2000, GASTROENTEROLOGY, V119, P254, DOI 10.1053/gast.2000.9159; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Hu JD, 2002, J INTERF CYTOK RES, V22, P1017, DOI 10.1089/107999002760624242; Huang GC, 2004, MOL CELL BIOL, V24, P8447, DOI 10.1128/MCB.24.19.8447-8456.2004; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Jarvelainen HA, 2003, TRENDS CELL BIOL, V13, P204, DOI 10.1016/S0962-8924(03)00032-1; Kawahara T, 2001, INFECT IMMUN, V69, P4382, DOI 10.1128/IAI.69.7.4382-4389.2001; Kim JM, 1998, J CLIN INVEST, V102, P1815, DOI 10.1172/JCI2466; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Opitz B, 2004, J BIOL CHEM, V279, P36426, DOI 10.1074/jbc.M403861200; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Shanahan F, 2002, LANCET, V359, P62, DOI 10.1016/S0140-6736(02)07284-7; Teshima S, 1999, FEBS LETT, V452, P243, DOI 10.1016/S0014-5793(99)00636-5; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; Zhang XW, 2004, CANCER RES, V64, P2474, DOI 10.1158/0008-5472.CAN-03-3443	34	107	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19021	19026		10.1074/jbc.M413776200	http://dx.doi.org/10.1074/jbc.M413776200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753091	hybrid			2022-12-25	WOS:000228932300057
J	Cowan, JW; Wang, XD; Guan, R; He, K; Jiang, J; Baumann, G; Black, RA; Wolfe, MS; Frank, SJ				Cowan, JW; Wang, XD; Guan, R; He, K; Jiang, J; Baumann, G; Black, RA; Wolfe, MS; Frank, SJ			Growth hormone receptor is a target for presenilin-dependent gamma-secretase cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED INTRAMEMBRANE PROTEOLYSIS; UBIQUITIN-PROTEASOME PATHWAY; P75 NEUROTROPHIN RECEPTOR; AMYLOID PRECURSOR PROTEIN; JAK2 TYROSINE KINASE; BINDING-PROTEIN; GH RECEPTOR; INTRACELLULAR DOMAIN; CYTOPLASMIC DOMAIN; DISULFIDE LINKAGE	Growth hormone receptor (GHR) is a cytokine receptor superfamily member that binds growth hormone (GH) via its extracellular domain and signals via interaction of its cytoplasmic domain with JAK2 and other signaling molecules. GHR is a target for inducible metalloprotease-mediated cleavage in its perimembranous extracellular domain, a process that liberates the extracellular domain as the soluble GH-binding protein and leaves behind a cell-associated GHR remnant protein containing the transmembrane and cytoplasmic domains. GHR metalloproteolysis can be catalyzed by tumor necrosis factor-alpha-converting enzyme (ADAM-17) and is associated with down-modulation of GH signaling. We now study the fate of the GHR remnant protein. By anti-GHR cytoplasmic domain immunoblotting, we observed that the remnant induced in response to phorbol ester or platelet-derived growth factor has a reliable pattern of appearance and disappearance in both mouse preadipocytes endogenously expressing GHR and transfected fibroblasts expressing rabbit GHR. Lactacystin, a specific proteasome inhibitor, did not appreciably change the time course of remnant appearance or clearance but allowed detection of the GHR stub, a receptor fragment slightly smaller than the remnant but containing the C terminus of the remnant (receptor cytoplasmic domain). In contrast, MG132, another (less specific) proteasome inhibitor, strongly inhibited remnant clearance and prevented stub appearance. Inhibitors of gamma-secretase, an aspartyl protease, also prevented the appearance of the stub, even in the presence of lactacystin, and concomitantly inhibited remnant clearance in the same fashion as MG132. In addition, mouse embryonic fibroblasts derived from presenilin 1 and 2 (PS1/2) knockouts recapitulated the gamma-secretase inhibitor studies, as compared with their littermate controls (PS1/2 wild type). Confocal microscopy indicated that the GHR cytoplasmic domain became localized to the nucleus in a fashion dependent on PS1/2 activity. These data indicate that the GHR is subject to sequential proteolysis by metalloprotease and gamma-secretase activities and may suggest GH-independent roles for the GHR.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA; Northwestern Univ, Sch Med, Dept Med, Ctr Endocrinol Metan & Mol Med, Chicago, IL 60611 USA; Vet Adm Chicago Hlth Syst, Lakeside Div, Chicago, IL 60611 USA; Amgen Inc, Seattle, WA 98101 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Vet Affairs Med Ctr, Endocrinol Sect, Med Serv, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Northwestern University; Amgen; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Frank, SJ (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, 1530 3rd Ave S,BDB 861, Birmingham, AL 35294 USA.	sjfrank@uab.edu	He, Kai/AHB-3118-2022	He, Kai/0000-0002-4378-9297	NIDDK NIH HHS [DK58259, DK46395] Funding Source: Medline; NIGMS NIH HHS [T-32 GM08111] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046395, R56DK046395, R56DK058259, R01DK058259, R01DK046395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008111] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alele J, 1998, ENDOCRINOLOGY, V139, P1927, DOI 10.1210/en.139.4.1927; ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; Amit T, 2001, J ENDOCRINOL, V169, P397, DOI 10.1677/joe.0.1690397; Amit T, 1996, ENDOCRINOLOGY, V137, P3986, DOI 10.1210/en.137.9.3986; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Baumann G, 2001, J PEDIATR ENDOCR MET, V14, P355; Bick T, 1996, ENDOCRINOLOGY, V137, P3977, DOI 10.1210/en.137.9.3977; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; DISTEFANO PS, 1993, J NEUROSCI, V13, P2405, DOI 10.1523/JNEUROSCI.13-06-02405.1993; dos Santos CMA, 2001, J BIOL CHEM, V276, P10839, DOI 10.1074/jbc.M003635200; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P148, DOI 10.1210/en.135.1.148; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Gebert CA, 1999, MOL ENDOCRINOL, V13, P38, DOI 10.1210/me.13.1.38; Goh ELK, 2002, ENDOCRINOLOGY, V143, P3590, DOI 10.1210/en.2002-220374; Goldsmith JF, 1997, AM J PHYSIOL-ENDOC M, V273, pE932, DOI 10.1152/ajpendo.1997.273.5.E932; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Gowrishankar K, 2004, J CELL SCI, V117, P4099, DOI 10.1242/jcs.01263; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Guan R, 2001, ENDOCRINOLOGY, V142, P1137, DOI 10.1210/en.142.3.1137; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HARLOW E, 1988, ANTIBODIES LAB MANUA, P632; HARRISON SM, 1995, ENDOCRINOLOGY, V136, P651, DOI 10.1210/en.136.2.651; He K, 2003, MOL ENDOCRINOL, V17, P2211, DOI 10.1210/me.2003-0256; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Jiang J, 2004, MOL ENDOCRINOL, V18, P2981, DOI 10.1210/me.2004-0102; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; Kanning KC, 2003, J NEUROSCI, V23, P5425, DOI 10.1523/jneurosci.23-13-05425.2003; Kim SO, 2002, ENDOCRINOLOGY, V143, P4856, DOI 10.1210/en.2002-220565; Kim SO, 1999, J BIOL CHEM, V274, P36015, DOI 10.1074/jbc.274.50.36015; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; LARON Z, 1995, J CLIN ENDOCR METAB, V80, P1426; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOBIE PE, 1994, J BIOL CHEM, V269, P31735; Lu CX, 2001, J BIOL CHEM, V276, P22892, DOI 10.1074/jbc.M011647200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Martini JF, 1997, J BIOL CHEM, V272, P18951, DOI 10.1074/jbc.272.30.18951; MASSA G, 1993, ACTA ENDOCRINOL-COP, V129, P559, DOI 10.1530/acta.0.1290559; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; MCGUFFIN WL, 1976, ENDOCRINOLOGY, V98, P1400; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moulin S, 2003, CELL SIGNAL, V15, P47, DOI 10.1016/S0898-6568(02)00054-2; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; MULLIS PE, 1995, MOL CELL ENDOCRINOL, V111, P181, DOI 10.1016/0303-7207(95)03567-Q; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Parks JS, 1997, J PEDIATR-US, V131, pS45, DOI 10.1016/S0022-3476(97)70011-8; RANK SJ, 2002, CYTOKINE REFERENCE O; SAITO Y, 1995, J BIOCHEM, V118, P521, DOI 10.1093/oxfordjournals.jbchem.a124939; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; SOTIROPOULOS A, 1993, ENDOCRINOLOGY, V132, P1863, DOI 10.1210/en.132.4.1863; Strous GJ, 2002, MOL CELL ENDOCRINOL, V197, P143, DOI 10.1016/S0303-7207(02)00258-7; SU CC, 1996, ANNU REV PHYSIOL, V58, P187; Takagi K, 2001, MOL CELL ENDOCRINOL, V182, P157, DOI 10.1016/S0303-7207(01)00583-4; Takagi K, 2001, BIOL PHARM BULL, V24, P744, DOI 10.1248/bpb.24.744; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TRIVEDI B, 1988, ENDOCRINOLOGY, V123, P2201, DOI 10.1210/endo-123-5-2201; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; van Kerkhof P, 2003, MOL CELL ENDOCRINOL, V201, P57, DOI 10.1016/S0303-7207(02)00434-3; van Kerkhof P, 2002, ENDOCRINOLOGY, V143, P1243, DOI 10.1210/en.143.4.1243; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; Wallace TA, 2004, AM J PHYSIOL-CELL PH, V287, pC981, DOI 10.1152/ajpcell.00085.2004; Wang XD, 2003, MOL ENDOCRINOL, V17, P1931, DOI 10.1210/me.2003-0120; Wang XD, 2002, J BIOL CHEM, V277, P50510, DOI 10.1074/jbc.M208738200; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Yarwood SJ, 1999, J BIOL CHEM, V274, P8662, DOI 10.1074/jbc.274.13.8662; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; Zhang LL, 1999, J BIOL CHEM, V274, P8966, DOI 10.1074/jbc.274.13.8966; Zhang Y, 2001, J BIOL CHEM, V276, P24565, DOI 10.1074/jbc.M101281200; Zhang Y, 1999, J BIOL CHEM, V274, P33072, DOI 10.1074/jbc.274.46.33072; Zhang Y, 2000, ENDOCRINOLOGY, V141, P4342, DOI 10.1210/en.141.12.4342; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200; Zhou YH, 1997, P NATL ACAD SCI USA, V94, P13215, DOI 10.1073/pnas.94.24.13215	91	57	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19331	19342		10.1074/jbc.M500621200	http://dx.doi.org/10.1074/jbc.M500621200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15743767	hybrid			2022-12-25	WOS:000228932300090
J	Komander, D; Kular, G; Deak, M; Alessi, DR; van Aalten, DMF				Komander, D; Kular, G; Deak, M; Alessi, DR; van Aalten, DMF			Role of T-loop phosphorylation in PDK1 activation, stability, and substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; S6 KINASE; IDENTIFICATION; MECHANISM; DOMAIN; POCKET; CRYSTALLOGRAPHY; ANGSTROM	3-Phosphoinositide-dependent protein kinase-1 (PDK1) phosphorylates the T-loop of several AGC (cAMP-dependent, cGMP-dependent, protein kinase C) family protein kinases, resulting in their activation. Previous structural studies have revealed that the alpha C-helix, located in the small lobe of the kinase domain of PDK1, is a key regulatory element, as it links a substrate interacting site termed the hydrophobic motif (HM) pocket with the phosphorylated Ser-241 in the T-loop. In this study we have demonstrated by mutational analysis that interactions between the phosphorylated Ser-241 and the alpha C-helix are not required for PDK1 activity or substrate binding through the HM-pocket but are necessary for PDK1 to be activated or stabilized by a peptide that binds to this site. The structure of an inactive T-loop mutant of PDK1, in which Ser-241 is changed to Ala, was also determined. This structure, together with surface plasmon resonance binding studies, demonstrates that the PDK1(S241A)-inactive mutant possesses an intact HM-pocket as well as an ordered alpha C-helix. These findings reveal that the integrity of the alpha C-helix and HM-pocket in PDK1 is not regulated by T-loop phosphorylation.	Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee, Scotland; Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee, Scotland	University of Dundee; University of Dundee	Komander, D (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, 237 Fulham Rd, London SW3 6JB, England.	david.komander@icr.ac.uk; dava@davapc1.bioch.dundee.ac.uk		Alessi, Dario/0000-0002-2140-9185; van Aalten, Daan/0000-0002-1499-6908	MRC [MC_U127015387] Funding Source: UKRI; Medical Research Council [MC_U127015387] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Cox S, 1995, BIOCHEMISTRY-US, V34, P16203, DOI 10.1021/bi00049a036; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fuse E, 1999, CANCER RES, V59, P1054; George S, 2004, SCIENCE, V304, P1325, DOI 10.1126/science.1096706; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Gibson RM, 1997, PROTEIN SCI, V6, P1825, DOI 10.1002/pro.5560060903; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Komander D, 2004, EMBO J, V23, P3918, DOI 10.1038/sj.emboj.7600379; Lang F, 2001, Sci STKE, V2001, pre17, DOI 10.1126/stke.2001.108.re17; Leon BC, 2001, BIOCHEMISTRY-US, V40, P10078, DOI 10.1021/bi010838e; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Skamnaki VT, 1999, BIOCHEMISTRY-US, V38, P14718, DOI 10.1021/bi991454f; Smith KJ, 2004, STRUCTURE, V12, P1067, DOI 10.1016/j.str.2004.02.040; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Wick MJ, 2003, J BIOL CHEM, V278, P42913, DOI 10.1074/jbc.M304172200; Xu ZB, 2004, J BIOL CHEM, V279, P50401, DOI 10.1074/jbc.M409216200; Yang J, 2004, J MOL BIOL, V336, P473, DOI 10.1016/j.jmb.2003.11.044; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6	47	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18797	18802		10.1074/jbc.M500977200	http://dx.doi.org/10.1074/jbc.M500977200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15741170	hybrid			2022-12-25	WOS:000228932300031
J	Maeda, A; Maeda, T; Imanishi, Y; Kuksa, V; Alekseev, A; Bronson, JD; Zhang, HB; Zhu, L; Sun, WY; Saperstein, DA; Rieke, F; Baehr, W; Palczewski, K				Maeda, A; Maeda, T; Imanishi, Y; Kuksa, V; Alekseev, A; Bronson, JD; Zhang, HB; Zhu, L; Sun, WY; Saperstein, DA; Rieke, F; Baehr, W; Palczewski, K			Role of photoreceptor-specific retinol dehydrogenase in the retinoid cycle in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; STARGARDT MACULAR DYSTROPHY; LEBER CONGENITAL AMAUROSIS; ROD OUTER SEGMENTS; ALL-TRANS-RETINOL; VERTEBRATE RETINA; SUBSTRATE-SPECIFICITY; PIGMENT EPITHELIUM; METARHODOPSIN-II; VISUAL PIGMENT	The retinoid cycle is a recycling system that replenishes the 11-cis-retinal chromophore of rhodopsin and cone pigments. Photoreceptor-specific retinol dehydrogenase (prRDH) catalyzes reduction of all-trans-retinal to all-trans-retinol and is thought to be a key enzyme in the retinoid cycle. We disrupted mouse prRDH ( human gene symbol RDH8) gene expression by targeted recombination and generated a homozygous prRDH knock-out (prRDH-/-) mouse. Histological analysis and electron microscopy of retinas from 6- to 8-week-old prRDH-/- mice revealed no structural differences of the photoreceptors or inner retina. For brief light exposure, absence of prRDH did not affect the rate of 11-cis-retinal regeneration or the decay of Meta II, the activated form of rhodopsin. Absence of prRDH, however, caused significant accumulation of all-trans-retinal following exposure to bright lights and delayed recovery of rod function as measured by electroretinograms and single cell recordings. Retention of all-trans-retinal resulted in slight overproduction of A2E, a condensation product of all-trans-retinal and phosphatidylethanolamine. We conclude that prRDH is an enzyme that catalyzes reduction of all-trans-retinal in the rod outer segment, most noticeably at higher light intensities and prolonged illumination, but is not an essential enzyme of the retinoid cycle.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Neurobiol & Anat, Salt Lake City, UT 84112 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu	Imanishi, Yoshikazu/E-8178-2010; Zhang, Houbin/A-8887-2012	Imanishi, Yoshikazu/0000-0003-4696-4836; Zhang, Houbin/0000-0002-2968-7454	NATIONAL EYE INSTITUTE [R01EY013385, R29EY008061, R01EY008061, R01EY011850, R01EY008123] Funding Source: NIH RePORTER; NEI NIH HHS [EY11850, EY13385, R01 EY008123, R01 EY013385, EY08123, EY08061, R01 EY008061, R01 EY011850] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; Ahn J, 2000, METHOD ENZYMOL, V315, P864; Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; ALPERN M, 1971, J PHYSIOL-LONDON, V217, P447, DOI 10.1113/jphysiol.1971.sp009580; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BONDS AB, 1974, J PHYSIOL-LONDON, V242, P237, DOI 10.1113/jphysiol.1974.sp010704; BRETON ME, 1994, INVEST OPHTH VIS SCI, V35, P295; Buczylko J, 1996, J BIOL CHEM, V271, P20621, DOI 10.1074/jbc.271.34.20621; CICERONE CM, 1981, J PHYSIOL-LONDON, V314, P213, DOI 10.1113/jphysiol.1981.sp013702; Cideciyan AV, 2000, VISUAL NEUROSCI, V17, P667, DOI 10.1017/S0952523800175029; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; ELDRED GE, 1993, NATURE, V364, P396; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Field GD, 2002, NEURON, V35, P733, DOI 10.1016/S0896-6273(02)00822-X; Field GD, 2002, NEURON, V34, P773, DOI 10.1016/S0896-6273(02)00700-6; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Fishman GA, 2004, ARCH OPHTHALMOL-CHIC, V122, P70, DOI 10.1001/archopht.122.1.70; Haeseleer F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/jbc.M208882200; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; Han W, 2004, J HUM GENET, V49, P16, DOI 10.1007/s10038-003-0100-9; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Hetling JR, 1999, J PHYSIOL-LONDON, V516, P593, DOI 10.1111/j.1469-7793.1999.0593v.x; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; Janecke AR, 2004, NAT GENET, V36, P850, DOI 10.1038/ng1394; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; Jang GF, 2000, J BIOL CHEM, V275, P28128; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kim TS, 2005, J BIOL CHEM, V280, P8694, DOI 10.1074/jbc.M413172200; Kuksa V, 2003, VISION RES, V43, P2959, DOI 10.1016/S0042-6989(03)00482-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199; Luo WQ, 2004, J NEUROSCI, V24, P2623, DOI 10.1523/JNEUROSCI.5302-03.2004; Maeda T, 2003, J NEUROCHEM, V85, P944, DOI 10.1046/j.1471-4159.2003.01741.x; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; PERLMAN I, 1978, J PHYSIOL-LONDON, V278, P141, DOI 10.1113/jphysiol.1978.sp012297; Perrault I, 2004, AM J HUM GENET, V75, P639, DOI 10.1086/424889; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Rattner A, 2004, J BIOL CHEM, V279, P42202, DOI 10.1074/jbc.M407928200; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Zhu L, 2004, J BIOL CHEM, V279, P53828, DOI 10.1074/jbc.M408472200	58	121	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18822	18832		10.1074/jbc.M501757200	http://dx.doi.org/10.1074/jbc.M501757200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755727	Green Accepted, hybrid			2022-12-25	WOS:000228932300034
J	Neutzner, A; Youle, RJ				Neutzner, A; Youle, RJ			Instability of the mitofusin Fzo1 regulates mitochondrial morphology during the mating response of the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; FUSION-COMPETENT MITOCHONDRIA; PROGRAMMED CELL-DEATH; SHUTTLE VECTORS; FISSION; PROTEIN; APOPTOSIS; EXPRESSION; MAINTENANCE; SPORULATION	Mitochondria form a highly dynamic network that is shaped by continuous fission and fusion of these organelles. In the yeast Saccharomyces cerevisiae two machineries are involved in this process, one of which includes the mitochondrial fusion promoting GTPase Fzo1. Although a role for the F-box protein Mdm30 in regulating the stability of Fzo1 has been proposed, the molecular basis for the regulation of the fission to fusion ratio of mitochondria remains unknown. To discern the mechanism of the regulation of mitochondrial morphology, we arrested cells at different stages of the cell cycle and examined mitochondrial morphology as well as the stability of mitochondrial fission and fusion proteins. In response to a G(1) arrest evoked by the mating pheromone alpha factor the mitochondrial network fragmented into small pieces, which was accompanied by dramatic down-regulation of Fzo1. Mating pheromone also triggered the degradation of Fzo1 produced under the control of a constitutive promoter, and Fzo1 was stabilized upon proteasome inhibition, indicating a role for the proteasome system in the degradation of Fzo1. However, deletion of MDM30 did not stabilize Fzo1 after mating pheromone treatment, showing a different mechanism from the previously reported process of steady state Fzo1 regulation. We show an example for a regulated change of the mitochondrial fission to fusion ratio during the life cycle of budding yeast. Proteasomal degradation of Fzo1 in response to the mating pheromone is proposed to mediate the remodeling of the mitochondrial network during the process of mating.	NINDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Youle, RJ (corresponding author), NINDS, Biochem Sect, Surg Neurol Branch, NIH, 35 Convent Dr, Bethesda, MD 20892 USA.	youler@ninds.nih.gov	Neutzner, Albert/ABC-4368-2020	Neutzner, Albert/0000-0001-9254-5558	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002859, Z01NS002859] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; Elion EA, 2000, CURR OPIN MICROBIOL, V3, P573, DOI 10.1016/S1369-5274(00)00143-0; Fannjiang Y, 2004, GENE DEV, V18, P2785, DOI 10.1101/gad.1247904; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Fritz S, 2003, MOL BIOL CELL, V14, P2303, DOI 10.1091/mbc.E02-12-0831; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gorsich SW, 2004, MOL BIOL CELL, V15, P4369, DOI 10.1091/mbc.E03-12-0875; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Hwa JJ, 2002, MECH DEVELOP, V116, P213, DOI 10.1016/S0925-4773(02)00141-7; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Jensen RE, 2000, MICROSC RES TECHNIQ, V51, P573, DOI 10.1002/1097-0029(20001215)51:6<573::AID-JEMT7>3.0.CO;2-2; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Kawano S, 1995, INT REV CYTOL, V161, P49; Kimata Y, 2000, J BIOL CHEM, V275, P10655, DOI 10.1074/jbc.275.14.10655; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; MIYAKAWA I, 1984, J CELL SCI, V66, P21; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Santel A, 2001, J CELL SCI, V114, P867; Scott SV, 2003, CURR OPIN CELL BIOL, V15, P482, DOI 10.1016/S0955-0674(03)00070-X; Sesaki H, 2001, J CELL BIOL, V152, P1123, DOI 10.1083/jcb.152.6.1123; Severin FF, 2002, CURR BIOL, V12, pR233, DOI 10.1016/S0960-9822(02)00776-5; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; SIKORSKI RS, 1989, GENETICS, V122, P19; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	35	81	84	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18598	18603		10.1074/jbc.M500807200	http://dx.doi.org/10.1074/jbc.M500807200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15760898	hybrid			2022-12-25	WOS:000228932300008
J	Dunn, KL; Davie, JR				Dunn, KL; Davie, JR			Stimulation of the Ras-MAPK pathway leads to independent phosphorylation of histone H3 on serine 10 and 28	ONCOGENE			English	Article						histone phosphorylation; H3 variants; Rasmitogen activated protein kinase signal transduction pathway	TRANSFORMED MOUSE FIBROBLASTS; EARLY GENE INDUCTION; H3 PHOSPHORYLATION; CHROMOSOME CONDENSATION; SER-10 PHOSPHORYLATION; ACTIVE CHROMATIN; TRANSCRIPTION; ACETYLATION; MEDIATE; KINASE	The Ras-mitogen activated protein kinase (Ras-MAPK) pathway plays an integral role in the formation of human malignancies. Stimulation of this pathway results in phosphorylation of histone H3 at serines 10 and 28 and expression of immediate-early genes. Phosphorylated (serine 10) H3, which is also acetylated on lysine 14, is associated with immediate-early genes. In this report, we investigated the relationship between these two H3 phosphorylation events in parental and ras-transformed fibroblasts. Immunoblot analyses of two-dimensional gel patterns demonstrated that all three H3 variants were phosphorylated after stimulation of the Ras-MAPK pathway and during mitosis. Following stimulation of the Ras-MAPK pathway, H3 phosphorylated on serines 10 and 28 was excluded from regions of highly condensed chromatin and was present in increased levels in ras-transformed cells. Although H3 phosphorylated at serine 10 or 28 was dynamically acetylated, H3 phosphorylated at serine 28 had a higher steady state of acetylation than that of H3 phosphorylated at serine 10. When visualized with indirect immunofluorescence, most foci of phosphorylated serine 28 H3 did not co-localize with foci of H3 phosphorylated on serine 10 or phosphoacetylated on serine 10 and lysine 14, suggesting that these two phosphorylation events act separately to promote gene expression.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada	University of Manitoba	Davie, JR (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	davie@cc.umanitoba.ca		Davie, James/0000-0002-0420-6888				Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Clayton AL, 2003, FEBS LETT, V546, P51, DOI 10.1016/S0014-5793(03)00451-4; DAVIE JR, 2003, SCI STKE, V195, pPE33; Dimitrov SI, 1997, METHODS, V12, P57, DOI 10.1006/meth.1997.0447; Drobic B, 2004, CANCER RES, V64, P9076, DOI 10.1158/0008-5472.CAN-04-2369; Edmunds JW, 2004, J CELL SCI, V117, P3715, DOI 10.1242/jcs.01346; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; ESPINO P, 2005, IN PRESS J CELL BIOC; Fischer AH, 1998, J CELL BIOCHEM, V70, P130, DOI 10.1002/(SICI)1097-4644(19980701)70:1<130::AID-JCB13>3.3.CO;2-8; HENDZEL MJ, 1990, BIOCHEM J, V271, P67, DOI 10.1042/bj2710067; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Henikoff S, 2004, TRENDS GENET, V20, P320, DOI 10.1016/j.tig.2004.05.004; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; LAITINEN J, 1990, J CELL BIOL, V111, P9, DOI 10.1083/jcb.111.1.9; Lim JH, 2004, MOL CELL, V15, P573, DOI 10.1016/j.molcel.2004.08.006; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; RIDSDALE JA, 1987, NUCLEIC ACIDS RES, V15, P1081, DOI 10.1093/nar/15.3.1081; Samuel SK, 1997, CANCER RES, V57, P147; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Strelkov IS, 2002, CANCER RES, V62, P75; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Taylor WR, 1995, FEBS LETT, V377, P51, DOI 10.1016/0014-5793(95)01314-8; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WATERBORG JH, 1993, J BIOL CHEM, V268, P4912; Workman JL, 2004, P NATL ACAD SCI USA, V101, P1429, DOI 10.1073/pnas.0308506101; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200; Zlatanova J, 1998, BIOPHYS J, V74, P2554, DOI 10.1016/S0006-3495(98)77963-9	41	62	68	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3492	3502		10.1038/sj.onc.1208521	http://dx.doi.org/10.1038/sj.onc.1208521			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735677				2022-12-25	WOS:000229038800011
J	Song, ES; Daily, A; Fried, MG; Juliano, MA; Juliano, L; Hersh, LB				Song, ES; Daily, A; Fried, MG; Juliano, MA; Juliano, L; Hersh, LB			Mutation of active site residues of insulin-degrading enzyme alters allosteric interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; ENDOTHELIN-CONVERTING ENZYME; DIRECTED MUTAGENESIS; EXTRACELLULAR LEVELS; MISSENSE MUTATIONS; PLASMA A-BETA-42; MOUSE MODEL; IN-VIVO; DEGRADATION	The active site glutamate (Glu(111)) and the active site histidine (His(112)) of insulin-degrading enzyme (IDE) were mutated. These mutant enzymes exhibit, in addition to a large decrease in catalytic activity, a change in the substrate-velocity response from a sigmoidal one seen with the native enzyme (Hill coefficient >2), to a hyperbolic response. With 2-aminobenzoyl-GGFLRKHGQN-(2,4-dinitrophenyl)ethylenediamine as substrate, ATP and triphosphate increase the reaction rate of the wild type enzyme some 50-80-fold. This effect is dampened with glutamate mutants to no effect or less than a 3-fold increase in activity and changed to inhibition with the histidine mutants. Sedimentation equilibrium shows the IDE mutants exhibit a similar oligomeric distribution as the wild type enzyme, being predominantly monomeric, with triphosphate having little if any effect on the oligomeric state. Triphosphate did induce aggregation of many of the IDE mutants. Thus, the oligomeric state of IDE does not correlate with kinetic properties. The His(112) mutants were shown to bind zinc, but with a lower affinity than the wild type enzyme. The glutamate mutants displayed an altered cleavage profile for the peptide beta-endorphin. Wild type IDE cleaved beta-endorphin at Leu(17)-Phe(18) and Phe(18)-Lys(19), whereas the glutamate mutants cleaved at these sites, but in addition at Lys(19)-Asn(20) and at Met(5)-Thr(6). Thus, active site mutations of IDE are suggested to not only reduce catalytic activity but also cause local conformational changes that affect the allosteric properties of the enzyme.	Univ Kentucky, Dept Mol & Cellular Biochem, Coll Med, Lexington, KY 40536 USA; Escola Paulista Med, Dept Biophys, BR-04023900 Sao Paulo, Brazil	University of Kentucky; Universidade Federal de Sao Paulo (UNIFESP)	Hersh, LB (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, Coll Med, 800 Rose St, Lexington, KY 40536 USA.	lhersh@uky.edu	Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822	NIA NIH HHS [AG19323] Funding Source: Medline; NIDA NIH HHS [DA02243] Funding Source: Medline; NIDDK NIH HHS [DK54289] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Authier F, 1996, CLIN INVEST MED, V19, P149; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; Carson JA, 2002, J NEUROCHEM, V81, P1, DOI 10.1046/j.1471-4159.2002.00855.x; Cha J, 1997, BIOCHEMISTRY-US, V36, P16019, DOI 10.1021/bi972223g; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Csuhai E, 1999, ANAL BIOCHEM, V269, P149, DOI 10.1006/abio.1999.4033; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; Eckman EA, 2001, J BIOL CHEM, V276, P24540, DOI 10.1074/jbc.M007579200; Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200; Ertekin-Taner N, 2004, HUM MUTAT, V23, P334, DOI 10.1002/humu.20016; Ertekin-Taner N, 2000, SCIENCE, V290, P2303, DOI 10.1126/science.290.5500.2303; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Farris W, 2004, AM J PATHOL, V164, P1425, DOI 10.1016/S0002-9440(10)63229-4; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Hersh LB, 2003, CURR PHARM DESIGN, V9, P449, DOI 10.2174/1381612033391676; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KUBO M, 1992, APPL ENVIRON MICROB, V58, P3779, DOI 10.1128/AEM.58.11.3779-3783.1992; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; Leissring MA, 2003, J BIOL CHEM, V278, P37314, DOI 10.1074/jbc.M305627200; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LI D, 1992, J BIOL CHEM, V267, P2414; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Marr RA, 2004, J MOL NEUROSCI, V22, P5, DOI 10.1385/JMN:22:1-2:5; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Mukherjee A, 2000, J NEUROSCI, V20, P8745; Mukherjee A, 2002, J ALZHEIMERS DIS, V4, P341, DOI 10.3233/JAD-2002-4501; Myers A, 2000, SCIENCE, V290, P2304, DOI 10.1126/science.290.5500.2304; PERLMAN RK, 1994, J BIOL CHEM, V269, P33140; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; Qiu WQ, 1997, J BIOL CHEM, V272, P6641, DOI 10.1074/jbc.272.10.6641; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; Safavi A, 1996, BIOCHEMISTRY-US, V35, P14318, DOI 10.1021/bi960582q; Seta KA, 1997, BIOCHEM BIOPH RES CO, V231, P167, DOI 10.1006/bbrc.1997.6066; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; Song ES, 2004, J BIOL CHEM, V279, P54216, DOI 10.1074/jbc.M411177200; Song ES, 2003, J BIOL CHEM, V278, P49789, DOI 10.1074/jbc.M308983200; STGEORGEHYSLOP PH, 1993, MOL GENETICS ALZHEIM; Thompson MW, 2003, ARCH BIOCHEM BIOPHYS, V413, P236, DOI 10.1016/S0003-9861(03)00123-1; Vazeux G, 1996, J BIOL CHEM, V271, P9069, DOI 10.1074/jbc.271.15.9069; Vekrellis K, 2000, J NEUROSCI, V20, P1657; WETTERHOLM A, 1992, P NATL ACAD SCI USA, V89, P9141, DOI 10.1073/pnas.89.19.9141; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zlokovic BV, 2004, J NEUROCHEM, V89, P807, DOI 10.1111/j.1471-4159.2004.02385.x	51	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17701	17706		10.1074/jbc.M501896200	http://dx.doi.org/10.1074/jbc.M501896200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749695	hybrid			2022-12-25	WOS:000228807200019
J	Chen, CS; Sun, XD; Ran, QM; Wilkinson, KD; Murphy, TJ; Simons, JW; Dong, JT				Chen, CS; Sun, XD; Ran, QM; Wilkinson, KD; Murphy, TJ; Simons, JW; Dong, JT			Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells	ONCOGENE			English	Article						KLF5; degradation; ubiquitin; proteasome; cancer	KRUPPEL-LIKE FACTOR; ELEMENT-BINDING PROTEIN-2; GROWTH FACTOR-A; DEPENDENT DEGRADATION; HUMAN BTEB2; EXPRESSION; SP1; REGULATOR; PHOSPHORYLATION; ACTIVATION	Ubiquitin-mediated proteolysis plays a central role in controlling intracellular levels of essential regulatory molecules such as p53, cyclins, myc, BRCA1, HIF-1 alpha, etc. The Kruppel-like factor 5 (KLF5) transcription factor regulates biological processes involved in carcinogenesis, angiogenesis, and smooth muscle cell differentiation. In carcinogenesis, KLF5's role has been indicated by frequent genetic deletion as well as functional studies. Here we show that KLF5 is an unstable protein with a short half-life. Destruction of KLF5 was prevented by each of the proteasome-specific inhibitors tested but not by an inhibitor for trypsin-like proteases and cysteine proteases or by a lysosome inhibitor in epithelial cells. Furthermore, KLF5 underwent ubiquitination, and deletion of a 56-amino-acid sequence adjacent to a known transactivation domain of KLF5 significantly reduced its ubiquitination and degradation. Interestingly, cancer cells appeared to be more active in KLF5 degradation than untransformed epithelial cells, yet their proteasome activity was not higher. These results suggest that KLF5 protein is degraded at least in part through ubiquitination-proteasome pathway, which may have become hyperactive for KLF5 in cancer cells.	Emory Univ, Sch Med, Winship Canc Ctr, Dept Oncol & Hematol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Urol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Emory University; Emory University	Dong, JT (corresponding author), Emory Univ, Sch Med, Winship Canc Ctr, Dept Oncol & Hematol, 1365-C Clifton Rd, Atlanta, GA 30322 USA.	jdong2@emory.edu		Dong, Jin-Tang/0000-0003-2349-5782	NATIONAL CANCER INSTITUTE [R01CA087921] Funding Source: NIH RePORTER; NCI NIH HHS [CA 87921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen CS, 2004, GENE, V330, P133, DOI 10.1016/j.gene.2004.01.014; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Grinstein E, 2002, ONCOGENE, V21, P1485, DOI 10.1038/sj.onc.1205211; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Kojima S, 1997, J BIOCHEM, V121, P389; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Miyamoto S, 2003, MOL CELL BIOL, V23, P8528, DOI 10.1128/MCB.23.23.8528-8541.2003; Murphy TJ, 2002, METHOD ENZYMOL, V345, P539; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Ogata T, 2000, J THORAC CARDIOV SUR, V119, P983, DOI 10.1016/S0022-5223(00)70093-6; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Taneyhill Lisa, 2004, BMC Developmental Biology, V4; Usui S, 2004, J BIOL CHEM, V279, P12300, DOI 10.1074/jbc.M305025200; Wada Y, 2001, J HEART LUNG TRANSPL, V20, P590, DOI 10.1016/S1053-2498(00)00210-2; Wada Y, 2000, TRANSPLANT P, V32, P1089, DOI 10.1016/S0041-1345(00)01136-2; Zhang XL, 2004, BIOCHEM BIOPH RES CO, V316, P139, DOI 10.1016/j.bbrc.2004.02.033; Zhang ZP, 2003, NUCLEIC ACIDS RES, V31, P2196, DOI 10.1093/nar/gkg310; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	39	112	116	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3319	3327		10.1038/sj.onc.1208497	http://dx.doi.org/10.1038/sj.onc.1208497			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735697				2022-12-25	WOS:000228881800010
J	Minard, ME; Herynk, MH; Collard, JG; Gallick, GE				Minard, ME; Herynk, MH; Collard, JG; Gallick, GE			The guanine nucleotide exchange factor Tiam1 increases colon carcinoma growth at metastatic sites in an orthotopic nude mouse model	ONCOGENE			English	Article						Tiam1; colon carcinoma; migration; metastasis	PLECKSTRIN HOMOLOGY DOMAIN; RENAL-CELL CARCINOMAS; TUMOR PROGRESSION; RAC; INVASION; ACTIVATION; SRC; EXPRESSION; MIGRATION; CANCER	Alterations in migration and adhesion are critical to invasion and metastasis. To examine signaling pathways important for colon tumor metastasis, cells of increased migratory potential from the low migratory SW480 human colorectal carcinoma parental cell line were biologically selected by serial migration through modified Boyden chambers. Several sublines were obtained with statistically significantly increased migration relative to the parental cell line. One highly migratory population was single-cell cloned and characterized. The migratory clones exhibit a four- to five-fold increase in protein and mRNA expression of T-lymphoma invasion and metastasis gene 1 (Tiam1), a guanine nucleotide exchange factor. To determine directly the role of Tiam1 in the migration of these migratory sublines, the parental SW480 cell line was transfected with a plasmid encoding the Tiam1 protein, and single cell clones were established. Ectopic expression of Tiam1 in these clones led to morphologic changes identical to biologically selected clones and increased migration. Finally, the implantation of clones that overexpress Tiam1 into the cecum of athymic mice resulted in tumor growth in the spleen, liver, and lung, whereas parental cells do not form tumors by this route of injection. These results demonstrate that overexpression of Tiam1 contributes to the metastatic phenotype of colon cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX 77030 USA; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Netherlands Cancer Institute	Gallick, GE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holocombe Blvd,Box 173, Houston, TX 77030 USA.	ggallick@mdanderson.org			NATIONAL CANCER INSTITUTE [U54CA090810] Funding Source: NIH RePORTER; NCI NIH HHS [U54 CA 090810, 2 R01 CA25567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2001, J BIOL CHEM, V276, P28443, DOI 10.1074/jbc.M009769200; ALBINI A, 1987, CANCER RES, V47, P3239; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; Ehler E, 1997, MOL CELL NEUROSCI, V9, P1, DOI 10.1006/mcne.1997.0602; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; Engers R, 2000, INT J CANCER, V88, P369, DOI 10.1002/1097-0215(20001101)88:3<369::AID-IJC8>3.0.CO;2-K; Engers R, 2001, J BIOL CHEM, V276, P41889, DOI 10.1074/jbc.M105049200; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HABETS GGM, 1995, ONCOGENE, V10, P1371; Hewitt RE, 2000, J PATHOL, V192, P446; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Supriatno, 2003, ONCOL REP, V10, P527; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Wu Ming-fu, 2003, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V25, P434	33	54	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2568	2573		10.1038/sj.onc.1208503	http://dx.doi.org/10.1038/sj.onc.1208503			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735692				2022-12-25	WOS:000228180600014
J	Dubrovska, A; Kanamoto, T; Lomnytska, M; Heldin, CH; Volodko, N; Souchelnytskyi, S				Dubrovska, A; Kanamoto, T; Lomnytska, M; Heldin, CH; Volodko, N; Souchelnytskyi, S			TGF ss 1/Smad3 counteracts BRCA1-dependent repair of DNA damage	ONCOGENE			English	Article						Smad3; BRCA1; transforming growth factor-ss; DNA repair; breast cancer	TGF-BETA; CANCER-SUSCEPTIBILITY; COLORECTAL-CANCER; PROGNOSTIC-FACTOR; MUTANT MICE; BRCA1; SMAD4; EXPRESSION; CELLS; GENE	Inactivation of the BRCA1 gene has been found to confer susceptibility to early-onset familial breast and ovarian cancers. BRCA1 regulates DNA repair, chromatin remodeling and affects gene transcription. Transforming growth factor-beta (TGF beta) is a potent regulator of growth, apoptosis and invasiveness of tumor cells, including breast cancer cells. Here we show that Smad3 which is a component of the TGF beta signaling pathway, forms a complex with BRCA1 in vitro and in vivo. The interaction is mediated by the MH1 domain of Smad3 and the G terminal part of BRCA1. We observed a co-localization of Smad3 and BRCA1 in nuclear complexes. We also found that TGF beta 1/Smad3 counteracted BRCA1-dependent repair of DNA double-strand breaks in human breast epithelial cells, as evaluated by BRCA1 nuclear foci formation, single-cell gel electrophoresis and cell survival assays. Thus, TGF beta 1/Smad3 suppresses BRCA1-dependent DNA repair in response to a DNA damaging agent.	Ludwig Inst Canc Res, Biomed Ctr, SE-75124 Uppsala, Sweden; Hiroshima Univ, Dept Ophthalmol & Visual Sci, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan; Lviv Natl Med Univ, Dept Oncol & Med Radiol, UA-79031 Lvov, Ukraine	Ludwig Institute for Cancer Research; Hiroshima University; Danylo Halytsky Lviv National Medical University	Souchelnytskyi, S (corresponding author), Ludwig Inst Canc Res, Biomed Ctr, Box 595, SE-75124 Uppsala, Sweden.	serhiy.souchelnytskyi@licr.uu.se	Souchelnytskyi, Serhiy/G-6491-2011; Lomnytska, Marta/GWZ-2220-2022; Dubrovska, Anna/AAE-8514-2019; Souchelnytskyi, Serhiy/J-9446-2014	Souchelnytskyi, Serhiy/0000-0001-8243-9276; Dubrovska, Anna/0000-0002-3375-1500; Lomnytska, Marta/0000-0003-2773-8446				Boulay JL, 2002, BRIT J CANCER, V87, P630, DOI 10.1038/sj.bjc.6600511; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Ewan KB, 2002, CANCER RES, V62, P5627; Glick A, 1999, P NATL ACAD SCI USA, V96, P14949, DOI 10.1073/pnas.96.26.14949; Kanamoto T, 2002, EMBO J, V21, P1219, DOI 10.1093/emboj/21.5.1219; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lomnytska M, 2004, PROTEOMICS, V4, P995, DOI 10.1002/pmic.200300659; Miyajima A, 2003, UROLOGY, V61, P1072, DOI 10.1016/S0090-4295(02)02553-0; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; MURRAY PA, 1993, BRIT J CANCER, V67, P1408, DOI 10.1038/bjc.1993.261; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Preobrazhenska O, 2002, ONCOGENE, V21, P5660, DOI 10.1038/sj.onc.1205732; Pulaski L, 2001, J BIOL CHEM, V276, P14344, DOI 10.1074/jbc.M011019200; Schmied BM, 2000, CARCINOGENESIS, V21, P1121, DOI 10.1093/carcin/21.6.1121; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Souchelnytskyi S, 2002, EXP ONCOL, V24, P3; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Xiangming C, 2001, CLIN CANCER RES, V7, P277; Xie W, 2002, CANCER RES, V62, P497; Yakmovych I, 2001, FASEB J, V15, P553; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	30	48	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2289	2297		10.1038/sj.onc.1208443	http://dx.doi.org/10.1038/sj.onc.1208443			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735739				2022-12-25	WOS:000227877400002
J	Li, YP; Chen, YL; John, J; Moylan, J; Jin, BW; Mann, DL; Reid, MB				Li, YP; Chen, YL; John, J; Moylan, J; Jin, BW; Mann, DL; Reid, MB			TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle	FASEB JOURNAL			English	Article						tumor necrosis factor; muscle wasting; ubituitin conjugating activity	NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTORS; CONJUGATING ACTIVITY; OXIDATIVE STRESS; MESSENGER-RNAS; PROTEIN LOSS; ACTIVATION; PATHWAY; INHIBITOR; ATROGIN-1	Atrogin1/MAFbx is an ubiquitin ligase that mediates muscle atrophy in a variety of catabolic states. We recently found that H2O2 stimulates atrogin1/MAFbx gene expression. Since the cytokine tumor necrosis factor-alpha (TNF-alpha) stimulates both reactive oxygen production and general activity of the ubiquitin conjugating pathway, we hypothesized that TNF-alpha would also increase atrogin1/MAFbx gene expression. As with H2O2, we found that TNF-alpha exposure upregulates atrogin1/MAF-bx mRNA within 2 h in C2C12 myotubes. Intraperitoneal injection of TNF-alpha increased atrogin1/MAFbx mRNA in skeletal muscle of adult mice within 4 h. Exposing myotubes to either TNF-alpha or H2O2 also produced general activation of the mitogen-activated protein kinases (MAPKs): p38, ERK1/2, and JNK. The increase in atrogin1/MAFbx gene expression induced by TNF-alpha was not altered significantly by ERK inhibitor PD98059 or the JNK inhibitor SP600125. In contrast, atrogin1/MAFbx up-regulation and the associated increase in ubiquitin conjugating activity were both blunted by p38 inhibitors, either SB203580 or curcumin. These data suggest that TNF-alpha acts via p38 to increase atrogin1/MAFbx gene expression in skeletal muscle.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Kentucky, Coll Med, Dept Physiol, Med Ctr, Lexington, KY 40502 USA	Baylor College of Medicine; University of Kentucky	Li, YP (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.	yiping@bcm.tmc.edu; michael.reid@uky.edu	Mann, Douglas Lowell/AAQ-3524-2021	Mann, Douglas/0000-0002-2516-0145	NHLBI NIH HHS [R01 HL042250, HL59878, R01 HL058081, HL58081, R01 HL061543, HL42250-10/10, R01 HL059878] Funding Source: Medline; NIAMS NIH HHS [R01 AR049022-02, AR049022, R01 AR049022] Funding Source: Medline; NIGMS NIH HHS [GM59203] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058081, R01HL042250, R01HL061543, R01HL059878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059203] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1994, LIFE SCI, V55, P1383, DOI 10.1016/0024-3205(94)00752-7; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anker SD, 1999, CURR OPIN CARDIOL, V14, P211, DOI 10.1097/00001573-199905000-00004; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Buck M, 1996, EMBO J, V15, P1753, DOI 10.1002/j.1460-2075.1996.tb00524.x; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Carter Yvette, 2003, Surg Infect (Larchmt), V4, P17, DOI 10.1089/109629603764655245; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; Childs TE, 2003, AM J PHYSIOL-CELL PH, V285, pC391, DOI 10.1152/ajpcell.00478.2002; Clanton TL, 1999, P SOC EXP BIOL MED, V222, P253, DOI 10.1046/j.1525-1373.1999.d01-142.x; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dehoux MJM, 2003, FEBS LETT, V544, P214, DOI 10.1016/S0014-5793(03)00505-2; Di Giovanni S, 2004, ANN NEUROL, V55, P195, DOI 10.1002/ana.10811; Finkel T, 2001, IUBMB LIFE, V52, P3, DOI 10.1080/15216540252774694; GARCIAMARTINEZ C, 1993, FEBS LETT, V323, P211, DOI 10.1016/0014-5793(93)81341-V; GARCIAMARTINEZ C, 1993, MOL CELL BIOCHEM, V125, P11, DOI 10.1007/BF00926829; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; Koistinen HA, 2003, DIABETOLOGIA, V46, P1324, DOI 10.1007/s00125-003-1196-3; KONDO H, 2000, HDB OXIDANTS ANTIOXI, P631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lecker SH, 1999, J CLIN INVEST, V104, P1411, DOI 10.1172/JCI7300; Li X, 2000, CIRCULATION, V102, P1690, DOI 10.1161/01.CIR.102.14.1690; Li YP, 2003, FASEB J, V17, P1048, DOI 10.1096/fj.02-0759com; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC806, DOI 10.1152/ajpcell.00129.2003; Li YP, 2001, CURR OPIN RHEUMATOL, V13, P483, DOI 10.1097/00002281-200111000-00005; LIU YC, 1990, BIOTECHNIQUES, V9, P558; Llovera M, 1997, BIOCHEM BIOPH RES CO, V230, P238, DOI 10.1006/bbrc.1996.5827; Obata T, 2000, CRIT CARE MED, V28, pN67, DOI 10.1097/00003246-200004001-00008; Reid MB, 2001, ACTA PHYSIOL SCAND, V171, P225, DOI 10.1046/j.1365-201x.2001.00824.x; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Spiers S, 2000, ANN NY ACAD SCI, V908, P341; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; TESSITORE L, 1993, BRIT J CANCER, V67, P15, DOI 10.1038/bjc.1993.4; Tisdale MJ, 2000, SCIENCE, V289, P2293, DOI 10.1126/science.289.5488.2293; Tracey Kevin J, 2002, Sci STKE, V2002, ppe21; Williamson D, 2003, J PHYSIOL-LONDON, V547, P977, DOI 10.1113/jphysiol.2002.036673; Wray CJ, 2003, INT J BIOCHEM CELL B, V35, P698, DOI 10.1016/S1357-2725(02)00341-2	46	428	444	1	29	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					362	370		10.1096/fj.04-2364com	http://dx.doi.org/10.1096/fj.04-2364com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746179	Green Accepted			2022-12-25	WOS:000227901300036
J	Fung, MM; Chu, YL; Fink, JL; Wallace, A; McGuire, KL				Fung, MM; Chu, YL; Fink, JL; Wallace, A; McGuire, KL			IL-2- and STAT5-regulated cytokine gene expression in cells expressing the Tax protein of HTLV-1	ONCOGENE			English	Article						IL-2; human; HTLV-1; T cell; Tax	JAK-STAT PATHWAY; IL-2 RECEPTOR; SERINE PHOSPHORYLATION; T-CELLS; CONSTITUTIVE ACTIVATION; BINDING PROTEIN; LEUKEMIA-CELLS; GROWTH-FACTOR; INTERLEUKIN-2; LYMPHOCYTES	Interleukin-2 (IL-2) mediates cell cycle progression and antiapoptosis in human T cells via several signal transduction pathways. The Tax protein of the human T-cell leukemia virus type I (HTLV-1) deregulates cell growth and alters the role of IL-2 in infected cells. However, Tax-immortalized cells stay dependent on IL-2, suggesting that events besides HTLV-1 gene expression are required for leukemia to develop. Here, IL-2-dependent and -independent events were analysed in a human T cell line immortalized by Tax. These studies show that, of the signaling pathways evaluated, only STAT5 remains dependent. Microarray analyses revealed several genes, including il-5, il-9 and il-13, are uniquely upregulated by IL-2 in the presence of Tax. Bioinformatics and supporting molecular biology show that some of these genes are STAT5 targets, explaining their IL-2 upregulation. These results suggest that IL-2 and viral proteins work together to induce gene expression, promoting the hypothesis that deregulation via the constitutive activation of STAT5 may lead to the IL-2-independent phenotype of HTLV-1-transformed cells.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; Univ Calif San Diego, San Diego Supercomp Ctr, La Jolla, CA 92093 USA; Scripps Res Inst, Inst Childhood & Neglected Dis, La Jolla, CA 92037 USA	California State University System; San Diego State University; University of California System; University of California San Diego; Scripps Research Institute	McGuire, KL (corresponding author), San Diego State Univ, Dept Biol, 5500 Campanile Dr, San Diego, CA 92182 USA.	kmcguire@sunstroke.sdsu.edu	Fink, Lynn/C-2031-2008	Fink, Lynn/0000-0003-2912-6048	NCRR NIH HHS [P41 RR08605-08] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008605] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; Albrecht B, 2002, MICROBIOL MOL BIOL R, V66, P396, DOI 10.1128/MMBR.66.3.396-406.2002; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; Boer AK, 2002, BLOOD, V100, P467, DOI 10.1182/blood.V100.2.467; Chung HK, 2003, BLOOD, V102, P4130, DOI 10.1182/blood-2003-04-1043; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Fung MM, 2003, CELL SIGNAL, V15, P625, DOI 10.1016/S0898-6568(03)00003-2; Gaffen SL, 2001, CYTOKINE, V14, P63, DOI 10.1006/cyto.2001.0862; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Hertz GZ, 1999, BIOINFORMATICS, V15, P563, DOI 10.1093/bioinformatics/15.7.563; HERTZ GZ, 1990, COMPUT APPL BIOSCI, V6, P81; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; HOUSSIAU FA, 1993, J IMMUNOL, V150, P2634; Iacobelli M, 1999, J IMMUNOL, V162, P3308; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KELLEHER K, 1991, BLOOD, V77, P1436; Kim HP, 2001, IMMUNITY, V15, P159, DOI 10.1016/S1074-7613(01)00167-4; KIRKEN RA, 1993, J BIOL CHEM, V268, P22765; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li-Weber M, 2001, EUR J IMMUNOL, V31, P3694, DOI 10.1002/1521-4141(200112)31:12<3694::AID-IMMU3694>3.0.CO;2-S; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Lu LR, 1998, EUR J IMMUNOL, V28, P805, DOI 10.1002/(SICI)1521-4141(199803)28:03<805::AID-IMMU805>3.0.CO;2-G; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; Matsushita K, 1997, LEUKEMIA RES, V21, P211, DOI 10.1016/S0145-2126(96)00109-9; McGuire KL, 1997, J IMMUNOL, V159, P1319; MCGUIRE KL, 1999, RECENT RES DEV IMMUN, V1, P149; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MURATA K, 1992, CANCER, V69, P966, DOI 10.1002/1097-0142(19920215)69:4&lt;966::AID-CNCR2820690422&gt;3.0.CO;2-H; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Ogata M, 1998, AM J HEMATOL, V59, P242, DOI 10.1002/(SICI)1096-8652(199811)59:3<242::AID-AJH11>3.3.CO;2-F; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; ROBB RJ, 1984, IMMUNOL TODAY, V5, P203, DOI 10.1016/0167-5699(84)90224-X; Robek MD, 1998, J VIROL, V72, P4458, DOI 10.1128/JVI.72.5.4458-4462.1998; Rohwer F, 1996, J IMMUNOL, V157, P643; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Ruckes T, 2001, BLOOD, V98, P1150, DOI 10.1182/blood.V98.4.1150; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Skinnider BF, 2002, LEUKEMIA LYMPHOMA, V43, P1203, DOI 10.1080/10428190290026259; Skinnider BF, 2001, INT ARCH ALLERGY IMM, V126, P267, DOI 10.1159/000049523; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; Waldele K, 2004, J VIROL, V78, P6081, DOI 10.1128/JVI.78.12.6081-6090.2004; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272; Ye JX, 2003, BLOOD, V102, P3963, DOI 10.1182/blood-2003-05-1490; YOSHIDA M, 1994, AIDS RES HUM RETROV, V10, P1193, DOI 10.1089/aid.1994.10.1193	61	28	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4624	4633		10.1038/sj.onc.1208507	http://dx.doi.org/10.1038/sj.onc.1208507			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15735688				2022-12-25	WOS:000230304500002
J	Henson, BS; Neubig, RR; Jang, I; Ogawa, T; Zhang, ZC; Carey, TE; D'Silva, NJ				Henson, BS; Neubig, RR; Jang, I; Ogawa, T; Zhang, ZC; Carey, TE; D'Silva, NJ			Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CHROMOSOMAL LOCALIZATION; STRUCTURAL ORGANIZATION; SIGNALING PATHWAYS; GALR1; HEAD; 18Q; IMMUNOREACTIVITY; MODULATION; EXPRESSION	In the United States, oral cancer accounts for more deaths annually than cervical cancer, leukemias, or Hodgkin's lymphoma. Studies have shown that aberrations of chromosome 18q develop with tumor progression and are associated with significantly decreased survival in head and neck cancer patients. The G-protein-coupled receptor, galanin receptor 1 ( GALR1), maps to this region of chromosome 18q. Although the role of GALR1 has been well characterized in neuronal cells, little is known regarding this receptor in nonneuronal cells. In this study, the expression, mitogenic function, and signaling mechanism of GALR1 are investigated in normal and malignant oral epithelial cells. mRNA expression was determined via reverse transcriptase-PCR. Protein quantification was done via immunoblot analysis and enzyme-linked immunosorbent assay. For functional and signaling studies, an inhibitory antibody was generated to the N-terminal ligand binding domain of GALR1. GALR1 protein and mRNA expression and GAL secretion were detected at variable levels in immortalized human oral keratinocytes and human oropharyngeal squamous cell carcinoma cell lines. Upon competitive inhibition of GALR1, proliferation was up-regulated in immortalized and malignant keratinocytes. Furthermore, studies with the inhibitory antibody and U0126, the MAPK inhibitor, show that GALR1 inhibits proliferation in immortalized and malignant keratinocytes by inactivating the MAPK pathway. GALR1s inhibitory effects on proliferation in epithelial cells raises the possibility that inactivation or disregulation of this receptor can lead to uncontrolled proliferation and neoplastic transformation.	Univ Michigan, Sch Dent, Dept Oral Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Dept Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Lab Head & Neck Canc Biol, Ann Arbor, MI 48109 USA; Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	D'Silva, NJ (corresponding author), Univ Michigan, Sch Dent, Dept Oral Med, 1011 N Univ Ave,Rm 5217, Ann Arbor, MI 48109 USA.	njdsilva@umich.edu	D'Silva, Nisha J/B-4734-2013	Carey, Thomas/0000-0002-5202-7518; Neubig, Richard/0000-0003-0501-0008	NATIONAL CANCER INSTITUTE [P50CA097248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K08DE014620] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA97248] Funding Source: Medline; NIDCR NIH HHS [DE00452-01, K08 DE14620-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Albanell J, 2001, CANCER RES, V61, P6500; BEDECS K, 1995, INT J BIOCHEM CELL B, V27, P337, DOI 10.1016/1357-2725(95)00008-D; Benya RV, 1999, AM J PHYSIOL-GASTR L, V276, pG64, DOI 10.1152/ajpgi.1999.276.1.G64; Berger A, 2004, ENDOCRINOLOGY, V145, P500, DOI 10.1210/en.2003-0649; Branchek TA, 2000, TRENDS PHARMACOL SCI, V21, P109, DOI 10.1016/S0165-6147(00)01446-2; Carey TE, 1994, ATLAS HUMAN TUMOR CE, P79; CRAWLEY JN, 1995, REGUL PEPTIDES, V59, P1, DOI 10.1016/0167-0115(95)00083-N; Frank CJ, 1997, CANCER RES, V57, P824; Goetzl EJ, 2004, IMMUNOL LETT, V93, P63, DOI 10.1016/j.imlet.2004.02.007; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hammond PJ, 1996, J NEUROENDOCRINOL, V8, P457, DOI 10.1046/j.1365-2826.1996.04747.x; Hochol A, 2000, PEPTIDES, V21, P147, DOI 10.1016/S0196-9781(99)00184-9; Holmes FE, 2000, P NATL ACAD SCI USA, V97, P11563, DOI 10.1073/pnas.210221897; HOYLE CHV, 1989, J ANAT, V166, P23; Iismaa TP, 1998, ANN NY ACAD SCI, V863, P56, DOI 10.1111/j.1749-6632.1998.tb10683.x; Jacoby AS, 1997, GENOMICS, V45, P496, DOI 10.1006/geno.1997.4960; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kakuyama H, 1997, EUR J PHARMACOL, V329, P85, DOI 10.1016/S0014-2999(97)10109-1; LANSFORD CD, 1999, HUMAN CELL CULTURE, V2, P185; Lingen MW, 1996, AM J PATHOL, V149, P247; Mazarati AM, 1998, J NEUROSCI, V18, P10070; Mazarati AM, 2000, J NEUROSCI, V20, P6276, DOI 10.1523/JNEUROSCI.20-16-06276.2000; McDonald AC, 2003, BONE, V33, P788, DOI 10.1016/S8756-3282(03)00244-8; Mitra RS, 2003, ONCOGENE, V22, P6243, DOI 10.1038/sj.onc.1206534; Nicholl J, 1995, GENOMICS, V30, P629, DOI 10.1006/geno.1995.1292; O'Meara G, 2000, P NATL ACAD SCI USA, V97, P11569, DOI 10.1073/pnas.210254597; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; Pearlstein RP, 1998, GENE CHROMOSOME CANC, V21, P333, DOI 10.1002/(SICI)1098-2264(199804)21:4<333::AID-GCC7>3.0.CO;2-#; Perumal P, 2003, J ENDOCRINOL, V179, P145, DOI 10.1677/joe.0.1790145; RATTAN S, 1991, GASTROENTEROLOGY, V100, P1762, DOI 10.1016/0016-5085(91)90682-B; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Seufferlein T, 1996, CANCER RES, V56, P5758; SKOFITSCH G, 1986, PEPTIDES, V7, P609, DOI 10.1016/0196-9781(86)90035-5; Sullivan KA, 1997, BIOCHEM BIOPH RES CO, V233, P823, DOI 10.1006/bbrc.1997.6542; Takebayashi S, 2000, CANCER RES, V60, P3397; Todd R, 1997, J ORAL MAXIL SURG, V55, P613, DOI 10.1016/S0278-2391(97)90495-X; Trejter M, 2002, INT J MOL MED, V10, P183; Wang S, 1998, BIOCHEMISTRY-US, V37, P6711, DOI 10.1021/bi9728405; Wittau N, 2000, ONCOGENE, V19, P4199, DOI 10.1038/sj.onc.1203777	39	49	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22564	22571		10.1074/jbc.M414589200	http://dx.doi.org/10.1074/jbc.M414589200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15767248	hybrid			2022-12-25	WOS:000229741800004
J	Kim, H; von Heijne, G; Nilsson, I				Kim, H; von Heijne, G; Nilsson, I			Membrane topology of the STT3 subunit of the oligosaccharyl transferase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; N-LINKED GLYCOSYLATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PROTEIN TOPOLOGY; IN-VIVO; SIGNAL; DEGRADATION; TRANSLOCASE; SEQUENCES	The highly conserved membrane protein STT3 is part of the oligosaccharyl transferase complex in the endoplasmic reticulum of eukaryotic cells. Various experimental observations strongly suggest that STT3 contains the active site of the complex. Here, we report a detailed topology study of STT3 from two different organisms, Saccharomyces cerevisiae and mouse, using in vivo and in vitro topology mapping assays. Our results suggest that STT3 has 11 transmembrane helices and an overall N-cyt-C-lum orientation.	Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden	Stockholm University	Nilsson, I (corresponding author), Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	ingmarie@dbb.su.se	Nilsson, IngMarie/H-2887-2012; von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569				Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Chavan M, 2003, J BIOL CHEM, V278, P51441, DOI 10.1074/jbc.M310456200; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; Devoto A, 1999, J BIOL CHEM, V274, P34993, DOI 10.1074/jbc.274.49.34993; Gilstring CF, 2000, J BIOL CHEM, V275, P31488, DOI 10.1074/jbc.M005047200; Hong GZ, 1996, GENOMICS, V31, P295, DOI 10.1006/geno.1996.0051; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; Karaoglu D, 1997, J BIOL CHEM, V272, P32513, DOI 10.1074/jbc.272.51.32513; Kelleher DJ, 2003, MOL CELL, V12, P101, DOI 10.1016/S1097-2765(03)00243-0; Kim H, 2003, J BIOL CHEM, V278, P10208, DOI 10.1074/jbc.M300163200; Kim H, 2003, P NATL ACAD SCI USA, V100, P7460, DOI 10.1073/pnas.1332735100; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Li GT, 2005, J BIOL CHEM, V280, P1864, DOI 10.1074/jbc.M410969200; LILJESTROM P, 1991, J VIROL, V65, P147; Melen K, 2003, J MOL BIOL, V327, P735, DOI 10.1016/S0022-2836(03)00182-7; Mingarro I, 2000, BMC Cell Biol, V1, P3, DOI 10.1186/1471-2121-1-3; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Nilsson I, 2003, J CELL BIOL, V161, P715, DOI 10.1083/jcb.200301043; Nilsson I, 2000, J BIOL CHEM, V275, P17338, DOI 10.1074/jbc.M002317200; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Strahl-Bolsinger S, 1999, J BIOL CHEM, V274, P9068, DOI 10.1074/jbc.274.13.9068; van Geest M, 1999, J BIOL CHEM, V274, P2816, DOI 10.1074/jbc.274.5.2816; Von Heijne G, 1998, ACTA PHYSIOL SCAND, V163, P17; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; Wilhovsky S, 2000, MOL BIOL CELL, V11, P1697, DOI 10.1091/mbc.11.5.1697; Yan G, 2002, J BIOL CHEM, V277, P47692, DOI 10.1074/jbc.M208136200; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	31	28	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20261	20267		10.1074/jbc.M412213200	http://dx.doi.org/10.1074/jbc.M412213200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781470	hybrid			2022-12-25	WOS:000229242000014
J	Lanzino, M; De Amicis, F; McPhaul, MJ; Marsico, S; Panno, ML; Ando, S				Lanzino, M; De Amicis, F; McPhaul, MJ; Marsico, S; Panno, ML; Ando, S			Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ER alpha) and modulates the functional ER alpha/androgen receptor interplay in MCF-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; HUMAN ANDROGEN RECEPTOR; MAMMARY-GLAND; GROWTH; EXPRESSION; GENE; TUMORIGENESIS; TRANSCRIPTION; RESISTANCE; PROSTATE	Overexpression of androgen receptor (AR) decreases estrogen receptor alpha (ER alpha) transactivation, which plays a basic role in hormone-dependent breast cancer. This transcriptional interference can be due to shared coactivators. Here we demonstrated that in MCF-7 cells ARA70, an AR-specific coactivator, interacted with endogenous ER alpha, increasing its transcriptional activity, and it was recruited to the pS2 gene promoter. Moreover, a dominant negative ARA70 down-regulated ER alpha transcriptional activity as well as pS2 mRNA. ARA70 overexpression reversed the AR down-regulatory effect on ER alpha signaling. However, in the presence of a progressive increase of transfected AR, ARA70 switched into enhancing the inhibitory effect of AR on ER alpha signaling. These opposite effects of ARA70 were further evidenced by coimmunoprecipitation assay in MCF-7wt, MCF-7-overexpressing AR, and HeLa cells, exogenously expressing an excess of ER alpha with respect to AR or an excess of AR with respect to ER alpha. Thus, ARA70 is a coactivator for ER alpha and may represent a functional link between ER alpha/AR modulating their cross-talk in models of estrogen signaling in MCF-7 and HeLa cells.	Univ Calabria, Dept Cell Biol, I-87030 Commenda Di Rende, Italy; Univ Calabria, Dept Pharmacobiol, I-87030 Commenda Di Rende, Italy; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Calabria; University of Calabria; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ando, S (corresponding author), Univ Calabria, Dept Cell Biol, I-87030 Commenda Di Rende, Italy.	sebastiano.ando@unical.it	McPhaul, Michael/AAC-7124-2020; MARSICO, Stefania/J-9938-2019	MARSICO, Stefania/0000-0003-1598-0526; De Amicis, Francesca/0000-0001-7079-1037; Lanzino, Marilena/0000-0002-6362-5396	NIDDK NIH HHS [DK03892] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK003892] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ando S, 2002, MOL CELL ENDOCRINOL, V193, P121, DOI 10.1016/S0303-7207(02)00105-3; BERNS EM, 2003, BREAST CANC RES THRE, V1, P121; Birrell SN, 1998, J MAMMARY GLAND BIOL, V3, P95, DOI 10.1023/A:1018730519839; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; FOEKENS JA, 1989, CANCER RES, V49, P5823; Fuqua SAW, 2001, J MAMMARY GLAND BIOL, V6, P407, DOI 10.1023/A:1014782813943; Gao Xiuhua, 2002, Mol Cancer, V1, P7, DOI 10.1186/1476-4598-1-7; Giguere Y, 2001, CANCER RES, V61, P5869; GOLDENBERG IS, 1975, CANCER, V36, P308, DOI 10.1002/1097-0142(197508)36:2<308::AID-CNCR2820360203>3.0.CO;2-1; Hackenberg R, 1996, J STEROID BIOCHEM, V56, P113, DOI 10.1016/0960-0760(95)00228-6; Kollara A, 2001, BREAST CANCER RES TR, V67, P245, DOI 10.1023/A:1017938608460; Liao DJ, 2002, J STEROID BIOCHEM, V80, P175, DOI 10.1016/S0960-0760(01)00185-6; LOBACCARO JM, 1993, NAT GENET, V5, P109, DOI 10.1038/ng1093-109; MARCELLI M, 1990, MOL ENDOCRINOL, V4, P1105, DOI 10.1210/mend-4-8-1105; Murphy LC, 2000, CANCER RES, V60, P6266; Murphy LC, 2002, BIOMED PHARMACOTHER, V56, P65, DOI 10.1016/S0753-3322(01)00157-3; POULIN R, 1989, ENDOCRINOLOGY, V125, P392, DOI 10.1210/endo-125-1-392; Rahman MM, 2003, J BIOL CHEM, V278, P19619, DOI 10.1074/jbc.M210941200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sommer S, 2001, SEMIN CANCER BIOL, V11, P339, DOI 10.1006/scbi.2001.0389; THORPE SM, 1988, ACTA ONCOL, V27, P1; Tikkanen MK, 2000, P NATL ACAD SCI USA, V97, P12536, DOI 10.1073/pnas.220427297; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527; ZOPPI S, 1992, MOL ENDOCRINOL, V6, P409, DOI 10.1210/me.6.3.409	30	70	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20421	20430		10.1074/jbc.M413576200	http://dx.doi.org/10.1074/jbc.M413576200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15772083	hybrid			2022-12-25	WOS:000229242000034
J	Limoli, CL; Giedzinski, E; Cleaver, JE				Limoli, CL; Giedzinski, E; Cleaver, JE			Alternative recombination pathways in UV-irradiated XP variant cells	ONCOGENE			English	Article						ultraviolet light; polymerase eta (Pol H or hRad30A); recombination; Mre11; Rad50; Rad51; XP variant cells	DOUBLE-STRAND BREAKS; DNA-POLYMERASE-ETA; XERODERMA PIGMENTOSUM-CELLS; HOMOLOGOUS RECOMBINATION; EXCISION REPAIR; REPLICATION INHIBITION; CELLULAR-RESPONSE; PYRIMIDINE DIMER; NUCLEAR FOCI; HISTONE H2AX	XP variant (XP-V) cells lack the damage-specific polymerase eta and exhibit prolonged replication arrest after UV irradiation due to impaired bypass of UV photoproducts. To analyse the outcome of the arrested replication forks, homologous recombination (HR, Rad51 events) and fork breakage (Rad50 events) were assayed by immunofluorescent detection of foci-positive cells. Within 1 h of irradiation, XP-V cells showed more Rad51-positive cells than normal cells, while neither cell type showed an increase in Rad50 foci. Beyond 1 h, the frequency of Rad51-positive cells reached similar levels in both cell types, then declined at higher UV doses. At these later times, Rad50-positive cells increased with dose and to a greater extent in XP-V cells. Few cells were simultaneously positive for both sets of foci, suggesting a mutually exclusive recruitment of recombination proteins, or that these pathways operate at different stages during S phase. Analysis of cells containing a vector of tandemly arranged enhanced green fluorescent protein genes also showed that UV-induced HR was higher in XP-V cells. These results suggest that cells make an early commitment to HR, and that at later times a subset of arrested forks degrade into double-strand breaks, two alternative pathways that are greater in XP-V cells.	Univ Calif San Francisco, Dept Radiat Oncol, Radiat Oncol Res Lab, San Francisco, CA 94103 USA; Univ Calif San Francisco, Ctr Canc, Auerback Melanoma Lab, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Limoli, CL (corresponding author), Univ Calif San Francisco, Dept Radiat Oncol, Radiat Oncol Res Lab, 1855 Folsom St,MCB-200, San Francisco, CA 94103 USA.	limoli@itsa.ucsf.edu	Limoli, Charles/AAW-1748-2020	Limoli, Charles/0000-0002-1321-4142	NIEHS NIH HHS [1 R01 ES 8061] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008061] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; Broughton BC, 2002, P NATL ACAD SCI USA, V99, P815, DOI 10.1073/pnas.022473899; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; CLEAVER JE, 1988, J INVEST DERMATOL, V90, P467, DOI 10.1111/1523-1747.ep12460917; Cleaver JE, 1999, CANCER RES, V59, P1102; Cleaver JE, 2002, DNA REPAIR, V1, P41, DOI 10.1016/S1568-7864(01)00004-0; Cordeiro-Stone M, 1999, J MOL BIOL, V289, P1207, DOI 10.1006/jmbi.1999.2847; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; GODWIN AR, 1994, P NATL ACAD SCI USA, V91, P12554, DOI 10.1073/pnas.91.26.12554; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche P, 2003, EMBO J, V22, P1223, DOI 10.1093/emboj/7595006; Laposa RR, 2003, CANCER RES, V63, P3909; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Li ZQ, 2002, P NATL ACAD SCI USA, V99, P4459, DOI 10.1073/pnas.062047799; Limoli CL, 2002, MUTAT RES-FUND MOL M, V510, P121, DOI 10.1016/S0027-5107(02)00257-9; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Limoli CL, 2000, P NATL ACAD SCI USA, V97, P7939, DOI 10.1073/pnas.130182897; Linke SP, 2003, CANCER RES, V63, P2596; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; PAINTER RB, 1980, MUTAT RES, V70, P337, DOI 10.1016/0027-5107(80)90023-8; PARK SD, 1979, NUCLEIC ACIDS RES, V6, P1151, DOI 10.1093/nar/6.3.1151; PARK SD, 1979, P NATL ACAD SCI USA, V76, P3927, DOI 10.1073/pnas.76.8.3927; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Scully R, 2000, ONCOGENE, V19, P6176, DOI 10.1038/sj.onc.1203971; Taghian DG, 1997, MOL CELL BIOL, V17, P6386, DOI 10.1128/MCB.17.11.6386; Thakur M, 2001, GENE CHROMOSOME CANC, V32, P222, DOI 10.1002/gcc.1186; TSUJIMURA T, 1990, P NATL ACAD SCI USA, V87, P1566, DOI 10.1073/pnas.87.4.1566; Wang Y, 2000, GENE DEV, V14, P927; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	37	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3708	3714		10.1038/sj.onc.1208515	http://dx.doi.org/10.1038/sj.onc.1208515			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15750628				2022-12-25	WOS:000229346300002
J	Huang, C; Thirone, ACP; Huang, XD; Klip, A				Huang, C; Thirone, ACP; Huang, XD; Klip, A			Differential contribution of insulin receptor substrates 1 versus 2 to insulin signaling and glucose uptake in L6 myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; STIMULATED GLUT4 TRANSLOCATION; SKELETAL-MUSCLE CELLS; KINASE C-ZETA; 3T3-L1 ADIPOCYTES; CORTICAL ACTIN; TYROSINE PHOSPHORYLATION; PROTEIN EXPRESSION; POTENTIAL ROLE; P38 MAPK	Insulin receptor substrates-1 and 2 (IRS-1 and IRS-2) are pivotal in relaying insulin signaling in insulin-responsive tissues such as muscle. However, the precise contribution of IRS-1 vis-a-vis IRS-2 in insulin-mediated metabolic and mitogenic responses has not been compared directly in differentiated muscle cells. This study aimed to determine the relative contribution of IRS-1 versus IRS-2 in these responses, using small interfering RNA ( siRNA)mediated specific gene silencing. In L6 myotubes, transfection of siRNA targeted specifically against IRS-1 (siIRS-1) or IRS-2 (siIRS-2) reduced the cognate protein expression by 70-75%. Insulin-induced ERK phosphorylation was much more sensitive to IRS-2 than IRS-1 ablation, whereas p38MAPK phosphorylation was reduced by 43 or 62% in myotubes treated with siIRS-1 or siIRS-2, respectively. Insulin-induced Akt1 and Akt2 phosphorylation was reduced in myotubes treated with siIRS-1, but only Akt2 phosphorylation was reduced in myotubes treated with siIRS-2. In contrast, siIRS-1 treatment caused a marked reduction in insulin-induced actin remodeling, glucose uptake, and GLUT4 translocation, and siIRS-2 was without effect on these responses. Notably, combined siIRS-1 and siIRS-2, although reducing each IRS by around 75%, caused no further drop in glucose uptake than that achieved with siIRS-1 alone, but abolished p38MAPK phosphorylation. We conclude that insulin-stimulated Akt1 phosphorylation, actin remodeling, GLUT4 translocation, and glucose uptake are regulated mainly by IRS-1, whereas IRS-2 contributes selectively to ERK signaling, and Akt2 and p38MAPK lie downstream of both IRS in muscle cells.	Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Klip, A (corresponding author), Hosp Sick Children, Cell Biol Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	amira@sickkids.ca	Huang, Carol/H-2248-2014					ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Arribas M, 2003, FEBS LETT, V536, P161, DOI 10.1016/S0014-5793(03)00049-8; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Bazuine M, 2003, EUR J BIOCHEM, V270, P3891, DOI 10.1046/j.1432-1033.2003.03771.x; Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524; Brozinick JT, 2004, J BIOL CHEM, V279, P40699, DOI 10.1074/jbc.M402697200; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Cai DS, 2003, J BIOL CHEM, V278, P25323, DOI 10.1074/jbc.M212430200; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Carvalho E, 1999, FASEB J, V13, P2173, DOI 10.1096/fasebj.13.15.2173; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791; Huang C, 2002, DIABETES, V51, P2090, DOI 10.2337/diabetes.51.7.2090; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; Jebailey L, 2004, MOL ENDOCRINOL, V18, P359, DOI 10.1210/me.2003-0294; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; KANAI F, 1993, J BIOL CHEM, V268, P14523; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Khayat ZA, 2000, J CELL SCI, V113, P279; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Leng Y, 2004, DIABETES, V53, P1436, DOI 10.2337/diabetes.53.6.1436; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; Miele C, 1999, J BIOL CHEM, V274, P3094, DOI 10.1074/jbc.274.5.3094; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; Niu WY, 2003, J BIOL CHEM, V278, P17953, DOI 10.1074/jbc.M211136200; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; Patel N, 2003, MOL CELL BIOL, V23, P4611, DOI 10.1128/MCB.23.13.4611-4626.2003; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Pirola L, 2003, J BIOL CHEM, V278, P15641, DOI 10.1074/jbc.M208984200; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; QUON MJ, 1994, J BIOL CHEM, V269, P27920; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; Sasaoka T, 2004, J BIOL CHEM, V279, P14835, DOI 10.1074/jbc.M311534200; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Sciacca L, 2003, ENDOCRINOLOGY, V144, P2650, DOI 10.1210/en.2002-0136; Sesti G, 2001, DIABETES-METAB RES, V17, P363, DOI 10.1002/dmrr.225; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Solow BT, 1999, MOL ENDOCRINOL, V13, P1784, DOI 10.1210/me.13.10.1784; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Somwar R, 1998, CLIN THER, V20, P125, DOI 10.1016/S0149-2918(98)80040-4; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, pE572, DOI 10.1152/ajpendo.1999.277.3.E572; Valverde AM, 1998, MOL ENDOCRINOL, V12, P688, DOI 10.1210/me.12.5.688; Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2; Wang QH, 1999, MOL CELL BIOL, V19, P4008; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Zhou LX, 1997, J BIOL CHEM, V272, P29829, DOI 10.1074/jbc.272.47.29829; Zierath JR, 2000, DIABETOLOGIA, V43, P821, DOI 10.1007/s001250051457	62	123	127	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19426	19435		10.1074/jbc.M412317200	http://dx.doi.org/10.1074/jbc.M412317200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15764603	hybrid			2022-12-25	WOS:000228932300101
J	Kobayashi, M; Takaori-Kondo, A; Miyauchi, Y; Iwai, K; Uchiyama, T				Kobayashi, M; Takaori-Kondo, A; Miyauchi, Y; Iwai, K; Uchiyama, T			Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIRION INFECTIVITY FACTOR; LIGASE COMPLEX; SOCS-BOX; ANTIVIRAL ACTIVITY; ENZYME APOBEC3G; PROTEIN; DEGRADATION; PRIMATE; P53	The human immunodeficiency virus type 1 (HIV-1) virion infectivity factor (Vif) overcomes the antiviral activity of APOBEC3G to protect HIV-1 DNA from G-to-A hypermutation. Vif targets APOBEC3G for ubiquitination and proteasomal degradation by forming an SCF-like E3 ubiquitin ligase complex composed of Cullin5, Elongin B, and Elongin C (Vif-BC-Cul5) through a novel SOCS-box motif. In this paper, we have established an in vitro ubiquitin conjugation assay with purified Vif-BC-Cul5 complex and reported that the Vif-BC-Cul5 complex could function as an E3 ligase for APOBEC3G in vitro. A Vif-BC-Cul5 complex promotes the in vitro ubiquitination of the wild type, APOBEC3G but not that of D128K mutant, which does not interact with Vif. We have also investigated several loss-of-function Vif mutants. One mutant, SLQ144/146AAA, lost its activity on APOBEC3G because it could not form a complex due to mutations in SOCS-box motif. Other mutants, C114S and C133S, also lost their activity because of loss of the E3 ligase activity of a Vif-BC-Cul5 complex, although these mutants retained the ability to bind to APOBEC3G as well as Cul5 complex. These findings suggest that the E3 ubiquitin ligase activity of the Vif-BC-Cul5 complex is essential for Vif function against APOBEC3G.	Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, Kyoto 6068507, Japan; Osaka City Univ, Grad Sch Med, Dept Mol Cell Biol, Osaka 5458585, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Kyoto University; Osaka Metropolitan University; Japan Science & Technology Agency (JST)	Takaori-Kondo, A (corresponding author), Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, 54 Shogoin Kawaracho, Kyoto 6068507, Japan.	atakaori@kuhp.kyoto-u.ac.jp	IWAI, KAZUHIRO/GSN-7385-2022	Iwai, Kazuhiro/0000-0001-5620-5951				Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Bogerd HP, 2004, P NATL ACAD SCI USA, V101, P3770, DOI 10.1073/pnas.0307713101; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Desrosiers RC, 1998, J VIROL, V72, P1431, DOI 10.1128/JVI.72.2.1431-1437.1998; GONCALVES J, 1994, J VIROL, V68, P704, DOI 10.1128/JVI.68.2.704-712.1994; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kobayashi M, 2004, J VIROL, V78, P8238, DOI 10.1128/JVI.78.15.8238-8244.2004; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mangeat B, 2004, J BIOL CHEM, V279, P14481, DOI 10.1074/jbc.C400060200; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mehle A, 2004, GENE DEV, V18, P2861, DOI 10.1101/gad.1249904; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schrofelbauer R, 2004, P NATL ACAD SCI USA, V101, P3927, DOI 10.1073/pnas.0307132101; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Simon JHM, 1999, J VIROL, V73, P2675, DOI 10.1128/JVI.73.4.2675-2681.1999; SIMON JHM, 1995, J VIROL, V69, P4166, DOI 10.1128/JVI.69.7.4166-4172.1995; Simon JHM, 1998, EMBO J, V17, P1259, DOI 10.1093/emboj/17.5.1259; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Xu HZ, 2004, P NATL ACAD SCI USA, V101, P5652, DOI 10.1073/pnas.0400830101; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	33	126	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18573	18578		10.1074/jbc.C500082200	http://dx.doi.org/10.1074/jbc.C500082200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15781449	hybrid			2022-12-25	WOS:000228932300005
J	Ran, XY; Song, JX				Ran, XY; Song, JX			Structural insight into the binding diversity between the Tyr-phosphorylated human EphrinBs and Nck2 SH2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPH RECEPTORS; BACKBONE DYNAMICS; PHOSPHOTYROSYL PEPTIDE; CRYSTAL-STRUCTURE; ADAPTER PROTEIN; SPECIFICITY; REVERSE; FAMILY; LIGANDS; PROGRAM	The binding interaction between the Nck2 SH2 domain and the phosphorylated ephrinB initiates a critical pathway for the reverse signaling network mediated by Eph receptor-ephrinB. Previously, the NMR structure and Tyr phosphorylations of the human ephrinB cytoplasmic domain have been studied. To obtain a complete story, it would be of significant interest to determine the structure of the Nck2 SH2 domain that shows a low sequence identity to other SH2 domains with known structures. Here, we report the determination of the solution structure of the human Nck2 SH2 domain and investigate its interactions with three phosphorylated ephrinB fragments by NMR spectroscopy. The results indicate that: 1) although the human Nck2 SH2 domain adopts a core tertiary fold common to all SH2 domains, it owns some unique properties such as a shorter C-terminal helix and unusual electrostatic potential surface. However, the most striking finding is that the C-terminal tail of the human Nck2 SH2 domain adopts a short antiparallel beta-sheet that, to the best of our knowledge, has never been identified in other SH2 domains. The truncation study suggests that one function of the C-terminal tail is to control the folding/solubility of the SH2 domain. 2) In addition to [Tyr(P)(304)]ephrinB2(301-322) and [Tyr(P)(316)]ephrinB2(301-322), here we identified [Tyr(P)(330)]ephrinB2(324-333) also capable of binding to the SH2 domain. The detailed NMR study indicated that the binding mechanisms for the three ephrinB fragments might be different. The binding with [Tyr(P)(304)]ephrinB2(301-322) and [Tyr(P)(316)]ephrinB2(301-322) might be mostly involved in the residues over the N-half of the SH2 domain and provoked a significant increase in the backbone and side chain dynamics of the SH2 domain on the microsecond-millisecond time scale. In contrast, binding with [Tyr(P)(330)]ephrinB2(324-333) might have most residues over both halves engaged but induced less profound conformational dynamics on the mu s-ms time scale.	Natl Univ Singapore, Dept Biochem, Singapore 119260, Singapore; Natl Univ Singapore, Dept Sci Biol, Singapore 119260, Singapore	National University of Singapore; National University of Singapore	Song, JX (corresponding author), Natl Univ Singapore, Dept Biochem, 10 Kent Ridge Crescent, Singapore 119260, Singapore.	bchsj@nus.edu.sg	Song, Jianxing/J-3617-2013; Song, Jianxing/H-8026-2012	Song, Jianxing/0000-0003-0224-6322				Battaglia AA, 2003, NAT NEUROSCI, V6, P339, DOI 10.1038/nn1034; Bradshaw JM, 2003, ADV PROTEIN CHEM, V61, P161; Braverman LE, 1999, J BIOL CHEM, V274, P5542, DOI 10.1074/jbc.274.9.5542; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; Campbell SJ, 2003, PROTEIN ENG, V16, P217, DOI 10.1093/proeng/gzg025; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cowan CA, 2002, TRENDS CELL BIOL, V12, P339, DOI 10.1016/S0962-8924(02)02317-6; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Gauthier LR, 2003, LIFE SCI, V74, P207, DOI 10.1016/j.lfs.2003.09.029; Guntert Peter, 2004, Methods Mol Biol, V278, P353; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Himanen JP, 2003, TRENDS NEUROSCI, V26, P46, DOI 10.1016/S0166-2236(02)00005-X; Holder N, 1999, DEVELOPMENT, V126, P2033; Huyer G, 1998, BIOCHEMISTRY-US, V37, P2741, DOI 10.1021/bi9722913; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kay LE, 1996, BIOCHEMISTRY-US, V35, P361, DOI 10.1021/bi9522312; Kay LE, 1998, NAT STRUCT BIOL, V5, P156, DOI 10.1038/nsb0298-156; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kristensen SM, 2000, J MOL BIOL, V299, P771, DOI 10.1006/jmbi.2000.3760; Ladbury JE, 2000, CHEM BIOL, V7, pR3, DOI 10.1016/S1074-5521(00)00067-3; Li MF, 2004, EUR J BIOCHEM, V271, P3512, DOI 10.1111/j.0014-2956.2004.04286.x; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Lu Q, 2001, CELL, V105, P69, DOI 10.1016/S0092-8674(01)00297-5; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; Murai KK, 2002, NEURON, V33, P159, DOI 10.1016/S0896-6273(02)00565-2; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Shi JH, 2004, J BIOL CHEM, V279, P24765, DOI 10.1074/jbc.M311744200; Song JX, 2003, J BIOL CHEM, V278, P24714, DOI 10.1074/jbc.M210625200; Song JX, 2002, BIOCHEMISTRY-US, V41, P10942, DOI 10.1021/bi025815u; Song JX, 2001, J BIOL CHEM, V276, P41205, DOI 10.1074/jbc.M103449200; Song JX, 1997, BIOCHEMISTRY-US, V36, P3760, DOI 10.1021/bi962720h; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; Toth J, 2001, DEV CELL, V1, P83, DOI 10.1016/S1534-5807(01)00002-8; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zhang WX, 1998, BIOCHEMISTRY-US, V37, P7119, DOI 10.1021/bi972077e; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19205	19212		10.1074/jbc.M500330200	http://dx.doi.org/10.1074/jbc.M500330200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15764601	hybrid			2022-12-25	WOS:000228932300077
J	Zheng, YH; Yamaguchi, H; Tian, CJ; Lee, MW; Tang, H; Wang, HG; Chen, Q				Zheng, YH; Yamaguchi, H; Tian, CJ; Lee, MW; Tang, H; Wang, HG; Chen, Q			Arsenic trioxide (As2O3) induces apoptosis through activation of Bax in hematopoietic cells	ONCOGENE			English	Article						apoptosis; arsenic trioxide; Bax; mitochondria; reactive oxygen species	CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; ACUTE PROMYELOCYTIC LEUKEMIA; DEPENDENT ANION CHANNEL; INDUCED CONFORMATIONAL-CHANGE; MITOCHONDRIAL-MEMBRANE; CASPASE ACTIVATION; BCL-2; PROTEIN; DEATH	This study explores the roles of Bax and other Bcl-2 family members play in arsenic trioxide (As2O3)-induced apoptosis. We showed that As2O3 treatment triggered Bax conformational change and subsequent translocation from cytosol to mitochondria to form various multimeric homo-oligomers in IM-9 cells. On the other hand, human leukemic Jurkat cells deficient in Bax showed dramatically reduced apoptosis in response to As2O3. Stable overexpression of Bcl-2 in IM-9 cells (IM-9/Bcl-2) inhibited As2O3-mediated Bax activation and apoptosis, and this inhibition could be partially averted by cell-permeable Bid-Bcl-2 homology (BH)3 peptide. Meanwhile, Bax conformational change and oligomerization induced by As2O3 were not inhibited by the pancaspase inhibitor z-VAD-fmk, although Bid cleavage could be completely abolished. Bax activation by As2O3 seemed to require stress-induced intracellular reactive oxygen species (ROS), since the ROS scavengers (N-acetyl-L-cysteine and lipoic acid) could completely block the conformational change and translocation of Bax from cytosol to mitochondria. These data suggest that As2O3 might exert the cell killing in part by inducing Bax activation through a Bcl-2-suppressible pathway in hematopoietic cells that is caspase independent and intracellular ROS regulated.	Chinese Acad Sci, Inst Zool, Lab Apoptosis & Canc Biol, Natl Key Lab Biomembrane & Membrene Biotechnol, Beijing 100080, Peoples R China; Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Chinese Acad Sci, Ctr Mol Immunol, Inst Microbiol, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Institute of Zoology, CAS; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Chinese Academy of Sciences; Institute of Microbiology, CAS	Chen, Q (corresponding author), Chinese Acad Sci, Inst Zool, Lab Apoptosis & Canc Biol, Natl Key Lab Biomembrane & Membrene Biotechnol, Beijing 100080, Peoples R China.	chenq@ioz.ac.cn	yang, zheng/HGC-7753-2022; Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Chen, Quan/0000-0001-7539-8728	NCI NIH HHS [CA82197, CA90315] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082197, R01CA090315] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Akao Y, 1998, BRIT J HAEMATOL, V102, P1055, DOI 10.1046/j.1365-2141.1998.00869.x; Anderson KC, 2002, CANCER J, V8, P12, DOI 10.1097/00130404-200201000-00003; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Buccellato LJ, 2004, J BIOL CHEM, V279, P6753, DOI 10.1074/jbc.M310145200; Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Chen Q, 1998, BLOOD, V92, P4545, DOI 10.1182/blood.V92.12.4545.424k41_4545_4553; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Doza YN, 1998, ONCOGENE, V17, P19, DOI 10.1038/sj.onc.1202168; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kirkland RA, 2002, J NEUROSCI, V22, P6480; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li YM, 1999, CANCER RES, V59, P776; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maeda H, 2004, CELL DEATH DIFFER, V11, P737, DOI 10.1038/sj.cdd.4401389; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Miller WH, 2002, CANCER RES, V62, P3893; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Priault M, 2003, CELL DEATH DIFFER, V10, P1068, DOI 10.1038/sj.cdd.4401270; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Roucou X, 2002, BIOCHEM J, V363, P547, DOI 10.1042/0264-6021:3630547; Rousselot P, 1999, CANCER RES, V59, P1041; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shi Y, 2003, BIOCHEM BIOPH RES CO, V305, P989, DOI 10.1016/S0006-291X(03)00871-4; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Tsujimoto Y, 2002, BIOCHIMIE, V84, P187, DOI 10.1016/S0300-9084(02)01370-6; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Voehringer DW, 2000, ANTIOXID REDOX SIGN, V2, P537, DOI 10.1089/15230860050192314; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Woo SH, 2002, INT J ONCOL, V21, P57; Xia T, 2002, CHINESE SCI BULL, V47, P553, DOI 10.1360/02tb9127; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yamaguchi H, 2002, CANCER RES, V62, P466; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762; Zheng YH, 2004, ONCOGENE, V23, P1239, DOI 10.1038/sj.onc.1207205	60	57	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3339	3347		10.1038/sj.onc.1208484	http://dx.doi.org/10.1038/sj.onc.1208484			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735709				2022-12-25	WOS:000228881800012
J	Matthews, JR; Clarke, AR				Matthews, JR; Clarke, AR			p53 mediates a default programme of mammary gland involution in the absence of STAT3	ONCOGENE			English	Article						p53; STAT3; p21Waf1; involution; mammary	CELL PROLIFERATION; APOPTOSIS; MICE; PATHWAYS; SUPPRESSION; ACTIVATION; DELETION; TARGETS; CANCER	Previous studies have demonstrated a proapoptotic role for the transcription factor STAT3 in involuting murine mammary epithelium, resulting in delayed involution and lower levels of apoptosis in the STAT3 null gland relative to wild-type controls. As p53 was implicated in the eventual involution of the STAT3 null gland, we examined the effect of STAT3 loss in the mammary gland in a p53 null background. Combined loss of STAT3 and p53 severely perturbed involution, with hyperdelayed loss of epithelium and reappearance of adipocytes. The early apoptotic response was almost completely abrogated, although elevated levels of delayed apoptosis persisted at days 6, 17 and 4 weeks of involution in STAT3-p53 doubly null mammary glands. A 5.7-fold upregulation of the cyclin-dependent kinase inhibitor p21Waf1 at 3 days of involution in STAT3 null glands was abolished in STAT3-p53 doubly null glands - suggesting that the critical factor triggering delayed involution in the STAT3 null gland is a p53-dependent rise in p21Waf1 levels around day 3 of involution. Further, STAT3-p53 doubly null glands showed significantly higher levels of proliferation compared to STAT3 or p53 singly null ( or wild-type) glands at days 6, 17 and 4 weeks of involution. Combined loss of STAT3 and p53 therefore results in hyperdelayed involution, demonstrating their synergistic physiological roles in normal involution. This inappropriate retention of p53-deficient cells may represent a novel mechanism of tumour predisposition.	Cardiff Univ, Sch Biosci, Dept Mammalian Genet, BIOSI 3, Cardiff CF1 3US, S Glam, Wales	Cardiff University	Clarke, AR (corresponding author), Cardiff Univ, Sch Biosci, Dept Mammalian Genet, BIOSI 3, Museum Ave, Cardiff CF1 3US, S Glam, Wales.	clarkear@cf.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X				Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Selbert S, 1998, TRANSGENIC RES, V7, P387, DOI 10.1023/A:1008848304391; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Tonner E, 2002, DEVELOPMENT, V129, P4547; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yi YJ, 2004, MOL BIOL CELL, V15, P2302, DOI 10.1091/mbc.E03-11-0785; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	18	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3083	3090		10.1038/sj.onc.1208512	http://dx.doi.org/10.1038/sj.onc.1208512			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735683				2022-12-25	WOS:000228728100002
J	Oka, M; Meacham, AM; Hamazaki, T; Rodic, N; Chang, LJ; Terada, N				Oka, M; Meacham, AM; Hamazaki, T; Rodic, N; Chang, LJ; Terada, N			De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2 '-deoxycytidine	ONCOGENE			English	Article						DNA methyltransferase; azacytidine; embryonic stem cell; differentiation; apoptosis	EMBRYONIC STEM-CELLS; COLON-CANCER; LENTIVIRAL VECTORS; SATELLITE REGIONS; MAMMALIAN-CELLS; MISMATCH REPAIR; MESSENGER-RNA; CPG ISLANDS; METHYLATION; EXPRESSION	The deoxycytidine analog 5-aza-2'-deoxycitidine (5-aza-dC) is a potent chemotherapeutic agent effective against selective types of cancer. The molecular mechanism by which 5-aza-dC induces cancer cell death, however, is not fully understood. It has been accepted that the mechanism of toxicity is due to the covalent binding between the DNA methyltransferase (Dnmt) and 5-aza-dC-substituted DNA. In order to de. ne which member of the Dnmt family plays a dominant role in the cytotoxicity, we examined the effect of 5-aza-dC on cell growth and apoptosis in various Dnmt null mutant embryonic stem (ES) cells. Of interest, Dnmt3a - Dnmt3b double null ES cells were highly resistant to 5-aza-dC when compared to wild type, Dnmt3a null, Dnmt3b null, or Dnmt1 null ES cells. The cellular sensitivity to 5-aza-dC correlated well with the expression status of Dnmt3 in both undifferentiated and differentiated ES cells. When exogenous Dnmt3a or Dnmt3b was expressed in double null ES cells, the sensitivity to 5-aza-dC was partially restored. These results suggest that the cytotoxic effect of 5-aza-dC may be mediated primarily through Dnmt3a and Dnmt3b de novo DNA methyltransferases. Further, the ability to form Dnmt-DNA adducts was similar in Dnmt1 and Dnmt3, and the expression level of Dnmt3 was not higher than that of Dnmt1 in ES cells. Therefore, Dnmt3-DNA adducts may be more effective for inducing apoptosis than Dnmt1-DNA adducts. These results imply a therapeutic potential of 5-aza-dC to cancers expressing Dnmt3.	Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA; Univ Florida, Dept Mol Genet & Microbiol, Powell Gene Therapy Ctr, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Terada, N (corresponding author), Univ Florida, Coll Med, Dept Pathol, POBA 100275, Gainesville, FL 32610 USA.	terada@pathology.ufl.edu						Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Baylin SB, 1998, ADV CANCER RES, V72, P141; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chen TP, 2002, J BIOL CHEM, V277, P38746, DOI 10.1074/jbc.M205312200; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; GABBARA S, 1995, BIOCHEM J, V307, P87, DOI 10.1042/bj3070087; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Girault I, 2003, CLIN CANCER RES, V9, P4415; Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314; GORCZYCA W, 1993, CANCER RES, V53, P3186; Hamaguchi I, 2000, J VIROL, V74, P10778, DOI 10.1128/JVI.74.22.10778-10784.2000; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Iwakuma T, 1999, VIROLOGY, V261, P120, DOI 10.1006/viro.1999.9850; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; KIZAKI H, 1993, IMMUNOPHARMACOLOGY, V25, P19, DOI 10.1016/0162-3109(93)90027-N; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Liu K, 2003, MOL CELL BIOL, V23, P2709, DOI 10.1128/MCB.23.8.2709-2719.2003; Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932; MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; MURAKAMI T, 1995, CANCER RES, V55, P3093; Nieto M, 2004, ONCOGENE, V23, P735, DOI 10.1038/sj.onc.1207175; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pfeifer A, 2002, P NATL ACAD SCI USA, V99, P2140, DOI 10.1073/pnas.251682798; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Schneider-Stock R, 2005, J PHARMACOL EXP THER, V312, P525, DOI 10.1124/jpet.104.074195; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Suetake I, 2001, CELL STRUCT FUNCT, V26, P79, DOI 10.1247/csf.26.79; TAKAGI H, 1995, EUR J BIOCHEM, V231, P282, DOI 10.1111/j.1432-1033.1995.tb20698.x; Trinh BN, 2002, MOL CELL BIOL, V22, P2906, DOI 10.1128/MCB.22.9.2906-2917.2002; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Weisenberger DJ, 2004, MOL CANCER RES, V2, P62; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Zaiss AK, 2002, J VIROL, V76, P7209, DOI 10.1128/JVI.76.14.7209-7219.2002; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200	56	102	104	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3091	3099		10.1038/sj.onc.1208540	http://dx.doi.org/10.1038/sj.onc.1208540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735669				2022-12-25	WOS:000228728100003
J	Yan, L; Donze, JR; Liu, LL				Yan, L; Donze, JR; Liu, LL			Inactivated MGMT by O-6-benzylguanine is associated with prolonged G(2)/M arrest in cancer cells treated with BCNU	ONCOGENE			English	Article						MGMT; cell cycle checkpoint; mitosis; DNA damage	DNA-DAMAGE CHECKPOINT; TERMINAL PROLIFERATION ARREST; BRAIN-TUMOR CELLS; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; DEPENDENT PROTEOLYSIS; CYCLE REGULATION; CARCINOMA-CELLS; GROWTH ARREST; COLON-CANCER; PHOSPHORYLATION	HCT116 and HCT15 cells that highly express O-6-methylguanine-DNA-methyltransferase (MGMT) displayed a transient cell cycle G2/M arrest in response to exposure to 1,3-bis(2-chloroethyl)-1-nitrosourea ( BCNU) alone; however, 70 - 80% of cells were arrested in G2/M after treatment with O-6-benzylguanine (BG) and BCNU. Cells accumulated in G2/M showed elevated levels of an inactive form of cyclin B1/p-Cdc2 (Tyr15) complex that was not associated with activation of Chk1/p-Cdc25C and was independent of p53/p21 status. The most prominent feature of cell death was the appearance of enlarged and multinucleated cells that was related to the inhibition of mitotic entry. In contrast, BG-resistant cell lines, HCT116 BBR and HCT15 BBR cells that contain mutations K165E and K165N of MGMT, respectively, displayed a normal cell cycle progression with a slight and transient increase in G2/M arrest at 24 h after treatments with either BCNU alone or BG combined with BCNU. The differences in the ability to progress toward G2/M after treatment with BG and BCNU between cells expressing wild-type MGMT and mutated MGMT were confirmed in CHO cells transfected with human wild type and K165E mutant MGMT cDNA, respectively. Thus, our findings suggest that BG-inactivated MGMT may be linked to cell signaling events, forcing cells into a permanent G2/M arrest in response to the DNA damages induced by BCNU.	Case Western Reserve Univ, Dept Med, Div Hematol & Oncol, Cleveland, OH 44106 USA	Case Western Reserve University	Liu, LL (corresponding author), Case Western Reserve Univ, Dept Med, Div Hematol & Oncol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	1x132@cwru.edu			NATIONAL CANCER INSTITUTE [R01CA082292] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA82292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguda BD, 1999, P NATL ACAD SCI USA, V96, P11352, DOI 10.1073/pnas.96.20.11352; Andreassen PR, 2001, CANCER RES, V61, P7660; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; FUNARI B, 1997, SCIENCE, V277, P1495; GERSON SL, 1993, BIOCHEM PHARMACOL, V45, P483, DOI 10.1016/0006-2952(93)90086-C; GIBSON NW, 1985, PHARMACOL THERAPEUT, V31, P153, DOI 10.1016/0163-7258(85)90042-7; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hirose Y, 2001, CANCER RES, V61, P5843; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Kaufmann WK, 1998, MUTAT RES-FUND MOL M, V400, P153, DOI 10.1016/S0027-5107(98)00041-4; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038/sj.onc.1204942; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Liu LL, 2002, CANCER RES, V62, P3070; Liu LL, 1996, CANCER RES, V56, P5375; Liu QH, 2000, GENE DEV, V14, P1448; LOCK RB, 1992, CANCER RES, V52, P1817; Monte M, 2003, J BIOL CHEM, V278, P30356, DOI 10.1074/jbc.M302902200; Mullapudi SRS, 2000, BIOCHEM J, V351, P393, DOI 10.1042/0264-6021:3510393; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Park JI, 2000, J CANCER RES CLIN, V126, P455, DOI 10.1007/s004320050013; PEGG AE, 1990, CANCER RES, V50, P6119; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Roninson IB, 2003, CANCER RES, V63, P2705; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shah MA, 2001, CLIN CANCER RES, V7, P2168; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Srivenugopal KS, 2000, CANCER RES, V60, P282; Srivenugopal KS, 1996, BIOCHEMISTRY-US, V35, P1328, DOI 10.1021/bi9518205; STAMATO TD, 1990, RADIAT RES, V121, P196, DOI 10.2307/3577504; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang XH, 1998, CANCER RES, V58, P5019; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	44	30	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2175	2183		10.1038/sj.onc.1208250	http://dx.doi.org/10.1038/sj.onc.1208250			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735757				2022-12-25	WOS:000227857900005
J	Wang, KW; Brems, JJ; Gamelli, RL; Ding, JW				Wang, KW; Brems, JJ; Gamelli, RL; Ding, JW			Reversibility of caspase activation and its role during glycochenodeoxycholate-induced hepatocyte apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SALT-INDUCED APOPTOSIS; FAS-INDUCED APOPTOSIS; RAT HEPATOCYTES; NEURONAL APOPTOSIS; EXPRESSION; GENE; NECROSIS; INHIBITION; RESISTANCE	The accumulation of glycochenodeoxycholate (GCDC) induced hepatocyte apoptosis in cholestasis. However, many hepatocytes still survived GCDC-induced apoptosis. The molecular mechanism for the survival of hepatocytes remains unclear. In the present study, isolated rat hepatocytes were cultured in William's E medium and treated with 50 mu M GCDC. DNA, RNA, cell lysate, and nuclear proteins were collected at different intervals for DNA fragmentation assay, reverse transcription PCR, Western blotting, and gel mobility shift assay, respectively. GCDC-induced active caspases were detected as early as 2 h by Western blotting and kinetic caspase assay, whereas hepatocyte apoptosis was found at 4 h by DNA fragmentation and terminal deoxynucleotidyl transferase-mediated dUPT nick-end labeling assay. When GCDC was removed, the increased caspases as well as NF-kappa B could be restored to control level. A1/Bfl-1 and inducible nitric oxide synthase ( iNOS) were up-regulated in 2 h of GCDC stimulation. After GCDC was removed, hepatocytes decreased expression of A1/Bfl-1, but not iNOS, to the control level. NF-kappa B activation coincided with the change of A1/Bfl-1. Survivin, cIAP1, cIAP2, XIAP, and A1/Bfl-1, but not iNOS, were down-regulated by pan-caspase inhibitor benzyloxycarbonyl-VAD- fluoromethyl ketone. In addition, benzyloxycarbonyl-VAD- fluoromethyl ketone inhibited release of cytochrome c and suppressed NF-kappa B activation. Our data suggested that caspase pathway is an important regulatory factor during hepatocyte apoptosis. GCDC-induced caspase response is reversible, which may activate anti-apoptotic genes to protect hepatocytes from apoptosis.	Loyola Univ, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA; Loyola Univ, Ctr Med, Dept Surg, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago	Wang, KW (corresponding author), Loyola Univ, Dept Cell Biol Neurobiol & Anat, Bldg 101,Rm 2726, Maywood, IL 60153 USA.	kwang1@lumc.edu						Albright CD, 2003, EXP MOL PATHOL, V74, P256, DOI 10.1016/S0014-4800(03)00002-9; Chan SL, 1999, J NEUROSCI RES, V57, P315, DOI 10.1002/(SICI)1097-4547(19990801)57:3<315::AID-JNR3>3.3.CO;2-R; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chiou Shiun-Kwei, 2003, Med Sci Monit, V9, pPI25; Contestabile Antonio, 2002, Cerebellum, V1, P41, DOI 10.1080/147342202753203087; Conway EM, 2002, GASTROENTEROLOGY, V123, P619, DOI 10.1053/gast.2002.34753; DEBELDER AJ, 1994, J HYPERTENS, V12, P617; Denault JB, 2003, J BIOL CHEM, V278, P34042, DOI 10.1074/jbc.M305110200; Ding JW, 1997, J VIROL, V71, P9223, DOI 10.1128/JVI.71.12.9223-9230.1997; Domachowske JB, 2000, J INFECT DIS, V181, P824, DOI 10.1086/315319; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Gonzalez B, 2000, MOL CELL BIOCHEM, V207, P19, DOI 10.1023/A:1007021710825; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hatano E, 2001, GASTROENTEROLOGY, V120, P1251, DOI 10.1053/gast.2001.23239; Hofmann AF, 2002, LIVER, V22, P14, DOI 10.1034/j.1600-0676.2002.00002.x; Kim PKM, 2002, ANN NY ACAD SCI, V962, P42, DOI 10.1111/j.1749-6632.2002.tb04054.x; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1998, MOL MED, V4, P179, DOI 10.1007/BF03401915; Knight TR, 2002, TOXICOL APPL PHARM, V181, P133, DOI 10.1006/taap.2002.9407; Kwon YH, 2003, J BIOL CHEM, V278, P30348, DOI 10.1074/jbc.M300996200; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LAUTERBURG BH, 1980, INT J ARTIF ORGANS, V3, P281, DOI 10.1177/039139888000300510; LI J, 1999, AM J PHYSIOL, V276, P1069; Lieser MJ, 1998, GASTROENTEROLOGY, V115, P693, DOI 10.1016/S0016-5085(98)70149-0; McNaughton L, 2002, P NATL ACAD SCI USA, V99, P17161, DOI 10.1073/pnas.0134112100; Muzio M, 1998, INT J CLIN LAB RES, V28, P141, DOI 10.1007/s005990050035; Newton K, 2003, GENE DEV, V17, P819, DOI 10.1101/gad.1077403; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Park IC, 1997, ANTICANCER RES, V17, P4619; Qi L, 2000, APOPTOSIS, V5, P379, DOI 10.1023/A:1009695811147; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Schoemaker MH, 2003, J HEPATOL, V39, P153, DOI 10.1016/S0168-8278(03)00214-9; Schoemaker MH, 2002, J HEPATOL, V36, P742, DOI 10.1016/S0168-8278(02)00063-6; Sodeman T, 2000, AM J PHYSIOL-GASTR L, V278, pG992, DOI 10.1152/ajpgi.2000.278.6.G992; Sola S, 2002, CLIN SCI, V103, P475, DOI 10.1042/CS20020196; Tatton WG, 1996, NEUROLOGY, V47, pS171, DOI 10.1212/WNL.47.6_Suppl_3.171S; Thompson MB, 1996, TOXICOL PATHOL, V24, P62, DOI 10.1177/019262339602400109; Tzeng E, 1998, SURGERY, V124, P278, DOI 10.1067/msy.1998.90569; Wang CY, 1999, MOL CELL BIOL, V19, P5923; XIE QW, 1994, J BIOL CHEM, V269, P4705; Xiong SG, 2003, J BIOL CHEM, V278, P17646, DOI 10.1074/jbc.M210905200; Zeid IM, 1997, HEPATOLOGY, V25, P81, DOI 10.1053/jhep.1997.v25.pm0008985269; ZEISEL SH, 1995, ADV EXP MED BIOL, V375, P65	47	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23490	23495		10.1074/jbc.M411607200	http://dx.doi.org/10.1074/jbc.M411607200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15767249	hybrid			2022-12-25	WOS:000229880000012
J	Cao, DL; Leffert, JJ; McCabe, J; Kim, B; Pizzorno, G				Cao, DL; Leffert, JJ; McCabe, J; Kim, B; Pizzorno, G			Abnormalities in uridine homeostatic regulation and pyrimidine nucleotide metabolism as a consequence of the deletion of the uridine phosphorylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; SALVAGE; URACIL; SLEEP; CELLS; 5-FLUOROURACIL; BIOSYNTHESIS; MODULATION; ACTIVATION; RELEASE	We report in the present study the critical role of uridine phosphorylase (UPase) in uridine homeostatic regulation and pyrimidine nucleotide metabolism, employing newly developed UPase-/- mice. Our data demonstrate that the abrogation of UPase activity led to greater than a 6-fold increase in uridine concentrations in plasma, a 5-6-fold increase in lung and gut, and a 2-3-fold increase in liver and kidney, as compared with wild type mice. Urine uridine levels increased 24-fold normal in UPase-/- mice. Uridine half-life and the plasma retention of pharmacological doses of uridine were significantly prolonged. Further, in these UPase-/- mice, abnormal uridine metabolism led to disorders of various nucleotide metabolisms. In the liver, gut, kidney, and lung of UPase-/- mice, total uridine ribonucleotide concentrations increased 2-3 times as compared with control mice. Cytidine ribonucleotides and adenosine and guanosine ribonucleotides also increased, although to a lesser extent, in these organs. Most significant deoxyribonucleotide changes were present in the gut and lung of UPase-/- mice. In these tissues, dTTP concentration increased more than 4-fold normal, and dCTP, dGTP, and dATP concentrations rose 1-2 times normal. In kidney, dTTP concentration increased 2-fold normal, and dCTP and dGTP concentrations rose less than 1-fold normal. In addition, the accumulated uridine in plasma and tissues efficiently reduced 5-fluorouracil host toxicity and altered the anesthetic effect of pentobarbital. These data indicate that UPase is a critical enzyme in the regulation of uridine homeostasis and pyrimidine nucleotide metabolism, and 5-fluorouracil activity.	Yale Univ, Sch Med, Dept Internal Med Oncol, New Haven, CT 06520 USA; So Illinois Univ, Sch Med, Inst Canc, Springfield, IL 62702 USA; Nevada Canc Inst, Las Vegas, NV 89135 USA	Yale University; Southern Illinois University System; Southern Illinois University; University of California System; University of California San Diego	Pizzorno, G (corresponding author), Yale Univ, Sch Med, Dept Internal Med Oncol, 333 Cedar St,SHM I 220, New Haven, CT 06520 USA.	Giuseppe.Pizzorno@yale.edu		Kim, Bradford/0000-0002-1832-5298	NCI NIH HHS [CA67035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson CM, 1997, TRENDS PHARMACOL SCI, V18, P387, DOI 10.1016/S0165-6147(97)01106-1; Barsotti C, 2002, J BIOL CHEM, V277, P9865, DOI 10.1074/jbc.M111418200; BECROFT DMO, 1969, J PEDIATR, V75, P885; Cao DL, 2004, DRUG TODAY, V40, P431, DOI 10.1358/dot.2004.40.5.850491; Cao DL, 2002, CANCER RES, V62, P2313; Cao DL, 1999, CANCER RES, V59, P4997; Cao DL, 1998, J BIOL CHEM, V273, P11429, DOI 10.1074/jbc.273.19.11429; Connolly GP, 1999, TRENDS PHARMACOL SCI, V20, P218, DOI 10.1016/S0165-6147(99)01298-5; DAGANI F, 1984, NEUROCHEM RES, V9, P1085, DOI 10.1007/BF00964804; DARNOWSKI JW, 1991, BIOCHEM PHARMACOL, V41, P2031, DOI 10.1016/0006-2952(91)90146-V; GASSER T, 1981, SCIENCE, V213, P777, DOI 10.1126/science.7256279; GELLER E, 1989, NEUROPHARMACOLOGY, V28, P271, DOI 10.1016/0028-3908(89)90103-2; Grem JL, 2000, INVEST NEW DRUG, V18, P299, DOI 10.1023/A:1006416410198; Harden TK, 1997, TRENDS PHARMACOL SCI, V18, P43, DOI 10.1016/S0165-6147(97)89795-7; HONDA K, 1985, NEUROSCI LETT, V62, P137, DOI 10.1016/0304-3940(85)90297-6; INOUE S, 1995, BEHAV BRAIN RES, V69, P91, DOI 10.1016/0166-4328(95)00014-K; Johansson M, 2003, BIOCHEM BIOPH RES CO, V307, P41, DOI 10.1016/S0006-291X(03)01062-3; KARLE JM, 1984, J BIOL CHEM, V259, P67; KIMURATAKEUCHI M, 1993, BRAIN RES BULL, V31, P33, DOI 10.1016/0361-9230(93)90007-X; KOUNI MH, 1993, CANCER RES, V53, P3687; Liu MP, 1998, CANCER RES, V58, P5418; LUCAS ZJ, 1967, SCIENCE, V156, P1237, DOI 10.1126/science.156.3779.1237; MOYER JD, 1985, BIOCHEM PHARMACOL, V34, P101, DOI 10.1016/0006-2952(85)90107-8; Page T, 1997, P NATL ACAD SCI USA, V94, P11601, DOI 10.1073/pnas.94.21.11601; PIZZORNO G, 1992, CANCER RES, V52, P1660; Pizzorno G, 2002, BBA-MOL BASIS DIS, V1587, P133, DOI 10.1016/S0925-4439(02)00076-5; SHAMBAUGH GE, 1979, AM J CLIN NUTR, V32, P1290, DOI 10.1093/ajcn/32.6.1290; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Traut TW, 1996, PROG NUCLEIC ACID RE, V53, P1, DOI 10.1016/S0079-6603(08)60142-7; VANGROENINGEN CJ, 1989, J NATL CANCER I, V81, P157; WICE BM, 1982, J BIOL CHEM, V257, P2578	31	44	47	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21169	21175		10.1074/jbc.M412343200	http://dx.doi.org/10.1074/jbc.M412343200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15772079	hybrid			2022-12-25	WOS:000229438800034
J	Galindo, M; Pratap, J; Young, DW; Hovhannisyan, H; Im, HJ; Choi, JY; Lian, JB; Stein, JL; Stein, GS; van Wijnen, AJ				Galindo, M; Pratap, J; Young, DW; Hovhannisyan, H; Im, HJ; Choi, JY; Lian, JB; Stein, JL; Stein, GS; van Wijnen, AJ			The bone-specific expression of Runx2 oscillates during the cell cycle to support a G(1)-related antiproliferative function in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; SKELETAL GENE-EXPRESSION; GROWTH-FACTOR BETA-1; MORPHOGENETIC PROTEIN-2; TRANSCRIPTION FACTORS; CLEIDOCRANIAL DYSPLASIA; SUBNUCLEAR DOMAINS; RUNX/CBFA/AML FACTORS; PARATHYROID-HORMONE; SIGNALING PATHWAYS	The Runx2 (CBFA1/AML3/PEBP2 alpha A) transcription factor promotes skeletal cell differentiation, but it also has a novel cell growth regulatory activity in osteoblasts. We addressed here whether Runx2 activity is functionally linked to cell cycle-related mechanisms that control normal osteoblast proliferation and differentiation. We found that the levels of Runx2 gene transcription, mRNA and protein, are each up-regulated with cessation of cell growth (i.e. G(0)/G(1) transition) in preconfluent MC3T3 osteoblastic cells that do not yet express mature bone phenotypic gene expression. Cell growth regulation of Runx2 is also observed in primary calvarial osteoblasts and other osteoblastic cells with relatively normal cell growth characteristics, but not in osteosarcoma cells (e. g. SAOS-2 and ROS17/2.8). Runx2 levels are cell cycle-regulated in MC3T3 cells with respect to the G(1)/S and M/G(1) transitions: expression oscillates from maximal levels during early G(1) to minimal levels during early S phase and mitosis. However, in normal or immortalized (e. g. ATDC5) chondrocytic cells, Runx2 expression is suppressed during quiescence, and Runx2 levels are not regulated during G(1) and S phase in ATDC5 cells. Antisense or small interfering RNA-mediated reduction of the low physiological levels of Runx2 in proliferating MC3T3 cells does not accelerate cell cycle progression. However, forced expression of Runx2 suppresses proliferation of MC3T3 preosteoblasts or C2C12 mesenchymal cells which have osteogenic potential. Forced elevation of Runx2 in synchronized MC3T3 cells causes a delay in G(1). We propose that Runx2 levels and function are biologically linked to a cell growth-related G(1) transition in osteoblastic cells.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA; Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA; Rush Univ, Med Ctr, Dept Internal Med, Rheumatol Sect, Chicago, IL 60612 USA; Kyungpook Natl Univ, Sch Med, Dept Biochem, Taegu 700422, South Korea	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Rush University; Rush University; Kyungpook National University	van Wijnen, AJ (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	andre.vanwijnen@umassmed.edu	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053220, R01AR039588, P01AR048818, R01AR049069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002647] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR48818, AR49069, AR39588, R01 AR039588, R01 AR053220, R01 AR053220-04, P01 AR048818, R01 AR049069] Funding Source: Medline; NIDDK NIH HHS [5P30 DK32520, P30 DK032520] Funding Source: Medline; BLRD VA [I01 BX002647] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); BLRD VA		Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Bernardin-Fried F, 2004, J BIOL CHEM, V279, P15678, DOI 10.1074/jbc.M310023200; Bodine PVN, 1996, ENDOCRINOLOGY, V137, P4592, DOI 10.1210/en.137.11.4592; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chang WZ, 2002, GENE, V299, P65, DOI 10.1016/S0378-1119(02)01013-2; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Drissi H, 2002, EXP CELL RES, V274, P323, DOI 10.1006/excr.2002.5474; Friedman AD, 2002, J CELL BIOCHEM, V86, P624, DOI 10.1002/jcb.10271; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Gurlek A, 2002, ENDOCR REV, V23, P763, DOI 10.1210/er.2001-0044; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Harrington KS, 2002, J CELL SCI, V115, P4167, DOI 10.1242/jcs.00095; Hoffmann A, 2001, CRIT REV EUKAR GENE, V11, P23; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Javed A, 1999, MOL CELL BIOL, V19, P7491; Javed A, 2000, J CELL SCI, V113, P2221; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kitzmann M, 1998, J CELL BIOL, V142, P1447, DOI 10.1083/jcb.142.6.1447; KODAMA HA, 1982, J CELL PHYSIOL, V112, P83, DOI 10.1002/jcp.1041120113; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; Lian JB, 2003, CONNECT TISSUE RES, V44, P141, DOI 10.1080/03008200390152232; Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378-1119(03)00748-0; McCarthy TL, 2000, CRIT REV ORAL BIOL M, V11, P409, DOI 10.1177/10454411000110040201; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 2001, INT J HEMATOL, V74, P252, DOI 10.1007/BF02982057; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Pratap J, 2003, CANCER RES, V63, P5357; Puri PL, 1997, ONCOGENE, V14, P1171, DOI 10.1038/sj.onc.1200941; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Reynaud EG, 2000, J BIOL CHEM, V275, P18767, DOI 10.1074/jbc.M907412199; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Staal A, 1996, ENDOCRINOLOGY, V137, P2001, DOI 10.1210/en.137.5.2001; Stein GS, 2003, CONNECT TISSUE RES, V44, P149, DOI 10.1080/03008900390152241; Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676; Sudhakar S, 2001, BIOCHEM BIOPH RES CO, V289, P616, DOI 10.1006/bbrc.2001.6033; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tintignac LA, 2000, EXP CELL RES, V259, P300, DOI 10.1006/excr.2000.4973; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; van Wijnen AJ, 2004, ONCOGENE, V23, P4209, DOI 10.1038/sj.onc.1207758; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Whitfield JF, 2002, CRIT REV EUKAR GENE, V12, P23, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i1.20; Wotton SF, 2004, ONCOGENE, V23, P5476, DOI 10.1038/sj.onc.1207729; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192; Xiao ZS, 2003, J CELL BIOCHEM, V88, P493, DOI 10.1002/jcb.10375; Yagi K, 2003, J CELL BIOCHEM, V88, P1077, DOI 10.1002/jcb.10467; Yakar S, 2002, ENDOCRINE, V19, P239, DOI 10.1385/ENDO:19:3:239; Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471-4914(02)02340-7; Zaidi SK, 2001, J CELL SCI, V114, P3093; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zaidi SK, 2003, P NATL ACAD SCI USA, V100, P14852, DOI 10.1073/pnas.2533076100; Zambotti A, 2002, J BIOL CHEM, V277, P41497, DOI 10.1074/jbc.M204271200; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	77	194	203	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20274	20285		10.1074/jbc.M413665200	http://dx.doi.org/10.1074/jbc.M413665200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781466	hybrid, Green Accepted			2022-12-25	WOS:000229242000016
J	Avril, T; Freeman, SD; Attrill, H; Clarke, RG; Crocker, PR				Avril, T; Freeman, SD; Attrill, H; Clarke, RG; Crocker, PR			Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASES SHP-1; CD33-RELATED SIGLECS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; HUMAN MONOCYTES; MSIGLEC-E; RECEPTOR; EXPRESSION; CELLS; CD33	Siglec-5 (CD170) is a member of the recently described human CD33-related siglec subgroup of sialic acid binding Ig-like lectins and is expressed on myeloid cells of the hemopoietic system. Similar to other CD33-related siglecs, Siglec-5 contains two tyrosine-based motifs in its cytoplasmic tail implicated in signaling functions. To investigate the role of these motifs in Siglec-5-dependent signaling, we used transfected rat basophil leukemia cells as a model system. Tyrosine phosphorylation of Siglec-5 led to recruitment of the tyrosine phosphatases SHP-1 and SHP-2, as seen in both pull-down assays and microscopy. Siglec-5 could efficiently inhibit Fc epsilon RI-mediated calcium fluxing and serotonin release after co-cross-linking. Surprisingly, a double tyrosine to alanine mutant of Siglec-5 could still mediate strong inhibition of serotonin release in the absence of detectable tyrosine phosphorylation, whereas a double tyrosine to phenylalanine mutant lost all inhibitory activity. In comparison, suppression of Siglec-5-dependent adhesion to red blood cells was reversed by either tyrosine to alanine or tyrosine to phenylalanine mutations of the membrane proximal tyrosine-based motif. Using an in vitro phosphatase assay with synthetic and recombinant forms of the cytoplasmic tail, it was shown that a double alanine mutant of Siglec-5 had weak, but significant SHP-1 activating properties similar to those of wild type, non-phosphorylated cytoplasmic tail, whereas a double phenylalanine mutant was inactive. These findings establish that Siglec-5 can be classified as an inhibitory receptor with the potential to mediate SHP-1 and/or SHP-2-dependent signaling in the absence of tyrosine phosphorylation.	Univ Dundee, Wellcome Trust Bioctr, Div Cell Biol & Immunol, Sch Life Sci, Dundee DD1 5EH, Scotland; Univ Birmingham, Sch Med, Dept Immunol, Birmingham B15 2TT, W Midlands, England	University of Dundee; University of Birmingham	Crocker, PR (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Div Cell Biol & Immunol, Sch Life Sci, Dow St, Dundee DD1 5EH, Scotland.	p.r.crocker@dundee.ac.uk	Avril, Tony/ABG-7611-2020	Avril, Tony/0000-0002-1129-8514; Crocker, Paul/0000-0001-6230-0293; Attrill, Helen/0000-0003-3212-6364; Freeman, Sylvie/0000-0003-1869-180X				Angata T, 2002, J BIOL CHEM, V277, P24466, DOI 10.1074/jbc.M202833200; Angata T, 2004, P NATL ACAD SCI USA, V101, P13251, DOI 10.1073/pnas.0404833101; Avril T, 2004, J IMMUNOL, V173, P6841, DOI 10.4049/jimmunol.173.11.6841; Beebe KD, 2000, BIOCHEMISTRY-US, V39, P13251, DOI 10.1021/bi0014397; Blery M, 1997, J BIOL CHEM, V272, P8989; Connolly NP, 2002, BRIT J HAEMATOL, V119, P221, DOI 10.1046/j.1365-2141.2002.03808.x; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Dietrich J, 2000, MICROBES INFECT, V2, P323, DOI 10.1016/S1286-4579(00)00294-X; Erickson-Miller CL, 2003, EXP HEMATOL, V31, P382, DOI 10.1016/S0301-472X(03)00046-8; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Ikehara Y, 2004, J BIOL CHEM, V279, P43117, DOI 10.1074/jbc.M403538200; Jackson DE, 2003, FEBS LETT, V540, P7, DOI 10.1016/S0014-5793(03)00224-2; Jones C, 2003, MOL MICROBIOL, V49, P1213, DOI 10.1046/j.1365-2958.2003.03634.x; Kitzig F, 2002, BIOCHEM BIOPH RES CO, V296, P355, DOI 10.1016/S0006-291X(02)00885-9; Lajaunias F, 2005, EUR J IMMUNOL, V35, P243, DOI 10.1002/eji.200425273; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; Lock K, 2004, IMMUNOBIOLOGY, V209, P199, DOI 10.1016/j.imbio.2004.04.007; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Nathan C, 2001, NAT IMMUNOL, V2, P17, DOI 10.1038/83124; Paul SP, 2000, BLOOD, V96, P483; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Schoenwaelder SM, 2000, CURR BIOL, V10, P1523, DOI 10.1016/S0960-9822(00)00831-9; Shlapatska LM, 2001, J IMMUNOL, V166, P5480, DOI 10.4049/jimmunol.166.9.5480; Staub E, 2004, CELL SIGNAL, V16, P435, DOI 10.1016/j.cellsig.2003.08.013; Stebbins CC, 2003, MOL CELL BIOL, V23, P6291, DOI 10.1128/MCB.23.17.6291-6299.2003; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; Tridandapani S, 2002, J BIOL CHEM, V277, P5082, DOI 10.1074/jbc.M110277200; Ulyanova T, 1999, EUR J IMMUNOL, V29, P3440, DOI 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.3.CO;2-3; Ulyanova T, 2001, J BIOL CHEM, V276, P14451, DOI 10.1074/jbc.M011650200; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; Yu ZB, 2001, BIOCHEM J, V353, P483, DOI 10.1042/0264-6021:3530483; Yu ZB, 2001, J BIOL CHEM, V276, P23816, DOI 10.1074/jbc.M102394200; Yusa S, 2002, J IMMUNOL, V168, P5047, DOI 10.4049/jimmunol.168.10.5047; Zhang JQ, 2000, J BIOL CHEM, V275, P22121, DOI 10.1074/jbc.M002788200; Zhang JQQ, 2004, EUR J IMMUNOL, V34, P1175, DOI 10.1002/eji.200324723	40	76	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19843	19851		10.1074/jbc.M502041200	http://dx.doi.org/10.1074/jbc.M502041200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769739	hybrid			2022-12-25	WOS:000229113700052
J	Dirr, HW; Little, T; Kuhnert, DC; Sayed, Y				Dirr, HW; Little, T; Kuhnert, DC; Sayed, Y			A conserved N-capping motif contributes significantly to the stabilization and dynamics of the C-terminal region of class alpha glutathione S-transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-PROTEIN; HIGH CATALYTIC EFFICIENCY; LIGAND-BINDING; HEAT-CAPACITY; ACTIVE-SITE; ELECTROSTATIC INTERACTIONS; HETEROLOGOUS EXPRESSION; LIPID-PEROXIDATION; CRYSTAL-STRUCTURES; ANOMALOUS PK(A)	Helix 9, the major structural element in the C-terminal region of class Alpha glutathione transferases, forms part of the active site of these enzymes where its dynamic properties modulate both catalytic and ligandin functions. A conserved aspartic acid N-capping motif for helix 9 was identified by sequence alignments of the C-terminal regions of class Alpha glutathione S-transferases (GSTs) and an analysis by the helix-coil algorithm AGADIR. The contribution of the N-capping motif to the stability and dynamics of the region was investigated by replacing the N-cap residue Asp-209 with a glycine in human glutathione S-transferase A1-1 (hGST A1-1) and in a peptide corresponding to its C-terminal region. Far-UV circular dichroism and AGADIR analyses indicate that, in the absence of tertiary interactions, the wild-type peptide displays a low intrinsic tendency to form a helix and that this tendency is reduced significantly by the Asp-to-Gly mutation. Disruption of the N-capping motif of helix 9 in hGST A1-1 alters the conformational dynamics of the C-terminal region and, consequently, the features of the H-site to which hydrophobic substrates (e. g. 1-chloro-2,4-dinitrobenzene (CDNB)) and nonsubstrates (e. g. 8-anilino-1-naphthalene sulfonate (ANS)) bind. Isothermal calorimetric and fluorescence data for complex formation between ANS and protein suggest that the D209G-induced perturbation in the C-terminal region prevents normal ligand-induced localization of the region at the active site, resulting in a less hydrophobic and more solvent-exposed H-site. Therefore, the catalytic efficiency of the enzyme with CDNB is diminished due to a lowered affinity for the electrophilic substrate and a lower stabilization of the transition state.	Univ Witwatersrand, Sch Mol & Cell Biol, Prot Struct Funct Res Programme, ZA-2050 Wits, South Africa	University of Witwatersrand	Dirr, HW (corresponding author), Univ Witwatersrand, Sch Mol & Cell Biol, Prot Struct Funct Res Programme, Jan Smuts Ave, ZA-2050 Wits, South Africa.	heinid@gecko.biol.wits.ac.za	Sayed, Yasien/AAA-3302-2021; Dirr, Heini W/F-7228-2010	Sayed, Yasien/0000-0002-1781-2115; Dirr, Heini/0000-0003-1455-7769				Aceto A, 1997, BIOCHEM J, V322, P229, DOI 10.1042/bj3220229; Allardyce CS, 1999, BIOCHEM J, V343, P525, DOI 10.1042/0264-6021:3430525; Anderson TA, 2003, BIOPHYS CHEM, V100, P341, DOI 10.1016/S0301-4622(02)00291-0; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Atkins WM, 1997, PROTEIN SCI, V6, P873; BICO P, 1995, BBA-PROTEIN STRUCT M, V1247, P225, DOI 10.1016/0167-4838(94)00236-A; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; BOARD PG, 1991, BIOCHEM J, V275, P171, DOI 10.1042/bj2750171; BRANDTS JF, 1973, BIOCHEMISTRY-US, V12, P2011, DOI 10.1021/bi00734a027; BROWN JE, 1971, BIOCHEMISTRY-US, V10, P470, DOI 10.1021/bi00779a019; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; BUETLER TM, 1992, BIOCHEM BIOPH RES CO, V188, P597, DOI 10.1016/0006-291X(92)91098-B; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; CHAKRABARTTY A, 1993, BIOCHEMISTRY-US, V32, P5560, DOI 10.1021/bi00072a010; Cocco R, 2001, J BIOL CHEM, V276, P32177, DOI 10.1074/jbc.M104057200; DASGUPTA S, 1993, INT J PEPT PROT RES, V41, P499; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Dirr HW, 1999, BIOCHEMISTRY-US, V38, P15631, DOI 10.1021/bi991179x; Doig AJ, 1997, PROTEIN SCI, V6, P147; Dragani B, 1997, J BIOL CHEM, V272, P25518, DOI 10.1074/jbc.272.41.25518; DUNITZ JD, 1994, SCIENCE, V264, P670, DOI 10.1126/science.264.5159.670; ELMASRY NF, 1994, PROTEIN ENG, V7, P777, DOI 10.1093/protein/7.6.777; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Freire E, 1997, PURE APPL CHEM, V69, P2253, DOI 10.1351/pac199769112253; Gustafsson A, 1999, BIOCHEMISTRY-US, V38, P16268, DOI 10.1021/bi991482y; Habig W H, 1981, Methods Enzymol, V77, P398; HAYES JD, 1992, BIOCHEM J, V285, P173, DOI 10.1042/bj2850173; Ibarra C, 2001, BIOCHEMISTRY-US, V40, P10614, DOI 10.1021/bi010672h; Ibarra CA, 2003, J BIOL CHEM, V278, P19257, DOI 10.1074/jbc.M301566200; Johnson WW, 1997, BIOCHEMISTRY-US, V36, P3056, DOI 10.1021/bi962537o; KETLEY JN, 1975, J BIOL CHEM, V250, P8670; Kirk WR, 1996, BIOPHYS J, V70, P69, DOI 10.1016/S0006-3495(96)79592-9; Kolobe D, 2004, BIOCHEM J, V382, P703, DOI 10.1042/BJ20040056; Kumaran S, 1999, J PEPT RES, V53, P284, DOI 10.1034/j.1399-3011.1999.00027.x; KURIAN E, 1998, THESIS MAYO FDN ROCH; Lacroix E, 1998, J MOL BIOL, V284, P173, DOI 10.1006/jmbi.1998.2145; Ladbury JE, 2004, CURR OPIN STRUC BIOL, V14, P562, DOI 10.1016/j.sbi.2004.08.001; Ladner JE, 2004, BIOCHEMISTRY-US, V43, P352, DOI 10.1021/bi035832z; Lartigue A, 2003, J BIOL CHEM, V278, P30213, DOI 10.1074/jbc.M304688200; LE T, 2002, PROTEINS, V48, P618; Loladze VV, 2001, PROTEIN SCI, V10, P1343, DOI 10.1110/ps.370101; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; MAKHATADZE GI, 1990, J MOL BIOL, V213, P375, DOI 10.1016/S0022-2836(05)80197-4; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Matulis D, 1998, BIOPHYS J, V74, P422, DOI 10.1016/S0006-3495(98)77799-9; Mosebi S, 2003, BIOCHEMISTRY-US, V42, P15326, DOI 10.1021/bi035671z; Myers JK, 1998, PROTEIN SCI, V7, P383; Nieslanik BS, 1999, BIOCHEMISTRY-US, V38, P6971, DOI 10.1021/bi9829130; Nieslanik BS, 2001, BIOCHEMISTRY-US, V40, P3536, DOI 10.1021/bi001869x; Nieslanik BS, 2000, J BIOL CHEM, V275, P17447, DOI 10.1074/jbc.M002083200; Nilsson LO, 2000, P NATL ACAD SCI USA, V97, P9408, DOI 10.1073/pnas.150084897; Nilsson LO, 2002, BBA-PROTEIN STRUCT M, V1597, P157; Oakley AJ, 1999, J MOL BIOL, V291, P913, DOI 10.1006/jmbi.1999.3029; Ory JJ, 1999, BIOPHYS J, V77, P1107, DOI 10.1016/S0006-3495(99)76961-4; Pal A, 2001, BIOCHEMISTRY-US, V40, P7047, DOI 10.1021/bi010363r; Ralat LA, 2004, J BIOL CHEM, V279, P50204, DOI 10.1074/jbc.M407445200; Ralat LA, 2003, PROTEIN SCI, V12, P2575, DOI 10.1110/ps.03249303; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Rohl CA, 1996, PROTEIN SCI, V5, P2623, DOI 10.1002/pro.5560051225; SACCHETTINI JC, 1992, J BIOL CHEM, V267, P23534; Sayed Y, 2000, FEBS LETT, V465, P169, DOI 10.1016/S0014-5793(99)01747-0; Sayed Y, 2002, BIOCHEM J, V363, P341, DOI 10.1042/0264-6021:3630341; SCHOLTZ JM, 1992, ANNU REV BIOPH BIOM, V21, P95, DOI 10.1146/annurev.bb.21.060192.000523; Schonbrunn E, 2000, P NATL ACAD SCI USA, V97, P6345, DOI 10.1073/pnas.120120397; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Sluis-Cremer N, 1998, EUR J BIOCHEM, V257, P434, DOI 10.1046/j.1432-1327.1998.2570434.x; SluisCremer N, 1996, EUR J BIOCHEM, V241, P484, DOI 10.1111/j.1432-1033.1996.00484.x; Sobolev V, 1996, PROTEINS, V25, P120, DOI 10.1002/(SICI)1097-0134(199605)25:1<120::AID-PROT10>3.3.CO;2-1; STENBERG G, 1992, PROTEIN EXPRES PURIF, V3, P80, DOI 10.1016/1046-5928(92)90060-A; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; VANGUNSTEREN WF, 1990, ANGEW CHEM INT EDIT, V29, P992, DOI 10.1002/anie.199009921; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wallace LA, 2000, BBA-PROTEIN STRUCT M, V1478, P325, DOI 10.1016/S0167-4838(00)00023-6; Wallace LA, 1998, BIOCHEMISTRY-US, V37, P5320, DOI 10.1021/bi972936z; Wallace LA, 1999, BIOCHEMISTRY-US, V38, P16686, DOI 10.1021/bi991239z; Wan WY, 1999, J MOL BIOL, V286, P1633, DOI 10.1006/jmbi.1999.2552; WANG RW, 1993, PROTEIN SCI, V2, P2085, DOI 10.1002/pro.5560021209; WIDERSTEN M, 1994, BIOCHEMISTRY-US, V33, P11717, DOI 10.1021/bi00205a007; Wiesner S, 1999, J MOL BIOL, V286, P233, DOI 10.1006/jmbi.1998.2490; Zhan YP, 2004, BIOCHEMISTRY-US, V43, P7244, DOI 10.1021/bi0363329	82	20	20	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19480	19487		10.1074/jbc.M413608200	http://dx.doi.org/10.1074/jbc.M413608200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15757902	hybrid			2022-12-25	WOS:000229113700009
J	Feldman, RI; Wu, JM; Polokoff, MA; Kochanny, MJ; Dinter, H; Zhu, DG; Biroc, SL; Alicke, B; Bryant, J; Yuan, SD; Buckman, BO; Lentz, D; Ferrer, M; Whitlow, M; Adler, M; Finster, S; Chang, Z; Arnaiz, DO				Feldman, RI; Wu, JM; Polokoff, MA; Kochanny, MJ; Dinter, H; Zhu, DG; Biroc, SL; Alicke, B; Bryant, J; Yuan, SD; Buckman, BO; Lentz, D; Ferrer, M; Whitlow, M; Adler, M; Finster, S; Chang, Z; Arnaiz, DO			Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; IN-VIVO; PHOSPHORYLATION; ACTIVATION; PDK1; AKT; IDENTIFICATION; SER-473; TRANSFORMATION; 3-KINASE	The phosphoinositide 3-kinase/3-phosphoinositide-dependent kinase 1 (PDK1)/Akt signaling pathway plays a key role in cancer cell growth, survival, and tumor angiogenesis and represents a promising target for anticancer drugs. Here, we describe three potent PDK1 inhibitors, BX-795, BX-912, and BX-320 (IC50 = 11-30 nM) and their initial biological characterization. The inhibitors blocked PDK1/Akt signaling in tumor cells and inhibited the anchorage-dependent growth of a variety of tumor cell lines in culture or induced apoptosis. A number of cancer cell lines with elevated Akt activity were > 30-fold more sensitive to growth inhibition by PDK1 inhibitors in soft agar than on tissue culture plastic, consistent with the cell survival function of the PDK1/Akt signaling pathway, which is particularly important for unattached cells. BX-320 inhibited the growth of LOX melanoma tumors in the lungs of nude mice after injection of tumor cells into the tail vein. The effect of BX-320 on cancer cell growth in vitro and in vivo indicates that PDK1 inhibitors may have clinical utility as anticancer agents.	Berlex Biosci, Dept Canc Res, Richmond, CA 94804 USA; Berlex Biosci, Dept Pharmacol, Richmond, CA 94804 USA; Berlex Biosci, Dept Chem, Richmond, CA 94804 USA; Berlex Biosci, Dept Syst Biol, Richmond, CA 94804 USA		Feldman, RI (corresponding author), Berlex Biosci, Dept Canc Res, 2600 Hilltop Dr, Richmond, CA 94804 USA.	rick_feldman@berlex.com						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Beattie JF, 2003, BIOORG MED CHEM LETT, V13, P2955, DOI 10.1016/S0960-894X(03)00202-6; Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437; BRYANT J, 2004, Patent No. 2004048343; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Flynn P, 2000, CURR BIOL, V10, P1439, DOI 10.1016/S0960-9822(00)00801-0; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Kawakami Y, 2004, J BIOL CHEM, V279, P47720, DOI 10.1074/jbc.M408797200; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Partovian C, 2004, CELL SIGNAL, V16, P951, DOI 10.1016/j.cellsig.2004.01.008; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Sayle KL, 2003, BIOORG MED CHEM LETT, V13, P3079, DOI 10.1016/S0960-894X(03)00651-6; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker Alex, 2003, Methods Mol Biol, V233, P171; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3	42	166	182	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19867	19874		10.1074/jbc.M501367200	http://dx.doi.org/10.1074/jbc.M501367200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772071	hybrid			2022-12-25	WOS:000229113700055
J	Miller-Podraza, H; Lanne, B; Angstrom, J; Teneberg, S; Milh, MA; Jovall, PA; Karlsson, H; Karlsson, KA				Miller-Podraza, H; Lanne, B; Angstrom, J; Teneberg, S; Milh, MA; Jovall, PA; Karlsson, H; Karlsson, KA			Novel binding epitope for Helicobacter pylori found in neolacto carbohydrate chains - Structure and cross-binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GASTRIC EPITHELIUM; BLOOD-GROUP ANTIGENS; HUMAN-GRANULOCYTES; CAMPYLOBACTER-PYLORI; MASS-SPECTROMETRY; HEPARAN-SULFATE; RECOGNITION; GLYCOSPHINGOLIPIDS; RECEPTOR; CELLS	Helicobacter pylori is a bacterium that colonizes the stomach of a majority of the global human population causing common gastric diseases like ulcers and cancer. It has an unusually complex pattern of binding to various host glycoconjugates including interaction with sialylated, sulfated, and fucosylated sequences. The present study describes an additional binding epitope comprising the neolacto internal sequence of GlcNAc beta 3Gal beta 4GlcNAc beta. The binding was detected on TLC plates as an interaction with a seven-sugar ganglioside of rabbit thymus. The glycolipid was purified and characterized as Neu5Gc alpha 3Gal beta 4GlcNAc beta 3Gal beta 4GlcNAc beta 3Gal beta 4Glc beta 1Cer with less than 10% of the fraction carrying a repeated lacto (type-1) core chain, Gal beta 3GlcNAc beta 3Gal beta 3GlcNAc beta. After stepwise chemical and enzymatic degradation and structural analysis of products the strongest binder was found to be the pentaglycosylceramide GlcNAc beta 3Gal beta 4GlcNAc beta 3Gal beta 4Glc beta 1Cer, whereas the hexa- and tetraglycosylceramides were less active, and the trihexosylceramide was inactive. Further studies revealed that the terminal GlcNAc beta of the pentaglycosylceramide may be exchanged for either GalNAc beta 3, GalNAc alpha 3, or Gal alpha 3 without loss of the activity. Calculated minimum energy conformers of these four isoreceptors show a substantial topographical similarity suggesting that this binding is a result of a molecular mimicry. Although the glycoconjugate composition of human gastric epithelial cells is not known in detail it is proposed that repeating N-acetyllactosamine units of glycoconjugates may serve as bacterial attachment sites in the stomach.	Univ Gothenburg, Inst Med Biochem, SE-40530 Gothenburg, Sweden	University of Gothenburg	Miller-Podraza, H (corresponding author), Univ Gothenburg, Inst Med Biochem, POB 440, SE-40530 Gothenburg, Sweden.	Halina.Miller-Podraza@medkem.gu.se						Abul-Milh M, 2001, GLYCOCONJUGATE J, V18, P253, DOI 10.1023/A:1012460824913; ANDERSSON B, 1983, J EXP MED, V158, P559, DOI 10.1084/jem.158.2.559; Angstrom J, 1998, GLYCOBIOLOGY, V8, P297, DOI 10.1093/glycob/8.4.297; Bertin Y, 1996, INFECT IMMUN, V64, P332, DOI 10.1128/IAI.64.1.332-342.1996; BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; CHMIELA M, 1995, APMIS, V103, P469, DOI 10.1111/j.1699-0463.1995.tb01133.x; CLAUSEN H, 1986, J BIOL CHEM, V261, P1380; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EGGE H, 1978, CHEM PHYS LIPIDS, V21, P349, DOI 10.1016/0009-3084(78)90046-4; EVANS DG, 1988, INFECT IMMUN, V56, P2896, DOI 10.1128/IAI.56.11.2896-2906.1988; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; Hakomori S, 1999, BBA-GEN SUBJECTS, V1473, P247, DOI 10.1016/S0304-4165(99)00183-X; HANSSON GC, 1990, METHOD ENZYMOL, V193, P733, DOI 10.1016/0076-6879(90)93447-S; HIRMO S, 1995, FEMS IMMUNOL MED MIC, V10, P301, DOI 10.1016/0928-8244(94)00081-4; Huesca M, 1996, INFECT IMMUN, V64, P2643, DOI 10.1128/IAI.64.7.2643-2648.1996; IARC, 1994, IARC MONOGRAPHS EVAL, VVolume 61, P1; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Israel DA, 2001, ALIMENT PHARM THER, V15, P1271, DOI 10.1046/j.1365-2036.2001.01052.x; ITO M, 1989, METHOD ENZYMOL, V179, P488; KANNAGI R, 1982, CANCER RES, V42, P5249; Karlsson A, 2001, GLYCOCONJUGATE J, V18, P231, DOI 10.1023/A:1013183124004; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P220; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P212; Karlsson KA, 1998, MOL MICROBIOL, V29, P1, DOI 10.1046/j.1365-2958.1998.00854.x; Karlsson KA, 2000, GLYCOBIOLOGY, V10, P761, DOI 10.1093/glycob/10.8.761; KOBAYASHI Y, 1993, INFECT IMMUN, V61, P4058, DOI 10.1128/IAI.61.10.4058-4063.1993; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; LELWALAGURUGE J, 1992, APMIS, V100, P908, DOI 10.1111/j.1699-0463.1992.tb04018.x; LEVERY SB, 1988, CARBOHYD RES, V178, P121, DOI 10.1016/0008-6215(88)80106-X; LINGWOOD CA, 1992, INFECT IMMUN, V60, P2470, DOI 10.1128/IAI.60.6.2470-2474.1992; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Miller-Podraza H, 1999, INFECT IMMUN, V67, P6309; MillerPodraza H, 1997, GLYCOCONJUGATE J, V14, P467, DOI 10.1023/A:1018599401772; MillerPodraza H, 1997, INFECT IMMUN, V65, P2480, DOI 10.1128/IAI.65.6.2480-2482.1997; Mouricout M, 1997, ADV EXP MED BIOL, V412, P109; Muthing J, 1996, GLYCOBIOLOGY, V6, P147, DOI 10.1093/glycob/6.2.147; Mysore JV, 1999, GASTROENTEROLOGY, V117, P1316, DOI 10.1016/S0016-5085(99)70282-9; NEEDS PW, 1993, CARBOHYD RES, V245, P1, DOI 10.1016/0008-6215(93)80055-J; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Simon PM, 1997, INFECT IMMUN, V65, P750, DOI 10.1128/IAI.65.2.750-757.1997; SLOMIANY BL, 1989, BIOCHEM INT, V19, P929; Solnick JV, 2004, P NATL ACAD SCI USA, V101, P2106, DOI 10.1073/pnas.0308573100; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P758, DOI 10.1021/bi951600r; Teneberg S, 2000, GLYCOBIOLOGY, V10, P1171, DOI 10.1093/glycob/10.11.1171; TENEBERG S, 1994, J BIOL CHEM, V269, P8554; Teneberg S, 1996, GLYCOBIOLOGY, V6, P599, DOI 10.1093/glycob/6.6.599; Teneberg S, 2002, J BIOL CHEM, V277, P19709, DOI 10.1074/jbc.M201113200; Unemo M, 2005, J BIOL CHEM, V280, P15390, DOI 10.1074/jbc.M412725200; WELLS MA, 1963, BIOCHEMISTRY-US, V2, P1259, DOI 10.1021/bi00906a015	55	31	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19695	19703		10.1074/jbc.M412688200	http://dx.doi.org/10.1074/jbc.M412688200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15743770	hybrid			2022-12-25	WOS:000229113700035
J	Alt, JR; Bouska, A; Fernandez, MR; Cerny, RL; Xiao, H; Eischen, CM				Alt, JR; Bouska, A; Fernandez, MR; Cerny, RL; Xiao, H; Eischen, CM			Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATM-DEPENDENT PHOSPHORYLATION; MYC-INDUCED LYMPHOMAGENESIS; ATAXIA-TELANGIECTASIA; MRE11 COMPLEX; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; PROTEIN COMPLEX; HISTONE H2AX; P53 PROTEIN; S-PHASE	Mdm2 directly regulates the p53 tumor suppressor. However, Mdm2 also has p53-independent activities, and the pathways that mediate these functions are unresolved. Here we report the identification of a specific association of Mdm2 with Mre11, Nbs1, and Rad50, a DNA double strand break repair complex. Mdm2 bound to the Mre11-Nbs1-Rad50 complex in primary cells and in cells containing inactivated p53 or p14/p19(ARF), a regulator of Mdm2. Further analysis revealed that Mdm2 directly bound to Nbs1 but not to Mre11 or Rad50. Amino acids 198-314 of Mdm(2) were required for Mdm2/Nbs1 association, and neither the N terminus forkhead-associated and breast cancer C-terminal domains nor the C terminus Mre11 binding domain of Nbs1 mediated the interaction of Nbs1 with Mdm2. Mdm2 co-localized with Nbs1 to sites of DNA damage following gamma-irradiation. Notably, Mdm2 overexpression inhibited DNA double strand break repair, and this was independent of p53 and ARF, the alternative reading frame of the Ink4alocus. The delay in DNA repair imposed by Mdm2 required the Nbs1 binding domain of Mdm2, but the ubiquitin ligase domain in Mdm2 was dispensable. Therefore, Nbs1 is a novel p53-independent Mdm2 binding protein and links Mdm2 to the Mre11-Nbs1-Rad50-regulated DNA repair response.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Lincoln	Eischen, CM (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, 987696 Nebraska Med Ctr, Omaha, NE 68198 USA.	ceischen@unmc.edu		Bouska, Alyssa/0000-0003-1324-6678; Fernandez, Mario/0000-0002-2017-9576	NATIONAL CANCER INSTITUTE [P30CA036727, T32CA009139, T32CA009476] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009476, CA09476, P30 CA36727, CA09139] Funding Source: Medline; NCRR NIH HHS [P20 RR15635] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALANI E, 1989, GENETICS, V122, P47; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; Asahara H, 2003, NUCLEIC ACIDS RES, V31, P2451, DOI 10.1093/nar/gkg342; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Collins AR, 2004, MOL BIOTECHNOL, V26, P249, DOI 10.1385/MB:26:3:249; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Dang JJ, 2002, CANCER RES, V62, P1222; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hiel JA, 2000, ARCH DIS CHILD, V82, P400; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Iwakuma T, 2003, MOL CANCER RES, V1, P993; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; KOBAYASHI H, 1995, MMS COMMUN, P103; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; O'Leary KA, 2004, MOL CELL BIOL, V24, P186, DOI 10.1128/MCB.24.1.186-191.2004; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Tomlinson GE, 1998, CANCER RES, V58, P3237; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang H, 2003, PROSTATE, V54, P194, DOI 10.1002/pros.10187; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	59	85	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18771	18781		10.1074/jbc.M413387200	http://dx.doi.org/10.1074/jbc.M413387200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15734743	hybrid			2022-12-25	WOS:000228932300028
J	Camden, JM; Schrader, AM; Camden, RE; Gonzalez, FA; Erb, L; Seye, CI; Weisman, GA				Camden, JM; Schrader, AM; Camden, RE; Gonzalez, FA; Erb, L; Seye, CI; Weisman, GA			P2Y(2) nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ADHESION MOLECULE-1 EXPRESSION; GROWTH-FACTOR RECEPTOR; KINASE-C; CONVERTING-ENZYME; ALZHEIMERS-DISEASE; CELL-ADHESION; EXTRACELLULAR ATP; ADAMS FAMILY; RELEASE	The amyloid precursor protein (APP) is proteolytically processed by beta- and gamma-secretases to release amyloid beta, the main component in senile plaques found in the brains of patients with Alzheimer disease. Alternatively, APP can be cleaved within the amyloid beta domain by alpha-secretase releasing the non-amyloidogenic product sAPP alpha, which has been shown to have neuroprotective properties. Several G protein-coupled receptors are known to activate alpha-secretase-dependent processing of APP; however, the role of G protein-coupled nucleotide receptors in APP processing has not been investigated. Here it is demonstrated that activation of the G protein-coupled P2Y(2) receptor (P2Y(2)R) subtype expressed in human 1321N1 astrocytoma cells enhanced the release of sAPP alpha in a time- and dose-dependent manner. P2Y(2)R-mediated sAPP alpha release was dependent on extracellular calcium but was not affected by 1,2-bis(2-aminophenoxy)ethane-N,N,N,-trimethylammonium salt, an intracellular calcium chelator, indicating that P2Y(2)R-stimulated intracellular calcium mobilization was not involved. Inhibition of protein kinase C (PKC) with GF109203 or by PKC down-regulation with phorbol ester pre-treatment had no effect on UTP-stimulated sAPP alpha release, indicating a PKC-independent mechanism. U0126, an inhibitor of the mitogen-activated protein kinase pathway, partially inhibited sAPP alpha release by UTP, whereas inhibitors of Src-dependent epidermal growth factor receptor transactivation by P2Y(2)Rs had no effect. The metalloprotease inhibitors phenanthroline and TAPI-2 and the furin inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethylketone also diminished UTP-induced sAPP alpha release. Furthermore, small interfering RNA silencing of an endogenous adamalysin, ADAM10 or ADAM17/TACE, partially suppressed P2Y(2)R-activated sAPP alpha release, whereas treatment of cells with both ADAM10 and ADAM17/TACE small interfering RNAs completely abolished UTP-activated sAPP alpha release. These results may contribute to an understanding of the non-amyloidogenic processing of APP.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; Univ Puerto Rico, Dept Chem, Rio Piedras, PR 00931 USA	University of Missouri System; University of Missouri Columbia; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico Rio Piedras	Weisman, GA (corresponding author), Univ Missouri, Dept Biochem, 540E Life Sci Ctr,1201 Rollins Rd, Columbia, MO 65211 USA.	weismang@missouri.edu		Erb, Laurie/0000-0001-6372-3378	NCRR NIH HHS [1 P20-RR15565] Funding Source: Medline; NIA NIH HHS [1 P01-AG18357] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015565] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG018357] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahn JS, 2000, AM J PHYSIOL-CELL PH, V279, pC286, DOI 10.1152/ajpcell.2000.279.2.C286; Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blacker M, 2002, J NEUROCHEM, V83, P1349, DOI 10.1046/j.1471-4159.2002.01228.x; BLAUG S, 2003, AM J PHYSIOL, V284, pC894; BOARDER MR, 1995, TRENDS PHARMACOL SCI, V16, P133, DOI 10.1016/S0165-6147(00)89001-X; BOWES MP, 1994, EXP NEUROL, V129, P112, DOI 10.1006/exnr.1994.1152; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CHECLER F, 1995, J NEUROCHEM, V65, P1431; DAVISSALINAS J, 1994, J BIOL CHEM, V269, P22623; Desdouits-Magnen J, 1998, J NEUROCHEM, V70, P524; Endres K, 2003, EUR J BIOCHEM, V270, P2386, DOI 10.1046/j.1432-1033.2003.03606.x; Erb L, 2001, J CELL BIOL, V153, P491, DOI 10.1083/jcb.153.3.491; ERB L, 1994, DRUG DEVELOP RES, V31, P267; Garrad RC, 1998, J BIOL CHEM, V273, P29437, DOI 10.1074/jbc.273.45.29437; Gendron Fernand-Pierre, 2003, Biomedical Research (Aligarh), V14, P47; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hotoda N, 2002, BIOCHEM BIOPH RES CO, V293, P800, DOI 10.1016/S0006-291X(02)00302-9; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Jolly-Tornetta C, 1998, J BIOL CHEM, V273, P14015, DOI 10.1074/jbc.273.22.14015; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; Kaido T, 2004, J BIOL CHEM, V279, P17731, DOI 10.1074/jbc.M308425200; KIM K, 1990, NEUROSCI RES COMMUN, V2, P121; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Lazarowski ER, 2001, NEWS PHYSIOL SCI, V16, P1; Le Gall SM, 2003, J BIOL CHEM, V278, P45255, DOI 10.1074/jbc.M307745200; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; Liu J, 2004, J BIOL CHEM, V279, P8212, DOI 10.1074/jbc.M312230200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSTIG KD, 1992, BIOCHIM BIOPHYS ACTA, V1134, P61, DOI 10.1016/0167-4889(92)90028-A; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Murdoch C, 2000, BLOOD, V95, P3032; Nitsch R M, 1994, J Neural Transm Suppl, V44, P21; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; NITSCH RM, 1993, ANN NY ACAD SCI, V695, P122, DOI 10.1111/j.1749-6632.1993.tb23039.x; NITSCH RM, 1995, ARZNEIMITTEL-FORSCH, V45-1, P435; Nitsch RM, 1997, J NEUROCHEM, V69, P704; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; Parkin ET, 2002, BIOCHEMISTRY-US, V41, P4972, DOI 10.1021/bi015936e; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Racchi M, 1999, J NEUROCHEM, V72, P2464, DOI 10.1046/j.1471-4159.1999.0722464.x; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SCHRADER AM, 2005, IN PRESS ARCH ORAL B, V50; Schultze-Mosgau A, 2000, MOL HUM REPROD, V6, P435, DOI 10.1093/molehr/6.5.435; Schwiebert EM, 2003, BBA-BIOMEMBRANES, V1615, P7, DOI 10.1016/S0005-2736(03)00210-4; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Seye CI, 2004, J BIOL CHEM, V279, P35679, DOI 10.1074/jbc.M401799200; Seye CI, 2003, J BIOL CHEM, V278, P24960, DOI 10.1074/jbc.M301439200; Seye CI, 2002, CIRCULATION, V106, P2720, DOI 10.1161/01.CIR.0000038111.00518.35; Seye CI, 1997, ARTERIOSCL THROM VAS, V17, P3602, DOI 10.1161/01.ATV.17.12.3602; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Slack BE, 1997, BIOCHEM J, V327, P245, DOI 10.1042/bj3270245; SLACK BE, 1993, ANN NY ACAD SCI, V695, P128, DOI 10.1111/j.1749-6632.1993.tb23040.x; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Turner JT, 1998, AM J PHYSIOL-CELL PH, V275, pC367, DOI 10.1152/ajpcell.1998.275.2.C367; Turner JT, 1997, AM J PHYSIOL-CELL PH, V273, pC1100, DOI 10.1152/ajpcell.1997.273.3.C1100; Wallace WC, 1997, MOL BRAIN RES, V52, P201, DOI 10.1016/S0169-328X(97)00258-1; Weerasinghe D, 1998, J CELL BIOL, V142, P595, DOI 10.1083/jcb.142.2.595; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Weisman GA, 1996, J PHARMACOL EXP THER, V277, P1; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916	79	110	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18696	18702		10.1074/jbc.M500219200	http://dx.doi.org/10.1074/jbc.M500219200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15778502	hybrid			2022-12-25	WOS:000228932300020
J	Fernandez-Tornero, C; Lozano, RM; Rivas, G; Jimenez, MA; Standker, L; Diaz-Gonzalez, D; Forssmann, WG; Cuevas, P; Romero, A; Gimenez-Gallego, G				Fernandez-Tornero, C; Lozano, RM; Rivas, G; Jimenez, MA; Standker, L; Diaz-Gonzalez, D; Forssmann, WG; Cuevas, P; Romero, A; Gimenez-Gallego, G			Synthesis of the blood circulating c-terminal fragment of insulin-like growth factor (IGF)-binding protein-4 in its native conformation - Crystallization, heparin and IGF binding, and osteogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; ESCHERICHIA-COLI; IN-VIVO; LIMITED PROTEOLYSIS; PURIFICATION; EXPRESSION; AFFINITY; IGFBP-4; DOMAIN; SITES	Insulin-like growth factor-binding proteins play a critical role in a wide variety of important physiological processes. It has been demonstrated that both an N-terminal and a C-terminal fragment of insulin-like growth factor-binding protein-4 exist and accumulate in the circulatory system, these fragments accounting for virtually the whole amino acid sequence of the protein. The circulating C-terminal fragment establishes three disulfide bridges, and the binding pattern of these has recently been defined. Here we show that the monodimensional H-1 NMR spectrum of the C-terminal fragment is typical of a protein with a relatively close packed tertiary structure. This fragment can be produced in its native conformation in Escherichia coli, without the requirement of further refolding procedures, when synthesis is coupled to its secretion from the cell. The recombinant protein crystallizes with the unit cell parameters of a hexagonal system. Furthermore, it binds strongly to heparin, acquiring a well defined oligomeric structure that interacts with insulin-like growth factors, and promotes bone formation in cultures of murine calvariae.	CSIC, Ctr Invest Biol, Dept Estructura & Func Prot, Madrid 28040, Spain; CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; IPF Pharmaceut GmbH, D-30625 Hannover, Germany; Hosp Ramon & Cajal, Dept Invest, E-28034 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Hospital Universitario Ramon y Cajal	Gimenez-Gallego, G (corresponding author), CSIC, Ctr Invest Biol, Dept Estructura & Func Prot, Ramiro Maeztu 9, Madrid 28040, Spain.	gimenez_gallego@cib.csic.es	Rivas, German/AFL-7528-2022; Romero, Antonio/K-5754-2014; Rivas, German/AAG-7458-2022; Fernandez-Tornero, Carlos/AAV-8028-2021; Fernandez-Tornero, Carlos/I-6888-2015; Jimenez, M. Angeles/C-7193-2008	Rivas, German/0000-0003-3450-7478; Romero, Antonio/0000-0002-6990-6973; Rivas, German/0000-0003-3450-7478; Fernandez-Tornero, Carlos/0000-0001-5097-731X; Fernandez-Tornero, Carlos/0000-0001-5097-731X; Jimenez, M. Angeles/0000-0001-6835-5850				ARAI T, 1994, J BIOL CHEM, V269, P20388; Arai T, 1996, ENDOCRINOLOGY, V137, P4571, DOI 10.1210/en.137.11.4571; Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; Binoux Michel, 1999, V17, P281; BLAT C, 1994, J CLIN INVEST, V93, P2286, DOI 10.1172/JCI117229; Chelius D, 2001, J ENDOCRINOL, V168, P283, DOI 10.1677/joe.0.1680283; CHERNAUSEK SD, 1995, J BIOL CHEM, V270, P11377, DOI 10.1074/jbc.270.19.11377; Clemmons David R., 1999, V17, P273; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; DELAURETO PP, 1995, BIOCHEMISTRY-US, V34, P12596, DOI 10.1021/bi00039a015; DENEFLE P, 1989, GENE, V85, P499, DOI 10.1016/0378-1119(89)90444-7; DIDONATO A, 1993, ANAL BIOCHEM, V212, P291, DOI 10.1006/abio.1993.1328; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; Headey SJ, 2003, J BIOMOL NMR, V25, P251, DOI 10.1023/A:1022880328909; Headey SJ, 2004, MOL ENDOCRINOL, V18, P2740, DOI 10.1210/me.2004-0248; Hunt A, 2001, SCIENCE, V293, P1784, DOI 10.1126/science.1065206; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; LASSARRE C, 1994, ENDOCRINOLOGY, V134, P1254, DOI 10.1210/en.134.3.1254; Laue T., 1993, ANAL ULTRACENTRIFUGA, P90; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; LINEMEYER DL, 1987, BIO-TECHNOL, V5, P960, DOI 10.1038/nbt0987-960; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; Maile Laura A., 1999, V17, P633; MASUI Y, 1983, EXPT MANIPULATION GE, P15; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P2641, DOI 10.1210/en.142.6.2641; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Oh Youngman, 1999, V17, P257; Ooi Guck T., 1999, V17, P111; ORTEGA S, 1992, BIO-TECHNOL, V10, P795, DOI 10.1038/nbt0792-795; Parker A, 1996, J BIOL CHEM, V271, P13523, DOI 10.1074/jbc.271.23.13523; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; PinedaLucena A, 1996, J MOL BIOL, V264, P162, DOI 10.1006/jmbi.1996.0631; PINEDALUCENA A, 1994, J MOL BIOL, V242, P81, DOI 10.1006/jmbi.1994.1558; PROBA K, 1995, GENE, V159, P203, DOI 10.1016/0378-1119(95)00018-2; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; Rivas G, 1996, J MOL RECOGNIT, V9, P31, DOI 10.1002/(SICI)1099-1352(199601)9:1<31::AID-JMR237>3.3.CO;2-F; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; ROSEN CJ, 1994, P SOC EXP BIOL MED, V206, P83; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIGNOR G, 1990, EUR J BIOCHEM, V189, P221, DOI 10.1111/j.1432-1033.1990.tb15480.x; Standker L, 2000, BIOCHEMISTRY-US, V39, P5082, DOI 10.1021/bi992513s; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; TANGEMANN K, 1997, INTEGRIN LIGAND INTE, P85; Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; Wu H., 1931, CHINESE J PHYSIOL, V5, P321; ZAZO M, 1992, GENE, V113, P231, DOI 10.1016/0378-1119(92)90400-J	55	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18899	18907		10.1074/jbc.M500587200	http://dx.doi.org/10.1074/jbc.M500587200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15735305	hybrid, Green Published			2022-12-25	WOS:000228932300042
J	Givens, ML; Rave-Harel, N; Goonewardena, VD; Kurotani, R; Berdy, SE; Swan, CH; Rubenstein, JLR; Robert, B; Mellon, PL				Givens, ML; Rave-Harel, N; Goonewardena, VD; Kurotani, R; Berdy, SE; Swan, CH; Rubenstein, JLR; Robert, B; Mellon, PL			Developmental regulation of gonadotropin-releasing hormone gene expression by the MSX and DLX homeodomain protein families	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-SPECIFIC EXPRESSION; TRANSCRIPTION FACTOR AP-2; HOMEOBOX GENES; CRANIOFACIAL DEVELOPMENT; RESTRICTED EXPRESSION; EMBRYONIC FOREBRAIN; OLFACTORY PLACODE; CELL-POPULATIONS; DEVELOPING MOUSE; BINDING-SITES	Gonadotropin-releasing hormone (GnRH) is the central regulator of the hypothalamic-pituitary-gonadal axis, controlling sexual maturation and fertility in diverse species from fish to humans. GnRH gene expression is limited to a discrete population of neurons that migrate through the nasal region into the hypothalamus during embryonic development. The GnRH regulatory region contains four conserved homeodomain binding sites (ATTA) that are essential for basal promoter activity and cell-specific expression of the GnRH gene. MSX and DLX are members of the Antennapedia class of non-Hox homeodomain transcription factors that regulate gene expression and influence development of the craniofacial structures and anterior forebrain. Here, we report that expression patterns of the Msx and Dlx families of homeodomain transcription factors largely coincide with the migratory route of GnRH neurons and co-express with GnRH in neurons during embryonic development. In addition, MSX and DLX family members bind directly to the ATTA consensus sequences and regulate transcriptional activity of the GnRH promoter. Finally, mice lacking MSX1 or DLX1 and 2 show altered numbers of GnRH-expressing cells in regions where these factors likely function. These findings strongly support a role for MSX and DLX in contributing to spatiotemporal regulation of GnRH transcription during development.	Univ Calif San Diego, Dept Reprod Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Langley Porter Psychiat Inst, San Francisco, CA 94143 USA; Inst Pasteur, CNRS, URA 2578, Unite Genet Mol & Morphogenese, F-75724 Paris, France	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Mellon, PL (corresponding author), Univ Calif San Diego, Dept Reprod Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	pmellon@ucsd.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD072754, P50HD012303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK063491, R01DK044838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007315] Funding Source: NIH RePORTER; NICHD NIH HHS [P50 HD012303, R01 HD072754] Funding Source: Medline; NIDA NIH HHS [T32 DA07315] Funding Source: Medline; NIDDK NIH HHS [R01 DK44838, R01 DK044838-17A1, R01 DK044838, R01 DK044838-16, P30 DK063491, P30 DK063491-019001] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alappat S, 2003, CELL RES, V13, P429, DOI 10.1038/sj.cr.7290185; Anderson SA, 1997, NEURON, V19, P27, DOI 10.1016/S0896-6273(00)80345-1; Bach A, 2003, DEVELOPMENT, V130, P4025, DOI 10.1242/dev.00609; Bendall AJ, 1999, DEVELOPMENT, V126, P4965; Bendall AJ, 2000, GENE, V247, P17, DOI 10.1016/S0378-1119(00)00081-0; BULFONE A, 1993, J NEUROSCI, V13, P3155; Catron KM, 1996, MECH DEVELOP, V55, P185, DOI 10.1016/0925-4773(96)00503-5; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; Cornell RA, 2000, CURR OPIN NEUROBIOL, V10, P63, DOI 10.1016/S0959-4388(99)00049-5; Dubois EA, 2002, BRAIN RES BULL, V57, P413, DOI 10.1016/S0361-9230(01)00676-1; Eisenstat DD, 1999, J COMP NEUROL, V414, P217, DOI 10.1002/(SICI)1096-9861(19991115)414:2<217::AID-CNE6>3.0.CO;2-I; Gauchat D, 2000, P NATL ACAD SCI USA, V97, P4493, DOI 10.1073/pnas.97.9.4493; Grove EA, 1998, DEVELOPMENT, V125, P2315; Houzelstein D, 1997, MECH DEVELOP, V65, P123, DOI 10.1016/S0925-4773(97)00065-8; Hu GZ, 2001, DEVELOPMENT, V128, P2373; ILER N, 1995, MECH DEVELOP, V53, P87, DOI 10.1016/0925-4773(95)00427-0; Iler N, 1996, BIOCHEM BIOPH RES CO, V227, P257, DOI 10.1006/bbrc.1996.1498; Kelley CG, 2002, MOL ENDOCRINOL, V16, P2413, DOI 10.1210/me.2002-0189; Kramer PR, 2000, ENDOCRINOLOGY, V141, P1823, DOI 10.1210/en.141.5.1823; Kramer PR, 2000, MECH DEVELOP, V94, P79, DOI 10.1016/S0925-4773(00)00316-6; Kraus P, 1999, J CELL BIOCHEM, P133; Lawson MA, 1998, MOL CELL ENDOCRINOL, V140, P157, DOI 10.1016/S0303-7207(98)00044-6; Lawson MA, 2002, ENDOCRINOLOGY, V143, P1404, DOI 10.1210/en.143.4.1404; LIVNE I, 1993, DEV BIOL, V159, P643, DOI 10.1006/dbio.1993.1271; MASON AJ, 1986, SCIENCE, V234, P1366, DOI 10.1126/science.3024317; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Nelson SB, 2000, MOL ENDOCRINOL, V14, P1509, DOI 10.1210/me.14.9.1509; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; Panganiban G, 2002, DEVELOPMENT, V129, P4371; Pernasetti F, 2001, ENDOCRINOLOGY, V142, P2284, DOI 10.1210/en.142.6.2284; Pimpinelli F, 2003, EUR J NEUROSCI, V18, P1410, DOI 10.1046/j.1460-9568.2003.02866.x; PORTEUS MH, 1994, J NEUROSCI, V14, P6370; Prioni S, 2002, NEUROCHEM RES, V27, P831, DOI 10.1023/A:1020217309987; Qiu MS, 1997, DEV BIOL, V185, P165, DOI 10.1006/dbio.1997.8556; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; Rave-Harel N, 2004, J BIOL CHEM, V279, P30287, DOI 10.1074/jbc.M402960200; REGINELLI AD, 1995, DEVELOPMENT, V121, P1065; Romanelli RG, 2004, J BIOL CHEM, V279, P117, DOI 10.1074/jbc.M307955200; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SCHWANZELFUKUDA M, 1992, ENDOCR REV, V13, P623, DOI 10.1210/er.13.4.623; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; Simonian SX, 2001, NEUROENDOCRINOLOGY, V73, P149, DOI 10.1159/000054631; Skynner MJ, 1999, J NEUROSCI, V19, P5955, DOI 10.1523/JNEUROSCI.19-14-05955.1999; Whitlock KE, 2003, DEV BIOL, V257, P140, DOI 10.1016/S0012-1606(03)00039-3; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; WRAY S, 1994, DEV BIOL, V166, P349, DOI 10.1006/dbio.1994.1320; Wu TJ, 1995, J NEUROENDOCRINOL, V7, P899, DOI 10.1111/j.1365-2826.1995.tb00733.x; Yu GY, 2001, DEV BRAIN RES, V130, P217, DOI 10.1016/S0165-3806(01)00239-5; Yun K, 2002, DEVELOPMENT, V129, P5029; Zerucha T, 2000, J NEUROSCI, V20, P709, DOI 10.1523/JNEUROSCI.20-02-00709.2000; Zerucha T, 2000, BIOCHEM CELL BIOL, V78, P593, DOI 10.1139/bcb-78-5-593; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	56	68	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19156	19165		10.1074/jbc.M502004200	http://dx.doi.org/10.1074/jbc.M502004200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15743757	Green Accepted, hybrid			2022-12-25	WOS:000228932300072
J	Gong, QM; Keeney, DR; Molinari, M; Zhou, ZF				Gong, QM; Keeney, DR; Molinari, M; Zhou, ZF			Degradation of trafficking-defective long QT syndrome type II mutant channels by the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; RETICULUM (ER)-ASSOCIATED DEGRADATION; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; N-GLYCANASE; MISFOLDED GLYCOPROTEINS; RETRO-TRANSLOCATION; CARDIAC-ARRHYTHMIA; SURFACE EXPRESSION; SECRETORY PROTEIN	Mutations in the human ether-a-go-go-related gene (hERG) cause chromosome 7-linked long QT syndrome type II (LQT2). We have shown previously that LQT2 mutations lead to endoplasmic reticulum ( ER) retention and rapid degradation of mutant hERG proteins. In this study we examined the role of the ubiquitin-proteasome pathway in the degradation of the LQT2 mutation Y611H. We showed that proteasome inhibitors N-acetyl-L-leucyl-L-leucyl-L-norleucinal and lactacystin but not lysosome inhibitor leupeptin inhibited the degradation of Y611H mutant channels. In addition, ER mannosidase I inhibitor kifunensine and down-regulation of EDEM ( ER degradation-enhancing alpha-mannosidase-like protein) also suppressed the degradation of Y611H mutant channels. Proteasome inhibition but not mannosidase inhibition led to the accumulation of full-length hERG protein in the cytosol. The hERG protein accumulated in the cytosol was deglycosylated. Proteasome inhibition also resulted in the accumulation of polyubiquitinated hERG channels. These results suggest that the degradation of LQT2 mutant channels is mediated by the cytosolic proteasome in a process that involves mannose trimming, polyubiquitination, and deglycosylation of mutant channels.	Oregon Hlth & Sci Univ, Dept Med, Div Mol Med, Portland, OR 97239 USA; Inst Res Biomed, CH-6500 Bellinzona, Switzerland	Oregon Health & Science University; Universita della Svizzera Italiana	Zhou, ZF (corresponding author), Oregon Hlth & Sci Univ, Dept Med, Div Mol Med, NRC3,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	zhouzh@ohsu.edu	Molinari, Maurizio/N-2587-2019	Molinari, Maurizio/0000-0002-7636-5829	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068854] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68854, R01 HL068854] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; Blom D, 2004, EMBO J, V23, P650, DOI 10.1038/sj.emboj.7600090; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; Delisle BP, 2004, CIRC RES, V94, P1418, DOI 10.1161/01.RES.0000128561.28701.ea; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fagioli C, 2001, J BIOL CHEM, V276, P12885, DOI 10.1074/jbc.M009603200; Ficker E, 2003, CIRC RES, V92, pE87, DOI 10.1161/01.RES.0000079028.31393.15; Gong QM, 2004, J MOL CELL CARDIOL, V37, P1225, DOI 10.1016/j.yjmcc.2004.10.002; Gong QM, 2002, AM J PHYSIOL-HEART C, V283, pH77, DOI 10.1152/ajpheart.00008.2002; Gouas L, 2004, CARDIOVASC RES, V63, P60, DOI 10.1016/j.cardiores.2004.02.011; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hirsch C, 2003, EMBO J, V22, P1036, DOI 10.1093/emboj/cdg107; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; January CT, 2000, J CARDIOVASC ELECTR, V11, P1413, DOI 10.1046/j.1540-8167.2000.01413.x; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kagan A, 2000, J BIOL CHEM, V275, P11241, DOI 10.1074/jbc.275.15.11241; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; Manganas LN, 2001, J BIOL CHEM, V276, P49427, DOI 10.1074/jbc.M109325200; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Park H, 2001, P NATL ACAD SCI USA, V98, P11163, DOI 10.1073/pnas.201393498; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; Suzuki T, 2000, J CELL BIOL, V149, P1039, DOI 10.1083/jcb.149.5.1039; Tokunaga F, 2000, J BIOL CHEM, V275, P40757, DOI 10.1074/jbc.M001073200; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; VanSlyke JK, 2002, J CELL BIOL, V157, P381, DOI 10.1083/jcb.200111045; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Xiong XM, 1999, J BIOL CHEM, V274, P2616, DOI 10.1074/jbc.274.5.2616; Yamashita F, 2001, J MOL CELL CARDIOL, V33, P197, DOI 10.1006/jmcc.2000.1300; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	52	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19419	19425		10.1074/jbc.M502327200	http://dx.doi.org/10.1074/jbc.M502327200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15760896	hybrid			2022-12-25	WOS:000228932300100
J	Gu, YJ; Gordon, DM; Amutha, B; Pain, D				Gu, YJ; Gordon, DM; Amutha, B; Pain, D			A GTP : AMP phosphotransferase, Adk2p, in Saccharomyces cerevisiae - Role of the C terminus in protein folding/stabilization, thermal tolerance, and enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENYLATE KINASE; PRECURSOR PROTEIN; IN-VIVO; INTERMEMBRANE SPACE; ESCHERICHIA-COLI; ATP SYNTHASE; YEAST; IMPORT; TRANSLOCATION; GENE	Adenylate kinases participate in maintaining the homeostasis of cellular nucleotides. Depending on the yeast strains, the GTP:AMP phosphotransferase is encoded by the nuclear gene ADK2 with or without a single base pair deletion/insertion near the 3' end of the open reading frame, and the corresponding protein exists as either Adk2p (short) or Adk2p (long) in the mitochondrial matrix. These two forms are identical except that the three C-terminal residues of Adk2p ( short) are changed in Adk2p ( long), and the latter contains an additional nine amino acids at the C terminus of the protein. The short form of Adk2p has so far been considered to be inactive (Schricker, R., Magdolen, V., Strobel, G., Bogengruber, E., Breitenbach, M., and Bandlow, W. (1995) J. Biol. Chem. 270, 31103-31110). Using purified proteins, we show that at the physiological temperature for yeast growth (30 degrees C), both short and long forms of Adk2p are enzymatically active. However, in contrast to the short form, Adk2p ( long) is quite resistant to thermal inactivation, urea denaturation, and degradation by trypsin. Unfolding of the long form by high concentrations of urea greatly stimulated its import into isolated mitochondria. Using an integration-based gene-swapping approach, we found that regardless of the yeast strains used, the steady state levels of endogenous Adk2p ( long) in mitochondria were 5-10-fold lower compared with those of Adk2p ( short). Together, these results suggest that the modified C-terminal domain in Adk2p ( long) is not essential for enzyme activity, but it contributes to and strengthens protein folding and/or stability and is particularly important for maintaining enzyme activity under stress conditions.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Pain, D (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, 185 S Orange Ave,MSB I-669, Newark, NJ 07103 USA.	painde@umdnj.edu						Amutha B, 2003, BIOCHEM J, V370, P805, DOI 10.1042/BJ20021415; Amutha B, 2004, BIOCHEM J, V381, P19, DOI 10.1042/BJ20040566; Angermayr M, 2001, FEBS LETT, V508, P427, DOI 10.1016/S0014-5793(01)03122-2; ATKINSON DE, 1977, CELLULAR ENERGY META, P85; Bae E, 2004, J BIOL CHEM, V279, P28202, DOI 10.1074/jbc.M401865200; Bandlow W, 1998, BIOCHEM J, V329, P359, DOI 10.1042/bj3290359; Boyer P.D, 1973, ENZYMES, P279; Criswell AR, 2003, J MOL BIOL, V330, P1087, DOI 10.1016/S0022-2836(03)00655-7; CRONAN JE, 1972, MOL GEN GENET, V116, P199, DOI 10.1007/BF00269765; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; Foury F, 2002, CURR OPIN CHEM BIOL, V6, P106, DOI 10.1016/S1367-5931(01)00276-9; Gavel OY, 2004, BIOPHYS CHEM, V110, P83, DOI 10.1016/j.bpc.2004.01.006; Gordon DM, 1999, HUM MOL GENET, V8, P2255, DOI 10.1093/hmg/8.12.2255; Gordon DM, 2001, BIOCHEM J, V356, P207, DOI 10.1042/0264-6021:3560207; Gordon DM, 2001, HUM MOL GENET, V10, P259, DOI 10.1093/hmg/10.3.259; Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200; Haney PJ, 1999, J BIOL CHEM, V274, P28453, DOI 10.1074/jbc.274.40.28453; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Janssen E, 2003, J BIOL CHEM, V278, P12937, DOI 10.1074/jbc.M211465200; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; KHOO JC, 1972, BIOCHIM BIOPHYS ACTA, V268, P98, DOI 10.1016/0005-2744(72)90202-1; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KONRAD M, 1993, J BIOL CHEM, V268, P11326; Kumar S, 2001, BIOPHYS J, V80, P2439, DOI 10.1016/S0006-3495(01)76213-3; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MAGDOLEN V, 1987, CURR GENET, V12, P405, DOI 10.1007/BF00434817; MAGDOLEN V, 1992, FEBS LETT, V299, P267, DOI 10.1016/0014-5793(92)80129-5; Munier-Lehmann H, 1999, PROTEINS, V36, P238, DOI 10.1002/(SICI)1097-0134(19990801)36:2<238::AID-PROT9>3.0.CO;2-K; Munier-Lehmann H, 2003, BIOCHEM J, V373, P515, DOI 10.1042/BJ20030284; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; Nobumoto M, 1998, J BIOCHEM, V123, P128; Noma T, 2001, BIOCHEM J, V358, P225, DOI 10.1042/0264-6021:3580225; Okajima T, 2002, BIOSCI BIOTECH BIOCH, V66, P2112, DOI 10.1271/bbb.66.2112; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; Ruan QQ, 2002, BIOPHYS J, V83, P3177, DOI 10.1016/S0006-3495(02)75320-4; SCHRICKER R, 1992, MOL GEN GENET, V233, P363, DOI 10.1007/BF00265432; Schricker R, 1995, J BIOL CHEM, V270, P31103, DOI 10.1074/jbc.270.52.31103; SCHRICKER R, 1992, GENE, V122, P111, DOI 10.1016/0378-1119(92)90038-Q; Schulke N, 1997, P NATL ACAD SCI USA, V94, P7314, DOI 10.1073/pnas.94.14.7314; Schulke N, 1999, J BIOL CHEM, V274, P22847, DOI 10.1074/jbc.274.32.22847; SCHULZ GE, 1987, COLD SPRING HARB SYM, V52, P429, DOI 10.1101/SQB.1987.052.01.050; Sepuri NBV, 1998, J BIOL CHEM, V273, P20941, DOI 10.1074/jbc.273.33.20941; Strobel G, 2002, MOL BIOL CELL, V13, P1439, DOI 10.1091/mbc.01-08-0396; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; TOMASSELLI AG, 1980, EUR J BIOCHEM, V103, P481, DOI 10.1111/j.1432-1033.1980.tb05972.x; TOMASSELLI AG, 1979, EUR J BIOCHEM, V93, P257, DOI 10.1111/j.1432-1033.1979.tb12818.x; Ulschmid JK, 2004, MOL BIOCHEM PARASIT, V136, P211, DOI 10.1016/j.molbiopara.2004.04.001; Vieille C, 2003, BIOCHEM J, V372, P577, DOI 10.1042/BJ20021377; Vozza A, 2004, J BIOL CHEM, V279, P20850, DOI 10.1074/jbc.M313610200; WATANABE K, 1982, EUR J BIOCHEM, V123, P587; Wolf-Watz M, 2004, NAT STRUCT MOL BIOL, V11, P945, DOI 10.1038/nsmb821; Yamada M, 1998, J MOL BIOL, V280, P551, DOI 10.1006/jmbi.1998.1876	53	5	7	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18604	18609		10.1074/jbc.M500847200	http://dx.doi.org/10.1074/jbc.M500847200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753074	hybrid			2022-12-25	WOS:000228932300009
J	Soccio, RE; Adams, RM; Maxwell, KN; Breslow, JL				Soccio, RE; Adams, RM; Maxwell, KN; Breslow, JL			Differential gene regulation of StarD4 and StarD5 cholesterol transfer proteins - Activation of StarD4 by sterol regulatory element-binding protein-2 and StarD5 by endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; LIVER-X-RECEPTOR; FATTY-ACID SYNTHESIS; LXR-ALPHA; NF-Y; TRANSCRIPTIONAL REGULATION; SYNTHASE PROMOTER; REDUCTASE GENE; TARGET GENES; EXPRESSION	The StarD4 and StarD5 proteins share similar to 30% identity, and each is a steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domain. We previously showed StarD4 expression is sterol-repressed, consistent with regulation by sterol regulatory element-binding proteins (SREBPs), whereas StarD5 is not sterol-regulated. Here we further address the regulation and function of StarD4 and StarD5. Unlike StAR, the START family prototype, StarD4 and StarD5 were not induced by steroidogenic stimuli in Leydig cells. However, StarD4 and StarD5 showed StAR-like activity in a cell culture steroidogenesis assay, indicating cholesterol transfer. In transgenic mice expressing active SREBPs, StarD4 was predominantly activated by SREBP-2 rather than SREBP-1a. The mouse and human StarD4 proximal promoters share similar to 70% identity, including several potential sterol regulatory elements (SREs). Reporters driven by the StarD4 promoter from either species were transfected into NIH-3T3 cells, and reporter activity was highly repressed by sterols. Site-directed mutagenesis of potential SREs identified a conserved functional SRE in the mouse (TCGGTCCAT) and human (TCATTCCAT) promoters. StarD5 was not sterol-repressed via SREBPs nor was it sterol-activated via liver X receptors (LXRs). Even though StarD4 and StarD5 were not LXR targets, their overexpression stimulated LXR reporter activity, suggesting roles in cholesterol metabolism. StarD5 expression increased 3-fold in free cholesterol-loaded macrophages, which activate the endoplasmic reticulum (ER) stress response. When NIH-3T3 cells were treated with agents to induce ER stress, StarD5 expression increased 6-8-fold. Because StarD4 is regulated by sterols via SREBP-2, whereas StarD5 is activated by ER stress, they likely serve distinct functions in cholesterol metabolism.	Rockefeller Univ, Biochem Genet & Metab Lab, New York, NY 10021 USA	Rockefeller University	Breslow, JL (corresponding author), Rockefeller Univ, Biochem Genet & Metab Lab, 1230 York Ave, New York, NY 10021 USA.	breslow@rockefeller.edu	Breslow, Jan L/B-7544-2008; Soccio, Raymond/M-7517-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032435] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32435] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amemiya-Kudo M, 2002, J LIPID RES, V43, P1220, DOI 10.1194/jlr.M100417-JLR200; Annicotte JS, 2001, BIOTECHNIQUES, V31, P993; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Bose HS, 2000, BIOCHEMISTRY-US, V39, P11722, DOI 10.1021/bi000911l; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Costet P, 2000, J BIOL CHEM, V275, P28240; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Edwards PA, 2000, BBA-MOL CELL BIOL L, V1529, P103, DOI 10.1016/S1388-1981(00)00140-2; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Ikeda Y, 2001, J BIOL CHEM, V276, P34259, DOI 10.1074/jbc.M103848200; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; Inoue J, 1998, J BIOCHEM-TOKYO, V123, P1191; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kim JH, 2001, J BIOL CHEM, V276, P18153, DOI 10.1074/jbc.M101661200; Lichtman AH, 1999, ARTERIOSCL THROM VAS, V19, P1938, DOI 10.1161/01.ATV.19.8.1938; Lund EG, 2003, ARTERIOSCL THROM VAS, V23, P1169, DOI 10.1161/01.ATV.0000056743.42348.59; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Maxwell KN, 2003, J LIPID RES, V44, P2109, DOI 10.1194/jlr.M300203-JLR200; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; OKUDA KI, 1994, J LIPID RES, V35, P361; Pandak WM, 2002, J BIOL CHEM, V277, P48158, DOI 10.1074/jbc.M205244200; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6; Schoonjans K, 2000, BBA-MOL CELL BIOL L, V1529, P114, DOI 10.1016/S1388-1981(00)00141-4; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Soccio RE, 2004, ARTERIOSCL THROM VAS, V24, P1150, DOI 10.1161/01.ATV.0000131264.66417.d5; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Soccio RE, 2002, P NATL ACAD SCI USA, V99, P6943, DOI 10.1073/pnas.052143799; Spencer TA, 2001, J MED CHEM, V44, P886, DOI 10.1021/jm0004749; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; Strauss JF, 2002, STEROIDS, V67, P947, DOI 10.1016/S0039-128X(02)00042-9; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Szanto A, 2004, MOL CELL BIOL, V24, P8154, DOI 10.1128/MCB.24.18.8154-8166.2004; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; Zhang M, 2002, J BIOL CHEM, V277, P33300, DOI 10.1074/jbc.M200003200	52	86	88	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19410	19418		10.1074/jbc.M501778200	http://dx.doi.org/10.1074/jbc.M501778200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15760897	hybrid			2022-12-25	WOS:000228932300099
J	Wang, D; Quick, MW				Wang, D; Quick, MW			Trafficking of the plasma membrane gamma-aminobutyric acid transporter GAT1 - Size and rates of an acutely recycling pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN DOPAMINE TRANSPORTER; RECEPTOR-MEDIATED ENDOCYTOSIS; BIOGENIC-AMINE TRANSPORTERS; GABA TRANSPORTER; GLUTAMATE TRANSPORTER; SYNTAXIN 1A; NEUROTRANSMITTER TRANSPORTERS; NOREPINEPHRINE TRANSPORTER; TYROSINE PHOSPHORYLATION	Plasma membrane neurotransmitter transporters rapidly traffic to and from the cell surface in neurons. This trafficking may be important in regulating neuronal signaling. Such regulation will be subject to the number of trafficking transporters and their trafficking rates. In the present study, we define an acutely recycling pool of endogenous gamma-aminobutyric acid transporters (GAT1) in cortical neurons that comprises approximately one-third of total cellular GAT1. Kinetic analysis of this pool estimates exocytosis and endocytosis time constants of 1.6 and 0.9 min, respectively, and thus approximately one-third of the recycling pool is plasma membrane resident in the basal state. Recent evidence shows that GAT1 substrates, second messengers, and interacting proteins regulate GAT1 trafficking. These triggers could act by altering trafficking rates or by changing the recycling pool size. In the present study we examine three GAT1 modulators. Calcium depletion decreases GAT1 surface expression by diminishing the recycling pool size. Sucrose increases GAT1 surface expression by blocking clathrin- and dynamin-dependent endocytosis, but it does not change the recycling pool size. Protein kinase C decreases surface GAT1 expression by increasing the endocytosis rate, but it does not change the exocytosis rate or the recycling pool size. Based upon estimates of GAT1 molecules in cortical boutons, the present data suggest that similar to 1000 transporters comprise the acutely recycling pool, of which 300 are on the surface in the basal state, and five transporters insert into the plasma membrane every second. This insertion could represent the fusion of one transporter-containing vesicle.	Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Grad Program Neurosci, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Quick, MW (corresponding author), Univ So Calif, Dept Biol Sci, HNB 228,3641 Watt Way, Los Angeles, CA 90089 USA.	mquick@usc.edu	Wang, Dan Ohtan/AAF-5704-2019; Wang, Dan Ohtan/E-1953-2011	Wang, Dan Ohtan/0000-0002-3126-8558; 	NATIONAL INSTITUTE ON DRUG ABUSE [R29DA010509, R01DA010509] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10509] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Aravanis AM, 2003, NEUROPHARMACOLOGY, V45, P797, DOI 10.1016/S0028-3908(03)00310-1; Bauman AL, 2000, J NEUROSCI, V20, P7571; Becker C, 2001, ENDOCRINOLOGY, V142, P5267, DOI 10.1210/en.142.12.5267; Beckman ML, 1998, J NEUROSCI, V18, P6103; Beckman ML, 1999, J NEUROSCI, V19; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; Chi LM, 2003, J PHARMACOL EXP THER, V307, P729, DOI 10.1124/jpet.103.055095; Chiu CS, 2002, J NEUROSCI, V22, P10251; Conti F, 1998, J COMP NEUROL, V396, P51, DOI 10.1002/(SICI)1096-9861(19980622)396:1<51::AID-CNE5>3.0.CO;2-H; COREY JL, 1994, J BIOL CHEM, V269, P14759; da Costa BLDA, 2000, BRAIN RES, V863, P132; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; Deken SL, 2003, J NEUROSCI, V23, P1563; Diamond JS, 2000, J NEUROPHYSIOL, V83, P2835, DOI 10.1152/jn.2000.83.5.2835; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Engel D, 1998, J PHYSIOL-LONDON, V512, P643, DOI 10.1111/j.1469-7793.1998.643bd.x; Ferguson SM, 2003, J NEUROSCI, V23, P9697; Fernandez-Alfonso T, 2004, NEURON, V41, P943, DOI 10.1016/S0896-6273(04)00113-8; Geerlings A, 2001, J BIOL CHEM, V276, P17584, DOI 10.1074/jbc.M010602200; Harwood HJ, 1997, BIOCHEM J, V323, P649, DOI 10.1042/bj3230649; Hesse S, 2003, J NEURAL TRANSM, V110, P923, DOI 10.1007/s00702-003-0008-8; Hoogland G, 2004, J NEUROSCI RES, V76, P881, DOI 10.1002/jnr.20128; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; Jayanthi LD, 2004, J BIOL CHEM, V279, P19315, DOI 10.1074/jbc.M311172200; JEFFERIES WA, 1985, IMMUNOLOGY, V54, P333; Jensen K, 2003, J NEUROPHYSIOL, V90, P2690, DOI 10.1152/jn.00240.2003; Jess U, 2002, BIOCHEM BIOPH RES CO, V294, P272, DOI 10.1016/S0006-291X(02)00460-6; Jiang HB, 2004, J BIOL CHEM, V279, P54380, DOI 10.1074/jbc.M409282200; Kuromi H, 2003, J NEUROCYTOL, V32, P551, DOI 10.1023/B:NEUR.0000020610.13554.3c; Law RM, 2000, J BIOL CHEM, V275, P23986, DOI 10.1074/jbc.M910283199; Lee A, 1999, CURR BIOL, V9, P261, DOI 10.1016/S0960-9822(99)80115-8; Lin CLG, 2001, NATURE, V410, P84, DOI 10.1038/35065084; Little KY, 2002, MOL PHARMACOL, V61, P436, DOI 10.1124/mol.61.2.436; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Lopez-Corcuera B, 2001, MOL MEMBR BIOL, V18, P13, DOI 10.1080/09687680120521; Masliah E, 2000, EXP NEUROL, V163, P381, DOI 10.1006/exnr.2000.7386; Melikian HE, 1999, J NEUROSCI, V19, P7699; Menne C, 2002, EUR J IMMUNOL, V32, P616, DOI 10.1002/1521-4141(200203)32:3<616::AID-IMMU616>3.3.CO;2-0; Morara S, 1996, NEUROREPORT, V7, P2993, DOI 10.1097/00001756-199611250-00039; Quick MW, 2002, P NATL ACAD SCI USA, V99, P5686, DOI 10.1073/pnas.082712899; Quick MW, 1997, J NEUROSCI, V17, P2967; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; Royle SJ, 2003, J PHYSIOL-LONDON, V553, P345, DOI 10.1113/jphysiol.2003.049221; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Schikorski T, 1997, J NEUROSCI, V17, P5858; Sung U, 2003, J NEUROSCI, V23, P1697; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Vanoni C, 2004, J CELL SCI, V117, P5417, DOI 10.1242/jcs.01411; VANRENSWOUDE J, 1982, P NATL ACAD SCI-BIOL, V79, P6186; WARDZALA LJ, 1978, J BIOL CHEM, V253, P8002; Waters J, 2002, J PHYSIOL-LONDON, V541, P811, DOI 10.1113/jphysiol.2001.013485; Whitworth TL, 2001, J BIOL CHEM, V276, P42932, DOI 10.1074/jbc.M107638200; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549	56	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18703	18709		10.1074/jbc.M500381200	http://dx.doi.org/10.1074/jbc.M500381200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15778221	hybrid			2022-12-25	WOS:000228932300021
J	Bannister, AJ; Schneider, R; Myers, FA; Thorne, AW; Crane-Robinson, C; Kouzarides, T				Bannister, AJ; Schneider, R; Myers, FA; Thorne, AW; Crane-Robinson, C; Kouzarides, T			Spatial distribution of di- and tri-methyl lysine 36 of histone H3 at active genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOTOS-SYNDROME; PHOSPHORYLATION; EXPRESSION; SET2	Methylation of lysine 4 of histone H3 (K4/H3) is linked to transcriptional activity, whereas methylation of K9/H3 is tightly associated with gene inactivity. These are well characterized sites of methylation within histones, but there are numerous other, less characterized, sites of modification. In Saccharomyces cerevisiae, methylation of K36/H3 has been linked to active genes, but little is known about this methylation in higher eukaryotes. Here we analyzed for the first time the levels and spatial distribution of di- and tri-methyl (di- and tri-Me) K36/H3 in metazoan genes. We analyzed chicken genes that are developmentally regulated, constitutively active, or inactive. We found that active genes contain high levels of these modifications compared with inactive genes. Furthermore, in actively transcribed regions the levels of di- and tri-Me K36/H3 peak toward the 3' end of the gene. This is in striking contrast to the distributions of di- and tri-Me K4/H3, which peak early in actively transcribed regions. Thus, di/tri-Me K4/H3 and di/tri-Me K36/H3 are both useful markers of active genes, but their genic distribution indicates differing roles. Our data suggest that the unique spatial distribution of di- and tri-Me K36/H3 plays a role in transcriptional termination and/or early RNA processing.	Wellcome Canc Res UK Gurdon Inst, Cambridge CB2 1QN, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QN, England; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; Univ Portsmouth, Biophys Labs, Inst Biomed & Biomol Sci, Portsmouth PO1 2DT, Hants, England	University of Cambridge; Max Planck Society; University of Portsmouth	Kouzarides, T (corresponding author), Wellcome Canc Res UK Gurdon Inst, Tennis Ct Rd, Cambridge CB2 1QN, England.	tk106@mole.bio.cam.ac.uk	, thorne/AAC-4984-2020	, thorne/0000-0002-8670-2358; Kouzarides, Tony/0000-0002-8918-4162; Bannister, Andrew/0000-0002-6312-4436; Myers, Fiona/0000-0001-5568-1817				Al-Mulla N, 2004, J PEDIAT HEMATOL ONC, V26, P204, DOI 10.1097/00043426-200403000-00013; Bird G, 2004, MOL CELL BIOL, V24, P8963, DOI 10.1128/MCB.24.20.8963-8969.2004; de Boer L, 2004, EUR J ENDOCRINOL, V151, P333, DOI 10.1530/eje.0.1510333; FELSENFELD G, 1993, GENE, V135, P119, DOI 10.1016/0378-1119(93)90056-9; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Landry J, 2003, MOL CELL BIOL, V23, P5972, DOI 10.1128/MCB.23.17.5972-5978.2003; Lin KT, 2004, MOL CELL BIOL, V24, P9176, DOI 10.1128/MCB.24.20.9176-9185.2004; Myers FA, 2001, J BIOL CHEM, V276, P20197, DOI 10.1074/jbc.M009472200; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Rayasam GV, 2003, EMBO J, V22, P3153, DOI 10.1093/emboj/cdg288; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; Visser R, 2003, CURR OPIN PEDIATR, V15, P598, DOI 10.1097/00008480-200312000-00010; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Zhou MS, 2004, J VIROL, V78, P13522, DOI 10.1128/JVI.78.24.13522-13533.2004	21	300	315	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17732	17736		10.1074/jbc.M500796200	http://dx.doi.org/10.1074/jbc.M500796200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15760899	hybrid			2022-12-25	WOS:000228807200023
J	Beharry, Z; Palzkill, T				Beharry, Z; Palzkill, T			Functional analysis of active site residues of the fosfomycin resistance enzyme FosA from Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; IN-VITRO ACTIVITY; CATALYTIC MECHANISM; ESCHERICHIA-COLI; PROTEIN FOSA; ANTIBIOTIC-RESISTANCE; URINARY-TRACT; EVOLUTION; BACTERIA; BINDING	The metalloglutathione transferase FosA catalyzes the conjugation of glutathione to carbon-1 of the antibiotic fosfomycin, rendering it ineffective as an antibacterial drug. Codon randomization and selection for the ability of resulting clones to confer fosfomycin resistance to Escherichia coli were used to identify residues critical for FosA function. Of the 24 codons chosen for randomization, 16 were found to be essential because only the wild type amino acid was selected. These included ligands to the Mn2+ and the K+, residues that furnish hydrogen bonds to fosfomycin, and residues located in a putative glutathione/fosfomycin-binding site. The remaining eight positions randomized were tolerant to substitutions. Site-directed mutagenesis of some of the essential and tolerant amino acids to alanine was performed, and the activity of the purified proteins was determined. Mutation of the residues that are within hydrogen bonding distance to the oxirane or phosphonate oxygens of fosfomycin resulted in variants with very low or no activity. Mutation of Ser(94), which bridges one of the phosphonate oxygens with a potassium ion, resulted in insoluble protein. The Y39A mutation in the putative glutathione-binding site resulted in a 4-fold increase in the apparent K-m for glutathione. Only two of the amino acids in the substrate-binding site are conserved in the related fosfomycin resistance proteins FosB and FosX, whereas no amino acids in the putative glutathione-binding site are conserved.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine	Palzkill, T (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.	timothyp@bcm.tmc.edu		Beharry, Zanna/0000-0002-3900-8523	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI032956, R01AI032956] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32956] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allerberger F, 1999, J ANTIMICROB CHEMOTH, V43, P211, DOI 10.1093/jac/43.2.211; Arca P, 1997, J ANTIMICROB CHEMOTH, V40, P393, DOI 10.1093/jac/40.3.393; ARCA P, 1988, ANTIMICROB AGENTS CH, V32, P1552, DOI 10.1128/AAC.32.10.1552; ARCA P, 1990, ANTIMICROB AGENTS CH, V34, P844, DOI 10.1128/AAC.34.5.844; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Armstrong RN, 2000, BIOCHEMISTRY-US, V39, P13625, DOI 10.1021/bi001814v; Babbitt PC, 1997, J BIOL CHEM, V272, P30591, DOI 10.1074/jbc.272.49.30591; Bernat BA, 1999, BIOCHEMISTRY-US, V38, P7462, DOI 10.1021/bi990391y; Bernat BA, 1998, J ORG CHEM, V63, P3778, DOI 10.1021/jo980014b; Bernat BA, 1997, BIOCHEMISTRY-US, V36, P3050, DOI 10.1021/bi963172a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caccuri AM, 2002, J BIOL CHEM, V277, P18777, DOI 10.1074/jbc.M201137200; Cao M, 2001, J BACTERIOL, V183, P2380, DOI 10.1128/JB.183.7.2380-2383.2001; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; ETIENNE J, 1989, FEMS MICROBIOL LETT, V61, P133, DOI 10.1016/0378-1097(89)90184-5; Fillgrove KL, 2003, J AM CHEM SOC, V125, P15730, DOI 10.1021/ja039307z; GARCIA P, 1995, ANTIMICROB AGENTS CH, V39, P1569, DOI 10.1128/AAC.39.7.1569; Grif K, 2001, J ANTIMICROB CHEMOTH, V48, P209, DOI 10.1093/jac/48.2.209; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horii T, 1999, ANTIMICROB AGENTS CH, V43, P789, DOI 10.1128/AAC.43.4.789; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; Laughlin LT, 1998, CHEM-BIOL INTERACT, V112, P41, DOI 10.1016/S0009-2797(97)00150-6; LEON J, 1982, ANTIMICROB AGENTS CH, V21, P608, DOI 10.1128/AAC.21.4.608; LIU SX, 1992, J BIOL CHEM, V267, P4296; Monden Koichi, 2002, Journal of Infection and Chemotherapy, V8, P218, DOI 10.1007/s10156-002-0186-6; Nicolle LE, 2002, AM J MED, V113, p35S; Okazaki Mitsuhiro, 2002, Journal of Infection and Chemotherapy, V8, P37; Petrosino J, 1999, J BIOL CHEM, V274, P2394, DOI 10.1074/jbc.274.4.2394; Rife CL, 2002, J AM CHEM SOC, V124, P11001, DOI 10.1021/ja026879v; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Shimizu M, 2000, ANTIMICROB AGENTS CH, V44, P2007, DOI 10.1128/AAC.44.7.2007-2008.2000; Smoukov SK, 2002, J AM CHEM SOC, V124, P2318, DOI 10.1021/ja012480f; SUAREZ JE, 1991, ANTIMICROB AGENTS CH, V35, P791, DOI 10.1128/AAC.35.5.791; Ungheri D, 2002, J CHEMOTHERAPY, V14, P237, DOI 10.1179/joc.2002.14.3.237	36	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17786	17791		10.1074/jbc.M501052200	http://dx.doi.org/10.1074/jbc.M501052200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15741169	hybrid			2022-12-25	WOS:000228807200029
J	Obata, Y; Yamamoto, K; Miyazaki, M; Shimotohno, K; Kohno, S; Matsuyama, T				Obata, Y; Yamamoto, K; Miyazaki, M; Shimotohno, K; Kohno, S; Matsuyama, T			Role of cyclophilin B in activation of interferon regulatory factor-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; CRYSTAL-STRUCTURE; VIRUS-INFECTION; GENE INDUCTION; DNA-BINDING; IRF-3; TRANSCRIPTION; IDENTIFICATION; PATHWAY; PHOSPHORYLATION	IRF-3 is a member of the interferon regulatory factors (IRFs) and plays a principal role in the induction of interferon-beta (IFN-beta) by virus infection. Virus infection results in the phosphorylation of IRF-3 by I kappa B kinase epsilon and TANK-binding kinase 1, leading to its dimerization and association with the coactivators CREB-binding protein/p300. The IRF-3 holocomplex translocates to the nucleus, where it induces IFN-beta. In the present study, we examined the molecular mechanism of IRF-3 activation. Using bacterial two-hybrid screening, we isolated molecules that interact with IRF-3. One of these was cyclophilin B, a member of the immunophilins with a cis-trans peptidyl-prolyl isomerase activity. A GST pull-down assay suggested that one of the autoinhibition domains of IRF-3 and the peptidyl-prolyl isomerase domain of cyclophilin B are required for the binding. A knockdown of cyclophilin B expression by RNA interference resulted in the suppression of virus-induced IRF-3 phosphorylation, leading to the inhibition of the subsequent dimerization, association with CREB-binding protein, binding to the target DNA element, and induction of IFN-beta. These findings indicate that cyclophilin B plays a critical role in IRF-3 activation.	Nagasaki Univ, Dept Mol Microbiol & Immunol, Grad Sch Biomed Sci, Nagasaki 8528523, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Dept Viral Oncol, Kyoto 6068507, Japan	Nagasaki University; Kyoto University	Matsuyama, T (corresponding author), Nagasaki Univ, Dept Mol Microbiol & Immunol, Grad Sch Biomed Sci, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.	tosim@net.nagasaki-u.ac.jp						Dove SL, 1997, NATURE, V386, P627, DOI 10.1038/386627a0; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Hu JC, 2000, METHODS, V20, P80, DOI 10.1006/meth.1999.0908; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P9430, DOI 10.1074/jbc.273.16.9430; Mamane Y, 2000, IMMUNITY, V12, P129, DOI 10.1016/S1074-7613(00)80166-1; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; Mori M, 2004, J BIOL CHEM, V279, P9698, DOI 10.1074/jbc.M310616200; Nagata T, 2000, J IMMUNOL, V165, P4281, DOI 10.4049/jimmunol.165.8.4281; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; PRICE ER, 1994, P NATL ACAD SCI USA, V91, P3931, DOI 10.1073/pnas.91.9.3931; Qin BY, 2003, NAT STRUCT BIOL, V10, P913, DOI 10.1038/nsb1002; Rycyzyn MA, 2002, P NATL ACAD SCI USA, V99, P6790, DOI 10.1073/pnas.092160699; Rycyzyn MA, 2000, MOL ENDOCRINOL, V14, P1175, DOI 10.1210/me.14.8.1175; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; SEN GC, 1992, J BIOL CHEM, V267, P5017; Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Suhara W, 2000, J BIOCHEM-TOKYO, V128, P301, DOI 10.1093/oxfordjournals.jbchem.a022753; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Takahasi K, 2003, NAT STRUCT BIOL, V10, P922, DOI 10.1038/nsb1001; VILCEK J, 1996, VIROLOGY, P375; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	29	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18355	18360		10.1074/jbc.M501684200	http://dx.doi.org/10.1074/jbc.M501684200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15764595	hybrid			2022-12-25	WOS:000228807200096
J	Shin, DH; Oganesyan, N; Jancarik, J; Yokota, H; Kim, R; Kim, SH				Shin, DH; Oganesyan, N; Jancarik, J; Yokota, H; Kim, R; Kim, SH			Crystal structure of a nicotinate phosphoribosyltransferase from Thermoplasma acidophilum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOLINIC ACID PHOSPHORIBOSYLTRANSFERASE; LIFE-SPAN EXTENSION; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; PROTEIN; BIOSYNTHESIS; SPECIFICITY; DATABASE; PATHWAY; DOMAIN	We have determined the crystal structure of nicotinate phosphoribosyltransferase from Themoplasma acidophilum (TaNAPRTase). The TaNAPRTase has three domains, an N-terminal domain, a central functional domain, and a unique C-terminal domain. The crystal structure revealed that the functional domain has a type II phosphoribosyltransferase fold that may be a common architecture for both nicotinic acid and quinolinic acid (QA) phosphoribosyltransferases (PRTase) despite low sequence similarity between them. Unlike QAPRTase, TaNAPRTase has a unique extra C-terminal domain containing a zinc knuckle-like motif containing 4 cysteines. The TaNAPRTase forms a trimer of dimers in the crystal. The active site pocket is formed at dimer interfaces. The complex structures with phosphoribosylpyrophosphate (PRPP) and nicotinate mononucleotide (NAMN) showed, surprisingly, that functional residues lining on the active site of TaNAPRTase are quite different from those of QAPRTase, although their substrates are quite similar to each other. The phosphate moiety of PRPP and NAMN is anchored to the phosphate-binding loops formed by backbone amides, as found in many alpha/beta barrel enzymes. The pyrophosphate moiety of PRPP is located at the entrance of the active site pocket, whereas the nicotinate moiety of NAMN is located deep inside. Interestingly, the nicotinate moiety of NAMN is intercalated between highly conserved aromatic residues Tyr(21) and Phe(138). Careful structural analyses combined with other NAPRTase sequence subfamilies reveal that TaNAPRTase represents a unique sequence subfamily of NAPRTase. The structures of TaNAPRTase also provide valuable insight for other sequence subfamilies such as pre-B cell colony-enhancing factor, known to have nicotinamide phosphoribosyltransferase activity.	Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Struct Genom Ctr, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Kim, SH (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Struct Genom Ctr, Berkeley, CA 94720 USA.	SHKim@cchem.berkeley.edu			NIGMS NIH HHS [GM 62412] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062412] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; ASLANIDIS C, 1990, NUCLEIC ACIDS RES, V20, P2069; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Denu JM, 2003, TRENDS BIOCHEM SCI, V28, P41, DOI 10.1016/S0968-0004(02)00005-1; Eads JC, 1997, STRUCTURE, V5, P47, DOI 10.1016/S0969-2126(97)00165-2; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Gross JW, 1998, BIOCHEMISTRY-US, V37, P4189, DOI 10.1021/bi972014w; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kim KK, 1997, STRUCTURE, V5, P1571, DOI 10.1016/S0969-2126(97)00306-7; Kim R, 1998, BIOTECHNOL LETT, V20, P207, DOI 10.1023/A:1005305330517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kucharczyk R, 1998, FEBS LETT, V424, P127, DOI 10.1016/S0014-5793(98)00153-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2003, CURR OPIN CELL BIOL, V15, P241, DOI 10.1016/S0955-0674(03)00006-1; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rajavel M, 1998, BIOCHEMISTRY-US, V37, P4181, DOI 10.1021/bi9720134; Rongvaux A, 2002, EUR J IMMUNOL, V32, P3225, DOI 10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L; Sharma V, 1998, STRUCTURE, V6, P1587, DOI 10.1016/S0969-2126(98)00156-7; Sinha SC, 2001, CURR OPIN STRUC BIOL, V11, P733, DOI 10.1016/S0959-440X(01)00274-3; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TRITZ GJ, 1987, ESCHERICHIA COLI SAL, P557; WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006	34	31	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18326	18335		10.1074/jbc.M501622200	http://dx.doi.org/10.1074/jbc.M501622200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15753098	hybrid			2022-12-25	WOS:000228807200092
J	Yamada, T; Carson, AR; Caniggia, I; Umebayashi, K; Yoshimori, T; Nakabayashi, K; Scherer, SW				Yamada, T; Carson, AR; Caniggia, I; Umebayashi, K; Yoshimori, T; Nakabayashi, K; Scherer, SW			Endothelial nitric-oxide synthase antisense (NOS3AS) gene encodes an autophagy-related protein (APG9-like2) highly expressed in trophoblast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLE TARGETING PATHWAY; SUSCEPTIBILITY LOCUS; MAMMALIAN-CELLS; ENOS-GENE; PREECLAMPSIA; YEAST; MEMBRANE; BECLIN-1; TUMORIGENESIS; DEGRADATION	Macroautophagy is an intracellular degradation system for the majority of proteins and some organelles that is conserved in all eukaryotic species. The precise role of autophagy in mammalian development and potential involvement in disease remain to be discerned. Yeast Atg9p is the first integral membrane protein shown to be essential for the cytoplasm to vacuole targeting (Cvt) pathway and autophagy, whereas its mammalian functional orthologue has yet to be identified. We have identified two human genes homologous to yeast Atg9p and designated these as APG9L1 and APG9L2. We have previously identified APG9L2 as NOS3AS, which participates in the post-transcriptional regulation of the endothelial nitric-oxide synthase (NOS3) gene on chromosome 7 through its antisense overlap. In human adult tissues, APG9L1 was ubiquitously expressed, whereas APG9L2 was highly expressed in placenta (trophoblast cells) and pituitary gland. In transient transfection assays we found that both proteins were primarily localized to the perinuclear region and also scattered throughout the cytosol as dots, a subset of which colocalized with an autophagosome-specific marker LC3 under starvation conditions. Finally, by the small interfering RNA-mediated knockdown of APG9L1 in HeLa cells, we demonstrated that APG9L1 is essential for starvation-induced autophagosome formation. In addition, APG9L2 can functionally complement APG9L1 in this process. These results, taken together with those of phylogenetic and sequence analyses, suggest that both APG9L1 and APG9L2 are functionally orthologous to the yATG9 in autophagosome formation. Moreover, APG9L2 is a vertebrate-specific gene that may have gained critical roles in mammalian-specific developmental events, such as placentation, through rapid evolution.	Hosp Sick Children, Program Genet & Genom Biol, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5G 2M9, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Dev & Fetal Hlth, Toronto, ON M5G 1X5, Canada; Natl Inst Genet, Dept Cell Genet, Mishima, Shizuoka 4110801, Japan	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Scherer, SW (corresponding author), Hosp Sick Children, Program Genet & Genom Biol, Res Inst, Rm 9107,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	steve@genet.sickkids.on.ca	Yamada, Takahiro/A-4001-2011; Scherer, Stephen W./B-3785-2013; Caniggia, Isabella/G-6466-2013	Scherer, Stephen W./0000-0002-8326-1999; Caniggia, Isabella/0000-0001-7340-2359				Arngrimsson R, 1999, HUM MOL GENET, V8, P1799, DOI 10.1093/hmg/8.9.1799; Arngrimsson R, 1997, AM J HUM GENET, V61, P354, DOI 10.1086/514843; Doelling JH, 2002, J BIOL CHEM, V277, P33105, DOI 10.1074/jbc.M204630200; Emanuelsson O, 2001, METHOD CELL BIOL, V65, P175, DOI 10.1016/S0091-679X(01)65011-8; Guo GL, 1999, HUM GENET, V105, P641, DOI 10.1007/s004390051156; Hanaoka H, 2002, PLANT PHYSIOL, V129, P1181, DOI 10.1104/pp.011024; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Lade JA, 1999, HYPERTENS PREGNANCY, V18, P81, DOI 10.3109/10641959909009613; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lewis I, 1999, AM J HUM GENET, V64, P310, DOI 10.1086/302179; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Marino G, 2003, J BIOL CHEM, V278, P3671, DOI 10.1074/jbc.M208247200; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Reggiori F, 2004, DEV CELL, V6, P79, DOI 10.1016/S1534-5807(03)00402-7; Robb GB, 2004, J BIOL CHEM, V279, P37982, DOI 10.1074/jbc.M400271200; Scherer SW, 2003, SCIENCE, V300, P767, DOI 10.1126/science.1083423; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sun K, 1997, ENDOCRINOLOGY, V138, P4912, DOI 10.1210/en.138.11.4912; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tucker KA, 2003, J BIOL CHEM, V278, P48445, DOI 10.1074/jbc.M309238200; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	37	90	138	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18283	18290		10.1074/jbc.M413957200	http://dx.doi.org/10.1074/jbc.M413957200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15755735	hybrid			2022-12-25	WOS:000228807200087
J	Aoyagi, K; Sugaya, T; Umeda, M; Yamamoto, S; Terakawa, S; Takahashi, M				Aoyagi, K; Sugaya, T; Umeda, M; Yamamoto, S; Terakawa, S; Takahashi, M			The activation of exocytotic sites by the formation of phosphatidylinositol 4,5-bisphosphate microdomains at syntaxin clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; ADRENAL CHROMAFFIN CELLS; PLASMA-MEMBRANE; NEUROTRANSMITTER RELEASE; PC12 CELLS; CA2+-ACTIVATED SECRETION; PHOSPHOLIPASE-C; FUSION; PI(4,5)P-2; MICROSCOPY	Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2) is a minor component of the lipid bilayer but plays an important role in various cellular functions, including exocytosis and endocytosis. Recently, PI(4,5)P-2 was shown to form microdomains in the plasma membrane. In this study, we investigated the relationship between the spatial organization of PI(4,5)P-2 microdomains and exocytotic machineries in clonal rat pheochromocytoma PC12 cells. Both PI(4,5)P-2 and syntaxin, a soluble N-ethylmaleimide-sensitive factor attachment protein receptor protein essential for exocytosis, exhibited punctate clusters in isolated plasma membranes. The number of PI(4,5)P-2 microdomains colocalizing with syntaxin clusters and large dense core vesicles (LDCVs) was decreased after catecholamine release. Alternatively, the expression of type I phosphatidylinositol-4-phosphate 5-kinase (PIP5KI) increased the number of PI(4,5)P-2 microdomains at syntaxin clusters with docked LDCVs and enhanced exocytotic activity, possibly by increasing the number of release sites. About half of the PI(4,5)P-2 microdomains were not colocalized with Thy-1, a specific marker of lipid rafts, and the colocalization of transfected PIP5KI with syntaxin clusters was observed. These results suggest that the formation of PI(4,5)P-2 microdomains at syntaxin clusters with docked LDCVs is essential for Ca2+-dependent exocytosis.	Kitasato Univ, Sch Med, Dept Biochem, Kanagawa 2288555, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, Tokyo 1538902, Japan; Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan; Hamamatsu Univ Sch Med, Photon Med Res Ctr, Shizuoka 4313192, Japan	Kitasato University; University of Tokyo; Kyoto University; Hamamatsu University School of Medicine	Takahashi, M (corresponding author), Kitasato Univ, Sch Med, Dept Biochem, Kanagawa 2288555, Japan.	masami@med.kitasato-u.ac.jp						Aikawa Y, 2003, J CELL BIOL, V162, P647, DOI 10.1083/jcb.200212142; Aoyagi K, 2001, BIOCHEM BIOPH RES CO, V286, P646, DOI 10.1006/bbrc.2001.5443; Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; Balla T, 2000, TRENDS PHARMACOL SCI, V21, P238, DOI 10.1016/S0165-6147(00)01500-5; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; BITTNER MA, 1992, J BIOL CHEM, V267, P16226; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; CHOW RH, 1994, P NATL ACAD SCI USA, V91, P12765, DOI 10.1073/pnas.91.26.12765; Cremona O, 2001, J CELL SCI, V114, P1041; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Iwasaki S, 2000, J BIOCHEM-TOKYO, V128, P407, DOI 10.1093/oxfordjournals.jbchem.a022768; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Janmey PA, 1999, CHEM PHYS LIPIDS, V101, P93, DOI 10.1016/S0009-3084(99)00058-4; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; Lang T, 2002, J CELL BIOL, V158, P751, DOI 10.1083/jcb.200203088; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Liu YM, 1998, BIOCHEM BIOPH RES CO, V245, P684, DOI 10.1006/bbrc.1998.8329; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Mashanov GI, 2004, J BIOL CHEM, V279, P15274, DOI 10.1074/jbc.M312140200; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; MAYER S, 1994, SCIENCE, V264, P1948; MIYAZAWA A, 1988, MOL IMMUNOL, V25, P1025; Neeb A, 1999, EUR J CELL BIOL, V78, P533, DOI 10.1016/S0171-9335(99)80018-1; Ohara-Imaizumi M, 2004, J BIOL CHEM, V279, P8403, DOI 10.1074/jbc.M308954200; Ohnishi H, 2001, P NATL ACAD SCI USA, V98, P10930, DOI 10.1073/pnas.191368198; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STOUT AL, 1989, APPL OPTICS, V28, P5237, DOI 10.1364/AO.28.005237; Telemenakis I, 1997, EUR J CELL BIOL, V74, P143; Tsuboi T, 2002, BIOPHYS J, V83, P172, DOI 10.1016/S0006-3495(02)75159-X; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; WICK PF, 1993, J BIOL CHEM, V268, P10983	51	136	138	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17346	17352		10.1074/jbc.M413307200	http://dx.doi.org/10.1074/jbc.M413307200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15741173	hybrid			2022-12-25	WOS:000228615500099
J	Singh, S; Korolev, S; Koroleva, O; Zarembinski, T; Collart, F; Joachimiak, A; Christendat, D				Singh, S; Korolev, S; Koroleva, O; Zarembinski, T; Collart, F; Joachimiak, A; Christendat, D			Crystal structure of a novel shikimate dehydrogenase from Haemophilus influenzae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHWAY; SPECIFICITY	To date two classes of shikimate dehydrogenases have been identified and characterized, YdiB and AroE. YdiB is a bifunctional enzyme that catalyzes the reversible reductions of dehydroquinate to quinate and dehydroshikimate to shikimate in the presence of either NADH or NADPH. In contrast, AroE catalyzes the reversible reduction of dehydroshikimate to shikimate in the presence of NADPH. Here we report the crystal structure and biochemical characterization of HI0607, a novel class of shikimate dehydrogenase annotated as shikimate dehydrogenase-like. The kinetic properties of HI0607 are remarkably different from those of AroE and YdiB. In comparison with YdiB, HI0607 catalyzes the oxidation of shikimate but not quinate. The turnover rate for the oxidation of shikimate is similar to 1000-fold lower compared with that of AroE. Phylogenetic analysis reveals three independent clusters representing three classes of shikimate dehydrogenases, namely AroE, YdiB, and this newly characterized shikimate dehydrogenase-like protein. In addition, mutagenesis studies of two invariant residues, Asp-103 and Lys-67, indicate that they are important catalytic groups that may function as a catalytic pair in the shikimate dehydrogenase reaction. This is the first study that describes the crystal structure as well as mutagenesis and mechanistic analysis of this new class of shikimate dehydrogenase.	Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA	University of Toronto; United States Department of Energy (DOE); Argonne National Laboratory	Christendat, D (corresponding author), Univ Toronto, Dept Bot, 25 Willcocks St, Toronto, ON M5S 3B2, Canada.	dinesh.christendat@utoronto.ca	Korolev, Sergey/ABA-7517-2020; Singh, Sasha/H-3612-2012	Singh, Sasha/0000-0003-0929-3164; Collart, Frank/0000-0001-6942-4483; Korolev, Sergey/0000-0001-9313-7126	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50 GM062414, GM62414-01, P50 GM062414-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahvazi B, 2000, BIOCHEM J, V349, P853, DOI 10.1042/bj3490853; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALINSKY D, 1971, BIOCHEMISTRY-US, V10, P1947; Campbell SA, 2004, INT J PARASITOL, V34, P5, DOI 10.1016/j.ijpara.2003.10.006; Christendat D, 2000, J BIOL CHEM, V275, P24608, DOI 10.1074/jbc.C000238200; Christendat D, 1998, BIOCHEMISTRY-US, V37, P15703, DOI 10.1021/bi981412b; DENNIS AW, 1972, INT J BIOCHEM, V3, P93, DOI 10.1016/0020-711X(72)90031-6; GILES NH, 1985, MICROBIOL REV, V49, P338, DOI 10.1128/MMBR.49.3.338-358.1985; HERRMANN KM, 1995, PLANT CELL, V7, P907; Herrmann KM, 1999, ANNU REV PLANT PHYS, V50, P473, DOI 10.1146/annurev.arplant.50.1.473; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; McConkey GA, 2000, EXP PARASITOL, V94, P23, DOI 10.1006/expr.1999.4467; Michel G, 2003, J BIOL CHEM, V278, P19463, DOI 10.1074/jbc.M300794200; Minor W, 2000, STRUCTURE, V8, pR105, DOI 10.1016/S0969-2126(00)00139-8; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Roberts CW, 2002, J INFECT DIS, V185, pS25, DOI 10.1086/338004; Stols L, 2002, PROTEIN EXPRES PURIF, V25, P8, DOI 10.1006/prep.2001.1603; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Vogan E, 2003, STRUCTURE, V11, P902, DOI 10.1016/S0969-2126(03)00165-5; Watanabe S, 2005, J BIOL CHEM, V280, P10340, DOI 10.1074/jbc.M409443200; Wheeler KA, 1996, BIOCHEM J, V315, P195, DOI 10.1042/bj3150195	25	32	38	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17101	17108		10.1074/jbc.M412753200	http://dx.doi.org/10.1074/jbc.M412753200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15735308	hybrid, Green Accepted			2022-12-25	WOS:000228615500069
J	Walther, RF; Atlas, E; Carrigan, A; Rouleau, Y; Edgecombe, A; Visentin, L; Lamprecht, C; Addicks, GC; Hache, RJG; Lefebvre, YA				Walther, RF; Atlas, E; Carrigan, A; Rouleau, Y; Edgecombe, A; Visentin, L; Lamprecht, C; Addicks, GC; Hache, RJG; Lefebvre, YA			A serine/threonine-rich motif is one of three nuclear localization signals that determine unidirectional transport of the mineralocorticoid receptor to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; BETA-HYDROXYSTEROID DEHYDROGENASE; GLUCOCORTICOID-RECEPTOR; LIVING CELLS; ANDROGEN RECEPTOR; SUBCELLULAR-LOCALIZATION; PROGESTERONE-RECEPTOR; INTRACELLULAR-LOCALIZATION; SUBNUCLEAR TRAFFICKING; ACTIVATION FUNCTION-1	The mineralocorticoid receptor (MR) is a tightly regulated nuclear hormone receptor that selectively transmits corticosteroid signals. Steroid treatment transforms MR from a transcriptionally inert state, in which it is distributed equally between the nucleus and cytoplasm, to an active completely nuclear transcription factor. We report here that MR is an atypical nuclear hormone receptor that moves unidirectionally from the cytoplasm to the nucleus. We show that nuclear import of MR is controlled through three nuclear localization signals (NLSs) of distinct types. Nuclear localization of naive MR was mediated primarily through a novel serine/ threonine-rich NLS (NL0) in the receptor N terminus. Specific amino acid substitutions that mimicked phosphorylation selectively enhanced or repressed NL0 activity, highlighting the potential for active regulation of this new type of NLS. The second NLS (NL2) within the ligand-binding domain also lacks a recognizable basic motif. Nuclear transfer through this signal was strictly dependent on steroid agonist, but was independent of the interaction of MR with coactivator proteins. The third MR NLS (NL1) is a bipartite basic motif localized to the C terminus of the MR DNA-binding domain with properties distinct from those of NL1 of the closely related glucocorticoid receptor. NL1 acted in concert with NL0 and NL2 to stimulate nuclear uptake of the agonist-treated receptor, but also directed the complete nuclear localization of MR in response to treatment with steroid antagonist. These results present MR as a nuclear hormone receptor whose unidirectional transfer to the nucleus may be regulated through multiple pathways.	Univ Ottawa, Ottawa Hosp, Ottawa Hlth Res Inst, Dept Med, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Ottawa Hosp, Ottawa Hlth Res Inst, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Ottawa Hosp, Ottawa Hlth Res Inst, Grad Program Biochem, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Hache, RJG (corresponding author), Univ Ottawa, Ottawa Hosp, Ottawa Hlth Res Inst, Dept Med, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	rhache@ohri.ca						ALNEMRI ES, 1991, J BIOL CHEM, V266, P18072; ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; Baumann CT, 2001, J BIOL CHEM, V276, P11237, DOI 10.1074/jbc.M011112200; Begitt A, 2000, P NATL ACAD SCI USA, V97, P10418, DOI 10.1073/pnas.190318397; BINART N, 1991, P NATL ACAD SCI USA, V88, P10681, DOI 10.1073/pnas.88.23.10681; Black BE, 2001, CURR BIOL, V11, P1749, DOI 10.1016/S0960-9822(01)00537-1; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Blom N, 1998, NUCLEIC ACIDS RES, V26, P382, DOI 10.1093/nar/26.1.382; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CHANDRAN UR, 1992, MOL ENDOCRINOL, V6, P837, DOI 10.1210/me.6.5.837; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; Freedman ND, 2004, MOL BIOL CELL, V15, P2276, DOI 10.1091/mbc.E03-11-0839; Fuse H, 2000, MOL ENDOCRINOL, V14, P889, DOI 10.1210/me.14.6.889; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Kitagawa H, 2002, MOL CELL BIOL, V22, P3698, DOI 10.1128/MCB.22.11.3698-3706.2002; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; LOMBES M, 1994, BIOCHEM J, V302, P191, DOI 10.1042/bj3020191; LOMBES M, 1990, P NATL ACAD SCI USA, V87, P1086, DOI 10.1073/pnas.87.3.1086; MADAN AP, 1993, P NATL ACAD SCI USA, V90, P3588, DOI 10.1073/pnas.90.8.3588; MARTINS VR, 1991, MOL ENDOCRINOL, V5, P217, DOI 10.1210/mend-5-2-217; NarayFejesToth A, 1996, J BIOL CHEM, V271, P15436, DOI 10.1074/jbc.271.26.15436; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Nishi M, 2001, MOL ENDOCRINOL, V15, P1077, DOI 10.1210/me.15.7.1077; Odermatt A, 2001, J BIOL CHEM, V276, P28484, DOI 10.1074/jbc.M100374200; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Ou XM, 2001, J BIOL CHEM, V276, P14299, DOI 10.1074/jbc.M005363200; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Planey SL, 2002, J BIOL CHEM, V277, P42188, DOI 10.1074/jbc.M205085200; Ploski JE, 2004, MOL CELL BIOL, V24, P4824, DOI 10.1128/MCB.24.11.4824-4834.2004; Poukka H, 2000, J CELL SCI, V113, P2991; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; ROBERTSON NM, 1993, MOL ENDOCRINOL, V7, P1226, DOI 10.1210/me.7.9.1226; Roozendaal B, 2002, NEUROBIOL LEARN MEM, V78, P578, DOI 10.1006/nlme.2002.4080; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SASANO H, 1992, J ENDOCRINOL, V132, P305, DOI 10.1677/joe.0.1320305; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; Savory JGA, 2001, MOL CELL BIOL, V21, P781, DOI 10.1128/MCB.21.3.781-793.2001; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Sousa N, 2002, REV NEUROSCIENCE, V13, P59; Steidl S, 2004, J MOL BIOL, V342, P515, DOI 10.1016/j.jmb.2004.07.011; Tang YT, 1997, MOL BIOL CELL, V8, P795, DOI 10.1091/mbc.8.5.795; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; vanSteensel B, 1996, J CELL SCI, V109, P787; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Walther RF, 2003, J BIOL CHEM, V278, P37858, DOI 10.1074/jbc.M306356200; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; Wolff T, 2002, J BIOL CHEM, V277, P12151, DOI 10.1074/jbc.M109103200; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yang J, 1997, J CELL BIOL, V137, P523, DOI 10.1083/jcb.137.3.523; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x	67	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17549	17561		10.1074/jbc.M501548200	http://dx.doi.org/10.1074/jbc.M501548200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15737989	hybrid			2022-12-25	WOS:000228615500124
J	Au, PYB; Martin, N; Chau, H; Moemeni, B; Chia, M; Liu, FF; Minden, M; Yeh, WC				Au, PYB; Martin, N; Chau, H; Moemeni, B; Chia, M; Liu, FF; Minden, M; Yeh, WC			The oncogene PDGF-B provides a key switch from cell death to survival induced by TNF	ONCOGENE			English	Article						TNF; PDGF-B; cell survival; NF-kappa B	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; MYC-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; GROWTH-FACTOR; DERMATOFIBROSARCOMA PROTUBERANS; IN-VITRO; ACTIVATION; ALPHA; INDUCTION	Tumor necrosis factor (TNF) induces both cell death and survival signals. NF-kappa B, a transcription factor activated by TNF, is critical for controlling survival signals through trans-activation of downstream target genes. However, few NF-kappa B target survival genes have been identified with direct roles in oncogenesis. We report that platelet-derived growth factor B (PDGF-B), an oncogene and growth factor, is highly induced by TNF in fibroblasts in an NF-kappa B-dependent manner. PDGF-B can rescue NF-kappa B deficient. broblasts from TNF-mediated killing, and inhibition of PDGF-B signaling sensitizes wild-type cells to TNF-induced death. Interestingly, PDGF-B-transformed NIH-3T3 cells are even more highly sensitized to TNF-induced cell death with PDGF-B inhibition. Our results suggest that while normal cells contain multiple TNF-induced survival signals, tumor cells may favor a specific survival gene that is abnormally upregulated in order to evade death signals.	Univ Toronto, Dept Med Biophys, Univ Hlth Network, AMDI cFIFBCR, Toronto, ON M5G 2C1, Canada; Univ Hlth Network, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Yeh, WC (corresponding author), Univ Toronto, Dept Med Biophys, Univ Hlth Network, AMDI cFIFBCR, 620 Univ Ave,Suite 7-706, Toronto, ON M5G 2C1, Canada.	wyeh@uhnres.utoronto.ca		Liu, Fei-Fei/0000-0003-4344-6486; Spence, Tara/0000-0001-7098-4103				Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BEG AA, 1996, SCIENCE, V274, P784; BRUSERUD O, 1995, LEUKEMIA RES, V19, P15, DOI 10.1016/0145-2126(94)00062-F; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Ekman S, 1999, ONCOGENE, V18, P2481, DOI 10.1038/sj.onc.1202606; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; Gibson EM, 2002, CANCER RES, V62, P488; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HELSON L, 1975, NATURE, V258, P731, DOI 10.1038/258731a0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JAATTELA M, 1995, ONCOGENE, V10, P2297; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KALTHOFF H, 1991, ONCOGENE, V6, P1015; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mahboobi S, 2002, J MED CHEM, V45, P1002, DOI 10.1021/jm010988n; Mak TW, 2002, ARTHRITIS RES THER, V4, pS243, DOI 10.1186/ar569; Manley PW, 2002, EUR J CANCER, V38, pS19, DOI 10.1016/S0959-8049(02)80599-8; Manna SK, 2000, J INTERF CYTOK RES, V20, P725, DOI 10.1089/10799900050116435; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Mochizuki Y, 2004, CLIN EXP METASTAS, V21, P39, DOI 10.1023/B:CLIN.0000017181.01474.35; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; Prins John, 1998, Biochemical Society Transactions, V26, pS314; Rudolph D, 2000, GENE DEV, V14, P854; Shimamura T, 2002, EXP CELL RES, V274, P157, DOI 10.1006/excr.2001.5449; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; Sjoblom T, 2001, CANCER RES, V61, P5778; Smith S, 2002, PLACENTA, V23, P322, DOI 10.1053/plac.2001.0783; Suzuki S, 2003, P NATL ACAD SCI USA, V100, P8276, DOI 10.1073/pnas.0932598100; Takeuchi H, 2004, BRIT J CANCER, V90, P1069, DOI 10.1038/sj.bjc.6601605; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	45	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3196	3205		10.1038/sj.onc.1208516	http://dx.doi.org/10.1038/sj.onc.1208516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735680				2022-12-25	WOS:000228728100013
J	Hara-Chikuma, M; Sohara, E; Rai, T; Ikawa, M; Okabe, M; Sasaki, S; Uchida, S; Verkman, AS				Hara-Chikuma, M; Sohara, E; Rai, T; Ikawa, M; Okabe, M; Sasaki, S; Uchida, S; Verkman, AS			Progressive adipocyte hypertrophy in aquaporin-7-deficient mice - Adipocyte glycerol permeability as a novel regulator of fat accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY COLLECTING DUCT; AQUAPORIN ADIPOSE; WATER CHANNEL; POSSIBLE INVOLVEMENT; MOLECULAR-CLONING; SKIN HYDRATION; EXPRESSION; RAT; TESTIS; CELLS	Aquaporin-7 (AQP7) is a water/glycerol transporting protein expressed in adipocyte plasma membranes. We report here remarkable age-dependent hypertrophy in adipocytes in AQP7-deficient mice. Wild type and AQP7 null mice had similar growth at 0 - 16 weeks as assessed by body weight; however, by 16 weeks AQP7 null mice had 3.7-fold increased body fat mass. Adipocytes from AQP7 null mice of age 16 weeks were greatly enlarged ( diameter 118 mu m) compared with wild type mice ( 39 mu m). Adipocytes from AQP7 null mice also accumulated excess glycerol ( 251 versus 86 nmol/mg of protein) and triglycerides (3.4 versus 1.7 mu mol/mg of protein). In contrast, at age 4 weeks, adipocyte volume and body fat mass were comparable in wild type and AQP7 null mice. To investigate the mechanism(s) responsible for the progressive adipocyte hypertrophy, glycerol permeability and fat metabolism were studied in adipocytes isolated from the younger mice. Plasma membrane glycerol permeability measured by [C-14] glycerol uptake was 3-fold reduced in AQP7-deficient adipocytes. However, adipocyte lipolysis, measured by free fatty acid release and hormone-sensitive lipase activity, and lipogenesis, measured by [C-14] glucose incorporation into triglycerides, were not affected by AQP7 deletion. These data suggest that adipocyte hypertrophy in AQP7 deficiency results from defective glycerol exit and consequent accumulation of glycerol and triglycerides. Increasing AQP7 expression/function in adipocytes may reduce adipocyte volume and fat mass in obesity.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Tokyo Med & Dent Univ, Dept Nephrol, Tokyo 1138519, Japan; Osaka Univ, Genome Informat Res Ctr, Osaka 5650871, Japan	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Tokyo Medical & Dental University (TMDU); Osaka University	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu	ikawa, masahito/A-5315-2009; Rai, Tatemitsu/K-7165-2019; Uchida, Shinichi/D-1111-2013; Okabe, Masaru/B-6917-2015	ikawa, masahito/0000-0001-9859-6217; Okabe, Masaru/0000-0002-0803-9044	NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL73854, HL59198] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Calamita G, 2001, BIOCHEM BIOPH RES CO, V288, P619, DOI 10.1006/bbrc.2001.5810; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Fasshauer M, 2003, HORM METAB RES, V35, P222; Hara M, 2003, P NATL ACAD SCI USA, V100, P7360, DOI 10.1073/pnas.1230416100; Hara M, 2002, J BIOL CHEM, V277, P46616, DOI 10.1074/jbc.M209003200; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; Kageyama Y, 2001, ANDROLOGIA, V33, P165, DOI 10.1046/j.1439-0272.2001.00443.x; Kimura Y, 1998, J ETHNOPHARMACOL, V59, P117, DOI 10.1016/S0378-8741(97)00115-3; Kishida K, 2000, J BIOL CHEM, V275, P20896, DOI 10.1074/jbc.M001119200; Kishida K, 2001, J BIOL CHEM, V276, P36251, DOI 10.1074/jbc.M106040200; Kuriyama H, 2002, DIABETES, V51, P2915, DOI 10.2337/diabetes.51.10.2915; Kuriyama H, 1997, BIOCHEM BIOPH RES CO, V241, P53, DOI 10.1006/bbrc.1997.7769; Ma TH, 2002, J BIOL CHEM, V277, P17147, DOI 10.1074/jbc.M200925200; MA TH, 1994, J BIOL CHEM, V269, P21845; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Maeda N, 2004, P NATL ACAD SCI USA, V101, P17801, DOI 10.1073/pnas.0406230101; Morimoto C, 1997, J LIPID RES, V38, P132; Nejsum LN, 2000, BIOCHEM BIOPH RES CO, V277, P164, DOI 10.1006/bbrc.2000.3638; RODBELL M, 1964, J BIOL CHEM, V239, P375; Saito K, 2004, J UROLOGY, V172, P2073, DOI 10.1097/01.ju.0000141499.08650.ab; Tordjman J, 2003, J BIOL CHEM, V278, P18785, DOI 10.1074/jbc.M206999200; Zhou ZH, 2003, NAT GENET, V35, P49, DOI 10.1038/ng1225	25	191	209	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15493	15496		10.1074/jbc.C500028200	http://dx.doi.org/10.1074/jbc.C500028200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15746100	hybrid			2022-12-25	WOS:000228444800005
J	Romero-Gallo, J; Sozmen, EG; Chytil, A; Russell, WE; Whitehead, R; Parks, WT; Holdren, MS; Her, MF; Gautam, S; Magnuson, M; Moses, HL; Grady, WM				Romero-Gallo, J; Sozmen, EG; Chytil, A; Russell, WE; Whitehead, R; Parks, WT; Holdren, MS; Her, MF; Gautam, S; Magnuson, M; Moses, HL; Grady, WM			Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative response after partial hepatectomy	ONCOGENE			English	Article						TGF-beta; liver regeneration	TRANSFORMING-GROWTH-FACTOR; CELL-CYCLE ARREST; LIVER EPITHELIAL-CELLS; RAT-LIVER; DNA-SYNTHESIS; II RECEPTOR; C-MYC; HEPATOCELLULAR-CARCINOMA; NUCLEAR-LOCALIZATION; GENE-EXPRESSION	The transforming growth factor beta (TGF-beta) signaling pathway, which is activated by the TGF-beta receptor complex consisting of type I and type II TGF-beta receptors (TGFBR1 and TGFBR2), regulates cell growth and death. TGF-beta and components of its signaling pathway, particularly TGFBR2, have been implicated as tumor suppressor genes and important antimitogenic factors in the gastrointestinal tract and liver. An in vivo approach to study these effects has been hindered by the embryonic lethality of Tgfbr2(-/-) mice and poor viability of the Tgfb1(-/-) mice. Consequently, we have developed a hepatocyte-specific Tgfbr2 knockout mouse, the Alb-cre Tgfbr2(flx/flx) mouse, to study the physiologically relevant effects of TGF-beta signaling on epithelial cell proliferation in vivo. After 70% hepatectomy, we observed increased proliferation and an increased liver mass : body weight ratio in the Alb-cre Tgfbr2(flx/flx) mice compared to Tgfbr2(flx/flx) mice. We also observed decreased expression and increased phosphorylation of p130 in the livers from the Alb-cre Tgfbr2(flx/flx) mice as well as increased expression of cyclin E, which is transcriptionally regulated, in part, by p130:E2F4. Consistent with these results, in a hepatocyte cell line derived from the Tgfbr2(flx/flx) mice, we found that TGF-beta increases the nuclear localization of E2F4, and presumably the transcriptional repression of the p130: E2F4 complex. Thus, we have demonstrated that TGF-beta signaling in vivo regulates the mitogenic response in the regenerating liver, affecting the liver mass : body weight ratio after partial hepatectomy, and that these mitogenic responses are accompanied by alterations in p130 expression and phosphorylation, implicating p130 as one of the proteins regulated in vivo by TGF-beta during liver regeneration.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; Vanderbilt Univ, Dept Med, Nashville, TN USA; Vanderbilt Univ, Dept Canc Biol, Nashville, TN USA; Vanderbilt Univ, Dept Pediat, Nashville, TN USA; Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; Beth Israel Deaconess Med Ctr, Dept Biostat, Boston, MA 02215 USA; Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA	Fred Hutchinson Cancer Center; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Washington; University of Washington Seattle; Harvard University; Beth Israel Deaconess Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Grady, WM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D4-100,POB 19024, Seattle, WA 98104 USA.	wgrady@fhcrc.org	Russell, William/A-7307-2009; Magnuson, Mark A/B-1335-2009; Magnuson, Mark/AAY-7172-2021	Magnuson, Mark A/0000-0002-8824-6499; Magnuson, Mark/0000-0002-8824-6499; Parks, W. Tony/0000-0001-7341-3277	NCI NIH HHS [R01CA85492, R01 CA102162] Funding Source: Medline; NIDDK NIH HHS [R01 DK53804, R01 DK60669-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102162, R01CA085492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060669, R01DK053804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akita K, 2002, GASTROENTEROLOGY, V123, P352, DOI 10.1053/gast.2002.34234; Albrecht JH, 1999, AM J PHYSIOL-GASTR L, V277, pG1207, DOI 10.1152/ajpgi.1999.277.6.G1207; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Allen KJ, 2000, J GASTROEN HEPATOL, V15, P1325, DOI 10.1046/j.1440-1746.2000.02328.x; BARBIROLI B, 1971, SCIENCE, V172, P738, DOI 10.1126/science.172.3984.738; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Bhowmick NA, 2003, P NATL ACAD SCI USA, V100, P15548, DOI 10.1073/pnas.2536483100; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bouzahzah B, 2000, CANCER RES, V60, P4531; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; CARR BI, 1986, CANCER RES, V46, P2330; CHARI RS, 1995, AM J SURG, V169, P126, DOI 10.1016/S0002-9610(99)80120-2; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046; Cipriano SC, 1998, ONCOGENE, V17, P1549, DOI 10.1038/sj.onc.1202069; COUGHLIN JP, 1987, J PEDIATR SURG, V22, P566, DOI 10.1016/S0022-3468(87)80223-3; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Enami Y, 2001, J Hepatobiliary Pancreat Surg, V8, P250, DOI 10.1007/s005340170025; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Factor VM, 1997, CANCER RES, V57, P2089; Fausto N, 1993, Prog Liver Dis, V11, P115; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Grasl-Kraupp B, 1998, HEPATOLOGY, V28, P717, DOI 10.1002/hep.510280318; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Herrera RE, 1996, MOL BIOL CELL, V7, P1335, DOI 10.1091/mbc.7.9.1335; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Iavarone A, 1997, NATURE, V387, P417; Im YH, 2001, CANCER RES, V61, P6665; Iwase S, 1997, J BIOL CHEM, V272, P12406, DOI 10.1074/jbc.272.19.12406; Kanzler S, 2001, ONCOGENE, V20, P5015, DOI 10.1038/sj.onc.1204544; Kiss A, 1997, CLIN CANCER RES, V3, P1059; KO TC, 1995, ONCOGENE, V10, P177; Kogure K, 2000, HEPATOLOGY, V31, P916, DOI 10.1053/he.2000.6100; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Li W, 2001, HEPATOLOGY, V33, P1377, DOI 10.1053/jhep.2001.24431; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; MACIASSILVA M, 2002, J BIOL CHEM, V21, P21; MCMAHON JB, 1986, CANCER RES, V46, P4665; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagoshi S, 1998, J GASTROEN HEPATOL, V13, P786, DOI 10.1111/j.1440-1746.1998.tb00734.x; Nakamura T, 2000, HEPATOLOGY, V32, P247, DOI 10.1053/jhep.2000.9109; Oberhammer F, 1996, MICROSC RES TECHNIQ, V34, P247, DOI 10.1002/(SICI)1097-0029(19960615)34:3<247::AID-JEMT7>3.0.CO;2-M; Oe S, 2004, HEPATOLOGY, V40, P1098, DOI 10.1002/hep.20426; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RICHARDS GM, 1974, ANAL BIOCHEM, V57, P369, DOI 10.1016/0003-2697(74)90091-8; RUSSELL W, 1988, J CELL PHYSL, V35, P253; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; RUSSELL WE, 1988, J CELL PHYSIOL, V135, P253, DOI 10.1002/jcp.1041350212; RUSSELL WE, 1983, AM J PHYSIOL, V245, P321; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Salvucci M, 1999, ONCOGENE, V18, P181, DOI 10.1038/sj.onc.1202279; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; SchulteHermann R, 1995, MUTAT RES-FUND MOL M, V333, P81, DOI 10.1016/0027-5107(95)00134-4; Scotte M, 1997, CYTOKINE, V9, P859, DOI 10.1006/cyto.1997.0273; SHIRAI Y, 1994, CANCER, V73, P2275, DOI 10.1002/1097-0142(19940501)73:9<2275::AID-CNCR2820730907>3.0.CO;2-T; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; STRAIN AJ, 1986, CELL BIOL INT REP, V10, P855, DOI 10.1016/0309-1651(86)90102-5; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Webber EM, 1998, HEPATOLOGY, V28, P1226, DOI 10.1002/hep.510280509; Wong MH, 2000, P NATL ACAD SCI USA, V97, P12601, DOI 10.1073/pnas.230237997; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200	84	90	99	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3028	3041		10.1038/sj.onc.1208475	http://dx.doi.org/10.1038/sj.onc.1208475			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735717				2022-12-25	WOS:000228649500012
J	Guo, Y; Yang, K; Harwalkar, J; Nye, JM; Mason, DR; Garrett, MD; Hitomi, M; Stacey, DW				Guo, Y; Yang, K; Harwalkar, J; Nye, JM; Mason, DR; Garrett, MD; Hitomi, M; Stacey, DW			Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis	ONCOGENE			English	Article						cyclin D1; proliferative signaling; cell cycle; S phase; proliferation	CELL-CYCLE PROGRESSION; SYNTHASE KINASE 3-BETA; NUCLEAR-PROTEIN; D1; BINDING; RAS; EXPRESSION; GROWTH; PROLIFERATION; P27(KIP1)	Continuing proliferation requires regulation of cyclin D1 levels in each cell cycle phase. Growth factors stimulate high levels during G2 phase, which commits the cell to continue through G1 phase with sufficient cyclin D1 to initiate DNA synthesis. Upon entry into S phase, however, cyclin D1 levels rapidly decline. Our goal is to understand the mechanism and importance of this S-phase suppression. Here, we demonstrate that cyclin D1 levels decline during S phase due to reduced protein stability, without alterations in the rate of protein synthesis. This decline depends upon Thr 286, since mutation of this site eliminates the normal pattern of cyclin D1 suppression during S phase. As evidence that phosphorylation of Thr 286 is responsible for this decline, Thr 286 is shown to be more efficiently phosphorylated during S phase than in other cell cycle periods. Finally, high cyclin D1 levels during S phase are shown to inhibit DNA synthesis. This inhibitory activity presumably blocks the growth of cells with altered cyclin D1 expression characteristics. Abnormal stimulation of cyclin D1 might result in levels high enough to promote G1/S phase transition even in the absence of appropriate growth stimuli. In such cells, however, the levels of cyclin D1 would presumably be too high to be suppressed during S phase, resulting in the inhibition of DNA synthesis.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA; Inst Canc Res, Haddow Labs, Canc Res UK, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	Cleveland Clinic Foundation; Cancer Research UK; University of London; Institute of Cancer Research - UK	Stacey, DW (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, NC2-151,9500 Euclid Ave, Cleveland, OH 44195 USA.	Staceyd@ccf.org		Mason, David/0000-0001-5122-0538	NCI NIH HHS [CA9219] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; ATADJA P, 1995, EXP CELL RES, V217, P205, DOI 10.1006/excr.1995.1080; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Fukami-Kobayashi J, 1999, EXP CELL RES, V246, P338, DOI 10.1006/excr.1998.4306; Guo Y, 2002, ONCOGENE, V21, P7545, DOI 10.1038/sj.onc.1205907; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; Hitomi M, 1999, CURR BIOL, V9, P1075, DOI 10.1016/S0960-9822(99)80476-X; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; LUKAS J, 1994, ONCOGENE, V9, P707; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Sa G, 2004, EXP CELL RES, V300, P427, DOI 10.1016/j.yexcr.2004.07.032; Sa G, 2002, CELL CYCLE, V1, P50, DOI 10.4161/cc.1.1.100; Scovassi AI, 1997, EXP CELL RES, V237, P127, DOI 10.1006/excr.1997.3770; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; WOODGETT JR, 2001, SCI STKE, pRE12; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	27	69	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2599	2612		10.1038/sj.onc.1208326	http://dx.doi.org/10.1038/sj.onc.1208326			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735756				2022-12-25	WOS:000228356700002
J	Zhang, M; Latham, DE; Delaney, MA; Chakravarti, A				Zhang, M; Latham, DE; Delaney, MA; Chakravarti, A			Survivin mediates resistance to antiandrogen therapy in prostate cancer	ONCOGENE			English	Article						survivin; flutamide; androgen; independent prostate cancer	GROWTH-FACTOR-I; ANDROGEN RECEPTOR MUTATIONS; SIGNALING PATHWAYS; TYROSINE KINASE; PROTEIN-KINASE; LNCAP CELLS; APOPTOSIS; EXPRESSION; GENE; PROLIFERATION	Resistance to antiandrogen therapy in patients with metastatic prostate cancer poses a major challenge, which, if overcome, may lead to significant advances in the treatment of these patients. Hormone resistance of prostate cancer develops, in part, from upregulation of antiapoptotic genes after androgen deprivation. Given the accumulating evidence that Survivin, a new member of the inhibitor of apoptosis (IAP) family, is associated with both cancer progression and drug resistance, we hypothesized that Survivin plays a potentially important role in hormone therapy resistance, and that targeting of Survivin may enhance sensitivity to antiandrogen therapy in prostate cancer. Patterns of Survivin expression were assessed in three prostate cancer cell lines LNCaP, PC-3, and DU-145 using quantitative Western analysis. All three cell lines were found to strongly express Survivin. In LNCaP cells with intact androgen receptors (ARs), it was observed that androgen stimulation with 5 alpha-dihydrotestosterone (DHT) increased Survivin expression. Conversely, treatment with Flutamide decreased Survivin expression in LNCaP cells. We next studied the functional effect of Survivin on sensitivity to Flutamide. LNCaP cells were infected with replication-deficient adenoviruses encoding either wild-type Survivin pAd-S(WT) or a phosphorylation-defective Survivin Thr34 -> Ala dominant-negative mutant pAd-S(T34A), and then treated with Flutamide. Cell viability and apoptosis were assessed in vitro and in vivo. It was determined that Survivin can mediate resistance to such antiandrogen therapies based on our assays. Direct androgen stimulation resulted in pan-cell cycle expression of Survivin, which was found to be mediated by AKT, as it was determined that exogenous insulin-like growth factor-1 (IGF-1), a known activator of AKT signaling, could increase Survivin expression and result in pan-cell cycle expression even in AR-negative prostate cancer cell lines PC-3 and DU-145. Given this alternative mechanism of Survivin expression and our findings that Survivin can mediate resistance to Flutamide treatment, we further investigated whether IGF-1-mediated activation of Survivin via AKT could mediate resistance to antiandrogen therapy. Both in vitro and in vivo, this was found to be the case, supporting a novel mechanism of resistance to antiandrogen therapy. Our study indicates that upregulation of Survivin via IGF-1 signaling confers resistance to Flutamide in prostate cancer cells. Targeted inhibition of Survivin appears to enhance the therapeutic effects of Flutamide in vitro and in vivo, revealing a novel strategy to enhance sensitivity to androgen ablation therapy.	Harvard Univ, Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA	Harvard University; Harvard Medical School	Chakravarti, A (corresponding author), Harvard Univ, Gen Hosp, Sch Med, Dept Radiat Oncol, 100 Blossom St,Founders House,Room 536, Boston, MA 02114 USA.	achakravarti@partners.org						Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801; Djavan B, 2001, WORLD J UROL, V19, P225, DOI 10.1007/s003450100220; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; GOLDSPIEL BR, 1990, DICP ANN PHARMAC, V24, P616, DOI 10.1177/106002809002400612; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kassen AE, 2000, PROSTATE, V44, P124, DOI 10.1002/1097-0045(20000701)44:2<124::AID-PROS5>3.0.CO;2-S; Kim IY, 1996, EXP CELL RES, V222, P103, DOI 10.1006/excr.1996.0013; Kishi H, 2004, J UROLOGY, V171, P1855, DOI 10.1097/01.ju.0000120317.88372.03; Koivisto P, 1997, CANCER RES, V57, P314; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYPRIANOU N, 1990, CANCER RES, V50, P3748; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, CANCER RES, V59, P3143; LIMONTA P, 1995, J STEROID BIOCHEM, V53, P401, DOI 10.1016/0960-0760(95)00086-F; Ling X, 2004, J BIOL CHEM, V279, P15196, DOI 10.1074/jbc.M310947200; Marcelli M, 2000, CANCER RES, V60, P944; McEleny KR, 2002, PROSTATE, V51, P133, DOI 10.1002/pros.10061; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Nickerson T, 2001, CANCER RES, V61, P6276; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Oh WK, 1998, J UROLOGY, V160, P1220, DOI 10.1016/S0022-5347(01)62501-1; Okamoto M, 1997, ENDOCRINOLOGY, V138, P5071, DOI 10.1210/en.138.11.5071; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007; Ruijter E, 1999, ENDOCR REV, V20, P22, DOI 10.1210/er.20.1.22; Shariat SF, 2004, CANCER, V100, P751, DOI 10.1002/cncr.20039; Shen RQ, 2000, ENDOCRINOLOGY, V141, P1699, DOI 10.1210/en.141.5.1699; Taplin ME, 1999, CANCER RES, V59, P2511; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Tsihlias J, 2000, ONCOGENE, V19, P670, DOI 10.1038/sj.onc.1203369; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287	45	176	186	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2474	2482		10.1038/sj.onc.1208490	http://dx.doi.org/10.1038/sj.onc.1208490			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735703				2022-12-25	WOS:000228180600005
J	Bu, X; Avraham, HK; Li, XY; Lim, B; Jiang, SX; Fu, YG; Pestell, RG; Avraham, S				Bu, X; Avraham, HK; Li, XY; Lim, B; Jiang, SX; Fu, YG; Pestell, RG; Avraham, S			Mayven induces c-Jun expression and cyclin D1 activation in breast cancer cells	ONCOGENE			English	Article						BTB/POZ domain; c-Jun; AP-1; Kelch domain; Mayven; breast cancer	ACUTE PROMYELOCYTIC LEUKEMIA; PROTEIN-PROTEIN-INTERACTION; RECEPTOR-ALPHA; ACROSOMAL PROCESS; KINASE-ACTIVITY; BTB/POZ DOMAIN; DNA-BINDING; CAENORHABDITIS-ELEGANS; HISTONE DEACETYLASE; FINGER PROTEINS	Mayven is a member of the kelch-related superfamily of proteins, characterized by a series of 'kelch' repeats at their carboxyl terminus and a BTB/POZ domain at their NH2-terminus. Little is known about the role of Mayven in cancer. Here, we report that Mayven expression was abundant and diffuse in primary human epithelial breast tumor cells as compared to normal breast epithelial cells, where Mayven was detected in the normal breast layer of the mammary ducts. Overexpression of Mayven resulted in an induction of c-Jun protein levels, as well as increased AP-1 (activating protein 1) transcriptional activity in MCF-7 and T47D breast cancer cells through its BTB/POZ domain. Furthermore, Mayven activated c-Jun N-terminal kinase in breast cancer cells. Mayven, through its BTB/POZ domain, induced cyclin D1 expression and cyclin DI promoter activity and promoted cell cycle progression from the G1 to Sphase. MCF-7 cells transduced with the recombinant retroviral sense Mayven (pMIG-W-Mayven) showed significant induction of c-Jun and cyclin DI mRNA expression and activities as compared to the retroviral vector alone, while MCF-7 cells transduced by the recombinant retroviral antisense Mayven (pMIG-W-Mayven-AS) demonstrated a significant decrease in c-Jun and cyclin D1 expression and activities. Given the crucial functions of cyclin D1 and AP-1 signaling in oncogenesis, our results strongly suggest that overexpression of Mayven may promote tumor growth through c-Jun and cyclin D1.	Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Georgetown Univ, Ctr Med, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Georgetown University	Avraham, S (corresponding author), Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	savraham@bidmc.harvard.edu		Avraham, Hava/0000-0002-7545-3640	NCI NIH HHS [1R01 CA096805] Funding Source: Medline; NHLBI NIH HHS [1R01 HL080699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096805] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AVRAHAM S, 2002, RECENT RES DEV BIOL, V1, P231; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Bomont P, 2000, NAT GENET, V26, P370, DOI 10.1038/81701; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Daschner PJ, 1999, BREAST CANCER RES TR, V53, P229, DOI 10.1023/A:1006138803392; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; DIBELLO PR, 1991, GENETICS, V129, P385; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eichinger L, 1996, EMBO J, V15, P5547, DOI 10.1002/j.1460-2075.1996.tb00939.x; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fu Maofu, 2004, Methods Mol Biol, V284, P15; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; GINIGER E, 1994, DEVELOPMENT, V120, P1385; GODT D, 1993, DEVELOPMENT, V119, P799; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HU S, 1995, GENE DEV, V9, P2936, DOI 10.1101/gad.9.23.2936; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Kaplan J, 1997, NUCLEIC ACIDS RES, V25, P1108, DOI 10.1093/nar/25.6.1108; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; Kobayashi A, 2000, MOL CELL BIOL, V20, P1733, DOI 10.1128/MCB.20.5.1733-1746.2000; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Li XM, 1997, J BIOL CHEM, V272, P27324, DOI 10.1074/jbc.272.43.27324; Liang XQ, 2004, ONCOGENE, V23, P5890, DOI 10.1038/sj.onc.1207776; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Liu YM, 2004, ONCOGENE, V23, P8238, DOI 10.1038/sj.onc.1207889; Mai A, 2004, EXP CELL RES, V300, P72, DOI 10.1016/j.yexcr.2004.06.023; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Ohmachi M, 1999, GENES CELLS, V4, P325, DOI 10.1046/j.1365-2443.1999.00264.x; OWEN C, 1993, J CELL BIOL, V123, P337, DOI 10.1083/jcb.123.2.337; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; RITKE MK, 1994, BIOCHEM PHARMACOL, V48, P525, DOI 10.1016/0006-2952(94)90282-8; ROBINSON DN, 1994, DEVELOPMENT, V120, P2015; Sanders MC, 1996, J BIOL CHEM, V271, P2651, DOI 10.1074/jbc.271.5.2651; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; Schrump DS, 1996, CANCER GENE THER, V3, P131; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shah S, 2002, J BIOL CHEM, V277, P25313, DOI 10.1074/jbc.M203158200; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; Szabo E, 1996, CANCER RES, V56, P305; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VARKEY JP, 1995, GENE DEV, V9, P1074, DOI 10.1101/gad.9.9.1074; VONBULOW M, 1995, EXP CELL RES, V219, P407, DOI 10.1006/excr.1995.1246; Wang Chenguang, 2004, Cancer Treat Res, V119, P217; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	71	17	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2398	2409		10.1038/sj.onc.1208466	http://dx.doi.org/10.1038/sj.onc.1208466			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735724				2022-12-25	WOS:000227877400012
J	Cairo, S; De Falco, F; Pizzo, M; Salomoni, P; Pandolfi, PP; Meroni, G				Cairo, S; De Falco, F; Pizzo, M; Salomoni, P; Pandolfi, PP; Meroni, G			PML interacts with Myc, and Myc target gene expression is altered in PML-null fibroblasts	ONCOGENE			English	Article						Myc; PML; G1 phase; gene expression	ACUTE PROMYELOCYTIC LEUKEMIA; MEDIATED TRANSCRIPTIONAL REPRESSION; RECURRING CHROMOSOMAL-ABNORMALITIES; C-MYC; TRANSGENIC MICE; NUCLEAR-BODIES; PREMATURE SENESCENCE; PROTEIN STABILITY; CELL-GROWTH; RAR-ALPHA	c-myc is a well-known proto-oncogene encoding for a transcription factor that needs to be tightly regulated in order to preserve cell homeostasis. The Promyelocytic Leukaemia gene product PML plays an important role in cell growth and survival, and resides in discrete subnuclear structures called Nuclear Bodies ( NB). We performed comparative analysis of the expression of 40 Myc target genes and of Myc binding to their regulatory regions both in wild-type and PML knockout cells. We demonstrate that if PML is absent, despite Myc binding to the DNA regulatory sequences is unchanged, the expression pro. le of several Myc target genes is altered. PML is largely involved in gene regulation, via recruitment of several transcription factors and cofactors to the NB. Consistently, we show that Myc partially localizes to the NB and physically interacts with PML, and that this localization depends on Myc expression levels. As deregulation occurs to both activated and repressed Myc target genes, we propose that PML influences Myc transcriptional activity through a mechanism that involves the control of Myc post-translational modifications.	TIGEM, I-80131 Naples, Italy; Cornell Univ, Mem Sloan Kettering Canc Ctr, Mol Biol Program, New York, NY 10021 USA; Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Meroni, G (corresponding author), TIGEM, Via P Castellino, I-80131 Naples, Italy.	meroni@tigem.it	Cairo, Stefano/O-2831-2016	Cairo, Stefano/0000-0002-4725-5970	Telethon [TGM03Z05, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Chiang YC, 2003, J BIOL CHEM, V278, P19286, DOI 10.1074/jbc.M212043200; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Le Beau MM, 2003, BLOOD, V102, P1072, DOI 10.1182/blood-2003-01-0155; Le Beau MM, 2002, BLOOD, V99, P2985, DOI 10.1182/blood.V99.8.2985; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Moller A, 2003, CANCER RES, V63, P4310; Naka K, 2002, BIOCHEM BIOPH RES CO, V299, P863, DOI 10.1016/S0006-291X(02)02755-9; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nikiforov MA, 2003, J BIOL CHEM, V278, P11094, DOI 10.1074/jbc.M212298200; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang ZG, 1998, SCIENCE, V279, P1547; Yin XY, 2001, ONCOGENE, V20, P4650, DOI 10.1038/sj.onc.1204606; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	43	34	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2195	2203		10.1038/sj.onc.1208338	http://dx.doi.org/10.1038/sj.onc.1208338			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735755				2022-12-25	WOS:000227857900007
J	Castino, R; Davies, J; Beaucourt, S; Isidoro, C; Murphy, D				Castino, R; Davies, J; Beaucourt, S; Isidoro, C; Murphy, D			Autophagy is a prosurvival mechanism in cells expressing an autosomal dominant familial neurohypophyseal diabetes insipidus mutant vasopressin transgene	FASEB JOURNAL			English	Article						apoptosis; transgenic; adFNDI; antidiuretic hormone; VP	HYPOTHALAMIC NEURONS; INHIBITION; HEREDITARY; INDUCTION; APOPTOSIS; MACROAUTOPHAGY; POLYGLUTAMINE; EXPANSIONS; DIVERSITY; BECLIN	Autosomal dominant familial neurohypophyseal diabetes insipidus (adFNDI) is a progressive, inherited neurodegenerative disorder that presents as polydipsia and polyuria as a consequence of a loss of secretion of the antidiuretic hormone vasopressin (VP) from posterior pituitary nerve terminals. VP gene mutations cause adFNDI. Rats expressing an adFNDI VP transgene (Cys67stop) show a neuronal pathology characterized by autophagic structures in the cell body. adFNDI has thus been added to the list of protein aggregation diseases, along with Alzheimer's, Parkinson's and Huntington's, which are associated with autophagy, a bulk process that delivers regions of cytosol to lysosomes for degradation. However, the role of autophagy in these diseases is unclear. To address the relationships between mutant protein accumulation, autophagy, cell survival, and cell death, we have developed a novel and tractable in vitro system. We have constructed adenoviral vectors (Ads) that express structural genes encoding either the Cys67stop mutant protein (Ad-VCAT-Cys67 stop) or an epitope-tagged wild-type VP precursor (Ad-VCAT). After infection of mouse neuroblastoma Neuro2a cells, Ad-VCAT encoded material enters neurite processes and accumulates in terminals, while the Cys67stop protein is confined to enlarged vesicles in the cell body. Similar to the intracellular derangements seen in the Cys67stop rats, these structures are of ER origin, and colocalize with markers of autophagy. Neither Ad-VCAT-Cys67 stop nor Ad-VCAT expression affected cell viability. However, inhibition of autophagy or lysosomal protein degradation, while having no effect on Ad-VCAT-expressing cells, significantly increased apoptotic cell death following Ad-VCAT-Cys67 stop expression. These data suggest that activation of autophagy by the stress of the expression of an adFNDI mutant protein is a prosurvival mechanism.	Univ Bristol, Mol Neuroendocrinol Res GRp, Henry Wellcome Labs Integrat Neurosci & Endocrino, Bristol BS1 3NY, Avon, England; Amedeo Avogadro Univ, Dept Med Sci, Lab Mol Pathol, I-28100 Novara, Italy	University of Bristol; University of Eastern Piedmont Amedeo Avogadro	Murphy, D (corresponding author), Univ Bristol, Mol Neuroendocrinol Res GRp, Henry Wellcome Labs Integrat Neurosci & Endocrino, Dorothy Hodgkin Bldg,Whitson St, Bristol BS1 3NY, Avon, England.	d.murphy@bristol.ac.uk	Isidoro, Ciro/J-6063-2016; Murphy, David/C-3967-2012	Isidoro, Ciro/0000-0002-5494-3034; Murphy, David/0000-0003-2946-0353; Beaucourt, Stephanie/0000-0001-9394-6425				Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; BRAVERMAN LE, 1965, ANN INTERN MED, V63, P503, DOI 10.7326/0003-4819-63-3-503; BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132; Burbach JPH, 2001, PHYSIOL REV, V81, P1197, DOI 10.1152/physrev.2001.81.3.1197; Castino R, 2002, INT J CANCER, V97, P775, DOI 10.1002/ijc.10139; Chen Quan, 2001, ScientificWorldJournal, V1, P142, DOI 10.1100/tsw.2001.233; Christensen JH, 2003, APMIS, V111, P92; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Davies J, 2002, J NEUROENDOCRINOL, V14, P629, DOI 10.1046/j.1365-2826.2002.00822.x; de Bree FM, 2000, FEBS LETT, V475, P175, DOI 10.1016/S0014-5793(00)01623-9; Demoz M, 2002, BIOL CHEM, V383, P1237, DOI 10.1515/BC.2002.137; GREEN JR, 1967, BRAIN, V90, P707, DOI 10.1093/brain/90.3.707; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HOYVIK H, 1991, J CELL BIOL, V113, P1305, DOI 10.1083/jcb.113.6.1305; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Klein JP, 2004, NEUROBIOL DIS, V15, P221, DOI 10.1016/j.nbd.2003.10.009; KNIGHT CG, 1976, BIOCHEM J, V155, P117, DOI 10.1042/bj1550117; Kurokawa H, 1998, RADIOLOGY, V207, P79, DOI 10.1148/radiology.207.1.9530302; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Mahoney CP, 2002, J CLIN ENDOCR METAB, V87, P870, DOI 10.1210/jc.87.2.870; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Munafo DB, 2002, TRAFFIC, V3, P472, DOI 10.1034/j.1600-0854.2002.30704.x; NAGAI I, 1984, ACTA ENDOCRINOL-COP, V105, P318, DOI 10.1530/acta.0.1050318; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243; Petiot A, 2002, CELL STRUCT FUNCT, V27, P431, DOI 10.1247/csf.27.431; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; REEVES WB, 1992, WILLIAMS TXB ENDOCRI, P311; Russell TA, 2003, J CLIN INVEST, V112, P1697, DOI 10.1172/JCI200318616; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Si-Hoe SL, 2000, FASEB J, V14, P1680; Waller S, 1996, ENDOCRINOLOGY, V137, P5068, DOI 10.1210/en.137.11.5068; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9	43	37	37	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					1021	+		10.1096/fj.04-3162fje	http://dx.doi.org/10.1096/fj.04-3162fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15781609				2022-12-25	WOS:000227901300011
J	Iida, M; Heike, T; Yoshimoto, M; Baba, S; Doi, H; Nakahata, T				Iida, M; Heike, T; Yoshimoto, M; Baba, S; Doi, H; Nakahata, T			Identification of cardiac stem cells with FLK1, CD31, and VE-cadherin expression during embryonic stem cell differentiation	FASEB JOURNAL			English	Article						embryoid bodies; ES cells; cardiomyocyte differentiation; blastocysts	COMMON PRECURSOR; C-KIT; RECEPTOR; MOUSE; MODEL	We evaluated the expression of the FLK1, one of the lateral mesoderim early markers where cardiogenesis occurs, to characterize and isolate cardiac stem/progenitor cells from ES cells. Dissociated cells from embryoid bodies (EBs) on day 3, 4, or 5 were collected into two subpopulations with or without FLK1 expression and coculture on OP9 stromal cells was continued to examine whether contracting colonies came out or not. FLK1(+) cells from EBs at days 3 and 4 formed spontaneous contracting colonies more efficiently than FLK1(-) cells on the same days, but not at day 5. Most contracting cardiac colonies derived from FLK1 cells mainly on day 4 were detected on endothelial cells along with hematopoietic cells. Further characterization of cells with these capabilities into three lineages revealed the FLK1(+) CD31-VE-cadherin phenotype. Our findings indicate that FLK1(+) cells, especially FLK1(+) CD31(-)VE-cadherin(-) cells, could act as cardiohemangioblasts to form cardiac cells as well as endothelial cells and hematopoietic cells.	Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Heike, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, Shogoin Kawahara Cho 54, Kyoto 6068507, Japan.	heike@kuhp.kyoto-u.ac.jp	Yoshimoto, Momoko/N-4238-2014; Yoshimoto, Momoko/AFP-3523-2022	Yoshimoto, Momoko/0000-0002-7272-6682; Yoshimoto, Momoko/0000-0002-7272-6682				BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; Boheler KR, 2002, CIRC RES, V91, P189, DOI 10.1161/01.RES.0000027865.61704.32; Choi K, 1998, DEVELOPMENT, V125, P725; Choi K, 2002, J HEMATOTH STEM CELL, V11, P91, DOI 10.1089/152581602753448568; Eichmann A, 1997, P NATL ACAD SCI USA, V94, P5141, DOI 10.1073/pnas.94.10.5141; Etzion S, 2002, CIRCULATION, V106, pI125, DOI 10.1161/01.cir.0000032888.55215.b8; Etzion S, 2001, J MOL CELL CARDIOL, V33, P1321, DOI 10.1006/jmcc.2000.1391; Faloon P, 2000, DEVELOPMENT, V127, P1931; Hidaka K, 2003, FASEB J, V17, P740, DOI 10.1096/fj.02-0104fje; Hirashima M, 1999, BLOOD, V93, P1253, DOI 10.1182/blood.V93.4.1253.404k31_1253_1263; Jamali M, 2001, J BIOL CHEM, V276, P42252, DOI 10.1074/jbc.M107814200; Kabrun N, 1997, DEVELOPMENT, V124, P2039; Kataoka H, 1997, DEV GROWTH DIFFER, V39, P729; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; KODAMA H, 1994, EXP HEMATOL, V22, P979; LINTS TJ, 1993, DEVELOPMENT, V119, P969; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Matsuyoshi N, 1997, P ASSOC AM PHYSICIAN, V109, P362; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; Reinecke H, 2002, J MOL CELL CARDIOL, V34, P251, DOI 10.1006/jmcc.2001.1494; Reinecke H, 2002, J MOL CELL CARDIOL, V34, P241, DOI 10.1006/jmcc.2001.1507; Sachinidis A, 2003, CARDIOVASC RES, V58, P278, DOI 10.1016/S0008-6363(03)00248-7; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Sucov HM, 1998, ANNU REV PHYSIOL, V60, P287, DOI 10.1146/annurev.physiol.60.1.287; WILSON V, 1993, DEVELOPMENT, V117, P1321; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568	29	39	43	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					371	378		10.1096/fj.04-1998com	http://dx.doi.org/10.1096/fj.04-1998com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746180	Green Submitted			2022-12-25	WOS:000227901300037
J	Kim, H; Rhee, SH; Kokkotou, E; Na, X; Savidge, T; Moyer, MP; Pothoulakis, C; LaMont, JT				Kim, H; Rhee, SH; Kokkotou, E; Na, X; Savidge, T; Moyer, MP; Pothoulakis, C; LaMont, JT			Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin E-2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; COLON-CANCER CELLS; NF-KAPPA-B; MESSENGER-RNA; CHOLERA-TOXIN; TRANSCRIPTIONAL REGULATION; SIGNAL-TRANSDUCTION; RESPONSIVE ELEMENT; HYDROGEN-PEROXIDE; INDUCED ENTERITIS	Clostridium difficile toxin A induces acute colitis with neutrophil infiltration and up-regulation of numerous pro-inflammatory mediators, but the contribution of cyclooxygenase-2 (COX-2) induction in this infection is unknown. We report here that toxin A induces expression of COX-2 and secretion of prostaglandin E2 (PGE(2)) in a dose- and time-dependent manner in cultured NCM460 human colonocytes and in human intestinal xenografts. This induction was blocked by SB203580, a p38 MAPK inhibitor, which also decreased the phosphorylation of MSK-1, CREB/ATF-1, and COX-2 promoter activity following toxin A stimulation. Gel shift assays indicated that CREB/ATF-1 was the major proteins binding to the COX-2-CRE. Moreover, colonocytes exposed to toxin A produced reactive oxygen species (ROS), which activated p38 MAPK, MSK-1, and CREB/ATF-1, leading to subsequent COX-2 induction and PGE2 secretion. In intact mice, blockage of p38 MAPK inhibited toxin A-mediated induction of COX-2 in enterocytes as well as lamina propria cells, and significantly blocked the toxin A-induced ileal secretion of fluid and PGE2. Furthermore, a selective COX-2 inhibitor also diminished toxin A-associated ileal fluid and PGE2 secretion. The main signaling pathway for toxin A induction of human COX-2 involves ROS-mediated activation of p38 MAPK, MSK-1, CREB, and ATF-1. Toxin A triggers ileal inflammation and secretion of fluid via COX-2 induction and release of PGE2.	Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat, Boston, MA 02215 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Gastroenterol, Boston, MA 02215 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Nutr, Boston, MA 02215 USA; INCELL Corp, San Antonio, TX 78249 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	LaMont, JT (corresponding author), Beth Israel Deaconess Med Ctr, Div Gastroenterol, Dana 501,330 Brookline Ave, Boston, MA 02215 USA.	jlamont@bidmc.harvard.edu			NIDDK NIH HHS [DK R37-38458, DK R01-33506] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alcantara C, 2001, J INFECT DIS, V184, P648, DOI 10.1086/322799; Beubler E, 2001, J PHARMACOL EXP THER, V297, P940; Beubler E, 2000, ANN NY ACAD SCI, V915, P339; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; ChavesOlarte E, 1997, J CLIN INVEST, V100, P1734, DOI 10.1172/JCI119698; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; D HE, 2000, GASTROENTEROLOGY, V119, P139, DOI 10.1053/gast.2000.8526; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Devaux Y, 2001, J IMMUNOL, V167, P3962, DOI 10.4049/jimmunol.167.7.3962; Ding M, 2002, MOL CELL BIOCHEM, V234, P81, DOI 10.1023/A:1015901232124; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Eckmann L, 1997, J CLIN INVEST, V100, P296, DOI 10.1172/JCI119535; Faour WH, 2003, J BIOL CHEM, V278, P26897, DOI 10.1074/jbc.M212790200; He D, 2002, GASTROENTEROLOGY, V122, P1048, DOI 10.1053/gast.2002.32386; HECHT G, 1988, J CLIN INVEST, V82, P1516, DOI 10.1172/JCI113760; Houglum K, 1997, J CLIN INVEST, V99, P1322, DOI 10.1172/JCI119291; Huang CS, 2001, J BIOL CHEM, V276, P40234, DOI 10.1074/jbc.M103684200; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Ishida Y, 2004, J IMMUNOL, V172, P3018, DOI 10.4049/jimmunol.172.5.3018; Jefferson KK, 1999, J IMMUNOL, V163, P5183; Jones MK, 1999, FASEB J, V13, P2186, DOI 10.1096/fasebj.13.15.2186; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; Kyne L, 2002, CLIN INFECT DIS, V34, P346, DOI 10.1086/338260; LANZA FL, 1991, AM J GASTROENTEROL, V86, P1743; Mahida YR, 1996, GUT, V38, P337, DOI 10.1136/gut.38.3.337; MATUCHANSKY C, 1976, GASTROENTEROLOGY, V71, P274; Mifflin RC, 2004, MOL PHARMACOL, V65, P470, DOI 10.1124/mol.65.2.470; NAKAYAMA H, 1992, NUCLEIC ACIDS RES, V20, P4939, DOI 10.1093/nar/20.18.4939; Nie M, 2003, MOL CELL BIOL, V23, P9233, DOI 10.1128/MCB.23.24.9233-9244.2003; Pothoulakis C, 1996, J CLIN INVEST, V98, P641, DOI 10.1172/JCI118835; POTHOULAKIS C, 1991, J CLIN INVEST, V88, P119, DOI 10.1172/JCI115267; Pothoulakis C, 2001, AM J PHYSIOL-GASTR L, V280, pG178, DOI 10.1152/ajpgi.2001.280.2.G178; POTHOULAKIS C, 1993, GASTROENTEROLOGY, V105, P701, DOI 10.1016/0016-5085(93)90886-H; Powell DW, 1991, HDB PHYSL GASTROINTE, P591; RIEGLER M, 1995, J CLIN INVEST, V95, P2004, DOI 10.1172/JCI117885; Roze C, 1998, GASTROENTEROLOGY, V115, P591, DOI 10.1016/S0016-5085(98)70138-6; Saukkonen K, 2003, CANCER RES, V63, P3032; Savidge TC, 2003, GASTROENTEROLOGY, V125, P413, DOI 10.1016/S0016-5085(03)00902-8; SAVIDGE TC, 1995, DIFFERENTIATION, V58, P361, DOI 10.1046/j.1432-0436.1995.5850361.x; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; TRIADAFILOPOULOS G, 1989, GASTROENTEROLOGY, V97, P1186, DOI 10.1016/0016-5085(89)91689-2; TRIADAFILOPOULOS G, 1987, GASTROENTEROLOGY, V93, P273, DOI 10.1016/0016-5085(87)91014-6; Warny M, 2000, J CLIN INVEST, V105, P1147, DOI 10.1172/JCI7545; WEYMER A, 1985, J CLIN INVEST, V76, P1828, DOI 10.1172/JCI112175; Wu DY, 2003, J BIOL CHEM, V278, P10983, DOI 10.1074/jbc.M207470200; Yamaoka K, 1998, J IMMUNOL, V160, P838; Ying LH, 1997, J BIOL CHEM, V272, P2412; Yu Y, 1998, J IMMUNOL, V161, P3746; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200	52	79	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21237	21245		10.1074/jbc.M413842200	http://dx.doi.org/10.1074/jbc.M413842200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15767259	hybrid			2022-12-25	WOS:000229438800042
J	Mann, K; Hainaut, P				Mann, K; Hainaut, P			Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53	ONCOGENE			English	Article						p53; WR1065; gene arrays; p21; S100A4; PTGF beta	TGF-BETA SUPERFAMILY; MACROPHAGE INHIBITORY CYTOKINE-1; CELL-CYCLE PROGRESSION; SEQUENCE-SPECIFIC DNA; HUMAN CANCER-CELLS; GROWTH-FACTOR-BETA; POLY(ADP-RIBOSE) POLYMERASE; SIGNALING PATHWAY; BINDING ACTIVITY; CARCINOMA CELLS	The aminothiol WR1065 exerts selective cytoprotective effects in normal cells compared to cancer cells and has clinical applications for the protection of normal cells in cancer patients undergoing radio- or chemotherapy. There is evidence that p53 is activated in response to WR1065. To examine the effects of WR1065 on the signalling pathways controlled by p53, isogeneic human colon carcinoma cell lines (HCT116) differing only in the presence or absence of wild-type p53 were used. Treatment with WR1065 resulted in G1 cell cycle arrest in the p53-positive cell line but not in the p53-negative cell line. Long-term exposure resulted in minimal apoptosis of either cell line. Changes in gene expression in p53-positive or -negative cells treated with WR1065 were examined using commercial human stress and cancer gene arrays (Clontech Atlas arrays). Genes found to be specifically upregulated in a p53-dependent manner included coproporphyrinogen oxidase, ICEre1-II cysteine protease, macrophage inhibitory cytokine-1 (also known as placental transforming growth factor beta), S100A4, and Waf1/p21. However, most proapoptotic genes typically upregulated by p53 in response to DNA damage were not activated. These studies show that WR1065 specifically modulates a subset of p53 target genes in a colon carcinoma cell line, consistent with the observation that this agent elicits essentially p53-dependent, cell cycle arrest responses.	Univ Alaska, Dept Biol Sci, Anchorage, AK 99508 USA; Univ Alaska, Biomed Program, Anchorage, AK 99508 USA; Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France	University of Alaska System; University of Alaska Anchorage; University of Alaska System; University of Alaska Anchorage; World Health Organization; International Agency for Research on Cancer (IARC)	Mann, K (corresponding author), Univ Alaska, Dept Biol Sci, 3211 Providence Dr, Anchorage, AK 99508 USA.	afkem@uaa.alaska.edu	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bauskin AR, 2000, EMBO J, V19, P2212, DOI 10.1093/emboj/19.10.2212; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CALABROJONES PM, 1985, INT J RADIAT BIOL, V47, P23, DOI 10.1080/09553008514550041; CAPIZZI RL, 1996, EUR J CANCER, V32, P5; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Daoud SS, 2003, CANCER RES, V63, P2782; ELDEIRY WS, 1993, CELL, V75, P17; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hainaut P, 2001, ANTIOXID REDOX SIGN, V3, P611, DOI 10.1089/15230860152542961; HAINAUT P, 1993, CANCER RES, V53, P4469; HARPER JW, 1993, CELL, V75, P805; Kataoka Y, 2002, INT J RADIAT ONCOL, V53, P180, DOI 10.1016/S0360-3016(01)02820-6; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; Kemp G, 1996, J CLIN ONCOL, V14, P2101, DOI 10.1200/JCO.1996.14.7.2101; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee DH, 2003, CANCER RES, V63, P4648; Lee EJ, 2003, BRIT J CANCER, V88, P754, DOI 10.1038/sj.bjc.6600779; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Liu T, 2003, CANCER RES, V63, P5034; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Marzatico F, 2000, CANCER CHEMOTH PHARM, V45, P172, DOI 10.1007/s002800050026; MEIER T, 1995, BIOCHEM PHARMACOL, V50, P489, DOI 10.1016/0006-2952(95)00164-U; Meplan C, 2000, BIOCHEM PHARMACOL, V59, P25, DOI 10.1016/S0006-2952(99)00297-X; Merwin JR, 2002, CARCINOGENESIS, V23, P1609, DOI 10.1093/carcin/23.10.1609; Miyafuji Y, 2001, J CELL PHYSIOL, V187, P356, DOI 10.1002/jcp.1084; North S, 2000, ONCOGENE, V19, P1206, DOI 10.1038/sj.onc.1203413; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; Pluquet O, 2003, BIOCHEM PHARMACOL, V65, P1129, DOI 10.1016/S0006-2952(02)01655-6; Pluquet O, 2003, J BIOL CHEM, V278, P11879, DOI 10.1074/jbc.M207396200; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; POLLA BS, 1990, BIOCHEM PHARMACOL, V40, P1469, DOI 10.1016/0006-2952(90)90442-N; POPLIN EA, 1994, CANCER CHEMOTH PHARM, V33, P415, DOI 10.1007/s002800050074; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Shen HX, 2001, J PHARMACOL EXP THER, V297, P1067; Tan MJ, 1999, FEBS LETT, V445, P265, DOI 10.1016/S0014-5793(99)00135-0; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yang H, 2003, MOL CANCER THER, V2, P1023	53	11	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3964	3975		10.1038/sj.onc.1208563	http://dx.doi.org/10.1038/sj.onc.1208563			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15750621				2022-12-25	WOS:000229435300012
J	Hay, T; Patrick, T; Winton, D; Sansom, OJ; Clarke, AR				Hay, T; Patrick, T; Winton, D; Sansom, OJ; Clarke, AR			Brca2 deficiency in the murine small intestine sensitizes to p53-dependent apoptosis and leads to the spontaneous deletion of stem cells	ONCOGENE			English	Article						Brca2; p53; small intestine; apoptosis; DNA damage	RADIATION; HYPERSENSITIVITY; BREAST; RAD51; P53; RECOMBINATION; INSTABILITY; EXPRESSION; MICE	The gene encoding the human BRCA2 tumour suppressor is mutated in a number of different tumour types, most notably inherited breast cancers. The primary role of BRCA2 is thought to lie in the maintenance of genomic stability via its role in the homologous recombination pathway. We generated mice in which Brca2 was deleted from virtually all cells within the adult small intestine, using a CYP1A1-driven Cre-Lox approach. We noted a significant p53-dependent increase in the levels of spontaneous apoptosis which persisted for several months after removal of the gene and ultimately we observed the spontaneous deletion of Brca2-deficient stem cells. Brca2 deficiency did not lead to gross changes in intestinal physiology but did enhance sensitivity to a variety of DNA crosslinking agents. Taken together, our results indicate that Brca2 plays an important role in the response to DNA damage in the small intestine. Furthermore, we show that Brca2 deficiency results in the spontaneous deletion of stem cells, thereby protecting the small intestine against tumorigenesis.	Cardiff Univ, Sch Biosci, Cardiff CF10 3US, Wales; Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2XY, England	Cardiff University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Clarke, AR (corresponding author), Cardiff Univ, Sch Biosci, Museum Ave, Cardiff CF10 3US, Wales.	clarkear@cardiff.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X				Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Cheung AMY, 2004, CANCER RES, V64, P1959, DOI 10.1158/0008-5472.CAN-03-2270; Cheung AMY, 2002, CANCER RES, V62, P6194; D'Andrea Antonello, 2002, Ital Heart J, V3, P34; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Donoho G, 2003, GENE CHROMOSOME CANC, V36, P317, DOI 10.1002/gcc.10148; Garcia SB, 1999, J PATHOL, V187, P61, DOI 10.1002/(SICI)1096-9896(199901)187:1<61::AID-PATH247>3.0.CO;2-I; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Liu YL, 2002, BREAST CANCER RES, V4, P9, DOI 10.1186/bcr417; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; Marshman E, 2001, J PATHOL, V195, P285; Morimatsu M, 1998, CANCER RES, V58, P3441; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2002, ONCOGENE, V21, P5934, DOI 10.1038/sj.onc.1205760; Scully R, 2000, BREAST CANCER RES, V2, P324, DOI 10.1186/bcr76; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242	26	19	21	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3842	3846		10.1038/sj.onc.1208533	http://dx.doi.org/10.1038/sj.onc.1208533			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15735671				2022-12-25	WOS:000229346300015
J	Krauser, JA; Guengerich, FP				Krauser, JA; Guengerich, FP			Cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation stereochemistry, kinetic deuterium isotope effects, and rate-limiting steps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CYTOCHROME-P-450-CATALYZED OXIDATION REACTIONS; LIVER MICROSOMAL CYTOCHROME-P-450; ACTIVE-SITE; DRUG-METABOLISM; ALIPHATIC HYDROXYLATION; MECHANISTIC ASPECTS; MULTIPLE PRODUCTS; MASS-SPECTROMETRY; ENZYMIC REACTIONS; N-DEALKYLATION	Testosterone 6 beta-hydroxylation is a prototypic reaction of cytochrome P450 ( P450) 3A4, the major human P450. Biomimetic reactions produced a variety of testosterone oxidation products with 6 beta-hydroxylation being only a minor reaction, indicating that P450 3A4 has considerable control over the course of steroid hydroxylation because 6 beta-hydroxylation is not dominant in a thermodynamically controlled oxidation of the substrate. Several isotopically labeled testosterone substrates were prepared and used to probe the catalytic mechanism of P450 3A4: (i) 2,2,4,6,6-H-2(5); (ii) 6,6(2)H(2); (iii) 6 alpha-H-2; (iv) 6 beta-H-2; and (v) 6 beta-H-3 testosterone. Only the 6 beta-hydrogen was removed by P450 3A4 and not the 6 alpha, indicating that P450 3A4 abstracts hydrogen and rebounds oxygen only at the beta face. Analysis of the rates of hydroxylation of 6 beta-H-1-, 6 beta-H-2-, and 6 beta-H-3-labeled testosterone and application of the Northrop method yielded an apparent intrinsic kinetic deuterium isotope effect ((D)k) of 15. The deuterium isotope effects on k(cat) and k(cat)/K-m in non-competitive reactions were only 2-3. Some "switching" to other hydroxylations occurred because of 6 beta-H-2 substitution. The high Dk value is consistent with an initial hydrogen atom abstraction reaction. Attenuation of the high Dk in the non-competitive experiments implies that C-H bond breaking is not a dominant rate-limiting step. Considerable attenuation of a high Dk value was also seen with a slower P450 3A4 reaction, the O-dealkylation of 7-benzyloxyquinoline. Thus P450 3A4 is an enzyme with regioselective flexibility but also considerable regioselectivity and stereoselectivity in product formation, not necessarily dominated by the ease of C-H bond breaking.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA090426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, T32ES007028] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90426] Funding Source: Medline; NIEHS NIH HHS [T32 ES07028, P30 ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Atkins WM, 2002, J BIOL CHEM, V277, P33258, DOI 10.1074/jbc.M204425200; Bell LC, 1997, J BIOL CHEM, V272, P29643, DOI 10.1074/jbc.272.47.29643; Bell-Parikh LC, 1999, J BIOL CHEM, V274, P23833, DOI 10.1074/jbc.274.34.23833; BJORKHEM I, 1972, EUR J BIOCHEM, V27, P354, DOI 10.1111/j.1432-1033.1972.tb01845.x; BJORKHEM I, 1982, HEPATIC CYTOCHROME P, V108, P645; BOND AM, 1988, ANAL CHEM, V60, P1023, DOI 10.1021/ac00161a015; CHA Y, 1989, SCIENCE, V243, P1325, DOI 10.1126/science.2646716; CLELAND WW, 1987, BIOORG CHEM, V15, P283, DOI 10.1016/0045-2068(87)90026-5; CLELAND WW, 1982, CRC CR REV BIOCH MOL, V13, P385; Dabrowski MJ, 2002, J AM CHEM SOC, V124, P11866, DOI 10.1021/ja027552x; DARBYSHIRE JF, 1994, BIOCHEMISTRY-US, V33, P2938, DOI 10.1021/bi00176a025; DJERASSI C, 1947, J AM CHEM SOC, V69, P2404, DOI 10.1021/ja01202a048; FLEISCHER EB, 1971, J AM CHEM SOC, V93, P3162, DOI 10.1021/ja00742a012; FOSTER AB, 1974, CHEM-BIOL INTERACT, V9, P327, DOI 10.1016/0009-2797(74)90128-8; Francisco WA, 2002, J AM CHEM SOC, V124, P8194, DOI 10.1021/ja025758s; Galetin A, 2003, DRUG METAB DISPOS, V31, P1108, DOI 10.1124/dmd.31.9.1108; GELB MH, 1982, BIOCHEMISTRY-US, V21, P370, DOI 10.1021/bi00531a026; GILLETTE JR, 1994, BIOCHEMISTRY-US, V33, P2927, DOI 10.1021/bi00176a024; GROVES JT, 1980, J AM CHEM SOC, V102, P6375, DOI 10.1021/ja00540a050; GROVES JT, 1979, J AM CHEM SOC, V101, P1032, DOI 10.1021/ja00498a040; GROVES JT, 1978, BIOCHEM BIOPH RES CO, V81, P154, DOI 10.1016/0006-291X(78)91643-1; Guengerich F. P., 2001, PRINCIPLES METHODS T, P1625; Guengerich FP, 1996, J BIOL CHEM, V271, P27321, DOI 10.1074/jbc.271.44.27321; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051; Guengerich FP, 2004, BIOCHEMISTRY-US, V43, P10775, DOI 10.1021/bi0491393; Guengerich FP, 2002, J BIOL CHEM, V277, P33711, DOI 10.1074/jbc.M205146200; Guengerich FP, 1997, BIOCHEMISTRY-US, V36, P14741, DOI 10.1021/bi9719399; GUENGERICH FP, 1988, J BIOL CHEM, V263, P8176; GUENGERICH FP, 2002, CYTOCHROME P450 STRU, P377; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Han MC, 2000, J LABELLED COMPD RAD, V43, P1149, DOI 10.1002/1099-1344(20001030)43:12<1149::AID-JLCR401>3.0.CO;2-4; Hanna IH, 1998, ARCH BIOCHEM BIOPHYS, V350, P324, DOI 10.1006/abbi.1997.0534; HARADA N, 1984, J BIOL CHEM, V259, P3005; Harlow GR, 1998, P NATL ACAD SCI USA, V95, P6636, DOI 10.1073/pnas.95.12.6636; HILL DH, 1994, J AM CHEM SOC, V116, P2889, DOI 10.1021/ja00086a022; HJELMELAND LM, 1977, BIOCHEM BIOPH RES CO, V76, P541, DOI 10.1016/0006-291X(77)90758-6; HOFLE G, 1978, ANGEW CHEM INT EDIT, V17, P569, DOI 10.1002/anie.197805691; HOLLAND HL, 1978, CAN J CHEM, V56, P3121, DOI 10.1139/v78-510; Hosea NA, 2000, BIOCHEMISTRY-US, V39, P5929, DOI 10.1021/bi992765t; HOSODA H, 1978, CHEM PHARM BULL, V26, P2181; HU Y, 1997, J CHEM SOC P1, V1, P3665; IMAOKA S, 1992, BIOCHEMISTRY-US, V31, P6063, DOI 10.1021/bi00141a015; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JONES JB, 1972, BIOCHIM BIOPHYS ACTA, V258, P800, DOI 10.1016/0005-2744(72)90181-7; Jones SR, 1996, STEROIDS, V61, P565, DOI 10.1016/S0039-128X(96)00114-6; Kenworthy KE, 2001, DRUG METAB DISPOS, V29, P1644; Khan KK, 2003, DRUG METAB DISPOS, V31, P356, DOI 10.1124/dmd.31.4.356; KIM JM, 1993, J AM CHEM SOC, V115, P10591, DOI 10.1021/ja00076a017; Knapp MJ, 2002, EUR J BIOCHEM, V269, P3113, DOI 10.1046/j.1432-1033.2002.03022.x; Kohen A, 1998, ACCOUNTS CHEM RES, V31, P397, DOI 10.1021/ar9701225; Korzekwa KR, 1998, BIOCHEMISTRY-US, V37, P4137, DOI 10.1021/bi9715627; KORZEKWA KR, 1989, BIOCHEMISTRY-US, V28, P9012, DOI 10.1021/bi00449a009; KORZEKWA KR, 1990, DRUG METAB DISPOS, V18, P974; Krafft ME, 1999, J ORG CHEM, V64, P2475, DOI 10.1021/jo982319w; Krauser JA, 2004, EUR J BIOCHEM, V271, P3962, DOI 10.1111/j.1432-1033.2004.04339.x; Kumar D, 2003, J AM CHEM SOC, V125, P13024, DOI 10.1021/ja036906x; MALHOTRA SK, 1964, J AM CHEM SOC, V86, P1997, DOI 10.1021/ja01064a018; Mash EA, 2000, SYNTHETIC COMMUN, V30, P367, DOI 10.1080/00397910008087329; Matsson O, 1998, ADV PHYS ORG CHEM, V31, P143; MAYER RT, 1990, BIOCHEM PHARMACOL, V40, P1645, DOI 10.1016/0006-2952(90)90467-Y; MICHAUD DP, 1985, J ORG CHEM, V50, P1835, DOI 10.1021/jo00211a009; MITOMA C, 1967, BIOCHIM BIOPHYS ACTA, V136, P566, DOI 10.1016/0304-4165(67)90016-5; MIWA GT, 1984, J BIOL CHEM, V259, P3000; MIWA GT, 1985, ARCH BIOCHEM BIOPHYS, V239, P155, DOI 10.1016/0003-9861(85)90822-7; MIWA GT, 1987, BIOESSAYS, V7, P215, DOI 10.1002/bies.950070506; Nomura K, 2000, CHEM PHARM BULL, V48, P344, DOI 10.1248/cpb.48.344; Northrop D. B., 1977, ISOTOPE EFFECTS ENZY, P122; NORTHROP DB, 1981, BIOCHEMISTRY-US, V20, P4056, DOI 10.1021/bi00517a017; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; NORTHROP DB, 1982, METHOD ENZYMOL, V87, P607; NUMAZAWA M, 1979, STEROIDS, V34, P347, DOI 10.1016/0039-128X(79)90085-0; Obach RS, 2000, DRUG METAB DISPOS, V28, P1069; Obach RS, 2001, DRUG METAB DISPOS, V29, P1599; OKAZAKI O, 1993, J BIOL CHEM, V268, P1546; OLEARY MH, 1989, ANNU REV BIOCHEM, V58, P377; Ortiz de Montellano P. R., 2005, CYTOCHROME P450 STRU; Parikh A, 1997, NAT BIOTECHNOL, V15, P784, DOI 10.1038/nbt0897-784; ROSENKRANZ G, 1950, J AM CHEM SOC, V72, P4077, DOI 10.1021/ja01165a066; Saltzman H., 1973, ORG SYNTH, P658; SHAPIRO RH, 1964, J AM CHEM SOC, V86, P2837, DOI 10.1021/ja01068a016; Shapley PA, 2000, J AM CHEM SOC, V122, P1079, DOI 10.1021/ja982171y; SHOU M, 1994, BIOCHEMISTRY-US, V33, P6450, DOI 10.1021/bi00187a009; Shou M, 2001, J BIOL CHEM, V276, P2256, DOI 10.1074/jbc.M008799200; Shou MG, 1999, BIOCHEM J, V340, P845, DOI 10.1042/0264-6021:3400845; Singh SB, 2003, J MED CHEM, V46, P1330, DOI 10.1021/jm020400s; SMITH DA, 1992, BIOCHEM PHARMACOL, V44, P2089, DOI 10.1016/0006-2952(92)90333-E; Smith M.B., 2007, ADV ORGANIC CHEM REA, V6th ed, DOI 10.1002/9780470084960.ch15; Stresser DM, 2002, DRUG METAB DISPOS, V30, P845, DOI 10.1124/dmd.30.7.845; Timberlake LD, 1999, J AM CHEM SOC, V121, P3618, DOI 10.1021/ja9808595; TOFT P, 1973, J LABELLED COMPD, V9, P413, DOI 10.1002/jlcr.2590090304; Ueng YF, 1997, BIOCHEMISTRY-US, V36, P370, DOI 10.1021/bi962359z; WAHALA K, 1995, J LABELLED COMPD RAD, V36, P493, DOI 10.1002/jlcr.2580360513; WAXMAN DJ, 1988, ARCH BIOCHEM BIOPHYS, V263, P424, DOI 10.1016/0003-9861(88)90655-8; WHITE RE, 1986, J AM CHEM SOC, V108, P6024, DOI 10.1021/ja00279a059; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Xu YC, 1996, J ORG CHEM, V61, P9086, DOI 10.1021/jo961257b; YAN SJ, 1984, J AM CHEM SOC, V106, P2961, DOI 10.1021/ja00322a037; Yang D, 1998, J AM CHEM SOC, V120, P5943, DOI 10.1021/ja980428m; Yang D, 1998, J ORG CHEM, V63, P8952, DOI 10.1021/jo981270r; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200; Yun CH, 2005, J BIOL CHEM, V280, P12279, DOI 10.1074/jbc.M411019200; Yun CH, 2000, BIOCHEMISTRY-US, V39, P11319, DOI 10.1021/bi000869u	103	75	77	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19496	19506		10.1074/jbc.M501854200	http://dx.doi.org/10.1074/jbc.M501854200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772082	hybrid			2022-12-25	WOS:000229113700011
J	Kuma, Y; Sabio, G; Bain, J; Shpiro, N; Marquez, R; Cuenda, A				Kuma, Y; Sabio, G; Bain, J; Shpiro, N; Marquez, R; Cuenda, A			BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELLULAR STRESSES; IDENTIFICATION; SUBSTRATE; PHOSPHORYLATION; SPECIFICITIES; MECHANISM; CYTOKINES; PATHWAY; FAMILY	The compound BIRB796 inhibits the stress-activated protein kinases p38 alpha and p38 beta and is undergoing clinical trials for the treatment of inflammatory diseases. Here we report that BIRB796 also inhibits the activity and the activation of SAPK3/p38 gamma. This occurs at higher concentrations of BIRB796 than those that inhibit p38 alpha and p38 alpha and at lower concentrations than those that inhibit the activation of JNK isoforms. We also show that at these concentrations, BIRB796 blocks the stress-induced phosphorylation of the scaffold protein SAP97, further establishing that this is a physiological substrate of SAPK3/p38 gamma. Our results demonstrate that BIRB796, in combination with SB203580, a compound that inhibits p38 alpha and p38 beta, but not the other p38 isoforms, can be used to identify physiological substrates of SAPK3/p38 gamma as well as those of p38 alpha and p38 beta.	Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Univ Dundee, Div Signal Transduct Therapy, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Cuenda, A (corresponding author), Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland.	a.i.cuenda@dundee.ac.uk	Marquez, Rudi/F-4045-2014; Sabio, Guadalupe/H-9733-2015	Sabio, Guadalupe/0000-0002-2822-0625; Marquez, Rudi/0000-0001-9777-2012				Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Branger J, 2002, J IMMUNOL, V168, P4070, DOI 10.4049/jimmunol.168.8.4070; Branger J, 2003, BLOOD, V101, P4446, DOI 10.1182/blood-2002-11-3338; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Feijoo C, 2005, J CELL SCI, V118, P397, DOI 10.1242/jcs.01655; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; Haydon CE, 2002, ARCH BIOCHEM BIOPHYS, V397, P224, DOI 10.1006/abbi.2001.2625; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kuma Y, 2004, BIOCHEM J, V379, P133, DOI 10.1042/BJ20031559; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; Pargellis C, 2002, NAT STRUCT BIOL, V9, P268, DOI 10.1038/nsb770; Regan J, 2002, J MED CHEM, V45, P2994, DOI 10.1021/jm020057r; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Sabio G, 2004, BIOCHEM J, V380, P19, DOI 10.1042/BJ20031628; Van den Blink B, 2004, J CLIN IMMUNOL, V24, P37, DOI 10.1023/B:JOCI.0000018061.58504.75	25	230	247	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19472	19479		10.1074/jbc.M414221200	http://dx.doi.org/10.1074/jbc.M414221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15755732	hybrid			2022-12-25	WOS:000229113700008
J	Hostetler, HA; Petrescu, AD; Kier, AB; Schroeder, F				Hostetler, HA; Petrescu, AD; Kier, AB; Schroeder, F			Peroxisome proliferator-activated receptor alpha interacts with high affinity and is conformationally responsive to endogenous ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING PROTEIN; FATTY-ACYL-COA; STEROL CARRIER PROTEIN-2; ORPHAN NUCLEAR RECEPTORS; COENZYME-A; PPAR-ALPHA; RAT-LIVER; MOLECULAR RECOGNITION; BETA-OXIDATION; PHYTANIC ACID	Although the peroxisome proliferator-activated receptor (PPAR alpha) binds and is activated by a variety of synthetic xenobiotics, the identity of the high affinity endogenous ligand(s) is incompletely resolved. Likewise, it is not known how putative endogenous ligands alter PPAR alpha conformation in order to affect transcriptional regulation. Direct fluorescence binding and fluorescence displacement assays showed for the first time that PPAR alpha exhibits high affinity (1-14 nM K-d values) for unsaturated long chain fatty acyl-CoAs as well as unsaturated long chain fatty acids commonly found in mammalian cells. Fluorescence resonance energy transfer between PPAR alpha aromatic amino acids and bound corresponding naturally occurring fluorescent ligands (i.e. cis-parinaroyl-CoA, trans-parinaric acid) yielded intermolecular distances of 25-29 angstrom, confirming close molecular interaction. Interestingly, although PPAR alpha also exhibited high affinity for saturated long chain fatty acyl-CoAs, regardless of chain length (1-13 nM K-d values), saturated long chain fatty acids were not significantly bound. In contrast to the similar affinities of PPAR alpha for fatty acyl-CoAs and unsaturated fatty acids, CoA thioesters of peroxisome proliferator drugs were bound with 5-6-fold higher affinities than their free acid forms. Circular dichroism demonstrated that high affinity ligands ( long chain fatty acyl-CoAs, unsaturated fatty acids), but not weak affinity ligands ( saturated fatty acids), elicited conformational changes in PPAR alpha structure, a hallmark of ligand-activated nuclear receptors. Finally, these ligand specificities and induced conformational changes correlated functionally with co-activator binding. In summary, since nuclear concentrations of these ligands are in the nanomolar range, long chain fatty acyl-CoAs and unsaturated fatty acids may both represent endogenous PPAR alpha ligands. Furthermore, the finding that saturated fatty acyl-CoAs, rather than saturated fatty acids, are high affinity PPAR alpha ligands provides a mechanism accounting for saturated fatty acid transactivation in cell-based assays.	Texas A&M Univ, Texas Vet Med Ctr, Dept Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Texas Vet Med Ctr, Dept Pathobiol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Schroeder, F (corresponding author), Texas A&M Univ, Texas Vet Med Ctr, Dept Physiol & Pharmacol, College Stn, TX 77843 USA.	fschroeder@cvm.tamu.edu			NIDDK NIH HHS [DK066732, DK41402, F32 DK066732, F32 DK066732-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK066732, R01DK041402] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARSLAND A, 1991, BIOCHEM PHARMACOL, V41, P53, DOI 10.1016/0006-2952(91)90010-3; BANNER CD, 1993, J LIPID RES, V34, P1583; BARTANA J, 1985, J BIOL CHEM, V260, P8404; BERGE RK, 1987, BIOCHIM BIOPHYS ACTA, V918, P60, DOI 10.1016/0005-2760(87)90009-9; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; Bonilla S, 2000, BRIT J NUTR, V83, P665, DOI 10.1017/S0007114500000842; Cronet P, 2001, STRUCTURE, V9, P699, DOI 10.1016/S0969-2126(01)00634-7; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; Egea PF, 2002, MOL ENDOCRINOL, V16, P987, DOI 10.1210/me.16.5.987; Elholm M, 2001, J BIOL CHEM, V276, P21410, DOI 10.1074/jbc.M101073200; Ellinghaus P, 1999, J BIOL CHEM, V274, P2766, DOI 10.1074/jbc.274.5.2766; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORSTER TH., 1967, COMPREHENSIVE BIOCH, P61; Francis GA, 2003, ANNU REV PHYSIOL, V65, P261, DOI 10.1146/annurev.physiol.65.092101.142528; Frolov A, 1998, J BIOL CHEM, V273, P11049, DOI 10.1074/jbc.273.18.11049; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; Frolov A, 2000, J BIOL CHEM, V275, P12769, DOI 10.1074/jbc.275.17.12769; Frolov A, 1997, LIPIDS, V32, P1201, DOI 10.1007/s11745-997-0154-5; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; Gossett RE, 1996, LIPIDS, V31, P895, DOI 10.1007/BF02522684; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; HERTZ R, 1987, BIOCHEM J, V245, P387, DOI 10.1042/bj2450387; HIBI AK, 2002, CELL MOL LIFE SCI, V59, P645; Huang H, 2002, J BIOL CHEM, V277, P29139, DOI 10.1074/jbc.M202923200; Huang H, 2004, BIOCHEMISTRY-US, V43, P2484, DOI 10.1021/bi0352318; HUBBELL T, 1994, BIOCHEMISTRY-US, V33, P3327, DOI 10.1021/bi00177a025; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; Jia YZ, 2003, J BIOL CHEM, V278, P47232, DOI 10.1074/jbc.M306363200; Jorgensen C, 2002, ANN NY ACAD SCI, V967, P431; KAWAGUCHI A, 1981, J BIOCHEM-TOKYO, V89, P337, DOI 10.1093/oxfordjournals.jbchem.a133207; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Lin QO, 1999, BIOCHEMISTRY-US, V38, P185, DOI 10.1021/bi9816094; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Martin GG, 2003, BIOCHEMISTRY-US, V42, P11520, DOI 10.1021/bi0346749; McArthur MJ, 1999, J LIPID RES, V40, P1371; Murakami K, 2001, BIOCHEM J, V353, P231, DOI 10.1042/0264-6021:3530231; NEMECZ G, 1991, J BIOL CHEM, V266, P17112; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; Petrescu AD, 2002, J BIOL CHEM, V277, P23988, DOI 10.1074/jbc.M201241200; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; Potier N, 2003, PROTEIN SCI, V12, P725, DOI 10.1110/ps.0232503; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; Rolf B, 1995, BBA-LIPID LIPID MET, V1259, P245, DOI 10.1016/0005-2760(95)00170-0; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; Serrero G, 2000, BBA-MOL CELL BIOL L, V1488, P245, DOI 10.1016/S1388-1981(00)00128-1; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Stehlin C, 2001, EMBO J, V20, P5822, DOI 10.1093/emboj/20.21.5822; Svensson S, 2003, EMBO J, V22, P4625, DOI 10.1093/emboj/cdg456; Wahli W, 1999, ADV EXP MED BIOL, V447, P199; Wolfrum C, 1999, J LIPID RES, V40, P708; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195	62	140	143	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18667	18682		10.1074/jbc.M412062200	http://dx.doi.org/10.1074/jbc.M412062200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15774422	hybrid			2022-12-25	WOS:000228932300017
J	Evangelopoulos, ME; Weis, J; Kruttgen, A				Evangelopoulos, ME; Weis, J; Kruttgen, A			Signalling pathways leading to neuroblastoma differentiation after serum withdrawal: HDL blocks neuroblastoma differentiation by inhibition of EGFR	ONCOGENE			English	Article						cholesterol; lipoproteins; rafts; neurotrophin	EPIDERMAL-GROWTH-FACTOR; HIGH-DENSITY LIPOPROTEINS; BREAST-CANCER-CELLS; CHOLESTEROL DEPLETION; FACTOR RECEPTORS; RETINOIC ACID; LIPID RAFTS; ACTIVATION; PROLIFERATION; BINDING	Neuroblastoma is the second most common pediatric malignancy, characterized by a high rate of unexplained spontaneous remissions. Much progress has been made in understanding neuroblastoma differentiation triggered by certain agents such as retinoic acid. However, little is known about the signalling pathways that lead to differentiation of neuroblastoma cells due to serum withdrawal. We found that in Neuro2a neuroblastoma cells, EGFR, ERK1/2 and Akt showed increased phosphorylation after serum withdrawal, and that the activation of EGFR was necessary for the activation of Akt and ERK1/2. Inhibition of EGFR, ERK1/2 and PI3K blocked neuroblastoma differentiation after serum withdrawal. Interestingly, addition of high-density lipoprotein (HDL) abrogated serum-withdrawal induced neuroblastoma differentiation, as well as the activation of EGFR. Our results demonstrate a novel role for serum-derived lipoproteins in the control of receptor tyrosine kinase activity.	Univ Bern, Inst Pathol, Div Neuropathol, CH-3010 Bern, Switzerland; Rhein Westfal TH Aachen, Inst Neuropathol, Univ Hosp, D-52074 Aachen, Germany	University of Bern; RWTH Aachen University; RWTH Aachen University Hospital	Kruttgen, A (corresponding author), Univ Bern, Inst Pathol, Div Neuropathol, Murtenstr 31, CH-3010 Bern, Switzerland.	akruettgen@ukaachen.de	Kruttgen, Alexander P/E-9232-2010; Weis, Joachim/G-1984-2014	Weis, Joachim/0000-0003-3280-6773; EVANGELOPOULOS, MARIA ELEFTHERIA/0000-0003-4654-7477				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Canon E, 2004, MOL BIOL CELL, V15, P5583, DOI 10.1091/mbc.E04-05-0439; Cao WM, 2004, CANCER RES, V64, P1515, DOI 10.1158/0008-5472.CAN-03-0675; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; Cortes-Canteli M, 2002, J BIOL CHEM, V277, P5460, DOI 10.1074/jbc.M108761200; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIAZNIDO J, 1991, J CELL SCI, P51; Dimitroulakos J, 1996, NAT MED, V2, P326, DOI 10.1038/nm0396-326; Evangelopoulos ME, 2004, J NEURO-ONCOL, V66, P101, DOI 10.1023/B:NEON.0000013492.37426.0c; FAN K, 1983, NEUROSCI LETT, V41, P205, DOI 10.1016/0304-3940(83)90248-3; Fidge NH, 1999, J LIPID RES, V40, P187; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GOSPODAROWICZ D, 1982, CANCER RES, V42, P3704; Grewal T, 2003, J BIOL CHEM, V278, P16478, DOI 10.1074/jbc.C300085200; Li HY, 2003, BLOOD, V101, P3628, DOI 10.1182/blood-2002-07-2283; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; Ma XF, 1998, AM J PHYSIOL-CELL PH, V274, pC1206, DOI 10.1152/ajpcell.1998.274.5.C1206; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Pahlman S, 2000, NEUROBLASTOMA, P9; Paratcha G, 2002, CURR OPIN NEUROBIOL, V12, P542, DOI 10.1016/S0959-4388(02)00363-X; Pignatelli M, 1999, FEBS LETT, V461, P37, DOI 10.1016/S0014-5793(99)01420-9; Ringerike T, 2002, J CELL SCI, V115, P1331; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Roepstorff K, 2002, J BIOL CHEM, V277, P18954, DOI 10.1074/jbc.M201422200; ROTHENEDER M, 1989, INT J CANCER, V43, P875, DOI 10.1002/ijc.2910430523; SCHUBERT D, 1969, P NATL ACAD SCI USA, V64, P316, DOI 10.1073/pnas.64.1.316; SEEDS NW, 1970, P NATL ACAD SCI USA, V66, P160, DOI 10.1073/pnas.66.1.160; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Ullrich A, 2002, ONCOLOGY-BASEL, V63, P1, DOI 10.1159/000066202; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; WALTER M, 1995, ARTERIOSCL THROM VAS, V15, P1975, DOI 10.1161/01.ATV.15.11.1975; Westover EJ, 2003, J BIOL CHEM, V278, P51125, DOI 10.1074/jbc.M304332200; Wong RWC, 2004, CYTOKINE GROWTH F R, V15, P147, DOI 10.1016/j.cytogfr.2004.01.004	38	82	83	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3309	3318		10.1038/sj.onc.1208494	http://dx.doi.org/10.1038/sj.onc.1208494			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735700				2022-12-25	WOS:000228881800009
J	Soenen-Cornu, V; Tourino, C; Bonnet, ML; Guillier, M; Flamant, S; Kotb, R; Bernheim, A; Bourhis, JH; Preudhomme, C; Fenaux, P; Turhan, AG				Soenen-Cornu, V; Tourino, C; Bonnet, ML; Guillier, M; Flamant, S; Kotb, R; Bernheim, A; Bourhis, JH; Preudhomme, C; Fenaux, P; Turhan, AG			Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro	ONCOGENE			English	Article						mesenchymal stem cells; hematopoiesis; myelodysplasia	BONE-MARROW-TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; STEM-CELLS; SITU HYBRIDIZATION; PROGENITOR CELLS; STROMAL CELLS; SYNDROME MDS; CHEMOTHERAPY; INVOLVEMENT; ENGRAFTMENT	Myelodysplastic syndromes (MDS) are clonal malignant stem cell disorders characterized by inefficient hematopoiesis. The role of the marrow microenvironment in the pathogenesis of the disease has been controversial and no study has been performed so far to characterize mesenchymal cells ( MC) from MDS patients and to analyse their ability to support hematopoiesis. To this end, we have isolated and characterized MC at diagnostic marrow samples (n = 12) and have purified their CD34+CD38- and CD34+CD38- counterparts ( n = 7) before using MC as a short- and long-term hematopoietic support. We show that MC can be readily isolated from MDS marrow and exhibit a major expansion potential as well as an intact osteoblastic differentiation ability. They do not harbor the abnormal marker identified by FISH in the hematopoietic cells and they stimulate the growth of autologous clonogenic cells. Conversely, highly purified stem cells and their cytokine-expanded progeny harbor the clonal marker with variable frequencies, and both normal and abnormal long-term culture-initiating cell-derived progeny can be effectively supported by autologous MC. Thus, we demonstrate that MDS marrow is an abundant source of MC appearing both cytogenetically and functionally noninvolved by the malignant process and able to support hematopoiesis, suggesting their possible usefulness in future cell therapy approaches.	Inst Gustave Roussy, INSERM, U362, Dept Biol Clin, Villejuif, France; CHU Lille, INSERM, U524, F-59037 Lille, France; CHU Lille, Hematol Lab, F-59037 Lille, France; Inst Gustave Roussy, Translat Res Cell Therapy Lab, Villejuif, France; Inst Gustave Roussy, Dept Med, Villejuif, France; Inst Gustave Roussy, Dept Pathol, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Turhan, AG (corresponding author), Inst Gustave Roussy, INSERM, U362, Dept Biol Clin, Rue Camille Desmoulins, Villejuif, France.	turali@igr.fr	Soenen, Valérie/U-9080-2018; Preudhomme, Claude/T-8553-2018	Soenen, Valérie/0000-0002-4618-9377; Preudhomme, Claude/0000-0002-1267-9546; FLAMANT, Stephane/0000-0003-2295-5943; TURHAN, Ali/0000-0002-4861-0137				Aizawa S, 1999, LEUKEMIA RES, V23, P239, DOI 10.1016/S0145-2126(98)00163-5; Angelopoulou M, 2003, EXP HEMATOL, V31, P413, DOI 10.1016/S0301-472X(03)00042-0; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; Bensidhoum M, 2004, BLOOD, V103, P3313, DOI 10.1182/blood-2003-04-1121; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; COUTINHO LH, 1990, BRIT J HAEMATOL, V75, P16, DOI 10.1111/j.1365-2141.1990.tb02611.x; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Deeg HJ, 2000, LEUKEMIA LYMPHOMA, V37, P405, DOI 10.3109/10428190009089441; Deeg HJ, 2002, LEUKEMIA RES, V26, P687, DOI 10.1016/S0145-2126(02)00015-2; Delforge M, 1998, BRIT J HAEMATOL, V102, P486, DOI 10.1046/j.1365-2141.1998.00797.x; DeWitte T, 1997, BLOOD, V90, P3853; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Guardiola P, 2002, BLOOD, V99, P4370, DOI 10.1182/blood.V99.12.4370; Heaney ML, 1999, NEW ENGL J MED, V340, P1649, DOI 10.1056/NEJM199905273402107; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Kadiyala S, 1997, CELL TRANSPLANT, V6, P125, DOI 10.1016/S0963-6897(96)00279-5; KANTARJIAN HM, 1986, J CLIN ONCOL, V4, P1748, DOI 10.1200/JCO.1986.4.12.1748; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Mauritzson N, 1999, EUR J HAEMATOL, V62, P95; Nevill TJ, 1998, BLOOD, V92, P1910, DOI 10.1182/blood.V92.6.1910.418k30_1910_1917; Nilsson L, 2000, BLOOD, V96, P2012, DOI 10.1182/blood.V96.6.2012.h8002012a_2012_2021; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Saitoh K, 1998, BLOOD, V92, P2886, DOI 10.1182/blood.V92.8.2886.420k11_2886_2892; SOENEN V, 1995, BRIT J HAEMATOL, V90, P701, DOI 10.1111/j.1365-2141.1995.tb05604.x; 't Anker PS, 2003, EXP HEMATOL, V31, P881, DOI 10.1016/S0301-472X(03)00202-9; Thanopoulou E, 2004, BLOOD, V103, P4285, DOI 10.1182/blood-2003-09-3192; Tourino C, 2001, Hematol J, V2, P108, DOI 10.1038/sj.thj.6200083; TURHAN AG, 1995, BLOOD, V85, P2154, DOI 10.1182/blood.V85.8.2154.bloodjournal8582154; Wattel E, 1999, LEUKEMIA, V13, P524, DOI 10.1038/sj.leu.2401387	30	58	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2441	2448		10.1038/sj.onc.1208405	http://dx.doi.org/10.1038/sj.onc.1208405			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735749				2022-12-25	WOS:000228180600002
J	Ferraroni, M; Seifert, J; Travkin, VM; Thiel, M; Kaschabek, S; Scozzafava, A; Golovleva, L; Schlomann, M; Briganti, F				Ferraroni, M; Seifert, J; Travkin, VM; Thiel, M; Kaschabek, S; Scozzafava, A; Golovleva, L; Schlomann, M; Briganti, F			Crystal structure of the hydroxyquinol 1,2-dioxygenase from Nocardioides simplex 3E, a key enzyme involved in polychlorinated aromatics biodegradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOCATECHUATE 3,4-DIOXYGENASE; 2,4,5-TRICHLOROPHENOXYACETIC ACID; BURKHOLDERIA-CEPACIA; P-NITROPHENOL; GENE-CLUSTER; PATTERN-RECOGNITION; SEQUENCE-ANALYSIS; DEGRADATION; PURIFICATION; METABOLISM	Hydroxyquinol 1,2- dioxygenase ( 1,2-HQD) catalyzes the ring cleavage of hydroxyquinol ( 1,2,4-trihydroxybenzene), a central intermediate in the degradation of aromatic compounds including a variety of particularly recalcitrant polychloro- and nitroaromatic pollutants. We report here the primary sequence determination and the analysis of the crystal structure of the 1,2-HQD from Nocardioides simplex 3E solved at 1.75 angstrom resolution using the multiple wavelength anomalous dispersion of the two catalytic irons (1 Fe/293 amino acids). The catalytic Fe(III) coordination polyhedron composed by the side chains of Tyr(164), Tyr(197), His(221), and His(223) resembles that of the other known intradiol-cleaving dioxygenases, but several of the tertiary structure features are notably different. One of the most distinctive characteristics of the present structure is the extensive openings and consequent exposure to solvent of the upper part of the catalytic cavity arranged to favor the binding of hydroxyquinols but not catechols. A co- crystallized benzoate-like molecule is also found bound to the metal center forming a distinctive hydrogen bond network as observed previously also in 4-chlorocatechol 1,2-dioxygenase from Rhodococcus opacus 1CP. This is the first structure of an intradiol dioxygenase specialized in hydroxyquinol ring cleavage to be investigated in detail.	Univ Florence, Dipartimento Chim, I-50019 Sesto Fiorentino, Italy; TU Bergakad Freiberg, Interdisziplinares Okol Zentrum, D-09599 Freiberg, Germany; Russian Acad Sci, Skryabin Inst Biochem & Physol Microorganisms, Pushchino 142290, Moscow Region, Russia	University of Florence; Technical University Freiberg; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences	Briganti, F (corresponding author), Univ Florence, Dipartimento Chim, Via Lastruccia 3, I-50019 Sesto Fiorentino, Italy.	fabrizio.briganti@unifi.it	Briganti, Fabrizio/C-6661-2012; Ferraroni, Marta/P-6441-2016	Ferraroni, Marta/0000-0001-7258-738X; Seifert, Jana/0000-0002-7690-8539; Scozzafava, Andrea/0000-0001-5020-3322; Ludmila, Golovleva/0000-0001-9773-8957				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON JJ, 1980, J BACTERIOL, V141, P534, DOI 10.1128/JB.141.2.534-543.1980; APAJALAHTI JHA, 1987, J BACTERIOL, V169, P5125, DOI 10.1128/jb.169.11.5125-5130.1987; Armengaud J, 1999, J BACTERIOL, V181, P3452, DOI 10.1128/JB.181.11.3452-3461.1999; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASHFORD D, 1997, ISCOPE97, V1343, P233; Benvenuti M, 1999, ACTA CRYSTALLOGR D, V55, P901, DOI 10.1107/S0907444998017715; Briganti F, 1998, FEBS LETT, V433, P58, DOI 10.1016/S0014-5793(98)00884-9; CHAPMAN PJ, 1976, J BACTERIOL, V125, P975, DOI 10.1128/JB.125.3.975-984.1976; Chauhan A, 2000, J APPL MICROBIOL, V88, P764, DOI 10.1046/j.1365-2672.2000.01018.x; Chauhan A, 2000, BIOCHEM BIOPH RES CO, V270, P733, DOI 10.1006/bbrc.2000.2500; D'Argenio DA, 1999, J BACTERIOL, V181, P6478; Daubaras DL, 1996, APPL ENVIRON MICROB, V62, P4276, DOI 10.1128/AEM.62.11.4276-4279.1996; DAUBARAS DL, 1995, APPL ENVIRON MICROB, V61, P1279, DOI 10.1128/AEM.61.4.1279-1289.1995; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DORN E, 1978, BIOCHEM J, V174, P73, DOI 10.1042/bj1740073; Eley KL, 2001, J ORG CHEM, V66, P2091, DOI 10.1021/jo001669r; Elgren TE, 1997, BIOCHEMISTRY-US, V36, P11504, DOI 10.1021/bi970691k; Eulberg D, 1997, J BACTERIOL, V179, P370, DOI 10.1128/jb.179.2.370-381.1997; Ferraroni M, 2004, J BIOL CHEM, V279, P27646, DOI 10.1074/jbc.M401692200; Golovleva L A, 1991, Biodegradation, V2, P201, DOI 10.1007/BF00124494; Golovleva LA, 1990, BIODEGRADATION, V1, P263, DOI 10.1007/BF00119763; HAGGBLOM MM, 1989, APPL ENVIRON MICROB, V55, P516; Hatta T, 1999, J BIOSCI BIOENG, V87, P267, DOI 10.1016/S1389-1723(99)80030-9; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; JAIN RK, 1994, APPL ENVIRON MICROB, V60, P3030, DOI 10.1128/AEM.60.8.3030-3032.1994; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kitagawa W, 2004, J BACTERIOL, V186, P4894, DOI 10.1128/JB.186.15.4894-4902.2004; KIYOHARA H, 1992, APPL ENVIRON MICROB, V58, P1276, DOI 10.1128/AEM.58.4.1276-1283.1992; KOZYREVA LP, 1993, MICROBIOLOGY+, V62, P78; Lange SJ, 1998, CURR OPIN CHEM BIOL, V2, P159, DOI 10.1016/S1367-5931(98)80057-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LATUS M, 1995, APPL ENVIRON MICROB, V61, P2453, DOI 10.1128/AEM.61.7.2453-2460.1995; Louie TM, 2002, J BACTERIOL, V184, P3492, DOI 10.1128/JB.184.13.3492-3500.2002; MALTSEVA OV, 1994, EUR J BIOCHEM, V226, P1053, DOI 10.1111/j.1432-1033.1994.01053.x; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806; Meulenberg R, 1996, BIODEGRADATION, V7, P303, DOI 10.1007/BF00115744; Murakami S, 1999, BIOSCI BIOTECH BIOCH, V63, P859, DOI 10.1271/bbb.63.859; NAKAI C, 1988, ARCH BIOCHEM BIOPHYS, V267, P701, DOI 10.1016/0003-9861(88)90079-3; Nielsen JE, 1999, PROTEIN ENG, V12, P657, DOI 10.1093/protein/12.8.657; OHLENDORF DH, 1988, NATURE, V336, P403, DOI 10.1038/336403a0; OHLENDORF DH, 1994, J MOL BIOL, V244, P586, DOI 10.1006/jmbi.1994.1754; Orville AM, 1997, BIOCHEMISTRY-US, V36, P10039, DOI 10.1021/bi970468n; Orville AM, 1997, BIOCHEMISTRY-US, V36, P10052, DOI 10.1021/bi970469f; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padilla L, 2000, J BASIC MICROB, V40, P243, DOI 10.1002/1521-4028(200008)40:4<243::AID-JOBM243>3.0.CO;2-D; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pieper DH, 2002, J BACTERIOL, V184, P1466, DOI 10.1128/JB.184.5.1466-1470.2002; Que L, 2001, SCIENCE, V292, P651; RIEBLE S, 1994, J BACTERIOL, V176, P4838, DOI 10.1128/jb.176.16.4838-4844.1994; Ritchie DW, 1999, J COMPUT CHEM, V20, P383, DOI 10.1002/(SICI)1096-987X(199903)20:4<383::AID-JCC1>3.0.CO;2-M; Sambrook J, 2001, MOL CLONING LAB MANU; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Solyanikova IP, 1996, BIOCHEMISTRY-MOSCOW+, V61, P461; STOLZ A, 1993, FEMS MICROBIOL LETT, V108, P219, DOI 10.1111/j.1574-6968.1993.tb06102.x; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; SZE ISY, 1984, J BACTERIOL, V159, P353, DOI 10.1128/JB.159.1.353-359.1984; Takenaka S, 2003, APPL ENVIRON MICROB, V69, P5410, DOI 10.1128/AEM.69.9.5410-5413.2003; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Travkin VM, 1997, FEBS LETT, V407, P69, DOI 10.1016/S0014-5793(97)00297-4; Uotila J. S., 1995, Biodegradation, V6, P119, DOI 10.1007/BF00695342; UOTILA JS, 1992, J BACTERIOL, V174, P5669, DOI 10.1128/JB.174.17.5669-5675.1992; VARGA J M, 1970, European Journal of Biochemistry, V12, P427, DOI 10.1111/j.1432-1033.1970.tb00869.x; Vetting MW, 2000, BIOCHEMISTRY-US, V39, P7943, DOI 10.1021/bi000151e; VONQUANTA, 1997, QUANTA SIMULATION SE; WILSON K, 2000, CURRENT PROTOCOLS MO, V1; Xun LY, 2004, J BIOL CHEM, V279, P6696, DOI 10.1074/jbc.M312072200; Xun LY, 1999, BIOCHEM BIOPH RES CO, V266, P322, DOI 10.1006/bbrc.1999.1805; ZABORINA O, 1995, J BACTERIOL, V177, P229, DOI 10.1128/jb.177.1.229-234.1995	72	39	41	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21144	21154		10.1074/jbc.M500666200	http://dx.doi.org/10.1074/jbc.M500666200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15772073	hybrid			2022-12-25	WOS:000229438800031
J	Petrovics, G; Liu, AJ; Shaheduzzaman, S; Furasato, B; Sun, C; Chen, YM; Nau, M; Ravindranath, L; Chen, YD; Dobi, A; Srikantan, V; Sesterhenn, IA; McLeod, DG; Vahey, M; Moul, JW; Srivastava, S				Petrovics, G; Liu, AJ; Shaheduzzaman, S; Furasato, B; Sun, C; Chen, YM; Nau, M; Ravindranath, L; Chen, YD; Dobi, A; Srikantan, V; Sesterhenn, IA; McLeod, DG; Vahey, M; Moul, JW; Srivastava, S			Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome	ONCOGENE			English	Article						ERG1; ETS transcription factor family; prostate cancer; proto-oncogene; overexpression	EXPRESSION; ONCOGENE; FAMILY	Transcription factors encoded by the ETS family of genes are central in integrating signals that regulate cell growth and differentiation, stress responses, and tumorigenesis. This study, analysing laser microdissected paired benign and malignant prostate epithelial cells from prostate cancer (CaP) patients ( n = 114; 228 specimen) by GeneChip and quantitative real-time RT-PCR, identifies ETS-related gene ( ERG), a member of the ETS transcription factor family, as the most frequently overexpressed proto-oncogene in the transcriptome of malignant prostate epithelial cells. Combined quantitative expression analysis of ERG with two other genes commonly overexpressed in CaP, AMACR and DD3, revealed overexpression of at least one of these three genes in virtually all CaP specimen ( 54 of 55). Comprehensive evaluation of quantitative ERG1 expression with clinicopathological features also suggested that ERG1 expression level in prostate tumor cells relative to benign epithelial cells is indicator of disease-free survival after radical prostatectomy.	Ctr Prostate Dis Res, Dept Surg, Rockville, MD 20852 USA; Uniformed Serv Univ Hlth Sci, US Mil Canc Inst, Rockville, MD 20852 USA; Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20306 USA; Walter Reed Army Inst Res, Lab Funct Genom, Rockville, MD 20850 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Walter Reed Army Med Ctr, Urol Serv, Washington, DC 20307 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Srivastava, S (corresponding author), Ctr Prostate Dis Res, Dept Surg, Rockville, MD 20852 USA.	gpetrovics@cpdr.org		Petrovics, Gyorgy/0000-0003-3732-284X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065977] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK065977] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baldus CD, 2004, P NATL ACAD SCI USA, V101, P3915, DOI 10.1073/pnas.0400272101; Bussemakers MJG, 1999, CANCER RES, V59, P5975; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Gavrilov D, 2001, EUR J CANCER, V37, P1033, DOI 10.1016/S0959-8049(01)00077-6; Gelmann EP, 2003, CRIT REV ONCOL HEMAT, V46, pS11; HART AH, 1995, ONCOGENE, V10, P1423; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Isaacs W, 2001, EPIDEMIOL REV, V23, P36, DOI 10.1093/oxfordjournals.epirev.a000794; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Owczarek CM, 2004, GENE, V324, P65, DOI 10.1016/j.gene.2003.09.047; Petrovics G, 2004, ONCOGENE, V23, P605, DOI 10.1038/sj.onc.1207069; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; Srikantan V, 2003, PROSTATE CANCER: DIAGNOSIS AND SURGICAL TREATMENT, P25	18	270	305	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3847	3852		10.1038/sj.onc.1208518	http://dx.doi.org/10.1038/sj.onc.1208518			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15750627				2022-12-25	WOS:000229346300016
J	Binks, MJ; Fernie-King, BA; Seilly, DJ; Lachmann, PJ; Sriprakash, KS				Binks, MJ; Fernie-King, BA; Seilly, DJ; Lachmann, PJ; Sriprakash, KS			Attribution of the various inhibitory actions of the streptococcal inhibitor of complement (SIC) to regions within the molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; EXTRACELLULAR PROTEIN; PYOGENES; GENE; STRAINS; VARIANTS; EPIDEMIC; EMM12	Some strains of Streptococcus pyogenes secrete a virulence factor called the streptococcal inhibitor of complement ( SIC) function. SIC is a polyfunctional protein that interacts with a number of host proteins and peptides, especially with those that are involved in host defense systems. In addition to inhibiting the complement-mediated lysis of cells, SIC inhibits lysozyme, secretory leukocyte proteinase inhibitor, and beta-defensins. SIC also binds to proteins associated with the cytoskeleton and thereby may cause cytoskeletal derangement. The SIC molecule has three distinct structural domains constituting the N-proximal short repeat region (SRR), the central long repeat region (LRR), and the C-proximal proline-rich region (PRR). To map various functions to the structural domains, we have analyzed recombinant subclones expressing various parts of SIC and elastase-generated discrete fragments of SIC for binding to various ligands and for determining their biological properties. The results demonstrate the following. ( a) SRR alone was sufficient to confer inhibition of complement function. (b) Anti-defensin and anti-lysozyme activities were mapped to the SRR plus LRR. ( c) The LRR plus PRR harbored ezrin binding activity.	Queensland Inst Med Res, Brisbane, Qld 4006, Australia; Univ Cambridge, Dept Vet Med, Cambridge CB3 0ES, England	QIMR Berghofer Medical Research Institute; University of Cambridge	Sriprakash, KS (corresponding author), Queensland Inst Med Res, 300 Herston Rd, Brisbane, Qld 4006, Australia.	sriS@qimr.edu.au	Lachmann, P J/I-7968-2019	Lachmann, P J/0000-0003-2849-3524; Sriprakash, Kadaba/0000-0001-7844-323X				Akesson P, 1996, J BIOL CHEM, V271, P1081, DOI 10.1074/jbc.271.2.1081; Binks M, 2004, INFECT IMMUN, V72, P3981, DOI 10.1128/IAI.72.7.3981-3986.2004; Binks M, 2003, INFECT IMMUN, V71, P6701, DOI 10.1128/IAI.71.12.6701-6706.2003; Fernie-King BA, 2004, IMMUNOLOGY, V111, P444, DOI 10.1111/j.0019-2805.2004.01837.x; Fernie-King BA, 2002, INFECT IMMUN, V70, P4908, DOI 10.1128/IAI.70.9.4908-4916.2002; Fernie-King BA, 2001, IMMUNOLOGY, V103, P390, DOI 10.1046/j.1365-2567.2001.01249.x; Frick IM, 2003, J BIOL CHEM, V278, P16561, DOI 10.1074/jbc.M301995200; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Hartas J, 1999, MICROB PATHOGENESIS, V26, P25, DOI 10.1006/mpat.1998.0244; Hoe NP, 1999, NAT MED, V5, P924, DOI 10.1038/11369; Hoe NP, 2002, P NATL ACAD SCI USA, V99, P7646, DOI 10.1073/pnas.112039899; Hoe NP, 2001, J INFECT DIS, V183, P633, DOI 10.1086/318543; Hoe NP, 2000, J INFECT DIS, V182, P1425, DOI 10.1086/315882; LACHMANN PJ, 1970, J EXP MED, V131, P643, DOI 10.1084/jem.131.4.643; Lachmann PJ, 2004, MOL IMMUNOL, V41, P265; Lukomski S, 2000, INFECT IMMUN, V68, P535, DOI 10.1128/IAI.68.2.535-542.2000; Ma XM, 2002, J CLIN MICROBIOL, V40, P3835, DOI 10.1128/JCM.40.10.3835-3837.2002; PODBIELSKI A, 1993, MOL GEN GENET, V237, P287, DOI 10.1007/BF00282810; Sriprakash KS, 2002, J MED MICROBIOL, V51, P589, DOI 10.1099/0022-1317-51-7-589	19	23	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20120	20125		10.1074/jbc.M414194200	http://dx.doi.org/10.1074/jbc.M414194200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769742	hybrid			2022-12-25	WOS:000229113700083
J	Buhrke, T; Loscher, S; Lenz, O; Schlodder, E; Zebger, I; Andersen, LK; Hildebrandt, P; Meyer-Klaucke, W; Dau, H; Friedrich, B; Haumann, M				Buhrke, T; Loscher, S; Lenz, O; Schlodder, E; Zebger, I; Andersen, LK; Hildebrandt, P; Meyer-Klaucke, W; Dau, H; Friedrich, B; Haumann, M			Reduction of unusual iron-sulfur clusters in the H-2-sensing regulatory Ni-Fe hydrogenase from Ralstonia eutropha H16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ABSORPTION; HISTIDINE PROTEIN-KINASE; ACTIVE-SITE; ALCALIGENES-EUTROPHUS; MANGANESE COMPLEX; H-2 SENSOR; RHODOBACTER-CAPSULATUS; STRUCTURAL-CHANGES; PHOTOSYSTEM-II; SPECTROSCOPY	The regulatory Ni-Fe hydrogenase (RH) from Ralstonia eutropha functions as a hydrogen sensor. The RH consists of the large subunit HoxC housing the Ni-Fe active site and the small subunit HoxB containing Fe-S clusters. The heterolytic cleavage of H-2 at the Ni-Fe active site leads to the EPR-detectable Ni-C state of the protein. For the first time, the simultaneous but EPR-invisible reduction of Fe-S clusters during Ni-C state formation was demonstrated by changes in the UV-visible absorption spectrum as well as by shifts of the iron K-edge from x-ray absorption spectroscopy in the wildtype double dimeric RHWT [HoxBC](2) and in a monodimeric derivative designated RHstop lacking the C-terminal 55 amino acids of HoxB. According to the analysis of iron EXAFS spectra, the Fe-S clusters of HoxB pronouncedly differ from the three Fe-S clusters in the small subunits of crystallized standard Ni-Fe hydrogenases. Each HoxBC unit of RHWT seems to harbor two [2Fe-2S] clusters in addition to a 4Fe species, which may be a [4Fe-3S-3O] cluster. The additional 4Fe-cluster was absent in RHstop. Reduction of Fe-S clusters in the hydrogen sensor RH may be a first step in the signal transduction chain, which involves complex formation between [HoxBC](2) and tetrameric HoxJ protein, leading to the expression of the energy converting Ni-Fe hydrogenases in R. eutropha.	Free Univ Berlin, FB Phys, D-14195 Berlin, Germany; Humboldt Univ, Inst Biol Mikrobiol, D-10115 Berlin, Germany; Tech Univ Berlin, Inst Chem, Max Volmer Lab Biophys Chem, D-10623 Berlin, Germany; DESY, EMBL Outstn, D-22603 Hamburg, Germany	Free University of Berlin; Humboldt University of Berlin; Technical University of Berlin; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Haumann, M (corresponding author), Free Univ Berlin, FB Phys, Arnimallee 14, D-14195 Berlin, Germany.	haumann@physik.fu-berlin.de	Lenz, Oliver/N-5130-2019; Meyer-Klaucke, Wolfram/G-1148-2010; Lenz, Oliver/C-1582-2019; Schlodder, Eberhard/AAP-6766-2021; Hildebrandt, Peter/J-5658-2014; MIchael, Haumann/A-7087-2013	Lenz, Oliver/0000-0003-4550-5128; Lenz, Oliver/0000-0003-4550-5128; Hildebrandt, Peter/0000-0003-1030-5900; Dau, Holger/0000-0001-6482-7494				Agarwalla S, 2004, J BIOL CHEM, V279, P34123, DOI 10.1074/jbc.M405702200; ALBRACHT SPJ, 1994, BBA-BIOENERGETICS, V1188, P167, DOI 10.1016/0005-2728(94)90036-1; Albracht SPJ, 2003, BBA-BIOENERGETICS, V1557, P41, DOI 10.1016/S0005-2728(02)00393-6; Arendsen AF, 1998, J BIOL INORG CHEM, V3, P81, DOI 10.1007/s007750050210; Armstrong FA, 2004, CURR OPIN CHEM BIOL, V8, P133, DOI 10.1016/j.cbpa.2004.02.004; Bernhard M, 2001, J BIOL CHEM, V276, P15592, DOI 10.1074/jbc.M009802200; BLACK LK, 1994, J BACTERIOL, V176, P7102, DOI 10.1128/JB.176.22.7102-7106.1994; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brecht M, 2003, J AM CHEM SOC, V125, P13075, DOI 10.1021/ja036624x; Buhrke T, 2004, MOL MICROBIOL, V51, P1677, DOI 10.1111/j.1365-2958.2003.03933.x; Cammack R., 1997, HYDROGEN FUEL LEARNI; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; COLPAS GJ, 1991, INORG CHEM, V30, P920, DOI 10.1021/ic00005a010; Cosper NJ, 2002, PROTEIN SCI, V11, P2969, DOI 10.1110/ps.0222402; Dau H, 2003, ANAL BIOANAL CHEM, V376, P562, DOI 10.1007/s00216-003-1982-2; Dau H, 2004, PHYS CHEM CHEM PHYS, V6, P4781, DOI 10.1039/b408146c; Drennan CL, 2001, P NATL ACAD SCI USA, V98, P11973, DOI 10.1073/pnas.211429998; Elsen S, 2003, J BACTERIOL, V185, P7111, DOI 10.1128/JB.185.24.7111-7119.2003; Elsen S, 1996, J BACTERIOL, V178, P5174, DOI 10.1128/jb.178.17.5174-5181.1996; Fischer J, 1996, ARCH MICROBIOL, V165, P289, DOI 10.1007/s002030050329; Frey M, 2002, CHEMBIOCHEM, V3, P153, DOI 10.1002/1439-7633(20020301)3:2/3<153::AID-CBIC153>3.0.CO;2-B; Garcin E, 1999, STRUCT FOLD DES, V7, P557, DOI 10.1016/S0969-2126(99)80072-0; Haumann M, 2003, BIOCHEMISTRY-US, V42, P11004, DOI 10.1021/bi034804d; Higuchi Y, 1999, STRUCT FOLD DES, V7, P549, DOI 10.1016/S0969-2126(99)80071-9; Kleihues L, 2000, J BACTERIOL, V182, P2716, DOI 10.1128/JB.182.10.2716-2724.2000; Klockenkamper R., 1996, TOTAL REFLECTION XRA; Kounosu A, 2004, J BIOL CHEM, V279, P12519, DOI 10.1074/jbc.M305923200; Lenz O, 1998, P NATL ACAD SCI USA, V95, P12474, DOI 10.1073/pnas.95.21.12474; Lippard S. J., 1994, PRINCIPLES BIOINORGA; Matias PM, 2001, J BIOL INORG CHEM, V6, P63, DOI 10.1007/s007750000167; MCDERMOTT AE, 1989, BIOCHEMISTRY-US, V28, P8056, DOI 10.1021/bi00446a013; Meinke C, 2000, BIOCHEMISTRY-US, V39, P7033, DOI 10.1021/bi9924258; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Nagashima S, 1998, NAT STRUCT BIOL, V5, P347, DOI 10.1038/nsb0598-347; Nakamaru-Ogiso E, 2002, J BIOL CHEM, V277, P1680, DOI 10.1074/jbc.M108796200; PENNERHAHN JE, 1983, J BIOL CHEM, V258, P2761; PETTIFER RF, 1985, J APPL CRYSTALLOGR, V18, P404, DOI 10.1107/S0021889885010627; Pierik AJ, 1998, FEBS LETT, V438, P231, DOI 10.1016/S0014-5793(98)01306-4; Pikus JD, 1996, BIOCHEMISTRY-US, V35, P9106, DOI 10.1021/bi960456m; Rousset M, 1998, P NATL ACAD SCI USA, V95, P11625, DOI 10.1073/pnas.95.20.11625; SCHINK B, 1978, BIOCHIMIE, V60, P297, DOI 10.1016/S0300-9084(78)80826-8; SCHINK B, 1979, BIOCHIM BIOPHYS ACTA, V567, P315, DOI 10.1016/0005-2744(79)90117-7; SCHNEIDER K, 1976, BIOCHIM BIOPHYS ACTA, V452, P66, DOI 10.1016/0005-2744(76)90058-9; TSANG HT, 1989, BIOCHEMISTRY-US, V28, P7233, DOI 10.1021/bi00444a015; Volbeda A, 1996, J AM CHEM SOC, V118, P12989, DOI 10.1021/ja962270g; VOLBEDA A, 1995, NATURE, V373, P556; Wolfe MT, 2002, J BACTERIOL, V184, P5898, DOI 10.1128/JB.184.21.5898-5902.2002; ZABINSKY SI, 1995, PHYS REV B, V52, P2995, DOI 10.1103/PhysRevB.52.2995	48	43	45	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19488	19495		10.1074/jbc.M500601200	http://dx.doi.org/10.1074/jbc.M500601200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15764814	hybrid			2022-12-25	WOS:000229113700010
J	Erwin, PA; Lin, AJ; Golan, DE; Michel, T				Erwin, PA; Lin, AJ; Golan, DE; Michel, T			Receptor-regulated dynamic S-nitrosylation of endothelial nitric-oxide synthase in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; PLASMALEMMAL CAVEOLAE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; ENOS ACTIVATION; ENZYME-ACTIVITY; PALMITOYLATION; AKT; TETRAHYDROBIOPTERIN; PHOSPHORYLATION	The endothelial isoform of nitric-oxide synthase (eNOS) is regulated by a complex pattern of post-translational modifications. In these studies, we show that eNOS is dynamically regulated by S-nitrosylation, the covalent adduction of nitric oxide (NO)-derived nitrosyl groups to the cysteine thiols of proteins. We report that eNOS is tonically S-nitrosylated in resting bovine aortic endothelial cells and that the enzyme undergoes rapid transient denitrosylation after addition of the eNOS agonist, vascular endothelial growth factor. eNOS is thereafter progressively renitrosylated to basal levels. The receptor-mediated decrease in eNOS S-nitrosylation is inversely related to enzyme phosphorylation at Ser(1179), a site associated with eNOS activation. We also document that targeting of eNOS to the cell membrane is required for eNOS S-nitrosylation. Acylation-deficient mutant eNOS, which is targeted to the cytosol, does not undergo S-nitrosylation. Using purified eNOS, we show that eNOS S-nitrosylation by exogenous NO donors inhibits enzyme activity and that eNOS inhibition is reversed by denitrosylation. We determine that the cysteines of the zinc-tetrathiolate that comprise the eNOS dimer interface are the targets of S-nitrosylation. Mutation of the zinc-tetrathiolate cysteines eliminates eNOS S-nitrosylation but does not eliminate NO synthase activity, arguing strongly that disruption of the zinc-tetrathiolate does not necessarily lead to eNOS monomerization in vivo. Taken together, these studies suggest that eNOS S-nitrosylation may represent an important mechanism for regulation of NO signaling pathways in the vascular wall.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, W Roxbury, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Michel, T (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St,Thorn Bldg,1210A, Boston, MA 02115 USA.	tmichel@research.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046457, R01HL032854, R37HL032854, U54HL070819, R01HL046457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036259, R37GM036259] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL070819, HL32854, HL46457] Funding Source: Medline; NIGMS NIH HHS [GM36259] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Ausubel FM, 2003, CURRENT PROTOCOLS MO; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; BUSCONI L, 1995, MOL PHARMACOL, V47, P655; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; Davis KL, 2001, ANNU REV PHARMACOL, V41, P203, DOI 10.1146/annurev.pharmtox.41.1.203; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gonzalez E, 2004, J BIOL CHEM, V279, P40659, DOI 10.1074/jbc.M407051200; Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200; Griffith OW, 1996, METHOD ENZYMOL, V268, P375; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Heller R, 1999, J BIOL CHEM, V274, P8254, DOI 10.1074/jbc.274.12.8254; Heller R, 2001, J BIOL CHEM, V276, P40, DOI 10.1074/jbc.M004392200; Hemmens B, 2000, J BIOL CHEM, V275, P35786, DOI 10.1074/jbc.M005976200; Hogg N, 1999, ANAL BIOCHEM, V272, P257, DOI 10.1006/abio.1999.4199; HUANG A, 2001, AM J PHYSIOL, V21, pC719; Igarashi J, 2003, P NATL ACAD SCI USA, V100, P10664, DOI 10.1073/pnas.1934494100; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; JAFFREY SR, 2001, SCI STKE; Kim JE, 2004, J BIOL CHEM, V279, P9758, DOI 10.1074/jbc.M312722200; Kolodziejski PJ, 2003, P NATL ACAD SCI USA, V100, P14263, DOI 10.1073/pnas.2435290100; Kou RQ, 2002, J BIOL CHEM, V277, P29669, DOI 10.1074/jbc.M204519200; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; Martinez-Ruiz A, 2004, CARDIOVASC RES, V62, P43, DOI 10.1016/j.cardiores.2004.01.013; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; Prabhakar P, 2000, J BIOL CHEM, V275, P19416, DOI 10.1074/jbc.M001952200; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Ravi K, 2004, P NATL ACAD SCI USA, V101, P2619, DOI 10.1073/pnas.0300464101; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stuart-Smith K, 2002, J CLIN PATHOL-MOL PA, V55, P360, DOI 10.1136/mp.55.6.360; Takahashi S, 2003, J BIOL CHEM, V278, P30821, DOI 10.1074/jbc.M304471200; Ting HH, 1996, J CLIN INVEST, V97, P22, DOI 10.1172/JCI118394; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; Wink DA, 1996, METHOD ENZYMOL, V268, P12; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891	46	157	159	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19888	19894		10.1074/jbc.M413058200	http://dx.doi.org/10.1074/jbc.M413058200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774480	hybrid			2022-12-25	WOS:000229113700058
J	Kapur, S; Mohan, S; Baylink, DJ; Lau, KHW				Kapur, S; Mohan, S; Baylink, DJ; Lau, KHW			Fluid shear stress synergizes with insulin-like growth factor-I (IGF-I) on osteoblast proliferation through integrin-dependent activation of IGF-I mitogenic signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNLOADING INDUCES RESISTANCE; ALPHA-V-BETA-3 INTEGRIN; TYROSINE PHOSPHORYLATION; MECHANICAL STIMULATION; BONE-RESORPTION; MESSENGER-RNA; RECEPTOR; RESPONSES; EXPRESSION; TRANSDUCTION	This study tested the hypothesis that shear stress interacts with the insulin-like growth factor-I (IGF-I) pathway to stimulate osteoblast proliferation. Human TE85 osteosarcoma cells were subjected to a steady shear stress of 20 dynes/cm(2) for 30 min followed by 24-h incubation with IGF-I (0-50 ng/ml). IGF-I increased proliferation dose-dependently (1.5-2.5-fold). Shear stress alone increased proliferation by 70%. The combination of shear stress and IGF-I stimulated proliferation (3.5- to 5.5-fold) much greater than the additive effects of each treatment alone, indicating a synergistic interaction. IGF-I dose-dependently increased the phosphorylation level of Erk1/2 by 1.2-5.3-fold and that of IGF-I receptor (IGF-IR) by 2-4- fold. Shear stress alone increased Erk1/2 and IGF-IR phosphorylation by 2- fold each. The combination treatment also resulted in synergistic enhancements in both Erk1/2 and IGF-IR phosphorylation ( up to 12- and 8-fold, respectively). Shear stress altered IGF-IR binding only slightly, suggesting that the synergy occurred primarily at the post-ligand binding level. Recent studies have implicated a role for integrin in the regulation of IGF-IR phosphorylation and IGF-I signaling. To test whether the synergy involves integrin-dependent mechanisms, the effect of echistatin ( a disintegrin) on proliferation in response to shear stress +/- IGF-I was measured. Echistatin reduced basal proliferation by similar to 60% and the shear stress-induced mitogenic response by similar to 20%. It completely abolished the mitogenic effect of IGF-I and that of the combination treatment. Shear stress also significantly reduced the amounts of co-immunoprecipitated SHP-2 and -1 with IGF-IR, suggesting that the synergy between shear stress and IGF-I in osteoblast proliferation involves integrin-dependent recruitment of SHP-2 and - 1 away from IGF-IR.	Loma Linda Univ, Jerry L Pettis Mem Vet Affairs Med Ctr, Musculoskeletal Dis Ctr 151, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Med, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Biochem, Loma Linda, CA 92357 USA	Loma Linda University; Loma Linda University; Loma Linda University	Lau, KHW (corresponding author), Loma Linda Univ, Jerry L Pettis Mem Vet Affairs Med Ctr, Musculoskeletal Dis Ctr 151, 11201 Benton St, Loma Linda, CA 92357 USA.	William.Lau@med.va.gov		Lau, Kin-Hing/0000-0003-1109-5052				ALENGHAT FJ, 2002, SCI STKE; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CANALIS E, 1988, J CLIN INVEST, V81, P277, DOI 10.1172/JCI113318; Carter DR, 2004, CLIN ORTHOP RELAT R, pS69, DOI 10.1097/01.blo.0000144970.05107.7e; Carter DR, 1998, CLIN ORTHOP RELAT R, pS41; CARVALHO RS, 1995, ARCH ORAL BIOL, V40, P257, DOI 10.1016/0003-9969(95)98814-F; Cheng MZ, 2002, J BONE MINER RES, V17, P593, DOI 10.1359/jbmr.2002.17.4.593; Clemmons DR, 2005, MOL ENDOCRINOL, V19, P1, DOI 10.1210/me.2004-0376; CLOVER J, 1994, BONE, V15, P585, DOI 10.1016/8756-3282(94)90305-0; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Gronthos S, 1997, J BONE MINER RES, V12, P1189, DOI 10.1359/jbmr.1997.12.8.1189; HILLAM RA, 1995, J BONE MINER RES, V10, P683; HILLSLEY MV, 1994, BIOTECHNOL BIOENG, V43, P573, DOI 10.1002/bit.260430706; HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo-122-1-254; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; Kapur S, 2004, BONE, V35, P525, DOI 10.1016/j.bone.2004.04.007; Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756-3282(02)00979-1; Lau KHW, 2002, BONE, V30, P705, DOI 10.1016/S8756-3282(02)00671-3; LAU KHW, 1985, BIOCHIM BIOPHYS ACTA, V840, P56, DOI 10.1016/0304-4165(85)90162-X; LAU KHW, J BONE MINER RES S1, V19, pS79; LEAN JM, 1995, AM J PHYSIOL-ENDOC M, V268, pE318, DOI 10.1152/ajpendo.1995.268.2.E318; Lee HS, 2000, J BONE MINER RES, V15, P1501, DOI 10.1359/jbmr.2000.15.8.1501; Lin TH, 1997, J BIOL CHEM, V272, P8849; Ling Y, 2005, J BIOL CHEM, V280, P3151, DOI 10.1074/jbc.M411035200; Ling Y, 2003, MOL ENDOCRINOL, V17, P1824, DOI 10.1210/me.2003-0143; Maile LA, 2003, MOL BIOL CELL, V14, P3519, DOI 10.1091/mbc.E03-04-0239; Maile LA, 2002, J BIOL CHEM, V277, P8955, DOI 10.1074/jbc.M109258200; Maile LA, 2002, ENDOCRINOLOGY, V143, P4259, DOI 10.1210/en.2002-220395; Mauck RL, 2003, TISSUE ENG, V9, P597, DOI 10.1089/107632703768247304; MikuniTakagaki Y, 1996, ENDOCRINOLOGY, V137, P2028, DOI 10.1210/en.137.5.2028; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MOHAN S, 1991, CLIN ORTHOP RELAT R, V263, P30; Mosley JR, 2000, J REHABIL RES DEV, V37, P189; Sakata T, 2004, J BONE MINER RES, V19, P436, DOI 10.1359/JBMR.0301241; Sakata T, 2003, BONE, V32, P669, DOI 10.1016/S8756-3282(03)00088-7; Salter DM, 1997, J BONE MINER RES, V12, P1133, DOI 10.1359/jbmr.1997.12.7.1133; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Tokimasa C, 2000, ARCH ORAL BIOL, V45, P871, DOI 10.1016/S0003-9969(00)00057-1; WERGEDAL JE, 1990, J BONE MINER RES, V5, P179, DOI 10.1002/jbmr.5650050212; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	42	52	56	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20163	20170		10.1074/jbc.M501460200	http://dx.doi.org/10.1074/jbc.M501460200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778506	hybrid			2022-12-25	WOS:000229113700089
J	Stein, U; Bergmann, S; Scheffer, GL; Scheper, RJ; Royer, HD; Schlag, PM; Walther, W				Stein, U; Bergmann, S; Scheffer, GL; Scheper, RJ; Royer, HD; Schlag, PM; Walther, W			YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene	ONCOGENE			English	Article						YB-1; MVP; 5-fluorouracil; drug resistance	BOX-BINDING-PROTEIN; RESISTANCE-RELATED PROTEIN; CANCER-CELL-LINES; TRANSCRIPTION FACTOR YB-1; SHORT-TERM EXPOSURE; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; BREAST-CANCER; MDR1 GENE; COLORECTAL CARCINOMAS	Vaults have been suggested to play a direct role in multidrug resistance ( MDR) to anticancer drugs. The human major vault protein ( MVP) also known as lung resistance- related protein ( LRP) represents the predominant component of vaults that may be involved in the defense against xenobiotics. Here, we demonstrate that besides MDR- related cytostatics, also the non- MDR-related drug 5-fluorouracil ( 5- FU) was able to induce MVP mRNA and protein expression. Treatment with 5- FU amplified the binding activity and interaction of the transcription factor Y- box binding protein- 1 ( YB- 1) with the Y- box of the human MVP gene promoter in a time-dependent manner. 5- FU also induced reporter expressions driven by a panel of newly generated MVP promoter deletion mutants. Interestingly, stably YB- 1 overexpressing cell clones showed enhanced binding of YB- 1 to the Y- box motif, associated with enhanced basal as well as 5- FU- inducible MVP promoter- driven reporter expressions. Moreover, transduction of YB- 1 cDNA led to increased expression of endogenous MVP protein. Under physiological conditions, we observed a strong coexpression of MVP and YB- 1 in human colon carcinoma specimen. In summary, our data demonstrate a direct involvement of YB- 1 in controlling basal and 5- FU-induced MVP promoter activity. Therefore, YB- 1 is directly linked to MVP- mediated drug resistance.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Free Univ Amsterdam, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; Ctr Adv European Studies & Res, D-53175 Bonn, Germany; Humboldt Univ, Charite, Div Surg & Surg Oncol, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Vrije Universiteit Amsterdam; Center of Advanced European Studies & Research (CAESAR); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stein, U (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	ustein@mdc-berlin.de	Royer, Hans-dieter/AAH-6293-2019	Stein, Ulrike/0000-0001-7006-282X; Walther, Wolfgang/0000-0003-2360-1370				ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Berger W, 2000, INT J CANCER, V88, P293, DOI 10.1002/1097-0215(20001015)88:2<293::AID-IJC23>3.0.CO;2-S; Cheng SH, 2000, TOXICOL APPL PHARM, V164, P134, DOI 10.1006/taap.2000.8903; Comerford KM, 2002, CANCER RES, V62, P3387; Emre N, 2004, BBA-GENE STRUCT EXPR, V1678, P33, DOI 10.1016/j.bbaexp.2004.01.005; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; Hu Y, 2002, INT J CANCER, V97, P149, DOI 10.1002/ijc.1590; Ise T, 1999, CANCER RES, V59, P342; Izquierdo MA, 1996, AM J PATHOL, V148, P877; Izquierdo MA, 1996, INT J CANCER, V65, P230; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kickhoefer VA, 1998, J BIOL CHEM, V273, P8971, DOI 10.1074/jbc.273.15.8971; Kitazono M, 1999, JNCI-J NATL CANCER I, V91, P1647, DOI 10.1093/jnci/91.19.1647; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; Komarov PG, 1998, ONCOL RES, V10, P185; Kumar A, 2001, GENE, V270, P221, DOI 10.1016/S0378-1119(01)00473-5; Kuwano M, 2003, CANCER SCI, V94, P9, DOI 10.1111/j.1349-7006.2003.tb01344.x; Labialle S, 2002, BIOCHEM PHARMACOL, V64, P943, DOI 10.1016/S0006-2952(02)01156-5; Lange C, 2000, BIOCHEM BIOPH RES CO, V278, P125, DOI 10.1006/bbrc.2000.3782; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Laurencot CM, 1997, INT J CANCER, V72, P1021; Meijer GA, 1999, J CLIN PATHOL, V52, P450, DOI 10.1136/jcp.52.6.450; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Meschini S, 2002, TOXICOL IN VITRO, V16, P389, DOI 10.1016/S0887-2333(02)00035-8; Midgley R, 1999, LANCET, V353, P391, DOI 10.1016/S0140-6736(98)07127-X; Mossink MH, 2003, ONCOGENE, V22, P7458, DOI 10.1038/sj.onc.1206947; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Pohl G, 1999, ANTICANCER RES, V19, P5051; Pohl G, 2001, ANTICANCER RES, V21, P201; Scheffer GL, 2000, CURR OPIN ONCOL, V12, P550, DOI 10.1097/00001622-200011000-00007; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578; SCHEPER RJ, 1993, CANCER RES, V53, P1475; Schneider J, 2001, BREAST CANCER RES, V3, P183, DOI 10.1186/bcr293; Schroeijers AB, 2001, J HISTOCHEM CYTOCHEM, V49, P1379, DOI 10.1177/002215540104901106; Scotto KW, 2003, ONCOGENE, V22, P7496, DOI 10.1038/sj.onc.1206950; Shibao K, 1999, INT J CANCER, V83, P732; Stein U, 2002, J CLIN ONCOL, V20, P3282, DOI 10.1200/JCO.2002.01.003; Stein U, 1997, JNCI-J NATL CANCER I, V89, P807, DOI 10.1093/jnci/89.11.807; Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200; Steiner E, 2004, BIOCHEM BIOPH RES CO, V317, P235, DOI 10.1016/j.bbrc.2004.03.029; Tebbutt NC, 2002, EUR J CANCER, V38, P1000, DOI 10.1016/S0959-8049(02)00062-X; Wyler B, 1997, BRIT J HAEMATOL, V97, P65, DOI 10.1046/j.1365-2141.1997.52649.x; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357; ZIJLSTRA JG, 1987, CANCER RES, V47, P1780	51	45	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 19	2005	24	22					3606	3618		10.1038/sj.onc.1208386	http://dx.doi.org/10.1038/sj.onc.1208386			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15750632				2022-12-25	WOS:000229221800008
J	Arima, Y; Nitta, M; Kuninaka, S; Zhang, DW; Fujiwara, T; Taya, Y; Nakao, M; Saya, H				Arima, Y; Nitta, M; Kuninaka, S; Zhang, DW; Fujiwara, T; Taya, Y; Nakao, M; Saya, H			Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CELL-CYCLE ARREST; DNA-DAMAGE; RECOMBINANT ADENOVIRUS; MAMMALIAN-CELLS; CDK INHIBITORS; ALPHA-AMANITIN; LARGE SUBUNIT; CANCER CELLS; IN-VIVO	The tumor suppressor p53 functions as a transcriptional activator to induce cell cycle arrest and apoptosis in response to DNA damage. Although p53 was also shown to mediate apoptosis in a manner independent of its transactivation activity, the mechanism and conditions that trigger such cell death have remained largely unknown. We have now shown that inhibition of RNA polymerase II-mediated transcription by alpha-amanitin or RNA interference induced p53-dependent apoptosis. Inhibition of pol II-mediated transcription resulted in down-regulation of p21(Cip1), which was caused by both transcriptional suppression and protein degradation, despite eliciting p53 accumulation, allowing the cells to progress into S phase and then to undergo apoptosis. This cell death did not require the transcription of p53 target genes and was preceded by translocation of the accumulated p53 to mitochondria. Our data thus suggested that blockade of pol II-mediated transcription induced p53 accumulation in mitochondria and was the critical factor for eliciting p53-dependent but transcription-independent apoptosis.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Surg, Div Surg Oncol, Okayama 7008558, Japan; Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, Tokyo 1040045, Japan; Kumamoto Univ, Inst Mol Embryol & Genet, Dept Regenerat Med, Kumamoto 8600811, Japan	Kumamoto University; Okayama University; National Cancer Center - Japan; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013; Kuninaka, Shinji/J-7158-2013; Arima, Yoshimi/J-8057-2013	Arima, Yoshimi/0000-0002-2384-1406				Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; Arima Y, 2004, GENES CELLS, V9, P131, DOI 10.1111/j.1356-9597.2004.00710.x; Attardi LD, 2000, GENE DEV, V14, P704; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Blagosklonny MV, 2002, CELL CYCLE, V1, P67, DOI 10.4161/cc.1.1.102; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bushnell DA, 2002, P NATL ACAD SCI USA, V99, P1218, DOI 10.1073/pnas.251664698; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gottifredi V, 2000, COLD SPRING HARB SYM, V65, P483, DOI 10.1101/sqb.2000.65.483; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khan QA, 2002, MOL CARCINOGEN, V33, P1, DOI 10.1002/mc.10013; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Luo ZH, 2001, MUTAT RES-DNA REPAIR, V486, P259, DOI 10.1016/S0921-8777(01)00097-0; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Wang G, 2000, EXP CELL RES, V254, P64, DOI 10.1006/excr.1999.4743; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	56	129	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19166	19176		10.1074/jbc.M410691200	http://dx.doi.org/10.1074/jbc.M410691200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753095	hybrid			2022-12-25	WOS:000228932300073
J	Prakash, A; Smith, E; Lee, CK; Levy, DE				Prakash, A; Smith, E; Lee, CK; Levy, DE			Tissue-specific positive feedback requirements for production of type I interferon following virus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; PLASMACYTOID DENDRITIC CELLS; TOLL-LIKE RECEPTORS; DIFFERENTIAL REGULATION; TARGETED DISRUPTION; REGULATORY FACTOR-7; ALPHA PRODUCTION; ACTIVATION; INNATE; EXPRESSION	Type I interferon (IFN) is synthesized by most nucleated cells following viral infection. Robust IFN production in cell culture requires positive feedback expression of inducible signaling components, such as the transcription factor IRF7. However, the role of positive feedback and IRF7 in vivo may be more complex. We found that IFN produced locally in the respiratory tract of influenza virus-infected mice displayed characteristics of positive feedback, including Stat1-dependent induction of IRF7 and IFN gene expression. IRF7 expression was similarly stimulus-dependent in most tissues. However, lymphoid tissue constitutively expressed high levels of IRF7 in the absence of induction or positive feedback, and this expression was largely confined to plasmacytoid dendritic cells ( DC). These cells rapidly produced large quantities of multiple IFN alpha species following viral infection without positive feedback, whereas other hematopoietic cells, including other DC subtypes, expressed little IRF7 and were poor IFN producers in the absence of positive feedback. These data reveal a dual mechanism for the regulation of IFN production by differential expression of IRF7, involving positive feedback at local sites of infection combined with robust systemic production by IRF7-expressing plasmacytoid DC.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University; New York University	Levy, DE (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.	del243@med.nyu.edu	Lee, Chien-Kuo/AAZ-1039-2020; Levy, David/AAG-6202-2019; Levy, David/GPS-4945-2022	Lee, Chien-Kuo/0000-0001-8189-6045; Levy, David/0000-0002-7320-7788; 	NIAID NIH HHS [R01 AI028900, R01 AI046503] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046503, R01AI028900] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Barchet W, 2002, J EXP MED, V195, P507, DOI 10.1084/jem.20011666; Barton GM, 2002, CURR TOP MICROBIOL, V270, P81; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Boonstra A, 2003, J EXP MED, V197, P101, DOI 10.1084/jem.20021908; Dai JH, 2004, J IMMUNOL, V173, P1535, DOI 10.4049/jimmunol.173.3.1535; Dalod M, 2003, J EXP MED, V197, P885, DOI 10.1084/jem.20021522; Dalod M, 2002, J EXP MED, V195, P517, DOI 10.1084/jem.20011672; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Durbin JE, 2000, J IMMUNOL, V164, P4220, DOI 10.4049/jimmunol.164.8.4220; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Garcia-Sastre A, 1998, J VIROL, V72, P8550; Gilliet M, 2002, J EXP MED, V195, P953, DOI 10.1084/jem.20020045; Hata N, 2001, BIOCHEM BIOPH RES CO, V285, P518, DOI 10.1006/bbrc.2001.5159; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Izaguirre A, 2003, J LEUKOCYTE BIOL, V74, P1125, DOI 10.1189/jlb.0603255; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Kerkmann M, 2003, J IMMUNOL, V170, P4465, DOI 10.4049/jimmunol.170.9.4465; Lee CK, 1999, J EXP MED, V190, P1451, DOI 10.1084/jem.190.10.1451; LeibundGut-Landmann S, 2004, NAT IMMUNOL, V5, P899, DOI 10.1038/ni1109; Levy DE, 2004, NAT IMMUNOL, V5, P699, DOI 10.1038/ni0704-699; Levy DE, 2003, CURR OPIN IMMUNOL, V15, P52, DOI 10.1016/S0952-7915(02)00011-0; Levy DE, 2002, J EXP MED, V195, pF15, DOI 10.1084/jem.20020075; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TOVEY MG, 1988, J IMMUNOL, V141, P3106; Tsujimura H, 2003, J IMMUNOL, V170, P1131, DOI 10.4049/jimmunol.170.3.1131; Tsujimura H, 2003, BLOOD, V101, P961, DOI 10.1182/blood-2002-05-1327; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	40	95	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18651	18657		10.1074/jbc.M501289200	http://dx.doi.org/10.1074/jbc.M501289200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15767254	Green Published, Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000228932300015
J	Espeseth, AS; Xu, M; Huang, Q; Coburn, CA; Jones, KLG; Ferrer, M; Zuck, PD; Strulovic, B; Price, EA; Wu, GX; Wolfe, AL; Lineberger, JE; Sardana, M; Tugusheva, K; Pietrak, BL; Crouthamel, MC; Lai, MT; Dodson, EC; Bazzo, R; Shi, XP; Simon, AJ; Li, YM; Hazuda, DJ				Espeseth, AS; Xu, M; Huang, Q; Coburn, CA; Jones, KLG; Ferrer, M; Zuck, PD; Strulovic, B; Price, EA; Wu, GX; Wolfe, AL; Lineberger, JE; Sardana, M; Tugusheva, K; Pietrak, BL; Crouthamel, MC; Lai, MT; Dodson, EC; Bazzo, R; Shi, XP; Simon, AJ; Li, YM; Hazuda, DJ			Compounds that bind APP and inhibit A beta processing in vitro suggest a novel approach to Alzheimer disease therapeutics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE INHIBITORS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; AMYLOID PRECURSOR PROTEIN; STRUCTURE-BASED DESIGN; BACE INHIBITORS; CELL-SURFACE; PEPTIDOMIMETIC INHIBITORS; NOTCH; SITE; PEPTIDE	Extracellular deposits of aggregated amyloid-beta (A beta) peptides are a hallmark of Alzheimer disease; thus, inhibition of A beta production and/or aggregation is an appealing strategy to thwart the onset and progression of this disease. The release of A beta requires processing of the amyloid precursor protein (APP) by both beta- and gamma-secretase. Using an assay that incorporates full-length recombinant APP as a substrate for beta-secretase ( BACE), we have identified a series of compounds that inhibit APP processing, but do not affect the cleavage of peptide substrates by BACE1. These molecules also inhibit the processing of APP and A beta by BACE2 and selectively inhibit the production of A beta(42) species by gamma-secretase in assays using CTF99. The compounds bind directly to APP, likely within the A beta domain, and therefore, unlike previously described inhibitors of the secretase enzymes, their mechanism of action is mediated through APP. These studies demonstrate that APP binding agents can affect its processing through multiple pathways, providing proof of concept for novel strategies aimed at selectively modulating A beta production.	Merck Res Labs, Virus & Cell Biol, Dept Biol Chem, West Point, PA 19486 USA; Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA; Merck Res Labs, Dept Automated Biotechnol, West Point, PA 19486 USA; Inst Ric Biol Mol, Dept Pharmacol, I-00040 Rome, Italy	Merck & Company; Merck & Company; Merck & Company	Hazuda, DJ (corresponding author), Merck Res Labs, Virus & Cell Biol, Dept Biol Chem, POB 4, West Point, PA 19486 USA.	daria_hazuda@merck.com						Agdeppa ED, 2003, NEUROSCIENCE, V117, P723, DOI 10.1016/S0306-4522(02)00907-7; Beher D, 2004, J BIOL CHEM, V279, P43419, DOI 10.1074/jbc.M404937200; Brady SF, 2004, BIOORG MED CHEM LETT, V14, P601, DOI 10.1016/j.bmcl.2003.11.061; Chen SH, 2004, BIOORG MED CHEM LETT, V14, P245, DOI 10.1016/j.bmcl.2003.09.085; Churcher I, 2003, J MED CHEM, V46, P2275, DOI 10.1021/jm034058a; Chyung JH, 2005, J BIOL CHEM, V280, P4383, DOI 10.1074/jbc.M409272200; Chyung JH, 2003, J BIOL CHEM, V278, P51035, DOI 10.1074/jbc.M304989200; Coburn CA, 2004, J MED CHEM, V47, P6117, DOI 10.1021/jm049388p; DE SB, 1999, NATURE, V398, P518; Dingwall C, 2001, J CLIN INVEST, V108, P1243, DOI 10.1172/JCI200114402; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Findeis MA, 2000, BBA-MOL BASIS DIS, V1502, P76, DOI 10.1016/S0925-4439(00)00034-X; Findeis Mark A., 2002, Current Topics in Medicinal Chemistry, V2, P417, DOI 10.2174/1568026024607508; Ghosh AK, 2001, J MED CHEM, V44, P2865, DOI 10.1021/jm0101803; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Hebert LE, 2001, ALZ DIS ASSOC DIS, V15, P169, DOI 10.1097/00002093-200110000-00002; Hom RK, 2004, J MED CHEM, V47, P158, DOI 10.1021/jm0304008; Hom RK, 2003, J MED CHEM, V46, P1799, DOI 10.1021/jm025619l; Howlett DR, 1999, BIOCHEM J, V340, P283, DOI 10.1042/0264-6021:3400283; Hu JD, 2003, BIOORG MED CHEM LETT, V13, P4335, DOI 10.1016/j.bmcl.2003.09.037; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Kinoshita A, 2003, J CELL SCI, V116, P3339, DOI 10.1242/jcs.00643; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lamar J, 2004, BIOORG MED CHEM LETT, V14, P239, DOI 10.1016/j.bmcl.2003.09.084; Lewis HD, 2003, BIOCHEMISTRY-US, V42, P7580, DOI 10.1021/bi034310g; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Ono M, 2002, NUCL MED BIOL, V29, P633, DOI 10.1016/S0969-8051(02)00326-8; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Searfoss GH, 2003, J BIOL CHEM, V278, P46107, DOI 10.1074/jbc.M307757200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Shi XP, 2003, J BIOL CHEM, V278, P21286, DOI 10.1074/jbc.M209859200; Shi XP, 2002, NEUROBIOL AGING, V23, pS180; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; SHI XP, 2005, JAD, V7, P2; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Stachel SJ, 2004, J MED CHEM, V47, P6447, DOI 10.1021/jm049379g; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Tarassishin L, 2004, P NATL ACAD SCI USA, V101, P17050, DOI 10.1073/pnas.0408007101; Tung JS, 2002, J MED CHEM, V45, P259, DOI 10.1021/jm0155695; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weggen S, 2003, J BIOL CHEM, V278, P31831, DOI 10.1074/jbc.M303592200; Wolfe MS, 2002, NAT REV DRUG DISCOV, V1, P859, DOI 10.1038/nrd938; Xu M, 2002, NEUROBIOL AGING, V23, P1023, DOI 10.1016/S0197-4580(02)00126-4; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154	53	26	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17792	17797		10.1074/jbc.M414331200	http://dx.doi.org/10.1074/jbc.M414331200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15737955	hybrid			2022-12-25	WOS:000228807200030
J	Fukushima, K; Ikehara, Y; Yamashita, K				Fukushima, K; Ikehara, Y; Yamashita, K			Functional role played by the glycosylphosphatidylinositol anchor glycan of CD48 in interleukin-18-induced interferon-gamma production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-A GENE; CARBOHYDRATE MOIETY; OLIGOSACCHARIDES; IDENTIFICATION; CYTOKINE; LECTIN; ALPHA	Interleukin (IL)-18 induces T cells and natural killer cells to produce not only interferon-gamma but also other cytokines by binding to the IL-18 receptor (IL-18R) alpha and beta subunits. However, little is known about how IL-18, IL-18R alpha, and IL-18R beta form a high-affinity complex on the cell surface and transduce the signal. We found that IL-18 and IL-18R alpha bind to glycosylphosphatidylinositol (GPI) glycan via the third mannose 6-phosphate diester and the second beta-GlcNAc-deleted mannose 6-phosphate of GPI glycan, respectively. To determine which GPI-anchored glycoprotein is involved in the complex of IL-18 and IL-18R alpha, IL-18R alpha of IL-18-stimulated KG-1 cells was immunoprecipitated together with CD48 by anti-IL-18R alpha antibody. More than 90% of CD48 was detected as beta-GlcNAc-deleted GPI-anchored glycoprotein, and soluble recombinant human CD48 without GPI glycan bound to IL-18R alpha,indicating that CD48 is associated with IL-18R alpha via both the peptide portion and the GPI glycan. To investigate whether the carbohydrate recognition of IL-18 is involved in physiological activities, KG-1 cells were digested with phosphatidylinositol- specific phospholipase C before IL-18 stimulation. Phosphatidylinositol-specific phospholipase C treatment inhibited the phosphorylation of tyrosine kinases and the following IL-18-dependent interferon-gamma production. These observations suggest that the complex formation of IL-18 alpha IL-18R alpha center dot CD48 via both the peptide portion and GPI glycan triggers the binding to IL-18R beta, and the IL-18 center dot IL-18R alpha center dot CD48 center dot IL-18R beta complex induces cellular signaling.	Sasaki Inst, Dept Biochem, Chiyoda Ku, Tokyo 1010062, Japan; Fukuoka Univ, Sch Med, Dept Cell Biol, Jonan Ku, Fukuoka 8140133, Japan	Fukuoka University	Yamashita, K (corresponding author), Sasaki Inst, Dept Biochem, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.	yamashita@sasaki.or.jp						BAENZIGER JU, 1979, J BIOL CHEM, V254, P789; Born TL, 2000, J BIOL CHEM, V275, P41529; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; ENDO T, 1988, J BIOCHEM-TOKYO, V103, P182, DOI 10.1093/oxfordjournals.jbchem.a122228; Fontes W, 1997, ARCH BIOCHEM BIOPHYS, V347, P201, DOI 10.1006/abbi.1997.0358; Fukushima K, 2004, ARCH BIOCHEM BIOPHYS, V426, P298, DOI 10.1016/j.abb.2004.02.028; Fukushima K, 2003, J BIOL CHEM, V278, P36296, DOI 10.1074/jbc.M304341200; Fukushima K, 1997, J BIOL CHEM, V272, P10579; GARNETT D, 1993, EUR J IMMUNOL, V23, P2540, DOI 10.1002/eji.1830231024; Gordon VM, 1999, J BIOL CHEM, V274, P27274, DOI 10.1074/jbc.274.38.27274; HEFTA SA, 1988, P NATL ACAD SCI USA, V85, P4648, DOI 10.1073/pnas.85.13.4648; ITO S, 1977, J BIOCHEM, V81, P1621, DOI 10.1093/oxfordjournals.jbchem.a131621; Kato Z, 2003, NAT STRUCT BIOL, V10, P966, DOI 10.1038/nsb993; KOCHIBE N, 1989, J BIOL CHEM, V264, P173; Kumar S, 2000, J BIOL CHEM, V275, P10308, DOI 10.1074/jbc.275.14.10308; LIANG CJ, 1980, J BIOCHEM-TOKYO, V88, P51; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; Nelson KL, 2000, J BIOL CHEM, V275, P19839, DOI 10.1074/jbc.M002785200; OGATA S, 1988, J BIOL CHEM, V263, P10489; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; RINDLER MJ, 1990, J BIOL CHEM, V265, P20784; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; SPIK G, 1975, FEBS LETT, V50, P296, DOI 10.1016/0014-5793(75)90053-8; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAI T, 1975, J BIOL CHEM, V250, P8569; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TAMM I, 1952, J EXP MED, V95, P71, DOI 10.1084/jem.95.1.71; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; TsujiTakayama K, 1997, BIOCHEM BIOPH RES CO, V237, P126, DOI 10.1006/bbrc.1997.7099; YAMASHITA K, 1981, J BIOL CHEM, V256, P4789	31	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18056	18062		10.1074/jbc.M413297200	http://dx.doi.org/10.1074/jbc.M413297200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15760905	hybrid			2022-12-25	WOS:000228807200062
J	Subramanian, P; Stahelin, RV; Szulc, Z; Bielawska, A; Cho, W; Chalfant, CE				Subramanian, P; Stahelin, RV; Szulc, Z; Bielawska, A; Cho, W; Chalfant, CE			Ceramide 1-phosphate acts as a positive allosteric activator of group IVA cytosolic phospholipase A(2)alpha and enhances the interaction of the enzyme with phosphatidylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; PROTEIN-KINASE-C; ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; MIXED MICELLES; KINETIC-ANALYSIS; LOXOSCELES-RECLUSA; CATALYTIC DOMAIN; MEMBRANE-BINDING; CELL-LINE; A(2)	Previous findings from our laboratory have demonstrated that cPLA(2)alpha is directly activated by the emerging bioactive sphingolipid, ceramide 1-phosphate (C-1-P) (1). In this study, a Triton X-100/phosphatidylcholine (PC) mixed micelle assay was utilized to determine the kinetics and specificity of this lipid-enzyme interaction. Using this assay, the addition of C-1-P induced a dramatic increase in the activity of cPLA(2)alpha (>15-fold) with a K-a of 2.4 mol % C-1-P/Triton X-100 micelle. This activation was highly specific as the addition of other lipids had insignificant effects on cPLA(2)alpha activity. Studies using surface-dilution kinetics revealed that C-1-P had no effect on the Michaelis-Menten constant, K-m(B), but decreased the dissociation constant (K-s(A)) value by 87%. Thus, C-1-P not only increases the membrane affinity of cPLA(2)alpha but also may act as an allosteric activator of the enzyme. Surface plasmon resonance analysis of the C-1-P/cPLA(2)alpha interaction verified a decrease in the dissociation constant, demonstrating that cPLA(2)alpha bound PC vesicles containing C-1-P with increased affinity (5-fold) compared with PC vesicles alone. The effect on the dissociation rate of cPLA(2)alpha was also found to be lipid-specific with the exception of phosphatidylinositol 4,5-bisphosphate, which caused a modest increase in vesicle affinity (2-fold). Lastly, the binding site for C-1-P was determined to be within the C2-domain of cPLA(2)alpha, unlike phosphatidylinositol 4,5-bisphosphate. These data demonstrate a novel interaction site for C-1-P and suggest that C-1-P may function to recruit cPLA(2)alpha to intracellular membranes as well as allosterically activate the membrane-associated enzyme.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA 23249 USA	Virginia Commonwealth University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Medical University of South Carolina; Hunter Holmes McGuire Veterinary Affairs Medical Center	Chalfant, CE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus,Rm 2-016,Sanger Hall,110, Richmond, VA 23298 USA.	cechalfant@vcu.edu	Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863; , Preeti/0000-0002-6062-6158	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598, R01GM068849, R01GM053987] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL072925] Funding Source: Medline; NIGMS NIH HHS [GM53987, GM68849, GM52598] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold R E, 1976, JACEP, V5, P262, DOI 10.1016/S0361-1124(76)80005-6; Balsinde J, 2000, J IMMUNOL, V164, P5398, DOI 10.4049/jimmunol.164.10.5398; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; BRUZIK KS, 1995, TETRAHEDRON LETT, V36, P2415, DOI 10.1016/0040-4039(95)00317-6; BYUN HS, 1994, J ORG CHEM, V59, P6495, DOI 10.1021/jo00100a069; CARBONARO PA, 1995, CUTIS, V56, P256; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Carre A, 2004, BIOCHEM BIOPH RES CO, V324, P1215, DOI 10.1016/j.bbrc.2004.09.181; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Das S, 2003, J BIOL CHEM, V278, P41431, DOI 10.1074/jbc.M304897200; Das S, 2002, J BIOL CHEM, V277, P23838, DOI 10.1074/jbc.M202322200; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5740; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; KURPIEWSKI G, 1981, BIOCHIM BIOPHYS ACTA, V678, P467, DOI 10.1016/0304-4165(81)90128-8; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Pettus BJ, 2003, J BIOL CHEM, V278, P38206, DOI 10.1074/jbc.M304816200; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; REES RS, 1988, TOXICON, V26, P1035, DOI 10.1016/0041-0101(88)90202-4; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; ROBSON RJ, 1979, BIOCHIM BIOPHYS ACTA, V573, P489, DOI 10.1016/0005-2760(79)90223-6; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; TAY A, 1995, GENOMICS, V26, P138, DOI 10.1016/0888-7543(95)80093-2; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079	43	98	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17601	17607		10.1074/jbc.M414173200	http://dx.doi.org/10.1074/jbc.M414173200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15743759	hybrid			2022-12-25	WOS:000228807200006
J	Zhao, K; Liu, MZ; Burgess, RR				Zhao, K; Liu, MZ; Burgess, RR			The global transcriptional response of Escherichia coli to induced sigma(32) protein involves sigma(32) regulon activation followed by inactivation and degradation of sigma(32) in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK RESPONSE; ATP-DEPENDENT PROTEASE; RNA-POLYMERASE; BACILLUS-SUBTILIS; GENE-EXPRESSION; GROWTH-CONDITIONS; DNAK; K-12; GENOME; PURIFICATION	sigma(32) is the first alternative sigma factor discovered in Escherichia coli and can direct transcription of many genes in response to heat shock stress. To define the physiological role of sigma(32), we have used transcription profiling experiments to identify, on a genome-wide basis, genes under the control of sigma(32) in E. coli by moderate induction of a plasmid-borne rpoH gene under defined, steady-state growth conditions. Together with a bioinformatics approach, we successfully confirmed genes known previously to be directly under the control of sigma(32) and also assigned many additional genes to the sigma(32) regulon. In addition, to understand better the functional relevance of the increased amount of sigma(32) to changes in the transcriptional level of sigma(32)-dependent genes, we measured the protein level of sigma(32) both before and after induction by a newly developed quantitative Western blot method. At a normal constant growth temperature (37 degrees C), we found that the sigma(32) protein level rapidly increased, plateaued, and then gradually decreased after induction, indicating sigma(32) can be regulated by genes in its regulon and that the mechanisms of sigma(32) synthesis, inactivation, and degradation are not strictly temperature-dependent. The decrease in the transcriptional level of sigma(32)-dependent genes occurs earlier than the decrease in full-length sigma(32) in the wild type strain, and the decrease in the transcriptional level of sigma(32)-dependent genes is greatly diminished in a Delta DnaK strain, suggesting that DnaK can act as an anti-sigma factor to functionally inactivate sigma(3)2 and thus reduce sigma(32)-dependent transcription in vivo.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Comp Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Burgess, RR (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	rburgess@wisc.edu		Burgess, Richard/0000-0001-9545-3165	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028575] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28575] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthony LC, 2003, METHOD ENZYMOL, V370, P181; Baichoo N, 2002, MOL MICROBIOL, V45, P1613, DOI 10.1046/j.1365-2958.2002.03113.x; Bailey TL, 1998, J COMPUT BIOL, V5, P211, DOI 10.1089/cmb.1998.5.211; Bergendahl V, 2003, METHOD ENZYMOL, V370, P192; Bergendahl V, 2003, J IMMUNOL METHODS, V277, P117, DOI 10.1016/S0022-1759(03)00183-2; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bockhorst J, 2003, BIOINFORMATICS, V19, pi34, DOI 10.1093/bioinformatics/btg1003; Britton RA, 2002, J BACTERIOL, V184, P4881, DOI 10.1128/JB.184.17.4881-4890.2002; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; BURGESS RR, 1970, FED PROC, V29, P1164; Cao M, 2002, J MOL BIOL, V316, P443, DOI 10.1006/jmbi.2001.5372; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHUANG SE, 1993, J BACTERIOL, V175, P2026, DOI 10.1128/JB.175.7.2026-2036.1993; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; ERICKSON JW, 1989, GENE DEV, V3, P1462, DOI 10.1101/gad.3.9.1462; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; Gomez JE, 1997, TUBERCLE LUNG DIS, V78, P175, DOI 10.1016/S0962-8479(97)90024-1; Goryshin IY, 1998, J BIOL CHEM, V273, P7367, DOI 10.1074/jbc.273.13.7367; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; GROSS CA, 1996, CELLULAR MOL BIOL, P1399; HALDENWANG WG, 1995, MICROBIOL REV, V59, P1; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Helmann JD, 2001, J BACTERIOL, V183, P7318, DOI 10.1128/JB.183.24.7318-7328.2001; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Ishihama A, 2000, ANNU REV MICROBIOL, V54, P499, DOI 10.1146/annurev.micro.54.1.499; Jishage M, 1996, J BACTERIOL, V178, P5447, DOI 10.1128/jb.178.18.5447-5451.1996; Kang YS, 2004, J BACTERIOL, V186, P4921, DOI 10.1128/JB.186.15.4921-4930.2004; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; Kuczynska-Wisnik D, 2001, BIOCHEM BIOPH RES CO, V284, P57, DOI 10.1006/bbrc.2001.4926; LEMAUX PG, 1978, CELL, V13, P427, DOI 10.1016/0092-8674(78)90317-3; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; Liu X, 2001, Pac Symp Biocomput, P127; Liu XY, 1996, MOL MICROBIOL, V21, P613, DOI 10.1111/j.1365-2958.1996.tb02569.x; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; McCarty JS, 1996, J MOL BIOL, V256, P829, DOI 10.1006/jmbi.1996.0129; Molle V, 2003, MOL MICROBIOL, V50, P1683, DOI 10.1046/j.1365-2958.2003.03818.x; Muffler A, 1997, J BACTERIOL, V179, P445; NAGAI H, 1994, P NATL ACAD SCI USA, V91, P10280, DOI 10.1073/pnas.91.22.10280; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Richmond CS, 1999, NUCLEIC ACIDS RES, V27, P3821, DOI 10.1093/nar/27.19.3821; Salgado H, 2004, NUCLEIC ACIDS RES, V32, pD303, DOI 10.1093/nar/gkh140; SAUER U, 1995, FEMS MICROBIOL REV, V17, P331, DOI 10.1111/j.1574-6976.1995.tb00216.x; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Stintzi A, 2003, J BACTERIOL, V185, P2009, DOI 10.1128/JB.185.6.2009-2016.2003; STRAUS DB, 1987, NATURE, V329, P348, DOI 10.1038/329348a0; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; STRAUS DB, 1989, GENE DEV, V3, P2003, DOI 10.1101/gad.3.12a.2003; Tatsuta T, 1998, MOL MICROBIOL, V30, P583, DOI 10.1046/j.1365-2958.1998.01091.x; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; WANG QP, 1989, J BACTERIOL, V171, P4248, DOI 10.1128/JB.171.8.4248-4253.1989; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Wosten MMSM, 1998, FEMS MICROBIOL REV, V22, P127, DOI 10.1016/S0168-6445(98)00011-4; YURA MKT, 2000, HEAT SHOCK RESPONSE, P3; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	65	108	115	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17758	17768		10.1074/jbc.M500393200	http://dx.doi.org/10.1074/jbc.M500393200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15757896	hybrid			2022-12-25	WOS:000228807200026
J	Cipriani, G; Rapizzi, E; Vannacci, A; Rizzuto, R; Moroni, F; Chiarugi, A				Cipriani, G; Rapizzi, E; Vannacci, A; Rizzuto, R; Moroni, F; Chiarugi, A			Nuclear poly(ADP-ribose) polymerase-1 rapidly triggers mitochondrial dysfunction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING FACTOR; NECROTIC CELL-DEATH; DNA-DAMAGE; IN-VITRO; PERMEABILITY TRANSITION; CEREBRAL-ISCHEMIA; NAD(+) DEPLETION; ADP-RIBOSE; INHIBITORS; PARP	To obtain further information on time course and mechanisms of cell death after poly(ADP-ribose) polymerase-1 (PARP-1) hyperactivation, we used HeLa cells exposed for 1 h to the DNA alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine. This treatment activated PARP-1 and caused a rapid drop of cellular NAD(H) and ATP contents, culminating 8-12 h later in cell death. PARP-1 antagonists fully prevented nucleotide depletion and death. Interestingly, in the early 60 min after challenge with N-methyl-N'-nitro-N-nitrosoguanidine, mitochondrial membrane potential and superoxide production significantly increased, whereas cellular ADP contents decreased. Again, these events were prevented by PARP-1 inhibitors, suggesting that PARP-1 hyperactivity leads to mitochondrial state 4 respiration. Mitochondrial membrane potential collapsed at later time points ( 3 h), when mitochondria released apoptosis-inducing factor and cytochrome c. Using immunocytochemistry and targeted luciferase transfection, we found that, despite an exclusive localization of PARP-1 and poly(ADP-ribose) in the nucleus, ATP levels first decreased in mitochondria and then in the cytoplasm of cells undergoing PARP-1 activation. PARP-1 inhibitors rescued ATP ( but not NAD( H) levels) in cells undergoing hyper-poly(ADP-ribosyl)ation. Glycolysis played a central role in the energy recovery, whereas mitochondria consumed ATP in the early recovery phase and produced ATP in the late phase after PARP-1 inhibition, further indicating that nuclear poly(ADP-ribosyl) ation rapidly modulates mitochondrial functioning. Together, our data provide evidence for rapid nucleus-mitochondria cross-talk during hyper-poly(ADP-ribosyl)ation-dependent cell death.	Univ Florence, Dept Pharmacol, I-50139 Florence, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy	University of Florence; University of Ferrara	Chiarugi, A (corresponding author), Univ Florence, Dept Pharmacol, Viale Pieraccini 6, I-50139 Florence, Italy.	alberto.chiarugi@unifi.it	Rizzuto, Rosario/B-6312-2008; Vannacci, Alfredo/A-1708-2008	Vannacci, Alfredo/0000-0001-5259-2026; Rizzuto, Rosario/0000-0001-7044-5097				Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; BANASIK M, 1992, J BIOL CHEM, V267, P1569; Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BURKLE A, 1993, CARCINOGENESIS, V14, P559, DOI 10.1093/carcin/14.4.559; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; Chance B, 2004, METHOD ENZYMOL, V385, P361; Chen M, 2004, CARDIOVASC RES, V63, P682, DOI 10.1016/j.cardiores.2004.04.018; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Chiarugi A, 2003, J PHARMACOL EXP THER, V305, P943, DOI 10.1124/jpet.103.048934; Chiarugi A, 2002, SCIENCE, V297, P200, DOI 10.1126/science.1074592; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Desnoyers S, 1996, EXP CELL RES, V227, P146, DOI 10.1006/excr.1996.0259; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Donzelli M, 1997, HISTOCHEM J, V29, P831, DOI 10.1023/A:1026485622824; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Dumitriu IE, 2004, CELL DEATH DIFFER, V11, P314, DOI 10.1038/sj.cdd.4401348; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; FAKAN S, 1988, EXP CELL RES, V179, P517, DOI 10.1016/0014-4827(88)90289-3; GAAL JC, 1987, TRENDS BIOCHEM SCI, V12, P129, DOI 10.1016/0968-0004(87)90061-2; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; HERCEG Z, 2001, BIOCHEM J, V477, P97; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; KAUFMANN SH, 1991, EXP CELL RES, V192, P524, DOI 10.1016/0014-4827(91)90072-3; Kawamoto Y, 1998, ANAL BIOCHEM, V262, P33, DOI 10.1006/abio.1998.2729; Kennedy HJ, 1999, BIOCHEM J, V342, P275, DOI 10.1042/0264-6021:3420275; Magni G, 2004, CELL MOL LIFE SCI, V61, P19, DOI 10.1007/s00018-003-3161-1; Moroni F, 2001, CELL DEATH DIFFER, V8, P921, DOI 10.1038/sj.cdd.4400884; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nicholls D., 2002, BIOENERGETICS, V3; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; O'Reilly CM, 2004, AM J PHYSIOL-CELL PH, V286, pC1139, DOI 10.1152/ajpcell.00371.2003; Perl A, 2004, TRENDS IMMUNOL, V25, P360, DOI 10.1016/j.it.2004.05.001; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Scovassi AI, 2004, FASEB J, V18, P1487, DOI 10.1096/fj.04-1841rev; Scovassi AI, 1999, MOL CELL BIOCHEM, V199, P125; Scovassi AI, 1998, EUR J HISTOCHEM, V42, P251; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Southan GJ, 2003, CURR MED CHEM, V10, P321, DOI 10.2174/0929867033368376; Virag L, 1998, J IMMUNOL, V161, P3753; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Vrablic AS, 2001, FASEB J, V15, P1739, DOI 10.1096/fj.00-0300com; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	52	129	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17227	17234		10.1074/jbc.M414526200	http://dx.doi.org/10.1074/jbc.M414526200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15750180	hybrid			2022-12-25	WOS:000228615500085
J	Qiao, B; Padilla, SR; Benya, PD				Qiao, B; Padilla, SR; Benya, PD			Transforming growth factor (TGF)-beta-activated kinase 1 mimics and mediates TGF-beta-induced stimulation of type II collagen synthesis in chondrocytes independent of Col2a1 transcription and Smad3 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; N-TERMINAL KINASE; KAPPA-B PATHWAY; ARTICULAR CHONDROCYTES; GENE-EXPRESSION; IN-VITRO; HYPERTROPHIC DIFFERENTIATION; REGULATORY SEQUENCES; TRANSDUCTION PATHWAY; CARTILAGE FORMATION	Transforming growth factor (TGF)-beta, bone morphogenetic protein (BMP), and interleukin-1 beta activate TGF-beta-activated kinase 1 (TAK1), which lies upstream of the p38 MAPK, JNK, and NF-kappa B pathways. Our knowledge remains incomplete of TAK1 target genes, requirement for cooperative signaling, and capacity for shared or segregated ligand-dependent responses. We show that adenoviral overexpression of TAK1a in articular chondrocytes stimulated type II collagen protein synthesis 3 - 6-fold and mimicked the response to TGF-beta 1 and BMP2. Both factors activated endogenous TAK1 and its activating protein, TAB1, and the collagen response was inhibited by dominant-negative TAK1a. Isoform-specific antibodies to TGF-beta blocked the response to endogenous and exogenous TGF-beta but not the response to TAK1a. Expression of Smad3 did not stimulate type II collagen synthesis or enhance that caused by TGF-beta 1 or TAK1a, in contrast to its effects on its endogenous targets, CTGF and plasminogen-activated inhibitor-1. TAK1a, overexpressed alone and immunoprecipitated, phosphorylated MKK6 and stimulated the plasminogen-activated inhibitor-1 promoter following transient transfection; both effects were enhanced by TAB1 coexpression, but type II collagen synthesis was not. Stimulation by TAK1a or TGF-beta did not require increased Col2a1 mRNA, and TAK1 actually reduced Col2a1 mRNA in parallel with the cartilage markers, SRY-type HMG box 9 (Sox9) and aggrecan. Thus, TAK1 increased target gene expression ( Col2a1) by translational or posttranslational mechanisms as a Smad3-independent response shared by TGF-beta 1 and BMP2.	Univ Calif Los Angeles, David Geffen Sch Med UCLA, UCLA Orthopaed Hosp, Dept Orthopaed Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Orthoped Hosp, J Vernon Luck Sr MD Res Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Benya, PD (corresponding author), Orthoped Hosp, 2400 S Flower St, Los Angeles, CA 90007 USA.	pbenya@LAOH.ucla.edu	Benya, Paul/I-3449-2015	Benya, Paul/0000-0002-1060-7127	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042894] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR42894] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alvarez J, 2002, DEVELOPMENT, V129, P1913; BENYA PD, 1988, J CELL BIOL, V106, P161, DOI 10.1083/jcb.106.1.161; BENYA PD, 1993, EXP CELL RES, V204, P268, DOI 10.1006/excr.1993.1033; BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092-8674(78)90056-9; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; BENYA PD, 1981, COLLAGEN REL RES, V1, P17; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BRADHAM DM, 1994, J CELL PHYSIOL, V158, P61, DOI 10.1002/jcp.1041580109; Chadjichristos C, 2002, J BIOL CHEM, V277, P43903, DOI 10.1074/jbc.M206111200; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; CHANG SC, 1994, J BIOL CHEM, V269, P28227; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Chimal-Monroy J, 1999, INT J DEV BIOL, V43, P59; ChimalMonroy J, 1997, INT J DEV BIOL, V41, P91; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; GALERA P, 1992, J CELL PHYSIOL, V153, P596, DOI 10.1002/jcp.1041530322; Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; Hanada M, 2001, J BIOL CHEM, V276, P5753, DOI 10.1074/jbc.M007773200; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HORTON WE, 1989, J CELL PHYSIOL, V141, P8, DOI 10.1002/jcp.1041410103; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kanei-Ishii C, 2004, GENE DEV, V18, P816, DOI 10.1101/gad.1170604; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Li MG, 2003, J BIOL CHEM, V278, P12013, DOI 10.1074/jbc.M211474200; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; Metsaranta M, 1996, MATRIX BIOL, V15, P39, DOI 10.1016/S0945-053X(96)90125-0; Miura Y, 2002, J BONE JOINT SURG AM, V84A, P793, DOI 10.2106/00004623-200205000-00015; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moustakas A, 2001, J CELL SCI, V114, P4359; Murakami S, 2000, J BIOL CHEM, V275, P3687, DOI 10.1074/jbc.275.5.3687; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nyberg-Hoffman C, 1999, NAT MED, V5, P955, DOI 10.1038/11400; Ohnishi H, 2004, J BIOL CHEM, V279, P8873, DOI 10.1074/jbc.M309698200; Pateder DB, 2001, J CELL PHYSIOL, V188, P343, DOI 10.1002/jcp.1118; Pizette S, 2000, DEV BIOL, V219, P237, DOI 10.1006/dbio.2000.9610; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Robbins JR, 2000, ARTHRITIS RHEUM, V43, P2189, DOI 10.1002/1529-0131(200010)43:10<2189::AID-ANR6>3.0.CO;2-S; ROSEN V, 1994, J BONE MINER RES, V9, P1759; Rountree RB, 2004, PLOS BIOL, V2, P1815, DOI 10.1371/journal.pbio.0020355; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Scharstuhl A, 2002, J IMMUNOL, V169, P507, DOI 10.4049/jimmunol.169.1.507; Sekiya I, 2002, P NATL ACAD SCI USA, V99, P4397, DOI 10.1073/pnas.052716199; Serra R, 1997, J CELL BIOL, V139, P541, DOI 10.1083/jcb.139.2.541; Settle SH, 2003, DEV BIOL, V254, P116, DOI 10.1016/S0012-1606(02)00022-2; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Shuler FD, 2000, J ORTHOPAED RES, V18, P585, DOI 10.1002/jor.1100180411; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Smit L, 2004, J BIOL CHEM, V279, P17232, DOI 10.1074/jbc.M307801200; Sonenberg N, 2000, TRANSLATIONAL CONTRO; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Tan LJ, 2003, J BIOL CHEM, V278, P17688, DOI 10.1074/jbc.M301676200; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35; Yang XH, 2004, J BIOL CHEM, V279, P38099, DOI 10.1074/jbc.C400318200; Yi SE, 2000, DEVELOPMENT, V127, P621; Zehentner BK, 1999, J BONE MINER RES, V14, P1734, DOI 10.1359/jbmr.1999.14.10.1734; Zeng L, 2002, GENE DEV, V16, P1990, DOI 10.1101/gad.1008002; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	80	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17562	17571		10.1074/jbc.M500646200	http://dx.doi.org/10.1074/jbc.M500646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15743758	hybrid			2022-12-25	WOS:000228615500125
J	Loiarro, M; Sette, C; Gallo, G; Ciacci, A; Fanto, N; Mastroianni, D; Carminati, P; Ruggiero, V				Loiarro, M; Sette, C; Gallo, G; Ciacci, A; Fanto, N; Mastroianni, D; Carminati, P; Ruggiero, V			Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL/INTERLEUKIN-1 RECEPTOR DOMAINS; SIGNAL-TRANSDUCTION; GENE; MICE; IL-1; PROTEINS; ADAPTERS; KINASE; IRAK	Myeloid differentiation factor 88 (MyD88) plays a crucial role in the signaling pathways triggered by interleukin (IL)-1 and Toll-like receptors in several steps of innate host defense. A crucial event in this signaling pathway is represented by dimerization of MyD88, which allows the recruitment of downstream kinases like IRAK-1 and IRAK-4. Herein, we have investigated the function of the Toll/IL-1 receptor (TIR) domain in MyD88 homodimerization in cell-free and in vitro experimental settings by using epta-peptides that mimic the BB-loop region of the conserved TIR domain of different proteins. By using a pull-down assay with purified glutathione S-transferase-MyD88 TIR or co-immunoprecipitation experiments, we found that epta-peptides derived from the TIR domain of MyD88 and IL-18R are the most effective in inhibiting homodimerization with either the isolated TIR or full-length MyD88. Moreover, we demonstrated that a cell permeable analog of MyD88 epta-peptide inhibits homodimerization of MyD88 TIR domains in an in vitro cell system and significantly reduces IL-1 signaling, as assayed by activation of the downstream transcription factor NF-kappa B. Our results indicate that the BB-loop in TIR domain of MyD88 is a good target for specific inhibition of MyD88-mediated signaling in vivo.	Sigma Tau Ind Farmaceut Riunite SpA, Dept Immunol, I-00040 Pomezia, RM, Italy; Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, I-00173 Rome, Italy; Tecnogen SCpA, I-81015 Piana Di Monte Verna, CE, Italy	University of Rome Tor Vergata	Ruggiero, V (corresponding author), Sigma Tau Ind Farmaceut Riunite SpA, Dept Immunol, Bldg LABIO,Via Pontina Km 30-400, I-00040 Pomezia, RM, Italy.	vito.ruggiero@Sigma-Tau.it	Sette, Claudio/S-4307-2019	Sette, Claudio/0000-0003-2864-8266				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bartfai T, 2003, P NATL ACAD SCI USA, V100, P7971, DOI 10.1073/pnas.0932746100; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bjorkbacka H, 2004, NAT MED, V10, P416, DOI 10.1038/nm1008; BODANSZKY M, 1993, PRINCIPLES PEPTIDE S; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Choe JY, 2003, J EXP MED, V197, P537, DOI 10.1084/jem.20021850; Dunne A, 2003, J BIOL CHEM, V278, P41443, DOI 10.1074/jbc.M301742200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hardiman G, 1996, ONCOGENE, V13, P2467; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Janssens S, 2002, TRENDS BIOCHEM SCI, V27, P474, DOI 10.1016/S0968-0004(02)02145-X; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Joosten LAB, 2003, J IMMUNOL, V171, P6145, DOI 10.4049/jimmunol.171.11.6145; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kueltzo LA, 2003, J PHARM SCI-US, V92, P1754, DOI 10.1002/jps.10448; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; O'Neill LAJ, 2004, SCIENCE, V303, P1481, DOI 10.1126/science.1096113; O'Neill LAJ, 2003, BIOCHEM SOC T, V31, P643, DOI 10.1042/BST0310643; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Radons J, 2002, J BIOL CHEM, V277, P16456, DOI 10.1074/jbc.M201000200; *SCHROD LLC, 2003, MACROMODEL 8 5; Takeuchi O, 2002, CURR TOP MICROBIOL, V270, P155; Ulevitch RJ, 2004, NAT REV IMMUNOL, V4, P512, DOI 10.1038/nri1396; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600	29	150	176	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15809	15814		10.1074/jbc.C400613200	http://dx.doi.org/10.1074/jbc.C400613200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15755740	hybrid			2022-12-25	WOS:000228444800044
J	Fan, F; Wey, JS; McCarty, MF; Belcheva, A; Liu, WB; Bauer, TW; Somcio, RJ; Wu, Y; Hooper, A; Hicklin, DJ; Ellis, LM				Fan, F; Wey, JS; McCarty, MF; Belcheva, A; Liu, WB; Bauer, TW; Somcio, RJ; Wu, Y; Hooper, A; Hicklin, DJ; Ellis, LM			Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells	ONCOGENE			English	Article						tyrosine kinase; angiogenesis; growth factor; colorectal cancer; signaling	BREAST-CANCER; TYROSINE KINASE; COLON-CANCER; TUMOR-CELLS; FACTOR VEGF; FLT-1; ANGIOGENESIS; PERMEABILITY; CARCINOMA; MIGRATION	Vascular endothelial growth factor ( VEGF) is associated with tumor angiogenesis and poor prognosis in human colorectal cancer (CRC). VEGF receptor-1 (VEGFR-1 or Flt-1) is a high-affinity receptor for VEGF and is typically considered specific to endothelial cells. Here we report the expression and function of VEGFR-1 in CRC cell lines. VEGFR-1 was expressed in all CRC cell lines studied as determined by RT-PCR, Western blot analysis, FACS, and ELISA. Treatment of the human CRC cell lines HT-29 and SW480 with VEGF-A ( a ligand for both VEGFR-1 and -2) or VEGF-B ( a ligand specific for VEGFR-1) led to activation of Erk-1/2, SAPK/JNK, and translocation of the p65 subunit of nuclear factor-kappa B into the nucleus. Both VEGF-A and -B led to significant induction of cell motility and invasiveness of CRC cells. Stimulation of cells with VEGF-A or -B also led to larger and more numerous colonies in soft agar. However, activation of VEGFR-1 did not increase CRC cell proliferation. In contrast to the previous paradigm that VEGFRs are not present on tumor cells of epithelial origin, we found that VEGFR-1 is present and functional on CRC cells, and activation by VEGF family ligands can activate processes involved in tumor progression and metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX USA; ImClone Syst Inc, New York, NY USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Eli Lilly	Ellis, LM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Box 444,1515 Holcombe Blvd, Houston, TX 77030 USA.	lellis@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672, R01CA112390] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA112390] Funding Source: Medline; PHS HHS [T32] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Arora N, 1999, CANCER RES, V59, P183; Bachelder RE, 2003, CANCER RES, V63, P5230; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bellamy WT, 1999, CANCER RES, V59, P728; BROWN LF, 1993, CANCER RES, V53, P4727; Chen WS, 2002, IN VIVO, V16, P439; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Folkman J, 2001, SEMIN ONCOL, V28, P536, DOI 10.1053/sonc.2001.29543; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hahn D, 2000, J UROLOGY, V164, P506, DOI 10.1016/S0022-5347(05)67414-9; Hasan J, 2001, EXPERT OPIN BIOL TH, V1, P703; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Jung Young D., 2001, Angiogenesis, V4, P155, DOI 10.1023/A:1012291524723; La Rosa S, 2003, HUM PATHOL, V34, P18, DOI 10.1053/hupa.2003.56; Lalla RV, 2003, ARCH OTOLARYNGOL, V129, P882, DOI 10.1001/archotol.129.8.882; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Liu WB, 2002, CANCER, V94, P934, DOI 10.1002/cncr.10122; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; Mayr-Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756-3282(01)00690-1; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; Patel N, 2003, J PHARMACOL EXP THER, V306, P838, DOI 10.1124/jpet.103.052167; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Ryden L, 2003, BREAST CANCER RES TR, V82, P147, DOI 10.1023/B:BREA.0000004357.92232.cb; Shaheen RM, 2001, INT J ONCOL, V18, P221; Stoeltzing O, 2003, ANN SURG ONCOL, V10, P722, DOI 10.1245/ASO.2003.07.019; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Von Marschall Z, 2000, GASTROENTEROLOGY, V119, P1358, DOI 10.1053/gast.2000.19578; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Zhukova LG, 2003, B EXP BIOL MED+, V135, P478, DOI 10.1023/A:1024975627843	38	276	300	4	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2647	2653		10.1038/sj.onc.1208246	http://dx.doi.org/10.1038/sj.onc.1208246			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735759				2022-12-25	WOS:000228356700006
J	Mo, YY; Yu, YN; Theodosiou, E; Ee, PLR; Beck, WT				Mo, YY; Yu, YN; Theodosiou, E; Ee, PLR; Beck, WT			A role for Ubc9 in tumorigenesis	ONCOGENE			English	Article						Ubc9; sumoylation; SUMO; Bcl-2; apoptosis	UBIQUITIN-CONJUGATING ENZYME; BREAST-CANCER CELLS; BCL-2 EXPRESSION; PROTEIN SUMO-1; RECEPTOR; P53; SUMOYLATION; ACTIVATION; INTERACTS; FAMILY	The post-translational modi. cations ubiquitination and sumoylation have been implicated in regulating many critical cellular pathways. Like ubiquitination, sumoylation is a multistep process involving maturation, activation, conjugation and deconjugation. Ubc9 is a sole E2-conjugating enzyme essential for sumoylation. We have previously shown that alterations of Ubc9 expression affect tumor drug responsiveness. However, it is not clear whether there is any link between sumoylation and tumorigenesis, even though alterations of the ubiquitination pathway can lead to the development of cancer. In this study, we found that Ubc9 expression levels were elevated in ovarian tumors compared to the matched normal ovarian specimens, suggesting that Ubc9 may play a role in tumorigenesis. To test this, we overexpressed a dominant-negative mutant of Ubc9 ( Ubc9-DN) and wildtype Ubc9 ( Ubc9-WT) in the MCF-7 human breast tumor cells. Inoculating these cells as xenografts in mice revealed that tumors expressing Ubc9-WT grew better than the vector control, while tumors expressing Ubc9-DN exhibited reduced growth. This pattern was also seen in these cells when grown in culture. To better understand the mechanism behind this observation, we pro. led gene expressions in these cells by microarray analysis and found alterations in expression of the pro-oncogene bcl-2 in these Ubc9-DN- and Ubc9-WT-expressing cells. Consistent with the bcl-2 results, subsequent studies revealed a higher rate of apoptosis and poor survival for the MCF-7 cells expressing Ubc9-DN, which are associated with downregulation of bcl-2. Together, these results suggest a role for Ubc9 in tumorigenesis at least partially through regulation of bcl-2 expression.	Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA; Univ Illinois, Dept Med, Hematol Oncol Sect, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60612 USA; Univ Illinois, Core Lab Mol Pharmacol, Gynecol Oncol Grp, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mo, YY (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol & Immunol, 911 N Rutledge,Room 1300A, Springfield, IL 62794 USA.	ymo@siumed.edu	EE, P.L. Rachel/C-7538-2014; 高, 雨莉/HGU-8187-2022; Mo, Yin-Yuan/B-6141-2011; Mo, Yin-Yuan/R-8255-2019	Ee, Pui Lai Rachel/0000-0002-7277-6233	NCI NIH HHS [CA40570, CA102630, CA27469, CA30103, R01 CA102630] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040570, R01CA102630, U10CA027469, R01CA030103] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ALDERSON LM, 1995, CANCER RES, V55, P999; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hayashi T, 2002, EXP CELL RES, V280, P212, DOI 10.1006/excr.2002.5634; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Lipkowitz S, 2003, BREAST CANCER RES, V5, P8, DOI 10.1186/bcr541; Martinez-Arribas F, 2003, ANTICANCER RES, V23, P565; Mo YY, 2004, CANCER RES, V64, P2793, DOI 10.1158/0008-5472.CAN-03-2410; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Zhang GJ, 1998, ONCOL REP, V5, P1211; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521	33	149	158	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2677	2683		10.1038/sj.onc.1208210	http://dx.doi.org/10.1038/sj.onc.1208210			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735760				2022-12-25	WOS:000228356700009
J	Vannucchi, S; Chiantore, MV; Fiorucci, G; Percario, ZA; Leone, S; Affabris, E; Romeo, A				Vannucchi, S; Chiantore, MV; Fiorucci, G; Percario, ZA; Leone, S; Affabris, E; Romeo, A			TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-beta in cervical carcinoma cells	ONCOGENE			English	Article						TRAIL; IFN-ss; apoptosis; cell cycle; SCC	NF-KAPPA-B; UP-REGULATION; LIGAND; EXPRESSION; INDUCTION; RECEPTORS; CANCER; DEATH; ACTIVATION; FAMILY	Interferon (IFN)-beta induces S-phase slowing and apoptosis in human papilloma virus (HPV)-positive cervical carcinoma cell line ME-180. Here, we show that apoptosis is a consequence of the S-phase lengthening imposed by IFN-beta, demonstrating the functional correlation between S-phase alteration and apoptosis induction. In ME-180 cells, where p53 function is inhibited by HPV E6 oncoprotein, IFN-beta effects on cell cycle and apoptosis occur independently of p53. The apoptosis due to IFN-beta is mediated by the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in a manner dependent on the S-phase deregulation. IFN-beta appears to increase TRAIL expression both directly at the mRNA level and indirectly by augmenting surface protein levels as a consequence of the induced S-phase cell accumulation. Moreover, the alteration of the S-phase due to IFN-beta promotes TRAIL-dependent apoptosis by potentiating cell sensitivity to TRAIL, possibly through induction of a proapoptotic NF-KB activity and TRAIL-R2 receptor expression. Interestingly, IFN-beta-induced TRAIL-dependent apoptotic events strongly differ in the requirement of caspase activity. These results show that IFN-beta may induce an apoptotic response by deregulating cell cycle. Understanding the linkage between these mechanisms appears to be of primary importance in the search for new IFN-based therapeutic strategies to circumvent cancer disease or improve clinical outcome.	Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, I-00161 Rome, Italy; CNR, Inst Mol Biol & Pathol, Rome, Italy; Univ Roma Tre, Dept Biol, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Roma Tre University	Romeo, A (corresponding author), Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, Viale Regina Elena 299, I-00161 Rome, Italy.	romeo@iss.it	CHIANTORE, MARIA VINCENZA/C-2948-2016; Fiorucci, Gianna/B-3064-2013; romeo, giovanna/P-8348-2015	CHIANTORE, MARIA VINCENZA/0000-0001-5163-2698; Leone, Stefano/0000-0001-6339-6397; AFFABRIS, Elisabetta/0000-0001-5142-8144; romeo, giovanna/0000-0002-7638-1001				ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Baetu TM, 2002, CYTOKINE GROWTH F R, V13, P199, DOI 10.1016/S1359-6101(02)00006-0; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; Chawla-Sarkar M, 2002, J IMMUNOL, V169, P847, DOI 10.4049/jimmunol.169.2.847; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Choi EA, 2003, CANCER RES, V63, P5299; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; FIORUCCI G, 2005, IN PRESS CURR PHARM, V10; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Ghosh SK, 2003, BLOOD, V101, P2321, DOI 10.1182/blood-2002-08-2525; Giandomenico V, 1998, EUR CYTOKINE NETW, V9, P619; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gong B, 2000, BIOCHEM BIOPH RES CO, V278, P747, DOI 10.1006/bbrc.2000.3872; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Muhlenbeck F, 2000, J BIOL CHEM, V275, P32208, DOI 10.1074/jbc.M000482200; Oshima K, 2001, CYTOKINE, V14, P193, DOI 10.1006/cyto.2001.0873; Percario ZA, 1999, CELL GROWTH DIFFER, V10, P263; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Sato K, 2001, EUR J IMMUNOL, V31, P3138, DOI 10.1002/1521-4141(200111)31:11<3138::AID-IMMU3138>3.0.CO;2-B; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sedger LM, 1999, J IMMUNOL, V163, P920; Sheikh MS, 1998, CANCER RES, V58, P1593; Shetty S, 2002, APOPTOSIS, V7, P413, DOI 10.1023/A:1020031023947; Shigeno M, 2003, ONCOGENE, V22, P1653, DOI 10.1038/sj.onc.1206139; Shin EC, 2002, EXP MOL MED, V34, P114, DOI 10.1038/emm.2002.17; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Toomey NL, 2001, ONCOGENE, V20, P7029, DOI 10.1038/sj.onc.1204895; Vannucchi S, 2000, ONCOGENE, V19, P5041, DOI 10.1038/sj.onc.1203883; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512; Wilson CA, 2002, CELL DEATH DIFFER, V9, P1321, DOI 10.1038/sj.cdd.4401107; Younes A, 2003, J CLIN ONCOL, V21, P3526, DOI 10.1200/JCO.2003.09.037	41	18	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2536	2546		10.1038/sj.onc.1208403	http://dx.doi.org/10.1038/sj.onc.1208403			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735750				2022-12-25	WOS:000228180600011
J	Sphyris, N; Harrison, DJ				Sphyris, N; Harrison, DJ			p53 deficiency exacerbates pleiotropic mitotic defects, changes in nuclearity and polyploidy in transdifferentiating pancreatic acinar cells	ONCOGENE			English	Article						pancreas acinar-ductal transdifferentiation; mitosis; centrosomes; polyploidy; aneuploidy; p53	KINASE INHIBITOR P21; CENTROSOME AMPLIFICATION; TRANSGENIC MICE; TETRAPLOIDY CHECKPOINT; EXOCRINE PANCREAS; CYCLE PROGRESSION; EXPRESSION; DIFFERENTIATION; NEOPLASIA; ARREST	In a primary culture model for pancreatic acinar-ductal transdifferentiation, cells exhibited increased proliferation, changes in nuclearity and polyploidy. We identify the `nucleus to centrosome' ratio of the progenitor cell, the dissemination of centrosomes at spindle poles and cytokinesis failure as critical determinants of mitosis outcome and centrosome inheritance. Abortive cytokinesis of mononuclear cells contributes to the binuclear cell pool, whereas enclosure of entire mitotic formations, within a single nuclear envelope, perpetuates polyploidization. Binuclear cell nuclei combine their genomes on a single metaphase plate, doubling descendant ploidy. Moreover, similar to 42% of binuclear and tetraploid cells assemble aberrant spindles with up to 8 centrosomes/poles. These phenotypes were exacerbated in p53-deficient cultures exhibiting increased S-phase entry, giant nuclei, multinucleation, multipolar mitoses and centrosome hyperamplification. The tendency of p53-proficient cells to spontaneously evade the tetraploidy checkpoint degenerates to uncontrolled polyploid progression in p53-deficient cultures, explaining why p53 abrogation alone rapidly descends to aneuploidy in this system. We detected constitutively nuclear mdm2, which may circumvent endogenous cell-cycle checkpoints, and pronounced accumulation of p21 and p27 in multinuclear cells and giant nuclei, consistent with roles in polyploidization. This in vitro model may recapitulate the processes underlying genomic instability in pancreatic tumours in vivo, and attests to the existence of a p53-dependent polyploidy checkpoint acting to limit the degree of polyploidization.	Univ Edinburgh, Sch Mol & Clin Med, Div Pathol, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Harrison, DJ (corresponding author), Univ Edinburgh, Sch Mol & Clin Med, Div Pathol, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	David.Harrison@ed.ac.uk	SPHYRIS, NATHALIE/GQY-6349-2022	Sphyris, Nathalie/0000-0003-1860-1958				Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; ARIAS AE, 1993, LAB INVEST, V69, P518; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; CLARKE AR, 1995, ONCOGENE, V11, P1913; Daujat S, 2001, TRENDS GENET, V17, P459, DOI 10.1016/S0168-9525(01)02369-1; Dazard JE, 2000, ONCOGENE, V19, P3693, DOI 10.1038/sj.onc.1203695; DELISLE RC, 1990, EUR J CELL BIOL, V51, P64; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200; HALL PA, 1992, J PATHOL, V166, P97, DOI 10.1002/path.1711660203; Haroske G, 1998, ANAL CELL PATHOL, V17, P189, DOI 10.1155/1998/390837; Hong FD, 1999, CARCINOGENESIS, V20, P1161, DOI 10.1093/carcin/20.7.1161; HOSHI H, 1993, AM J PHYSIOL, V265, pG1177, DOI 10.1152/ajpgi.1993.265.6.G1177; Khan SH, 1998, CANCER RES, V58, P396; Kikuchi J, 1997, BLOOD, V89, P3980, DOI 10.1182/blood.V89.11.3980; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Nagata Y, 1997, J CELL BIOL, V139, P449, DOI 10.1083/jcb.139.2.449; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; Poluha W, 1996, MOL CELL BIOL, V16, P1335; PURDIE CA, 1994, ONCOGENE, V9, P603; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RAMEL S, 1995, PANCREAS, V11, P213, DOI 10.1097/00006676-199510000-00001; Rooney RJ, 2001, CELL GROWTH DIFFER, V12, P505; Roy L, 2001, BLOOD, V97, P2238, DOI 10.1182/blood.V97.8.2238; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; Sato N, 1999, CLIN CANCER RES, V5, P963; Sato N, 2001, CANCER GENET CYTOGEN, V126, P13, DOI 10.1016/S0165-4608(00)00384-8; SCARPELLI DG, 1984, ENV HLTH PERSPECT, V56, P217; Sluder G, 2004, CURR OPIN CELL BIOL, V16, P49, DOI 10.1016/j.ceb.2003.11.006; SPHYRIS N, 2005, IN PRESS PANCREAS, V30; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; VILA MR, 1994, LAB INVEST, V71, P423; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245	44	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2184	2194		10.1038/sj.onc.1208249	http://dx.doi.org/10.1038/sj.onc.1208249			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735758				2022-12-25	WOS:000227857900006
J	Hwang, YYC; Shaw, S; Kaneko, M; Redd, H; Marrero, MB; Ramasamy, R				Hwang, YYC; Shaw, S; Kaneko, M; Redd, H; Marrero, MB; Ramasamy, R			Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury	FASEB JOURNAL			English	Article						protein kinase C; niacin; sorbitol dehydrogenase	PROTEIN-KINASE-C; DIABETIC-RATS; REPERFUSION INJURY; INHIBITION; HEART; CARDIOMYOPATHY; DYSFUNCTION; ACTIVATION; PROTECTION; INCREASES	The aldose reductase pathway has been demonstrated to be a key component of myocardial ischemia reperfusion injury. Previously, we demonstrated that increased lactate/pyruvate ratio, a measure of cytosolic NADH/NAD+, is an important change that drives the metabolic cascade mediating ischemic injury. This study investigated signaling mechanisms by which the aldose reductase pathway mediates myocardial ischemic injury. Specifically, the influence of the aldose reductase pathway flux on JAK-STAT signaling was examined in perfused hearts. Induction of global ischemia in rats resulted in JAK2 activation followed by STAT5 activation. Pharmacological inhibition of aldose reductase or sorbitol dehydrogenase blocked JAK2 and STAT5 activation and was associated with lower lactate/pyruvate ratio and lower protein kinase C activity. Niacin, known to lower cytosolic NADH/NAD+ ratio independent of the aldose reductase pathway inhibition, also blocked JAK2 and STAT5 activation. Inhibition of protein kinase C also blocked JAK2 and STAT5 activation. Transgenic mice overexpressing human aldose reductase exhibited increased JAK2 and STAT5 activation. Pharmacological inhibition of JAK2 reduced ischemic injury and improved functional recovery similar to that observed in aldose reductase pathway inhibited mice hearts. These data, for the first time, demonstrate JAK-STAT signaling by the aldose reductase pathway in ischemic hearts and is, in part, due to changes in cytosolic redox state.	Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, New York, NY 10032 USA; Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA	Columbia University; University System of Georgia; Augusta University	Ramasamy, R (corresponding author), Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, P&17,401 Columbia Univ,630 W 168th St, New York, NY 10032 USA.	rr260@columbia.edu		Ramasamy, Ravichandran/0000-0002-3666-3346	NHLBI NIH HHS [HL-68954, HL-61783] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061783, R01HL068954] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Booz GW, 2002, J MOL CELL CARDIOL, V34, P1443, DOI 10.1006/jmcc.2002.2076; Changelian PS, 2003, SCIENCE, V302, P875, DOI 10.1126/science.1087061; Hahn HS, 2002, CIRC RES, V91, P741, DOI 10.1161/01.RES.0000037091.64492.69; Hattori R, 2001, J MOL CELL CARDIOL, V33, P1929, DOI 10.1006/jmcc.2001.1456; Hwang YC, 2001, FASEB J, V15, P243, DOI 10.1096/fj.01-0368fje; Hwang YYC, 2004, FASEB J, V18, P1192, DOI 10.1096/fj.03-1400com; Hwang YYC, 2003, FASEB J, V17, P2331, DOI 10.1096/fj.03-0128fje; Inagaki K, 2003, CIRCULATION, V108, P869, DOI 10.1161/01.CIR.0000081943.93653.73; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; KASHIWAGI A, 1992, METABOLISM, V41, P1041, DOI 10.1016/0026-0495(92)90283-G; Lundmark JL, 1999, AM J PHYSIOL-HEART C, V277, pH999, DOI 10.1152/ajpheart.1999.277.3.H999; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mascareno E, 2001, CIRCULATION, V104, P325, DOI 10.1161/01.CIR.104.3.325; Park JW, 1998, INT J CARDIOL, V65, P139, DOI 10.1016/S0167-5273(98)00117-X; Podewski EK, 2003, CIRCULATION, V107, P798, DOI 10.1161/01.CIR.0000057545.82749.FF; Ramasamy R, 1997, DIABETES, V46, P292, DOI 10.2337/diabetes.46.2.292; Ramasamy R, 1999, CARDIOVASC RES, V42, P130, DOI 10.1016/S0008-6363(98)00303-4; Ramasamy R, 1998, AM J PHYSIOL-HEART C, V275, pH195, DOI 10.1152/ajpheart.1998.275.1.H195; Shaw S, 2003, J BIOL CHEM, V278, P30634, DOI 10.1074/jbc.M305008200; Strasser RH, 1999, CIRC RES, V85, P77; Tracey WR, 2000, AM J PHYSIOL-HEART C, V279, pH1447, DOI 10.1152/ajpheart.2000.279.4.H1447; Trueblood N, 1998, AM J PHYSIOL-HEART C, V275, pH75, DOI 10.1152/ajpheart.1998.275.1.H75; Trueblood NA, 2000, AM J PHYSIOL-HEART C, V279, pH764, DOI 10.1152/ajpheart.2000.279.2.H764; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; XIA P, 1995, J CLIN INVEST, V96, P733, DOI 10.1172/JCI118117; Xuan YT, 2001, P NATL ACAD SCI USA, V98, P9050, DOI 10.1073/pnas.161283798	27	40	43	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					795	+		10.1096/fj.04-2780fje	http://dx.doi.org/10.1096/fj.04-2780fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746188				2022-12-25	WOS:000227901300029
J	Matsushita, M; Kozak, JA; Shimizu, Y; McLachlin, DT; Yamaguchi, H; Wei, FY; Tomizawa, K; Matsui, H; Chait, BT; Cahalan, MD; Nairn, AC				Matsushita, M; Kozak, JA; Shimizu, Y; McLachlin, DT; Yamaguchi, H; Wei, FY; Tomizawa, K; Matsui, H; Chait, BT; Cahalan, MD; Nairn, AC			Channel function is dissociated from the intrinsic kinase activity and autophosphorylation of TRPM7/ChaK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-2 KINASE; HEAVY-CHAIN KINASE; MIC CHANNELS; PROTEIN; PHOSPHORYLATION; HYPOMAGNESEMIA; MUTATION; DOMAIN; CRAC; MG2+	TRPM7/ChaK1 is a unique channel/kinase that contains a TRPM channel domain with 6 transmembrane segments fused to a novel serine-threonine kinase domain at its C terminus. The goal of this study was to investigate a possible role of kinase activity and autophosphorylation in regulation of channel activity of TRPM7/ChaK1. Residues essential for kinase activity were identified by site-directed mutagenesis. Two major sites of autophosphorylation were identified in vitro by mass spectrometry at Ser(1511) and Ser(1567), and these sites were found to be phosphorylated in intact cells. TRPM7/ChaK1 is a cation-selective channel that exhibits strong outward rectification and inhibition by millimolar levels of internal [Mg2+]. Mutation of the two autophosphorylation sites or of a key catalytic site that abolished kinase activity did not alter channel activity measured by whole-cell recording or Ca2+ influx. Inhibition by internal Mg2+ was also unaffected in the autophosphorylation site or "kinase-dead" mutants. Moreover, kinase activity was enhanced by Mg2+, was decreased by Zn2+, and was unaffected by Ca2+. In contrast, channel activity was inhibited by all three of these divalent cations. However, deletion of much of C-terminal kinase domain resulted in expression of an apparently inactive channel. We conclude that neither current activity nor regulation by internal Mg2+ is affected by kinase activity or autophosphorylation but that the kinase domain may play a structural role in channel assembly or subcellular localization.	Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA; Okayama Univ, Sch Med, Dept Physiol 1, Okayama 7008558, Japan; Nara Inst Sci & Technol, Dept Biol Struct, Nara 6300101, Japan; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spectrometry, New York, NY 10021 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	Yale University; Okayama University; Nara Institute of Science & Technology; Rockefeller University; Rockefeller University; University of California System; University of California Irvine	Nairn, AC (corresponding author), Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA.	angus.nairn@yale.edu	Wei, Fan-Yan/AAD-8461-2021; Tomizawa, Kazuhito/F-2405-2015	Tomizawa, Kazuhito/0000-0002-5663-2627; Wei, Fan-Yan/0000-0002-4843-724X; Nairn, Angus/0000-0002-7075-0195	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS014609, R01NS014609] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00862] Funding Source: Medline; NIGMS NIH HHS [GM50402] Funding Source: Medline; NINDS NIH HHS [NS14609] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chubanov V, 2004, P NATL ACAD SCI USA, V101, P2894, DOI 10.1073/pnas.0305252101; Clapham DE, 2003, PHARMACOL REV, V55, P591, DOI 10.1124/pr.55.4.6; Diggle TA, 1999, FEBS LETT, V457, P189, DOI 10.1016/S0014-5793(99)01034-0; Drennan D, 2004, PROG BIOPHYS MOL BIO, V85, P1, DOI 10.1016/S0079-6107(03)00060-9; Fleig A, 2004, TRENDS PHARMACOL SCI, V25, P633, DOI 10.1016/j.tips.2004.10.004; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Jiang XP, 2003, J BIOL CHEM, V278, P42867, DOI 10.1074/jbc.M304487200; Kolman MF, 1997, J BIOL CHEM, V272, P16904, DOI 10.1074/jbc.272.27.16904; Kozak JA, 2003, BIOPHYS J, V84, P922, DOI 10.1016/S0006-3495(03)74909-1; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; Krutchinsky AN, 2001, ANAL CHEM, V73, P5066, DOI 10.1021/ac010682o; Luo X, 2001, J BIOL CHEM, V276, P17836, DOI 10.1074/jbc.M009366200; MONTIES B, 2001, BIOPOLYMERS, V1, P1; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; Nairn AC, 2001, PROG MOLEC, V27, P91; NAIRN AC, 2003, ATYPICAL PROTEIN KIN, P567; Pavur KS, 2000, BIOCHEMISTRY-US, V39, P12216, DOI 10.1021/bi0007270; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8; Ryazanova LV, 2004, J BIOL CHEM, V279, P3708, DOI 10.1074/jbc.M308820200; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901; Yamaguchi H, 2001, MOL CELL, V7, P1047, DOI 10.1016/S1097-2765(01)00256-8; Zakharov SI, 2003, BRIT J PHARMACOL, V138, P234, DOI 10.1038/sj.bjp.0705074	30	148	150	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20793	20803		10.1074/jbc.M413671200	http://dx.doi.org/10.1074/jbc.M413671200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781465	hybrid, Green Published			2022-12-25	WOS:000229242000077
J	Tafolla, E; Wang, SH; Wong, B; Leong, J; Kapila, YL				Tafolla, E; Wang, SH; Wong, B; Leong, J; Kapila, YL			JNK1 and JNK2 oppositely regulate p53 in signaling linked to apoptosis triggered by an altered fibronectin matrix - JNK links FAK and p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; FOCAL ADHESION KINASE; GINGIVAL CREVICULAR FLUID; V-REGION; MOLECULAR-FORMS; ACTIVATION; PHOSPHORYLATION; DEGRADATION; SUPPRESSION; EXPRESSION	The extracellular matrix regulates many cellular processes, including survival, and alterations in the matrix or in matrix survival signals can trigger apoptosis. Previously, we showed that an altered fibronectin matrix triggers apoptosis in primary cells via a novel pathway regulated by transcriptionally mediated decreases in p53 and c-Myc levels. Here we report that this apoptotic mechanism is propagated by decreased phosphorylation of focal adhesion kinase (FAK), which is linked to increased phosphorylation of c-Jun N-terminal kinase (JNK) and to decreased levels of p53. FAK is physically and spatially linked to JNK and p53, which relocalize from the nucleus to the cell membrane to mediate this interaction. Further, p53 participates in a feedback mechanism with JNK to regulate this apoptotic process and is oppositely regulated by JNK1 and JNK2.	Univ Michigan, Sch Dent, Dept Periodont Prevent Geriatr, Ann Arbor, MI 48109 USA; Univ Calif San Francisco, Sch Dent, Dept Stomatol, San Francisco, CA 94143 USA	University of Michigan System; University of Michigan; University of California System; University of California San Francisco	Kapila, YL (corresponding author), Univ Michigan, Sch Dent, Dept Periodont Prevent Geriatr, Rm 5213,1011 N Univ Ave, Ann Arbor, MI 48109 USA.	ykapila@umich.edu	Kapila, Yvonne/AAG-5418-2021		NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [T32DE007306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013725, T35DE007103] Funding Source: NIH RePORTER; NIDCR NIH HHS [T35-DE07103, T32-DE07306, R01 DE13725] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; AKHTAR S, 1991, LIFE SCI, V49, P1793, DOI 10.1016/0024-3205(91)90480-Y; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Buschmann T, 2000, CANCER RES, V60, P896; CARSONS S, 1985, ARTHRITIS RHEUM, V28, P601, DOI 10.1002/art.1780280602; CLEMMENSEN I, 1982, ARTHRITIS RHEUM, V25, P25, DOI 10.1002/art.1780250104; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; GRIFFITHS AM, 1989, CLIN CHIM ACTA, V184, P133, DOI 10.1016/0009-8981(89)90283-0; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Huynh QH, 2002, J PERIODONTOL, V73, P1101, DOI 10.1902/jop.2002.73.10.1101; Ilic D, 1998, J CELL BIOL, V143, P547; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kapila YL, 1997, J BIOL CHEM, V272, P18932, DOI 10.1074/jbc.272.30.18932; Kapila YL, 1996, MATRIX BIOL, V15, P251, DOI 10.1016/S0945-053X(96)90116-X; Kapila YL, 2002, J BIOL CHEM, V277, P8482, DOI 10.1074/jbc.M108932200; Kapila YL, 1999, J BIOL CHEM, V274, P30906, DOI 10.1074/jbc.274.43.30906; Kapila YL, 1998, J PERIODONTOL, V69, P1008, DOI 10.1902/jop.1998.69.9.1008; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; Metzler B, 2000, AM J PATHOL, V156, P1875, DOI 10.1016/S0002-9440(10)65061-4; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Shklyaev SS, 2001, ANTICANCER RES, V21, P2569; TAFOLLA E, 2003, J DENT RES B, V82, P2213; TAFOLLA E, 2004, J DENT RES B, V83, P1621; TALONPOIKA J, 1993, SCAND J DENT RES, V101, P375; TALONPOIKA J, 1989, SCAND J DENT RES, V97, P415; Townsend PA, 2000, EUR J CANCER, V36, P397, DOI 10.1016/S0959-8049(99)00275-0; Wang JP, 2000, MOL CARCINOGEN, V29, P179, DOI 10.1002/1098-2744(200011)29:3<179::AID-MC7>3.0.CO;2-K; XIE DL, 1992, J RHEUMATOL, V19, P1448	30	48	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19992	19999		10.1074/jbc.M500331200	http://dx.doi.org/10.1074/jbc.M500331200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778501	hybrid			2022-12-25	WOS:000229113700069
J	Kuwada, SK; Kuang, JQ; Li, XF				Kuwada, SK; Kuang, JQ; Li, XF			Integrin alpha 5/beta 1 expression mediates HER-2 down-regulation in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MALIGNANT PHENOTYPE; COLORECTAL-CANCER; CARCINOMA CELLS; ERBB RECEPTORS; C-CBL; FIBRONECTIN; UBIQUITINATION; GELDANAMYCIN; DEGRADATION	HER-2 is constitutively activated and overexpressed in many cancers, and its inhibition in colon cancer cells diminishes tumorigenicity and induces apoptosis. Little is known about the regulation of HER-2 signaling in colon cancer cells. Integrin alpha 5/beta 1 expression is frequently lost in colorectal cancer cells compared with normal intestinal epithelium, and colon cancer cells lacking integrin alpha 5/beta 1 expression utilize HER-2 signaling for proliferation and tumorigenicity. Re-expression of integrin alpha 5/beta 1 in colon cancer cells abrogated their tumorigenicity, but how this occurs is not well known. Stable expression of integrin alpha 5/beta 1 in colon cancer cells with little or no detectable integrin alpha 5/beta 1 protein expression resulted in the post-transcriptional down-regulation of HER-2 protein. Integrin alpha 5/beta 1 was found to interact with HER-2, and the cytoplasmic domain of integrin alpha 5/beta 1 was sufficient to mediate HER-2 down-regulation. Integrin alpha 5/beta 1-mediated down-regulation of HER-2 was the result of increased lysosomal targeting. The inhibition of HER-2 signaling represents a potential mechanism by which integrin alpha 5/beta 1 exerts its tumor suppressor-like activity in colon cancer cells. These results also suggest that a novel function for integrin alpha 5/beta 1 is the control of HER-2 expression.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Salt Lake City Vet Adv Hlth Care Syst, Dept Med, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Kuwada, SK (corresponding author), 2000 Circle Hope, Salt Lake City, UT 84112 USA.							Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; Baulida J, 1996, J BIOL CHEM, V271, P5251; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; De Bosscher K, 2004, BIOCHEM J, V379, P209, DOI 10.1042/BJ20031886; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Kapitanovic S, 1997, GASTROENTEROLOGY, V112, P1103, DOI 10.1016/S0016-5085(97)70120-3; KAPITANOVIC S, 1994, CANCER DETECT PREV, V18, P97; Klapper LN, 2000, CANCER RES, V60, P3384; Kumar R, 2001, SEMIN ONCOL, V28, P27, DOI 10.1016/S0093-7754(01)90279-9; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; Kuwada SK, 2004, INT J CANCER, V109, P291, DOI 10.1002/ijc.11686; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Li J, 1999, J BIOL CHEM, V274, P11209, DOI 10.1074/jbc.274.16.11209; Mann M, 2001, GASTROENTEROLOGY, V120, P1713, DOI 10.1053/gast.2001.24844; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nakamura I, 2003, ENDOCRINOLOGY, V144, P4739, DOI 10.1210/en.2003-0615; Nathanson DR, 2003, INT J CANCER, V105, P796, DOI 10.1002/ijc.11137; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Normanno N, 2003, J CELL PHYSIOL, V194, P13, DOI 10.1002/jcp.10194; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; Ross JS, 2001, CANCER INVEST, V19, P554, DOI 10.1081/CNV-100103852; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Saci A, 2000, BIOCHEM J, V351, P669, DOI 10.1042/0264-6021:3510669; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Shimizu H, 2003, ONCOGENE, V22, P831, DOI 10.1038/sj.onc.1206203; STALLMACH A, 1994, GASTROENTEROLOGY, V106, P19, DOI 10.1016/S0016-5085(94)94031-2; Tikhomirov O, 2003, CANCER RES, V63, P39; Tikhomirov O, 2001, J BIOL CHEM, V276, P33675, DOI 10.1074/jbc.M101394200; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; Wang DH, 1999, J BIOL CHEM, V274, P12840, DOI 10.1074/jbc.274.18.12840; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; Zutter MM, 1998, CURR TOP MICROBIOL, V231, P167; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	41	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19027	19035		10.1074/jbc.M410540200	http://dx.doi.org/10.1074/jbc.M410540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757908	hybrid			2022-12-25	WOS:000228932300058
J	Li, XA; Guo, L; Dressman, JL; Asmis, R; Smart, EJ				Li, XA; Guo, L; Dressman, JL; Asmis, R; Smart, EJ			A novel ligand-independent apoptotic pathway induced by scavenger receptor class B, type I and suppressed by endothelial nitric-oxide synthase and high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL APOPTOSIS; DEFICIENT MICE; OXIDIZED LDL; SR-BII; ATHEROSCLEROSIS; ACTIVATION; DYSFUNCTION; INHIBITION; CAVEOLAE; DISEASE	Scavenger receptor class B, type I (SR-BI)/ApoE double null mice develop severe atherosclerosis within 4 weeks, whereas ApoE null mice take several months to develop the disease, indicating that SR-BI plays a pivotal role in atherosclerosis. Importantly, SR-BI/ApoE double null mice have lower plasma cholesterol levels than ApoE null mice, suggesting involvement of a nonlipids mechanism. In the present study, we revealed a novel ligand-independent apoptotic pathway induced by SR-BI, and regulated by endothelial nitric-oxide synthase ( eNOS) and high density lipoprotein (HDL). SR-BI significantly induces apoptosis in three independent cell systems. In contrast to known ligand-dependent apoptotic pathways, SR-BI-induced apoptosis is ligand-independent. We further showed that SR-BI-induced apoptosis is suppressed by eNOS and HDL. By using a single site mutation, we demonstrated that SR-BI induces apoptosis through a highly conserved CXXS redox motif. We finally demonstrated that SR-BI-induced apoptosis is via the caspase-8 pathway. We hypothesize that in healthy cells, the SR-BI apoptotic pathway is turned off by eNOS and HDL which prevents inappropriate apoptotic damage to the vascular wall. When HDL levels are low, oxidative stress causes the relocation of eNOS away from caveolae, which turns on SR-BI-induced apoptosis and rapidly clears damaged cells to prevent further inflammatory damage to neighboring cells. The current studies offer a new paradigm in which to study the non-cholesterol effects of SR-BI, HDL, and eNOS on the development of atherosclerosis and potentially other cardiovascular diseases.	Univ Kentucky, Sch Med, Dept Pediat, Lexington, KY 40536 USA; Univ Kentucky, Sch Med, Dept Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Smart, EJ (corresponding author), Univ Kentucky, Sch Med, Dept Pediat, 423 Sanders Brown,800 Limestone St, Lexington, KY 40536 USA.	ejsmart@uky.edu	Asmis, Reto/W-1344-2019		NHLBI NIH HHS [HL64056, HL68509, HL62844] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068509, R01HL062844, R01HL064056] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Asai K, 2000, ARTERIOSCL THROM VAS, V20, P1493, DOI 10.1161/01.ATV.20.6.1493; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen JW, 2004, CIRC RES, V94, P370, DOI 10.1161/01.RES.0000113782.07824.BE; Choy JC, 2001, J MOL CELL CARDIOL, V33, P1673, DOI 10.1006/jmcc.2001.1419; Dimmeler S, 1997, CIRCULATION, V95, P1760; Drew BG, 2004, P NATL ACAD SCI USA, V101, P6999, DOI 10.1073/pnas.0306266101; Eckhardt ERM, 2004, J BIOL CHEM, V279, P14372, DOI 10.1074/jbc.M313793200; Estevez AG, 2002, ANN NY ACAD SCI, V962, P207, DOI 10.1111/j.1749-6632.2002.tb04069.x; Fomenko DE, 2002, PROTEIN SCI, V11, P2285, DOI 10.1110/ps.0218302; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; HANSSON GK, 1985, AM J PATHOL, V121, P123; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Knowles JW, 2000, J CLIN INVEST, V105, P451, DOI 10.1172/JCI8376; Kolodgie FD, 1999, APOPTOSIS, V4, P5, DOI 10.1023/A:1009645730270; Kotamraju S, 2001, J BIOL CHEM, V276, P17316, DOI 10.1074/jbc.M011731200; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Kuhlencordt PJ, 2001, CIRCULATION, V104, P448, DOI 10.1161/hc2901.091399; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Li XA, 2002, J BIOL CHEM, V277, P11058, DOI 10.1074/jbc.M110985200; Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Norata GD, 2002, NUTR METAB CARDIOVAS, V12, P297; Ohgami N, 2001, J BIOL CHEM, V276, P13348, DOI 10.1074/jbc.M011613200; Ozaki M, 2002, J CLIN INVEST, V110, P331, DOI 10.1172/JCI200215215; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; Shaul PW, 2003, J PHYSIOL-LONDON, V547, P21, DOI 10.1113/jphysiol.2002.031534; Shi WB, 2002, CIRCULATION, V105, P2078, DOI 10.1161/01.CIR.0000015853.59427.32; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Tall AR, 2002, CIRC RES, V90, P244, DOI 10.1161/res.90.3.244; TYMMS MJ, 2001, GENE KNOCKOUT PROTOC, P205; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Van Eck M, 2003, J BIOL CHEM, V278, P23699, DOI 10.1074/jbc.M211233200; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986	46	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19087	19096		10.1074/jbc.M500944200	http://dx.doi.org/10.1074/jbc.M500944200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15749707	hybrid			2022-12-25	WOS:000228932300065
J	Willets, JM; Nahorski, SR; Challiss, RAJ				Willets, JM; Nahorski, SR; Challiss, RAJ			Roles of phosphorylation-dependent and -independent mechanisms in the regulation of M-1 muscarinic acetylcholine receptors by G protein-coupled receptor kinase 2 in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE REGULATION; HOMOLOGY DOMAIN; DESENSITIZATION; ACTIVATION; SIGNAL; G-ALPHA(Q); ARRESTINS; MICE; M1	When co-expressed with the inositol 1,4,5-trisphosphate biosensor eGFP-PHPLC delta, G protein-coupled receptor kinase 2 (GRK2) can suppress M-1 muscarinic acetylcholine (mACh) receptor-mediated phospholipase C signaling in hippocampal neurons through a phosphorylation-independent mechanism, most likely involving the direct binding of the RGS homology domain of GRK2 to G alpha(q/11). To define the importance of this mechanism in comparison with classical, phosphorylation-dependent receptor regulation by GRKs, we have examined M-1 mACh receptor signaling in hippocampal neurons following depletion of GRK2 and also in the presence of non-G alpha(q/11)-binding GRK2 mutants. Depletion of neuronal GRK2 using an antisense strategy almost completely inhibited M-1 mACh receptor desensitization without enhancing acute agonist-stimulated phospholipase C activity. By stimulating neurons with a submaximal agonist concentration before (R1) and after (R2) a period of exposure to a maximal agonist concentration, an index (R2/R1) of agonist-induced desensitization of signaling could be obtained. Co-transfection of neurons with either a non-G alpha(q/11)-binding (D110A) GRK2 mutant or the catalytically inactive (D110A,K220R)GRK2 did not suppress acute M-1 mACh receptor-stimulated inositol 1,4,5-trisphosphate production. However, using the desensitization (R2/R1) protocol, it could be shown that expression of (D110A)GRK2 enhanced, whereas (D110A,K220R)GRK2 inhibited, agonist-induced M-1 mACh receptor desensitization. In Chinese hamster ovary cells, the loss of G alpha(q/11) binding did not affect the ability of the (D110A)GRK2 mutant to phosphorylate M-1 mACh receptors, whereas expression of (D110A,K220R)GRK2 had no effect on receptor phosphorylation. These data indicate that in hippocampal neurons endogenous GRK2 is a key regulator of M-1 mACh receptor signaling and that the regulatory process involves both phosphorylation-dependent and -independent mechanisms.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Willets, JM (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England.	jmw23@le.ac.uk	Challiss, R.A. John/A-9412-2008	Challiss, John/0000-0001-5506-2848				Anagnostaras SG, 2003, NAT NEUROSCI, V6, P51, DOI 10.1038/nn992; Berkeley JL, 2003, MOL PHARMACOL, V63, P128, DOI 10.1124/mol.63.1.128; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Day PW, 2003, BIOCHEMISTRY-US, V42, P9176, DOI 10.1021/bi034442+; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dhami GK, 2004, J BIOL CHEM, V279, P16614, DOI 10.1074/jbc.M314090200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FROTSCHER M, 1985, J COMP NEUROL, V239, P237, DOI 10.1002/cne.902390210; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; Hamilton SE, 1997, P NATL ACAD SCI USA, V94, P13311, DOI 10.1073/pnas.94.24.13311; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Iwata K, 2005, J BIOL CHEM, V280, P2197, DOI 10.1074/jbc.M408834200; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miyakawa T, 2001, J NEUROSCI, V21, P5239, DOI 10.1523/JNEUROSCI.21-14-05239.2001; Mundell SJ, 2000, J BIOL CHEM, V275, P12900, DOI 10.1074/jbc.275.17.12900; Nash MS, 2004, J BIOL CHEM, V279, P49036, DOI 10.1074/jbc.M407277200; Ovsepian SV, 2004, EUR J NEUROSCI, V20, P1267, DOI 10.1111/j.1460-9568.2004.03582.x; Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Power AE, 2003, NEUROBIOL LEARN MEM, V80, P178, DOI 10.1016/S1074-7427(03)00086-8; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Sallese M, 2000, FASEB J, V14, P2569, DOI 10.1096/fj.00-0072com; Santini F, 2000, J CELL SCI, V113, P2463; Schell MJ, 2001, J BIOL CHEM, V276, P37537, DOI 10.1074/jbc.M104101200; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Sweatt JD, 2004, CURR OPIN NEUROBIOL, V14, P311, DOI 10.1016/j.conb.2004.04.001; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; WAINER BH, 1985, NEUROSCI LETT, V54, P45, DOI 10.1016/S0304-3940(85)80116-6; Waugh MG, 1999, BIOCHEM J, V338, P175, DOI 10.1042/0264-6021:3380175; Wess J, 2004, ANNU REV PHARMACOL, V44, P423, DOI 10.1146/annurev.pharmtox.44.101802.121622; Willets J, 2001, EUR J PHARMACOL, V431, P133, DOI 10.1016/S0014-2999(01)01360-7; Willets JM, 1999, J NEUROCHEM, V73, P1781, DOI 10.1046/j.1471-4159.1999.0731781.x; Willets JM, 2004, J NEUROSCI, V24, P4157, DOI 10.1523/JNEUROSCI.5506-03.2004; Willets JM, 2003, MOL PHARMACOL, V64, P1059, DOI 10.1124/mol.64.5.1059; Willets JM, 2001, MOL PHARMACOL, V60, P321, DOI 10.1124/mol.60.2.321	43	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18950	18958		10.1074/jbc.M412682200	http://dx.doi.org/10.1074/jbc.M412682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15743771	hybrid			2022-12-25	WOS:000228932300048
J	Bykov, VJN; Zache, N; Stridh, H; Westman, J; Bergman, J; Selivanova, G; Wiman, KG				Bykov, VJN; Zache, N; Stridh, H; Westman, J; Bergman, J; Selivanova, G; Wiman, KG			PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis	ONCOGENE			English	Article						p53 mutation; cancer therapy; chemotherapeutic drugs; PRIMA-1; synergy	MUTANT P53; BREAST-CANCER; RESTORATION; GROWTH; INFORMATION; CONFORMATION; THERAPY; PEPTIDE; RESCUE; DOMAIN	Mutant p53-carrying tumors are often more resistant to chemotherapeutical drugs. We demonstrate here that the mutant p53-reactivating compound PRIMA-1(MET) acts synergistically with several chemotherapeutic drugs to inhibit tumor cell growth. Combined treatment with cisplatin and PRIMA-1(MET) resulted in a synergistic induction of tumor cell apoptosis and inhibition of human tumor xenograft growth in vivo in SCID mice. The induction of mutant p53 levels by chemotherapeutic drugs is likely to increase the sensitivity of tumor cells to PRIMA-1(MET). Thus, the combination of PRIMA-1(MET) with currently used chemotherapeutic drugs may represent a novel and more efficient therapeutic strategy for treatment of mutant p53-carrying tumors.	CCK, Dept Oncol Pathol, Stockholm, Sweden; Aprea AB, Stockholm, Sweden; Novum, Dept Biosci, Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Wiman, KG (corresponding author), CCK, Dept Oncol Pathol, Stockholm, Sweden.	klas.wiman@cck.ki.se	Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Selivanova, Galina/0000-0002-8698-4332; Nakade Bykov, Vladimir/0000-0002-7199-8942				BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Campling Barbara G, 2003, Methods Mol Med, V75, P53; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; Keshelava N, 2001, CANCER RES, V61, P6185; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; OConnor PM, 1997, CANCER RES, V57, P4285; Ohnishi Ken, 2002, Mol Cancer, V1, P4, DOI 10.1186/1476-4598-1-4; Ohnishi T, 1999, INT J RADIAT BIOL, V75, P1095; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Sugikawa E, 1999, ANTICANCER RES, V19, P3099; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343	24	183	184	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3484	3491		10.1038/sj.onc.1208419	http://dx.doi.org/10.1038/sj.onc.1208419			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735745				2022-12-25	WOS:000229038800010
J	Schimanski, CC; Schmitz, G; Kashyap, A; Bosserhoff, AK; Bataille, F; Schafer, SC; Lehr, HA; Berger, MR; Galle, PR; Strand, S; Strand, D				Schimanski, CC; Schmitz, G; Kashyap, A; Bosserhoff, AK; Bataille, F; Schafer, SC; Lehr, HA; Berger, MR; Galle, PR; Strand, S; Strand, D			Reduced expression of Hugl-1, the human homologue of Drosophila tumour suppressor gene lgl, contributes to progression of colorectal cancer	ONCOGENE			English	Article						lgl; Hugl-1; tumour suppressor; colon cancer	LETHAL-GIANT-LARVAE; CELL POLARITY; PROTEIN; MUTATIONS; COMPLEX; REGION; MAPS; APC; NEOPLASMS; PATHWAYS	The human gene, human giant larvae (Hugl-1/Llg1/Lgl1) has significant homology to the Drosophila tumour suppressor gene lethal( 2) giant larvae (lgl). The lgl gene codes for a cortical cytoskeleton protein, Lgl, that binds Myosin II and is involved in maintaining cell polarity and epithelial integrity. The human protein, Hugl-1 contains several conserved functional domains found in Lgl, suggesting that these proteins may have closely related functions. Whether loss of Hugl expression plays a role in human tumorigenesis has so far not been extensively investigated. Thus, we evaluated tumour tissues from 94 patients undergoing surgery for colorectal cancer (CRC) for loss of Hugl-1 transcription and compared our findings with the clinical data from each of these patients. We found that Hugl-1 was lost in 75% of tumour samples and these losses were associated with advanced stage and particularly with lymph node metastases. Reduced Hugl-1 expression during the adenoma-carcinoma sequence occurring as early as in colorectal adenomas was detected by both immunohistochemical and reverse transcription polymerase chain reaction analysis. Functional assays with ecdysone-inducible cell lines revealed that Hugl-1 expression increased cell adhesion and decreased cell migration. Our studies thus indicate that downregulation of Hugl-1 contributes to CRC progression.	Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-55101 Mainz, Germany; Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany; Johannes Gutenberg Univ Mainz, Inst Pathol, D-55131 Mainz, Germany; German Canc Res Ctr, Unit Toxicol & Chemotherapy, D-69120 Heidelberg, Germany	Johannes Gutenberg University of Mainz; University of Regensburg; Johannes Gutenberg University of Mainz; Helmholtz Association; German Cancer Research Center (DKFZ)	Strand, D (corresponding author), Johannes Gutenberg Univ Mainz, Dept Internal Med 1, Obere Zahlbacherstr 63, D-55101 Mainz, Germany.	dstrand@uni-mainz.de	Galle, Peter/ABE-2872-2021; Bosserhoff, Anja/GNH-4801-2022; Galle, Peter R/T-5292-2018	Galle, Peter/0000-0001-8294-0992; Galle, Peter R/0000-0001-8294-0992; Bosserhoff, Anja/0000-0001-8147-394X				AGRAWAL N, 1995, DEV BIOL, V172, P218, DOI 10.1006/dbio.1995.0017; Boulay JL, 2001, GENE CHROMOSOME CANC, V31, P240, DOI 10.1002/gcc.1140; CHEN KS, 1995, AM J HUM GENET, V56, P175; CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Fuja TJ, 2004, CANCER RES, V64, P942, DOI 10.1158/0008-5472.CAN-03-2100; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Guanti G, 2000, Acta Chir Iugosl, V47, P23; HOULSTON RS, 1992, ANN HUM GENET, V56, P99, DOI 10.1111/j.1469-1809.1992.tb01136.x; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Kagami M, 1998, GENETICS, V149, P1717; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Koyama K, 1996, CYTOGENET CELL GENET, V72, P78, DOI 10.1159/000134167; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Larsson K, 1998, J BIOL CHEM, V273, P33610, DOI 10.1074/jbc.273.50.33610; Leslie A, 2003, CANCER RES, V63, P4656; Lin HT, 2004, GYNECOL ONCOL, V93, P422, DOI 10.1016/j.ygyno.2004.01.025; Micheli A, 2002, ANN ONCOL, V13, P840, DOI 10.1093/annonc/mdf127; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PARKIN DM, 1993, INT J CANCER, V54, P594; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Roth S, 2000, J MED GENET, V37, P298, DOI 10.1136/jmg.37.4.298; Scheurlen WG, 1999, GENE CHROMOSOME CANC, V25, P230, DOI 10.1002/(SICI)1098-2264(199907)25:3<230::AID-GCC5>3.0.CO;2-E; Scheurlen WG, 1997, GENE CHROMOSOME CANC, V18, P50, DOI 10.1002/(SICI)1098-2264(199701)18:1<50::AID-GCC6>3.0.CO;2-0; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1995, ONCOGENE, V11, P291; STRAND D, 1998, MOL B INT U, V3, P61; Takagi Y, 1998, BRIT J CANCER, V78, P1152, DOI 10.1038/bjc.1998.645; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; TIMMONS L, 1993, DEV BIOL, V158, P364, DOI 10.1006/dbio.1993.1195; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; WOODHOUSE E, 1994, CELL GROWTH DIFFER, V5, P151; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Yam JWP, 2001, ONCOGENE, V20, P58, DOI 10.1038/sj.onc.1203982; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6	42	115	123	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3100	3109		10.1038/sj.onc.1208520	http://dx.doi.org/10.1038/sj.onc.1208520			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735678				2022-12-25	WOS:000228728100004
J	Mukherjee, T; Hombria, JCG; Zeidler, MP				Mukherjee, T; Hombria, JCG; Zeidler, MP			Opposing roles for Drosophila JAK/STAT signalling during cellular proliferation	ONCOGENE			English	Article						hopscotch; janus kinase; proliferation; STAT92E; unpaired	STAT PROTEINS; PATHWAY; GENE; RECEPTOR; KINASE; GROWTH; CELLS; NOTCH; IDENTIFICATION; ONCOGENESIS	The JAK/STAT signalling pathway mediates both anti-proliferative responses following interferon stimulation and cellular proliferation in response to cytokines such as interleukins and growth factors. Central to these responses are the seven vertebrate STAT molecules, misregulation of which is implicated in a variety of malignancies. We have investigated the proliferative role of the single Drosophila STAT92E, part of the evolutionarily conserved JAK/STAT cascade. During second instar larval wing disc development pathway activity is both necessary and sufficient to promote proliferation of this epithelial cell type. However by later stages, endogenous STAT92E is stimulated by a noncannonical mechanism to exert pronounced antiproliferative effects. Ectopic canonical activation is sufficient to further decrease proliferation and leads to the premature arrest of cells in the G2 phase of the cell cycle. The single STAT92E present in Drosophila therefore mediates both proproliferative functions analogous to vertebrate interleukin-stimulated STAT3 and antiproliferative functions analogous to interferon-stimulated STAT1. Pro- and antiproliferative roles therefore represent ancestral activities conserved through evolution and subsequently assigned to distinct molecules.	Max Planck Inst Biophys Chem, Dept Mol Dev Biol, D-37077 Gottingen, Germany; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Pablo Olavide, Ctr Andaluz Biol Desarrollo, Seville 41013, Spain	Max Planck Society; University of Cambridge; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD)	Zeidler, MP (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Dev Biol, Fassberg 11, D-37077 Gottingen, Germany.	mzeidle@gwdg.de	Hombría, James C-G/L-2036-2014; Zeidler, Martin/E-6209-2010	Hombría, James C-G/0000-0003-4183-5250; Zeidler, Martin/0000-0003-2942-1135				Bach EA, 2003, GENETICS, V165, P1149; Baonza A, 2000, P NATL ACAD SCI USA, V97, P2609, DOI 10.1073/pnas.040576497; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Castles FG, 2002, J EUR SOC POLICY, V12, P75, DOI 10.1177/0952872002012001564; Chen HW, 2002, GENE DEV, V16, P388, DOI 10.1101/gad.955202; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Cohen S. M., 1993, DEV DROSOPHILA MELAN, P747; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; Giraldez AJ, 2003, DEVELOPMENT, V130, P6533, DOI 10.1242/dev.00904; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; Henriksen MA, 2002, GENE DEV, V16, P2379, DOI 10.1101/gad.1020702; Hou SX, 2002, DEV CELL, V3, P765, DOI 10.1016/S1534-5807(02)00376-3; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Ito K, 1997, DEVELOPMENT, V124, P761; Jacobs HW, 1998, GENE DEV, V12, P3741, DOI 10.1101/gad.12.23.3741; Jager H, 2001, GENE DEV, V15, P2572, DOI 10.1101/gad.207301; Johansen KA, 2003, DEVELOPMENT, V130, P135, DOI 10.1242/dev.00202; Kamakura S, 2004, NAT CELL BIOL, V6, P547, DOI 10.1038/ncb1138; LEHMANN R, 1994, PRACTICAL US CELL MO, V44, P576; Li JH, 2003, DEV CELL, V5, P787, DOI 10.1016/S1534-5807(03)00328-9; Martin-Castellanos C, 2002, DEVELOPMENT, V129, P1003; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; PERRIMON N, 1986, DEV BIOL, V118, P28, DOI 10.1016/0012-1606(86)90070-9; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; RODRIGUEZFRADE JM, 2003, ACTIVATION BIOL, P191; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; SILVA CM, 2003, SIGNAL TRANSDUCERS A, P223; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; White K, 2001, METHOD CELL BIOL, V66, P321; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; XU T, 1993, DEVELOPMENT, V117, P1223; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Yang LH, 2003, DEV CELL, V4, P359, DOI 10.1016/S1534-5807(03)00059-5; Zeidler MP, 1999, GENE DEV, V13, P1342, DOI 10.1101/gad.13.10.1342	48	43	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2503	2511		10.1038/sj.onc.1208487	http://dx.doi.org/10.1038/sj.onc.1208487			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735706				2022-12-25	WOS:000228180600008
J	Mohr, A; Zwacka, RM; Jarmy, G; Buneker, C; Schrezenmeier, H; Dohner, K; Beltinger, C; Wiesneth, M; Debatin, KM; Stahnke, K				Mohr, A; Zwacka, RM; Jarmy, G; Buneker, C; Schrezenmeier, H; Dohner, K; Beltinger, C; Wiesneth, M; Debatin, KM; Stahnke, K			Caspase-8L expression protects CD34+hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis	ONCOGENE			English	Article						caspase-8; stem cell; apoptosis; splice variant; leukaemia; CD95	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; TUMOR-NECROSIS-FACTOR; DIFFERENTIAL EXPRESSION; NORMAL HEMATOPOIESIS; DOMINANT EXPRESSION; COMPLEX-FORMATION; INTERFERON-GAMMA; CD34(+) CELLS; MARROW-CELLS; FAS ANTIGEN	Regulation of sensitivity or resistance for apoptosis by death receptor ligand systems is a key control mechanism in the hematopoietic system. Dysfunctional or deregulated apoptosis can potentially contribute to the development of immune deficiencies, autoimmune diseases, and leukemia. Control of homeostasis starts at the level of hematopoietic stem cells (HSC). To this end, we found that CD34+ hematopoietic progenitor cells are constitutively resistant to CD95-mediated apoptosis and cannot be sensitized during short-term culture to death receptor-mediated apoptosis by cytokines. Detailed analysis of the death machinery revealed that CD34+ cells do not express caspase-8a/b, a crucial constituent of the death-inducing signaling complex (DISC) of death receptors. Instead, we found a smaller splice variant termed caspase-8L to be present in HSC. Forced expression of caspase-8L using a recombinant lentiviral vector was able to protect hematopoietic cells from death receptor-induced apoptosis even in the presence of caspase-8a/b. Furthermore, we found that caspase-8L is recruited to the DISC after CD95 triggering, thereby preventing CD95 from connecting to the caspase cascade. These results demonstrate an antiapoptotic function of caspase-8L and suggest a critical role as apoptosis regulator in HSC. Similar to CD34+ HSC, stem cell-derived leukemic blasts from AML(M0) patients only expressed caspase-8L. Additionally we found, caspase-8L expression in several AML and ALL samples. Thus, caspase-8L expression might explain constitutive resistance to CD95-mediated apoptosis in CD34+ progenitor cells and might participate in the development of stem cell-derived and other leukemias by providing protection from regulatory apoptosis.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany; Univ Ulm, Div Gene Therapy, D-89081 Ulm, Germany; Univ Ulm, Inst Clin Transfus Med & Immunogenet, D-89081 Ulm, Germany; Univ Hosp Ulm, Dept Internal Med 3, D-89081 Ulm, Germany	Ulm University; Ulm University; Ulm University; Ulm University	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	klaus-michael.debatin@medizin.uni-ulm.de	Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Zwacka, Ralf/0000-0003-2821-0387; Mohr, Andrea/0000-0002-4295-0341				AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; Barcena A, 1999, EXP HEMATOL, V27, P1428, DOI 10.1016/S0301-472X(99)00080-6; Bouscary D, 1997, LEUKEMIA, V11, P839, DOI 10.1038/sj.leu.2400654; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; DEBATIN KM, 1994, EUR J IMMUNOL, V24, P753, DOI 10.1002/eji.1830240339; Debatin KM, 2003, SEMIN CANCER BIOL, V13, P149, DOI 10.1016/S1044-579X(02)00132-3; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Dror Y, 2001, BLOOD, V97, P3011, DOI 10.1182/blood.V97.10.3011; Dybedal I, 2003, BLOOD, V102, P118, DOI 10.1182/blood-2002-07-2286; FALK MH, 1992, BLOOD, V79, P3300; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Himeji D, 2002, BLOOD, V99, P4070, DOI 10.1182/blood.V99.11.4070; Horiuchi T, 2000, BIOCHEM BIOPH RES CO, V272, P877, DOI 10.1006/bbrc.2000.2841; IWAI K, 1994, BLOOD, V84, P1201; Jarmy G, 2001, J MED VIROL, V64, P223, DOI 10.1002/jmv.1040; Josefsen D, 1999, EXP HEMATOL, V27, P1451, DOI 10.1016/S0301-472X(99)00073-9; Kim H, 2002, STEM CELLS, V20, P174, DOI 10.1634/stemcells.20-2-174; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Lotem J, 2002, ONCOGENE, V21, P3284, DOI 10.1038/sj.onc.1205319; MACIEJEWSKI J, 1995, BLOOD, V85, P3183, DOI 10.1182/blood.V85.11.3183.bloodjournal85113183; MACIEJEWSKI JP, 1995, BRIT J HAEMATOL, V91, P245, DOI 10.1111/j.1365-2141.1995.tb05277.x; Martin DA, 1999, P NATL ACAD SCI USA, V96, P4552, DOI 10.1073/pnas.96.8.4552; Mohr A, 2004, GENE THER, V11, P534, DOI 10.1038/sj.gt.3302154; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OWEN JJT, 1992, ANN NY ACAD SCI, V663, P305, DOI 10.1111/j.1749-6632.1992.tb38673.x; Perlman H, 2001, EUR J IMMUNOL, V31, P2421, DOI 10.1002/1521-4141(200108)31:8<2421::AID-IMMU2421>3.0.CO;2-W; Philpott NJ, 1997, BRIT J HAEMATOL, V97, P146, DOI 10.1046/j.1365-2141.1997.d01-2126.x; Pietschmann T, 1999, J VIROL, V73, P2613, DOI 10.1128/JVI.73.4.2613-2621.1999; Sato T, 1997, BRIT J HAEMATOL, V97, P356, DOI 10.1046/j.1365-2141.1997.562704.x; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Stahnke K, 1998, EXP HEMATOL, V26, P844; Stahnke K, 2004, APOPTOSIS, V9, P457, DOI 10.1023/B:APPT.0000031454.62937.fa; Straus SE, 1999, ANN INTERN MED, V130, P591, DOI 10.7326/0003-4819-130-7-199904060-00020; Straus SE, 2001, BLOOD, V98, P194, DOI 10.1182/blood.V98.1.194; Strauss G, 2003, J IMMUNOL, V171, P1172, DOI 10.4049/jimmunol.171.3.1172; Sugahara K, 2002, INT J HEMATOL, V76, P50, DOI 10.1007/BF02982718; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaishnaw AK, 1999, J CLIN INVEST, V103, P355, DOI 10.1172/JCI5121; VIBHUTI A, 2002, BRIT J HAEMATOL, V117, P993; Wickremasinghe RG, 1999, BLOOD, V93, P3587, DOI 10.1182/blood.V93.11.3587.411k46_3587_3600; Zwacka RM, 2000, J GENE MED, V2, P334, DOI 10.1002/1521-2254(200009/10)2:5<334::AID-JGM129>3.0.CO;2-Q	49	42	44	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2421	2429		10.1038/sj.onc.1208432	http://dx.doi.org/10.1038/sj.onc.1208432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735742				2022-12-25	WOS:000227877400014
J	Cai, Y; Stafford, LJ; Bryan, BA; Mitchell, D; Liu, MY				Cai, Y; Stafford, LJ; Bryan, BA; Mitchell, D; Liu, MY			G-protein-activated phospholipase C-beta, new partners for cell polarity proteins Par3 and Par6	ONCOGENE			English	Article						PLC-beta; cell polarity; cell asymmetric division; PDZ domain; G-protein	CAENORHABDITIS-ELEGANS EMBRYOS; KINASE-C; DROSOPHILA NEUROBLASTS; PLANAR POLARITY; GENE-EXPRESSION; DIRECT BINDING; G-ALPHA; DIVISION; CDC42; LOCALIZATION	Cell polarity and asymmetric cell division are fundamental traits of all living cells and play an essential role in embryonic development, neuronal cell chirality formation, and maintenance of mammalian epithelial cell morphology. Heterotrimeric GTP-binding proteins ( G proteins) are involved in directing cell polarity and asymmetric cell division in different organisms. However, the mechanism for G-protein-mediated cell polarity and asymmetric cell division is poorly understood. In this study, we have demonstrated that G-protein-activated phospholipase C-beta (PLC-beta) interacts with cell polarity proteins Par3 and Par6 ( Par: partition-defective) to form protein complexes and to mediate downstream signal transduction. The interactions between PLC-beta and Par proteins are direct and require the extreme C-terminal-specific sequence motifs of PLC-beta and the PDZ (PSD95/Dlg/ZO-1) domains of Par proteins. Binding of Par proteins with PLC-beta stimulates PLC-beta enzymatic activity, leading to the hydrolysis of phosphatidylinositol-4,5-bisphosphate, and the production of diacylglycerol and inositol 1,4, 5-triphosphate, important mediators in cell polarity and cell asymmetric division processes. Furthermore, we have shown that coexpression of PLC-beta with Par proteins induces transcriptional activation coupled to intracellular Ca2+ and the Wnt signaling pathway. Therefore, our data suggest that the interaction of PLC-beta with cell polarity Par proteins may serve as a nexus to transduce extracellular signals to transcriptional regulation through G-protein-mediated signaling pathway in cell polarity and cell asymmetric division.	Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, Alkek Inst Biosci & Technol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Liu, MY (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, Alkek Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamhsc.edu		Liu, Mingyao/0000-0001-7339-5048	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064792] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL64792] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basham SE, 1999, DEV BIOL, V215, P253, DOI 10.1006/dbio.1999.9447; Bohm H, 1997, CURR BIOL, V7, P603, DOI 10.1016/S0960-9822(06)00260-0; Brandt D, 2002, J BIOL CHEM, V277, P20903, DOI 10.1074/jbc.M200946200; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Chant T, 1999, ANNU REV CELL DEV BI, V15, P365, DOI 10.1146/annurev.cellbio.15.1.365; Cocco L, 2001, MARC MALPIG SYMP SER, V7, P31; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Fanto M, 2004, J CELL SCI, V117, P527, DOI 10.1242/jcs.00973; Fanto M, 1999, NATURE, V397, P523, DOI 10.1038/17389; Gomes JE, 2002, CURR BIOL, V12, pR444, DOI 10.1016/S0960-9822(02)00939-9; Gong Y, 2004, NATURE, V430, P689, DOI 10.1038/nature02796; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Herman MA, 2002, SEMIN CELL DEV BIOL, V13, P233, DOI 10.1016/S1084-9521(02)00051-4; Jan YN, 2001, NAT REV NEUROSCI, V2, P772, DOI 10.1038/35097516; Jan YN, 2003, NEURON, V40, P229, DOI 10.1016/S0896-6273(03)00631-7; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kemphues K, 2000, CELL, V101, P345, DOI 10.1016/S0092-8674(00)80844-2; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kerschbaum HH, 1997, J IMMUNOL, V159, P1628; Kim SK, 2000, NAT CELL BIOL, V2, pE143, DOI 10.1038/35019620; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Manzoli L, 1999, ANTICANCER RES, V19, P3753; Meili R, 2003, CELL, V114, P153, DOI 10.1016/S0092-8674(03)00553-1; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Roegiers F, 2004, CURR OPIN CELL BIOL, V16, P195, DOI 10.1016/j.ceb.2004.02.010; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schneider SQ, 2003, ANNU REV GENET, V37, P221, DOI 10.1146/annurev.genet.37.110801.142443; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; van Haasteren G, 1999, J RECEPT SIGNAL TR R, V19, P481, DOI 10.3109/10799899909036666; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Xia CZ, 2001, J BIOL CHEM, V276, P19770, DOI 10.1074/jbc.M006266200; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	46	23	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4293	4300		10.1038/sj.onc.1208593	http://dx.doi.org/10.1038/sj.onc.1208593			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15782111				2022-12-25	WOS:000229815300012
J	Claperon, A; Rose, C; Gane, P; Collec, E; Bertrand, O; Ouimet, T				Claperon, A; Rose, C; Gane, P; Collec, E; Bertrand, O; Ouimet, T			The Kell protein of the common K2 phenotype is a catalytically active metalloprotease, whereas the rare Kell K1 antigen is inactive - Identification of novel substrates for the Kell protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIN-CONVERTING ENZYME-1; BLOOD-GROUP PROTEIN; MEMBRANE-BOUND METALLOPROTEASE; NEUTRAL ENDOPEPTIDASE-24.11; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; GROUP SYSTEM; NEPRILYSIN; INHIBITION; CELLS	Kell blood group is a highly polymorphic system containing over 20 different antigens borne by the protein Kell, a 93-kDa type II glycoprotein that displays high sequence homology with members of the M13 family of zinc-dependent metalloproteases whose prototypical member is neprilysin. Kell K1 is an antigen expressed in 9% of the Caucasian population, characterized by a point mutation (T193M) of the Kell K2 antigen, and located within a putative N-glycosylation consensus sequence. Recently, a recombinant, non-physiological, soluble form of Kell was shown to cleave Big ET-3 to produce the mature vasoconstrictive peptide. To better characterize the enzymatic activity of the Kell protein and the possible differences introduced by antigenic point mutations affecting post-translational processing, the membrane-bound forms of the Kell K1 and Kell K2 antigens were expressed either in K562 cells, an erythroid cell line, or in HEK293 cells, a non-erythroid system, and their pharmacological profiles and enzymatic specificities toward synthetic and natural peptides were evaluated. Results presented herein reveal that the two antigens possess considerable differences in their enzymatic activities, although not in their trafficking pattern. Indeed, although both antigens are expressed at the cell surface, Kell K1 protein is shown to be inactive, whereas the Kell K2 antigen binds neprilysin inhibitory compounds such as phosphoramidon and thiorphan with high affinity, cleaves the precursors of the endothelin peptides, and inactivates members of the tachykinin family with enzymatic properties resembling those of other members of the M13 family of metalloproteases to which it belongs.	Ctr Paul Broca, INSERM, U573, F-75014 Paris, France; Inst Natl Transfus Sanguine, INSERM, Groupement Interet Publ, UMRS 665, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Ouimet, T (corresponding author), Ctr Paul Broca, INSERM, U573, 2ter Rue Alesia, F-75014 Paris, France.	ouimet@broca.inserm.fr						BARETT AJ, 1998, HDB PROTEOLYTIC ENZY, P1033; Camara-Clayette V, 2001, BIOCHEM J, V356, P171, DOI 10.1042/0264-6021:3560171; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chu THT, 2001, BRIT J HAEMATOL, V113, P32, DOI 10.1046/j.1365-2141.2001.02695.x; Daniels GL, 1996, BLOOD, V88, P4045, DOI 10.1182/blood.V88.10.4045.bloodjournal88104045; Du L, 1996, GENOMICS, V36, P22, DOI 10.1006/geno.1996.0421; Eckman EA, 2001, J BIOL CHEM, V276, P24540, DOI 10.1074/jbc.M007579200; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Facchinetti P, 2003, NEUROSCIENCE, V118, P627, DOI 10.1016/S0306-4522(02)01002-3; Gane P, 2001, BRIT J HAEMATOL, V113, P680, DOI 10.1046/j.1365-2141.2001.02757.x; GAVRAS H, 1978, NEW ENGL J MED, V298, P991, DOI 10.1056/NEJM197805042981803; Ghaddar G, 2000, BIOCHEM J, V347, P419, DOI 10.1042/0264-6021:3470419; GOOSSENS D, 1987, J IMMUNOL METHODS, V101, P193, DOI 10.1016/0022-1759(87)90150-5; GROS C, 1989, P NATL ACAD SCI USA, V86, P7580, DOI 10.1073/pnas.86.19.7580; HO MF, 1994, CELL, V77, P869, DOI 10.1016/0092-8674(94)90136-8; Ikeda K, 1999, J BIOL CHEM, V274, P32469, DOI 10.1074/jbc.274.45.32469; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; JABER A, 1991, BRIT J HAEMATOL, V79, P311, DOI 10.1111/j.1365-2141.1991.tb04539.x; Johnson GD, 1999, J BIOL CHEM, V274, P4053, DOI 10.1074/jbc.274.7.4053; KHAMLICHI S, 1995, EUR J BIOCHEM, V228, P931, DOI 10.1111/j.1432-1033.1995.tb20342.x; Kiryu-Seo S, 2000, P NATL ACAD SCI USA, V97, P4345, DOI 10.1073/pnas.070509897; LAFRANCE MH, 1994, BIOCHEM J, V302, P451, DOI 10.1042/bj3020451; Lee S, 2000, SEMIN HEMATOL, V37, P113, DOI 10.1016/S0037-1963(00)90036-2; Lee S, 1999, BLOOD, V94, P1440, DOI 10.1182/blood.V94.4.1440.416k01_1440_1450; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; Lee S, 2003, BLOOD, V102, P3028, DOI 10.1182/blood-2003-05-1564; LEE SH, 1995, BLOOD, V85, P912, DOI 10.1182/blood.V85.4.912.bloodjournal854912; MALFROY B, 1978, NATURE, V276, P523, DOI 10.1038/276523a0; MARSH WL, 1990, TRANSFUSION, V30, P158, DOI 10.1046/j.1537-2995.1990.30290162904.x; MASOUREDIS S P, 1980, Haematologia, V13, P59; MATSAS R, 1983, P NATL ACAD SCI-BIOL, V80, P3111, DOI 10.1073/pnas.80.10.3111; MILGRAM SL, 1994, J CELL SCI, V107, P737; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; Oefner C, 2000, J MOL BIOL, V296, P341, DOI 10.1006/jmbi.1999.3492; Oefner PJ, 2002, J CHROMATOGR B, V782, P3, DOI 10.1016/S1570-0232(02)00699-2; Ouimet T, 2004, PROTEIN PEPTIDE LETT, V11, P479, DOI 10.2174/0929866043406625; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; PATEY G, 1981, SCIENCE, V212, P113, DOI 10.1126/science.7015510; Petrescu SM, 1997, J BIOL CHEM, V272, P15796, DOI 10.1074/jbc.272.25.15796; ROQUES BP, 1980, NATURE, V288, P286, DOI 10.1038/288286a0; Rose C, 2002, BIOCHEM J, V363, P697, DOI 10.1042/0264-6021:3630697; Russo D, 2000, BLOOD, V96, P340, DOI 10.1182/blood.V96.1.340.013k45_340_346; Russo D, 1999, BBA-BIOMEMBRANES, V1461, P10, DOI 10.1016/S0005-2736(99)00148-0; Russo D, 1998, J BIOL CHEM, V273, P13950, DOI 10.1074/jbc.273.22.13950; Savage P, 1998, J CARDIOVASC PHARM, V31, pS16, DOI 10.1097/00005344-199800001-00007; Schweizer A, 1999, J BIOL CHEM, V274, P20450, DOI 10.1074/jbc.274.29.20450; Shimada K, 1996, BIOCHEM J, V315, P863, DOI 10.1042/bj3150863; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Tanja O, 2000, BIOCHEM BIOPH RES CO, V271, P565, DOI 10.1006/bbrc.2000.2664; Valdenaire O, 1999, MOL BRAIN RES, V64, P211, DOI 10.1016/S0169-328X(98)00321-0; Voisin S, 2004, J BIOL CHEM, V279, P46172, DOI 10.1074/jbc.M407333200; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	53	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21272	21283		10.1074/jbc.M500100200	http://dx.doi.org/10.1074/jbc.M500100200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15769748	hybrid			2022-12-25	WOS:000229438800046
J	Merkel, M; Loeffler, B; Kluger, M; Fabig, N; Geppert, G; Pennacchio, LA; Laatsch, A; Heeren, J				Merkel, M; Loeffler, B; Kluger, M; Fabig, N; Geppert, G; Pennacchio, LA; Laatsch, A; Heeren, J			Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CHOLESTEROL LEVELS; GENE-CLUSTER; MICE; A5; HYPERTRIGLYCERIDEMIA; METABOLISM; CLEARANCE; MECHANISM; LIPOLYSIS	Apolipoprotein A5 (APOA5) is associated with differences in triglyceride levels and familial combined hyperlipidemia. In genetically engineered mice, apoAV plasma levels are inversely correlated with plasma triglycerides. To elucidate the mechanism by which apoAV influences plasma triglycerides, metabolic studies and in vitro assays resembling physiological conditions were performed. In human APOA5 transgenic mice (hAPOA5tr), catabolism of chylomicrons and very low density lipoprotein (VLDL) was accelerated due to a faster plasma hydrolysis of triglycerides by lipoprotein lipase (LPL). Hepatic VLDL and intestinal chylomicron production were not affected. The functional interplay between apoAV and LPL was further investigated by cross-breeding a human LPL transgene with the apoa5 knock-out and the hAPOA5tr to an lpl-deficient background. Increased LPL activity completely normalized hypertriglyceridemia of apoa5-deficient mice; however, overexpression of human apoAV modulated triglyceride levels only slightly when LPL was reduced. To reflect the physiological situation in which LPL is bound to cell surface proteoglycans, we examined hydrolysis in the presence or absence of proteoglycans. Without proteoglycans, apoAV derived either from triglyceride-rich lipoproteins, hAPOA5tr high density lipoprotein, or a recombinant source did not alter the LPL hydrolysis rate. In the presence of proteoglycans, however, apoAV led to a significant and dose-dependent increase in LPL-mediated hydrolysis of VLDL triglycerides. These results were confirmed in cell culture using a proteoglycan-deficient cell line. A direct interaction between LPL and apoAV was found by ligand blotting. It is proposed, that apoAV reduces triglyceride levels by guiding VLDL and chylomicrons to proteoglycan-bound LPL for lipolysis.	Univ Hamburg, Hosp Eppendorf, Dept Internal Med, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, IBM 2, D-20246 Hamburg, Germany; Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA	University of Hamburg; University of Hamburg; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Merkel, M (corresponding author), Univ Hamburg, Hosp Eppendorf, Dept Internal Med, Martinistr 52, D-20246 Hamburg, Germany.	merkel@uke.uni-hamburg.de		Merkel, Martin/0000-0002-2850-5110; Pennacchio, Len/0000-0002-8748-3732				AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Baroukh N, 2004, ARTERIOSCL THROM VAS, V24, P1297, DOI 10.1161/01.ATV.0000130463.68272.1d; Beckstead JA, 2003, BIOCHEMISTRY-US, V42, P9416, DOI 10.1021/bi034509t; de Man FHAF, 1997, J LIPID RES, V38, P2465; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Evans D, 2003, J MOL MED-JMM, V81, P645, DOI 10.1007/s00109-003-0465-4; Fruchart-Najib J, 2004, BIOCHEM BIOPH RES CO, V319, P397, DOI 10.1016/j.bbrc.2004.05.003; Goldberg IJ, 1996, J LIPID RES, V37, P693; Groenendijk M, 2001, ATHEROSCLEROSIS, V157, P1, DOI 10.1016/S0021-9150(01)00539-1; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Heeren J, 2002, J MOL MED-JMM, V80, P576, DOI 10.1007/s00109-002-0351-5; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; Lai CQ, 2004, J LIPID RES, V45, P2096, DOI 10.1194/jlr.M400192-JLR200; LevakFrank S, 1997, J BIOL CHEM, V272, P17182, DOI 10.1074/jbc.272.27.17182; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; Merkel M, 2002, J BIOL CHEM, V277, P7405, DOI 10.1074/jbc.M107914200; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; O'Brien PJ, 2005, CLIN CHEM, V51, P351, DOI 10.1373/clinchem.2004.040824; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; Pennacchio LA, 2003, ARTERIOSCL THROM VAS, V23, P529, DOI 10.1161/01.ATV.0000054194.78240.45; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Pittman R C, 1986, Methods Enzymol, V129, P612; Sakurabayashi I, 2001, CLIN CHIM ACTA, V312, P87, DOI 10.1016/S0009-8981(01)00591-5; Schaap FG, 2004, J BIOL CHEM, V279, P27941, DOI 10.1074/jbc.M403240200; Talmud PJ, 2002, HUM MOL GENET, V11, P3039, DOI 10.1093/hmg/11.24.3039; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; Vergnes L, 2000, ARTERIOSCL THROM VAS, V20, P2267, DOI 10.1161/01.ATV.20.10.2267; Weinberg RB, 2003, J BIOL CHEM, V278, P34438, DOI 10.1074/jbc.M303784200; Weinstock PH, 1997, J LIPID RES, V38, P1782; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319	31	234	260	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21553	21560		10.1074/jbc.M411412200	http://dx.doi.org/10.1074/jbc.M411412200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15774484	hybrid			2022-12-25	WOS:000229438800078
J	Feng, L; Yuan, J; Toogood, H; Tumbula-Hansen, D; Soll, D				Feng, L; Yuan, J; Toogood, H; Tumbula-Hansen, D; Soll, D			Aspartyl-tRNA synthetase requires a conserved proline in the anticodon-binding loop for tRNA(Asn) recognition in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMUS-THERMOPHILUS; ESCHERICHIA-COLI; ASPARAGINE; AMINOACYLATION; MECHANISM; EVOLUTION; IDENTITY	Most prokaryotes require Asp-tRNAAsn for the synthesis of Asn-tRNA(Asn). This misacylated tRNA species is synthesized by a non-discriminating aspartyl-tRNA synthetase (AspRS) that acylates both tRNA(Asp) and tRNA(Asn) with aspartate. In contrast, a discriminating AspRS forms only Asp-tRNA(Asp). Here we show that a conserved proline (position 77) in the L1 loop of the non-discriminating Deinococcus radiodurans AspRS2 is required for tRNA(Asn) recognition in vivo. Escherichia coli trpA34 was transformed with DNA from a library of D. radiodurans aspS2 genes with a randomized codon 77 and then subjected to in vivo selection for Asp-tRNA(Asn) formation by growth in minimal medium. Only proline codons were found at position 77 in the aspS2 genes isolated from 21 of the resulting viable colonies. However, when the aspS temperature-sensitive E. coli strain CS89 was transformed with the same DNA library and then screened for Asp-tRNA(Asp) formation in vivo by growth at the nonpermissive temperature, codons for seven other amino acids besides proline were identified at position 77 in the isolates examined. Thus, replacement of proline 77 by cysteine, isoleucine, leucine, lysine, phenylalanine, serine, or valine resulted in mutant D. radiodurans AspRS2 enzymes still capable of forming Asp-tRNA(Asp) but unable to recognize tRNA(Asn). This strongly suggests that proline 77 is responsible for the non-discriminatory tRNA recognition properties of this enzyme.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University; Yale University	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.	soll@trna.chem.yale.edu		Toogood, Helen/0000-0003-4797-0293; Hansen, Debra T./0000-0003-4395-8297				Becker HD, 1996, BIOCHEMISTRY-US, V35, P7447, DOI 10.1021/bi9601058; Becker HD, 1998, P NATL ACAD SCI USA, V95, P12832, DOI 10.1073/pnas.95.22.12832; Berthet-Colominas C, 1998, EMBO J, V17, P2947, DOI 10.1093/emboj/17.10.2947; Brevet A, 2003, J BIOL CHEM, V278, P30927, DOI 10.1074/jbc.M302618200; Charron C, 2003, EMBO J, V22, P1632, DOI 10.1093/emboj/cdg148; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Dock-Bregeon AC, 2004, MOL CELL, V16, P375, DOI 10.1016/S1097-2765(04)00591-X; Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5; Feng L, 2003, P NATL ACAD SCI USA, V100, P5676, DOI 10.1073/pnas.0631525100; FENG L, 2004, AMINOACYL TRNA SYNTH, P314; Hendrickson TL, 2003, MOL B INT U, P34; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Kowal AK, 2001, P NATL ACAD SCI USA, V98, P2268, DOI 10.1073/pnas.031488298; Li T, 1999, FEBS LETT, V462, P302, DOI 10.1016/S0014-5793(99)01550-1; Min B, 2003, J BACTERIOL, V185, P3524, DOI 10.1128/JB.185.12.3524-3526.2003; Min B, 2002, P NATL ACAD SCI USA, V99, P2678, DOI 10.1073/pnas.012027399; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; SHARPLES GJ, 1991, MUTAT RES, V264, P93, DOI 10.1016/0165-7992(91)90122-K; SHIRVANEE L, 1990, J BIOL CHEM, V265, P6624; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; Tumbula-Hansen D, 2002, J BIOL CHEM, V277, P37184, DOI 10.1074/jbc.M204767200	22	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20638	20641		10.1074/jbc.M500874200	http://dx.doi.org/10.1074/jbc.M500874200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781458	hybrid			2022-12-25	WOS:000229242000060
J	Ortega-Perez, I; Cano, E; Were, F; Villar, M; Vazquez, J; Redondo, JM				Ortega-Perez, I; Cano, E; Were, F; Villar, M; Vazquez, J; Redondo, JM			c-jun N-terminal kinase (JNK) positively regulates NFATc2 transactivation through phosphorylation within the N-terminal regulatory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; ACTIVATED PROTEIN-KINASE; TRAP MASS-SPECTROMETRY; T-CELLS; GENE-EXPRESSION; NUCLEAR FACTOR; TRANSCRIPTIONAL ACTIVITY; SIGNAL-TRANSDUCTION; PHOSPHATASE CALCINEURIN; IDENTIFICATION	The nuclear factor of activated T cells ( NFAT) family of transcription factors regulates the transcription of cytokine genes and other genes involved in the regulation and function of the immune system. NFAT activity is regulated by the phosphatase calcineurin, which binds and dephosphorylates the NFAT N-terminal regulatory domain, a critical step required for nuclear translocation and transcriptional activity. Here we show that the mitogen-activated protein kinase ( MAPK) JNK activates NFATc2-dependent transcription. Mass spectrometry revealed that JNK phosphorylates at least six residues within the NFATc2 regulatory domain in vitro. Transfection of cells with a chimeric construct encoding the GAL-4 DNA binding domain linked to wild-type NFATc2 showed that JNK stimulates the NFATc2 transactivation domain in activated Jurkat T lymphocytes, an effect that is inhibited by dominant-negative versions of JNK. Likewise, the mutation of the phosphorylation sites identified revealed that Thr(116) and Ser(170) are critical for the transactivation of NFATc2 by JNK. In addition, clustered mutation of the SP-conserved motifs of NFATc2 showed that SP1 and SP2, but not SP3, are also important for the inducible transactivation of NFATc2. Furthermore, mass spectrometry analysis of NFATc2-transfected cells indicated that the activation of the JNK pathway results in the in vivo phosphorylation of Thr(116). Our results indicate that, unlike other NFAT members, the transcriptional activity of NFATc2 is up-regulated by JNK. JNK-mediated phosphorylation of NFATs thus appears to play a differential physiological role among NFAT family members.	Ctr Nacl Invest Cardiovasc, Madrid 28760, Spain; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Redondo, JM (corresponding author), Ctr Nacl Invest Cardiovasc, Ronda Poniente 5, Madrid 28760, Spain.	jmredondo@cbm.uam.es	Cano, Eva/A-2049-2010; Villar-Rayo, Marga M/J-4155-2012; Vazquez, Jesus/B-7697-2015; Redondo, Juan Miguel/H-6351-2015	Cano, Eva/0000-0003-2750-6135; Villar-Rayo, Marga M/0000-0003-4172-9079; Vazquez, Jesus/0000-0003-1461-5092; Redondo, Juan Miguel/0000-0001-5779-9122				Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Behrens A, 2001, P NATL ACAD SCI USA, V98, P1769, DOI 10.1073/pnas.98.4.1769; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chen Y, 2001, J BIOL CHEM, V276, P8350, DOI 10.1074/jbc.M008431200; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Gregorio R, 2001, J BIOL CHEM, V276, P27003, DOI 10.1074/jbc.M100885200; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; GOMEZ DA, 2000, J BIOL CHEM, V275, P13872; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Kiani A, 2001, BLOOD, V98, P1480, DOI 10.1182/blood.V98.5.1480; Li YS, 1996, MOL CELL BIOL, V16, P5947; Liang QR, 2003, EMBO J, V22, P5079, DOI 10.1093/emboj/cdg474; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Marina A, 1999, J MASS SPECTROM, V34, P17, DOI 10.1002/(SICI)1096-9888(199901)34:1<17::AID-JMS746>3.3.CO;2-Y; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; Ogueta S, 2000, J MASS SPECTROM, V35, P556; Okamura H, 2004, MOL CELL BIOL, V24, P4184, DOI 10.1128/MCB.24.10.4184-4195.2004; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Rainio EM, 2002, J IMMUNOL, V168, P1524, DOI 10.4049/jimmunol.168.4.1524; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Rodriguez A, 1999, ANAL BIOCHEM, V272, P171, DOI 10.1006/abio.1999.4156; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sheridan CM, 2002, J BIOL CHEM, V277, P48664, DOI 10.1074/jbc.M207029200; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu CC, 2003, MOL CELL BIOL, V23, P6442, DOI 10.1128/MCB.23.18.6442-6454.2003; Yang TTC, 2005, MOL CELL BIOL, V25, P907, DOI 10.1128/MCB.25.3.907-920.2005; Yang TTC, 2002, MOL CELL BIOL, V22, P3892, DOI 10.1128/MCB.22.11.3892-3904.2002; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	54	53	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20867	20878		10.1074/jbc.M501898200	http://dx.doi.org/10.1074/jbc.M501898200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15743762	hybrid			2022-12-25	WOS:000229242000085
J	Li, XF; Zhang, YZ; Kang, HS; Liu, WZ; Liu, P; Zhang, JG; Harris, SE; Wu, DQ				Li, XF; Zhang, YZ; Kang, HS; Liu, WZ; Liu, P; Zhang, JG; Harris, SE; Wu, DQ			Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN-5; HIGH-BONE-MASS; NEGATIVE REGULATOR; DICKKOPF PROTEINS; BMP ANTAGONIST; BETA-CATENIN; GENE; MUTATION; DENSITY; FAMILY	The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass. In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293T cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by overexpression of Wnt co-receptor low density lipoprotein receptor-related protein (LRP) 5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transduction of canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the high bone mass phenotype associated with the loss of sclerostin may be attributed, at least in part, to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA; Univ Texas, Hlth Sci Ctr, Dept Periodont & Cellular Struct Biol, San Antonio, TX 78229 USA	University of Connecticut; University of Missouri System; University of Missouri Kansas City; University of Texas System; University of Texas Health San Antonio	Wu, DQ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.							Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006-291X(02)02951-0; Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537; Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003-0498; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Dale TC, 1998, BIOCHEM J, V329, P209; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gumbiner BM, 1998, CURR OPIN GENET DEV, V8, P430, DOI 10.1016/S0959-437X(98)80114-7; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Itasaki N, 2003, DEVELOPMENT, V130, P4295, DOI 10.1242/dev.00674; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200; Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Monaghan AP, 1999, MECH DEVELOP, V87, P45, DOI 10.1016/S0925-4773(99)00138-0; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Nusse R, 2001, NATURE, V411, P254, DOI 10.1038/35077199; Pandur P, 2001, BIOESSAYS, V23, P207, DOI 10.1002/1521-1878(200103)23:3<207::AID-BIES1029>3.0.CO;2-0; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; Winkler DG, 2004, J BIOL CHEM, V279, P36293, DOI 10.1074/jbc.M400521200; Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200; Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677-4684.2004	40	1011	1092	3	72	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19883	19887		10.1074/jbc.M413274200	http://dx.doi.org/10.1074/jbc.M413274200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778503	hybrid			2022-12-25	WOS:000229113700057
J	de Garavilla, L; Greco, MN; Sukumar, N; Chen, ZW; Pineda, AO; Mathews, FS; Di Cera, E; Giardino, EC; Wells, GI; Haertlein, BJ; Kauffman, JA; Corcoran, TW; Derian, CK; Eckardt, AJ; Damiano, BP; Andrade-Gordon, P; Maryanoff, BE				de Garavilla, L; Greco, MN; Sukumar, N; Chen, ZW; Pineda, AO; Mathews, FS; Di Cera, E; Giardino, EC; Wells, GI; Haertlein, BJ; Kauffman, JA; Corcoran, TW; Derian, CK; Eckardt, AJ; Damiano, BP; Andrade-Gordon, P; Maryanoff, BE			A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase - Molecular mechanisms and anti-inflammatory activity in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; ANGSTROM CRYSTAL-STRUCTURE; ANGIOTENSIN-II; NEUTROPHIL RECRUITMENT; INDUCED SPUTUM; CELL BIOLOGY; INFLAMMATION; ADHESION; PROTEINASES; CYTOKINE	Certain leukocytes release serine proteases that sustain inflammatory processes and cause disease conditions, such as asthma and chronic obstructive pulmonary disease. We identified beta-ketophosphonate 1 (JNJ-10311795; RWJ-355871) as a novel, potent dual inhibitor of neutrophil cathepsin G ( K-i = 38 nM) and mast cell chymase ( K-i = 2.3 nM). The x-ray crystal structures of 1 complexed with human cathepsin G ( 1.85 angstrom) and human chymase ( 1.90 angstrom) reveal the molecular basis of the dual inhibition. Ligand 1 occupies the S-1 and S-2 subsites of cathepsin G and chymase similarly, with the 2-naphthyl in S-1, the 1-naphthyl in S-2, and the phosphonate group in a complex network of hydrogen bonds. Surprisingly, however, the carboxamido- N-(naphthalene-2-carboxyl) piperidine group is found to bind in two distinct conformations. In cathepsin G, this group occupies the hydrophobic S-3/S-4 subsites, whereas in chymase, it does not; rather, it folds onto the 1-naphthyl group of the inhibitor itself. Compound 1 exhibited noteworthy anti-inflammatory activity in rats for glycogen-induced peritonitis and lipopolysaccharide-induced airway inflammation. In addition to a marked reduction in neutrophil influx, 1 reversed increases in inflammatory mediators interleukin-1 alpha, interleukin-1 beta, tissue necrosis factor-alpha, and monocyte chemotactic protein-1 in the glycogen model and reversed increases in airway nitric oxide levels in the lipopolysaccharide model. These findings demonstrate that it is possible to inhibit both cathepsin G and chymase with a single molecule and suggest an exciting opportunity in the treatment of asthma and chronic obstructive pulmonary disease.	Johnson & Johnson Pharmaceut Res & Dev, Drug Discovery, Spring House, PA 19477 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Johnson & Johnson; Johnson & Johnson USA; Washington University (WUSTL)	Maryanoff, BE (corresponding author), Johnson & Johnson Pharmaceut Res & Dev, Drug Discovery, Spring House, Spring House, PA 19477 USA.	bmaryano@prdus.jnj.com			NHLBI NIH HHS [HL58141, HL73813, HL49413] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL073813, R01HL058141, R01HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; Barnes PJ, 2003, ANNU REV MED, V54, P113, DOI 10.1146/annurev.med.54.101601.152209; BORISH L, 1992, MED CLIN N AM, V76, P765, DOI 10.1016/S0025-7125(16)30325-X; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARTER CW, 1979, J BIOL CHEM, V254, P2219; CAUGHEY GH, 1994, AM J RESP CRIT CARE, V150, pS138, DOI 10.1164/ajrccm/150.6_Pt_2.S138; CAUGHEY GH, 1995, CLIN ALLERGY IMMUNOL, V6, P305; Chertov O, 2000, IMMUNOL REV, V177, P68, DOI 10.1034/j.1600-065X.2000.17702.x; Compton SJ, 1998, J IMMUNOL, V161, P1939; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635, DOI 10.1164/ajrccm.160.5.9811058; Greco MN, 2002, J AM CHEM SOC, V124, P3810, DOI 10.1021/ja017506h; HANSON RD, 1990, J BIOL CHEM, V265, P1524; Hart PH, 2001, IMMUNOL CELL BIOL, V79, P149, DOI 10.1046/j.1440-1711.2001.00983.x; Hirche TO, 2004, AM J RESP CELL MOL, V30, P576, DOI 10.1165/rcmb.2003-0253OC; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; Hof P, 1996, EMBO J, V15, P5481, DOI 10.1002/j.1460-2075.1996.tb00933.x; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P28; Huang XR, 2003, J AM SOC NEPHROL, V14, P1738, DOI 10.1097/01.ASN.0000071512.93927.4E; Iwamura H, 2002, INFLAMM RES, V51, P160, DOI 10.1007/PL00000288; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lehr H A, 1994, Curr Opin Hematol, V1, P92; Lindberg BF, 1997, PEPTIDES, V18, P847, DOI 10.1016/S0196-9781(97)00011-9; McGrath ME, 1997, BIOCHEMISTRY-US, V36, P14318, DOI 10.1021/bi971403n; Miller HRP, 2002, IMMUNOLOGY, V105, P375, DOI 10.1046/j.1365-2567.2002.01375.x; Mulligan MS, 1998, INFLAMM RES, V47, P251, DOI 10.1007/s000110050326; MUROHARA T, 1995, J PHARMACOL EXP THER, V274, P1246; Nishimoto M, 2001, CIRCULATION, V104, P1274, DOI 10.1161/hc3601.094304; Orito K, 2004, TOHOKU J EXP MED, V203, P287, DOI 10.1620/tjem.203.287; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OWEN CA, 1995, SEMIN CELL BIOL, V6, P367, DOI 10.1016/S1043-4682(05)80007-8; Owen CA, 1998, J IMMUNOL, V160, P1436; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; Pearlman DS, 1999, J ALLERGY CLIN IMMUN, V104, pS132, DOI 10.1016/S0091-6749(99)70308-8; Pereira PJB, 1999, J MOL BIOL, V286, P163, DOI 10.1006/jmbi.1998.2462; PICCIONI PD, 1992, CHEST, V102, P1470, DOI 10.1378/chest.102.5.1470; Rhee JS, 2003, CURR MOL MED, V3, P387, DOI 10.2174/1566524033479753; Richards D, 2003, 11TH IEEE INTERNATIONAL REQUIREMENTS ENGINEERING CONFERENCE, PROCEEDINGS, P373; RICHARDSON D, 1993, PIANO KEYBOARD, P15; ROUSSEL A, 1991, SILICON GRAPHICS GEO; SCHECHTER NM, 2000, MAST CELLS BASOPHILS, P275; Shapiro SD, 2002, BIOCHEM SOC T, V30, P98, DOI 10.1042/BST0300098; Simon S R, 1993, Agents Actions Suppl, V42, P27; Stockley RA, 1999, AM J RESP CRIT CARE, V160, pS49, DOI 10.1164/ajrccm.160.supplement_1.13; SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003-2697(83)90019-2; Tani Kenji, 2001, Journal of Medical Investigation, V48, P133; Tomimori Y, 2003, EUR J PHARMACOL, V478, P179, DOI 10.1016/j.ejphar.2003.08.050; Traves SL, 2002, THORAX, V57, P590, DOI 10.1136/thorax.57.7.590; Tremblay Guy M, 2003, Curr Opin Investig Drugs, V4, P556; Underwood DC, 2000, AM J PHYSIOL-LUNG C, V279, pL895, DOI 10.1152/ajplung.2000.279.5.L895; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Yao V, 2003, ANZ J SURG, V73, P1052, DOI 10.1046/j.1445-2197.2003.t01-18-.x; [No title captured]	55	67	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18001	18007		10.1074/jbc.M501302200	http://dx.doi.org/10.1074/jbc.M501302200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15741158	hybrid			2022-12-25	WOS:000228807200055
J	Ezraty, B; Dahlgren, B; Deutscher, MP				Ezraty, B; Dahlgren, B; Deutscher, MP			The RNase Z homologue encoded by Escherichia coli elaC gene is RNase BN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL NUCLEOTIDES; PROCESSING ENZYME; PRECURSORS; MUTANT; EXORIBONUCLEASES; IDENTIFICATION; SUPPRESSOR; MATURATION; MOLECULES; K-12	In eukaryotes, archaea, and in some eubacteria, removal of 3' precursor sequences during maturation of tRNA is catalyzed by an endoribonuclease, termed RNase Z. In contrast, in Escherichia coli, a variety of exoribonucleases carry out final 3' maturation. Yet, E. coli retains an RNase Z homologue, ElaC, whose function is under active study. We have overexpressed and purified to homogeneity His-tagged ElaC and show here that it is, in fact, the previously described enzyme, RNase BN. Thus, purified ElaC displays structural and catalytic properties identical to those ascribed to RNase BN. In addition, an elaC mutant strain behaves identically to a known RNase BN- strain, CAN. Finally, we show that wild type elaC can complement the mutation in strain CAN and that the elaC gene in strain CAN carries a nonsense mutation that results in loss of RNase BN activity. These data correct a previous misassignment for the gene encoding RNase BN. Based on the fact that the original RNase BN mutation has now been identified, we propose that the elaC gene be renamed rbn.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Deutscher, MP (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.	mdeutsch@med.miami.edu		Ezraty, Benjamin/0000-0003-3818-6907	NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHA PK, 1983, P NATL ACAD SCI-BIOL, V80, P3301, DOI 10.1073/pnas.80.11.3301; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Callahan C, 1996, J BACTERIOL, V178, P7329, DOI 10.1128/jb.178.24.7329-7332.1996; Cheng ZF, 2002, J BIOL CHEM, V277, P21624, DOI 10.1074/jbc.M202942200; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; de la Sierra-Gallay IL, 2005, NATURE, V433, P657, DOI 10.1038/nature03284; DEUTSCHER MP, 1984, CRC CR REV BIOCH MOL, V17, P45, DOI 10.3109/10409238409110269; DEUTSCHER MP, 1978, NUCLEIC ACIDS RES, V5, P3821, DOI 10.1093/nar/5.10.3821; Deutscher Murray P., 1995, P51; KELLY KO, 1992, J BACTERIOL, V174, P6682, DOI 10.1128/JB.174.20.6682-6684.1992; Li ZW, 2002, RNA, V8, P97, DOI 10.1017/S1355838202014929; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; MAISURIAN AN, 1973, MOL GEN GENET, V120, P227, DOI 10.1007/BF00267154; MAISURYAN AN, 1975, GENETIKA+, V11, P114; Minagawa A, 2004, J BIOL CHEM, V279, P15688, DOI 10.1074/jbc.M313951200; Morl M, 2001, EMBO REP, V2, P17, DOI 10.1093/embo-reports/kve006; Nashimoto M, 1997, NUCLEIC ACIDS RES, V25, P1148, DOI 10.1093/nar/25.6.1148; Pellegrini O, 2003, EMBO J, V22, P4534, DOI 10.1093/emboj/cdg435; Rudd KE, 2000, NUCLEIC ACIDS RES, V28, P60, DOI 10.1093/nar/28.1.60; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; Schilling O, 2005, J BIOL CHEM, V280, P17857, DOI 10.1074/jbc.M500591200; Schilling O, 2004, BIOCHEM BIOPH RES CO, V320, P1365, DOI 10.1016/j.bbrc.2004.05.227; SEIDMAN JG, 1975, CELL, V5, P389, DOI 10.1016/0092-8674(75)90058-6; Vogel A, 2002, J BIOL CHEM, V277, P29078, DOI 10.1074/jbc.M112047200; ZANIEWSKI R, 1984, J BIOL CHEM, V259, P1651; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	27	37	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16542	16545		10.1074/jbc.C500098200	http://dx.doi.org/10.1074/jbc.C500098200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15764599	hybrid			2022-12-25	WOS:000228615500002
J	Gray, MJ; Zhang, J; Ellis, LM; Semenza, GL; Evans, DB; Watowich, SS; Gallick, GE				Gray, MJ; Zhang, J; Ellis, LM; Semenza, GL; Evans, DB; Watowich, SS; Gallick, GE			HIF-1 alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complexthat regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas	ONCOGENE			English	Article						HIF-1a; VEGF; STAT3; Src; hypoxia; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; INDUCIBLE FACTOR-I; HUMAN COLORECTAL-CANCER; DNA-BINDING ACTIVITY; C-SRC; SIGNAL-TRANSDUCTION; TUMOR-GROWTH; CELL-LINE; V-SRC	Hypoxia stimulates a number of pathways critical to cancer cell survival, including the activation of vascular endothelial growth factor ( VEGF) transcription. In normal fibroblasts, hypoxia-induced activation of the protein tyrosine kinase, Src, is required for VEGF expression. We show here in both pancreatic and prostate carcinoma cell lines cobalt chloride ( used to mimic hypoxia) - induced VEGF expression requires Src activation and leads to increased steady-state levels of HIF-1 alpha and increased phosphorylation of signal and transducer of transcription 3 (STAT3). STAT3 and hypoxia-inducible factor (HIF)-1 alpha bind simultaneously to the VEGF promoter, where they form a molecular complex with the transcription coactivators CBP/p300 and Ref-1/APE. Expression of activated Src from an inducible promoter is sufficient to increase VEGF expression and form these STAT3/HIF-1 alpha-containing promoter complexes. Inhibition of DNA binding by expression of either STAT3 or HIF-1 alpha dominant negative mutants significantly reduces VEGF expression. These data suggest that the binding of both STAT3 and HIF-1 alpha to the VEGF promoter is required for maximum transcription of VEGF mRNA following hypoxia.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Vasc Program, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System; UTMD Anderson Cancer Center; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center	Gallick, GE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ggallick@mdanderson.org		Watowich, Stephanie/0000-0003-1969-659X	NCI NIH HHS [U54 CA 090810-01, 2RO-1 CA65527] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA090810, R01CA065527] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bardos JI, 2004, BIOESSAYS, V26, P262, DOI 10.1002/bies.20002; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Buchler P, 2003, PANCREAS, V26, P56, DOI 10.1097/00006676-200301000-00010; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ellis LM, 1996, EUR J CANCER, V32A, P2451, DOI 10.1016/S0959-8049(96)00389-9; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Folkman J, 1992, Semin Cancer Biol, V3, P65; Fontanini G, 2002, BRIT J CANCER, V86, P558, DOI 10.1038/sj.bjc.6600130; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hartenbach EM, 1997, CANCER LETT, V121, P169, DOI 10.1016/S0304-3835(97)00350-9; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ishigami SI, 1998, BRIT J CANCER, V78, P1379, DOI 10.1038/bjc.1998.688; Itakura J, 1997, CLIN CANCER RES, V3, P1309; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jackson MW, 1997, J UROLOGY, V157, P2323, DOI 10.1016/S0022-5347(01)64774-8; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Joung YH, 2003, EXP MOL MED, V35, P350, DOI 10.1038/emm.2003.46; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MINCHENKO A, 1994, LAB INVEST, V71, P374; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nam DH, 2004, ONCOL REP, V11, P863; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; Niedergethmann M, 2002, PANCREAS, V25, P122, DOI 10.1097/00006676-200208000-00002; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; Ray S, 2002, MOL ENDOCRINOL, V16, P824, DOI 10.1210/me.16.4.824; Schaefer LK, 1999, BIOCHEM BIOPH RES CO, V266, P481, DOI 10.1006/bbrc.1999.1853; Schuringa JJ, 2001, FEBS LETT, V495, P71, DOI 10.1016/S0014-5793(01)02354-7; Semenza GL, 2002, INTERNAL MED, V41, P79, DOI 10.2169/internalmedicine.41.79; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Senger DR, 1996, AM J PATHOL, V149, P293; SHWEIKI D, 1992, NATURE, V359, P845; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Stoeltzing O, 2003, AM J PATHOL, V163, P1001, DOI 10.1016/S0002-9440(10)63460-8; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Uehara M, 2004, ORAL ONCOL, V40, P321, DOI 10.1016/j.oraloncology.2003.08.020; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yahata Y, 2003, J BIOL CHEM, V278, P40026, DOI 10.1074/jbc.M301866200; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Ziel KA, 2004, FASEB J, V18, P986, DOI 10.1096/fj.03-1160fje	81	313	339	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3110	3120		10.1038/sj.onc.1208513	http://dx.doi.org/10.1038/sj.onc.1208513			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735682				2022-12-25	WOS:000228728100005
J	Sansom, OJ; Bishop, SM; Bird, A; Clarke, AR				Sansom, OJ; Bishop, SM; Bird, A; Clarke, AR			MBD2 deficiency does not accelerate p53 mediated lymphomagenesis	ONCOGENE			English	Article						MBD2; p53; DNA methylation; tumorigenesis; chemoprevention; genomic instability	DNA HYPOMETHYLATION; TUMORIGENESIS; MICE; SUPPRESSION; INSTABILITY; TUMORS	Recent studies using hypomorphic DNA methyltransferase 1 (DNMT1) alleles have suggested that strategies aiming to reduce DNA methylation may increase genomic instability and lymphomagenesis. Given our recent finding that loss of methyl-binding domain protein 2 (Mbd2) suppresses intestinal tumorigenesis, we have tested whether loss of Mbd2 increases lymphomagenesis by intercrossing Mbd2 deficient mice with p53 deficient and p53 heterozygous mice. Unlike DNMT1, loss of Mbd2 does not accelerate lymphomagenesis, arguing that MBD2 may represent a better potential therapeutic target than DNMT1.	Univ Cardiff, Cardiff Sci Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	Cardiff University; University of Edinburgh	Clarke, AR (corresponding author), Univ Cardiff, Cardiff Sci Biosci, Museum Ave,POB 911, Cardiff CF10 3US, S Glam, Wales.	clarkear@cardiff.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X; Bird, Adrian/0000-0002-8600-0372; Sansom, Owen J./0000-0001-9540-3010				Campbell PM, 2004, CARCINOGENESIS, V25, P499, DOI 10.1093/carcin/bgh045; Eads CA, 2002, CANCER RES, V62, P1296; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lengauer C, 2003, SCIENCE, V300, P442, DOI 10.1126/science.1084468; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; Trinh BN, 2002, MOL CELL BIOL, V22, P2906, DOI 10.1128/MCB.22.9.2906-2917.2002; Yang AS, 2003, SCIENCE, V302	13	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2430	2432		10.1038/sj.onc.1208166	http://dx.doi.org/10.1038/sj.onc.1208166			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735763				2022-12-25	WOS:000227877400015
J	Joshi, B; Ordonez-Ercan, D; Dasgupta, P; Chellappan, S				Joshi, B; Ordonez-Ercan, D; Dasgupta, P; Chellappan, S			Induction of human metallothionein 1G promoter by VEGF and heavy metals: differential involvement of E2F and metal transcription factors	ONCOGENE			English	Article						VEGF; metallothionein; E2F1; MTF-1; MRE	GENE-EXPRESSION; HISTONE DEACETYLASE; FACTOR-I; TRANSGENIC MICE; FACTOR MTF-1; CELL-LINES; REPRESSES TRANSCRIPTION; MOLECULAR-MECHANISMS; INDUCED APOPTOSIS; OXIDATIVE STRESS	The E2F transcription factors induce the expression of many genes in response to specific extracellular stimuli. Here, we show that human metallothionein 1G (hMT1G) promoter is upregulated by E2F1 upon VEGF stimulation of human aortic endothelial cells. Analysis of the hMT1G promoter showed the presence of many potential E2F-binding sites flanked by potential SP1 sites and metal response elements (MREs). hMT1G promoter could be induced by E2F1 in transient transfections; further, deletion analysis suggested that the region spanning the E2F-binding sites was necessary for VEGF-mediated induction. E2Fs 1-5 could bind to the hMT1G promoter in a chromatin immunoprecipitation assay. VEGF stimulation led to an increased binding of E2Fs 1-3 to the endogenous hMT1G promoter; at the same time, the binding of Rb, p107 and p130 to the promoter was abolished. VEGF stimulation also led to the increased acetylation E2F1 as well as the histones in the hMT1G promoter region. Stimulation with metals or VEGF led to dissociation of histone deacetylase 1 (HDAC1) from the promoter, leading to acetylation of histones. Induction of the hMT1G promoter upon exposure to heavy metals such as Zn and Cd is mediated by the MRE. Interestingly, mutation of MRE affected the metal response, but not the VEGF response of the hMT1G promoter. In contrast, deletion of the E2F-binding sites did not affect the metal response. Based on these findings, we conclude that induction of the hMT1G promoter by VEGF and heavy metals occurs through the utilization of different transcription factors.	H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Chellappan, S (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	chellasp@moffitt.usf.edu			NCI NIH HHS [CA63136] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063136] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe Mayumi, 2001, Angiogenesis, V4, P289, DOI 10.1023/A:1016018617152; Benjamin D, 2001, NUCLEIC ACIDS RES, V29, P3603, DOI 10.1093/nar/29.17.3603; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; Boccellino M, 2002, LIPIDS, V37, P1047, DOI 10.1007/s11745-002-0999-7; Brehm A, 1999, BRIT J CANCER, V80, P38; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Butler RA, 2001, TOXICOL SCI, V59, P101, DOI 10.1093/toxsci/59.1.101; Cai L, 1998, ANTICANCER RES, V18, P4667; Chaya D, 2001, J BIOL CHEM, V276, P44385, DOI 10.1074/jbc.M108214200; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Dalton TP, 1997, MOL CELL BIOL, V17, P2781, DOI 10.1128/MCB.17.5.2781; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Favot L, 2003, CARDIOVASC RES, V59, P479, DOI 10.1016/S0008-6363(03)00433-4; Friedline JA, 1998, AM J PATHOL, V152, P23; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Ghoshal K, 2001, PROG NUCLEIC ACID RE, V66, P357; Ghoshal K, 2000, J BIOL CHEM, V275, P539, DOI 10.1074/jbc.275.1.539; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Ghoshal K, 1998, J BIOL CHEM, V273, P27904, DOI 10.1074/jbc.273.43.27904; Ghoshal K, 2002, METHOD ENZYMOL, V353, P476; Ghoshal K, 2001, MOL CELL BIOL, V21, P8301, DOI 10.1128/MCB.21.24.8301-8317.2001; Gui CY, 2001, MOL CELL BIOL, V21, P1155, DOI 10.1128/MCB.21.4.1155-1163.2001; Hellemans G, 1999, NEPHRON, V83, P331, DOI 10.1159/000045425; Hunt KK, 1997, CANCER RES, V57, P4722; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jacob ST, 1999, GENE EXPRESSION, V7, P301; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KAGI JHR, 1960, J BIOL CHEM, V235, P3460; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kelly EJ, 1996, J NUTR, V126, P1782; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KOJIMA Y, 1991, METHOD ENZYMOL, V205, P419; Kondo Y, 1997, MOL PHARMACOL, V52, P195, DOI 10.1124/mol.52.2.195; LaRochelle O, 2001, BIOCHEM J, V353, P591, DOI 10.1042/0264-6021:3530591; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Lee DK, 1999, BIOCHEM J, V337, P59, DOI 10.1042/0264-6021:3370059; Levadoux-Martin M, 2001, BIOCHEM J, V355, P473, DOI 10.1042/0264-6021:3550473; Lichtlen P, 2001, SWISS MED WKLY, V131, P647; Lichtlen P, 2001, BIOESSAYS, V23, P1010, DOI 10.1002/bies.1146; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Majumder S, 1999, J BIOL CHEM, V274, P28584, DOI 10.1074/jbc.274.40.28584; Majumder S, 1999, ONCOGENE, V18, P6287, DOI 10.1038/sj.onc.1203004; Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; Mididoddi S, 1996, TOXICOL LETT, V85, P17, DOI 10.1016/0378-4274(96)03632-6; Moffatt P, 1997, DRUG METAB REV, V29, P261, DOI 10.3109/03602539709037585; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nguyen A, 2000, CANCER LETT, V160, P133, DOI 10.1016/S0304-3835(00)00534-6; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; Searle P F, 1987, Experientia Suppl, V52, P407; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377; Somji S, 2001, CANCER DETECT PREV, V25, P62; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; Wang S, 1999, MOL CELL BIOL, V19, P7447; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	80	27	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2204	2217		10.1038/sj.onc.1208206	http://dx.doi.org/10.1038/sj.onc.1208206			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735762				2022-12-25	WOS:000227857900008
J	Ziel, KA; Grishko, V; Campbell, CC; Breit, JF; Wilson, GL; Gillespie, MN				Ziel, KA; Grishko, V; Campbell, CC; Breit, JF; Wilson, GL; Gillespie, MN			Oxidants in signal transduction: impact on DNA integrity and gene expression	FASEB JOURNAL			English	Article						VEGF; mitochondrial DNA damage; reactive oxygen species; nuclear genomic integrity	SMOOTH-MUSCLE-CELLS; OXIDATIVE BASE MODIFICATIONS; HYPOXIA-INDUCIBLE FACTOR-1; ARTERY ENDOTHELIAL-CELLS; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; BENDING PROPENSITY; PULMONARY-ARTERIES; MAMMALIAN-CELLS; NUCLEAR-DNA	Physiological stimuli using reactive oxygen species (ROS) as second messengers caused nucleotide-specific base modifications in the hypoxic response element of the VEGF gene in lung vascular cells, with the 3' guanine of the HIF-1 DNA recognition sequence uniformly targeted. Modeling this effect by replacing the targeted guanine with an abasic site increased incorporation of HIF-1 and the bi-functional DNA repair enzyme and transcriptional coactivator, Ref-1/Ape1, into the transcriptional complex and engendered more robust reporter gene expression. Oxidants generated in the context of physiological signaling thus affect nuclear DNA integrity and may facilitate gene expression by optimizing DNA-protein interactions.	Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Ctr Lung Biol, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA	University of South Alabama; University of South Alabama; University of South Alabama	Gillespie, MN (corresponding author), Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688 USA.	mgillesp@jaguar1.usouthal.edu						Ayadi L, 2000, J BIOMOL STRUCT DYN, V17, P645, DOI 10.1080/07391102.2000.10506555; Babal P, 2000, AM J PHYSIOL-LUNG C, V278, pL610, DOI 10.1152/ajplung.2000.278.3.L610; Babal P, 2002, AM J PHYSIOL-LUNG C, V282, pL840, DOI 10.1152/ajplung.00347.2001; Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BRUKNER I, 1995, J BIOMOL STRUCT DYN, V13, P309, DOI 10.1080/07391102.1995.10508842; CHAN WCW, 2000, P SOC PHOTO-OPT INS, V1, P2; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; COLLINS AR, 1993, CARCINOGENESIS, V14, P1733, DOI 10.1093/carcin/14.9.1733; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; Dobson AW, 2002, AM J PHYSIOL-LUNG C, V283, pL205, DOI 10.1152/ajplung.00443.2001; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Epe B, 2002, BIOL CHEM, V383, P467, DOI 10.1515/BC.2002.049; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Gabrielian A, 1996, FEBS LETT, V393, P124, DOI 10.1016/0014-5793(96)00837-X; Giese B, 2002, ANNU REV BIOCHEM, V71, P51, DOI 10.1146/annurev.biochem.71.083101.134037; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Grishko V, 2001, FASEB J, V15, P1267, DOI 10.1096/fj.00-0755fje; Grishko V, 2001, AM J PHYSIOL-LUNG C, V280, pL1300, DOI 10.1152/ajplung.2001.280.6.L1300; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Henle ES, 1999, J BIOL CHEM, V274, P962, DOI 10.1074/jbc.274.2.962; Hoffmann S, 2004, FREE RADICAL BIO MED, V36, P765, DOI 10.1016/j.freeradbiomed.2003.12.019; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; Killilea DW, 2000, AM J PHYSIOL-LUNG C, V279, pL408, DOI 10.1152/ajplung.2000.279.2.L408; Lhomme J, 1999, BIOPOLYMERS, V52, P65, DOI 10.1002/1097-0282(1999)52:2<65::AID-BIP1>3.0.CO;2-U; Liu JQ, 2003, AM J PHYSIOL-LUNG C, V285, pL322, DOI 10.1152/ajplung.00337.2002; LOFT S, 1994, FASEB J, V8, P534, DOI 10.1096/fasebj.8.8.8181672; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Malins DC, 2000, P NATL ACAD SCI USA, V97, P12442, DOI 10.1073/pnas.230438797; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; Mitra S, 2002, FREE RADICAL BIO MED, V33, P15, DOI 10.1016/S0891-5849(02)00819-5; Munteanu MG, 1998, TRENDS BIOCHEM SCI, V23, P341, DOI 10.1016/S0968-0004(98)01265-1; Odom DT, 2001, NUCLEIC ACIDS RES, V29, P2026, DOI 10.1093/nar/29.10.2026; Pflaum M, 1997, CARCINOGENESIS, V18, P2225, DOI 10.1093/carcin/18.11.2225; Rachofsky EL, 2001, COMB CHEM HIGH T SCR, V4, P675; Rai P, 2001, J MOL BIOL, V312, P1089, DOI 10.1006/jmbi.2001.5010; Richard DE, 2000, J BIOL CHEM, V275, P26765; Rodriguez H, 1997, ARCH BIOCHEM BIOPHYS, V338, P207, DOI 10.1006/abbi.1996.9820; Salazar JJ, 1997, MUTAT RES-DNA REPAIR, V385, P139, DOI 10.1016/S0921-8777(97)00047-5; Shukla A, 2003, AM J PHYSIOL-LUNG C, V285, pL1018, DOI 10.1152/ajplung.00038.2003; Spinella F, 2002, J BIOL CHEM, V277, P27850, DOI 10.1074/jbc.M202421200; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thannickal VJ, 2000, FASEB J, V14, P1741, DOI 10.1096/fj.99-0878com; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Ziel KA, 2004, FASEB J, V18, P986, DOI 10.1096/fj.03-1160fje	48	48	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					387	394		10.1096/fj.04-2805com	http://dx.doi.org/10.1096/fj.04-2805com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746182				2022-12-25	WOS:000227901300039
J	Seeliger, MA; Spichty, M; Kelly, SE; Bycroft, M; Freund, SMV; Karplus, M; Itzhaki, LS				Seeliger, MA; Spichty, M; Kelly, SE; Bycroft, M; Freund, SMV; Karplus, M; Itzhaki, LS			Role of conformational heterogeneity in domain swapping and adapter function of the Cks proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-REGULATORY PROTEIN; SIDE-CHAIN ENTROPY; CELL-CYCLE; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY; UBIQUITIN LIGASE; SACCHAROMYCES-CEREVISIAE; MUTATIONAL ANALYSIS; MOLECULAR-DYNAMICS; PLAUSIBLE MODEL	Cks proteins are adapter molecules that coordinate the assembly of multiprotein complexes. They share the ability to domain swap by exchanging a beta-strand, beta 4. Here we use NMR spectroscopy and molecular dynamics simulations to investigate the dynamic properties of human Cks1 and its response on assembly with components of the SCFSkp2 ubiquitin ligation machinery. In the NMR experiment with the free form of Cks1, a subset of residues displayed elevated R-2 values and the cross-peaks of neighboring residues were missing from the spectrum, indicating a substantial conformational exchange contribution on the microsecond to millisecond time scale. Strikingly the region of greatest conformational variability was the beta 4-strand that domain swaps to form the dimer. Binding of the ligand common to all Cks proteins, Cdk2, suppressed the conformational heterogeneity. This response was specific to Cdk2 binding; in contrast, binding of Skp2, a ligand unique to human Cks1, did not alter the dynamic behavior. Short time (< 5 ns) molecular dynamics simulations indicate that residues of Cks1 that form the binding site for phosphorylated ligands are considerably more flexible in the free form of Cks1 than they are in the Cdk2- Cks1 complex. A cooperative interaction between Cdk2 and Cks1 is suggested, which reduces the configurational entropy of Cks1 and therefore facilitates phosphoprotein binding. Indications of an unusual dynamic behavior of strand beta 4 in the free form of Cks1 were obtained from longer time scale ( 50 ns) dynamics simulations. A spontaneous reversible unzipping of hydrogen bonds between beta 4 and beta 2 was observed, suggesting an early intermediate structure for unfolding and/or domain swapping. We propose that the dynamic properties of the beta-sheet and its modification upon ligand binding underlie the domain swapping ability and the adapter function of Cks proteins.	Univ Cambridge, Chem Lab, MRC Ctr Prot Engn, Cambridge CB2 1EW, England; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Univ Strasbourg 1, Inst Sci & Ingn Supramol, F-67083 Strasbourg, France; Hutchison MRC Res Ctr, MRC Canc Cell Unit, Cambridge CB2 2XZ, England	MRC Laboratory Molecular Biology; University of Cambridge; Harvard University; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Freund, SMV (corresponding author), Univ Cambridge, Chem Lab, MRC Ctr Prot Engn, Lensfield Rd, Cambridge CB2 1EW, England.	smvf100@cus.cam.ac.uk; marci@tammy.harvard.edu; lsi10@cam.ac.uk	Bycroft, Mark/D-9446-2017; Seeliger, Markus A/D-6409-2013	Spichty, Martin/0000-0002-2533-9073; Bycroft, Mark/0000-0002-0673-2216; Seeliger, Markus/0000-0003-0990-1756				Alonso DOV, 2000, STRUCTURE, V8, P101, DOI 10.1016/S0969-2126(00)00083-6; Andricioaei I, 2001, J CHEM PHYS, V115, P6289, DOI 10.1063/1.1401821; ARVAI AS, 1995, J MOL BIOL, V249, P835, DOI 10.1006/jmbi.1995.0341; Barrientos LG, 2002, STRUCTURE, V10, P673, DOI 10.1016/S0969-2126(02)00758-X; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; BIRCK C, 1995, FEBS LETT, V363, P145, DOI 10.1016/0014-5793(95)00300-X; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bourne Y, 2000, STRUCT FOLD DES, V8, P841, DOI 10.1016/S0969-2126(00)00175-1; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; BOURNE Y, 1995, P NATL ACAD SCI USA, V92, P10232, DOI 10.1073/pnas.92.22.10232; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROOKS CL, 1983, J CHEM PHYS, V79, P6312, DOI 10.1063/1.445724; Buchberger A, 2000, BIOCHEMISTRY-US, V39, P11137, DOI 10.1021/bi0008231; COOPER A, 1984, EUR BIOPHYS J BIOPHY, V11, P103, DOI 10.1007/BF00276625; Feher VA, 1999, NATURE, V400, P289, DOI 10.1038/22357; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; Fuentes EJ, 2004, J MOL BIOL, V335, P1105, DOI 10.1016/j.jmb.2003.11.010; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gouet P, 1999, STRUCTURE, V7, P1517, DOI 10.1016/S0969-2126(00)88342-2; GRZESIEK S, 1993, J AM CHEM SOC, V115, P4369, DOI 10.1021/ja00063a068; KARPLUS M, 1981, MACROMOLECULES, V14, P325, DOI 10.1021/ma50003a019; Kay LE, 1998, NAT STRUCT BIOL, V5, P513, DOI 10.1038/755; Kay LE, 1996, BIOCHEMISTRY-US, V35, P361, DOI 10.1021/bi9522312; Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008; Khandelwal P, 2002, BIOCHEMISTRY-US, V41, P11425, DOI 10.1021/bi026333l; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; Lazaridis T, 1999, PROTEINS, V35, P133, DOI 10.1002/(SICI)1097-0134(19990501)35:2<133::AID-PROT1>3.0.CO;2-N; Lee AL, 2000, NAT STRUCT BIOL, V7, P72; Lewis RJ, 2002, J MOL BIOL, V316, P235, DOI 10.1006/jmbi.2001.5331; Loh AP, 2001, BIOCHEMISTRY-US, V40, P4590, DOI 10.1021/bi002418f; Lukin JA, 2003, P NATL ACAD SCI USA, V100, P517, DOI 10.1073/pnas.232715799; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; McElroy C, 2002, J MOL BIOL, V323, P463, DOI 10.1016/S0022-2836(02)00940-3; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Morris MC, 2003, NATURE, V423, P1009, DOI 10.1038/nature01720; MOY FJ, 1994, BIOCHEMISTRY-US, V33, P10731, DOI 10.1021/bi00201a022; Odaert B, 2002, J BIOL CHEM, V277, P12375, DOI 10.1074/jbc.M111741200; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; Riek R, 2000, TRENDS BIOCHEM SCI, V25, P462, DOI 10.1016/S0968-0004(00)01665-0; Rousseau F, 1998, J MOL BIOL, V284, P503, DOI 10.1006/jmbi.1998.2173; Rousseau F, 2001, P NATL ACAD SCI USA, V98, P5596, DOI 10.1073/pnas.101542098; Schymkowitz JWH, 2001, NAT STRUCT BIOL, V8, P888, DOI 10.1038/nsb1001-888; Schymkowitz JWH, 2000, STRUCTURE, V8, P89, DOI 10.1016/S0969-2126(00)00084-8; Seeliger MA, 2003, NAT STRUCT BIOL, V10, P718, DOI 10.1038/nsb962; Seeliger MA, 2003, J MOL BIOL, V325, P189, DOI 10.1016/S0022-2836(02)01202-0; Seeliger MA, 2002, BIOCHEMISTRY-US, V41, P1202, DOI 10.1021/bi0113465; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V257, P12, DOI 10.1006/bbrc.1999.0409; Sitry D, 2002, J BIOL CHEM, V277, P42233, DOI 10.1074/jbc.M205254200; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Vitagliano L, 2002, PROTEINS, V46, P97, DOI 10.1002/prot.10033; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; Wand AJ, 2001, NAT STRUCT BIOL, V8, P926, DOI 10.1038/nsb1101-926; Wang CY, 2004, J MOL BIOL, V342, P525, DOI 10.1016/j.jmb.2004.07.001; Xu K, 2003, BIOCHEM J, V371, P957, DOI 10.1042/BJ20021722	58	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30448	30459		10.1074/jbc.M501450200	http://dx.doi.org/10.1074/jbc.M501450200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15772084	hybrid, Green Submitted			2022-12-25	WOS:000231362500058
J	Chowdhury, AK; Watkins, T; Parinandi, NL; Saatian, B; Kleinberg, ME; Usatyuk, PV; Natarajan, V				Chowdhury, AK; Watkins, T; Parinandi, NL; Saatian, B; Kleinberg, ME; Usatyuk, PV; Natarajan, V			Src-mediated tyrosine phosphorylation of p47(phox) in hyperoxia-induced activation of NADPH oxidase and generation of reactive oxygen species in lung endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; PROTEIN-KINASE-C; VASCULAR NAD(P)H OXIDASES; SUPEROXIDE-PRODUCTION; DIABETIC-NEPHROPATHY; MOLECULAR-MECHANISM; COMPONENT P47(PHOX); ARACHIDONIC-ACID; PHOSPHOLIPASE-D; ANGIOTENSIN-II	Superoxide (O-2(.)) production by nonphagocytes, similar to phagocytes, is by activation of the NADPH oxidase multicomponent system. Although activation of neutrophil NADPH oxidase involves extensive serine phosphorylation of p47(phox), the role of tyrosine phosphorylation of p47(phox) in NADPH oxidase-dependent O-2(.) production is unclear. We have shown recently that hyperoxia-induced NADPH oxidase activation in human pulmonary artery endothelial cells (HPAECs) is regulated by mitogen-activated protein kinase signal transduction. Here we provided evidence on the role of nonreceptor tyrosine kinase, Src, in hyperoxia-induced tyrosine phosphorylation of p47(phox) and NADPH oxidase activation in HPAECs. Exposure of HPAECs to hyperoxia for 1 h resulted in increased O-2(.). and reactive oxygen species (ROS) production and enhanced tyrosine phosphorylation of Src as determined by Western blotting with phospho-Src antibodies. Pretreatment of HPAECs with the Src kinase inhibitor PP2 (1 mu M) or transient expression of a dominant-negative mutant of Src attenuated hyperoxia-induced tyrosine phosphorylation of Src and ROS production. Furthermore, exposure of cells to hyperoxia enhanced tyrosine phosphorylation of p47(phox) and its translocation to cell peripheries that were attenuated by PP2. In vitro, Src phosphorylated recombinant p47(phox) in a time-dependent manner. Src immunoprecipitates of cell lysates from control cells revealed the presence of immunodetectable p47(phox) and p67(phox), suggesting the association of oxidase components with Src under basal conditions. Moreover, exposure of HPAECs to hyperoxia for 1 h enhanced the association of p47(phox), but not p67(phox), with Src. These results indicated that Src-dependent tyrosine phosphorylation of p47(phox) regulates hyperoxia-induced NADPH oxidase activation and ROS production in HPAECs.	Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Dept Med, Baltimore, MD 21224 USA; Ohio State Univ, Dept Med, Div Pulm Crit Care & Sleep, Columbus, OH 43210 USA; Univ Maryland, Sch Med, Div Infect Dis, Baltimore, MD 21201 USA	Johns Hopkins University; University System of Ohio; Ohio State University; University System of Maryland; University of Maryland Baltimore	Natarajan, V (corresponding author), Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Dept Med, Mason F Lord Bldg,Ctr Tower,Rm 675,5200 Eastern A, Baltimore, MD 21224 USA.	vnataraj@jhmi.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069909, P01HL058064] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 69909, P01 HL 58064] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1992, J BIOL CHEM, V267, P16767; Ago T, 2003, P NATL ACAD SCI USA, V100, P4474, DOI 10.1073/pnas.0735712100; Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730; Babior BM, 2002, ANTIOXID REDOX SIGN, V4, P35, DOI 10.1089/152308602753625834; Babior BM, 2000, IUBMB LIFE, V50, P267, DOI 10.1080/15216540051080976; Barazzone C, 1998, AM J RESP CELL MOL, V19, P573, DOI 10.1165/ajrcmb.19.4.3173; Cai H, 2003, TRENDS PHARMACOL SCI, V24, P471, DOI 10.1016/S0165-6147(03)00233-5; Capellier G, 1999, Minerva Anestesiol, V65, P388; Chen QD, 2003, J IMMUNOL, V170, P5302, DOI 10.4049/jimmunol.170.10.5302; Clark L A, 1999, Respir Care Clin N Am, V5, P203; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; Dodd-O JM, 2000, AM J PHYSIOL-HEART C, V279, pH303, DOI 10.1152/ajpheart.2000.279.1.H303; Edwards Steven W., 1996, Methods (Orlando), V9, P563, DOI 10.1006/meth.1996.0064; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; Fisher AB, 1999, CHEST, V116, p25S, DOI 10.1378/chest.116.suppl_1.25S; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Hohler B, 2000, HISTOCHEM CELL BIOL, V114, P29; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Iyer S, 1996, J NEUROSCI RES, V46, P531, DOI 10.1002/(SICI)1097-4547(19961201)46:5<531::AID-JNR2>3.0.CO;2-K; Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC; Kitada M, 2003, DIABETES, V52, P2603, DOI 10.2337/diabetes.52.10.2603; Lal AS, 1999, BIOCHEM J, V338, P359, DOI 10.1042/0264-6021:3380359; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; Li JM, 2003, J AM SOC NEPHROL, V14, pS221, DOI 10.1097/01.ASN.0000077406.67663.E7; Li JM, 2001, CARDIOVASC RES, V52, P477, DOI 10.1016/S0008-6363(01)00407-2; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Meyer JW, 2000, FEBS LETT, V472, P1, DOI 10.1016/S0014-5793(00)01397-1; Oeckler RA, 2003, CIRC RES, V92, P23, DOI 10.1161/01.RES.0000051860.84509.CE; Parinandi NL, 2001, ARCH BIOCHEM BIOPHYS, V396, P231, DOI 10.1006/abbi.2001.2609; PARINANDI NL, 2002, AM J PHYSIOL, V284, P626; Peng GH, 2003, BIOCHEM J, V373, P221, DOI 10.1042/BJ20021629; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Robinson JM, 2004, HISTOCHEM CELL BIOL, V122, P273, DOI 10.1007/s00418-004-0702-0; Roy S, 2003, ANTIOXID REDOX SIGN, V5, P217, DOI 10.1089/152308603764816578; Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16; Shi S, 2000, AM J PHYSIOL-LUNG C, V279, pL441, DOI 10.1152/ajplung.2000.279.3.L441; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Takeya R, 2003, MOL CELLS, V16, P271; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Touyz RM, 2003, ARTERIOSCL THROM VAS, V23, P981, DOI 10.1161/01.ATV.0000069236.27911.68; Usatyuk PV, 2004, J BIOL CHEM, V279, P11789, DOI 10.1074/jbc.M311184200; Wei ZH, 1999, CIRC RES, V85, P682, DOI 10.1161/01.RES.85.8.682; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yuzawa S, 2004, GENES CELLS, V9, P443, DOI 10.1111/j.1356-9597.2004.00733.x	53	122	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20700	20711		10.1074/jbc.M411722200	http://dx.doi.org/10.1074/jbc.M411722200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15774483	hybrid			2022-12-25	WOS:000229242000068
J	Kahlig, H; Kolarich, D; Zayni, S; Scheberl, A; Kosma, P; Schaffer, C; Messner, P				Kahlig, H; Kolarich, D; Zayni, S; Scheberl, A; Kosma, P; Schaffer, C; Messner, P			N-acetylmuramic acid as capping element of alpha-D-fucose-containing S-layer glycoprotein glycans from Geobacillus tepidamans GS5-97(T)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-SPECIFIC POLYSACCHARIDE; STEAROTHERMOPHILUS NRS 2004/3A; LINKAGE REGION; STRUCTURAL-CHARACTERIZATION; LIPOPOLYSACCHARIDE; CHAIN; STRAINS; TYROSINE; CORE; IDENTIFICATION	Geobacillus tepidamans GS5-97(T) is a novel Gram-positive, moderately thermophilic bacterial species that is covered by a glycosylated surface layer (S-layer) protein. The isolated and purified S-layer glycoprotein SgtA was ultrastructurally and chemically investigated and showed several novel properties. By SDS-PAGE, SgtA was separated into four distinct bands in an apparent molecular mass range of 106-166 kDa. The three high molecular mass bands gave a positive periodic acid-Schiff staining reaction, whereas the 106-kDa band was nonglycosylated. Glycosylation of SgtA was investigated by means of chemical analyses, 600-MHz nuclear magnetic resonance spectroscopy, and electrospray ionization quadrupole time-of-fight mass spectrometry. Glycopeptides obtained after Pronase digestion revealed the glycan structure [-> 2)-alpha-L-Rhap-(1 -> 3)-alpha-D-Fucp-(1 ->](n= similar to 20), with D-fucopyranose having never been identified before as a constituent of S-layer glycans. The rhamnose residue at the nonreducing end of the terminal repeating unit of the glycan chain was di-substituted. For the first time, (R)-N-acetylmuramic acid, the key component of prokaryotic peptidoglycan, was found in an alpha-linkage to carbon 3 of the terminal rhamnose residue, serving as capping motif of an S-layer glycan. In addition, that rhamnose was substituted at position 2 with a beta-N-acetylglucosamine residue. The S-layer glycan chains were bound via the trisaccharide core -> 2)-alpha-L-Rhap-(1 -> 3)-alpha-L-Rhap-(1 -> 3)-alpha-L-Rhap-(1 -> to carbon 3 of beta-D-galactose, which was attached in O-glycosidic linkage to serine and threonine residues of SgtA of G. tepidamans GS5-97T.	Univ Nat Resources & Appl Life Sci, Ctr NanoBiotechnol, A-1180 Vienna, Austria; Univ Vienna, Dept Organ Chem, A-1090 Vienna, Austria; Univ Nat Resources & Appl Life Sci, Dept Chem, A-1190 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; University of Vienna; University of Natural Resources & Life Sciences, Vienna	Schaffer, C (corresponding author), Univ Nat Resources & Appl Life Sci, Ctr NanoBiotechnol, A-1180 Vienna, Austria.	christina.schaeffer@boku.ac.at	Kolarich, Daniel/B-6893-2012; Kolarich, Daniel/AAJ-3550-2020; Schäffer, Christina/V-3404-2018; Kosma, Paul/Y-7443-2019; Messner, Paul/Q-5345-2017	Kolarich, Daniel/0000-0002-8452-1350; Kolarich, Daniel/0000-0002-8452-1350; Schäffer, Christina/0000-0003-1613-7258; Kosma, Paul/0000-0001-5342-7161; Messner, Paul/0000-0002-3246-5801; Kaehlig, Hanspeter/0000-0002-3898-6501				ALTMAN E, 1995, EUR J BIOCHEM, V229, P308, DOI 10.1111/j.1432-1033.1995.0308l.x; ALTMAN E, 1992, BIOCHIM BIOPHYS ACTA, V1117, P71, DOI 10.1016/0304-4165(92)90164-P; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P84, DOI 10.1007/BF00731873; BOCK K, 1994, J BIOL CHEM, V269, P7137; CHRISTIAN R, 1993, J BACTERIOL, V175, P1250, DOI 10.1128/JB.175.5.1250-1256.1993; Clarke BR, 2004, J BIOL CHEM, V279, P35709, DOI 10.1074/jbc.M404738200; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; Forsberg LS, 2000, J BIOL CHEM, V275, P18851, DOI 10.1074/jbc.M001090200; Gunawardena S, 1998, CARBOHYD RES, V309, P65, DOI 10.1016/S0008-6215(98)00115-3; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; ITO T, 1994, CARBOHYD RES, V256, P113, DOI 10.1016/0008-6215(94)84231-0; Jolly L, 2001, INT DAIRY J, V11, P733, DOI 10.1016/S0958-6946(01)00117-0; Kahlig H, 2002, MONATSH CHEM, V133, P589, DOI 10.1007/s007060200031; Katzenellenbogen E, 2003, EUR J BIOCHEM, V270, P2732, DOI 10.1046/j.1432-1033.2003.03640.x; Kocharova NA, 2002, CARBOHYD RES, V337, P1667, DOI 10.1016/S0008-6215(02)00022-8; LIPKIND GM, 1988, CARBOHYD RES, V175, P59, DOI 10.1016/0008-6215(88)80156-3; LIPKIND GM, 1992, CARBOHYD RES, V237, P11; MESSNER P, 1984, INT J SYST BACTERIOL, V34, P202, DOI 10.1099/00207713-34-2-202; Messner P, 2003, Fortschr Chem Org Naturst, V85, P51; Novotny R, 2003, GLYCOCONJUGATE J, V20, P435, DOI 10.1023/B:GLYC.0000038290.74944.65; Novotny R, 2004, MICROBIOL-SGM, V150, P953, DOI 10.1099/mic.0.26672-0; Olsthoorn MA, 2000, EUR J BIOCHEM, V267, P2014, DOI 10.1046/j.1432-1327.2000.01205.x; Perepelov AV, 2002, CARBOHYD RES, V337, P2463, DOI 10.1016/S0008-6215(02)00226-4; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Reeves PP, 2002, CURR TOP MICROBIOL, V264, P109; Sadovskaya I, 2000, EUR J BIOCHEM, V267, P1640, DOI 10.1046/j.1432-1327.2000.01156.x; Samuel G, 2003, CARBOHYD RES, V338, P2503, DOI 10.1016/j.carres.2003.07.009; Schaffer C, 1996, MICROB DRUG RESIST, V2, P17, DOI 10.1089/mdr.1996.2.17; Schaffer C, 1999, GLYCOBIOLOGY, V9, P407, DOI 10.1093/glycob/9.4.407; Schaffer C, 1999, MICROBIOL-UK, V145, P1575, DOI 10.1099/13500872-145-7-1575; Schaffer C, 2000, EUR J BIOCHEM, V267, P5482, DOI 10.1046/j.1432-1327.2000.01610.x; Schaffer C, 2004, INT J SYST EVOL MICR, V54, P2361, DOI 10.1099/ijs.0.63227-0; Schaffer C, 2002, J BIOL CHEM, V277, P6230, DOI 10.1074/jbc.M108873200; Schaffer C, 2001, BIOCHIMIE, V83, P591, DOI 10.1016/S0300-9084(01)01299-8; Senchenkova SN, 1996, CARBOHYD RES, V293, P71, DOI 10.1016/0008-6215(96)00192-9; Valvano MA, 2003, FRONT BIOSCI-LANDMRK, V8, pS452, DOI 10.2741/1079; van Heijenoort J, 2001, GLYCOBIOLOGY, V11, p25R; Vinogradov E, 2002, CARBOHYD RES, V337, P961; Vinogradov E, 2002, J BIOL CHEM, V277, P25070, DOI 10.1074/jbc.M202683200; Vinogradov E, 2000, EUR J BIOCHEM, V267, P7230, DOI 10.1046/j.1432-1327.2000.01835.x; Yoshida Y, 1999, J BIOL CHEM, V274, P16933, DOI 10.1074/jbc.274.24.16933	41	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20292	20299		10.1074/jbc.M501724200	http://dx.doi.org/10.1074/jbc.M501724200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781455	hybrid			2022-12-25	WOS:000229242000018
J	Fernandez-Tornero, C; Garcia, E; de Pascual-Teresa, B; Lopez, R; Gimenez-Gallego, G; Romero, A				Fernandez-Tornero, C; Garcia, E; de Pascual-Teresa, B; Lopez, R; Gimenez-Gallego, G; Romero, A			Ofloxacin-like antibiotics inhibit pneumococcal cell wall-degrading virulence factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-PNEUMONIAE; LYTIC ENZYMES; AUTOMATED DOCKING; BINDING-PROTEINS; PURIFICATION; AMIDASE; AUTOLYSIN; STEP; INSIGHTS; BIOLOGY	The search for new drugs against Streptococcus pneumoniae (pneumococcus) is driven by the 1.5 million deaths it causes annually. Choline-binding proteins attach to the pneumococcal cell wall through domains that recognize choline moieties, and their involvement in pneumococcal virulence makes them potential targets for drug development. We have defined chemical criteria involved in the docking of small molecules from a three-dimensional structural library to the major pneumococcal autolysin (LytA) choline binding domain. These criteria were used to identify compounds that could interfere with the attachment of this protein to the cell wall, and several quinolones that fit this framework were found to inhibit the cell wall-degrading activity of LytA. Furthermore, these compounds produced similar effects on other enzymes with different catalytic activities but that contained a similar choline binding domain; that is, autolysin (LytC) and the phage lytic enzyme (Cpl-1). Finally, we resolved the crystal structure of the complex between the choline binding domain of LytA and ofloxacin at a resolution of 2.6 angstrom. These data constitute an important launch pad from which effective drugs to combat pneumococcal infections can be developed.	CSIC, Dept Estructura & Func Prot, Madrid 28040, Spain; CSIC, Dept Mol Microbiol, Ctr Invest Biol, Madrid 28040, Spain; Univ San Pablo, Fac Ciencias Expt & Salud, Dept CC Quim, CEU, Madrid 28668, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); San Pablo CEU University	Romero, A (corresponding author), European Mol Biol Lab, Grenoble Outstn, 6 Rue Jules Horowitz,BP 181, F-38042 Grenoble, France.	romero@cib.csic.es	Romero, Antonio/K-5754-2014; Fernandez-Tornero, Carlos/AAV-8028-2021; Fernandez-Tornero, Carlos/I-6888-2015; de Pascual-Teresa, Beatriz/J-4318-2012	Romero, Antonio/0000-0002-6990-6973; Fernandez-Tornero, Carlos/0000-0001-5097-731X; Fernandez-Tornero, Carlos/0000-0001-5097-731X; de Pascual-Teresa, Beatriz/0000-0002-1101-0373; Partearroyo Lacaba, Olvido/0000-0002-1692-4481				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berry AM, 2000, INFECT IMMUN, V68, P133, DOI 10.1128/IAI.68.1.133-140.2000; BRIESE T, 1985, EUR J BIOCHEM, V146, P417, DOI 10.1111/j.1432-1033.1985.tb08668.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen DK, 1999, NEW ENGL J MED, V341, P233, DOI 10.1056/NEJM199907223410403; De las Rivas B, 2002, J BACTERIOL, V184, P4988, DOI 10.1128/JB.184.18.4988-5000.2002; DIAZ E, 1991, J BIOL CHEM, V266, P5464; Fernandez-Tornero C, 2002, J MOL BIOL, V321, P163, DOI 10.1016/S0022-2836(02)00596-X; Fernandez-Tornero C, 2001, NAT STRUCT BIOL, V8, P1020, DOI 10.1038/nsb724; FISCHER W, 2000, STREPTOCOCCUS PNEUMO, P155; GARCIA E, 1985, MOL GEN GENET, V201, P225, DOI 10.1007/BF00425663; GARCIA JL, 1987, J VIROL, V61, P2573; GARCIA JL, 1987, ARCH MICROBIOL, V149, P52, DOI 10.1007/BF00423136; Garcia JL, 2000, STREPTOCOCCUS PNEUMO, P231; Garcia P, 1999, MOL MICROBIOL, V33, P128, DOI 10.1046/j.1365-2958.1999.01455.x; GARCIA P, 1990, GENE, V86, P81, DOI 10.1016/0378-1119(90)90116-9; GIUDICELLI S, 1984, J BACTERIOL, V158, P1188, DOI 10.1128/JB.158.3.1188-1190.1984; Gosink KK, 2000, INFECT IMMUN, V68, P5690, DOI 10.1128/IAI.68.10.5690-5695.2000; Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608; Hollingshead SK, 2001, CURR OPIN MICROBIOL, V4, P71, DOI 10.1016/S1369-5274(00)00167-3; HOLTJE JV, 1975, J BIOL CHEM, V250, P6072; Hooper D. C., 2001, CLIN INFECT DIS   S1, V32, P9; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; Jorgensen WL, 2004, SCIENCE, V303, P1813, DOI 10.1126/science.1096361; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Lopez R, 2004, FEMS MICROBIOL REV, V28, P553, DOI 10.1016/j.femsre.2004.05.002; Lopez R, 2004, PNEUMOCCOCUS, P75; McCormick AW, 2003, NAT MED, V9, P424, DOI 10.1038/nm839; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; PATON JH, 1988, DRUGS, V36, P193, DOI 10.2165/00003495-198836020-00004; Romero P, 2004, J BACTERIOL, V186, P8229, DOI 10.1128/JB.186.24.8229-8239.2004; ROUSSEL A, 1991, TURBO FRODO SILICON, P77; Sahm DF, 2000, ANTIMICROB AGENTS CH, V44, P2521, DOI 10.1128/AAC.44.9.2521-2524.2000; SANCHEZPUELLES JM, 1992, EUR J BIOCHEM, V203, P153, DOI 10.1111/j.1432-1033.1992.tb19840.x; SANZ JM, 1988, FEBS LETT, V232, P308, DOI 10.1016/0014-5793(88)80759-2; Shoichet BK, 2002, CURR OPIN CHEM BIOL, V6, P439, DOI 10.1016/S1367-5931(02)00339-3; Sotriffer CA, 2000, METHODS, V20, P280, DOI 10.1006/meth.1999.0922; TUMMINO PJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P523, DOI 10.1006/abbi.1995.1069; Tuomanen E, 1999, CURR OPIN MICROBIOL, V2, P35, DOI 10.1016/S1369-5274(99)80006-X; Voigt JH, 2001, J CHEM INF COMP SCI, V41, P702, DOI 10.1021/ci000150t; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WREN BW, 1991, MOL MICROBIOL, V5, P797, DOI 10.1111/j.1365-2958.1991.tb00752.x	45	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19948	19957		10.1074/jbc.M501236200	http://dx.doi.org/10.1074/jbc.M501236200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769740	hybrid, Green Published			2022-12-25	WOS:000229113700064
J	Persikov, AV; Ramshaw, JAM; Brodsky, B				Persikov, AV; Ramshaw, JAM; Brodsky, B			Prediction of collagen stability from amino acid sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELICAL STRUCTURE; I COLLAGEN; OSTEOGENESIS IMPERFECTA; MOLECULAR-STRUCTURE; ASYMMETRIC ACETYLCHOLINESTERASE; ELECTROSTATIC INTERACTIONS; THERMODYNAMIC SCALE; FORMING TENDENCIES; THERMAL-STABILITY; PEPTIDE MODELS	An algorithm was derived to relate the amino acid sequence of a collagen triple helix to its thermal stability. This calculation is based on the triple helical stabilization propensities of individual residues and their intermolecular and intramolecular interactions, as quantitated by melting temperature values of host-guest peptides. Experimental melting temperature values of a number of triple helical peptides of varying length and sequence were successfully predicted by this algorithm. However, predicted T-m values are significantly higher than experimental values when there are strings of oppositely charged residues or concentrations of like charges near the terminus. Application of the algorithm to collagen sequences highlights regions of unusually high or low stability, and these regions often correlate with biologically significant features. The prediction of stability from sequence indicates an understanding of the major forces maintaining this protein motif. The use of highly favorable KGE and KGD sequences is seen to complement the stabilizing effects of imino acids in modulating stability and may become dominant in the collagenous domains of bacterial proteins that lack hydroxyproline. The effect of single amino acid mutations in the X and Y positions can be evaluated with this algorithm. An interactive collagen stability calculator based on this algorithm is available online.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; CSIRO, Parkville, Vic 3052, Australia	Rutgers State University New Brunswick; Rutgers State University Medical Center; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Brodsky, B (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	brodsky@umdnj.edu	Ramshaw, John AM/A-9411-2011	Ramshaw, John A.M./0000-0002-2131-3685	NIGMS NIH HHS [GM60048] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060048] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANACHI RB, 1995, FEBS LETT, V368, P551, DOI 10.1016/0014-5793(95)00738-U; Andersson EC, 1998, P NATL ACAD SCI USA, V95, P7574, DOI 10.1073/pnas.95.13.7574; BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BACHINGER HP, 1991, INT J BIOL MACROMOL, V13, P152, DOI 10.1016/0141-8130(91)90040-2; Ballo R, 1998, AM J MED GENET, V80, P6, DOI 10.1002/(SICI)1096-8628(19981102)80:1<6::AID-AJMG2>3.0.CO;2-0; Bann JG, 2000, J BIOL CHEM, V275, P24466, DOI 10.1074/jbc.M003336200; Beck K, 2000, P NATL ACAD SCI USA, V97, P4273, DOI 10.1073/pnas.070050097; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Brodsky B, 2005, ADV PROTEIN CHEM, V70, P301, DOI 10.1016/S0065-3233(05)70009-7; Buevich AV, 2004, J BIOL CHEM, V279, P46890, DOI 10.1074/jbc.M407061200; CHAN D, 1993, J BIOL CHEM, V268, P15238; Chung LD, 2004, EMBO J, V23, P3020, DOI 10.1038/sj.emboj.7600318; Deprez P, 2000, BIOCHEM J, V350, P283, DOI 10.1042/0264-6021:3500283; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; Doss-Pepe E, 2004, BBA-PROTEINS PROTEOM, V1698, P187, DOI 10.1016/j.bbapap.2003.11.034; Doss-Pepe E, 2000, BIOCHEMISTRY-US, V39, P14884, DOI 10.1021/bi001108u; Emsley J, 2004, J MOL BIOL, V335, P1019, DOI 10.1016/j.jmb.2003.11.030; Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4; KADLER KE, 1988, J BIOL CHEM, V263, P10517; Kramer RZ, 2000, J MOL BIOL, V301, P1191, DOI 10.1006/jmbi.2000.4017; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Kramer RZ, 2001, J MOL BIOL, V311, P131, DOI 10.1006/jmbi.2001.4849; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007; Mohs A, 2005, BIOCHEMISTRY-US, V44, P1793, DOI 10.1021/bi0482708; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; Persikov AV, 2000, BIOCHEMISTRY-US, V39, P14960, DOI 10.1021/bi001560d; Persikov AV, 2003, J AM CHEM SOC, V125, P11500, DOI 10.1021/ja036673+; Persikov AV, 2005, BIOCHEMISTRY-US, V44, P1414, DOI 10.1021/bi048216r; Persikov AV, 2004, HUM MUTAT, V24, P330, DOI 10.1002/humu.20091; Persikov AV, 2004, PROTEIN SCI, V13, P893, DOI 10.1110/ps.03501704; Persikov AV, 2002, J MOL BIOL, V316, P385, DOI 10.1006/jmbi.2001.5342; PIEZ KA, 1970, BIOCHEMISTRY-US, V9, P4134, DOI 10.1021/bi00823a016; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; RAMACHANDRAN GN, 1963, INT REV CONNECT TISS, V68, P127; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; Rasmussen M, 2003, J BIOL CHEM, V278, P32313, DOI 10.1074/jbc.M304709200; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; Shah NK, 1997, BIOCHEMISTRY-US, V36, P5878, DOI 10.1021/bi963146c; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; Steichen C, 2003, J BACTERIOL, V185, P1903, DOI 10.1128/JB.185.6.1903-1910.2003; Steplewski A, 2004, J STRUCT BIOL, V148, P326, DOI 10.1016/j.jsb.2004.07.006; SUTOH K, 1974, BIOPOLYMERS, V13, P2391, DOI 10.1002/bip.1974.360131118; SWINDELLS MB, 1995, NAT STRUCT BIOL, V2, P596, DOI 10.1038/nsb0795-596; VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023; Wagschal K, 1999, PROTEIN SCI, V8, P2312; Wang Z, 2001, HUM MUTAT, V17, P263, DOI 10.1002/humu.22; WERKMEISTER JA, 2003, BIOMATERIALS HDB, P229; Xu Y, 2002, J BIOL CHEM, V277, P27312, DOI 10.1074/jbc.M201163200; Xu YJ, 2003, BIOCHEMISTRY-US, V42, P8696, DOI 10.1021/bi034006n; Yang W, 1997, BIOCHEMISTRY-US, V36, P6930, DOI 10.1021/bi970051h	52	267	283	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19343	19349		10.1074/jbc.M501657200	http://dx.doi.org/10.1074/jbc.M501657200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753081	hybrid			2022-12-25	WOS:000228932300091
J	Harada, A; Katoh, H; Negishi, M				Harada, A; Katoh, H; Negishi, M			Direct interaction of Rnd1 with FRS2 beta regulates Rnd1-induced down-regulation of RhoA activity and is involved in fibroblast growth factor-induced neurite outgrowth in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P85 BETA-PIX; ACTIN CYTOSKELETON; SMALL GTPASES; FAMILY; ACTIVATION; PROTEIN; PHOSPHORYLATION; EXPRESSION; KINASE; ROLES	The Rho family of small GTPases has been implicated in the reorganization of the actin cytoskeleton and subsequent morphological changes in various cells. Rnd1, a member of this family, has a low intrinsic GTPase activity and exerts antagonistic effects on RhoA signaling. However, how the activity of Rnd1 is regulated has not yet been elucidated. Here we have demonstrated that Rnd1 directly associates with FRS2 alpha and FRS2 beta, which are docking proteins of fibroblast growth factor (FGF) receptors and play important roles in the intracellular signals induced by FGFs. The interaction of FRS2 beta with Rnd1 suppresses the inhibitory effect of Rnd1 on RhoA. Rnd1 binds to the COOH-terminal region of FRS2 beta including tyrosine residues essential for the interaction with Shp2. When FGF receptor 1 is activated, it phosphorylates FRS2 beta, recruits Shp2, and releases Rnd1 from FRS2 beta. The liberated Rnd1 then inhibits RhoA activity. Furthermore, knockdown of Rnd1 by Rnd1-specific short interfering RNAs suppress the FGF-induced neurite outgrowth in PC12 cells. These results suggest that the activity of Rnd1 is regulated by FGF receptor through FRS2 beta and that Rnd1 plays an important role in the FGF signaling during neurite outgrowth.	Kyoto Univ, Grad Sch Biostat, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Grad Sch Biostat, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan.	mnegishi@pharm.kyoto-u.ac.jp		Katoh, Hironori/0000-0002-8191-8117				Aoki J, 2000, BIOCHEM BIOPH RES CO, V278, P604, DOI 10.1006/bbrc.2000.3842; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Da Silva JS, 2002, NAT REV NEUROSCI, V3, P694, DOI 10.1038/nrn918; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; Gotoh N, 2004, FEBS LETT, V564, P14, DOI 10.1016/S0014-5793(04)00287-X; Gritti A, 1996, J NEUROSCI, V16, P1091; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hansen SH, 2000, MOL CELL BIOL, V20, P9364, DOI 10.1128/MCB.20.24.9364-9375.2000; Ishikawa Y, 2003, J NEUROSCI, V23, P11065; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Kakimoto T, 2004, J BIOL CHEM, V279, P14104, DOI 10.1074/jbc.M312763200; Katoh H, 2002, MOL CELL BIOL, V22, P2952, DOI 10.1128/MCB.22.9.2952-2964.2002; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Li AJ, 2002, EUR J NEUROSCI, V16, P1313, DOI 10.1046/j.1460-9568.2002.02193.x; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Negishi M, 2002, J BIOCHEM, V132, P157, DOI 10.1093/oxfordjournals.jbchem.a003205; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Oinuma I, 2003, J BIOL CHEM, V278, P25671, DOI 10.1074/jbc.M303047200; REN XD, 2000, METHOD ENZYMOL, V256, P215; Reuss B, 2003, CELL TISSUE RES, V313, P139, DOI 10.1007/s00441-003-0756-7; Riento K, 2003, MOL CELL BIOL, V23, P4219, DOI 10.1128/MCB.23.12.4219-4229.2003; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shin EY, 2004, J BIOL CHEM, V279, P1994, DOI 10.1074/jbc.M307330200; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; Tashiro A, 2000, CEREB CORTEX, V10, P927, DOI 10.1093/cercor/10.10.927; TOGARI A, 1985, J NEUROSCI, V5, P307; Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4; Wunnenberg-Stapleton K, 1999, DEVELOPMENT, V126, P5339; XU H, 1998, J BIOL CHEM, V20, P13049	33	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18418	18424		10.1074/jbc.M411356200	http://dx.doi.org/10.1074/jbc.M411356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15738000	hybrid			2022-12-25	WOS:000228807200104
J	Yan, Y; Spieker, RS; Kim, M; Stoeger, SM; Cowan, KH				Yan, Y; Spieker, RS; Kim, M; Stoeger, SM; Cowan, KH			BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation	ONCOGENE			English	Article						BRCA1; Cdc2; Cdc25C; Chk1; ERK1/2 and Wee1	DNA-DAMAGE RESPONSE; 14-3-3 PROTEIN-BINDING; TYROSINE PHOSPHORYLATION; IONIZING IRRADIATION; CANCER SUSCEPTIBILITY; CARCINOMA-CELLS; WEE1 KINASE; S-PHASE; BRCA1; CHECKPOINT	Germline mutations in the BRCA1 gene are associated with an increased susceptibility to the development of breast and ovarian cancers. Evidence suggests that BRCA1 protein plays a key role in mediating DNA damage-induced checkpoint responses. Several studies have shown that ectopic expression of BRCA1 in human cells can trigger cellular responses similar to those induced by DNA damage, including G2/M cell cycle arrest and apoptosis. While the effects of ectopic BRCA1 expression on the G2/M transition and apoptosis have been extensively studied, the factors that dictate the balance between these two responses remain poorly understood. We have recently shown that ectopic expression of BRCA1 in MCF-7 human breast cancer cells resulted in activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) and G2/M cell cycle arrest. Furthermore, inhibition of BRCA1-induced ERK1/2 activation using mitogen-activated protein kinase kinase 1 and 2 (MEK1/2)-specific inhibitors resulted in increased apoptosis, suggesting a potential role of ERK1/2 kinases in BRCA1-mediated G2/M checkpoint response. In this study, we assessed the role of ERK1/2 kinases in the regulation of BRCA1-mediated G2/M cell cycle arrest. Results indicate that BRCA1-induced G2/M cell cycle arrest and ERK1/2 activation correlate with changes in the level and/or activity of several key regulators of the G2/M checkpoint, including activation of Chk1 and Wee1 kinases, induction of 14-3-3, and down-regulation of Cdc25C. Furthermore, inhibition of ERK1/2 kinases using MEK1/2-specific inhibitors results in a marked attenuation of the BRCA1-induced G2/M arrest. Biochemical studies established that ERK1/2 inhibition abolished the effects of BRCA1 on components of the G2/M checkpoint, including regulation of Cdc25C expression and activation of Wee1 and Chk1 kinases. These results implicate a critical role of ERK1/2 signaling in the regulation of BRCA1 function on controlling the G2/M checkpoint responses.	Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Childrens Natl Med Ctr, Washington, DC 20010 USA	University of Nebraska System; University of Nebraska Medical Center; Children's National Health System	Cowan, KH (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	kcowan@unmc.edu			NCI NIH HHS [P30 CA036727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Chen JJ, 2000, CANCER RES, V60, P5037; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deng CX, 2000, BIOESSAYS, V22, P728; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gatei M, 2000, CANCER RES, V60, P3299; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kawabe T, 2004, MOL CANCER THER, V3, P513; KHARBANDA S, 1994, CANCER RES, V54, P1412; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Qin J, 2003, RADIAT RES, V159, P139, DOI 10.1667/0033-7587(2003)159[0139:MAOTDD]2.0.CO;2; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang Y, 2000, GENE DEV, V14, P927; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Yan Y, 2002, J BIOL CHEM, V277, P33422, DOI 10.1074/jbc.M201147200; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Yang XH, 1999, BREAST CANCER RES TR, V54, P1, DOI 10.1023/A:1006189906896; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837	52	50	54	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3285	3296		10.1038/sj.onc.1208492	http://dx.doi.org/10.1038/sj.onc.1208492			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735702				2022-12-25	WOS:000228881800007
J	Iype, T; Francis, J; Garmey, JC; Schisler, JC; Nesher, R; Weir, GC; Becker, TC; Newgard, CB; Griffen, SC; Mirmira, RG				Iype, T; Francis, J; Garmey, JC; Schisler, JC; Nesher, R; Weir, GC; Becker, TC; Newgard, CB; Griffen, SC; Mirmira, RG			Mechanism of insulin gene regulation by the pancreatic transcription factor Pdx-1 - Application of pre-mRNA analysis and chromatin immunoprecipitation to assess formation of functional transcriptional complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; BETA-CELLS; ACTIVATION DOMAINS; DIABETES-MELLITUS; POLYMERASE-II; TARGET GENES; IN-VITRO; EXPRESSION; GLUCOSE; P300	The homeodomain factor Pdx-1 regulates an array of genes in the developing and mature pancreas, but whether regulation of each specific gene occurs by a direct mechanism ( binding to promoter elements and activating basal transcriptional machinery) or an indirect mechanism ( via regulation of other genes) is unknown. To determine the mechanism underlying regulation of the insulin gene by Pdx-1, we performed a kinetic analysis of insulin transcription following adenovirus-mediated delivery of a small interfering RNA specific for pdx-1 into insulinoma cells and pancreatic islets to diminish endogenous Pdx-1 protein. insulin transcription was assessed by measuring both a long half-life insulin mRNA ( mature mRNA) and a short half-life insulin pre-mRNA species by real-time reverse transcriptase-PCR. Following progressive knock-down of Pdx-1 levels, we observed coordinate decreases in pre-mRNA levels ( to about 40% of normal levels at 72 h). In contrast, mature mRNA levels showed strikingly smaller and delayed declines, suggesting that the longer half-life of this species underestimates the contribution of Pdx-1 to insulin transcription. Chromatin immunoprecipitation assays revealed that the decrease in insulin transcription was associated with decreases in the occupancies of Pdx-1 and p300 at the proximal insulin promoter. Although there was no corresponding change in the recruitment of RNA polymerase II to the proximal promoter, its recruitment to the insulin coding region was significantly reduced. Our results suggest that Pdx-1 directly regulates insulin transcription through formation of a complex with transcriptional coactivators on the proximal insulin promoter. This complex leads to enhancement of elongation by the basal transcriptional machinery.	Univ Virginia, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Diabet, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27704 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA; Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA	University of Virginia; University of Virginia; University of Virginia; Duke University; Duke University; Duke University; Duke University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; University of California System; University of California Davis	Mirmira, RG (corresponding author), Univ Virginia Hlth Syst, 450 Ray C Hunt Dr,Box 801407, Charlottesville, VA 22908 USA.	mirmira@virginia.edu	Schisler, Jonathan C./C-1301-2008; Mirmira, Raghavendra G/AAD-7592-2020	Schisler, Jonathan C./0000-0001-7382-2783; Mirmira, Raghavendra G/0000-0002-5013-6075	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R13DK056047, U19DK061251, R01DK060581, K08DK002619] Funding Source: NIH RePORTER; NIDDK NIH HHS [U19 DK61251, K08 DK002619, R01 DK60581, U01 DK56047] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Bain JR, 2004, DIABETES, V53, P2190, DOI 10.2337/diabetes.53.9.2190; Blau J, 1996, MOL CELL BIOL, V16, P2044; Brown SA, 1998, EMBO J, V17, P3146, DOI 10.1093/emboj/17.11.3146; Burger LL, 2004, ENDOCRINOLOGY, V145, P71, DOI 10.1210/en.2003-1047; Chakrabarti SK, 2003, TRENDS ENDOCRIN MET, V14, P78, DOI 10.1016/S1043-2760(02)00039-5; Chakrabarti SK, 2003, J BIOL CHEM, V278, P23617, DOI 10.1074/jbc.M303423200; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Cissell MA, 2003, J BIOL CHEM, V278, P751, DOI 10.1074/jbc.M205905200; DANDOYDRON F, 1991, NUCLEIC ACIDS RES, V19, P4925, DOI 10.1093/nar/19.18.4925; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FROMONTRACINE M, 1990, MOL ENDOCRINOL, V4, P669, DOI 10.1210/mend-4-5-669; GIDDINGS SJ, 1988, J BIOL CHEM, V263, P3845; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Holland AM, 2002, P NATL ACAD SCI USA, V99, P12236, DOI 10.1073/pnas.192255099; Iype T, 2004, MOL ENDOCRINOL, V18, P1363, DOI 10.1210/me.2004-0006; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kadonaga JT, 2004, CELL, V116, P247, DOI 10.1016/S0092-8674(03)01078-X; Kajimoto Y, 1997, J CLIN INVEST, V100, P1840, DOI 10.1172/JCI119712; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; Kelpe CL, 2003, J BIOL CHEM, V278, P30015, DOI 10.1074/jbc.M302548200; KORANYI L, 1989, MOL ENDOCRINOL, V3, P1895, DOI 10.1210/mend-3-11-1895; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Le Lay J, 2004, J BIOL CHEM, V279, P22228, DOI 10.1074/jbc.M312673200; Liberzon A, 2004, NUCLEIC ACIDS RES, V32, P54, DOI 10.1093/nar/gkh156; Liu AH, 2004, MOL CELL BIOL, V24, P4372, DOI 10.1128/MCB.24.10.4372-4383.2004; Lottmann H, 2001, J MOL MED-JMM, V79, P321, DOI 10.1007/s001090100229; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Mosley AL, 2004, MOL ENDOCRINOL, V18, P2279, DOI 10.1210/me.2003-0463; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; Peshavaria M, 2000, MOL ENDOCRINOL, V14, P1907, DOI 10.1210/me.14.12.1907; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Prendergast KA, 2004, BIOL REPROD, V70, P364, DOI 10.1095/biolreprod.103.021733; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Qiu Y, 2004, J BIOL CHEM, V279, P9796, DOI 10.1074/jbc.M307577200; Ritz-Laser B, 1999, ENDOCRINOLOGY, V140, P4005, DOI 10.1210/en.140.9.4005; Stanojevic V, 2004, ENDOCRINOLOGY, V145, P2918, DOI 10.1210/en.2003-1188; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Thomas MK, 2001, J CLIN INVEST, V108, P319, DOI 10.1172/JCI200112029; Tillmar L, 2002, J BIOL CHEM, V277, P1099, DOI 10.1074/jbc.M108340200; Wang HY, 2001, J BIOL CHEM, V276, P25279, DOI 10.1074/jbc.M101233200; Wang JH, 1997, P NATL ACAD SCI USA, V94, P4360, DOI 10.1073/pnas.94.9.4360; WELSH M, 1985, J BIOL CHEM, V260, P3590; Yang ZD, 2004, TRANSPLANTATION, V77, P55, DOI 10.1097/01.TP.0000104844.48064.81; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	55	89	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16798	16807		10.1074/jbc.M414381200	http://dx.doi.org/10.1074/jbc.M414381200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15743769	hybrid			2022-12-25	WOS:000228615500032
J	Roessner, CA; Williams, HJ; Scott, AI				Roessner, CA; Williams, HJ; Scott, AI			Genetically engineered production of 1-desmethylcobyrinic acid, 1-desmethylcobyrinic acid a,c-diamide, and cobyrinic acid a,c-diamide in Escherichia coli implies a role for CbiD in c-1 methylation in the anaerobic pathway to cobalamin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; PSEUDOMONAS-DENITRIFICANS; VITAMIN-B-12 BIOSYNTHESIS; UROPORPHYRINOGEN-III; TIGHT REGULATION; EXPRESSION; GENES; IDENTIFICATION; VECTORS; CLONING	Co-expression of the cobA gene from Propionibacterium freudenreichii and the cbiA, - C, - D, - E, - T, - F, - G, - H, - J, - K, - L, and - P genes from Salmonella enterica serovar typhimurium in Escherichia coli resulted in the production of cobyrinic acid a, c-diamide. A cbiD deletion mutant of this strain produced 1-desmethylcobyrinic acid a, c-diamide, indicating that CbiD is involved in C-1 methylation in the anaerobic pathway to cobalamin. Strains that did not have the cbiP gene also produced 1-desmethylcobyrinic acid a, c-diamide, and strains that had neither cbiP nor cbiA synthesized 1-desmethylcobyrinic acid even in the presence of cbiD, suggesting that CbiA and CbiP are necessary for CbiD activity.	Texas A&M Univ, Dept Chem, Ctr Biol NMR, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Roessner, CA (corresponding author), Texas A&M Univ, Dept Chem, Ctr Biol NMR, College Stn, TX 77843 USA.	c-roessner@tamu.edu			NIDDK NIH HHS [DK32034] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032034, R37DK032034] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BATTERSBY AR, 1982, J CHEM SOC PERK T 1, P2265, DOI 10.1039/p19820002265; BLANCHE F, 1991, J BACTERIOL, V173, P6046, DOI 10.1128/jb.173.19.6046-6051.1991; BLANCHE F, 1995, ANGEW CHEM INT EDIT, V34, P383, DOI 10.1002/anie.199503831; Bruggemann H, 2004, SCIENCE, V305, P671, DOI 10.1126/science.1100330; DEBUSSCHE L, 1993, J BACTERIOL, V175, P7430, DOI 10.1128/JB.175.22.7430-7440.1993; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; LUNDRIGAN MD, 1989, J BACTERIOL, V171, P154, DOI 10.1128/jb.171.1.154-161.1989; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Raux E, 1998, BIOCHEM J, V335, P167, DOI 10.1042/bj3350167; Raux E, 1996, J BACTERIOL, V178, P753, DOI 10.1128/jb.178.3.753-767.1996; Roessner CA, 2001, VITAM HORM, V61, P267; ROESSNER CA, 1992, FEBS LETT, V301, P73, DOI 10.1016/0014-5793(92)80213-Z; Roper JM, 2000, J BIOL CHEM, V275, P40316, DOI 10.1074/jbc.M007146200; ROTH JR, 1993, J BACTERIOL, V175, P3303, DOI 10.1128/jb.175.11.3303-3316.1993; Santander PJ, 1997, CHEM BIOL, V4, P659, DOI 10.1016/S1074-5521(97)90221-0; SATTLER I, 1995, J BACTERIOL, V177, P1564, DOI 10.1128/jb.177.6.1564-1569.1995; SCHREIBER SL, 1991, TETRAHEDRON, V47, P2543, DOI 10.1016/S0040-4020(01)81788-9; SCOTT AI, 1984, BIOORG CHEM, V12, P356, DOI 10.1016/0045-2068(84)90017-8; Warren MJ, 2002, NAT PROD REP, V19, P390, DOI 10.1039/B108967F; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	21	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16748	16753		10.1074/jbc.M501805200	http://dx.doi.org/10.1074/jbc.M501805200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15741157	hybrid			2022-12-25	WOS:000228615500026
J	Le Pera, I; Iuliano, R; Florio, T; Susini, C; Trapasso, F; Santoro, M; Chiariotti, L; Schettini, G; Viglietto, G; Fusco, A				Le Pera, I; Iuliano, R; Florio, T; Susini, C; Trapasso, F; Santoro, M; Chiariotti, L; Schettini, G; Viglietto, G; Fusco, A			The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue	ONCOGENE			English	Article						protein tyrosine phosphatases; r-PTP eta; HPTP eta/DEP-1; c-Src; cell adhesion	THYROID EPITHELIAL-CELLS; MATRIX ADHESION; FAMILY KINASES; SOMATOSTATIN INHIBITION; SIGNAL-TRANSDUCTION; COLORECTAL-CANCER; FOCAL ADHESIONS; SARCOMA-VIRUS; IN-VITRO; PROTEIN	The expression of the receptor protein tyrosine phosphatase r-PTP eta is drastically reduced in rat and human malignant thyroid cells, whereas its restoration reverts the neoplastic phenotype of retrovirally transformed rat thyroid cells. Moreover, reduced levels and loss of heterozygosity of DEP-1, the human homolog of r-PTP eta, have been found in many human neoplasias. Here, we report that the r-PTP eta protein binds to c-Src in living cells and dephosphorylates the c-Src inhibitory tyrosine phosphorylation site (Tyr 529), thereby increasing c-Src tyrosine kinase activity in malignant rat thyroid cells stably transfected with r-PTP eta. Tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin was enhanced in r-PTP eta-expressing cells. This was associated with increased adhesion of malignant r-PTP eta-transfected thyroid cells vs both untransfected cells and cells stably transfected with an inactive r-PTP eta mutant. Treatment of rat thyroid cells with the c-Src inhibitor PP2 decreased cell adhesion to a higher extent in r-PTP eta-transfected cells than in mock-transfected or stably transfected cells with the inactive r-PTP eta mutant, indicating that r-PTP eta regulates cell - substratum adhesion by activating c-Src. Interestingly, the extent of both c-Src dephosphorylation at Tyr 529, FAK and paxillin phosphorylation, and the increased cell adhesion were associated with the degree of r-PTP eta expression.	Univ Naples Federico II, Sch Med, CNR,Dept Biol & Mol & Cellular Pathol, Endocrinol & Expt Oncol Ctr, I-80131 Naples, Italy; Magna Graecia Univ Catanzaro, Med Sch Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy; Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy; CHU Rangueil, IFR 31, INSERM, U531, F-31403 Toulouse, France; Univ Molise, Dept SpeS, I-86100 Campobasso, Italy; NOGEC, CEINGE, I-80145 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; University of Genoa; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Molise; CEINGE Biotecnologie Avanzate	Fusco, A (corresponding author), Univ Naples Federico II, Sch Med, CNR,Dept Biol & Mol & Cellular Pathol, Endocrinol & Expt Oncol Ctr, I-80131 Naples, Italy.	afusco@napoli.com	Florio, Tullio/A-2211-2012; FLORIO, TULLIO/ABG-3182-2020; Viglietto, Giuseppe/AAC-2852-2019; Chiariotti, Lorenzo/AAC-5262-2022	Florio, Tullio/0000-0002-2394-996X; Viglietto, Giuseppe/0000-0003-2327-7515; Fusco, Alfredo/0000-0003-3332-5197; CHIARIOTTI, Lorenzo/0000-0001-6097-4171				Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Baker JE, 2001, MOL CELL BIOL, V21, P2393, DOI 10.1128/MCB.21.7.2393-2403.2001; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chiang GG, 2000, J BIOL CHEM, V275, P6055, DOI 10.1074/jbc.275.9.6055; de la Fuente-Garcia MA, 1998, BLOOD, V91, P2800, DOI 10.1182/blood.V91.8.2800.2800_2800_2809; Florio T, 2001, MOL ENDOCRINOL, V15, P1838, DOI 10.1210/me.15.10.1838; FUSCO A, 1985, J VIROL, V56, P284, DOI 10.1128/JVI.56.1.284-292.1985; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Iuliano R, 2004, ONCOGENE, V23, P8432, DOI 10.1038/sj.onc.1207766; Iuliano R, 2003, CANCER RES, V63, P882; Iuliano R, 2001, FEBS LETT, V500, P41, DOI 10.1016/S0014-5793(01)02580-7; Jandt E, 2003, ONCOGENE, V22, P4175, DOI 10.1038/sj.onc.1206652; Jones RJ, 2002, BRIT J CANCER, V87, P1128, DOI 10.1038/sj.bjc.6600594; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Keane MM, 1996, CANCER RES, V56, P4236; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; Martelli ML, 1998, EXP CELL RES, V245, P195, DOI 10.1006/excr.1998.4257; Massa A, 2004, J BIOL CHEM, V279, P29004, DOI 10.1074/jbc.M403573200; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Petrone A, 2000, J CELL SCI, V113, P2345; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; Tangye SG, 1998, J IMMUNOL, V161, P3803; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Trapasso F, 2004, CARCINOGENESIS, V25, P2107, DOI 10.1093/carcin/bgh224; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zimmermann P, 2001, MOL BIOL CELL, V12, P339, DOI 10.1091/mbc.12.2.339	45	45	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3187	3195		10.1038/sj.onc.1208510	http://dx.doi.org/10.1038/sj.onc.1208510			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735685				2022-12-25	WOS:000228728100012
J	Perez-Mancera, PA; Gonzalez-Herrero, I; Perez-Caro, M; Gutierrez-Cianca, N; Flores, T; Gutierrez-Adan, A; Pintado, B; Sanchez-Martin, M; Sanchez-Garcia, I				Perez-Mancera, PA; Gonzalez-Herrero, I; Perez-Caro, M; Gutierrez-Cianca, N; Flores, T; Gutierrez-Adan, A; Pintado, B; Sanchez-Martin, M; Sanchez-Garcia, I			SLUG in cancer development	ONCOGENE			English	Article						SLUG; development; cancer	TRANSCRIPTION FACTOR SNAIL; E-CADHERIN; GENE-EXPRESSION; ABL; REPRESSOR	The SNAIL-related zinc-finger transcription factor, SLUG (SNAI2), is critical for the normal development of neural crest-derived cells and loss-of-function SLUG mutations have been proven to contribute to piebaldism and Waardenburg syndrome type 2 in a dose-dependent fashion. While aberrant induction of SLUG has been documented in cancer cells, relatively little is known about the consequences of SLUG overexpression in malignancy. To investigate the potential role of SLUG overexpression in development and in cancer, we generated mice carrying a tetracycline-repressible Slug transgene. These mice were morphologically normal at birth, and developed mesenchymal tumours ( leukaemia and sarcomas) in almost all cases examined. Suppression of the Slug transgene did not rescue the malignant phenotype. Furthermore, the BCR ABL oncogene, which induces Slug expression in leukaemic cells, did not induce leukaemia in Slug-deficient mice, implicating Slug in BCR - ABL leukaemogenesis in vivo. Overall, the findings indicate that while Slug overexpression is not sufficient to cause overt morphogenetic defects in mice, they demonstrate a specific and critical role for Slug in the pathogenesis of mesenchymal tumours.	Univ Salamanca, CSIC, IBMCC, Lab 13, Salamanca 37007, Spain; Univ Salamanca, Serv Anat Patol, Salamanca 37007, Spain; Ctr Invest & Tecnol, Area Reprod Anim, Madrid 28040, Spain; Univ Salamanca, Dept Med, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, CSIC, IBMCC, Lab 13, Campus Unamuno, Salamanca 37007, Spain.	isg@usal.es	Pintado, Belen/N-3233-2014; González-Herrero, Inés/G-8546-2015; Sanchez-Martin, Manuel/N-5327-2016; SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Gutierrez-Adan, Alfonso/A-1485-2014	Pintado, Belen/0000-0002-8485-2520; González-Herrero, Inés/0000-0003-1142-4362; Sanchez-Martin, Manuel/0000-0001-8370-1336; Gutierrez-Adan, Alfonso/0000-0001-9893-9179; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Becker MW, 2002, CANCER CELL, V2, P249, DOI 10.1016/S1535-6108(02)00156-3; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; Cohen ME, 1998, GENOMICS, V51, P468, DOI 10.1006/geno.1998.5367; GarciaHernandez B, 1997, P NATL ACAD SCI USA, V94, P13239, DOI 10.1073/pnas.94.24.13239; Hajra KM, 2002, CANCER RES, V62, P1613; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1016/S0012-1606(98)80005-5; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Oram KF, 2003, ANAT REC PART A, V271A, P189, DOI 10.1002/ar.a.10027; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Perez-Losada J, 2003, ONCOGENE, V22, P4205, DOI 10.1038/sj.onc.1206467; Perez-Losada J, 2002, BLOOD, V100, P1274, DOI 10.1182/blood.V100.4.1274.h81602001274_1274_1286; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; Sanchez-Martin M, 2002, HUM MOL GENET, V11, P3231, DOI 10.1093/hmg/11.25.3231; Sanchez-Martin MS, 2003, AM J MED GENET A, V122A, P125, DOI 10.1002/ajmg.a.20345; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SANCHEZMARTIN M, 2004, ATLAS GENET CYTOGENE; Schultze N, 1996, NAT BIOTECHNOL, V14, P499, DOI 10.1038/nbt0496-499; Sefton M, 1998, DEVELOPMENT, V125, P3111; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Tabernero MD, 2001, LEUKEMIA, V15, P406, DOI 10.1038/sj.leu.2402060	27	87	99	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3073	3082		10.1038/sj.onc.1208505	http://dx.doi.org/10.1038/sj.onc.1208505			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735690				2022-12-25	WOS:000228728100001
J	Abdelrahim, M; Liu, SX; Safe, S				Abdelrahim, M; Liu, SX; Safe, S			Induction of endoplasmic reticulum-induced stress genes in Panc-1 pancreatic cancer cells is dependent on Sp proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; NF-Y CBF; BINDING PROTEIN; CA2+ DEPLETION; ELEMENT; ACTIVATION; PROMOTER; ATF6; IDENTIFICATION; TRANSACTIVATION	Endoplasmic reticulum ( ER) stress plays a critical role in multiple diseases, and pharmacologically active drugs can induce cell death through ER stress pathways. Stress-induced genes are activated through assembly of transcription factors on ER stress response elements (ERSEs) in target gene promoters. Gel mobility shift and chromatin immunoprecipitation assays have confirmed interactions of NF-Y and YY1 with the distal motifs of the tripartite ERSE from the glucose-related protein 78 (GRP78) gene promoter. The GC-rich nonanucleotide (N-9) sequence, which forms the ER stress response binding factor (ERSF) complex binds TFII-I and ATF6; however, we have now shown that in Panc-1 pancreatic cancer cells, this complex also binds Sp1, Sp3, and Sp4 proteins. Sp proteins are constitutively bound to the ERSE; however, activation of GRP78 protein ( or reporter gene) by thapsigargin or tunicamycin is inhibited after cotransfection with small inhibitory RNAs for Sp1, Sp3, and Sp4. This study demonstrates that Sp transcription factors are important for stress-induced responses through their binding to ERSEs.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ Syst Hlth, Ctr Sci, Inst Biosci & Technol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu			NCI NIH HHS [CA108178, P20-CA-10193] Funding Source: Medline; NIEHS NIH HHS [ES09106] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2004, CANCER RES, V64, P6740, DOI 10.1158/0008-5472.CAN-04-0713; Abdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Foti DM, 1999, J BIOL CHEM, V274, P30402, DOI 10.1074/jbc.274.43.30402; Hagg M, 2004, MOL CANCER THER, V3, P489; Hampton RY, 2000, CURR BIOL, V10, pR518, DOI 10.1016/S0960-9822(00)00583-2; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hong J, 2004, ENDOCRINOLOGY, V145, P5774, DOI 10.1210/en.2004-0686; Ito M, 1997, J CLIN INVEST, V99, P1897, DOI 10.1172/JCI119357; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; LI WWF, 1993, J BIOL CHEM, V268, P12003; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Marcus N, 1997, DNA CELL BIOL, V16, P1123, DOI 10.1089/dna.1997.16.1123; Merad-Boudia M, 1998, BIOCHEM PHARMACOL, V56, P645, DOI 10.1016/S0006-2952(97)00647-3; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Safe S, 2004, PROG NUCLEIC ACID RE, V77, P1, DOI 10.1016/S0079-6603(04)77001-4; Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436; Wang Y, 2000, J BIOL CHEM, V275, P27013; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	35	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16508	16513		10.1074/jbc.C500030200	http://dx.doi.org/10.1074/jbc.C500030200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15760841	hybrid			2022-12-25	WOS:000228444800125
J	Baczko, I; Jones, L; McGuigan, CF; Fox, JEM; Gandhi, M; Giles, WR; Clanachan, AS; Light, PE				Baczko, I; Jones, L; McGuigan, CF; Fox, JEM; Gandhi, M; Giles, WR; Clanachan, AS; Light, PE			Plasma-membrane K-ATP channel-mediated cardioprotection involves posthypoxic reductions in calcium overload and contractile dysfunction: mechanistic insights into cardioplegia	FASEB JOURNAL			English	Article						ischemia/reperfusion; plasma membrane ATP-sensitive potassium channel; Na+/Ca2+ exchanger; diastolic [Ca2+](i); potassium channel opener	SENSITIVE POTASSIUM CHANNELS; NA+/CA2+ EXCHANGER; RAT HEARTS; VENTRICULAR MYOCYTES; METABOLIC INHIBITION; CARDIAC MYOCYTES; BETA-OXIDATION; CA2+ OVERLOAD; DIAZOXIDE; ACTIVATION	Our recent data demonstrate that activation of pmK(ATP) channels polarizes the membrane of cardiornyocytes and reduces Na+/Ca2+ exchange-mediated Ca2+ overload. However, it is important that these findings be extended into contractile models of hypoxia/reoxygenation injury to further test the notion that pmK(ATP) channel activation affords protection against contractile dysfunction and calcium overload. Single rat heart right ventricular myocytes were enzymatically isolated, and cell contractility and Ca2+ transients in field-stimulated myocytes were measured in a cellular model of metabolic inhibition and reoxygenation. Activation of pmK(ATP) with P-1075 (5 mu M) or inhibition of the Na+/Ca2+ exchanger with KB-R7943 (5 mu M) reduced reoxygenation-induced diastolic Ca2+ overload and improved the rate and magnitude of posthypoxic contractile recovery during the first few minutes of reoxygenation. Moreover, diastolic Ca2+ overload and posthypoxic contractile dysfunction were aggravated in ventricular myocytes either subjected to specific blockade of pmK(ATP) with HMR1098 (20 mu M) or expressing the dominant-negative pmK(ATP) construct Kir6.2(AAA) in the presence of P-1075. Our results suggest that a common mechanism, involving resting membrane potential-modulated increases in diastolic [Ca2+](i), is responsible for the development of contractile dysfunction during reoxygenation following metabolic inhibition. This novel and highly plausible cellular mechanism for pmK(ATP)-mediated cardioprotection may have direct clinical relevance as evidenced by the following findings: a hypokalemic polarizing cardioplegia solution supplemented with the pmK(ATP) opener P-1075 improved Ca2+ homeostasis and recovery of function compared with hyperkalemic depolarizing St. Thomas' cardioplegia following contractile arrest in single ventricular myocytes and working rat hearts. We therefore propose that activation of pmK(ATP) channels improves posthypoxic cardiac function via reductions in abnormal diastolic Ca2+ homeostasis mediated by reverse-mode Na+/Ca2+ exchange.	Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB, Canada; UCSD, Dept Bioengn, La Jolla, CA USA	University of Alberta; University of Calgary; University of California System; University of California San Diego	Light, PE (corresponding author), Univ Alberta, Dept Pharmacol, 9-58 Med Sci, Edmonton, AB T6G 2H7, Canada.	peter.light@ualberta.ca	Baczko, István/I-7752-2019	Baczko, István/0000-0002-9588-0797				Baczko I, 2004, BRIT J PHARMACOL, V141, P1059, DOI 10.1038/sj.bjp.0705702; Baczko I, 2003, J PHYSIOL-LONDON, V550, P889, DOI 10.1113/jphysiol.2003.043372; Baumann P, 2002, AM J PHYSIOL-HEART C, V283, pH2296, DOI 10.1152/ajpheart.00393.2002; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; BOUCHARD RA, 1993, J PHYSIOL-LONDON, V472, P391, DOI 10.1113/jphysiol.1993.sp019953; Chambers DJ, 1999, ANN THORAC SURG, V68, P1960, DOI 10.1016/S0003-4975(99)01020-6; Cohen MV, 1996, ANNU REV MED, V47, P21, DOI 10.1146/annurev.med.47.1.21; COHEN NM, 1995, ANN THORAC SURG, V60, P858, DOI 10.1016/0003-4975(95)00210-C; COLE WC, 1991, CIRC RES, V69, P571, DOI 10.1161/01.RES.69.3.571; D'hahan N, 1999, P NATL ACAD SCI USA, V96, P12162, DOI 10.1073/pnas.96.21.12162; Dobson GP, 2004, J THORAC CARDIOV SUR, V127, P794, DOI 10.1016/S0022-5223(03)01192-9; Dong H, 2002, BIOPHYS J, V82, P1943, DOI 10.1016/S0006-3495(02)75543-4; Dong H, 2001, J BIOL CHEM, V276, P25919, DOI 10.1074/jbc.M103401200; Eigel BN, 2001, AM J PHYSIOL-HEART C, V281, pH2184, DOI 10.1152/ajpheart.2001.281.5.H2184; Finegan BA, 2003, ANESTHESIOLOGY, V98, P379, DOI 10.1097/00000542-200302000-00018; Fox JEM, 2005, J CARDIOVASC PHARM, V45, P30, DOI 10.1097/00005344-200501000-00006; Fox JEM, 2002, BRIT J PHARMACOL, V135, P480, DOI 10.1038/sj.bjp.0704455; GALINANES M, 1992, CARDIOVASC RES, V26, P1063, DOI 10.1093/cvr/26.11.1063; Gao WD, 1996, CIRC RES, V78, P455; Gogelein H, 2000, CARDIOVASC DRUG REV, V18, P157; Grimmsmann T, 1998, BRIT J PHARMACOL, V123, P781, DOI 10.1038/sj.bjp.0701663; Gross GJ, 2003, AM J PHYSIOL-HEART C, V285, pH921, DOI 10.1152/ajpheart.00421.2003; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; Grover GJ, 1995, CARDIOVASC RES, V30, P731; Hanley PJ, 2005, J PHYSIOL-LONDON, V562, P307, DOI 10.1113/jphysiol.2004.073932; Hanley PJ, 2003, J PHYSIOL-LONDON, V547, P387, DOI 10.1113/jphysiol.2002.037044; Hanley PJ, 2002, J PHYSIOL-LONDON, V542, P735, DOI 10.1113/jphysiol.2002.023960; HEARSE DJ, 1995, CARDIOVASC RES, V30, P1; HOSODA H, 1994, ANN THORAC SURG, V58, P1631, DOI 10.1016/0003-4975(94)91649-7; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Jovanovic N, 1999, FASEB J, V13, P923, DOI 10.1096/fasebj.13.8.923; Kim SJ, 2001, CIRC RES, V89, P831, DOI 10.1161/hh2101.098547; Kobayashi S, 2004, AM J PHYSIOL-HEART C, V287, pH1072, DOI 10.1152/ajpheart.00133.2004; Lalli MJ, 1998, PFLUG ARCH EUR J PHY, V436, P957, DOI 10.1007/s004240050729; Lawrence CL, 2001, BRIT J PHARMACOL, V134, P535, DOI 10.1038/sj.bjp.0704289; LEUNG JM, 1993, J CARDIAC SURG, V8, P220; Light PE, 2001, FASEB J, V15, P2586, DOI 10.1096/fj.01-0188com; Lin R, 2004, ANN THORAC SURG, V78, P970, DOI 10.1016/j.athoracsur.2004.03.084; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; Liu YG, 2001, MOL PHARMACOL, V59, P225, DOI 10.1124/mol.59.2.225; Magee WP, 2003, AM J PHYSIOL-HEART C, V284, pH903, DOI 10.1152/ajpheart.00784.2002; MARBAN E, 1989, CIRCULATION, V80, P17; MCPHERSON CD, 1993, AM J PHYSIOL, V265, pH1809, DOI 10.1152/ajpheart.1993.265.5.H1809; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PARRATT JR, 1994, TRENDS PHARMACOL SCI, V15, P19, DOI 10.1016/0165-6147(94)90129-5; Schafer C, 2001, CARDIOVASC RES, V51, P241, DOI 10.1016/S0008-6363(01)00282-6; Shimoni Y, 1998, AM J PHYSIOL-ENDOC M, V275, pE568, DOI 10.1152/ajpendo.1998.275.4.E568; SMALLWOOD JK, 1988, J CARDIOVASC PHARM, V12, P102, DOI 10.1097/00005344-198807000-00014; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; Suzuki M, 2003, CIRCULATION, V107, P682, DOI 10.1161/01.CIR.0000055187.67365.81; XU XP, 1993, J PHARMACOL EXP THER, V266, P978; YAO Z, 1994, CIRCULATION, V89, P1768; Zingman LV, 2002, P NATL ACAD SCI USA, V99, P13278, DOI 10.1073/pnas.212315199	55	29	33	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					980	+		10.1096/fj.04-3008fje	http://dx.doi.org/10.1096/fj.04-3008fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15774423	Green Accepted			2022-12-25	WOS:000227901300015
J	Imamura, T; Kerjean, A; Heams, T; Kupiec, JJ; Thenevin, C; Paldi, A				Imamura, T; Kerjean, A; Heams, T; Kupiec, JJ; Thenevin, C; Paldi, A			Dynamic CpG and non-CpG methylation of the Peg1/Mest gene in the mouse oocyte and preimplantation embryo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; IMPRINTED GENE; METHYLTRANSFERASES; ESTABLISHMENT; EXPRESSION; REGION; CELLS; H19	In somatic tissues, the CpG island of the imprinted Peg1/Mest gene is methylated on the maternal allele. We have examined the methylation of CpG and non-CpG sites of this differentially methylated CpG island in freshly ovulated oocytes, in vitro aged oocytes, and preimplantation embryos. The CpG methylation pattern was heterogeneous in freshly ovulated oocytes, despite the fact that they all were arrested in metaphase II. After short in vitro culture, Peg1/Mest became hyper-methylated, whereas prolonged in vitro culture resulted in demethylation in a fraction of oocytes. Non-CpG methylation also occurred in a stage-specific manner. On alleles that were fully methylated at CpG sites, this modification was found, and it became reduced in two-cell stage embryos and blastocysts. These observations suggest that the process of establishment of the methylation imprint at this locus is more dynamic than previously thought.	GENETHON, F-91002 Evry, France; Inst Jacques Monod, INSERM E367, F-75005 Paris, France; Inst Cochin, F-75014 Paris, France; Natl Inst Basic Biol, Div Behav Biol, Okazaki, Aichi 4448585, Japan; Ecole Prat Hautes Etud, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE)	Paldi, A (corresponding author), GENETHON, 1 Bis Rue Int,BP60, F-91002 Evry, France.	paldi@genethon.fr	Paldi, Andras/J-5757-2013; Hu, Ruogu/B-2203-2008	IMAMURA, TAKUYA/0000-0002-1825-2084				Aranyi T, 2002, GENOMICS, V80, P558, DOI 10.1006/geno.2002.7011; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Dean W, 1998, DEVELOPMENT, V125, P2273; Doherty AS, 2000, BIOL REPROD, V62, P1526, DOI 10.1095/biolreprod62.6.1526; El-Maarri O, 2001, NAT GENET, V27, P341, DOI 10.1038/85927; Geuns E, 2003, HUM MOL GENET, V12, P2873, DOI 10.1093/hmg/ddg315; Imamura T, 2004, BIOCHEM BIOPH RES CO, V322, P593, DOI 10.1016/j.bbrc.2004.07.159; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; Kerjean A, 2000, HUM MOL GENET, V9, P2183, DOI 10.1093/hmg/9.14.2183; Kerjean A, 2003, EUR J HUM GENET, V11, P493, DOI 10.1038/sj.ejhg.5200990; Lefebvre L, 1997, HUM MOL GENET, V6, P1907, DOI 10.1093/hmg/6.11.1907; Lorincz MC, 2001, P NATL ACAD SCI USA, V98, P10034, DOI 10.1073/pnas.201392598; Lucifero D, 2002, GENOMICS, V79, P530, DOI 10.1006/geno.2002.6732; Malone CS, 2001, P NATL ACAD SCI USA, V98, P10404, DOI 10.1073/pnas.181206898; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; MCCLELLAND M, 1994, NUCLEIC ACIDS RES, V22, P3640, DOI 10.1093/nar/22.17.3640; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Paldi A, 2003, CURR TOP DEV BIOL, V53, P115, DOI 10.1016/S0070-2153(03)53003-4; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Rougier N, 1998, GENE DEV, V12, P2108, DOI 10.1101/gad.12.14.2108; Shiota K, 2002, DIFFERENTIATION, V69, P162, DOI 10.1046/j.1432-0436.2002.690406.x; Tarin JJ, 1999, BIOL REPROD, V61, P1347, DOI 10.1095/biolreprod61.5.1347; WONNACOTT R. J., 1972, INTRO STAT; Woodcock DM, 1997, J BIOL CHEM, V272, P7810, DOI 10.1074/jbc.272.12.7810	24	80	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20171	20175		10.1074/jbc.M501749200	http://dx.doi.org/10.1074/jbc.M501749200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778220	hybrid			2022-12-25	WOS:000229113700090
J	Charruyer, A; Grazide, S; Bezombes, C; Muller, S; Laurent, G; Jaffrezou, JP				Charruyer, A; Grazide, S; Bezombes, C; Muller, S; Laurent, G; Jaffrezou, JP			UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; ULTRAVIOLET-LIGHT; PLASMA-MEMBRANE; LYSOSOMAL SPHINGOMYELINASE; CERAMIDE GENERATION; TERMINAL KINASE; LIPID RAFTS; PROTEIN; CELLS; SKIN	The initiation of UV light-induced signaling in mammalian cells is largely considered to be subsequent to DNA damage. Several studies have also described ceramide (CER), a lipid second messenger, as a major contributor in mediating UV light-induced c-Jun N-terminal kinase (JNK) activation and cell death. It is demonstrated here that UV-C light irradiation of U937 cells results in the activation and translocation of a Zn2+-independent acid sphingomyelinase, leading to CER accumulation in raft microdomains. These CER-enriched rafts aggregate and play a functional role in JNK activation. The observation that UV-C light also induced CER generation and the externalization of acid sphingomyelinase and JNK in human platelets conclusively rules out the involvement of a nuclear signal generated by DNA damage in the initiation of a UV light response, which is generated at the plasma membrane.	CHU Purpan, Ctr Physiopathol Toulouse Purpan, INSERM, U563, F-31024 Toulouse, France; CHU Purpan, Hematol Serv, F-31059 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Jaffrezou, JP (corresponding author), CHU Purpan, Ctr Physiopathol Toulouse Purpan, INSERM, U563, F-31024 Toulouse, France.	jean-pierre.jaffrezou@toulouse.inserm.fr	Bezombes, Christine/G-2743-2017; Bezombes, christine/X-8479-2019; Bezombes, Christine/AAC-1724-2020	Bezombes, christine/0000-0003-4079-4872; Muller, Sabina/0000-0002-4580-2758				ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; Barthelman M, 1998, CANCER RES, V58, P711; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Bettaieb A, 1996, BLOOD, V88, P1465, DOI 10.1182/blood.V88.4.1465.bloodjournal8841465; Birch-Machin MA, 2000, CLIN EXP DERMATOL, V25, P141, DOI 10.1046/j.1365-2230.2000.00605.x; Bodin S, 2001, BIOCHEMISTRY-US, V40, P15290, DOI 10.1021/bi0109313; Bugaud F, 1999, BLOOD, V94, P3800, DOI 10.1182/blood.V94.11.3800.423k25_3800_3805; Chang H, 2003, FREE RADICAL RES, V37, P655, DOI 10.1080/1071576031000094907; Chatterjee M, 2001, MOL CELL BIOCHEM, V219, P21, DOI 10.1023/A:1011083818452; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; Dai Q, 2004, ONCOGENE, V23, P3650, DOI 10.1038/sj.onc.1207430; de Gassart A, 2003, BLOOD, V102, P4336, DOI 10.1182/blood-2003-03-0871; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Galjart N, 2003, CURR OPIN CELL BIOL, V15, P48, DOI 10.1016/S0955-0674(02)00007-8; Gniadecki R, 2002, J INVEST DERMATOL, V118, P582, DOI 10.1046/j.1523-1747.2002.01716.x; Goss VL, 2003, CELL SIGNAL, V15, P709, DOI 10.1016/S0898-6568(03)00009-3; Grassme H, 2002, J BIOL CHEM, V277, P30289, DOI 10.1074/jbc.M200494200; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Grazide S, 2002, FASEB J, V16, P1685, DOI 10.1096/fj.01-0794fje; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Gulbins E, 2004, J MOL MED, V82, P357, DOI 10.1007/s00109-004-0539-y; Gulbins E, 2002, BBA-MOL CELL BIOL L, V1585, P139, DOI 10.1016/S1388-1981(02)00334-7; Herrling T, 2003, FREE RADICAL BIO MED, V35, P59, DOI 10.1016/S0891-5849(03)00241-7; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAFFREZOU JP, 1995, BBA-MOL CELL RES, V1266, P1, DOI 10.1016/0167-4889(94)00219-5; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kiyokawa E, 2004, BIOCHEMISTRY-US, V43, P9766, DOI 10.1021/bi049561j; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; Magnoni C, 2002, TOXICOL IN VITRO, V16, P349, DOI 10.1016/S0887-2333(02)00024-3; Matsumura Y, 2004, TOXICOL APPL PHARM, V195, P298, DOI 10.1016/j.taap.2003.08.019; Nakai Y, 2000, J NEUROSCI RES, V62, P521, DOI 10.1002/1097-4547(20001115)62:4<521::AID-JNR6>3.0.CO;2-8; Nichols BJ, 2003, CURR BIOL, V13, P686, DOI 10.1016/S0960-9822(03)00209-4; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rajendran L, 2003, P NATL ACAD SCI USA, V100, P8241, DOI 10.1073/pnas.1331629100; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Solomon S, 2002, IMMUNOBIOLOGY, V205, P108, DOI 10.1078/0171-2985-00114; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Yamaji A, 1998, J BIOL CHEM, V273, P5300, DOI 10.1074/jbc.273.9.5300; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200	45	106	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19196	19204		10.1074/jbc.M412867200	http://dx.doi.org/10.1074/jbc.M412867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15769735	hybrid			2022-12-25	WOS:000228932300076
J	Chowdhury, B; Tsokos, CG; Krishnan, S; Robertson, J; Fisher, CU; Warke, RG; Warke, VG; Nambiar, MP; Tsokos, GC				Chowdhury, B; Tsokos, CG; Krishnan, S; Robertson, J; Fisher, CU; Warke, RG; Warke, VG; Nambiar, MP; Tsokos, GC			Decreased stability and translation of T cell receptor zeta mRNA with an alternatively spliced 3 '-untranslated region contribute to zeta chain down-regulation in patients with systemic lupus erythematosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; AU-RICH ELEMENTS; TCR-ZETA; SUSCEPTIBILITY GENES; TCR/CD3 COMPLEX; EXPRESSION; BINDING; PROTEIN; CYCLOOXYGENASE-2; IDENTIFICATION	The molecular mechanisms involved in the aberrant expression of T cell receptor (TCR) zeta chain of patients with systemic lupus erythematosus are not known. Previously we demonstrated that although normal T cells express high levels of TCR zeta mRNA with wild-type (WT) 3' untranslated region (3' UTR), systemic lupus erythematosus T cells display significantly high levels of TCR zeta mRNA with the alternatively spliced (AS) 3' UTR form, which is derived by splice deletion of nucleotides 672-1233 of the TCR zeta transcript. Here we report that the stability of TCR zeta mRNA with an AS 3' UTR is low compared with TCR zeta mRNA with WT 3' UTR. AS 3' UTR, but not WT 3' UTR, conferred similar instability to the luciferase gene. Immunoblotting of cell lysates derived from transfected COS-7 cells demonstrated that TCR zeta with AS 3' UTR produced low amounts of 16-kDa protein. In vitro transcription and translation also produced low amounts of protein from TCR zeta with AS 3' UTR. Taken together our findings suggest that nucleotides 672-1233 bp of TCR zeta 3' UTR play a critical role in its stability and also have elements required for the translational regulation of TCR zeta chain expression in human T cells.	Walter Reed Army Inst Res, Dept Cellular Injury, Silver Spring, MD 20910 USA; Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Uniformed Services University of the Health Sciences - USA	Tsokos, CG (corresponding author), Walter Reed Army Inst Res, Dept Cellular Injury, Bldg 503,Rm 1A32,503 Robert Grant Ave, Silver Spring, MD 20910 USA.	gtsokos@usuhs.mil	tsokos, george C/O-3360-2013	tsokos, george C/0000-0001-9589-2360	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042269] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI42269] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brundula V, 1999, ARTHRITIS RHEUM-US, V42, P1908, DOI 10.1002/1529-0131(199909)42:9<1908::AID-ANR17>3.0.CO;2-7; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; Caballero JJ, 2004, BIOCHEM BIOPH RES CO, V319, P247, DOI 10.1016/j.bbrc.2004.04.178; Cok SJ, 2004, J BIOL CHEM, V279, P8196, DOI 10.1074/jbc.M308475200; Cok SJ, 2003, J BIOL CHEM, V278, P36157, DOI 10.1074/jbc.M302547200; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Day NE, 2003, LEUKEMIA RES, V27, P1027, DOI 10.1016/S0145-2126(03)00072-9; Donnini M, 2004, J BIOL CHEM, V279, P20154, DOI 10.1074/jbc.M314071200; Enyedy EJ, 2001, ARTHRITIS RHEUM, V44, P1114, DOI 10.1002/1529-0131(200105)44:5<1114::AID-ANR192>3.0.CO;2-B; Gaffney PM, 1998, P NATL ACAD SCI USA, V95, P14875, DOI 10.1073/pnas.95.25.14875; Gay E, 2000, BIOCHEM BIOPH RES CO, V267, P509, DOI 10.1006/bbrc.1999.2000; Giunchi L, 1999, MOL CELL BIOCHEM, V195, P47; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; Hviid TVF, 2003, IMMUNOGENETICS, V55, P63, DOI 10.1007/s00251-003-0547-z; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; JENSEN JP, 1992, J IMMUNOL, V148, P2563; Jensen LE, 2004, J IMMUNOL, V173, P6248, DOI 10.4049/jimmunol.173.10.6248; Krishnan S, 2004, J IMMUNOL, V172, P7821, DOI 10.4049/jimmunol.172.12.7821; Liossis SNC, 1998, J CLIN INVEST, V101, P1448, DOI 10.1172/JCI1457; Moser KL, 1998, P NATL ACAD SCI USA, V95, P14869, DOI 10.1073/pnas.95.25.14869; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; Nambiar MP, 2003, ARTHRITIS RHEUM, V48, P1948, DOI 10.1002/art.11072; Nambiar MP, 2002, ARTHRITIS RHEUM-US, V46, P163, DOI 10.1002/1529-0131(200201)46:1<163::AID-ART10065>3.0.CO;2-J; Nambiar MP, 2001, J AUTOIMMUN, V16, P133, DOI 10.1006/jaut.2000.0475; Nambiar MP, 2001, ARTHRITIS RHEUM, V44, P1336, DOI 10.1002/1529-0131(200106)44:6<1336::AID-ART226>3.0.CO;2-8; Nishimori T, 2004, LIFE SCI, V74, P2505, DOI 10.1016/j.lfs.2003.10.017; NOCENTINI G, 1995, EUR J IMMUNOL, V25, P1405, DOI 10.1002/eji.1830250540; Pang M, 1998, ARTHRITIS RHEUM, V41, P1456, DOI 10.1002/1529-0131(199808)41:8<1456::AID-ART16>3.0.CO;2-0; Pesole G, 2001, GENE, V276, P73, DOI 10.1016/S0378-1119(01)00674-6; Roe DF, 2004, MOL BRAIN RES, V120, P91, DOI 10.1016/j.molbrainres.2003.09.019; Ronchetti S, 1997, CELL IMMUNOL, V178, P124, DOI 10.1006/cimm.1997.1131; Rydziel S, 2004, J BIOL CHEM, V279, P5397, DOI 10.1074/jbc.M311984200; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; Shai R, 1999, HUM MOL GENET, V8, P639, DOI 10.1093/hmg/8.4.639; Stacey M., 1997, Chromosome Research, V5, P279, DOI 10.1023/A:1018484006430; Takeuchi T, 1998, Nihon Naika Gakkai Zasshi, V87, P1724; Takeuchi T, 1998, INT IMMUNOL, V10, P911, DOI 10.1093/intimm/10.7.911; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Thermann R, 1998, EMBO J, V17, P3484, DOI 10.1093/emboj/17.12.3484; Tsokos GC, 2003, TRENDS IMMUNOL, V24, P259, DOI 10.1016/S1471-4906(03)00100-5; Tsuzaka K, 2003, J IMMUNOL, V171, P2496, DOI 10.4049/jimmunol.171.5.2496; Tsuzaka K, 1998, J AUTOIMMUN, V11, P381, DOI 10.1006/jaut.1998.0223; VASSILOPOULOS D, 1995, J IMMUNOL, V155, P2269; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; Wilson GM, 1999, MOL CELL BIOL, V19, P4056; Yu H, 2003, J BIOL CHEM, V278, P13912, DOI 10.1074/jbc.M213027200	47	58	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18959	18966		10.1074/jbc.M501048200	http://dx.doi.org/10.1074/jbc.M501048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15743765	hybrid			2022-12-25	WOS:000228932300049
J	Jones, DH; Li, TY; Arystarkhova, E; Barr, KJ; Wetzel, RK; Peng, J; Markham, K; Sweadner, KJ; Fong, GH; Kidder, GM				Jones, DH; Li, TY; Arystarkhova, E; Barr, KJ; Wetzel, RK; Peng, J; Markham, K; Sweadner, KJ; Fong, GH; Kidder, GM			Na,K-ATPase from mice lacking the gamma subunit (FXYD2) exhibits altered Na+ affinity and decreased thermal stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLEMMAN-LIKE PROTEIN; RENAL MAGNESIUM LOSS; K-ATPASE; IMMUNOCYTOCHEMICAL LOCALIZATION; ALPHA-SUBUNIT; NA/K-ATPASE; PREIMPLANTATION DEVELOPMENT; FUNCTIONAL INTERACTION; CELLULAR-DISTRIBUTION; MOLECULAR-CLONING	The gamma subunit of the Na,K-ATPase, a 7-kDa single-span membrane protein, is a member of the FXYD gene family. Several FXYD proteins have been shown to bind to Na, K-ATPase and modulate its properties, and each FXYD protein appears to alter enzyme kinetics differently. Different results have sometimes been obtained with different experimental systems, however. To test for effects of gamma in a native tissue environment, mice lacking a functional gamma subunit gene (Fxyd2) were generated. These mice were viable and without observable pathology. Prior work in the mouse embryo showed that gamma is expressed at the blastocyst stage. However, there was no delay in blastocele formation, and the expected Mendelian ratios of offspring were obtained even with Fxyd2(-/-) dams. In adult Fxyd2(-/-) mouse kidney, splice variants of gamma that have different nephron segment-specific expression patterns were absent. Purified gamma-deficient renal Na, K-ATPase displayed higher apparent affinity for Na+ without significant change in apparent affinity for K+. Affinity for ATP, which was expected to be decreased, was instead slightly increased. The results suggest that regulation of Na+ sensitivity is a major functional role for this protein, whereas regulation of ATP affinity may be context-specific. Most importantly, this implies that gamma and other FXYD proteins have their effects by local and not global conformation change. Na, K-ATPase lacking the gamma subunit had increased thermal lability. Combined with other evidence that gamma participates in an early step of thermal denaturation, this indicates that FXYD proteins may play an important structural role in the enzyme complex.	Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Obstet & Gynaecol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Pathol, London, ON N6A 5C1, Canada; Childrens Hlth Res Inst, London, ON N6C 2V5, Canada; Massachusetts Gen Hosp, Lab Membrane Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; St Josephs Hlth Ctr, Lawson Res Inst, London, ON N6A 1Y5, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Western University (University of Western Ontario)	Kidder, GM (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Dent Sci Bldg,Dock 15, London, ON N6A 5C1, Canada.	gerald.kidder@fmd.uwo.ca		Markham, Kathryn/0000-0002-8564-2090	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036271] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL36271] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aizman R, 2002, AM J PHYSIOL-RENAL, V283, pF569, DOI 10.1152/ajprenal.00376.2001; ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Arystarkhova E, 2003, ANN NY ACAD SCI, V986, P416, DOI 10.1111/j.1749-6632.2003.tb07223.x; Arystarkhova E, 2002, J BIOL CHEM, V277, P10162, DOI 10.1074/jbc.M111552200; Arystarkhova E, 2002, AM J PHYSIOL-RENAL, V282, pF393, DOI 10.1152/ajprenal.00146.2001; Barcroft LC, 2004, MECH DEVELOP, V121, P417, DOI 10.1016/j.mod.2004.04.005; Barcroft LC, 2002, REPRODUCTION, V124, P387, DOI 10.1530/rep.0.1240387; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; Brown D, 1996, HISTOCHEM CELL BIOL, V105, P261, DOI 10.1007/BF01463929; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; CRAMBERT G, 2003, SCI STKE; DeSousa PA, 1997, J CELL SCI, V110, P1751; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; ERBACH GT, 1994, BIOL REPROD, V50, P1027, DOI 10.1095/biolreprod50.5.1027; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; Feschenko MS, 2003, J NEUROSCI, V23, P2161; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; Fuller W, 2004, FASEB J, V18, P197, DOI 10.1096/fj.03-0213fje; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; Grinberg AV, 2001, EUR J BIOCHEM, V268, P5027, DOI 10.1046/j.0014-2956.2001.02436.x; Houghton FD, 2002, BIOL REPROD, V66, P1403, DOI 10.1095/biolreprod66.5.1403; Jia LG, 2005, AM J PHYSIOL-HEART C, V288, pH1982, DOI 10.1152/ajpheart.00142.2004; Jones DH, 1997, J CELL BIOL, V139, P1545, DOI 10.1083/jcb.139.6.1545; Jones DH, 2001, PHYSIOL GENOMICS, V6, P129, DOI 10.1152/physiolgenomics.2001.6.3.129; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; Laughery MD, 2003, J BIOL CHEM, V278, P34794, DOI 10.1074/jbc.M302899200; Li CM, 2004, J BIOL CHEM, V279, P38895, DOI 10.1074/jbc.M406697200; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; MACPHEE DJ, 1994, DEV BIOL, V162, P259, DOI 10.1006/dbio.1994.1083; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; Mahmmoud YA, 2003, J BIOL CHEM, V278, P37427, DOI 10.1074/jbc.M305126200; Meij IC, 2003, ANN NY ACAD SCI, V986, P437, DOI 10.1111/j.1749-6632.2003.tb07226.x; Meij IC, 2000, NAT GENET, V26, P265, DOI 10.1038/81543; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; Or E, 1996, BIOCHEMISTRY-US, V35, P6853, DOI 10.1021/bi960093q; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEINERBOBIS G, 1994, BBA-BIOMEMBRANES, V1193, P226, DOI 10.1016/0005-2736(94)90157-0; SIEGEL GJ, 1984, J HISTOCHEM CYTOCHEM, V32, P1309, DOI 10.1177/32.12.6094658; Silverman BD, 2005, CARDIOVASC RES, V65, P93, DOI 10.1016/j.cardiores.2004.09.005; STRUDGATSKY D, 2005, J BIOL CHEM, V278, P46064; Sweadner KJ, 2000, BIOCHEM BIOPH RES CO, V279, P196, DOI 10.1006/bbrc.2000.3907; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Therien AG, 2001, J BIOENERG BIOMEMBR, V33, P407, DOI 10.1023/A:1010619623841; Tupling AR, 2004, J BIOL CHEM, V279, P52382, DOI 10.1074/jbc.M409336200; WATSON AJ, 1988, DEV BIOL, V126, P80, DOI 10.1016/0012-1606(88)90241-2; Wetzel RK, 2004, J BIOL CHEM, V279, P41750, DOI 10.1074/jbc.M405622200; Wetzel RK, 2003, AM J PHYSIOL-RENAL, V285, pF121, DOI 10.1152/ajprenal.00241.2002; Wetzel RK, 2001, AM J PHYSIOL-RENAL, V281, pF531, DOI 10.1152/ajprenal.2001.281.3.F531; Zouzoulas A, 2003, J BIOL CHEM, V278, P40437, DOI 10.1074/jbc.M308610200	60	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19003	19011		10.1074/jbc.M500697200	http://dx.doi.org/10.1074/jbc.M500697200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755730	hybrid			2022-12-25	WOS:000228932300055
J	Sharp, DA; Lawrence, DA; Ashkenazi, A				Sharp, DA; Lawrence, DA; Ashkenazi, A			Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; NF-KAPPA-B; C-FLIP; TUMOR-CELLS; EXPRESSION; PROLIFERATION; RECRUITMENT; INTERACTS; MECHANISM; FAS	Death receptors trigger apoptosis by activating the apical cysteine proteases caspase-8 and -10 within a death-inducing signaling complex (DISC). c-FLIP (cellular FLICE inhibitory protein) is an enzymatically inactive relative of caspase-8 and -10 that binds to the DISC. Two major c-FLIP variants result from alternative mRNA splicing: a short, 26-kDa protein (c-FLIPS) and a long, 55-kDa form (c-FLIPL). The role of c-FLIPS as an inhibitor of death receptor-mediated apoptosis is well established; however, the function of c-FLIPL remains controversial. Although overexpression of transfected c-FLIPL inhibits apoptosis, ectopic expression at lower levels supports caspase-8 activation and cell death. Simultaneous ablation of both c-FLIP variants augments death receptor-mediated apoptosis, but the impact of selective depletion of c-FLIPL on caspase-8 activation and subsequent apoptosis is not well defined. To investigate this, we developed small interfering RNAs that specifically knock down expression of c-FLIPL in several cancer cell lines and studied their effect on apoptosis initiation by Apo2L/TRAIL (Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand). Knockdown of c-FLIPL augmented DISC recruitment, activation, processing, and release of caspase-8, thereby enhancing effector-caspase stimulation and apoptosis. Thus, endogenous c-FLIPL functions primarily as an inhibitor of death receptor-mediated apoptosis.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech	Ashkenazi, A (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	aa@gene.com	Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bin LH, 2002, FEBS LETT, V510, P37, DOI 10.1016/S0014-5793(01)03222-7; Boatright KM, 2004, BIOCHEM J, V382, P651, DOI 10.1042/BJ20040809; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Burns TF, 2001, J BIOL CHEM, V276, P37879; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Dutton A, 2004, P NATL ACAD SCI USA, V101, P6611, DOI 10.1073/pnas.0400765101; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ganten TM, 2004, CELL DEATH DIFFER, V11, pS86, DOI 10.1038/sj.cdd.4401437; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Grambihler A, 2003, J BIOL CHEM, V278, P26831, DOI 10.1074/jbc.M303229200; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Mathas S, 2004, J EXP MED, V199, P1041, DOI 10.1084/jem.20031080; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Rippo MR, 2004, ONCOGENE, V23, P7753, DOI 10.1038/sj.onc.1208051; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zhang XP, 2004, CANCER RES, V64, P7086, DOI 10.1158/0008-5472.CAN-04-1498	48	128	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19401	19409		10.1074/jbc.M413962200	http://dx.doi.org/10.1074/jbc.M413962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15760909	hybrid			2022-12-25	WOS:000228932300098
J	Shi, LF; Zhao, GH; Qiu, DM; Godfrey, WR; Vogel, H; Rando, TA; Hu, H; Kao, PN				Shi, LF; Zhao, GH; Qiu, DM; Godfrey, WR; Vogel, H; Rando, TA; Hu, H; Kao, PN			NF90 regulates cell cycle exit and terminal myogenic differentiation by direct binding to the 3 '-untranslated region of MyoD and p21(WAF1/CIP1) mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SKELETAL-MUSCLE DEVELOPMENT; ACTIVATED T-CELLS; DNA-BINDING; MICE DEFICIENT; TRANSCRIPTION FACTOR; NUCLEAR FACTOR-90; EXPRESSION; MUTATION; CLONING	NF90 and splice variant NF110/ILF3/NFAR are double-stranded RNA-binding proteins that regulate gene expression. Mice with targeted disruption of NF90 were engineered. NF90(-/-) mice were born small and weak and succumbed to perinatal death within 12 h because of neuromuscular respiratory failure. Lung inflation and morphology were normal in NF90(-/-) mice. The diaphragm and other skeletal muscles in NF90(-/-) mice demonstrated disorganized arrangement and paucity of myofibers, evidence of myocyte degeneration and increased apoptosis. The expression of myogenic regulators, MyoD, myogenin, and p21(WAF1/CIP1), was severely decreased in NF90(-/-) mice. These myogenic transcription factors and cell cycle inhibitors are regulated in part through post-transcriptional mRNA stabilization. Northwestern blotting revealed that NF90 is the principal and specific p21(WAF1/CIP1) and MyoD 3'-untranslated region RNA-binding protein in developing skeletal muscles. NF90 regulates transcription factors and a cell cycle inhibitor essential for skeletal muscle differentiation and for survival.	Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA; Dendreon Corp, Cellular Immunol, Seattle, WA 98121 USA; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Neurol Serv, Palo Alto, CA 94304 USA	Stanford University; Dendreon; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Kao, PN (corresponding author), Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA.	peterkao@stanford.edu	Godfrey, Wayne/AAL-7219-2020	Vogel, Otto Hannes/0000-0002-0960-3508; Rando, Thomas/0000-0001-5843-8564	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039624] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL62588] Funding Source: Medline; NIAID NIH HHS [R01-AI39624] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aoki Y, 1998, AM J PHYSIOL-LUNG C, V275, pL1164, DOI 10.1152/ajplung.1998.275.6.L1164; Avila J, 2004, PHYSIOL REV, V84, P361, DOI 10.1152/physrev.00024.2003; Baltzis D, 2002, J BIOL CHEM, V277, P38364, DOI 10.1074/jbc.M203564200; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; Brownawell AM, 2002, J CELL BIOL, V156, P53, DOI 10.1083/jcb.200110082; Brzostowski J, 2000, EMBO J, V19, P3683, DOI 10.1093/emboj/19.14.3683; Buaas FW, 1999, MAMM GENOME, V10, P451, DOI 10.1007/s003359901022; CHEN X, 1993, BIOCHEM BIOPH RES CO, V191, P18, DOI 10.1006/bbrc.1993.1178; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; Inanlou MR, 2003, DEV BIOL, V261, P324, DOI 10.1016/S0012-1606(03)00319-1; Isken O, 2003, EMBO J, V22, P5655, DOI 10.1093/emboj/cdg562; Kablar B, 2000, HISTOL HISTOPATHOL, V15, P649, DOI 10.14670/HH-15.649; Kablar B, 2003, DEV BIOL, V258, P307, DOI 10.1016/S0012-1606(03)00139-8; KAO PN, 1994, J BIOL CHEM, V269, P20691; Kassar-Duchossoy L, 2004, NATURE, V431, P466, DOI 10.1038/nature02876; Krasnoselskaya-Riz I, 2002, AIDS RES HUM RETROV, V18, P591, DOI 10.1089/088922202753747941; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; Larcher JC, 2004, FASEB J, V18, P1761, DOI 10.1096/fj.04-1763fje; Lee CG, 1998, P NATL ACAD SCI USA, V95, P13709, DOI 10.1073/pnas.95.23.13709; Liao HJ, 1998, P NATL ACAD SCI USA, V95, P8514, DOI 10.1073/pnas.95.15.8514; Lu JY, 2004, J BIOL CHEM, V279, P12974, DOI 10.1074/jbc.M310433200; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; Meagher MJ, 2001, MOL CELL BIOL, V21, P2880, DOI 10.1128/MCB.21.8.2880-2890.2001; Meagher MJ, 1999, GENE, V228, P197, DOI 10.1016/S0378-1119(98)00615-5; Orford RL, 1998, MOL CELL BIOL, V18, P5557, DOI 10.1128/MCB.18.9.5557; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; Pires-daSilva A, 2001, DEV BIOL, V233, P319, DOI 10.1006/dbio.2001.0169; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Reichman TW, 2002, MOL CELL BIOL, V22, P343, DOI 10.1128/MCB.22.1.343-356.2002; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Satoh M, 1999, J BIOL CHEM, V274, P34598, DOI 10.1074/jbc.274.49.34598; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Saunders LR, 2001, J BIOL CHEM, V276, P32300, DOI 10.1074/jbc.M104207200; Scarlett GP, 2004, J BIOL CHEM, V279, P52447, DOI 10.1074/jbc.M406107200; SCHUMACHER JM, 1995, J CELL BIOL, V129, P1023, DOI 10.1083/jcb.129.4.1023; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; Shin HJ, 2002, ARCH VIROL, V147, P471, DOI 10.1007/s007050200001; St Johnston D, 2001, EMBO J, V20, P6169, DOI 10.1093/emboj/20.22.6169; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tian B, 2004, NAT REV MOL CELL BIO, V5, P1013, DOI 10.1038/nrm1528; Ting NSY, 1998, J BIOL CHEM, V273, P2136, DOI 10.1074/jbc.273.4.2136; van der Giessen K, 2003, J BIOL CHEM, V278, P47119, DOI 10.1074/jbc.M308889200; VENUTI JM, 1995, J CELL BIOL, V128, P563, DOI 10.1083/jcb.128.4.563; Vivian JL, 1999, DEV BIOL, V208, P44, DOI 10.1006/dbio.1998.9182; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang QD, 2004, J BIOL CHEM, V279, P4952, DOI 10.1074/jbc.M310162200; Xu YH, 1999, MOL GENET METAB, V68, P441, DOI 10.1006/mgme.1999.2934; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zhao GH, 2005, EXP CELL RES, V305, P312, DOI 10.1016/j.yexcr.2004.12.030; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	62	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18981	18989		10.1074/jbc.M411034200	http://dx.doi.org/10.1074/jbc.M411034200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15746098	hybrid			2022-12-25	WOS:000228932300052
J	Obata, T; Shiraiwa, Y				Obata, T; Shiraiwa, Y			A novel eukaryotic selenoprotein in the haptophyte alga Emiliania huxleyi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; CHLAMYDOMONAS-REINHARDTII; SELENIUM; SELENOCYSTEINE; PROTOZOA; SYSTEM	The diversity of selenoproteins raises the question of why many life forms require selenium. Especially in photosynthetic organisms, the biochemical basis for the requirement for selenium is unclear because there is little information on selenoproteins. We found six selenium-containing proteins in a haptophyte alga, Emiliania huxleyi, which requires selenium for growth. The 27-kDa protein EhSEP2 was isolated, and its cDNA was cloned. The deduced amino acid sequence revealed that EhSEP2 is homologous to protein disulfide isomerase (PDI) and contains a highly conserved thioredoxin domain. The nucleotide sequence contains an in-frame TGA codon encoding selenocysteine at the position corresponding to the cysteine residue in the reaction center of known PDIs. However, no typical selenocysteine insertion sequence was found in the EhSEP2 cDNA. The EhSEP2 mRNA level was related to the abundance of selenium. E. huxleyi possesses a novel PDI-like selenoprotein and may have a novel type of selenocysteine insertion machinery.	Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba	Shiraiwa, Y (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058572, Japan.	emilhux@biol.tsukuba.ac.jp	Shiraiwa, Yoshihiro/AAD-2501-2022; Obata, Toshihiro/AAX-4353-2020	Obata, Toshihiro/0000-0001-8931-7722				Cavalier-Smith T, 2003, EUR J PROTISTOL, V39, P338, DOI 10.1078/0932-4739-00002; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Danbara A, 1999, PLANT CELL PHYSIOL, V40, P762, DOI 10.1093/oxfordjournals.pcp.a029603; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Doblin MA, 1999, J PLANKTON RES, V21, P1153, DOI 10.1093/plankt/21.6.1153; Eshdat Y, 1997, PHYSIOL PLANTARUM, V100, P234, DOI 10.1034/j.1399-3054.1997.1000204.x; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Fu LH, 2002, J BIOL CHEM, V277, P25983, DOI 10.1074/jbc.M202912200; Hanawa Y., 2004, JPN J PHYCOL S, V52, P95; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kryukov GV, 2004, EMBO REP, V5, P538, DOI 10.1038/sj.embor.7400126; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LoSchiavo F, 2000, EUR J CELL BIOL, V79, P294, DOI 10.1078/S0171-9335(04)70032-1; Novoselov SV, 2002, EMBO J, V21, P3681, DOI 10.1093/emboj/cdf372; Obata T, 2004, PLANT CELL PHYSIOL, V45, P1434, DOI 10.1093/pcp/pch164; Osaka T, 2003, BIOCHEM BIOPH RES CO, V300, P236, DOI 10.1016/S0006-291X(02)02806-1; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; PRICE NM, 1988, PLANT PHYSIOL, V86, P192, DOI 10.1104/pp.86.1.192; Solovyov A, 2004, J BIOL CHEM, V279, P34095, DOI 10.1074/jbc.M405640200; Sun XL, 2002, METHOD ENZYMOL, V347, P49; Weiss SL, 1998, RNA, V4, P816, DOI 10.1017/S1355838298971990	26	37	41	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18462	18468		10.1074/jbc.M501517200	http://dx.doi.org/10.1074/jbc.M501517200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15743763	hybrid			2022-12-25	WOS:000228807200109
J	Petrescu, AD; Hertz, R; Bar-Tana, J; Schroeder, F; Kier, AB				Petrescu, AD; Hertz, R; Bar-Tana, J; Schroeder, F; Kier, AB			Role of regulatory F-domain in hepatocyte nuclear factor-4 alpha ligand specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; ACID-BINDING PROTEIN; ACYL-COA THIOESTERS; CIRCULAR-DICHROISM; FATTY-ACIDS; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; HETERODIMERIC COMPLEX; ANDROGEN RECEPTOR; REPRESSOR DOMAIN	The F-domain of rat HNF-4 alpha 1 has a crucial impact on the ligand binding affinity, ligand specificity and secondary structure of HNF-4 alpha. (i) Fluorescent binding assays indicate that wild-type, full-length HNF-4 alpha ( amino acids 1 - 455) has high affinity (K-d = 0.06 - 12 nM) for long chain fatty acyl-CoAs (LCFA-CoA) and low affinity (K-d = 58 - 296 nM) for unesterified long chain fatty acids (LCFAs). LCFA-CoA binding was due to close molecular interaction as shown by fluorescence resonance energy transfer ( FRET) from full-length HNF-4 alpha tryptophan ( FRET donor) to bound cis-parinaroyl-CoA ( FRET acceptor), which yielded an intermolecular distance of 33 angstrom, although no FRET to cis-parinaric acid was detected. (ii) Deleting the N-terminal A-D-domains, comprising the AF1 and DNA binding functions, only slightly affected affinities for LCFA-CoAs (K-d = 0.9 - 4 nM) and LCFAs (K-d = 93 - 581 nM). ( iii) Further deletion of the F-domain robustly reduced affinities for LCFA-CoA and reversed ligand specificity ( i. e. high affinity for LCFAs (K-d = 1.5 - 32 nM) and low affinity for LCFA-CoAs (K-d = 54 - 302 nM)). No FRET from HNF-4 alpha-E ( amino acids 132-370) tryptophan ( FRET donor) to bound cis-parinaroyl-CoA ( FRET acceptor) was detected, whereas an intermolecular distance of 28 angstrom was calculated from FRET between HNF-4 alpha-E and cis-parinaric acid. (iv) Circular dichroism showed that LCFA-CoA, but not LCFA, altered the secondary structure of HNF-4 alpha only when the F-domain was present. ( v) cis-Parinaric acid bound to HNF-4 alpha with intact F-domain was readily displaceable by S-hexadecyl-CoA, a nonhydrolyzable thioether analogue of LCFA-CoAs. Truncation of the F-domain significantly decreased cis-parinaric acid displacement. Hence, the C-terminal F-domain of HNF-4 alpha regulated ligand affinity, ligand specificity, and ligand-induced conformational change of HNF-4 alpha. Thus, characteristics of F-domain-truncated mutants may not reflect the properties of full-length HNF-4 alpha.	Texas A&M Univ, Dept Pathobiol, Texas Vet Med Ctr, College Stn, TX 77843 USA; Texas A&M Univ, Dept Physiol & Pharmacol, Texas Vet Med Ctr, College Stn, TX 77843 USA; Hebrew Univ Jerusalem, Sch Med, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Hebrew University of Jerusalem	Kier, AB (corresponding author), Texas A&M Univ, Dept Pathobiol, Texas Vet Med Ctr, College Stn, TX 77843 USA.	akier@cvm.tamu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM072041] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41402] Funding Source: Medline; NIGMS NIH HHS [NIH P20 GM072041] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Couette B, 1998, MOL ENDOCRINOL, V12, P855, DOI 10.1210/me.12.6.855; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Egea PF, 2002, MOL ENDOCRINOL, V16, P987, DOI 10.1210/me.16.5.987; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; Faergeman NJ, 1997, BIOCHEM J, V323, P1; FORSTER T., 1967, COMPR BIOCHEM, V22, P61; Fraser JD, 1997, J BIOL CHEM, V272, P13892, DOI 10.1074/jbc.272.21.13892; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; Frolov A, 1997, LIPIDS, V32, P1201, DOI 10.1007/s11745-997-0154-5; Gossett RE, 1996, LIPIDS, V31, P895, DOI 10.1007/BF02522684; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hani E, 1998, J CLIN INVEST, V101, P521, DOI 10.1172/JCI1403; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HERTZ R, 1994, EUR J BIOCHEM, V221, P611, DOI 10.1111/j.1432-1033.1994.tb18773.x; Hertz R, 2003, J BIOL CHEM, V278, P22578, DOI 10.1074/jbc.M212138200; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hertz R, 2001, BIOCHEM PHARMACOL, V61, P1057, DOI 10.1016/S0006-2952(01)00578-0; Huang H, 2004, BIOCHEMISTRY-US, V43, P2484, DOI 10.1021/bi0352318; Iyemere VP, 1998, NUCLEIC ACIDS RES, V26, P2098, DOI 10.1093/nar/26.9.2098; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; Jiang GQ, 1997, MOL CELL BIOL, V17, P6546, DOI 10.1128/MCB.17.11.6546; Knudsen J, 1999, MOL CELL BIOCHEM, V192, P95, DOI 10.1023/A:1006830606060; McArthur MJ, 1999, J LIPID RES, V40, P1371; Murphy EJ, 1999, BBA-MOL CELL BIOL L, V1436, P413, DOI 10.1016/S0005-2760(98)00150-7; Naiki T, 2002, J BIOL CHEM, V277, P14011, DOI 10.1074/jbc.M105403200; Navas MA, 1999, DIABETES, V48, P1459, DOI 10.2337/diabetes.48.7.1459; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARKER CA, 1968, PHOTOLUMINESCENCE SO, P260; Petrescu AD, 2003, J BIOL CHEM, V278, P51813, DOI 10.1074/jbc.M303858200; Petrescu AD, 2002, J BIOL CHEM, V277, P23988, DOI 10.1074/jbc.M201241200; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; Reid J, 2002, J BIOL CHEM, V277, P20079, DOI 10.1074/jbc.M201003200; Ruse MD, 2002, MOL CELL BIOL, V22, P1626, DOI 10.1128/MCB.22.6.1626-1638.2002; Schwartz JA, 2002, J BIOL CHEM, V277, P13202, DOI 10.1074/jbc.M112215200; SKLAR LA, 1977, BIOCHEMISTRY-US, V16, P5100, DOI 10.1021/bi00642a024; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stehlin C, 2001, EMBO J, V20, P5822, DOI 10.1093/emboj/20.21.5822; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; Suaud L, 1997, BIOCHEM BIOPH RES CO, V235, P820, DOI 10.1006/bbrc.1997.6888; Svensson S, 2003, EMBO J, V22, P4625, DOI 10.1093/emboj/cdg456; Tahiri B, 2001, BIOCHEMISTRY-US, V40, P8431, DOI 10.1021/bi010146q; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	53	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16714	16727		10.1074/jbc.M405906200	http://dx.doi.org/10.1074/jbc.M405906200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15741159	hybrid			2022-12-25	WOS:000228615500023
J	Waltregny, D; Glenisson, W; Tran, SL; North, BJ; Verdin, E; Colige, A; Castronovo, V				Waltregny, D; Glenisson, W; Tran, SL; North, BJ; Verdin, E; Colige, A; Castronovo, V			Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility	FASEB JOURNAL			English	Article						siRNA; cytoskeleton; collagen lattice contraction	HUMAN SIR2; CLASS-I; PROTEIN SIR2; P53; CLONING; EXPRESSION; NAD; MICROTUBULE; FIBROBLASTS; TUBULIN	Although originally characterized as nuclear enzymes controlling the stability of nucleosomes, histone deacetylases (HDACs) may also exert their activity within the cytosol. Recently, we have demonstrated that HDAC8, a class I HDAC, is a novel, prominently cytosolic marker of smooth muscle differentiation. As HDAC8 displays a striking stress fiber-like pattern of distribution and is coexpressed in vivo with smooth muscle alpha-actin (alpha-SMA) and smooth muscle myosin heavy chain, we have explored the possible participation of this HDAC in smooth muscle cytoskeleton regulation. Cell fractionation assays performed with primary human smooth muscle cells (HSMCs) showed that HDAC8, in contrast to HDAC1 and HDAC3, was enriched in cytoskeleton-bound protein fractions and insoluble cell pellets, suggesting an association of HDAC8 with the cystoskeleton. Coimmunoprecipitation experiments using HSMCs, NIH-3T3 cells, and human prostate tissue lysates further demonstrated that HDAC8 associates with alpha-SMA but not with P-actin. HDAC8 silencing through RNA interference strongly reduced the capacity of HSMCs to contract collagen lattices. Mock transfections had no effect on HSMC contractily, and transfections with small interfering RNAs (siRNAs) specific for HDAC6, a cytosolic HDAC that functions as an alpha-tubulin deacetylase, resulted in a weak contraction inhibition. Although mock- and HDAC6 siRNA-transfected HSMCs showed no noticeable morphological changes, HDAC8 siRNA-transfected HSMCs displayed a size reduction with diminished cell spreading after replating. Altogether, our findings indicate that HDAC8 associates with the smooth muscle actin cytoskeleton and may regulate the contractile capacity of smooth muscle cells.	Univ Liege, Metastasis Res Lab, Liege, Belgium; Univ Liege, Dept Urol, Liege, Belgium; Univ Liege, Lab Connect Tissues Biol, Liege, Belgium; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA	University of Liege; University of Liege; University of Liege; University of California System; University of California San Francisco; The J David Gladstone Institutes	Waltregny, D (corresponding author), CHU Sart Tilman, Metastasis Res Lab, Pathol Bldg,Bat B23,Level 1, B-4000 Liege, Belgium.	David.Waltregny@ulg.ac.be	Verdin, Eric/AAB-7999-2019	Verdin, Eric/0000-0003-3703-3183				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Avalos JL, 2002, MOL CELL, V10, P523, DOI 10.1016/S1097-2765(02)00628-7; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; Buggy JJ, 2000, BIOCHEM J, V350, P199, DOI 10.1042/0264-6021:3500199; Carraway CAC, 2000, PRACT APPROACH SER, P51; CHAPONNIER C, 1995, J CELL BIOL, V130, P887, DOI 10.1083/jcb.130.4.887; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; DELVOYE P, 1983, J INVEST DERMATOL, V81, P267, DOI 10.1111/1523-1747.ep12518288; DELVOYE P, 1991, J INVEST DERMATOL, V97, P898, DOI 10.1111/1523-1747.ep12491651; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Forte JG, 1998, AM J PHYSIOL-CELL PH, V274, pC97, DOI 10.1152/ajpcell.1998.274.1.C97; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Hu ED, 2003, J PHARMACOL EXP THER, V307, P720, DOI 10.1124/jpet.103.055541; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Kao HY, 2000, GENE DEV, V14, P55; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; LAMBERT CA, 1992, LAB INVEST, V66, P444; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NEGEE PC, 1990, SCIENCE, V247, P841; Niessen P, 2004, EXP CELL RES, V292, P170, DOI 10.1016/j.yexcr.2003.09.005; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Onyango P, 2002, P NATL ACAD SCI USA, V99, P13653, DOI 10.1073/pnas.222538099; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Ruzanov PV, 1999, J CELL SCI, V112, P3487; Sadekova S, 2000, MOL BIOL CELL, V11, P65, DOI 10.1091/mbc.11.1.65; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Smith JS, 2002, TRENDS CELL BIOL, V12, P404, DOI 10.1016/S0962-8924(02)02342-5; SNABES MC, 1981, J BIOL CHEM, V256, P6291; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JJ, 2002, NUCLEIC ACIDS RES, V30, P1114, DOI 10.1093/nar/30.5.1114; van den Brule FA, 2001, J PATHOL, V193, P80, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH730>3.0.CO;2-2; Van den Wyngaert I, 2000, FEBS LETT, V478, P77, DOI 10.1016/S0014-5793(00)01813-5; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Waltregny D, 2004, EUR J HISTOCHEM, V48, P273; Waltregny D, 2004, AM J PATHOL, V165, P553, DOI 10.1016/S0002-9440(10)63320-2; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; WHEELER TM, 1994, PROSTATE, V25, P274, DOI 10.1002/pros.2990250507; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zeng LF, 2003, J BIOL CHEM, V278, P24594, DOI 10.1074/jbc.M301955200; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	64	158	164	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					966	+		10.1096/fj.04-2303fje	http://dx.doi.org/10.1096/fj.04-2303fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15772115				2022-12-25	WOS:000227901300014
J	Chow, FA; Anderson, KA; Noeldner, PK; Means, AR				Chow, FA; Anderson, KA; Noeldner, PK; Means, AR			The autonomous activity of calcium/calmodulin-dependent protein kinase IV is required for its role in transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MOLECULAR-CLONING; CALMODULIN-BINDING; SIGNALING COMPLEX; CALCIUM SIGNALS; PHOSPHATASE 2A; ACTIVATION; PHOSPHORYLATION; MECHANISM; NUCLEAR	Calcium/calmodulin-dependent kinase IV (CaMKIV) is a multifunctional serine/threonine kinase that is positively regulated by two main events. The first is the binding of calcium/calmodulin (Ca2+/CaM), which relieves intramolecular autoinhibition of the enzyme and leads to basal kinase activity. The second is activation by the upstream kinase, Ca2+/calmodulin-dependent kinase kinase. Phosphorylation of Ca2+/CaM-bound CaMKIV on its activation loop threonine ( residue Thr(200) in human CaMKIV) by Ca2+/calmodulin-dependent kinase kinase leads to increased CaMKIV kinase activity. It has also been repeatedly noted that activation of CaMKIV is accompanied by the generation of Ca2+/CaM-independent or autonomous activity, although the significance of this event has been unclear. Here we demonstrate the importance of autonomous activity to CaMKIV biological function. We show that phosphorylation of CaMKIV on Thr(200) leads to the generation of a fully Ca2+/CaM-independent enzyme. By analyzing the behavior of wild-type and mutant CaMKIV proteins in biochemical experiments and cellular transcriptional assays, we demonstrate that CaMKIV autonomous activity is necessary and sufficient for CaMKIV-mediated transcription. The ability of wild-type CaMKIV to drive cAMP response element-binding protein-mediated transcription is strictly dependent upon an initiating Ca2+ stimulus, which leads to kinase activation and development of autonomous activity in cells. Mutant CaMKIV proteins that are incapable of developing autonomous activity within a cellular context fail to drive transcription, whereas certain CaMKIV mutants that possess constitutive autonomous activity drive transcription in the absence of a Ca2+ stimulus and independent of Ca2+/ CaM binding or Thr(200) phosphorylation.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	means001@mc.duke.edu			NICHD NIH HHS [HD07503] Funding Source: Medline; NIGMS NIH HHS [GM-33976] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KA, 2004, J BIOL CHEM, V279, P31708, DOI 10.1074/jbc.M404523200; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Bading H, 2000, EUR J BIOCHEM, V267, P5280, DOI 10.1046/j.1432-1327.2000.01565.x; Bading H, 1997, BIOCHEM BIOPH RES CO, V236, P541, DOI 10.1006/bbrc.1997.7037; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; COLBRAN RJ, 1992, NEUROCHEM INT, V21, P469, DOI 10.1016/0197-0186(92)90080-B; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Finkbeiner S, 1997, BIOESSAYS, V19, P657, DOI 10.1002/bies.950190803; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; Hardingham GE, 1998, CELL CALCIUM, V23, P131, DOI 10.1016/S0143-4160(98)90111-7; Heist EK, 1998, CELL CALCIUM, V23, P103; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; Kane CD, 2000, EMBO J, V19, P691, DOI 10.1093/emboj/19.4.691; Kitani T, 1997, J BIOCHEM-TOKYO, V122, P243; Krebs J, 1998, BBA-MOL CELL RES, V1448, P183, DOI 10.1016/S0167-4889(98)00142-6; Lemrow SM, 2004, J BIOL CHEM, V279, P11664, DOI 10.1074/jbc.M312613200; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; Means AR, 1997, RECENT PROG HORM RES, V52, P389; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; SAKAGAMI H, 1992, MOL BRAIN RES, V16, P20, DOI 10.1016/0169-328X(92)90189-I; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SLAUGHTER GR, 1985, BIOCHEM BIOPH RES CO, V126, P295, DOI 10.1016/0006-291X(85)90605-9; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; SODERLING TR, 1990, ADV SEC MESS PHOSPH, V24, P206; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tokumitsu H, 1999, J BIOL CHEM, V274, P15803, DOI 10.1074/jbc.274.22.15803; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tokumitsu H, 2004, J BIOL CHEM, V279, P40296, DOI 10.1074/jbc.M406534200; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; Tokumitsu H, 2001, BIOCHEMISTRY-US, V40, P13925, DOI 10.1021/bi010863k; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; WILSON IA, 1985, P NATL ACAD SCI USA, V82, P5255, DOI 10.1073/pnas.82.16.5255; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	46	46	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20530	20538		10.1074/jbc.M500067200	http://dx.doi.org/10.1074/jbc.M500067200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15769749	hybrid			2022-12-25	WOS:000229242000047
J	Suntoke, TR; Chan, DC				Suntoke, TR; Chan, DC			The fusion activity of HIV-1 gp41 depends on interhelical interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL MEMBRANE-FUSION; COILED-COIL POCKET; CRYSTAL-STRUCTURE; ENVELOPE GLYCOPROTEIN; HELICAL INTERACTIONS; INHIBITORY-ACTIVITY; ATOMIC-STRUCTURE; CORE STRUCTURE; ECTODOMAIN	Infection by human immunodeficiency virus type I requires the fusogenic activity of gp41, the transmembrane subunit of the viral envelope protein. Crystallographic studies have revealed that fusion-active gp41 is a "trimer-of-hairpins" in which three central N-terminal helices form a trimeric coiled coil surrounded by three antiparallel C-terminal helices. This structure is stabilized primarily by hydrophobic, interhelical interactions, and several critical contacts are made between residues that form a deep cavity in the N-terminal trimer and the C-helix residues that pack into this cavity. In addition, the trimer-of-hairpins structure has an extensive network of hydrogen bonds within a conserved glutamine-rich layer of poorly understood function. Formation of the trimer-of-hairpins structure is thought to directly force the viral and target membranes together, resulting in membrane fusion and viral entry. We test this hypothesis by constructing four series of gp41 mutants with disrupted interactions between the N- and C-helices. Notably, in the three series containing mutations within the cavity, gp41 activity correlates well with the stability of the N- C interhelical interaction. In contrast, a fourth series of mutants involving the glutamine layer residue Gln-653 show fusion defects even though the stability of the hairpin is close to wild-type. These results provide evidence that gp41 hairpin stability is critical for mediating fusion and suggest a novel role for the glutamine layer in gp41 function.	CALTECH, Div Biol, Pasadena, CA 91125 USA; MIT, Div Biol, Cambridge, MA 02139 USA	California Institute of Technology; Massachusetts Institute of Technology (MIT)	Chan, DC (corresponding author), CALTECH, Div Biol, Mc 114-96,1200 E Calif Blvd, Pasadena, CA 91125 USA.	dchan@caltech.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056552] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM56552] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bar S, 2004, J VIROL, V78, P811, DOI 10.1128/JVI.78.2.811-820.2004; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; Eckert DM, 1998, J MOL BIOL, V284, P859, DOI 10.1006/jmbi.1998.2214; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Ferrer M, 1999, NAT STRUCT BIOL, V6, P953; FERSHT A, 1999, STRUCTURE MECH PROTE, P508; Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5; Greenberg M, 2004, REV MED VIROL, V14, P321, DOI 10.1002/rmv.440; Greenberg ML, 2004, J ANTIMICROB CHEMOTH, V54, P333, DOI 10.1093/jac/dkh330; Ji H, 1999, J VIROL, V73, P8578, DOI 10.1128/JVI.73.10.8578-8586.1999; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Knappenberger JA, 2002, J MOL BIOL, V321, P1, DOI 10.1016/S0022-2836(02)00592-2; Lu J, 2004, J VIROL, V78, P4628, DOI 10.1128/JVI.78.9.4628-4637.2004; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Lu M, 1999, J VIROL, V73, P4433, DOI 10.1128/JVI.73.5.4433-4438.1999; Lu M, 2001, J VIROL, V75, P11146, DOI 10.1128/JVI.75.22.11146-11156.2001; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Mo HM, 2004, VIROLOGY, V329, P319, DOI 10.1016/j.virol.2004.08.025; Scales SJ, 2001, P NATL ACAD SCI USA, V98, P14262, DOI 10.1073/pnas.251547598; Shu W, 2000, BIOCHEMISTRY-US, V39, P1634, DOI 10.1021/bi9921687; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Thomas ST, 2001, P NATL ACAD SCI USA, V98, P10670, DOI 10.1073/pnas.191381798; Wang SL, 2002, BIOCHEMISTRY-US, V41, P7283, DOI 10.1021/bi025648y; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200; Yang ZN, 1999, J STRUCT BIOL, V126, P131, DOI 10.1006/jsbi.1999.4116	29	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19852	19857		10.1074/jbc.M502196200	http://dx.doi.org/10.1074/jbc.M502196200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772068	Green Accepted, hybrid			2022-12-25	WOS:000229113700053
J	Vidal, GA; Naresh, A; Marrero, L; Jones, FE				Vidal, GA; Naresh, A; Marrero, L; Jones, FE			Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MAMMARY-GLAND; CLEAVAGE; RECEPTOR; NOTCH; ACTIVATION; PROTEOLYSIS; EXPRESSION; ISOFORM; DOMAIN	Transmembrane receptors typically transmit cellular signals following growth factor stimulation by coupling to and activating downstream signaling cascades. Reports of proteolytic processing of cell surface receptors to release an intracellular domain (ICD) has raised the possibility of novel signaling mechanisms directly mediated by the receptor ICD. The receptor tyrosine kinase ERBB4/HER4 ( referred to here as ERBB4) undergoes sequential processing by tumor necrosis factor-alpha converting enzyme and presenilin-dependent gamma-secretase to release the ERBB4 ICD (4ICD). Our recent data suggests that regulation of gene expression by the ERBB4 nuclear protein and the proapoptotic activity of ERBB4 involves the gamma-secretase release of 4ICD. To determine the role gamma-secretase processing plays in ERBB4 signaling, we generated an ERBB4 allele with the transmembrane residue substitution V673I (ERBB4-V673I). We demonstrate that ERBB4-V673I fails to undergo processing by gamma-secretase but retains normal cell surface signaling activity. In contrast to wild-type ERBB4, however, ERBB4-V673I was excluded from the nuclei of transfected cells and failed to activate STAT5A stimulation of the beta-casein promoter. These results support the contention that gamma-secretase processing of ERBB4 is necessary to release a functional 4ICD nuclear protein which directly regulates gene expression. We also demonstrate that 4ICD failed to accumulate within mitochondria of ERBB4-V673I transfected cells and the potent proapoptotic activity of ERBB4 was completely abolished in cells expressing ERBB4-V673I. Our results provide the first formal demonstration that proteolytic processing of ERBB4 is a critical event regulating multiple receptor signaling activities.	Tulane Univ, Hlth Sci Ctr, Dept Biochem, Tulane Canc Ctr, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Dept Struct & Cellular Biol, Tulane Canc Ctr, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, Morphol & Imaging Core Lab, New Orleans, LA 70112 USA	Tulane University; Tulane University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Jones, FE (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Biochem, Tulane Canc Ctr, New Orleans, LA 70112 USA.	fjones@tulane.edu		Vidal, Gregory/0000-0003-3325-6224	NCI NIH HHS [R01CA96717, R01CA95783] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095783, R01CA096717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Black RA, 2003, BIOCHEM SOC SYMP, V70, P39, DOI 10.1042/bss0700039; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Bouillet P, 2002, J CELL SCI, V115, P1567; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Burow ME, 2001, J STEROID BIOCHEM, V78, P409, DOI 10.1016/S0960-0760(01)00117-0; DE SB, 1999, NATURE, V398, P518; De Strooper B, 2001, NAT CELL BIOL, V3, pE221, DOI 10.1038/ncb1001-e221; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jones FE, 2003, CELL CYCLE, V2, P555, DOI 10.4161/cc.2.6.598; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Lai C, 2004, BIOCHEM BIOPH RES CO, V314, P535, DOI 10.1016/j.bbrc.2003.12.131; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Ni CY, 2003, J BIOL CHEM, V278, P4561, DOI 10.1074/jbc.M210504200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Weiss FU, 1997, J CELL PHYSIOL, V173, P187, DOI 10.1002/(SICI)1097-4652(199711)173:2<187::AID-JCP19>3.0.CO;2-D; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208	40	108	116	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19777	19783		10.1074/jbc.M412457200	http://dx.doi.org/10.1074/jbc.M412457200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15746097	hybrid			2022-12-25	WOS:000229113700044
J	Wang, XS; Mader, MM; Toth, JE; Yu, XH; Jin, NJ; Campbell, RM; Smallwood, JK; Christe, ME; Chatterjee, A; Goodson, T; Vlahos, CJ; Matter, WF; Bloem, LJ				Wang, XS; Mader, MM; Toth, JE; Yu, XH; Jin, NJ; Campbell, RM; Smallwood, JK; Christe, ME; Chatterjee, A; Goodson, T; Vlahos, CJ; Matter, WF; Bloem, LJ			Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; IN-VIVO; THERAPEUTIC TARGETS; MAP KINASES; CELL-CYCLE; PROTEIN; STRESS; EXPRESSION; PATHWAY; ZAK	Mixed lineage kinase 7 (MLK7) is a mitogen-activated protein kinase kinase kinase (MAPKKK) that activates the pro-apoptotic signaling pathways p38 and JNK. A library of potential kinase inhibitors was screened, and a series of dihydropyrrolopyrazole quinolines was identified as highly potent inhibitors of MLK7 in vitro catalytic activity. Of this series, an aryl-substituted dihydropyrrolopyrazole quinoline (DHP-2) demonstrated an IC50 of 70 nM for inhibition of pJNK formation in COS-7 cell MLK7/JNK co-transfection assays. In stimulated cells, DHP-2 at 200 nM or MLK7 small interfering RNA completely blocked anisomycin and UV induced but had no effect on interleukin-1 beta or tumor necrosis factor-alpha-induced p38 and JNK activation. Additionally, the compound blocked anisomycin and UV-induced apoptosis in COS-7 cells. Heart tissue homogenates from MLK7 transgenic mice treated with DHP-2 at 30 mg/kg had reduced JNK and p38 activation with no apparent effect on ERK activation, demonstrating that this compound can be used to block MLK7-driven MAPK pathway activation in vivo. Taken together, these data demonstrate that MLK7 is the MAPKKK required for modulation of the stress-activated MAPKs downstream of anisomycin and UV stimulation and that DHP-2 can be used to block MLK7 pathway activation in cells as well as in vivo.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Cardiovasc Discovery Res, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lead Optimizat Biol, Indianapolis, IN 46285 USA; Eli Lilly & Co, Discovery Chem Res, Indianapolis, IN 46285 USA	Eli Lilly; Eli Lilly; Eli Lilly	Bloem, LJ (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Cardiovasc Discovery Res, Indianapolis, IN 46285 USA.	L.Bloem@lilly.com						Bloem LJ, 2001, J MOL CELL CARDIOL, V33, P1739, DOI 10.1006/jmcc.2001.1437; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; CHATTERJEE A, 2004, CHEM ABSTR 2358, V141; Cho YY, 2004, CANCER RES, V64, P3855, DOI 10.1158/0008-5472.CAN-04-0201; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Christe M, 2004, J MOL CELL CARDIOL, V37, P705, DOI 10.1016/j.yjmcc.2004.06.004; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gotoh I, 2001, J BIOL CHEM, V276, P4276, DOI 10.1074/jbc.M008595200; Gross EA, 2002, J BIOL CHEM, V277, P13873, DOI 10.1074/jbc.M111994200; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Liao P, 2002, CIRC RES, V90, P190, DOI 10.1161/hh0202.104220; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Liu TC, 2000, BIOCHEM BIOPH RES CO, V274, P811, DOI 10.1006/bbrc.2000.3236; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Mao XH, 2004, EXP CELL RES, V292, P304, DOI 10.1016/j.yexcr.2003.09.012; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Maroney Anna C., 2002, Current Medicinal Chemistry - Central Nervous System Agents, V2, P143, DOI 10.2174/1568015023358201; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Murakata C, 2002, BIOORG MED CHEM LETT, V12, P147, DOI 10.1016/S0960-894X(01)00690-4; Petrich BG, 2002, CIRC RES, V91, P640, DOI 10.1161/01.RES.0000035854.11082.01; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Saporito MS, 2002, PROGR MED CHEM, V40, P23, DOI 10.1016/S0079-6468(08)70081-X; Sawyer JS, 2004, BIOORG MED CHEM LETT, V14, P3581, DOI 10.1016/j.bmcl.2004.04.007; See F, 2004, J AM COLL CARDIOL, V44, P1679, DOI 10.1016/j.jacc.2004.07.038; Stadheim TA, 2002, LEUKEMIA RES, V26, P55, DOI 10.1016/S0145-2126(01)00099-6; Tosti E, 2004, J BIOL CHEM, V279, P47652, DOI 10.1074/jbc.M409961200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vlahos CJ, 2003, NAT REV DRUG DISCOV, V2, P99, DOI 10.1038/nrd1009; Wang LH, 2004, ANNU REV PHARMACOL, V44, P451, DOI 10.1146/annurev.pharmtox.44.101802.121840; Wang Yibin, 2001, Current Opinion in Pharmacology, V1, P134, DOI 10.1016/S1471-4892(01)00029-7; Yang JJ, 2003, BIOCHEM BIOPH RES CO, V301, P71, DOI 10.1016/S0006-291X(02)02980-7; Yang JJ, 2002, BIOCHEM BIOPH RES CO, V297, P105, DOI 10.1016/S0006-291X(02)02123-X; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yu XH, 2003, BIOCHEM BIOPH RES CO, V310, P452, DOI 10.1016/j.bbrc.2003.09.075	35	53	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19298	19305		10.1074/jbc.M413059200	http://dx.doi.org/10.1074/jbc.M413059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15737997	hybrid			2022-12-25	WOS:000228932300087
J	Anai, M; Shojima, N; Katagiri, H; Ogihara, T; Sakoda, H; Onishi, Y; Ono, H; Fujishiro, M; Fukushima, Y; Horike, N; Viana, A; Kikuchi, M; Noguchi, N; Takahashi, S; Takata, K; Oka, Y; Uchijima, Y; Kurihara, H; Asano, T				Anai, M; Shojima, N; Katagiri, H; Ogihara, T; Sakoda, H; Onishi, Y; Ono, H; Fujishiro, M; Fukushima, Y; Horike, N; Viana, A; Kikuchi, M; Noguchi, N; Takahashi, S; Takata, K; Oka, Y; Uchijima, Y; Kurihara, H; Asano, T			A novel protein kinase B (PKB)/AKT-binding protein enhances PKB kinase activity and regulates DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; AKT; INSULIN; INHIBITION; SURVIVAL; PHOSPHORYLATION; PKB/AKT; HOMOLOG; GROWTH; ENTRY	Protein kinase B (PKB)/Akt reportedly plays a role in the survival and/or proliferation of cells. We identified a novel protein, which binds to PKB, using a yeast two-hybrid screening system. This association was demonstrated not only in vivo by overexpressing both proteins or by coimmunoprecipitation of the endogenous proteins, but also in vitro using glutathione S-transferase fusion proteins. Importantly, this protein specifically associates with the C terminus of PKB but not with other AGC kinases and enhances PKB phosphorylation and kinase activation without growth factor stimulation. Thus, we termed this Akt-specific binding protein APE (Akt-phosphorylation enhancer). Since APE-induced phosphorylation of PKB did not occur in cells treated with wortmannin or LY294002, APE itself is not a kinase but seems to enhance or prolong the phosphoinositide 3-kinase-dependent phosphorylation of PKB. In cells in which APE was suppressed by small interfering RNA, DNA synthesis was significantly reduced with suppression of PKB phosphorylation, suggesting a synergistic role of APE in PKB-induced proliferation. On the other hand, in cells overexpressing both PKB and APE, despite markedly increased basal phosphorylation of PKB, both DNA rereplication and subsequent Chk2 phosphorylation and apoptosis were seen, suggesting the involvement of APE in the regulation of cell cycling replication licensing. Taking these observations together, APE appears to be a novel regulator of PKB phosphorylation. Furthermore, the interaction between APE and PKB, possibly dependent on the expression levels of both proteins, may be a novel molecular mechanism leading to proliferation and/or apoptosis.	Univ Tokyo, Grad Sch Med, Dept Physiol Chem & Metab, Bunkyo Ku, Tokyo 1138655, Japan; Asahi Life Fdn, Inst Adult Dis, Dept Internal Med, Chiyoda Ku, Tokyo 1000005, Japan; Tohoku Univ, Grad Sch Med, Dept Internal Med, Div Mol Metab & Diabet,Aoba Ku, Sendai, Miyagi 9808574, Japan; Gunma Univ, Inst Cellular & Mol Regulat, Dept Cell Biol, Gunma 3718512, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Anim Sci, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo; Asahi Life Foundation; Tohoku University; Gunma University; University of Tokyo; University of Tokyo	Asano, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Physiol Chem & Metab, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	asano-tky@umin.ac.jp	Onishi, Yukiko/AAU-9057-2021	Onishi, Yukiko/0000-0003-1180-5982; Kurihara, Hiroki/0000-0002-6476-5593				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Iynedjian PB, 2005, BIOCHEM J, V386, P113, DOI 10.1042/BJ20041425; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Kamikubo Y, 2003, J BIOL CHEM, V278, P17609, DOI 10.1074/jbc.M211974200; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Lawlor MA, 2001, J CELL SCI, V114, P2903; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Yamada T, 2001, J BIOL CHEM, V276, P5339, DOI 10.1074/jbc.M005685200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	30	100	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18525	18535		10.1074/jbc.M500586200	http://dx.doi.org/10.1074/jbc.M500586200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15753085	hybrid			2022-12-25	WOS:000228807200117
J	Lutzmann, M; Kunze, R; Stangl, K; Stelter, P; Toth, KF; Bottcher, B; Hurt, E				Lutzmann, M; Kunze, R; Stangl, K; Stelter, P; Toth, KF; Bottcher, B; Hurt, E			Reconstitution of Nup157 and Nup145N into the Nup84 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; MESSENGER-RNA EXPORT; SCANNING-ELECTRON-MICROSCOPY; BIOGENESIS PATHWAY; PROTEOMIC ANALYSIS; IMPORTIN-BETA; NUCLEOPORIN; TRANSPORT; PURIFICATION; ORGANIZATION	About 30 different nucleoporins (Nups) constitute the nuclear pore complex. We have affinity-purified 28 of these nuclear pore proteins and identified new nucleoporin interactions by this analysis. We found that Nup157 and Nup170, two members of the large structural Nups, and the Gly-Leu-Phe-Gly nucleoporin Nup145N specifically co-purified with members of the Nup84 complex. In addition, Nup145N co-enriched during Nup157 purification. By in vitro reconstitution, we demonstrate that Nup157 and Nup145N form a nucleoporin subcomplex. Moreover, we show that Nup157 and Nup145N bind to the heptameric Nup84 complex. This assembly thus represents approximately one-third of all nucleoporins. To characterize Nup157 structurally, we purified and analyzed it by electron microscopy. Nup157 is a hollow sphere that resembles a clamp or a gripping hand. Thus, we could reconstitute an interaction between a large structural Nup, an FG repeat Nup, and a major structural module of the nuclear pore complex.	Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany; European Mol Biol Lab, D-6900 Heidelberg, Germany; Heidelberg Univ, Kirchhoff Inst Phys, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg	Hurt, E (corresponding author), Heidelberg Univ, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	cg5@ix.urz.uni-heidelberg.de	Ed Hurt, Dr./AAE-8874-2019; Bottcher, Bettina/E-9397-2010	Ed Hurt, Dr./0000-0002-4535-8255; Bottcher, Bettina/0000-0002-7962-4849				AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Belgareh N, 2001, J CELL BIOL, V154, P1147, DOI 10.1083/jcb.200101081; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Berke IC, 2004, J CELL BIOL, V167, P591, DOI 10.1083/jcb.200408109; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Denning DP, 2003, P NATL ACAD SCI USA, V100, P2450, DOI 10.1073/pnas.0437902100; Devos D, 2004, PLOS BIOL, V2, P2085, DOI 10.1371/journal.pbio.0020380; Fabre E, 1997, ANNU REV GENET, V31, P277, DOI 10.1146/annurev.genet.31.1.277; Fahrenkrog B, 2003, NAT REV MOL CELL BIO, V4, P757, DOI 10.1038/nrm1230; Fischer T, 2002, EMBO J, V21, P5843, DOI 10.1093/emboj/cdf590; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; Fontoura BMA, 2001, P NATL ACAD SCI USA, V98, P3208, DOI 10.1073/pnas.061014698; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GOLDBERG MW, 1992, J CELL BIOL, V119, P1429, DOI 10.1083/jcb.119.6.1429; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; Harel A, 2003, MOL CELL, V11, P853, DOI 10.1016/S1097-2765(03)00116-3; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Kosova B, 1999, J BIOL CHEM, V274, P22646, DOI 10.1074/jbc.274.32.22646; Lutzmann M, 2002, EMBO J, V21, P387, DOI 10.1093/emboj/21.3.387; Nehrbass U, 1996, J CELL BIOL, V133, P1153, DOI 10.1083/jcb.133.6.1153; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Ris H, 1997, SCANNING, V19, P368, DOI 10.1002/sca.4950190504; Rosenblum JS, 1999, P NATL ACAD SCI USA, V96, P11370, DOI 10.1073/pnas.96.20.11370; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rout MP, 2003, TRENDS CELL BIOL, V13, P622, DOI 10.1016/j.tcb.2003.10.007; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Shulga N, 2000, J CELL BIOL, V149, P1027, DOI 10.1083/jcb.149.5.1027; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Siniossoglou S, 2000, J CELL BIOL, V149, P41, DOI 10.1083/jcb.149.1.41; Stoffler D, 2003, J MOL BIOL, V328, P119, DOI 10.1016/S0022-2836(03)00266-3; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Teixeira MT, 1999, J BIOL CHEM, V274, P32439, DOI 10.1074/jbc.274.45.32439; Teixeira MT, 1997, EMBO J, V16, P5086, DOI 10.1093/emboj/16.16.5086; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Vasu S, 2001, J CELL BIOL, V155, P339, DOI 10.1083/jcb.200108007; Walther TC, 2003, CELL, V113, P195, DOI 10.1016/S0092-8674(03)00235-6; Weirich CS, 2004, MOL CELL, V16, P749, DOI 10.1016/j.molcel.2004.10.032; Zabel U, 1996, J CELL BIOL, V133, P1141, DOI 10.1083/jcb.133.6.1141	48	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18442	18451		10.1074/jbc.M412787200	http://dx.doi.org/10.1074/jbc.M412787200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15741174	Green Accepted, hybrid			2022-12-25	WOS:000228807200107
J	Barnes, K; McIntosh, E; Whetton, AD; Daley, GQ; Bentley, J; Baldwin, SA				Barnes, K; McIntosh, E; Whetton, AD; Daley, GQ; Bentley, J; Baldwin, SA			Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation	ONCOGENE			English	Article						Glivec; GLUT1; TonB210; protein kinase B; Bcr-Abl; apoptosis	COLONY-STIMULATING FACTORS; TYROSINE KINASE; PROGENITOR CELLS; GROWTH-FACTOR; HEMATOPOIETIC-CELLS; POSITIVE CELLS; INTERLEUKIN-3; APOPTOSIS; SURVIVAL; IMATINIB	In chronic myeloid leukaemia (CML) expression of the chimeric tyrosine kinase, Bcr-Abl, promotes the inappropriate survival of haemopoietic stem cells by a nonautocrine mechanism in the absence of IL-3. Stimulation of glucose uptake appears to play an important role in the suppression of apoptosis by this cytokine in normal haemopoietic cells. To investigate whether the cell survival mechanisms mediated by the oncoprotein and cytokine showed any similarities, we employed a haemopoietic cell line, TonB210, engineered for inducible expression of Bcr-Abl. Tyrosine kinase expression in cytokine-deprived cells was found to mimic the effect of IL-3 in maintaining a higher V-max for hexose uptake. In both IL-3-treated cells and those expressing Bcr-Abl, high rates of hexose uptake were associated with the retention at the cell surface of approximately 80% of the total cellular content of the GLUT1 glucose transporter. In contrast, treatment of Bcr-Abl-expressing cells for 6 h with the Bcr-Abl kinase inhibitor Glivec (10 &mu; M), in the absence of IL-3, led to internalization of approximately 90% of the cell-surface transporters and drastically decreased (4.4&PLUSMN; 0.9 (mean&PLUSMN; s.e.m., 4)-fold) the V-max for hexose uptake, without significant effect on the K-m for this process or on the total cellular transporter content. These effects were not the result of any significant loss in cell viability, and preceded the onset of apoptosis caused by inhibition of Bcr-Abl. Both IL-3 treatment and expression of Bcr-Abl led to enhanced phosphorylation of Akt ( protein kinase B). The stimulation of transport by IL-3 and Bcr-Abl in TonB210 cells was inhibitable by phosphatidylinositol 3-kinase inhibitors, indicating the involvement of this kinase in the signal transduction pathway. These findings suggest that inhibition of glucose transport plays an important role in the therapeutic action of Glivec, and that the signal transduction pathways involved in transport stimulation by Bcr-Abl may offer novel therapeutic targets for CML.	Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England; Univ Manchester, Inst Sci & Technol, Manchester M60 1QD, Lancs, England; Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA; St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England	University of Leeds; University of Manchester; Massachusetts Institute of Technology (MIT); Whitehead Institute; Cancer Research UK; Saint James's University Hospital; University of Leeds	Barnes, K (corresponding author), Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England.	k.barnes@leeds.ac.uk		WHETTON, ANTHONY D/0000-0002-1098-3878				Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Bentley J, 2003, J BIOL CHEM, V278, P39337, DOI 10.1074/jbc.M305689200; Bentley J, 2001, BRIT J HAEMATOL, V112, P212, DOI 10.1046/j.1365-2141.2001.02428.x; BERRIDGE MV, 1995, J CELL PHYSIOL, V163, P466, DOI 10.1002/jcp.1041630306; Boren J, 2001, J BIOL CHEM, V276, P37747; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; CHAPMAN RS, 1996, HEMATOPOIETIC CELL G, P151; Chopra R, 1999, BLOOD REV, V13, P211, DOI 10.1054/blre.1999.0119; DAVIES A, 1990, BIOCHEM J, V266, P799; Dorsey JF, 2002, LEUKEMIA, V16, P1589, DOI 10.1038/sj.leu.2402678; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2004, ADV CANCER RES, V91, P1, DOI 10.1016/S0065-230X(04)91001-9; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Gottschalk S, 2004, CLIN CANCER RES, V10, P6661, DOI 10.1158/1078-0432.CCR-04-0039; HEYWORTH CM, 1992, BLOOD, V80, P2230; Hoover RR, 2001, ONCOGENE, V20, P5826, DOI 10.1038/sj.onc.1204549; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; Kansara M, 2004, EXP CELL RES, V293, P321, DOI 10.1016/j.yexcr.2003.10.027; Karnauskas R, 2003, ONCOGENE, V22, P688, DOI 10.1038/sj.onc.1206159; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; Marley SB, 2004, BRIT J HAEMATOL, V125, P500, DOI 10.1111/j.1365-2141.2004.04933.x; McCoy KD, 1997, J BIOL CHEM, V272, P17276, DOI 10.1074/jbc.272.28.17276; Nagar B, 2002, CANCER RES, V62, P4236; NEFESH I, 1991, INT IMMUNOL, V3, P827, DOI 10.1093/intimm/3.8.827; OWEN PJ, 1993, J BIOL CHEM, V268, P15696; Pierce A, 1998, ONCOGENE, V17, P667, DOI 10.1038/sj.onc.1201969; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Tang XW, 2000, J BIOL CHEM, V275, P13142, DOI 10.1074/jbc.275.17.13142; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	36	71	73	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 5	2005	24	20					3257	3267		10.1038/sj.onc.1208461	http://dx.doi.org/10.1038/sj.onc.1208461			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735728				2022-12-25	WOS:000228881800004
J	Johns, TG; Mellman, I; Cartwright, GA; Ritter, G; Old, LJ; Burgess, AW; Scott, AM				Johns, TG; Mellman, I; Cartwright, GA; Ritter, G; Old, LJ; Burgess, AW; Scott, AM			The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor	FASEB JOURNAL			English	Article						epidermal growth factor receptor; glycosylation; endoplasmic reticulum; antibody therapy	GROWTH-FACTOR RECEPTOR; GLYCOSYLATION-DEPENDENT ACQUISITION; CONFERS ENHANCED TUMORIGENICITY; HUMAN GLIOBLASTOMA CELLS; MONOCLONAL-ANTIBODY; LIGAND-BINDING; CARCINOMA-CELLS; LUNG CARCINOMAS; CANCER-THERAPY; MUTANT	Overexpression of the EGFR is commonly caused by EGFR gene amplification and is sometimes associated with expression of a variant EGFR (de2-7 EGFR or EGFRvIII) bearing an internal deletion in its extracellular domain. mAb 806 is a novel EGFR antibody with significant antitumor activity that recognizes both the de2-7 EGFR and a subset of the wild-type (wt) EGFR when overexpressed, but does not bind the EGFR expressed in normal tissues. Recently, we demonstrated that the mAb 806 epitope is restricted to a short cysteine loop of the EGFR (amino acids 287-302) that is only available for antibody binding in a transitional form of the receptor, which occurs as the receptor changes from its inactive tethered conformation to a dimeric untethered form. The truncation associated with the de2-7 EGFR mutation renders this receptor constitutively untethered, leading to increased binding of mAb 806. We now show that mAb 806 preferentially binds the immature high-mannose wt and de2-7 EGFR precursors normally located in the endoplasmic reticulum, indicating that this form of the wt EGFR is also constitutively untethered. Using the unique specificity of mAb 806, we clearly demonstrated the presence of these high-mannose EGFR precursors on the cell surface. Given that the high-mannose forms of the wt EGFR must be untethered they may contribute to the spontaneous EGFR signaling reported in cells overexpressing the receptor. These precursor forms of the EGFR thus represent novel tumor targets and contribute to the exceptional selectivity of mAb 806 for EGFR when overexpressed in cancer cells. As our observations are likely to apply to other receptors overexpressed in cancer, they suggest a strategy for developing antitumor antibodies even when the target receptor is expressed in normal tissue.	Austin Hosp, Ludwig Inst Canc Res, Oncogen Signalling Lab, Tumour Targeting Program, Heidelberg, Vic 3084, Australia; Royal Melbourne Hosp, Epithelial Biochem Lab, Parkville, Vic 3050, Australia; Yale Univ, Sch Med, Ludwig Inst Canc Res, Dept Cell Biol, New Haven, CT USA; Mem Sloan Kettering Canc Ctr, Ludwig Inst Canc Res, New York Branch, New York, NY 10021 USA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Ludwig Institute for Cancer Research; Yale University; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center	Johns, TG (corresponding author), Austin Hosp, Ludwig Inst Canc Res, Oncogen Signalling Lab, Tumour Targeting Program, Level 6,Studley Rd, Heidelberg, Vic 3084, Australia.	Terry.Johns@ludwig.edu.au	Johns, Terrance/C-2441-2008; Mellman, Ira/ABG-5896-2020	Johns, Terrance/0000-0002-8874-4543; Scott, Andrew/0000-0002-6656-295X				Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Baselga J, 2002, ONCOLOGIST, V7, P2; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; GAMOU S, 1988, J BIOCHEM-TOKYO, V104, P388, DOI 10.1093/oxfordjournals.jbchem.a122478; Ge H, 2002, INT J CANCER, V98, P357, DOI 10.1002/ijc.10224; Hakomori S, 1996, CANCER RES, V56, P5309; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; HILLS D, 1995, INT J CANCER, V63, P537, DOI 10.1002/ijc.2910630414; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; JOHNS TG, 2005, IN PRESS J BIOL CHEM; Jungbluth AA, 2003, P NATL ACAD SCI USA, V100, P639, DOI 10.1073/pnas.232686499; Kil SJ, 1999, J BIOL CHEM, V274, P3141, DOI 10.1074/jbc.274.5.3141; Klingler-Hoffmann M, 2003, INT J CANCER, V105, P331, DOI 10.1002/ijc.11085; KWOK TT, 1991, BRIT J CANCER, V64, P251, DOI 10.1038/bjc.1991.286; Luwor RB, 2001, CANCER RES, V61, P5355; Mendelsohn J, 2002, J CLIN ONCOL, V20, p1S, DOI 10.1200/JCO.2002.07.121; Mishima K, 2001, CANCER RES, V61, P5349; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Nagane M, 1996, CANCER RES, V56, P5079; Narita Y, 2002, CANCER RES, V62, P6764; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Olapade-Olaopa EO, 2000, BRIT J CANCER, V82, P186; Orntoft TF, 1999, ELECTROPHORESIS, V20, P362, DOI 10.1002/(SICI)1522-2683(19990201)20:2<362::AID-ELPS362>3.3.CO;2-M; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; Ryu JS, 1999, ENDOCRINOLOGY, V140, P3904, DOI 10.1210/en.140.9.3904; SLIEKER LJ, 1985, J BIOL CHEM, V260, P687; SLIEKER LJ, 1986, J BIOL CHEM, V261, P5233; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Walker F, 2004, J BIOL CHEM, V279, P22387, DOI 10.1074/jbc.M401244200; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Zhen YJ, 2003, BIOCHEMISTRY-US, V42, P5478, DOI 10.1021/bi027101p	38	63	74	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					780	+		10.1096/fj.04-1766fje	http://dx.doi.org/10.1096/fj.04-1766fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15774576				2022-12-25	WOS:000227901300013
J	Sakhalkar, HS; Hanes, J; Fu, J; Benavides, U; Malgor, R; Borruso, CL; Kohn, LD; Kujiaka, DT; Goetz, DJ				Sakhalkar, HS; Hanes, J; Fu, J; Benavides, U; Malgor, R; Borruso, CL; Kohn, LD; Kujiaka, DT; Goetz, DJ			Enhanced adhesion of ligand-conjugated biodegradable particles to colitic venules	FASEB JOURNAL			English	Article						colitis; inflammation; endothelial cell adhesion molecules; biodegradable polymer; targeted drug delivery; microspheres	ACTIVATED ENDOTHELIAL-CELLS; INFLAMMATORY-BOWEL-DISEASE; E-SELECTIN IMMUNOCONJUGATE; TARGETED DRUG-DELIVERY; ULCERATIVE-COLITIS; CROHNS-DISEASE; P-SELECTIN; DEXAMETHASONE; NANOPARTICLES; EXPRESSION	The expression of certain endothelial cell adhesion molecules (ECAMs) is increased in the vasculature of the inflamed bowel (e.g., colitis), thereby providing an opportunity for targeted drug delivery. We recently demonstrated that biodegradable particles conjugated with ligands to ECAMs exhibit significant selective adhesion to ECAM expressing endothelium. In the present study, we used a murine model of colitis to determine whether poly(lactic acid)-poly(ethylene glycol) particles conjugated with a VCAM-I ligand (alpha-V) exhibit enhanced adhesion to colitic vasculature. In post-capillary venules of the colon, significantly more alpha-V particles accumulate in colitic mice relative to (i) control mice (i.e., selectivity) and (ii) particles bearing a control ligand (i.e., ligand efficiency). The selectivity and ligand efficiency of alpha-V particles were a function of the total number of particles infused. The highest selectivity observed within our test regime was 3, while ligand efficiency increased linearly with the number of particles injected to a value of 24. This work represents a significant step towards achieving a targeted drug delivery scheme for the treatment of inflammatory bowel disease and indicates that the efficiency of targeting is dependent on the dose regime.	Ohio Univ, Dept Chem Engn, Stocker Ctr 172, Athens, OH 45701 USA; Ohio Univ, Dept Biol Sci, Athens, OH 45701 USA; Ohio Univ, Edison Biotechnol Inst, Athens, OH 45701 USA; Ohio Univ, Dept Biomed Sci, Athens, OH 45701 USA; Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD USA	Ohio University; Ohio University; Ohio University; Ohio University; Johns Hopkins University	Goetz, DJ (corresponding author), Ohio Univ, Dept Chem Engn, Stocker Ctr 172, Athens, OH 45701 USA.	goetzd@ohio.edu			NIGMS NIH HHS [GM57640] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM057640] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asgeirsdottir SA, 2003, BIOCHEM PHARMACOL, V65, P1729, DOI 10.1016/S0006-2952(03)00122-9; Caprilli R, 2002, ALIMENT PHARM THER, V16, P1579, DOI 10.1046/j.1365-2036.2002.01319.x; Chapman PT, 1996, ARTHRITIS RHEUM, V39, P1371, DOI 10.1002/art.1780390815; Chourasia MK, 2003, J PHARM PHARM SCI, V6, P33; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Dickerson JB, 2001, BIOTECHNOL BIOENG, V73, P500, DOI 10.1002/bit.1085; Eniola AO, 2002, BIOMATERIALS, V23, P2167, DOI 10.1016/S0142-9612(01)00349-0; Everts M, 2002, J IMMUNOL, V168, P883, DOI 10.4049/jimmunol.168.2.883; Everts M., 2001, DRUG TARGETING ORGAN, P171; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Fiocchi C, 1997, AM J PHYSIOL-GASTR L, V273, pG769, DOI 10.1152/ajpgi.1997.273.4.G769; Fu J, 2004, MACROMOLECULES, V37, P7174, DOI 10.1021/ma049853s; GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245; GRISHAM MB, 1999, INFLAMM BOWEL DIS, P55; Kirsner JB, 1999, ITAL J GASTROENTEROL, V31, P651; Kok RJ, 2002, PHARM RES-DORDR, V19, P1730, DOI 10.1023/A:1020769716288; Lamprecht A, 2001, J PHARMACOL EXP THER, V299, P775; Langer R, 1998, NATURE, V392, P5; MURTHY SNS, 1993, DIGEST DIS SCI, V38, P1722, DOI 10.1007/BF01303184; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Panes J, 1998, GASTROENTEROLOGY, V114, P1066, DOI 10.1016/S0016-5085(98)70328-2; Sakhalkar HS, 2003, P NATL ACAD SCI USA, V100, P15895, DOI 10.1073/pnas.2631433100; Salem AK, 2001, BIOMACROMOLECULES, V2, P575, DOI 10.1021/bm010030+; SCHURMANN GM, 1995, GUT, V36, P411, DOI 10.1136/gut.36.3.411; Shigematsu T, 2001, AM J PHYSIOL-GASTR L, V281, pG1309, DOI 10.1152/ajpgi.2001.281.5.G1309; Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/s0168-3659(00)00339-4; Soriano A, 2000, LAB INVEST, V80, P1541, DOI 10.1038/labinvest.3780164; Spragg DD, 1997, P NATL ACAD SCI USA, V94, P8795, DOI 10.1073/pnas.94.16.8795; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Wiewrodt R, 2002, BLOOD, V99, P912, DOI 10.1182/blood.V99.3.912; Xu CT, 2004, WORLD J GASTROENTERO, V10, P2311	31	38	39	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					792	+		10.1096/fj.04-2668fje	http://dx.doi.org/10.1096/fj.04-2668fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15764649				2022-12-25	WOS:000227901300016
J	Madden, DR; Armstrong, N; Svergun, D; Perez, J; Vachette, P				Madden, DR; Armstrong, N; Svergun, D; Perez, J; Vachette, P			Solution X-ray scattering evidence for agonist- and antagonist-induced modulation of cleft closure in a glutamate receptor ligand-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION CHANNELS; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; AMPA RECEPTOR; PROTEIN; GLUR2; CORE; ACTIVATION; STEREOCHEMISTRY; MECHANISMS	Agonist-induced conformational changes in the ligand-binding domains (LBD) of glutamate receptor ion channels provide the driving force for molecular rearrangements that mediate channel opening and subsequent desensitization. The resulting regulated transmembrane ion fluxes form the basis for most excitatory neuronal signaling in the brain. Crystallographic analysis of the GluR2 LBD core has revealed a ligand-binding cleft located between two lobes. Channel antagonists stabilize an open cleft, whereas agonists stabilize a closed cleft. The crystal structure of the apo form is similar to the antagonist-bound, open state. To understand the conformational behavior of the LBD in the absence of crystal lattice constraints, and thus better to appreciate the thermodynamic constraints on ligand binding, we have undertaken a solution x-ray scattering study using two different constructs encoding either the core or an extended LBD. In agreement with the GluR2 crystal structures, the LBD is more compact in the presence of agonist than it is in the presence of antagonist. However, the time-averaged conformation of the ligand-free core in solution is intermediate between the open, antagonist-bound state and the closed, agonist-bound state, suggesting a conformational equilibrium. Addition of peptide moieties that connect the core domain to the other functional domains in each channel subunit appears to constrain the conformational equilibrium in favor of the open state.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Deutsch Elektron Synchrotron, EMBL, Hamburg Outstn, European Mol Biol Lab, D-22603 Hamburg, Germany; Univ Paris 11, CNRS UMR 00130, Lab Utilisat Rayonnement Electromagnet, F-91898 Orsay, France	Dartmouth College; Columbia University; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); UDICE-French Research Universities; Universite Paris Saclay	Vachette, P (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	patrice.vachette@ibbmc.u-psud.fr		Svergun, Dmitri/0000-0003-0830-5696				Abele R, 2000, J BIOL CHEM, V275, P21355, DOI 10.1074/jbc.M909883199; Abele R, 1999, BIOCHEMISTRY-US, V38, P10949, DOI 10.1021/bi982928y; Arinaminpathy Y, 2002, BIOPHYS J, V82, P676, DOI 10.1016/S0006-3495(02)75430-1; Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Bjorkman AJ, 1998, J MOL BIOL, V279, P651, DOI 10.1006/jmbi.1998.1785; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; Chen GQ, 2000, TETRAHEDRON, V56, P9409, DOI 10.1016/S0040-4020(00)00825-5; Chen GQ, 1998, PROTEIN SCI, V7, P2623, DOI 10.1002/pro.5560071216; Dingledine R, 1999, PHARMACOL REV, V51, P7; Dubuisson JM, 1997, J APPL CRYSTALLOGR, V30, P49, DOI 10.1107/S002188989600876X; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; Guinier A., 1955, SMALL ANGLE SCATTERI; Hogner A, 2002, J MOL BIOL, V322, P93, DOI 10.1016/S0022-2836(02)00650-2; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Jin RS, 2003, BIOCHEMISTRY-US, V42, P5201, DOI 10.1021/bi020632t; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Ledvina PS, 1998, PROTEIN SCI, V7, P2550, DOI 10.1002/pro.5560071208; Madden DR, 2000, EUR J BIOCHEM, V267, P4281; Madden DR, 2004, BIOCHEMISTRY-US, V43, P15838, DOI 10.1021/bi048447y; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Madden DR, 2001, J BIOL CHEM, V276, P37821; Magnusson U, 2002, J BIOL CHEM, V277, P14077, DOI 10.1074/jbc.M200514200; MAO B, 1982, J BIOL CHEM, V257, P1131; Mayer ML, 2001, J MOL BIOL, V311, P815, DOI 10.1006/jmbi.2001.4884; McFeeters RL, 2002, BIOCHEMISTRY-US, V41, P10472, DOI 10.1021/bi026010p; NEWCOMER ME, 1981, J BIOL CHEM, V256, P3218; OH BH, 1993, J BIOL CHEM, V268, P11348; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; WALMSLEY AR, 1992, J BIOL CHEM, V267, P8064; WO ZG, 1995, TRENDS NEUROSCI, V18, P161	35	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23637	23642		10.1074/jbc.M414523200	http://dx.doi.org/10.1074/jbc.M414523200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15755731	hybrid			2022-12-25	WOS:000229880000030
J	Halbach, A; Lorenzen, S; Landgraf, C; Volkmer-Engert, R; Erdmann, R; Rottensteiner, H				Halbach, A; Lorenzen, S; Landgraf, C; Volkmer-Engert, R; Erdmann, R; Rottensteiner, H			Function of the PEX19-binding site of human adrenoleukodystrophy protein as targeting motif in man and yeast - PMP targeting is evolutionarily conserved	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL MEMBRANE-PROTEINS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; BIOGENESIS; SIGNALS; IMPORT; MULTIPLE; RECEPTOR; PEX19P; IDENTIFICATION	We predicted in human peroxisomal membrane proteins (PMPs) the binding sites for PEX19, a key player in the topogenesis of PMPs, by virtue of an algorithm developed for yeast PMPs. The best scoring PEX19-binding site was found in the adrenoleukodystrophy protein ( ALDP). The identified site was indeed bound by human PEX19 and was also recognized by the orthologous yeast PEX19 protein. Likewise, both human and yeast PEX19 bound with comparable affinities to the PEX19- binding site of the yeast PMP Pex13p. Interestingly, the identified PEX19- binding site of ALDP coincided with its previously determined targeting motif. We corroborated the requirement of the ALDP PEX19-binding site for peroxisomal targeting in human fibroblasts and showed that the minimal ALDP fragment targets correctly also in yeast, again in a PEX19-binding site-dependent manner. Furthermore, the human PEX19-binding site of ALDP proved interchangeable with that of yeast Pex13p in an in vivo targeting assay. Finally, we showed in vitro that most of the predicted binding sequences of human PMPs represent true binding sites for human PEX19, indicating that human PMPs harbor common PEX19-binding sites that do resemble those of yeast. Our data clearly revealed a role for PEX19- binding sites as PMP-targeting motifs across species, thereby demonstrating the evolutionary conservation of PMP signal sequences from yeast to man.	Ruhr Univ Bochum, Inst Physiol, Abt Syst Biochem, D-44780 Bochum, Germany; Univ Klinikum Charite, Inst Med Immunol, D-10115 Berlin, Germany	Ruhr University Bochum; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Erdmann, R (corresponding author), Ruhr Univ Bochum, Inst Physiol, Abt Syst Biochem, D-44780 Bochum, Germany.	Ralf.Erdmann@rub.de	Lorenzen, Stephan/C-8960-2009	Lorenzen, Stephan/0000-0003-4857-6087; Volkmer, Rudolf/0000-0003-4710-1143				Baerends RJS, 2000, FEMS MICROBIOL REV, V24, P291; Biermanns M, 2003, EUR J CELL BIOL, V82, P155, DOI 10.1078/0171-9335-00310; Biermanns M, 2001, BIOCHEM BIOPH RES CO, V285, P649, DOI 10.1006/bbrc.2001.5220; Brosius U, 2002, J BIOL CHEM, V277, P774, DOI 10.1074/jbc.M108155200; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; Fransen M, 2002, MOL CELL PROTEOMICS, V1, P243, DOI 10.1074/mcp.M100025-MCP200; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; Geuze HJ, 2003, MOL BIOL CELL, V14, P2900, DOI 10.1091/mbc.E02-11-0734; Gloeckner CJ, 2000, BIOCHEM BIOPH RES CO, V271, P144, DOI 10.1006/bbrc.2000.2572; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; Honsho M, 2002, J BIOL CHEM, V277, P44513, DOI 10.1074/jbc.M206139200; Honsho M, 2001, J BIOL CHEM, V276, P9375, DOI 10.1074/jbc.M003304200; Jones JM, 2004, J CELL BIOL, V164, P57, DOI 10.1083/jcb.200304111; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; LANDGRAF C, PLOS BIOL 2004; Landgraf P, 2003, EUR J CELL BIOL, V82, P401, DOI 10.1078/0171-9335-00331; Mullen RT, 1999, PLANT CELL, V11, P2167, DOI 10.1105/tpc.11.11.2167; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Pause B, 2000, FEBS LETT, V471, P23, DOI 10.1016/S0014-5793(00)01332-6; Rottensteiner H, 2004, MOL BIOL CELL, V15, P3406, DOI 10.1091/mbc.E04-03-0188; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; Sambrook J., 2002, MOL CLONING LAB MANU; Smith KD, 1999, NEUROCHEM RES, V24, P521, DOI 10.1023/A:1022535930009; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; Stein K, 2002, MOL CELL BIOL, V22, P6056, DOI 10.1128/MCB.22.17.6056-6069.2002; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; Titorenko VI, 1998, TRENDS BIOCHEM SCI, V23, P231, DOI 10.1016/S0968-0004(98)01226-2; Wang XD, 2001, J BIOL CHEM, V276, P10897, DOI 10.1074/jbc.M010883200; Will GK, 1999, MOL CELL BIOL, V19, P2265	35	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21176	21182		10.1074/jbc.M501750200	http://dx.doi.org/10.1074/jbc.M501750200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15781447	hybrid			2022-12-25	WOS:000229438800035
J	van Buul, JD; Anthony, EC; Fernandez-Borja, M; Burridge, K; Hordijk, PL				van Buul, JD; Anthony, EC; Fernandez-Borja, M; Burridge, K; Hordijk, PL			Proline-rich tyrosine kinase 2 (Pyk2) mediates vascular endothelial- cadherin-based cell-cell adhesion by regulating beta-catenin tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; RHO-FAMILY GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; BARRIER FUNCTION; IN-VIVO; LEUKOCYTE TRANSMIGRATION; ACTIN CYTOSKELETON; EPITHELIAL-CELLS; RAC; PERMEABILITY	Vascular endothelial-cadherin ( VE-cadherin) controls endothelial cell-cell adhesion and preserves endothelial integrity. In order to maintain endothelial barrier function, VE-cadherin function is tightly regulated through mechanisms that involve protein phosphorylation and cytoskeletal dynamics. Here, we show that loss of VE-cadherin function results in intercellular gap formation and a drop in electrical resistance of monolayers of primary human endothelial cells. Detailed analysis revealed that loss of endothelial cell-cell adhesion, induced by VE-cadherin-blocking antibodies, is preceded by and dependent on a rapid activation of Rac1 and increased production of reactive oxygen species. Moreover, VE-cadherin-associated beta-catenin is tyrosine-phosphorylated upon loss of cell-cell contact. Finally, the redox-sensitive proline-rich tyrosine kinase 2 ( Pyk2) is activated and recruited to cell-cell junctions following the loss of VE-cadherin homotypic adhesion. Conversely, the inhibition of Pyk2 activity in endothelial cells by the expression of CRNK (CADTK/ CAK beta-related non-kinase), an N-terminal deletion mutant that acts in a dominant negative fashion, not only abolishes the increase in beta-catenin tyrosine phosphorylation but also prevents the loss of endothelial cell-cell contact. These results implicate Pyk2 in the reduced cell-cell adhesion induced by the Rac-mediated production of ROS through the tyrosine phosphorylation of beta-catenin. This signaling is initiated upon loss of VE-cadherin function and is important for our insight in the modulation of endothelial integrity.	Univ Amsterdam, Acad Med Ctr, Dept Mol Cell Biol, Sanquin Re & Landsteiner Lab, NL-1066 CX Amsterdam, Netherlands; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of Amsterdam; Academic Medical Center Amsterdam; University of North Carolina; University of North Carolina Chapel Hill	Hordijk, PL (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Mol Cell Biol, Sanquin Re & Landsteiner Lab, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.	p.hordijk@sanquin.nl	van Buul, Jaap D/AAJ-4371-2021	van Buul, Jaap D/0000-0003-0054-7949; Hordijk, Peter/0000-0002-3348-078X	NHLBI NIH HHS [HL45100] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander JS, 2001, MICROCIRCULATION, V8, P389; [Anonymous], 2000, SCI STKE, V2000, P2000, DOI [10.1126/stke.2000.62.tw8, DOI 10.1126/STKE.2000.62.TW8]; Bogatcheva NV, 2002, VASC PHARMACOL, V39, P201, DOI 10.1016/S1537-1891(03)00009-0; Cheng JJ, 2002, J BIOL CHEM, V277, P48152, DOI 10.1074/jbc.M110937200; Corada M, 2002, BLOOD, V100, P905, DOI 10.1182/blood.V100.3.905; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Daou GB, 2004, FREE RADICAL BIO MED, V37, P208, DOI 10.1016/j.freeradbiomed.2004.04.018; Dejana E, 1999, EXP CELL RES, V252, P13, DOI 10.1006/excr.1999.4601; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Frank GD, 2000, BIOCHEM BIOPH RES CO, V270, P761, DOI 10.1006/bbrc.2000.2505; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Gotsch U, 1997, J CELL SCI, V110, P583; Hordijk PL, 1999, J CELL SCI, V112, P1915; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Kim HS, 2003, J BIOL CHEM, V278, P37497, DOI 10.1074/jbc.M211739200; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lampugnani MG, 1997, J CELL SCI, V110, P2065; Liao F, 2002, CANCER RES, V62, P2567; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nawroth R, 2002, EMBO J, V21, P4885, DOI 10.1093/emboj/cdf497; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Shaw SK, 2001, J IMMUNOL, V167, P2323, DOI 10.4049/jimmunol.167.4.2323; Sorokin A, 2001, J BIOL CHEM, V276, P21521, DOI 10.1074/jbc.M008869200; Tai LK, 2002, ARTERIOSCL THROM VAS, V22, P1790, DOI 10.1161/01.ATV.0000034475.40227.40; Tang H, 2000, J BIOL CHEM, V275, P8389, DOI 10.1074/jbc.275.12.8389; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; van Buul JD, 2002, J IMMUNOL, V168, P588, DOI 10.4049/jimmunol.168.2.588; van Buul JD, 2004, ARTERIOSCL THROM VAS, V24, P824, DOI 10.1161/01.ATV.0000122854.76267.5c; van Wetering S, 2003, AM J PHYSIOL-CELL PH, V285, pC343, DOI 10.1152/ajpcell.00048.2003; van Wetering S, 2002, J CELL SCI, V115, P1837; Vastrik I, 1999, CURR BIOL, V9, P991, DOI 10.1016/S0960-9822(99)80447-3; Vestweber D, 2000, J PATHOL, V190, P281; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; Waschke J, 2004, AM J PHYSIOL-HEART C, V287, pH704, DOI 10.1152/ajpheart.01076.2003; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Zhao XX, 2003, J BIOL CHEM, V278, P40788, DOI 10.1074/jbc.M302208200	44	93	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21129	21136		10.1074/jbc.M500898200	http://dx.doi.org/10.1074/jbc.M500898200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15778498	Green Published, hybrid			2022-12-25	WOS:000229438800029
J	Baneres, JL; Mesnier, D; Martin, A; Joubert, L; Dumuis, A; Bockaert, J				Baneres, JL; Mesnier, D; Martin, A; Joubert, L; Dumuis, A; Bockaert, J			Molecular characterization of a purified 5-HT4 receptor - A structural basis for drug efficacy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BACTERIAL EXPRESSION; GPCR FUNCTION; AGONISTS; BINDING; RHODOPSIN; OVEREXPRESSION; PURIFICATION; ACTIVATION; PREDICTION	Serotonin 5-HT4(a) receptor, a G-protein-coupled receptor (GPCR), was produced as a functional isolated protein using Escherichia coli as an expression system. The isolated receptor was characterized at the molecular level by circular dichroism (CD) and steady-state fluorescence. A specific change in the near-UV CD band associated with the GPCR disulfide bond connecting the third transmembrane domain to the second extracellular loop (e2) was observed upon agonist binding to the purified receptor. This is a direct experimental evidence for a change in the conformation of the e2 loop upon receptor activation. Different variations were obtained depending whether the ligand was an agonist ( partial or full) or an inverse agonist. In contrast, antagonist binding did not induce any variation. These observations provide a first direct evidence for the fact that free ( or antagonist-occupied), active (partial- or full agonist-occupied) and silent (inverse agonist-occupied) states of the receptor involve different arrangements of the e2 loop. Finally, ligand-induced changes in the fluorescence emission profile of the purified receptor confirmed that the partial agonist stabilized a single, well-defined, conformational state and not a mixture of different states. This result is of particular interest in a pharmacological perspective since it directly demonstrates that the efficacy of a drug is likely due to the stabilization of a ligand-specific state rather than selection of a mixture of different conformational states of the receptor.	Fac Pharm Montpellier, CNRS, UMR 5074, F-34093 Montpellier, France; Univ Montpellier 2, Univ Montpellier 1, INSERM U661, UMR 5203,CNRS, F-34094 Montpellier, France; Inst Genom Fonct, Dept Neurobiol, F-34094 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier	Baneres, JL (corresponding author), Fac Pharm Montpellier, CNRS, UMR 5074, 15 Ave Ch Flahault, F-34093 Montpellier, France.	baneres@univ-montp1.fr		Baneres, jean-louis/0000-0001-7078-1285				Alves ID, 2003, J BIOL CHEM, V278, P48890, DOI 10.1074/jbc.M306866200; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Baneres JL, 2003, J MOL BIOL, V329, P801, DOI 10.1016/S0022-2836(03)00438-8; Bockaert J, 2002, INT REV CYTOL, V212, P63; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Claeysen S, 2003, J BIOL CHEM, V278, P699, DOI 10.1074/jbc.C200588200; Claeysen S, 1996, FEBS LETT, V398, P19, DOI 10.1016/S0014-5793(96)01132-5; Fasman GD, 1996, CIRCULAR DICHROISM C, P381; GERALD C, 1995, EMBO J, V14, P2806, DOI 10.1002/j.1460-2075.1995.tb07280.x; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Joubert L, 2002, J BIOL CHEM, V277, P25502, DOI 10.1074/jbc.M202539200; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Kiefer H, 2000, RECEPTOR CHANNEL, V7, P109; Kobilka BK, 2002, J PEPT RES, V60, P317, DOI 10.1034/j.1399-3011.2002.21062.x; KULIOPULOS A, 1987, P NATL ACAD SCI USA, V84, P8893, DOI 10.1073/pnas.84.24.8893; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P189; Li M, 2004, PROTEIN EXPRES PURIF, V33, P1, DOI 10.1016/j.pep.2003.08.023; LUMMIS SCR, 1992, MOL PHARMACOL, V41, P18; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; Nikiforovich GV, 2003, BIOCHEMISTRY-US, V42, P9110, DOI 10.1021/bi034586o; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Ryan RO, 2003, PROTEIN EXPRES PURIF, V27, P98, DOI 10.1016/S1046-5928(02)00568-5; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Seifert R, 2001, J PHARMACOL EXP THER, V297, P1218; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; Sillen A, 2001, SPR S FLUOR, V1, P413; Stanasila L, 1998, BIOCHIMIE, V80, P563, DOI 10.1016/S0300-9084(00)80021-8; Surya A, 1998, TRENDS PHARMACOL SCI, V19, P243; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Tate CG, 2001, FEBS LETT, V504, P94, DOI 10.1016/S0014-5793(01)02711-9; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; Weiss HM, 2002, EUR J BIOCHEM, V269, P82, DOI 10.1046/j.0014-2956.2002.02618.x; Woody RW, 1996, CIRCULAR DICHROISM C, P109; Yan ECY, 2003, P NATL ACAD SCI USA, V100, P9262, DOI 10.1073/pnas.1531970100	38	128	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20253	20260		10.1074/jbc.M412009200	http://dx.doi.org/10.1074/jbc.M412009200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15774473	Green Published, hybrid			2022-12-25	WOS:000229242000013
J	Dames, SA; Mulet, JM; Rathgeb-Szabo, K; Hall, MN; Grzesiek, S				Dames, SA; Mulet, JM; Rathgeb-Szabo, K; Hall, MN; Grzesiek, S			The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; DISULFIDE BOND FORMATION; MODEL-FREE APPROACH; MAMMALIAN TARGET; SACCHAROMYCES-CEREVISIAE; IN-VITRO; TOR; GROWTH; NMR; COMPLEXES	The target of rapamycin ( TOR) is a highly conserved Ser/Thr kinase that plays a central role in the control of cellular growth. TOR has a characteristic multidomain structure. Only the kinase domain has catalytic function; the other domains are assumed to mediate interactions with TOR substrates and regulators. Except for the rapamycin-binding domain, there are no high-resolution structural data available for TOR. Here, we present a structural, biophysical, and mutagenesis study of the extremely conserved COOH-terminal FATC domain. The importance of this domain for TOR function has been highlighted in several publications. We show that the FATC domain, in its oxidized form, exhibits a novel structural motif consisting of an alpha-helix and a COOH-terminal disulfide-bonded loop between two completely conserved cysteine residues. Upon reduction, the flexibility of the loop region increases dramatically. The structural data, the redox potential of the disulfide bridge, and the biochemical data of a cysteine to serine mutant indicate that the intracellular redox potential can affect the cellular amount of the TOR protein via the FATC domain. Because the amount of TOR mRNA is not changed, the redox state of the FATC disulfide bond is probably influencing the degradation of TOR.	Univ Basel, Dept Biol Struct, CH-4056 Basel, Switzerland; Univ Basel, Dept Biochem, Biozentrum, CH-4056 Basel, Switzerland	University of Basel; University of Basel	Dames, SA (corresponding author), Univ Basel, Dept Biol Struct, Klingelbergstr 70, CH-4056 Basel, Switzerland.	sonja.dames@unibas.ch	Mulet, Jose Miguel/B-9063-2016	Mulet, Jose Miguel/0000-0002-9087-3838; Grzesiek, Stephan/0000-0003-1998-4225; Dames, Sonja/0000-0001-7495-6943; Hall, Michael N/0000-0002-2998-0757				Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Bhattacharyya R, 2003, J MOL BIOL, V331, P925, DOI 10.1016/S0022-2836(03)00759-9; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Cai JY, 2000, FREE RADICAL BIO MED, V29, P334, DOI 10.1016/S0891-5849(00)00312-9; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P157; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Fernandez-Checa JC, 2003, BIOCHEM BIOPH RES CO, V304, P471, DOI 10.1016/S0006-291X(03)00619-3; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Grauschopf U, 2003, EMBO J, V22, P3503, DOI 10.1093/emboj/cdg356; Grey MJ, 2003, J AM CHEM SOC, V125, P14324, DOI 10.1021/ja0367389; Grzesiek S, 1997, PROTEIN SCI, V6, P1248, DOI 10.1002/pro.5560060613; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harris Thurl E, 2003, Sci STKE, V2003, pre15; Helliwell SB, 1998, GENETICS, V148, P99; Huang CS, 2002, CANCER RES, V62, P5689; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Huth JR, 1997, PROTEIN SCI, V6, P2359; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kunz J, 2000, J BIOL CHEM, V275, P37011, DOI 10.1074/jbc.M007296200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Linke K, 2003, ANTIOXID REDOX SIGN, V5, P425, DOI 10.1089/152308603768295168; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Loo G, 2003, J NUTR BIOCHEM, V14, P64, DOI 10.1016/S0955-2863(02)00251-6; Mulet JM, 2004, YEAST, V21, P569, DOI 10.1002/yea.1126; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Ostergaard H, 2004, J CELL BIOL, V166, P337, DOI 10.1083/jcb.200402120; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Takahashi T, 2000, GENES CELLS, V5, P765, DOI 10.1046/j.1365-2443.2000.00365.x; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Zhang XW, 2002, J BIOL CHEM, V277, P28127, DOI 10.1074/jbc.M202625200; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	55	106	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20558	20564		10.1074/jbc.M501116200	http://dx.doi.org/10.1074/jbc.M501116200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15772072	hybrid, Green Accepted			2022-12-25	WOS:000229242000050
J	Levy-Adam, F; Abboud-Jarrous, G; Guerrini, M; Beccati, D; Vlodavsky, I; Ilan, N				Levy-Adam, F; Abboud-Jarrous, G; Guerrini, M; Beccati, D; Vlodavsky, I; Ilan, N			Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-METASTASIS; MAMMALIAN HEPARANASE; EXPRESSION; HEPARIN; ANGIOGENESIS; INVOLVEMENT; INHIBITION; CANCER; ROLES; GLYCOSAMINOGLYCANS	The endo-beta-glucuronidase, heparanase, is an enzyme that cleaves heparan sulfate at specific intra-chain sites, yielding heparan sulfate fragments with appreciable size and biological activities. Heparanase activity has been traditionally correlated with cell invasion associated with cancer metastasis, angiogenesis, and inflammation. In addition, heparanase up-regulation has been documented in a variety of primary human tumors, correlating with increased vascular density and poor postoperative survival, suggesting that heparanase may be considered as a target for anticancer drugs. In an attempt to identify the protein motif that would serve as a target for the development of heparanase inhibitors, we looked for protein domains that mediate the interaction of heparanase with its heparan sulfate substrate. We have identified three potential heparin binding domains and provided evidence that one of these is mapped at the N terminus of the 50-kDa active heparanase subunit. A peptide corresponding to this region (Lys(158)-Asp(171)) physically associates with heparin and heparan sulfate. Moreover, the peptide inhibited heparanase enzymatic activity in a dose-responsive manner, presumably through competition with the heparan sulfate substrate. Furthermore, antibodies directed to this region inhibited heparanase activity, and a deletion construct lacking this domain exhibited no enzymatic activity. NMR titration experiments confirmed residues Lys(158)-Asn(162) as amino acids that firmly bound heparin. Deletion of a second heparin binding domain sequence (Gln(270)-Lys(280)) yielded an inactive enzyme that failed to interact with cell surface heparan sulfate and hence accumulated in the culture medium of transfected HEK293 cells to exceptionally high levels. The two heparin/heparan sulfate recognition domains are potentially attractive targets for the development of heparanase inhibitors.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Oncol, IL-91120 Jerusalem, Israel; G Ronzoni Inst Chem & Biochem Res, I-20133 Milan, Italy	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hebrew University of Jerusalem; Hadassah University Medical Center	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, POB 9649, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il		Guerrini, Marco/0000-0001-7246-9113	NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106456-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abboud-Jarrous G, 2005, J BIOL CHEM, V280, P13568, DOI 10.1074/jbc.M413370200; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Casu B, 2004, J MED CHEM, V47, P838, DOI 10.1021/jm030893g; Casu B, 2002, BIOCHEMISTRY-US, V41, P10519, DOI 10.1021/bi020118n; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P44084, DOI 10.1074/jbc.M402131200; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Gong F, 2003, J BIOL CHEM, V278, P35152, DOI 10.1074/jbc.M300925200; Goshen R, 1996, MOL HUM REPROD, V2, P679, DOI 10.1093/molehr/2.9.679; HISCOCK DRR, 1994, J BIOL CHEM, V269, P4539; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hulett MD, 2000, BIOCHEMISTRY-US, V39, P15659, DOI 10.1021/bi002080p; Hwang TL, 1998, J MAGN RESON, V135, P280, DOI 10.1006/jmre.1998.1598; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Katz A, 2002, ISRAEL MED ASSOC J, V4, P996; Koliopanos A, 2001, CANCER RES, V61, P4655; Kramer KL, 2003, ANNU REV GENET, V37, P461, DOI 10.1146/annurev.genet.37.061103.090226; Levidiotis V, 2004, J AM SOC NEPHROL, V15, P68, DOI 10.1097/01.ASN.0000103229.25389.40; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; Marchetti D, 2003, INT J CANCER, V104, P167, DOI 10.1002/ijc.10930; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Miao HQ, 1999, INT J CANCER, V83, P424, DOI 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.3.CO;2-C; Munoz EM, 2004, ARTERIOSCL THROM VAS, V24, P1549, DOI 10.1161/01.ATV.0000137189.22999.3f; NAKAJIMA M, 1991, J BIOL CHEM, V266, P9661; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Ohkawa T, 2004, LAB INVEST, V84, P1289, DOI 10.1038/labinvest.3700159; Okada Y, 2002, J BIOL CHEM, V277, P42488, DOI 10.1074/jbc.M206510200; Parish CR, 1999, CANCER RES, V59, P3433; PARISH CR, 1987, INT J CANCER, V40, P511, DOI 10.1002/ijc.2910400414; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Pisano C, 2005, GLYCOBIOLOGY, V15, p1C, DOI 10.1093/glycob/cwi007; Rohloff J, 2002, BRIT J CANCER, V86, P1270, DOI 10.1038/sj.bjc.6600232; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Sato T, 2004, J SURG ONCOL, V87, P174, DOI 10.1002/jso.20097; Schulz JG, 2003, J BIOL CHEM, V278, P48651, DOI 10.1074/jbc.M308424200; Simizu S, 2003, CANCER LETT, V193, P83, DOI 10.1016/S0304-3835(02)00719-X; Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5; Verrecchio A, 2000, J BIOL CHEM, V275, P7701, DOI 10.1074/jbc.275.11.7701; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Xiao Y, 2003, HEPATOL RES, V26, P192, DOI 10.1016/S1386-6346(03)00107-4; Yang JK, 2004, J MOL BIOL, V335, P155, DOI 10.1016/j.jmb.2003.10.026; Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068; Zetser A, 2003, CANCER RES, V63, P7733	56	110	119	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20457	20466		10.1074/jbc.M414546200	http://dx.doi.org/10.1074/jbc.M414546200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15760902	hybrid			2022-12-25	WOS:000229242000038
J	Chavez, JA; Holland, WL; Bar, J; Sandhoff, K; Summers, SA				Chavez, JA; Holland, WL; Bar, J; Sandhoff, K; Summers, SA			Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CELLS; NECROSIS-FACTOR-ALPHA; KINASE-B (PKB)/AKT; GLUCOSE-UPTAKE; LIPOPROTEIN-LIPASE; RESISTANCE; SPHINGOSINE; DIACYLGLYCEROL; ACCUMULATION; SENSITIVITY	Recent studies indicate that insulin resistance and type 2 diabetes result from the accumulation of lipids in tissues not suited for fat storage, such as skeletal muscle and the liver. To elucidate the mechanisms linking exogenous fats to the inhibition of insulin action, we evaluated the effects of free fatty acids (FFAs) on insulin signal transduction in cultured C2C12 myotubes. As we described previously ( Chavez, J. A., and Summers, S. A. ( 2003) Arch. Biochem. Biophys. 419, 101 - 109), long-chain saturated FFAs inhibited insulin stimulation of Akt/protein kinase B, a central regulator of glucose uptake and anabolic metabolism. Moreover, these FFAs stimulated the de novo synthesis of ceramide and sphingosine, two sphingolipids shown previously to inhibit insulin action. To determine the contribution of either sphingolipid in FFA-dependent inhibition of insulin action, we generated C2C12 myotubes that constitutively overexpress acid ceramidase (AC), an enzyme that catalyzes the lysosomal conversion of ceramide to sphingosine. AC overexpression negated the inhibitory effects of saturated FFAs on insulin signaling while blocking their stimulation of ceramide accumulation. By contrast, AC overexpression stimulated the accrual of sphingosine. These results support a role for aberrant accumulation of ceramide, but not sphingosine, in the inhibition of muscle insulin sensitivity by exogenous FFAs.	Univ Utah, Dept Internal Med, Div Endocrinol Diabet & Metab, Salt Lake City, UT 84132 USA; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	Utah System of Higher Education; University of Utah; University of Bonn	Summers, SA (corresponding author), Univ Utah, Dept Internal Med, Div Endocrinol Diabet & Metab, Salt Lake City, UT 84132 USA.	scott.summers@hsc.utah.edu	/AAE-5384-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058784] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK58784] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 2004, DIABETES, V53, P25, DOI 10.2337/diabetes.53.1.25; Bachmann OP, 2001, DIABETES, V50, P2579, DOI 10.2337/diabetes.50.11.2579; Chavez JA, 2003, ARCH BIOCHEM BIOPHYS, V419, P101, DOI 10.1016/j.abb.2003.08.020; Chavez JA, 2003, J BIOL CHEM, V278, P10297, DOI 10.1074/jbc.M212307200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Dobrzyn A, 2004, ACTA PHYSIOL SCAND, V181, P313, DOI 10.1111/j.1365-201X.2004.01295.x; Dobrzyn A, 2002, AM J PHYSIOL-ENDOC M, V282, pE277, DOI 10.1152/ajpendo.00151.2001; Edsall LC, 1999, ANAL BIOCHEM, V272, P80, DOI 10.1006/abio.1999.4157; el Bawab Samer, 2002, Subcell Biochem, V36, P187; Ferreira LDMCB, 2001, DIABETES, V50, P1064, DOI 10.2337/diabetes.50.5.1064; Gorski J, 1998, MOL CELL BIOCHEM, V178, P113, DOI 10.1023/A:1006820907955; Hajduch E, 2001, DIABETOLOGIA, V44, P173, DOI 10.1007/s001250051596; Hansen BC, 1999, ANN NY ACAD SCI, V892, P1, DOI 10.1111/j.1749-6632.1999.tb07782.x; Hegarty BD, 2003, ACTA PHYSIOL SCAND, V178, P373, DOI 10.1046/j.1365-201X.2003.01162.x; Helge JW, 2004, EXP PHYSIOL, V89, P119, DOI 10.1113/expphysiol.2003.002605; HUNNICUTT JW, 1994, DIABETES, V43, P540, DOI 10.2337/diabetes.43.4.540; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kim YB, 2002, J BIOL CHEM, V277, P32915, DOI 10.1074/jbc.M204710200; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Li CM, 2002, GENOMICS, V79, P218, DOI 10.1006/geno.2002.6686; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Montell E, 2001, AM J PHYSIOL-ENDOC M, V280, pE229, DOI 10.1152/ajpendo.2001.280.2.E229; MURRAY DK, 1990, LIFE SCI, V46, P1843, DOI 10.1016/0024-3205(90)90236-K; NELSON DH, 1986, BIOCHEM BIOPH RES CO, V138, P463, DOI 10.1016/0006-291X(86)90303-7; Neschen S, 2002, AM J PHYSIOL-ENDOC M, V282, pE395, DOI 10.1152/ajpendo.00414.2001; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Powell DJ, 2003, MOL CELL BIOL, V23, P7794, DOI 10.1128/MCB.23.21.7794-7808.2003; RANDLE PJ, 1963, LANCET, V1, P785; Riboni L, 1999, BIOCHEM J, V338, P147, DOI 10.1042/0264-6021:3380147; Riboni L, 2000, J NEUROCHEM, V75, P503, DOI 10.1046/j.1471-4159.2000.0750503.x; ROBERTSON DG, 1989, J BIOL CHEM, V264, P6773; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Schmitz-Peiffer C, 2000, CELL SIGNAL, V12, P583, DOI 10.1016/S0898-6568(00)00110-8; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Seelan RS, 2000, GENE CHROMOSOME CANC, V29, P137, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1018>3.0.CO;2-E; Sinha R, 2002, DIABETES, V51, P1022, DOI 10.2337/diabetes.51.4.1022; Storz P, 1999, EUR J BIOCHEM, V266, P17, DOI 10.1046/j.1432-1327.1999.00809.x; Straczkowski M, 2004, DIABETES, V53, P1215, DOI 10.2337/diabetes.53.5.1215; Stratford S, 2004, J BIOL CHEM, V279, P36608, DOI 10.1074/jbc.M406499200; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Summers SA, 1999, ANN NY ACAD SCI, V892, P169, DOI 10.1111/j.1749-6632.1999.tb07795.x; Teruel T, 2001, DIABETES, V50, P2563, DOI 10.2337/diabetes.50.11.2563; Thompson AL, 2000, AM J PHYSIOL-ENDOC M, V279, pE577, DOI 10.1152/ajpendo.2000.279.3.E577; TURINSKY J, 1990, J BIOL CHEM, V265, P16880; Wang CN, 1998, DIABETES, V47, P24, DOI 10.2337/diabetes.47.1.24; Wang Li-Ping, 2003, Methods Mol Med, V83, P127; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200	56	162	170	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20148	20153		10.1074/jbc.M412769200	http://dx.doi.org/10.1074/jbc.M412769200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774472	hybrid			2022-12-25	WOS:000229113700087
J	Katsuma, S; Hatae, N; Yano, T; Ruike, Y; Kimura, M; Hirasawa, A; Tsujimoto, G				Katsuma, S; Hatae, N; Yano, T; Ruike, Y; Kimura, M; Hirasawa, A; Tsujimoto, G			Free fatty acids inhibit serum deprivation-induced apoptosis through GPR120 in a murine enteroendocrine cell line STC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BREAST-CANCER CELLS; SELECTIVE REGULATION; INSULIN-SECRETION; PROLIFERATION; KINASE; ACTIVATION; EXPRESSION; PALMITATE; GPR40	Free fatty acids (FFAs) provide an important energy source and also act as signaling molecules. FFAs are known to exert a variety of physiological responses via their G protein-coupled receptors (GPCRs), such as the GPR40 family. Recently, we identified a novel FFA receptor, GPR120, that promotes secretion of glucagon-like peptide-1 (Hirasawa, A., Tsumaya, K., Awaji, T., Katsuma, S., Adachi, T., Yamada, M., Sugimoto, Y., Miyazaki, S., and Tsujimoto, G. (2005) Nat. Med. 11, 90-94). Here we showed that FFAs inhibit serum deprivation-induced apoptosis of murine enteroendocrine STC-1 cells, which express two types of GPCRs, GPR120 and GPR40, for unsaturated long chain FFA. We first found that linolenic acid potently activated ERK and Akt/protein kinase B (Akt) in STC-1 cells. ERK kinase inhibitors significantly reduced the antiapoptotic effects of linolenic acid. Inhibitors for phosphatidylinositol 3-kinase (PI3K), a major target of which is Akt, significantly reduced the anti-apoptotic effects. Transfection of STC-1 cells with the dominant-negative form of Akt also inhibited the anti-apoptotic effect. These results suggested that the activation of ERK and PI3K-Akt pathways is required for FFA-induced anti-apoptotic effects on STC-1 cells. Transient transfection of STC-1 cells with GPR120 cDNA, but not GPR40 cDNA, enhanced inhibition of caspase-3 activation. RNA interference experiments showed that reduced expression of GPR120, but not GPR40, resulted in reduced ERK activation and reduced effects of FFAs on caspase-3 inhibition. Collectively, these results demonstrated that FFAs promote the activation of ERK and PI3K-Akt pathways mainly via GPR120, leading to the anti-apoptotic effect of STC-1 cells.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genom Drug Discovery Sci, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Inst Chem Res, Bioinformat Ctr, Kyoto 6110011, Japan	Kyoto University; Kyoto University	Tsujimoto, G (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genom Drug Discovery Sci, Sakyo Ku, 46-29 Yoshida Shimoadachi Cho, Kyoto 6068501, Japan.	gtsuji@pharm.kyoto-u.ac.jp						Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Dugourd C, 2003, HYPERTENSION, V41, P882, DOI 10.1161/01.HYP.0000060821.62417.35; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hardy S, 2000, CANCER RES, V60, P6353; Hardy S, 2003, J BIOL CHEM, V278, P31861, DOI 10.1074/jbc.M300190200; Hatae N, 2003, J BIOL CHEM, V278, P17977, DOI 10.1074/jbc.M301312200; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Izumi Y, 2001, CIRC RES, V88, P1120, DOI 10.1161/hh1101.091267; KATADA T, 1986, J BIOL CHEM, V261, P5215; Katsuma S, 2002, GENES CELLS, V7, P1217, DOI 10.1046/j.1365-2443.2002.00594.x; Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Lu ZH, 2003, BIOCHEM BIOPH RES CO, V303, P1002, DOI 10.1016/S0006-291X(03)00449-2; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Sidhu SS, 2000, J PHYSIOL-LONDON, V528, P165, DOI 10.1111/j.1469-7793.2000.00165.x; Thompson AL, 2000, AM J PHYSIOL-ENDOC M, V279, pE577, DOI 10.1152/ajpendo.2000.279.3.E577; Ulloth JE, 2003, J NEUROCHEM, V84, P655, DOI 10.1046/j.1471-4159.2003.01571.x; Welters HJ, 2004, FEBS LETT, V560, P103, DOI 10.1016/S0014-5793(04)00079-1; Xiong YM, 2004, P NATL ACAD SCI USA, V101, P1045, DOI 10.1073/pnas.2637002100; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yonezawa T, 2004, BIOCHEM BIOPH RES CO, V314, P805, DOI 10.1016/j.bbrc.2003.12.175; Zhan YM, 2003, ARTERIOSCL THROM VAS, V23, P795, DOI 10.1161/01.ATV.0000066132.32063.F2	34	146	162	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19507	19515		10.1074/jbc.M412385200	http://dx.doi.org/10.1074/jbc.M412385200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774482	hybrid			2022-12-25	WOS:000229113700012
J	Onorato, TM; Chakraborty, S; Haldar, D				Onorato, TM; Chakraborty, S; Haldar, D			Phosphorylation of rat liver mitochondrial glycerol-3-phosphate acyltransferase by casein kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCEROL PHOSPHATE ACYLTRANSFERASE; ACETYL-COA CARBOXYLASE; ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; FATTY-ACID OXIDATION; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; GLYCEROPHOSPHATE ACYLTRANSFERASE; TRIACYLGLYCEROL-SYNTHESIS; PHOSPHOLIPID-SYNTHESIS; TERMINAL DOMAIN	We have previously shown rat liver mitochondrial glycerol-3-phosphate acyltransferase (mtGAT), which catalyzes the first step in de novo glycerolipid biosynthesis, is stimulated by casein kinase 2 (CK2) and that a phosphorylated protein of similar to 85 kDa is present in CK2-treated mitochondria. In this paper, we have identified the P-32-labeled 85-kDa protein as mtGAT. We have also investigated whether the phosphorylation of mtGAT is because of CK2. Mitochondria were treated with CK2 and [gamma-P-32]GTP as the phosphate donor. Autoradiography, Western blot, and immunoprecipitation results showed mtGAT was phosphorylated by CK2. Next, we incubated mitochondria with CK2 and either ATP or GTP, in the presence of heparin, a known inhibitor of CK2. Heparin inhibited CK2-induced stimulation of mtGAT activity; this inhibition resulted in decreased P-32-labeling of mtGAT. Additionally, mitochondria were treated with CK2 and [gamma-P-32]ATP in the presence of staurosporine ( a serine/threonine protein kinase inhibitor), genistein ( a tyrosine kinase inhibitor), and 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB, a CK2 inhibitor). Only DRB, the CK2 inhibitor, greatly reduced the amount of P-32-incorporation into mtGAT by CK2. Finally, isolated mitochondrial outer membrane was incubated with cytosol in the presence of [gamma-P-32]GTP; P-32-labeled mtGAT was detected. Collectively, these data suggest that CK2 phosphorylates mtGAT. The impact of our results in the regulation of mtGAT and other anabolic processes is discussed.	St Johns Univ, Dept Sci Biol, Jamaica, NY 11439 USA	Saint John's University	Haldar, D (corresponding author), St Johns Univ, Dept Sci Biol, 8000 Utopia Pkwy, Jamaica, NY 11439 USA.	haldard@stjohns.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM057643] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-57643] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100; Agarwal AK, 2003, TRENDS ENDOCRIN MET, V14, P214, DOI 10.1016/S1043-2760(03)00078-X; Balija VS, 2000, J BIOL CHEM, V275, P31668, DOI 10.1074/jbc.M002963200; BATES EJ, 1979, BIOCHEM J, V182, P751, DOI 10.1042/bj1820751; Bhat BG, 1999, BBA-MOL CELL BIOL L, V1439, P415, DOI 10.1016/S1388-1981(99)00103-1; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARI G, 1971, FEBS LETT, V17, P300, DOI 10.1016/0014-5793(71)80169-2; DESAUTELS M, 1982, J BIOL CHEM, V257, P1673; FAMULSKI KS, 1983, FEBS LETT, V157, P124, DOI 10.1016/0014-5793(83)81129-6; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Gonzalez-Baro MR, 2001, J BIOL CHEM, V276, P43182, DOI 10.1074/jbc.M107885200; Haldar D, 1983, Trans N Y Acad Sci, V41, P173; HALDAR D, 1979, J BIOL CHEM, V254, P4502; HALDAR D, 1990, J BIOL CHEM, V265, P11014; Hammond LE, 2002, MOL CELL BIOL, V22, P8204, DOI 10.1128/MCB.22.23.8204-8214.2002; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P347, DOI 10.1111/j.1432-1033.1988.tb14203.x; HESLER CB, 1985, J BIOL CHEM, V260, P7452; HOLLAND R, 1985, FEBS LETT, V181, P308, DOI 10.1016/0014-5793(85)80282-9; Igal RA, 2001, J BIOL CHEM, V276, P42205, DOI 10.1074/jbc.M103386200; Lewin TM, 2004, J BIOL CHEM, V279, P13488, DOI 10.1074/jbc.M314032200; Lewin TM, 2001, ARCH BIOCHEM BIOPHYS, V396, P119, DOI 10.1006/abbi.2001.2604; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; Linden D, 2004, J LIPID RES, V45, P1279, DOI 10.1194/jlr.M400010-JLR200; MARTOS C, 1985, BIOCHEM J, V225, P321, DOI 10.1042/bj2250321; MONROY G, 1972, J BIOL CHEM, V247, P6884; Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783; Mylonis I, 2003, BIOCHEM BIOPH RES CO, V301, P650, DOI 10.1016/S0006-291X(02)03055-3; Niefind K, 1999, NAT STRUCT BIOL, V6, P1100, DOI 10.1038/70033; NIKONOV AV, 1998, RRD LIP RES 2, V2, P207; O'Farrell F, 1999, BBA-PROTEIN STRUCT M, V1433, P68, DOI 10.1016/S0167-4838(99)00147-8; Onorato TM, 2002, BIOCHEM BIOPH RES CO, V296, P1091, DOI 10.1016/S0006-291X(02)02064-8; ONORATO TM, 2002, LIPIDS GLYCEROLIPID; Park H, 2002, J BIOL CHEM, V277, P32571, DOI 10.1074/jbc.M201692200; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; PIEDIMONTE G, 1988, J CELL BIOCHEM, V36, P91, DOI 10.1002/jcb.240360110; ROCK CO, 1981, ARCH BIOCHEM BIOPHYS, V211, P113, DOI 10.1016/0003-9861(81)90436-7; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Ruderman NB, 2003, ACTA PHYSIOL SCAND, V178, P435, DOI 10.1046/j.1365-201X.2003.01164.x; SAGGERSON ED, 1987, BIOCHEM J, V243, P289, DOI 10.1042/bj2430289; Salvi M, 2002, BBA-MOL CELL RES, V1589, P181, DOI 10.1016/S0167-4889(02)00174-X; Sambrook J, 2001, MOL CLONING LAB MANU; Sasaki K, 2003, J BIOL CHEM, V278, P30945, DOI 10.1074/jbc.M212167200; SCHLAME M, 1993, J BIOL CHEM, V268, P74; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Trembley JH, 2003, J BIOL CHEM, V278, P2265, DOI 10.1074/jbc.M207518200; Tuteja N, 2003, PLANT PHYSIOL, V132, P2108, DOI 10.1104/pp.103.024273; Uchida T, 1996, BBA-LIPID LIPID MET, V1304, P89, DOI 10.1016/S0005-2760(96)00109-9; Vaglio P, 1996, FEBS LETT, V380, P25, DOI 10.1016/0014-5793(95)01542-6; van Gurp M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI 10.1016/S0006-291X(03)00621-1; VANCURA A, 1991, BIOCHEM BIOPH RES CO, V175, P339, DOI 10.1016/S0006-291X(05)81240-9; VANCURA A, 1992, J BIOL CHEM, V267, P14353; VANCURA A, 1994, J BIOL CHEM, V269, P27209; WEST L, 2005, BIOCHIM BIOPHYS ACTA, V1687, P164; Wu XF, 2003, BIOCHEM BIOPH RES CO, V304, P333, DOI 10.1016/S0006-291X(03)00594-1; YET SF, 1993, BIOCHEMISTRY-US, V32, P9486, DOI 10.1021/bi00087a029	57	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19527	19534		10.1074/jbc.M410422200	http://dx.doi.org/10.1074/jbc.M410422200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778226	hybrid			2022-12-25	WOS:000229113700014
J	Chandra, D; Choy, G; Daniel, PT; Tang, DG				Chandra, D; Choy, G; Daniel, PT; Tang, DG			Bax-dependent regulation of Bak by voltage-dependent anion channel 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 HOMOLOG BAX; INDUCED APOPTOSIS; CELL-DEATH; MITOCHONDRIAL ACTIVATION; MUTATIONAL INACTIVATION; COLORECTAL CANCERS; DEFICIENT MICE; PATHWAY; REQUIREMENT	Many studies have demonstrated a critical role of Bax in mediating apoptosis, but the role of Bak in regulating cancer cell apoptotic sensitivities in the presence or absence of Bax remains incompletely understood. Using isogenic cells with defined genetic deficiencies, here we show that in response to intrinsic, extrinsic, and endoplasmic reticulum stress stimuli, HCT116 cells show clear-cut apoptotic sensitivities in the order of Bax(+)/Bak(+) > Bax(+)/Bak(-) >> Bax(-)/Bak(+) >> Bax(-)/Bak(-). Small interference RNA-mediated knockdown of Bak in Bax-deficient cells renders HCT116 cells completely resistant to apoptosis induction. Surprisingly, however, Bak knockdown in Bax-expressing cells only slightly affects the apoptotic sensitivities. Bak, like Bax, undergoes the N terminus exposure upon apoptotic stimulation in both Bax-expressing and Bax-deficient cells. Gel filtration, chemical cross-linking, and co-immunoprecipitation experiments reveal that different from Bax, which normally exists as monomers in unstimulated cells and is oligomerized by apoptotic stimulation, most Bak in unstimulated HCT116 cells exists in two distinct protein complexes, one of which contains voltage-dependent anion channel (VDAC) 2. During apoptosis, Bak and Bax form both homo- and hetero-oligomeric complexes that still retain some VDAC-2. However, the oligomeric VDAC-2 complexes are diminished, and Bak does not interact with VDAC-2 in Bax-deficient HCT116 cells. These results highlight VDAC-2 as a critical inhibitor of Bak-mediated apoptotic responses.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	University of Texas System; UTMD Anderson Cancer Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Pk Rd 1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Chandra, Dhyan/0000-0001-7272-9384	NATIONAL CANCER INSTITUTE [R01CA090297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023374] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90297] Funding Source: Medline; NIA NIH HHS [AG023374] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Barnhart BC, 2004, EMBO J, V23, P3175, DOI 10.1038/sj.emboj.7600325; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Chandra D, 2003, J BIOL CHEM, V278, P17408, DOI 10.1074/jbc.M300750200; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Chandra D, 2002, J BIOL CHEM, V277, P50842, DOI 10.1074/jbc.M207622200; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; de Bruin EC, 2003, CELL DEATH DIFFER, V10, P1204, DOI 10.1038/sj.cdd.4401296; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Egger L, 2003, CELL DEATH DIFFER, V10, P1188, DOI 10.1038/sj.cdd.4401288; Eischen CM, 2002, CANCER RES, V62, P2184; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; Fannjiang Y, 2003, DEV CELL, V4, P575, DOI 10.1016/S1534-5807(03)00091-1; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; He Q, 2003, ONCOGENE, V22, P2674, DOI 10.1038/sj.onc.1206363; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Kandasamy K, 2003, CANCER RES, V63, P1712; Kondo S, 2000, CANCER RES, V60, P4328; Krajewska M, 1996, AM J PATHOL, V148, P1567; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Liu JW, 2005, ONCOGENE, V24, P2020, DOI 10.1038/sj.onc.1208385; Liu JW, 2002, CANCER RES, V62, P2976; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ravi R, 2002, CANCER RES, V62, P1583; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; Seo SY, 2004, J BIOL CHEM, V279, P42240, DOI 10.1074/jbc.M406775200; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Tang DG, 1998, CANCER RES, V58, P3466; Theodorakis P, 2002, CANCER RES, V62, P3373; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zalk R, 2005, BIOCHEM J, V386, P73, DOI 10.1042/BJ20041356; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	55	81	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19051	19061		10.1074/jbc.M501391200	http://dx.doi.org/10.1074/jbc.M501391200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757910	hybrid			2022-12-25	WOS:000228932300061
J	Luer, C; Schauer, S; Mobius, K; Schulze, J; Schubert, WD; Heinz, DW; Jahn, D; Moser, J				Luer, C; Schauer, S; Mobius, K; Schulze, J; Schubert, WD; Heinz, DW; Jahn, D; Moser, J			Complex formation between glutamyl-tRNA reductase and glutamate-1-semialdehyde 2,1-aminomutase in Escherichia coli during the initial reactions of porphyrin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-SEMIALDEHYDE AMINOTRANSFERASE; CHLOROPHYLL BIOSYNTHESIS; 1ST ENZYME; PURIFICATION; SEQUENCE; HEME; GENE	In Escherichia coli the first common precursor of all tetrapyrroles, 5-aminolevulinic acid, is synthesized from glutamyl-tRNA (Glu-tRNA(Glu)) in a two-step reaction catalyzed by glutamyl-tRNA reductase (GluTR) and glutamate-1-semialdehyde 2,1-aminomutase (GSA-AM). To protect the highly reactive reaction intermediate glutamate-1-semialdehyde (GSA), a tight complex between these two enzymes was proposed based on their solved crystal structures. The existence of this hypothetical complex was verified by two independent biochemical techniques. Co-immunoprecipitation experiments using antibodies directed against E. coli GluTR and GSA-AM demonstrated the physical interaction of both enzymes in E. coli cell-free extracts and between the recombinant purified enzymes. Additionally, the formation of a GluTR.GSA-AM complex was identified by gel permeation chromatography. Complex formation was found independent of Glu-tRNA(Glu) and cofactors. The analysis of a GluTR mutant truncated in the 80-amino acid C-terminal dimerization domain (GluTR-A338Stop) revealed the importance of GluTR dimerization for complex formation. The in silico model of the E. coli GluTR.GSA-AM complex suggested direct metabolic channeling between both enzymes to protect the reactive aldehyde species GSA. In accordance with this proposal, side product formation catalyzed by GluTR was observed via high performance liquid chromatography analysis in the absence of the GluTR.GSA-AM complex.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, D-38106 Braunschweig, Germany; Swiss Fed Inst Technol, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland; German Res Ctr Biotechnol, Div Struct Biol, D-38124 Braunschweig, Germany	Braunschweig University of Technology; Swiss Federal Institutes of Technology Domain; ETH Zurich; Helmholtz Association; Helmholtz-Center for Infection Research	Moser, J (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, Spielmannstr 7, D-38106 Braunschweig, Germany.	j.moser@tu-bs.de	Schubert, Wolf-Dieter/A-5617-2009	Schubert, Wolf-Dieter/0000-0003-4998-519X; Jahn, Dieter/0000-0002-4064-9205				Beeckmans S, 1999, METHODS, V19, P278, DOI 10.1006/meth.1999.0857; BOREL F, 1993, FEBS LETT, V324, P162, DOI 10.1016/0014-5793(93)81385-D; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Frankenberg N, 1999, BIOCHEMISTRY-US, V38, P13968, DOI 10.1021/bi9906468; Hennig M, 1997, P NATL ACAD SCI USA, V94, P4866, DOI 10.1073/pnas.94.10.4866; HOOBER JK, 1988, CARLSBERG RES COMMUN, V53, P11, DOI 10.1007/BF02908411; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; ILAG LL, 1992, BIOCHEMISTRY-US, V31, P7143, DOI 10.1021/bi00146a016; ILAG LL, 1991, J BACTERIOL, V173, P3408, DOI 10.1128/jb.173.11.3408-3413.1991; JAHN D, 1992, TRENDS BIOCHEM SCI, V17, P215, DOI 10.1016/0968-0004(92)90380-R; JORDAN PM, 1990, BIOSYNTHESIS HEME CH; LIN SX, 1992, PROTEIN EXPRES PURIF, V3, P71, DOI 10.1016/1046-5928(92)90058-5; Moser J, 2001, EMBO J, V20, P6583, DOI 10.1093/emboj/20.23.6583; Moser J, 1999, J BIOL CHEM, V274, P30679, DOI 10.1074/jbc.274.43.30679; Reichelt J, 2005, BIOINFORMATICS, V21, P1291, DOI 10.1093/bioinformatics/bti138; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schauer S, 2003, PROTEIN EXPRES PURIF, V31, P271, DOI 10.1016/S1046-5928(03)00184-0; Schauer S, 2002, J BIOL CHEM, V277, P48657, DOI 10.1074/jbc.M206924200; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; Schubert WD, 2002, PHOTOSYNTH RES, V74, P205, DOI 10.1023/A:1020963711861; VERKAMP E, 1989, J BACTERIOL, V171, P4728, DOI 10.1128/jb.171.9.4728-4735.1989; Wang LY, 1999, J BACTERIOL, V181, P1211, DOI 10.1128/JB.181.4.1211-1219.1999	23	57	62	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18568	18572		10.1074/jbc.M500440200	http://dx.doi.org/10.1074/jbc.M500440200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757895	hybrid			2022-12-25	WOS:000228932300004
J	Raibaud, S; Schwarz-Linek, US; Kim, JH; Jenkins, HT; Baines, ER; Gurusiddappa, S; Hook, M; Potts, JR				Raibaud, S; Schwarz-Linek, US; Kim, JH; Jenkins, HT; Baines, ER; Gurusiddappa, S; Hook, M; Potts, JR			Borrelia burgdorferi binds fibronectin through a tandem beta-zipper, a common mechanism of fibronectin binding in staphylococci, streptococci, and spirochetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL ADHERENCE; MODULE PAIR; PROTEIN; PROGRAM; F1; IDENTIFICATION; PYOGENES; SEQUENCE; AFFINITY; MSCRAMMS	BBK32 is a fibronectin-binding protein from the Lyme disease-causing spirochete Borrelia burgdorferi. In this study, we show that BBK32 shares sequence similarity with fibronectin module-binding motifs previously identified in proteins from Streptococcus pyogenes and Staphylococcus aureus. Nuclear magnetic resonance spectroscopy and isothermal titration calorimetry are used to confirm the binding sites of BBK32 peptides within the N-terminal domain of fibronectin and to measure the affinities of the interactions. Comparison of chemical shift perturbations in fibronectin F1 modules on binding of peptides from BBK32, FnBPA from S. aureus, and SfbI from S. pyogenes provides further evidence for a shared mechanism of binding. Despite the different locations of the bacterial attachment sites in BBK32 compared with SfbI from S. pyogenes and FnBPA from S. aureus, an antiparallel orientation is observed for binding of the N-terminal domain of fibronectin to each of the pathogens. Thus, these phylogenetically and morphologically distinct bacterial pathogens have similar mechanisms for binding to human fibronectin.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Texas, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA	University of Oxford; University of Texas System; University of Texas Health Science Center Houston	Potts, JR (corresponding author), Univ Oxford, Dept Biochem, Oxford OX1 3QU, England.	jennifer.potts@bioch.ox.ac.uk	Jenkins, Huw/E-1094-2011	Jenkins, Huw/0000-0002-3302-6966; Schwarz-Linek, Ulrich/0000-0003-0526-223X				Fikrig E, 2000, J IMMUNOL, V164, P5344, DOI 10.4049/jimmunol.164.10.5344; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Grab DJ, 1998, BBA-MOL BASIS DIS, V1407, P135, DOI 10.1016/S0925-4439(98)00038-6; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Heikkila T, 2003, J INFECT DIS, V187, P1888, DOI 10.1086/375371; HousePompeo K, 1996, J BIOL CHEM, V271, P1379, DOI 10.1074/jbc.271.3.1379; Ingham KC, 2004, J BIOL CHEM, V279, P42945, DOI 10.1074/jbc.M406984200; Jadoun J, 1998, J INFECT DIS, V178, P147, DOI 10.1086/515589; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; JOH HJ, 1994, BIOCHEMISTRY-US, V33, P6086, DOI 10.1021/bi00186a007; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kim JH, 2004, J BIOL CHEM, V279, P41706, DOI 10.1074/jbc.M401691200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MA Y, 1991, INFECT IMMUN, V59, P671, DOI 10.1128/IAI.59.2.671-678.1991; MADIGAN M, 2000, BROCK BIOL MICRORGAN; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Molinari G, 1997, INFECT IMMUN, V65, P1357, DOI 10.1128/IAI.65.4.1357-1363.1997; Penkett CJ, 2000, BIOCHEMISTRY-US, V39, P2887, DOI 10.1021/bi992267k; Potts JR, 1999, BIOCHEMISTRY-US, V38, P8304, DOI 10.1021/bi990202b; Probert WS, 1998, MOL MICROBIOL, V30, P1003, DOI 10.1046/j.1365-2958.1998.01127.x; Probert WS, 2001, INFECT IMMUN, V69, P4129, DOI 10.1128/IAI.69.6.4129-4133.2001; Schwarz-Linek U, 2004, J BIOL CHEM, V279, P39017, DOI 10.1074/jbc.M405083200; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; Schwarz-Linek U, 2004, MOL MICROBIOL, V52, P631, DOI 10.1111/j.1365-2958.2004.04027.x; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; Smith R, 2000, EMERG INFECT DIS, V6, P404, DOI 10.3201/eid0604.000416; SOFFE N, 1995, J MAGN RESON SER A, V116, P117, DOI 10.1006/jmra.1995.1197; Talay SR, 2000, CELL MICROBIOL, V2, P521, DOI 10.1046/j.1462-5822.2000.00076.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083	30	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18803	18809		10.1074/jbc.M501731200	http://dx.doi.org/10.1074/jbc.M501731200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15737988	hybrid			2022-12-25	WOS:000228932300032
J	Schwartz, JW; Novarino, G; Piston, DW; DeFelice, LJ				Schwartz, JW; Novarino, G; Piston, DW; DeFelice, LJ			Substrate binding stoichiometry and kinetics of the norepinephrine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; HUMAN DOPAMINE TRANSPORTER; TERNARY COMPLEX MODEL; SEROTONIN TRANSPORTER; MULTIFREQUENCY PHASE; LIVING CELLS; ORTHOSTATIC INTOLERANCE; FUNCTIONAL CONSEQUENCES; MODULATION FLUOROMETRY; TRANSMEMBRANE SEGMENT	The human norepinephrine (NE) transporter (hNET) attenuates neuronal signaling by rapid NE clearance from the synaptic cleft, and NET is a target for cocaine and amphetamines as well as therapeutics for depression, obsessive-compulsive disorder, and post-traumatic stress disorder. In spite of its central importance in the nervous system, little is known about how NET substrates, such as NE, 1-methyl-4-tetrahydropyridinium (MPP+), or amphetamine, interact with NET at the molecular level. Nor do we understand the mechanisms behind the transport rate. Previously we introduced a fluorescent substrate similar to MPP+, which allowed separate and simultaneous binding and transport measurement (Schwartz, J. W., Blakely, R. D., and DeFelice, L. J. (2003) J. Biol. Chem. 278, 9768-9777). Here we use this substrate, 4-(4-(dimethylamino)styrl)-N-methyl-pyridinium (ASP(+)), in combination with green fluorescent protein-tagged hNETs to measure substrate-transporter stoichiometry and substrate binding kinetics. Calibrated confocal microscopy and fluorescence correlation spectroscopy reveal that hNETs, which are homo-multimers, bind one substrate molecule per transporter subunit. Substrate residence at the transporter, obtained from rapid on-off kinetics revealed in fluorescence correlation spectroscopy, is 526 mu s. Substrate residence obtained by infinite dilution is 1000 times slower. This novel examination of substrate-transporter kinetics indicates that a single ASP(+) molecule binds and unbinds thousands of times before being transported or ultimately dissociated from hNET. Calibrated fluorescent images combined with mass spectroscopy give a transport rate of 0.06 ASP(+)/hNET-protein/s, thus 36,000 on-off binding events (and 36 actual departures) occur for one transport event. Therefore binding has a low probability of resulting in transport. We interpret these data to mean that inefficient binding could contribute to slow transport rates.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA; Univ Roma La Sapienza, Dipartimento Biol Cellulare & Sviluppo, I-00185 Rome, Italy	Vanderbilt University; Vanderbilt University; Vanderbilt University; Sapienza University Rome	DeFelice, LJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.	lou.defelice@vanderbilt.edu		De Felice, Louis/0000-0002-4594-3171	NCI NIH HHS [CA68485] Funding Source: Medline; NIDA NIH HHS [DA-6338] Funding Source: Medline; NIMH NIH HHS [MH 58921] Funding Source: Medline; NINDS NIH HHS [NS-34075] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034075] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALCALA JR, 1985, ANAL INSTRUM, V14, P225; Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600-0854.2001.21104.x; Axelrod J, 1969, Prog Brain Res, V31, P21; Bacia K, 2003, METHODS, V29, P74, DOI 10.1016/S1046-2023(02)00291-8; Backs J, 2001, J MOL CELL CARDIOL, V33, P461, DOI 10.1006/jmcc.2000.1319; Blakely RD, 2001, J NEUROSCI, V21, P8319, DOI 10.1523/JNEUROSCI.21-21-08319.2001; BONISCH H, 1986, N-S ARCH PHARMACOL, V332, P131, DOI 10.1007/BF00511402; BRUNS D, 1993, NEURON, V10, P559, DOI 10.1016/0896-6273(93)90159-O; Bruns D, 1998, METHOD ENZYMOL, V296, P593; Carvelli L, 2004, P NATL ACAD SCI USA, V101, P16046, DOI 10.1073/pnas.0403299101; Clark MS, 1998, BRAIN RES PROTOC, V2, P273, DOI 10.1016/S1385-299X(98)00004-X; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; DeFelice LJ, 2004, TRENDS NEUROSCI, V27, P352, DOI 10.1016/j.tins.2004.04.007; DELCASTILLO J, 1957, PROC R SOC SER B-BIO, V146, P369; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Foote S., 1995, PHARM PHYSL CENTRAL; FRIEDRICH U, 1986, N-S ARCH PHARMACOL, V333, P246, DOI 10.1007/BF00512937; GALLI A, 1995, J EXP BIOL, V198, P2197; Galli A, 1996, P NATL ACAD SCI USA, V93, P8671, DOI 10.1073/pnas.93.16.8671; Garland EM, 2002, ANN NY ACAD SCI, V971, P506, DOI 10.1111/j.1749-6632.2002.tb04515.x; GRATTON E, 1984, ANNU REV BIOPHYS BIO, V13, P105; Gu HH, 1996, J BIOL CHEM, V271, P6911, DOI 10.1074/jbc.271.12.6911; Hahn MK, 2003, J NEUROSCI, V23, P4470; Hanson KM, 2002, BIOPHYS J, V83, P1682, DOI 10.1016/S0006-3495(02)73936-2; Hastrup H, 2003, J BIOL CHEM, V278, P45045, DOI 10.1074/jbc.C300349200; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Haupts U, 1998, P NATL ACAD SCI USA, V95, P13573, DOI 10.1073/pnas.95.23.13573; Hess ST, 2002, BIOPHYS J, V83, P2300, DOI 10.1016/S0006-3495(02)73990-8; Ingram SL, 2002, NAT NEUROSCI, V5, P971, DOI 10.1038/nn920; JAMESON DM, 1984, APPL SPECTROSC REV, V20, P55, DOI 10.1080/05704928408081716; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Jayanthi LD, 2002, BRIT J PHARMACOL, V135, P1927, DOI 10.1038/sj.bjp.0704658; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Kocabas AM, 2003, J NEUROCHEM, V85, P1513, DOI 10.1046/j.1471-4159.2003.01793.x; LAKOWICZ JR, 1999, PRINCIPLES FLUORESEN; Larsson HP, 1996, BIOPHYS J, V70, P733, DOI 10.1016/S0006-3495(96)79613-3; Maes M, 1999, NEUROPSYCHOPHARMACOL, V20, P188, DOI 10.1016/S0893-133X(98)00058-X; MASON JN, 2004, IN PRESS J NEUROSCI; Meissner O, 2003, BIOCHEMISTRY-US, V42, P1667, DOI 10.1021/bi0263356; Norgaard-Nielsen K, 2002, FEBS LETT, V524, P87, DOI 10.1016/S0014-5793(02)03008-9; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; Pifl C, 1996, J PHARMACOL EXP THER, V277, P1437; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramsey IS, 2002, J BIOL CHEM, V277, P14475, DOI 10.1074/jbc.M110783200; Robertson D, 2001, ANN NY ACAD SCI, V940, P527; Rudnick G, 1998, METHOD ENZYMOL, V296, P233; Sacchetti G, 1999, BRIT J PHARMACOL, V128, P1332, DOI 10.1038/sj.bjp.0702926; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Savchenko V, 2003, MOL CELL NEUROSCI, V24, P1131, DOI 10.1016/S1044-7431(03)00235-5; SCHILDKRAUT JJ, 1965, J PSYCHIAT RES, V3, P213, DOI 10.1016/0022-3956(65)90003-8; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Schwartz JW, 2003, J BIOL CHEM, V278, P9768, DOI 10.1074/jbc.M209824200; Schwille P, 1999, BIOPHYS J, V77, P2251, DOI 10.1016/S0006-3495(99)77065-7; Schwille P, 2001, CELL BIOCHEM BIOPHYS, V34, P383, DOI 10.1385/CBB:34:3:383; Shannon JR, 2000, NEW ENGL J MED, V342, P541, DOI 10.1056/NEJM200002243420803; Siggia ED, 2000, BIOPHYS J, V79, P1761, DOI 10.1016/S0006-3495(00)76428-9; Sitte HH, 2004, MOL INTERV, V4, P38, DOI 10.1124/mi.4.1.38; Stachon A, 1996, CELL PHYSIOL BIOCHEM, V6, P72, DOI 10.1159/000154796; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Trendelenburg AU, 1999, J NEUROCHEM, V73, P1431, DOI 10.1046/j.1471-4159.1999.0731431.x; VALENTINO RJ, 1983, BRAIN RES, V270, P363, DOI 10.1016/0006-8993(83)90615-7; Vrljic M, 2002, BIOPHYS J, V83, P2681, DOI 10.1016/S0006-3495(02)75277-6; Yernool D, 2003, BIOCHEMISTRY-US, V42, P12981, DOI 10.1021/bi030161q; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018	65	45	45	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19177	19184		10.1074/jbc.M412923200	http://dx.doi.org/10.1074/jbc.M412923200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757904	hybrid			2022-12-25	WOS:000228932300074
J	Dauer, DJ; Ferraro, B; Song, LX; Yu, B; Mora, L; Buettner, R; Enkemann, S; Jove, R; Haura, EB				Dauer, DJ; Ferraro, B; Song, LX; Yu, B; Mora, L; Buettner, R; Enkemann, S; Jove, R; Haura, EB			Stat3 regulates genes common to both wound healing and cancer	ONCOGENE			English	Article						STAT proteins; cancer; wound healing; Stat3; lung cancer	BUTYLATED HYDROXYTOLUENE BHT; CONSTITUTIVE ACTIVATION; PLASMINOGEN-ACTIVATOR; SIGNAL TRANSDUCER; EPITHELIAL-CELLS; BINDING PROTEIN; CARCINOMA-CELLS; LUNG-CARCINOMA; IL-6 RESPONSE; EXPRESSION	Wound healing and cancer are both characterized by cell proliferation, remodeling of extracellular matrix, cell invasion and migration, new blood vessel formation, and modulation of blood coagulation. The mechanisms that link wound healing and cancer are poorly understood. We report here that Stat3, a common signaling mechanism involved in oncogenesis and tissue injury, regulates a common set of genes involved in wound healing and cancer. Using oligonucleotide gene arrays and quantitative real-time PCR, we evaluated changes in global gene expression resulting from expression of Stat3 in lung epithelial cells. We report here previously uncharacterized genes induced by Stat3 implicated in signaling pathways common to both wound healing and cancer including cell invasion and migration, angiogenesis, modulation of coagulation, and repression of interferon-inducible genes. Consistent with these results, we found increased Stat3 activity associated with wound healing in chronically inflamed mouse lungs and increased Stat3 activity was identified at the leading edge of lung tumors invading adjacent nontumor stroma. These findings provide a molecular basis for understanding cancer as a deregulation of normal wound healing processes.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Expt Therapeut Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Haura, EB (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program, MRC3 East,Room 3056,12902 Magnolia Dr, Tampa, FL 33612 USA.	hauraeb@mofitt.usf.edu						Bauer AK, 2001, EXP LUNG RES, V27, P197, DOI 10.1080/019021401300053948; Bauer AK, 2001, TOXICOLOGY, V169, P1, DOI 10.1016/S0300-483X(01)00475-9; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Christensen PJ, 2004, AM J PHYSIOL-LUNG C, V286, pL68, DOI 10.1152/ajplung.00079.2003; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Duan HO, 2003, J BIOL CHEM, V278, P41270, DOI 10.1074/jbc.M304210200; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Epperly MW, 2000, RADIAT RES, V154, P365, DOI 10.1667/0033-7587(2000)154[0365:DPRROM]2.0.CO;2; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; Gao HW, 2004, J IMMUNOL, V172, P7703, DOI 10.4049/jimmunol.172.12.7703; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He B, 2003, BIOCHEM BIOPH RES CO, V301, P386, DOI 10.1016/S0006-291X(02)03071-1; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hokuto I, 2004, J CLIN INVEST, V113, P28, DOI 10.1172/JCI200419491; Hur GC, 2003, CLIN CANCER RES, V9, P5768; Hutt JA, 2000, J BIOL CHEM, V275, P29123, DOI 10.1074/jbc.M004476200; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Kano A, 2003, J EXP MED, V198, P1517, DOI 10.1084/jem.20030077; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Khatri P, 2002, GENOMICS, V79, P266, DOI 10.1006/geno.2002.6698; Khatri P, 2004, NUCLEIC ACIDS RES, V32, pW449, DOI 10.1093/nar/gkh409; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Lakka SS, 2001, CLIN CANCER RES, V7, P1087; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; Mora LB, 2002, CANCER RES, V62, P6659; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Palumbo JS, 2000, BLOOD, V96, P3302, DOI 10.1182/blood.V96.10.3302; Palumbo JS, 2002, CANCER RES, V62, P6966; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Reiland J, 1999, PROSTATE, V41, P78; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; SAUNDERS NA, 1994, AM J RESP CELL MOL, V11, P147, DOI 10.1165/ajrcmb.11.2.8049075; Schumann RR, 1996, MOL CELL BIOL, V16, P3490; Severgnini M, 2004, AM J PHYSIOL-LUNG C, V286, pL1282, DOI 10.1152/ajplung.00349.2003; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Steinman RA, 2003, ONCOGENE, V22, P3608, DOI 10.1038/sj.onc.1206523; Sue RD, 2004, J IMMUNOL, V172, P3860, DOI 10.4049/jimmunol.172.6.3860; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; WAKABAYASHI H, 1995, CANCER RES, V55, P4458; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143, DOI 10.1152/physiolgenomics.2000.2.3.143; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	59	313	323	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3397	3408		10.1038/sj.onc.1208469	http://dx.doi.org/10.1038/sj.onc.1208469			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735721				2022-12-25	WOS:000229038800002
J	Bachler, C; Flukiger-Bruhwiler, K; Schneider, P; Bahler, P; Erni, B				Bachler, C; Flukiger-Bruhwiler, K; Schneider, P; Bahler, P; Erni, B			From ATP as substrate to ADP as coenzyme - Functional evolution of the nucleotide binding subunit of dihydroxyacetone kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHOSPHOTRANSFERASE SYSTEM; CITROBACTER-FREUNDII; PHOSPHOENOLPYRUVATE; TRANSCRIPTION; MECHANISM; GLYCEROL; PROTEIN	Dihydroxyacetone kinases are a family of sequence-related enzymes that utilize either ATP or a protein of the phosphoenolpyruvate: sugar phosphotransferase system (PTS) as a source of high energy phosphate. The PTS is a multicomponent system involved in carbohydrate uptake and control of carbon metabolism in bacteria. Phylogenetic analysis suggests that the PTS-dependent dihydroxyacetone kinases evolved from an ATP-dependent ancestor. Their nucleotide binding subunit, an eight-helix barrel of regular up-down topology, retains ADP as phosphorylation site for the double displacement of phosphate from a phospho-histidine of the PTS protein to dihydroxyacetone. ADP is bound essentially irreversibly with a t(1/2) of 100 min. Complexation with ADP increases the thermal unfolding temperature of dihydroxyacetone L from 40 (apo- form) to 65 degrees C (holoenzyme). ADP assumes the same role as histidines, cysteines, and aspartic acids in histidine kinases and PTS proteins. This conversion of a substrate binding site into a cofactor binding site reflects a remarkable instance of parsimonious evolution.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland	University of Bern	Erni, B (corresponding author), Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland.	erni@ibc.unibe.ch						Bachler C, 2005, EMBO J, V24, P283, DOI 10.1038/sj.emboj.7600517; BACHLER C, 2004, EMBO J; DANIEL R, 1995, J BACTERIOL, V177, P4392, DOI 10.1128/jb.177.15.4392-4401.1995; Deppenmeier U, 2002, APPL MICROBIOL BIOT, V60, P233, DOI 10.1007/s00253-002-1114-5; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FORAGE RG, 1982, J BACTERIOL, V151, P591, DOI 10.1128/JB.151.2.591-599.1982; Garcia-Alles LF, 2004, BIOCHEMISTRY-US, V43, P13037, DOI 10.1021/bi048575m; Gutknecht R, 2001, EMBO J, V20, P2480, DOI 10.1093/emboj/20.10.2480; Herz S, 2002, PHYTOCHEMISTRY, V60, P3, DOI 10.1016/S0031-9422(02)00056-0; KUNDIG W, 1971, J BIOL CHEM, V246, P1392; Luers GH, 1998, YEAST, V14, P759; MAO QC, 1995, J BIOL CHEM, V270, P5258, DOI 10.1074/jbc.270.10.5258; Molin M, 2003, J BIOL CHEM, V278, P1415, DOI 10.1074/jbc.M203030200; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; Siebold C, 2003, J BIOL CHEM, V278, P48236, DOI 10.1074/jbc.M305942200; Siebold C, 2003, P NATL ACAD SCI USA, V100, P8188, DOI 10.1073/pnas.0932787100; Siebold C, 2001, FEBS LETT, V504, P104, DOI 10.1016/S0014-5793(01)02705-3; Tessier FJ, 2003, BIOCHEM J, V369, P705, DOI 10.1042/BJ20020668; Vetter IR, 1999, Q REV BIOPHYS, V32, P1, DOI 10.1017/S0033583599003480; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N	21	31	31	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18321	18325		10.1074/jbc.M500279200	http://dx.doi.org/10.1074/jbc.M500279200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15753087	hybrid			2022-12-25	WOS:000228807200091
J	Leroch, M; Kirchberger, S; Haferkamp, I; Wahl, M; Neuhaus, HE; Tjaden, J				Leroch, M; Kirchberger, S; Haferkamp, I; Wahl, M; Neuhaus, HE; Tjaden, J			Identification and characterization of a novel plastidic adenine nucleotide uniporter from Solanum tuberosum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-GLUCOSE PYROPHOSPHORYLASE; PHOSPHATE-TRANSLOCATOR; STARCH SYNTHESIS; ADP/ATP CARRIER; MOLECULAR CHARACTERIZATION; ENVELOPE MEMBRANES; TRANSPORT PROTEINS; MAIZE ENDOSPERM; EXPRESSION; MITOCHONDRIAL	Homologs of BT1 ( the Brittle1 protein) are found to be phylogenetically related to the mitochondrial carrier family and appear to occur in both mono- and dicotyle-donous plants. Whereas BT1 from cereals is probably involved in the transport of ADP-glucose, which is essential for starch metabolism in endosperm plastids, BT1 from a noncereal plant, Solanum tuberosum (StBT1), catalyzes an adenine nucleotide uniport when functionally integrated into the bacterial cytoplasmic membrane. Import studies into intact Escherichia coli cells harboring StBT1 revealed a narrow substrate spectrum with similar affinities for AMP, ADP, and ATP of about 300 - 400 mu M. Transiently expressed StBT1-green fluorescent protein fusion protein in tobacco leaf protoplasts showed a plastidic localization of the StBT1. In vitro synthesized radioactively labeled StBT1 was targeted to the envelope membranes of isolated spinach chloroplasts. Furthermore, we showed by real time reverse transcription-PCR a ubiquitous expression pattern of the StBT1 in autotrophic and heterotrophic potato tissues. We therefore propose that StBT1 is a plastidic adenine nucleotide uniporter used to provide the cytosol and other compartments with adenine nucleotides exclusively synthesized inside plastids.	Tech Univ Kaiserslautern, D-67663 Kaiserslautern, Germany	University of Kaiserslautern	Tjaden, J (corresponding author), Tech Univ Kaiserslautern, Erwin Schroedinger Str 22, D-67663 Kaiserslautern, Germany.	tjaden@rhrk.uni-kl.de						ANDERSON JD, 1979, PLANT PHYSIOL, V63, P100, DOI 10.1104/pp.63.1.100; ApRees T, 1995, CUR TOP PL, V14, P143; BATZ O, 1994, BBA-GEN SUBJECTS, V1200, P148, DOI 10.1016/0304-4165(94)90129-5; Beckles DM, 2001, PLANT PHYSIOL, V126, P261, DOI 10.1104/pp.126.1.261; Beckles DM, 2001, PLANT PHYSIOL, V125, P818, DOI 10.1104/pp.125.2.818; Boldt R, 2003, PHYSIOL PLANTARUM, V117, P297, DOI 10.1034/j.1399-3054.2003.00030.x; Burton RA, 2002, PLANT PHYSIOL, V130, P1464, DOI 10.1104/pp.010363; CAO HP, 1995, PHYSIOL PLANTARUM, V95, P176, DOI 10.1111/j.1399-3054.1995.tb00825.x; Catoni E, 2003, FEBS LETT, V534, P87, DOI 10.1016/S0014-5793(02)03782-1; Clausen C, 2004, PLANTA, V220, P30, DOI 10.1007/s00425-004-1325-3; Dean JD, 2002, PLANT MOL BIOL REP, V20, P347, DOI 10.1007/BF02772122; Denyer K, 1996, PLANT PHYSIOL, V112, P779, DOI 10.1104/pp.112.2.779; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; Eicks M, 2002, PLANT PHYSIOL, V128, P512, DOI 10.1104/pp.010576; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; EMES MJ, 1999, PLANT CARBOHYDRATE B, P231; Fischer K, 1997, PLANT CELL, V9, P453, DOI 10.1105/tpc.9.3.453; Flugge UI, 1999, ANNU REV PLANT PHYS, V50, P27, DOI 10.1146/annurev.arplant.50.1.27; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; FLUGGE UI, 1992, BIOCHIM BIOPHYS ACTA, V1110, P112, DOI 10.1016/0005-2736(92)90301-2; Geigenberger P, 2001, PLANT PHYSIOL, V125, P1667, DOI 10.1104/pp.125.4.1667; Haferkamp I, 2002, EUR J BIOCHEM, V269, P3172, DOI 10.1046/j.1432-1033.2002.02991.x; Kammerer B, 1998, PLANT CELL, V10, P105, DOI 10.1105/tpc.10.1.105; Klingenberg M, 1979, Methods Enzymol, V56, P245; KLINGENBERG M, 1993, SOC GEN PHY, V48, P201; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; Knappe S, 2003, PLANT PHYSIOL, V131, P1178, DOI 10.1104/pp.016519; Kost B, 1998, PLANT J, V16, P393, DOI 10.1046/j.1365-313x.1998.00304.x; KRAUSE DC, 1985, P NATL ACAD SCI USA, V82, P3015, DOI 10.1073/pnas.82.9.3015; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Linka N, 2003, GENE, V306, P27, DOI 10.1016/S0378-1119(03)00429-3; LIU TTY, 1992, PLANT PHYSIOL, V99, pS39; MAHE A, 1992, MOL PLANT MICROBE IN, V5, P242, DOI 10.1094/MPMI-5-242; MANGOLD HK, 1967, DUNNSCHICHT CHROMATO, P749; Miguel E, 2000, MOL PLANT MICROBE IN, V13, P421, DOI 10.1094/MPMI.2000.13.4.421; Millar AH, 2003, PLANT PHYSIOL, V131, P443, DOI 10.1104/pp.009985; Moffatt Barbara A, 2002, Arabidopsis Book, V1, pe0018, DOI 10.1199/tab.0018; MOHLMANN T, 1994, PLANTA, V194, P492, DOI 10.1007/BF00714461; Mohlmann T, 1998, EUR J BIOCHEM, V252, P353, DOI 10.1046/j.1432-1327.1998.2520353.x; Mohlmann T, 1997, BIOCHEM J, V324, P503, DOI 10.1042/bj3240503; MULLERROBER B, 1992, EMBO J, V11, P1229, DOI 10.1002/j.1460-2075.1992.tb05167.x; Neuhaus HE, 1996, BIOCHEM J, V318, P945, DOI 10.1042/bj3180945; Neuhaus HE, 2000, BBA-BIOMEMBRANES, V1465, P307, DOI 10.1016/S0005-2736(00)00146-2; NEUHAUS HE, 1993, PLANT PHYSIOL, V101, P573, DOI 10.1104/pp.101.2.573; Neuhaus HE, 1997, PLANT J, V11, P73, DOI 10.1046/j.1365-313X.1997.11010073.x; Neuhaus HE, 2000, ANNU REV PLANT PHYS, V51, P111, DOI 10.1146/annurev.arplant.51.1.111; Niittyla T, 2004, SCIENCE, V303, P87, DOI 10.1126/science.1091811; OKITA TW, 1992, PLANT PHYSIOL, V100, P560, DOI 10.1104/pp.100.2.560; Palmieri L, 2001, EMBO J, V20, P5049, DOI 10.1093/emboj/20.18.5049; Patron NJ, 2004, PLANT PHYSIOL, V135, P2088, DOI 10.1104/pp.104.045203; Picault N, 2002, J BIOL CHEM, V277, P24204, DOI 10.1074/jbc.M202702200; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sancenon V, 2004, J BIOL CHEM, V279, P15348, DOI 10.1074/jbc.M313321200; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; Shannon JC, 1996, PLANT PHYSIOL, V110, P835, DOI 10.1104/pp.110.3.835; Shannon JC, 1998, PLANT PHYSIOL, V117, P1235, DOI 10.1104/pp.117.4.1235; Spetea C, 2004, P NATL ACAD SCI USA, V101, P1409, DOI 10.1073/pnas.0308164100; STARK DM, 1992, SCIENCE, V258, P287, DOI 10.1126/science.258.5080.287; Stasolla C, 2004, FRONT BIOSCI-LANDMRK, V9, P1506, DOI 10.2741/1343; Stasolla C, 2003, J PLANT PHYSIOL, V160, P1271, DOI 10.1078/0176-1617-01169; STUBBS M, 1981, INT ENCYCL PHARM TH, V107, P283; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sturzenbaum SR, 2001, COMP BIOCHEM PHYS B, V130, P281, DOI 10.1016/S1096-4959(01)00440-7; SULLIVAN TD, 1991, PLANT CELL, V3, P1337, DOI 10.1105/tpc.3.12.1337; SULLIVAN TD, 1995, PLANTA, V196, P477, DOI 10.1007/BF00203647; Thorbjornsen T, 1996, PLANT J, V10, P243, DOI 10.1046/j.1365-313X.1996.10020243.x; Tjaden J, 1998, PLANT J, V16, P531, DOI 10.1046/j.1365-313X.1998.00317.x; Tjaden J, 2004, MOL MICROBIOL, V51, P1439, DOI 10.1111/j.1365-2958.2004.03918.x; Tjaden J, 1998, J BIOL CHEM, V273, P9630, DOI 10.1074/jbc.273.16.9630; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Versaw WK, 2002, PLANT CELL, V14, P1751, DOI 10.1105/tpc.002220; Voncken F, 2002, MOL MICROBIOL, V44, P1441, DOI 10.1046/j.1365-2958.2002.02959.x; WAGNER R, 1989, EUR J BIOCHEM, V182, P165, DOI 10.1111/j.1432-1033.1989.tb14813.x; WEBER A, 1995, BIOCHEMISTRY-US, V34, P2621, DOI 10.1021/bi00008a028; Weber A, 2002, J EXP BOT, V53, P865, DOI 10.1093/jexbot/53.370.865; Wendt UK, 2000, PLANT J, V23, P723, DOI 10.1046/j.1365-313x.2000.00840.x; Winkler HH, 1999, TRENDS BIOCHEM SCI, V24, P64, DOI 10.1016/S0968-0004(98)01334-6; WINKLER HH, 1986, METHOD ENZYMOL, V125, P253; YAGIL E, 1975, J BACTERIOL, V121, P401, DOI 10.1128/JB.121.2.401-405.1975; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	83	78	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17992	18000		10.1074/jbc.M412462200	http://dx.doi.org/10.1074/jbc.M412462200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15737999	hybrid			2022-12-25	WOS:000228807200054
J	Hunt, J; Beavil, RL; Calvert, RA; Gould, HJ; Sutton, BJ; Beavil, AJ				Hunt, J; Beavil, RL; Calvert, RA; Gould, HJ; Sutton, BJ; Beavil, AJ			Disulfide linkage controls the affinity and stoichiometry of IgE Fc epsilon 3-4 binding to Fc epsilon RI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; GAMMA RECEPTOR; FRAGMENT; COMPLEX; REVEALS; DOMAIN; GLYCOSYLATION; FLEXIBILITY; C-EPSILON-3; RESIDUES	IgE antibodies cause long-term sensitization of tissue mast cells and blood basophils toward allergen-induced cross-linking and triggering of allergic inflammation. This persistence of IgE binding is due to its uniquely high affinity for the receptor Fc epsilon RI and in particular its slow rate of dissociation once bound. The binding interface consists of two subsites, one contributed by each C epsilon 3 domain of IgE Fc in a 1: 1 complex. We have investigated the contributions of C epsilon 3 disulfide linkage and glycosylation to the kinetics and affinity of binding of an Fc subfragment (Fc epsilon 3 - 4) to a soluble receptor fragment (sFc epsilon RI alpha). In contrast to IgG Fc where deglycosylation abrogates receptor binding activity, the removal of the N-linked carbohydrate at Asn-394 in Fc epsilon 3-4 only reduces binding affinity by a factor of 4, principally because of a faster off-rate. Removal of the inter-heavy chain disulfide bond unexpectedly resulted in a fragment with a much faster off-rate and the potential to form a complex with a 2: 1 stoichiometry (sFc epsilon RI alpha: Fc epsilon 3 4). This permitted the determination of the affinity of a single, natively folded C epsilon 3 domain for the first time. The low affinity K-a approximate to 10(5)-10(6) M-1, similar to that determined previously for an isolated and partially folded C epsilon 3 domain, demonstrates that substantial reduction in affinity can be achieved by preventing the engagement of one of the two C epsilon 3 domains. Recent structural data indicate that conformational change in IgE is required to allow both C epsilon 3 domains to bind, and thus an allosteric inhibitor that prevents access to the second C epsilon 3 has the potential to reduce the ability of IgE to sensitize allergic effector cells.	Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; Kings Coll London, Div Asthma Allergy & Lung Biol, London SE1 1UL, England	University of London; King's College London; University of London; King's College London	Beavil, AJ (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England.	andrew.beavil@kcl.ac.uk	Beavil, Andrew/B-5624-2009	Beavil, Andrew/0000-0002-0768-122X; Gould, Hannah/0000-0003-0411-688X				BASU M, 1993, J BIOL CHEM, V268, P13118; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; Cook JPD, 1997, BIOCHEMISTRY-US, V36, P15579, DOI 10.1021/bi9713005; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; Henry AJ, 1997, BIOCHEMISTRY-US, V36, P15568, DOI 10.1021/bi971299+; Henry AJ, 2000, BIOCHEMISTRY-US, V39, P7406, DOI 10.1021/bi9928391; HENRY AJ, 1996, HUMAN IGE INTERACTIO; KENTEN J, 1984, P NATL ACAD SCI-BIOL, V81, P2955, DOI 10.1073/pnas.81.10.2955; KENTEN JH, 1982, P NATL ACAD SCI-BIOL, V79, P6661, DOI 10.1073/pnas.79.21.6661; Keown MB, 1997, EUR BIOPHYS J BIOPHY, V25, P471, DOI 10.1007/s002490050062; KEOWN MB, 1995, P NATL ACAD SCI USA, V92, P1841, DOI 10.1073/pnas.92.6.1841; Keown MB, 1998, BIOCHEMISTRY-US, V37, P8863, DOI 10.1021/bi972354h; Krapp S, 2003, J MOL BIOL, V325, P979, DOI 10.1016/S0022-2836(02)01250-0; Maenaka K, 2001, J BIOL CHEM, V276, P44898, DOI 10.1074/jbc.M106819200; McDonnell JM, 2001, NAT STRUCT BIOL, V8, P437, DOI 10.1038/87603; Mimura Y, 2001, J BIOL CHEM, V276, P45539, DOI 10.1074/jbc.M107478200; Price NE, 2005, J BIOL CHEM, V280, P2324, DOI 10.1074/jbc.M409458200; Radaev S, 2001, J BIOL CHEM, V276, P16469, DOI 10.1074/jbc.M100350200; Radaev S, 2001, J BIOL CHEM, V276, P16478, DOI 10.1074/jbc.M100351200; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Shi JG, 1997, BIOCHEMISTRY-US, V36, P2112, DOI 10.1021/bi961231e; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Stamos J, 2004, STRUCTURE, V12, P1289, DOI 10.1016/j.str.2004.04.015; TAKATSU K, 1975, J IMMUNOL, V114, P1838; TAYLOR MAJ, 1992, PROTEIN ENG, V5, P455, DOI 10.1093/protein/5.5.455; Wan T, 2002, NAT IMMUNOL, V3, P681, DOI 10.1038/ni811; Wurzburg BA, 2000, IMMUNITY, V13, P375, DOI 10.1016/S1074-7613(00)00037-6; Wurzburg BA, 2002, MOL IMMUNOL, V38, P1063, DOI 10.1016/S0161-5890(02)00035-4	30	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16808	16814		10.1074/jbc.M500965200	http://dx.doi.org/10.1074/jbc.M500965200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15743766	hybrid			2022-12-25	WOS:000228615500033
J	Qiu, RD; Pei, WH; Zhang, LS; Lin, JQ; Ji, GY				Qiu, RD; Pei, WH; Zhang, LS; Lin, JQ; Ji, GY			Identification of the putative staphylococcal AgrB catalytic residues involving the proteolytic cleavage of AgrD to generate autoinducing peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; COMPLETE GENOME SEQUENCE; BIOSYNTHESIS-ACTIVATING PHEROMONE; BACILLUS-SUBTILIS; ENTEROCOCCUS-FAECALIS; TRANSMEMBRANE TOPOLOGY; SIGNAL-TRANSDUCTION; CELL COMMUNICATION; AUREUS; VIRULENCE	The P2 operon of the staphylococcal accessory gene regulator (agr) encodes four genes (agrA, - B, - C, and - D) whose products compose a quorum sensing system: AgrA and AgrC resemble a two-component signal transduction system of which AgrC is a sensor kinase and AgrA is a response regulator; AgrD, a polypeptide that is integrated into the cytoplasmic membrane via an amphipathic alpha-helical motif in its N-terminal region, is the propeptide for an autoinducing peptide that is the ligand for AgrC; and AgrB is a novel membrane protein that involves in the processing of AgrD propeptide and possibly the secretion of the mature autoinducing peptide. In this study, we demonstrated that AgrB had endopeptidase activity, and identified 2 amino acid residues in AgrB ( cysteine 84 and histidine 77) that might form a putative cysteine endopeptidase catalytic center in the proteolytic cleavage of AgrD at its C-terminal processing site. Computer analysis revealed that the cysteine and histidine residues were conserved among the potential AgrB homologous proteins, suggesting that the Agr quorum sensing system homologues might also exist in other Gram-positive bacteria.	Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA; Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Catholic University of America; Uniformed Services University of the Health Sciences - USA	Ji, GY (corresponding author), Catholic Univ Amer, Dept Biol, 620 Michigan Ave NE, Washington, DC 20064 USA.	ji@cua.edu		Qiu, Rongde/0000-0003-2078-9718	NIAID NIH HHS [R01AI46445] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046445] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANHOLT R, 1982, J BIOL CHEM, V257, P7122; CHEUNG AL, 1994, J BACTERIOL, V176, P4168, DOI 10.1128/JB.176.13.4168-4172.1994; Coorssen JR, 2003, J CELL SCI, V116, P2087, DOI 10.1242/jcs.00374; DEVOS WM, 1995, MOL MICROBIOL, V17, P427, DOI 10.1111/j.1365-2958.1995.mmi_17030427.x; Donvito B, 1997, FEMS MICROBIOL LETT, V151, P139, DOI 10.1016/S0378-1097(97)00149-3; DRIESSEN AJM, 1993, METHOD ENZYMOL, V221, P394, DOI 10.1016/0076-6879(93)21032-4; Dufour P, 2002, J BACTERIOL, V184, P1180, DOI 10.1128/jb.184.4.1180-1186.2002; Glaser P, 2001, SCIENCE, V294, P849; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HAVARSTEIN LS, 1995, P NATL ACAD SCI USA, V92, P11140, DOI 10.1073/pnas.92.24.11140; Hoffmaster AR, 2004, P NATL ACAD SCI USA, V101, P8449, DOI 10.1073/pnas.0402414101; JI G, 2004, IN PRESS J BACTERIOL; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; Ji GY, 1997, SCIENCE, V276, P2027, DOI 10.1126/science.276.5321.2027; Jiang M, 2000, J BACTERIOL, V182, P303, DOI 10.1128/JB.182.2.303-310.2000; Kalkum M, 2003, P NATL ACAD SCI USA, V100, P2795, DOI 10.1073/pnas.0436605100; Kane CD, 2002, J BACTERIOL, V184, P4409, DOI 10.1128/JB.184.16.4409-4419.2002; Kleerebezem M, 1997, MOL MICROBIOL, V24, P895, DOI 10.1046/j.1365-2958.1997.4251782.x; Kleerebezem M, 2003, P NATL ACAD SCI USA, V100, P1990, DOI 10.1073/pnas.0337704100; Koenig RL, 2004, J BACTERIOL, V186, P7549, DOI 10.1128/JB.186.22.7549-7555.2004; Lina G, 1998, MOL MICROBIOL, V28, P655, DOI 10.1046/j.1365-2958.1998.00830.x; Lyon GJ, 2002, BIOCHEMISTRY-US, V41, P10095, DOI 10.1021/bi026049u; Lyon GJ, 2002, J BIOL CHEM, V277, P6247, DOI 10.1074/jbc.M109989200; Mayville P, 1999, P NATL ACAD SCI USA, V96, P1218, DOI 10.1073/pnas.96.4.1218; McDowell P, 2001, MOL MICROBIOL, V41, P503, DOI 10.1046/j.1365-2958.2001.02539.x; Nakayama J, 2001, MOL MICROBIOL, V41, P145, DOI 10.1046/j.1365-2958.2001.02486.x; Nakayama J, 2001, BIOSCI BIOTECH BIOCH, V65, P2322, DOI 10.1271/bbb.65.2322; Nelson KE, 2004, NUCLEIC ACIDS RES, V32, P2386, DOI 10.1093/nar/gkh562; Nolling J, 2001, J BACTERIOL, V183, P4823, DOI 10.1128/JB.183.16.4823-4838.2001; Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x; Novick RP, 1999, CURR OPIN MICROBIOL, V2, P40, DOI 10.1016/S1369-5274(99)80007-1; NOVICK RP, 1995, MOL GEN GENET, V248, P446, DOI 10.1007/BF02191645; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; Otto M, 1998, FEBS LETT, V424, P89, DOI 10.1016/S0014-5793(98)00145-8; Perego M, 1996, P NATL ACAD SCI USA, V93, P1549, DOI 10.1073/pnas.93.4.1549; Perego M, 1997, P NATL ACAD SCI USA, V94, P8612, DOI 10.1073/pnas.94.16.8612; Qin X, 2000, INFECT IMMUN, V68, P2579, DOI 10.1128/IAI.68.5.2579-2586.2000; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; Sambrook J, 2001, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; Solomon M, 1999, PLANT CELL, V11, P431, DOI 10.1105/tpc.11.3.431; Stephenson S, 2003, J BACTERIOL, V185, P4861, DOI 10.1128/JB.185.16.4861-4871.2003; Sturme MHJ, 2002, ANTON LEEUW INT J G, V81, P233, DOI 10.1023/A:1020522919555; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; Van Wamel WJB, 1998, FEMS MICROBIOL LETT, V163, P1, DOI 10.1016/S0378-1097(98)00132-3; VANDENESCH F, 1993, FEMS MICROBIOL LETT, V111, P115, DOI 10.1016/0378-1097(93)90191-4; Zhang LS, 2004, J BACTERIOL, V186, P6706, DOI 10.1128/JB.186.20.6706-6713.2004; Zhang LS, 2004, J BIOL CHEM, V279, P19448, DOI 10.1074/jbc.M311349200; Zhang LS, 2002, J BIOL CHEM, V277, P34736, DOI 10.1074/jbc.M205367200; Zhang SP, 2000, J BACTERIOL, V182, P2321, DOI 10.1128/JB.182.8.2321-2325.2000	52	56	65	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16695	16704		10.1074/jbc.M411372200	http://dx.doi.org/10.1074/jbc.M411372200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734745	hybrid			2022-12-25	WOS:000228615500021
J	Prandini, MH; Dreher, I; Bouillot, S; Benkerri, S; Moll, T; Huber, P				Prandini, MH; Dreher, I; Bouillot, S; Benkerri, S; Moll, T; Huber, P			The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis	ONCOGENE			English	Article						cadherin; endothelium; promoter regions; tumour angiogenesis; transgenic mice	VASCULAR-ENDOTHELIAL-CADHERIN; MAMMALIAN-CELLS; GENE PROMOTER; EXPRESSION; GROWTH; MOUSE; MEMBRANE; ANTIBODY; PROTEIN; MICE	Vascular endothelial (VE)-cadherin is exclusively expressed at interendothelial junctions of normal and tumour vessels. In this report, we characterized the transcriptional activity of the human VE-cadherin promoter. Transient transfection assays revealed that sequences at positions -1135/-744 and -166/-5 base pairs are critical for promoter activity in endothelial cells. We show that specific sequences in the proximal region interact with Ets and Sp1 family members. Transgenic mice were created and the human VE-cadherin promoter was able to confer correct temporal and spatial expression on the LacZ gene in embryos. In adults, the transgene was specifically and strongly expressed in the lung, heart, ovary, spleen and kidney glomeruli, whereas expression was weak or absent in the vasculature of other organs, including the brain, thymus, liver and skeletal muscle. Neovessels in tumour grafts and Matrigel implants harboured strong stainings, indicating that promoter activity is enhanced in angiogenic situations. Furthermore, Matrigel and transfection assays showed that VE-cadherin promoter is subjected to bFGF induction. Transgene expression was also noticed in extravascular sites of the central nervous system, suggesting that silencer elements may be located elsewhere in the gene. These results are a first step towards addressing the organ- and tumour-specific regulation of the VE-cadherin gene.	CEA Grenoble, CEA INSERM Joseph Fourier Univ EMI 0219, Dept Cellular Responses & Dynam, DVE,DRDC, F-38054 Grenoble, France; Cardion, Erkrath, Germany	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Huber, P (corresponding author), CEA Grenoble, CEA INSERM Joseph Fourier Univ EMI 0219, Dept Cellular Responses & Dynam, DVE,DRDC, 17 Rue Martyrs, F-38054 Grenoble, France.	phuber@cea.fr	Huber, Philippe/C-7971-2019	Huber, Philippe/0000-0002-4153-7694; BOUILLOT, Stephanie/0000-0001-7567-557X				Adachi H, 2002, J BIOL CHEM, V277, P24014, DOI 10.1074/jbc.M201854200; Aird WC, 1997, J CELL BIOL, V138, P1117, DOI 10.1083/jcb.138.5.1117; Apostel F, 2002, BBA-GENE STRUCT EXPR, V1577, P384, DOI 10.1016/S0167-4781(02)00412-8; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; Boudreau N, 1997, J CELL BIOL, V139, P257, DOI 10.1083/jcb.139.1.257; Breier G, 1996, BLOOD, V87, P630, DOI 10.1182/blood.V87.2.630.bloodjournal872630; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Bronner C, 2002, ANTICANCER RES, V22, P605; Call GB, 2002, MOL CELL ENDOCRINOL, V189, P85, DOI 10.1016/S0303-7207(01)00744-4; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661; Corada M, 2002, BLOOD, V100, P905, DOI 10.1182/blood.V100.3.905; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Dancer A, 2003, GENE THER, V10, P1170, DOI 10.1038/sj.gt.3301981; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; Gao XP, 2000, AM J PHYSIOL-LUNG C, V279, pL1218, DOI 10.1152/ajplung.2000.279.6.L1218; GARLANDA C, 1994, P NATL ACAD SCI USA, V91, P7291, DOI 10.1073/pnas.91.15.7291; Gill M, 2001, CIRC RES, V88, P167; GIMBRONE M A JR, 1978, TCA (Tissue Culture Association) Manual, V4, P813, DOI 10.1007/BF00918403; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Gory S, 1999, BLOOD, V93, P184, DOI 10.1182/blood.V93.1.184.401a20_184_192; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; Gotsch U, 1997, J CELL SCI, V110, P583; Gulino D, 1998, J BIOL CHEM, V273, P29786, DOI 10.1074/jbc.273.45.29786; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; Hordijk PL, 1999, J CELL SCI, V112, P1915; Huber P, 1996, GENOMICS, V32, P21, DOI 10.1006/geno.1996.0072; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Kouklis P, 2003, J BIOL CHEM, V278, P16230, DOI 10.1074/jbc.M212591200; Kurz DJ, 2003, ARTERIOSCL THROM VAS, V23, P748, DOI 10.1161/01.ATV.0000069624.55424.61; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Liao F, 2002, CANCER RES, V62, P2567; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; Palmer G, 2001, GENE, V279, P49, DOI 10.1016/S0378-1119(01)00747-8; Pasqualini R, 2002, TRENDS MOL MED, V8, P563, DOI 10.1016/S1471-4914(02)02429-2; PASSANITI A, 1992, LAB INVEST, V67, P519; Peterkofsky B, 1999, J CELL BIOCHEM, V73, P408, DOI 10.1002/(SICI)1097-4644(19990601)73:3<408::AID-JCB12>3.3.CO;2-4; Pourtier-Manzanedo A, 2003, ONCOGENE, V22, P1795, DOI 10.1038/sj.onc.1206215; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; Rehli M, 2002, TRENDS IMMUNOL, V23, P375, DOI 10.1016/S1471-4906(02)02259-7; Shi Q, 1999, CIRC RES, V85, P479, DOI 10.1161/01.RES.85.6.479; Shiraishi M, 2002, BIOL CHEM, V383, P893, DOI 10.1515/BC.2002.096; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Wong RK, 1999, AM J PHYSIOL-HEART C, V276, pH736; Zhao JQ, 2000, NEOPLASIA, V2, P531, DOI 10.1038/sj.neo.7900114	54	52	59	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2992	3001		10.1038/sj.onc.1208483	http://dx.doi.org/10.1038/sj.onc.1208483			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735710	Green Submitted, Green Accepted			2022-12-25	WOS:000228649500008
J	Kremenevskaja, N; von Wasielewski, R; Rao, AS; Schofl, C; Andersson, T; Brabant, G				Kremenevskaja, N; von Wasielewski, R; Rao, AS; Schofl, C; Andersson, T; Brabant, G			Wnt-5a has tumor suppressor activity in thyroid carcinoma	ONCOGENE			English	Article						Wnt; beta-catenin; thyroid cancer; tumor suppression	BETA-CATENIN GENE; SIGNALING PATHWAY; ECTOPIC EXPRESSION; OVARIAN CARCINOMAS; FRIZZLED HOMOLOGS; SOMATIC MUTATIONS; EXON 3; PROTEIN; CANCER; CELLS	Stabilization of beta-catenin by inhibition of its phosphorylation is characteristic of an activation of the canonical Wnt/beta-catenin signaling pathway and is associated with various human carcinomas. It contrasts to an as yet incompletely characterized action of an alternative noncanonical Wnt signaling pathway on neoplastic transformation. The aim of the present study was to test the effects of a member of the noncanonical Wnt signaling pathway, Wnt-5a, in primary thyroid carcinomas and in thyroid carcinoma cell lines. Compared to normal tissue Wnt-5a mRNA expression was clearly increased in thyroid carcinomas. Immunohistochemically, a bell-shaped response was observed with low to undetectable levels in normal tissue and in anaplastic tumors whereas differentiated thyroid carcinomas showed strong positive immunostaining for Wnt-5a. Transfection of Wnt-5a in a thyroid tumor cell line FTC-133 was able to reduce proliferation, migration, invasiveness and clonogenicity in these cells. These effects of Wnt-5a are associated with membranous b-catenin translocation and c-myc oncogene suppression and are mediated through an increase in intracellular Ca2+ release, which via CaMKII pathways promotes beta-catenin phosphorylation. Specific inhibition of beta-catenin phosphorylation by W-7, a calmodulin inhibitor, or by KN-93, a CaMKII inhibitor, supports these. findings whereas PKC inhibitors were without effect. This interaction occurs downstream of GSK-3 beta as no Wnt-5a effect was seen on the Ser(9) phosphorylation of GSK-3 beta. Our data are compatible with the hypothesis that Wnt-5a serves as an antagonist to the canonical Wnt- signaling pathway with tumor suppressor activity in differentiated thyroid carcinomas.	Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Pathol, Hannover, Germany; Malmo Univ Hosp, Malmo, Sweden	Hannover Medical School; Hannover Medical School; Lund University; Skane University Hospital	Brabant, G (corresponding author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	brabant.georg@mh-hannover.de		Andersson, Tommy/0000-0003-4032-5769; Annavarapu, Srinivas/0000-0002-0340-935X				Ahumada A, 2002, SCIENCE, V298, P2006, DOI 10.1126/science.1073776; Bui TD, 1997, BIOCHEM BIOPH RES CO, V239, P911, DOI 10.1006/bbrc.1997.7530; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Fukuchi T, 1998, CANCER RES, V58, P3526; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Helmbrecht K, 2001, ENDOCRINOLOGY, V142, P5261, DOI 10.1210/en.142.12.5261; IOZZO RV, 1995, CANCER RES, V55, P3495; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Jeng YM, 2000, CANCER LETT, V152, P45, DOI 10.1016/S0304-3835(99)00433-4; Jonsson M, 2002, CANCER RES, V62, P409; Kitaeva MN, 1997, CANCER RES, V57, P4478; Kobayashi K, 1999, JPN J CANCER RES, V90, P55, DOI 10.1111/j.1349-7006.1999.tb00665.x; Koch A, 1999, CANCER RES, V59, P269; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Meng QH, 2000, BREAST CANCER RES TR, V63, P147, DOI 10.1023/A:1006495824158; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Miyoshi Y, 1998, CANCER RES, V58, P2524; Olson DJ, 1998, TUMOR BIOL, V19, P244, DOI 10.1159/000030014; OLSON DJ, 1994, CELL GROWTH DIFFER, V5, P197; Olson DJ, 1997, CELL GROWTH DIFFER, V8, P417; Palacios J, 1998, CANCER RES, V58, P1344; Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164; Park WS, 1999, CANCER RES, V59, P4257; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Taki M, 2003, CANCER SCI, V94, P593, DOI 10.1111/j.1349-7006.2003.tb01488.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.0.CO;2-#; Wright K, 1999, INT J CANCER, V82, P625, DOI 10.1002/(SICI)1097-0215(19990827)82:5<625::AID-IJC1>3.0.CO;2-2; Yamada T, 2000, CANCER RES, V60, P4761; Zhang T, 2001, CANCER RES, V61, P8664	42	219	244	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2144	2154		10.1038/sj.onc.1208370	http://dx.doi.org/10.1038/sj.onc.1208370			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735754				2022-12-25	WOS:000227857900002
J	Wang, F; Zhu, Y; Huang, Y; McAvoy, S; Johnson, WB; Cheung, TH; Chung, TKH; Lo, KWK; Yim, SF; Yu, MMY; Ngan, HYS; Wong, YF; Smith, DI				Wang, F; Zhu, Y; Huang, Y; McAvoy, S; Johnson, WB; Cheung, TH; Chung, TKH; Lo, KWK; Yim, SF; Yu, MMY; Ngan, HYS; Wong, YF; Smith, DI			Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis	ONCOGENE			English	Article						transcriptional regulation; KLF2; WEE1	TUMOR-SUPPRESSOR GENE; COLORECTAL-CANCER; KINASE INHIBITOR; TYROSINE KINASES; PROSTATE-CANCER; PROTEIN-KINASE; CELL-GROWTH; FACTOR KLF2; G2 ARREST; CHECKPOINT	Human Kruppel-like factor 2 (KLF2) is a Cys(2)/His(2) zinc-finger-containing transcriptional factor, which is involved in multiple cellular pathways. Utilizing gene expression profiling to identify aberrantly expressed genes in ovarian cancer, we found that KLF2 was significantly and specifically downregulated in ovarian tumors. After reintroducing KLF2 into ovarian cancer cell lines, we observed decreased cell growth and increased sensitivity to DNA damage-induced apoptosis. Analysis of genes that could be potential targets of KLF2 revealed that KLF2 negatively regulated WEE1 expression. WEE1 encodes a tyrosine kinase that regulates the G2/M cell cycle transition. Expression of KLF2 markedly repressed the transcription of WEE1 by directly binding to an SPI/CPBP motif located between -252 bp and the start codon of the WEE1 promoter. Both activation and zinc-finger domains of KLF2 were required for this suppression of Wee1 expression. In addition, we demonstrated that Wee1 expression prevents cancer cells from undergoing apoptosis in response to DNA damage; however, this resistance was abolished by coexpression of KLF2, which inhibits WEE1 transcription. Thus, the level of WEE1 is regulated by KLF2 and enhanced KLF2 expression sensitizes cells to DNA damage-induced apoptosis.	Mayo Clin, Coll Med, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN USA; Mayo Clin, Coll Med, Dept Mol Pharmacol, Rochester, MN USA; Mayo Clin, Coll Med, Dept Expt Therapeut, Rochester, MN USA; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China	Mayo Clinic; Mayo Clinic; Mayo Clinic; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong	Smith, DI (corresponding author), Mayo Fdn, Mayo Clin, Ctr Canc, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	smith.david@mayo.edu		Ngan, Hextan Y S/0000-0003-3945-159X; CHUNG, Tony/0000-0002-6362-8546				Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Buckley AF, 2001, NAT IMMUNOL, V2, P698, DOI 10.1038/90633; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; Denkinger DJ, 2001, GENE, V281, P133, DOI 10.1016/S0378-1119(01)00792-2; Dent P, 2001, CLIN CANCER RES, V7, P775; Elder RT, 2001, VIROLOGY, V287, P359, DOI 10.1006/viro.2001.1007; Huddleson JP, 2004, BIOL CHEM, V385, P723, DOI 10.1515/BC.2004.088; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Li J, 2002, RADIAT RES, V157, P322, DOI 10.1667/0033-7587(2002)157[0322:WTTIGP]2.0.CO;2; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132; Tourret J, 1996, Prog Cell Cycle Res, V2, P91; Vax VV, 2003, ENDOCR-RELAT CANCER, V10, P397, DOI 10.1677/erc.0.0100397; Wang YL, 2004, CANCER BIOL THER, V3, P305, DOI 10.4161/cbt.3.3.697; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yuan HD, 2004, J VIROL, V78, P8183, DOI 10.1128/JVI.78.15.8183-8190.2004; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	32	70	71	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3875	3885		10.1038/sj.onc.1208546	http://dx.doi.org/10.1038/sj.onc.1208546			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15735666				2022-12-25	WOS:000229435300003
J	Liu, GY; Kulasingam, V; Alexander, RT; Touret, N; Fong, AM; Patel, DD; Robinson, LA				Liu, GY; Kulasingam, V; Alexander, RT; Touret, N; Fong, AM; Patel, DD; Robinson, LA			Recycling of the membrane-anchored chemokine, CX(3)CL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRACTALKINE RECEPTOR CX(3)CR1; TNF-ALPHA; CLEAVAGE; GLUT4; INSULIN; PH; ADHESION; CELLS; MECHANISMS; ADIPOCYTES	CX(3)CL1 ( fractalkine) plays an important role in inflammation by acting as both chemoattractant and as an adhesion molecule. As for other chemokines, expression of CX(3)CL1 is known to be regulated at the level of transcription and translation. The unique transmembrane structure of CX(3)CL1 raises the possibility of additional functional regulation by altering its abundance at the cell surface. This could be accomplished in principle by changes in traffic between subcellular compartments. To analyze this possibility we examined the subcellular distribution of CX(3)CL1 in human ECV-304 cells stably expressing untagged or green fluorescent protein-tagged forms of the chemokine. CX(3)CL1 was present in two distinct compartments, diffusely on the plasma membrane and in a punctate juxtanuclear compartment. The latter shared some features with, yet was distinct from the conventional endocytic pathway and may represent a specialized recycling subcompartment. Accordingly, surface CX(3)CL1 was found to be in dynamic equilibrium with the juxtanuclear vesicular compartment. Intracellular CX(3)CL1 co-localized with the SNARE (soluble N-ethylmaleimide factor attachment protein receptor) proteins syntaxin-13 and VAMP-3. Cleavage of VAMP-3 by tetanus toxin or impairment of syntaxin-13 function by expression of a dominant-negative allele inhibited the ability of internalized CX(3)CL1 to traffic back to the plasma membrane. These data demonstrate the existence of a dynamic, SNARE-mediated recycling of CX(3)CL1 from the cell surface to and from an endomembrane storage compartment. The intracellular storage depot may serve as a source of the chemokine that could be rapidly mobilized by stimuli.	Hosp Sick Children, Dept Paediat, Inst Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada; Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC 27599 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of North Carolina; University of North Carolina Chapel Hill	Robinson, LA (corresponding author), Hosp Sick Children, Dept Paediat, Inst Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	lisa.robinson@sickkids.ca	Alexander, R. Todd/G-1373-2012	Kulasingam, Vathany/0000-0001-5610-873X				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Brown D, 2003, AM J PHYSIOL-RENAL, V284, pF893, DOI 10.1152/ajprenal.00387.2002; Chao DS, 1999, J CELL BIOL, V144, P869, DOI 10.1083/jcb.144.5.869; Collins RF, 2002, J IMMUNOL, V169, P3250, DOI 10.4049/jimmunol.169.6.3250; Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Feng LL, 1999, KIDNEY INT, V56, P612, DOI 10.1046/j.1523-1755.1999.00604.x; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Fong AM, 2000, J BIOL CHEM, V275, P3781, DOI 10.1074/jbc.275.6.3781; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Gentzsch M, 2004, MOL BIOL CELL, V15, P2684, DOI 10.1091/mbc.E04-03-0176; Govers R, 2004, MOL CELL BIOL, V24, P6456, DOI 10.1128/MCB.24.14.6456-6466.2004; Haller C, 1998, EUR J CELL BIOL, V75, P353, DOI 10.1016/S0171-9335(98)80068-X; Harrison JK, 1999, J LEUKOCYTE BIOL, V66, P937, DOI 10.1002/jlb.66.6.937; Haskell CA, 2001, J CLIN INVEST, V108, P679, DOI 10.1172/JCI12976; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; Huang XH, 2001, AM J PHYSIOL-CELL PH, V281, pC740, DOI 10.1152/ajpcell.2001.281.3.C740; Hughes SE, 1996, EXP CELL RES, V225, P171, DOI 10.1006/excr.1996.0168; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Katsura T, 1996, AM J PHYSIOL-RENAL, V270, pF548, DOI 10.1152/ajprenal.1996.270.3.F548; Kerfoot SM, 2003, EUR J IMMUNOL, V33, P729, DOI 10.1002/eji.200323502; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; Lesnik P, 2003, J CLIN INVEST, V111, P333, DOI 10.1172/JCI200315555; Lidell ME, 2003, J BIOL CHEM, V278, P13944, DOI 10.1074/jbc.M210069200; Lippincott-Schwartz J, 1999, METHOD CELL BIOL, V58, P261; Liu LB, 2003, J BIOL CHEM, V278, P30157, DOI 10.1074/jbc.M301511200; Lucas AD, 2001, AM J PATHOL, V158, P855, DOI 10.1016/S0002-9440(10)64034-5; Ludwig A, 2002, J IMMUNOL, V168, P604, DOI 10.4049/jimmunol.168.2.604; Machen TE, 2003, AM J PHYSIOL-CELL PH, V285, pC205, DOI 10.1152/ajpcell.00008.2003; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; McCaffrey MW, 2001, FEBS LETT, V495, P21, DOI 10.1016/S0014-5793(01)02359-6; Muehlhoefer A, 2000, J IMMUNOL, V164, P3368, DOI 10.4049/jimmunol.164.6.3368; Olson TS, 2002, AM J PHYSIOL-REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001; Pastor-Soler N, 2003, J BIOL CHEM, V278, P49523, DOI 10.1074/jbc.M309543200; Randhawa VK, 2000, MOL BIOL CELL, V11, P2403, DOI 10.1091/mbc.11.7.2403; Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615; Robinson LA, 2000, J IMMUNOL, V165, P6067, DOI 10.4049/jimmunol.165.11.6067; Rudich A, 2003, ACTA PHYSIOL SCAND, V178, P297, DOI 10.1046/j.1365-201X.2003.01163.x; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Sheff D, 2002, J CELL BIOL, V156, P797, DOI 10.1083/jcb.20111048; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; Su T, 1999, FEBS LETT, V453, P391, DOI 10.1016/S0014-5793(99)00763-2; Sun TX, 2002, AM J PHYSIOL-RENAL, V282, pF998, DOI 10.1152/ajprenal.00257.2001; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; TAKAHASI K, 1992, IN VITRO CELL DEV-AN, V28A, P380; Terebiznik MR, 2002, NAT CELL BIOL, V4, P766, DOI 10.1038/ncb854; Touret N, 2003, J BIOL CHEM, V278, P25548, DOI 10.1074/jbc.M212374200; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Umehara H, 2001, TRENDS IMMUNOL, V22, P602, DOI 10.1016/S1471-4906(01)02051-8; van Kerkhof P, 2001, J BIOL CHEM, V276, P3778, DOI 10.1074/jbc.M007326200; Volk R, 1999, J BIOL CHEM, V274, P24417, DOI 10.1074/jbc.274.34.24417; Ward ES, 2005, MOL BIOL CELL, V16, P2028, DOI 10.1091/mbc.E04-08-0735; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200; Yao XB, 2003, ANNU REV PHYSIOL, V65, P103, DOI 10.1146/annurev.physiol.65.072302.114200; YI Z, 1993, J BIOL CHEM, V268, P5615; Yoshikawa M, 2004, FEBS LETT, V561, P105, DOI 10.1016/S0014-5793(04)00132-2; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071; Zhang XM, 2004, J BIOL CHEM, V279, P43027, DOI 10.1074/jbc.M402264200	63	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19858	19866		10.1074/jbc.M413073200	http://dx.doi.org/10.1074/jbc.M413073200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774461	Green Published, hybrid			2022-12-25	WOS:000229113700054
J	Nagaike, T; Suzuki, T; Katoh, T; Ueda, T				Nagaike, T; Suzuki, T; Katoh, T; Ueda, T			Human mitochondrial mRNAs are stabilized with polyadenylation regulated by mitochondria-specific poly(A) polymerase and polynucleotide phosphorylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; DEVELOPMENTAL REGULATION; DEGRADATION; SEQUENCE; IDENTIFICATION; TRANSLATION; SUBUNIT-8; CHLOROPLAST; TRANSCRIPTS; EXONUCLEASE	Mammalian mitochondrial (mt) mRNAs have short poly(A) tails at their 3' termini that are post-transcriptionally synthesized by mt poly(A) polymerase (PAP). The polyadenylation of mt mRNAs is known to be a key process needed to create UAA stop codons that are not encoded in mtDNA. In some cases, polyadenylation is required for the tRNA maturation by editing of its 3' terminus. However, little is known about the functional roles the poly(A) tail of mt mRNAs plays in mt translation and RNA turnover. Here we show human mt PAP (hmtPAP) and human polynucleotide phosphorylase (hPNPase) control poly(A) synthesis in human mitochondria. Partial inactivation of hmtPAP by RNA interference using small interfering RNA in HeLa cells resulted in shortened poly(A) tails and decreased steady state levels of some mt mRNAs as well as their translational products. Moreover, knocking down hmtPAP generated markedly defective mt membrane potentials and reduced oxygen consumption. In contrast, knocking down hPNPase showed significantly extended poly(A) tails of mt mRNAs. These results demonstrate that the poly(A) length of human mt mRNAs is controlled by polyadenylation by hmtPAP and deadenylation by hPNPase, and polyadenylation is required for the stability of mt mRNAs.	Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Kashiwa, Chiba 2770882, Japan	University of Tokyo; University of Tokyo	Suzuki, T (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	ts@chembio.t.u-tokyo.ac.jp	Ueda, Takuya/K-5217-2014; Suzuki, Tsutomu/J-1776-2015	Ueda, Takuya/0000-0002-7760-8271; Suzuki, Tsutomu/0000-0002-9731-1731; Katoh, Takayuki/0000-0001-6550-6203				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BHAT GJ, 1992, MOL BIOCHEM PARASIT, V52, P231, DOI 10.1016/0166-6851(92)90055-O; BRADLEY P, 2003, MICROBIOLOGY, V149, P2173; BUTOW RA, 1989, GENOME, V31, P757, DOI 10.1139/g89-134; CAMOUGRAND N, 1995, J MOL BIOL, V247, P588, DOI 10.1006/jmbi.1995.0165; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; Chekanova JA, 2003, RNA, V9, P1476, DOI 10.1261/rna.5128903; Chrzanowska-Lightowlers ZMA, 2004, BIOCHEM J, V377, P725, DOI 10.1042/bj20031556; DIECKMANN CL, 1984, J BIOL CHEM, V259, P4722; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; Ellis TP, 2004, J BIOL CHEM, V279, P15728, DOI 10.1074/jbc.M314162200; Gagliardi D, 2004, TRENDS GENET, V20, P260, DOI 10.1016/j.tig.2004.04.006; Gagliardi D, 1999, EMBO J, V18, P3757, DOI 10.1093/emboj/18.13.3757; GROUDINSKY O, 1993, MOL GEN GENET, V240, P419, DOI 10.1007/BF00280396; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; Kadaba S, 2004, GENE DEV, V18, P1227, DOI 10.1101/gad.1183804; KATOH T, 2003, NUCL ACIDS RES S, V3, P249; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kuai L, 2004, P NATL ACAD SCI USA, V101, P8581, DOI 10.1073/pnas.0402888101; Kudla J, 1996, EMBO J, V15, P7137, DOI 10.1002/j.1460-2075.1996.tb01105.x; Leszczyniecka M, 2002, P NATL ACAD SCI USA, V99, P16636, DOI 10.1073/pnas.252643699; MANON S, 1989, BIOCHIM BIOPHYS ACTA, V985, P127, DOI 10.1016/0005-2736(89)90356-8; MANTHEY GM, 1995, EMBO J, V14, P4031, DOI 10.1002/j.1460-2075.1995.tb00074.x; Martin G, 2004, RNA, V10, P899, DOI 10.1261/rna.5242304; Mohanty BK, 2000, P NATL ACAD SCI USA, V97, P11966, DOI 10.1073/pnas.220295997; Nagaike T, 2001, J BIOL CHEM, V276, P40041, DOI 10.1074/jbc.M106202200; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; PELISSIER P, 1995, CURR GENET, V27, P409, DOI 10.1007/BF00311209; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; Perrin R, 2004, J BIOL CHEM, V279, P25440, DOI 10.1074/jbc.M401182200; Piwowarski J, 2003, J MOL BIOL, V329, P853, DOI 10.1016/S0022-2836(03)00528-X; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; READ LK, 1994, MOL BIOCHEM PARASIT, V68, P297, DOI 10.1016/0166-6851(94)90174-0; READ LK, 1992, J BIOL CHEM, V267, P1123; Read RL, 2002, P NATL ACAD SCI USA, V99, P12079, DOI 10.1073/pnas.192467799; Rott R, 2003, J BIOL CHEM, V278, P15771, DOI 10.1074/jbc.M211571200; Ryan CM, 2003, J BIOL CHEM, V278, P32753, DOI 10.1074/jbc.M303552200; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Saitoh S, 2002, CELL, V109, P563, DOI 10.1016/S0092-8674(02)00753-5; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; Temperley RJ, 2003, HUM MOL GENET, V12, P2341, DOI 10.1093/hmg/ddg238; Tomecki R, 2004, NUCLEIC ACIDS RES, V32, P6001, DOI 10.1093/nar/gkh923; Tomita K, 1996, NUCLEIC ACIDS RES, V24, P4987, DOI 10.1093/nar/24.24.4987; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Umeda N, 2005, J BIOL CHEM, V280, P1613, DOI 10.1074/jbc.M409306200; Walter M, 2002, EMBO J, V21, P6905, DOI 10.1093/emboj/cdf686; Wang LT, 2002, NATURE, V419, P312, DOI 10.1038/nature01039; Yehudai-Resheff S, 2001, MOL CELL BIOL, V21, P5408, DOI 10.1128/MCB.21.16.5408-5416.2001; Yokobori S, 1997, J MOL BIOL, V265, P95, DOI 10.1006/jmbi.1996.0728	50	154	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19721	19727		10.1074/jbc.M500804200	http://dx.doi.org/10.1074/jbc.M500804200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769737	hybrid			2022-12-25	WOS:000229113700038
J	Zhang, W; Zheng, SS; Storz, P; Min, W				Zhang, W; Zheng, SS; Storz, P; Min, W			Protein kinase D specifically mediates apoptosis signal-regulating kinase 1-JNK signaling induced by H2O2 but not tumor necrosis factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION LOOP PHOSPHORYLATION; NF-KAPPA-B; INDUCED ASK1 ACTIVATION; D-DEPENDENT ACTIVATION; OXIDATIVE STRESS; CELL-DEATH; ASK1-MEDIATED APOPTOSIS; INDEPENDENT MANNER; ENDOTHELIAL-CELLS; INHIBITOR 14-3-3	Although both tumor necrosis factor (TNF) and H2O2 induce activation of c-Jun N-terminal kinase (JNK) kinase cascades, it is not known whether they utilize distinct intracellular signaling pathways. In this study, we first examined a variety of pharmacological inhibitors on TNF and H2O2-induced JNK activation. Go6983 or staurosporine, which inhibits protein kinase C isoforms had no effects on TNF or H2O2-induced JNK activation. However, Go6976 and calphostin, which can inhibit protein kinase C as well as protein kinase D (PKD), blocked H2O2- but not TNF-induced JNK activation, suggesting that PKD may be specifically involved in H2O2-induced JNK activation. Consistently, H2O2, but not TNF, induced phosphorylation of PKD and translocation of PKD from endothelial cell membrane to cytoplasm where it associates with the JNK upstream activator, apoptosis signal-regulating kinase 1 (ASK1). The association is mediated through the pleckstrin homology domain of PKD and the C-terminal domain of ASK1. Inhibition of PKD by Go6976 or by small interfering RNA of PKD blocked H2O2-induced ASK1-JNK activation and endothelial cell apoptosis. Interestingly, H2O2 induced 14-3-3 binding to PKD via the phospho-Ser-205/208 and phospho-Ser-219/223 and H2O2-induced 14-3-3 binding of PKD was specifically blocked by Go6976 but not by Go6983. More significantly, the 14-3-3-binding defective forms of PKD failed to associate with ASK1 and to activate JNK signaling, highlighting the importance of 143-3 binding of PKD in H2O2-induced activation of ASK1-JNK cascade. Thus, our data have identified PKD as a critical mediator in H2O2- but not TNF-induced ASK1-JNK signaling.	Yale Univ, Sch Med, Dept Pathol,Boyer Ctr Mol Med, Interdisciplinary Program Vasc Biol & Transplanta, New Haven, CT 06510 USA; Zhejiang Univ, Coll Med, Affiliated Hosp 1,Minist Hlth China, Key Lab Combined Multiorgan Transplantat, Hangzhou 310003, Peoples R China; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA	Yale University; Zhejiang University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Min, W (corresponding author), Yale Univ, Sch Med, Dept Pathol,Boyer Ctr Mol Med, Interdisciplinary Program Vasc Biol & Transplanta, BCMM 454,295 Congress Ave, New Haven, CT 06510 USA.	wang.min@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065978] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01HL65978-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADLEY JR, 1993, AM J PATHOL, V142, P1598; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Song JJ, 2003, J BIOL CHEM, V278, P47245, DOI 10.1074/jbc.M213201200; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Storz P, 2004, MOL PHARMACOL, V66, P870, DOI 10.1124/mol.104.000687; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Takeda K, 2004, EMBO REP, V5, P161, DOI 10.1038/sj.embor.7400072; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 2004, J BIOL CHEM, V279, P27482, DOI 10.1074/jbc.M402875200; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790	33	80	86	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19036	19044		10.1074/jbc.M414674200	http://dx.doi.org/10.1074/jbc.M414674200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755722	hybrid			2022-12-25	WOS:000228932300059
J	Biswal, BK; Cherney, MM; Wang, MT; Chan, L; Yannopoulos, CG; Bilimoria, D; Nicolas, O; Bedard, J; James, MNG				Biswal, BK; Cherney, MM; Wang, MT; Chan, L; Yannopoulos, CG; Bilimoria, D; Nicolas, O; Bedard, J; James, MNG			Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HCVNS5B POLYMERASE; THIOPHENE-2-CARBOXYLIC ACIDS; REVERSE-TRANSCRIPTASE; POTENT INHIBITORS; IDENTIFICATION; SITE; PROGRAM; REPLICATION; DISCOVERY; COMPLEX	Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus (HCV) from two crystal forms have been determined. Similar to the three-dimensional structures of HCV polymerase genotype 1b and other known polymerases, the structures of the HCV polymerase genotype 2a in both crystal forms can be depicted in the classical right-hand arrangement with fingers, palm, and thumb domains. The main structural differences between the molecules in the two crystal forms lie at the interface of the fingers and thumb domains. The relative orientation of the thumb domain with respect to the fingers and palm domains and the beta-flap region is altered. Structural analysis reveals that the NS5B polymerase in crystal form I adopts a "closed" conformation that is believed to be the active form, whereas NS5B in crystal form II adopts an "open" conformation and is thus in the inactive form. In addition, we have determined the structures of two NS5B polymerase/ non-nucleoside inhibitor complexes. Both inhibitors bind at a common binding site, which is nearly 35 angstrom away from the polymerase active site and is located in the thumb domain. The binding pocket is predominantly hydrophobic in nature, and the enzyme inhibitor complexes are stabilized by hydrogen bonding and van der Waals interactions. Inhibitors can only be soaked in crystal form I and not in form II; examination of the enzyme-inhibitor complex reveals that the enzyme has undergone a dramatic conformational change from the form I ( active) complex to the form II ( inactive).	Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada; ViroChem Pharma Inc, Laval, PQ H7V 4A7, Canada	University of Alberta	James, MNG (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada.	Michael.james@ualberta.ca	Wang, Meitian/D-3208-2013	Biswal, Bichitra/0000-0002-5927-3244; Wang, Meitian/0000-0002-5340-3036				Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Alaoui-Ismaili MH, 2000, J HUMAN VIROL, V3, P306; Bartenschlager R, 1997, INTERVIROLOGY, V40, P378, DOI 10.1159/000150570; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Chan L, 2004, BIOORG MED CHEM LETT, V14, P793, DOI 10.1016/j.bmcl.2003.10.067; Chan L, 2004, BIOORG MED CHEM LETT, V14, P797, DOI 10.1016/j.bmcl.2003.10.068; Chan L, 2003, J MED CHEM, V46, P1283, DOI 10.1021/jm0340400; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; DeLano WL, 2002, PYMOL USERS MANUAL; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Hagedorn CH, 2000, CURR TOP MICROBIOL, V242, P225; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Labonte P, 2002, J BIOL CHEM, V277, P38838, DOI 10.1074/jbc.M204657200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lesburg C A, 2000, Curr Opin Investig Drugs, V1, P289; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Love RA, 2003, J VIROL, V77, P7575, DOI 10.1128/JVI.77.13.7575-7581.2003; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; O'Farrell D, 2003, J MOL BIOL, V326, P1025, DOI 10.1016/S0022-2836(02)01439-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RICE CM, 1996, FIELDS VIROLOGY, V1, P931; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Wang MT, 2003, J BIOL CHEM, V278, P9489, DOI 10.1074/jbc.M209397200	35	170	185	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18202	18210		10.1074/jbc.M413410200	http://dx.doi.org/10.1074/jbc.M413410200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746101	hybrid			2022-12-25	WOS:000228807200078
J	He, BA; Reguart, N; You, L; Mazieres, J; Xu, ZD; Lee, AY; Mikami, I; McCormick, F; Jablons, DM				He, BA; Reguart, N; You, L; Mazieres, J; Xu, ZD; Lee, AY; Mikami, I; McCormick, F; Jablons, DM			Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations	ONCOGENE			English	Article						human; Wnt-1; colorectal cancer; apoptosis	HUMAN LUNG-CANCER; BETA-CATENIN; MONOCLONAL-ANTIBODY; COLON-CARCINOMA; EXPRESSION; DOCETAXEL; PATHWAY; GENES; HYPERMETHYLATION; ACTIVATION	Aberrant Wnt signaling, mainly through mutations of APC and in some cases of CTNNB1 or AXIN2, has been found in the majority of colorectal cancers. Recently, frequent promoter hypermethylation was identified to cause silencing of the secreted frizzled-related protein ( sFRP) family in colorectal cancer. Restoration of sFRP in colorectal cancer cells attenuates Wnt signaling even in the presence of downstream mutations. Here we show that Wnt inhibitory factor-1 (WIF-1), a different secreted antagonist of Wnt signaling, is also silenced by promoter hypermethylation in colorectal cancer cells. Restoration of WIF-1 function, Wnt-1 siRNA, or a monoclonal anti-Wnt-1 antibody that we developed attenuates Wnt-1 signaling and induces significant apoptosis in these cells containing downstream mutations and expressing Wnt-1. In addition, this monoclonal anti-Wnt-1 antibody showed synergistic effects with docetaxel in treating these colorectal cancer cells and great efficacy in treating primary colorectal cancer cultures freshly prepared from patients. Therefore, our data support the hypothesis that constitutive Wnt signaling may be required to complement downstream mutations in the evolution of colorectal cancer. Furthermore, our results suggest that blockade of the Wnt signal may have a therapeutic role in the treatment of colorectal cancer.	Univ Calif San Francisco, Ctr Comprehens Canc, Dept Surg, Thorac Oncol Lab, San Francisco, CA 94115 USA; Hosp Germans Trias & Pujol, Inst Catala Oncol, Med Oncol Serv, Barcelona, Spain; Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, F-31052 Toulouse, France	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Catalan Institute of Oncology; Hospital Germans Trias i Pujol; UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Jablons, DM (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Dept Surg, Thorac Oncol Lab, 1600 Divisadero St,C322C,Box 1674, San Francisco, CA 94115 USA.	jablonsd@surgery.ucsf.edu	MAZIERES, JULIEN/M-3986-2014	MAZIERES, JULIEN/0000-0002-5921-7613	NCI NIH HHS [R01 CA093708-01A3, R01 CA093708] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093708] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISSERY MC, 1991, CANCER RES, V51, P4845; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Ciani L, 2004, J CELL BIOL, V164, P243, DOI 10.1083/jcb.200309096; Clark TB, 1998, CANCER INVEST, V16, P314, DOI 10.3109/07357909809084650; Dimitriadis A, 2001, CANCER LETT, V166, P185, DOI 10.1016/S0304-3835(01)00428-1; Dunne AL, 2004, ONCOL RES, V14, P447, DOI 10.3727/0965040041791455; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; He B, 2004, NEOPLASIA, V6, P7, DOI 10.1016/S1476-5586(04)80048-4; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Heighway J, 2002, ONCOGENE, V21, P7749, DOI 10.1038/sj.onc.1205979; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Karantanis E, 1994, Eur J Surg Oncol, V20, P653; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; STERNBERG CN, 1994, BRIT J CANCER, V70, P376, DOI 10.1038/bjc.1994.309; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227	30	180	192	0	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3054	3058		10.1038/sj.onc.1208511	http://dx.doi.org/10.1038/sj.onc.1208511			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735684				2022-12-25	WOS:000228649500015
J	Fang, J; Xia, C; Cao, ZX; Zheng, JZ; Reed, E; Jiang, BH				Fang, J; Xia, C; Cao, ZX; Zheng, JZ; Reed, E; Jiang, BH			Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways	FASEB JOURNAL			English	Article						vascular endothelial growth factor; ovarian cancer; hypoxia inducible factor 1; tumor growth; HUVEC	ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR; FACTOR 1-ALPHA HIF-1-ALPHA; OVARIAN-CANCER; TUMOR ANGIOGENESIS; DEPENDENT PHOSPHORYLATION; GENE-TRANSCRIPTION; KINASE ACTIVATION; PROTEIN-KINASE; MAP KINASE	Apigenin is a nontoxic dietary flavonoid that has been shown to possess anti-tumor properties and therefore poses special interest for the development of a novel chemopreventive and/or chemotherapeutic agent for cancer. Ovarian cancer is one of the most common causes of cancer death among women. Here we demonstrate that apigenin inhibits expression of vascular endothelial growth factor (VEGF) in human ovarian cancer cells. VEGF plays an important role in tumor angiogenesis and growth. We found that apigenin inhibited VEGF expression at the transcriptional level through expression of hypoxia-inducible factor 1 alpha (HIF-1 alpha). Apigenin inhibited expression of HIF-1 alpha and VEGF via the PI3K/AK-T/p70S6K1 and HDM2/ p53 pathways. Apigenin inhibited tube formation in vitro by endothelial cells. These findings reveal a novel role of apigenin in inhibiting HIF-1 and VEGF expression that is important for tumor angiogenesis and growth, identifying new signaling molecules that mediate this regulation.	W Virginia Univ, Dept Microbiol Immunol & Cell Biol, MBR Canc Ctr, Morgantown, WV 26506 USA	West Virginia University	Jiang, BH (corresponding author), W Virginia Univ, Dept Microbiol Immunol & Cell Biol, MBR Canc Ctr, Morgantown, WV 26506 USA.	bhjiang@hsc.wvu.edu		Jiang, Bing-Hua/0000-0003-4526-2031	NCRR NIH HHS [RR16440] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016440] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Angelov L, 1999, CANCER RES, V59, P5536; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Blancher C, 2001, CANCER RES, V61, P7349; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; BOONE CW, 1990, CANCER RES, V50, P2; Borgstrom P, 1996, CANCER RES, V56, P4032; Brekken RA, 2000, CANCER RES, V60, P5117; Byrne AT, 2003, CLIN CANCER RES, V9, P5721; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Duthie G, 2000, CURR OPIN LIPIDOL, V11, P43, DOI 10.1097/00041433-200002000-00007; Fang J, 2004, MOL PHARMACOL, V66, P178, DOI 10.1124/mol.66.1.178; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fotsis T, 1997, CANCER RES, V57, P2916; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Gupta S, 2001, BIOCHEM BIOPH RES CO, V287, P914, DOI 10.1006/bbrc.2001.5672; Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Knowles HJ, 2003, CANCER RES, V63, P1764; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PEREZ RP, 1991, SEMIN ONCOL, V18, P186; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang LW, 2000, ADV ENG MATER, V2, P110, DOI 10.1002/(SICI)1527-2648(200003)2:3<110::AID-ADEM110>3.0.CO;2-4; Wong C, 2003, GYNECOL ONCOL, V91, P513, DOI 10.1016/j.ygyno.2003.08.022; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; Yin F, 2001, ANTICANCER RES, V21, P413; Zhang L, 2003, CANCER RES, V63, P4225; Zhang L, 2002, AM J PATHOL, V161, P2295, DOI 10.1016/S0002-9440(10)64505-1; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	62	242	257	3	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					342	353		10.1096/fj.04-2175com	http://dx.doi.org/10.1096/fj.04-2175com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746177				2022-12-25	WOS:000227901300034
J	Kim, NH; Choi, JK; Jeong, BH; Kim, JI; Kwon, MS; Carp, RI; Kim, YS				Kim, NH; Choi, JK; Jeong, BH; Kim, JI; Kwon, MS; Carp, RI; Kim, YS			Effect of transition metals (Mn, Cu, Fe) and deoxycholic acid (DA) on the conversion of PrPC to PrPres	FASEB JOURNAL			English	Article						protein misfolding cyclic amplification; manganese; metal-catalyzed oxidation	CELLULAR PRION PROTEIN; SCRAPIE-INFECTED MICE; METHIONINE RESIDUES; OXIDATIVE STRESS; COPPER; AGGREGATION; RECOMBINANT; DISEASE; ACCUMULATION; CONFORMATION	The PMCA (protein misfolding cyclic amplification) technique has been shown to drive the amplification of misfolded prion protein by PrPSc seeds during several cycles of incubation-sonication. Here, we report that cyclic amplification of normal hamster brain homogenates treated with a number of transition metals (manganese [Mn], copper [Cu], and iron [Fe]) leads to conversion of PrPc into protease-resistant PrPres. The efficiency of PrPres formation and the glycoforms induced by Mn were different from those obtained by Cu and Fe. Previous results have shown higher Mn and lower Cu levels in the affinity-purified PrPSc from the brain of prion diseases compared with normal hamster brain homogenates. We focused on Mn because we observed higher levels of Mn in whole brain, mitochondria, and scrapie-associated fibril-enriched fractions from the brains of animals with prion disease. In C the presence of minute quantities of Mn-induced PrPres template with a large amount of PrPC, PrPres amplification is observed. A metal chelater, EDTA reverses the effect of Mn on PrPres amplification, suggesting that Mn may play a role in the formation of PrPres. It has been proposed that metal-catalyzed oxidation of PrP leads to the oxidation of amino acids and extensive aggregation of oxidized PrP. Carboxyl acids such as deoxycholic acid (DA) are oxidized molecules produced by 3' oxidation pathway. In in vitro studies, the potent effect of Mn on PrPres amplification is augmented by DA in a dose-dependent manner. On the basis of the evidence of the elevated Mn levels in scrapie-associated fibril (SAF)-enriched preparations from the brains of animals with prion disease, Mn-loaded PrP and oxidized molecules such as carboxyl acids may contribute to the formation of the scrapie isoform of PrP in prion diseases.	Hallym Univ, Coll Med, Ilsong Inst Life Sci, Anyang 431060, Kyounggi Do, South Korea; Kangwon Natl Univ, Dept Vet Med, Chunchon, Kangwon Do, South Korea; New York State Inst Basic Res Dev Disabil, Staten Isl, NY 10314 USA	Hallym University; Kangwon National University; Institute for Basic Research in Developmental Disabilities	Kim, YS (corresponding author), Hallym Univ, Coll Med, Ilsong Inst Life Sci, Ilsong Bldg,1605-4 Gwanyang Dong, Anyang 431060, Kyounggi Do, South Korea.	yskim@hallym.ac.kr	Jeong, Byung-Hoon/AAA-3425-2020	Jeong, Byung-Hoon/0000-0002-4525-9994				Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; Borlongan CV, 1997, NEUROSCI BIOBEHAV R, V21, P289, DOI 10.1016/S0149-7634(96)00027-9; Brown DR, 2000, EMBO J, V19, P1180, DOI 10.1093/emboj/19.6.1180; Cardinale A, 2005, J BIOL CHEM, V280, P685, DOI 10.1074/jbc.M407360200; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; DOI S, 1988, J GEN VIROL, V69, P955, DOI 10.1099/0022-1317-69-4-955; Giese A, 2004, BIOCHEM BIOPH RES CO, V320, P1240, DOI 10.1016/j.bbrc.2004.06.075; Gill AC, 2000, EMBO J, V19, P5324, DOI 10.1093/emboj/19.20.5324; Jobling MF, 2001, BIOCHEMISTRY-US, V40, P8073, DOI 10.1021/bi0029088; Kim BH, 2004, MOL BRAIN RES, V124, P40, DOI 10.1016/j.molbrainres.2004.02.005; Kim JI, 2001, ANN NY ACAD SCI, V928, P182, DOI 10.1111/j.1749-6632.2001.tb05648.x; Kim NH, 2000, BRAIN RES, V884, P98, DOI 10.1016/S0006-8993(00)02907-3; Kourie JI, 2001, CROAT MED J, V42, P359; Lehmann S, 2002, CURR OPIN CHEM BIOL, V6, P187, DOI 10.1016/S1367-5931(02)00295-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maji SK, 2002, TETRAHEDRON, V58, P8695, DOI 10.1016/S0040-4020(02)01093-1; McKenzie D, 1998, J BIOL CHEM, V273, P25545, DOI 10.1074/jbc.273.40.25545; Milatovic D, 2002, BRAIN RES, V957, P330, DOI 10.1016/S0006-8993(02)03669-7; MORITA A, 1994, BIOL TRACE ELEM RES, V42, P165, DOI 10.1007/BF02785387; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Quaglio E, 2001, J BIOL CHEM, V276, P11432, DOI 10.1074/jbc.M009666200; Requena JR, 2004, ARCH BIOCHEM BIOPHYS, V432, P188, DOI 10.1016/j.abb.2004.09.012; Requena JR, 2001, P NATL ACAD SCI USA, V98, P7170, DOI 10.1073/pnas.121190898; Ruiz FH, 2000, BIOCHEM BIOPH RES CO, V269, P491, DOI 10.1006/bbrc.2000.2270; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Satheeshkumar KS, 2002, CHEM COMMUN, P2244, DOI 10.1039/b206886a; Shaked GM, 2002, ANN NEUROL, V52, P416, DOI 10.1002/ana.10298; Shiraishi N, 2002, FEBS LETT, V511, P118, DOI 10.1016/S0014-5793(01)03324-5; Soto C, 2001, TRENDS MOL MED, V7, P109, DOI 10.1016/S1471-4914(01)01931-1; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Washo-Stultz D, 2002, CANCER LETT, V177, P129, DOI 10.1016/S0304-3835(01)00786-8; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0; Wong BS, 2000, BIOCHEM BIOPH RES CO, V276, P1217, DOI 10.1006/bbrc.2000.3604; Wong BS, 2000, BIOCHEM BIOPH RES CO, V275, P249, DOI 10.1006/bbrc.2000.3158; Wong BS, 1999, BIOCHEM BIOPH RES CO, V259, P352, DOI 10.1006/bbrc.1999.0802; Wong BS, 2000, BIOCHEM BIOPH RES CO, V269, P726, DOI 10.1006/bbrc.2000.2355; Wong BS, 2001, J NEUROCHEM, V79, P689, DOI 10.1046/j.1471-4159.2001.00625.x; Wong BS, 2001, J NEUROCHEM, V78, P1400, DOI 10.1046/j.1471-4159.2001.00522.x; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Xiong LW, 2001, J NEUROCHEM, V79, P669, DOI 10.1046/j.1471-4159.2001.00606.x	43	61	65	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					783	+		10.1096/fj.04-2117fje	http://dx.doi.org/10.1096/fj.04-2117fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15758042				2022-12-25	WOS:000227901300022
J	Thangam, EB; Venkatesha, RT; Zaidi, AK; Jordan-Sciutto, KL; Goncharov, DA; Kryrnskaya, VP; Amrani, Y; Panettieri, RA; Ali, H				Thangam, EB; Venkatesha, RT; Zaidi, AK; Jordan-Sciutto, KL; Goncharov, DA; Kryrnskaya, VP; Amrani, Y; Panettieri, RA; Ali, H			Airway smooth muscle cells enhance C3a-induced mast cell degranulation following cell-cell contact	FASEB JOURNAL			English	Article						complement; asthma; chemokine; cytokine	FC-EPSILON-RI; SIGNAL-REGULATED KINASE; AFFINITY IGE RECEPTOR; CHEMOKINE PRODUCTION; C3A ANAPHYLATOXIN; HUMAN-LEUKOCYTES; UP-REGULATION; C5A RECEPTOR; CUTTING EDGE; ACTIVATION	Growing evidence suggests that anaphylatoxins, C3a and C5a, play important roles in innate immunity and may also participate in the pathogenesis of asthma. Previous studies with animal models and immunohistochemistry analysis of lung tissue indicated that anaphylatoxins may regulate airway hyperresponsiveness (AHR) in asthma via the activation of their cell surface G protein-coupled receptors (C3aR and C5aR) in airway smooth muscle (ASM) cells. Using RTPCR, flow cytometry, and confocal microscopy, we made the surprising observation that while C3aR and C5aR were expressed in human mast cells, they were not present in cultured primary human or murine ASM cells. Furthermore, we could not detect C3aR in smooth muscle-positive cells of human trachea or bronchus. Interestingly, incubation of human mast cells with ASM cells, but not its culture supernatant, caused a significant enhancement of C3a-induced mast cell degranulation. Although stem cell factor (SCF) and its receptor c-kit are constitutively expressed on ASM cells and mast cells, respectively, neutralizing antibodies to SCF and c-kit failed to inhibit ASM cell-mediated enhancement of mast cell degranulation. However, dexamethasone-treated ASM cells were normal for cell surface SCF expression but were significantly less effective in enhancing C3a-induced mast cell degranulation when compared with untreated cells. These findings suggest that cell-cell interaction between ASM cells and mast cells, via a SCF-c-kit-independent but dexamethasone-sensitive mechanism, enhances C3a-induced mast cell degranulation, which likely regulates ASM function, thus contributing to the pathogenesis of asthma.	Univ Penn, Sch Dent Med, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Ali, H (corresponding author), Univ Penn, Sch Dent Med, Dept Pathol, 240 S 40th St, Philadelphia, PA 19104 USA.	ali@path.dental.upenn.edu	Amrani, Yassine/Q-6323-2019; Amrani, Yassine/A-1826-2013; panettieri, reynold/AAG-9485-2019; Jordan-Sciutto, Kelly L/A-1046-2007	Amrani, Yassine/0000-0002-7042-6926; 	NHLBI NIH HHS [HL67663, R01 HL063372, P50 HL067663, R01 HL055301, P01 HL067663, 2R01-HL64063, 1R01-HL63372, 2R01-HL-55301, R01 HL064063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064063, P01HL067663, P50HL067663, R01HL055301, R01HL063372] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahamed J, 2001, J IMMUNOL, V167, P3559, DOI 10.4049/jimmunol.167.7.3559; Ali H, 2000, J IMMUNOL, V165, P7215, DOI 10.4049/jimmunol.165.12.7215; ALI H, 1994, J BIOL CHEM, V269, P24557; Amrani Y, 2003, INT J BIOCHEM CELL B, V35, P272, DOI 10.1016/S1357-2725(02)00259-5; Amrani Y, 1999, J IMMUNOL, V163, P2128; Amrani Y, 2000, MOL PHARMACOL, V58, P237, DOI 10.1124/mol.58.1.237; Andrade MVM, 2004, J IMMUNOL, V172, P7254, DOI 10.4049/jimmunol.172.12.7254; Bachar O, 2004, EUR J IMMUNOL, V34, P1196, DOI 10.1002/eji.200324569; Bautsch W, 2000, J IMMUNOL, V165, P5401, DOI 10.4049/jimmunol.165.10.5401; Berger P, 2003, FASEB J, V17, P2139, DOI 10.1096/fj.03-0041fje; BISCHOFF SC, 1990, P NATL ACAD SCI USA, V87, P6813, DOI 10.1073/pnas.87.17.6813; Boels K, 2003, BRIT J PHARMACOL, V140, P932, DOI 10.1038/sj.bjp.0705521; Brightling CE, 2003, CLIN EXP ALLERGY, V33, P1711, DOI 10.1111/j.1365-2222.2003.01827.x; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Choi WS, 2002, J IMMUNOL, V168, P5682, DOI 10.4049/jimmunol.168.11.5682; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; ELLATI SG, 1994, J INVEST DERMATOL, V102, P803, DOI 10.1111/1523-1747.ep12378589; Fayyazi A, 1999, AM J PATHOL, V154, P495, DOI 10.1016/S0002-9440(10)65295-9; Fayyazi A, 2000, IMMUNOLOGY, V99, P38, DOI 10.1046/j.1365-2567.2000.00911.x; Freund V, 2002, EUR RESPIR J, V20, P458, DOI 10.1183/09031936.02.00269202; GALLI SJ, 1993, AM J PATHOL, V142, P965; Gerard NP, 2002, CURR OPIN IMMUNOL, V14, P705, DOI 10.1016/S0952-7915(02)00410-7; GLOVSKY MM, 1979, J CLIN INVEST, V64, P804, DOI 10.1172/JCI109527; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Gonzalez-Espinosa C, 2003, J EXP MED, V197, P1453, DOI 10.1084/jem.20021806; Hartmann K, 1997, BLOOD, V89, P2863, DOI 10.1182/blood.V89.8.2863; Hawlisch H, 2004, MOL IMMUNOL, V41, P123, DOI 10.1016/j.molimm.2004.03.019; Henson P, 2000, NAT IMMUNOL, V1, P190, DOI 10.1038/79723; Howarth Peter H, 2004, J Allergy Clin Immunol, V114, pS32, DOI 10.1016/j.jaci.2004.04.041; Huang CD, 2003, AM J RESP CELL MOL, V28, P330, DOI 10.1165/rcmb.2002-0040OC; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Hundley TR, 2001, J IMMUNOL, V167, P1629, DOI 10.4049/jimmunol.167.3.1629; Ito A, 2003, BLOOD, V101, P2601, DOI 10.1182/blood-2002-07-2265; Kacani L, 2001, J IMMUNOL, V166, P3410, DOI 10.4049/jimmunol.166.5.3410; Kassel O, 1999, EUR RESPIR J, V13, P951, DOI 10.1034/j.1399-3003.1999.13e04.x; Kassel O, 1998, MOL PHARMACOL, V54, P1073, DOI 10.1124/mol.54.6.1073; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Krug N, 2001, AM J RESP CRIT CARE, V164, P1841, DOI 10.1164/ajrccm.164.10.2010096; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; Martin U, 1997, J EXP MED, V186, P199, DOI 10.1084/jem.186.2.199; Maruoka S, 2000, AM J RESP CRIT CARE, V161, P922, DOI 10.1164/ajrccm.161.3.9906059; Nilsson G, 1996, J IMMUNOL, V157, P1693; Page S, 2001, AM J PHYSIOL-LUNG C, V281, pL1313, DOI 10.1152/ajplung.2001.281.6.L1313; Pan ZXK, 1998, J IMMUNOL, V160, P3038; Panettieri RA, 2003, RESP PHYSIOL NEUROBI, V137, P277, DOI 10.1016/S1569-9048(03)00153-8; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Penn RB, 2001, J BIOL CHEM, V276, P32648, DOI 10.1074/jbc.M104143200; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; Robinson DS, 2004, J ALLERGY CLIN IMMUN, V114, P58, DOI 10.1016/j.jaci.2004.03.034; Sayama Koichi, 2002, BMC Immunol, V3, P5, DOI 10.1186/1471-2172-3-5; Song RP, 2003, AM J PHYSIOL-LUNG C, V284, pL50, DOI 10.1152/ajplung.00212.2002; STIMLER NP, 1980, AM J PATHOL, V100, P327; Takabayashi T, 1998, J INFECT DIS, V177, P1622, DOI 10.1086/515316; TAKAMINE J, 1901, J PHYSL, V27, P29; Taube C, 2004, J IMMUNOL, V172, P6398, DOI 10.4049/jimmunol.172.10.6398; Tkaczyk C, 2004, BLOOD, V104, P207, DOI 10.1182/blood-2003-08-2769; Tkaczyk C, 2003, J BIOL CHEM, V278, P48474, DOI 10.1074/jbc.M301350200; Tliba O, 2003, BRIT J PHARMACOL, V140, P1159, DOI 10.1038/sj.bjp.0705558; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Venkatesha RT, 2005, MOL IMMUNOL, V42, P581, DOI 10.1016/j.molimm.2004.09.009; Woolhiser MR, 2004, CLIN IMMUNOL, V110, P172, DOI 10.1016/j.clim.2003.11.007; Yamamoto T, 2000, IMMUNOLOGY, V99, P435, DOI 10.1046/j.1365-2567.2000.00973.x; Zhu YM, 2003, J BIOL CHEM, V278, P29366, DOI 10.1074/jbc.M301785200; Zwirner J, 1997, EUR J IMMUNOL, V27, P2317, DOI 10.1002/eji.1830270928; Zwirner J, 1999, IMMUNOLOGY, V97, P166	67	42	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					798	+		10.1096/fj.04-2797fje	http://dx.doi.org/10.1096/fj.04-2797fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15758041				2022-12-25	WOS:000227901300024
J	Le-Niculescu, H; Niesman, I; Fischer, T; DeVries, L; Farquhar, MG				Le-Niculescu, H; Niesman, I; Fischer, T; DeVries, L; Farquhar, MG			Identification and characterization of GIV, a novel G alpha(i/s)-interacting protein found on COPI, endoplasmic reticulum-Golgi transport vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC-G-PROTEINS; GTP-BINDING PROTEINS; TRIMERIC G-PROTEIN; BETA-COP; 2-HYBRID SYSTEM; LEUCINE-ZIPPER; ALPHA-SUBUNITS; COILED-COIL; RAT-LIVER; CELLS	In this report, we characterize GIV (G alpha-interacting vesicle-associated protein), a novel protein that binds members of the G alpha(i) and G alpha(s) subfamilies of heterotrimeric G proteins. The G alpha interaction site was mapped to an 83-amino acid region of GIV that is enriched in highly charged amino acids. BLAST searches revealed two additional mammalian family members, Daple and an uncharacterized protein, FLJ00354. These family members share the highest homology at the G alpha binding domain, are homologous at the N terminus and central coiled coil domain but diverge at the C terminus. Using affinity-purified IgG made against two different regions of the protein, we localized GIV to COPI, endoplasmic reticulum (ER)-Golgi transport vesicles concentrated in the Golgi region in GH3 pituitary cells and COS7 cells. Identification as COPI vesicles was based on colocalization with beta-COP, a marker for these vesicles. GIV also codistributes in the Golgi region with endogenous calnuc and the KDEL receptor, which are cis Golgi markers and with G alpha(i3)-yellow fluorescent protein expressed in COS7 cells. By immunoelectron microscopy, GIV colocalizes with beta-COP and G alpha(i3) on vesicles found in close proximity to ER exit sites and to cis Golgi cisternae. In cell fractions prepared from rat liver, GIV is concentrated in a carrier vesicle fraction (CV2) enriched in ER-Golgi transport vesicles. beta-COP and several G alpha(i3) subunits (G alpha (i1-3), G alpha s) are also most enriched in CV2. Our results demonstrate the existence of a novel G alpha-interacting protein associated with COPI transport vesicles that may play a role in G alpha-mediated effects on vesicle trafficking within the Golgi and/or between the ER and the Golgi.	Univ Calif San Diego, Dept Cellular & Mol Med, George Palade Labs Cellular & Mol Med, La Jolla, CA 92093 USA; Inst Rech Pierre Fabre CRPF, Dept Biol Cellulaire & Mol, F-81106 Castres, France	University of California System; University of California San Diego	Farquhar, MG (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, George Palade Labs Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mfarquhar@ucsd.edu		Fischer, Thierry/0000-0002-9542-322X; Niesman, Ingrid/0000-0001-9767-6629	NATIONAL CANCER INSTITUTE [R01CA100768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017780, R01DK017780] Funding Source: NIH RePORTER; NCI NIH HHS [CA 100768] Funding Source: Medline; NIDDK NIH HHS [DK 17780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; ALI N, 1989, BIOCHEM J, V261, P905, DOI 10.1042/bj2610905; AUDIGIER Y, 1988, J BIOL CHEM, V263, P16352; Barlowe C, 2000, TRAFFIC, V1, P371, DOI 10.1034/j.1600-0854.2000.010501.x; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; Chen NF, 2003, J BIOL CHEM, V278, P15285, DOI 10.1074/jbc.M300841200; Coleman R Edward, 1998, Clin Positron Imaging, V1, P15, DOI 10.1016/S1095-0397(97)00004-6; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; Crouch MF, 2000, IMMUNOL CELL BIOL, V78, P408, DOI 10.1046/j.1440-1711.2000.00929.x; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; De Vries L, 2002, METHOD ENZYMOL, V344, P657; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; Elenko E, 2003, MOL PHARMACOL, V64, P11, DOI 10.1124/mol.64.1.11; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HELMS JB, 1995, FEBS LETT, V369, P84, DOI 10.1016/0014-5793(95)00620-O; HENDRICKS LC, 1993, MOL BIOL CELL, V4, P413, DOI 10.1091/mbc.4.4.413; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Jin MJ, 1996, J BIOL CHEM, V271, P30105, DOI 10.1074/jbc.271.47.30105; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; Lin P, 1999, J CELL BIOL, V145, P279, DOI 10.1083/jcb.145.2.279; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; Madden TL, 1996, METHOD ENZYMOL, V266, P131; Malsam J, 2005, SCIENCE, V307, P1095, DOI 10.1126/science.1108061; MOCHIZUKI N, 1995, FEBS LETT, V373, P155, DOI 10.1016/0014-5793(95)01031-9; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Natochin M, 2002, BIOCHEMISTRY-US, V41, P258, DOI 10.1021/bi015708k; Natochin M, 2001, BIOCHEMISTRY-US, V40, P5322, DOI 10.1021/bi015505w; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Oshita A, 2003, GENES CELLS, V8, P1005, DOI 10.1111/j.1365-2443.2003.00692.x; PIMPLIKAR SW, 1993, J CELL SCI, P27; RASENICK MM, 1990, ADV SEC MESS PHOSPH, V24, P381; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Roychowdhury S, 1999, J BIOL CHEM, V274, P13485, DOI 10.1074/jbc.274.19.13485; Sarma T, 2003, FASEB J, V17, P848, DOI 10.1096/fj.02-0730com; SAUCAN L, 1994, J CELL BIOL, V125, P733, DOI 10.1083/jcb.125.4.733; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STOW JL, 1993, J CELL SCI, P33; Sunio A, 1999, MOL BIOL CELL, V10, P847, DOI 10.1091/mbc.10.4.847; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Tall GG, 2003, J BIOL CHEM, V278, P8356, DOI 10.1074/jbc.M211862200; TOUTANT M, 1987, FEBS LETT, V215, P339, DOI 10.1016/0014-5793(87)80174-6; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WADA I, 1991, J BIOL CHEM, V266, P19599; Walenta JH, 2001, J CELL BIOL, V152, P923, DOI 10.1083/jcb.152.5.923; Weiss TS, 2001, P NATL ACAD SCI USA, V98, P14961, DOI 10.1073/pnas.261572098; WILSON BS, 1994, ENDOCRINOLOGY, V134, P233, DOI 10.1210/en.134.1.233; WILSON BS, 1993, P NATL ACAD SCI USA, V90, P1681, DOI 10.1073/pnas.90.5.1681; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Zheng B, 2004, MOL BIOL CELL, V15, p322A, DOI 10.1091/mbc.e04-06-0446; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	63	114	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22012	22020		10.1074/jbc.M501833200	http://dx.doi.org/10.1074/jbc.M501833200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15749703	hybrid			2022-12-25	WOS:000229557900044
J	Martinez, A; Zudaire, E; Julian, M; Moody, TW; Cuttitta, F				Martinez, A; Zudaire, E; Julian, M; Moody, TW; Cuttitta, F			Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo	ONCOGENE			English	Article						GRP; lung cancer; angiogenesis; nonpeptidic antagonist; tumor growth	MICROVASCULAR ENDOTHELIAL-CELLS; LUNG-CANCER CELLS; BOMBESIN-LIKE PEPTIDES; AUTOCRINE GROWTH; GENE-EXPRESSION; POTENTIAL ROLE; NUDE-MICE; RECEPTOR; HYPOXIA; ANTAGONISTS	Angiogenesis is becoming a major target for antitumor therapies, and identifying new angiogenic factors and their specific inhibitors may provide new avenues for tumor management. Here we identify gastrin-releasing peptide (GRP) as a new angiogenic molecule that is secreted by tumors and acts directly upon GRP receptors in the endothelial cells. Addition of GRP increases endothelial cell migration and cord formation in vitro, and induces angiogenesis in an in vivo assay. We have recently identified a small molecule GRP blocker, compound 77427. This inhibitor significantly reduced endothelial cell cord formation in vitro and angiogenesis in vivo. Conversely, when applied to VEGF-induced angiogenesis, the small molecule did not have any effect, demonstrating its specificity. Furthermore, this GRP blocker was able to reduce lung tumor cell growth in vitro as demonstrated by MTT and clonogenic assays. When applied to a xenograft model with lung cancer cells, compound 77427 reduced tumor volume to undetectable sizes, although when the treatment was suspended, tumors began to grow again at normal rates. Our collective observations indicate that GRP is a new angiogenic peptide and that its inhibition offers an attractive tool to reduce tumor burden.	NCI, Cell & Canc Biol Branch, NIH, Bethesda, MD 20892 USA; NCI, Vasc Biol Fac, NIH, Bethesda, MD 20892 USA; San Pablo CEU Univ, Dept Chem Sci, Madrid 28668, Spain	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); San Pablo CEU University	Martinez, A (corresponding author), CSIC, Inst Cajal, Dept Cell Biol & Neuroanat, Av Doctor Arce 37, E-28002 Madrid, Spain.	amartinez@cajal.csic.es	Cuttitta, Frank/B-4758-2016; Martinez, Alfredo/GQH-5998-2022	Martinez, Alfredo/0000-0003-4882-4044	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC000192, Z01SC000173] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISBY JE, 2003, ANGIOGENESIS, V6, P289; Chaudhry A, 1999, CLIN CANCER RES, V5, P3385; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Damge C, 1998, EUR J PHARMACOL, V347, P77, DOI 10.1016/S0014-2999(98)00088-0; Festuccia C, 2002, EXP CELL RES, V280, P1, DOI 10.1006/excr.2002.5609; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Groger M, 2000, J IMMUNOL, V165, P5428, DOI 10.4049/jimmunol.165.10.5428; Hayashi S, 2001, EXP NEUROL, V171, P285, DOI 10.1006/exnr.2001.7759; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; JOHNSON DE, 1989, AM REV RESPIR DIS, V140, P1807, DOI 10.1164/ajrccm/140.6.1807; Kiaris H, 1999, ONCOGENE, V18, P7168, DOI 10.1038/sj.onc.1203213; Kim S, 2002, ANN SURG, V235, P621, DOI 10.1097/00000658-200205000-00003; Lango MN, 2002, J NATL CANCER I, V94, P375; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; Levine L, 2003, CANCER RES, V63, P3495; Lockwood CJ, 2004, J CLIN ENDOCR METAB, V89, P1467, DOI 10.1210/jc.2003-030141; Los M, 2001, SEMIN ONCOL, V28, P93, DOI 10.1016/S0093-7754(01)90047-8; Lui VWY, 2003, ONCOGENE, V22, P6183, DOI 10.1038/sj.onc.1206720; Mantey SA, 2001, J BIOL CHEM, V276, P9219, DOI 10.1074/jbc.M008737200; Martinez A, 2004, CANCER RES, V64, P6489, DOI 10.1158/0008-5472.CAN-04-0103; Martinez A, 2002, J NATL CANCER I, V94, P1226; Martinez A, 2004, ENDOCRINOLOGY, V145, P3858, DOI 10.1210/en.2003-1251; Michiels C, 1998, CELL ADHES COMMUN, V5, P367, DOI 10.3109/15419069809010782; Moody TW, 1996, PEPTIDES, V17, P1337, DOI 10.1016/S0196-9781(96)00195-7; Moody TW, 2004, J BIOL CHEM, V279, P23580, DOI 10.1074/jbc.M401938200; Moody TW, 2003, EUR J PHARMACOL, V474, P21, DOI 10.1016/S0014-2999(03)01996-4; Moody TW, 2003, LUNG CANCER-J IASLC, V39, P279, DOI 10.1016/S0169-5002(02)00525-1; Moody TW, 1996, J CELL BIOCHEM, P247; Nock BA, 2005, J MED CHEM, V48, P100, DOI 10.1021/jm049437y; Ohinata K, 2000, FEBS LETT, V473, P207, DOI 10.1016/S0014-5793(00)01529-5; Ohinata K, 2001, PEPTIDES, V22, P1809, DOI 10.1016/S0196-9781(01)00524-1; Otto M, 2001, PATHOBIOLOGY, V69, P159, DOI 10.1159/000048771; Safronova O, 2003, INFLAMM RES, V52, P480, DOI 10.1007/s00011-003-1205-5; Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com; Scheurer SB, 2004, PROTEOMICS, V4, P1737, DOI 10.1002/pmic.200300689; Schuller HM, 2000, EUR J PHARMACOL, V393, P265, DOI 10.1016/S0014-2999(00)00094-7; Shi YH, 2004, WORLD J GASTROENTERO, V10, P1082; Shimizu K, 2004, BIOL PHARM BULL, V27, P599, DOI 10.1248/bpb.27.599; SHIRAHIGE Y, 1994, BIOMED PHARMACOTHER, V48, P465, DOI 10.1016/0753-3322(94)90007-8; SISSONS M, 1990, PHYSIOL BOHEMOSLOV, V39, P305; Soffer SZ, 2001, J PEDIATR SURG, V36, P1177, DOI 10.1053/jpsu.2001.25747; VIGNE P, 1995, EUR J BIOCHEM, V233, P414, DOI 10.1111/j.1432-1033.1995.414_2.x; Wachsberger P, 2003, CLIN CANCER RES, V9, P1957; Whitley JC, 2000, J ENDOCRINOL, V166, P649, DOI 10.1677/joe.0.1660649	44	39	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4106	4113		10.1038/sj.onc.1208581	http://dx.doi.org/10.1038/sj.onc.1208581			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15750618				2022-12-25	WOS:000229680300009
J	Hausmann, S; Zheng, SS; Fabrega, C; Schneller, SW; Lima, CD; Shuman, S				Hausmann, S; Zheng, SS; Fabrega, C; Schneller, SW; Lima, CD; Shuman, S			Encephalitozoon cuniculi mRNA cap (guanine N-7) methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; STABLE NITROGEN ANALOGS; METHYL ACCEPTOR SITE; VACCINIA VIRUS; CAPPING ENZYME; SACCHAROMYCES-CEREVISIAE; SUBUNIT ASSOCIATION; ESCHERICHIA-COLI; (GUANINE-7-)METHYLTRANSFERASE; APPARATUS	The Encephalitozoon cuniculi mRNA cap ( guanine N-7) methyltransferase Ecm1 has been characterized structurally but not biochemically. Here we show that purified Ecm1 is a monomeric protein that catalyzes methyl transfer from S-adenosylmethionine ( AdoMet) to GTP. The reaction is cofactor-independent and optimal at pH 7.5. Ecm1 also methylates GpppA, GDP, and dGTP but not ATP, CTP, UTP, ITP, or m(7)GTP. The affinity of Ecm1 for the cap dinucleotide GpppA (K-m 0.1 mM) is higher than that for GTP ( Km 1 mM) or GDP (K-m 2.4 mM). Methylation of GTP by Ecm1 in the presence of 5 mu M AdoMet is inhibited by the reaction product AdoHcy (IC50 4 mu M) and by substrate analogs sinefungin (IC50 1.5 mu M), aza-AdoMet (IC50 100 mu M), and carbocyclic aza-AdoMet (IC50 35 mu M). The crystal structure of an Ecm1(.)aza-AdoMet binary complex reveals that the inhibitor occupies the same site as AdoMet. Structure-function analysis of Ecm1 by alanine scanning and conservative substitutions identified functional groups necessary for methyltransferase activity in vivo. Amino acids Lys-54, Asp-70, Asp-78, and Asp-94, which comprise the AdoMet-binding site, and Phe-141, which contacts the cap guanosine, are essential for cap methyltransferase activity in vitro.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA; Auburn Univ, Dept Chem & Biochem, Auburn, AL 36849 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Auburn University System; Auburn University	Shuman, S (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Fabrega, Carme/AAZ-5469-2021; Fàbrega, MCarme/K-9847-2014	Fàbrega, MCarme/0000-0003-3816-7634; Lima, Christopher/0000-0002-9163-6092	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI056540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470, R01GM061906] Funding Source: NIH RePORTER; NIAID NIH HHS [AI56540] Funding Source: Medline; NIGMS NIH HHS [GM61906, GM52470] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBOSA E, 1978, J BIOL CHEM, V253, P7692; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; CONG PJ, 1992, J BIOL CHEM, V267, P16424; Fabrega C, 2004, MOL CELL, V13, P77, DOI 10.1016/S1097-2765(03)00522-7; Ghosh AK, 1996, J ORG CHEM, V61, P6175, DOI 10.1021/jo960670g; Hausmann S, 2002, J BIOL CHEM, V277, P96, DOI 10.1074/jbc.M109649200; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; HIGMAN MA, 1994, J BIOL CHEM, V269, P14982; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LIU S, 1992, ANTIVIR RES, V19, P247, DOI 10.1016/0166-3542(92)90083-H; MAO XD, 1994, J BIOL CHEM, V269, P24472; Mao XD, 1996, BIOCHEMISTRY-US, V35, P6900, DOI 10.1021/bi960221a; MAO XD, 1995, MOL CELL BIOL, V15, P4167; Mao XD, 1996, MOL CELL BIOL, V16, P475; MARTIN SA, 1975, J BIOL CHEM, V250, P9330; MARTIN SA, 1976, J BIOL CHEM, V251, P7313; MINNICK AA, 1988, J ORG CHEM, V53, P4952, DOI 10.1021/jo00256a010; NILES EG, 1994, BIOCHEMISTRY-US, V33, P9898, DOI 10.1021/bi00199a011; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443; PUGH CSG, 1978, J BIOL CHEM, V253, P4075; REICH NO, 1990, J BIOL CHEM, V265, P8966; Saha N, 1999, J BIOL CHEM, V274, P16553, DOI 10.1074/jbc.274.23.16553; Schwer B, 2000, GENETICS, V155, P1561; Shuman S, 2001, COLD SPRING HARB SYM, V66, P301, DOI 10.1101/sqb.2001.66.301; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; Takata Y, 2003, BIOCHEMISTRY-US, V42, P8394, DOI 10.1021/bi034245a; Thompson MJ, 1996, CHEM COMMUN, P791, DOI 10.1039/cc9960000791; Thompson MJ, 1999, J ORG CHEM, V64, P7467, DOI 10.1021/jo9907742; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V251, P27, DOI 10.1006/bbrc.1998.9402; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; Yamada-Okabe T, 1999, MICROBIOL-UK, V145, P3023, DOI 10.1099/00221287-145-11-3023; Yang MM, 2004, J ORG CHEM, V69, P3993, DOI 10.1021/jo040119g	35	31	33	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20404	20412		10.1074/jbc.M501073200	http://dx.doi.org/10.1074/jbc.M501073200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15760890	hybrid			2022-12-25	WOS:000229242000032
J	Pyo, JO; Jang, MH; Kwon, YK; Lee, HJ; Jun, JIL; Woo, HN; Cho, DH; Choi, B; Lee, H; Kim, JH; Mizushima, N; Oshumi, Y; Jung, YK				Pyo, JO; Jang, MH; Kwon, YK; Lee, HJ; Jun, JIL; Woo, HN; Cho, DH; Choi, B; Lee, H; Kim, JH; Mizushima, N; Oshumi, Y; Jung, YK			Essential roles of Atg5 and FADD in autophagic cell death - Dissection of autophagic cell death into vacuole formation and cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; CARDIOMYOPATHY; MYOPATHY	Autophagic cell death is characterized by the accumulation of vacuoles in physiological and pathological conditions. However, its molecular event is unknown. Here, we show that Atg5, which is known to function in autophagy, contributes to autophagic cell death by interacting with Fas-associated protein with death domain ( FADD). Down-regulation of Atg5 expression in HeLa cells suppresses cell death and vacuole formation induced by IFN-gamma. Inversely, ectopic expression of Atg5 using adenoviral delivery induces autophagic cell death. Deletion mapping analysis indicates that procell death activity resides in the middle and C-terminal region of Atg5. Cells harboring the accumulated vacuoles triggered by IFN-gamma or Atg5 expression become dead, and vacuole formation precedes cell death. 3-Methyladenine or expression of Atg5(K130R) mutant blocks both cell death and vacuole formation triggered by IFN-gamma, whereas benzyloxycarbonyl-VAD-fluoromethyl ketone (Z-VAD-fmk) inhibits only cell death but not vacuole formation. Atg5 interacts with FADD via death domain in vitro and in vivo, and the Atg5-mediated cell death, but not vacuole formation, is blocked in FADD-deficient cells. These results suggest that Atg5 plays a crucial role in IFN-gamma-induced autophagic cell death by interacting with FADD.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Ulsan Med Sch, Seoul 138736, South Korea; Yonsei Med Sch, Seoul 120749, South Korea; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan	Gwangju Institute of Science & Technology (GIST); University of Ulsan; Yonsei University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Jung, YK (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju 500712, South Korea.	ykjung@gist.ac.kr	Ohsumi, Yoshinori/C-6449-2009; Mizushima, Noboru/C-3635-2009; Lee, Ho-June/D-8855-2014	Ohsumi, Yoshinori/0000-0003-2384-2166; Mizushima, Noboru/0000-0002-6258-6444; Lee, Ho-June/0000-0002-7019-2533; Woo, Ha-Na/0000-0002-6771-8151; Jung, Yong-Keun/0000-0002-9686-3120				Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bursch W, 2000, J CELL SCI, V113, P1189; CATALSO AM, 1995, NEURON, V3, P671; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Choi YH, 2001, J BIOL CHEM, V276, P25073, DOI 10.1074/jbc.M102941200; Cohen O, 1999, J CELL BIOL, V146, P141; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Lee CY, 2003, CURR BIOL, V13, P350, DOI 10.1016/S0960-9822(03)00085-X; Lee CY, 2002, DEV BIOL, V250, P101, DOI 10.1006/dbio.2002.0784; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; SELGEN PO, 1982, P NATL ACAD SCI USA, V79, P1889; Song S, 2003, MOL CELL, V12, P553, DOI 10.1016/j.molcel.2003.08.005; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Yamamoto A, 2001, NEUROLOGY, V57, P903, DOI 10.1212/WNL.57.5.903; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; ZAKERI Z, 1995, CELL DEATH DIFFER, V2, P87	29	449	471	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20722	20729		10.1074/jbc.M413934200	http://dx.doi.org/10.1074/jbc.M413934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15778222	hybrid			2022-12-25	WOS:000229242000070
J	van den Born, J; Salmivirta, K; Henttinen, T; Ostman, N; Ishimaru, T; Miyaura, S; Yoshida, K; Salmivirta, M				van den Born, J; Salmivirta, K; Henttinen, T; Ostman, N; Ishimaru, T; Miyaura, S; Yoshida, K; Salmivirta, M			Novel heparan sulfate structures revealed by monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; SEQUENCE-ANALYSIS; DOMAIN-STRUCTURE; PROTEOGLYCANS; EXPRESSION; BINDING; GROWTH-FACTOR-2; 2-O-SULFATION; GLYPICAN-1; DIVERSITY	The sulfated glycosaminoglycan heparan sulfate (HS) is found ubiquitously on cell surfaces, in the extracellular matrix, and intracellularly as HS proteoglycans. Because of the structural heterogeneity of HS, tissue-derived HS preparations represent a mixture of HS chains originating from different cell types and tissue loci. Monoclonal anti-HS antibodies have been employed to detect the localization of specific HS epitopes in tissues, but limited information has been available on the saccharide structures recognized by the antibodies. We have studied the saccharide epitope structures of four anti-HS antibodies, HepSS1, JM13, JM403, and 10E4, which all recognize distinct HS species as demonstrated by different patterns of immunoreactivity upon staining of embryonic rat and adult human tissues. The epitopes recognized by JM13 and HepSS1 were found almost exclusively in basement membrane HS, whereas JM403 and 10E4 reacted also with cell-associated HS species. The binding of HepSS1, JM403, and 10E4 to HS was dependent on the GlcN N-substitution of the polysaccharide rather than O-sulfation. HepSS1 thus interacted with N-sulfated HS domains, JM403 binding was critically dependent on N-unsubstituted GlcN residues, and 10E4 bound to "mixed" HS domains containing both N-acetylated and N-sulfated disaccharide units. By contrast, JM13 binding seemed to require the presence of 2-O-sulfated glucuronic acid residues.	Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Seikagaku Corp, Cent Res Labs, Tokyo 2070021, Japan; Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol & Immunol, NL-1007 MB Amsterdam, Netherlands; Uppsala Univ, Dept Anim Physiol, SE-75123 Uppsala, Sweden; Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Natl Publ Hlth Inst, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University; Seikagaku Corporation; Vrije Universiteit Amsterdam; Uppsala University; University of Turku; Finland National Institute for Health & Welfare	Salmivirta, M (corresponding author), Univ Turku, Turku Ctr Biotechnol, Tykistokatu 6, FIN-20520 Turku, Finland.	markku.salmivirta@btk.fi						Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Cheng F, 2002, J BIOL CHEM, V277, P44431, DOI 10.1074/jbc.M205241200; Conrad H. E., 1998, HEPARIN BINDING PROT; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; Friedl A, 1997, AM J PATHOL, V150, P1443; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; IVERIUS PH, 1971, BIOCHEM J, V124, P677, DOI 10.1042/bj1240677; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; KURE S, 1986, J IMMUNOL, V137, P3900; Leteux C, 2001, J BIOL CHEM, V276, P12539, DOI 10.1074/jbc.M010291200; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Loo BM, 2001, J BIOL CHEM, V276, P16868, DOI 10.1074/jbc.M011226200; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Mani K, 2004, GLYCOBIOLOGY, V14, P599, DOI 10.1093/glycob/cwh067; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; Pikas DS, 2000, BIOCHEMISTRY-US, V39, P4552, DOI 10.1021/bi992524l; Rong JH, 2000, BIOCHEM J, V346, P463, DOI 10.1042/0264-6021:3460463; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Safaiyan F, 1999, J BIOL CHEM, V274, P36267, DOI 10.1074/jbc.274.51.36267; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Thesleff I, 2003, J CELL SCI, V116, P1647, DOI 10.1242/jcs.00410; Thesleff I, 2001, Adv Dent Res, V15, P14; Thesleff I, 2002, INT REV CYTOL, V217, P93; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15; VANDENBORN J, 1991, LAB INVEST, V65, P287; Vives RR, 1999, BIOCHEM J, V339, P767, DOI 10.1042/0264-6021:3390767; Westling C, 2002, J BIOL CHEM, V277, P49247, DOI 10.1074/jbc.M209139200; Yip GW, 2002, DEVELOPMENT, V129, P2109	37	97	98	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20516	20523		10.1074/jbc.M502065200	http://dx.doi.org/10.1074/jbc.M502065200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15778504	hybrid, Green Published			2022-12-25	WOS:000229242000045
J	Bazzini, C; Vezzoli, V; Sironi, C; Dossena, S; Ravasio, A; De Biasi, S; Garavaglia, ML; Rodighiero, S; Meyer, G; Fascio, U; Furst, J; Ritter, M; Botta, G; Paulmichl, M				Bazzini, C; Vezzoli, V; Sironi, C; Dossena, S; Ravasio, A; De Biasi, S; Garavaglia, ML; Rodighiero, S; Meyer, G; Fascio, U; Furst, J; Ritter, M; Botta, G; Paulmichl, M			Thiazide-sensitive NaCl-cotransporter in the intestine possible role of hydrochlorothiazide in the intestinal Ca2+ uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT GALLBLADDER EPITHELIUM; SODIUM-CHLORIDE COTRANSPORTER; MONOVALENT CATION CURRENTS; CL-COTRANSPORTER; STRONTIUM TRANSPORT; CALCIUM-ABSORPTION; GITELMANS-SYNDROME; GENE-EXPRESSION; N-GLYCOSYLATION; MESSENGER-RNA	Thiazides, such as hydrochlorothiazide (HCTZ), are used to control blood pressure and to reduce renal calcium excretion. These effects are a result of interactions with the NaCl-cotransporter (NCC). This is demonstrated by the fact that mutations within the NCC protein lead to salt-resistant hypotension and hypocalciuria, paralleled by an increase in bone mineral density. These symptoms are also known as Gitelman syndrome. It has become increasingly evident that the effect of HCTZ on blood pressure and calcium homeostasis cannot be attributed exclusively to kidney functions, where the primary action of HCTZ on NCC is postulated to occur. We demonstrated the presence of the NCC transporter in the rat small intestine (ileum and jejunum) and human HT-29 cells, by using reverse transcription-PCR, Northern blot, Western blot, and immunofluorescence. Furthermore, we show that HCTZ modulates Ca2+ uptake by intestinal cells, while affecting the electrical parameters of the cellular membrane, thus suggesting a functional interaction between NCC and the epithelial voltage-dependent calcium channel. The experiments presented here support the hypothesis of a direct involvement of the intestinal cells in the interaction between HCTZ and NaCl, as well as calcium homeostasis.	Univ Milan, Dept Biomol Sci & Biotechnol, I-20133 Milan, Italy; Innsbruck Med Univ, Dept Physiol & Med Phys, A-6020 Innsbruck, Austria; Ctr Interdipartimentale Microscopia Aranzata, I-20133 Milan, Italy; Ctr Interdisciplinare Mat & Interface Nanostrutur, I-20133 Milan, Italy; Paracelsus Private Med Univ, A-5020 Salzburg, Austria	University of Milan; Medical University of Innsbruck; Paracelsus Private Medical University	Botta, G (corresponding author), Univ Milan, Dept Biomol Sci & Biotechnol, Via Celoria 26, I-20133 Milan, Italy.	guido.botta@unimi.it; markus.paulmichl@unimi.it	Rodighiero, Simona/AAP-9816-2020; Ritter, Markus/AAG-4987-2020; Ravasio, Andrea/H-6722-2012; Ravasio, Andrea/G-6167-2011; Dossena, Silvia/G-1437-2018; Garavaglia, Maria Lisa/AFV-3214-2022; Bazzini, Claudia/G-8214-2011; Meyer, Giuliano/G-8062-2011	Ritter, Markus/0000-0001-7346-7750; Ravasio, Andrea/0000-0001-7835-5133; Rodighiero, Simona/0000-0003-4236-7823; Vezzoli, Valeria/0000-0001-6396-7284				Abuladze N, 1998, J AM SOC NEPHROL, V9, P819; Aubin R, 1996, KIDNEY INT, V50, P1476, DOI 10.1038/ki.1996.461; Barley NF, 2001, AM J PHYSIOL-GASTR L, V280, pG285, DOI 10.1152/ajpgi.2001.280.2.G285; Barry ELR, 1998, J MEMBRANE BIOL, V161, P55, DOI 10.1007/s002329900314; Barry ELR, 1997, AM J PHYSIOL-CELL PH, V272, pC109, DOI 10.1152/ajpcell.1997.272.1.C109; BERNSTEIN PL, 1995, J AM SOC NEPHROL, V6, P732; Bostonjoglo M, 1998, J AM SOC NEPHROL, V9, P1347; Bouillon R, 2003, J CELL BIOCHEM, V88, P332, DOI 10.1002/jcb.10360; Bronner F, 1998, J NUTR, V128, P917, DOI 10.1093/jn/128.5.917; Chang HI, 1996, BIOCHEM BIOPH RES CO, V223, P324, DOI 10.1006/bbrc.1996.0893; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; CREMASCHI D, 1994, J MEMBRANE BIOL, V141, P29; CREMASCHI D, 1995, J MEMBRANE BIOL, V147, P159; Cremaschi D, 2000, J MEMBRANE BIOL, V176, P53, DOI 10.1007/s002320001075; De Jong JC, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017904.77985.03; Delpire E, 2002, ANNU REV PHYSIOL, V64, P803, DOI 10.1146/annurev.physiol.64.081501.155847; DONATH A, 1970, HELV PAEDIATR ACTA, V25, P293; DONATH A, 1971, ISRAEL J MED SCI, V7, P393; Ellison DH, 2000, AM J PHYSIOL-RENAL, V279, pF616, DOI 10.1152/ajprenal.2000.279.4.F616; Friedman PA, 2000, EXP NEPHROL, V8, P343; GALL MA, 1992, AM J HYPERTENS, V5, P257, DOI 10.1093/ajh/5.5.257; Gamba G, 2001, AM J PHYSIOL-RENAL, V281, pF781, DOI 10.1152/ajprenal.2001.281.5.F781; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gawenis LR, 2002, AM J PHYSIOL-GASTR L, V282, pG776, DOI 10.1152/ajpgi.00297.2001; GESEK FA, 1992, J CLIN INVEST, V90, P429, DOI 10.1172/JCI115878; Hodin RA, 1996, CELL GROWTH DIFFER, V7, P647; Hoenderop JGJ, 2000, J AM SOC NEPHROL, V11, P1171, DOI 10.1681/ASN.V1171171; Hoenderop JGJ, 2002, BBA-PROTEINS PROTEOM, V1600, P6, DOI 10.1016/S1570-9639(02)00438-7; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 2002, ANNU REV PHYSIOL, V64, P529, DOI 10.1146/annurev.physiol.64.081501.155921; Hoover RS, 2003, J AM SOC NEPHROL, V14, P271, DOI 10.1097/01.ASN.0000043903.93452.D0; JORGENSEN FS, 1974, ACTA MED SCAND, V195, P33; Kumar V, 2003, BBA-MOL BASIS DIS, V1639, P185, DOI 10.1016/j.bbadis.2003.09.006; LaCroix AZ, 2000, ANN INTERN MED, V133, P516, DOI 10.7326/0003-4819-133-7-200010030-00010; Loffing J, 2001, AM J PHYSIOL-RENAL, V281, pF1021, DOI 10.1152/ajprenal.0085.2001; MacKenzie S, 2001, BIOCHEM BIOPH RES CO, V282, P991, DOI 10.1006/bbrc.2001.4673; Matthews JB, 1998, J CLIN INVEST, V101, P2072, DOI 10.1172/JCI1042; Meyer G, 1997, CELL MOL LIFE SCI, V53, P769, DOI 10.1007/s000180050097; Musch MW, 1998, PFLUG ARCH EUR J PHY, V436, P415, DOI 10.1007/s004240050651; Nijenhuis T, 2003, KIDNEY INT, V64, P555, DOI 10.1046/j.1523-1755.2003.00128.x; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; Nilius B, 2001, BRIT J PHARMACOL, V134, P453, DOI 10.1038/sj.bjp.0704272; Orsenigo MN, 1997, J MEMBRANE BIOL, V158, P257, DOI 10.1007/s002329900262; Peng JB, 2003, NEWS PHYSIOL SCI, V18, P158, DOI 10.1152/nips.01440.2003; Pickkers P, 1999, HYPERTENSION, V33, P1043, DOI 10.1161/01.HYP.33.4.1043; Plotkin MD, 1996, KIDNEY INT, V50, P174, DOI 10.1038/ki.1996.300; Reilly RF, 2000, PHYSIOL REV, V80, P277, DOI 10.1152/physrev.2000.80.1.277; Rejnmark L, 2001, J INTERN MED, V250, P144, DOI 10.1046/j.1365-2796.2001.00868.x; Rottingen JA, 2000, ACTA PHYSIOL SCAND, V169, P203; Schmieder S, 2001, BIOCHEM BIOPH RES CO, V286, P635, DOI 10.1006/bbrc.2001.5407; Schultheis PJ, 1998, J BIOL CHEM, V273, P29150, DOI 10.1074/jbc.273.44.29150; Sebastian A, 2000, AM J MED, V109, P429, DOI 10.1016/S0002-9343(00)00582-9; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; SUNDARAM U, 1991, AM J PHYSIOL, V260, pG440, DOI 10.1152/ajpgi.1991.260.3.G440; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; Tosco M, 2002, CELL PHYSIOL BIOCHEM, V12, P9, DOI 10.1159/000047822; TSIEN RY, 1985, CELL CALCIUM, V6, P145, DOI 10.1016/0143-4160(85)90041-7; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Vidyasagar S, 2002, J PHYSIOL-LONDON, V539, P163, DOI 10.1113/jphysiol.2001.013056; YENDT ER, 1965, T AM CLIN CLIMAT ASS, V77, P96; Zhuang LY, 2002, LAB INVEST, V82, P1755, DOI 10.1097/01.LAB.0000043910.41414.E7	61	33	35	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19902	19910		10.1074/jbc.M411961200	http://dx.doi.org/10.1074/jbc.M411961200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15781471	hybrid			2022-12-25	WOS:000229113700060
J	Johnsen, L; Dalhus, B; Leiros, I; Nissen-Meyer, J				Johnsen, L; Dalhus, B; Leiros, I; Nissen-Meyer, J			1.6-angstrom crystal structure of EntA-im - A bacterial immunity protein conferring immunity to the antimicrobial activity of the pediocin-like bacteriocin enterocin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS IIA BACTERIOCINS; LEUCONOSTOC-MESENTEROIDES; 3-DIMENSIONAL STRUCTURE; MUTATIONAL ANALYSIS; SAKACIN-P; MEMBRANE; RESIDUES; MODEL; GENE; RECOGNITION	Many Gram-positive bacteria produce ribosomally synthesized antimicrobial peptides, often termed bacteriocins. Genes encoding pediocin-like bacteriocins are generally cotranscribed with or in close vicinity to a gene encoding a cognate immunity protein that protects the bacteriocin-producer from their own bacteriocin. We present the first crystal structure of a pediocin-like immunity protein, EntA-im, conferring immunity to the bacteriocin enterocin A. Determination of the structure of this 103-amino acid protein revealed that it folds into an antiparallel four-helix bundle with a flexible C-terminal part. The fact that the immunity protein conferring immunity to carnobacteriocin B2 also consists of a four-helix bundle (Sprules, T., Kawulka, K. E., and Vederas, J. C. ( 2004) Biochemistry 43, 11740-11749) strongly indicates that this is a conserved structural motif in all pediocin-like immunity proteins. The C-terminal half of the immunity protein contains a region that recognizes the C-terminal half of the cognate bacteriocin, and the flexibility in the C-terminal end of the immunity protein might thus be an important characteristic that enables the immunity protein to interact with its cognate bacteriocin. By homology modeling of three other pediocin-like immunity proteins and calculation of the surface charge distribution for EntA-im and the three structure models, different charge distributions were observed. The differences in the latter part of helix 3, the beginning of helix 4, and the loop connecting these helices might also be of importance in determining the specificity.	Univ Oslo, Dept Mol Biosci, Program Biochem & Mol Biol, N-0316 Oslo, Norway; Natl Univ Hosp, Sect Mol Microbiol, Inst Med Microbiol, N-0027 Oslo, Norway; European Synchrotron Radiat Facil, Macromol Crystallog Grp, F-38043 Grenoble, France	University of Oslo; University of Oslo; National Hospital Norway; European Synchrotron Radiation Facility (ESRF)	Johnsen, L (corresponding author), Univ Oslo, Dept Mol Biosci, Program Biochem & Mol Biol, POB 1041, N-0316 Oslo, Norway.	line.johnsen@biokjemi.uio.no	Nissen-Meyer, Jon/Y-8727-2019; Leiros, Ingar/AAM-2940-2020; Dalhus, Bjørn/AAK-2895-2020; Nissen-Meyer, Jon/A-5581-2008	Leiros, Ingar/0000-0001-9333-4541				AXELSSON L, 1995, J BACTERIOL, V177, P2125, DOI 10.1128/jb.177.8.2125-2137.1995; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen YH, 1997, APPL ENVIRON MICROB, V63, P4770, DOI 10.1128/AEM.63.12.4770-4777.1997; CHIKINDAS ML, 1993, APPL ENVIRON MICROB, V59, P3577, DOI 10.1128/AEM.59.11.3577-3584.1993; Dalhus B, 2003, ACTA CRYSTALLOGR D, V59, P1291, DOI 10.1107/S0907444903009879; Dayem MA, 1996, FEMS MICROBIOL LETT, V138, P251, DOI 10.1016/0378-1097(96)00119-X; Eijsink VGH, 1998, APPL ENVIRON MICROB, V64, P3275; Ennahar S, 2000, FEMS MICROBIOL REV, V24, P85, DOI 10.1111/j.1574-6976.2000.tb00534.x; Fimland G, 1996, APPL ENVIRON MICROB, V62, P3313, DOI 10.1128/AEM.62.9.3313-3318.1996; Fimland G, 2002, BIOCHEMISTRY-US, V41, P9508, DOI 10.1021/bi025856q; Fimland G, 2002, MICROBIOL-SGM, V148, P3661, DOI 10.1099/00221287-148-11-3661; FREMAUX C, 1995, MICROBIOL-SGM, V141, P1637, DOI 10.1099/13500872-141-7-1637; Frishman D, 1997, PROTEINS, V27, P329, DOI 10.1002/(SICI)1097-0134(199703)27:3<329::AID-PROT1>3.0.CO;2-8; Gallagher NLF, 1997, BIOCHEMISTRY-US, V36, P15062, DOI 10.1021/bi971263h; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HASTINGS JW, 1991, J BACTERIOL, V173, P7491, DOI 10.1128/jb.173.23.7491-7500.1991; Huhne K, 1996, MICROBIOL-SGM, V142, P1437, DOI 10.1099/13500872-142-6-1437; Johnsen L, 2004, APPL ENVIRON MICROB, V70, P2647, DOI 10.1128/AEM.70.5.2647-2652.2004; Johnsen L, 2005, J BIOL CHEM, V280, P9243, DOI 10.1074/jbc.M412712200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kazazic M, 2002, MICROBIOL-SGM, V148, P2019, DOI 10.1099/00221287-148-7-2019; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Metivier A, 1998, MICROBIOL-SGM, V144, P2837, DOI 10.1099/00221287-144-10-2837; Miller KW, 1998, APPL ENVIRON MICROB, V64, P1997; Moll GN, 1999, ANTON LEEUW INT J G, V76, P185, DOI 10.1023/A:1002002718501; NES IF, 2002, UNMODIFIED PEPTIDE B, P81; NISSENMEYER J, 1993, J GEN MICROBIOL, V139, P1503, DOI 10.1099/00221287-139-7-1503; NissenMeyer J, 1997, ARCH MICROBIOL, V167, P67, DOI 10.1007/s002030050418; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; QUADRI LEN, 1995, J BACTERIOL, V177, P1144, DOI 10.1128/JB.177.5.1144-1151.1995; Quadri LEN, 1997, J BACTERIOL, V179, P6163, DOI 10.1128/jb.179.19.6163-6171.1997; Sprules T, 2004, BIOCHEMISTRY-US, V43, P11740, DOI 10.1021/bi048854+; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uteng M, 2003, BIOCHEMISTRY-US, V42, P11417, DOI 10.1021/bi034572i; VENEMA K, 1994, MOL MICROBIOL, V14, P521, DOI 10.1111/j.1365-2958.1994.tb02186.x; VENEMA K, 1995, MOL MICROBIOL, V17, P515, DOI 10.1111/j.1365-2958.1995.mmi_17030515.x; Wang YJ, 1999, BIOCHEMISTRY-US, V38, P15438, DOI 10.1021/bi991351x	41	32	33	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19045	19050		10.1074/jbc.M501386200	http://dx.doi.org/10.1074/jbc.M501386200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753083	hybrid			2022-12-25	WOS:000228932300060
J	Lu, T; Hong, MP; Lee, HC				Lu, T; Hong, MP; Lee, HC			Molecular determinants of cardiac K-ATP channel activation by epoxyeicosatrienoic acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; BINDING-SITE; 11,12-EPOXYEICOSATRIENOIC ACID; ARACHIDONIC-ACID; SMOOTH-MUSCLE; C-TERMINUS; INHIBITION; KIR6.2; CYTOCHROME-P450; IDENTIFICATION	We have previously reported that epoxyeicosatrienoic acids (EETs), the cytochrome P450 epoxygenase metabolites of arachidonic acid, are potent stereospecific activators of the cardiac K-ATP channel. The epoxide group in EET is critical for reducing channel sensitivity to ATP, thereby activating the channel. This study is to identify the molecular sites on the K-ATP channels for EET-mediated activation. We investigated the effects of EETs on Kir6.2 Delta C26 with or without the coexpression of SUR2A and on Kir6.2 mutants of positively charged residues known to affect channel activity coexpressed with SUR2A in HEK293 cells. The ATP IC50 values were significantly increased in Kir6.2 R27A, R50A, K185A, and R201A but not in R16A, K47A, R54A, K67A, R192A, R195A, K207A, K222A, and R314A mutants. Similar to native cardiac KATP channel, 5 mu M 11,12-EET increased the ATP IC50 by 9.6-fold in Kir6.2/SUR2A wild type and 8.4-fold in Kir6.2 Delta C26. 8,9- and 14,15-EET regioisomers activated the Kir6.2 channel as potently as 11,12-EET. 8,9- and 11,12-EET failed to change the ATP sensitivity of Kir6.2 K185A, R195A, and R201A, whereas their effects were intact in the other mutants. 14,15-EET had a similar effect with K185A and R201A mutants, but instead of R195A, it failed to activate Kir6.2R192A. These results indicate that activation of Kir6.2 by EETs does not require the SUR2A subunit, and the region in the Kir6.2 C terminus from Lys-185 to Arg-201 plays a critical role in EET-mediated Kir6.2 channel activation. Based on computer modeling of the Kir6.2 structure, we infer that the EET-Kir6.2 interaction may allosterically change the ATP binding site on Kir6.2, reducing the channel sensitivity to ATP.	Mayo Clin, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN 55905 USA	Mayo Clinic	Lu, T (corresponding author), Mayo Clin, Dept Med, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.	Lu.tong@mayo.edu	Hong, Min Pyo/B-5337-2008; Lu, Tong/A-7745-2009	Lu, Tong/0000-0002-2393-7643	NHLBI NIH HHS [HL-63754, R01 HL063754, HL-74180] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063754, R56HL074180, R01HL074180] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; Antcliff JF, 2005, EMBO J, V24, P229, DOI 10.1038/sj.emboj.7600487; Archer SL, 2003, CIRCULATION, V107, P769, DOI 10.1161/01.CIR.0000047278.28407.C2; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Bienengraeber M, 2004, NAT GENET, V36, P382, DOI 10.1038/ng1329; Campbell WB, 2000, TRENDS PHARMACOL SCI, V21, P125, DOI 10.1016/S0165-6147(00)01472-3; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Cukras CA, 2002, J GEN PHYSIOL, V119, P581, DOI 10.1085/jgp.20028562; Cukras CA, 2002, J GEN PHYSIOL, V120, P437, DOI 10.1085/jgp.20028621; Dabrowski M, 2004, J PHYSIOL-LONDON, V557, P347, DOI 10.1113/jphysiol.2003.059105; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Fox JEM, 2004, MOL ENDOCRINOL, V18, P679, DOI 10.1210/me.2003-0431; Gross GJ, 2003, AM J PHYSIOL-HEART C, V285, pH921, DOI 10.1152/ajpheart.00421.2003; Haruna T, 2000, PFLUG ARCH EUR J PHY, V441, P200, DOI 10.1007/s004240000428; Hodgson DM, 2003, EMBO J, V22, P1732, DOI 10.1093/emboj/cdg192; John SA, 2003, J PHYSIOL-LONDON, V552, P23, DOI 10.1113/jphysiol.2003.048843; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Lee HC, 1999, J PHYSIOL-LONDON, V519, P153, DOI 10.1111/j.1469-7793.1999.0153o.x; Li PL, 1997, CIRC RES, V80, P877; Lu T, 2002, MOL PHARMACOL, V62, P1076, DOI 10.1124/mol.62.5.1076; Lu T, 2001, J PHYSIOL-LONDON, V537, P811; Lu T, 2001, J PHYSIOL-LONDON, V534, P651, DOI 10.1111/j.1469-7793.2001.t01-1-00651.x; MacGregor GG, 2002, P NATL ACAD SCI USA, V99, P2726, DOI 10.1073/pnas.042688899; Nithipatikom K, 2001, ANAL BIOCHEM, V292, P115, DOI 10.1006/abio.2001.5044; Potente M, 2003, J BIOL CHEM, V278, P29619, DOI 10.1074/jbc.M305385200; Potente M, 2002, J BIOL CHEM, V277, P15671, DOI 10.1074/jbc.M110806200; Proks P, 1999, J PHYSIOL-LONDON, V514, P19, DOI 10.1111/j.1469-7793.1999.019af.x; Reimann F, 1999, J PHYSIOL-LONDON, V520, P661, DOI 10.1111/j.1469-7793.1999.00661.x; Ribalet B, 2003, BIOPHYS J, V84, P266, DOI 10.1016/S0006-3495(03)74847-4; Schulze D, 2003, J BIOL CHEM, V278, P10500, DOI 10.1074/jbc.M208413200; Schulze D, 2003, J PHYSIOL-LONDON, V552, P357, DOI 10.1113/jphysiol.2003.047035; Seino S, 2003, J DIABETES COMPLICAT, V17, P2, DOI 10.1016/S1056-8727(02)00274-X; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Suzuki M, 2003, CIRCULATION, V107, P682, DOI 10.1161/01.CIR.0000055187.67365.81; Suzuki M, 2001, CIRC RES, V88, P570, DOI 10.1161/01.RES.88.6.570; Trapp S, 2003, EMBO J, V22, P2903, DOI 10.1093/emboj/cdg282; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Vanoye CG, 2002, J BIOL CHEM, V277, P23260, DOI 10.1074/jbc.M112004200; Wu S, 1997, J BIOL CHEM, V272, P12551, DOI 10.1074/jbc.272.19.12551; Xiao YF, 1998, J PHYSIOL-LONDON, V508, P777, DOI 10.1111/j.1469-7793.1998.777bp.x; Zeldin DC, 2001, J BIOL CHEM, V276, P36059, DOI 10.1074/jbc.R100030200; Zhang YD, 2001, AM J PHYSIOL-HEART C, V280, pH2430, DOI 10.1152/ajpheart.2001.280.6.H2430; ZHU Y, 1995, HYPERTENSION, V25, P854, DOI 10.1161/01.HYP.25.4.854; Zingman LV, 2002, P NATL ACAD SCI USA, V99, P13278, DOI 10.1073/pnas.212315199	46	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19097	19104		10.1074/jbc.M414065200	http://dx.doi.org/10.1074/jbc.M414065200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15760904	hybrid			2022-12-25	WOS:000228932300066
J	Mahtouk, K; Hose, D; Reme, T; De Vos, J; Jourdan, M; Moreaux, J; Fiol, G; Raab, M; Jourdan, E; Grau, V; Moos, M; Goldschmidt, H; Baudard, M; Rossi, JF; Cremer, FW; Klein, B				Mahtouk, K; Hose, D; Reme, T; De Vos, J; Jourdan, M; Moreaux, J; Fiol, G; Raab, M; Jourdan, E; Grau, V; Moos, M; Goldschmidt, H; Baudard, M; Rossi, JF; Cremer, FW; Klein, B			Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells	ONCOGENE			English	Article						amphiregulin; myeloma; EGF receptor	MALIGNANT PLASMA-CELLS; LUNG-CANCER; SIGNAL-TRANSDUCTION; INTERFERON-ALPHA; INTERLEUKIN-6; PROLIFERATION; GEFITINIB; SURVIVAL; ERBB2; LINES	A hallmark of plasma cells is the expression of syndecan-1, which has major functions in epithelial cells, in particular as the coreceptor of heparin-binding growth factors. We previously found that heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a growth factor for malignant plasma cells. As amphiregulin (AREG) is another heparin-binding factor of the EGF family, we investigated its role in multiple myeloma (MM). Using Affymetrix DNA microarrays, we show here that the AREG gene was expressed by purified primary myeloma cells from 65 patients and that the expression was higher than in normal bone marrow (BM) plasma cells or plasmablastic cells. AREG stimulated IL-6 production and growth of BM stromal cells. Using real-time reverse transcriptase polymerase chain reaction, we found that MM cells expressed ErbB receptors and that AREG promoted their growth. Furthermore, PD169540 (a pan-ErbB inhibitor) and IRESSA (an ErbB1-specific inhibitor) induced apoptosis of primary myeloma cells from 10/14 and 4/14 patients, respectively, and there was a synergistic effect with dexamethasone. Altogether, our data provide strong evidence that AREG plays an important role in the biology of MM and emphasize the advantages of using ErbB inhibitors, which might target myeloma cells as well as the tumor environment.	INSERM, U475, F-34000 Montpellier, France; Hop St Eloi, CHU Montpellier, Unit Cellular Therapy, F-34000 Montpellier, France; Univ Klinikum Heidelberg, Med Klin & Poliklin 5, D-69115 Heidelberg, Germany; CHU Nimes, Internal Med Dept B, F-30900 Nimes, France; Hop Lapeyronie, CHU Montpellier, Dept Clin Hematol, F-34000 Montpellier, France; Univ Klinikum Heidelberg, Inst Humangenet, D-69120 Heidelberg, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Ruprecht Karls University Heidelberg; Universite de Montpellier; CHU de Nimes; Universite de Montpellier; CHU de Montpellier; Ruprecht Karls University Heidelberg	Klein, B (corresponding author), INSERM, U475, 99 Rue Puech Villa, F-34197 Montpellier, France.	klein@montp.inserm.fr	De Vos, John/A-5703-2010; moreaux, jerome/HGA-5649-2022; J, Moreaux/ABA-2974-2021	De Vos, John/0000-0003-1880-4130; J, Moreaux/0000-0002-5717-3207				Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; Badache A, 2001, CANCER RES, V61, P383; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Claudio JO, 2002, BLOOD, V100, P2175, DOI 10.1182/blood-2002-01-0008; Costes V, 1999, HUM PATHOL, V30, P1405, DOI 10.1016/S0046-8177(99)90160-0; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Gu ZJ, 2000, LEUKEMIA, V14, P188, DOI 10.1038/sj.leu.2401632; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hynes NE, 2001, ENDOCR-RELAT CANCER, V8, P151, DOI 10.1677/erc.0.0080151; Inui S, 1997, J CELL PHYSIOL, V171, P291, DOI 10.1002/(SICI)1097-4652(199706)171:3<291::AID-JCP7>3.0.CO;2-J; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; JOURDAN M, 1991, J IMMUNOL, V147, P4402; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Klein B, 2003, INT J HEMATOL, V78, P106, DOI 10.1007/BF02983377; KLEIN B, 1989, BLOOD, V73, P517; LU ZY, 1995, BLOOD, V85, P2521, DOI 10.1182/blood.V85.9.2521.bloodjournal8592521; LU ZY, 1995, BLOOD, V86, P3123; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mahtouk K, 2004, BLOOD, V103, P1829, DOI 10.1182/blood-2003-05-1510; Manegold C, 2003, ADV EXP MED BIOL, V532, P247; Nylander N, 1998, IN VITRO CELL DEV-AN, V34, P182; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; Rebouissou C, 1998, BLOOD, V91, P4727, DOI 10.1182/blood.V91.12.4727.412k35_4727_4737; Sakuma T, 1997, J BIOCHEM-TOKYO, V122, P474; Shao JY, 2003, CANCER RES, V63, P5218; Tarte K, 2000, BLOOD, V96, p514A; Trikha M, 2003, CLIN CANCER RES, V9, P4653; UCHIYAMA H, 1993, BLOOD, V82, P3712; Walters DK, 2003, ONCOGENE, V22, P3598, DOI 10.1038/sj.onc.1206512; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Wang YD, 2002, ONCOGENE, V21, P2584, DOI 10.1038/sj.onc.1205355; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745; ZHANG XG, 1994, BLOOD, V83, P3654	38	77	83	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3512	3524		10.1038/sj.onc.1208536	http://dx.doi.org/10.1038/sj.onc.1208536			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735670	Green Accepted, Green Submitted			2022-12-25	WOS:000229038800013
J	Smith, D; Gray, J; Mitchell, L; Antholine, WE; Hosler, JP				Smith, D; Gray, J; Mitchell, L; Antholine, WE; Hosler, JP			Assembly of cytochrome-c oxidase in the absence of assembly protein Surf1p leads to loss of the active site heme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOBACTER-SPHAEROIDES; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL COX1P; PROTON UPTAKE; SUBUNIT-III; WILD-TYPE; YEAST; PURIFICATION; EXPRESSION	Surf1p is a protein of the inner membrane of mitochondria that functions in the assembly of cytochrome-c oxidase. The specifics of the role of Surf1p have remained unresolved. Numerous mutations in human Surf1p lead to severe mitochondrial disease. A homolog of human Surf1p is encoded by the genome of the alpha-proteobacterium Rhodobacter sphaeroides, which synthesizes a mitochondria-llike aa(3)-type cytochrome-c oxidase. The gene for Surf1p was deleted from the genome of R. sphaeroides. The resulting aa(3)-type oxidase was purified and analyzed by biochemical methods plus optical and EPR spectroscopy. The oxidase that assembled in the absence of Surf1p was composed of three subpopulations with structurally distinct heme a(3)-Cu-B active sites. 50% of the oxidase lacked heme a(3), 10-15% contained heme a3 but lacked Cu-B, and 35-40% had a normal heme (3)-Cu-B active site with normal activity. Cu-A assembly was unaffected. All of the oxidase contained low-spin heme a, but the environment of the heme a center was slightly altered in the 50% of the enzyme that lacked heme a3. Introduction of a normal copy of the gene for Surf1p on an exogenous plasmid resulted in a single population of normally assembled, highly active enzyme. The data indicate that Surf1p plays a role in facilitating the insertion of heme a3 into the active site of cytochrome-c oxidase. The results suggest that maturation of the heme a(3)-Cu-B center is a step that limits the association of subunits I and II in the assembly of mitochondrial cytochrome oxidase.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; Med Coll Wisconsin, Natl Biomed Esr Ctr, Dept Biophys, Milwaukee, WI 53226 USA	University of Mississippi; University of Mississippi Medical Center; Medical College of Wisconsin	Hosler, JP (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.	jhosler@biochem.umsmed.edu			NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB001980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056824] Funding Source: NIH RePORTER; NIBIB NIH HHS [EB001980] Funding Source: Medline; NIGMS NIH HHS [GM56824] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1976, BIOCHIM BIOPHYS ACTA, V422, P260, DOI 10.1016/0005-2744(76)90137-6; Agostino A, 2003, HUM MOL GENET, V12, P399, DOI 10.1093/hmg/ddg038; Barrientos A, 2004, EMBO J, V23, P3472, DOI 10.1038/sj.emboj.7600358; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Bratton MR, 1999, BIOCHEMISTRY-US, V38, P16236, DOI 10.1021/bi9914107; Bratton MR, 2000, BIOCHEMISTRY-US, V39, P12989, DOI 10.1021/bi0003083; Brown BM, 2004, BIOCHEMISTRY-US, V43, P13541, DOI 10.1021/bi048469k; CAO J, 1992, J BIOL CHEM, V267, P24273; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Choudhary M, 2004, J BACTERIOL, V186, P2019, DOI 10.1128/JB.186.7.2019-2027.2004; DONOHUE TJ, 1991, METHOD ENZYMOL, V204, P459; ERASO JM, 1994, J BACTERIOL, V176, P32, DOI 10.1128/JB.176.1.32-43.1994; GARCIAHORSMAN JA, 1994, BIOCHEMISTRY-US, V33, P3113, DOI 10.1021/bi00176a046; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Hiser L, 2001, J BIOL CHEM, V276, P45403, DOI 10.1074/jbc.M107016200; HOSLER JP, 1992, J BIOL CHEM, V267, P24264; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; Hunter DJB, 1997, FEBS LETT, V412, P43, DOI 10.1016/S0014-5793(97)00735-7; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Mashkevich G, 1997, J BIOL CHEM, V272, P14356, DOI 10.1074/jbc.272.22.14356; McEwan AG, 2002, FEBS LETT, V518, P10, DOI 10.1016/S0014-5793(02)02532-2; Mills DA, 2003, BIOCHEMISTRY-US, V42, P7410, DOI 10.1021/bi0341307; MITCHELL DM, 1995, FEBS LETT, V368, P148, DOI 10.1016/0014-5793(95)00626-K; MITCHELL DM, 1995, FEBS LETT, V374, P371, DOI 10.1016/0014-5793(95)01149-9; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; MITCHELL R, 1995, BIOCHEMISTRY-US, V34, P7576, DOI 10.1021/bi00023a003; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; Nijtmans LGJ, 2001, FEBS LETT, V498, P46, DOI 10.1016/S0014-5793(01)02447-4; Pecina P, 2004, PHYSIOL RES, V53, pS213; Perez-Martinez X, 2003, EMBO J, V22, P5951, DOI 10.1093/emboj/cdg566; Rich P. R., 1997, BIOENERGETICS, P418, DOI [10.1007/978-3-0348-8994-0_10, DOI 10.1007/978-3-0348-8994-0_10]; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SHAPLEIGH JP, 1992, MOL MICROBIOL, V6, P635, DOI 10.1111/j.1365-2958.1992.tb01511.x; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STEVENS TH, 1982, J BIOL CHEM, V257, P2106; Svensson-Ek M, 2002, J MOL BIOL, V321, P329, DOI 10.1016/S0022-2836(02)00619-8; TWEEDLE MF, 1978, J BIOL CHEM, V253, P8065; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005; Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200; Zhen Y, 1998, PROTEIN EXPRES PURIF, V13, P326, DOI 10.1006/prep.1998.0903	42	75	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17652	17656		10.1074/jbc.C500061200	http://dx.doi.org/10.1074/jbc.C500061200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15764605	hybrid			2022-12-25	WOS:000228807200012
J	Berquin, IM; Pang, B; Dziubinski, ML; Scott, LM; Chen, YQ; Nolan, GP; Ethier, SP				Berquin, IM; Pang, B; Dziubinski, ML; Scott, LM; Chen, YQ; Nolan, GP; Ethier, SP			Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells	ONCOGENE			English	Article						YB-1; NSEP1; EGF; EGFR; breast cancer; expression cloning	GROWTH-FACTOR RECEPTOR; HUMAN BREAST-CANCER; TOPOISOMERASE-II-ALPHA; GENE-EXPRESSION; NUCLEAR EXPRESSION; TUMOR PROGRESSION; FACTOR YB-1; IN-VITRO; DNA; ACTIVATION	The epidermal growth factor receptor ( EGFR) is linked to poor outcome in breast cancer, and resistance to hormonal therapy is often accompanied by activation of growth factor receptors. To investigate the mechanism(s) by which EGFR becomes activated in breast cancer, we screened a cDNA expression library for genes that mediate EGF-independent proliferation of human mammary epithelial cells (HMECs). We isolated the NSEP1 cDNA encoding Y-box-binding protein 1 (YB-1), a multifunctional transcriptional and translational regulator. This cDNA conferred growth factor independence to HMECs. YB-1-transduced cells overexpressed EGFR, but ErbB-2 (Her-2/neu) levels were unchanged. Moreover, EGFR was constitutively phosphorylated in the absence of exogenous ligand. In these cells, an EGFR-blocking antibody failed to inhibit proliferation, conditioned medium activity could not be detected, and the synthesis of EGFR ligands was reduced compared to parental cells. This suggests that EGFR is activated in a ligand-independent fashion. However, cell growth could be blocked with an ErbB kinase inhibitor, indicating that EGFR signaling plays a major role in YB-1-induced growth factor independence. Taken together, our results demonstrate that YB-1 overexpression can induce EGF independence in HMECs via activation of the EGFR pathway. This could represent one of the mechanisms by which YB-1 contributes to breast tumor aggressiveness.	Wake Forest Univ, Dept Pathol, Winston Salem, NC 27157 USA; Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Wake Forest Univ, Dept Canc Biol, Winston Salem, NC 27157 USA; Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	Wake Forest University; University of Michigan System; University of Michigan; Wake Forest University; Stanford University	Berquin, IM (corresponding author), Med Ctr Blvd, Winston Salem, NC 27157 USA.	iberquin@wfubmc.edu	Nolan, Garry/AAE-7903-2019; Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708; Nolan, Garry/0000-0002-8862-9043	NCI NIH HHS [R01 CA77416] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077416] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Berquin IM, 2001, ONCOGENE, V20, P4019, DOI 10.1038/sj.onc.1204537; Brandt R, 2000, ONCOGENE, V19, P2129, DOI 10.1038/sj.onc.1203520; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; Fox SB, 1997, J MAMMARY GLAND BIOL, V2, P131, DOI 10.1023/A:1026399613946; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Gaudreault I, 2004, NUCLEIC ACIDS RES, V32, P316, DOI 10.1093/nar/gkh170; Gee JMW, 2003, ENDOCRINOLOGY, V144, P5105, DOI 10.1210/en.2003-0705; Gimenez-Bonafe P, 2004, PROSTATE, V59, P337, DOI 10.1002/pros.20023; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; Gu CD, 2001, ANTICANCER RES, V21, P2357; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kajino K, 2001, INTERVIROLOGY, V44, P311, DOI 10.1159/000050063; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kersting C, 2004, LAB INVEST, V84, P582, DOI 10.1038/labinvest.3700077; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KOLLURI R, 1991, NUCLEIC ACIDS RES, V19, P4771, DOI 10.1093/nar/19.17.4771; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LI SW, 1992, J CELL PHYSIOL, V153, P103, DOI 10.1002/jcp.1041530114; Marenstein DR, 2001, J BIOL CHEM, V276, P21242, DOI 10.1074/jbc.M101594200; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Nair PN, 2001, ONCOGENE, V20, P8203, DOI 10.1038/sj.onc.1205044; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Rao GS, 2000, INT J RADIAT ONCOL, V48, P1519, DOI 10.1016/S0360-3016(00)01358-4; Rubinstein DB, 2002, CANCER RES, V62, P4985; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; SAKURA H, 1988, GENE, V73, P499; Salomon DS, 2000, CONT ENDOCRINOL, P137; Sartor CI, 1997, CANCER RES, V57, P978; Sato J D, 1983, Mol Biol Med, V1, P511; Sawano A, 2002, DEV CELL, V3, P245, DOI 10.1016/S1534-5807(02)00224-1; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Shibao K, 1999, INT J CANCER, V83, P732; Shirakata Y, 2000, J BIOL CHEM, V275, P5748, DOI 10.1074/jbc.275.8.5748; Smaill JB, 2000, J MED CHEM, V43, P1380, DOI 10.1021/jm990482t; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; Swamynathan SK, 2002, BIOCHEM BIOPH RES CO, V296, P451, DOI 10.1016/S0006-291X(02)00875-6; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Wan YS, 2001, CELL SIGNAL, V13, P139, DOI 10.1016/S0898-6568(00)00146-7; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WILLINGHAM MC, 1985, ATLAS IMMUNOFLUORESC; Woods Ignatoski Kathleen M., 1999, Endocrinology, V140, P3615; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865	61	52	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3177	3186		10.1038/sj.onc.1208504	http://dx.doi.org/10.1038/sj.onc.1208504			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735691				2022-12-25	WOS:000228728100011
J	Galli, UM; Sauter, M; Lecher, B; Maurer, S; Herbst, H; Roemer, K; Mueller-Lantzsch, N				Galli, UM; Sauter, M; Lecher, B; Maurer, S; Herbst, H; Roemer, K; Mueller-Lantzsch, N			Human endogenous retrovirus rec interferes with germ cell development in mice and may cause carcinoma in situ, the predecessor lesion of germ cell tumors	ONCOGENE			English	Article						endogenous retrovirus; Rec; Rev; Rex; germ cell tumor; PLZF	HTDV/HERV-K; PROTEIN; PLZF; EXPRESSION; TESTIS; IDENTIFICATION; FAMILY; CORF	Germ cell tumors (GCTs) are among the most common malignancies in young men. We have previously documented that patients with GCT frequently produce serum antibodies directed against proteins encoded by human endogenous retrovirus ( HERV) type K sequences. Transcripts originating from the env gene of HERV-K, including the rec-relative of human immunodeficiency virus rev, are highly expressed in GCTs. We report here that mice that inducibly express HERV-K rec show a disturbed germ cell development and may exhibit, by 19 months of age, changes reminiscent of carcinoma in situ, the predecessor lesion of classic seminoma in humans. This provides the first direct evidence that the expression of a human endogenous retroviral gene previously established as a marker in human germ cell tumors may contribute to organ-specific tumorigenesis in a transgenic mouse model.	Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany; Univ Mainz, MFD Diagnost Lab GdbR, D-55131 Mainz, Germany; Univ Hosp, Inst Pathol, D-48149 Munster, Germany	Saarland University; Johannes Gutenberg University of Mainz; University of Munster	Mueller-Lantzsch, N (corresponding author), Univ Saarland, Sch Med, Dept Virol, Bldg 47, D-66421 Homburg, Germany.	vinmue@uniklinik-saarland.de						Barbulescu M, 1999, CURR BIOL, V9, P861, DOI 10.1016/S0960-9822(99)80390-X; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Boese A, 2000, ONCOGENE, V19, P4328, DOI 10.1038/sj.onc.1203794; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Herbst H, 1996, AM J PATHOL, V149, P1727; Jurka J, 1998, CURR OPIN STRUC BIOL, V8, P333, DOI 10.1016/S0959-440X(98)80067-5; LEIBMOSCH C, 1996, VIRUS GENES, V11, P133; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; LOWER R, 1995, J VIROL, V69, P141; LOWER R, 1993, P NATL ACAD SCI USA, V90, P4480, DOI 10.1073/pnas.90.10.4480; Magin C, 1999, J VIROL, V73, P9496, DOI 10.1128/JVI.73.11.9496-9507.1999; Mangeney M, 1998, P NATL ACAD SCI USA, V95, P14920, DOI 10.1073/pnas.95.25.14920; Mayer J, 1999, NAT GENET, V21, P257, DOI 10.1038/6766; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Meng XJ, 2001, CANCER RES, V61, P3267; MOLLER H, 1993, EUR UROL, V23, P8; MOSTOFI FK, 1980, CANCER, V45, P1735, DOI 10.1002/cncr.1980.45.s7.1735; Patience C, 1997, TRENDS GENET, V13, P116, DOI 10.1016/S0168-9525(97)01057-3; Sauter M, 1996, CANCER RES, V56, P4362; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Veeramachaneni DNR, 1999, INT J ANDROL, V22, P97; Yang J, 1999, P NATL ACAD SCI USA, V96, P13404, DOI 10.1073/pnas.96.23.13404	25	91	96	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3223	3228		10.1038/sj.onc.1208543	http://dx.doi.org/10.1038/sj.onc.1208543			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735668	Bronze			2022-12-25	WOS:000228728100016
J	Mashour, GA; Drissel, SN; Frahm, S; Farassati, F; Martuza, RL; Mautner, VF; Rohrborn, AK; Kurtz, A				Mashour, GA; Drissel, SN; Frahm, S; Farassati, F; Martuza, RL; Mautner, VF; Rohrborn, AK; Kurtz, A			Differential modulation of malignant peripheral nerve sheath tumor growth by omega-3 and omega-6 fatty acids	ONCOGENE			English	Article						neurofibromatosis type 1; malignant peripheral nerve sheath tumor; essential fatty acids; fatty-acid binding protein; tumor growth regulation	LIPID-BINDING PROTEIN; NEUROFIBROMATOSIS TYPE-1; DOCOSAHEXAENOIC ACID; RHESUS-MONKEYS; SCHWANN-CELLS; CANCER CELLS; BRAIN; TUMORIGENESIS; EXPRESSION; OMEGA-3-FATTY-ACIDS	Neurofibromatosis type 1 (NF1) is a common genetic disorder of the nervous system resulting in neurofibromas and malignant peripheral nerve sheath tumors (MPNST). In this study, we report the modulation of murine and human MPNST cell growth by the fatty acids docosahexaenoic acid (DHA) and arachidonic acid (AA). DHA demonstrated a tendency to stimulate cell growth at low doses and induce apoptosis at high doses, paralleled by the activation of ERK and caspase-3. Furthermore, high-dose DHA reversed the stimulation of MPNST cell growth by a number of growth factors suggested to have a pathogenic effect in NF1 and inhibited MPNST growth in vivo. AA was found to have a reciprocal activity in vitro, stimulating MPNST cell growth at comparable concentrations and reducing DHA activation of ERK. These findings introduce fatty acids as a possible regulator of MPNST development in NF1 patients.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Neurosurg Lab, Charlestown, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA USA; Univ Bonn, Inst Neuropathol, D-5300 Bonn, Germany; Univ Hamburg, Dept Neurosurg, Hamburg, Germany; Klinikum Nord, Dept Neurol, Hamburg, Germany	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Bonn; University of Hamburg; Klinikum Nurnberg Nord	Kurtz, A (corresponding author), RKI, Stem Cells, Seestr 10, D-13353 Berlin, Germany.	kurtza@rki.de		Kurtz, Andreas/0000-0003-3301-6546	NINDS NIH HHS [NS37895] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS037895] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Badache A, 1998, J CELL PHYSIOL, V177, P334, DOI 10.1002/(SICI)1097-4652(199811)177:2<334::AID-JCP15>3.0.CO;2-9; Brand A, 2001, J NEUROCHEM, V76, P910, DOI 10.1046/j.1471-4159.2001.00085.x; Chung BH, 2001, CARCINOGENESIS, V22, P1201, DOI 10.1093/carcin/22.8.1201; Collett ED, 2001, AM J PHYSIOL-CELL PH, V280, pC1066, DOI 10.1152/ajpcell.2001.280.5.C1066; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; Dugoff L, 1996, AM J MED GENET, V66, P7, DOI 10.1002/(SICI)1096-8628(19961202)66:1<7::AID-AJMG2>3.0.CO;2-R; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Frahm S, 2004, NEUROBIOL DIS, V16, P85, DOI 10.1016/j.nbd.2004.01.006; Ghebremeskel K, 2000, LIPIDS, V35, P567, DOI 10.1007/s11745-000-557-3; Golubic M, 1998, NUTR CANCER, V30, P97, DOI 10.1080/01635589809514648; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; Hall J G, 1981, Adv Neurol, V29, P125; Hardman WE, 2002, J NUTR, V132, p3508S, DOI 10.1093/jn/132.11.3508S; Holman RT, 1998, J NUTR, V128, p427S, DOI 10.1093/jn/128.2.427S; Huson S. M., 1994, P160; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; Isikoglu M., 2002, Archives of Gynecology and Obstetrics, V267, P41, DOI 10.1007/s004040100239; KURTZ A, 1994, DEVELOPMENT, V120, P2637; Kurtz A, 2002, J CHILD NEUROL, V17, P578, DOI 10.1177/088307380201700807; Li HZ, 2002, CANCER RES, V62, P4507; Liu GM, 2001, P NATL ACAD SCI USA, V98, P7510, DOI 10.1073/pnas.131195198; Mashour GA, 2004, CLIN CANCER RES, V10, P5677, DOI 10.1158/1078-0432.CCR-03-0769; Mashour GA, 2001, ONCOGENE, V20, P97, DOI 10.1038/sj.onc.1204026; McLaughlin ME, 2003, CANCER RES, V63, P752; Miller SJ, 2003, MOL CELL BIOL, V23, P2213, DOI 10.1128/MCB.23.6.2213-2224.2003; NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021; NEURINGER M, 1984, J CLIN INVEST, V73, P272, DOI 10.1172/JCI111202; Pettersson F, 2004, ONCOGENE, V23, P7053, DOI 10.1038/sj.onc.1207956; REISBICK S, 1990, PHYSIOL BEHAV, V47, P315, DOI 10.1016/0031-9384(90)90149-X; RUYLE M, 1990, P NATL ACAD SCI USA, V87, P7902, DOI 10.1073/pnas.87.20.7902; Shaikh SR, 2003, BIOCHEMISTRY-US, V42, P12028, DOI 10.1021/bi034931+; SWAPP GH, 1973, BRIT J DERMATOL, V88, P431, DOI 10.1111/j.1365-2133.1973.tb15445.x; Theobald HE, 2004, AM J CLIN NUTR, V79, P558; Xu LZ, 1996, J BIOL CHEM, V271, P24711	36	12	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2367	2374		10.1038/sj.onc.1208425	http://dx.doi.org/10.1038/sj.onc.1208425			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735744				2022-12-25	WOS:000227877400009
J	Ceruti, JM; Scassa, ME; Flo, JM; Varone, CL; Canepa, ET				Ceruti, JM; Scassa, ME; Flo, JM; Varone, CL; Canepa, ET			Induction of p19INK4d in response to ultraviolet light improves DNA repair and confers resistance to apoptosis in neuroblastoma cells	ONCOGENE			English	Article						apoptosis; CDK4/6; DNA repair; INK4; neuroblastoma; UV	NUCLEOTIDE EXCISION-REPAIR; D-DEPENDENT KINASES; NF-KAPPA-B; TUMOR-SUPPRESSOR; CDK INHIBITORS; 5-AMINOLEVULINATE SYNTHASE; INK4 INHIBITORS; DEFICIENT CELLS; CANCER; CYCLE	The genetic instability driving tumorigenesis is fuelled by DNA damage and by errors made by the DNA replication. Upon DNA damage the cell organizes an integrated response not only by the classical DNA repair mechanisms but also involving mechanisms of replication, transcription, chromatin structure dynamics, cell cycle progression, and apoptosis. In the present study, we investigated the role of p19INK4d in the response driven by neuroblastoma cells against DNA injury caused by UV irradiation. We show that p19INK4d is the only INK4 protein whose expression is induced by UV light in neuroblastoma cells. Furthermore, p19INK4d translocation from cytoplasm to nucleus is observed after UV irradiation. Ectopic expression of p19INK4d clearly reduces the UV-induced apoptosis as well as enhances the cellular ability to repair the damaged DNA. It is clearly shown that DNA repair is the main target of p19INK4d effect and that diminished apoptosis is a downstream event. Importantly, experiments performed with CDK4 mutants suggest that these p19INK4d effects would be independent of its role as a cell cycle checkpoint gene. The results presented herein uncover a new role of p19INK4d as regulator of DNA-damage-induced apoptosis and suggest that it protects cells from undergoing apoptosis by allowing a more efficient DNA repair. We propose that, in addition to its role as cell cycle inhibitor, p19INK4d is involved in maintenance of DNA integrity and, therefore, would contribute to cancer prevention.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Mol Biol Lab, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Lab Inmunoquim, RA-1428 Buenos Aires, DF, Argentina	University of Buenos Aires; University of Buenos Aires	Canepa, ET (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Mol Biol Lab, Ciudad Univ Pabellon 2 Piso 4, RA-1428 Buenos Aires, DF, Argentina.	ecanepa@qb.fcen.uba.ar		Varone, Cecilia/0000-0001-5930-4082; Canepa, Eduardo T./0000-0002-4322-1650				Al-Mohanna MA, 2004, ONCOGENE, V23, P201, DOI 10.1038/sj.onc.1206927; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; Barret JM, 2002, BIOCHEM PHARMACOL, V63, P251, DOI 10.1016/S0006-2952(01)00835-8; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chaussade L, 2001, ONCOGENE, V20, P6587, DOI 10.1038/sj.onc.1204798; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Cunningham JJ, 2001, CELL GROWTH DIFFER, V12, P387; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fan CG, 2002, J CELL SCI, V115, P4843, DOI 10.1242/jcs.00151; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lim MA, 2003, P NATL ACAD SCI USA, V100, P14006, DOI 10.1073/pnas.2335486100; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lutzen A, 2004, EXP CELL RES, V292, P123, DOI 10.1016/j.yexcr.2003.08.018; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Martin G. Steven, 2003, Cancer Cell, V4, P167, DOI 10.1016/S1535-6108(03)00216-2; Matsuzaki Y, 2002, FEBS LETT, V517, P272, DOI 10.1016/S0014-5793(02)02647-9; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Miyamoto Y, 2004, J CELL BIOL, V165, P617, DOI 10.1083/jcb.200312008; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Newton-Bishop JA, 1999, BRIT J CANCER, V80, P295, DOI 10.1038/sj.bjc.6690354; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Rittie L, 2002, AGEING RES REV, V1, P705, DOI 10.1016/S1568-1637(02)00024-7; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; SADEE W, 1987, CANCER RES, V47, P5207; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sandal T, 2002, ONCOLOGIST, V7, P73, DOI 10.1634/theoncologist.7-1-73; Scassa ME, 2004, J BIOL CHEM, V279, P28082, DOI 10.1074/jbc.M401792200; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Sun YQ, 2004, MOL CELL BIOL, V24, P1531, DOI 10.1128/MCB.24.4.1531-1539.2004; Thullberg M, 2000, ONCOGENE, V19, P2870, DOI 10.1038/sj.onc.1203579; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Varone CL, 1999, ARCH BIOCHEM BIOPHYS, V372, P261, DOI 10.1006/abbi.1999.1470; Wang GD, 2004, ONCOL REP, V12, P955; Wilson AJ, 2003, CANCER RES, V63, P5401; Wu SY, 2004, J BIOL CHEM, V279, P34898, DOI 10.1074/jbc.M405616200; Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zindy F, 1999, P NATL ACAD SCI USA, V96, P13462, DOI 10.1073/pnas.96.23.13462; Zindy F, 1997, CELL GROWTH DIFFER, V8, P1139; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	69	42	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4065	4080		10.1038/sj.onc.1208570	http://dx.doi.org/10.1038/sj.onc.1208570			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15750620	Green Published			2022-12-25	WOS:000229680300006
J	Hutt, DM; Baltz, JM; Ngsee, JK				Hutt, DM; Baltz, JM; Ngsee, JK			Synaptotagmin VI and VIII and syntaxin 2 are essential for the mouse sperm acrosome reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZONA-PELLUCIDA; PHOSPHOLIPID-BINDING; TRANSMITTER RELEASE; INTRACELLULAR CA2+; MOLECULAR-CLONING; CALCIUM-CHANNELS; SNARE COMPLEXES; C2B DOMAIN; PROTEIN; EXOCYTOSIS	The sperm acrosome is a large secretory granule that undergoes calcium-stimulated exocytosis by a mechanism analogous to neuronal secretion. In neurons the core SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex, composed of syntaxin (Stx), SNAP-25, and VAMP2, mediates vesicle fusion, whereas calcium regulation is thought to be accomplished by the synaptotagmin (Syt) family, some of which exhibit calcium-dependent binding to syntaxin and SNAP-25. Sperm express Syt VI and VIII and Stx2, which are co-localized to the acrosomal compartment where they might mediate exocytosis in response to calcium influx. Therefore, we examined the calcium dependence and isoform-specific interaction of Syt and Stx. We found that Stx2 binds to Syt I, VI, and VIII in a calcium-dependent manner with EC50 values of 175, 233, and 96 mu M calcium, respectively. We also determined that the EC50 for calcium of the acrosome reaction in streptolysin O-permeabilized sperm is 87 mu M, which closely coincides with the calcium sensitivity of Stx2 and Syt VIII interaction. Consistent with this is the greater potency of recombinant Syt VIII, VI, and Stx2 compared with other isoforms in inhibiting the acrosome reaction in streptolysin O-permeabilized sperm. Similarly, introduction of Syt VIII-specific antibodies was equally effective in inhibiting the acrosome fusion. Taken together, our data suggest a critical role for Syt VIII and Stx2 in membrane fusion and acrosome reaction in the sperm.	Univ Ottawa, Ottawa Hlth Res Inst, Dept Cellular & Mol Med, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Obstet & Gynecol, Div Reprod Med, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Ngsee, JK (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Dept Cellular & Mol Med, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	jngsee@ohri.ca		Baltz, Jay/0000-0002-9749-2480				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; BAILEY JL, 1994, MOL REPROD DEV, V39, P297, DOI 10.1002/mrd.1080390307; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Brahmaraju M, 2004, BIOCHEM BIOPH RES CO, V318, P148, DOI 10.1016/j.bbrc.2004.04.006; BROADIE K, 1994, P NATL ACAD SCI USA, V91, P10727, DOI 10.1073/pnas.91.22.10727; Butz S, 1999, J BIOL CHEM, V274, P18290, DOI 10.1074/jbc.274.26.18290; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Charvin N, 1997, EMBO J, V16, P4591, DOI 10.1093/emboj/16.15.4591; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FLORMAN HM, 1994, DEV BIOL, V165, P152, DOI 10.1006/dbio.1994.1242; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; Fukuda M, 2003, BIOCHEM BIOPH RES CO, V306, P64, DOI 10.1016/S0006-291X(03)00911-2; Fukuda M, 2003, J BIOCHEM, V133, P641, DOI 10.1093/jb/mvg082; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; GREEN DPL, 1978, J CELL SCI, V32, P165; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; Hutt DM, 2002, BIOL REPROD, V66, P50, DOI 10.1095/biolreprod66.1.50; Irion U, 1999, CURR BIOL, V9, P1373, DOI 10.1016/S0960-9822(00)80082-2; Katafuchi K, 2000, MOL REPROD DEV, V57, P375, DOI 10.1002/1098-2795(200012)57:4&lt;375::AID-MRD10&gt;3.0.CO;2-Z; Kierszenbaum AL, 2000, MOL REPROD DEV, V57, P309, DOI 10.1002/1098-2795(200012)57:4&lt;309::AID-MRD1&gt;3.0.CO;2-W; Kobori H, 2000, BIOL REPROD, V63, P113, DOI 10.1095/biolreprod63.1.113; Larson JL, 1999, MOL REPROD DEV, V52, P445, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;445::AID-MRD14&gt;3.0.CO;2-6; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; MartinMoutot N, 1996, J BIOL CHEM, V271, P6567, DOI 10.1074/jbc.271.12.6567; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Meizel S, 1997, DEV BIOL, V182, P67, DOI 10.1006/dbio.1997.8477; Michaut M, 2000, P NATL ACAD SCI USA, V97, P9996, DOI 10.1073/pnas.180206197; Michaut M, 2001, DEV BIOL, V235, P521, DOI 10.1006/dbio.2001.0316; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; Murase T, 1996, BIOCHEM J, V320, P1017, DOI 10.1042/bj3201017; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Ramalho-Santos J, 2000, DEV BIOL, V223, P54, DOI 10.1006/dbio.2000.9745; Ramalho-Santos J, 2001, EXP CELL RES, V267, P45, DOI 10.1006/excr.2000.5119; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rickman C, 2004, BIOCHEM J, V378, P681, DOI 10.1042/BJ20031407; ROLDAN ERS, 1994, SCIENCE, V266, P1578, DOI 10.1126/science.7985030; Schulz JR, 1997, DEV BIOL, V191, P80, DOI 10.1006/dbio.1997.8712; Schulz JR, 1998, J BIOL CHEM, V273, P24355, DOI 10.1074/jbc.273.38.24355; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; SHI QX, 1995, BIOL REPROD, V52, P373, DOI 10.1095/biolreprod52.2.373; SPUNGIN B, 1995, J CELL SCI, V108, P2525; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Teng FYH, 2001, GENOME BIOL, V2; Terrian DM, 1997, EUR J CELL BIOL, V73, P198; Thompson CC, 1996, J NEUROSCI, V16, P7832; Tomes CN, 2002, DEV BIOL, V243, P326, DOI 10.1006/dbio.2002.0567; von Poser C, 2001, EUR J CELL BIOL, V80, P41; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Yunes R, 2000, BIOL REPROD, V62, P1084, DOI 10.1095/biolreprod62.4.1084	67	43	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20197	20203		10.1074/jbc.M412920200	http://dx.doi.org/10.1074/jbc.M412920200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15774481	hybrid			2022-12-25	WOS:000229242000006
J	Patil, MA; Chua, MS; Pan, KH; Lin, R; Lih, CJ; Cheung, ST; Ho, C; Li, R; Fan, ST; Cohen, SN; Chen, X; So, S				Patil, MA; Chua, MS; Pan, KH; Lin, R; Lih, CJ; Cheung, ST; Ho, C; Li, R; Fan, ST; Cohen, SN; Chen, X; So, S			An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma	ONCOGENE			English	Article						HCC; microarrays; gene expression; tumor markers	GENOME-WIDE ANALYSIS; IDENTIFICATION; CANCER; LIVER; GLYPICAN-3; PATTERNS; MARKERS	Hepatocellular carcinoma (HCC) is one of the major causes of cancer deaths worldwide. New diagnostic and therapeutic options are needed for more effective and early detection and treatment of this malignancy. We identified 703 genes that are highly expressed in HCC using DNA microarrays, and further characterized them in order to uncover novel tumor markers, oncogenes, and therapeutic targets for HCC. Using Gene Ontology annotations, genes with functions related to cell proliferation and cell cycle, chromatin, repair, and transcription were found to be significantly enriched in this list of highly expressed genes. We also identified a set of genes that encode secreted ( e. g. GPC3, LCN2, and DKK1) or membrane-bound proteins ( e. g. GPC3, IGSF1, and PSK-1), which may be attractive candidates for the diagnosis of HCC. A significant enrichment of genes highly expressed in HCC was found on chromosomes 1q, 6p, 8q, and 20q, and we also identified chromosomal clusters of genes highly expressed in HCC. The microarray analyses were validated by RT-PCR and PCR. This approach of integrating other biological information with gene expression in the analysis helps select aberrantly expressed genes in HCC that may be further studied for their diagnostic or therapeutic utility.	Stanford Univ, Dept Surg, Stanford, CA 94305 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Stanford Univ, Asian Liver Ctr, Stanford, CA 94305 USA; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Ctr Study Liver Dis, Hong Kong, Hong Kong, Peoples R China; Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA	Stanford University; University of California System; University of California San Francisco; Stanford University; University of Hong Kong; University of Hong Kong; University of California System; University of California San Francisco	Chen, X (corresponding author), Stanford Univ, Dept Surg, 300 Pasteur Dr,H3680, Stanford, CA 94305 USA.	xinchen@itsa.ucsf.edu; samso@stanford.edu	Cheung, Siu-Tim/C-4238-2009; Fan, Sheung Tat/C-4138-2009	Cheung, Siu-Tim/0000-0003-2147-315X; Chua, Mei-Sze/0000-0002-3282-4894	NCI NIH HHS [K01 CA096774] Funding Source: Medline; NIDDK NIH HHS [DK26743-22] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA096774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bohen SP, 2003, P NATL ACAD SCI USA, V100, P1926, DOI 10.1073/pnas.0437875100; Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456; Capurro M, 2003, GASTROENTEROLOGY, V125, P89, DOI 10.1016/S0016-5085(03)00689-9; Chen X, 2004, MODERN PATHOL, V17, P1198, DOI 10.1038/modpathol.3800167; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cheung ST, 2002, CANCER RES, V62, P4711; Crawley JJ, 2002, GENOME BIOL, V3; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El-Serag HB, 2002, J CLIN GASTROENTEROL, V35, pS72, DOI 10.1097/00004836-200211002-00002; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Gollin SM, 2004, CURR OPIN ONCOL, V16, P25, DOI 10.1097/00001622-200401000-00006; Helton WS, 2003, J GASTROINTEST SURG, V7, P401, DOI 10.1016/S1091-255X(02)00161-0; Hippo Y, 2004, CANCER RES, V64, P2418, DOI 10.1158/0008-5472.CAN-03-2191; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Lafaro KJ, 2015, SURG ONCOL CLIN N AM, V24, P1, DOI 10.1016/j.soc.2014.09.001; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Lee JS, 2002, HEPATOLOGY, V35, P1134, DOI 10.1053/jhep.2002.33165; LIN TY, 1987, BRIT J SURG, V74, P839, DOI 10.1002/bjs.1800740931; Mor E, 1998, ANN INTERN MED, V129, P643, DOI 10.7326/0003-4819-129-8-199810150-00013; Neo SY, 2004, HEPATOLOGY, V39, P944, DOI 10.1002/hep.20105; Nguyen MH, 2002, J CLIN GASTROENTEROL, V35, pS86, DOI 10.1097/00004836-200211002-00004; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Nishida N, 2003, HISTOL HISTOPATHOL, V18, P897, DOI 10.14670/HH-18.897; Okabe H, 2001, CANCER RES, V61, P2129; Pan KH, 2002, P NATL ACAD SCI USA, V99, P2118, DOI 10.1073/pnas.251687398; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Smith MW, 2003, CANCER RES, V63, P859; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Zhang H, 2003, P NATL ACAD SCI USA, V100, P3251, DOI 10.1073/pnas.2627983100	36	113	131	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3737	3747		10.1038/sj.onc.1208479	http://dx.doi.org/10.1038/sj.onc.1208479			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15735714				2022-12-25	WOS:000229346300005
J	Claudet, C; Angelov, D; Bouvet, P; Dimitrov, S; Bednar, J				Claudet, C; Angelov, D; Bouvet, P; Dimitrov, S; Bednar, J			Histone octamer instability under single molecule experiment conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE PARTICLE; INDIVIDUAL NUCLEOSOMES; CHROMATIN FIBER; DNA; TRANSCRIPTION; BINDING; DISSOCIATION; DISRUPTION; REVEALS; RELEASE	We have studied the sample concentration-dependent and external stress-dependent stability of native and reconstituted nucleosomal arrays. Whereas upon stretching a single chromatin fiber in a solution of very low chromatin concentration the statistical distribution of DNA length released upon nucleosome unfolding shows only one population centered around similar to 25 nm, in nucleosome stabilizing conditions a second population with average length of similar to 50 nm was observed. Using radioactively labeled histone H3 and H2B, we demonstrate that upon lowering the chromatin concentration to very low values, first the linker histones are released, followed by the H2A-H2B dimer, whereas the H3-H4 tetramer remains stably attached to DNA even at the lowest concentration studied. The nucleosomal arrays reconstituted on a 5 S rDNA tandem repeat exhibited similar behavior. This suggests that the 25-nm disruption length is a consequence of the histone H2A-H2B dimer dissociation from the histone octamer. In nucleosome stabilizing conditions, a full similar to 145 bp is constrained in the nucleosome. Our data demonstrate that the nucleosome stability and histone octamer integrity can be severely degraded in experiments where the sample concentration is low.	CNRS, Spectrometrie Phys Lab, UMR 5588, F-38402 St Martin Dheres, France; Ecole Normale Super Lyon, CNRS, UMR 5161, F-69007 Lyon, France; Inst Albert Bonniot, Lab Biol Mol & Cellulaire Differenciat, U309, F-38706 La Tronche, France; Ecole Normale Super Lyon, Lab Rech Joliot Curie, F-69007 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Ecole Normale Superieure de Lyon (ENS de LYON)	Bednar, J (corresponding author), CNRS, Spectrometrie Phys Lab, UMR 5588, BP87,140 Av Phys, F-38402 St Martin Dheres, France.	jbednar@spectro.ujf-grenoble.fr	Bednar, Jan/H-3648-2017; Angelov, Dimitar/K-2004-2017; Bednar, Jan/K-2162-2012; dimitrov, stefan/M-7697-2013; , Bouvet/AAC-8779-2020	Bednar, Jan/0000-0003-0879-6405; Angelov, Dimitar/0000-0002-5511-6647; dimitrov, stefan/0000-0002-1326-3630; Claudet, Cyrille/0000-0002-7733-8283; Bouvet, Philippe/0000-0003-4524-2233				Angelov D, 2004, EMBO J, V23, P3815, DOI 10.1038/sj.emboj.7600400; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; AUSIO J, 1984, J MOL BIOL, V176, P77, DOI 10.1016/0022-2836(84)90383-8; AUSIO J, 1984, J MOL BIOL, V177, P373, DOI 10.1016/0022-2836(84)90291-2; Bennink ML, 2001, NAT STRUCT BIOL, V8, P606, DOI 10.1038/89646; Brower-Toland BD, 2002, P NATL ACAD SCI USA, V99, P1960, DOI 10.1073/pnas.022638399; BURTON DR, 1978, NUCLEIC ACIDS RES, V5, P3643, DOI 10.1093/nar/5.10.3643; COTTON RW, 1981, NUCLEIC ACIDS RES, V9, P445, DOI 10.1093/nar/9.2.445; Cui Y, 2000, P NATL ACAD SCI USA, V97, P127, DOI 10.1073/pnas.97.1.127; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; Hayes JJ, 2001, CURR OPIN GENET DEV, V11, P124, DOI 10.1016/S0959-437X(00)00168-4; Kagalwala MN, 2004, EMBO J, V23, P2092, DOI 10.1038/sj.emboj.7600220; Katsani KR, 2003, CURR TOP MICROBIOL, V274, P113; Kulic IM, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.228101; LIBERTINI LJ, 1980, NUCLEIC ACIDS RES, V8, P3517, DOI 10.1093/nar/8.16.3517; LILLEY DMJ, 1979, NUCLEIC ACIDS RES, V7, P377, DOI 10.1093/nar/7.2.377; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1999, METH MOL B, V119, P1; Marko JF, 2003, BIOCHEM CELL BIOL, V81, P209, DOI 10.1139/o03-047; Marko JF, 1997, BIOPHYS J, V73, P2173, DOI 10.1016/S0006-3495(97)78248-1; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Scrittori L, 2001, J BIOL CHEM, V276, P30002, DOI 10.1074/jbc.M102701200; Thastrom A, 2004, BIOCHEMISTRY-US, V43, P736, DOI 10.1021/bi0302043; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; van Holde K.E., 1988, CHROMATIN; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; Wuite GJL, 2000, BIOPHYS J, V79, P1155, DOI 10.1016/S0006-3495(00)76369-7; YAGER TD, 1989, BIOCHEMISTRY-US, V28, P2271, DOI 10.1021/bi00431a045; Zlatanova J, 2002, J MUSCLE RES CELL M, V23, P377, DOI 10.1023/A:1023498120458	32	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19958	19965		10.1074/jbc.M500121200	http://dx.doi.org/10.1074/jbc.M500121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772075	Green Submitted, Green Published, hybrid			2022-12-25	WOS:000229113700065
J	Matsuda, S; Kamiya, Y; Yuzaki, M				Matsuda, S; Kamiya, Y; Yuzaki, M			Roles of the N-terminal domain on the function and quaternary structure of the ionotropic glutamate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-GATED CHANNELS; ION CHANNELS; SUBUNIT STOICHIOMETRY; KAINATE RECEPTORS; NMDA RECEPTORS; AMPA; DESENSITIZATION; TETRAMERIZATION; OLIGOMERIZATION; DETERMINANTS	The alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid (AMPA) subtype of ionotropic glutamate receptors (iGluRs) mediates fast excitatory neurotransmission in the mammalian brain. Although the most N-terminal leucine/isoleucine/valine-binding protein (LIVBP) domain is suggested to play a role in the initial assembly of iGluR subunits, it is unclear how this domain is arranged and functions in intact iGluRs. Similarly, although recent crystallographic analyses indicate that the isolated ligand-binding lysine/arginine/ornithine-binding protein domain forms a 2-fold symmetric dimer, the subunit stoichiometry of intact iGluRs remains elusive. Here, we developed a new approach to address these issues. The LIVBP domain of the GluR1 subunit of AMPA receptors was replaced by leucine-zipper peptides designed to form stable symmetric dimers, trimers, tetramers, or pentamers. All these mutant GluR1s were expressed in human embryonic kidney 293 cells and were transported to the cell surface as well as wild type GluR1. Functional and biochemical analyses indicated that these oligomerizing peptides specifically controlled the formation of the expected number of subunits in a channel complex. However, the channel function was only restored by the tetramer-forming peptide. Although the purified LIVBP domain of GluR1 formed a dimmer in solution, a dimer-forming peptide could not restore the function of GluR1. Moreover, a cross-linking assay indicated that four LIVBP domains are located in proximity to each other. These results suggest that the function of the LIVBP domain is not simply to form initial dimers but to adopt a conformation compatible with the overall tetrameric arrangement of subunits in intact AMPA receptors.	Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan; Yokohama City Univ, Sch Med, Dept Anesthesiol, Kanagawa 2360004, Japan	Keio University; Yokohama City University	Yuzaki, M (corresponding author), Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.	myuzaki@sc.itc.keio.ac.jp	Yuzaki, Michisuke/K-5328-2013; Matsuda, Shinji/GRR-5226-2022; Matsuda, Shinji/L-4727-2013	Yuzaki, Michisuke/0000-0002-5750-3544; Kamiya, Yoshinori/0000-0001-9790-9867				Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Ayalon G, 2005, J BIOL CHEM, V280, P15053, DOI 10.1074/jbc.M408413200; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; Bowie D, 2002, J NEUROSCI, V22, P3392; BROSE N, 1993, J BIOL CHEM, V268, P22663; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; Dingledine R, 1999, PHARMACOL REV, V51, P7; FerrerMontiel AV, 1996, P NATL ACAD SCI USA, V93, P2741, DOI 10.1073/pnas.93.7.2741; Greger IH, 2003, NEURON, V40, P763, DOI 10.1016/S0896-6273(03)00668-8; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hawkins LM, 1999, J BIOL CHEM, V274, P27211, DOI 10.1074/jbc.274.38.27211; He YJ, 2000, P NATL ACAD SCI USA, V97, P895, DOI 10.1073/pnas.97.2.895; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; Kohda K, 2000, NAT NEUROSCI, V3, P315, DOI 10.1038/73877; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Kuusinen A, 1999, J BIOL CHEM, V274, P28937, DOI 10.1074/jbc.274.41.28937; Leuschner WD, 1999, J BIOL CHEM, V274, P16907, DOI 10.1074/jbc.274.24.16907; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; Mansour M, 2001, NEURON, V32, P841, DOI 10.1016/S0896-6273(01)00520-7; Matsuda S, 2002, EUR J NEUROSCI, V16, P1507, DOI 10.1046/j.1460-9568.2002.02219.x; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Nakagawa T, 2005, NATURE, V433, P545, DOI 10.1038/nature03328; Opella SJ, 1999, NAT STRUCT BIOL, V6, P374, DOI 10.1038/7610; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; Pasternack A, 2002, J BIOL CHEM, V277, P49662, DOI 10.1074/jbc.M208349200; Robbins MJ, 1999, J NEUROCHEM, V72, P2539, DOI 10.1046/j.1471-4159.1999.0722539.x; Robert A, 2001, J NEUROSCI, V21, P5574, DOI 10.1523/JNEUROSCI.21-15-05574.2001; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Rothberg BS, 2003, J GEN PHYSIOL, V122, P501, DOI 10.1085/jgp.200308928; Safferling M, 2001, BIOCHEMISTRY-US, V40, P13948, DOI 10.1021/bi011143g; Shammat IM, 1999, NEURON, V23, P809, DOI 10.1016/S0896-6273(01)80038-6; Sobolevsky AI, 2004, NEURON, V41, P367, DOI 10.1016/S0896-6273(04)00008-X; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; Wang Y, 2003, EUR J NEUROSCI, V17, P1581, DOI 10.1046/j.1460-9568.2003.02595.x; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; Xia HH, 2002, J BIOL CHEM, V277, P47765, DOI 10.1074/jbc.M207122200; Zerangue N, 2000, P NATL ACAD SCI USA, V97, P3591, DOI 10.1073/pnas.060016797; Zhong HM, 2002, NATURE, V420, P193, DOI 10.1038/nature01201	43	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20021	20029		10.1074/jbc.M410513200	http://dx.doi.org/10.1074/jbc.M410513200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15781472	hybrid			2022-12-25	WOS:000229113700072
J	Novi, F; Stanasila, L; Giorgi, F; Corsini, GU; Cotecchia, S; Maggio, R				Novi, F; Stanasila, L; Giorgi, F; Corsini, GU; Cotecchia, S; Maggio, R			Paired activation of two components within muscarinic M-3 receptor dimers is required for recruitment of beta-arrestin-1 to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; CRYSTAL-STRUCTURE; VISUAL ARRESTIN; BETA-ARRESTIN; CROSS-TALK; BINDING; PHOSPHORYLATION; INTERNALIZATION; DOPAMINE; DIMERIZATION	beta-Arrestins regulate the functioning of G protein-coupled receptors in a variety of cellular processes including receptor-mediated endocytosis and activation of signaling molecules such as ERK. A key event in these processes is the G protein-coupled receptor-mediated recruitment of beta-arrestins to the plasma membrane. However, despite extensive knowledge in this field, it is still disputable whether activation of signaling pathways via beta-arrestin recruitment entails paired activation of receptor dimers. To address this question, we investigated the ability of different muscarinic receptor dimers to recruit beta-arrestin-1 using both co-immunoprecipitation and fluorescence microscopy in COS-7 cells. Experimentally, we first made use of a mutated muscarinic M-3 receptor, which is deleted in most of the third intracellular loop (M-3-short). Although still capable of activating phospholipase C, this receptor loses almost completely the ability to recruit beta-arrestin- 1 following carbachol stimulation in COS-7 cells. Subsequently, M-3-short was co-expressed with the M-3 receptor. Under these conditions, the M-3/M-3-short heterodimer could not recruit beta-arrestin- 1 to the plasma membrane, even though the control M-3/M-3 homodimer could. We next tested the ability of chimeric adrenergic muscarinic alpha(2)/M-3 and M-3/alpha(2) heterodimeric receptors to co-immunoprecipitate with beta-arrestin- 1 following stimulation with adrenergic and muscarinic agonists. beta-Arrestin-1 co-immunoprecipitation could be induced only when carbachol or clonidine were given together and not when the two agonists were supplied separately. Finally, we tested the reciprocal influence that each receptor may exert on the M-2/M-3 heterodimer to recruit beta-arrestin-1. Remarkably, we observed that M-2/M-3 heterodimers recruit significantly greater amounts of beta-arrestin-1 than their respective M-3/M-3 or M-2/M-2 homodimers. Altogether, these findings provide strong evidence in favor of the view that binding of beta-arrestin-1 to muscarinic M-3 receptors requires paired stimulation of two receptor components within the same receptor dimer.	Univ Pisa, Dept Neurosci, I-56100 Pisa, Italy; Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Pisa; University of Lausanne	Maggio, R (corresponding author), Univ Pisa, Dept Neurosci, Via Roma 55, I-56100 Pisa, Italy.	r.maggio@drugs.med.unipi.it	maggio, Roberto/Q-2032-2015	Maggio, Roberto/0000-0003-4436-2356				Agnati LF, 2003, PHARMACOL REV, V55, P509, DOI 10.1124/pr.55.3.2; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; Budd DC, 2001, J BIOL CHEM, V276, P4581, DOI 10.1074/jbc.M008827200; Chinault SL, 2004, J BIOL CHEM, V279, P16091, DOI 10.1074/jbc.M311099200; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dessy C, 2000, EMBO J, V19, P4272, DOI 10.1093/emboj/19.16.4272; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hillion J, 2002, J BIOL CHEM, V277, P18091, DOI 10.1074/jbc.M107731200; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Hornigold DC, 2003, BRIT J PHARMACOL, V138, P1340, DOI 10.1038/sj.bjp.0705178; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Maggio R, 1999, J PHARMACOL EXP THER, V291, P251; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAGGIO R, 1994, EUR J PHARM-MOLEC PH, V268, P459, DOI 10.1016/0922-4106(94)90075-2; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Mhaouty-Kodja S, 1999, MOL PHARMACOL, V55, P339, DOI 10.1124/mol.55.2.339; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Novi F, 2004, J BIOL CHEM, V279, P7476, DOI 10.1074/jbc.M306818200; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Scarselli M, 2001, J BIOL CHEM, V276, P30308, DOI 10.1074/jbc.M102297200; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	35	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19768	19776		10.1074/jbc.M411281200	http://dx.doi.org/10.1074/jbc.M411281200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769745	hybrid			2022-12-25	WOS:000229113700043
J	Zhang, XL; Li, J; Sejas, DP; Pang, QS				Zhang, XL; Li, J; Sejas, DP; Pang, QS			The ATM/p53/p21 pathway influences cell fate decision between apoptosis and senescence in reoxygenated hematopoietic progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FANCONI-ANEMIA; DNA-DAMAGE; C-MYC; IN-VIVO; ATM; P53; INSTABILITY; HYPOXIA	Hematopoietic cells are often exposed to transient hypoxia as they develop and migrate between blood and tissues. We tested the hypothesis that hypoxia-thenreoxygenation represent a stress for hematopoietic progenitor cells. Here we report that reoxygenation-generated oxidative stress induced senescence, tested as staining for SA-beta-galactosidase (SA-beta-gal), of bone marrow progenitor cells. Reoxygenation induced significant DNA damage and inhibited colony formation in lineage-depleted bone marrow cells enriched for progenitor cells. These reoxygenated cells exhibited a prolonged G(0)/G(1) accumulation without significant apoptosis after 24 h of treatments. Reoxygenated bone marrow progenitor cells expressed SA-beta-gal and senescence-associated proteins p53 and p21(WAF1). Reoxygenated Fancc(-/-) progenitor cells, which underwent significant apoptosis and senescence, tested as staining for SA-beta-gal, also expressed p16(INK4A). Suppression of apoptosis by the pancaspase inhibitor benzyloxycarbonyl-VAD-fluoromethyl ketone dramatically increased senescent Fancc(-/-) progenitor cells. Senescence induction, tested as staining for SA-beta-gal, in reoxygenated progenitor cells was closely correlated with extent of DNA damage and phosphorylation of ATM at Ser-1981 and p53 at Ser-15. Moreover, inhibition of ATM signaling reduced SA-beta-gal positivity but increased apoptosis of reoxygenated progenitor cells. Thus, these results suggest that the ATM/p53/p21 pathway influences cell fate decision between apoptosis and senescence in reoxygenated hematopoietic progenitor cells.	Cincinnati Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Pang, QS (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Expt Hematol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	qishen.pang@cchmc.org						AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bagby GC, 2003, CURR OPIN HEMATOL, V10, P68, DOI 10.1097/00062752-200301000-00011; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Chen M, 1996, NAT GENET, V12, P448, DOI 10.1038/ng0496-448; Chen QM, 2000, ANN NY ACAD SCI, V908, P111; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Hammond EM, 2004, DNA REPAIR, V3, P1117, DOI 10.1016/j.dnarep.2004.03.035; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Huang S, 2003, ONCOGENE, V22, P3721, DOI 10.1038/sj.onc.1206490; KOGURE K, 1982, NEUROCHEM RES, V7, P437, DOI 10.1007/BF00965496; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Maciejewski JP, 2003, ARCH MED RES, V34, P520, DOI 10.1016/j.arcmed.2003.09.009; Saadatzadeh MR, 2004, J BIOL CHEM, V279, P16805, DOI 10.1074/jbc.M313721200; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J; Tischkowitz M, 2004, BRIT J HAEMATOL, V126, P176, DOI 10.1111/j.1365-2141.2004.05023.x; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8	23	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19635	19640		10.1074/jbc.M502262200	http://dx.doi.org/10.1074/jbc.M502262200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15753076	hybrid			2022-12-25	WOS:000229113700027
J	Bai, Y; Onuma, H; Bai, X; Medvedev, AV; Misukonis, M; Weinberg, JB; Cao, WH; Robidoux, J; Floering, LM; Daniel, KW; Collins, S				Bai, Y; Onuma, H; Bai, X; Medvedev, AV; Misukonis, M; Weinberg, JB; Cao, WH; Robidoux, J; Floering, LM; Daniel, KW; Collins, S			Persistent nuclear factor-kappa B activation in UCP2-/- mice leads to enhanced nitric oxide and inflammatory cytokine production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL UNCOUPLING PROTEINS; NADPH PHAGOCYTE OXIDASE; BETA-CELL DYSFUNCTION; MACROPHAGES IN-VITRO; BACTERIAL LIPOPOLYSACCHARIDE; EXPERIMENTAL SALMONELLOSIS; ANTIMICROBIAL ACTIONS; TRANSCRIPTION FACTOR; INSULIN-RESISTANCE; P50 HOMODIMERS	One of the phenotypes of mice with targeted disruption of the uncoupling protein-2 gene (Ucp2-/-) is greater macrophage phagocytic activity and free radical production, resulting in a striking resistance to infectious microorganisms. In this study, the molecular mechanisms of this enhanced immune response were investigated. We found that levels of nitric oxide measured in either plasma or isolated macrophages from Ucp2-/- mice are significantly elevated in response to bacterial lipopolysaccharide challenge compared with similarly treated Ucp2+/+ mice. Likewise, expression of inducible nitric-oxide synthase and inflammatory cytokines is higher in Ucp2-/- mice in vivo and in vitro. Key steps in the activation cascade of nuclear factor (NF)-kappa B, including I kappa B kinase and nuclear translocation of NF-kappa B subunits, are all remarkably enhanced in Ucp2-/- mice, most notably even under basal conditions. The elevated basal activity of I kappa B kinase in macrophages from Ucp2-/- mice can be blocked by cell-permeable inhibitors of superoxide and hydrogen peroxide generation, but not by a specific inhibitor for inducible nitric-oxide synthase. Isolated mitochondria from Ucp2-/- cells produced more superoxide/hydrogen peroxide. We conclude that mitochrondrially derived reactive oxygen from Ucp2-/- cells constitutively activates NF-kappa B, resulting in a "primed" state to both potentiate and amplify the inflammatory response upon subsequent stimulation.	CIIT Ctr Hlth Res, Endocrine Biol Program, Div Biol Sci, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Vet Adm Med Ctr, Div Hematol Oncol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Vet Adm Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Collins, S (corresponding author), CIIT Ctr Hlth Res, Endocrine Biol Program, Div Biol Sci, 6 Davis Dr,POB 12137, Res Triangle Pk, NC 27709 USA.	scollins@ciit.org		Robidoux, JAcques/0000-0002-4809-4734; Medvedev, Alexander/0000-0001-6983-1687	NIDDK NIH HHS [R01-DK54024, R01 DK054024] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054024] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; Blanc J, 2003, CIRCULATION, V107, P388, DOI 10.1161/01.CIR.0000051722.66074.60; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Bonetta L, 2004, NAT METHODS, V1, P169, DOI 10.1038/nmeth1104-169; Bourke E, 2000, J BIOL CHEM, V275, P39996, DOI 10.1074/jbc.M007693200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bureau F, 2000, J IMMUNOL, V165, P5822, DOI 10.4049/jimmunol.165.10.5822; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Chase AJ, 2002, ARTERIOSCL THROM VAS, V22, P765, DOI 10.1161/01.ATV.0000015078.09208.92; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; Couplan E, 2002, J BIOL CHEM, V277, P26268, DOI 10.1074/jbc.M202535200; Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013; De Plaen IG, 1998, BBA-LIPID LIPID MET, V1392, P185, DOI 10.1016/S0005-2760(98)00024-1; Dulloo AG, 2001, BRIT J NUTR, V86, P123, DOI 10.1079/BJN2001412; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Jaburek M, 2004, J BIOL CHEM, V279, P53097, DOI 10.1074/jbc.M405339200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jezek P, 2004, PHYSIOL RES, V53, pS199; Kim SH, 2002, J CELL BIOL, V159, P821, DOI 10.1083/jcb.200112131; Kizaki T, 2002, P NATL ACAD SCI USA, V99, P9392, DOI 10.1073/pnas.142206299; Krauss S, 2003, J CLIN INVEST, V112, P1831, DOI 10.1172/JCI200319774; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Lembertas AV, 1997, J CLIN INVEST, V100, P1240, DOI 10.1172/JCI119637; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; LIEW FY, 1990, J IMMUNOL, V144, P4794; LIOCHEV SI, 1995, ARCH BIOCHEM BIOPHYS, V318, P408, DOI 10.1006/abbi.1995.1247; Mastroeni P, 2000, J EXP MED, V192, P237, DOI 10.1084/jem.192.2.237; Matsuura M, 2003, EUR J BIOCHEM, V270, P4016, DOI 10.1046/j.1432-1033.2003.03792.x; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741; Nedergaard J, 1999, J BIOENERG BIOMEMBR, V31, P475, DOI 10.1023/A:1005400507802; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Oberkofler H, 2005, ARTERIOSCL THROM VAS, V25, P604, DOI 10.1161/01.ATV.0000153141.42033.22; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Pecqueur C, 2001, J MOL MED, V79, P48, DOI 10.1007/s001090000150; Pi JB, 2003, FREE RADICAL BIO MED, V35, P102, DOI 10.1016/S0891-5849(03)00269-7; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; Shoelson SE, 2003, INT J OBESITY, V27, pS49, DOI 10.1038/sj.ijo.0802501; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; Vancurova I, 2002, J VIROL, V76, P1533, DOI 10.1128/JVI.76.3.1533-1536.2002; Vazquez-Torres A, 2000, J EXP MED, V192, P227, DOI 10.1084/jem.192.2.227; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; Werner ER, 2002, J BIOL CHEM, V277, P10129, DOI 10.1074/jbc.M107326200; Willerson JT, 2004, CIRCULATION, V109, P2, DOI 10.1161/01.CIR.0000129535.04194.38; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	61	107	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19062	19069		10.1074/jbc.M500566200	http://dx.doi.org/10.1074/jbc.M500566200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757894	Green Accepted, hybrid			2022-12-25	WOS:000228932300062
J	Chen, HX; Rubin, E; Zhang, HP; Chung, S; Jie, CC; Garrett, E; Biswal, S; Sukumar, S				Chen, HX; Rubin, E; Zhang, HP; Chung, S; Jie, CC; Garrett, E; Biswal, S; Sukumar, S			Identification of transcriptional targets of HOXA5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PLEIOTROPHIN GENE-EXPRESSION; MAMMARY-GLAND DEVELOPMENT; DNA-BINDING; HOMEODOMAIN PROTEINS; HOMEOBOX GENES; MESSENGER-RNA; SPECIFICITY; ACTIVATION; CANCER	The homeobox gene HOXA5 encodes a transcription factor that has been shown to play important roles in embryogenesis, hematopoiesis, and tumorigenesis. In order to decipher downstream signaling pathways of HOXA5, we utilized oligonucleotide microarray analysis to identify genes that are differentially expressed in HOXA5-induced cells compared with uninduced cells. Comparative analysis of gene expression changes after 9 h of HOXA5 induction in Hs578T breast cancer cells identified 306 genes whose expression was modulated at least 2-fold. Ten of these 306 genes were also up-regulated by at least 2-fold at 6 h post-induction. The expression of all of these 10 genes was confirmed by semi-quantitative reverse transcription-PCR. Among these 10 genes, which are most likely to be direct targets of HOXA5, we initiated an investigation into the pleiotrophin gene by first cloning its promoter. Transient transfection assays indicated that HOXA5 can specifically activate the pleiotrophin promoter. Promoter deletion, chromatin immunoprecipitation assay, and gel-shift assays were performed to show that HOXA5 can directly bind to one binding site on the pleiotrophin promoter. These data strongly suggest that microarray analysis can successfully identify many potential direct downstream genes of HOXA5. Further functional analysis of these targets will allow us to better understand the diverse functions of HOXA5 in embryonic development and tumorigenesis.	Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Breast Canc Program, Baltimore, MD 21231 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat & Clin Trials, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Sukumar, S (corresponding author), Johns Hopkins Univ Hosp, Ctr Comprehens Canc, 1650 Orleans St,CRB410, Baltimore, MD 21231 USA.	saras@jhmi.edu			NATIONAL CANCER INSTITUTE [P50CA088843] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA88843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Aubin J, 1997, DEV BIOL, V192, P432, DOI 10.1006/dbio.1997.8746; Aubin J, 2002, DEVELOPMENT, V129, P4075; Aubin J, 1999, AM J PHYSIOL-CELL PH, V277, pC965, DOI 10.1152/ajpcell.1999.277.5.C965; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Chen HX, 2003, CANCER BIOL THER, V2, P524, DOI 10.4161/cbt.2.5.525; Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004; Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117; Crooks GM, 1999, BLOOD, V94, P519, DOI 10.1182/blood.V94.2.519.414k20_519_528; Deuel TF, 2002, ARCH BIOCHEM BIOPHYS, V397, P162, DOI 10.1006/abbi.2001.2705; DONY C, 1987, EMBO J, V6, P2965, DOI 10.1002/j.1460-2075.1987.tb02602.x; Dorsam ST, 2004, BLOOD, V103, P1676, DOI 10.1182/blood-2003-07-2202; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Fuller JF, 1999, BLOOD, V93, P3391, DOI 10.1182/blood.V93.10.3391.410k26_3391_3400; Ghannam G, 2004, J BIOL CHEM, V279, P866, DOI 10.1074/jbc.M307280200; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Goodwin RG, 1998, APOPTOSIS, V3, P83, DOI 10.1023/A:1009640823621; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; Hedlund E, 2004, J NEUROSCI RES, V75, P307, DOI 10.1002/jnr.10844; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Lewis MT, 2000, BREAST CANCER RES, V2, P158, DOI 10.1186/bcr49; LI YS, 1992, J BIOL CHEM, V267, P26011; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LI YS, 1992, BIOCHEM BIOPH RES CO, V184, P427, DOI 10.1016/0006-291X(92)91211-8; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Mannervik M, 1999, BIOESSAYS, V21, P267, DOI 10.1002/(SICI)1521-1878(199904)21:4<267::AID-BIES1>3.3.CO;2-3; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; ODENWALD WF, 1989, GENE DEV, V3, P158, DOI 10.1101/gad.3.2.158; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; PELLERIN I, 1994, MOL CELL BIOL, V14, P4532, DOI 10.1128/MCB.14.7.4532; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Phelan ML, 1997, J BIOL CHEM, V272, P8635, DOI 10.1074/jbc.272.13.8635; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Raman V, 2000, J BIOL CHEM, V275, P26551, DOI 10.1074/jbc.C000324200; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; Sanlioglu S, 1998, J NEUROBIOL, V36, P559, DOI 10.1002/(SICI)1097-4695(19980915)36:4<559::AID-NEU9>3.0.CO;2-V; Sharkey M, 1997, TRENDS GENET, V13, P145, DOI 10.1016/S0168-9525(97)01096-2; Shen J, 2000, EXP CELL RES, V259, P274, DOI 10.1006/excr.2000.4963; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; SilosSantiago I, 1996, J NEUROBIOL, V31, P283, DOI 10.1002/(SICI)1097-4695(199611)31:3<283::AID-NEU2>3.0.CO;2-6; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Suzuki M, 2003, J BIOL CHEM, V278, P30148, DOI 10.1074/jbc.M303932200; TANI M, 1989, J NEUROSCI RES, V24, P457, DOI 10.1002/jnr.490240402; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Tkatchenko AV, 2001, DEVELOPMENT, V128, P1547; VANDERWINDEN JM, 1992, ANAT EMBRYOL, V186, P387; Vigano MA, 1998, MOL CELL BIOL, V18, P6201, DOI 10.1128/MCB.18.11.6201; Yeh HJ, 1998, J NEUROSCI, V18, P3699; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732; Zhao YX, 2001, DEVELOPMENT, V128, P3197	56	45	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19373	19380		10.1074/jbc.M413528200	http://dx.doi.org/10.1074/jbc.M413528200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757903	hybrid			2022-12-25	WOS:000228932300095
J	Caillaud, A; Hovanessian, AG; Levy, DE; Marie, IJ				Caillaud, A; Hovanessian, AG; Levy, DE; Marie, IJ			Regulatory serine residues mediate phosphorylation-dependent and phosphorylation-independent activation of interferon regulatory factor 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; IKK-EPSILON; POSITIVE FEEDBACK; CRYSTAL-STRUCTURE; VIRAL-INFECTION; VIRUS-INFECTION; KINASES; COMPLEX; GENES; FACTOR-7	Interferon regulatory factor (IRF)7 is a key transcription factor required for establishment of antiviral resistance. In response to infection, IRF7 is activated by phosphorylation through the action of the non-canonical I kappa B kinases, I kappa B kinase-epsilon and TANK-binding kinase 1. Activation leads to nuclear retention, DNA binding, and derepression of transactivation ability. Clusters of serine residues located in the carboxyl-terminal regulatory domain of IRF7 are putative targets of virus-activated kinases. However, the exact sites of phosphorylation have not yet been established. Here, we report a comprehensive structure-activity examination of potential IRF7 phosphorylation sites through analysis of mutant proteins in which specific serine residues were altered to alanine or aspartate. Phosphorylation patterns of these mutants were analyzed by two-dimensional gel electrophoresis, and their transcriptional activity was monitored by reporter assays. Essential phosphorylation events were mapped to amino acids 437-438 and a redundant set of sites at either amino acids 429-431 or 441. IRF7 recovered from infected cells was heterogeneously phosphorylated at these sites, and greater phosphorylation correlated with increased transactivation. Interestingly, a distinct serine cluster conserved in the related protein IRF3 was also essential for IRF7 activation and distal phosphorylation. However, the essential role of this motif did not appear to be fulfilled by phosphorylation. Rather, these serine residues and an adjacent leucine were required for phosphorylation at distal sites and may determine a conformational element required for function.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, NYU Canc Inst, New York, NY 10016 USA; Inst Pasteur, Unite Virol & Immunol Cellulaire, F-75724 Paris, France	New York University; New York University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Marie, IJ (corresponding author), NYU, Sch Med, Dept Pathol, 550 1St Ave, New York, NY 10016 USA.	mariei01@med.nyu.edu	Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Levy, David/0000-0002-7320-7788; Marie, Isabelle/0000-0002-3091-7624	NIAID NIH HHS [P01 AI048204, R01 AI028900, R01 AI046503, U54 AI05715801, P01 AI48204] Funding Source: Medline; PHS HHS [R01 A146503] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046503, P01AI048204, R01AI028900] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Holzberg D, 2003, J BIOL CHEM, V278, P40213, DOI 10.1074/jbc.M304058200; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P805, DOI 10.1093/nar/13.3.805; Levy DE, 2004, NAT IMMUNOL, V5, P699, DOI 10.1038/ni0704-699; Levy DE, 1998, METHODS, V15, P167, DOI 10.1006/meth.1998.0621; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Mori M, 2004, J BIOL CHEM, V279, P9698, DOI 10.1074/jbc.M310616200; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Qin BY, 2003, NAT STRUCT BIOL, V10, P913, DOI 10.1038/nsb1002; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Takahasi K, 2003, NAT STRUCT BIOL, V10, P922, DOI 10.1038/nsb1001; tenOever BR, 2004, J VIROL, V78, P10636, DOI 10.1128/JVI.78.19.10636-10649.2004; Yang HM, 2003, J BIOL CHEM, V278, P15495, DOI 10.1074/jbc.M212940200	26	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17671	17677		10.1074/jbc.M411389200	http://dx.doi.org/10.1074/jbc.M411389200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15743772	Green Accepted, hybrid			2022-12-25	WOS:000228807200015
J	Meani, N; Minardi, S; Licciulli, S; Gelmetti, V; Lo Coco, F; Nervi, C; Pelicci, PG; Muller, H; Alcalay, M				Meani, N; Minardi, S; Licciulli, S; Gelmetti, V; Lo Coco, F; Nervi, C; Pelicci, PG; Muller, H; Alcalay, M			Molecular signature of retinoic acid treatment in acute promyelocytic leukemia	ONCOGENE			English	Article						differentiation therapy; acute myeloid leukemia; transcriptional regulation; expression profiling; transcription factor binding sites	PML-RAR-ALPHA; GENE-EXPRESSION; INDUCED DIFFERENTIATION; TRANSLOCATION PRODUCTS; FUSION PROTEINS; CELLS; IDENTIFICATION; HEMATOPOIESIS; METHYLATION; COMMITMENT	Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by a block of differentiation at the promyelocytic stage. APL patients respond to pharmacological concentrations of all-trans retinoic acid ( RA) and disease remission correlates with terminal differentiation of leukemic blasts. The PML/RAR oncogenic transcription factor is responsible for both the pathogenesis of APL and for its sensitivity to RA. In order to identify physiological targets of RA therapy, we analysed gene expression profiles of RA-treated APL blasts and found 1056 common target genes. Comparing these results to those obtained in RA-treated U937 cell lines revealed that transcriptional response to RA is largely dependent on the expression of PML/RAR. Several genes involved in the control of differentiation and stem cell renewal are early targets of RA regulation, and may be important effectors of RA response. Modulation of chromatin modifying genes was also observed, suggesting that specific structural changes in local chromatin domains may be required to promote RA-mediated differentiation. Computational analysis of upstream genomic regions in RA target genes revealed nonrandom distribution of transcription factor binding sites, indicating that specific transcriptional regulatory complexes may be involved in determining RA response.	Italian Fdn Canc Res, IFOM, Inst Mol Oncol, I-20139 Milan, Italy; European Inst Oncol, I-20141 Milan, Italy; San Raffaele Biomed Sci Pk Rome, I-00128 Rome, Italy; Univ Roma Tor Vergata, Dept Biopathol, Rome, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Rome Tor Vergata	Alcalay, M (corresponding author), Italian Fdn Canc Res, IFOM, Inst Mol Oncol, Via Adamello 16, I-20139 Milan, Italy.	myriam.alcalay@ifom-ieo-campus.it	Pelicci, Pier Giuseppe/AAL-6572-2020; Alcalay, Myriam/B-3182-2016; Alcalay, Myriam/AAB-4300-2019	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Muller, Heiko/0000-0001-9873-3146; NERVI, Clara/0000-0001-9341-0188; Minardi, Simone Paolo/0000-0001-7303-3821				Alberta JA, 2003, BLOOD, V101, P2570, DOI 10.1182/blood-2002-06-1656; Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Benedetti L, 1996, BLOOD, V87, P1939; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; FAZI F, 2005, IN PRESS ONCOGENE; Finocchiaro G, 2004, BIOINFORMATICS, V20, P3670, DOI 10.1093/bioinformatics/bth416; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Guo Y, 2003, BLOOD, V102, P2428, DOI 10.1182/blood-2003-02-0634; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hollander M, 1973, NONPARAMETRIC STAT M; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Lee KH, 2002, BIOCHEM BIOPH RES CO, V296, P1125, DOI 10.1016/S0006-291X(02)02043-0; Leone G, 2003, CLIN IMMUNOL, V109, P89, DOI 10.1016/S1521-6616(03)00207-9; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; Meng GY, 2000, GENE, V242, P59, DOI 10.1016/S0378-1119(99)00477-1; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Ohneda O, 2001, BLOOD, V98, P2134, DOI 10.1182/blood.V98.7.2134; Park DJ, 2003, BLOOD, V102, P3727, DOI 10.1182/blood-2003-02-0412; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Radtke F, 2002, IMMUNOL REV, V187, P65, DOI 10.1034/j.1600-065X.2002.18706.x; Segalla S, 2003, MOL CELL BIOL, V23, P8795, DOI 10.1128/MCB.23.23.8795-8808.2003; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200; Wang JR, 2004, MOL CELL BIOL, V24, P2423, DOI 10.1128/MCB.24.6.2423-2443.2004; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Witcher M, 2003, BLOOD, V102, P237, DOI 10.1182/blood-2002-09-2725; Zheng XM, 2004, BLOOD, V103, P3535, DOI 10.1182/blood-2003-09-3335	37	43	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3358	3368		10.1038/sj.onc.1208498	http://dx.doi.org/10.1038/sj.onc.1208498			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735696				2022-12-25	WOS:000228881800014
J	Mattioli, M; Agnelli, L; Fabris, S; Baldini, L; Morabito, F; Bicciato, S; Verdelli, D; Intini, D; Nobili, L; Cro, L; Pruneri, G; Callea, V; Stelitano, C; Maiolo, AT; Lombardi, L; Neri, A				Mattioli, M; Agnelli, L; Fabris, S; Baldini, L; Morabito, F; Bicciato, S; Verdelli, D; Intini, D; Nobili, L; Cro, L; Pruneri, G; Callea, V; Stelitano, C; Maiolo, AT; Lombardi, L; Neri, A			Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma	ONCOGENE			English	Article						gene expression profiling; IGH translocations; MGUS; multiple myeloma; plasma cell leukemia	GROWTH-FACTOR RECEPTOR-3; CHROMOSOMAL TRANSLOCATIONS; T(4/14) TRANSLOCATION; CYCLIN D1; B-CELLS; C-MAF; PROTEIN; DYSREGULATION; FGFR3; PROLIFERATION	Multiple myeloma (MM) is the most common form of plasma cell dyscrasia, characterized by a marked heterogeneity of genetic lesions and clinical course. It may develop from a premalignant condition (monoclonal gammopathy of undetermined significance, MGUS) or progress from intramedullary to extramedullary forms (plasma cell leukemia, PCL). To provide insights into the molecular characterization of plasma cell dyscrasias and to investigate the contribution of specific genetic lesions to the biological and clinical heterogeneity of MM, we analysed the gene expression profiles of plasma cells isolated from seven MGUS, 39MM and six PCL patients by means of DNA microarrays. MMs resulted highly heterogeneous at transcriptional level, whereas the differential expression of genes mainly involved in DNA metabolism and proliferation distinguished MGUS from PCLs and the majority of MM cases. The clustering of MM patients was mainly driven by the presence of the most recurrent translocations involving the immunoglobulin heavy-chain locus. Distinct gene expression patterns have been found to be associated with different lesions: the overexpression of CCND2 and genes involved in cell adhesion pathways was observed in cases with deregulated MAF and MAFB, whereas genes upregulated in cases with the t(4; 14) showed apoptosis-related functions. The peculiar. finding in patients with the t(11; 14) was the downregulation of the a-subunit of the IL-6 receptor. In addition, we identified a set of cancer germline antigens specifically expressed in a subgroup of MM patients characterized by an aggressive clinical evolution, a finding that could have implications for patient classification and immunotherapy.	Univ Milan, Osped Maggiore, IRCCS, UO Ematol 1,Dipartimento Sci Med, I-20122 Milan, Italy; Univ Milan, Osped Maggiore, IRCCS, Lab Ematol Sperimentale & Genet Mol, I-20122 Milan, Italy; Azienda Osped Bianchi Melacrino Morelli, Div Ematol, Reggio Di Calabria, Italy; Azienda Osped Bianchi Melacrino Morelli, Ctr Trapianto Midollo, Reggio Di Calabria, Italy; Univ Padua, Dipartimento Proc Chim Ingn, Padua, Italy; Ist Europeo Oncol, Div Patol, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Padua; IRCCS European Institute of Oncology (IEO)	Neri, A (corresponding author), Univ Milan, Osped Maggiore Milano, IRCCS, Dipartimento Sci Med,Ctr G Marcora,UO Ematol 2, Via Francesco Sforza 35, I-20122 Milan, Italy.	neri.a@policlinico.mi.it	Pruneri, Giancarlo/AAC-7767-2022; BICCIATO, Silvio/J-4466-2019; Bicciato, Silvio/C-9825-2009; nobili, rita lucia/I-9513-2014; Morabito, Francesco Carlo/AAB-9698-2019; Agnelli, Luca/H-8238-2012; Neri, Antonino/I-9690-2014; Morabito, Fortunato/I-7819-2012; Mattioli, Michela/K-3951-2013	Pruneri, Giancarlo/0000-0002-7963-7172; BICCIATO, Silvio/0000-0002-1944-7078; Bicciato, Silvio/0000-0002-1944-7078; nobili, rita lucia/0000-0001-9965-2444; Morabito, Francesco Carlo/0000-0003-0734-9136; Neri, Antonino/0000-0001-9047-5912; Mattioli, Michela/0000-0002-1692-9178; Fabris, Sonia/0000-0003-1341-0503; Cro, Lilla Marcella/0000-0002-6007-5667; Baldini, Luca/0000-0003-2964-9981; Agnelli, Luca/0000-0003-0582-6170; Critelli, Salvatore/0000-0001-7325-0228				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; ANDERSON KC, 2002, AM SOC HEMATOL ED PR, P214; Barille-Nion Sophie, 2003, Hematology Am Soc Hematol Educ Program, P248; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Califano A, 2000, BIOINFORMATICS, V16, P341, DOI 10.1093/bioinformatics/16.4.341; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chen XY, 2002, J BIOL CHEM, V277, P10512, DOI 10.1074/jbc.M108765200; Chesi M, 1996, BLOOD, V88, P674, DOI 10.1182/blood.V88.2.674.bloodjournal882674; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Coles LS, 1996, NUCLEIC ACIDS RES, V24, P2311, DOI 10.1093/nar/24.12.2311; Davies FE, 2003, BLOOD, V102, P4504, DOI 10.1182/blood-2003-01-0016; De Backer O, 1999, CANCER RES, V59, P3157; De Vos J, 2002, ONCOGENE, V21, P6848, DOI 10.1038/sj.onc.1205868; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; Dring AM, 2004, CLIN CANCER RES, V10, P5692, DOI 10.1158/1078-0432.CCR-04-0467; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fabris S, 2005, GENE CHROMOSOME CANC, V42, P117, DOI 10.1002/gcc.20123; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fonseca R, 2002, BLOOD, V99, P3735, DOI 10.1182/blood.V99.10.3735; Garlisi CG, 2001, AM J RESP CELL MOL, V24, P90, DOI 10.1165/ajrcmb.24.1.4224; Hanamura I, 2001, JPN J CANCER RES, V92, P638, DOI 10.1111/j.1349-7006.2001.tb01142.x; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; Ho P Joy, 2002, Rev Clin Exp Hematol, V6, P276, DOI 10.1046/j.1468-0734.2002.00081.x; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Imaizumi Tadaatsu, 2004, J Atheroscler Thromb, V11, P15; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; Keats JJ, 2003, BLOOD, V101, P1520, DOI 10.1182/blood-2002-06-1675; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; McShane LM, 2002, BIOINFORMATICS, V18, P1462, DOI 10.1093/bioinformatics/18.11.1462; Moreau P, 2002, BLOOD, V100, P1579, DOI 10.1182/blood-2002-03-0749; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Rasmussen T, 2003, BRIT J HAEMATOL, V123, P253, DOI 10.1046/j.1365-2141.2003.04577.x; Rawstron AC, 2000, BLOOD, V96, P3880, DOI 10.1182/blood.V96.12.3880.h8003880_3880_3886; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Robbiani DF, 2004, NEW ENGL J MED, V351, P197, DOI 10.1056/NEJM200407083510223; Ronchetti D, 1999, BLOOD, V93, P1330, DOI 10.1182/blood.V93.4.1330.404k04_1330_1337; Sahara N, 2002, BRIT J HAEMATOL, V117, P882, DOI 10.1046/j.1365-2141.2002.03513.x; Schadt EE, 2001, J CELL BIOCHEM, V84, P120, DOI 10.1002/jcb.10073; Seidl S, 2003, LANCET ONCOL, V4, P557, DOI 10.1016/S1470-2045(03)01195-1; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Stewart JP, 2004, BRIT J HAEMATOL, V126, P72, DOI 10.1111/j.1365-2141.2004.04996.x; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; van Baren N, 1999, BLOOD, V94, P1156; Zhan FH, 2003, BLOOD, V101, P1128, DOI 10.1182/blood-2002-06-1737; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745	53	106	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2461	2473		10.1038/sj.onc.1208447	http://dx.doi.org/10.1038/sj.onc.1208447			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735737	Green Published			2022-12-25	WOS:000228180600004
J	Rathore, D; Nagarkatti, R; Jani, D; Chattopadhyay, R; de la Vega, P; Kumar, S; McCutchan, TF				Rathore, D; Nagarkatti, R; Jani, D; Chattopadhyay, R; de la Vega, P; Kumar, S; McCutchan, TF			An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; VACCINE; HEPARIN; ANTIGEN; REGION; SPOROZOITE; RECEPTORS; INFECTION; MEMBRANE; BINDING	Circumsporozoite, a predominant surface protein, is involved in invasion of liver cells by Plasmodium sporozoites, which leads to malaria. We have previously reported that the amino terminus region ( amino acids 27 117) of P. falciparum circumsporozoite protein plays a critical role in the invasion of liver cells by the parasite. Here we show that invasion-blocking antibodies are induced by a polypeptide encoding these 91 amino acids, only when it is presented in the absence of the rest of the protein. This suggests that when present in the whole protein, the amino terminus remains immunologically cryptic. A single reactive epitope was identified and mapped to a stretch of 21 amino acids from position 93 to 113. The epitope is configurational in nature, since its recognition was affected by deleting as little as 3 amino acids from either end of the 21-residue peptide. Lysine 104, the only known polymorphic position in the epitope, affected its recognition by the antibodies, and its conversion to leucine in the protein led to a substantial loss of binding activity of the protein to the hepatocytes. This indicated that in the protein, the epitope serves as a binding ligand and facilitates the interaction between sporozoite and hepatic cells. When considered along with the observation that in its native state this motif is immunologically unresponsive, we suggest that hiding functional moieties of the protein from the immune system is an evasion strategy to preserve liver cell binding function and may be of importance in designing anti-sporozoite vaccines.	Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA; NIAID, Growth & Dev Sect, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA; USN, Med Res Ctr, Malaria Program, Silver Spring, MD 20910 USA; US FDA, Div Emerging & Transfus Transmitted Dis, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA	Virginia Polytechnic Institute & State University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Defense; United States Navy; US Food & Drug Administration (FDA)	McCutchan, TF (corresponding author), Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA.	Tmccutchan@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000208, ZIAAI000208] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; ANDERS RF, 1986, CIBA F SYMP, V119, P164; CALLE JMC, 1992, J IMMUNOL, V149, P2695; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; Chattopadhyay R, 2003, J BIOL CHEM, V278, P25977, DOI 10.1074/jbc.M300865200; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DELACRUZ VF, 1989, J IMMUNOL, V142, P3568; DELPORTILLO HA, 1987, MOL BIOCHEM PARASIT, V24, P289, DOI 10.1016/0166-6851(87)90161-7; Escalante AA, 2002, MOL BIOCHEM PARASIT, V125, P83, DOI 10.1016/S0166-6851(02)00216-5; Frevert U, 1998, EMBO J, V17, P3816, DOI 10.1093/emboj/17.14.3816; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; KUMAR S, 1988, NATURE, V334, P258, DOI 10.1038/334258a0; Lally KM, 2001, INT J CANCER, V93, P841, DOI 10.1002/ijc.1420; LOCKYER MJ, 1988, NUCLEIC ACIDS RES, V16, P9041, DOI 10.1093/nar/16.18.9041; Nardin EH, 2000, J INFECT DIS, V182, P1486, DOI 10.1086/315871; OZAKI LS, 1983, CELL, V34, P815, DOI 10.1016/0092-8674(83)90538-X; Rathore D, 2000, P NATL ACAD SCI USA, V97, P8530, DOI 10.1073/pnas.140224597; Rathore D, 2003, J BIOL CHEM, V278, P40905, DOI 10.1074/jbc.M306250200; Rathore D, 2000, INFECT IMMUN, V68, P740, DOI 10.1128/IAI.68.2.740-743.2000; Rathore D, 2002, J BIOL CHEM, V277, P7092, DOI 10.1074/jbc.M106862200; Rathore D, 2001, MOL BIOCHEM PARASIT, V118, P75, DOI 10.1016/S0166-6851(01)00369-3; Rathore D, 2001, BIOCHEMISTRY-US, V40, P11518, DOI 10.1021/bi0105476; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Sidjanski SP, 1997, MOL BIOCHEM PARASIT, V90, P33, DOI 10.1016/S0166-6851(97)00124-2; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595	28	52	60	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20524	20529		10.1074/jbc.M414254200	http://dx.doi.org/10.1074/jbc.M414254200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781464	hybrid			2022-12-25	WOS:000229242000046
J	Shen, C; Nettleton, D; Jiang, M; Kim, SK; Powell-Coffman, JA				Shen, C; Nettleton, D; Jiang, M; Kim, SK; Powell-Coffman, JA			Roles of the HIF-1 hypoxia-inducible factor during hypoxia response in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED SUSPENDED ANIMATION; C-ELEGANS; PROLYL 4-HYDROXYLASE; GENE-EXPRESSION; STRUCTURAL BASIS; PROTEIN; HIF-1-ALPHA; DISEASE; MUTANTS; MAINTENANCE	The human hypoxia-inducible transcription factor HIF-1 is a critical regulator of cellular and systemic responses to low oxygen levels. When oxygen levels are high, the HIF-1 alpha subunit is hydroxylated and is targeted for degradation by the von Hippel-Lindau tumor suppressor protein (VHL). This regulatory pathway is evolutionarily conserved, and the Caenorhabditis elegans hif-1 and vhl-1 genes encode homologs of the HIF-1 alpha subunit and VHL. To understand and describe more fully the molecular basis for hypoxia response in this important genetic model system, we compared hypoxia-induced changes in mRNA expression in wild-type, hif-1-deficient, and vhl-1-deficient C. elegans using whole genome microarrays. These studies identified 110 hypoxia-regulated gene expression changes, 63 of which require hif- 1 function. Mutation of vhl- 1 abrogates most hif-1-dependent changes in mRNA expression. Genes regulated by C. elegans hif- 1 have predicted functions in signal transduction, metabolism, transport, and extracellular matrix remodeling. We examined the in vivo requirement for 16 HIF-1 target genes and discovered that the phy-2 prolyl 4-hydroxylase alpha subunit is critical for survival in hypoxic conditions. Some HIF-1 target genes negatively regulate formation of stress-resistant dauer larvae. The microarray data presented herein also provide clear evidence for an HIF-1-independent pathway for hypoxia response, and this pathway regulates the expression of multiple heat shock proteins and several transcription factors.	Iowa State Univ, Dept Genet Dev & Cell Biol, Ames, IA 50011 USA; Iowa State Univ, Dept Stat, Ames, IA 50011 USA; Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA	Iowa State University; Iowa State University; Stanford University	Powell-Coffman, JA (corresponding author), Iowa State Univ, Dept Genet Dev & Cell Biol, 2108 Mol Biol Bldg, Ames, IA 50011 USA.	japc@iastate.edu		Nettleton, Dan/0000-0002-6045-1036; Powell-Coffman, Jo Anne/0000-0001-9164-7499				Ailion M, 2003, GENETICS, V165, P127; Bishop T, 2004, PLOS BIOL, V2, P1549, DOI 10.1371/journal.pbio.0020289; BRENNER S, 1974, GENETICS, V77, P71; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Dong QF, 2004, NUCLEIC ACIDS RES, V32, pD354, DOI 10.1093/nar/gkh046; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Friedman L, 2000, P NATL ACAD SCI USA, V97, P4736, DOI 10.1073/pnas.97.9.4736; Gray JM, 2004, NATURE, V430, P317, DOI 10.1038/nature02714; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hong M, 2004, J MOL BIOL, V344, P369, DOI 10.1016/j.jmb.2004.09.077; Hopfl G, 2004, AM J PHYSIOL-REG I, V286, pR608, DOI 10.1152/ajpregu.00538.2003; Horman S, 2003, J BIOL CHEM, V278, P41970, DOI 10.1074/jbc.M302403200; Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Jiang HQ, 2001, P NATL ACAD SCI USA, V98, P7916, DOI 10.1073/pnas.141234698; Jiang M, 2001, P NATL ACAD SCI USA, V98, P218, DOI 10.1073/pnas.011520898; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; LARSEN PL, 1995, GENETICS, V139, P1567; McElwee JJ, 2004, J BIOL CHEM, V279, P44533, DOI 10.1074/jbc.M406207200; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Nystul TG, 2004, P NATL ACAD SCI USA, V101, P9133, DOI 10.1073/pnas.0403312101; Padilla PA, 2002, MOL BIOL CELL, V13, P1473, DOI 10.1091/mbc.01-12-0594; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Riihimaa P, 2002, J BIOL CHEM, V277, P18238, DOI 10.1074/jbc.M200895200; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Scott BA, 2002, SCIENCE, V296, P2388, DOI 10.1126/science.1072302; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sym M, 2000, CURR BIOL, V10, P527, DOI 10.1016/S0960-9822(00)00468-1; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Treinin M, 2003, PHYSIOL GENOMICS, V14, P17, DOI 10.1152/physiolgenomics.00179.2002; Van Voorhies WA, 2000, J EXP BIOL, V203, P2467; WANG GL, 1993, J BIOL CHEM, V268, P21513; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000; Zhang M, 2004, AM J PATHOL, V165, P843, DOI 10.1016/S0002-9440(10)63347-0	52	155	202	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20580	20588		10.1074/jbc.M501894200	http://dx.doi.org/10.1074/jbc.M501894200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781453	hybrid			2022-12-25	WOS:000229242000053
J	Yi-Brunozzi, HY; Le Grice, SFJ				Yi-Brunozzi, HY; Le Grice, SFJ			Investigating HIV-1 polypurine tract geometry via targeted insertion of abasic lesions in the (-)-DNA template and (+)-RNA primer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 REVERSE-TRANSCRIPTASE; COLI RIBONUCLEASE HI; SEQUENCE FEATURES IMPORTANT; MURINE LEUKEMIA-VIRUS; RNASE-H; DNA-TEMPLATE; RECOGNITION; SUBSTRATE; COMPLEX	A variety of biochemical and structural studies indicate that two regions of the human immunodeficiency virus type 1 (HIV-1) polypurine tract ( PPT)-containing RNA/DNA hybrid deviate from standard Watson-Crick geometry. However, it is unclear whether and how these regions cooperate to ensure PPT primer selection by reverse transcriptase-associated ribonuclease H and subsequent removal from nascent (+)-DNA. To address these issues, we synthesized oligonucleotides containing abasic lesions in either the PPT (+)-RNA primer or (-)-DNA template to locally remove nucleobases, although retaining the sugar-phosphate backbone. KMnO4 footprinting indicates such lesions locally alter duplex structure, whereas thermal melting studies show significantly reduced stability when lesions are positioned around the scissile bond. Substituting the (-)DNA template between positions -15 and -13 altered cleavage specificity, whereas equivalent substitutions of the (+)- RNA had almost no effect. The unpaired base of the DNA template observed crystallographically (-11C) could also be removed without significant loss of cleavage specificity. With respect to the scissile -1/+1 phosphodiester bond, template nucleobases could be removed without loss of cleavage specificity, whereas equivalent lesions in the RNA primer were inhibitory. Our data suggest an interaction between the p66 thumb subdomain of HIV-1 reverse transcriptase, and the DNA template in the "unzipped" portion of the RNA/DNA hybrid could aid in positioning the ribonuclease H catalytic center at the PPT/U3 junction and also provides insights into nucleic acid geometry around the scissile bond required for hydrolysis.	NCI, Reverse Transcriptase Biochem Sect, Resistance Mech Lab, HIV Drug Resistance Program,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Le Grice, SFJ (corresponding author), NCI, Reverse Transcriptase Biochem Sect, Resistance Mech Lab, HIV Drug Resistance Program,NIH, Frederick, MD 21702 USA.	slegrice@nciferf.gov			DIVISION OF BASIC SCIENCES - NCI [Z01BC010492] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Coppel Y, 1997, BIOCHEMISTRY-US, V36, P4817, DOI 10.1021/bi962677y; Dash C, 2004, J BIOL CHEM, V279, P37095, DOI 10.1074/jbc.M403306200; Farah JA, 1997, J MOL BIOL, V272, P699, DOI 10.1006/jmbi.1997.1259; Fedoroff OY, 1997, J MOL BIOL, V269, P225, DOI 10.1006/jmbi.1997.1024; Forgacs E, 1997, J BIOL CHEM, V272, P8525, DOI 10.1074/jbc.272.13.8525; GOLJER I, 1995, J BIOL CHEM, V270, P22980, DOI 10.1074/jbc.270.39.22980; Haruki M, 2000, BIOCHEMISTRY-US, V39, P13939, DOI 10.1021/bi001469+; Horton NC, 1998, P NATL ACAD SCI USA, V95, P13489, DOI 10.1073/pnas.95.23.13489; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; IWAI S, 1995, FEBS LETT, V368, P315, DOI 10.1016/0014-5793(95)00683-Z; JACOBOMOLINA A, 1991, P NATL ACAD SCI USA, V88, P10895, DOI 10.1073/pnas.88.23.10895; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; Kopka ML, 2003, J MOL BIOL, V334, P653, DOI 10.1016/j.jmb.2003.09.057; Kvaratskhelia M, 2002, J BIOL CHEM, V277, P16689, DOI 10.1074/jbc.M109914200; LATHAM GJ, 1994, J BIOL CHEM, V269, P28527; Latham GJ, 2000, J BIOL CHEM, V275, P15025, DOI 10.1074/jbc.M000279200; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; Lener D, 2003, J BIOL CHEM, V278, P26526, DOI 10.1074/jbc.M302374200; Lhomme J, 1999, BIOPOLYMERS, V52, P65, DOI 10.1002/1097-0282(1999)52:2<65::AID-BIP1>3.0.CO;2-U; Lima WF, 2004, J BIOL CHEM, V279, P36317, DOI 10.1074/jbc.M405035200; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; Nielsen KE, 2000, BIOCONJUGATE CHEM, V11, P228, DOI 10.1021/bc990121s; Petersen M, 2002, J AM CHEM SOC, V124, P5974, DOI 10.1021/ja012288d; Petersen M, 2000, J MOL RECOGNIT, V13, P44, DOI 10.1002/(SICI)1099-1352(200001/02)13:1<44::AID-JMR486>3.0.CO;2-6; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; Rausch JW, 1997, J BIOL CHEM, V272, P8602, DOI 10.1074/jbc.272.13.8602; Rausch JW, 2004, INT J BIOCHEM CELL B, V36, P1752, DOI 10.1016/j.biocel.2004.02.016; Rausch JW, 2003, P NATL ACAD SCI USA, V100, P11279, DOI 10.1073/pnas.1932546100; Reddy YVR, 2000, J MOL BIOL, V298, P597, DOI 10.1006/jmbi.2000.3673; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Schultz SJ, 2000, J BIOL CHEM, V275, P32299, DOI 10.1074/jbc.M000021200; Schultz SJ, 2003, J VIROL, V77, P5275, DOI 10.1128/JVI.77.9.5275-5285.2003; UCHIYAMA Y, 1994, J MOL BIOL, V243, P782, DOI 10.1016/0022-2836(94)90047-7; Wilhelm M, 2001, J BIOL CHEM, V276, P47695, DOI 10.1074/jbc.M106067200; Zou Y, 1999, EMBO J, V18, P4889, DOI 10.1093/emboj/18.17.4889	36	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20154	20162		10.1074/jbc.M411228200	http://dx.doi.org/10.1074/jbc.M411228200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778225	hybrid			2022-12-25	WOS:000229113700088
J	Arbel-Goren, R; Levy, Y; Ronen, D; Zick, Y				Arbel-Goren, R; Levy, Y; Ronen, D; Zick, Y			Cyclin-dependent kinase inhibitors and JNK act as molecular switches, regulating the choice between growth arrest and apoptosis induced by galectin-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING PROTEIN; CELL-CYCLE; TRANSCRIPTION FACTOR; T-CELLS; ACTIVATION; EXPRESSION; INDUCTION; ADHESION; P21; PHOSPHORYLATION	Galectin-8, a mammalian beta-galactoside binding lectin, functions as an extracellular matrix protein that forms high affinity interactions with integrins. Here we demonstrated that soluble galectin-8 inhibits cell cycle progression and induces growth arrest. These effects cannot be attributed to interference with cell adhesion but can be attributed to a 4-5-fold increase in the cellular content of the cyclin-dependent kinase inhibitor p21, which was already evident following a 4-h incubation of H1299 cells with galectin-8. The increase in p21 levels was preceded by a 3-5-fold increase in JNK and protein kinase B (PKB) activities. Accordingly, SP600125, the inhibitor of JNK, and wortmannin, the inhibitor of phosphatidylinositol 3-kinase, which is the upstream activator of PKB, inhibited the increase in the cellular content of p21. Furthermore, overexpression of a dominant inhibitory form of SEK1, the upstream kinase regulator of JNK, inhibited both JNK activation and p21 accumulation. When p21 expression was inhibited by cycloheximide, galectin-8 directed the cells toward apoptosis, which involves induction of poly(ADP-ribose) polymerase cleavage. Indeed, galectin-8-induced apoptosis was 2-fold higher in HTC (p21-null) cells when compared with parental HTC cells. Because overexpression of galectin-8 attenuates the rate of DNA synthesis, stable colonies that overexpress and secrete galectin-8 can be generated only in cells overexpressing a growth factor receptor, such as the insulin receptor. These results implicate galectin-8 as a modulator of cellular growth through up-regulation of p21. This process involves activation of JNK, which enhances the synthesis of p21, combined with the activation of PKB, which inhibits p21 degradation. These effects of the lectin depended upon protein-sugar interactions and were induced when galectin-8 was present as a soluble ligand or when it was overexpressed in cells.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Zick, Y (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	yehiel.zick@weizmann.ac.il	Zick, Yehiel/K-1479-2012					Adams L, 1996, BBA-MOL CELL RES, V1312, P137, DOI 10.1016/0167-4889(96)00031-6; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Alderton F, 2001, MOL PHARMACOL, V59, P1119, DOI 10.1124/mol.59.5.1119; Amati B, 2001, NAT CELL BIOL, V3, pE112, DOI 10.1038/35074634; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Avraham A, 1998, EUR J IMMUNOL, V28, P2320, DOI 10.1002/(SICI)1521-4141(199808)28:08<2320::AID-IMMU2320>3.0.CO;2-K; Ball K L, 1997, Prog Cell Cycle Res, V3, P125; Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cambier S, 2000, CANCER RES, V60, P7084; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; Coffman JA, 2004, DEV CELL, V6, P321, DOI 10.1016/S1534-5807(04)00067-X; Danguy A, 2001, HISTOL HISTOPATHOL, V16, P861, DOI 10.14670/HH-16.861; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Hadari YR, 2000, J CELL SCI, V113, P2385; Hadari YR, 1997, TRENDS GLYCOSCI GLYC, V9, P103, DOI 10.4052/tigg.9.103; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hernandez JD, 2002, GLYCOBIOLOGY, V12, p127R, DOI 10.1093/glycob/cwf081; Hotta K, 2001, J BIOL CHEM, V276, P34089, DOI 10.1074/jbc.M105097200; Hughes RC, 2001, BIOCHIMIE, V83, P667; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kashio Y, 2003, J IMMUNOL, V170, P3631, DOI 10.4049/jimmunol.170.7.3631; Kim HRC, 1999, CANCER RES, V59, P4148; Kobayashi K, 2001, BBA-MOL BASIS DIS, V1537, P79, DOI 10.1016/S0925-4439(01)00059-X; Kuwabara I, 2002, J BIOL CHEM, V277, P3487, DOI 10.1074/jbc.M109360200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahm H, 2001, J CANCER RES CLIN, V127, P375, DOI 10.1007/s004320000207; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Levy Y, 2001, J BIOL CHEM, V276, P31285, DOI 10.1074/jbc.M100340200; Levy Y, 2003, J BIOL CHEM, V278, P14533, DOI 10.1074/jbc.M207380200; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; Lundberg AS, 1999, EUR J CANCER, V35, P531; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mainiero F, 2000, IMMUNITY, V12, P7, DOI 10.1016/S1074-7613(00)80154-5; Muschen M, 2000, J MOL MED-JMM, V78, P312, DOI 10.1007/s001090000112; Nagy N, 2003, CANCER, V97, P1849, DOI 10.1002/cncr.11268; Nagy N, 2002, GUT, V50, P392, DOI 10.1136/gut.50.3.392; Novelli F, 1999, J CELL PHYSIOL, V178, P102, DOI 10.1002/(SICI)1097-4652(199901)178:1<102::AID-JCP13>3.0.CO;2-6; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Poirier F, 2002, BIOCHEM SOC SYMP, V69, P95; Rabinovich GA, 2000, CELL DEATH DIFFER, V7, P747, DOI 10.1038/sj.cdd.4400708; Rabinovich GA, 2002, J LEUKOCYTE BIOL, V71, P741; RODAN SB, 1987, CANCER RES, V47, P4961; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sangfelt O, 2000, FRONT BIOSCI-LANDMRK, V5, pD479, DOI 10.2741/Sangfelt; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; Yang RY, 2003, CELL MOL LIFE SCI, V60, P267, DOI 10.1007/s000180300022; Yang RY, 2001, J BIOL CHEM, V276, P20252, DOI 10.1074/jbc.M010914200; Yoshii T, 2002, J BIOL CHEM, V277, P6852, DOI 10.1074/jbc.M107668200; Zick Y, 2002, GLYCOCONJUGATE J, V19, P517, DOI 10.1023/B:GLYC.0000014081.55445.af	69	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19105	19114		10.1074/jbc.M502060200	http://dx.doi.org/10.1074/jbc.M502060200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753078	hybrid			2022-12-25	WOS:000228932300067
J	Nakaya, Y; Yamane, T; Shiraishi, H; Wang, HQ; Matsubara, E; Sato, T; Dolios, G; Wang, R; De Strooper, B; Shoji, M; Komano, H; Yanagisawa, K; Ihara, Y; Fraser, P; St George-Hyslop, P; Nishimura, M				Nakaya, Y; Yamane, T; Shiraishi, H; Wang, HQ; Matsubara, E; Sato, T; Dolios, G; Wang, R; De Strooper, B; Shoji, M; Komano, H; Yanagisawa, K; Ihara, Y; Fraser, P; St George-Hyslop, P; Nishimura, M			Random mutagenesis of presenilin-1 identifies novel mutants exclusively generating long amyloid beta-peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ALZHEIMERS-DISEASE; ASPARTYL PROTEASE; PRECURSOR PROTEIN; ACTIVE-SITE; ENDOPROTEOLYSIS; COMPLEX; INHIBITOR; APP	Familial Alzheimer disease-causing mutations in the presenilins increase production of longer pathogenic amyloid beta-peptides (A beta(42/43)) by altering gamma-secretase activity. The mechanism underlying this effect remains unknown, although it has been proposed that heteromeric macromolecular complexes containing presenilins mediate gamma-secretase cleavage of the amyloid beta-precursor protein. Using a random mutagenesis screen of presenilin-1 (PS1) for PS1 endoproteolysis-impairing mutations, we identified five unique mutants, including R278I-PS1 and L435H-PS1, that exclusively generated a high level of A beta(43), but did not support physiological PS1 endoproteolysis or A beta(40) generation. These mutants did not measurably alter the molecular size or subcellular localization of PS1 complexes. Pharmacological studies indicated that the up-regulation of activity for A beta(43) generation by these mutations was not further enhanced by the difluoroketone inhibitor DFK167 and was refractory to inhibition by sulindac sulfide. These results suggest that PS1 mutations can lead to a wide spectrum of changes in the activity and specificity of gamma-secretase and that the effects of PS1 mutations and gamma-secretase inhibitors on the specificity are mediated through a common mechanism.	Shiga Univ Med Sci, Mol Neurosci Res Ctr, Shiga 5202192, Japan; Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto 6068507, Japan; Natl Inst Logev Sci, Dept Dementia Res, Aichi 4748522, Japan; Okayama Univ, Grad Sch Med & Dens, Dept Neurol, Okayama 7008558, Japan; Univ Tokyo, Fac Med, Dept Neuropathol, Tokyo 1130033, Japan; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada	Shiga University of Medical Science; Kyoto University; Okayama University; University of Tokyo; Icahn School of Medicine at Mount Sinai; KU Leuven; University of Toronto	Nishimura, M (corresponding author), Shiga Univ Med Sci, Mol Neurosci Res Ctr, Shiga 5202192, Japan.	mnishimu@belle.shiga-med.ac.jp	De Strooper, Bart/F-6507-2012; de+Strooper, Bart/Z-1638-2019; Wang, Rong/A-8721-2009	De Strooper, Bart/0000-0001-5455-5819; Shoji, Mikio/0000-0003-1027-1712	NIA NIH HHS [AG10491] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG010491] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beher D, 2004, J BIOL CHEM, V279, P43419, DOI 10.1074/jbc.M404937200; Beher D, 2002, J NEUROCHEM, V82, P563, DOI 10.1046/j.1471-4159.2002.00985.x; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Campbell WA, 2003, J NEUROCHEM, V85, P1563, DOI 10.1046/j.1471-4159.2003.01799.x; Campbell WA, 2002, BIOCHEMISTRY-US, V41, P3372, DOI 10.1021/bi015810h; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Godbolt AK, 2004, NEUROLOGY, V63, P1702, DOI 10.1212/01.WNL.0000143060.98164.1A; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Ikeuchi T, 2003, J BIOL CHEM, V278, P7010, DOI 10.1074/jbc.M209252200; Jacobsen H, 1999, J BIOL CHEM, V274, P35233, DOI 10.1074/jbc.274.49.35233; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Komano H, 2002, J BIOL CHEM, V277, P39627, DOI 10.1074/jbc.M205255200; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lleo A, 2004, NAT MED, V10, P1065, DOI 10.1038/nm1112; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; Shirotani K, 2000, J BIOL CHEM, V275, P3681, DOI 10.1074/jbc.275.5.3681; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Tomita T, 2001, J BIOL CHEM, V276, P33273, DOI 10.1074/jbc.M011152200; Wang J, 2004, NEUROBIOL DIS, V15, P654, DOI 10.1016/j.nbd.2003.12.008; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weggen S, 2003, J BIOL CHEM, V278, P31831, DOI 10.1074/jbc.M303592200; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wrigley JDJ, 2004, J NEUROCHEM, V90, P1312, DOI 10.1111/j.1471-4159.2004.02596.x; Xia WM, 2000, NEUROBIOL DIS, V7, P673, DOI 10.1006/nbdi.2000.0322; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800	52	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19070	19077		10.1074/jbc.M501130200	http://dx.doi.org/10.1074/jbc.M501130200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15764596	Green Published, hybrid, Green Submitted			2022-12-25	WOS:000228932300063
J	Picard, M; Toyoshima, C; Champeil, P				Picard, M; Toyoshima, C; Champeil, P			The average conformation at micromolar [Ca2+] of Ca2+-ATPase with bound nucleotide differs from that adopted with the transition state analog ADP center dot AlFx or with AMPPCP under crystallization conditions at millimolar [Ca2+]	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; CALCIUM ADENOSINE-TRIPHOSPHATASE; TRANSPORT SITES; BINDING; ATPASE; DISSOCIATION; OCCLUSION; KINETICS; CA-2+; PHOSPHOENZYME	Crystalline forms of detergent-solubilized sarcoplasmic reticulum Ca2+-ATPase, obtained in the presence of either a substrate analog, AMPPCP, or a transition state complex, ADP.fluoroaluminate, were recently described to share the same general architecture despite the fact that, when studied in a test tube, these forms show different functional properties. Here, we show that the differences in the properties of the E1.AMPPCP and the E1.ADP.AlFx membraneous (or solubilized) forms are much less pronounced when these properties are examined in the presence of 10 mM Ca2+ (the concentration prevailing in the crystallization media) than when they are examined in the presence of the few micromolar of Ca2+ known to be sufficient to saturate the transport sites. This concerns various properties, including ATPase susceptibility to proteolytic cleavage by proteinase K, ATPase reactivity toward SH-directed Ellman's reagent, ATPase intrinsic fluorescence properties ( here described for the E1.ADP.AlFx complex for the first time), and also the rates of Ca-45(2+)-Ca-40(2+) exchange at site "II." These results solve the above paradox at least partially and suggest that the presence of a previously unrecognized Ca2+ ion in the E1.AMPPCP crystals should be re-investigated. A contrario, they emphasize the fact that the average conformation of the E1.AMPPCP complex under usual conditions in the test tube differs from that found in the crystalline form. The extended conformation of nucleotide revealed by the E1.AMPPCP crystalline form might be only indicative of the requirements for further processing of the complex, toward the transition state leading to phosphorylation and Ca2+ occlusion.	CEA, Dept Biol Joliot Curie, Serv Biophys Fonct Membranaires, CNRS,Unite Rech Associee 2096, F-91191 Gif Sur Yvette, France; Univ Paris Sud, CEA Saclay, IFR46, F-91191 Gif Sur Yvette, France; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo, Japan	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Tokyo	Champeil, P (corresponding author), CEA, Dept Biol Joliot Curie, Serv Biophys Fonct Membranaires, CNRS,Unite Rech Associee 2096, F-91191 Gif Sur Yvette, France.	champeil@dsvidf.cea.fr	Toyoshima, Chikashi/R-4153-2019; Picard, Martin/A-3236-2016	Picard, Martin/0000-0002-6518-8900; Toyoshima, Chikashi/0000-0001-9640-0778				BAYLEY P, 1984, BIOCHEM BIOPH RES CO, V120, P185, DOI 10.1016/0006-291X(84)91431-1; Champeil P, 1997, BIOCHEMISTRY-US, V36, P12383, DOI 10.1021/bi9709699; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; CHAMPEIL P, 1986, FEBS LETT, V206, P93, DOI 10.1016/0014-5793(86)81347-3; Champeil P, 2001, J BIOL CHEM, V276, P5795, DOI 10.1074/jbc.M006980200; CHAMPEIL P, 1978, J BIOL CHEM, V253, P1179; COAN C, 1982, BIOCHEMISTRY-US, V21, P3214, DOI 10.1021/bi00256a028; COAN CR, 1977, J BIOL CHEM, V252, P3044; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; DEFORESTA B, 1990, EUR J BIOCHEM, V194, P383; DEFORESTA B, 1990, ANAL BIOCHEM, V189, P59, DOI 10.1016/0003-2697(90)90044-A; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; FORGE V, 1993, J BIOL CHEM, V268, P10961; FROEHLICH JP, 1985, BIOCHEMISTRY-US, V24, P126, DOI 10.1021/bi00322a018; HENAO F, 1992, J BIOL CHEM, V267, P10302; Hua SM, 2002, BIOCHEMISTRY-US, V41, P11405, DOI 10.1021/bi026181u; Inesi G, 2004, J BIOL CHEM, V279, P31629, DOI 10.1074/jbc.M403211200; INESI G, 1987, J BIOL CHEM, V262, P16338; Kim HY, 2002, J BIOL CHEM, V277, P46651, DOI 10.1074/jbc.M204866200; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; Ma HL, 2003, J BIOL CHEM, V278, P28938, DOI 10.1074/jbc.M304120200; MAHANEY JE, 1995, BIOCHEMISTRY-US, V34, P4864, DOI 10.1021/bi00014a044; MINTZ E, 1995, J BIOL CHEM, V270, P27160, DOI 10.1074/jbc.270.45.27160; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; Montigny C, 2004, J BIOL CHEM, V279, P43971, DOI 10.1074/jbc.M407142200; Ogawa H, 1998, BIOPHYS J, V75, P41, DOI 10.1016/S0006-3495(98)77493-4; OGAWA Y, 1986, J BIOCHEM-TOKYO, V100, P1305, DOI 10.1093/oxfordjournals.jbchem.a121837; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PANG DC, 1977, J BIOL CHEM, V252, P3262; Peeraer Y, 2004, EUR J BIOCHEM, V271, P3421, DOI 10.1111/j.0014-2956.2004.04277.x; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; ROSS DC, 1987, J BIOL CHEM, V262, P12977; SHIGEKAWA M, 1982, J BIOL CHEM, V257, P7657; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; STEWART JMM, 1989, BIOCHEMISTRY-US, V28, P4695, DOI 10.1021/bi00437a028; SUZUKI H, 1994, BIOCHEMISTRY-US, V33, P8240, DOI 10.1021/bi00193a010; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2003, FEBS LETT, V555, P106, DOI 10.1016/S0014-5793(03)01086-X; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; VERJOVSKIALMEIDA S, 1978, BIOCHEMISTRY-US, V17, P5006, DOI 10.1021/bi00616a023; VILSEN B, 1992, J BIOL CHEM, V267, P3539; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1986, BIOCHIM BIOPHYS ACTA, V855, P429, DOI 10.1016/0005-2736(86)90089-1; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P7309, DOI 10.1021/bi00483a022; YASUOKA K, 1982, J BIOCHEM-TOKYO, V91, P1629, DOI 10.1093/oxfordjournals.jbchem.a133854; YATES DW, 1978, BIOCHEM J, V159, P719	51	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18745	18754		10.1074/jbc.M501596200	http://dx.doi.org/10.1074/jbc.M501596200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757892	Green Submitted, hybrid			2022-12-25	WOS:000228932300026
J	Van Craenenbroeck, K; Clark, SD; Cox, MJ; Oak, JN; Liu, F; Van Tol, HHM				Van Craenenbroeck, K; Clark, SD; Cox, MJ; Oak, JN; Liu, F; Van Tol, HHM			Folding efficiency is rate-limiting in dopamine D4 receptor biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIT HYPERACTIVITY DISORDER; MESSENGER-RNA LEVELS; ENDOPLASMIC-RETICULUM; PHARMACOLOGICAL CHAPERONES; QUALITY-CONTROL; CHEMICAL CHAPERONES; TARDIVE-DYSKINESIA; 7-REPEAT ALLELE; NOVELTY SEEKING; D4 GENE	Dopamine receptors are G protein-coupled receptors that are critically involved in locomotion, reward, and cognitive processes. The D2 class of dopamine receptors (DRD2, -3, and -4) is the target for antipsychotic medication. DRD4 has been implicated in cognition, and genetic studies have found an association between a highly polymorphic repeat sequence in the human DRD4 coding region and attention deficit hyperactivity disorder. Using DRD4 as a model, we show that antipsychotics can function as potent pharmacological chaperones up-regulating receptor expression and can also rescue a non-functional DRD4 folding mutant. This chaperone-mediated up-regulation involves reduced degradation by the 26 S proteasome; likely via the stabilization of newly synthesized receptor in the endoplasmic reticulum. Dopamine itself can function as a chaperone when shuttled into the cell by means of the dopamine transporter. Furthermore, different repeat variants of DRD4 display differential sensitivity to this chaperone effect. These data suggest that folding efficiency may be rate-limiting for dopamine receptor biogenesis and that this efficiency differs between receptor variants. Consequently, the clinical profile of dopaminergic ligands, including antipsychotics, may include their ability to serve as pharmacological chaperones.	Ctr Addict & Mental Hlth, Mol Neurobiol Lab, Toronto, ON M5T 1R8, Canada; Univ Toronto, Dept Psychiat, Toronto, ON, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON, Canada; Univ Toronto, Inst Med Sci, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto; University of Toronto	Van Tol, HHM (corresponding author), Ctr Addict & Mental Hlth, Mol Neurobiol Lab, 250 Coll St, Toronto, ON M5T 1R8, Canada.	hubert.van.tol@utoronto.ca						ASGHARI V, 1995, J NEUROCHEM, V65, P1157, DOI 10.1046/j.1471-4159.1995.65031157.x; Attaix D, 2001, CURR OPIN CLIN NUTR, V4, P45, DOI 10.1097/00075197-200101000-00009; Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; BLIN J, 1989, J NEUROL NEUROSUR PS, V52, P1248, DOI 10.1136/jnnp.52.11.1248; Chang FM, 1996, HUM GENET, V98, P91, DOI 10.1007/s004390050166; Cresswell P, 2000, TRAFFIC, V1, P301, DOI 10.1034/j.1600-0854.2000.010402.x; Damask SP, 1996, MOL BRAIN RES, V41, P241, DOI 10.1016/0169-328X(96)00101-5; Ding YC, 2002, P NATL ACAD SCI USA, V99, P309, DOI 10.1073/pnas.012464099; Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Falkenburger BH, 2001, SCIENCE, V293, P2465, DOI 10.1126/science.1060645; Faraone SV, 2001, AM J PSYCHIAT, V158, P1052, DOI 10.1176/appi.ajp.158.7.1052; FILTZ TM, 1993, MOL PHARMACOL, V44, P371; FILTZ TM, 1994, J PHARMACOL EXP THER, V271, P1574; FOX CA, 1994, EXP NEUROL, V130, P288, DOI 10.1006/exnr.1994.1207; Halaban R, 2001, J BIOL CHEM, V276, P11933, DOI 10.1074/jbc.M008703200; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Kotecha SA, 2002, NEURON, V35, P1111, DOI 10.1016/S0896-6273(02)00859-0; LaHoste GJ, 1996, MOL PSYCHIATR, V1, P121; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; LICHTER JB, 1993, HUM MOL GENET, V2, P767, DOI 10.1093/hmg/2.6.767; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; MELHUS H, 1992, J BIOL CHEM, V267, P12036; Morello JP, 2000, TRENDS PHARMACOL SCI, V21, P466, DOI 10.1016/S0165-6147(00)01575-3; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; Oak JN, 2001, MOL PHARMACOL, V60, P92, DOI 10.1124/mol.60.1.92; Ohashi T, 2003, HISTOCHEM CELL BIOL, V119, P257, DOI 10.1007/s00418-003-0511-x; Oldenhof J, 1998, BIOCHEMISTRY-US, V37, P15726, DOI 10.1021/bi981634+; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; PRISTUPA ZB, 1994, MOL PHARMACOL, V45, P125; QIAN YF, 1993, J PHARMACOL EXP THER, V267, P1582; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Scheetz AJ, 2000, NAT NEUROSCI, V3, P211, DOI 10.1038/72915; Schoots O, 2003, PHARMACOGENOMICS J, V3, P343, DOI 10.1038/sj.tpj.6500208; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; See RE, 1996, NEUROSCIENCE, V72, P99, DOI 10.1016/0306-4522(95)00540-4; Seeman P, 2000, P NATL ACAD SCI USA, V97, P7673, DOI 10.1073/pnas.97.14.7673; SEEMAN P, 1984, SCIENCE, V225, P728, DOI 10.1126/science.6147018; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; Segman R, 1999, MOL PSYCHIATR, V4, P247, DOI 10.1038/sj.mp.4000511; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; SRIVASTAVA LK, 1990, J MOL NEUROSCI, V2, P155, DOI 10.1007/BF02896840; Swanson J, 2000, P NATL ACAD SCI USA, V97, P4754, DOI 10.1073/pnas.080070897; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Turrone P, 2003, PSYCHOPHARMACOLOGY, V165, P166, DOI 10.1007/s00213-002-1259-z; VANTOL HHM, 1992, NATURE, V358, P149; VANTOL HHM, 1990, NEUROSCI LETT, V111, P303, DOI 10.1016/0304-3940(90)90279-I; Wong AHC, 2003, PROG NEURO-PSYCHOPH, V27, P1091, DOI 10.1016/j.pnpbp.2003.09.005	52	93	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19350	19357		10.1074/jbc.M414043200	http://dx.doi.org/10.1074/jbc.M414043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755724	hybrid			2022-12-25	WOS:000228932300092
J	Oliveira, AM; Perez-Atayde, AR; Dal Cin, P; Gebhardt, MC; Chen, CJ; Neff, JR; Demetri, GD; Rosenberg, AE; Bridge, JA; Fletcher, JA				Oliveira, AM; Perez-Atayde, AR; Dal Cin, P; Gebhardt, MC; Chen, CJ; Neff, JR; Demetri, GD; Rosenberg, AE; Bridge, JA; Fletcher, JA			Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes	ONCOGENE			English	Article						aneurysmal bone cyst; USP6; translocation	MOLECULAR-CLONING; FUSION ONCOGENES; PROTEIN; 17P13; CELL; IDENTIFICATION; ABERRATIONS; CHERUBISM; MUTATIONS; CADHERIN	Aneurysmal bone cysts (ABC) are locally aggressive bone tumors that often feature chromosome 17p13 rearrangements. One of the ABC 17p13 rearrangements-t(16; 17)(q22; p13)-was recently shown to create a CDH11-USP6 fusion in which the USP6/TRE17 oncogene is overexpressed through juxtaposition with the CDH11 promoter. Herein, we characterize four different ABC translocations involving 17p13, and we show that each is associated with a novel USP6 fusion oncogene. Specifically, we demonstrate that t(1;17), t(3;17), t(9;17), and t(17;17) result in USP6 fusions with TRAP150 (thyroid receptor-associated protein 150), ZNF9 ((Z) under bari (N) under barc (F) under bar inger (9) under bar), Osteomodulin, and COL1A1 (Collagen 1A1), respectively. The oncogenic mechanism in these fusion genes is akin to CDH11-USP6, with the USP6 coding sequences juxtaposed to the promoter regions in each of the four novel translocation partners. The novel fusion partners appear well suited to drive USP6 transcription in the bone/mesenchymal context: osteomodulin is expressed strongly in osteoblastic lineages, and the COL1A1 promoter has an oncogenic role in the mesenchymal cancer dermatofibrosarcoma protuberans. In summary, these studies show that USP6 oncogenic activation results from heterogeneous genomic mechanisms involving USP6 transcriptional upregulation by juxtaposition with ectopic promoters.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Orthoped Surg, Boston, MA 02215 USA; Childrens Hosp, Med Ctr, Dept Orthoped Surg, Boston, MA 02115 USA; Univ Nebraska, Med Ctr, Dept Orthopaed Surg, Omaha, NE USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Univ Nebraska, Med Ctr, Dept Pathol, Omaha, NE USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Mayo Clinic; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; University of Nebraska System; University of Nebraska Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; University of Nebraska System; University of Nebraska Medical Center; Harvard University; Dana-Farber Cancer Institute	Oliveira, AM (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	oliveira.andre@mayo.edu; jfletcher@partners.org						Althof PA, 2004, MODERN PATHOL, V17, P518, DOI 10.1038/modpathol.3800090; Argani P, 1998, MODERN PATHOL, V11, P65; Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515; BYERS PH, 2004, METABOLIC BASIS MOL, P5241; Dal Cin P, 2000, GENE CHROMOSOME CANC, V28, P233, DOI 10.1002/(SICI)1098-2264(200006)28:2<233::AID-GCC13>3.0.CO;2-H; DEDIOS AMV, 1992, CANCER, V69, P2921, DOI 10.1002/1097-0142(19920615)69:12<2921::AID-CNCR2820691210>3.0.CO;2-E; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096-203; Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200; Hibbard MK, 2000, CANCER RES, V60, P4869; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Kurahashi H, 2000, HUM MOL GENET, V9, P1665, DOI 10.1093/hmg/9.11.1665; Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125; Masuda-Robens JM, 2003, MOL CELL BIOL, V23, P2151, DOI 10.1128/MCB.23.6.2151-2161.2003; Miah SMS, 2004, GENES CELLS, V9, P993, DOI 10.1111/j.1365-2443.2004.00784.x; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; O'Brien KP, 1998, GENE CHROMOSOME CANC, V23, P187, DOI 10.1002/(SICI)1098-2264(199810)23:2<187::AID-GCC13>3.3.CO;2-R; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; Panoutsakopoulos G, 1999, GENE CHROMOSOME CANC, V26, P265, DOI 10.1002/(SICI)1098-2264(199911)26:3<265::AID-GCC12>3.0.CO;2-#; Paulding CA, 2003, P NATL ACAD SCI USA, V100, P2507, DOI 10.1073/pnas.0437015100; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; Rosenberg AENGP, 2002, WHO CLASSIFICATION T; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; Sinnett D, 1998, BIOTECHNIQUES, V24, P752, DOI 10.2144/98245bm12; Spiteri E, 2003, HUM MOL GENET, V12, P1823, DOI 10.1093/hmg/ddg203; Ueki Y, 2001, NAT GENET, V28, P125, DOI 10.1038/88832; Winnepenninckx W, 2001, VIRCHOWS ARCH, V439, P636, DOI 10.1007/s004280100449; Wyatt-Ashmead J, 2001, PEDIATR DEVEL PATHOL, V4, P418, DOI 10.1007/s10024-001-0035-0	32	144	148	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3419	3426		10.1038/sj.onc.1208506	http://dx.doi.org/10.1038/sj.onc.1208506			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735689				2022-12-25	WOS:000229038800004
J	Ribeiro, CMP; Paradiso, AM; Schwab, U; Perez-Vilar, J; Jones, L; O'Neal, W; Boucher, RC				Ribeiro, CMP; Paradiso, AM; Schwab, U; Perez-Vilar, J; Jones, L; O'Neal, W; Boucher, RC			Chronic airway Infection/Inflammation induces a Ca-i(2+)-dependent hyperinflammatory response in human cystic fibrosis airway epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ENDOPLASMIC-RETICULUM STRESS; GLUCOSE-REGULATED PROTEINS; INTRACELLULAR CALCIUM; ER STRESS; CELL DIFFERENTIATION; GENE-EXPRESSION; KINASE-C; INFECTION; ACTIVATION	Hyperinflammatory responses to infection have been postulated as a component of cystic fibrosis (CF) lung disease. Studies have linked intracellular calcium (Ca-i(2+)) mobilization with inflammatory responses in several systems. We have reported that the pro-inflammatory mediator bradykinin (BK) promotes larger Ca-i(2+) signals in CF compared with normal bronchial epithelia, a response that reflects endoplasmic reticulum (ER)/Ca2+ store expansion induced by chronic luminal airway infection/inflammation. The present study investigated whether CF airway epithelia were hyperinflammatory and, if so, whether the hyperinflammatory CF phenotype was linked to larger Ca2+ stores in the ER. We found that Delta F508 CF bronchial epithelia were hyperinflammatory as defined by an increased basal and mucosal BK-induced interleukin (IL)-8 secretion. However, the CF hyperinflammation expressed in short-term ( 6 - 11-day-old) primary cultures of Delta F508 bronchial epithelia was lost in long-term ( 30 - 40-day-old) primary cultures of Delta F508 bronchial epithelia, indicating this response was independent of mutant cystic fibrosis transmembrane conductance regulator. Exposure of 30 - 40-day-old cultures of normal airway epithelia to supernatant from mucopurulent material (SMM) from CF airways reproduced the increased basal and mucosal BK-stimulated IL-8 secretion of short-term CF cultures. The BK-triggered increased IL-8 secretion in SMM-treated cultures was mediated by an increased Ca-i(2+) mobilization consequent to an ER expansion associated with increases in protein synthesis ( total, cytokines, and antimicrobial factors). The increased ER-dependent, Ca-i(2+)-mediated hyperinflammatory epithelial response may represent a general beneficial airway epithelial adaptation to transient luminal infection. However, in CF airways, the Ca-i(2+)-mediated hyperinflammation may be ineffective in promoting the eradication of infection in thickened mucus and, consequently, may have adverse effects in the lung.	Univ N Carolina, Cyst Fibrosis Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ribeiro, CMP (corresponding author), Univ N Carolina, Cyst Fibrosis Ctr, CB 7248,7013 Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.	carla_ribeiro@med.unc.edu	Ribeiro, Carla Maria P/A-6955-2009		NHLBI NIH HHS [HL60280, HL34322] Funding Source: Medline; NIDDK NIH HHS [P30 DK34987] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322, P50HL060280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; ARMSTRONG DS, 1995, BRIT MED J, V310, P1571, DOI 10.1136/bmj.310.6994.1571; Armstrong DS, 1997, AM J RESP CRIT CARE, V156, P1197, DOI 10.1164/ajrccm.156.4.96-11058; Bals R, 1999, J CLIN INVEST, V103, P303, DOI 10.1172/JCI6277; Berger M, 2002, AM J RESP CRIT CARE, V165, P857, DOI 10.1164/ajrccm.165.7.2202030a; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Charlier N, 2002, J GEN VIROL, V83, P1887, DOI 10.1099/0022-1317-83-8-1887; COLIGAN JE, 1983, METHOD ENZYMOL, V91, P413; Diamond G, 2000, IMMUNOL REV, V173, P27, DOI 10.1034/j.1600-065X.2000.917304.x; Eremeeva ME, 1998, MICROBIOL-SGM, V144, P2037, DOI 10.1099/00221287-144-8-2037; Gewirtz AT, 2000, J CLIN INVEST, V105, P79, DOI 10.1172/JCI8066; Guo Q, 1997, J NEUROSCI, V17, P4212; Han B, 2000, AM J PHYSIOL-CELL PH, V278, pC344, DOI 10.1152/ajpcell.2000.278.2.C344; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Ho LJ, 2001, J IMMUNOL, V166, P1499, DOI 10.4049/jimmunol.166.3.1499; Hsuan SL, 1999, MICROB PATHOGENESIS, V26, P263, DOI 10.1006/mpat.1998.0271; Hu QH, 1999, J BIOL CHEM, V274, P33995, DOI 10.1074/jbc.274.48.33995; Jefferson KK, 1999, J IMMUNOL, V163, P5183; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; Kimata Y, 2003, MOL BIOL CELL, V14, P2559, DOI 10.1091/mbc.E02-11-0708; Koller DY, 1997, AM J RESP CRIT CARE, V155, P1050, DOI 10.1164/ajrccm.155.3.9116985; KONSTAN MW, 1994, AM J RESP CRIT CARE, V150, P448, DOI 10.1164/ajrccm.150.2.8049828; Konstan MW, 1997, PEDIATR PULM, V24, P137, DOI 10.1002/(SICI)1099-0496(199708)24:2<137::AID-PPUL13>3.0.CO;2-3; Korkotian E, 1999, J BIOL CHEM, V274, P21673, DOI 10.1074/jbc.274.31.21673; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; LEIGH MW, 1998, DISORDERS RESP TRACT; LEVINE SJ, 1995, J INVEST MED, V43, P241; Lewis RS, 2003, BIOCHEM SOC T, V31, P925; LOOK DC, 2004, PEDIATR PULM, V27, P165; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Muhlebach MS, 2002, AM J RESP CRIT CARE, V165, P911, DOI 10.1164/ajrccm.165.7.2107114; Muhlebach MS, 1999, AM J RESP CRIT CARE, V160, P186, DOI 10.1164/ajrccm.160.1.9808096; Ouellet M, 1999, J BIOL CHEM, V274, P35029, DOI 10.1074/jbc.274.49.35029; Paradiso AM, 2001, J GEN PHYSIOL, V117, P53, DOI 10.1085/jgp.117.1.53; PARADISO AM, 1991, AM J PHYSIOL, V261, pL63, DOI 10.1152/ajplung.1991.261.2.L63; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; PATTERSON PH, 1995, CURR OPIN NEUROBIOL, V5, P642, DOI 10.1016/0959-4388(95)80070-0; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; Quinlan KL, 1999, J IMMUNOL, V163, P5656; Ratner AJ, 2001, J BIOL CHEM, V276, P19267, DOI 10.1074/jbc.M007703200; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Ribeiro CMP, 2005, J BIOL CHEM, V280, P10202, DOI 10.1074/jbc.M410317200; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; Rodgers HC, 2002, AM J PHYSIOL-LUNG C, V283, pL612, DOI 10.1152/ajplung.00483.2001; Su HL, 2002, J VIROL, V76, P4162, DOI 10.1128/JVI.76.9.4162-4171.2002; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Urano F, 2000, J CELL SCI, V113, P3697; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; WIEST DL, 1990, J CELL BIOL, V110, P1501, DOI 10.1083/jcb.110.5.1501; Worlitzsch D, 2002, J CLIN INVEST, V109, P317, DOI 10.1172/JCI0213870; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	57	117	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17798	17806		10.1074/jbc.M410618200	http://dx.doi.org/10.1074/jbc.M410618200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746099	hybrid			2022-12-25	WOS:000228807200031
J	Singh, V; Evans, GB; Lenz, DH; Mason, JM; Clinch, K; Mee, S; Painter, GF; Tyler, PC; Furneaux, RH; Lee, JE; Howell, PL; Schramm, VL				Singh, V; Evans, GB; Lenz, DH; Mason, JM; Clinch, K; Mee, S; Painter, GF; Tyler, PC; Furneaux, RH; Lee, JE; Howell, PL; Schramm, VL			Femtomolar transition state analogue inhibitors of 5 '-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUORUM-SENSING SIGNAL; PHOSPHORYLASE; LUXS; DYNAMICS	Escherichia coli 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase (MTAN) hydrolyzes its substrates to form adenine and 5-methylthioribose (MTR) or S-ribosylhomocysteine (SRH). 5'-Methylthioadenosine (MTA) is a by-product of polyamine synthesis and SRH is a precursor to the biosynthesis of one or more quorum sensing autoinducer molecules. MTAN is therefore involved in quorum sensing, recycling MTA from the polyamine pathway via adenine phosphoribosyltransferase and recycling MTR to methionine. Hydrolysis of MTA by E. coli MTAN involves a highly dissociative transition state with ribooxacarbenium ion character. Iminoribitol mimics of MTA at the transition state of MTAN were synthesized and tested as inhibitors. 5'-Methylthio-Immucillin-A (MT-ImmA) is a slow-onset tight-binding inhibitor giving a dissociation constant (K-i*) of 77 pM. Substitution of the methylthio group with a p-Cl-phenylthio group gives a more powerful inhibitor with a dissociation constant of 2 pM. DADMe-Immucillins are better inhibitors of E. coli MTAN, since they are more closely related to the highly dissociative nature of the transition state. MT-DADMe-Immucillin-A binds with a K-i* value of 2 pM. Replacing the 5'-methyl group with other hydrophobic groups gave 17 transition state analogue inhibitors with dissociation constants from 10(-12) to 10(-14) M. The most powerful inhibitor was 5'-p-Cl-phenylthio-DADMe-Immucillin-A (pClPhT-DADMe-ImmA) with a K-i* value of 47 fM (47 x 10(-15) M). These are among the most powerful non-covalent inhibitors reported for any enzyme, binding 9-91 million times tighter than the MTA and SAH substrates, respectively. The inhibitory potential of these transition state analogue inhibitors supports a transition state structure closely resembling a fully dissociated ribooxacarbenium ion. Powerful inhibitors of MTAN are candidates to disrupt key bacterial pathways including methylation, polyamine synthesis, methionine salvage, and quorum sensing. The accompanying article reports crystal structures of MTAN with these analogues.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Ind Res Ltd, Carbohydrate Chem Team, Lower Hutt, New Zealand; Hosp Sick Children, Res Inst, Program Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	Yeshiva University; Albert Einstein College of Medicine; Callaghan Innovation; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Schramm, VL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	vern@aecom.yu.edu	Evans, Gary/B-8343-2011; Evans, Gary/I-4123-2019; Furneaux, Richard Hubert/B-4157-2015	Evans, Gary/0000-0002-6973-2002; Evans, Gary/0000-0002-6973-2002; Furneaux, Richard Hubert/0000-0003-0973-2606; Clinch, Keith/0000-0002-3300-4396				Birck MR, 2004, J AM CHEM SOC, V126, P2447, DOI 10.1021/ja039260h; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; Chen XY, 2000, J AM CHEM SOC, V122, P1609, DOI 10.1021/ja992750i; Cornell KA, 1996, BIOCHEM BIOPH RES CO, V228, P724, DOI 10.1006/bbrc.1996.1723; Daniels R, 2004, FEMS MICROBIOL REV, V28, P261, DOI 10.1016/j.femsre.2003.09.004; Evans GB, 2004, J MED CHEM, V47, P3275, DOI 10.1021/jm0306475; Evans GB, 2004, J ORG CHEM, V69, P2217, DOI 10.1021/jo035744k; Evans GB, 2003, J MED CHEM, V46, P5271, DOI 10.1021/jm030305z; Evans GB, 2003, ORG LETT, V5, P3639, DOI 10.1021/ol035293q; Evans GB, 2000, TETRAHEDRON, V56, P3053, DOI 10.1016/S0040-4020(00)00194-0; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; Lee JE, 2005, J BIOL CHEM, V280, P18274, DOI 10.1074/jbc.M414471200; Lee JE, 2004, BIOCHEMISTRY-US, V43, P5159, DOI 10.1021/bi035492h; Lee JE, 2003, J BIOL CHEM, V278, P8761, DOI 10.1074/jbc.M210836200; Lee JE, 2001, STRUCTURE, V9, P941, DOI 10.1016/S0969-2126(01)00656-6; Lee JE, 2001, ACTA CRYSTALLOGR D, V57, P150, DOI 10.1107/S0907444900014669; Lewandowicz A, 2004, BIOCHEMISTRY-US, V43, P1458, DOI 10.1021/bi0359123; Mendieta J, 2004, BIOCHEMISTRY-US, V43, P405, DOI 10.1021/bi034793o; MENTCH F, 1987, BIOCHEMISTRY-US, V26, P921, DOI 10.1021/bi00377a037; Miles RW, 1998, BIOCHEMISTRY-US, V37, P8615, DOI 10.1021/bi980658d; Miller MB, 2002, CELL, V110, P303, DOI 10.1016/S0092-8674(02)00829-2; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; Miller ST, 2004, MOL CELL, V15, P677, DOI 10.1016/j.molcel.2004.07.020; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MYERS RW, 1989, J BIOL CHEM, V264, P10547; PAJULA RL, 1979, FEBS LETT, V99, P343, DOI 10.1016/0014-5793(79)80988-6; RAGIONE ED, 1985, BIOCHEM J, V232, P335, DOI 10.1042/bj2320335; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P5694, DOI 10.1021/bi034003a; Schramm VL, 1999, METHOD ENZYMOL, V308, P301; Schramm VL, 2005, ARCH BIOCHEM BIOPHYS, V433, P13, DOI 10.1016/j.abb.2004.08.035; Schramm VL, 2003, ACCOUNTS CHEM RES, V36, P588, DOI 10.1021/ar0200495; Singh V, 2004, BIOCHEMISTRY-US, V43, P9, DOI 10.1021/bi0358420; TABOR CW, 1983, METHOD ENZYMOL, V94, P29; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; Winzer K, 2002, MICROBIOL-SGM, V148, P909, DOI 10.1099/00221287-148-4-909; Withers H, 2001, CURR OPIN MICROBIOL, V4, P186, DOI 10.1016/S1369-5274(00)00187-9; WOLFENDE.R, 1969, NATURE, V223, P704, DOI 10.1038/223704a0; Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i; Xavier KB, 2003, CURR OPIN MICROBIOL, V6, P191, DOI 10.1016/S1369-5274(03)00028-6; Yoshida M, 2004, J BIOL CHEM, V279, P46008, DOI 10.1074/jbc.M404393200; Zappia V, 1988, Adv Exp Med Biol, V250, P165; Zhao G, 2003, BIOORG MED CHEM LETT, V13, P3897, DOI 10.1016/j.bmcl.2003.09.015; Zhou GC, 2004, J AM CHEM SOC, V126, P5690, DOI 10.1021/ja038159+	43	114	127	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18265	18273		10.1074/jbc.M414472200	http://dx.doi.org/10.1074/jbc.M414472200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749708	hybrid			2022-12-25	WOS:000228807200085
J	Li, K; Chen, ZH; Kato, N; Gale, M; Lemon, SM				Li, K; Chen, ZH; Kato, N; Gale, M; Lemon, SM			Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C-VIRUS; TOLL-LIKE RECEPTOR-3; DOUBLE-STRANDED-RNA; PATTERN-RECOGNITION RECEPTORS; RESPIRATORY SYNCYTIAL VIRUS; CELL-LINES; ADAPTIVE IMMUNITY; VIRAL-INFECTION; GENE-EXPRESSION; DENDRITIC CELLS	Innate cellular antiviral defenses are likely to influence the outcome of infections by many human viruses, including hepatitis B and C viruses, agents that frequently establish persistent infection leading to chronic hepatitis, cirrhosis, and liver cancer. However, little is known of the pathways by which hepatocytes, the cell type within which these hepatitis agents replicate, sense infection, and initiate protective responses. We show that cultured hepatoma cells, including Huh7 cells, do not activate the interferon (IFN)-beta promoter in response to extracellular poly(I-C). In contrast, the addition of poly(I-C) to culture media activates the IFN-beta promoter and results in robust expression of IFN-stimulated genes (ISG) in PH5CH8 cells, which are derived from non-neoplastic hepatocytes transformed with large T antigen. Small interfering RNA knockdown of TLR3 or its adaptor, Toll-interleukin-1 receptor domain-containing adaptor inducing IFN-beta ( TRIF), blocked extracellular poly(I-C) signaling in PH5CH8 cells, whereas poly(I-C) responsiveness could be conferred on Huh7 hepatoma cells by ectopic expression of Toll-like receptor 3 ( TLR3). In contrast to poly(I-C), both cell types signal the presence of Sendai virus infection through a TLR3-independent intracellular pathway requiring expression of retinoic acid-inducible gene I (RIG-I), a putative cellular RNA helicase. Silencing of RIG-I expression impaired only the response to Sendai virus and not extracellular poly( I-C). We conclude that hepatocytes contain two distinct antiviral signaling pathways leading to expression of type I IFNs, one dependent upon TLR3 and the other dependent on RIG-I, with little cross-talk between these pathways.	Univ Texas, Med Branch, Inst Human Infect & Immun, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Okayama Univ, Grad Sch Med & Dent, Dept Mol Biol, Okayama 7008558, Japan; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Medical Branch Galveston; Okayama University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Li, K (corresponding author), Univ Texas, Med Branch, Inst Human Infect & Immun, Dept Microbiol & Immunol, 301 Univ Blvd, Galveston, TX 77555 USA.	kuli@utmb.edu; smlemon@utmb.edu		Gale, Michael/0000-0002-6332-7436	NIAID NIH HHS [U19-AI40035, U01-AI48235] Funding Source: Medline; NIDA NIH HHS [R21-DA018054] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI048235, U19AI040035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA018054] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bartenschlager R, 2001, ANTIVIR RES, V52, P1, DOI 10.1016/S0166-3542(01)00164-4; Bartenschlager R, 2003, ANTIVIR RES, V60, P91, DOI 10.1016/j.antiviral.2003.08.016; Beignon AS, 2003, NAT IMMUNOL, V4, P939, DOI 10.1038/ni1003-939; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Boehme KW, 2004, J VIROL, V78, P7867, DOI 10.1128/JVI.78.15.7867-7873.2004; Cocude C, 2003, J GEN VIROL, V84, P3215, DOI 10.1099/vir.0.19300-0; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dolganiuc A, 2004, GASTROENTEROLOGY, V127, P1513, DOI 10.1053/j.gastro.2004.08.067; Edelmann KH, 2004, VIROLOGY, V322, P231, DOI 10.1016/j.virol.2004.01.033; Foy E, 2005, P NATL ACAD SCI USA, V102, P2986, DOI 10.1073/pnas.0408707102; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Fredericksen B, 2002, VIRAL IMMUNOL, V15, P29, DOI 10.1089/088282402317340215; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Haynes LM, 2001, J VIROL, V75, P10730, DOI 10.1128/JVI.75.22.10730-10737.2001; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hoebe K, 2004, NAT IMMUNOL, V5, P971, DOI 10.1038/ni1004-971; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100; Ikeda M, 1998, VIRUS RES, V56, P157, DOI 10.1016/S0168-1702(98)00063-X; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Janssens S, 2003, CLIN MICROBIOL REV, V16, P637, DOI 10.1128/CMR.16.4.637-646.2003; Kang DC, 2004, ONCOGENE, V23, P1789, DOI 10.1038/sj.onc.1207300; Kato N, 1996, JPN J CANCER RES, V87, P787, DOI 10.1111/j.1349-7006.1996.tb02101.x; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Keskinen P, 1999, VIROLOGY, V263, P364, DOI 10.1006/viro.1999.9983; Kmiec Z, 2001, ADV ANAT EMBRYOL CEL, V161, P1; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lanford RE, 2003, J VIROL, V77, P1092, DOI 10.1128/JVI.77.2.1092-1104.2003; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; Levy DE, 2004, NAT IMMUNOL, V5, P699, DOI 10.1038/ni0704-699; Levy DE, 2003, CURR OPIN IMMUNOL, V15, P52, DOI 10.1016/S0952-7915(02)00011-0; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; LOHMANN V, 1999, SCIENCE, V285, P110; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Matsumoto M, 2004, MICROBIOL IMMUNOL, V48, P147, DOI 10.1111/j.1348-0421.2004.tb03500.x; McCormick CJ, 2004, J GEN VIROL, V85, P429, DOI 10.1099/vir.0.19676-0; Miettinen M, 2001, GENES IMMUN, V2, P349, DOI 10.1038/sj.gene.6363791; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Noguchi M, 1996, IN VITRO CELL DEV-AN, V32, P135; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Ronni T, 1998, J INTERF CYTOK RES, V18, P773, DOI 10.1089/jir.1998.18.773; Scholle F, 2004, J VIROL, V78, P1513, DOI 10.1128/JVI.78.3.1513-1524.2004; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; SUMPTER R, 2005, J VIROL, V79, P2689, DOI DOI 10.1128/JVI.79.5.2689-2699.2005; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; TWU JS, 1988, P NATL ACAD SCI USA, V85, P252, DOI 10.1073/pnas.85.1.252; WHITTEN TM, 1991, J VIROL, V65, P4699, DOI 10.1128/JVI.65.9.4699-4704.1991; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yi M, 2002, J VIROL, V76, P1171, DOI 10.1128/JVI.76.3.1171-1180.2002; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhu Q, 2003, J VIROL, V77, P9204, DOI 10.1128/JVI.77.17.9204-9210.2003	60	291	306	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16739	16747		10.1074/jbc.M414139200	http://dx.doi.org/10.1074/jbc.M414139200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15737993	hybrid			2022-12-25	WOS:000228615500025
J	Verschuur, M; de Jong, M; Felida, L; de Maat, MPM; Vos, HL				Verschuur, M; de Jong, M; Felida, L; de Maat, MPM; Vos, HL			A hepatocyte nuclear factor-3 site in the fibrinogen beta promoter is important for interleukin 6-induced expression, and its activity is influenced by the adjacent-148C/T polymorphism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIC-HEART-DISEASE; PLASMA-FIBRINOGEN; MYOCARDIAL-INFARCTION; GENETIC-VARIATION; RISK-FACTORS; ATHEROTHROMBOTIC DISEASE; LINKAGE DISEQUILIBRIUM; ALPHA-FIBRINOGEN; FACTOR-VII; BINDING	An elevated plasma fibrinogen level is an independent risk factor for cardiovascular disease. Therefore, an understanding of the regulation of fibrinogen expression is important. Inflammation and genetic variation of the fibrinogen beta gene regulate plasma fibrinogen levels, and there are indications that inflammation and genetic variation interact. The aim of our study was to gain more understanding of the regulation of the inflammatory response of the fibrinogen beta gene and to determine the effects of genetic variation. Luciferase reporter gene assays in hepatoma cells, mutation analysis, and electrophoretic mobility shift assays were used to investigate the transcriptional regulation of the fibrinogen beta promoter. We identified a hepatocyte nuclear factor-3 (HNF-3) site located just upstream of previously identified interleukin-6 (IL6)-responsive sequences. This HNF-3 site is essential for a full response of the promoter to IL6, which is a new function for HNF-3. The activity of the CCAAT box/enhancer-binding protein site ( located 18 nucleotides downstream of the HNF-3 site and important to the IL6 response) depends on the integrity of the HNF-3 site and vice versa, explaining the necessity of HNF-3 in the IL6 response of the fibrinogen beta promoter. Furthermore, small interfering RNA to HNF-3 reduces the fibrinogen beta mRNA levels. The rare T allele of the - 148C/T polymorphism, which is present between the binding sites of HNF-3 and CCAAT box/ enhancer-binding protein, interferes with this mechanism, and this polymorphism is in our assay system the only genetic determinant of IL6-induced promoter activity among six polymorphisms in the fibrinogen beta promoter.	Leiden Univ, Med Ctr, Ctr Hemostasis & Thrombosis Res, Dept Hematol, NL-2300 RC Leiden, Netherlands; TNO Qual Life, Gaubius Lab, NL-2301 CE Leiden, Netherlands; Erasmus MC, Dept Hematol, NL-3015 GE Rotterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Organization Applied Science Research; Erasmus University Rotterdam; Erasmus MC	Vos, HL (corresponding author), Leiden Univ, Med Ctr, Ctr Hemostasis & Thrombosis Res, Dept Hematol, POB 9600, NL-2300 RC Leiden, Netherlands.	h.l.vos@lumc.nl						ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; Antes TJ, 2001, DNA CELL BIOL, V20, P67, DOI 10.1089/104454901750070265; BAUMANN RE, 1994, HUM GENET, V94, P165; BAUMANN RE, 1993, THROMB HAEMOSTASIS, V69, P961; Brown ET, 1998, BLOOD, V92, P3286, DOI 10.1182/blood.V92.9.3286.421k20_3286_3293; Brull DJ, 2002, THROMB HAEMOSTASIS, V87, P37; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Cook DG, 2001, AM J EPIDEMIOL, V153, P799, DOI 10.1093/aje/153.8.799; COSTA RH, 1994, LIVER GENE TRANSCRIP, P183; Cotton JM, 2000, THROMB HAEMOSTASIS, V84, P926, DOI 10.1055/s-0037-1614144; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; de Maat MPM, 1998, ARTERIOSCL THROM VAS, V18, P265, DOI 10.1161/01.ATV.18.2.265; Erren M, 1999, ARTERIOSCL THROM VAS, V19, P2355, DOI 10.1161/01.ATV.19.10.2355; Ferrer-Antunes C, 1998, THROMB RES, V92, P207, DOI 10.1016/S0049-3848(98)00143-1; Folsom AR, 2001, THROMB HAEMOSTASIS, V86, P366; Gervois P, 2001, J BIOL CHEM, V276, P33471, DOI 10.1074/jbc.M102839200; Green FR, 2001, ANN NY ACAD SCI, V936, P549; Herrick S, 1999, INT J BIOCHEM CELL B, V31, P741, DOI 10.1016/S1357-2725(99)00032-1; HUMPHRIES SE, 1987, LANCET, V1, P1452, DOI 10.1016/S0140-6736(87)92205-7; Humphries SE, 1997, THROMB HAEMOSTASIS, V78, P457; Kleemann R, 2003, BLOOD, V101, P545, DOI 10.1182/blood-2002-06-1762; KOOPMAN JL, 1997, MED INTELL UNIT, P125; KOSTER T, 1994, THROMB HAEMOSTASIS, V71, P719; LIU ZY, 1995, J BIOL CHEM, V270, P7580, DOI 10.1074/jbc.270.13.7580; LOCKER J, 1996, TRANSCRIPTION FACTOR, P12; Lou XJ, 1998, P NATL ACAD SCI USA, V95, P12591, DOI 10.1073/pnas.95.21.12591; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; Montgomery HE, 1996, ARTERIOSCL THROM VAS, V16, P386, DOI 10.1161/01.ATV.16.3.386; NAITO M, 1990, ATHEROSCLEROSIS, V83, P9, DOI 10.1016/0021-9150(90)90124-2; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROY SN, 1990, J BIOL CHEM, V265, P6389; SCARABIN PY, 1993, ARTERIOSCLER THROMB, V13, P886, DOI 10.1161/01.ATV.13.6.886; Scarabin PY, 1998, THROMB HAEMOSTASIS, V80, P749; Schuit AJ, 1997, THROMB HAEMOSTASIS, V78, P845; Slomiany BA, 2000, BIOTECHNIQUES, V28, P938, DOI 10.2144/00285st08; THOMAS A, 1994, HUM MUTAT, V3, P79, DOI 10.1002/humu.1380030117; TybjaergHansen A, 1997, J CLIN INVEST, V99, P3034, DOI 10.1172/JCI119499; van't Hooft FM, 1999, ARTERIOSCL THROM VAS, V19, P3063, DOI 10.1161/01.ATV.19.12.3063; Vasse M, 1996, BRIT J HAEMATOL, V93, P955, DOI 10.1046/j.1365-2141.1996.d01-1731.x; WRAGG S, 2001, THROMB HAEMOSTASIS S; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; Zhang ZX, 2000, BLOOD, V96, P3466, DOI 10.1182/blood.V96.10.3466.h8003466_3466_3472; Zito F, 1997, ARTERIOSCL THROM VAS, V17, P3489, DOI 10.1161/01.ATV.17.12.3489	46	37	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16763	16771		10.1074/jbc.M501973200	http://dx.doi.org/10.1074/jbc.M501973200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15737987	hybrid, Green Published			2022-12-25	WOS:000228615500028
J	Yang, F; Jiang, Q; Zhao, JH; Ren, Y; Sutton, MD; Feng, J				Yang, F; Jiang, Q; Zhao, JH; Ren, Y; Sutton, MD; Feng, J			Parkin stabilizes microtubules through strong binding mediated by three independent domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; ROTENONE INHIBITION; ALPHA-SYNUCLEIN; LEWY BODIES; PC12 CELLS; DISEASE; PROTEIN; TUBULIN; DEGRADATION; COMPLEX	Mutations of parkin, a protein-ubiquitin isopeptide ligase (E3), appear to be the most frequent cause of familial Parkinson's disease (PD). Our previous studies have demonstrated that parkin binds strongly to alpha/beta tubulin heterodimers and microtubules. Here we show that the strong binding between parkin and tubulin, as well as that between parkin and microtubules, was mediated by three independent domains: linker, RING1, and RING2. These redundant strong interactions made it virtually impossible to separate parkin from microtubules by high concentrations of salt (3.8 M) or urea (0.5 M). Parkin co-purified with tubulin and was found in highly purified tubulin preparation. Expression of either full-length parkin or any of its three microtubule-binding domains significantly attenuated colchicine-induced microtubule depolymerization. The abilities of parkin to bind to and stabilize microtubules were not affected by PD-linked mutations that abrogate its E3 ligase activity. Thus, the tubulin/microtubule-binding activity of parkin and its E3 ligase activity are independent. The strong binding between parkin and tubulin/ microtubules through three redundant interaction domains may not only stabilize microtubules but also guarantee the anchorage of this E3 ligase on microtubules. Because many misfolded proteins are transported on microtubules, the localization of parkin on microtubules may provide an important environment for its E3 ligase activity toward misfolded substrates.	SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Feng, J (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, 124 Sherman Hall, Buffalo, NY 14214 USA.	jianfeng@buffalo.edu			NINDS NIH HHS [NS41722] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041722] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ardley HC, 2003, MOL BIOL CELL, V14, P4541, DOI 10.1091/mbc.E03-02-0078; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BRINKLEY BR, 1974, EXP CELL RES, V85, P41, DOI 10.1016/0014-4827(74)90210-9; Cappelletti G, 1999, J NEUROSCI RES, V56, P28, DOI 10.1002/(SICI)1097-4547(19990401)56:1<28::AID-JNR4>3.0.CO;2-2; Cappelletti G, 2001, CELL BIOL INT, V25, P981, DOI 10.1006/cbir.2001.0772; CHANCE B, 1963, J BIOL CHEM, V238, P418; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Cleveland DW, 1989, CURR OPIN CELL BIOL, V1, P10, DOI 10.1016/S0955-0674(89)80030-4; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Dekker MCJ, 2003, BRAIN, V126, P1722, DOI 10.1093/brain/awg172; deRijk MC, 1995, NEUROLOGY, V45, P2143, DOI 10.1212/WNL.45.12.2143; DRUBIN D, 1988, J CELL BIOL, V106, P1583, DOI 10.1083/jcb.106.5.1583; Feng Jian, 2003, Current Neuropharmacology, V1, P301, DOI 10.2174/1570159033477053; GALLOWAY PG, 1992, AM J PATHOL, V140, P809; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Huynh DP, 2003, HUM MOL GENET, V12, P2587, DOI 10.1093/hmg/ddg269; Imai Y, 2003, J BIOL CHEM, V278, P51901, DOI 10.1074/jbc.M309655200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jiang HB, 2004, J BIOL CHEM, V279, P54380, DOI 10.1074/jbc.M409282200; JOSHI HC, 1989, J CELL BIOL, V109, P663, DOI 10.1083/jcb.109.2.663; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; MARSHALL LE, 1978, BIOCHIM BIOPHYS ACTA, V543, P590, DOI 10.1016/0304-4165(78)90315-X; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Ren Y, 2003, J NEUROSCI, V23, P3316; Shen J, 2004, NEURON, V44, P575, DOI 10.1016/j.neuron.2004.11.008; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; Waterman-Storer CM, 1998, CURR BIOL, V8, P798, DOI 10.1016/S0960-9822(98)70321-5; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhao JH, 2003, J CELL SCI, V116, P4011, DOI 10.1242/jcs.00700	34	102	103	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17154	17162		10.1074/jbc.M500843200	http://dx.doi.org/10.1074/jbc.M500843200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15737990	hybrid			2022-12-25	WOS:000228615500076
J	Colletti, KS; Xu, YY; Yamboliev, I; Pari, GS				Colletti, KS; Xu, YY; Yamboliev, I; Pari, GS			Human cytomegalovirus UL84 is a phosphoprotein that exhibits UTPase activity and is a putative member of the DExD/H box family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN-BINDING-PROTEIN; EPSTEIN-BARR-VIRUS; NUCLEAR-LOCALIZATION SIGNAL; DEPENDENT DNA-REPLICATION; HERPES-SIMPLEX VIRUS-1; LARGE-T-ANTIGEN; TYPE-1 ORIGIN; LYTIC ORIGIN; HELICASE ACTIVITY; VIRAL ORIGIN	Human cytomegalovirus (HCMV) UL84 is required for lytic DNA replication and is proposed to be the key factor in initiation of viral DNA synthesis. We now show that UL84 has a high degree of homology to the DExD/H (where x can be any amino acid) box family of helicases, displays UTPase activity, and is phosphorylated at serine residues. Affinity column-purified UL84-FLAG fusion protein was used in an in vitro nucleoside triphosphatase (NTPase) assay to show that UL84 has NTPase activity, preferring UTP. This UTPase activity was linear with respect to enzyme concentration and slightly enhanced by the addition of nucleic acid substrates. UL84 UTPase was the highest at low salt concentrations, a pH of 7.5, and a temperature of 45 degrees C. The enzyme preferred Mg2+ as the divalent cation but was also able to catalyze the UTPase reaction in the presence of Mn2+, Ca2+, and Zn2+ albeit at lower levels. The evidence presented here suggests that the UL84 UTPase activity may be part of an energy-generating system for helicase activity associated with the initiation of HCMV DNA replication.	Univ Nevada, Dept Microbiol & Immunol, Reno, NV 89557 USA; Univ Nevada, Cell & Mol Biol Program, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno	Pari, GS (corresponding author), Univ Nevada, Dept Microbiol, Sch Med, Howard Bldg, Reno, NV 89557 USA.	gpari@med.unr.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045096] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45096] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbate EA, 2004, GENE DEV, V18, P1981, DOI 10.1101/gad.1220104; AuCoin DP, 2004, VIROLOGY, V318, P542, DOI 10.1016/j.virol.2003.10.016; AuCoin DP, 2002, J VIROL, V76, P7890, DOI 10.1128/JVI.76.15.7890-7896.2002; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; Bronstein JC, 2001, PROTEIN EXPRES PURIF, V22, P276, DOI 10.1006/prep.2001.1446; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; Colletti KS, 2004, J VIROL, V78, P9203, DOI 10.1128/JVI.78.17.9203-9214.2004; DODSON MS, 1993, J BIOL CHEM, V268, P1213; El-Guindy AS, 2004, J VIROL, V78, P7634, DOI 10.1128/JVI.78.14.7634-7644.2004; El-Guindy AS, 2002, J VIROL, V76, P11199, DOI 10.1128/JVI.76.22.11199-11208.2002; FIERER DS, 1995, J BIOL CHEM, V270, P7330, DOI 10.1074/jbc.270.13.7330; FIXMAN ED, 1995, J VIROL, V69, P2998, DOI 10.1128/JVI.69.5.2998-3006.1995; Gao ZG, 1998, J VIROL, V72, P8559, DOI 10.1128/JVI.72.11.8559-8567.1998; Gebert S, 1997, J VIROL, V71, P7048, DOI 10.1128/JVI.71.9.7048-7060.1997; HAMMERSCHMIDT W, 1988, CELL, V55, P427, DOI 10.1016/0092-8674(88)90028-1; He XD, 2000, J VIROL, V74, P5726, DOI 10.1128/JVI.74.12.5726-5728.2000; He XD, 2001, P NATL ACAD SCI USA, V98, P3024, DOI 10.1073/pnas.061028298; Isler JA, 2001, J VIROL, V75, P628, DOI 10.1128/JVI.75.2.628-637.2001; Joo WS, 1998, MOL CELL BIOL, V18, P2677, DOI 10.1128/MCB.18.5.2677; Kim J, 2004, J BIOL CHEM, V279, P4394, DOI 10.1074/jbc.M308637200; Kim RJ, 2002, J VIROL, V76, P11785, DOI 10.1128/JVI.76.23.11785-11792.2002; KOLMAN JL, 1993, P NATL ACAD SCI USA, V90, P10115, DOI 10.1073/pnas.90.21.10115; Lentz MR, 2002, VIRUS RES, V83, P213, DOI 10.1016/S0168-1702(02)00003-5; Liao GL, 2001, J VIROL, V75, P8792, DOI 10.1128/JVI.75.18.8792-8802.2001; LIEBERMAN PM, 1990, J VIROL, V64, P1143, DOI 10.1128/JVI.64.3.1143-1155.1990; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; Macao B, 2004, J BIOL CHEM, V279, P29211, DOI 10.1074/jbc.M400371200; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; Marintcheva B, 2001, J BIOL CHEM, V276, P6605, DOI 10.1074/jbc.M007743200; Mitchell MS, 2004, VIROLOGY, V321, P217, DOI 10.1016/j.virol.2003.11.006; Murata LB, 1999, J BIOL CHEM, V274, P37079, DOI 10.1074/jbc.274.52.37079; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; Prichard MN, 1998, J VIROL, V72, P6997, DOI 10.1128/JVI.72.9.6997-7004.1998; Reese DK, 2004, J VIROL, V78, P2921, DOI 10.1128/JVI.78.6.2921-2934.2004; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; SCHEFFNER M, 1991, EUR J BIOCHEM, V195, P49, DOI 10.1111/j.1432-1033.1991.tb15674.x; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SCHEPERS A, 1993, J VIROL, V67, P4237, DOI 10.1128/JVI.67.7.4237-4245.1993; Schepers A, 1996, VIROLOGY, V220, P367, DOI 10.1006/viro.1996.0325; Sheikh S, 2003, J GEN VIROL, V84, P277, DOI 10.1099/vir.0.18527-0; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Trego KS, 2003, J VIROL, V77, P12646, DOI 10.1128/JVI.77.23.12646-12659.2003; Tuteja N, 2004, EUR J BIOCHEM, V271, P1849, DOI 10.1111/j.1432-1033.2004.04094.x; Wang Y, 2004, J VIROL, V78, P8615, DOI 10.1128/JVI.78.16.8615-8629.2004; WEIR HM, 1990, J GEN VIROL, V71, P1379, DOI 10.1099/0022-1317-71-6-1379; Xu YY, 2004, J VIROL, V78, P11664, DOI 10.1128/JVI.78.21.11664-11677.2004; Xu YY, 2004, J VIROL, V78, P10360, DOI 10.1128/JVI.78.19.10360-10369.2004; Xu YY, 2002, J VIROL, V76, P8931, DOI 10.1128/JVI.76.17.8931-8938.2002; Zhi Y, 1999, J VIROL, V73, P3246, DOI 10.1128/JVI.73.4.3246-3257.1999	50	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11955	11960		10.1074/jbc.C400603200	http://dx.doi.org/10.1074/jbc.C400603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15778228	hybrid			2022-12-25	WOS:000227761800127
J	Youn, CK; Kim, SH; Lee, DY; Song, SH; Chang, IY; Hyun, JW; Chung, MH; You, HJ				Youn, CK; Kim, SH; Lee, DY; Song, SH; Chang, IY; Hyun, JW; Chung, MH; You, HJ			Cadmium down-regulates human OGG1 through suppression of Sp1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							8-OXOGUANINE DNA GLYCOSYLASE; ALVEOLAR EPITHELIAL-CELLS; ZINC-FINGER PROTEINS; HAMSTER OVARY CELLS; TRANSCRIPTION FACTORS; SACCHAROMYCES-CEREVISIAE; 8-HYDROXYGUANINE REPAIR; MUTATIONAL SPECTRUM; MAMMALIAN-CELLS; REACTIVE OXYGEN	Cadmium is a well known human and animal carcinogen and is a ubiquitous contaminant in the environment. Although the carcinogenic mechanism of cadmium is a multifactorial process, oxidative DNA damage is believed to be of prime importance. In particular, cadmium suppresses the capacity of cells to repair oxidative DNA damage. In this study, cadmium treatment led to a significant increase in gamma-ray-induced 8-oxoguanine (8-oxoG) formation. Western blotting and semi-quantitative reverse transcription-PCR revealed that cadmium treatment caused a decrease in the expression level of human OGG1 (8-oxoguanine-DNA glycosylase-1; hOGG1) in human fibroblast GM00637 and HeLa S3 cells. In addition, the cadmium-mediated decrease in hOGG1 transcription was the result of decreased binding of the transcription factor Sp1 to the hOGG1 promoter. Finally, we show that an increase in the functional hOGG1 expression level could inhibit the cadmium-mediated increase in gamma-ray-induced 8-oxoG accumulation as well as in gamma-radiation-induced mutation frequency at the HPRT (hypoxanthine-guanine phosphoribosyltransferase) gene locus. These results suggest that cadmium attenuates removal of gamma-ray-induced 8-oxoG adducts, which in turn increases the mutation frequency, and that this effect might, at least in part, result from suppression of hOGG1 transcription via inactivation of Sp1 as a result of cadmium treatment.	Chosun Univ, Sch Med, Dept Pharmacol, Kwangju 501759, South Korea; Chosun Univ, Sch Med, Dept Anat, Kwangju 501759, South Korea; Chosun Univ, Res Ctr Prot Mat, Kwangju 501759, South Korea; Jeju Natl Univ, Coll Med, Dept Biochem, Cheju 690756, South Korea; Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea	Chosun University; Chosun University; Chosun University; Jeju National University; Seoul National University (SNU)	You, HJ (corresponding author), Chosun Univ, Sch Med, Dept Pharmacol, 375 Seosuk Dong, Kwangju 501759, South Korea.	hjyou@mail.chosun.ac.kr		Chang, In-Youb/0000-0002-8911-7541; You, Ho Jin/0000-0002-0530-4017				Arai T, 2003, CANCER RES, V63, P4287; AYLETT BJ, 1979, CHEM BIOCH BIOL CADM, P267; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Blons H, 1999, MOL CARCINOGEN, V26, P254; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Chao JI, 2001, MUTAT RES-GEN TOX EN, V498, P7, DOI 10.1016/S1383-5718(01)00249-2; CHENG KC, 1992, J BIOL CHEM, V267, P166; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; Dally H, 1997, CARCINOGENESIS, V18, P1021, DOI 10.1093/carcin/18.5.1021; Dhenaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2; Emami KH, 1998, NUCLEIC ACIDS RES, V26, P839, DOI 10.1093/nar/26.3.839; Fatur T, 2003, MUTAT RES-FUND MOL M, V529, P109, DOI 10.1016/S0027-5107(03)00112-X; Fatur T, 2002, FOOD CHEM TOXICOL, V40, P1069, DOI 10.1016/S0278-6915(02)00058-3; Filipic M, 2004, MUTAT RES-FUND MOL M, V546, P81, DOI 10.1016/j.mrfmmm.2003.11.006; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; Goering PL, 1994, HDB EXPT PHARM TOXIC, V115, P189, DOI DOI 10.1007/978-3-642-79162-8_9; Gong PF, 2000, IND HEALTH, V38, P224, DOI 10.2486/indhealth.38.224; HARTMANN A, 1994, ENVIRON MOL MUTAGEN, V23, P299, DOI 10.1002/em.2850230407; HARTWIG A, 1994, ENVIRON HEALTH PERSP, V102, P45, DOI 10.2307/3431762; Hartwig A, 2002, TOXICOL LETT, V127, P47, DOI 10.1016/S0378-4274(01)00482-9; Hartwig A, 2001, ANTIOXID REDOX SIGN, V3, P625, DOI 10.1089/15230860152542970; Hartwig A, 1998, TOXICOL LETT, V103, P235, DOI 10.1016/S0378-4274(98)00312-9; Hirano T, 1997, TOXICOL APPL PHARM, V147, P9, DOI 10.1006/taap.1997.8260; Hodges NJ, 2002, CARCINOGENESIS, V23, P55, DOI 10.1093/carcin/23.1.55; Hwua YS, 1998, CARCINOGENESIS, V19, P881, DOI 10.1093/carcin/19.5.881; International Agency for Research on Cancer, 1993, IARC MON EV CARC RIS, V58, P41; Jeong HG, 2004, J BIOL CHEM, V279, P34138, DOI 10.1074/jbc.M402530200; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; Kim HN, 2001, CARCINOGENESIS, V22, P265, DOI 10.1093/carcin/22.2.265; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Kuipers GK, 2000, MUTAT RES-DNA REPAIR, V461, P189, DOI 10.1016/S0921-8777(00)00050-1; Kuo FC, 1997, J EXP MED, V186, P1547, DOI 10.1084/jem.186.9.1547; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lee MR, 2004, J BIOL CHEM, V279, P9857, DOI 10.1074/jbc.M311132200; LIN RH, 1994, ENVIRON MOL MUTAGEN, V23, P143, DOI 10.1002/em.2850230212; Liu F, 2000, FREE RADICAL BIO MED, V28, P55, DOI 10.1016/S0891-5849(99)00196-3; Lloyd DR, 1997, CHEM RES TOXICOL, V10, P393, DOI 10.1021/tx960158q; Lloyd DR, 1998, CHEM RES TOXICOL, V11, P420, DOI 10.1021/tx970156l; LOEB LA, 1991, CANCER RES, V51, P3075; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; Misra RR, 1998, TOXICOLOGY, V126, P103, DOI 10.1016/S0300-483X(98)00003-1; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; OCHI T, 1985, MUTAT RES, V143, P137, DOI 10.1016/S0165-7992(85)80024-5; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Potts RJ, 2003, TOXICOLOGY, V184, P189, DOI 10.1016/S0300-483X(02)00579-6; Potts RJ, 2001, TOXICOLOGY, V161, P25, DOI 10.1016/S0300-483X(00)00419-4; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; ROSSMAN TG, 1992, TOXICITY CARCINOGENI, P367; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; Shinmura K, 2001, ANTIOXID REDOX SIGN, V3, P597, DOI 10.1089/15230860152542952; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; TAKENAKA S, 1983, J NATL CANCER I, V70, P367; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Tsurudome Y, 1999, CARCINOGENESIS, V20, P1573, DOI 10.1093/carcin/20.8.1573; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; WAALKES MP, 1994, REGUL TOXICOL PHARM, V20, P119, DOI 10.1006/rtph.1994.1040; Waalkes MP, 2000, J INORG BIOCHEM, V79, P241, DOI 10.1016/S0162-0134(00)00009-X; WAALKES MP, 1984, TOXICOL APPL PHARM, V75, P539, DOI 10.1016/0041-008X(84)90190-X; WAALKES MP, 1992, CRIT REV TOXICOL, V22, P175, DOI 10.3109/10408449209145323; Watkin RD, 2003, TOXICOLOGY, V184, P157, DOI 10.1016/S0300-483X(02)00577-2; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yamane A, 2004, CARCINOGENESIS, V25, P1689, DOI 10.1093/carcin/bgh166; Yang JL, 1996, CHEM RES TOXICOL, V9, P1360, DOI 10.1021/tx960122y; Youn CK, 2004, CANCER RES, V64, P4849, DOI 10.1158/0008-5472.CAN-04-0348; Zawia NH, 2000, NEUROTOXICOLOGY, V21, P1069	79	67	70	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25185	25195		10.1074/jbc.M412793200	http://dx.doi.org/10.1074/jbc.M412793200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15760895	hybrid			2022-12-25	WOS:000230114000103
J	Boehden, GS; Baumann, C; Siehler, S; Wiesmuller, L				Boehden, GS; Baumann, C; Siehler, S; Wiesmuller, L			Wild-type p53 stimulates homologous recombination upon sequence-specific binding to the ribosomal gene cluster repeat	ONCOGENE			English	Article						homologous recombination; microsatellite repeat; p53 recognition sequence; replication-associated recombination	REPLICATION FORK BLOCKING; MICROSATELLITE INSTABILITY; DNA-REPLICATION; TETRANUCLEOTIDE REPEATS; FOB1 PROTEIN; TRANSCRIPTION; DISSOCIATION; INHIBITION; COMPLEX; SITES	p53 plays a central role in the maintenance of the genome integrity, both as a gatekeeper and a caretaker. Sequence-specific recognition of DNA is underlying the ability of p53 to transcriptionally transactivate target genes during checkpoint control and to regulate DNA replication at the TGCCT repeat from the ribosomal gene cluster (RGC). In contrast, suppression of recombination by p53 has been observed with nonconsensus DNA sequences. In this study, we discovered that wild-type p53 stimulates homologous recombination adjacent to the RGC repeat, whereas downregulation is seen with a mutated version thereof and with a microsatellite repeat sequence. Analysis of the causes possibly underlying the enhancement of homologous recombination revealed that p53 binding to the RGC element delays DNA synthesis. This was demonstrated after integration of the corresponding DNA fragments into our Simian virus 40-based model system, which was used to study recombination on replicating minichromosomes. Differently, with plasmid-based substrates, p53 did not stimulate recombination at the RGC sequence. Thus, in combination with our previous findings, p53 may promote homologous recombination by two separate mechanisms involving either molecular interactions with topoisomerase I or/and by specific binding to certain genomic regions, thereby causing replication fork stalling and recombination.	Univ Frauenklin, D-89075 Ulm, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Ulm University; Heinrich Pette Institute; University of Hamburg	Wiesmuller, L (corresponding author), Univ Frauenklin, Prittwitzstr 43, D-89075 Ulm, Germany.	lisa.wiesmueller@medizin.uni-ulm.de						Achanta G, 2001, CANCER RES, V61, P8723; Ahrendt SA, 2000, CANCER RES, V60, P2488; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; ARIIZUMI K, 1993, MOL CELL BIOL, V13, P5629, DOI 10.1128/MCB.13.9.5629; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; Boehden GS, 2004, CARCINOGENESIS, V25, P1305, DOI 10.1093/carcin/bgh092; Boehden GS, 2003, ONCOGENE, V22, P4111, DOI 10.1038/sj.onc.1206632; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Brazdova M, 2002, NUCLEIC ACIDS RES, V30, P4966, DOI 10.1093/nar/gkf616; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Danaee H, 2002, ONCOGENE, V21, P4894, DOI 10.1038/sj.onc.1205619; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Gerber JK, 1997, CELL, V90, P559, DOI 10.1016/S0092-8674(00)80515-2; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; JAXEL C, 1988, NUCLEIC ACIDS RES, V16, P11157, DOI 10.1093/nar/16.23.11157; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; KANDA T, 1994, MOL CELL BIOL, V14, P2651, DOI 10.1128/MCB.14.4.2651; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kobayashi T, 1998, GENE DEV, V12, P3821, DOI 10.1101/gad.12.24.3821; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; Pluciennik A, 2002, J BIOL CHEM, V277, P34074, DOI 10.1074/jbc.M202127200; Richard GF, 2000, EMBO REP, V1, P122, DOI 10.1093/embo-reports/kvd031; Rothstein R, 2000, GENE DEV, V14, P1; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Stephan H, 2002, NUCLEIC ACIDS RES, V30, P5087, DOI 10.1093/nar/gkf659; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; TSUI S, 1989, J VIROL, V63, P5175, DOI 10.1128/JVI.63.12.5175-5183.1989; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Xiao G, 1998, ONCOGENE, V16, P1171, DOI 10.1038/sj.onc.1201631; Yoon D, 2004, J MOL BIOL, V336, P639, DOI 10.1016/j.jmb.2003.12.050; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000	47	10	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4183	4192		10.1038/sj.onc.1208592	http://dx.doi.org/10.1038/sj.onc.1208592			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15782112				2022-12-25	WOS:000229815300003
J	Law, RHP; Irving, JA; Buckle, AM; Ruzyla, K; Buzza, M; Bashtannyk-Puhalovich, TA; Beddoe, TC; Nguyen, K; Worrall, DM; Bottomley, SP; Bird, PI; Rossjohn, J; Whisstock, JC				Law, RHP; Irving, JA; Buckle, AM; Ruzyla, K; Buzza, M; Bashtannyk-Puhalovich, TA; Beddoe, TC; Nguyen, K; Worrall, DM; Bottomley, SP; Bird, PI; Rossjohn, J; Whisstock, JC			The high resolution crystal structure of the human tumor suppressor maspin reveals a novel conformational switch in the G-helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIUM-DERIVED FACTOR; REACTIVE CENTER LOOP; CANCER CELLS; SERPIN; OVALBUMIN; ALPHA(1)-ANTITRYPSIN; PROTEASE; INHIBITION; MECHANISM; PROTEINS	Maspin is a serpin that acts as a tumor suppressor in a range of human cancers, including tumors of the breast and lung. Maspin is crucial for development, because homozygous loss of the gene is lethal; however, the precise physiological role of the molecule is unclear. To gain insight into the function of human maspin, we have determined its crystal structure in two similar, but nonisomorphous crystal forms, to 2.1- and 2.8-angstrom resolution, respectively. The structure reveals that maspin adopts the native serpin fold in which the reactive center loop is expelled fully from the A beta- sheet, makes minimal contacts with the core of the molecule, and exhibits a high degree of flexibility. A buried salt bridge unique to maspin orthologues causes an unusual bulge in the region around the D and E alpha- helices, an area of the molecule demonstrated in other serpins to be important for cofactor recognition. Strikingly, the structural data reveal that maspin is able to undergo conformational change in and around the G alpha- helix, switching between an open and a closed form. This change dictates the electrostatic character of a putative cofactor binding surface and highlights this region as a likely determinant of maspin function. The high resolution crystal structure of maspin provides a detailed molecular framework to elucidate the mechanism of function of this important tumor suppressor.	Monash Univ, Fac Med, Sch Biomed Sci, Monash Ctr Synchrotron Sci,Prot Crystallog Unit, Clayton, Vic 3800, Australia; Monash Univ, Fac Med, Sch Biomed Sci, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Monash Univ, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia; Monash Univ, ARC Ctr Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia; Univ Coll Dublin, Conway Inst, Dublin 2, Ireland	Monash University; Monash University; Monash University; Monash University; University College Dublin	Whisstock, JC (corresponding author), Monash Univ, Fac Med, Sch Biomed Sci, Monash Ctr Synchrotron Sci,Prot Crystallog Unit, Clayton, Vic 3800, Australia.	James.Whisstock@med.monash.edu.au	Beddoe, Travis/F-3415-2014; Rossjohn, Jamie/F-9032-2013; Buckle, Ashley/P-8366-2016; Irving, James/P-3860-2019; Irving, James A/I-8467-2015	Beddoe, Travis/0000-0003-4550-2277; Rossjohn, Jamie/0000-0002-2020-7522; Buckle, Ashley/0000-0003-2943-9044; Irving, James/0000-0003-3204-6356; Whisstock, James/0000-0003-4200-5611; law, ruby/0000-0001-5432-5781; Bird, Phillip/0000-0002-6695-606X				Al-Ayyoubi M, 2004, J BIOL CHEM, V279, P55540, DOI 10.1074/jbc.M409957200; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200; Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabrita LD, 2004, BIOCHEMISTRY-US, V43, P9834, DOI 10.1021/bi0491346; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; Clements CS, 2003, P NATL ACAD SCI USA, V100, P11059, DOI 10.1073/pnas.1833158100; Gao F, 2004, DEVELOPMENT, V131, P1479, DOI 10.1242/dev.01048; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; HOPKINS PCR, 1994, SCIENCE, V265, P1893; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; James EL, 1999, J BIOL CHEM, V274, P9482, DOI 10.1074/jbc.274.14.9482; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESK AM, 1986, BIOSEQUENCES PERSPEC, P23; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Meyer C, 2002, J BIOL CHEM, V277, P45400, DOI 10.1074/jbc.M208339200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakamura H, 1996, Q REV BIOPHYS, V29, P1, DOI 10.1017/S0033583500005746; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Ngamkitidechakul C, 2003, J BIOL CHEM, V278, P31796, DOI 10.1074/jbc.M302408200; Nicholls A., 1992, GRASP GRAPHICAL REPR; Odero-Marah VA, 2002, BIOCHEM BIOPH RES CO, V295, P800, DOI 10.1016/S0006-291X(02)00764-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; Reis JS, 2001, PATHOL RES PRACT, V197, P817, DOI 10.1078/0344-0338-00165; Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Simonovic M, 2001, P NATL ACAD SCI USA, V98, P11131, DOI 10.1073/pnas.211268598; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Stratikos E, 1996, PROTEIN SCI, V5, P2575, DOI 10.1002/pro.5560051220; Tew DJ, 2001, J MOL BIOL, V313, P1161, DOI 10.1006/jmbi.2001.5104; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; Whisstock JC, 2000, J MOL BIOL, V301, P1287, DOI 10.1006/jmbi.2000.3982; Whisstock JC, 2000, J MOL BIOL, V296, P685, DOI 10.1006/jmbi.1999.3520; Yamasaki M, 2003, J BIOL CHEM, V278, P35524, DOI 10.1074/jbc.M305926200; Zhang M, 2004, FRONT BIOSCI-LANDMRK, V9, P2218, DOI 10.2741/1392; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	54	51	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22356	22364		10.1074/jbc.M412043200	http://dx.doi.org/10.1074/jbc.M412043200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15760906	hybrid			2022-12-25	WOS:000229557900081
J	Ioannidis, P; Mahaira, LG; Perez, SA; Gritzapis, AD; Sotiropoulou, PA; Kavalakis, GJ; Antsaklis, AI; Baxevanis, CN; Papamichail, M				Ioannidis, P; Mahaira, LG; Perez, SA; Gritzapis, AD; Sotiropoulou, PA; Kavalakis, GJ; Antsaklis, AI; Baxevanis, CN; Papamichail, M			CRD-BP/IMP1 expression characterizes cord blood CD34(+) stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING-PROTEIN; HUMAN-BREAST-CANCER; MESSENGER-RNA; GROWTH-FACTOR; CRD-BP; GENE-EXPRESSION; SELF-RENEWAL; PROGENITOR CELLS; CODING REGION; BONE-MARROW	The coding region determinant-binding protein/insulin-like growth factor II mRNA-binding protein (CRDBP/IMP1) is an RNA-binding protein specifically recognizing c-myc, leader 3' IGF-II and tau mRNAs, and the H19 RNA. CRD-BP/IMP1 is predominantly expressed in embryonal tissues but is de novo activated and/or over-expressed in various human neoplasias. To address the question of whether CRD-BP/IMP1 expression characterizes certain cell types displaying distinct proliferation and/or differentiation properties (i.e. stem cells), we isolated cell subpopulations from human bone marrow, mobilized peripheral blood, and cord blood, all sources known to contain stem cells, and monitored for its expression. CRD-BP/IMP1 was detected only in cord blood-derived CD34(+) stem cells and not in any other cell type of either adult or cord blood origin. Adult BM CD34(+) cells cultured in the presence of 5'-azacytidine expressed de novo CRD-BP/IMP1, suggesting that epigenetic modifications may be responsible for its silencing in adult non-expressing cells. Furthermore, by applying the short interfering RNA methodology in MCF-7 cells, we observed, subsequent to knocking down CRD-BP/IMP1, decreased c-myc expression, increased IGF-II mRNA levels, and reduced cell proliferation rates. These data 1) suggest a normal role for CRD-BP/IMP1 in pluripotent stem cells with high renewal capacity, like the CB CD34(+) cells, 2) indicate that altered methylation may directly or indirectly affect its expression in adult cells, 3) imply that its de novo activation in cancer cells may affect the expression of c-Myc and insulin-like growth factor II, and 4) indicate that the inhibition of CRD-BP/IMP1 expression might affect cancer cell proliferation.	St Savas Hosp, Canc Immunol Immunotherapy Ctr, Athens 11522, Greece; Obstet & Gynecol Univ Clin 1st, Alexandras Matern Hosp, Athens 11521, Greece	Alexandra Hospital	Perez, SA (corresponding author), St Savas Hosp, Canc Immunol Immunotherapy Ctr, 171,Alexandras Ave, Athens 11522, Greece.	perez@ciic.gr		GRITZAPIS, ANGELOS/0000-0003-3031-2710				ARANDAABREU GE, 1999, J NEUROCHEM, V22, P8827; Atlas R, 2004, J NEUROCHEM, V89, P613, DOI 10.1111/j.1471-4159.2004.02371.x; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; Doyle GA, 2000, CANCER RES, V60, P2756; El-Osta A, 2004, LEUKEMIA, V18, P233, DOI 10.1038/sj.leu.2403218; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gu LJ, 2004, INT J ONCOL, V24, P671; Hansen TVO, 2004, MOL CELL BIOL, V24, P4448, DOI 10.1128/MCB.24.10.4448-4464.2004; Ioannidis P, 2004, CANCER LETT, V209, P245, DOI 10.1016/j.canlet.2003.12.015; Ioannidis P, 2003, INT J CANCER, V104, P54, DOI 10.1002/ijc.10794; Ioannidis P, 2001, INT J CANCER, V94, P480, DOI 10.1002/ijc.1512; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; KARN J, 1989, ONCOGENE, V4, P773; Kim DK, 1999, STEM CELLS, V17, P286, DOI 10.1002/stem.170286; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003-4819-122-1-199501010-00009; Liao BS, 2004, J BIOL CHEM, V279, P48716, DOI 10.1074/jbc.M405853200; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ng YY, 2004, J LEUKOCYTE BIOL, V75, P314, DOI 10.1189/jlb.0603287; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Nielsen J, 2003, BIOCHEM J, V376, P383, DOI 10.1042/BJ20030943; Oh IH, 2000, BLOOD, V96, P4160, DOI 10.1182/blood.V96.13.4160.h8004160_4160_4168; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; Piacibello W, 1999, BLOOD, V93, P3736, DOI 10.1182/blood.V93.11.3736.411k01_3736_3749; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; Puri MC, 2003, P NATL ACAD SCI USA, V100, P12753, DOI 10.1073/pnas.2133552100; Ross J, 2001, ONCOGENE, V20, P6544, DOI 10.1038/sj.onc.1204838; Rummukainen J, 2001, CANCER GENET CYTOGEN, V126, P1, DOI 10.1016/S0165-4608(00)00387-3; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; Satoh Y, 2004, J BIOL CHEM, V279, P24986, DOI 10.1074/jbc.M400407200; Schwartz GN, 1996, STEM CELLS, V14, P337, DOI 10.1002/stem.140337; Shojaei F, 2004, BLOOD, V103, P2530, DOI 10.1182/blood-2003-09-3209; Steidl U, 2002, BLOOD, V99, P2037, DOI 10.1182/blood.V99.6.2037; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Tanavde VM, 2002, EXP HEMATOL, V30, P816, DOI 10.1016/S0301-472X(02)00818-4; Tessier CR, 2004, CANCER RES, V64, P209, DOI 10.1158/0008-5472.CAN-03-2927; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; YEE D, 1988, CANCER RES, V48, P6691; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhang JY, 2003, CANCER EPIDEM BIOMAR, V12, P136	44	58	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20086	20093		10.1074/jbc.M410036200	http://dx.doi.org/10.1074/jbc.M410036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769738	hybrid			2022-12-25	WOS:000229113700079
J	Liu, G; Chen, XB				Liu, G; Chen, XB			The C-terminal sterile alpha motif and the extreme C terminus regulate the transcriptional activity of the alpha isoform of p73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; PHYSICAL INTERACTION; APOPTOTIC RESPONSE; BINDING-PROTEIN; SAM DOMAIN; P53 FAMILY; ACETYLATION; P63; ACTIVATION; GENE	p73, a member of the p53 family, is expressed from two separate promoters, generating TA and Delta N variants. Each variant potentially encodes at least seven alternatively spliced isoforms (alpha-eta). Interestingly, we and others have shown that the alpha isoform of p73 has a weaker transcriptional activity than the beta isoform. Because the alpha isoform has an extended C terminus consisting of a sterile alpha motif (SAM) and an extreme C terminus, it appears that the C terminus is inhibitory. However, how the C terminus inhibits the transcriptional activity of p73 has not been determined. Here, we found that both the SAM and the extreme C terminus exert their inhibitory activity by preventing the accessibility of p300/CBP to the activation domain in p73. Specifically, we showed that the SAM and the extreme C terminus together or individually are capable of repressing the function of p73 activation domain, but neither interacts directly with the activation domain, or suppresses the DNA-binding activity, of the p73 protein. We also showed that the intact state of the SAM and the extreme C terminus is essential for their inhibitory functions such that a small deletion of either the SAM or the extreme C terminus abolishes its inhibitory activity. Furthermore, we showed that both inhibitory domains in the C terminus are capable of suppressing the function of a cis heterologous activation domain from p53 or Gal4. Finally, we showed that both inhibitory domains suppress the ability of p73 to interact with the transcriptional coactivators p300/CBP that are necessary for the initiation of transcription.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, MCLM 660,1918 Univ Blvd, Birmingham, AL 35294 USA.	xchen@uab.edu		, Gang/0000-0002-6999-7633; Liu, Gang/0000-0003-2615-131X	NATIONAL CANCER INSTITUTE [R01CA081237] Funding Source: NIH RePORTER; NCI NIH HHS [CA081237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Bork P, 1998, NAT GENET, V18, P313, DOI 10.1038/ng0498-313; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Gong JG, 1999, NATURE, V399, P806; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Ishimoto O, 2002, CANCER RES, V62, P636; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Liu L, 1999, MOL CELL BIOL, V19, P1202; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Nimura Y, 1998, INT J CANCER, V78, P437, DOI 10.1002/(SICI)1097-0215(19981109)78:4<437::AID-IJC8>3.0.CO;2-V; Nomoto S, 1998, CANCER RES, V58, P1380; Ozaki T, 2003, ONCOGENE, V22, P3231, DOI 10.1038/sj.onc.1206382; Park EK, 2004, MOL BIOL CELL, V15, P1647, DOI 10.1091/mbc.E03-09-0674; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Tsao H, 1999, CANCER RES, V59, P172; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wang WK, 2000, ACTA CRYSTALLOGR D, V56, P769, DOI 10.1107/S0907444900005059; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zhu JH, 1998, CANCER RES, V58, P5061	61	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20111	20119		10.1074/jbc.M413889200	http://dx.doi.org/10.1074/jbc.M413889200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769743	hybrid			2022-12-25	WOS:000229113700082
J	Aranyi, T; Ratajewski, M; Bardoczy, V; Pulaski, L; Bors, A; Tordai, A; Varadi, A				Aranyi, T; Ratajewski, M; Bardoczy, V; Pulaski, L; Bors, A; Tordai, A; Varadi, A			Identification of a DNA methylation-dependent activator sequence in the pseudoxanthoma elasticum gene, ABCC6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-CELLS; MRP6 GENE; MUTATIONS; TRANSPORTER; RESISTANCE; SENSITIVITY; ALIGNMENT; PROMOTER; ISLANDS; TISSUES	ABCC6 encodes MRP6, a member of the ABC protein family with an unknown physiological role. The human ABCC6 and its two pseudogenes share 99% identical DNA sequence. Loss-of-function mutations of ABCC6 are associated with the development of pseudoxanthoma elasticum (PXE), a recessive hereditary disorder affecting the elastic tissues. Various disease-causing mutations were found in the coding region; however, the mutation detection rate in the ABCC6 coding region of bona fide PXE patients is only similar to 80%. This suggests that polymorphisms or mutations in the regulatory regions may contribute to the development of the disease. Here, we report the first characterization of the ABCC6 gene promoter. Phylogenetic in silico analysis of the 5' regulatory regions revealed the presence of two evolutionarily conserved sequence elements embedded in CpG islands. The study of DNA methylation of ABCC6 and the pseudogenes identified a correlation between the methylation of the CpG island in the proximal promoter and the ABCC6 expression level in cell lines. Both activator and repressor sequences were uncovered in the proximal promoter by reporter gene assays. The most potent activator sequence was one of the conserved elements protected by DNA methylation on the endogenous gene in non-expressing cells. Finally, in vitro methylation of this sequence inhibits the transcriptional activity of the luciferase promoter constructs. Altogether these results identify a DNA methylation-dependent activator sequence in the ABCC6 promoter.	Hungarian Acad Sci, Inst Enzymol, H-1113 Budapest, Hungary; Polish Acad Sci, Ctr Med Biol, PL-93232 Lodz, Poland; Natl Med Ctr, Inst Hematol & Immunol, Dept Mol Diagnost, H-1113 Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Polish Academy of Sciences	Aranyi, T (corresponding author), Hungarian Acad Sci, Inst Enzymol, Karolina Ut 29, H-1113 Budapest, Hungary.	aranyi@enzim.hu; varadi@enzim.hu	Aranyi, Tamas/AAJ-9629-2021; Ratajewski, Marcin/I-4657-2019; Varadi, Andras/A-2055-2012	Aranyi, Tamas/0000-0002-2087-6275; Ratajewski, Marcin/0000-0001-5391-5843; Pulaski, Lukasz/0000-0001-8063-801X				Aessopos A, 2002, BLOOD, V99, P30, DOI 10.1182/blood.V99.1.30; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Beck K, 2003, J HISTOCHEM CYTOCHEM, V51, P887, DOI 10.1177/002215540305100704; Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; Chassaing N, 2004, J INVEST DERMATOL, V122, P608, DOI 10.1111/j.0022-202X.2004.22312.x; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; De Smet C, 1999, MOL CELL BIOL, V19, P7327; DEAN M, 2002, HUMAN ATP BINDING CA; Down TA, 2002, GENOME RES, V12, P458, DOI 10.1101/gr.216102; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gheduzzi Dealba, 2004, Hum Mutat, V24, P438, DOI 10.1002/humu.9284; GOODMAN RM, 1963, MEDICINE, V42, P297, DOI 10.1097/00005792-196309000-00001; Grant CE, 1997, GENOMICS, V45, P368, DOI 10.1006/geno.1997.4950; Hu XF, 2003, EUR J HUM GENET, V11, P215, DOI 10.1038/sj.ejhg.5200953; Hubbard T, 2005, NUCLEIC ACIDS RES, V33, pD447, DOI 10.1093/nar/gki138; Ilias A, 2002, J BIOL CHEM, V277, P16860, DOI 10.1074/jbc.M110918200; Imamura T, 2001, GENOMICS, V76, P117, DOI 10.1006/geno.2001.6607; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Knudsen S, 1999, BIOINFORMATICS, V15, P356, DOI 10.1093/bioinformatics/15.5.356; Kool M, 1999, CANCER RES, V59, P175; Le Saux O, 1999, GENOMICS, V62, P1, DOI 10.1006/geno.1999.5925; Le Saux O, 2000, NAT GENET, V25, P223, DOI 10.1038/76102; LEBWOHL M, 1994, J AM ACAD DERMATOL, V30, P103, DOI 10.1016/S0190-9622(08)81894-4; LEBWOHL M, 1987, NEW ENGL J MED, V317, P347, DOI 10.1056/NEJM198708063170604; Lian ZR, 2001, HEPATOLOGY, V34, P146, DOI 10.1053/jhep.2001.25545; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Madon J, 2000, MOL PHARMACOL, V57, P634, DOI 10.1124/mol.57.3.634; MCCREEDY CA, 1989, SURGERY, V105, P170; Morgenstern B, 2004, NUCLEIC ACIDS RES, V32, pW33, DOI 10.1093/nar/gkh373; Noji Y, 2004, INTERNAL MED, V43, P1171, DOI 10.2169/internalmedicine.43.1171; Pulkkinen L, 2001, HUM GENET, V109, P356, DOI 10.1007/s004390100582; Ringpfeil F, 2000, P NATL ACAD SCI USA, V97, P6001, DOI 10.1073/pnas.100041297; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pW249, DOI 10.1093/nar/gkh372; SCHORDERET DF, 1992, P NATL ACAD SCI USA, V89, P957, DOI 10.1073/pnas.89.3.957; SCHUG J, 1997, ISMB, V5, P268; Shiota K, 2002, GENES CELLS, V7, P961, DOI 10.1046/j.1365-2443.2002.00574.x; Spinzi G, 1996, AM J GASTROENTEROL, V91, P1631; Struk B, 2000, J MOL MED, V78, P282, DOI 10.1007/s001090000114; Struk B, 1997, HUM MOL GENET, V6, P1823, DOI 10.1093/hmg/6.11.1823; Szakacs G, 2004, CANCER CELL, V6, P129, DOI 10.1016/j.ccr.2004.06.026; Trip MD, 2002, CIRCULATION, V106, P773, DOI 10.1161/01.CIR.0000028420.27813.C0; Tusnady GE, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni012; Uitto J, 2001, TRENDS MOL MED, V7, P13, DOI 10.1016/S1471-4914(00)01869-4; VILJOEN DL, 1987, CLIN GENET, V32, P100; Wang J, 2001, J HUM GENET, V46, P699, DOI 10.1007/s100380170003; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; YOSHIDA S, 2004, EYE, V19, P215	50	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18643	18650		10.1074/jbc.M501139200	http://dx.doi.org/10.1074/jbc.M501139200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15760889	hybrid			2022-12-25	WOS:000228932300014
J	Berasain, C; Garcia-Trevijano, ER; Castillo, J; Erroba, E; Santamaria, M; Lee, DC; Prieto, J; Avila, MA				Berasain, C; Garcia-Trevijano, ER; Castillo, J; Erroba, E; Santamaria, M; Lee, DC; Prieto, J; Avila, MA			Novel role for amphiregulin in protection from liver injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; ANTI-FAS ANTIBODY; RAT-LIVER; HEPATOCYTE APOPTOSIS; CARBON-TETRACHLORIDE; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; PARTIAL-HEPATECTOMY; MOUSE HEPATOCYTES; FACTOR RECEPTOR	Clinically, the Fas and Fas ligand system plays a central role in the development of hepatocyte apoptosis, a process contributing to a broad spectrum of liver diseases. Therefore, the development of therapies aimed at the inhibition of hepatocyte apoptosis is a major issue. Activation of the epidermal growth factor receptor has been shown to convey survival signals to the hepatocyte. To learn about the endogenous response of epidermal growth factor receptor ligands during Fas-mediated liver injury we investigated the expression of epidermal growth factor, transforming growth factor alpha, heparin-binding epidermal growth factor-like growth factor, betacellulin, epiregulin, and amphiregulin in the liver of mice challenged with Fas-agonist antibody. Amphiregulin expression, barely detectable in healthy liver, was significantly up-regulated. Amphiregulin administration abrogated Fas-mediated liver injury in mice and showed direct anti-apoptotic effects in primary hepatocytes. Amphiregulin activated the Akt and signal transducer and activator of transcription-3 survival pathways, and up-regulated Bcl-xL expression. Amphiregulin knock-out mice showed signs of chronic liver damage in the absence of any noxious treatment, and died faster than wild type mice in response to lethal doses of Fas-agonist antibody. In contrast, these mice were more resistant against sublethal liver damage, supporting the hypothesis that chronic liver injury can precondition hepatocytes inducing resistance to subsequent cell death. These results show that amphiregulin is a protective factor induced in response to liver damage and that it may be therapeutic in liver diseases.	Univ Navarra, Clin Univ, Dept Med,Ctr Invest Med Aplicada, Div Hepatol & Gene Therapy,Fac Med, Pamplona 31008, Spain; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of Navarra; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Prieto, J (corresponding author), Univ Navarra, Clin Univ, Dept Med,Ctr Invest Med Aplicada, Div Hepatol & Gene Therapy,Fac Med, Pio XII 55, Pamplona 31008, Spain.	jprieto@unav.es; maavila@unav.es	Berasain, Carmen/E-4139-2016; Santamaria, Monica/H-4737-2013; Avila, Matias A/Y-6342-2019; Ruiz García-Trevijano, Elena R./ABE-1014-2021	Berasain, Carmen/0000-0001-7075-2476; Avila, Matias A/0000-0001-6570-3557; Ruiz García-Trevijano, Elena R./0000-0002-3985-1270; Castillo Aliaga, Josefa/0000-0002-4092-0085; Prieto, Jesus/0000-0002-1091-9593	NATIONAL CANCER INSTITUTE [R01CA043793] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43793, CA 49793] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berasain C, 2005, GASTROENTEROLOGY, V128, P424, DOI 10.1053/j.gastro.2004.11.006; Berasain C, 2004, BBA-MOL BASIS DIS, V1690, P276, DOI 10.1016/j.bbadis.2004.08.002; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; Bustos M, 2003, GASTROENTEROLOGY, V125, P192, DOI 10.1016/S0016-5085(03)00698-X; Canbay A, 2004, HEPATOLOGY, V39, P273, DOI 10.1002/hep.20051; Carver RS, 2002, GASTROENTEROLOGY, V123, P2017, DOI 10.1053/gast.2002.37060; Coutant A, 2002, HEPATOLOGY, V36, P1079, DOI 10.1053/jhep.2002.36160; Czaja MJ, 2003, AM J PHYSIOL-GASTR L, V284, pG875, DOI 10.1152/ajpgi.00549.2002; CZAJA MJ, 1995, GASTROENTEROLOGY, V108, P1849, DOI 10.1016/0016-5085(95)90149-3; Deaciuc IV, 2002, ALCOHOL CLIN EXP RES, V26, P864, DOI 10.1097/00000374-200206000-00017; Desbarats J, 2000, NAT MED, V6, P920, DOI 10.1038/78688; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; Eichhorst ST, 2004, NAT MED, V10, P602, DOI 10.1038/nm1049; Fabregat I, 2000, HEPATOLOGY, V32, P528, DOI 10.1053/jhep.2000.9774; Faouzi S, 2001, J BIOL CHEM, V276, P49077, DOI 10.1074/jbc.M109791200; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Feldstein AE, 2003, GASTROENTEROLOGY, V125, P437, DOI 10.1016/S0016-5085(03)00907-7; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Galun E, 2002, BBA-MOL CELL RES, V1592, P345, DOI 10.1016/S0167-4889(02)00326-9; Haga S, 2003, J CLIN INVEST, V112, P989, DOI 10.1172/JCI200317970; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; Kanda D, 2002, FEBS LETT, V519, P11, DOI 10.1016/S0014-5793(02)02677-7; Kanzler S, 2000, SEMIN CANCER BIOL, V10, P173, DOI 10.1006/scbi.2000.0318; Kiso S, 1996, BIOCHEM BIOPH RES CO, V220, P285, DOI 10.1006/bbrc.1996.0397; Koniaris LG, 2003, J AM COLL SURGEONS, V197, P634, DOI 10.1016/S1072-7515(03)00374-0; Kosai K, 1998, BIOCHEM BIOPH RES CO, V244, P683, DOI 10.1006/bbrc.1998.8293; Kovalovich K, 2001, J BIOL CHEM, V276, P26605, DOI 10.1074/jbc.M100740200; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Leu JI, 2003, J CLIN INVEST, V111, P129, DOI 10.1172/JCI200316712; Lin MT, 2001, CARCINOGENESIS, V22, P1947, DOI 10.1093/carcin/22.12.1947; LU GL, 2002, AM J PHYSIOL, V283, pG256; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Martinez-Chantar ML, 2002, FASEB J, V16, P1292, DOI 10.1096/fj.02-0078fje; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Mosesson Y, 2004, SEMIN CANCER BIOL, V14, P262, DOI 10.1016/j.semcancer.2004.04.005; Musallam L, 2001, AM J PHYSIOL-GASTR L, V280, pG1360, DOI 10.1152/ajpgi.2001.280.6.G1360; Natori S, 2001, J HEPATOL, V34, P248, DOI 10.1016/S0168-8278(00)00089-1; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Peralta C, 2000, AM J PHYSIOL-GASTR L, V279, pG163, DOI 10.1152/ajpgi.2000.279.1.G163; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Roberts RA, 2000, HEPATOLOGY, V31, P420, DOI 10.1002/hep.510310223; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; Rust C, 2000, AM J MED, V108, P567, DOI 10.1016/S0002-9343(00)00370-3; Schulze-Bergkamen H, 2004, HEPATOLOGY, V39, P645, DOI 10.1002/hep.20138; Selzner M, 2003, GASTROENTEROLOGY, V125, P256, DOI 10.1016/S0016-5085(03)00811-4; Selzner N, 2003, GASTROENTEROLOGY, V125, P917, DOI 10.1016/S0016-5085(03)01048-5; Shi JL, 1998, AM J PATHOL, V153, P515, DOI 10.1016/S0002-9440(10)65594-0; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Talapatra S, 2001, J PHARMACOL EXP THER, V298, P873; Taub R, 2003, J CLIN INVEST, V112, P978, DOI 10.1172/JCI20031200319974; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Vogel A, 2004, HEPATOLOGY, V39, P433, DOI 10.1002/hep.20077; WEBBER EM, 1993, HEPATOLOGY, V18, P1422, DOI 10.1016/0270-9139(93)90234-E; Wuestefeld T, 2003, J BIOL CHEM, V278, P11281, DOI 10.1074/jbc.M208470200	60	106	107	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19012	19020		10.1074/jbc.M413344200	http://dx.doi.org/10.1074/jbc.M413344200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753092	hybrid, Green Published			2022-12-25	WOS:000228932300056
J	Schopfer, FJ; Baker, PRS; Giles, G; Chumley, P; Batthyany, C; Crawford, J; Patel, RP; Hogg, N; Branchaud, BP; Lancaster, JR; Freeman, BA				Schopfer, FJ; Baker, PRS; Giles, G; Chumley, P; Batthyany, C; Crawford, J; Patel, RP; Hogg, N; Branchaud, BP; Lancaster, JR; Freeman, BA			Fatty acid transduction of nitric oxide signaling - Nitrolinoleic acid is a hydrophobically stabilized nitric oxide donor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID PEROXYL RADICALS; NEF REACTION; GUANYLATE-CYCLASE; CATALYTIC CONSUMPTION; ALPHA-TOCOPHEROL; RELAXING FACTOR; IN-VIVO; NO; CELL; ACTIVATION	The aqueous decay and concomitant release of nitric oxide ((NO)-N-center dot) by nitrolinoleic acid (10-nitro-9,12-octadecadienoic acid and 12-nitro-9,12-octadecadienoic acid; LNO2) are reported. Mass spectrometric analysis of reaction products supports a modified Nef reaction as the mechanism accounting for the generation of (NO)-N-center dot by the aqueous reactions of fatty acid nitroalkene derivatives. Nitrolinoleic acid is stabilized by an aprotic milieu, with LNO2 decay and (NO)-N-center dot release strongly inhibited by phosphatidylcholine/cholesterol liposome membranes and detergents when present at levels above their critical micellar concentrations. The release of (NO)-N-center dot from LNO2 was induced by UV photolysis and triiodide-based ozone chemiluminescence reactions currently used to quantify putative protein nitrosothiol and N-nitrosamine derivatives. This reactivity of LNO2 complicates the qualitative and quantitative analysis of biological oxides of nitrogen when applying UV photolysis and triiodide-based analytical systems to biological preparations typically abundant in nitrated fatty acids. The results reveal that nitroalkene derivatives of linoleic acid are pluripotent signaling mediators that act not only via receptor-dependent mechanisms, but also by transducing the signaling actions of (NO)-N-center dot via pathways subject to regulation by the relative distribution of LNO2 to hydrophobic versus aqueous microenvironments.	Univ Alabama, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35233 USA; Univ Alabama, Ctr Free Rad Biol, Birmingham, AL 35233 USA; Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Medical College of Wisconsin; University of Oregon	Freeman, BA (corresponding author), Univ Alabama, Dept Anesthesiol, 304-8 Biomed Res Bldg 2,901 19th St S, Birmingham, AL 35233 USA.	freerad@uab.edu	Giles, Gregory/C-6368-2009; Schopfer, Francisco Jose/AAE-8125-2020; Schopfer, Francisco/AAW-6505-2021; Freeman, Bruce A/H-9342-2012; Batthyany, Carlos I./A-6478-2009; Giles, Gregory/X-7155-2019	Giles, Gregory/0000-0002-8225-0462; Schopfer, Francisco Jose/0000-0001-9526-695X; Giles, Gregory/0000-0002-8225-0462; Batthyany, Carlos/0000-0002-0627-1982; Patel, Rakesh/0000-0002-1526-4303	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007457, R01HL074391, R01HL058115, R01HL064937, R01HL070146, R01HL071189, R37HL058115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055792, R01GM055792] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58115, HL074391, T32HL07457, HL71189, HL70146, HL64937] Funding Source: Medline; NIDDK NIH HHS [DK46935] Funding Source: Medline; NIGMS NIH HHS [GM55792] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; ARMAND J, 1965, B SOC CHIM FR, P3246; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; Baker PRS, 2004, P NATL ACAD SCI USA, V101, P11577, DOI 10.1073/pnas.0402587101; Balazy M, 2001, J PHARMACOL EXP THER, V299, P611; Ballini R, 2004, TETRAHEDRON, V60, P1017, DOI 10.1016/j.tet.2003.11.016; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Coffey MJ, 2001, P NATL ACAD SCI USA, V98, P8006, DOI 10.1073/pnas.141136098; Coles B, 2002, CIRC RES, V91, P375, DOI 10.1161/01.RES.0000032114.68919.EF; Coles B, 2002, J BIOL CHEM, V277, P5832, DOI 10.1074/jbc.M105209200; Crawford JH, 2004, BLOOD, V104, P1375, DOI 10.1182/blood-2004-03-0880; CUNDALL RB, 1968, J CHEM SOC B, P98, DOI 10.1039/j29680000098; Denicola A, 1998, P NATL ACAD SCI USA, V95, P3566, DOI 10.1073/pnas.95.7.3566; Denicola A, 2002, J BIOL CHEM, V277, P932, DOI 10.1074/jbc.M106589200; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; FEUER H, 1962, J AM CHEM SOC, V84, P688, DOI 10.1021/ja00863a048; Gladwin MT, 2002, J BIOL CHEM, V277, P27818, DOI 10.1074/jbc.M203236200; HAWTHORNE MF, 1957, J AM CHEM SOC, V79, P2510, DOI 10.1021/ja01567a042; HOGG N, 1995, FREE RADICAL RES, V22, P47, DOI 10.3109/10715769509147527; Hogg N, 2002, ANNU REV PHARMACOL, V42, P585, DOI 10.1146/annurev.pharmtox.42.092501.104328; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; Janero DR, 2004, P NATL ACAD SCI USA, V101, P16958, DOI 10.1073/pnas.0406075101; KORNBLUM N, 1965, J AM CHEM SOC, V87, P1742, DOI 10.1021/ja01086a023; LEITCH LC, 1955, CAN J CHEM, V33, P400, DOI 10.1139/v55-047; Lim DG, 2002, P NATL ACAD SCI USA, V99, P15941, DOI 10.1073/pnas.232409599; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; Nef J., 1894, LIEBIGS ANN CHEM, V280, P263; NOLAND WE, 1955, CHEM REV, V55, P137, DOI 10.1021/cr50001a003; O'Donnell VB, 2000, J BIOL CHEM, V275, P38239, DOI 10.1074/jbc.M001802200; O'Donnell VB, 1999, J BIOL CHEM, V274, P20083, DOI 10.1074/jbc.274.29.20083; ODonnell VB, 1997, BIOCHEMISTRY-US, V36, P15216, DOI 10.1021/bi971891z; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; Pinnick H. W., 1990, ORG REACT, V38, P655, DOI [10.1002/0471264180.or038.03, DOI 10.1002/0471264180.0R038.03]; Rubbo H, 2000, J BIOL CHEM, V275, P10812, DOI 10.1074/jbc.275.15.10812; Schopfer FJ, 2003, TRENDS BIOCHEM SCI, V28, P646, DOI 10.1016/j.tibs.2003.10.006; Schopfer FJ, 2005, P NATL ACAD SCI USA, V102, P2340, DOI 10.1073/pnas.0408384102; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; SZOKA F, 1980, ANNU REV BIOPHYS BIO, V9, P467, DOI 10.1146/annurev.bb.09.060180.002343; Thatcher GRJ, 2004, FREE RADICAL BIO MED, V37, P1122, DOI 10.1016/j.freeradbiomed.2004.06.013; VANTAMELEN EE, 1952, J AM CHEM SOC, V74, P2615, DOI 10.1021/ja01130a044; WILSON H, 1972, J AM CHEM SOC, V94, P2283, DOI 10.1021/ja00762a019	43	143	157	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19289	19297		10.1074/jbc.M414689200	http://dx.doi.org/10.1074/jbc.M414689200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15764811	hybrid			2022-12-25	WOS:000228932300086
J	Yagur-Kroll, S; Amster-Choder, O				Yagur-Kroll, S; Amster-Choder, O			Dynamic membrane topology of the Escherichia coli beta-glucoside transporter BglF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; MANNITOL PERMEASE; TRANSCRIPTIONAL ANTITERMINATOR; PROTEIN-STRUCTURE; LACTOSE PERMEASE; CARBOHYDRATE TRANSPORTERS; SULFHYDRYL-REAGENTS; BACILLUS-SUBTILIS; SUBSTRATE-BINDING; CHANNEL STRUCTURE	The Escherichia coli BglF protein, a permease of the phosphoenolpyruvate-dependent phosphotransferase system, catalyzes transport and phosphorylation of beta-glucosides. In addition, BglF regulates bgl operon expression by controlling the activity of the transcriptional regulator BglG via reversible phosphorylation. BglF is composed of three domains; one is hydrophobic, which presumably forms the sugar translocation channel. We studied the topology of this domain by Cys-replacement mutagenesis and chemical modification by thiol reagents. Most Cys substitutions were well tolerated, as demonstrated by the ability of the mutant proteins to catalyze BglF activities. Our results suggest that the membrane domain contains eight transmembrane helices and an alleged cytoplasmic loop that contains two additional helices. The latter region forms a dynamic structure, as evidenced by the alternation of residues near its ends between faced-in and faced-out states. We suggest that this region, together with the two transmembrane helices encompassing it, forms the sugar translocation channel. BglF periplasmic loops are close to the membrane, the first being a reentrant loop. This is the first systematic topological study carried out with an intact phosphotransferase system permease and the first demonstration of a reentrant loop in this group of proteins.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Amster-Choder, O (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, POB 12272, IL-91120 Jerusalem, Israel.	amster@cc.huji.ac.il						Aboulwafa M, 2003, MICROBIOL-SGM, V149, P763, DOI 10.1099/mic.0.25731-0; Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; AMSTERCHODER O, 1990, SCIENCE, V249, P540, DOI 10.1126/science.2200123; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; Beutler R, 2000, BIOCHEMISTRY-US, V39, P3745, DOI 10.1021/bi992679t; BRIGGS CE, 1992, RES MICROBIOL, V143, P139, DOI 10.1016/0923-2508(92)90003-7; BUHR A, 1993, J BIOL CHEM, V268, P11599; Chen Q, 1998, BIOCHEMISTRY-US, V37, P17040, DOI 10.1021/bi980067n; Chen Q, 1999, J BACTERIOL, V181, P462, DOI 10.1128/JB.181.2.462-468.1999; Chen Q, 1997, EMBO J, V16, P4617, DOI 10.1093/emboj/16.15.4617; Chen Q, 2001, J BIOL CHEM, V276, P44751, DOI 10.1074/jbc.M108729200; Chen Q, 2000, J BACTERIOL, V182, P2033, DOI 10.1128/JB.182.7.2033-2036.2000; Chen Q, 1998, BIOCHEMISTRY-US, V37, P8714, DOI 10.1021/bi9731652; CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FOX CF, 1968, P NATL ACAD SCI USA, V59, P988, DOI 10.1073/pnas.59.3.988; Gasol E, 2004, J BIOL CHEM, V279, P31228, DOI 10.1074/jbc.M402428200; Getz EB, 1999, ANAL BIOCHEM, V273, P73, DOI 10.1006/abio.1999.4203; Grunewald M, 2002, J BIOL CHEM, V277, P26074, DOI 10.1074/jbc.M202248200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Idelson M, 1998, J BACTERIOL, V180, P660, DOI 10.1128/JB.180.3.660-666.1998; JACOBSON GR, 1993, J BIOENERG BIOMEMBR, V25, P621; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Koning RI, 1999, J MOL BIOL, V287, P845, DOI 10.1006/jmbi.1999.2650; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; LENGELER JW, 1990, BIOCHIM BIOPHYS ACTA, V1018, P155, DOI 10.1016/0005-2728(90)90238-Y; LENGELER JW, 1990, PHILOS T ROY SOC B, V326, P489, DOI 10.1098/rstb.1990.0027; LOLKEMA JS, 1992, BIOCHEMISTRY-US, V31, P5514, DOI 10.1021/bi00139a013; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MAHADEVAN S, 1987, J BACTERIOL, V169, P2570, DOI 10.1128/jb.169.6.2570-2578.1987; Nilsson J, 2002, PROTEIN SCI, V11, P2974, DOI 10.1110/ps.0226702; Nilsson J, 2000, FEBS LETT, V486, P267, DOI 10.1016/S0014-5793(00)02321-8; Ninio S, 2004, FEBS LETT, V562, P193, DOI 10.1016/S0014-5793(04)00240-6; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Ren XY, 2001, J BIOL CHEM, V276, P9572, DOI 10.1074/jbc.M007823200; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; SaraceniRichards CA, 1997, J BACTERIOL, V179, P1135, DOI 10.1128/jb.179.4.1135-1142.1997; SCHAEFLER S, 1967, J BACTERIOL, V93, P254, DOI 10.1128/JB.93.1.254-263.1967; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; Siebold C, 2001, FEBS LETT, V504, P104, DOI 10.1016/S0014-5793(01)02705-3; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Tusnady GE, 2001, J CHEM INF COMP SCI, V41, P364, DOI 10.1021/ci0001280; Venkatesan P, 2000, BIOCHEMISTRY-US, V39, P10649, DOI 10.1021/bi0004394; Vervoort EB, 2005, J MOL BIOL, V346, P733, DOI 10.1016/j.jmb.2004.12.011; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; VonHeijne G, 1996, PROG BIOPHYS MOL BIO, V66, P113, DOI 10.1016/S0079-6107(97)85627-1; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; YAMADA Y, 1991, J BIOL CHEM, V266, P17863; Zhang W, 2003, BIOCHEMISTRY-US, V42, P4904, DOI 10.1021/bi034078e; Zhuang JP, 1999, ARCH BIOCHEM BIOPHYS, V372, P89, DOI 10.1006/abbi.1999.1458	65	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19306	19318		10.1074/jbc.M410896200	http://dx.doi.org/10.1074/jbc.M410896200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755739	hybrid			2022-12-25	WOS:000228932300088
J	Bhatt, KV; Spofford, LS; Aram, G; McMullen, M; Pumiglia, K; Aplin, AE				Bhatt, KV; Spofford, LS; Aram, G; McMullen, M; Pumiglia, K; Aplin, AE			Adhesion control of cyclin D1 and p27(Kip1) levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling	ONCOGENE			English	Article						BRAF; cyclin D1; integrins; melanocytes; mitogen-activated protein kinase; p27(Kip1)	ACTIVATED PROTEIN-KINASE; METASTATIC MELANOMA; GROWTH; EXPRESSION; PROGRESSION; MUTATIONS; RAS; ARREST; GENE; MAP	Mutations in BRAF, a component of extracellular signal-regulated kinases 1 and 2 (ERK) cascade, are frequent in melanoma. It is important to understand how BRAF mutations contribute to malignant traits including anchorage- and growth factor-independence. We have previously shown that effficient activation of ERK in normal human epidermal melanocytes (NHEM) requires both adhesion to the extracellular matrix and growth factors. Mutant V599E BRAF is sufficient to promote ERK activation independent of adhesion and growth factors. Here, we analysed regulation of G1 cell cycle events in NHEM and human melanoma cells. We show that S phase entry in NHEM requires both adhesion and growth factor signaling through the MEK-ERK pathway. This control correlates with induction of cyclin D1 and downregulation of p27(Kip1), two key G1 cell cycle events. In melanoma cells expressing V599E BRAF, cyclin D1 was constitutively expressed independent of adhesion but dependent upon MEK activation and nuclear accumulation of ERK. Reduction of cyclin D1 levels by RNA interference inhibited S phase entry in melanoma cells. Importantly, express ion of V599E BRAF in NHEM was sufficient to promote cyclin D1 promoter activity in the absence of adhesion. Additionally, p27(Kip1) levels were downregulated in V599E BRAF-expressing melanoma cells and active BRAF was sufficient to downregulate p27(Kip1) in serum-starved NHEM. Thus, adhesion-growth factor cooperation, leading to efficient activation of ERK, regulates cyclin D1 and p27(Kip1) levels in human melanocytes and mutant BRAF overrides adhesion-growth factor control of these two G1 cell cycle proteins in melanomas. These findings provide important insight into how BRAF mutations contribute to aberrant human melanocyte proliferation.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Aplin, AE (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave,MC-165, Albany, NY 12208 USA.	aplina@mail.amc.edu		Pumiglia, Kevin/0000-0003-4655-0334	NATIONAL CANCER INSTITUTE [R01CA081419] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER; NCI NIH HHS [CA81419, R01 CA081419-06, R01 CA081419] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07194] Funding Source: Medline; NIGMS NIH HHS [GM067893] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BARTKOVA J, 1995, ONCOGENE, V10, P775; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; CannonAlbright LA, 1996, SEMIN ONCOL, V23, P667; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Collisson EA, 2003, CANCER RES, V63, P5669; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Dong JL, 2003, CANCER RES, V63, P3883; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Govindarajan B, 2003, J BIOL CHEM, V278, P9790, DOI 10.1074/jbc.M212929200; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; GRINNELL F, 1992, J CELL SCI, V101, P1; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HARA M, 1994, J CELL SCI, V107, P2739; Hedley SJ, 1997, PIGM CELL RES, V10, P54, DOI 10.1111/j.1600-0749.1997.tb00466.x; Hingorani SR, 2003, CANCER RES, V63, P5198; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; JIANG HP, 1995, ONCOGENE, V10, P1855; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Kumar R, 2003, CLIN CANCER RES, V9, P3362; Lai JM, 2002, MOL CELL BIOL, V22, P7581, DOI 10.1128/MCB.22.21.7581-7592.2002; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Le Gall M, 1998, ONCOGENE, V17, P1271, DOI 10.1038/sj.onc.1202057; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; McMahon M, 2001, METHOD ENZYMOL, V332, P401; McMullen M, 2004, ONCOGENE, V23, P1275, DOI 10.1038/sj.onc.1207243; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sauter ER, 1998, MOL CARCINOGEN, V23, P132, DOI 10.1002/(SICI)1098-2744(199811)23:3<132::AID-MC2>3.0.CO;2-1; Sauter ER, 2002, CANCER RES, V62, P3200; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SCOTT G, 1992, J INVEST DERMATOL, V99, P787, DOI 10.1111/1523-1747.ep12614749; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Takano N, 2002, PIGM CELL RES, V15, P192, DOI 10.1034/j.1600-0749.2002.01079.x; Treinies I, 1999, MOL CELL BIOL, V19, P321; Viglietto G, 2002, CELL CYCLE, V1, P394, DOI 10.4161/cc.1.6.263; WANTANABE G, 1996, P NATL ACAD SCI USA, V93, P12861; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	65	116	121	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3459	3471		10.1038/sj.onc.1208544	http://dx.doi.org/10.1038/sj.onc.1208544			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735667				2022-12-25	WOS:000229038800008
J	Huseby, D; Barklis, RL; Alfadhli, A; Barklis, E				Huseby, D; Barklis, RL; Alfadhli, A; Barklis, E			Assembly of human immunodeficiency virus precursor Gag proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA-VIRUS; HIV-1 CAPSID PROTEIN; PARTICLES IN-VITRO; ELECTRON-MICROSCOPY; HEXAGONAL ORGANIZATION; CRYSTAL-STRUCTURE; LIPID MONOLAYER; TYPE-1; DOMAIN; DIMERIZATION	To investigate the mechanism by which human immunodeficiency virus (HIV) precursor Gag (PrGag) proteins assemble to form immature virus particles, we examined the in vitro assembly of MACANC proteins, composed of the PrGag matrix, capsid, and nucleocapsid domains. In the absence of other components, MACANC proteins assembled efficiently at physiological temperature but inefficiently at lower temperatures. However, the addition of RNA reduced the temperature sensitivity of assembly reactions. Assembly of MACANC proteins also was affected by pH because the proteins preferentially formed tubes at pH 6.0, whereas spheres were obtained at pH 8.0. Because neither tubes nor spheres were amenable to analysis of protein-protein contacts, we also examined the membrane-bound assemblies of MACANC proteins. Interestingly, MACANC proteins organized on membranes in tightly packed hexameric rings. The observed hexamer spacing of 79.7 angstrom is consistent with the notion that more PrGag proteins assemble into virions than are needed to provide capsid proteins for mature virus cores. Our data are also consistent with a model for PrGag contacts in immature virions where capsid hexamers are tightly packed, where nucleocapsid domains align beneath capsid C-terminal domains, and where matrix domains form trimers at the nexus of three neighbor hexamers.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Microbiol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Barklis, RL (corresponding author), Mail Code L220,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	barklis@ohsu.edu		Huseby, Douglas/0000-0001-9974-578X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060170] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM060170] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; Arvidson B, 2003, VIROLOGY, V308, P166, DOI 10.1016/S0042-6822(02)00142-3; Barklis E, 1998, J BIOL CHEM, V273, P7177, DOI 10.1074/jbc.273.13.7177; Barklis E, 1997, EMBO J, V16, P1199, DOI 10.1093/emboj/16.6.1199; Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785; Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; Campbell S, 1999, J VIROL, V73, P2270, DOI 10.1128/JVI.73.3.2270-2279.1999; CAMPBELL S, 1995, J VIROL, V69, P6487, DOI 10.1128/JVI.69.10.6487-6497.1995; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; Ehrlich LS, 2001, BIOPHYS J, V81, P586, DOI 10.1016/S0006-3495(01)75725-6; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Fuller SD, 1997, CURR BIOL, V7, P729, DOI 10.1016/S0960-9822(06)00331-9; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; Ganser BK, 1999, SCIENCE, V283, P80, DOI 10.1126/science.283.5398.80; Ganser-Pornillos BK, 2004, J VIROL, V78, P2545, DOI 10.1128/JVI.78.5.2545-2552.2004; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; Gross I, 2000, EMBO J, V19, P103, DOI 10.1093/emboj/19.1.103; Hardt S, 1996, J STRUCT BIOL, V116, P68, DOI 10.1006/jsbi.1996.0012; Hill CP, 1996, P NATL ACAD SCI USA, V93, P3099, DOI 10.1073/pnas.93.7.3099; Johnson MC, 2002, J VIROL, V76, P11177, DOI 10.1128/JVI.76.22.11177-11185.2002; Li S, 2000, NATURE, V407, P409, DOI 10.1038/35030177; Ma YM, 2004, J VIROL, V78, P52, DOI 10.1128/JVI.78.1.52-60.2004; Ma YM, 2002, J VIROL, V76, P5452, DOI 10.1128/JVI.76.11.5452-5462.2002; Mayo K, 2003, J MOL BIOL, V325, P225, DOI 10.1016/S0022-2836(02)01176-2; Mayo K, 2002, VIROLOGY, V298, P30, DOI 10.1006/viro.2002.1452; Mayo K, 2002, J MOL BIOL, V316, P667, DOI 10.1006/jmbi.2001.5354; McDermott J, 2000, J MOL BIOL, V302, P121, DOI 10.1006/jmbi.2000.4030; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; Morikawa Y, 2004, J BIOL CHEM, V279, P31964, DOI 10.1074/jbc.M313432200; Nermut MV, 1998, J STRUCT BIOL, V123, P143, DOI 10.1006/jsbi.1998.4024; NERMUT MV, 1994, VIROLOGY, V198, P288, DOI 10.1006/viro.1994.1032; Provitera P, 2001, BIOCHEMISTRY-US, V40, P5565, DOI 10.1021/bi002040l; RAO ZH, 1995, NATURE, V378, P743, DOI 10.1038/378743a0; SCHMID MF, 1993, ULTRAMICROSCOPY, V48, P251, DOI 10.1016/0304-3991(93)90099-J; Swanstrom R., 1997, P263; Tang C, 2002, NAT STRUCT BIOL, V9, P537, DOI 10.1038/nsb806; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; Wilk T, 2001, J VIROL, V75, P759, DOI 10.1128/JVI.75.2.759-771.2001; Zhang YQ, 1998, J VIROL, V72, P1782, DOI 10.1128/JVI.72.3.1782-1789.1998	43	41	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17664	17670		10.1074/jbc.M412325200	http://dx.doi.org/10.1074/jbc.M412325200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15734744	hybrid			2022-12-25	WOS:000228807200014
J	Pastushok, L; Moraes, TF; Ellison, MJ; Xiao, W				Pastushok, L; Moraes, TF; Ellison, MJ; Xiao, W			A single Mms2 "key" residue insertion into a Ubc13 pocket determines the interface specificity of a human Lys63 ubiquitin conjugation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA POSTREPLICATION REPAIR; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; POLYUBIQUITIN CHAINS; MULTIUBIQUITIN CHAIN; ANGSTROM RESOLUTION; PROTEIN; YEAST; PATHWAY; MUTAGENESIS	Human Ubc13 and Mms2 ( or its homolog, Uev1) form a unique ubiquitin-conjugating enzyme (Ubc) complex that generates atypical Lys(63)-linked ubiquitin conjugates. Such conjugates are attached to specific targets that modulate the activity of various cellular processes including DNA repair, mitotic progression, and nuclear factor-kappa B signaling. Whereas Ubc13 is a typical Ubc, Mms2 is a non-catalytic Ubc variant. Substantial biochemical evidence has revealed a mechanism whereby Mms2 properly orients ubiquitin to allow for Lys(63) conjugation by Ubc13; however, how this specific Ubc13-Mms2 complex is formed and why Mms2 does not form a complex with other Ubcs have not been reported. In order to address these questions, we used a structure-based approach to design mutations and characterize the human Ubc13-Mms2 interface. We used the yeast two-hybrid assay, glutathione S-transferase pull-downs, and surface plasmon resonance to test in vivo and in vitro binding. These experiments were paired with functional complementation and ubiquitin conjugation studies to provide in vivo and in vitro functional data. The results in this study allowed us to identify important residues of the Ubc13-Mms2 interface, determine a correlation between heterodimer formation and function, and conclude why Mms2 forms a specific complex with Ubc13 but not other Ubc proteins.	Univ Saskatchewan, Dept Microbiol & Immunol, Saskatoon, SK S7N 5E5, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Inst Biomol Design, Edmonton, AB T6G 2H7, Canada	University of Saskatchewan; University of Alberta; University of Alberta	Xiao, W (corresponding author), Univ Saskatchewan, Dept Microbiol & Immunol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	wei.xiao@usask.ca		Xiao, Wei/0000-0001-7568-0782				ADAMES AG, 1997, METHODS YEAST GENETI; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Ashley C, 2002, GENE, V285, P183, DOI 10.1016/S0378-1119(02)00409-2; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Bothos J, 2003, ONCOGENE, V22, P7101, DOI 10.1038/sj.onc.1206831; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; Brusky J, 2000, CURR GENET, V37, P168, DOI 10.1007/s002940050515; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; Franko J, 2001, BBA-GENE STRUCT EXPR, V1519, P70, DOI 10.1016/S0167-4781(01)00223-8; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; James P, 1996, GENETICS, V144, P1425; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; Ke SH, 1997, NUCLEIC ACIDS RES, V25, P3371, DOI 10.1093/nar/25.16.3371; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Li ZQ, 2002, P NATL ACAD SCI USA, V99, P4459, DOI 10.1073/pnas.062047799; McKenna S, 2003, BIOCHEMISTRY-US, V42, P7922, DOI 10.1021/bi034480t; McKenna S, 2003, J BIOL CHEM, V278, P13151, DOI 10.1074/jbc.M212353200; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; Pastushok L, 2004, ADV PROTEIN CHEM, V69, P279; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; SZABO A, 1995, CURR OPIN STRUC BIOL, V5, P699, DOI 10.1016/0959-440X(95)80064-6; Ulrich HD, 2003, J BIOL CHEM, V278, P7051, DOI 10.1074/jbc.M212195200; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wooff J, 2004, FEBS LETT, V566, P229, DOI 10.1016/j.febslet.2004.04.038; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xiao W, 1998, NUCLEIC ACIDS RES, V26, P3908, DOI 10.1093/nar/26.17.3908; Xiao W, 1999, MUTAT RES-DNA REPAIR, V435, P1, DOI 10.1016/S0921-8777(99)00034-8; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	42	41	42	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17891	17900		10.1074/jbc.M410469200	http://dx.doi.org/10.1074/jbc.M410469200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749714	hybrid			2022-12-25	WOS:000228807200042
J	Song, ZY; Wu, M				Song, ZY; Wu, M			Identification of a novel nucleolar localization signal and a degradation signal in Survivin-deltaEx3: a potential link between nucleolus and protein degradation	ONCOGENE			English	Article						Survivin-deltaEx3; subcellular localization; antiapoptosis; nucleolus; ubiquitination	NUCLEAR-LOCALIZATION; SPLICE VARIANTS; SURVIVIN; APOPTOSIS; UBIQUITIN; DOMAINS; HERPESVIRUS; EXPRESSION; DISRUPT; CANCER	For a long time, as the most prominent subnuclear structure, nucleolus has been recognized as a main site where rRNA processing and ribosomal subunit assemblies take place. It has not been until recently that additional functions of nucleolus have begun to be proposed. In this study, we for the first time demonstrate that Survivin-deltaEx3, a novel functionally splice variant of Survivin localizes in the nucleoli where it degrades rapidly through ubiquitin-proteosome pathway. Several lines of evidences provided in this report support this finding (i) a novel nucleolar localization sequence (NoLS, MQRKPTIRRKNLRLRRK) and a novel degradation signal (aa92 - aa137) within Survivin-deltaEx3 were identified (ii) proteasome inhibitors MG132 or ALLN greatly inhibits degradation of Survivin-deltaEx3 and polyubiquitination of Survivin-deltaEx3 was detected (iii) heterologous proteins such as TAT-PTD or p14ARF, when fused to this putative degradation signal, result in a significant degradation within the nucleolus. In addition, the nucleolar localization and degradation of Survivin-deltaEx3 appear to be required for its antiapoptotic function, since neither NoLS-deleted nor degradation signal-deleted Survivin-deltaEx3 retains protective effect against Doxorubicin-induced apoptosis. Thus, our results have provided evidences to suggest that besides cytosol, nucleus, endoplsmic reticulum (ER) or lysosomes, nucleolus may also operate important protein degradation pathway, which has been overlooked previously.	Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Wu, M (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.	wumian88@yahoo.com	Wu, Mian/H-2494-2018	Wu, Mian/0000-0002-2714-0500				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; Everett RD, 1997, EMBO J, V16, P566, DOI 10.1093/emboj/16.3.566; Galcheva-Gargova Z, 1998, MOL BIOL CELL, V9, P2963, DOI 10.1091/mbc.9.10.2963; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Latonen L, 2003, CELL SIGNAL, V15, P95, DOI 10.1016/S0898-6568(02)00044-X; Lenk U, 2000, J BIOL CHEM, V275, P39403, DOI 10.1074/jbc.M006949200; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Lindsten K, 2003, NAT BIOTECHNOL, V21, P897, DOI 10.1038/nbt851; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Mahotka C, 1999, CANCER RES, V59, P6097; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Olson MOJ, 2002, INT REV CYTOL, V219, P199; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pokrovskaja K, 2001, J GEN VIROL, V82, P345, DOI 10.1099/0022-1317-82-2-345; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rudin CM, 1997, ANNU REV MED, V48, P267; Satyamoorthy K, 2001, TRENDS MOL MED, V7, P191, DOI 10.1016/S1471-4914(01)02013-5; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Song ZY, 2004, MOL BIOL CELL, V15, P1287, DOI 10.1091/mbc.E03-07-0512; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wang HW, 2002, EMBO J, V21, P2602, DOI 10.1093/emboj/21.11.2602; Wurm T, 2001, J VIROL, V75, P9345, DOI 10.1128/JVI.75.19.9345-9356.2001; Yamada Y, 2003, J NEUROSURG, V99, P738, DOI 10.3171/jns.2003.99.4.0738; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhao J, 2000, J CELL SCI, V113, P4363	44	45	48	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2723	2734		10.1038/sj.onc.1208097	http://dx.doi.org/10.1038/sj.onc.1208097			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735764				2022-12-25	WOS:000228356700014
J	Birrell, MA; McCluskie, K; Wong, SS; Donnelly, LE; Barnes, PJ; Belvisi, MG				Birrell, MA; McCluskie, K; Wong, SS; Donnelly, LE; Barnes, PJ; Belvisi, MG			Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappa B-independent mechanism	FASEB JOURNAL			English	Article						rodent; lung; neutrophils; airway inflammation; rat	NITRIC-OXIDE SYNTHASE; NATURAL POLYPHENOLIC COMPOUND; LYMPHOCYTE-PROLIFERATION; PERITONEAL-MACROPHAGES; TRANS-RESVERATROL; MONOCYTE ADHESION; GENE-EXPRESSION; IN-VITRO; ACTIVATION; APOPTOSIS	Consumption of a naturally occurring polyphenol, resveratrol, in particular through drinking moderate amounts of red wine, has been suggested to be beneficial to health. A plethora of in vitro studies published demonstrate various anti-inflammatory actions of resveratrol. The aim of this research was to determine whether any of these anti-inflammatory effects translate in vivo in a rodent model of LPS induced airway inflammation. Resveratrol reduced lung tissue neutrophilia to a similar magnitude as that achieved by treatment with budesonide. This was associated with a reduction in pro-inflammatory cytokines and prostanoid levels. Interestingly, the reduction did not appear to be due to an impact on NF-kappa B activation or the expression of the respective genes as suggested by various in vitro publications. These results suggest that resveratrol may possess anti-inflammatory properties via a novel mechanism. Elucidation of this mechanism may lead to potential new therapies for the treatment of chronic inflammation.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Resp Pharmacol Grp, London SW3 6LY, England	Imperial College London	Belvisi, MG (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Resp Pharmacol Grp, Dovehouse St, London SW3 6LY, England.	m.belvisi@imperial.ac.uk	Belvisi, Maria G/A-3055-2009	Donnelly, Louise/0000-0002-0753-5425; Barnes, Peter/0000-0002-5122-4018				Adams AE, 1999, J CELL BIOCHEM, V74, P587, DOI 10.1002/(SICI)1097-4644(19990915)74:4<587::AID-JCB8>3.0.CO;2-G; Alonso A, 1996, EUR J IMMUNOL, V26, P2165, DOI 10.1002/eji.1830260931; Asensi M, 2002, FREE RADICAL BIO MED, V33, P387, DOI 10.1016/S0891-5849(02)00911-5; Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490; Banerjee S, 2002, CANCER RES, V62, P4945; Bhat KPL, 2001, ANTIOXID REDOX SIGN, V3, P1041, DOI 10.1089/152308601317203567; Boscolo P, 2003, ANN CLIN LAB SCI, V33, P226; Bowers JL, 2000, ENDOCRINOLOGY, V141, P3657, DOI 10.1210/en.141.10.3657; Brzozowski T, 2000, J PHYSIOL-PARIS, V94, P83, DOI 10.1016/S0928-4257(00)00145-5; BURRELL R, 1988, AM REV RESPIR DIS, V137, P100, DOI 10.1164/ajrccm/137.1.100; Cho DI, 2002, LIFE SCI, V71, P2071, DOI 10.1016/S0024-3205(02)01971-9; Clement MV, 1998, BLOOD, V92, P996; Culpitt SV, 2003, THORAX, V58, P942, DOI 10.1136/thorax.58.11.942; Dallal O, 2003, BIOL NEONATE, V83, P201, DOI 10.1159/000068921; deMoraes VLG, 1996, BRIT J PHARMACOL, V117, P1792; DONNELLY LE, 2002, AM J CRIT CARE MED, V165, pA614; Estrov Z, 2003, BLOOD, V102, P987, DOI 10.1182/blood-2002-11-3550; Fauconneau B, 1997, LIFE SCI, V61, P2103, DOI 10.1016/S0024-3205(97)00883-7; Feng YH, 2002, ACTA PHARMACOL SIN, V23, P1002; Ferrero ME, 1998, AM J CLIN NUTR, V68, P1208, DOI 10.1093/ajcn/68.6.1208; Ferrero ME, 1998, TRANSPLANT P, V30, P4191, DOI 10.1016/S0041-1345(98)01388-8; Flohe S, 1999, CYTOKINE, V11, P796, DOI 10.1006/cyto.1998.0490; FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6; Gao XH, 2001, BIOCHEM PHARMACOL, V62, P1299, DOI 10.1016/S0006-2952(01)00775-4; German JB, 2000, ANNU REV NUTR, V20, P561, DOI 10.1146/annurev.nutr.20.1.561; Haddad E, 2001, BRIT J PHARMACOL, V132, P1715, DOI 10.1038/sj.bjp.0704022; Haddad EB, 2002, J IMMUNOL, V169, P974, DOI 10.4049/jimmunol.169.2.974; Holmes-McNary M, 2000, CANCER RES, V60, P3477; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Hsieh TC, 1999, CANCER RES, V59, P2596; Hsieh TC, 2002, BIOCHEM BIOPH RES CO, V297, P1311, DOI 10.1016/S0006-291X(02)02384-7; Jang DS, 1999, BIOCHEM PHARMACOL, V57, P705, DOI 10.1016/S0006-2952(98)00350-5; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Kawada N, 1998, HEPATOLOGY, V27, P1265, DOI 10.1002/hep.510270512; Kuo PL, 2002, LIFE SCI, V72, P23, DOI 10.1016/S0024-3205(02)02177-X; LIU X, 1996, MULT SCLER, V1, P2; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Martin AR, 2004, BIOCHEM PHARMACOL, V67, P1399, DOI 10.1016/j.bcp.2003.12.024; Martinez J, 2000, BIOCHEM PHARMACOL, V59, P865, DOI 10.1016/S0006-2952(99)00380-9; MASFERRER JL, 1994, J PHARMACOL EXP THER, V270, P1340; McCluskie K, 2004, J PHARMACOL EXP THER, V311, P625, DOI 10.1124/jpet.104.068890; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; Nunokawa Y, 1996, BIOCHEM BIOPH RES CO, V223, P347, DOI 10.1006/bbrc.1996.0897; OLeary EC, 1997, AM J RESP CELL MOL, V16, P267, DOI 10.1165/ajrcmb.16.3.9070611; OLeary EC, 1996, AM J RESP CELL MOL, V15, P97, DOI 10.1165/ajrcmb.15.1.8679228; PaceAsciak CR, 1996, CLIN CHIM ACTA, V246, P163, DOI 10.1016/0009-8981(96)06236-5; Pendurthi UR, 2002, THROMB RES, V106, P243, DOI 10.1016/S0049-3848(02)00141-X; Ramos CDL, 2003, CYTOKINE, V21, P214, DOI 10.1016/S1043-4666(03)00050-4; REMICK DG, 1990, AM J PATHOL, V136, P49; Rodgers HC, 2002, AM J PHYSIOL-LUNG C, V283, pL612, DOI 10.1152/ajplung.00483.2001; Rotondo S, 1998, BRIT J PHARMACOL, V123, P1691, DOI 10.1038/sj.bjp.0701784; Rovai LE, 1998, J LEUKOCYTE BIOL, V64, P494, DOI 10.1002/jlb.64.4.494; Rupnow HL, 2002, BIOL REPROD, V66, P468, DOI 10.1095/biolreprod66.2.468; Sanz MJ, 2002, BRIT J PHARMACOL, V135, P1872, DOI 10.1038/sj.bjp.0704644; Stanford SJ, 2000, BRIT J PHARMACOL, V129, P835, DOI 10.1038/sj.bjp.0703151; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Surh YJ, 1999, CANCER LETT, V140, P1, DOI 10.1016/S0304-3835(99)00039-7; Tessitore L, 2000, CARCINOGENESIS, V21, P1619, DOI 10.1093/carcin/21.8.1619; Tsai SH, 1999, BRIT J PHARMACOL, V126, P673, DOI 10.1038/sj.bjp.0702357; ULICH TR, 1995, AM J PHYSIOL-LUNG C, V268, pL245, DOI 10.1152/ajplung.1995.268.2.L245; Underwood SL, 1997, BRIT J PHARMACOL, V122, P439, DOI 10.1038/sj.bjp.0701398; WU CC, 1995, P NATL ACAD SCI USA, V92, P3473, DOI 10.1073/pnas.92.8.3473; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zeldin DC, 2001, AM J RESP CELL MOL, V25, P457, DOI 10.1165/ajrcmb.25.4.4505; Zhong M, 1999, PHYTOMEDICINE, V6, P79, DOI 10.1016/S0944-7113(99)80039-7	65	139	152	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					840	+		10.1096/fj.04-2691fje	http://dx.doi.org/10.1096/fj.04-2691fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15734790				2022-12-25	WOS:000227591900003
J	Masuda, S; Murakami, M; Takanezawa, Y; Aoki, J; Arai, H; Ishikawa, Y; Ishii, T; Arioka, M; Kudo, I				Masuda, S; Murakami, M; Takanezawa, Y; Aoki, J; Arai, H; Ishikawa, Y; Ishii, T; Arioka, M; Kudo, I			Neuronal expression and neuritogenic action of group X secreted phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; HUMAN GROUP-IIA; GROUP-V; NEURITE OUTGROWTH; A(2) ENZYMES; PC12 CELLS; RECEPTOR-BINDING; PROSTAGLANDIN PRODUCTION; MAMMALIAN-CELLS; N-CADHERIN	Although individual mammalian secreted phospholipase A(2) (sPLA(2)) enzymes exhibit unique tissue and cellular distributions, the cell type-specific functions of each enzyme remain largely unknown. In this study, we found by immunohistochemistry that group X sPLA(2) (sPLA(2)-X) is uniquely located in the peripheral neuronal fibers, an observation that was supported by detection of its transcript and protein in the neuronal cell line PC12 and in primary dorsal root ganglia neurons. Adenoviral expression of sPLA(2)-X in PC12 cells facilitated neurite outgrowth, particularly when combined with a suboptimal concentration of nerve growth factor. In neuronally differentiated PC12 cells, sPLA(2)-X was preferentially localized in the Golgi apparatus and growth cones, and proteolytic conversion of the proenzyme to mature enzyme mainly occurred after the secretion process. The neurite-extending ability of sPLA(2)-X depended on the production of its catalytic product, lysophosphatidylcholine. Moreover, nerve growth factor-induced neurite extension of PC12 cells was modestly but significantly attenuated by an anti-sPLA(2)-X antibody or by a small interfering RNA for sPLA(2)-X. These observations suggest the potential contribution of sPLA(2)-X to neuronal differentiation, and possibly repair, under certain conditions.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1138613, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Toho Univ, Sch Med, Dept Pathol, Ohta Ku, Tokyo 1438540, Japan	Showa University; Tokyo Metropolitan Institute of Medical Science; University of Tokyo	Murakami, M (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	mako@pharm.showa-u.ac.jp		Takanezawa, Yasukazu/0000-0002-9220-5825; Aoki, Junken/0000-0001-9435-1896				Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; de Turco EBR, 2002, J NEUROSCI RES, V68, P558, DOI 10.1002/jnr.10239; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOHERTY P, 1992, J CELL BIOL, V117, P1093, DOI 10.1083/jcb.117.5.1093; Garcia-Pastor P, 1999, J PHARMACOL EXP THER, V289, P166; Hamaguchi K, 2003, BBA-MOL CELL BIOL L, V1635, P37, DOI 10.1016/j.bbalip.2003.10.004; Hanasaki K, 2002, J BIOL CHEM, V277, P29116, DOI 10.1074/jbc.M202867200; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; KATER SB, 1991, J NEUROSCI, V11, P891; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Kishimoto T, 2002, CLIN BIOCHEM, V35, P411, DOI 10.1016/S0009-9120(02)00327-2; Kolko M, 1996, J BIOL CHEM, V271, P32722, DOI 10.1074/jbc.271.51.32722; Kolko M, 2003, NEUROSCI LETT, V338, P164, DOI 10.1016/S0304-3940(02)01385-X; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LAURITZEN I, 1994, BRAIN RES, V651, P353, DOI 10.1016/0006-8993(94)90719-6; Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; Masuda S, 2005, BIOCHEM J, V387, P27, DOI 10.1042/BJ20041307; Masuda S, 2005, FEBS J, V272, P655, DOI 10.1111/j.1742-4658.2004.04489.x; Masuda S, 2004, BBA-MOL CELL BIOL L, V1686, P61, DOI 10.1016/j.bbalip.2004.08.017; Matsuzawa A, 1996, BIOCHEM J, V318, P701, DOI 10.1042/bj3180701; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; Munoz NM, 2003, J BIOL CHEM, V278, P38813, DOI 10.1074/jbc.M302476200; MURAKAMI M, 1992, BIOCHIM BIOPHYS ACTA, V1124, P17, DOI 10.1016/0005-2760(92)90120-K; Murakami M, 2003, J BIOL CHEM, V278, P10657, DOI 10.1074/jbc.M211325200; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; NAKANO T, 1994, BIOCHEM BIOPH RES CO, V198, P10, DOI 10.1006/bbrc.1994.1002; Nakashima S, 2004, BRAIN RES, V1015, P207, DOI 10.1016/j.brainres.2004.04.069; Nakashima S, 2003, BIOCHEM J, V376, P655, DOI 10.1042/BJ20030830; Nicolas JP, 1997, J BIOL CHEM, V272, P7173, DOI 10.1074/jbc.272.11.7173; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Seeds MC, 2000, AM J RESP CELL MOL, V23, P37, DOI 10.1165/ajrcmb.23.1.4034; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Tanaka M, 2004, FEBS LETT, V571, P197, DOI 10.1016/j.febslet.2004.06.083; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, J BIOL CHEM, V275, P7492, DOI 10.1074/jbc.275.11.7492; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Wakatsuki S, 1999, J BIOCHEM-TOKYO, V126, P1151, DOI 10.1093/oxfordjournals.jbchem.a022561; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Wei S, 2003, NEUROSCIENCE, V121, P891, DOI 10.1016/S0306-4522(03)00525-6; Xu Y, 2002, BBA-MOL CELL BIOL L, V1582, P81, DOI 10.1016/S1388-1981(02)00140-3; Yagami T, 2002, BRAIN RES, V949, P197, DOI 10.1016/S0006-8993(02)03144-X; Yagami T, 2002, MOL PHARMACOL, V61, P114, DOI 10.1124/mol.61.1.114; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	58	50	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23203	23214		10.1074/jbc.M500985200	http://dx.doi.org/10.1074/jbc.M500985200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15781456	hybrid			2022-12-25	WOS:000229741800078
J	Galibert, L; Diemer, GS; Liu, Z; Johnson, RS; Smith, JL; Walzer, T; Comeau, MR; Rauch, CT; Wolfson, MF; Sorensen, RA; de Vries, ARV; Branstetter, DG; Koelling, RM; Scholler, J; Fanslow, WC; Baum, PR; Derry, JM; Yan, W				Galibert, L; Diemer, GS; Liu, Z; Johnson, RS; Smith, JL; Walzer, T; Comeau, MR; Rauch, CT; Wolfson, MF; Sorensen, RA; de Vries, ARV; Branstetter, DG; Koelling, RM; Scholler, J; Fanslow, WC; Baum, PR; Derry, JM; Yan, W			Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR TSLC1; SINGLE-CHAIN FV; CUTTING EDGE; IMMUNOGLOBULIN SUPERFAMILY; ADHESION MOLECULE; PHAGE; ANTIBODIES; EXPRESSION; GENE; IDENTIFICATION	Dendritic cells (DCs) are a phenotypically and functionally heterogenous population of leukocytes with distinct subsets serving a different set of specialized immune functions. Here we applied an in vitro whole cell panning approach using antibody phage display technology to identify cell-surface epitopes specifically expressed on human blood BDCA3(+) DCs. A single- chain antibody fragment (anti-1F12 scFv) was isolated that recognizes a conserved surface antigen expressed on both human BDCA3(+) DCs and mouse CD8 alpha(+) DCs. We demonstrate that anti-1F12 scFv binds Nectin-like protein 2 (Necl2, Tslc1, SynCaM, SgIGSF, or Igsf4), an adhesion molecule involved in tumor suppression, synapse formation, and spermatogenesis. Thus, Necl2 defines a specialized subset of DCs in both mouse and human. We further show that Necl2 binds Class-I-restricted T-cell-associated molecule ( CRTAM), a receptor primarily expressed on activated cytotoxic lymphocytes. When present on antigen presenting cells, Necl2 regulates IL-22 expression by activated CD8(+) T-cells. We propose that Necl2/CRTAM molecular pair could regulate a large panel of cell/cell interactions both within and outside of the immune system.	Amgen Inc, Dept Mol Sci, Seattle, WA 98119 USA; Amgen Inc, Dept Prot Sci, Seattle, WA 98119 USA; Amgen Inc, Dept Inflammat, Seattle, WA 98119 USA; Amgen Inc, Dept Oncol, Seattle, WA 98119 USA; Amgen Inc, Dept Pathol, Seattle, WA 98119 USA	Amgen; Amgen; Amgen; Amgen; Amgen	Yan, W (corresponding author), Amgen Inc, Dept Mol Sci, AW2-D-3291,1201 Amgen Ct, Seattle, WA 98119 USA.	ywei@amgen.com	Walzer, Thierry/L-9418-2014	Walzer, Thierry/0000-0002-0857-8179				Aliberti J, 2003, BLOOD, V101, P305, DOI 10.1182/blood-2002-04-1088; Andrews DM, 2003, NAT IMMUNOL, V4, P175, DOI 10.1038/ni880; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Barry SC, 2001, HUM GENE THER, V12, P1103, DOI 10.1089/104303401750214311; Belz GT, 2004, J IMMUNOL, V172, P1996, DOI 10.4049/jimmunol.172.4.1996; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; Bjorck P, 2002, HUM IMMUNOL, V63, P1094, DOI 10.1016/S0198-8859(02)00747-4; Brasel K, 2000, BLOOD, V96, P3029, DOI 10.1182/blood.V96.9.3029.h8003029_3029_3039; Caux C, 2000, SPRINGER SEMIN IMMUN, V22, P345, DOI 10.1007/s002810000053; de Vries ARV, 1999, EUR J IMMUNOL, V29, P3898, DOI 10.1002/(SICI)1521-4141(199912)29:12<3898::AID-IMMU3898>3.0.CO;2-2; De Vries ARV, 1999, IMMUNOLOGY, V98, P55; DEKRUIF J, 1995, P NATL ACAD SCI USA, V92, P3938, DOI 10.1073/pnas.92.9.3938; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Donskoy E, 2003, J IMMUNOL, V170, P3514, DOI 10.4049/jimmunol.170.7.3514; Du Pasquier L, 2000, Curr Top Microbiol Immunol, V248, P160; Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Edwards AD, 2003, J IMMUNOL, V171, P47, DOI 10.4049/jimmunol.171.1.47; Ettehadieh E, 2002, CYTOTECHNOLOGY, V38, P11, DOI 10.1023/A:1021121107801; Fernandez NC, 1999, NAT MED, V5, P405, DOI 10.1038/7403; Fredericks ZL, 2004, PROTEIN ENG DES SEL, V17, P95, DOI 10.1093/protein/gzh012; Fukuda M, 1999, J CELL BIOL, V147, P467, DOI 10.1083/jcb.147.3.467; Fukuhara H, 2003, ONCOGENE, V22, P6160, DOI 10.1038/sj.onc.1206744; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hubert FX, 2004, J IMMUNOL, V172, P7485, DOI 10.4049/jimmunol.172.12.7485; Huls GA, 1999, NAT BIOTECHNOL, V17, P276, DOI 10.1038/7023; Ito T, 2003, CANCER RES, V63, P6320; Iyoda T, 2002, J EXP MED, V195, P1289, DOI 10.1084/jem.20020161; Jego Gaetan, 2005, V8, P124; Kamath AT, 2000, J IMMUNOL, V165, P6762, DOI 10.4049/jimmunol.165.12.6762; Kamath AT, 2002, BLOOD, V100, P1734, DOI 10.1182/blood.V100.5.1734.h81702001734_1734_1741; Kennedy J, 2000, J LEUKOCYTE BIOL, V67, P725, DOI 10.1002/jlb.67.5.725; Koenderman L, 2000, J LEUKOCYTE BIOL, V68, P58; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Lekkerkerker A, 1999, J IMMUNOL METHODS, V231, P53, DOI 10.1016/S0022-1759(99)00140-4; Maldonado-Lopez R, 1999, J EXP MED, V189, P587, DOI 10.1084/jem.189.3.587; Mao XL, 2004, ONCOGENE, V23, P5632, DOI 10.1038/sj.onc.1207756; Mao XL, 2003, CANCER RES, V63, P7979; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pulendran B, 1997, J IMMUNOL, V159, P2222; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Ridgway JBB, 1999, CANCER RES, V59, P2718; Rondot S, 2001, NAT BIOTECHNOL, V19, P75, DOI 10.1038/83567; Sakisaka T, 2004, CURR OPIN CELL BIOL, V16, P513, DOI 10.1016/j.ceb.2004.07.007; Schiavoni G, 2002, J EXP MED, V196, P1415, DOI 10.1084/jem.20021263; Schultz N, 2003, P NATL ACAD SCI USA, V100, P12201, DOI 10.1073/pnas.1635054100; Shadidi M, 2001, BIOCHEM BIOPH RES CO, V280, P548, DOI 10.1006/bbrc.2000.4158; Sheehy ME, 2001, J IMMUNOL METHODS, V249, P99, DOI 10.1016/S0022-1759(00)00329-X; Shingai T, 2003, J BIOL CHEM, V278, P35421, DOI 10.1074/jbc.M305387200; Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031; Sundberg JP, 2003, J INVEST DERMATOL, V120, P771, DOI 10.1046/j.1523-1747.2003.12135.x; Suzuki S, 2004, P NATL ACAD SCI USA, V101, P8981, DOI 10.1073/pnas.0402139101; Taylor JA, 1997, RAPID COMMUN MASS SP, V11, P1067, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1067::AID-RCM953>3.0.CO;2-L; Topping KP, 2000, INT J ONCOL, V16, P187; Tsujimura H, 2003, J IMMUNOL, V170, P1131, DOI 10.4049/jimmunol.170.3.1131; Uchino K, 2003, CANCER-AM CANCER SOC, V98, P1002, DOI 10.1002/cncr.11599; VanEwijk W, 1997, P NATL ACAD SCI USA, V94, P3903, DOI 10.1073/pnas.94.8.3903; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; Wakayama T, 2003, BIOL REPROD, V68, P1755, DOI 10.1095/biolreprod.102.012344; Wakayama T, 2001, MOL REPROD DEV, V60, P158, DOI 10.1002/mrd.1072; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Yrlid U, 2003, APMIS, V111, P756, DOI 10.1034/j.1600-0463.2003.11107807.x	66	139	159	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21955	21964		10.1074/jbc.M502095200	http://dx.doi.org/10.1074/jbc.M502095200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15781451	hybrid			2022-12-25	WOS:000229557900037
J	Kallen, J; Sedrani, R; Zenke, G; Wagner, J				Kallen, J; Sedrani, R; Zenke, G; Wagner, J			Structure of human cyclophilin a in complex with the novel immunosuppressant sanglifehrin a at 1.6 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES SP A92-308110; X-RAY-STRUCTURE; CYCLOSPORINE-A; CRYSTAL-STRUCTURE; BINDING IMMUNOSUPPRESSANT; CALCINEURIN; IMMUNOPHILIN; DEGRADATION; REFINEMENT; MECHANISM	Sanglifehrin A (SFA) is a novel immunosuppressant isolated from Streptomyces sp. that binds strongly to the human immunophilin cyclophilin A ( CypA). SFA exerts its immunosuppressive activity through a mode of action different from that of all other known immunophilin-binding substances, namely cyclosporine A (CsA), FK506, and rapamycin. We have determined the crystal structure of human CypA in complex with SFA at 1.6 angstrom resolution. The high resolution of the structure revealed the absolute configuration at all 17 chiral centers of SFA as well as the details of the CypA/SFA interactions. In particular, it was shown that the 22-membered macrocycle of SFA is deeply embedded in the same binding site as CsA and forms six direct hydrogen bonds with CypA. The effector domain of SFA, on the other hand, has a chemical and three-dimensional structure very different from CsA, already strongly suggesting different immunosuppressive mechanisms. Furthermore, two CypA center dot SFA complexes form a dimer in the crystal as well as in solution as shown by light scattering and size exclusion chromatography experiments. This observation raises the possibility that the dimer of CypA center dot SFA complexes is the molecular species mediating the immunosuppressive effect.	Novartis Inst BioMed Res, Prot Struct Unit, CH-4002 Basel, Switzerland; Novartis Inst BioMed Res, Protease Platform, CH-4002 Basel, Switzerland; Novartis Inst BioMed Res, Transplantat Res, CH-4002 Basel, Switzerland	Novartis; Novartis; Novartis	Kallen, J (corresponding author), Novartis Inst BioMed Res, Prot Struct Unit, CH-4002 Basel, Switzerland.	joerg.kallen@pharma.novartis.com						Allen A, 2004, J IMMUNOL, V172, P4797, DOI 10.4049/jimmunol.172.8.4797; ANDERSON PS, 1994, PERSPECT DRUG DISCOV, V2, P3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banteli R, 2001, BIOORG MED CHEM LETT, V11, P1609, DOI 10.1016/S0960-894X(01)00293-1; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BRUENGER AT, 1993, XPLOR VERSION 3 1 SY; Fehr T, 1999, J ANTIBIOT, V52, P474, DOI 10.7164/antibiotics.52.474; Huai Q, 2002, P NATL ACAD SCI USA, V99, P12037, DOI 10.1073/pnas.192206699; Jin L, 2002, P NATL ACAD SCI USA, V99, P13522, DOI 10.1073/pnas.212504399; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALLEN J, 1992, FEBS LETT, V300, P286, DOI 10.1016/0014-5793(92)80865-E; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KALLEN J, 1997, BIOTECHNOLOGY, V7, P536; KE HM, 1992, J MOL BIOL, V228, P539, DOI 10.1016/0022-2836(92)90841-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Metternich R, 1999, J ORG CHEM, V64, P9632, DOI 10.1021/jo9912395; MIKOL V, 1993, J MOL BIOL, V234, P1119, DOI 10.1006/jmbi.1993.1664; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nicolaou KC, 2000, J AM CHEM SOC, V122, P3830, DOI 10.1021/ja994285v; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paquette LA, 2002, J AM CHEM SOC, V124, P4257, DOI 10.1021/ja020091v; Pemberton TJ, 2003, FEBS LETT, V555, P335, DOI 10.1016/S0014-5793(03)01270-5; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sanglier JJ, 1999, J ANTIBIOT, V52, P466, DOI 10.7164/antibiotics.52.466; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Sedrani R, 2003, J AM CHEM SOC, V125, P3849, DOI 10.1021/ja021327y; Steinschulte C, 2003, J IMMUNOL, V171, P542, DOI 10.4049/jimmunol.171.2.542; Woltman AM, 2004, J IMMUNOL, V172, P6482, DOI 10.4049/jimmunol.172.10.6482; Zenke G, 2001, J IMMUNOL, V166, P7165, DOI 10.4049/jimmunol.166.12.7165; Zhang LH, 2001, J BIOL CHEM, V276, P43534, DOI 10.1074/jbc.M104257200; Zhang LH, 2001, J IMMUNOL, V166, P5611, DOI 10.4049/jimmunol.166.9.5611; Zhao YD, 1996, BIOCHEMISTRY-US, V35, P7362, DOI 10.1021/bi960278x	34	30	40	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21965	21971		10.1074/jbc.M501623200	http://dx.doi.org/10.1074/jbc.M501623200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15772070	hybrid			2022-12-25	WOS:000229557900038
J	Yun, JH; Zhong, Q; Kwak, JY; Lee, WH				Yun, JH; Zhong, Q; Kwak, JY; Lee, WH			Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest	ONCOGENE			English	Article						Brca1; mitomycin C; DNA interstrand crosslink (ICL) repair; Rad51; S phase	FANCONI-ANEMIA; CHROMOSOME BREAKAGE; BRCA1; CHECKPOINT; PROTEIN; SUSCEPTIBILITY; INVOLVEMENT; RADIATION; PATHWAY; COMPLEX	Hypersensitivity of Brca1-deficient cells to interstrand crosslinking (ICL) agents such as cisplatin and mitomycin C (MMC) implicates an important role for Brca1 in cellular response to the ICL DNA damage repair. However, the detailed mechanism of how Brca1 is involved in the ICL response remains unclear. In this study, we analysed the cellular response to MMC treatment using isogenic mouse embryonic fibroblasts (MEFs) including wild type, p53(-/-) and p53(-/-) Brca1(-/-). Marked hypersensitivity of p53(-/-) Brca1(-/-) MEFs to MMC was found, and the reconstitution of Brca1 expression in these cells restored resistance to MMC. Upon MMC treatment, wild-type MEF was temporarily arrested at G2/M phase but subsequently resumed a normal cell cycle progression. In contrast, Brca1-deficient MEF exhibited a marked time-dependent accumulation of cells arrested at S phase and a prolonged increase in the G2/M population, followed by extensive cell deaths. Importantly, DNA damage-induced Rad51 foci were not formed in these cells, suggesting a defect in homologous recombination. Such defects are fully rescued by reconstitution of Brca1 expression in Brca1-deficient MEF, suggesting that Brca1 directly plays an essential role in ICL repair, which depends on homologous recombination during S phase.	Univ Calif Irvine, Sch Med, Dept Biol Chem, Irvine, CA 92697 USA; Dong A Univ, Coll Med, Med Res Ctr Canc Mol Therapy, Pusan 602714, South Korea; Dong A Univ, Coll Med, Dept Biochem, Pusan 602714, South Korea	University of California System; University of California Irvine; Dong A University; Dong A University	Lee, WH (corresponding author), Univ Calif Irvine, Sch Med, Dept Biol Chem, 124 Sprague Hall,839 Med Sci Court, Irvine, CA 92697 USA.	whlee@uci.edu	Zhong, Qing/GLT-4858-2022	Zhong, Qing/0000-0001-6979-955X	NATIONAL CANCER INSTITUTE [R01CA094170] Funding Source: NIH RePORTER; NCI NIH HHS [CA94170] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; BERGER R, 1993, CANCER GENET CYTOGEN, V69, P13, DOI 10.1016/0165-4608(93)90104-T; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen JJ, 1999, CANCER RES, V59, p1752S; COLLINS AR, 1993, MUTAT RES, V293, P99, DOI 10.1016/0921-8777(93)90062-L; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; DARDALHON M, 1995, MUTAT RES-DNA REPAIR, V336, P49, DOI 10.1016/0921-8777(94)00037-7; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; ElShamy WM, 2004, NAT CELL BIOL, V6, P954, DOI 10.1038/ncb1171; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Hartmann JT, 1999, INT J CANCER, V83, P866, DOI 10.1002/(SICI)1097-0215(19991210)83:6<866::AID-IJC34>3.0.CO;2-9; Heinrich MC, 1998, BLOOD, V91, P275, DOI 10.1182/blood.V91.1.275.275_275_287; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Kruyt FAE, 1997, CANCER RES, V57, P2244; KUBBIES M, 1985, AM J HUM GENET, V37, P1022; Kupfer GM, 1996, BLOOD, V88, P1019; Larminat F, 2004, BIOL CELL, V96, P545, DOI 10.1016/j.biolcel.2004.06.001; McHugh PJ, 2000, MOL CELL BIOL, V20, P3425, DOI 10.1128/MCB.20.10.3425-3433.2000; METZLER M, 1986, J CANCER RES CLIN, V112, P210, DOI 10.1007/BF00395914; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Niedernhofer LJ, 2004, MOL CELL BIOL, V24, P5776, DOI 10.1128/MCB.24.13.5776-5787.2004; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rothfuss A, 2004, MOL CELL BIOL, V24, P123, DOI 10.1128/MCB.24.1.123-134.2004; Sala-Trepat M, 2000, EXP CELL RES, V260, P208, DOI 10.1006/excr.2000.4994; SASAKI MS, 1973, CANCER RES, V33, P1829; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Ting NSY, 2004, DNA REPAIR, V3, P935, DOI 10.1016/j.dnarep.2004.03.026; van den Bosch M, 2002, BIOL CHEM, V383, P873; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu VPCC, 2000, GENE DEV, V14, P1400; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	43	35	36	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4009	4016		10.1038/sj.onc.1208575	http://dx.doi.org/10.1038/sj.onc.1208575			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15782115				2022-12-25	WOS:000229680300001
J	Honda, K; Smith, MA; Zhu, XW; Baus, D; Merrick, WC; Tartakoff, AM; Hattier, T; Harris, PL; Siedlak, SL; Fujioka, H; Liu, Q; Moreira, PI; Miller, FP; Nunomura, A; Shimohama, S; Perry, G				Honda, K; Smith, MA; Zhu, XW; Baus, D; Merrick, WC; Tartakoff, AM; Hattier, T; Harris, PL; Siedlak, SL; Fujioka, H; Liu, Q; Moreira, PI; Miller, FP; Nunomura, A; Shimohama, S; Perry, G			Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED FENTON REACTIONS; ION-BINDING-SITES; OXIDATIVE DAMAGE; AMYLOID-BETA; HYDROGEN-PEROXIDE; PROMINENT FEATURE; DNA CONSTITUENTS; HEME OXYGENASE-1; SENILE PLAQUES; METAL-BINDING	Oxidative modification of cytoplasmic RNA in vulnerable neurons is an important, well documented feature of the pathophysiology of Alzheimer disease. Here we report that RNA-bound iron plays a pivotal role for RNA oxidation in vulnerable neurons in Alzheimer disease brain. The cytoplasm of hippocampal neurons showed significantly higher redox activity and iron(II) staining than age-matched controls. Notably, both were susceptible to RNase, suggesting a physical association of iron( II) with RNA. Ultrastructural analysis further suggested an endoplasmic reticulum association. Both rRNA and mRNA showed twice the iron binding as tRNA. rRNA, extremely abundant in neurons, was considered to provide the greatest number of iron binding sites among cytoplasmic RNA species. Interestingly, the difference of iron binding capacity disappeared after denaturation of RNA, suggesting that the higher order structure may contribute to the greater iron binding of rRNA. Reflecting the difference of iron binding capacity, oxidation of rRNA by the Fenton reaction formed 13 times more 8-hydroxyguanosine than tRNA. Consistent with in situ findings, ribosomes purified from Alzheimer hippocampus contained significantly higher levels of RNase-sensitive iron( II) and redox activity than control. Furthermore, only Alzheimer rRNA contains 8-hydroxyguanosine in reverse transcriptase-PCR. Addressing the biological significance of ribosome oxidation by redox-active iron, in vitro translation with oxidized ribosomes from rabbit reticulocyte showed a significant reduction of protein synthesis. In conclusion these results suggest that rRNA provides a binding site for redoxactive iron and serves as a redox center within the cytoplasm of vulnerable neurons in Alzheimer disease in advance of the appearance of morphological change indicating neurodegeneration.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Univ Coimbra, Ctr Neurosci & Cell Biol Coimbra, P-3004517 Coimbra, Portugal; Asahikawa Med Coll, Dept Psychiat & Neurol, Asahikawa, Hokkaido 0788510, Japan; Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto 6068507, Japan	Case Western Reserve University; Case Western Reserve University; Universidade de Coimbra; Asahikawa Medical College; Kyoto University	Perry, G (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	george.perry@case.edu	Moreira, Paula/B-3608-2009; Zhu, Xiongwei/A-9629-2009; Perry, George/A-8611-2009; Smith, Mark A/A-9053-2009	Moreira, Paula/0000-0001-5177-6747; Zhu, Xiongwei/0000-0003-2092-6508; Perry, George/0000-0002-6547-0172; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038648] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26796] Funding Source: Medline; NINDS NIH HHS [NS38648] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alberts B., 1994, MOL BIOL CELL; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Bayer TA, 2003, P NATL ACAD SCI USA, V100, P14187, DOI 10.1073/pnas.2332818100; Berens C, 1998, CHEM BIOL, V5, P163, DOI 10.1016/S1074-5521(98)90061-8; Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0; Cate JH, 1996, STRUCTURE, V4, P1221, DOI 10.1016/S0969-2126(96)00129-3; Chen BX, 1996, J HISTOCHEM CYTOCHEM, V44, P819, DOI 10.1177/44.8.8756754; Colwell BA, 2003, J INORG BIOCHEM, V94, P100, DOI 10.1016/S0162-0134(02)00626-8; CONNOR JR, 1992, J NEUROSCI RES, V31, P327, DOI 10.1002/jnr.490310214; CONNOR JR, 1992, J NEUROSCI RES, V31, P75, DOI 10.1002/jnr.490310111; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Deibel MA, 1996, J NEUROL SCI, V143, P137, DOI 10.1016/S0022-510X(96)00203-1; Ding QX, 2004, J NEUROCHEM, V91, P1211, DOI 10.1111/j.1471-4159.2004.02802.x; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Gabbita SP, 1998, J NEUROCHEM, V71, P2034, DOI 10.1046/j.1471-4159.1998.71052034.x; Gonzalez RL, 2001, METHOD ENZYMOL, V338, P421; Henle ES, 1996, J BIOL CHEM, V271, P21177, DOI 10.1074/jbc.271.35.21177; Henle ES, 1999, J BIOL CHEM, V274, P962, DOI 10.1074/jbc.274.2.962; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; JOHNSON G, 1992, MOL BRAIN RES, V15, P319; Kemper W M, 1979, Methods Enzymol, V60, P638; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; LANGSTROM NS, 1989, MOL BRAIN RES, V5, P259, DOI 10.1016/0169-328X(89)90060-0; Lloyd DR, 1999, MUTAT RES-FUND MOL M, V424, P23, DOI 10.1016/S0027-5107(99)00005-6; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Lovell MA, 2001, ARCH NEUROL-CHICAGO, V58, P392, DOI 10.1001/archneur.58.3.392; Luo YZ, 1996, J BIOL CHEM, V271, P21167, DOI 10.1074/jbc.271.35.21167; LUO YZ, 1994, P NATL ACAD SCI USA, V91, P12438, DOI 10.1073/pnas.91.26.12438; MANN DMA, 1981, J NEUROL NEUROSUR PS, V44, P97, DOI 10.1136/jnnp.44.2.97; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MORRIS CM, 1994, NEURODEGENERATION, V3, P267; Nunomura A, 2004, NEUROBIOL DIS, V17, P108, DOI 10.1016/j.nbd.2004.06.003; Nunomura A, 1999, J NEUROSCI, V19, P1959; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Polacek N, 1998, RNA, V4, P1282, DOI 10.1017/S1355838298980347; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pyle AM, 2002, J BIOL INORG CHEM, V7, P679, DOI 10.1007/s00775-002-0387-6; Quintana C, 2000, CELL MOL BIOL, V46, P807; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Rottkamp CA, 2001, FREE RADICAL BIO MED, V30, P447, DOI 10.1016/S0891-5849(00)00494-9; SAJDELSULKOWSKA EM, 1984, SCIENCE, V225, P947, DOI 10.1126/science.6206567; Sayre LM, 2000, J NEUROCHEM, V74, P270, DOI 10.1046/j.1471-4159.2000.0740270.x; SCHIPPER HM, 1995, ANN NEUROL, V37, P758, DOI 10.1002/ana.410370609; Shan X, 2003, J NEUROSCI, V23, P4913; Shiman R, 2000, J MOL BIOL, V302, P79, DOI 10.1006/jmbi.2000.4031; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; SMITH MA, 1994, AM J PATHOL, V145, P42; Smith MA, 2000, ANTIOXID REDOX SIGN, V2, P413, DOI 10.1089/15230860050192198; van Rensburg SJ, 2004, METAB BRAIN DIS, V19, P89, DOI 10.1023/B:MEBR.0000027420.50736.62	52	217	239	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20978	20986		10.1074/jbc.M500526200	http://dx.doi.org/10.1074/jbc.M500526200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15767256	hybrid			2022-12-25	WOS:000229438800011
J	Slupianek, A; Gurdek, E; Koptyra, M; Nowicki, MO; Siddiqui, KM; Groden, J; Skorski, T				Slupianek, A; Gurdek, E; Koptyra, M; Nowicki, MO; Siddiqui, KM; Groden, J; Skorski, T			BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin	ONCOGENE			English	Article						BCR/ABL; BLM; RAD51; homologous recombination repair; drug resistance	RECQ FAMILY HELICASES; SYNDROME GENE-PRODUCT; BLOOMS-SYNDROME; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; FUNCTIONAL INTERACTION; ATAXIA-TELANGIECTASIA; GENOTOXIC TREATMENT; STAT5 ACTIVATION; SYNDROME PROTEIN	Bloom protein (BLM) is a 3'-5' helicase, mutated in Bloom syndrome, which plays an important role in response to DNA double-strand breaks and stalled replication forks. Here, we show that BCR/ABL tyrosine kinase, which also modulates DNA repair capacity, is associated with elevated expression of BLM. Downregulation of BLM by antisense cDNA or dominant-negative mutant inhibits homologous recombination repair (HRR) and increases sensitivity to cisplatin in BCR/ABL-positive cells. Bone marrow cells from mice heterozygous for BLM mutation, BLMCin/+, transfected with BCR/ABL display increased sensitivity to cisplatin compared to those obtained from the wild-type littermates. BCR/ABL promotes interactions of BLM with RAD51, while simultaneous overexpression of BLM and RAD51 in normal cells increases drug resistance. These data suggest that BLM collaborates with RAD51 to facilitate HRR and promotes the resistance of BCR/ABL-positive leukemia cells to DNA-damaging agents.	Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Philadelphia, PA 19122 USA; Univ Cincinnati, Coll Med, Howard Hughes Med Inst, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Howard Hughes Medical Institute; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Slupianek, A (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Biolife Sci Bldg,Room 419 TS,1900 N 12th St, Philadelphia, PA 19122 USA.	aslupian@temple.edu; tomasz.skorski@temple.edu		Nowicki, Michal/0000-0002-5807-0007; Koptyra, Mateusz/0000-0002-3857-6633	NCI NIH HHS [U01 CA 84291, R01 CA 89052] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084291, R01CA089052] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Arlinghaus Ralph, 2004, Cancer Treat Res, V119, P239; BARTRAM CR, 1976, ANN HUM GENET, V40, P79, DOI 10.1111/j.1469-1809.1976.tb00166.x; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; Bischof O, 2001, J BIOL CHEM, V276, P12068, DOI 10.1074/jbc.M006462200; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; CANITROT Y, 2003, BLOOD, V26, P26; Collis SJ, 2001, NUCLEIC ACIDS RES, V29, P1534, DOI 10.1093/nar/29.7.1534; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Dierov J, 2004, CANCER CELL, V5, P275, DOI 10.1016/S1535-6108(04)00056-X; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; Dutertre S, 2002, J BIOL CHEM, V277, P6280, DOI 10.1074/jbc.M105735200; EPNER DE, 1990, ANN INTERN MED, V113, P3, DOI 10.7326/0003-4819-113-1-3; Fabre F, 2002, P NATL ACAD SCI USA, V99, P16887, DOI 10.1073/pnas.252652399; Freire R, 2001, NUCLEIC ACIDS RES, V29, P3172, DOI 10.1093/nar/29.15.3172; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Goss KH, 2002, SCIENCE, V297, P2051, DOI 10.1126/science.1074340; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Heath C, 2004, J BIOL CHEM, V279, P6666, DOI 10.1074/jbc.M308743200; Helleday T, 2003, MUTAT RES-FUND MOL M, V532, P103, DOI 10.1016/j.mrfmmm.2003.08.013; Hoser G, 2003, LEUKEMIA RES, V27, P267, DOI 10.1016/S0145-2126(02)00163-7; Imamura O, 2001, ONCOGENE, V20, P1143, DOI 10.1038/sj.onc.1204195; Issaad C, 2000, LEUKEMIA, V14, P662, DOI 10.1038/sj.leu.2401730; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Kawabe T, 2000, ONCOGENE, V19, P4764, DOI 10.1038/sj.onc.1203841; KAYTOR MD, 1995, GENETICS, V140, P1441; Keeshan K, 2001, LEUKEMIA, V15, P1823, DOI 10.1038/sj.leu.2402309; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Langland G, 2002, CANCER RES, V62, P2766; Laurent E, 2003, CLIN CANCER RES, V9, P3722; Li WH, 2004, J CELL BIOL, V165, P801, DOI 10.1083/jcb.200402095; Lindner I, 2003, J IMMUNOL, V171, P1780, DOI 10.4049/jimmunol.171.4.1780; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MAXWELL SA, 1987, CANCER RES, V47, P1731; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Nieborowska-Skorska M, 2002, BLOOD, V99, P4531, DOI 10.1182/blood.V99.12.4531; Nowicki MO, 2004, BLOOD, V104, P3746, DOI 10.1182/blood-2004-05-1941; Nowicki MO, 2003, ONCOGENE, V22, P3952, DOI 10.1038/sj.onc.1206620; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Poppe B, 2001, CANCER GENET CYTOGEN, V128, P39, DOI 10.1016/S0165-4608(01)00392-2; Raderschall E, 2002, CANCER RES, V62, P219; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rosell Rafael, 2003, Cancer Control, V10, P297; SCHILD D, 1995, GENETICS, V140, P115; SIP M, 1992, BIOCHEMISTRY-US, V31, P2508, DOI 10.1021/bi00124a010; SIRARD C, 1994, BLOOD, V83, P1575; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 2002, ONCOGENE, V21, P8591, DOI 10.1038/sj.onc.1206087; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Slupianek A, 2002, MOL CELL BIOL, V22, P4189, DOI 10.1128/MCB.22.12.4189-4201.2002; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Turley H, 2001, BRIT J CANCER, V85, P261, DOI 10.1054/bjoc.2001.1874; van der Kuip H, 2001, BLOOD, V98, P1532, DOI 10.1182/blood.V98.5.1532; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Wu A, 2003, J CELL PHYSIOL, V195, P453, DOI 10.1002/jcp.10261; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Yamamoto M, 2004, BIOCHEM BIOPH RES CO, V319, P1272, DOI 10.1016/j.bbrc.2004.05.113; Zdraveski ZZ, 2000, CHEM BIOL, V7, P39, DOI 10.1016/S1074-5521(00)00064-8	64	20	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3914	3922		10.1038/sj.onc.1208545	http://dx.doi.org/10.1038/sj.onc.1208545			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15750625				2022-12-25	WOS:000229435300007
J	Skurk, C; Izumiya, Y; Maatz, H; Razeghi, P; Shiojima, I; Sandri, M; Sato, K; Zeng, L; Schiekofer, S; Pimentel, D; Lecker, S; Taegtmeyer, H; Goldberg, AL; Walsh, K				Skurk, C; Izumiya, Y; Maatz, H; Razeghi, P; Shiojima, I; Sandri, M; Sato, K; Zeng, L; Schiekofer, S; Pimentel, D; Lecker, S; Taegtmeyer, H; Goldberg, AL; Walsh, K			The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE ATROPHY; LEFT-VENTRICULAR MASS; GLYCOGEN-SYNTHASE KINASE-3-BETA; UBIQUITIN LIGASE COMPLEX; GENE-EXPRESSION; TRANSGENIC MICE; IN-VIVO; F-BOX; MYOCARDIAL-CONTRACTILITY; PROTEIN-SYNTHESIS	Although signaling mechanisms inducing cardiac hypertrophy have been extensively studied, little is known about the mechanisms that reverse cardiac hypertrophy. Here, we describe the existence of a similar Akt/forkhead signaling axis in cardiac myocytes in vitro and in vivo, which is regulated by insulin, insulin-like growth factor (IGF), stretch, pressure overload, and angiotensin II stimulation. FOXO3a gene transfer prevented both IGF and stretch-induced hypertrophy in rat neonatal cardiac myocyte cultures in vitro. Transduction with FOXO3a also caused a significant reduction in cardiomyocyte size in mouse hearts in vivo. Akt/FOXO signaling regulated the expression of multiple atrophy-related genes "atrogenes," including the ubiquitin ligase atrogin-1 ( MAFbx). In cardiac myocyte cultures, transduction with constitutively active Akt or treatment with IGF suppressed atrogin-1 mRNA expression, whereas transduction with FOXO3a stimulated its expression. FOXO3a transduction activated the atrogin-1 promoter in both cultured myocytes and mouse heart. Thus, in cardiomyocytes, as in skeletal muscle, FOXO3a activates an atrogene transcriptional program, which retards or prevents hypertrophy and is down-regulated by multiple physiological and pathological stimuli of myocyte growth.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA 02115 USA; Univ Texas, Sch Med, Houston, TX 77030 USA	Boston University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Texas System	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.	kxwalsh@bu.edu		Walsh, Kenneth/0000-0001-7580-2276; Pimentel, David/0000-0002-0537-7195	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052, R37AG015052, R01AG017241] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66957, P01 HL066957] Funding Source: Medline; NIAMS NIH HHS [AR40197, R01 AR040197] Funding Source: Medline; NIA NIH HHS [R01 AG017241, AG15052, R01 AG015052, AG17241, R37 AG015052] Funding Source: Medline; NIDDK NIH HHS [R01 DK062307, DK062307] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BENES AJ, 1985, J CELL SCI, V75, P35; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Brancaccio M, 2003, NAT MED, V9, P68, DOI 10.1038/nm805; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Condorelli G, 2002, P NATL ACAD SCI USA, V99, P12333, DOI 10.1073/pnas.172376399; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; DESIMONE GD, 1994, BRIT HEART J, V71, P287; Deval C, 2001, BIOCHEM J, V360, P143, DOI 10.1042/0264-6021:3600143; Devereux RB, 2004, JAMA-J AM MED ASSOC, V292, P2350, DOI 10.1001/jama.292.19.2350; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Himeno E, 1996, AM HEART J, V131, P313, DOI 10.1016/S0002-8703(96)90360-9; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Jagoe RT, 2002, FASEB J, V16, P1697, DOI 10.1096/fj.02-0312com; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Li HH, 2004, J CLIN INVEST, V114, P1058, DOI 10.1172/JCl200422220; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; McMullen JR, 2004, J BIOL CHEM, V279, P4782, DOI 10.1074/jbc.M310405200; McMullen JR, 2003, P NATL ACAD SCI USA, V100, P12355, DOI 10.1073/pnas.1934654100; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; PAPADIMITRIOU JM, 1974, CIRC RES, V35, P127, DOI 10.1161/01.RES.35.1.127; Petroff MGV, 2001, NAT CELL BIOL, V3, P867, DOI 10.1038/ncb1001-867; Pham FH, 2001, ADV ENZYME REGUL, V41, P73, DOI 10.1016/S0065-2571(00)00007-8; Razeghi P, 2003, CIRCULATION, V108, P2536, DOI 10.1161/01.CIR.0000096481.45105.13; SAAD MJA, 1995, BIOCHEM J, V310, P741, DOI 10.1042/bj3100741; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Schneider MR, 2002, J ENDOCRINOL, V172, P423, DOI 10.1677/joe.0.1720423; Shibata R, 2004, NAT MED, V10, P1384, DOI 10.1038/nm1137; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shiojima I, 2002, J BIOL CHEM, V277, P37670, DOI 10.1074/jbc.M204572200; Shiraishi I, 2004, CIRC RES, V94, P884, DOI 10.1161/01.RES.0000124394.01180.BE; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Sugden PH, 2003, CIRC RES, V93, P1179, DOI 10.1161/01.RES.0000106132.04301.F5; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; THAIK CM, 1995, J CLIN INVEST, V96, P1093, DOI 10.1172/JCI118095; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; TOMANEK RJ, 1982, CIRC RES, V51, P295, DOI 10.1161/01.RES.51.3.295; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Wilkins BJ, 2002, J PHYSIOL-LONDON, V541, P1, DOI 10.1113/jphysiol.2002.017129; Wray CJ, 2003, INT J BIOCHEM CELL B, V35, P698, DOI 10.1016/S1357-2725(02)00341-2; Yang HL, 2005, ONCOGENE, V24, P1924, DOI 10.1038/sj.onc.1208352; Yu ZH, 1996, CIRC RES, V79, P691, DOI 10.1161/01.RES.79.4.691; Zafeiridis A, 1998, CIRCULATION, V98, P656, DOI 10.1161/01.CIR.98.7.656; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	60	255	265	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20814	20823		10.1074/jbc.M500528200	http://dx.doi.org/10.1074/jbc.M500528200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781459	hybrid, Green Accepted			2022-12-25	WOS:000229242000079
J	Martins, AHB; Resende, RR; Majumder, P; Faria, M; Casarini, DE; Tarnok, A; Colli, W; Pesquero, JB; Ulrich, H				Martins, AHB; Resende, RR; Majumder, P; Faria, M; Casarini, DE; Tarnok, A; Colli, W; Pesquero, JB; Ulrich, H			Neuronal differentiation of P19 embryonal carcinoma cells modulates kinin B2 receptor gene expression and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORADRENALINE RELEASE; BRADYKININ RECEPTORS; TISSUE KALLIKREIN; CALCIUM WAVES; PC-12 CELLS; CROSS-TALK; IDENTIFICATION; CA2+; STIMULATION; ACTIVATION	Kinins are vasoactive oligopeptides generated upon proteolytic cleavage of low and high molecular weight kininogens by kallikreins. These peptides have a well established signaling role in inflammation and homeostasis. Nevertheless, emerging evidence suggests that bradykinin and other kinins are stored in the central nervous system and may act as neuromediators in the control of nociceptive response. Here we show that the kinin-B2 receptor (B2BKR) is differentially expressed during in vitro neuronal differentiation of P19 cells. Following induction by retinoic acid, cells form embryonic bodies and then undergo neuronal differentiation, which is complete after 8 and 9 days. Immunochemical staining revealed that B2BKR protein expression was below detection limits in nondifferentiated P19 cells but increased during the course of neuronal differentiation and peaked on days 8 and 9. Measurement of [Ca2+](i) in the absence and presence of bradykinin showed that most undifferentiated cells are unresponsive to bradykinin application, but following differentiation, P19 cells express high molecular weight neurofilaments, secrete bradykinin into the culture medium, and respond to bradykinin application with a transient increase in [Ca2+](i). However, inhibition of B2BKR activity with HOE-140 during early differentiation led to a decrease in the size of embryonic bodies formed. Pretreatment of differentiating P19 cells with HOE-140 on day 5 resulted in a reduction of the calcium response induced by the cholinergic agonist carbamoylcholine and decreased expression levels of M1-M3 muscarinic acetylcholine receptors, indicating crucial functions of the B2BKR during neuronal differentiation.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05513970 Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Biofis, BR-04023062 Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Nefrol, BR-04044020 Sao Paulo, Brazil; Univ Leipzig, Cardiac Ctr Leipzig, D-04280 Leipzig, Germany	Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP); Leipzig University	Ulrich, H (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, Caixa Postal 26077, BR-05513970 Sao Paulo, Brazil.	henning@iq.usp.br	Ulrich, Henning/AAX-8586-2021; Colli, Walter/G-1188-2012; Colli, Walter/AAW-7649-2021; Pesquero, Joao/C-1470-2012; Colli, Walter/ABA-5440-2021; Majumder, Paromita/AAK-9704-2020; Ulrich, Henning/C-5245-2013	Ulrich, Henning/0000-0002-2114-3815; Colli, Walter/0000-0001-7305-4673; Pesquero, Joao/0000-0002-4507-632X; Majumder, Paromita/0000-0002-1340-2290; Ulrich, Henning/0000-0002-2114-3815; Casarini, Dulce/0000-0003-1912-4292; Resende, Rodrigo/0000-0002-2003-0739				Arganaraz GA, 2004, BRAIN RES, V1006, P114, DOI 10.1016/j.brainres.2003.12.050; Baptista HA, 2002, MOL PHARMACOL, V62, P1344, DOI 10.1124/mol.62.6.1344; BAUMGARTNER MK, 1993, DEV BRAIN RES, V72, P305, DOI 10.1016/0165-3806(93)90197-I; BHOOLA KD, 1992, BRIT J RHEUMATOL, V31, P509; Burke MA, 2003, J NEUROBIOL, V55, P191, DOI 10.1002/neu.10174; BUSH AB, 1991, J NEUROCHEM, V57, P562, DOI 10.1111/j.1471-4159.1991.tb03787.x; Calixto JB, 2000, PAIN, V87, P1, DOI 10.1016/S0304-3959(00)00335-3; Canzoniero LMT, 1996, J NEUROSCI RES, V45, P226; Cardoso CC, 2004, BIOL CHEM, V385, P295, DOI 10.1515/BC.2004.025; Casarini DE, 1999, AM J PHYSIOL-RENAL, V277, pF66, DOI 10.1152/ajprenal.1999.277.1.F66; CHAU LY, 1993, J NEUROCHEM, V60, P454, DOI 10.1111/j.1471-4159.1993.tb03172.x; De Jaco A, 2002, J NEUROSCI RES, V70, P756, DOI 10.1002/jnr.10436; Dendorfer A, 1996, PFLUG ARCH EUR J PHY, V432, pR99; DIXON BS, 1997, KIDNEY INT S, V61, P514; Drube S, 2000, BRIT J PHARMACOL, V131, P1553, DOI 10.1038/sj.bjp.0703764; El-Dahr SS, 2000, PEDIATR NEPHROL, V14, P288, DOI 10.1007/s004670050761; ElDahr SS, 1997, MICROSC RES TECHNIQ, V39, P222, DOI 10.1002/(SICI)1097-0029(19971101)39:3<222::AID-JEMT3>3.0.CO;2-M; Eurin J, 2002, NEUROPEPTIDES, V36, P257, DOI 10.1016/S0143-4179(02)00025-2; Fink CC, 2000, BIOPHYS J, V79, P163, DOI 10.1016/S0006-3495(00)76281-3; Gomez TM, 2003, METHOD ENZYMOL, V361, P407; Graness A, 1997, BIOCHEM J, V327, P147, DOI 10.1042/bj3270147; Green BT, 2003, J PHARMACOL EXP THER, V305, P733, DOI 10.1124/jpet.102.047829; HALLETT MB, 1990, PEPTIDE HORMONE ACTI, P115; HOCK FJ, 1991, BRIT J PHARMACOL, V103, P774; IRVING AJ, 1992, CELL CALCIUM, V13, P293, DOI 10.1016/0143-4160(92)90064-Y; Iwadate H, 2002, CAN J PHYSIOL PHARM, V80, P245, DOI 10.1139/Y02-026; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Jong YJI, 2002, INT IMMUNOPHARMACOL, V2, P1833, DOI 10.1016/S1567-5769(02)00168-6; Kansui Y, 2002, HYPERTENSION, V39, P29, DOI 10.1161/hy0102.098309; KOZLOWSKI MR, 1988, NEUROPEPTIDES, V12, P207, DOI 10.1016/0143-4179(88)90056-X; Kurz T, 1997, J MOL CELL CARDIOL, V29, P2561, DOI 10.1006/jmcc.1997.0492; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SD, 2000, NEUROSCI LETT, V294, P130, DOI 10.1016/S0304-3940(00)01563-9; Lee YJ, 2002, MOL CELL NEUROSCI, V19, P186, DOI 10.1006/mcne.2001.1073; Lin PX, 1996, J NEUROCHEM, V66, P233; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma QP, 2001, NEUROREPORT, V12, P2311, DOI 10.1097/00001756-200108080-00006; Mahabeer R, 2000, METAB BRAIN DIS, V15, P325, DOI 10.1023/A:1011131510491; Marceau F, 1998, PHARMACOL REV, V50, P357; Martin AK, 1999, BRIT J PHARMACOL, V126, P1559, DOI 10.1038/sj.bjp.0702464; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MONGE JC, 1995, J BIOL CHEM, V270, P15385, DOI 10.1074/jbc.270.25.15385; Morinelli TA, 2001, PEPTIDES, V22, P2169, DOI 10.1016/S0196-9781(01)00545-9; Niemann S, 1996, NEUROSCI LETT, V207, P49, DOI 10.1016/0304-3940(96)12485-X; Parnas D, 1998, J MOL NEUROSCI, V10, P17, DOI 10.1007/BF02737082; Parnas D, 1995, INT J DEV NEUROSCI, V13, P767, DOI 10.1016/0736-5748(95)00052-6; Pizard A, 2001, BIOCHEMISTRY-US, V40, P15743, DOI 10.1021/bi011600t; PURKISS JR, 1995, J NEUROCHEM, V64, P1175; Pyle SJ, 2001, DEV BRAIN RES, V132, P103, DOI 10.1016/S0165-3806(01)00289-9; Reber BFX, 1996, PFLUG ARCH EUR J PHY, V432, P893, DOI 10.1007/s004240050213; REETZ G, 1994, J NEUROCHEM, V62, P890; Regoli D, 1998, EUR J PHARMACOL, V348, P1, DOI 10.1016/S0014-2999(98)00165-4; Schelb V, 2001, N-S ARCH PHARMACOL, V364, P359; STAINES WA, 1994, NEUROSCIENCE, V58, P735, DOI 10.1016/0306-4522(94)90451-0; STEPHENS GJ, 1993, GLIA, V9, P269, DOI 10.1002/glia.440090405; Tarnok A, 1997, CYTOMETRY, V27, P65, DOI 10.1002/(SICI)1097-0320(19970101)27:1<65::AID-CYTO8>3.0.CO;2-K; Taub JS, 2003, CANCER RES, V63, P2037; THAYER SA, 1988, J NEUROSCI, V8, P4089; Wu J, 2002, INT J CANCER, V98, P29, DOI 10.1002/ijc.10142; YANO K, 1984, J BIOL CHEM, V259, P201; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0	65	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19576	19586		10.1074/jbc.M502513200	http://dx.doi.org/10.1074/jbc.M502513200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767251	hybrid			2022-12-25	WOS:000229113700020
J	Collins, RF; Frye, SA; Balasingham, S; Ford, RC; Tonjum, T; Derrick, JP				Collins, RF; Frye, SA; Balasingham, S; Ford, RC; Tonjum, T; Derrick, JP			Interaction with type IV pili induces structural changes in the bacterial outer membrane secretin PilQ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMING PROTEIN PILIN; NEISSERIA-GONORRHOEAE; 3-DIMENSIONAL RECONSTRUCTION; ELECTRON-MICROSCOPY; FILAMENTOUS PHAGE; ESCHERICHIA-COLI; NEEDLE COMPLEX; BIOGENESIS; MENINGITIDIS; MOTILITY	Type IV pili are cell surface organelles found on many Gram-negative bacteria. They mediate a variety of functions, including adhesion, twitching motility, and competence for DNA uptake. The type IV pilus is a helical polymer of pilin protein subunits and is capable of rapid polymerization or depolymerization, generating large motor forces in the process. Here we show that a specific interaction between the outer membrane secretin PilQ and the type IV pilus fiber can be detected by far-Western analysis and sucrose density gradient centrifugation. Transmission electron microscopy of preparations of purified pili, to which the purified PilQ oligomer had been added, showed that PilQ was uniquely located at one end of the pilus fiber, effectively forming a "mallet-type" structure. Determination of the three-dimensional structure of the PilQ-type IV pilus complex at 26-angstrom resolution showed that the cavity within the protein complex was filled. Comparison with a previously determined structure of PilQ at 12-angstrom resolution indicated that binding of the pilus fiber induced a dissociation of the "cap" feature and lateral movement of the "arms" of the PilQ oligomer. The results demonstrate that the PilQ structure exhibits a dynamic response to the binding of its transported substrate and suggest that the secretin could play an active role in type IV pilus assembly as well as secretion.	Univ Manchester, Fac Life Sci, Manchester M60 1QD, Lancs, England; Univ Oslo, Rikshosp, Inst Microbiol, NO-0027 Oslo, Norway; Univ Oslo, Rikshosp, Ctr Mol Biol & Neurosci, NO-0027 Oslo, Norway	University of Manchester; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway	Derrick, JP (corresponding author), Univ Manchester, Fac Life Sci, Sackville St,POB 88, Manchester M60 1QD, Lancs, England.	Jeremy.Derrick@manchester.ac.uk	Tønjum, Tone/J-4581-2014	Tonjum, Tone/0000-0002-1709-6921; Ford, Robert/0000-0002-0958-1505; Frye, Stephan/0000-0002-0786-8481; Derrick, Jeremy/0000-0002-4350-5354				Aas FE, 2002, MOL MICROBIOL, V46, P1441, DOI 10.1046/j.1365-2958.2002.03265.x; Alm RA, 1997, GENE, V192, P89, DOI 10.1016/S0378-1119(96)00805-0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bitter W, 1998, MOL MICROBIOL, V27, P209, DOI 10.1046/j.1365-2958.1998.00677.x; Bitter W, 1999, TRENDS MICROBIOL, V7, P4, DOI 10.1016/S0966-842X(98)01398-5; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Blom AM, 2001, J IMMUNOL, V166, P6764, DOI 10.4049/jimmunol.166.11.6764; BRANDEN CI, 1990, NATURE, V343, P687, DOI 10.1038/343687a0; Brinton C., 1978, IMMUNOBIOLOGY NEISER, P155; Collins RF, 2004, J BIOL CHEM, V279, P39750, DOI 10.1074/jbc.M405971200; Collins RF, 2003, J BACTERIOL, V185, P2611, DOI 10.1128/JB.185.8.2611-2617.2003; Darzins A, 1997, GENE, V192, P109, DOI 10.1016/S0378-1119(97)00037-1; Drake SL, 1997, MOL MICROBIOL, V23, P657, DOI 10.1046/j.1365-2958.1997.2511618.x; Forest KT, 1997, GENE, V192, P165, DOI 10.1016/S0378-1119(97)00008-5; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; Frank J., 1996, 3 DIMENSIONAL ELECT, Ved, ppp 54; FROHOLM LO, 1973, ACTA PATH MICRO IM B, VB 81, P525; FROSCH M, 1990, MOL MICROBIOL, V4, P1215, DOI 10.1111/j.1365-2958.1990.tb00697.x; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; Guilvout I, 1999, J BACTERIOL, V181, P7212, DOI 10.1128/JB.181.23.7212-7220.1999; Hahn E, 2000, J STRUCT BIOL, V132, P241, DOI 10.1006/jsbi.2000.4323; HECKELS JE, 1989, CLIN MICROBIOL REV, V2, pS66, DOI 10.1128/CMR.2.Suppl.S66-S73.1989; Herdendorf TJ, 2002, J BACTERIOL, V184, P6465, DOI 10.1128/JB.184.23.6465-6471.2002; HOBBS M, 1993, MOL MICROBIOL, V10, P233, DOI 10.1111/j.1365-2958.1993.tb01949.x; HOLZENBURG A, 1994, MICRON, V25, P447, DOI 10.1016/0968-4328(94)00034-4; HOVMOLLER S, 1992, ULTRAMICROSCOPY, V41, P121, DOI 10.1016/0304-3991(92)90102-P; Hwang JW, 2003, J BACTERIOL, V185, P6695, DOI 10.1128/JB.185.22.6695-6701.2003; JONSSON AB, 1994, MOL MICROBIOL, V13, P403, DOI 10.1111/j.1365-2958.1994.tb00435.x; Kimbrough TG, 2002, MICROBES INFECT, V4, P75, DOI 10.1016/S1286-4579(01)01512-X; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Maier B, 2002, P NATL ACAD SCI USA, V99, P16012, DOI 10.1073/pnas.242523299; McBride MJ, 2001, ANNU REV MICROBIOL, V55, P49, DOI 10.1146/annurev.micro.55.1.49; Merz AJ, 2000, NATURE, V407, P98, DOI 10.1038/35024105; Morand PC, 2004, EMBO J, V23, P2009, DOI 10.1038/sj.emboj.7600200; Mu XQ, 2002, J BACTERIOL, V184, P4868, DOI 10.1128/JB.184.17.4868-4874.2002; Nouwen N, 1999, P NATL ACAD SCI USA, V96, P8173, DOI 10.1073/pnas.96.14.8173; Nunn D, 1999, TRENDS CELL BIOL, V9, P402, DOI 10.1016/S0962-8924(99)01634-7; Opalka N, 2003, J MOL BIOL, V325, P461, DOI 10.1016/S0022-2836(02)01246-9; PARGE HE, 1990, J BIOL CHEM, V265, P2278; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; POTTS WJ, 1988, MOL MICROBIOL, V2, P647, DOI 10.1111/j.1365-2958.1988.tb00073.x; Prince SM, 2001, ACTA CRYSTALLOGR D, V57, P1164, DOI 10.1107/S0907444901009416; PUGSLEY AP, 1993, MOL MICROBIOL, V10, P665, DOI 10.1111/j.1365-2958.1993.tb00938.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RUDEL T, 1995, NATURE, V373, P357, DOI 10.1038/373357a0; Ruprecht J, 2001, PROG BIOPHYS MOL BIO, V75, P121, DOI 10.1016/S0079-6107(01)00004-9; Sauvonnet N, 2000, EMBO J, V19, P2221, DOI 10.1093/emboj/19.10.2221; Shevchik VE, 1997, EMBO J, V16, P3007, DOI 10.1093/emboj/16.11.3007; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; Stone KD, 1996, MOL MICROBIOL, V20, P325, DOI 10.1111/j.1365-2958.1996.tb02620.x; STROM MS, 1993, ANNU REV MICROBIOL, V47, P565, DOI 10.1146/annurev.micro.47.1.565; SWANSON J, 1971, J EXP MED, V134, P886, DOI 10.1084/jem.134.4.886; Thanassi DG, 2002, J MOL MICROB BIOTECH, V4, P11; Tonjum T, 1998, MOL MICROBIOL, V29, P111, DOI 10.1046/j.1365-2958.1998.00910.x; Tonjum T, 1997, GENE, V192, P155, DOI 10.1016/S0378-1119(97)00018-8; TONJUM T, 1995, MOL MICROBIOL, V16, P451, DOI 10.1111/j.1365-2958.1995.tb02410.x; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Winther-Larsen HC, 2001, P NATL ACAD SCI USA, V98, P15276, DOI 10.1073/pnas.261574998; Wolfgang M, 2000, EMBO J, V19, P6408, DOI 10.1093/emboj/19.23.6408; Wolfgang M, 1998, P NATL ACAD SCI USA, V95, P14973, DOI 10.1073/pnas.95.25.14973; ZHANG QY, 1992, P NATL ACAD SCI USA, V89, P5366, DOI 10.1073/pnas.89.12.5366	64	58	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18923	18930		10.1074/jbc.M411603200	http://dx.doi.org/10.1074/jbc.M411603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753075	hybrid			2022-12-25	WOS:000228932300045
J	Yang, SH; Shrivastav, A; Kisinski, C; Sharma, RK; Chen, MH; Berthiaume, LG; Peters, LL; Chuang, PT; Young, SG; Bergo, MO				Yang, SH; Shrivastav, A; Kisinski, C; Sharma, RK; Chen, MH; Berthiaume, LG; Peters, LL; Chuang, PT; Young, SG; Bergo, MO			N-myristoyltransferase 1 is essential in early mouse development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN N-MYRISTOYLTRANSFERASE; MYRISTOYL-COA; ESSENTIAL ENZYME; CELLS; RNAI	N-Myristoyltransferase (NMT) transfers myristate to an amino-terminal glycine of many eukaryotic proteins. In yeast, worms, and flies, this enzyme is essential for viability of the organism. Humans and mice possess two distinct but structurally similar enzymes, NMT1 and NMT2. These two enzymes have similar peptide specificities, but no one has examined the functional importance of the enzymes in vivo. To address this issue, we performed both genetic and biochemical studies. Northern blots with RNA from adult mice and in situ hybridization studies of day 13.5 embryos revealed widespread expression of both Nmt1 and Nmt2. To determine whether the two enzymes are functionally redundant, we generated Nmt1-deficient mice carrying a beta-galactosidase marker gene. beta-Galactosidase staining of tissues from heterozygous Nmt1-deficient (Nmt1+/-) mice and embryos confirmed widespread expression of Nmt1. Intercrosses of Nmt1+/- mice yielded no viable homozygotes (Nmt1-/-), and heterozygotes were born at a less than predicted frequency. Nmt1-/- embryos died between embryonic days 3.5 and 7.5. Northern blots revealed lower levels of Nmt2 expression in early development than at later time points, a potential explanation for the demise of Nmt1-/- embryos. To explore this concept, we generated Nmt1-/- embryonic stem (ES) cells. The Nmt2 mRNA could be detected in Nmt1-/- ES cells, but the total NMT activity levels were reduced by similar to 95%, suggesting that Nmt2 contributes little to total enzyme activity levels in these early embryo cells. The Nmt1-/- ES cells were functionally abnormal; they yielded small embryoid bodies in in vitro differentiation experiments and did not contribute normally to organogenesis in chimeric mice. We conclude that Nmt1 is not essential for the viability of mammalian cells but is required for development, likely because it is the principal N-myristoyltransferase in early embryogenesis.	Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA; Univ Saskatchewan, Coll Med, Dept Pathol, Saskatoon, SK S7N 4H4, Canada; Saskatchewan Canc Agcy, Hlth Res Div, Saskatoon, SK S7N 4H4, Canada; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California Los Angeles; University of Saskatchewan; University of Saskatchewan; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of Alberta; University of California System; University of California San Francisco	Young, SG (corresponding author), Univ Calif Los Angeles, Dept Med, Div Cardiol, 650 Charles E Young Dr,S 47-123,CHS Bldg, Los Angeles, CA 90095 USA.	sgyoung@mednet.ucla.edu		Peters, Luanne/0000-0002-0784-0534; Young, Stephen/0000-0001-7270-3176; Berthiaume, Luc/0000-0003-0926-059X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066600, U01HL066611, U01HL066590, U01HL066621] Funding Source: NIH RePORTER; NHLBI NIH HHS [U01 HL066611, HL66621, HL66600, HL66590] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Austin CP, 2004, NAT GENET, V36, P921, DOI 10.1038/ng0904-921; CRONMILLER C, 1978, DEV BIOL, V67, P465, DOI 10.1016/0012-1606(78)90212-9; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; Giang DG, 1998, J BIOL CHEM, V273, P6595, DOI 10.1074/jbc.273.12.6595; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; HUANG L, 1995, J CLIN INVEST, V95, P5152; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; KING MJ, 1991, ANAL BIOCHEM, V199, P149, DOI 10.1016/0003-2697(91)90082-5; Li BH, 2002, MOL CELL BIOL, V22, P4997, DOI 10.1128/MCB.22.14.4997-5005.2002; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LODGE JK, 1994, P NATL ACAD SCI USA, V91, P12008, DOI 10.1073/pnas.91.25.12008; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Ntwasa M, 2001, EXP CELL RES, V262, P134, DOI 10.1006/excr.2000.5086; Price HP, 2003, J BIOL CHEM, V278, P7206, DOI 10.1074/jbc.M211391200; Raju RVS, 1999, BIOCHEM BIOPH RES CO, V257, P284, DOI 10.1006/bbrc.1999.0439; Raju RVS, 1998, BIOCHEMISTRY-US, V37, P14928, DOI 10.1021/bi980891b; Raju RVS, 1997, ARCH BIOCHEM BIOPHYS, V348, P134, DOI 10.1006/abbi.1997.0333; Selvakumar P, 2002, INT J MOL MED, V10, P493; Shiraishi T, 2001, BIOCHEM BIOPH RES CO, V282, P1201, DOI 10.1006/bbrc.2001.4696; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Takamune N, 2002, FEBS LETT, V527, P138, DOI 10.1016/S0014-5793(02)03199-X; WEINBURG RA, 1995, MOL MICROBIOL, V16, P241, DOI 10.1111/j.1365-2958.1995.tb02296.x; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361	25	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18990	18995		10.1074/jbc.M412917200	http://dx.doi.org/10.1074/jbc.M412917200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753093	hybrid			2022-12-25	WOS:000228932300053
J	Yang, X; Li, JF; Qin, HY; Yang, H; Li, JL; Zhou, P; Liang, YM; Han, H				Yang, X; Li, JF; Qin, HY; Yang, H; Li, JL; Zhou, P; Liang, YM; Han, H			Mint represses transactivation of the type II collagen gene enhancer through interaction with alpha A-crystallin-binding protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE-SPECIFIC ENHANCER; AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; BINDING-PROTEIN; CAMPOMELIC DYSPLASIA; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; CARTILAGE FORMATION; NUCLEAR PROTEINS; CELL-DEVELOPMENT	Collagen type II is an extracellular matrix protein important for cartilage and bone formation, and its expression is controlled by multiple cis- and trans-acting elements, including the zinc finger transcription factor alpha A-crystallin-binding protein 1 (CRYBP1). Here we show that MSX2-interacting nuclear target protein ( MINT), a conserved transcriptional repressor, associates with CRYBP1 and negatively regulates the transactivation of the collagen type II gene (Col2a1) enhancer. We identified CRYBP1 as a binding partner of MINT by screening a mouse embryonic cDNA library using the yeast two-hybrid system. We demonstrated that the C terminus of MINT interacts with the C terminus of CRYBP1 using the mammalian cell two-hybrid assay, glutathione S-transferase pull-down, and co-immunoprecipitation analyses. Furthermore, MINT and CRYBP1 form a complex on the Col2a1 enhancer, as shown by chromatin immunoprecipitation and gel shift assays. In the presence of CRYBP1, overexpression of MINT or its C-terminal fragment in cells repressed a reporter construct driven by the Col2a1 enhancer elements. This transcription repression is dependent on histone deacetylase, the main co-repressor recruited by MINT. The present study shows that MINT is involved in CRYBP1-mediated Col2a1 gene repression and may play a role in regulation of cartilage development.	Fourth Mil Med Univ, Dept Med Genet & Dev Biol, State Key Lab Canc Biol, Xian 710032, Peoples R China	Air Force Military Medical University	Han, H (corresponding author), Fourth Mil Med Univ, Dept Med Genet & Dev Biol, State Key Lab Canc Biol, Changle Xi St 17, Xian 710032, Peoples R China.	huahan@fmmu.edu.cn		han, hua/0000-0002-1872-9700				Ariyoshi M, 2003, GENE DEV, V17, P1909, DOI 10.1101/gad.266203; ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Bassett JHD, 2003, TRENDS ENDOCRIN MET, V14, P356, DOI 10.1016/S1043-2760(03)00144-90; Basson M, 1996, GENE DEV, V10, P1953, DOI 10.1101/gad.10.15.1953; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bi WM, 2001, P NATL ACAD SCI USA, V98, P6698, DOI 10.1073/pnas.111092198; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BRADY JP, 1995, J BIOL CHEM, V270, P1221, DOI 10.1074/jbc.270.3.1221; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; Chen FL, 2000, CURR BIOL, V10, P943, DOI 10.1016/S0960-9822(00)00625-4; de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Huang WD, 2000, MOL CELL BIOL, V20, P4149, DOI 10.1128/MCB.20.11.4149-4158.2000; KANTOROW M, 1993, GENE, V131, P159, DOI 10.1016/0378-1119(93)90289-F; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; Kuang B, 2000, DEVELOPMENT, V127, P1517; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; Kuroda K, 2003, IMMUNITY, V18, P301, DOI 10.1016/S1074-7613(03)00029-3; KWOK C, 1995, AM J HUM GENET, V57, P1028; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Lefebvre W, 2002, J BONE MINER METAB, V20, P121, DOI 10.1007/s007740200017; MAEKAWA T, 1989, J BIOL CHEM, V264, P14591; MANINA E, 2001, DEVELOPMENT, V128, P5423; MITCHELMORE C, 1991, NUCLEIC ACIDS RES, V19, P141, DOI 10.1093/nar/19.1.141; MUCHARDT C, 1992, J VIROL, V66, P244, DOI 10.1128/JVI.66.1.244-250.1992; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; NAKAMURA T, 1990, MOL CELL BIOL, V10, P3700, DOI 10.1128/MCB.10.7.3700; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Oswald F, 2002, EMBO J, V21, P5417, DOI 10.1093/emboj/cdf549; Qin HY, 2004, NUCLEIC ACIDS RES, V32, P1492, DOI 10.1093/nar/gkh295; Robson H, 2000, ENDOCRINOLOGY, V141, P3887, DOI 10.1210/en.141.10.3887; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Sierra OL, 2004, J BIOL CHEM, V279, P32913, DOI 10.1074/jbc.M314098200; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Stevens DA, 2000, J BONE MINER RES, V15, P2431, DOI 10.1359/jbmr.2000.15.12.2431; Tanaka K, 2002, MOL CELL BIOL, V22, P4256, DOI 10.1128/MCB.22.12.4256-4267.2002; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Wiellette EL, 1999, DEVELOPMENT, V126, P5373; Wirth J, 1996, HUM GENET, V97, P186, DOI 10.1007/BF02265263; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; Yamagiwa H, 2004, MOL BIOTECHNOL, V28, P1, DOI 10.1385/MB:28:1:01; Yoon BS, 2004, J CELL BIOCHEM, V93, P93, DOI 10.1002/jcb.20211; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989; ZHOU G, 1995, J CELL SCI, V108, P3677	50	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18710	18716		10.1074/jbc.M500859200	http://dx.doi.org/10.1074/jbc.M500859200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15778499	hybrid			2022-12-25	WOS:000228932300022
J	Boulanger, J; Vezina, A; Mongrain, S; Boudreau, F; Perreault, N; Auclair, BA; Laine, J; Asselin, C; Rivard, N				Boulanger, J; Vezina, A; Mongrain, S; Boudreau, F; Perreault, N; Auclair, BA; Laine, J; Asselin, C; Rivard, N			Cdk2-dependent phosphorylation of homeobox transcription factor CDX2 regulates its nuclear translocation and proteasome-mediated degradation in human intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; NF-KAPPA-B; COLORECTAL CARCINOMAS; GENE-TRANSCRIPTION; TUMOR SUPPRESSION; ISOMALTASE GENE; TRANSGENIC MICE; MESSENGER-RNA; INHIBITOR P27; COLON-CANCER	By having demonstrated previously that p27(Kip1), a potent inhibitor of G(1) cyclin-cyclin-dependent kinases complexes, increases markedly during intestinal epithelial cell differentiation, we examined the effect of p27(Kip1) on the activity of the transcription factor CDX2. The present results revealed the following. 1) p27(Kip1) interacts with the CDX2 transcription factor. 2) In contrast to CDX2 mRNA levels, CDX2 protein expression levels significantly increased as soon as Caco-2/15 cells reached confluence, slowed their proliferation, and began their differentiation. The mechanism of CDX2 regulation is primarily related to protein stability, because inhibition of proteasome activity increased CDX2 levels. The half-life of CDX2 protein was significantly enhanced in differentiated versus undifferentiated proliferative intestinal epithelial cells. 3) Cdk2 interacted with CDX2 and phosphorylated CDX2, as determined by pull-down glutathione S-transferase and immunoprecipitation experiments with proliferating undifferentiated Caco-2/15 cell extracts. 4) Treatment of Caco-2/15 cells with MG132 ( a proteasome inhibitor) and ( R)-roscovitine ( a specific Cdk2 inhibitor) induced an increase in CDX2 protein levels. 5) Conversely, ectopic expression of Cdk2 resulted in decreased expression of CDX2 protein. 6) Of note, treatment of proliferative Caco-2/15 cells with ( R)roscovitine or leptomycin ( an inhibitor of nuclear export through CRM1) led to an accumulation of CDX2 into the nucleus. These data suggest that CDX2 undergoes CRM1-dependent nuclear export and cytoplasmic degradation in cells in which Cdk2 is activated, such as in proliferative intestinal epithelial cells. The targeted degradation of CDX2 following its phosphorylation by Cdk2 identifies a new mechanism through which CDX2 activity can be regulated in coordination with the cell cycle machinery.	Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Canadian Inst,Hlth Res Grp Funct Dev & Physiopath, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Rivard, N (corresponding author), Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Canadian Inst,Hlth Res Grp Funct Dev & Physiopath, Sherbrooke, PQ J1H 5N4, Canada.	Nathalie.Rivard@USherbrooke.ca						BEAULIEU JF, 1991, BIOCHEM J, V15, P599; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Brown G, 2003, EXP CELL RES, V291, P282, DOI 10.1016/S0014-4827(03)00393-8; CAIRNIE AB, 1965, EXP CELL RES, V39, P539, DOI 10.1016/0014-4827(65)90056-X; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ding IM, 2000, AM J PHYSIOL-CELL PH, V278, pC110, DOI 10.1152/ajpcell.2000.278.1.C110; Ding QM, 1998, AM J PHYSIOL-CELL PH, V275, pC1193, DOI 10.1152/ajpcell.1998.275.5.C1193; DOELL RG, 1965, P NATL ACAD SCI USA, V54, P1268, DOI 10.1073/pnas.54.4.1268; EE HC, 1995, AM J PATHOL, V147, P586; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; Evers BM, 1999, AM J PHYSIOL-CELL PH, V276, pC1243, DOI 10.1152/ajpcell.1999.276.6.C1243; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Gheorghiu I, 2001, J BIOL CHEM, V276, P44331, DOI 10.1074/jbc.M107591200; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Harlow E., 1988, ANTIBODIES LAB MANUA; Hinoi T, 2003, J BIOL CHEM, V278, P44608, DOI 10.1074/jbc.M307435200; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Houde M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/jbc.M100236200; JAMES R, 1994, J BIOL CHEM, V269, P15229; Julien C, 2003, J BIOL CHEM, V278, P42615, DOI 10.1074/jbc.M302724200; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KARAM SM, 1999, FRONT BIOSCI, V4, P286; Kim S, 2002, GASTROENTEROLOGY, V123, P1163, DOI 10.1053/gast.2002.36043; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lantz KA, 2004, J CLIN INVEST, V114, P512, DOI 10.1172/JCI200421149; LEACH FS, 1993, CANCER RES, V53, P1986; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; Li JQ, 2002, HUM PATHOL, V33, P1006, DOI 10.1053/hupa.2002.125774; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Mallow EB, 1996, J BIOL CHEM, V271, P4038; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; MENARD D, 1987, J PEDIATR GASTR NUTR, V6, P509, DOI 10.1097/00005176-198707000-00003; MENARD D, 1989, GROWTH PROMOTING FAC, P123; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Park CS, 2004, J BIOL CHEM, V279, P19592, DOI 10.1074/jbc.M314208200; Passmore LA, 2004, BIOCHEM J, V379, P513, DOI 10.1042/BJ20040198; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Qualtrough D, 2002, GUT, V51, P184, DOI 10.1136/gut.51.2.184; QUARONI A, 1985, DEV BIOL, V111, P267, DOI 10.1016/0012-1606(85)90482-8; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Rings EHHM, 2001, GASTROENTEROLOGY, V121, P1437, DOI 10.1053/gast.2001.29618; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Song BL, 2003, ACTA BIOCH BIOPH SIN, V35, P6; Stappenbeck TS, 1998, CURR OPIN CELL BIOL, V10, P702, DOI 10.1016/S0955-0674(98)80110-5; Streeter GL, 1920, CONTRIB EMBRYOL, V11, P145; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; Tian JQ, 1999, AM J PHYSIOL-CELL PH, V276, pC1245, DOI 10.1152/ajpcell.1999.276.6.C1245; Tintignac LA, 2000, EXP CELL RES, V259, P300, DOI 10.1006/excr.2000.4973; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; TRABER PG, 1989, MOL CELL BIOL, V9, P5169; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; Wang A, 1996, J CANCER RES CLIN, V122, P122, DOI 10.1007/BF01226270; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Yagi OK, 1999, BRIT J CANCER, V79, P440, DOI 10.1038/sj.bjc.6690068	79	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18095	18107		10.1074/jbc.M502184200	http://dx.doi.org/10.1074/jbc.M502184200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15741163	hybrid			2022-12-25	WOS:000228807200067
J	Fest, T; Guffei, A; Williams, G; Silva, S; Mai, S				Fest, T; Guffei, A; Williams, G; Silva, S; Mai, S			Uncoupling of genomic instability and tumorigenesis in a mouse model of Burkitt's lymphoma expressing a conditional box II-deleted Myc protein	ONCOGENE			English	Article						genome instability; c-Myc; Burkitt's lymphoma; SCID mice	C-MYC; REPRESSES TRANSCRIPTION; TRANSACTIVATION DOMAIN; APOPTOSIS; TRANSFORMATION; HYPERMUTATION; ACTIVATION; MUTATIONS; INDUCTION; ONCOGENES	Burkitt's lymphomas (BL) are characterized by the constitutive expression of c-Myc protein. In total, 50-60% of all BL cells carry mutant c-Myc proteins. Using a mouse model of spontaneously immortalized pro-B-lymphocytes (Ba/F3), we have investigated genomic instability mediated by the conditional expression of either wild-type (WT) or deletion box II Delta 106-Myc proteins. We found that both proteins mediate common as well as differing types of chromosomal rearrangements as documented by spectral karyotyping (SKY). A higher level of genomic instability is induced by the Delta 106-Myc protein. To examine the tumorigenic potential of WT or Delta 106-driven Ba/F3 cells, in vivo tumorigenesis studies were performed in SCID mice. Under the experimental conditions of this study, WT but not Delta 106-Myc expressing Ba/F3 cells triggered tumorigenesis in SCID mice. Therefore, the genomic instability phenotype induced by Delta 106-Myc can be genetically uncoupled from its tumorigenic potential.	Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Genom Ctr Canc Res & Diag, Winnipeg, MB R3E 0V9, Canada; Lab Univ Hematol, UPRES 2233 1247, F-35043 Rennes, France; Hlth Sci Ctr, Hematopathol Lab, Winnipeg, MB R3A 1R9, Canada	University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba	Fest, T (corresponding author), Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	thierry.fest@univ-rennes1.fr; smai@cc.umanitoba.ca	Mai, Sabine/E-5667-2017	Mai, Sabine/0000-0002-5797-2201; fest, thierry/0000-0002-6437-4189				AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Fest T, 2002, ONCOGENE, V21, P2981, DOI 10.1038/sj/onc/1205274; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Gaidano G, 2003, BLOOD, V102, P1833, DOI 10.1182/blood-2002-11-3606; GORUPPI S, 1994, ONCOGENE, V9, P1537; KLEIN G, 1986, AIDS RES HUM RETROV, V2, pS167; Kumagai H, 2003, SCAND J GASTROENTERO, V38, P687, DOI 10.1080/00365520310003435; Kuttler F, 2001, ONCOGENE, V20, P6084, DOI 10.1038/sj.onc.1204827; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mai Sabine, 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P179; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Raffeld M, 1995, Curr Top Microbiol Immunol, V194, P265; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697	21	11	11	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2944	2953		10.1038/sj.onc.1208467	http://dx.doi.org/10.1038/sj.onc.1208467			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735723				2022-12-25	WOS:000228649500003
J	Michaelson, JS; Cho, S; Browning, B; Zheng, TS; Lincecum, JM; Wang, MZ; Hsu, YM; Burkly, LC				Michaelson, JS; Cho, S; Browning, B; Zheng, TS; Lincecum, JM; Wang, MZ; Hsu, YM; Burkly, LC			Tweak induces mammary epithelial branching morphogenesis	ONCOGENE			English	Article						Tweak; Fn14; breast cancer; TNF; MMP-9	TUMOR-NECROSIS-FACTOR; FACTOR SCATTER FACTOR; KAPPA-B ACTIVATION; MONOCLONAL-ANTIBODIES; ENDOTHELIAL-CELLS; CDNA MICROARRAY; CANCER-THERAPY; FACTOR FAMILY; IN-VITRO; RECEPTOR	Members of the tumor necrosis factor (TNF) superfamily regulate cell survival and proliferation and have been implicated in cancer. Tweak (TNF-related weak inducer of apoptosis) has pleiotropic biological functions including proapoptotic, proangiogenic and proinflammatory activities. We explored a role for Tweak in mammary gland transformation using a three-dimensional model culture system. Tweak stimulates a branching morphogenic phenotype, similar to that induced by pro-oncogenic factors, in Eph4 mammary epithelial cells cultured in matrigel. Increased proliferation and invasiveness are observed, with a concomitant inhibition of functional differentiation. Levels of matrix metalloproteinase-9 (MMP- 9) are significantly increased following Tweak treatment. Notably, MMP inhibitors are sufficient to block the branching phenotype induced by Tweak. The capacity to promote proliferation, inhibit differentiation and induce invasion suggests a role for Tweak in mammary gland tumorigenesis. Consistent with this, we have observed elevated protein levels of the Tweak receptor, Fn14, in human breast tumor cell lines and xenograft models as well as in primary human breast tumors. Together, our results suggest that the Tweak/Fn14 pathway may be protumorigenic in human breast cancer.	Biogen Idec, Dept Transcript Profiling, Cambridge, MA USA; Biogen Idec, Dept Prot Chem, Cambridge, MA USA	Biogen; Biogen	Michaelson, JS (corresponding author), BiogenIdec, Dept Exploratory Sci, 12 Cambridge Ctr,Bio6-320, Cambridge, MA USA.	Jennifer.Michaelson@BiogenIdec.com						BARSKY SH, 1983, LANCET, V1, P296; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Brown SAN, 2003, BIOCHEM J, V371, P395, DOI 10.1042/BJ20021730; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Chicheportiche Y, 2002, ARTHRITIS RES, V4, P126, DOI 10.1186/ar388; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; Gaide O, 2003, NAT MED, V9, P614, DOI 10.1038/nm861; Han HY, 2002, CANCER RES, V62, P2890; Harada N, 2002, BIOCHEM BIOPH RES CO, V299, P488, DOI 10.1016/S0006-291X(02)02670-0; IP MM, 1992, ENDOCRINOLOGY, V130, P2833, DOI 10.1210/en.130.5.2833; Jakubowski A, 2002, J CELL SCI, V115, P267; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Kaptein A, 2000, FEBS LETT, V485, P135, DOI 10.1016/S0014-5793(00)02219-5; Kessler D, 2001, J BIOL CHEM, V276, P36575, DOI 10.1074/jbc.M101602200; Lee PPH, 2001, J CELL PHYSIOL, V188, P75, DOI 10.1002/jcp.1090; Lee PPH, 2000, ENDOCRINOLOGY, V141, P3764, DOI 10.1210/en.141.10.3764; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Mariani L, 2001, J NEURO-ONCOL, V53, P161, DOI 10.1023/A:1012253317934; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Nakayama M, 2003, BIOCHEM BIOPH RES CO, V306, P819, DOI 10.1016/S0006-291X(03)01051-9; Nakayama M, 2002, J IMMUNOL, V168, P734, DOI 10.4049/jimmunol.168.2.734; Nakayama M, 2000, J EXP MED, V192, P1373, DOI 10.1084/jem.192.9.1373; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; Pinkas J, 2002, CANCER RES, V62, P4781; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; Saas P, 2000, GLIA, V32, P102, DOI 10.1002/1098-1136(200010)32:1<102::AID-GLIA100>3.0.CO;2-U; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Schneider P, 1999, EUR J IMMUNOL, V29, P1785, DOI 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U; Shea-Eaton WK, 2001, ENDOCRINOLOGY, V142, P2558, DOI 10.1210/en.142.6.2558; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tran NL, 2003, AM J PATHOL, V162, P1313, DOI 10.1016/S0002-9440(10)63927-2; Varela LM, 2001, J CELL PHYSIOL, V188, P120, DOI 10.1002/jcp.1103; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Wilson CA, 2002, CELL DEATH DIFFER, V9, P1321, DOI 10.1038/sj.cdd.4401107; Younes A, 2003, J CLIN ONCOL, V21, P3526, DOI 10.1200/JCO.2003.09.037	41	73	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 14	2005	24	16					2613	2624		10.1038/sj.onc.1208208	http://dx.doi.org/10.1038/sj.onc.1208208			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735761				2022-12-25	WOS:000228356700003
J	Guazzaroni, MAE; Krell, T; Felipe, A; Ruiz, R; Meng, CX; Zhang, XD; Gallegos, MT; Ramos, JL				Guazzaroni, MAE; Krell, T; Felipe, A; Ruiz, R; Meng, CX; Zhang, XD; Gallegos, MT; Ramos, JL			The multidrug efflux regulator TtgV recognizes a wide range of structurally different effectors in solution and complexed with target DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA DOT-T1E; GRAM-NEGATIVE BACTERIA; TRANSCRIPTIONAL REGULATOR; ESCHERICHIA-COLI; BINDING PROTEIN; PUMP; REPRESSOR; QACR; MECHANISM; TOLERANCE	TtgV modulates the expression of the ttgGHI operon, which encodes an efflux pump that extrudes a wide variety of chemicals including mono- and binuclear aromatic hydrocarbons, aliphatic alcohols, and antibiotics of dissimilar chemical structure. Using a 'lacZ fusion to the ttgG promoter, we show that the most efficient in vivo inducers were 1-naphthol, 2,3-dihydroxynaphthalene, 4-nitrotoluene, benzonitrile, and indole. The thermodynamic parameters for the binding of different effector molecules to purified TtgV were determined by isothermal titration calorimetry. For the majority of effectors, the interaction was enthalpy-driven and counterbalance by unfavorable entropy changes. The TtgV-effector dissociation constants were found to vary between 2 and 890 mu M. There was a relationship between TtgV affinity for the different effectors and their potential to induce gene expression in vivo, indicating that the effector binding constant is a major determinant for efficient efflux pump gene expression. Equilibrium dialysis and isothermal titration calorimetry studies indicated that a TtgV dimer binds one effector molecule. No evidence for the simultaneous binding of multiple effectors to TtgV was obtained. The binding of TtgV to a 63-bp DNA fragment containing its cognate operator was tight and entropy-driven (K-D = 2.4 +/- 0.35 nM, Delta H = 5.5 +/- 0.04 kcal/mol). The TtgV-DNA complex was shown to bind 1-napthol with an affinity comparable with the free soluble TtgV protein, K-D = 4.8 +/- 0.19 and 3.0 +/- 0.15 mu M, respectively. The biological relevance of this finding is discussed.	CSIC, Dept Biochem & Mol & Cellular Biol Plants, Estac Expt Zaidin, E-18008 Granada, Spain; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Ctr Struct Biol, London SW7 2AZ, England	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ); Imperial College London; University of London; Institute of Cancer Research - UK	Ramos, JL (corresponding author), CSIC, Dept Biochem & Mol & Cellular Biol Plants, Estac Expt Zaidin, Prof Albareda,1, E-18008 Granada, Spain.	jlramos@eez.csic.es	Krell, Tino/G-7296-2015; Guazzaroni, María Eugenia MEG/E-2599-2013; Gallegos, María-Trinidad M.T./K-6501-2014; Guazzaroni, María-Eugenia/Y-9268-2019	Krell, Tino/0000-0002-9040-3166; Guazzaroni, María Eugenia MEG/0000-0002-4657-3731; Gallegos, María-Trinidad M.T./0000-0001-7633-8807; Guazzaroni, María-Eugenia/0000-0002-4657-3731; Zhang, Xiaodong/0000-0001-9786-7038; Ramos, Juan L./0000-0002-8731-7435				Ausubel FM, 1991, CURRENT PROTOCOLS MO; Berens C, 2003, EUR J BIOCHEM, V270, P3109, DOI 10.1046/j.1432-1033.2003.03694.x; Chatterjee A, 2004, J BACTERIOL, V186, P6809, DOI 10.1128/JB.186.20.6809-6814.2004; DiRusso CC, 1998, J BIOL CHEM, V273, P33652, DOI 10.1074/jbc.273.50.33652; Gallegos MT, 1996, J BACTERIOL, V178, P2356, DOI 10.1128/jb.178.8.2356-2361.1996; Gerischer U, 1998, J BACTERIOL, V180, P1512, DOI 10.1128/JB.180.6.1512-1524.1998; Grkovic S, 2003, BIOCHEMISTRY-US, V42, P15226, DOI 10.1021/bi035447+; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Grkovic S, 2001, J BACTERIOL, V183, P7102, DOI 10.1128/JB.183.24.7102-7109.2001; Guazzaroni ME, 2004, J BACTERIOL, V186, P2921, DOI 10.1128/JB.186.10.2921-2927.2004; Heldwein EEZ, 2001, NATURE, V409, P378, DOI 10.1038/35053138; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; Kavanoor M, 1997, BIOPHYS CHEM, V66, P43, DOI 10.1016/S0301-4622(97)00002-1; Kok RG, 1998, J BACTERIOL, V180, P5058, DOI 10.1128/JB.180.19.5058-5069.1998; Lee EH, 2003, J BACTERIOL, V185, P7145, DOI 10.1128/JB.185.24.7145-7152.2003; Lee EW, 2003, ANTIMICROB AGENTS CH, V47, P3733, DOI 10.1128/AAC.47.12.3733-3738.2003; Middlemiss JK, 2004, J BACTERIOL, V186, P1258, DOI 10.1128/JB.186.5.1258-1269.2004; Murray DS, 2004, J BIOL CHEM, V279, P14365, DOI 10.1074/jbc.M313870200; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Ramos JL, 2002, ANNU REV MICROBIOL, V56, P743, DOI 10.1146/annurev.micro.56.012302.161038; Ramos JL, 1998, J BACTERIOL, V180, P3323, DOI 10.1128/JB.180.13.3323-3329.1998; RAMOS JL, 1995, J BACTERIOL, V177, P3911, DOI 10.1128/jb.177.14.3911-3916.1995; Rojas A, 2004, APPL ENVIRON MICROB, V70, P3637, DOI 10.1128/aem.70.6.3637-3643.2004; Rojas A, 2003, J BACTERIOL, V185, P4755, DOI 10.1128/JB.185.16.4755-4763.2003; Rojas A, 2001, J BACTERIOL, V183, P3967, DOI 10.1128/JB.183.13.3967-3973.2001; Schnappinger D, 1999, J BIOL CHEM, V274, P6405, DOI 10.1074/jbc.274.10.6405; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Schumacher MA, 2004, EMBO J, V23, P2923, DOI 10.1038/sj.emboj.7600288; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; SPAINK HP, 1987, PLANT MOL BIOL, V9, P27, DOI 10.1007/BF00017984; Teran W, 2003, ANTIMICROB AGENTS CH, V47, P3067, DOI 10.1128/AAC.47.10.3067-3072.2003; Trautwein G, 2001, J BACTERIOL, V183, P873, DOI 10.1128/JB.183.3.873-881.2001; Vazquez-Laslop N, 1999, BIOCHEMISTRY-US, V38, P16925, DOI 10.1021/bi991988g; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yoshida K, 2004, J BACTERIOL, V186, P5640, DOI 10.1128/JB.186.17.5640-5648.2004; Yu EW, 2003, J BACTERIOL, V185, P5657, DOI 10.1128/JB.185.19.5657-5664.2003	37	51	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20887	20893		10.1074/jbc.M500783200	http://dx.doi.org/10.1074/jbc.M500783200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15767250	hybrid			2022-12-25	WOS:000229242000087
J	Madsen, KL; Beuming, T; Niv, MY; Chang, CW; Dev, KK; Weinstein, H; Gether, U				Madsen, KL; Beuming, T; Niv, MY; Chang, CW; Dev, KK; Weinstein, H; Gether, U			Molecular determinants for the complex binding specificity of the PDZ domain in PICK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ALPHA; PROTEIN PICK1; CARBOXYL-TERMINUS; CRYSTAL-STRUCTURE; RECOGNITION; INTERACTS; AMPA; RECEPTORS; DYNAMICS; ERBIN	PICK1 ( protein interacting with C kinase 1) contains a single PDZ domain known to mediate interaction with the C termini of several receptors, transporters, ion channels, and kinases. In contrast to most PDZ domains, the PICK1 PDZ domain interacts with binding sequences classifiable as type I ( terminating in (S/T) X Phi; X, any residue) as well as type II (Phi X Phi; Phi, any hydrophobic residue). To enable direct assessment of the affinity of the PICK1 PDZ domain for its binding partners we developed a purification scheme for PICK1 and a novel quantitative binding assay based on fluorescence polarization. Our results showed that the PICK1 PDZ domain binds the type II sequence presented by the human dopamine transporter (-WLKV) with an almost 15-fold and > 100-fold higher affinity than the type I sequences presented by protein kinase C alpha (-QSAV) and the beta(2)-adrenergic receptor (-DSLL), respectively. Mutational analysis of Lys(83) in the alpha B1 position of the PDZ domain suggested that this residue mimics the function of hydrophobic residues present in this position in regular type II PDZ domains. The PICK1 PDZ domain was moreover found to prefer small hydrophobic residues in the C-terminal P( 0) position of the ligand. Molecular modeling predicted a rank order of (Val > Ile > Leu) that was verified experimentally with up to a similar to 16-fold difference in binding affinity between a valine and a leucine in P(0). The results define the structural basis for the unusual binding pattern of the PICK1 PDZ domain by substantiating the critical role of the alpha B1 position (Lys83) and of discrete side chain differences in position P(0) of the ligands.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Neuropharmacol Grp, DK-2200 Copenhagen, Denmark; Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA; Novartis Inst BioMed Res, Dept Neurosci Res, CH-4002 Basel, Switzerland	University of Copenhagen; Cornell University; Novartis	Gether, U (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Neuropharmacol Grp, DK-2200 Copenhagen, Denmark.	gether@neuropharm.ku.dk	Niv, Masha Y/E-3148-2010; Niv, Masha/AAL-1123-2020; Madsen, Kenneth/C-7778-2012; WEINSTEIN, HAREL/O-8245-2019	Madsen, Kenneth/0000-0001-9274-6691; WEINSTEIN, HAREL/0000-0003-3473-9818; Gether, Ulrik/0000-0002-0020-3807; Dev, Kumlesh/0000-0003-4274-9119; Niv, Masha/0000-0001-8275-8795	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012408] Funding Source: NIH RePORTER; NIDA NIH HHS [P01 DA 12408] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Baron A, 2002, J BIOL CHEM, V277, P50463, DOI 10.1074/jbc.M208848200; Beuming T, 2005, BIOINFORMATICS, V21, P827, DOI 10.1093/bioinformatics/bti098; Bezprozvanny I, 2001, FEBS LETT, V509, P457, DOI 10.1016/S0014-5793(01)03214-8; Birrane G, 2003, J BIOL CHEM, V278, P1399, DOI 10.1074/jbc.C200571200; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Boudin H, 2000, NEURON, V28, P485, DOI 10.1016/S0896-6273(00)00127-6; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; Chung HJ, 2000, J NEUROSCI, V20, P7258; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Dev KK, 2004, J BIOL CHEM, V279, P41393, DOI 10.1074/jbc.M404499200; Dev KK, 1999, NEUROPHARMACOLOGY, V38, P635, DOI 10.1016/S0028-3908(98)00230-5; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Duggan A, 2002, J BIOL CHEM, V277, P5203, DOI 10.1074/jbc.M104748200; El Far O, 2000, EUR J NEUROSCI, V12, P4215, DOI 10.1046/j.1460-9568.2000.01309.x; Excoffon KJDA, 2004, J CELL SCI, V117, P4401, DOI 10.1242/jcs.01300; Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Hassan SA, 2003, PROTEINS, V51, P109, DOI 10.1002/prot.10330; Hassan SA, 2002, PROTEINS, V47, P45, DOI 10.1002/prot.10059; Hirbec H, 2002, J BIOL CHEM, V277, P15221, DOI 10.1074/jbc.C200112200; Hirbec H, 2003, NEURON, V37, P625, DOI 10.1016/S0896-6273(02)01191-1; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Jaulin-Bastard F, 2001, J BIOL CHEM, V276, P15256, DOI 10.1074/jbc.M010032200; Kang BS, 2003, STRUCTURE, V11, P845, DOI 10.1016/S0969-2126(03)00125-4; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kurschner C, 1998, MOL CELL NEUROSCI, V11, P161, DOI 10.1006/mcne.1998.0679; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; Lim IA, 2002, J BIOL CHEM, V277, P21697, DOI 10.1074/jbc.M112339200; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Lin SHS, 2001, MOL PHARMACOL, V60, P916, DOI 10.1124/mol.60.5.916; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Novak KAP, 2002, BIOORG MED CHEM LETT, V12, P2471, DOI 10.1016/S0960-894X(02)00345-1; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; Piserchio A, 2002, J BIOL CHEM, V277, P6967, DOI 10.1074/jbc.M109453200; Reina J, 2002, NAT STRUCT BIOL, V9, P621, DOI 10.1038/nsb815; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; STRICKER NL, 1997, NAT STRUCT BIOL, V4, P336; Takeya R, 2000, BIOCHEM BIOPH RES CO, V267, P149, DOI 10.1006/bbrc.1999.1932; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; van Ham M, 2003, MOL BIOL REP, V30, P69, DOI 10.1023/A:1023941703493; Wang WL, 2003, J BIOL CHEM, V278, P37705, DOI 10.1074/jbc.M304619200; Williams ME, 2003, J NEUROSCI, V23, P11279; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3	54	65	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20539	20548		10.1074/jbc.M500577200	http://dx.doi.org/10.1074/jbc.M500577200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15774468	hybrid			2022-12-25	WOS:000229242000048
J	Choudhuri, T; Pal, S; Das, T; Sa, G				Choudhuri, T; Pal, S; Das, T; Sa, G			Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G(2) phase of cell cycle in a p53-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASES; CDK INHIBITORS; D1; EXPRESSION; CARCINOMA; PROTEINS; RAS; PROLIFERATION; HYPERPLASIA; PROTECTION	Curcumin (diferuloylmethane) is known to induce apoptosis in tumor cells. In asynchronous cultures, with time-lapse video-micrography in combination with quantitative fluorescence microscopy, we have demonstrated that curcumin induces apoptosis at G(2) phase of cell cycle in deregulated cyclin D1-expressed mammary epithelial carcinoma cells, leaving its normal counterpart unaffected. In our search toward delineating the molecular mechanisms behind such differential activities of curcumin, we found that it selectively increases p53 expression at G2 phase of carcinoma cells and releases cytochrome c from mitochondria, which is an essential requirement for apoptosis. Further experiments using p53-null as well as dominant-negative and wildtype p53-transfected cells have established that curcumin induces apoptosis in carcinoma cells via a p53-dependent pathway. On the other hand, curcumin reversibly inhibits normal mammary epithelial cell cycle progression by down-regulating cyclin D1 expression and blocking its association with Cdk4/Cdk6 as well as by inhibiting phosphorylation and inactivation of retinoblastoma protein. In addition, curcumin significantly up-regulates cell cycle inhibitory protein (p21Waf-1) in normal cells and arrests them in G(0) phase of cell cycle. Therefore, these cells escape from curcumin-induced apoptosis at G2 phase. Interestingly, these processes remain unaffected by curcumin in carcinoma cells where cyclin D1 expression is high. Similarly, in ectopically overexpressed system, curcumin cannot down-regulate cyclin D1 and thus block cell cycle progression. Hence, these cells progress into G2 phase and undergo apoptosis. These observations together suggest that curcumin may have a possible therapeutic potential in breast cancer patients.	Bose Inst, Calcutta Improvement Trust Scheme 7 M P 1 12, Kolkata 700054, W Bengal, India	Department of Science & Technology (India); Bose Institute	Sa, G (corresponding author), Bose Inst, Calcutta Improvement Trust Scheme 7 M P 1 12, Kolkata 700054, W Bengal, India.	gauri@boseinst.ernet.in	Choudhuri, Tathagata/F-8139-2011					Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Blagosklonny MV, 2001, CANCER RES, V61, P4301; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Choudhuri T, 2002, FEBS LETT, V512, P334, DOI 10.1016/S0014-5793(02)02292-5; Chuang SE, 2000, FOOD CHEM TOXICOL, V38, P991, DOI 10.1016/S0278-6915(00)00101-0; COCO MJ, 1999, CANCER RES, V59, P1134; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FOX PL, 1994, ONCOGENE, V9, P3519; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; Holy JM, 2002, MUTAT RES-GEN TOX EN, V518, P71, DOI 10.1016/S1383-5718(02)00076-1; Kawamori T, 1999, CANCER RES, V59, P597; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LIU JY, 1993, CARCINOGENESIS, V14, P857, DOI 10.1093/carcin/14.5.857; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MIYASHITA T, 1995, CELL, V80, P293; Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048; Oyama Y, 1998, EUR J PHARMACOL, V360, P65, DOI 10.1016/S0014-2999(98)00635-9; Pal S, 2001, BIOCHEM BIOPH RES CO, V288, P658, DOI 10.1006/bbrc.2001.5823; Park MJ, 2002, INT J ONCOL, V21, P379; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Ramachandran C, 1999, BREAST CANCER RES TR, V54, P269, DOI 10.1023/A:1006170224414; Rinaldi AL, 2002, CANCER RES, V62, P5451; Sa G, 2004, EXP CELL RES, V300, P427, DOI 10.1016/j.yexcr.2004.07.032; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; Sa G, 2002, CELL CYCLE, V1, P50, DOI 10.4161/cc.1.1.100; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sikora E, 1997, BIOCHEM PHARMACOL, V54, P899, DOI 10.1016/S0006-2952(97)00251-7; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang YJ, 1997, J PHARMACEUT BIOMED, V15, P1867, DOI 10.1016/S0731-7085(96)02024-9; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	41	256	268	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20059	20068		10.1074/jbc.M410670200	http://dx.doi.org/10.1074/jbc.M410670200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15738001	hybrid			2022-12-25	WOS:000229113700076
J	Kawamura, T; Ono, K; Morimoto, T; Wada, H; Hirai, M; Hidaka, K; Morisaki, T; Heike, T; Nakahata, T; Kita, T; Hasegawa, K				Kawamura, T; Ono, K; Morimoto, T; Wada, H; Hirai, M; Hidaka, K; Morisaki, T; Heike, T; Nakahata, T; Kita, T; Hasegawa, K			Acetylation of GATA-4 is involved in the differentiation of embryonic stem cells into cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE ACTIVITY; TRANSCRIPTION FACTOR GATA-4; P300; HEART; HATS; COACTIVATOR; RECRUITMENT; INHIBITION; ACTIVATION; PATHWAY	Differentiation of embryonic stem (ES) cells into cardiac myocytes requires activation of a cardiac-specific gene program. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) govern gene expression patterns by being recruited to target genes through association with specific transcription factors. One of the HATs, p300, serves as a coactivator of cardiac-specific transcription factors such as GATA-4. The HAT activity of p300 is required for acetylation and DNA binding of GATA-4 and its full transcriptional activity as well as for promotion of a transcriptionally active chromatin configuration. However, the roles of HATs and HDACs in post-translational modification of GATA-4 during the differentiation of ES cells into cardiac myocytes remain unknown. In an ES cell model of developing embryoid bodies, an acetylated form of GATA-4 and its DNA binding increased concomitantly with the expression of p300 during the differentiation of ES cells into cardiac myocytes. Treatment of ES cells with trichostatin A (TSA), a specific HDAC inhibitor, induced acetylation of histone-3/4 near GATA sites within the atrial natriuretic factor promoter. In addition, TSA augmented the increase in an acetylated form of GATA-4 and its DNA binding during the ES cell differentiation. Finally, TSA facilitated the expression of green fluorescence protein under the control of the cardiac-specific Nkx-2.5 promoter and of endogenous cardiac beta- myosin heavy chain during the differentiation. These findings demonstrate that acetylation of GATA-4 as well as of histones is involved in the differentiation of ES cells into cardiac myocytes.	Natl Hosp Org, Kyoto Med Ctr, Div Translat Res, Fushimi Ku, Kyoto 6128555, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, Kyoto 6068507, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Biosci, Suita, Osaka 5658565, Japan	Kyoto University; Kyoto University; National Cerebral & Cardiovascular Center - Japan	Hasegawa, K (corresponding author), Natl Hosp Org, Kyoto Med Ctr, Div Translat Res, Fushimi Ku, 1-1 Mukaihata Cho, Kyoto 6128555, Japan.	koj@kuhp.kyoto-u.ac.jp		Wada, Hiromichi/0000-0002-8980-224X				Chan HM, 2001, J CELL SCI, V114, P2363; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Grepin C, 1997, DEVELOPMENT, V124, P2387; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hamamori Y, 2003, J CLIN INVEST, V112, P824, DOI 10.1172/JC1200319834; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; Hidaka K, 2003, FASEB J, V17, P740, DOI 10.1096/fj.02-0104fje; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Kakita T, 1999, J BIOL CHEM, V274, P34096, DOI 10.1074/jbc.274.48.34096; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kook H, 2003, J CLIN INVEST, V112, P863, DOI 10.1172/JCI200319137; Lagace DC, 2004, J BIOL CHEM, V279, P18851, DOI 10.1074/jbc.M312795200; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lezzi Simona, 2002, Proceedings of the National Academy of Sciences of the United States of America, V99, P7757; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Marin-Husstege M, 2002, J NEUROSCI, V22, P10333; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Partanen M, 1999, INT J DEV BIOL, V43, P487; Sachinidis A, 2003, CARDIOVASC RES, V58, P278, DOI 10.1016/S0008-6363(03)00248-7; Shikama N, 2003, EMBO J, V22, P5175, DOI 10.1093/emboj/cdg502; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Viger RS, 1998, DEVELOPMENT, V125, P2665; Yanazume T, 2003, MOL CELL BIOL, V23, P3593, DOI 10.1128/MCB.23.10.3593-3606.2003; Yanazume T, 2002, J BIOL CHEM, V277, P8618, DOI 10.1074/jbc.M107924200; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	30	104	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19682	19688		10.1074/jbc.M412428200	http://dx.doi.org/10.1074/jbc.M412428200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15764815	hybrid			2022-12-25	WOS:000229113700033
J	Milhas, D; Cuvillier, O; Therville, N; Clave, P; Thomsen, M; Levade, T; Benoist, H; Segui, B				Milhas, D; Cuvillier, O; Therville, N; Clave, P; Thomsen, M; Levade, T; Benoist, H; Segui, B			Caspase-10 triggers bid cleavage and caspase cascade activation in FasL-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT CELL-DEATH; CYTOCHROME-C RELEASE; SIGNALING COMPLEX; T-LYMPHOCYTES; RECEPTOR; PATHWAY; PROTEASE; DISEASE; MITOCHONDRIA; INITIATION	In contrast to caspase-8, controversy exists as to the ability of caspase-10 to mediate apoptosis in response to FasL. Herein, we have shown activation of caspase-10, -3, and -7 as well as B cell lymphoma-2-interacting domain ( Bid) cleavage and cytochrome c release in caspase-8-deficient Jurkat (I9-2) cells treated with FasL. Apoptosis was clearly induced as illustrated by nuclear and DNA fragmentation. These events were inhibited by benzyloxycarbonyl-VAD-fluoromethyl ketone, a broad spectrum caspase inhibitor, indicating that caspases were functionally and actively involved. Benzyloxycarbonyl-AEVD-fluoromethyl ketone, a caspase-10 inhibitor, had a comparable effect. FasL-induced cell death was not completely abolished by caspase inhibitors in agreement with the existence of a cytotoxic caspase-independent pathway. In subpopulations of I9-2 cells displaying distinct caspase-10 expression levels, cell sensitivity to FasL correlated with caspase-10 expression. A robust caspase activation, Bid cleavage, and DNA fragmentation were observed in cells with high caspase-10 levels but not in those with low levels. In vitro, caspase-10, as well as caspase-8, could cleave Bid to generate active truncated Bid (p15). Altogether, our data strongly suggest that caspase-10 can serve as an initiator caspase in Fas signaling leading to Bid processing, caspase cascade activation, and apoptosis.	INSERM, Inst Louis Bugnard, U466, F-31432 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Segui, B (corresponding author), INSERM, Inst Louis Bugnard, U466, BP 84225, F-31432 Toulouse, France.	bruno.segui@toulouse.inserm.fr	Levade, Thierry/O-8948-2014; Clave, Pere/P-9070-2016; Ségui, Bruno/O-8957-2014; Thomsen, Mogens/B-7651-2011; CUVILLIER, Olivier/S-1631-2019; CUVILLIER, Olivier/B-2567-2009; Benoist, Hervé/P-2927-2014; Therville, Nicole/P-2371-2014	Clave, Pere/0000-0002-0696-8560; Ségui, Bruno/0000-0002-6119-1889; Thomsen, Mogens/0000-0002-4546-0129; CUVILLIER, Olivier/0000-0003-3346-375X; CUVILLIER, Olivier/0000-0003-3346-375X; Therville, Nicole/0000-0002-7068-1361				BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; Davidson WF, 2002, J IMMUNOL, V169, P6218, DOI 10.4049/jimmunol.169.11.6218; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P699, DOI 10.1006/bbrc.1999.1888; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074/jbc.M406543200; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Segui B, 1999, J BIOL CHEM, V274, P37251, DOI 10.1074/jbc.274.52.37251; Shimizu M, 1999, J IMMUNOL, V162, P7350; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Vonarbourg C, 2002, EUR J IMMUNOL, V32, P2376, DOI 10.1002/1521-4141(200208)32:8<2376::AID-IMMU2376>3.0.CO;2-V; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wyllie A, 1998, NATURE, V391, P20, DOI 10.1038/34040	33	99	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19836	19842		10.1074/jbc.M414358200	http://dx.doi.org/10.1074/jbc.M414358200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772077	hybrid			2022-12-25	WOS:000229113700051
J	Wang, Y; Ko, BCB; Yang, JY; Lam, TTL; Jiang, ZR; Zhang, JS; Chung, SK; Chung, SSM				Wang, Y; Ko, BCB; Yang, JY; Lam, TTL; Jiang, ZR; Zhang, JS; Chung, SK; Chung, SSM			Transgenic mice expressing dominant-negative osmotic-response element-binding protein (OREBP) in lens exhibit fiber cell elongation defect associated with increased DNA breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDOSE REDUCTASE GENE; STIMULATES TRANSCRIPTION; CYCLE DELAY; HYPERTONICITY; P53; APOPTOSIS; STRESS; MOUSE; NFAT5; SPERMIOGENESIS	Osmotic-response element-binding protein (OREBP), also known as TonEBP or NFAT5, is thought to be responsible for the induction of osmolyte-accumulating genes when cells are under hypertonic stress. Recent studies suggest that OREBP also plays a role in water reabsorption in the kidney, T-cell proliferation, and embryonic development. We developed transgenic mice that express the dominant-negative OREBP (OREBPdn) specifically in the lens because our earlier studies showed that it is particularly sensitive to osmotic stress. The transgenic mice developed nuclear cataract soon after birth, suggesting defects in lens development. The developing transgenic lenses showed incomplete elongation of fiber cells and formation of vacuoles. This is accompanied by evidence of DNA strand breaks, activation of p53, and induction of checkpoint kinase, suggesting that the developing fiber cells lacking OREBP are in a similar physiological state as cells experiencing hypertonic stress. These results indicate that OREBP-mediated accumulation of osmolytes is essential during elongation of the lens fiber cells.	Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Open Lab Chem Biol, Inst Mol Technol Drug Discovery & Synth, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; China Med Univ, Affiliated Hosp 4, Dept Ophthalmol, Shenyang, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; China Medical University	Ko, BCB (corresponding author), Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China.	cbko@hkucc.hku.hk; yyang@hkucc.hku.hk	Ko, Chi-bun/ACH-7514-2022	Ko, Ben Chi Bun/0000-0003-2027-5899				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Dmitrieva N, 2000, J BIOL CHEM, V275, P18243, DOI 10.1074/jbc.M000522200; Dmitrieva NI, 2004, P NATL ACAD SCI USA, V101, P2317, DOI 10.1073/pnas.0308463100; Dmitrieva NI, 2001, COMP BIOCHEM PHYS A, V130, P411, DOI 10.1016/S1095-6433(01)00439-1; Go WY, 2004, P NATL ACAD SCI USA, V101, P10673, DOI 10.1073/pnas.0403139101; Ho SN, 2003, ARCH BIOCHEM BIOPHYS, V413, P151, DOI 10.1016/S0003-9861(03)00130-9; Huang AM, 2000, GENETICS, V156, P1219; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jiang ZR, 2000, INVEST OPHTH VIS SCI, V41, P1467; Kishi H, 2001, J BIOL CHEM, V276, P39115, DOI 10.1074/jbc.M105134200; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; Kultz D, 2001, P NATL ACAD SCI USA, V98, P1999, DOI 10.1073/pnas.98.4.1999; KUSZAK J, 2000, PRINCIPLES PRACTICE, V2, P1355; Lam AKM, 2004, J BIOL CHEM, V279, P48048, DOI 10.1074/jbc.M407224200; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; LIN LR, 1993, INVEST OPHTH VIS SCI, V34, P2352; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lopez-Rodriguez C, 2004, P NATL ACAD SCI USA, V101, P2392, DOI 10.1073/pnas.0308703100; Maouyo D, 2002, AM J PHYSIOL-RENAL, V282, pF802, DOI 10.1152/ajprenal.00123.2001; Marcon L, 2004, BIOL REPROD, V70, P910, DOI 10.1095/biolreprod.103.022541; Michea L, 2000, AM J PHYSIOL-RENAL, V278, pF209, DOI 10.1152/ajprenal.2000.278.2.F209; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; O'Neill WC, 1999, AM J PHYSIOL-CELL PH, V276, pC995, DOI 10.1152/ajpcell.1999.276.5.C995; PARMELEE JT, 1988, J CELL PHYSIOL, V134, P491, DOI 10.1002/jcp.1041340323; Pokroy R, 2002, INVEST OPHTH VIS SCI, V43, P1736; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shim EH, 2002, EMBO REP, V3, P857, DOI 10.1093/embo-reports/kvf175; Smith A, 1998, BIOTECHNIQUES, V25, P496, DOI 10.2144/98253rr05; Trama J, 2002, J IMMUNOL, V169, P5477, DOI 10.4049/jimmunol.169.10.5477; Woo SK, 2002, INT REV CYTOL, V215, P189; Woo SK, 2002, MOL CELL BIOL, V22, P5753, DOI 10.1128/MCB.22.16.5753-5760.2002	36	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19986	19991		10.1074/jbc.M501689200	http://dx.doi.org/10.1074/jbc.M501689200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774462	hybrid			2022-12-25	WOS:000229113700068
J	Yoon, IS; Pietrzik, CU; Kang, DE; Koo, EH				Yoon, IS; Pietrzik, CU; Kang, DE; Koo, EH			Sequences from the low density lipoprotein receptor-related protein (LRP) cytoplasmic domain enhance amyloid beta protein production via the beta-secretase pathway without altering amyloid precursor protein/LRP nuclear signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E RECEPTOR; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; CYTOSOLIC ADAPTER; SCAFFOLD PROTEINS; PEPTIDE; FE65; METABOLISM; MODULATION; CLEARANCE	Increasing evidence suggests that the low density lipoprotein receptor-related protein (LRP) affects the processing of amyloid precursor protein (APP) and amyloid beta (A beta) protein production as well as mediates the clearance of A beta from the brain. Recent studies indicate that the cytoplasmic domain of LRP is critical for this modulation of APP processing requiring perhaps a complex between APP, the adaptor protein FE65, and LRP. In this study, we expressed a small LRP domain consisting of the C-terminal 97 amino acids of the cytoplasmic domain, or LRP-soluble tail (LRP-ST), in CHO cells to test the hypothesis that the APP(.)LRP complex can be disrupted. We anticipated that LRP-ST would inhibit the normal interaction between LRP and APP and therefore perturb APP processing to resemble a LRP-deficient state. Surprisingly, CHO cells expressing LRP-ST demonstrated an increase in both sAPP secretion and A beta production compared with control CHO cells in a manner reminiscent of the cellular effects of the APP "Swedish mutation." The increase in sAPP secretion consisted mainly of sAPP beta, consistent with the increase in A beta release. Further, this effect is LRP-independent, as the same alterations remained when LRP-ST was expressed in LRP-deficient cells but not when the construct was membrane-anchored. Finally, deletion experiments suggested that the last 50 amino acid residues of LRP-ST contain the important domain for altering APP processing and A beta production. These observations indicate that there are cellular pathways that may suppress A beta generation but that can be altered to facilitate A beta production.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Koo, EH (corresponding author), Univ Calif San Diego, Dept Neurosci, 9500 Gilman Dr,Mail Code 0691, La Jolla, CA 92093 USA.	edkoo@ucsd.edu	Kang, David E./E-5234-2012	Kang, David E./0000-0002-7132-821X	NATIONAL INSTITUTE ON AGING [R01AG012376] Funding Source: NIH RePORTER; NIA NIH HHS [AG12376] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; EMI N, 1991, J VIROL, V65, P1202, DOI 10.1128/JVI.65.3.1202-1207.1991; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Ho CS, 2002, J BIOL CHEM, V277, P27021, DOI 10.1074/jbc.M201823200; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; King GD, 2003, NEUROSCIENCE, V120, P143, DOI 10.1016/S0306-4522(03)00284-7; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Mueller HT, 2000, J BIOL CHEM, V275, P39302, DOI 10.1074/jbc.M008453200; Narita M, 1997, J NEUROCHEM, V69, P1904; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; SISODIA SS, 1993, J NEUROSCI, V13, P3136; Strickland DK, 2003, J THROMB HAEMOST, V1, P1663, DOI 10.1046/j.1538-7836.2003.00330.x; Tanahashi H, 1999, BIOCHEM BIOPH RES CO, V258, P385, DOI 10.1006/bbrc.1999.0639; Taru H, 2002, J BIOL CHEM, V277, P27567, DOI 10.1074/jbc.M203713200; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Zerbinatti CV, 2004, P NATL ACAD SCI USA, V101, P1075, DOI 10.1073/pnas.0305803101	43	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20140	20147		10.1074/jbc.M413729200	http://dx.doi.org/10.1074/jbc.M413729200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772078	hybrid			2022-12-25	WOS:000229113700086
J	Jones, LP; Li, ML; Halama, ED; Ma, YX; Lubet, R; Grubbs, CJ; Deng, CX; Rosen, EM; Furth, PA				Jones, LP; Li, ML; Halama, ED; Ma, YX; Lubet, R; Grubbs, CJ; Deng, CX; Rosen, EM; Furth, PA			Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer	ONCOGENE			English	Article						Brca1; tamoxifen; mammary gland; transgenic mice	ESTROGEN-RECEPTOR MODULATORS; BRCA2 MUTATION CARRIERS; TRANSGENIC MICE; TUMOR; WOMEN; GLAND; PREVENTION; INHIBITION; ALPHA; RISK	Loss of full-length Brca1 in mammary epithelial cells of the mouse mammary tumor virus (MMTV)-Cre Brca1 conditional exon 11 deletion mouse model results in the development of mammary adenocarcinomas with similar genetic changes to those found in human BRCA1-mutation-related breast cancers. We used this experimental model to evaluate the chemopreventive effect of tamoxifen on the development of mammary preneoplasia and adenocarcinoma. No protective effects of tamoxifen administration on mammary cancer development were found. Instead, tamoxifen treatment significantly increased rates of mammary epithelial cell proliferation and the prevalence of mammary hyperplasia at 6 months of age. Tamoxifen-exposed mice developed adenocarcinomas at younger ages than control mice and a higher percentage of mice developed adenocarcinomas by 12 months of age. Both whole mouse and tissue culture cell models were used to test if loss of full-length Brca1 was associated with a relative increase in the agonist activity of tamoxifen. Tamoxifen induced increased ductal growth in MMTV-Cre Brca1 conditional mice compared to wild type. Estrogen receptor alpha (ER alpha) expression was downregulated in the tamoxifen-induced hyperplasias. Reducing BRCA1 levels in MCF-7 cells using siRNA resulted in a relative increase in the agonist activity of tamoxifen. Results suggest a model of mammary cancer progression in which loss of full-length Brca1 altered the agonist/antagonist activity of tamoxifen, resulting in tamoxifen-induced mammary epithelial cell proliferation with subsequent loss of ERalpha expression and development of ER alpha-negative hyperplasias and adenocarcinomas.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20057 USA; NCI, Div Chemoprevent, Bethesda, MD 20892 USA; Univ Alabama, Chemoprevent Ctr, Birmingham, AL USA; NIDDKD, NIH, Bethesda, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Furth, PA (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Res Bldg Room E520A,3970 Reservoir Rd, Washington, DC 20057 USA.	paf3@georgetown.edu	deng, chuxia/N-6713-2016		DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005024] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009686, N01-CN-05024, 2T32CA09-686-08] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachelier Richard, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P512; Bischoff ED, 1999, J NATL CANCER I, V91, P2118, DOI 10.1093/jnci/91.24.2118; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Brown PH, 2000, BREAST CANCER RES TR, V62, P1, DOI 10.1023/A:1006484604454; Cavalli LR, 2004, CANCER GENET CYTOGEN, V149, P38, DOI 10.1016/S0165-4608(03)00282-6; Cheng GJ, 2004, P NATL ACAD SCI USA, V101, P3739, DOI 10.1073/pnas.0307864100; Chlebowski RT, 2002, ANNU REV MED, V53, P519, DOI 10.1146/annurev.med.53.082901.103925; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dutertre M, 2000, J PHARMACOL EXP THER, V295, P431; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Gallo M A, 1997, Semin Oncol, V24, pS1; Graham JD, 2000, J STEROID BIOCHEM, V74, P255, DOI 10.1016/S0960-0760(00)00101-1; Grubbs CJ, 2003, CANCER LETT, V201, P17, DOI 10.1016/S0304-3835(03)00461-0; Heldring N, 2004, MOL CELL BIOL, V24, P3445, DOI 10.1128/MCB.24.8.3445-3459.2004; Jordan VC, 2004, CANCER CELL, V5, P207, DOI 10.1016/S1535-6108(04)00059-5; Kadouri L, 2004, INT J CANCER, V108, P399, DOI 10.1002/ijc.11531; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251; KOTOULA V, 1993, HISTOL HISTOPATHOL, V8, P627; Kurokawa H, 2003, CLIN CANCER RES, V9, p511S; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lonard DM, 2004, MOL CELL BIOL, V24, P14, DOI 10.1128/MCB.24.1.14-24.2004; McDonnell DP, 2002, AM J CARDIOL, V90, p35F, DOI 10.1016/S0002-9149(01)02221-4; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; Menard S, 2000, CANCER RES, V60, P273; Metcalfe K, 2004, J CLIN ONCOL, V22, P2328, DOI 10.1200/JCO.2004.04.033; Moller P, 2002, INT J CANCER, V101, P555, DOI 10.1002/ijc.10641; Mote PA, 2004, GENE CHROMOSOME CANC, V39, P236, DOI 10.1002/gcc.10321; Narod SA, 2000, LANCET, V356, P1876, DOI 10.1016/S0140-6736(00)03258-X; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Osborne CK, 2003, BREAST, V12, P362, DOI 10.1016/S0960-9776(03)00137-1; OSBORNE M P, 1990, Steroids, V55, P114, DOI 10.1016/0039-128X(90)90006-W; PLOTKIN D, 1978, JAMA-J AM MED ASSOC, V240, P2644, DOI 10.1001/jama.240.24.2644; Rebbeck TR, 2001, CANCER RES, V61, P5420; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; REDDEL RR, 1984, EUR J CANCER CLIN ON, V20, P1419, DOI 10.1016/0277-5379(84)90062-2; Reiter R, 2004, ONCOGENE, V23, P403, DOI 10.1038/sj.onc.1207202; Rendi MH, 2004, CANCER RES, V64, P3566, DOI 10.1158/0008-5472.CAN-04-0234; Robson M, 2002, EUR J CANCER, V38, pS18; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Schrag D, 2000, JAMA-J AM MED ASSOC, V283, P617, DOI 10.1001/jama.283.5.617; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; Tilli MT, 2003, AM J PATHOL, V163, P1713, DOI 10.1016/S0002-9440(10)63529-8; VELDHUIS JD, 1979, JAMA-J AM MED ASSOC, V241, P2506, DOI 10.1001/jama.241.23.2506; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Xiong JB, 2003, MOL CELL BIOL, V23, P8668, DOI 10.1128/MCB.23.23.8668-8690.2003; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yang XH, 2003, CANCER RES, V63, P2425; Yoshidome K, 2000, CANCER RES, V60, P6901; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	55	44	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3554	3562		10.1038/sj.onc.1208426	http://dx.doi.org/10.1038/sj.onc.1208426			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15750629				2022-12-25	WOS:000229221800003
J	Muro, I; Means, JC; Clem, RJ				Muro, I; Means, JC; Clem, RJ			Cleavage of the apoptosis inhibitor DIAP1 by the apical caspase DRONC in both normal and apoptotic Drosophila cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; CYTOCHROME-C; DEATH; ACTIVATION; HID; REAPER; DEGRADATION; MECHANISMS; DARK; IAP	In Drosophila S2 cells, the apical caspase DRONC undergoes a low level of spontaneous autoprocessing. Unintended apoptosis is prevented by the inhibitor of apoptosis DIAP1, which targets the processed form of DRONC for degradation through its E3 ubiquitin protein ligase activity. Recent reports have demonstrated that shortly after the initiation of apoptosis in S2 cells, DIAP1 is cleaved following aspartate residue Asp-20 by the effector caspase DrICE. Here we report a novel caspase-mediated cleavage of DIAP1 in S2 cells. In both living and dying S2 cells, DIAP1 is cleaved by DRONC after glutamate residue Glu-205, located between the first and second BIR domains. The mutation of Glu-205 prevented the interaction of DIAP1 and processed DRONC but had no effect on the interaction with full-length DRONC. The mutation of Glu-205 also had a negative effect on the ability of overexpressed DIAP1 to prevent apoptosis stimulated by the proapoptotic protein Reaper or by UV light. These results expand our knowledge of the events that occur in the Drosophila apoptosome prior to and after receiving an apoptotic signal.	Kansas State Univ, Div Biol, Manhattan, KS 66506 USA	Kansas State University	Clem, RJ (corresponding author), Kansas State Univ, Div Biol, Ackert Hall, Manhattan, KS 66506 USA.	rclem@ksu.edu		Clem, Rollie/0000-0002-2368-720X	NCI NIH HHS [R29 CA78602] Funding Source: Medline; NCRR NIH HHS [P20 RR16475, P20 RR107686] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078602] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Chai JJ, 2003, NAT STRUCT BIOL, V10, P892, DOI 10.1038/nsb989; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Dorstyn L, 2004, J CELL BIOL, V167, P405, DOI 10.1083/jcb.200408054; Green MC, 2004, VIRUS RES, V105, P89, DOI 10.1016/j.virusres.2004.04.017; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Igaki T, 2002, J BIOL CHEM, V277, P23103, DOI 10.1074/jbc.C200222200; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Muro I, 2002, J BIOL CHEM, V277, P49644, DOI 10.1074/jbc.M203464200; Muro I, 2004, J CELL SCI, V117, P5035, DOI 10.1242/jcs.01376; Olson MR, 2003, J BIOL CHEM, V278, P4028, DOI 10.1074/jbc.M209734200; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Yan N, 2004, NAT STRUCT MOL BIOL, V11, P420, DOI 10.1038/nsmb764; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yokokura T, 2004, J BIOL CHEM, V279, P52603, DOI 10.1074/jbc.M409691200; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	33	30	30	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18683	18688		10.1074/jbc.M501206200	http://dx.doi.org/10.1074/jbc.M501206200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15774476	Green Accepted, hybrid			2022-12-25	WOS:000228932300018
J	Shogomori, H; Hammond, AT; Ostermeyer-Fay, AG; Barr, DJ; Feigenson, GW; London, E; Brown, DA				Shogomori, H; Hammond, AT; Ostermeyer-Fay, AG; Barr, DJ; Feigenson, GW; London, E; Brown, DA			Palmitoylation and intracellular domain interactions both contribute to raft targeting of linker for activation of T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORDERED-LIPID DOMAINS; INFLUENZA-VIRUS HEMAGGLUTININ; MODEL MEMBRANES; ANCHORED PROTEINS; ANTIGEN RECEPTOR; PLASMA-MEMBRANE; TRITON X-100; CHOLESTEROL; LOCALIZATION; LAT	Some transmembrane proteins must associate with lipid rafts to function. However, even if acylated, transmembrane proteins should not pack well with ordered raft lipids, and raft targeting is puzzling. Acylation is necessary for raft targeting of linker for activation of T cells (LAT). To determine whether an acylated transmembrane domain is sufficient, we examined raft association of palmitoylated and nonpalmitoylated LAT transmembrane peptides in lipid vesicles by a fluorescence quenching assay, by microscopic examination, and by association with detergent-resistant membranes (DRMs). All three assays detected very low raft association of the nonacylated LAT peptide. DRM association was the same as a control random transmembrane peptide. Acylation did not measurably enhance raft association by the first two assays but slightly enhanced DRM association. The palmitoylated LAT peptide and a FLAG-tagged LAT transmembrane domain construct expressed in cells showed similar DRM association when both were reconstituted into mixed vesicles ( containing cell-derived proteins and lipids and excess artificial raft-forming lipids) before detergent extraction. We conclude that the acylated LAT transmembrane domain has low inherent raft affinity. Full-length LAT in mixed vesicles associated better with DRMs than the peptide. However, cells appeared to contain two pools of LAT, with very different raft affinities. Since some LAT ( but not the transmembrane domain construct) was isolated in a protein complex, and the Myc- and FLAG-tagged forms of LAT could be mutually co-immunoprecipitated, oligomerization or interactions with other proteins may enhance raft affinity of one pool of LAT. We conclude that both acylation and other factors, possibly protein-protein interactions, target LAT to rafts.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA; Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cornell University; Cornell University	Brown, DA (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	deborah.brown@sunysb.edu			NIGMS NIH HHS [GM48596, GM47897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Akashi K, 1996, BIOPHYS J, V71, P3242, DOI 10.1016/S0006-3495(96)79517-6; Arcaro A, 2001, J EXP MED, V194, P1485, DOI 10.1084/jem.194.10.1485; Baumgart T, 2003, NATURE, V425, P821, DOI 10.1038/nature02013; Bock J, 2003, FEBS LETT, V534, P169, DOI 10.1016/S0014-5793(02)03784-5; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Chazal N, 2003, MICROBIOL MOL BIOL R, V67, P226, DOI 10.1128/MMBR.67.2.226-237.2003; Cherukuri A, 2004, J IMMUNOL, V172, P370, DOI 10.4049/jimmunol.172.1.370; Cunningham O, 2003, EMBO J, V22, P5994, DOI 10.1093/emboj/cdg588; de Planque MRR, 2003, MOL MEMBR BIOL, V20, P271, DOI 10.1080/09687680310001605352; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Fastenberg ME, 2003, BIOCHEMISTRY-US, V42, P12376, DOI 10.1021/bi034718d; FLORINE KI, 1987, BIOCHEMISTRY-US, V26, P2978, DOI 10.1021/bi00385a004; Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; Higuchi H, 2003, EMBO J, V22, P1790, DOI 10.1093/emboj/cdg177; Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; JING SQ, 1990, J BIOL CHEM, V265, P11555; Korlach J, 1999, P NATL ACAD SCI USA, V96, P8461, DOI 10.1073/pnas.96.15.8461; Kosugi A, 2001, IMMUNITY, V14, P669, DOI 10.1016/S1074-7613(01)00146-7; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Lew S, 1997, ANAL BIOCHEM, V251, P113, DOI 10.1006/abio.1997.2232; Li M, 2002, J VIROL, V76, P11845, DOI 10.1128/JVI.76.23.11845-11852.2002; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; LONDON E, 1981, BIOCHEMISTRY-US, V20, P1939, DOI 10.1021/bi00510a033; LONDON E, 1981, BIOCHIM BIOPHYS ACTA, V649, P89, DOI 10.1016/0005-2736(81)90012-2; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Ostermeyer AG, 2004, J CELL BIOL, V164, P69, DOI 10.1083/jcb.200303037; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Polozova A, 2000, BIOPHYS J, V79, P2632, DOI 10.1016/S0006-3495(00)76502-7; Popik W, 2004, J BIOL CHEM, V279, P704, DOI 10.1074/jbc.M306380200; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Puertollano R, 1998, J BIOL CHEM, V273, P12740, DOI 10.1074/jbc.273.21.12740; Rawat SS, 2003, MOL MEMBR BIOL, V20, P243, DOI 10.1080/0968768031000104944; Ren JH, 1997, BIOCHEMISTRY-US, V36, P10213, DOI 10.1021/bi9709295; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Shogomori H, 2003, BIOL CHEM, V384, P1259, DOI 10.1515/BC.2003.139; Shrimpton CN, 2002, J EXP MED, V196, P1057, DOI 10.1084/jem.20020143; Silvius JR, 1996, BIOCHEMISTRY-US, V35, P15198, DOI 10.1021/bi9615506; Silvius JR, 2003, BBA-BIOMEMBRANES, V1610, P174, DOI 10.1016/S0005-2736(03)00016-6; Sommers CL, 2004, BIOESSAYS, V26, P61, DOI 10.1002/bies.10384; Subczynski WK, 2003, BBA-BIOMEMBRANES, V1610, P231, DOI 10.1016/S0005-2736(03)00021-X; Takeda M, 2003, P NATL ACAD SCI USA, V100, P14610, DOI 10.1073/pnas.2235620100; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; van Duyl BY, 2002, FEBS LETT, V523, P79, DOI 10.1016/S0014-5793(02)02939-3; Walmsley AR, 2003, J BIOL CHEM, V278, P37241, DOI 10.1074/jbc.M302036200; Wang TY, 2001, BIOCHEMISTRY-US, V40, P13031, DOI 10.1021/bi0112311; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v; Yamabhai M, 2002, J BIOL CHEM, V277, P24843, DOI 10.1074/jbc.C200277200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	67	100	102	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18931	18942		10.1074/jbc.M500247200	http://dx.doi.org/10.1074/jbc.M500247200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753089	hybrid			2022-12-25	WOS:000228932300046
J	Tamamura, Y; Otani, T; Kanatani, N; Koyama, E; Kitagaki, J; Komori, T; Yamada, Y; Costantini, F; Wakisaka, S; Pacifici, M; Iwamoto, M; Enomoto-Iwamoto, M				Tamamura, Y; Otani, T; Kanatani, N; Koyama, E; Kitagaki, J; Komori, T; Yamada, Y; Costantini, F; Wakisaka, S; Pacifici, M; Iwamoto, M; Enomoto-Iwamoto, M			Developmental regulation of Wnt/beta-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; ARTICULAR-CARTILAGE; NEGATIVE REGULATOR; PATTERN-FORMATION; JOINT FORMATION; WNT; EXPRESSION; BONE; PATHWAY; GENE	Studies have suggested that continuous Wnt/beta-catenin signaling in nascent cartilaginous skeletal elements blocks chondrocyte hypertrophy and endochondral ossification, whereas signaling starting at later stages stimulates hypertrophy and ossification, indicating that Wnt/beta-catenin roles are developmentally regulated. To test this conclusion further, we created transgenic mice expressing a fusion mutant protein of beta-catenin and LEF (CA-LEF) in nascent chondrocytes. Transgenic mice had severe skeletal defects, particularly in limbs. Growth plates were totally disorganized, lacked maturing chondrocytes expressing Indian hedgehog and collagen X, and failed to undergo endochondral ossification. Interestingly, the transgenic cartilaginous elements were ill defined, intermingled with surrounding connective and vascular tissues, and even displayed abnormal joints. However, when activated beta-catenin mutant (Delta-beta-catenin) was expressed in chondrocytes already engaged in maturation such as those present in chick limbs, chondrocyte maturation and bone formation were greatly enhanced. Differential responses to Wnt/beta-catenin signaling were confirmed in cultured chondrocytes. Activation in immature cells blocked maturation and actually de-stabilized their phenotype, as revealed by reduced expression of chondrocyte markers, abnormal cytoarchitecture, and loss of proteoglycan matrix. Activation in mature cells instead stimulated hypertrophy, matrix mineralization, and expression of terminal markers such as metalloprotease (MMP)-13 and vascular endothelial growth factor. Because proteoglycans are crucial for cartilage function, we tested possible mechanisms for matrix loss. Delta-beta-Catenin expression markedly increased expression of MMP-2, MMP-3, MMP-7, MMP-9, MT3-MMP, and ADAMTS5. In conclusion, Wnt/beta-catenin signaling regulates chondrocyte phenotype, maturation, and function in a developmentally regulated manner, and regulated action by this pathway is critical for growth plate organization, cartilage boundary definition, and endochondral ossification.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Orthopaed Surg, Philadelphia, PA 19107 USA; Nagasaki Univ, Sch Dent, Dept Oral Cytol & Cell Biol, Nagasaki 8528501, Japan; Osaka Univ, Fac Dent, Suita, Osaka 5650871, Japan; NIDCR, Mol Biol Sect, NIH, Bethesda, MD 20892 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Jefferson University; Nagasaki University; Osaka University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Columbia University	Iwamoto, M (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Orthoped Surg, 1015 Walnut St,Curtis Bldg,Suite 501, Philadelphia, PA 19107 USA.	Motomi.Iwamoto@jefferson.edu			NIAMS NIH HHS [AR47543, AR46000, AR050507] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047543, R01AR046000, R01AR050507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000483] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Caterson B, 2000, MATRIX BIOL, V19, P333, DOI 10.1016/S0945-053X(00)00078-0; Cawston T, 1999, ANN NY ACAD SCI, V878, P120, DOI 10.1111/j.1749-6632.1999.tb07678.x; Church V, 2002, J CELL SCI, V115, P4809, DOI 10.1242/jcs.00152; de Crombrugghe B, 2001, CURR OPIN CELL BIOL, V13, P721, DOI 10.1016/S0955-0674(00)00276-3; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; EDWARDS JCW, 1994, J ANAT, V185, P355; Enomoto-Iwamoto M, 2002, DEV BIOL, V251, P142, DOI 10.1006/dbio.2002.0802; Enomoto-Iwamoto M, 1998, J CELL BIOL, V140, P409, DOI 10.1083/jcb.140.2.409; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Guo XZ, 2004, GENE DEV, V18, P2404, DOI 10.1101/gad.1230704; Hartmann C, 2001, CELL, V104, P341, DOI 10.1016/S0092-8674(01)00222-7; Hartmann C, 2000, DEVELOPMENT, V127, P3141; HIRAKI Y, 1991, BIOCHEM BIOPH RES CO, V175, P971, DOI 10.1016/0006-291X(91)91660-5; Hoang BH, 1998, DEV DYNAM, V212, P364, DOI 10.1002/(SICI)1097-0177(199807)212:3<364::AID-AJA4>3.0.CO;2-F; Horton William A., 1993, P641; Horton William A., 1993, P73; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Iwamoto M, 2000, J CELL BIOL, V150, P27, DOI 10.1083/jcb.150.1.27; Iwamoto M, 2003, OSTEOARTHR CARTILAGE, V11, P6, DOI 10.1053/joca.2002.0860; IWAMOTO M, 1993, EXP CELL RES, V207, P413, DOI 10.1006/excr.1993.1209; Iwasaki M, 1997, MECH DEVELOP, V69, P197, DOI 10.1016/S0925-4773(97)00145-7; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kalembeyi I, 1997, INT J DEV BIOL, V41, P569; Kanda S, 2003, J BIOL CHEM, V278, P8244, DOI 10.1074/jbc.M210635200; Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654; Kawakami Y, 2001, CELL, V104, P891, DOI 10.1016/S0092-8674(01)00285-9; Kawakami Y, 1999, DEV GROWTH DIFFER, V41, P29; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagaki J, 2003, OSTEOARTHR CARTILAGE, V11, P36, DOI 10.1053/joca.2002.0863; Lee KKH, 2001, DEV BIOL, V234, P188, DOI 10.1006/dbio.2001.0249; Loughlin J, 2004, P NATL ACAD SCI USA, V101, P9757, DOI 10.1073/pnas.0403456101; Maes C, 2004, J CLIN INVEST, V113, P188, DOI 10.1172/JCI200419383; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PACIFICI M, 1993, DEV DYNAM, V198, P123, DOI 10.1002/aja.1001980206; PACIFICI M, 1991, EXP CELL RES, V192, P266, DOI 10.1016/0014-4827(91)90185-W; Pacifici M, 2000, CONNECT TISSUE RES, V41, P175, DOI 10.3109/03008200009005288; Rudnicki JA, 1997, DEV BIOL, V185, P104, DOI 10.1006/dbio.1997.8536; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Sen M, 2000, P NATL ACAD SCI USA, V97, P2791, DOI 10.1073/pnas.050574297; Storm EE, 1999, DEV BIOL, V209, P11, DOI 10.1006/dbio.1999.9241; Surendran K, 2002, AM J PHYSIOL-RENAL, V282, pF431, DOI 10.1152/ajprenal.0009.2001; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Vleminckx K, 1999, MECH DEVELOP, V81, P65, DOI 10.1016/S0925-4773(98)00225-1; Wada N, 1999, INT J DEV BIOL, V43, P495; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324	62	261	317	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19185	19195		10.1074/jbc.M414275200	http://dx.doi.org/10.1074/jbc.M414275200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15760903	hybrid			2022-12-25	WOS:000228932300075
J	Yamada, T; Ohoka, Y; Kogo, M; Inagaki, S				Yamada, T; Ohoka, Y; Kogo, M; Inagaki, S			Physical and functional interactions of the lysophosphatidic acid receptors with PDZ domain-containing Rho guanine nucleotide exchange factors (RhoGEFs)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-ASSOCIATED RHO; PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; NEURITE RETRACTION; G(12) FAMILY; P115 RHOGEF; ACTIVATION; KINASE; LARG; PLEXIN-B1	Lysophosphatidic acid (LPA) is a serum-derived phospholipid that induces a variety of biological responses in various cells via heterotrimeric G protein-coupled receptors (GPCRs) including LPA1, LPA2, and LPA3. LPA-induced cytoskeletal changes are mediated by Rho family small GTPases, such as RhoA, Rac1, and Cdc42. One of these small GTPases, RhoA, may be activated via G alpha(12/13)-linked Rho-specific guanine nucleotide exchange factors (RhoGEFs) under LPA stimulation although the detailed mechanisms are poorly understood. Here, we show that the C terminus of LPA1 and LPA2 but not LPA3 interact with the PDZ domains of PDZ domain-containing RhoGEFs, PDZ-RhoGEF, and LARG, which are comprised of PDZ, RGS, Dbl homology (DH), and pleckstrin homology (PH) domains. In LPA(1)- and LPA(2)-transfected HEK293 cells, LPA-induced RhoA activation was observed although the C terminus of LPA1 and LPA2 mutants, which failed to interact with the PDZ domains, did not cause LPA-induced RhoA activation. Furthermore, overexpression of the PDZ domains of PDZ domain-containing RhoGEFs served as dominant negative mutants for LPA-induced RhoA activation. Taken together, these results indicate that formation of the LPA receptor/PDZ domain-containing RhoGEF complex plays a pivotal role in LPA-induced RhoA activation.	Osaka Univ, Fac Med, Sch Allied Hlth Sci, Neurobiol Grp, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Dent, Dept Oral & Maxillafacial Surg 1, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Ohoka, Y (corresponding author), Osaka Univ, Fac Med, Sch Allied Hlth Sci, Neurobiol Grp, Yamadaoka 1-7, Suita, Osaka 5650871, Japan.	yohoka@sahs.med.osaka-u.ac.jp; inagaki@sahs.med.osaka-u.ac.jp	Kogo, Mikihiko/ABD-7080-2020	Kogo, Mikihiko/0000-0002-4556-2491				Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Driessens MHE, 2002, FEBS LETT, V529, P168, DOI 10.1016/S0014-5793(02)03323-9; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Gavarini S, 2004, BIOL CELL, V96, P373, DOI 10.1016/j.biolcel.2004.03.001; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hirotani M, 2002, BIOCHEM BIOPH RES CO, V297, P32, DOI 10.1016/S0006-291X(02)02122-8; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Ishii M, 2003, LIFE SCI, V74, P163, DOI 10.1016/j.lfs.2003.09.004; Jeanneteau F, 2004, MOL BIOL CELL, V15, P696, DOI 10.1091/mbc.E03-05-0293; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lu Q, 2001, CELL, V105, P69, DOI 10.1016/S0092-8674(01)00297-5; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Oh YS, 2004, MOL CELL BIOL, V24, P5069, DOI 10.1128/MCB.24.11.5069-5079.2004; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; Sakai T, 1999, J BIOL CHEM, V274, P29666, DOI 10.1074/jbc.274.42.29666; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Togashi H, 2000, J BIOL CHEM, V275, P29570, DOI 10.1074/jbc.M003726200; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Wang Q, 2004, J BIOL CHEM, V279, P28831, DOI 10.1074/jbc.C400105200; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Xiang Y, 2003, P NATL ACAD SCI USA, V100, P10776, DOI 10.1073/pnas.1831718100; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Yoshida A, 2001, JPN J PHARMACOL, V87, P104, DOI 10.1254/jjp.87.104; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	45	74	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19358	19363		10.1074/jbc.M414561200	http://dx.doi.org/10.1074/jbc.M414561200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755723	hybrid			2022-12-25	WOS:000228932300093
J	Hamard, PJ; Dalbies-Tran, R; Hauss, C; Davidson, I; Kedinger, C; Chatton, B				Hamard, PJ; Dalbies-Tran, R; Hauss, C; Davidson, I; Kedinger, C; Chatton, B			A functional interaction between ATF7 and TAF12 that is modulated by TAF4	ONCOGENE			English	Article						ATF7; ATFa; TAF4; TAF12; TFIID; MAP kinase	TATA-BINDING PROTEIN; THYROID-HORMONE RECEPTORS; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; C-JUN; MAMMALIAN-CELLS; HISTONE FOLD; CYCLIC-AMP; IN-VIVO; TAF(II)-CONTAINING COMPLEXES	The ATF7 proteins, which are members of the cyclic AMP responsive binding protein (CREB)/activating transcription factor (ATF) family of transcription factors, display quite versatile properties: they can interact with the adenovirus E1a oncoprotein, mediating part of its transcriptional activity; they heterodimerize with the Jun, Fos or related transcription factors, likely modulating their DNA-binding specificity; they also recruit to the promoter a stress-induced protein kinase (JNK2). In the present study, we investigate the functional relationships of ATF7 with hsTAF12 (formerly hsTAF(II)20/15), which has originally been identified as a component of the general transcription factor TFIID. We show that overexpression of hsTAF12 potentiates ATF7-induced transcriptional activation through direct interaction with ATF7, suggesting that TAF12 is a functional partner of ATF7. In support of this conclusion, chromatin immunoprecipitation experiments confirm the interaction of ATF7 with TAF12 on an ATF7-responsive promoter, in the absence of any artificial overexpression of both proteins. We also show that the TAF12-dependent transcriptional activation is competitively inhibited by TAF4. Although both TAF12 isoforms (TAF12-1 and -2, formerly TAF(II)20 and TAF(II)15) interact with the ATF7 activation region through their histone-fold domain, only the largest, hsTAF12-1, mediates transcriptional activation through its N-terminal region.	Univ Strasbourg 1, Ecole Super Biotechnol Strasbourg, CNRS, UMR7100, F-67412 Illkirch Graffenstaden, France; ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chatton, B (corresponding author), Univ Strasbourg 1, Ecole Super Biotechnol Strasbourg, CNRS, UMR7100, Parc Innovat,Bd Sebastien Brant,BP10413, F-67412 Illkirch Graffenstaden, France.	bchatton@esbs.u-strasbg.fr	CHATTON, Bruno/R-3813-2019; Hamard, Pierre-Jacques/B-7740-2015	Hamard, Pierre-Jacques/0000-0002-2484-6161; CHATTON, Bruno/0000-0003-4515-7119; Davidson, Irwin/0000-0001-5533-1171				Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Bhaumik SR, 2002, MOL CELL BIOL, V22, P7365, DOI 10.1128/MCB.22.21.7365-7371.2002; Bocco JL, 1996, ONCOGENE, V12, P1971; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; Cline J, 1996, NUCLEIC ACIDS RES, V24, P3546, DOI 10.1093/nar/24.18.3546; De Graeve F, 1999, ONCOGENE, V18, P3491, DOI 10.1038/sj.onc.1202723; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; Gangloff YG, 2001, TRENDS BIOCHEM SCI, V26, P250, DOI 10.1016/S0968-0004(00)01741-2; Goetz J, 1996, J BIOL CHEM, V271, P29589, DOI 10.1074/jbc.271.47.29589; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Lavigne AC, 1999, MOL CELL BIOL, V19, P5050; Leurent C, 2004, EMBO J, V23, P719, DOI 10.1038/sj.emboj.7600111; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; LIU F, 1990, NATURE, V345, P361; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Martinez E, 2002, PLANT MOL BIOL, V50, P925, DOI 10.1023/A:1021258713850; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Mazzarelli JM, 1997, J VIROL, V71, P7978, DOI 10.1128/JVI.71.10.7978-7983.1997; Mencia M, 2002, MOL CELL, V9, P823, DOI 10.1016/S1097-2765(02)00490-2; Mengus G, 2000, J BIOL CHEM, V275, P10064, DOI 10.1074/jbc.275.14.10064; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Munz C, 2003, J BIOL CHEM, V278, P21510, DOI 10.1074/jbc.M212764200; Perletti L, 1999, J BIOL CHEM, V274, P15301, DOI 10.1074/jbc.274.22.15301; Pham AD, 1999, MECH DEVELOP, V84, P3, DOI 10.1016/S0925-4773(99)00051-9; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; Purrello M, 1998, ONCOGENE, V16, P1633, DOI 10.1038/sj.onc.1201673; Shen WC, 2003, EMBO J, V22, P3395, DOI 10.1093/emboj/cdg336; Steghens JP, 1998, BIOCHEM J, V336, P109, DOI 10.1042/bj3360109; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Walker AK, 2001, EMBO J, V20, P5269, DOI 10.1093/emboj/20.18.5269; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; Werten S, 2002, J BIOL CHEM, V277, P45502, DOI 10.1074/jbc.M206587200; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0	58	20	24	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3472	3483		10.1038/sj.onc.1208565	http://dx.doi.org/10.1038/sj.onc.1208565			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735663				2022-12-25	WOS:000229038800009
J	Boni, S; Lavergne, JP; Boulant, S; Cahour, A				Boni, S; Lavergne, JP; Boulant, S; Cahour, A			Hepatitis C virus core protein acts as a trans-modulating factor on internal translation initiation of the viral RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-ENTRY SITE; 5' NONTRANSLATED REGION; QUASI-SPECIES PRESENT; MEDIATED TRANSLATION; CODING SEQUENCES; IN-VITRO; DEPENDENT TRANSLATION; UNTRANSLATED REGION; NONCODING REGION; REPLICATION	Translation initiation of hepatitis C virus (HCV) RNA occurs through an internal ribosome entry site (IRES) located at its 5' end. As a positive-stranded virus, HCV uses the genomic RNA template for translation and replication, but the transition between these two processes remains poorly understood. HCV core protein (HCV-C) has been proposed as a good candidate to modulate such a regulation. However, current data are still the subject of controversy in attributing any potential role in HCV translation to the HCV core protein. Here we demonstrate that HCV-C displays binding activities toward both HCV IRES and the 40 S ribosomal subunit by using centrifugation on sucrose gradients. To gain further insight into these interactions, we investigated the effect of exogenous addition of purified HCV-C on HCV IRES activity by using an in vitro reporter assay. We found that HCV IRES-mediated translation was specifically modulated by HCV-C provided in trans, in a dose-dependent manner, with up to a 5-fold stimulation of the IRES efficiency upon addition of low amounts of HCV-C, followed by a decrease at high doses. Interestingly, mutations within some domains of the IRES as well as the presence of an upstream reporter gene both lead to changes in the expected effects, consistent with the high dependence of HCV IRES function on its overall structure. Collectively, these results indicate that the HCV core protein is involved in a tight modulation of HCV translation initiation, depending on its concentration, and they suggest an important biological role of this protein in viral gene expression.	Grp Hosp Pitie Salpetriere, Unite Propre Rech & Enseignement Super EA 2387, Ctr Europeen Rech Virol & Immunol, Lab Virol,IFR 113 Immun & Infect, F-75651 Paris, France; Univ Lyon 1, Lab Bioinformat & RMN Struct, Inst Biol & Chim Prot, CNRS,IFR 128 Biosci Lyon Gerland,UMR5086, F-69367 Lyon, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Cahour, A (corresponding author), Grp Hosp Pitie Salpetriere, Unite Propre Rech & Enseignement Super EA 2387, Ctr Europeen Rech Virol & Immunol, Lab Virol,IFR 113 Immun & Infect, 83 Bd Hop, F-75651 Paris, France.	cahour@idf.ext.jussieu.fr	Boulant, Steeve/W-3754-2019	Boulant, Steeve/0000-0001-8614-4993				Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Bergqvist A, 2001, J VIROL, V75, P772, DOI 10.1128/JVI.75.2.772-781.2001; Boulant S, 2003, J BIOL CHEM, V278, P45785, DOI 10.1074/jbc.M307174200; BROWN EA, 1992, NUCLEIC ACIDS RES, V20, P5041, DOI 10.1093/nar/20.19.5041; Bukh J, 1999, VIROLOGY, V262, P470, DOI 10.1006/viro.1999.9941; Chang M, 2003, AM J PATHOL, V163, P433, DOI 10.1016/S0002-9440(10)63673-5; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CORTAY JC, 1994, J BIOL CHEM, V269, P14885; Cristofari G, 2004, NUCLEIC ACIDS RES, V32, P2623, DOI 10.1093/nar/gkh579; Dumas E, 2003, NUCLEIC ACIDS RES, V31, P1275, DOI 10.1093/nar/gkg199; Fan ZY, 1999, J MED VIROL, V59, P131, DOI 10.1002/(SICI)1096-9071(199910)59:2<131::AID-JMV1>3.3.CO;2-3; Fletcher SP, 2002, RNA, V8, P1558, DOI 10.1017/S1355838202023038; Gamarnik AV, 1998, GENE DEV, V12, P2293, DOI 10.1101/gad.12.15.2293; HAMBIDGE SJ, 1992, P NATL ACAD SCI USA, V89, P10272, DOI 10.1073/pnas.89.21.10272; He YP, 2003, J GEN VIROL, V84, P535, DOI 10.1099/vir.0.18658-0; Honda M, 2000, GASTROENTEROLOGY, V118, P152, DOI 10.1016/S0016-5085(00)70424-0; Honda M, 1999, J VIROL, V73, P4941, DOI 10.1128/JVI.73.6.4941-4951.1999; Honda M, 1999, J VIROL, V73, P1165, DOI 10.1128/JVI.73.2.1165-1174.1999; Honda M, 1996, RNA, V2, P955; HOOFNAGLE JH, 1997, HEPATOLOGY S1, V26, P15; HUNT SL, 1993, VIROLOGY, V197, P801, DOI 10.1006/viro.1993.1661; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Ji H, 2004, P NATL ACAD SCI USA, V101, P16990, DOI 10.1073/pnas.0407402101; Jubin Ronald, 2003, Curr Opin Investig Drugs, V4, P162; Kato J, 2002, J MED VIROL, V66, P187, DOI 10.1002/jmv.2129; Kieft JS, 1999, J MOL BIOL, V292, P513, DOI 10.1006/jmbi.1999.3095; Kieft JS, 2001, RNA, V7, P194, DOI 10.1017/S1355838201001790; Kim YK, 2003, RNA, V9, P599, DOI 10.1261/rna.2185603; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; Laporte J, 2000, J VIROL, V74, P10827, DOI 10.1128/JVI.74.22.10827-10833.2000; Laporte J, 2003, BLOOD, V101, P52, DOI 10.1182/blood-2002-03-0818; Large MK, 1999, J IMMUNOL, V162, P931; Li DS, 2003, J GEN VIROL, V84, P815, DOI 10.1099/vir.0.18697-0; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Malet I, 1998, BIOCHEM BIOPH RES CO, V253, P257, DOI 10.1006/bbrc.1998.9740; Malet I, 2003, J VIROL METHODS, V109, P161, DOI 10.1016/S0166-0934(03)00067-3; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Matsumoto M, 1996, VIROLOGY, V218, P43, DOI 10.1006/viro.1996.0164; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Nolandt O, 1997, J GEN VIROL, V78, P1331, DOI 10.1099/0022-1317-78-6-1331; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Ray PS, 2004, NUCLEIC ACIDS RES, V32, P1678, DOI 10.1093/nar/gkh328; RAY RB, 1995, VIRUS RES, V37, P209, DOI 10.1016/0168-1702(95)00034-N; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; REBOUD AM, 1980, J BIOL CHEM, V255, P6954; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; Rijnbrand RCA, 2000, CURR TOP MICROBIOL, V242, P85; Ruggli N, 1996, J VIROL, V70, P3478, DOI 10.1128/JVI.70.6.3478-3487.1996; Sansonno D, 2004, J VIRAL HEPATITIS, V11, P27, DOI 10.1046/j.1365-2893.2003.00474.x; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; SCHEPER GC, 1991, BIOCHIM BIOPHYS ACTA, V1089, P220, DOI 10.1016/0167-4781(91)90011-A; Shimoike T, 1999, J VIROL, V73, P9718, DOI 10.1128/JVI.73.12.9718-9725.1999; TANAKA T, 1992, VIRUS RES, V23, P39; Tanaka Y, 2000, VIROLOGY, V270, P229, DOI 10.1006/viro.2000.0252; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; Wang TH, 2000, J VIROL, V74, P11347, DOI 10.1128/JVI.74.23.11347-11358.2000; Zhang J, 2002, VIROLOGY, V293, P141, DOI 10.1006/viro.2001.1270; Zhao WD, 2000, J VIROL, V74, P6223, DOI 10.1128/JVI.74.13.6223-6226.2000	62	39	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17737	17748		10.1074/jbc.M501826200	http://dx.doi.org/10.1074/jbc.M501826200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15760888	hybrid			2022-12-25	WOS:000228807200024
J	Lah, J; Simic, M; Vesnaver, G; Marianovsky, I; Glaser, G; Engelberg-Kulka, H; Loris, R				Lah, J; Simic, M; Vesnaver, G; Marianovsky, I; Glaser, G; Engelberg-Kulka, H; Loris, R			Energetics of structural transitions of the addiction antitoxin MazE - Is a programmed bacterial cell death dependent on the intrinsically flexible nature of the antitoxins?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NATIVELY UNFOLDED PROTEINS; HEAT-CAPACITY CHANGES; ESCHERICHIA-COLI; TOXIN-ANTITOXIN; UNSTRUCTURED PROTEINS; CRYSTAL-STRUCTURE; F-PLASMID; SECONDARY STRUCTURE; NUTRITIONAL STRESS; PROTHYMOSIN-ALPHA	The Escherichia coli mazEF addiction module plays a crucial role in the cell death program that is triggered under various stress conditions. It codes for the toxin MazF and the antitoxin MazE, which interferes with the lethal action of the toxin. To better understand the role of various conformations of MazE in bacterial life, its order-disorder transitions were monitored by differential scanning calorimetry, spectropolarimetry, and fluorimetry. The changes in spectral and thermodynamic properties accompanying MazE dimer denaturation can be described in terms of a compensating reversible process of the partial folding of the unstructured C-terminal half ( high mean net charge, low mean hydrophobicity) and monomerization coupled with the partial unfolding of the structured N-terminal half ( low mean net charge, high mean hydrophobicity). At pH <= 4.5 and T < 50 degrees C, the unstructured polypeptide chains of the MazE dimer fold into (pre) molten globule-like conformations that thermally stabilize the dimeric form of the protein. The simulation based on the thermodynamic and structural information on various addiction modules suggests that both the conformational adaptability of the dimeric antitoxin form ( binding to the toxins and DNA) and the reversible transformation to the more flexible monomeric form are essential for the regulation of bacterial cell life and death.	Univ Ljubljana, Fac Chem & Chem Technol, Ljubljana 1000, Slovenia; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Cellular Biochem, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Free Univ Brussels, Inst Mol Biol, Lab Ultrastruct, B-1050 Brussels, Belgium; Vlaams Inst Biotechnol, B-1050 Brussels, Belgium	University of Ljubljana; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB)	Lah, J (corresponding author), Univ Ljubljana, Fac Chem & Chem Technol, Askerceva 5, Ljubljana 1000, Slovenia.	jurij.lah@fkkt.uni-lj.si	Loris, Remy/GPG-0894-2022	Loris, Remy/0000-0002-8862-3338				Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; Amitai S, 2004, J BACTERIOL, V186, P8295, DOI 10.1128/JB.186.24.8295-8300.2004; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BECH FW, 1985, EMBO J, V4, P1059, DOI 10.1002/j.1460-2075.1985.tb03739.x; BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; Brady GP, 1997, BIOPHYS J, V72, P913, DOI 10.1016/S0006-3495(97)78725-3; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Chaires JB, 1997, BIOPOLYMERS, V44, P201, DOI 10.1002/(SICI)1097-0282(1997)44:3<201::AID-BIP2>3.0.CO;2-Z; Cherny I, 2004, J BIOL CHEM, V279, P8252, DOI 10.1074/jbc.M308263200; Christensen SK, 2004, MOL MICROBIOL, V51, P1705, DOI 10.1046/j.1365-2958.2003.03941.x; Christensen SK, 2003, J MOL BIOL, V332, P809, DOI 10.1016/S0022-2836(03)00922-7; Christensen SK, 2001, P NATL ACAD SCI USA, V98, P14328, DOI 10.1073/pnas.251327898; Couturier M, 1998, TRENDS MICROBIOL, V6, P269, DOI 10.1016/S0966-842X(98)01311-0; Dao-Thi MH, 2000, J MOL BIOL, V299, P1373, DOI 10.1006/jmbi.2000.3815; Dao-Thi MH, 2002, J BIOL CHEM, V277, P3733, DOI 10.1074/jbc.M105505200; DAVIS TL, 1992, MOL MICROBIOL, V6, P1981, DOI 10.1111/j.1365-2958.1992.tb01371.x; DEFEYTER R, 1989, MOL GEN GENET, V218, P481, DOI 10.1007/BF00332413; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; EBERL L, 1992, MOL MICROBIOL, V6, P1969, DOI 10.1111/j.1365-2958.1992.tb01370.x; Engelberg-Kulka H, 1998, P NATL ACAD SCI USA, V95, P15481, DOI 10.1073/pnas.95.26.15481; Engelberg-Kulka H, 1999, ANNU REV MICROBIOL, V53, P43, DOI 10.1146/annurev.micro.53.1.43; Engelberg-Kulka H, 2004, TRENDS MICROBIOL, V12, P66, DOI 10.1016/j.tim.2003.12.008; Engelberg-Kulka H, 2001, ASM NEWS, V67, P617; FINKELSTEIN AV, 1989, PROTEIN ENG, V3, P1, DOI 10.1093/protein/3.1.1; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; FREIRE E, 1989, COMMENTS MOL CELL BI, V6, P123; Gast K, 2003, EUR BIOPHYS J BIOPHY, V31, P586, DOI 10.1007/s00249-002-0254-y; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; Gerdes K, 2000, J BACTERIOL, V182, P561, DOI 10.1128/JB.182.3.561-572.2000; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gotfredsen M, 1998, MOL MICROBIOL, V29, P1065, DOI 10.1046/j.1365-2958.1998.00993.x; Grady R, 2003, MOL MICROBIOL, V47, P1419, DOI 10.1046/j.1365-2958.2003.03387.x; Gurney R.W., 1953, IONIC PROCESSES SOLU; Hayes F, 2003, SCIENCE, V301, P1496, DOI 10.1126/science.1088157; Hazan R, 2004, MOL GENET GENOMICS, V272, P227, DOI 10.1007/s00438-004-1048-y; Hazan R, 2004, J BACTERIOL, V186, P3663, DOI 10.1128/JB.186.11.3663-3669.2004; Hazan R, 2001, J BACTERIOL, V183, P2046, DOI 10.1128/JB.183.6.2046-2050.2001; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOLTZER A, 1995, BIOPOLYMERS, V35, P595, DOI 10.1002/bip.360350605; HORTON N, 1992, PROTEIN SCI, V1, P169; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janin J, 1996, PROTEINS, V24, pR1, DOI 10.1002/prot.340240402; JENSEN RB, 1995, MOL MICROBIOL, V17, P205, DOI 10.1111/j.1365-2958.1995.mmi_17020205.x; Kamada K, 2003, MOL CELL, V11, P875, DOI 10.1016/S1097-2765(03)00097-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lah J, 2004, J MOL BIOL, V342, P73, DOI 10.1016/j.jmb.2004.07.005; Lah J, 2003, J BIOL CHEM, V278, P14101, DOI 10.1074/jbc.M209855200; Lah N, 2003, J BIOL CHEM, V278, P24673, DOI 10.1074/jbc.M303194200; LEE KH, 1994, PROTEINS, V20, P68, DOI 10.1002/prot.340200108; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; Loladze VV, 2001, PROTEIN SCI, V10, P1343, DOI 10.1110/ps.370101; Loris R, 2003, J BIOL CHEM, V278, P28252, DOI 10.1074/jbc.M302336200; Loris R, 1999, J MOL BIOL, V285, P1667, DOI 10.1006/jmbi.1998.2395; Magnuson P, 1996, J BIOL CHEM, V271, P18705, DOI 10.1074/jbc.271.31.18705; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Marianovsky I, 2001, J BIOL CHEM, V276, P5975, DOI 10.1074/jbc.M008832200; MASUDA YJ, 1993, J BACTERIOL, V175, P6850, DOI 10.1128/jb.175.21.6850-6856.1993; METZGER S, 1988, J BIOL CHEM, V263, P15699; MIKI T, 1992, J MOL BIOL, V225, P39, DOI 10.1016/0022-2836(92)91024-J; MURPHY KP, 1994, PROTEINS, V18, P63, DOI 10.1002/prot.340180108; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Oberer M, 1999, BIOL CHEM, V380, P1413, DOI 10.1515/BC.1999.181; OBERER M, 1999, BIOCHEM J, V361, P41; PAGE MI, 1977, ANGEW CHEM INT EDIT, V16, P449, DOI 10.1002/anie.197704491; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Press W.H., 1992, NUMERICAL RECIPES, V2, P650; Privalov P L, 1986, Methods Enzymol, V131, P4; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Rawlings DE, 1999, FEMS MICROBIOL LETT, V176, P269, DOI 10.1111/j.1574-6968.1999.tb13672.x; Ren JS, 2000, BIOCHEMISTRY-US, V39, P8439, DOI 10.1021/bi000474a; RODIONOVA NA, 1989, MOL BIOL+, V23, P528; RUIZECHEVARRIA MJ, 1995, J MOL BIOL, V247, P568, DOI 10.1006/jmbi.1995.0163; RUIZECHEVARRIA MJ, 1991, MOL GEN GENET, V225, P355, DOI 10.1007/BF00261674; Sat B, 2003, J BACTERIOL, V185, P1803, DOI 10.1128/JB.185.6.1803-1807.2003; Sat B, 2001, J BACTERIOL, V183, P2041, DOI 10.1128/JB.183.6.2041-2045.2001; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Shortle D, 2001, SCIENCE, V293, P487, DOI 10.1126/science.1060438; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TAM JE, 1989, J BACTERIOL, V171, P2353, DOI 10.1128/jb.171.5.2353-2360.1989; TAM JE, 1989, MOL GEN GENET, V219, P26, DOI 10.1007/BF00261153; Tamura A, 1997, J MOL BIOL, V273, P1048, DOI 10.1006/jmbi.1997.1368; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; TSUCHIMOTO S, 1993, MOL GEN GENET, V237, P81, DOI 10.1007/BF00282787; Uversky VN, 1999, BIOCHEMISTRY-US, V38, P15009, DOI 10.1021/bi990752+; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Uversky VN, 2002, FEBS LETT, V514, P181, DOI 10.1016/S0014-5793(02)02359-1; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; VanMelderen L, 1996, J BIOL CHEM, V271, P27730, DOI 10.1074/jbc.271.44.27730; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; XIE D, 1994, PROTEINS, V19, P291, DOI 10.1002/prot.340190404; YARMOLINSKY MB, 1995, SCIENCE, V267, P836, DOI 10.1126/science.7846528; Zhang JJ, 2003, J BIOL CHEM, V278, P32300, DOI 10.1074/jbc.M304767200; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7; Zhang YL, 2005, J BIOL CHEM, V280, P3143, DOI 10.1074/jbc.M411811200	103	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17397	17407		10.1074/jbc.M501128200	http://dx.doi.org/10.1074/jbc.M501128200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15735309	hybrid			2022-12-25	WOS:000228615500105
J	Wang, W; Jobbagy, Z; Bird, TH; Eiden, MV; Anderson, WB				Wang, W; Jobbagy, Z; Bird, TH; Eiden, MV; Anderson, WB			Cell signaling through the protein kinases cAMP-dependent protein kinase, protein kinase C epsilon, and RAF-1 regulates amphotropic murine leukemia virus envelope protein-induced syncytium formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE-UPTAKE; RETROVIRUS RECEPTOR; MEMBRANE-FUSION; UP-REGULATION; PKC-EPSILON; LIPID RAFTS; VIRAL ENTRY; HERV-W; ACTIVATION; EXPRESSION	Amphotropic murine leukemia virus ( A-MuLV) utilizes the PiT2 sodium-dependent phosphate transporter as its cell surface receptor to infect mammalian cells. The process of A-MuLV infection requires cleavage of the R peptide from the envelope protein. This occurs within virions thereby rendering them competent to fuse with target cells. Envelope proteins lacking the inhibitory R peptide ( e. g. envelope ( R-) proteins) induce viral envelope-mediated cell-cell fusion ( syncytium). Here we have performed studies to determine if cell signaling through protein kinases is involved in the regulation of PiT2-mediated A-MuLV envelope ( R-)-induced syncytium formation. Truncated A-MuLV retroviral envelope protein lacking the inhibitory R peptide ( R-) was used to induce viral envelope-mediated cell-cell fusion. Signaling through cyclic AMP to activate PKA was found to inhibit envelope-induced cell-cell fusion, whereas treatment of cells with PKA inhibitors H89, KT5720, and PKA Cat alpha siRNA all enhanced this cell fusion process. It was noted that activation of PKC, as well as overexpression of PKC epsilon, up-regulated A-MuLV envelope protein-induced cell-cell fusion, whereas exposure to PKC inhibitors and expression of a kinase-inactive dominant-negative mutant of PKC epsilon (K437R) inhibited syncytium formation. v-ras transformed NIH3T3 cells were highly susceptible to A-MuLV envelope-induced cell-cell fusion, whereas expression of a dominant-negative mutant of Ras (N17Ras) inhibited this cell fusion process. Importantly, activation of Raf-1 protein kinase also is required for A-MuLV envelope-induced syncytium formation. Expression of constitutively active BXB Raf supported, whereas expression of a dominant-negative mutant of Raf-1 (Raf301) blocked, A-MuLV-induced cell-cell fusion. These results indicate that specific cell signaling components are involved in regulating PiT2-mediated A-MuLV-induced cell-cell fusion. Selective pharmacological modulation of these signaling components may be an effective means of altering cell susceptibility to viral-mediated cytopathic effects.	NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA; NIMH, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Anderson, WB (corresponding author), NCI, Cellular Oncol Lab, NIH, Bldg 37,Rm 4124,37 Convent Dr, Bethesda, MD 20892 USA.	andersow@mail.nih.gov			NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002592, Z01MH002592] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANDERSON WB, 1985, ADV CYCLIC NUCL PROT, V19, P287; Bell R M, 1986, Symp Fundam Cancer Res, V39, P145; Blond JL, 1999, J VIROL, V73, P1175, DOI 10.1128/JVI.73.2.1175-1185.1999; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BURGER KNJ, 1990, EXPERIENTIA, V46, P631, DOI 10.1007/BF01939702; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Chien ML, 1998, VIROLOGY, V240, P109, DOI 10.1006/viro.1997.8933; Chien ML, 1997, J VIROL, V71, P4564, DOI 10.1128/JVI.71.6.4564-4570.1997; COFFIN JMF, 1996, FIELDS VIROLOGY, V2; Cole SW, 1999, J IMMUNOL, V162, P1392; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Cristillo AD, 2002, FASEB J, V16, DOI 10.1096/fj.01-0744com; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Farrell KB, 2002, J VIROL, V76, P4267, DOI 10.1128/JVI.76.9.4267-4274.2002; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Forestell SP, 1997, GENE THER, V4, P600, DOI 10.1038/sj.gt.3300420; Frendo JL, 2003, MOL CELL BIOL, V23, P3566, DOI 10.1128/MCB.23.10.3566-3574.2003; Fu MF, 2004, J BIOL CHEM, V279, P29436, DOI 10.1074/jbc.M313466200; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hong DH, 1999, AM J PHYSIOL-GASTR L, V277, pG1041, DOI 10.1152/ajpgi.1999.277.5.G1041; Jobbagy Z, 1999, J BIOL CHEM, V274, P7067, DOI 10.1074/jbc.274.11.7067; Jobbagy Z, 2000, J VIROL, V74, P2847, DOI 10.1128/JVI.74.6.2847-2854.2000; JONES JS, 1993, J VIROL, V67, P67, DOI 10.1128/JVI.67.1.67-74.1993; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; Keryer G, 1998, J CELL SCI, V111, P995; Lee M, 2003, BIOCHEM BIOPH RES CO, V311, P1026, DOI 10.1016/j.bbrc.2003.10.107; LEHEL C, 1994, J BIOL CHEM, V269, P4761; Lu XB, 2000, VIROLOGY, V276, P251, DOI 10.1006/viro.2000.0555; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; MILLER DG, 1993, J VIROL, V67, P5346, DOI 10.1128/JVI.67.9.5346-5352.1993; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOHAGHEGHPOUR N, 1991, J BIOL CHEM, V266, P7233; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; OCHO M, 1980, EXP CELL BIOL, V48, P421; OLAH Z, 1995, BIOCHEM BIOPH RES CO, V214, P340, DOI 10.1006/bbrc.1995.2293; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; OLAH Z, 1993, BIOCHIM BIOPHYS ACTA, V1176, P333, DOI 10.1016/0167-4889(93)90063-U; Overbaugh J, 2001, MICROBIOL MOL BIOL R, V65, P371, DOI 10.1128/MMBR.65.3.371-389.2001; Pastan I, 1974, Adv Cancer Res, V19, P303, DOI 10.1016/S0065-230X(08)60057-3; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PINTER A, 1979, J VIROL, V30, P157, DOI 10.1128/JVI.30.1.157-165.1979; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAGHEB JA, 1994, J VIROL, V68, P3220, DOI 10.1128/JVI.68.5.3220-3231.1994; REIN A, 1994, J VIROL, V68, P1773, DOI 10.1128/JVI.68.3.1773-1781.1994; Rodrigues P, 1999, J VIROL, V73, P3789, DOI 10.1128/JVI.73.5.3789-3799.1999; Root CN, 2000, J GEN VIROL, V81, P2697, DOI 10.1099/0022-1317-81-11-2697; Salaun C, 2002, J VIROL, V76, P4304, DOI 10.1128/JVI.76.9.4304-4311.2002; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Tsurudome M, 2000, CRIT REV IMMUNOL, V20, P167; VANZEIJL M, 1994, P NATL ACAD SCI USA, V91, P1168, DOI 10.1073/pnas.91.3.1168; WILSON CA, 1992, J VIROL, V66, P7262, DOI 10.1128/JVI.66.12.7262-7269.1992	56	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16772	16783		10.1074/jbc.M411537200	http://dx.doi.org/10.1074/jbc.M411537200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15741175	hybrid			2022-12-25	WOS:000228615500029
J	Siligan, C; Ban, J; Bachmaier, R; Spahn, L; Kreppel, M; Schaefer, KL; Poremba, C; Aryee, DNT; Kovar, H				Siligan, C; Ban, J; Bachmaier, R; Spahn, L; Kreppel, M; Schaefer, KL; Poremba, C; Aryee, DNT; Kovar, H			EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin	ONCOGENE			English	Article						chromatin immunoprecipitation; Ewing's sarcoma; EWS-FLI1; MAP kinase phosphatase; RNA interference	FUSION PROTEINS; UP-REGULATION; TRANSCRIPTIONAL ACTIVATION; PROGNOSTIC IMPACT; DNA-BINDING; CELL-LINES; EWS/FLI-1; DIFFERENTIATION; ONCOPROTEINS; EXPRESSION	In all, 85% of Ewing's sarcoma family tumors (ESFT), a neoplasm of unknown histogenesis, express EWS-FLI1 transcription factor gene fusions. To characterize direct target genes avoiding artificial model systems, we cloned genomic DNA from ESFT chromatin precipitating with EWS-FLI1. We now present a comprehensive list of 99 putative transcription factor targets identified, for the first time, by a hypothesis-free approach based on physical interaction. Gene-derived chromatin fragments co-precipitating with EWS-FLI1 were nonrandomly distributed over the human genome and localized predominantly to the upstream region and the first two introns of the genes. At least 20% of putative direct EWS-FLI1 targets were neural genes. One-third of genes recovered showed a significant ESFT-specific expression pattern and were found to be altered upon RNAi-mediated knockdown of EWS-FLI1. Among them, MK-STYX, encoding a MAP kinase phosphatase-like protein, was consistently expressed in ESFT. EWS-FLI1 was found to drive MK-STYX expression by binding to a single ETS binding motif within the first gene intron. MK-STYX serves as precedence for successful recovery of direct EWS-FLI1 targets from the authentic ESFT cellular context, the most relevant system to study oncogenic mechanisms for the discovery of new therapeutic targets in this disease.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Univ Dusseldorf, Inst Pathol, D-40225 Dusseldorf, Germany	Saint Anna Children's Hospital; Heinrich Heine University Dusseldorf	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.	heinrich.kovar@ccri.univie.ac.at		Kovar, Heinrich/0000-0001-6873-9109				Arvand A, 2001, CANCER RES, V61, P5311; Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chansky HA, 2001, CANCER RES, V61, P3586; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; Delva L, 2004, ONCOGENE, V23, P4389, DOI 10.1038/sj.onc.1207578; Deneen B, 2003, CANCER RES, V63, P4268; Deneen B, 2003, MOL CELL BIOL, V23, P3897, DOI 10.1128/MCB.23.11.3897-3908.2003; Deneen B, 2001, ONCOGENE, V20, P6731, DOI 10.1038/sj.onc.1204875; Dohjima T, 2003, MOL THER, V7, P811, DOI 10.1016/S1525-0016(03)00101-1; Eliazer S, 2003, MOL CELL BIOL, V23, P482, DOI 10.1128/MCB.23.2.482-492.2003; Fuchs B, 2004, CLIN CANCER RES, V10, P1344, DOI 10.1158/1078-0432.CCR-03-0038; Fuchs B, 2003, FEBS LETT, V553, P104, DOI 10.1016/S0014-5793(03)00984-0; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hattinger CM, 2002, BRIT J CANCER, V86, P1763, DOI 10.1038/sj.bjc.6600332; Hattinger CM, 1999, GENE CHROMOSOME CANC, V24, P243, DOI 10.1002/(SICI)1098-2264(199903)24:3<243::AID-GCC10>3.0.CO;2-A; Im YH, 2000, CANCER RES, V60, P1536; Kovar H, 2001, CANCER RES, V61, P5992; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; LESSNICK SL, 1995, ONCOGENE, V10, P423; Matsui Y, 2003, J BIOL CHEM, V278, P11369, DOI 10.1074/jbc.M300164200; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; Ohkura N, 2002, J BIOL CHEM, V277, P535, DOI 10.1074/jbc.M109018200; OHNO T, 1993, CANCER RES, V53, P5859; Rorie CJ, 2004, CANCER RES, V64, P1266, DOI 10.1158/0008-5472.CAN-03-3274; Schaefer KL, 2004, CANCER RES, V64, P3395, DOI 10.1158/0008-5472.CAN-03-0809; Spahn L, 2002, CANCER RES, V62, P4583; Staal A, 1996, MOL ENDOCRINOL, V10, P1444, DOI 10.1210/me.10.11.1444; Takahashi A, 2003, CANCER RES, V63, P8338; Teitell MA, 1999, LAB INVEST, V79, P1535; Thompson AD, 1996, ONCOGENE, V13, P2649; Torchia EC, 2003, CANCER RES, V63, P3464; Watanabe G, 2003, GENE CHROMOSOME CANC, V36, P224, DOI 10.1002/gcc.10153; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wishart MJ, 1998, TRENDS BIOCHEM SCI, V23, P301, DOI 10.1016/S0968-0004(98)01241-9; Wishart MJ, 2002, P NATL ACAD SCI USA, V99, P2112, DOI 10.1073/pnas.251686198; Zwerner JP, 2003, EXP CELL RES, V290, P414, DOI 10.1016/S0014-4827(03)00371-9	47	59	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2512	2524		10.1038/sj.onc.1208455	http://dx.doi.org/10.1038/sj.onc.1208455			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735734				2022-12-25	WOS:000228180600009
J	Xue, L; Firestone, GL; Bjeldanes, LF				Xue, L; Firestone, GL; Bjeldanes, LF			DIM stimulates IFN gamma gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways	ONCOGENE			English	Article						IFN gamma; JNK; p38; transcriptional regulation; breast cancer cells	PROTEIN-KINASE-C; TRANSCRIPTION FACTOR INTERACTIONS; INTERFERON-GAMMA; BINDING-PROTEIN; TUMOR-CELLS; T-CELLS; 3,3'-DIINDOLYLMETHANE DIM; ESTROGEN-RECEPTOR; MESSENGER-RNA; IN-VITRO	3,3'-Diindolylmethane (DIM) is a promising anticancer agent derived from Brassica vegetables, but the mechanisms of DIM action are largely unknown. We have shown that DIM can upregulate the expression and stimulate the secretion of interferon-gamma (IFN gamma) in the human MCF-7 breast cancer cell line. This novel effect may provide important clues to explain the anticancer effects of DIM because it is well known that IFNy plays an important role in preventing the development of primary and transplanted tumors. Utilizing promoter deletions, we show here that the region between -108 and -36bp in the IFN gamma promoter, which contains two conserved and essential regulatory elements, is required for DIM-induced IFN gamma expression. DIM activates both JNK and p38 pathways, induces the phosphorylation of c-Jun and ATF-2, and increases the binding of the homodimer or heterodimer of c-Jun/ATF-2 to the proximal AP-1 (.) CREB-ATF-binding element. Moreover, studies with specific enzyme inhibitors showed that up-stream Ca2+-dependent kinase(s) is required for the inducing effects of DIM in MCF-7 cells. These results establish that DIM-induced IFN gamma expression in human breast tumor cells is mediated by activation of both JNK and p38 pathways, which is ultimately dependent on intracellular calcium signaling.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Bjeldanes, LF (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, 119 Morgan Hall, Berkeley, CA 94720 USA.	lfb@nature.berkeley.edu			NCI NIH HHS [CA102360, CA69056, R01 CA102360-01A1, R01 CA102360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102360, R01CA069056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; Auborn KJ, 2002, ANTIVIR THER, V7, P1; Awasthi N, 2004, INVEST OPHTH VIS SCI, V45, P222, DOI 10.1167/iovs.03-0571; BENJAMIN D, 1986, AM J HEMATOL, V22, P169, DOI 10.1002/ajh.2830220207; Burchert A, 2004, BLOOD, V103, P3480, DOI 10.1182/blood-2003-08-2970; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Chen I, 1998, CARCINOGENESIS, V19, P1631, DOI 10.1093/carcin/19.9.1631; CHRIVIA JC, 1990, J EXP MED, V172, P661, DOI 10.1084/jem.172.2.661; CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Cram EJ, 2001, J BIOL CHEM, V276, P22332, DOI 10.1074/jbc.M010539200; Csiszar A, 2000, CLIN EXP IMMUNOL, V122, P464, DOI 10.1046/j.1365-2249.2000.01369.x; Cui XJ, 2003, MOL ENDOCRINOL, V17, P575, DOI 10.1210/me.2002-0318; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; DIMARZIO P, 1994, J EXP MED, V179, P1731, DOI 10.1084/jem.179.5.1731; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Firestone GL, 2003, J NUTR, V133, p2448S, DOI 10.1093/jn/133.7.2448S; Garcia-Fernandez MO, 2003, BREAST CANCER RES TR, V77, P15, DOI 10.1023/A:1021196504944; Ge XK, 1996, BIOCHEM BIOPH RES CO, V228, P153, DOI 10.1006/bbrc.1996.1631; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GRUBBS CJ, 1995, ANTICANCER RES, V15, P709; Hong C, 2002, BIOCHEM PHARMACOL, V63, P1085, DOI 10.1016/S0006-2952(02)00856-0; Hong CB, 2002, CARCINOGENESIS, V23, P1297, DOI 10.1093/carcin/23.8.1297; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KASAHARA T, 1983, J IMMUNOL, V130, P1784; KASAHARA T, 1983, J IMMUNOL, V131, P2379; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; Kiang JG, 1999, MOL CELL BIOCHEM, V199, P179, DOI 10.1023/A:1006946329581; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; Lazennec G, 2001, J STEROID BIOCHEM, V77, P193, DOI 10.1016/S0960-0760(01)00060-7; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; Mueller H, 1997, BIOL CHEM, V378, P1023, DOI 10.1515/bchm.1997.378.9.1023; Nachshon-Kedmi M, 2004, BRIT J CANCER, V91, P1358, DOI 10.1038/sj.bjc.6602145; Nachshon-Kedmi M, 2003, FOOD CHEM TOXICOL, V41, P745, DOI 10.1016/S0278-6915(03)00004-8; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Ogretmen B, 1996, INT J CANCER, V67, P608, DOI 10.1002/(SICI)1097-0215(19960904)67:5<608::AID-IJC3>3.0.CO;2-Y; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; PANG YB, 1992, BLOOD, V80, P724; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; Penix LA, 1996, J BIOL CHEM, V271, P31964, DOI 10.1074/jbc.271.50.31964; RADY PL, 1995, CYTOKINE, V7, P793, DOI 10.1006/cyto.1995.0095; Riby JE, 2000, BIOCHEM PHARMACOL, V60, P167, DOI 10.1016/S0006-2952(00)00307-5; Rosfjord EC, 1999, EXP CELL RES, V248, P260, DOI 10.1006/excr.1998.4390; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Sun SS, 2004, CELL STRESS CHAPERON, V9, P76; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WATTENBERG LW, 1978, CANCER RES, V38, P1410; Wiatrak Brian J, 2003, Curr Opin Otolaryngol Head Neck Surg, V11, P433, DOI 10.1097/00020840-200312000-00005; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Yin F, 2004, ONCOGENE, V23, P4614, DOI 10.1038/sj.onc.1207598; Young HA, 1997, PROG NUCLEIC ACID RE, V56, P109, DOI 10.1016/S0079-6603(08)61004-1	59	60	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 31	2005	24	14					2343	2353		10.1038/sj.onc.1208434	http://dx.doi.org/10.1038/sj.onc.1208434			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735741				2022-12-25	WOS:000227877400007
J	Johansson, FK; Goransson, H; Westermark, B				Johansson, FK; Goransson, H; Westermark, B			Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice	ONCOGENE			English	Article						glioma; PDGF; Sox10; tumor progression; retroviral insertional mutagenesis	PDGF ALPHA-RECEPTOR; GROWTH-FACTOR; HUMAN GLIOMAS; AUTOCRINE STIMULATION; MALIGNANT PROGRESSION; MESSENGER-RNA; IN-VIVO; MICROARRAY; IDENTIFICATION; INVASION	Retroviral tagging previously identified putative cancer-causing genes in a mouse brain tumor model where a recombinant Moloney murine leukemia virus encoding the platelet-derived growth factor B-chain (MMLV/PDGFB) was intracerebrally injected in newborn mice. In the present study, expression analysis using cDNA arrays revealed several similarities of virus-induced mouse gliomas with human brain tumors. Brain tumors with short latency contained on average 8.0 retroviral insertions and resembled human glioblastoma multiforme (GBM) whereas long-latency gliomas were of lower grade, similar to human oligodendrogliomia (OD) and had 2.3 insertions per tumor. Several known and novel genes of tumor progression or cell markers were differentially expressed between OD- and GBM-like tumors. Array and quantitative real-time PCR analysis demonstrated elevated expression similar to Pdgfr alpha of retrovirally tagged genes Abhd2, Ddr1, Fos, Ng2, Ppfibp1, Rad51b and Sulf2 in both glioma types compared to neonatal and adult normal brain. The retrovirally tagged genes Plekhb1, Prex1, Prkg2, Sox10 and 1200004M23Rik were upregulated in the tumors but had a different expression profile than Pdgfr alpha whereas Rap1gap, GO, Neurl and Camk2b were downregulated in the tumors. The present study accentuates the proposed role of the retrovirally tagged genes in PDGF-driven gliomagenesis and indicates that insertional mutagenesis can promote glioma progression.	Univ Uppsala Hosp, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden	Uppsala University; Uppsala University Hospital	Westermark, B (corresponding author), Univ Uppsala Hosp, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden.	bengt.westermark@genpat.uu.se	Swartling, Fredrik J/B-8170-2014	Swartling, Fredrik J/0000-0002-8460-4367; Westermark, Bengt/0000-0001-7153-5545				Biglari A, 2004, CANCER GENE THER, V11, P721, DOI 10.1038/sj.cgt.7700783; Chekenya M, 1999, INT J DEV NEUROSCI, V17, P421, DOI 10.1016/S0736-5748(99)00019-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Deng YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; FUJIMOTO M, 1988, NEUROLOGY, V38, P289, DOI 10.1212/WNL.38.2.289; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; HERMANSON M, 1992, CANCER RES, V52, P3213; Hesselager G, 2003, CANCER RES, V63, P4305; Huang HT, 2000, CANCER RES, V60, P6868; Johansson FK, 2004, P NATL ACAD SCI USA, V101, P11334, DOI 10.1073/pnas.0402716101; Kargul GJ, 2001, NAT GENET, V28, P17, DOI 10.1038/ng0501-17; Konduri SD, 2002, ONCOGENE, V21, P8705, DOI 10.1038/sj.onc.1205949; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lafuente JV, 2000, NEUROPATHOLOGY, V20, P176, DOI 10.1046/j.1440-1789.2000.00329.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lonnstedt I, 2002, STAT SINICA, V12, P31; Nakamura H, 1998, ONCOGENE, V16, P1009, DOI 10.1038/sj.onc.1201618; Nishiyama A, 1996, J NEUROSCI RES, V43, P315, DOI 10.1002/(SICI)1097-4547(19960201)43:3<315::AID-JNR6>3.3.CO;2-3; NISTER M, 1988, CANCER RES, V48, P3910; Ohnishi T, 1998, CLIN EXP METASTAS, V16, P729, DOI 10.1023/A:1006532812408; Popko B, 2002, J NEUROPATH EXP NEUR, V61, P329, DOI 10.1093/jnen/61.4.329; PRINGLE NP, 1993, DEVELOPMENT, V117, P525; Rajaraman R, 1978, Ann N Y Acad Sci, V312, P444, DOI 10.1111/j.1749-6632.1978.tb16832.x; Rickman DS, 2001, CANCER RES, V61, P6885; Rorive S, 2001, GLIA, V33, P241, DOI 10.1002/1098-1136(200103)33:3<241::AID-GLIA1023>3.0.CO;2-1; Saal LH, 2002, GENOME BIOL, V3; Sallinen SL, 2000, CANCER RES, V60, P6617; Schultz C, 2002, CANCER RES, V62, P6270; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; Tombes RM, 1999, BBA-MOL CELL RES, V1452, P1, DOI 10.1016/S0167-4889(99)00113-5; Uhrbom L, 1998, CANCER RES, V58, P5275; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; Yamaoka K, 2000, J NEUROSCI RES, V59, P722, DOI 10.1002/(SICI)1097-4547(20000315)59:6<722::AID-JNR4>3.0.CO;2-H; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	40	59	59	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3896	3905		10.1038/sj.onc.1208553	http://dx.doi.org/10.1038/sj.onc.1208553			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15750623				2022-12-25	WOS:000229435300005
J	McCullough, LD; Zeng, ZY; Li, H; Landree, LE; McFadden, J; Ronnett, GV				McCullough, LD; Zeng, ZY; Li, H; Landree, LE; McFadden, J; Ronnett, GV			Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SYNTHASE INHIBITOR; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE; CELL-DEATH; GLUCOSE-TRANSPORT; NEURONAL-ACTIVITY; GENE-EXPRESSION; AICA RIBOSIDE; FOOD-INTAKE; APOPTOSIS	The restoration of energy balance during ischemia is critical to cellular survival; however, relatively little is known concerning the regulation of neuronal metabolic pathways in response to central nervous system ischemia. AMP-activated protein kinase ( AMPK), a master sensor of energy balance in peripheral tissues, is phosphorylated and activated when energy balance is low. We investigated whether AMPK might also modulate neuronal energy homeostasis during ischemia. We utilized two model systems of ischemia, middle cerebral artery occlusion in vivo and oxygen-glucose deprivation in vitro, to delineate changes in AMPK activity incurred from a metabolic stress. AMPK is highly expressed in cortical and hippocampal neurons under both normal and ischemic conditions. AMPK activity, as assessed by phosphorylation status, is increased following both middle cerebral artery occlusion and oxygen-glucose deprivation. Pharmacological inhibition of AMPK by either C75, a known modulator of neuronal ATP levels, or compound C reduced stroke damage. In contrast, activation of AMPK by 5-aminoimidazole-4-carboxamide ribonucleoside exacerbated damage. Mice deficient in neuronal nitric-oxide synthase demonstrated a decrease in both stroke damage and AMPK activation compared with wild type, suggesting a possible interaction between NO and AMPK activation in stroke. These data demonstrate a role for AMPK in the response of neurons during metabolic stress and suggest that in ischemia the activation of AMPK is deleterious. The ability to manipulate pharmacologically neuronal energy balance during ischemia represents an innovative approach to neuroprotection.	Univ Connecticut, Ctr Hlth, Dept Neurol & Neurosci, Farmington, CT 06030 USA; FASgen Inc, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA	University of Connecticut; Johns Hopkins University; Johns Hopkins University	McCullough, LD (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurol & Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA.	lmcculllough@uchc.edu; gronnett@jhmi.edu	McCullough, Louise/R-2824-2019					Almeida A, 2001, P NATL ACAD SCI USA, V98, P15294, DOI 10.1073/pnas.261560998; Almeida A, 2004, NAT CELL BIOL, V6, P45, DOI 10.1038/ncb1080; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Blazquez C, 2001, FEBS LETT, V489, P149, DOI 10.1016/S0014-5793(01)02089-0; Blazquez C, 1999, J NEUROCHEM, V73, P1674, DOI 10.1046/j.1471-4159.1999.731674.x; Bolanos Juan P., 2004, Molecular Aspects of Medicine, V25, P61, DOI 10.1016/j.mam.2004.02.009; Bouzier-Sore AK, 2002, J PHYSIOL-PARIS, V96, P273, DOI 10.1016/S0928-4257(02)00016-5; Brorson JR, 1999, J NEUROSCI, V19, P147, DOI 10.1523/JNEUROSCI.19-01-00147.1999; Brucklacher RM, 2002, DEV NEUROSCI-BASEL, V24, P411, DOI 10.1159/000069051; Carling D, 2004, CURR BIOL, V14, pR220, DOI 10.1016/j.cub.2004.02.048; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Choi SL, 2001, BIOCHEM BIOPH RES CO, V287, P92, DOI 10.1006/bbrc.2001.5544; CLOUGHHELFMAN C, 1990, BRAIN RES BULL, V25, P203, DOI 10.1016/0361-9230(90)90277-7; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Cox SE, 1997, BIOCHEM SOC T, V25, pS583, DOI 10.1042/bst025s583; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Fryer LGD, 2000, DIABETES, V49, P1978, DOI 10.2337/diabetes.49.12.1978; Gadalla AE, 2004, J NEUROCHEM, V88, P1272, DOI 10.1046/j.1471-4159.2003.02253.x; Gao S, 2003, P NATL ACAD SCI USA, V100, P5628, DOI 10.1073/pnas.1031698100; Garcia-Gil M, 2003, NEUROSCIENCE, V117, P811, DOI 10.1016/S0306-4522(02)00836-9; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Hardie DG, 2002, BIOCHEM SOC T, V30, P1064, DOI 10.1042/BST0301064; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Jung JE, 2004, NEUROSCI LETT, V354, P197, DOI 10.1016/j.neulet.2003.10.012; Kefas BA, 2003, J MOL ENDOCRINOL, V30, P151, DOI 10.1677/jme.0.0300151; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kim EK, 2004, J BIOL CHEM, V279, P19970, DOI 10.1074/jbc.M402165200; Kim MS, 2004, NAT MED, V10, P727, DOI 10.1038/nm1061; KINGMA JG, 1994, CARDIOVASC RES, V28, P1003, DOI 10.1093/cvr/28.7.1003; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kury P, 2004, EUR J NEUROSCI, V19, P1708, DOI 10.1111/j.1460-9568.2004.03226.x; Landree LE, 2004, J BIOL CHEM, V279, P3817, DOI 10.1074/jbc.M310991200; Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200; Leon H, 2004, CAN J PHYSIOL PHARM, V82, P409, DOI 10.1139/Y04-050; Love S, 2003, PROG NEURO-PSYCHOPH, V27, P267, DOI 10.1016/S0278-5846(03)00022-8; Luo HR, 2003, P NATL ACAD SCI USA, V100, P11712, DOI 10.1073/pnas.1634990100; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Marsin AS, 2002, J BIOL CHEM, V277, P30778, DOI 10.1074/jbc.M205213200; McCullough L, 2004, J NEUROSCI, V24, P257, DOI 10.1523/JNEUROSCI.4485-03.2004; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; McCullough LD, 2005, J CEREBR BLOOD F MET, V25, P502, DOI 10.1038/sj.jcbfm.9600059; Meisse D, 2002, FEBS LETT, V526, P38, DOI 10.1016/S0014-5793(02)03110-1; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Morrow VA, 2003, J BIOL CHEM, V278, P31629, DOI 10.1074/jbc.M212831200; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Nicotera P, 1998, TOXICOL LETT, V103, P139; OBRIEN MD, 1974, ARCH NEUROL-CHICAGO, V30, P456, DOI 10.1001/archneur.1974.00490360032007; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Snider BJ, 1999, ANN NY ACAD SCI, V893, P243, DOI 10.1111/j.1749-6632.1999.tb07829.x; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1996, BRAIN RES BULL, V41, P131, DOI 10.1016/S0361-9230(96)00159-1; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Toung TJK, 2002, CRIT CARE MED, V30, P644, DOI 10.1097/00003246-200203000-00025; Turnley AM, 1999, J NEUROCHEM, V72, P1707, DOI 10.1046/j.1471-4159.1999.721707.x; Virag L, 2003, TOXICOL LETT, V140, P113, DOI 10.1016/S0378-4274(02)00508-8; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; WOJTASZEWSKI JF, 2003, AM J PHYSIOL, V284, pC813; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 2003, J BIOL CHEM, V278, P28434, DOI 10.1074/jbc.M303946200; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE622, DOI 10.1152/ajpendo.2000.279.3.E622; Zou MH, 2004, J BIOL CHEM, V279, P43940, DOI 10.1074/jbc.M404421200; Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442; Zou MH, 2002, J BIOL CHEM, V277, P32552, DOI 10.1074/jbc.M204512200	81	285	306	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20493	20502		10.1074/jbc.M409985200	http://dx.doi.org/10.1074/jbc.M409985200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15772080	hybrid			2022-12-25	WOS:000229242000042
J	Spolitak, T; Dawson, JH; Ballou, DP				Spolitak, T; Dawson, JH; Ballou, DP			Reaction of ferric cytochrome P450cam with peracids - Kinetic characterization of intermediates on the reaction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; COMPOUND-I FORMATION; TYROSYL RADICAL FORMATION; C PEROXIDASE; HORSERADISH-PEROXIDASE; MYCOBACTERIUM-TUBERCULOSIS; CATALASE-PEROXIDASE; HYDROGEN-PEROXIDE; WILD-TYPE; MULTIFREQUENCY EPR	Reactions of substrate-free ferric cytochrome P450cam with peracids to generate Fe = O intermediates have previously been investigated with contradictory results. Using stopped-flow spectrophotometry, the reaction with m-chloroperoxybenzoic acid demonstrated an Fe-IV = O + porphyrin pi-cation radical (Cpd I) (Egawa, T., Shimada, H., and Ishimura, Y. ( 1994) Biochem. Biophys. Res. Commun. 201, 1464-1469). By contrast, with peracetic acid, Fe-IV = O plus a tyrosyl radical were observed by freeze-quench Mossbauer and EPR spectroscopy (Schunemann, V., Jung, C., Trautwein, A. X., Mandon, D., and Weiss, R. ( 2000) FEBS Lett. 479, 149-154). Our detailed kinetic studies have resolved these contradictory results. At pH > 7, a significant fraction of Cpd I is formed transiently, whereas at low pH only a species with a Soret band at 406 nm, presumably Fe-IV = O + tyrosyl radical, is observed. Evidence for formation of an acylperoxo complex en route to Cpd I was obtained. Because of rapid heme destruction, steps subsequent to formation of the highly oxidized forms could not be fully characterized. Heme destruction was avoided by including peroxidase substrates ( e. g. guaiacol), which were oxidized to characteristic peroxidase products as the Fe-III-P450 was regenerated. Addition of ascorbate to either of the high valent species also reforms the FeIII state with only a small loss of heme absorbance. These results indicate that typical peroxidase chemistry occurs with P450cam and offer an explanation for the contrasting results reported earlier. The delineation of improved conditions (pH, temperature, choice of peracid) for generating highly oxidized species with P450cam should be valuable for their further characterization.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Univ S Carolina, Sch Med, Columbia, SC 29208 USA	University of Michigan System; University of Michigan; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Dawson, JH (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.	dawson@sc.edu	dballou@umich.edu, David P/A-1298-2007; Dawson, John/HDM-6702-2022	Dawson, John H/0000-0002-4902-4295	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026730, R37GM020877, R01GM020877] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26730, GM20877] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENECKY MJ, 1993, BIOCHEMISTRY-US, V32, P11929, DOI 10.1021/bi00095a024; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; Bonagura CA, 2003, BIOCHEMISTRY-US, V42, P5600, DOI 10.1021/bi034058c; BRUICE TC, 1983, J CHEM SOC CHEM COMM, P14, DOI 10.1039/c39830000014; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; COTTON ML, 1973, CAN J BIOCHEM CELL B, V51, P627, DOI 10.1139/o73-078; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; Dorlet P, 2002, BIOCHEMISTRY-US, V41, P6107, DOI 10.1021/bi015871f; Dunford H. B., 1999, HEME PEROXIDASES; EGAWA T, 1991, J BIOL CHEM, V266, P10246; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; Erman JE, 2002, BBA-PROTEIN STRUCT M, V1597, P193, DOI 10.1016/S0167-4838(02)00317-5; FISHEL LA, 1991, BIOCHEMISTRY-US, V30, P1986, DOI 10.1021/bi00221a036; Goodin DB, 1996, J BIOL INORG CHEM, V1, P360, DOI 10.1007/s007750050065; Green MT, 2004, SCIENCE, V304, P1653, DOI 10.1126/science.1096897; Groves JT, 2003, P NATL ACAD SCI USA, V100, P3569, DOI 10.1073/pnas.0830019100; GROVES JT, 1988, J AM CHEM SOC, V110, P8443, DOI 10.1021/ja00233a021; Gunther MR, 2000, FREE RADICAL BIO MED, V28, P709, DOI 10.1016/S0891-5849(00)00164-7; Harris D, 2001, J INORG BIOCHEM, V83, P309, DOI 10.1016/S0162-0134(00)00177-X; Hersleth HP, 2002, J BIOL INORG CHEM, V7, P299, DOI 10.1007/s007750100296; HORI H, 1985, J BIOL CHEM, V260, P349; HOUSEMAN ALP, 1993, BIOCHEMISTRY-US, V32, P4430, DOI 10.1021/bi00067a036; HUYETT JE, 1995, J AM CHEM SOC, V117, P9033, DOI 10.1021/ja00140a021; Isaac IS, 1999, ESSAYS BIOCHEM, V34, P51, DOI 10.1042/bse0340051; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Ivancich A, 2003, J AM CHEM SOC, V125, P14093, DOI 10.1021/ja035582+; Ivancich A, 1997, BIOCHEMISTRY-US, V36, P9356, DOI 10.1021/bi970886s; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; Kellner DG, 2002, J BIOL CHEM, V277, P9641, DOI 10.1074/jbc.C100745200; LANG G, 1976, BIOCHIM BIOPHYS ACTA, V451, P250, DOI 10.1016/0304-4165(76)90275-0; Liu A, 1998, BIOCHEMISTRY-US, V37, P16369, DOI 10.1021/bi981471p; MILLER VP, 1995, J BIOL CHEM, V270, P18413, DOI 10.1074/jbc.270.31.18413; Palamakumbura AH, 1999, BIOCHEMISTRY-US, V38, P15647, DOI 10.1021/bi991497w; PALCIC MM, 1980, BIOCHEM BIOPH RES CO, V94, P1123, DOI 10.1016/0006-291X(80)90535-5; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4342, DOI 10.1021/bi00013a024; Pfister TD, 2001, BIOCHEMISTRY-US, V40, P14942, DOI 10.1021/bi011400h; Pond AE, 1998, INORG CHIM ACTA, V276, P250; Prasad S, 2004, BIOCHEM BIOPH RES CO, V314, P610, DOI 10.1016/j.bbrc.2003.12.141; Rodriguez-Lopez JN, 2000, BIOCHEMISTRY-US, V39, P13201, DOI 10.1021/bi001150p; RodriguezLopez JN, 1997, J BIOL CHEM, V272, P5469, DOI 10.1074/jbc.272.9.5469; ROE JA, 1993, J BIOL CHEM, V268, P20037; SCHULZ CE, 1984, BIOCHEMISTRY-US, V23, P4743, DOI 10.1021/bi00315a033; Schunemann V, 2002, J INORG BIOCHEM, V91, P586, DOI 10.1016/S0162-0134(02)00476-2; Schunemann V, 2000, FEBS LETT, V479, P149, DOI 10.1016/S0014-5793(00)01886-X; Schunemann V, 2004, J BIOL CHEM, V279, P10919, DOI 10.1074/jbc.M307884200; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SLIGAR SG, 1999, ESSAYS BIOCHEM, P71; SLIGAR SG, 1977, MICROSOMES DRUG OXID; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; Tsaprailis G., 1995, ADV INORG CHEM, V43, P79; vanDeurzen MPJ, 1997, TETRAHEDRON, V53, P13183, DOI 10.1016/S0040-4020(97)00477-8; VITELLO LB, 1990, BIOCHIM BIOPHYS ACTA, V1038, P90, DOI 10.1016/0167-4838(90)90015-8; WAGNER GC, 1983, FEBS LETT, V156, P244, DOI 10.1016/0014-5793(83)80505-5; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; Zhao XB, 2004, J BIOL CHEM, V279, P7606, DOI 10.1074/jbc.M311884200	60	106	106	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20300	20309		10.1074/jbc.M501761200	http://dx.doi.org/10.1074/jbc.M501761200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781454	hybrid			2022-12-25	WOS:000229242000019
J	Kaplan-Albuquerque, N; Bogaert, YE; Van Putten, V; Weiser-Evans, MC; Nemenoff, RA				Kaplan-Albuquerque, N; Bogaert, YE; Van Putten, V; Weiser-Evans, MC; Nemenoff, RA			Patterns of gene expression differentially regulated by platelet-derived growth factor and hypertrophic stimuli in vascular smooth muscle cells - Markers for phenotypic modulation and response to injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE-VASOPRESSIN; ALPHA-ACTIN; EXTRACELLULAR-MATRIX; ANGIOTENSIN-II; PROTEOGLYCANS; LOCALIZATION; MECHANISM; COLLAGEN; UNIQUE; PDGF	In vascular smooth muscle cells (VSMC), platelet-derived growth factor ( PDGF) suppresses expression of multiple smooth muscle contractile proteins, useful markers of differentiation. Conversely, hypertrophic agents induce expression of these genes. The goal of this study was to employ genomic approaches to identify classes of genes differentially regulated by PDGF and hypertrophic stimuli. Changes in gene expression were determined using Affymetrix RAE-230 GeneChips in rat aortic VSMC stimulated with PDGF. For comparison with a model hypertrophic stimulus, a microarray was performed with VSMC stably expressing constitutively active G alpha(16), which strongly induces smooth muscle marker expression. We identified 75 genes whose expression was increased by exposure to PDGF and decreased by expression of G alpha(16) and 97 genes whose expression was decreased by PDGF and increased by G alpha(16). These genes included many smooth muscle-specific proteins; several extracellular matrix, cytoskeletal, and chemotaxis-related proteins; cell signaling molecules; and transcription factors. Changes in gene expression for many of these were confirmed by PCR or immuno-blotting. The contribution of signaling pathways activated by PDGF to the gene expression profile was examined in VSMC stably expressing gain-of-function H-Ras or myristoylated Akt. Among the genes that were confirmed to be differentially regulated were CCAAT/enhancer-binding protein delta, versican, and nexilin. All of these genes also had altered expression in injured aortas, consistent with a role for PDGF in the response of injured VSMC. These data indicate that genes that are differentially regulated by PDGF and hypertrophic stimuli may represent families of genes and potentially be biomarkers for vascular injury.	Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nemenoff, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Med, 4200 E 9th Ave,Box C-281, Denver, CO 80262 USA.	Raphael.Nemenoff@UCHSC.edu			NCI NIH HHS [CA103618] Funding Source: Medline; NIDDK NIH HHS [DK 19928] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA103618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams LD, 2000, CIRC RES, V87, P623, DOI 10.1161/01.RES.87.7.623; Akai J, 2002, MECH DEVELOP, V119, pS191, DOI 10.1016/S0925-4773(03)00115-1; Arai A, 2002, J BIOL CHEM, V277, P24453, DOI 10.1074/jbc.M202216200; Barber RE, 1996, BIOCHEM J, V320, P479, DOI 10.1042/bj3200479; Campos AH, 2003, CIRC RES, V92, P111, DOI 10.1161/01.RES.0000049100.22673.F6; CARAMELO C, 1988, BIOCHEM J, V254, P625, DOI 10.1042/bj2540625; Cen B, 2004, J CELL BIOCHEM, V93, P74, DOI 10.1002/jcb.20199; CHAMLEYCAMPBELL JH, 1981, ATHEROSCLEROSIS, V40, P347, DOI 10.1016/0021-9150(81)90145-3; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Evanko SP, 1999, J HISTOCHEM CYTOCHEM, V47, P1331, DOI 10.1177/002215549904701013; Franco CD, 2002, TRENDS CARDIOVAS MED, V12, P143, DOI 10.1016/S1050-1738(01)00165-7; Garat C, 2000, J BIOL CHEM, V275, P22537, DOI 10.1074/jbc.M003000200; Geary RL, 2002, ARTERIOSCL THROM VAS, V22, P2010, DOI 10.1161/01.ATV.0000038147.93527.35; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GEISTERFER AAT, 1989, HYPERTENSION, V14, P413, DOI 10.1161/01.HYP.14.4.413; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; Grabe Niels, 2002, In Silico Biology, V2, pS1; Han SY, 2002, J BIOL CHEM, V277, P47167, DOI 10.1074/jbc.M204270200; Higashita R, 1997, J BIOL CHEM, V272, P25845, DOI 10.1074/jbc.272.41.25845; Hou GP, 2002, CIRC RES, V90, P1147, DOI 10.1161/01.RES.0000022166.74073.F8; Kaplan-Albuquerque N, 2003, J BIOL CHEM, V278, P39830, DOI 10.1074/jbc.M305991200; Kaplan-Albuquerque N, 2003, AM J PHYSIOL-HEART C, V285, pH1444, DOI 10.1152/ajpheart.00306.2003; Kenagy RD, 2005, J HISTOCHEM CYTOCHEM, V53, P131, DOI 10.1369/jhc.4A6493.2005; KIELTY CM, 1985, BIOCHEM J, V227, P545, DOI 10.1042/bj2270545; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; Lee RT, 2001, J BIOL CHEM, V276, P13847, DOI 10.1074/jbc.M010556200; Li XM, 1997, BIOCHEM J, V327, P709, DOI 10.1042/bj3270709; Liu HW, 2003, AM J RESP CELL MOL, V29, P39, DOI 10.1165/rcmb.2002-0206OC; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Mourani PM, 2004, CIRCULATION, V109, P1299, DOI 10.1161/01.CIR.0000118462.22970.BE; Ohtsuka T, 1998, J CELL BIOL, V143, P1227, DOI 10.1083/jcb.143.5.1227; Owens GK, 1997, AGENT ACTION SUPPL, V48, P3; Owens GK, 1996, J HYPERTENS, V14, pS55; OWENS GK, 1991, ADV EXP MED BIOL, V308, P71; Owens GK, 1998, ACTA PHYSIOL SCAND, V164, P623, DOI 10.1111/j.1365-201X.1998.tb10706.x; OWENS GK, 1995, PHYSIOL REV, V75, P487; Psichari E, 2002, J BIOL CHEM, V277, P29490, DOI 10.1074/jbc.M112368200; Raines EW, 2004, CYTOKINE GROWTH F R, V15, P237, DOI 10.1016/j.cytogfr.2004.03.004; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; Sobue K, 1999, MOL CELL BIOCHEM, V190, P105, DOI 10.1023/A:1006941621170; Sobue K, 1998, HORM RES, V50, P15, DOI 10.1159/000053119; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; VANPUTTEN V, 1994, CIRC RES, V75, P1126, DOI 10.1161/01.RES.75.6.1126; Weissberg P L, 1995, Blood Press Suppl, V2, P68; Wight TN, 2004, CIRC RES, V94, P1158, DOI 10.1161/01.RES.0000126921.29919.51; Yang ZH, 2001, CIRC RES, V89, P503, DOI 10.1161/hh1801.096265	48	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19966	19976		10.1074/jbc.M500917200	http://dx.doi.org/10.1074/jbc.M500917200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774477	hybrid			2022-12-25	WOS:000229113700066
J	Merighi, S; Benini, A; Mirandola, P; Gessi, S; Varani, K; Leung, E; Maclennan, S; Borea, PA				Merighi, S; Benini, A; Mirandola, P; Gessi, S; Varani, K; Leung, E; Maclennan, S; Borea, PA			A(3) adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; PROTEIN-COUPLED RECEPTORS; COLON-CARCINOMA GROWTH; SMOOTH-MUSCLE-CELLS; BIOCHEMICAL-CHARACTERIZATION; PATHWAY; RAF; AKT; EXPRESSION; DIFFERENTIATION	Adenosine exerts its effects through four subtypes of G-protein-coupled receptors: A(1), A(2A), A(2B), and A(3). Stimulation of the human A(3) receptor has been suggested to influence cell death and proliferation. The phosphatidylinositide-3-OH kinase (PI3K)/Akt and the Raf/mitogen-activated protein kinase (MAPK/ERK) kinase (MEK)/mitogen-activated protein kinase (MAPK) pathways have central roles in the regulation of cell survival and proliferation. Due to their importance, the cross-talk between these two pathways has been investigated. Here, we show that the A(3) adenosine receptor agonist Cl-IB-MECA stimulates PI3K-dependent phosphorylation of Akt leading to the reduction of basal levels of ERK1/2 phosphorylation, which in turn inhibits cell proliferation. The response to Cl-IB-MECA was not blocked by A(1), A(2A), or A(2B) receptor antagonists, although it was abolished by A(3) receptor antagonists. Furthermore, the response to Cl-IB-MECA was generated at the cell surface, since the inhibition of A(3) receptor expression, by using small interfering RNA, abolished agonist effects. Using A375 cells, we show that A(3) adenosine receptor stimulation results in PI3K-dependent phosphorylation of Akt, leading to the reduction of basal levels of ERK1/2 phosphorylation, which in turn inhibits cell proliferation.	Univ Ferrara, Dept Clin & Expt Med, Pharmacol Unit, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Nazl Eccellenza Sviluppo Metodol Innovat Stud, I-44100 Ferrara, Italy; Univ Parma, Osped Maggiore, Inst Normal Human Anat, Dept Human Anat Pharmacol & Forens Med, I-43100 Parma, Italy; King Pharmaceut, Cary, NC 27513 USA	University of Ferrara; University of Ferrara; University of Parma; University Hospital of Parma; Pfizer	Borea, PA (corresponding author), Univ Ferrara, Dept Clin & Expt Med, Pharmacol Unit, 17-19 Via Fossato Mortara, I-44100 Ferrara, Italy.	bpa@dns.unife.it	Gessi, Stefania/AAS-3844-2020; Mirandola, Prisco/L-3137-2015	Mirandola, Prisco/0000-0002-5058-3924; Gessi, Stefania/0000-0002-2197-5611; MERIGHI, STEFANIA/0000-0003-0839-6671				Bar-Yehuda S, 2001, NEOPLASIA, V3, P125, DOI 10.1038/sj.neo.7900138; Baraldi PG, 2004, J MED CHEM, V47, P1434, DOI 10.1021/jm0309654; Begum N, 2000, AM J PHYSIOL-CELL PH, V278, pC81, DOI 10.1152/ajpcell.2000.278.1.C81; Brambilla R, 2000, N-S ARCH PHARMACOL, V361, P225, DOI 10.1007/s002109900186; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feoktistov I, 2004, HYPERTENSION, V44, P649, DOI 10.1161/01.HYP.0000144800.21037.a5; Fishman P, 2000, J CELL PHYSIOL, V183, P393, DOI 10.1002/(SICI)1097-4652(200006)183:3<393::AID-JCP12>3.0.CO;2-G; Fishman P, 2004, ONCOGENE, V23, P2465, DOI 10.1038/sj.onc.1207355; Fishman P, 1998, CANCER RES, V58, P3181; Fishman P, 2002, ONCOGENE, V21, P4060, DOI 10.1038/sj.onc.1205531; Fishman P, 2001, EXP CELL RES, V269, P230, DOI 10.1006/excr.2001.5327; Fredholm BB, 2001, BIOCHEM PHARMACOL, V61, P443, DOI 10.1016/S0006-2952(00)00570-0; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Gao ZH, 2001, MOL PHARMACOL, V59, P76, DOI 10.1124/mol.59.1.76; Gessi S, 2004, CLIN CANCER RES, V10, P5895, DOI 10.1158/1078-0432.CCR-1134-03; Guan KL, 2000, J BIOL CHEM, V275, P27354; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Haberberger RV, 2002, J INVEST DERMATOL, V119, P943, DOI 10.1046/j.1523-1747.2002.00182.x; Hammarberg C, 2004, BIOCHEM PHARMACOL, V67, P129, DOI 10.1016/j.bcp.2003.08.031; Hammarberg C, 2003, J NEUROCHEM, V86, P1051, DOI 10.1046/j.1471-4159.2003.01919.x; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; Klotz KN, 1999, N-S ARCH PHARMACOL, V360, P103, DOI 10.1007/s002109900044; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Merighi S, 2003, PHARMACOL THERAPEUT, V100, P31, DOI 10.1016/S0163-7258(03)00084-6; Merighi S, 2003, DRUG DEVELOP RES, V58, P377, DOI 10.1002/ddr.10181; Merighi S, 2003, BIOCHEM PHARMACOL, V66, P739, DOI 10.1016/S0006-2952(03)00400-3; Merighi S, 2002, J INVEST DERMATOL, V119, P923, DOI 10.1046/j.1523-1747.2002.00111.x; Merighi S, 2001, BRIT J PHARMACOL, V134, P1215, DOI 10.1038/sj.bjp.0704352; Mirandola P, 2004, BLOOD, V104, P2418, DOI 10.1182/blood-2004-04-1294; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Ohana G, 2003, BRIT J CANCER, V89, P1552, DOI 10.1038/sj.bjc.6601315; Ohana G, 2001, J CELL PHYSIOL, V186, P19, DOI 10.1002/1097-4652(200101)186:1<19::AID-JCP1011>3.0.CO;2-3; Ralevic V, 1998, PHARMACOL REV, V50, P413; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Ruiz-Hidalgo MJ, 2002, EXP CELL RES, V274, P178, DOI 10.1006/excr.2001.5464; Schulte G, 2000, MOL PHARMACOL, V58, P477, DOI 10.1124/mol.58.3.477; Schulte G, 2003, CELL SIGNAL, V15, P813, DOI 10.1016/S0898-6568(03)00058-5; Schulte G, 2002, MOL PHARMACOL, V62, P1137, DOI 10.1124/mol.62.5.1137; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Slominski A, 2002, J INVEST DERMATOL, V119, P1449, DOI 10.1046/j.1523-1747.2002.19617.x; Slominski A, 2002, J INVEST DERMATOL, V119, P934, DOI 10.1046/j.1523-1747.2002.00156.x; Varani K, 2000, MOL PHARMACOL, V57, P968; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	52	97	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19516	19526		10.1074/jbc.M413772200	http://dx.doi.org/10.1074/jbc.M413772200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774470	hybrid			2022-12-25	WOS:000229113700013
J	Prabhu, KS; Arner, RJ; Vunta, H; Reddy, CC				Prabhu, KS; Arner, RJ; Vunta, H; Reddy, CC			Up-regulation of human myo-inositol oxygenase by hyperosmotic stress in renal proximal tubular epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDOSE REDUCTASE INHIBITOR; D-GLUCURONATE REDUCTASE; BINDING PROTEIN; PERIPHERAL-NERVE; DIABETIC-RATS; INOSITOL; GENE; TRANSCRIPTION; PURIFICATION; GLUCOSE	myo-Inositol oxygenase (MIOX) catalyzes the oxidative cleavage of myo-inositol (MI) to give D-glucuronic acid, a committed step in MI catabolism. D-Glucuronic acid is further metabolized to xylitol via the glucuronate-xylulose pathway. Although accumulation of polyols such as xylitol and sorbitol is associated with MI depletion in diabetic complications, no causal relationship has been established. Therefore we are examining the role of MIOX in diabetic nephropathy. Here we present evidence that the basis for the depletion of MI in diabetes is likely to be mediated by the increased expression of MIOX, which is induced by sorbitol, mannitol, and xylitol in a porcine renal proximal tubular epithelial cell line, LLC-PK1. To understand the molecular mechanism of regulation of MIOX expression by polyols, we have cloned the human MIOX gene locus of 10 kb containing 5.6 kb of the 5' upstream sequence. Analysis of the 5' upstream sequence led to the identification of an osmotic response element (ORE) in the promoter region, which is present similar to 2 kb upstream of the translation start site. Based on luciferase reporter and electrophoretic mobility shift assays, polyols increased the ORE-dependent expression of MIOX. In addition, we demonstrate that the activity of the promoter is dependent on the binding of the transcription factor, tonicity element-binding protein, or osmotic response element-binding protein, to the ORE site. These results suggest that the expression of MIOX is up-regulated by a positive feedback mechanism where xylitol, one of the products of MI catabolism via the glucuronate-xylulose pathway, induces an overexpression of MIOX.	Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Reddy, CC (corresponding author), Penn State Univ, Dept Vet Sci, 115 William L Henning Bldg, University Pk, PA 16802 USA.	ccr1@psu.edu						Arner RJ, 2001, BIOCHEM J, V360, P313, DOI 10.1042/bj3600313; BertiMattera L, 1996, METABOLISM, V45, P320, DOI 10.1016/S0026-0495(96)90285-1; BHATNAGAR A, 1992, BIOCHEM MED METAB B, V48, P91, DOI 10.1016/0885-4505(92)90055-4; BURG MB, 1995, AM J PHYSIOL, V268, P983; CHARALAMPOUS FC, 1959, J BIOL CHEM, V234, P220; COHEN AM, 1995, DIABETOLOGIA, V38, P899; DELMONTE MA, 1991, DIABETES, V40, P1335, DOI 10.2337/diabetes.40.10.1335; Ferraris JD, 1999, AM J PHYSIOL-CELL PH, V276, pC667, DOI 10.1152/ajpcell.1999.276.3.C667; FINEGOLD D, 1983, DIABETES, V32, P988, DOI 10.2337/diabetes.32.11.988; GREENE DA, 1987, J CLIN INVEST, V79, P1479, DOI 10.1172/JCI112977; HANKES LV, 1969, ANN NY ACAD SCI, V165, P564; HOLUB BJ, 1986, ANNU REV NUTR, V6, P563, DOI 10.1146/annurev.nu.06.070186.003023; Hu E, 2000, AM J PHYSIOL-RENAL, V279, pF426, DOI 10.1152/ajprenal.2000.279.3.F426; Irarrazabal CE, 2004, P NATL ACAD SCI USA, V101, P8809, DOI 10.1073/pnas.0403062101; Ito T, 2004, BIOCHEM J, V382, P177, DOI 10.1042/BJ20031838; Kabashima T, 2003, P NATL ACAD SCI USA, V100, P5107, DOI 10.1073/pnas.0730817100; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; Ko BCB, 2002, J BIOL CHEM, V277, P46085, DOI 10.1074/jbc.M208138200; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; KOLLER F, 1979, H-S Z PHYSIOL CHEM, V360, P507, DOI 10.1515/bchm2.1979.360.1.507; Larner Joseph, 2002, Int J Exp Diabetes Res, V3, P47, DOI 10.1080/15604280212528; LIN LR, 1991, EXP EYE RES, V52, P93, DOI 10.1016/0014-4835(91)90132-X; LUCAS VA, 1986, EXP EYE RES, V42, P151, DOI 10.1016/0014-4835(86)90039-4; NABER NI, 1987, BIOCHIM BIOPHYS ACTA, V911, P365, DOI 10.1016/0167-4838(87)90078-1; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Raccah D, 1998, J DIABETES COMPLICAT, V12, P154, DOI 10.1016/S1056-8727(97)00093-7; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rauchman MI, 1997, AM J PHYSIOL-RENAL, V273, pF9, DOI 10.1152/ajprenal.1997.273.1.F9; REDDY CC, 1981, J BIOL CHEM, V256, P8510; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; STEVENS MJ, 1993, AM J PHYSIOL, V265, pE428, DOI 10.1152/ajpendo.1993.265.3.E428; Sundkvist G, 2000, DIABETIC MED, V17, P259, DOI 10.1046/j.1464-5491.2000.00261.x; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; WINEGRAD AI, 1987, DIABETES, V36, P396, DOI 10.2337/diab.36.3.396; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298	35	42	45	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19895	19901		10.1074/jbc.M502621200	http://dx.doi.org/10.1074/jbc.M502621200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778219	hybrid			2022-12-25	WOS:000229113700059
J	Slagsvold, T; Aasland, R; Hirano, S; Bache, KG; Raiborg, C; Trambaiolo, D; Wakatsuki, S; Stenmark, H				Slagsvold, T; Aasland, R; Hirano, S; Bache, KG; Raiborg, C; Trambaiolo, D; Wakatsuki, S; Stenmark, H			Eap45 in mammalian ESCRT-II binds ubiquitin via a phosphoinositide-interacting GLUE domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOSOME-ASSOCIATED COMPLEX; RECEPTOR DOWN-REGULATION; MULTIVESICULAR-BODY; CRYSTAL-STRUCTURE; GRAM DOMAIN; CUE DOMAIN; PROTEIN; HRS; ENDOCYTOSIS; TRANSPORT	Ubiquitination serves as a key sorting signal in the lysosomal degradation of endocytosed receptors through the ability of ubiquitinated membrane proteins to be recognized and sorted by ubiquitin-binding proteins along the endocytic route. The ESCRT-II complex in yeast contains one such protein, Vps36, which harbors a ubiquitin-binding NZF domain and is required for vacuolar sorting of ubiquitinated membrane proteins. Surprisingly, the presumptive mammalian ortholog Eap45 lacks the ubiquitin-binding module of Vps36, and it is thus not clear whether mammalian ESCRT-II functions to bind ubiquitinated cargo. In this paper, we provide evidence that Eap45 contains a novel ubiquitin-binding domain, GLUE (GRAM-like ubiquitin-binding in Eap45), which binds ubiquitin with similar affinity and specificity as other ubiquitin-binding domains. The GLUE domain shares similarities in its primary and predicted secondary structures to phosphoinositide-binding GRAM and PH domains. Accordingly, we find that Eap45 binds to a subset of 3-phosphoinositides, suggesting that ubiquitin recognition could be coordinated with phosphoinositide binding. Furthermore, we show that Eap45 colocalizes with ubiquitinated proteins on late endosomes. These results are consistent with a role for Eap45 in endosomal sorting of ubiquitinated cargo.	Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway; Univ Bergen, Dept Mol Biol, HIB, N-5020 Bergen, Norway; KEK, IMSS, Struct Biol Res Ctr, Photon Factory, Tsukuba, Ibaraki 3050801, Japan	University of Oslo; University of Bergen; High Energy Accelerator Research Organization (KEK)	Stenmark, H (corresponding author), Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway.	stenmark@ulrik.uio.no	Bache, Kristi G./AAD-9335-2020; Stenmark, Harald/B-8868-2008	Wakatsuki, Soichi/0000-0001-5896-7968				Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Begley MJ, 2003, MOL CELL, V12, P1391, DOI 10.1016/S1097-2765(03)00486-6; Berger P, 2003, P NATL ACAD SCI USA, V100, P12177, DOI 10.1073/pnas.2132732100; Bilodeau PS, 2003, J CELL BIOL, V163, P237, DOI 10.1083/jcb.200305007; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P483, DOI 10.1016/S0968-0004(00)01664-9; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hierro A, 2004, NATURE, V431, P221, DOI 10.1038/nature02914; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350; Mueller TD, 2004, J BIOL CHEM, V279, P11926, DOI 10.1074/jbc.M312865200; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Raiborg C, 2002, CELL STRUCT FUNCT, V27, P403, DOI 10.1247/csf.27.403; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, J CELL SCI, V114, P2255; Sato M, 2003, NAT CELL BIOL, V5, P1016, DOI 10.1038/ncb1054; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Simonsen A, 1998, EUR J CELL BIOL, V75, P223, DOI 10.1016/S0171-9335(98)80116-7; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Slagsvold T, 2004, DEV CELL, V7, P457, DOI 10.1016/j.devcel.2004.09.007; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Stang E, 2004, MOL BIOL CELL, V15, P3591, DOI 10.1091/mbc.E04-01-0041; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Teo H, 2004, DEV CELL, V7, P559, DOI 10.1016/j.devcel.2004.09.003; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tsujita K, 2004, J BIOL CHEM, V279, P13817, DOI 10.1074/jbc.M312294200; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8	48	128	133	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19600	19606		10.1074/jbc.M501510200	http://dx.doi.org/10.1074/jbc.M501510200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15755741	hybrid			2022-12-25	WOS:000229113700023
J	Zeugner, A; Byrdin, M; Bouly, JP; Bakrim, N; Giovani, B; Brettel, K; Ahmad, M				Zeugner, A; Byrdin, M; Bouly, JP; Bakrim, N; Giovani, B; Brettel, K; Ahmad, M			Light-induced electron transfer in Arabidopsis cryptochrome-1 correlates with in vivo function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA PHOTOLYASE; ESCHERICHIA-COLI; PHOTOACTIVATION; DYNAMICS; PROTEIN; CRY1; PHOTORECEPTORS; FLAVOPROTEINS; INHIBITION; BINDING	Cryptochromes are blue light-activated photoreceptors found in multiple organisms with significant similarity to photolyases, a class of light-dependent DNA repair enzymes. Unlike photolyases, cryptochromes do not repair DNA and instead mediate blue light-dependent developmental, growth, and/or circadian responses by an as yet unknown mechanism of action. It has recently been shown that Arabidopsis cryptochrome-1 retains photolyase-like photoreduction of its flavin cofactor FAD by intraprotein electron transfer from tryptophan and tyrosine residues. Here we demonstrate that substitution of two conserved tryptophans that are constituents of the flavin-reducing electron transfer chain in Escherichia coli photolyase impairs light-induced electron transfer in the Arabidopsis cryptochrome-1 photoreceptor in vitro. Furthermore, we show that these substitutions result in marked reduction of light-activated autophosphorylation of cryptochrome-1 in vitro and of its photoreceptor function in vivo, consistent with biological relevance of the electron transfer reaction. These data support the possibility that light-induced flavin reduction via the tryptophan chain is the primary step in the signaling pathway of plant cryptochrome.	Univ Paris 06, F-75252 Paris, France; CEA, Serv Bioengn, F-91191 Gif Sur Yvette, France; CNRS, URA 2096, F-91191 Gif Sur Yvette, France; Penn State Univ, Media, PA 19063 USA	UDICE-French Research Universities; Sorbonne Universite; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	Zeugner, A (corresponding author), Univ Paris 06, Casier 156,4 Pl Jussieu, F-75252 Paris, France.	ahmad@ccr.jussieu.fr		Ahmad, Margaret/0000-0003-4524-5813; byrdin, martin/0000-0002-6389-8714				AHMAD M, 1995, PLANT J, V8, P653, DOI 10.1046/j.1365-313X.1995.08050653.x; Ahmad M, 2002, PLANT PHYSIOL, V129, P774, DOI 10.1104/pp.010969; Ahmad M, 1998, PLANT CELL, V10, P197, DOI 10.1105/tpc.10.2.197; Bouly JP, 2003, EUR J BIOCHEM, V270, P2921, DOI 10.1046/j.1432-1033.2003.03691.x; Brautigam CA, 2004, P NATL ACAD SCI USA, V101, P12142, DOI 10.1073/pnas.0404851101; Brudler R, 2003, MOL CELL, V11, P59, DOI 10.1016/S1097-2765(03)00008-X; Byrdin M, 2004, BBA-BIOENERGETICS, V1655, P64, DOI 10.1016/j.bbabio.2003.07.001; Byrdin M, 2003, P NATL ACAD SCI USA, V100, P8676, DOI 10.1073/pnas.1531645100; Carell T, 2001, CURR OPIN CHEM BIOL, V5, P491, DOI 10.1016/S1367-5931(00)00239-8; Cheung MS, 1999, BIOPHYS J, V76, P1241, DOI 10.1016/S0006-3495(99)77287-5; Christie JM, 2001, J BIOL CHEM, V276, P11457, DOI 10.1074/jbc.R100004200; Froy O, 2002, CURR BIOL, V12, P147, DOI 10.1016/S0960-9822(01)00656-X; Giovani B, 2003, NAT STRUCT BIOL, V10, P489, DOI 10.1038/nsb933; Green CB, 2004, CURR BIOL, V14, pR847, DOI 10.1016/j.cub.2004.09.040; HEELIS PF, 1982, CHEM SOC REV, V11, P15, DOI 10.1039/cs9821100015; LI YF, 1991, BIOCHEMISTRY-US, V30, P6322, DOI 10.1021/bi00239a034; Lin CT, 2003, ANNU REV PLANT BIOL, V54, P469, DOI 10.1146/annurev.arplant.54.110901.160901; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; Mataga N, 2002, J PHYS CHEM B, V106, P8917, DOI 10.1021/jp0205741; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; Shalitin D, 2003, PLANT CELL, V15, P2421, DOI 10.1105/tpc.013011; Weber S, 2002, P NATL ACAD SCI USA, V99, P1319, DOI 10.1073/pnas.032469399; Yang HQ, 2000, CELL, V103, P815, DOI 10.1016/S0092-8674(00)00184-7; Zhong DP, 2001, P NATL ACAD SCI USA, V98, P11867, DOI 10.1073/pnas.211440398; Zhu HS, 2001, CURR BIOL, V11, P1945, DOI 10.1016/S0960-9822(01)00601-7	29	134	139	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19437	19440		10.1074/jbc.C500077200	http://dx.doi.org/10.1074/jbc.C500077200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774475	hybrid			2022-12-25	WOS:000229113700002
J	Jeschke, G; Bender, A; Schweikardt, T; Panek, G; Decker, H; Paulsen, H				Jeschke, G; Bender, A; Schweikardt, T; Panek, G; Decker, H; Paulsen, H			Localization of the N-terminal domain in light-harvesting chlorophyll a/b protein by EPR measurements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX-II LHCII; BINDING PROTEIN; CONFORMATIONAL-CHANGES; PHOSPHORYLATION SITE; MEMBRANE-PROTEIN; DISTANCE; RESONANCE; STATE; TRIMERIZATION; TRANSITION	The conformational distribution of the N-terminal domain of the major light-harvesting chlorophyll a/b protein ( LHCIIb) has been characterized by electron-electron double resonance yielding distances between spin labels placed in various domains of the protein. Distance distributions involving residue 3 near the N terminus turned out to be bimodal, revealing that this domain, which is involved in regulatory functions such as balancing the energy flow through photosystems ( PS) I and II, exists in at least two conformational states. Models of the conformational sub-ensembles were generated on the basis of experimental distance restraints from measurements on LHCIIb monomers and then checked for consistency with the experimental distance distribution between residues 3 in trimers. Only models where residue 3 is located above the core of the protein and extends into the aqueous phase on the stromal side fit the trimer data. In the other state, which consequently is populated only in monomers, the N-terminal domain extends sideways from the protein core. The two conformational states may correspond to two functional states of LHCIIb, namely trimeric LHCIIb associated with PSII in stacked thylakoid membranes and presumably monomeric LHCIIb associated with PSI in nonstacked thylakoids. The switch between these two is known to be triggered by phosphorylation of Thr-6. A similar phosphorylation-induced conformational change of the N-terminal domain has been observed by others in bovine annexin IV which, due to the conformational switch, also loses its membrane-aggregating property.	Johannes Gutenberg Univ Mainz, Inst Allgemeine Bot, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Mol Biophys, D-55128 Mainz, Germany; Max Planck Inst Polymer Res, D-55021 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Max Planck Society	Paulsen, H (corresponding author), Johannes Gutenberg Univ Mainz, Inst Allgemeine Bot, Mullerweg 6, D-55099 Mainz, Germany.	paulsen@mail.uni-mainz.de	Paulsen, Harald/D-3742-2011	Schweikardt, Thorsten/0000-0002-1304-7970; Jeschke, Gunnar/0000-0001-6853-8585				Allen JF, 2001, TRENDS PLANT SCI, V6, P317, DOI 10.1016/S1360-1385(01)02010-6; Allen JF, 2003, SCIENCE, V299, P1530, DOI 10.1126/science.1082833; Booth PJ, 1996, BIOCHEMISTRY-US, V35, P5103, DOI 10.1021/bi953053f; Borbat PP, 2002, J AM CHEM SOC, V124, P5304, DOI 10.1021/ja020040y; Borbat PP, 1999, CHEM PHYS LETT, V313, P145, DOI 10.1016/S0009-2614(99)00972-0; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Garab G, 2002, BIOCHEMISTRY-US, V41, P15121, DOI 10.1021/bi026157g; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOBE S, 1995, BIOCHEMISTRY-US, V34, P10224, DOI 10.1021/bi00032a016; HOBE S, 1994, EMBO J, V13, P3423, DOI 10.1002/j.1460-2075.1994.tb06647.x; Holt NE, 2005, SCIENCE, V307, P433, DOI 10.1126/science.1105833; Horton P, 2000, PHILOS T R SOC B, V355, P1361, DOI 10.1098/rstb.2000.0698; HUBBELL WL, 1994, CURR OPIN STRUC BIOL, V4, P566, DOI 10.1016/S0959-440X(94)90219-4; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; Jeschke G, 2004, APPL MAGN RESON, V26, P223, DOI 10.1007/BF03166574; Jeschke G, 2004, J MAGN RESON, V169, P1, DOI 10.1016/j.jmr.2004.03.024; Jeschke G, 2004, BIOPHYS J, V86, P2551, DOI 10.1016/S0006-3495(04)74310-6; Jeschke G, 2002, J MAGN RESON, V155, P72, DOI 10.1006/jmre.2001.2498; Johnson AE, 2005, FEBS LETT, V579, P916, DOI 10.1016/j.febslet.2004.11.046; Kaetzel MA, 2001, BIOCHEMISTRY-US, V40, P4192, DOI 10.1021/bi002507s; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; MILOV AD, 1981, FIZ TVERD TELA+, V23, P975; Nilsson A, 1997, J BIOL CHEM, V272, P18350, DOI 10.1074/jbc.272.29.18350; Pannier M, 2000, J MAGN RESON, V142, P331, DOI 10.1006/jmre.1999.1944; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; ROTH M, 1989, NATURE, V340, P659, DOI 10.1038/340659a0; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Steinhoff HJ, 2002, FRONT BIOSCI-LANDMRK, V7, pC97, DOI 10.2741/stein; Tucker MJ, 2005, J PHYS CHEM B, V109, P4788, DOI 10.1021/jp044347q; Vink M, 2004, BIOCHEMISTRY-US, V43, P7824, DOI 10.1021/bi030267l; Wentworth M, 2004, BIOCHEMISTRY-US, V43, P501, DOI 10.1021/bi034975i; Zer H, 2003, TRENDS BIOCHEM SCI, V28, P467, DOI 10.1016/S0968-0004(03)00173-7; Zer H, 1999, P NATL ACAD SCI USA, V96, P8277, DOI 10.1073/pnas.96.14.8277; Zer H, 2003, BIOCHEMISTRY-US, V42, P728, DOI 10.1021/bi020451r	41	55	58	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18623	18630		10.1074/jbc.M501171200	http://dx.doi.org/10.1074/jbc.M501171200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755729	hybrid			2022-12-25	WOS:000228932300011
J	Pajor, AM; Randolph, KM				Pajor, AM; Randolph, KM			Conformationally sensitive residues in extracellular loop 5 of the Na+/dicarboxylate co-transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE RESIDUES; SUBSTRATE-BINDING; DOMAIN; TRANSPORTER; MUTAGENESIS; SEROTONIN; SITE; REVEALS; HELIX	The Na+/dicarboxylate co-transporter, NaDC-1, from the kidney and small intestine, transports three sodium ions together with one divalent anion substrate, such as succinate(2-). A previous study (Pajor, A. M. (2001) J. Biol. Chem. 276, 29961-29968), identified four amino acids, Ser-478, Ala-480, Ala-481, and Thr-482, near the extracellular end of transmembrane helix (TM) 9 that are likely to form part of the permeation pathway of the transporter. All four cysteine-substituted mutants were sensitive to inhibition by the membrane-impermeant reagent [2-(trimethylammonium) ethyl]-methanethiosulfonate ( MTSET) and protected by substrate. In the present study, we continued the cysteine scan through extracellular loop 5 and TM10, from Thr-483 to Val-528. Most cysteine substitutions were well tolerated, although cysteine mutations of some residues, particularly within the TM, produced proteins that were not expressed on the plasma membrane. Six residues in the extracellular loop (Thr-483, Thr-484, Leu-485, Leu-487, Ile-489, and Met-493) were sensitive to chemical labeling by MTSET, depending on the conformational state of the protein. Transport inhibition by MTSET could be prevented by substrate regardless of temperature, suggesting that the likely mechanism of substrate protection is steric hindrance rather than large-scale conformational changes associated with translocation. We conclude that extracellular loop 5 in NaDC-1 appears to have a functional role, and it is likely to be located in or near the substrate translocation pore in the protein. Conformational changes in the protein affect the accessibility of the residues in extracellular loop 5 and provide further evidence of large-scale changes in the structure of NaDC-1 during the transport cycle.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Pajor, AM (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 301 Univ Blvd, Galveston, TX 77555 USA.	ampajor@utmb.edu		Randolph, Kathleen/0000-0003-4394-0978	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046269] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46269, R01 DK046269] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; Emmerlich V, 2003, P NATL ACAD SCI USA, V100, P11122, DOI 10.1073/pnas.1832002100; Grunewald M, 2002, J BIOL CHEM, V277, P26074, DOI 10.1074/jbc.M202248200; Hamasaki N, 2002, BIOCHEMISTRY-US, V41, P3852, DOI 10.1021/bi011918l; He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488; Henry LK, 2003, J BIOL CHEM, V278, P37052, DOI 10.1074/jbc.M305514200; Kahn ES, 1999, BIOCHEMISTRY-US, V38, P6151, DOI 10.1021/bi9827722; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Leighton BH, 2002, J BIOL CHEM, V277, P29847, DOI 10.1074/jbc.M202508200; Li HY, 2003, AM J PHYSIOL-CELL PH, V285, pC1188, DOI 10.1152/ajpcell.00162.2003; Markovich D, 2004, PFLUG ARCH EUR J PHY, V447, P594, DOI 10.1007/s00424-003-1128-6; Pajor AM, 1999, BIOCHEM J, V344, P205, DOI 10.1042/0264-6021:3440205; Pajor AM, 1998, BBA-BIOMEMBRANES, V1370, P98, DOI 10.1016/S0005-2736(97)00249-6; Pajor AM, 1999, SEMIN NEPHROL, V19, P195; Pajor AM, 2000, J MEMBRANE BIOL, V175, P1, DOI 10.1007/s002320001049; Pajor AM, 1998, BIOCHEM J, V331, P257, DOI 10.1042/bj3310257; Pajor AM, 2001, J BIOL CHEM, V276, P29961, DOI 10.1074/jbc.M011387200; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Segel I.H., 1975, ENZYME KINETICS; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; Wang HP, 2000, AM J PHYSIOL-CELL PH, V278, pC1019, DOI 10.1152/ajpcell.2000.278.5.C1019; Yao XZ, 2002, BIOCHEMISTRY-US, V41, P1083, DOI 10.1021/bi0156761; Yao XZ, 2000, AM J PHYSIOL-RENAL, V279, pF54, DOI 10.1152/ajprenal.2000.279.1.F54; Zhang FF, 2001, BBA-BIOMEMBRANES, V1511, P80, DOI 10.1016/S0005-2736(00)00385-0; Zomot E, 2003, J BIOL CHEM, V278, P42950, DOI 10.1074/jbc.M209307200	29	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18728	18735		10.1074/jbc.M501265200	http://dx.doi.org/10.1074/jbc.M501265200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15774465	Green Accepted, hybrid			2022-12-25	WOS:000228932300024
J	von Arnim, CAF; Kinoshita, A; Peltan, ID; Tangredi, MM; Herl, L; Lee, BM; Spoelgen, R; Hshieh, TT; Ranganathan, S; Battey, FD; Liu, CX; Bacskai, BJ; Sever, S; Irizarry, MC; Strickland, DK; Hyman, BT				von Arnim, CAF; Kinoshita, A; Peltan, ID; Tangredi, MM; Herl, L; Lee, BM; Spoelgen, R; Hshieh, TT; Ranganathan, S; Battey, FD; Liu, CX; Bacskai, BJ; Sever, S; Irizarry, MC; Strickland, DK; Hyman, BT			The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; LIFETIME IMAGING MICROSCOPY; RESONANCE ENERGY-TRANSFER; ALZHEIMERS-DISEASE; LIPID RAFTS; CLEAVING ENZYME; TYROSINE PHOSPHORYLATION; INTRACELLULAR DOMAIN; CYTOPLASMIC DOMAIN; ASPARTYL PROTEASE	BACE is a transmembrane protease with beta-secretase activity that cleaves the amyloid precursor protein (APP). After BACE cleavage, APP becomes a substrate for gamma-secretase, leading to release of amyloid-beta peptide (A beta), which accumulates in senile plaques in Alzheimer disease. APP and BACE are co-internalized from the cell surface to early endosomes. APP is also known to interact at the cell surface and be internalized by the low density lipoprotein receptor-related protein (LRP), a multifunctional endocytic and signaling receptor. Using a new fluorescence resonance energy transfer ( FRET)based assay of protein proximity, fluorescence lifetime imaging (FLIM), and co-immunoprecipitation we demonstrate that the light chain of LRP interacts with BACE on the cell surface in association with lipid rafts. Surprisingly, the BACE-LRP interaction leads to an increase in LRP C-terminal fragment, release of secreted LRP in the media and subsequent release of the LRP intracellular domain from the membrane. Taken together, these data suggest that there is a close interaction between BACE and LRP on the cell surface, and that LRP is a novel BACE substrate.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Alzheimer Unit,Alzheimer Dis Res Lab, Charlestown, MA 02129 USA; Univ Maryland, Sch Med, Dept Surg, Rockville, MD 20855 USA; Univ Maryland, Sch Med, Dept Physiol, Rockville, MD 20855 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Renal Unit, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Hyman, BT (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Alzheimer Unit,Alzheimer Dis Res Lab, 114 16th St 2009, Charlestown, MA 02129 USA.	bhyman@partners.org	Peltan, Ithan/J-1853-2019; Bacskai, Brian/AAE-9583-2021	Peltan, Ithan/0000-0003-1730-234X; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710, R01HL050784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015379, R37AG012406, R01AG012406, P50AG005134] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50784, HL54710] Funding Source: Medline; NIA NIH HHS [AG15379, P50AG05134, AG12406] Funding Source: Medline; NIBIB NIH HHS [EB00768] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Abbenante G, 2000, BIOCHEM BIOPH RES CO, V268, P133, DOI 10.1006/bbrc.2000.2098; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Bacskai BJ, 2003, J BIOMED OPT, V8, P368, DOI 10.1117/1.1584442; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Berezovska O, 1999, MOL BRAIN RES, V69, P273, DOI 10.1016/S0169-328X(99)00119-9; Berezovska O, 2003, J NEUROSCI, V23, P4560; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Higashi S, 2003, BIOCHEMISTRY-US, V42, P6514, DOI 10.1021/bi020643m; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kametaka S, 2003, J BIOL CHEM, V278, P15239, DOI 10.1074/jbc.M208611200; Kao SC, 2004, J BIOL CHEM, V279, P1942, DOI 10.1074/jbc.M309219200; Kawarabayashi T, 2004, J NEUROSCI, V24, P3801, DOI 10.1523/JNEUROSCI.5543-03.2004; Kinoshita A, 2003, J CELL SCI, V116, P3339, DOI 10.1242/jcs.00643; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Kinoshita A, 2002, J BIOL CHEM, V277, P28530, DOI 10.1074/jbc.M203372200; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Kornilova AY, 2003, J BIOL CHEM, V278, P16470, DOI 10.1074/jbc.C300019200; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Li YH, 2001, MOL NEUROBIOL, V23, P53; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Liscum L, 2002, J LIPID RES, V43, P1708, DOI 10.1194/jlr.M200179-JLR200; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mikhailenko I, 2001, J BIOL CHEM, V276, P39484, DOI 10.1074/jbc.M104382200; Orlando LR, 2002, NEUROPHARMACOLOGY, V43, P161, DOI 10.1016/S0028-3908(02)00113-2; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Quinn KA, 1999, EXP CELL RES, V251, P433, DOI 10.1006/excr.1999.4590; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; Sever S, 2000, J CELL BIOL, V150, P1137, DOI 10.1083/jcb.150.5.1137; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; von Arnim CAF, 2004, J CELL SCI, V117, P5437, DOI 10.1242/jcs.01422; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	50	216	220	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17777	17785		10.1074/jbc.M414248200	http://dx.doi.org/10.1074/jbc.M414248200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749709	hybrid			2022-12-25	WOS:000228807200028
J	Katsumi, A; Naoe, T; Matsushita, T; Kaibuchi, K; Schwartz, MA				Katsumi, A; Naoe, T; Matsushita, T; Kaibuchi, K; Schwartz, MA			Integrin activation and matrix binding mediate cellular responses to mechanical stretch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; MECHANOTRANSDUCTION; TENSION; STRESS; FIBROBLASTS; MODULATION; GROWTH; RAC	Mechanical tension is a critical determinant of cell growth, differentiation, apoptosis, migration, and development. Integrins have been implicated in sensing force but little is known about how forces are transduced to biochemical signals. We now show that mechanical strain stimulates conformational activation of integrin alpha v beta 3 in NIH3T3 cells. Integrin activation is mediated by phosphoinositol 3-kinase and is followed by an increase in integrin binding to extracellular matrix proteins. Mechanical stretch stimulation of JNK was dependent on new integrin binding to extracellular matrix. These data define a molecular mechanism for the role of integrins in mechanotransduction.	Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Mellon Prostate Res Inst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Mellon Prostate Res Inst, Dept Biomed Engn, Charlottesville, VA 22908 USA; Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Showa Ku, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Hematol, Showa Ku, Aichi 4668550, Japan	University of Virginia; University of Virginia; University of Virginia; Nagoya University; Nagoya University	Schwartz, MA (corresponding author), Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA.	maschwartz@virginia.edu	Naoe, Tomoki/I-1888-2012; Matsushita, Tadadshi/I-7349-2014	schwartz, martin/0000-0002-2071-1243	NHLBI NIH HHS [R01 HL075092] Funding Source: Medline; NIGMS NIH HHS [R01GM47214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAY D, 1984, DEV BIOL, V102, P379, DOI 10.1016/0012-1606(84)90202-1; Chicurel ME, 1998, NATURE, V392, P730, DOI 10.1038/33719; Davis MJ, 2001, AM J PHYSIOL-HEART C, V280, pH1427, DOI 10.1152/ajpheart.2001.280.4.H1427; Farge E, 2003, CURR BIOL, V13, P1365, DOI 10.1016/S0960-9822(03)00576-1; HASTON WS, 1983, EXP CELL RES, V146, P117, DOI 10.1016/0014-4827(83)90330-0; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; KOLEGA J, 1986, J CELL BIOL, V102, P1400, DOI 10.1083/jcb.102.4.1400; Lee AA, 1996, AM J PHYSIOL-CELL PH, V271, pC1400, DOI 10.1152/ajpcell.1996.271.4.C1400; MacKenna DA, 1998, J CLIN INVEST, V101, P301, DOI 10.1172/JCI1026; Ozaki S, 2000, P NATL ACAD SCI USA, V97, P11286, DOI 10.1073/pnas.210197897; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Sawada Y, 2001, J CELL SCI, V114, P1221; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; Shimizu Y, 1999, ADV IMMUNOL, V72, P325, DOI 10.1016/S0065-2776(08)60024-3; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; Suzuma I, 2002, J BIOL CHEM, V277, P1047, DOI 10.1074/jbc.M105336200; TERRACIO L, 1988, IN VITRO CELL DEV B, V24, P53; THUBRIKAR MJ, 1995, ANN THORAC SURG, V59, P1594, DOI 10.1016/0003-4975(94)01037-D; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200	26	177	187	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16546	16549		10.1074/jbc.C400455200	http://dx.doi.org/10.1074/jbc.C400455200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15760908	hybrid			2022-12-25	WOS:000228615500003
J	Taki, M; Kagawa, S; Nishizaki, M; Mizuguchi, H; Hayakawa, T; Kyo, S; Nagai, K; Urata, Y; Tanaka, N; Fujiwara, T				Taki, M; Kagawa, S; Nishizaki, M; Mizuguchi, H; Hayakawa, T; Kyo, S; Nagai, K; Urata, Y; Tanaka, N; Fujiwara, T			Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD)	ONCOGENE			English	Article						RGD; adenovirus; telomerase; replication; gene therapy	GENE-THERAPY; TRANSGENE EXPRESSION; CANCER-CELLS; RECEPTOR EXPRESSION; GLIOMA-CELLS; FIBER KNOB; BAX GENE; IN-VITRO; VECTOR; PROMOTER	Replication-competent oncolytic viruses are being developed for human cancer therapy. We previously reported that an attenuated adenovirus (OBP-301, 'Telomelysin'), in which the hTERT promoter element drives expression of E1A and E1B genes linked with an IRES, could replicate in cancer cells, and causes selective lysis of cancer cells. We further constructed OBP-405 ('Telomelysin-RGD') that contains an RGD motif in the HI loop of the fiber knob. We examined whether OBP-405 could be effective in overcoming the limitations of OBP-301, specifically their inefficient infection into cells lacking the primary receptor, the coxsackievirus and adenovirus receptor ( CAR). By flow cytometric analysis, H1299 ( lung) and SW620 ( colorectal) tumor cells showed high levels of CAR expression, whereas LN444 ( glioblastoma), LNZ308 ( glioblastoma), and H1299-R5 ( lung) tumor cells were negative for CAR expression. A quantitative realtime PCR analysis demonstrated that fiber-modified OBP-405 infected more efficiently than OBP-301, although the intracellular replication rate of both viruses was consistent. The comparative antitumor effect of fiber-modified OBP-405 and unmodified OBP-301 for human cancer cells was evaluated in vitro by XTT assay as well as in vivo by using athymic mice carrying xenografts. OBP-405 had a profound oncolytic effect on human cancer cell lines compared to OBP-301, in particular on cells with low CAR expression. Intratumoral injection of 107 plaque-forming units of OBP-405 into CAR-negative H1299-R5 lung tumor xenografts in nu/nu mice resulted in a significant inhibition of tumor growth and long-term survival in all treated mice. Moreover, selective replication of OBP-405 in the distant, uninjected H1299-R5 tumors was demonstrated. Our results suggest that fiber-modified replication-competent adenovirus OBP-405 exhibits a broad target range by increasing infection efficiency, an outcome that has important implications for the treatment of human cancers.	Okayama Univ Hosp, Ctr Gene & Cell Therapy, Okayama 7008558, Japan; Okayama Univ, Sch Med & Dent, Dept Surg, Div Surg Oncol, Okayama 7008558, Japan; Natl Inst Hlth Sci, Div Cellular & Gene Therapy Prod, Tokyo 1588501, Japan; Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Oncolys Biopharma Inc, Tokyo 1060031, Japan	Okayama University; Okayama University; National Institute of Health Sciences - Japan; Kanazawa University; Oncolys BioPharma	Fujiwara, T (corresponding author), Okayama Univ Hosp, Ctr Gene & Cell Therapy, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	toshi_f@md.okayama-u.ac.jp	Kagawa, Shunsuke/B-2189-2011	Mizuguchi, Hiroyuki/0000-0003-0594-8178; Kagawa, Shunsuke/0000-0002-3610-8211				Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Davydova J, 2004, CANCER RES, V64, P4319, DOI 10.1158/0008-5472.CAN-04-0064; DeWeese TL, 2001, CANCER RES, V61, P7464; Dmitriev I, 1998, J VIROL, V72, P9706, DOI 10.1128/JVI.72.12.9706-9713.1998; Fang BL, 2003, CURR OPIN MOL THER, V5, P475; Fechner H, 2000, GENE THER, V7, P1954, DOI 10.1038/sj.gt.3301321; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Gu J, 2000, CANCER RES, V60, P5359; Gu J, 2002, ONCOGENE, V21, P4757, DOI 10.1038/sj.onc.1205582; Hemminki A, 2003, CANCER RES, V63, P847; HUARD J, 1995, GENE THER, V2, P107; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Kohn EC, 2004, SEMIN ONCOL, V31, P39, DOI 10.1053/j.seminoncol.2004.01.009; Komata T, 2001, CANCER RES, V61, P5796; Krasnykh V, 1998, J VIROL, V72, P1844, DOI 10.1128/JVI.72.3.1844-1852.1998; Lamfers MLM, 2002, CANCER RES, V62, P5736; Li YM, 1999, CANCER RES, V59, P325; MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; Miller CR, 1998, CANCER RES, V58, P5738; Mizuguchi H, 2001, GENE THER, V8, P730, DOI 10.1038/sj.gt.3301453; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; PRINCE GA, 1993, J VIROL, V67, P101, DOI 10.1128/JVI.67.1.101-111.1993; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; Tango Y, 2004, CANCER SCI, V95, P459, DOI 10.1111/j.1349-7006.2004.tb03232.x; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Umeoka T, 2004, CANCER RES, V64, P6259, DOI 10.1158/0008-5472.CAN-04-1335; Wickham TJ, 1997, J VIROL, V71, P8221, DOI 10.1128/JVI.71.11.8221-8229.1997; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Wood M, 1999, CANCER GENE THER, V6, P367, DOI 10.1038/sj.cgt.7700090	36	70	74	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3130	3140		10.1038/sj.onc.1208460	http://dx.doi.org/10.1038/sj.onc.1208460			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735729				2022-12-25	WOS:000228728100007
J	Ouyang, K; Wu, CH; Cheng, HP				Ouyang, K; Wu, CH; Cheng, HP			Ca2+-induced Ca2+ release in sensory neurons - Low gain amplification confers intrinsic stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; RYANODINE RECEPTORS; CALCIUM-RELEASE; LOCAL-CONTROL; MUSCLE; SPARKS; ADAPTATION; MODULATION; CHANNEL	Ca2+-induced Ca2+ release (CICR) is a ubiquitous mechanism by which Ca2+ release from the endoplasmic reticulum amplifies the trigger Ca2+ entry and generates propagating Ca2+ waves. To elucidate the mechanisms that control this positive feedback, we investigated the spatial and temporal kinetics and measured the gain function of CICR in small sensory neurons from mammalian dorsal root ganglions ( DRGs). We found that subsurface Ca2+ release units (CRUs) are under tight local control by Ca2+ entry, whereas medullar CRUs as a "common pool" system are recruited by inwardly propagating CICR. Active CRUs often displayed repetitive Ca2+ sparks, conferring the ability to encode a "memory" of neuronal activity well beyond the duration of an action potential. Store Ca2+ reserve was able to support all CRUs each to fire similar to 15 sparks, excluding use-dependent inactivation or store depletion as the major CICR termination mechanism. Importantly, CICR in DRG neurons operated in a low gain, linear regime ( gain = 0.54), which conferred intrinsic stability to CICR. Combined with high Ca2+ current density ( - 156 pA/pF at - 10 mV), such a low gain CICR system generated large intracellular Ca2+ transients without jeopardizing the stability. These findings provide the first demonstration that CICR operating in a low gain regime can be harnessed to provide a robust and graded amplification of Ca2+ signal in the absence of counteracting inhibitory mechanism.	Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China; Peking Univ, Coll Life Sci, Natl Lab Biomembrane & Membrane Biotechnol, Beijing 100871, Peoples R China; NIA, Lab Cardiovasc Sci, NIH, Baltimore, MD 21224 USA	Peking University; Peking University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Cheng, HP (corresponding author), Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China.	chengp@grc.nia.nih.gov	Heping, Cheng/AAE-2680-2019; cheng, heping/A-7299-2011; ouyang, kunfu/B-3073-2011	Heping, Cheng/0000-0002-9604-6702; ouyang, kunfu/0000-0003-0292-375X				Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Bers D.M., 2001, EXCITATION CONTRACTI, V2nd ed.; Brochet DXP, 2005, P NATL ACAD SCI USA, V102, P3099, DOI 10.1073/pnas.0500059102; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; ENDO M, 1970, NATURE, V228, P34, DOI 10.1038/228034a0; FORD LE, 1970, SCIENCE, V167, P58, DOI 10.1126/science.167.3914.58; Franzini-Armstrong C, 1999, BIOPHYS J, V77, P1528, DOI 10.1016/S0006-3495(99)77000-1; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; Gyorke I, 1998, BIOPHYS J, V75, P2801, DOI 10.1016/S0006-3495(98)77723-9; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; Hua SY, 2000, CELL CALCIUM, V27, P195, DOI 10.1054/ceca.2000.0114; Lokuta AJ, 2002, FEBS LETT, V511, P90, DOI 10.1016/S0014-5793(01)03312-9; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; Santana LF, 1996, CIRC RES, V78, P166, DOI 10.1161/01.RES.78.1.166; Sham JSK, 1998, P NATL ACAD SCI USA, V95, P15096, DOI 10.1073/pnas.95.25.15096; Shannon TR, 2003, CIRC RES, V93, P40, DOI 10.1161/01.RES.0000079967.11815.19; Song LS, 1998, J PHYSIOL-LONDON, V512, P677, DOI 10.1111/j.1469-7793.1998.677bd.x; Stern MD, 2004, CELL CALCIUM, V35, P591, DOI 10.1016/j.ceca.2004.01.013; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; Szentesi P, 2004, CIRC RES, V95, P807, DOI 10.1161/01.RES.0000146029.80463.7d; Trafford AW, 2000, J PHYSIOL-LONDON, V522, P259, DOI 10.1111/j.1469-7793.2000.t01-2-00259.x; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Wang SQ, 2004, CIRC RES, V94, P1011, DOI 10.1161/01.RES.0000125883.68447.A1; Wang SQ, 2001, NATURE, V410, P592, DOI 10.1038/35069083; WIER WG, 1994, J PHYSIOL-LONDON, V474, P463, DOI 10.1113/jphysiol.1994.sp020037; Wier WG, 1999, CIRC RES, V85, P770, DOI 10.1161/01.RES.85.9.770; Yang DM, 2001, J BIOL CHEM, V276, P40210, DOI 10.1074/jbc.M106944200	32	19	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15898	15902		10.1074/jbc.C500026200	http://dx.doi.org/10.1074/jbc.C500026200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15749692	hybrid, Green Submitted			2022-12-25	WOS:000228444800055
J	Park, S; James, CD				Park, S; James, CD			ECop (EGFR-Coamplifed and overexpressed protein), a novel protein, regulates NF-kappa B transcriptional activity and associated apoptotic response in an I kappa B alpha-dependent manner	ONCOGENE			English	Article						ecop; gene amplificatio; NF-kappa B; I kappa B alpha; apoptosis	HUMAN SARCOMAS; HUMAN GENES; CELL-LINES; REGION; AMPLIFICATION; IDENTIFICATION; CANCER; COAMPLIFICATION; UBIQUITINATION; SENSITIVITY	In the present study, we describe the function of a novel protein, ECop (EGFR-Coamplified and overexpressed protein), in the regulation of NF-kB activity. Ectopic expression of ECop increases NF-kB transcriptional activity by promoting nuclear translocation and DNA binding of NF-kB, and ECop-induced NF-kB activation confers cellular resistance to apoptotic challenge. In ECop knockdown cells, NF-kB transcriptional activity is suppressed due to delayed IkB alpha degradation, which results in a delayed nuclear translocation as well as decreased DNA binding of NF-kB. Suppression of NF-kB activation by ECop knockdown increases cellular susceptibility to apoptosis. These results suggest that ECop is a key regulator of NF-kB signaling, and that high-level, amplification-mediated ECop expression, such as that occurring in tumors with amplified EGFR, could contribute to resistance to apoptosis.	Mayo Fdn & Grad Sch, Tumor Biol Program, Rochester, MN 55905 USA; Mayo Fdn & Grad Sch, Div Expt Pathol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	James, CD (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St,SW Hilton Bldg Room 80-D, Rochester, MN USA.	james.david@mayo.edu	James, Charles D/E-2721-2012	James, Charles D/0000-0002-1027-203X				ALBERTS B., 1994, MOL BIOL CELL, P551; Amit S, 2003, SEMIN CANCER BIOL, V13, P15, DOI 10.1016/S1044-579X(02)00096-2; Amler LC, 1996, GENE CHROMOSOME CANC, V15, P134, DOI 10.1002/(SICI)1098-2264(199602)15:2<134::AID-GCC9>3.0.CO;2-4; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; BEG AA, 1996, SCIENCE, V274, P784; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Eley GD, 2002, NEURO-ONCOLOGY, V4, P86, DOI 10.1093/neuonc/4.2.86; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawai H, 2002, MOL CELL BIOL, V22, P6079, DOI 10.1128/MCB.22.17.6079-6088.2002; KHATIB ZA, 1993, CANCER RES, V53, P5535; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Park S, 2003, CANCER RES, V63, P723; SCHUURING E, 1992, ONCOGENE, V7, P355; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; SMITH K, 1993, ONCOGENE, V8, P933; TANIGAMI A, 1992, GENOMICS, V13, P21, DOI 10.1016/0888-7543(92)90196-Y; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; VAN AD, 1996, SCIENCE, V274, P787; Wang XY, 1998, ONCOGENE, V16, P191, DOI 10.1038/sj.onc.1201476; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058	28	32	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2495	2502		10.1038/sj.onc.1208496	http://dx.doi.org/10.1038/sj.onc.1208496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735698				2022-12-25	WOS:000228180600007
J	Woerner, SM; Kloor, M; Mueller, A; Rueschoff, J; Friedrichs, N; Buettner, R; Buzello, M; Kienle, P; Knaebel, HP; Kunstmann, E; Pagenstecher, C; Schackert, HK; Moslein, G; Vogelsang, H; Doeberitz, MV; Gebert, JF				Woerner, SM; Kloor, M; Mueller, A; Rueschoff, J; Friedrichs, N; Buettner, R; Buzello, M; Kienle, P; Knaebel, HP; Kunstmann, E; Pagenstecher, C; Schackert, HK; Moslein, G; Vogelsang, H; Doeberitz, MV; Gebert, JF		German HNPCC Consort	Microsatellite instability of selective target genes in HNPCC-associated colon adenomas	ONCOGENE			English	Article						colon adenoma; DNA mismatch repair; coding microsatellites; microsatellite instability; Selective Target genes	NONPOLYPOSIS COLORECTAL-CANCER; II RECEPTOR GENE; REPAIR-DEFICIENT CANCERS; FACTOR-BETA RECEPTOR; FRAMESHIFT MUTATIONS; GENOMIC INSTABILITY; REPEATED SEQUENCES; MUTATOR PHENOTYPE; PROXIMAL COLON; CARCINOMAS	Microsatellite instability (MSI) occurs in most hereditary nonpolyposis colorectal cancers (HNPCC) and less frequently in sporadic tumors as the result of DNA mismatch repair (MMR) deficiency. Instability at coding microsatellites (cMS) in specific target genes causes frameshift mutations and functional inactivation of affected proteins, thereby providing a selective growth advantage to MMR deficient cells. At present, little is known about Selective Target Gene frameshift mutations in preneoplastic lesions. In this study, we examined 30 HNPCC-associated MSI-H colorectal adenomas of different grades of dysplasia for frameshift mutations in 26 cMS-bearing genes, which, according to our previous model, represent Selective Target genes of MSI. About 30% (8/26) of these genes showed a high mutation frequency (>= 50%) in colorectal adenomas, similar to the frequencies reported for colorectal carcinomas. Mutations in one gene (PTHL3) occurred significantly less frequently in MSI adenomas compared to published mutation rates in MSI carcinomas (36.0 vs 85.7%, P = 0.023). Biallelic inactivation was observed in nine genes, thus emphasizing the functional impact of cMS instability on MSI tumorigenesis. Some genes showed a high frequency of frameshift mutations already at early stages of MSI colorectal tumorigenesis that increased with grade of dysplasia and transition to carcinoma. These include known Target Genes like BAX and TGFBR2, as well as three novel candidates, MACS, NDUFC2, and TAF1B. Overall, we have identified genes of potential relevance for the initiation and progression of MSI tumorigenesis, thus representing promising candidates for novel diagnostic and therapeutic approaches directed towards MMR deficient tumors.	Univ Heidelberg, Inst Mol Pathol, D-69120 Heidelberg, Germany; Univ Gottingen, Dept Gen Surg, D-3400 Gottingen, Germany; Klinikum Kassel, Dept Pathol, Kassel, Germany; Univ Hosp Bonn, Inst Pathol, Bonn, Germany; Univ Heidelberg, Inst Pathol, Heidelberg, Germany; Univ Heidelberg, Dept Surg, D-6900 Heidelberg, Germany; Ruhr Univ Bochum, Knappschaftskrankenhaus, Dept Internal Med, D-4630 Bochum, Germany; Ruhr Univ Bochum, D-4630 Bochum, Germany; Univ Hosp Bonn, Inst Human Genet, Bonn, Germany; Dresden Univ Technol, Dept Surg Res, D-8027 Dresden, Germany; Univ Dusseldorf, Dept Surg, D-4000 Dusseldorf, Germany; Univ Technol, Dept Surg, Munich, Germany	Ruprecht Karls University Heidelberg; University of Gottingen; Klinikum Kassel; University of Bonn; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruhr University Bochum; Ruhr University Bochum; University of Bonn; Technische Universitat Dresden; Heinrich Heine University Dusseldorf; Technical University of Munich	Gebert, JF (corresponding author), Univ Heidelberg, Inst Mol Pathol, Neuenheimer Feld 220-221, D-69120 Heidelberg, Germany.	johannes.gebert@med.uni-heidelberg.de	Vogelsang, Holger/AAB-1244-2020; Woerner, Stefan/A-2187-2010; von Knebel Doeberitz, Magnus/D-2372-2016	von Knebel Doeberitz, Magnus/0000-0002-0498-6781				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1997, GASTROENTEROLOGY, V112, P33, DOI 10.1016/S0016-5085(97)70216-6; Alazzouzi H, 2005, HUM MOL GENET, V14, P235, DOI 10.1093/hmg/ddi021; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Boland CR, 1998, CANCER RES, V58, P5248; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; Duval A, 2002, ANN GENET-PARIS, V45, P71, DOI 10.1016/S0003-3995(02)01115-2; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Furlan D, 2002, J PATHOL, V197, P603, DOI 10.1002/path.1162; Goel A, 2003, CANCER RES, V63, P1608; Grady WM, 1998, CANCER RES, V58, P3101; HOLM S, 1979, SCAND J STAT, V6, P65; Iino H, 2000, GUT, V47, P37, DOI 10.1136/gut.47.1.37; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kim NG, 2002, ONCOGENE, V21, P5081, DOI 10.1038/sj.onc.1205703; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Li LS, 2003, AM J PATHOL, V163, P1429, DOI 10.1016/S0002-9440(10)63500-6; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; Loeffen JLCM, 1998, BIOCHEM BIOPH RES CO, V253, P415, DOI 10.1006/bbrc.1998.9786; Lothe RA, 1997, MOL MED TODAY, V3, P61, DOI 10.1016/S1357-4310(96)10055-1; Loukola A, 1999, AM J PATHOL, V155, P1849, DOI 10.1016/S0002-9440(10)65503-4; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616; Mori Y, 2001, CANCER RES, V61, P6046; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARSONS R, 1995, CANCER RES, V55, P5548; Percesepe A, 2000, GENE CHROMOSOME CANC, V27, P424, DOI 10.1002/(SICI)1098-2264(200004)27:4<424::AID-GCC13>3.0.CO;2-M; *R DEV COR TEAM, 2004, LANG ENV STAT COMP; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Samowitz WS, 1999, AM J PATHOL, V154, P1637, DOI 10.1016/S0002-9440(10)65418-1; Samowitz WS, 1997, GASTROENTEROLOGY, V112, P1515, DOI 10.1016/S0016-5085(97)70032-5; Schwartz S, 1999, CANCER RES, V59, P2995; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Sugai T, 2003, J PATHOL, V200, P168, DOI 10.1002/path.1340; Sutter C, 1999, MOL CELL PROBE, V13, P157, DOI 10.1006/mcpr.1999.0231; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Woerner SM, 2001, INT J CANCER, V93, P12, DOI 10.1002/ijc.1299; Yagi OK, 1998, GASTROENTEROLOGY, V114, P268, DOI 10.1016/S0016-5085(98)70477-9	48	65	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2525	2535		10.1038/sj.onc.1208456	http://dx.doi.org/10.1038/sj.onc.1208456			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735733				2022-12-25	WOS:000228180600010
J	Simon, M; Grandage, VL; Linch, DC; Khwaja, A				Simon, M; Grandage, VL; Linch, DC; Khwaja, A			Constitutive activation of the Wnt/ss-catenin signalling pathway in acute myeloid leukaemia	ONCOGENE			English	Article						leukaemia; ss-catenin; CD34; differentiation	HEMATOPOIETIC STEM-CELLS; EFFICIENT GENE-TRANSFER; BETA-CATENIN; SELF-RENEWAL; TRANSLOCATION PRODUCTS; COLORECTAL-CANCER; FLT3 MUTATIONS; PROLIFERATION; LEUKEMOGENESIS; EXPRESSION	The beta-catenin protein is at the core of the canonical Wnt signalling pathway. Wnt stimulation leads to beta-catenin accumulation, nuclear translocation and interaction with T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors to regulate genes important for embryonic development and proliferation. Wnt/beta-catenin can promote stem cell self-renewal and is dysregulated in colon carcinoma. We have examined the role of the Wnt pathway in the development of acute myeloid leukaemia (AML) and find that the beta-catenin protein is: readily detected in primary AML samples. Using transfection of a TCF/LEF reporter construct into primary AML cells and normal human progenitors, we find increased reporter activity in 16/25 leukaemia samples. Retrovirally mediated expression of a mutant active beta-catenin in normal progenitors preserves CD34 expression and impairs myelomonocytic differentiation. Activation of TCF/LEF signalling decreases factor withdrawal-induced apoptosis of normal progenitors. A significant proportion of ANIL cases show aberrant expression of components of the Wnt pathway including Wnt-1, Wnt-2b and LEF-1. These results provide evidence for the involvement of the Wnt/beta-catenin pathway in the pathogenesis of AML.	UCL Royal Free & Univ Coll, Sch Med, Dept Haematol, London WC1E 6HX, England	University of London; University College London; UCL Medical School	Khwaja, A (corresponding author), UCL Royal Free & Univ Coll, Sch Med, Dept Haematol, 98 Chenies Mews, London WC1E 6HX, England.	a.khwaja@ucl.ac.uk	Khwaja, Asim/C-1509-2008					Abraham SC, 2002, AM J PATHOL, V160, P1361, DOI 10.1016/S0002-9440(10)62563-1; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982; Cobas M, 2004, J EXP MED, V199, P221, DOI 10.1084/jem.20031615; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Kelly PF, 2000, BLOOD, V96, P1206, DOI 10.1182/blood.V96.4.1206.h8001206_1206_1214; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kottaridis PD, 2002, BLOOD, V100, P2393, DOI 10.1182/blood-2002-02-0420; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Lai W, 2003, J IMMUNOL METHODS, V282, P93, DOI 10.1016/j.jim.2003.07.015; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Quentmeier H, 2003, LEUKEMIA, V17, P120, DOI 10.1038/sj.leu.2402740; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282; Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Trompeter HI, 2003, J IMMUNOL METHODS, V274, P245, DOI 10.1016/S0022-1759(02)00431-3; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Uematsu K, 2003, CANCER RES, V63, P4547; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Watts MJ, 2002, BRIT J HAEMATOL, V118, P117, DOI 10.1046/j.1365-2141.2002.03561.x; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Zheng XM, 2004, BLOOD, V103, P3535, DOI 10.1182/blood-2003-09-3335	44	172	184	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2410	2420		10.1038/sj.onc.1208431	http://dx.doi.org/10.1038/sj.onc.1208431			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735743				2022-12-25	WOS:000227877400013
J	Grabocka, E; Wedegaertner, PB				Grabocka, E; Wedegaertner, PB			Functional consequences of G alpha(13) mutations that disrupt interaction with p115RhoGEF	ONCOGENE			English	Article						signal transduction; heterotrimeric G protein; Rho GTPase; RGS protein; guanine nucleotide; exchange factor	STRESS FIBER FORMATION; PROTEIN ALPHA-SUBUNIT; SERUM RESPONSE FACTOR; PLASMA-MEMBRANE RECRUITMENT; RHO-FAMILY GTPASES; G-BETA-GAMMA; EXCHANGE FACTOR; P115 RHOGEF; LYSOPHOSPHATIDIC ACID; NEURITE RETRACTION	The G-protein alpha subunit, alpha(13), regulates cell growth and differentiation through the monomeric Rho GTPase. alpha(13) activates Rho through direct stimulation of the guanine nucleotide exchange factor p115RhoGEF, which contains a regulator of G-protein signaling homology domain ( RH) in its N-terminus. Through its RH domain, p115RhoGEF also functions as a GAP for G alpha(13). The mechanism for the G alpha(13)/p115RhoGEF interaction is not well understood. Here, we determined specific alpha(13) residues important for its interaction with p115RhoGEF. GST-pulldowns and co-immunoprecipitation assays revealed that individually mutating alpha(13) residues Lys204, Glu229, or Arg232 to opposite charge residues disrupts the interaction of activated alpha(13) with the RH domain of p115RhoGEF or full-length p115RhoGEF. We further demonstrate that mutation of Glu229, and to a lesser extent Lys204 or Arg232, disrupts the ability of activated alpha(13) to induce the recruitment of p115RhoGEF to the plasma membrane (PM) and to activate Rho-mediated serum response element-luciferase gene transcription. Interestingly, an alpha(13) mutant where a conserved Gly was mutated to a Ser (G205S) retained its ability to bind to p115RhoGEF, induce p115RhoGEF recruitment to the PM, and activate Rho-dependent signaling, even though identical Gly to Ser mutations in other a disrupt their interaction with regulator of G-protein signaling (RGS) proteins. These results demonstrate that, whereas several features of a typical alpha/RGS interaction are preserved in the alpha(13)/p115RhoGEF interaction, there are also significant differences.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Wedegaertner, PB (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St,839 BLSB, Philadelphia, PA 19107 USA.	P_Wedegaertner@mail.jci.tju.edu		Grabocka, E/0000-0001-7196-8498; Grabocka, Elda/0000-0002-8768-0955	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062884] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062884, GM62884] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Bhattacharyya R, 2003, BIOCHEM J, V371, P709, DOI 10.1042/BJ20021897; Bhattacharyya R, 2003, FEBS LETT, V540, P211, DOI 10.1016/S0014-5793(03)00267-9; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chen Z, 2003, J BIOL CHEM, V278, P9912, DOI 10.1074/jbc.M212695200; Chen Z, 2001, NAT STRUCT BIOL, V8, P805, DOI 10.1038/nsb0901-805; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1997, J CELL SCI, V110, P2417; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Meigs TE, 2002, J BIOL CHEM, V277, P24594, DOI 10.1074/jbc.M201984200; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Nakamura S, 2004, MOL PHARMACOL, V66, P1029, DOI 10.1124/mol.104.002287; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Offermanns S, 2000, REV PHYSIOL BIOCH P, V140, P63; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wells C, 2002, METHOD ENZYMOL, V345, P371; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5	48	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2155	2165		10.1038/sj.onc.1208414	http://dx.doi.org/10.1038/sj.onc.1208414			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735747	Green Accepted			2022-12-25	WOS:000227857900003
J	Serviddio, G; Di Venosa, N; Federici, A; D'Agostino, D; Rollo, T; Prigigallo, F; Altomare, E; Fiore, T; Vendemiale, G				Serviddio, G; Di Venosa, N; Federici, A; D'Agostino, D; Rollo, T; Prigigallo, F; Altomare, E; Fiore, T; Vendemiale, G			Brief hypoxia before normoxic reperfusion (postconditioning) protects the heart against ischemia-reperfusion injury by preventing mitochondria peroxyde production and glutathione depletion	FASEB JOURNAL			English	Article						hypoxic reperfusion; ischemia-reperfusion; mitochondria; oxidative stress	COMPLEX-I ACTIVITY; MYOCARDIAL-ISCHEMIA; NITRIC-OXIDE; RAT-HEART; CARDIOPULMONARY BYPASS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; DAMAGE; CARDIOLIPIN; GENERATION	Several recent works have shown that a brief ischemia applied during the onset of reperfusion (postconditioning) is cardioprotective in different animal models and that the early minutes of reperfusion are critical to its cardioprotection. This effect has been related to prevention of oxidative stress, but mechanisms have not been clearly demonstrated. The present study tested the hypothesis that mitochondria play a central role in peroxide production and oxidative stress during reperfusion and are responsible for the protective effect of postconditioning. Isolated perfused rat hearts were subjected to complete global ischemia for 45 min and reperfused for 40 min. Normoxic group was reperfused with a Krebs-Henseleit solution with the preischemic pO(2) level (600 mmHg); in the "hypoxic group,"normoxic reperfusion was preceded by 3 min with 150 mmHg pO(2). Reperfusion was stopped at 3 and 40 min. The rate of hydroperoxide production, GSH, GSSG, and carbonyl protein levels were measured in mitochondria at 3 min and at the end of reperfusion. GSH and GSSG were also measured in tissue. Hemodinamic function was monitored during the experiment. LVEDp increased and LVDp decreased in the normoxic group but not in the hypoxic group. The rate of mitochondrial peroxide production was higher in normoxic than in the hypoxic group 3 min after reperfusion and at its conclusion. Accordingly, GSH was oxidized in normoxic but not in hypoxic hearts. Mitochondria carbonyl proteins were significantly higher in normoxic than in the hypoxic group at the end of reperfusion. In this model, 1) hypoxic reperfusion at the onset of reperfusion reduces myocardial injury; 2) the major rate of mitochondrial peroxide production is 3 min after the onset of reperfusion; 3) cardioprotection of postconditioning correlates with reduced mitochondria peroxide production and prevention of GSH oxidation.	Univ Foggia, Dept Med & Occupat Sci, Mol Biol Lab, I-71100 Foggia, Italy; Univ Bari, Dept Emergency & Transplantat, I-70121 Bari, Italy; Univ Bari, Dept Pharmacol & Human Physiol, I-70121 Bari, Italy	University of Foggia; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Vendemiale, G (corresponding author), Univ Foggia, Dept Med & Occupat Sci, Mol Biol Lab, Viale Pinto, I-71100 Foggia, Italy.	g.vendemiale@unifg.it	D'AGOSTINO, DONATO/B-1679-2012; serviddio, gaetano/C-7629-2011	serviddio, gaetano/0000-0002-6424-7841; federici, antonio/0000-0001-5102-9995; D'AGOSTINO, DONATO/0000-0001-5887-7655				AMBROSIO G, 1991, J MOL CELL CARDIOL, V23, P1359, DOI 10.1016/0022-2828(91)90183-M; BABBS CF, 1991, AM J PATHOL, V139, P1069; BROWN JM, 1988, J CLIN INVEST, V81, P1297, DOI 10.1172/JCI113448; Buja LM, 1998, LAB INVEST, V78, P1345; COHEN MV, 1994, CIRC RES, V74, P998, DOI 10.1161/01.RES.74.5.998; Diaz RJ, 2004, CARDIOVASC RES, V62, P4, DOI 10.1016/j.cardiores.2004.01.036; FERRARI R, 1991, AM J MED, V91, pS95, DOI 10.1016/0002-9343(91)90291-5; FULLER EO, 1985, J MOL CELL CARDIOL, V17, P71, DOI 10.1016/S0022-2828(85)80093-6; Ihnken K, 1998, J THORAC CARDIOV SUR, V116, P327, DOI 10.1016/S0022-5223(98)70134-5; IHNKEN K, 1995, J THORAC CARDIOV SUR, V110, P1255, DOI 10.1016/S0022-5223(95)70012-9; JEROUDI MO, 1994, AM J CARDIOL, V73, pB2, DOI 10.1016/0002-9149(94)90257-7; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Kajstura J, 1996, LAB INVEST, V74, P86; Kin H, 2004, CARDIOVASC RES, V62, P74, DOI 10.1016/j.cardiores.2004.01.006; KUSUOKA H, 1992, ANNU REV PHYSIOL, V54, P243, DOI 10.1146/annurev.ph.54.030192.001331; LEFER DJ, 1993, CIRCULATION, V88, P2337, DOI 10.1161/01.CIR.88.5.2337; Leichtweis S, 2001, ACTA PHYSIOL SCAND, V172, P1, DOI 10.1046/j.1365-201X.2001.00820.x; Levine RL, 2000, METH MOL B, V99, P15; LIU YG, 1992, AM J PHYSIOL, V263, pH1107, DOI 10.1152/ajpheart.1992.263.4.H1107; MORITA K, 1994, J CLIN INVEST, V93, P2658, DOI 10.1172/JCI117279; OKAMOTO F, 1986, J THORAC CARDIOV SUR, V92, P613; Paradies G, 2002, GENE, V286, P135, DOI 10.1016/S0378-1119(01)00814-9; Paradies G, 2004, CIRC RES, V94, P53, DOI 10.1161/01.RES.0000109416.56608.64; PENG CF, 1989, AM HEART J, V117, P515, DOI 10.1016/0002-8703(89)90723-0; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Serviddio G, 2004, HEPATOLOGY, V39, P711, DOI 10.1002/hep.20101; Sun K, 2004, WORLD J GASTROENTERO, V10, P1934; VANDEPLASSCHE G, 1989, J MOL CELL CARDIOL, V21, P383, DOI 10.1016/0022-2828(89)90649-4; Vendemiale G, 2001, TOXICOL LETT, V123, P209, DOI 10.1016/S0378-4274(01)00401-5; YELLON DM, 1990, CARDIOSCIENCE, V1, P89; Zhao ZQ, 2003, AM J PHYSIOL-HEART C, V285, pH579, DOI 10.1152/ajpheart.01064.2002	31	87	102	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					354	361		10.1096/fj.04-2338com	http://dx.doi.org/10.1096/fj.04-2338com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746178				2022-12-25	WOS:000227901300035
J	Kim, YS; Kim, JM; Jung, DL; Kang, JE; Lee, S; Kim, JS; Seol, W; Shin, HC; Kwon, HS; Van Lint, C; Hernandez, N; Hur, MW				Kim, YS; Kim, JM; Jung, DL; Kang, JE; Lee, S; Kim, JS; Seol, W; Shin, HC; Kwon, HS; Van Lint, C; Hernandez, N; Hur, MW			Artificial zinc finger fusions targeting Sp1-binding sites and the trans-activator-responsive element potently repress transcription and replication of HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-BINDING PROTEINS; LONG TERMINAL REPEAT; PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE; HUMAN-CELLS; TAT; RNA; PROMOTER; RECEPTOR	Tat activates transcription by interacting with Sp1, NF-kappa B, positive transcription elongation factor b, and trans-activator-responsive element (TAR). Tat and Sp1 play major roles in transcription by protein-protein interactions at human immunodeficiency virus, type 1 (HIV-1) long terminal repeat. Sp1 activates transcription by interacting with cyclin T1 in the absence of Tat. To disrupt the transcription activation by Tat and Sp1, we fused Sp1-inhibiting polypeptides, zinc finger polypeptide, and the TAR-binding mutant Tat (TatdMt) together. A designed or natural zinc finger and Tat mutant fusion was used to target the fusion to the key regulatory sites (GC box and TAR) on the long terminal repeat and nascent short transcripts to disrupt the molecular interaction that normally result in robust transcription. The designed zinc finger and TatdMt fusions were targeted to the TAR, and they potently repressed both transcription and replication of HIV-1. The Sp1-yinhibiting POZ domain, TatdMt, and zinc fingers are key functional domains important in repression of transcription and replication. The designed artificial zinc fingers were targeted to the high affinity Sp1-binding site, and by being fused with TatdMt and POZ domain, they strongly block both Sp1-cyclin T1-dependent transcription and Tat-dependent transcription, even in the presence of excess expressed Tat.	Yonsei Univ, Sch Med, Inst Genet Sci, Dept Biochem & Mol Biol, Seoul 120752, South Korea; Inje Univ, Indang Inst Mol Biol, Lab Retroviruses & Gene Therapy, Seoul 100032, South Korea; Inje Univ, Dept Med Lab Sci, Seoul 100032, South Korea; BK21 Project Med Sci, Seoul 120752, South Korea; VectorCore A Inc, Taejon 305345, South Korea; Toolgen Inc, Taejon 305390, South Korea; Univ Libre Brussels, Inst Biol & Med Mol, Chim Biol Lab, B-6041 Gosselies, Belgium; Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA	Yonsei University; Inje University; Inje University; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	Hur, MW (corresponding author), Yonsei Univ, Sch Med, Inst Genet Sci, Dept Biochem & Mol Biol, 134 ShinChonDong, Seoul 120752, South Korea.	mwhur2@yumc.yonsei.ac.kr	KIM, Jin-Soo/M-6918-2013	KIM, Jin-Soo/0000-0003-4847-1306; Hernandez, Nouria/0000-0003-1465-4585; Hur, Man-Wook/0000-0002-3416-1334				Amado RG, 1999, HUM GENE THER, V10, P2255, DOI 10.1089/10430349950017239; Bae KH, 2003, NAT BIOTECHNOL, V21, P275, DOI 10.1038/nbt796; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1; Gea-Banacloche JC, 1999, AIDS, V13, pS25; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Isalan M, 2001, NAT BIOTECHNOL, V19, P656, DOI 10.1038/90264; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kim YS, 1996, J NEUROSCI RES, V43, P652, DOI 10.1002/(SICI)1097-4547(19960315)43:6<652::AID-JNR2>3.0.CO;2-D; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Lee DK, 2003, CURR TOP MED CHEM, V3, P645, DOI 10.2174/1568026033452384; Lee DK, 2002, J BIOL CHEM, V277, P26761, DOI 10.1074/jbc.M202078200; Lee MTM, 2003, J VIROL, V77, P11964, DOI 10.1128/JVI.77.22.11964-11972.2003; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Morrison DJ, 1999, NUCLEIC ACIDS RES, V27, P1251, DOI 10.1093/nar/27.5.1251; Park IW, 2001, J IMMUNOL, V167, P2766, DOI 10.4049/jimmunol.167.5.2766; Pendergrast PS, 2002, MOL BIOL CELL, V13, P915, DOI 10.1091/mbc.01-08-0383; Pierson T, 2000, J VIROL, V74, P7824, DOI 10.1128/JVI.74.17.7824-7833.2000; Reynolds L, 2003, P NATL ACAD SCI USA, V100, P1615, DOI 10.1073/pnas.252770699; Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67; Segal DJ, 2000, CURR OPIN CHEM BIOL, V4, P34, DOI 10.1016/S1367-5931(99)00048-4; Segal DJ, 2004, J BIOL CHEM, V279, P14509, DOI 10.1074/jbc.M400349200; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; Wong-Staal F, 1998, HUM GENE THER, V9, P2407, DOI 10.1089/hum.1998.9.16-2407; Yedavalli VSRK, 2003, J BIOL CHEM, V278, P6404, DOI 10.1074/jbc.M209162200	31	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21545	21552		10.1074/jbc.m414136200	http://dx.doi.org/10.1074/jbc.m414136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15743774	Green Accepted, hybrid			2022-12-25	WOS:000229438800077
J	Akimoto, T; Pohnert, SC; Li, P; Zhang, M; Gumbs, C; Rosenberg, PB; Williams, RS; Yan, Z				Akimoto, T; Pohnert, SC; Li, P; Zhang, M; Gumbs, C; Rosenberg, PB; Williams, RS; Yan, Z			Exercise stimulates Pgc-1 alpha transcription in skeletal muscle through activation of the p38 MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA COACTIVATOR-1-ALPHA EXPRESSION; JUN NH2-TERMINAL KINASE; PROTEIN-KINASE; MITOCHONDRIAL BIOGENESIS; GENE-EXPRESSION; CONTRACTILE ACTIVITY; MEF2 FAMILY; AMP KINASE; FIBER-TYPE; CALCINEURIN	Peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC-1 alpha) promotes mitochondrial biogenesis and slow fiber formation in skeletal muscle. We hypothesized that activation of the p38 mitogen-activated protein kinase ( MAPK) pathway in response to increased muscle activity stimulated Pgc-1 alpha gene transcription as part of the mechanisms for skeletal muscle adaptation. Here we report that a single bout of voluntary running induced a transient increase of Pgc-1 alpha mRNA expression in mouse plantaris muscle, concurrent with an activation of the p38 MAPK pathway. Activation of the p38 MAPK pathway in cultured C2C12 myocytes stimulated Pgc-1 alpha promoter activity, which could be blocked by the specific inhibitors of p38, SB203580 and SB202190, or a dominant negative p38. Furthermore, the p38-mediated increase in Pgc-1 alpha promoter activity was enhanced by increased expression of the downstream transcription factor ATF2 and completely blocked by ATF2 Delta N, a dominant negative ATF2. Skeletal muscle-specific expression of a constitutively active activator of p38, MKK6E, in transgenic mice resulted in enhanced Pgc-1 alpha and cytochrome oxidase IV protein expression in fast-twitch skeletal muscles. These findings suggest that contractile activity-induced activation of the p38 MAPK pathway promotes Pgc-1 alpha gene expression and skeletal muscle adaptation.	Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27704 USA	Duke University	Yan, Z (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Cardiol, 4321 Med Pk Dr,Suite 200, Durham, NC 27704 USA.	zhen.yan@duke.edu	Akimoto, Takayuki/H-6704-2012	Akimoto, Takayuki/0000-0002-8874-7779; Rosenberg, Paul/0000-0002-5659-160X; Yan, Zhen/0000-0002-4826-9813				ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; Akimoto T, 2004, AM J PHYSIOL-CELL PH, V287, pC1311, DOI 10.1152/ajpcell.00248.2004; Akimoto T, 2004, AM J PHYSIOL-CELL PH, V287, pC790, DOI 10.1152/ajpcell.00425.2003; Allen DL, 2001, J APPL PHYSIOL, V90, P1900, DOI 10.1152/jappl.2001.90.5.1900; Ambrosino C, 2003, MOL CELL BIOL, V23, P370, DOI 10.1128/MCB.23.1.370-381.2003; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; Booth FW, 2002, J APPL PHYSIOL, V93, P3, DOI 10.1152/japplphysiol.00073.2002; Boppart MD, 2001, AM J PHYSIOL-CELL PH, V280, pC352, DOI 10.1152/ajpcell.2001.280.2.C352; Boppart MD, 2000, J PHYSIOL-LONDON, V526, P663, DOI 10.1111/j.1469-7793.2000.00663.x; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100; Fan M, 2004, GENE DEV, V18, P278, DOI 10.1101/gad.1152204; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Holmes BF, 2004, AM J PHYSIOL-ENDOC M, V287, pE739, DOI 10.1152/ajpendo.00080.2004; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, pC1669, DOI 10.1152/ajpcell.00409.2002; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Li YQ, 2000, CELL SIGNAL, V12, P751, DOI 10.1016/S0898-6568(00)00120-0; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Nader GA, 2001, J APPL PHYSIOL, V90, P1936, DOI 10.1152/jappl.2001.90.5.1936; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Nielsen JN, 2003, BIOCHEM BIOPH RES CO, V312, P1147, DOI 10.1016/j.bbrc.2003.11.041; Niu WY, 2003, J BIOL CHEM, V278, P17953, DOI 10.1074/jbc.M211136200; Ojuka EO, 2003, FASEB J, V17, P675, DOI 10.1096/fj.02-0951com; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Steinmuller L, 2003, BIOL CHEM, V384, P667, DOI 10.1515/BC.2003.074; SUZUKI M, 1983, J NUTR SCI VITAMINOL, V29, P545, DOI 10.3177/jnsv.29.545; Terada S, 2004, AM J PHYSIOL-ENDOC M, V286, pE208, DOI 10.1152/ajpendo.00051.2003; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Waters RE, 2004, AM J PHYSIOL-CELL PH, V287, pC1342, DOI 10.1152/ajpcell.00247.2004; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379; Williams RS, 1996, HDB PHYSL EXERCISE R, P1124; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yan Z, 2003, J BIOL CHEM, V278, P8826, DOI 10.1074/jbc.M209879200; Yan Z, 2001, J BIOL CHEM, V276, P17361, DOI 10.1074/jbc.M101251200; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599; [No title captured]	51	485	509	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19587	19593		10.1074/jbc.M408862200	http://dx.doi.org/10.1074/jbc.M408862200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767263	hybrid			2022-12-25	WOS:000229113700021
J	Bautista, JA; Rappaport, F; Guergova-Kuras, M; Cohen, RO; Golbeck, JH; Wang, JY; Beal, D; Diner, BA				Bautista, JA; Rappaport, F; Guergova-Kuras, M; Cohen, RO; Golbeck, JH; Wang, JY; Beal, D; Diner, BA			Biochemical and biophysical characterization of photosystem I from phytoene desaturase and xi-carotene desaturase deletion mutants of Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIDIRECTIONAL ELECTRON-TRANSFER; PRIMARY CHARGE SEPARATION; IRON-SULFUR CENTERS; SYNECHOCOCCUS-SP; PHOTOCHEMICAL PROPERTIES; VIVO ANALYSIS; WILD-TYPE; A(1); PLASTOCYANIN; TEMPERATURE	In photosystem I, oxidation of reduced acceptor A(1) - through iron-sulfur cluster F-X is biphasic with half-times of similar to 5-30 ns ("fast" phase) and similar to 150-300 ns ("slow" phase). Whether these biphasic kinetics reflect unidirectional electron transfer, involving only the PsaA-side phylloquinone or bi-directional electron transfer, involving both the PsaA- and PsaB-side phylloquinones, has been the source of some controversy. Brettel ( Brettel, K. ( 1988) FEBS Lett. 239, 93 - 98) and Joliot and Joliot ( Joliot, P., and Joliot, A. ( 1999) Biochemistry 38, 11130 - 11136) have attributed to nearby carotenoids electrochromic band shifts, accompanying A(1) reduction, centered at similar to 450 and 500-510 nm. As a test of these assignments, we separately deleted in Synechocystis sp. PCC 6803 the genes that encode phytoene desaturase ( encoded by crtP (pds)) and zeta-carotene desaturase ( encoded by crtQ (zds)). The pds(-) and zds(-) strains synthesize phytoene and zeta-carotene, respectively, both of which absorb to shorter wavelength than zeta-carotene. Compared with wild type, the mutant A(1)(-)(FeS) similar to A(1)(FeS)(-) difference spectra, measured in cells and photosystem I complexes, retain the electrochromic band shift centered at 450 nm but show a complete loss of the electrochromic band shifts centered at 500 - 510 nm. Thus, the latter clearly arise from beta-carotene. In the wild type, the electrochromic band shift of the slow phase ( centered at 500 nm) is shifted by 6 nm to the blue compared with the fast phase ( centered at 506 nm). Thus, the carotenoid pigments acting as electrochromic markers during the fast and slow phases of A(1)(-) oxidation are different, indicating the involvement of both the PsaA- and the PsaB-side phylloquinones in photosystem I electron transport.	EI Du Pont Nemours & Co, Cent Res & Dev, Expt Stn, Wilmington, DE 19880 USA; Univ Paris 06, UMR 7141, CNRS, Inst Biol Phys Chim, F-75005 Paris, France; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA	DuPont; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Diner, BA (corresponding author), EI Du Pont Nemours & Co, Cent Res & Dev, Expt Stn, Wilmington, DE 19880 USA.	bruce.a.diner@usa.dupont.com		Rappaport, Fabrice/0000-0001-9377-4934				Agalarov R, 2003, BBA-BIOENERGETICS, V1604, P7, DOI 10.1016/S0005-2728(03)00024-0; Bautista JA, 1998, PHOTOSYNTH RES, V55, P49, DOI 10.1023/A:1005955425420; Beal D, 1999, REV SCI INSTRUM, V70, P202, DOI 10.1063/1.1149566; BRETTEL K, 1988, FEBS LETT, V239, P93, DOI 10.1016/0014-5793(88)80552-0; BRETTEL K, 1986, FEBS LETT, V203, P220, DOI 10.1016/0014-5793(86)80746-3; Brettel K, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P611; BRITTON G, 1985, METHOD ENZYMOL, V111, P113, DOI 10.1016/S0076-6879(85)11007-4; Britton G., 1995, SPECTROSCOPY-US, V1B, P13; Britton G., 1995, CAROTENOIDS B; Cohen RO, 2004, BIOCHEMISTRY-US, V43, P4741, DOI 10.1021/bi035633f; COUFAL J, 1989, PHOTOSYNTHETICA, V23, P603; Diner BA, 1998, METHOD ENZYMOL, V297, P337; DOBEK K, 2004, P 13 INT C PHOT MONT, P91; Fairclough WV, 2003, BBA-BIOENERGETICS, V1606, P43, DOI 10.1016/S0005-2728(03)00083-5; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; Frank HA, 1996, PHOTOCHEM PHOTOBIOL, V63, P257, DOI 10.1111/j.1751-1097.1996.tb03022.x; Fromme P, 2001, BBA-BIOENERGETICS, V1507, P5, DOI 10.1016/S0005-2728(01)00195-5; Giorgi LB, 1996, J BIOL CHEM, V271, P2093, DOI 10.1074/jbc.271.4.2093; Guergova-Kuras M, 2001, P NATL ACAD SCI USA, V98, P4437, DOI 10.1073/pnas.081078898; HASHIMOTO H, 1988, J PHYS CHEM-US, V92, P2101, DOI 10.1021/j100319a004; Heathcote P, 1996, BIOCHEMISTRY-US, V35, P6644, DOI 10.1021/bi9526185; HECKS B, 1994, BIOCHEMISTRY-US, V33, P8619, DOI 10.1021/bi00195a001; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; Ishikita H, 2003, J BIOL CHEM, V278, P52002, DOI 10.1074/jbc.M306434200; Joliot P, 1999, BIOCHEMISTRY-US, V38, P11130, DOI 10.1021/bi990857c; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KOBAYASHI M, 1988, BIOCHIM BIOPHYS ACTA, V936, P81, DOI 10.1016/0005-2728(88)90254-X; LEIBL W, 1995, BIOCHEMISTRY-US, V34, P10237, DOI 10.1021/bi00032a018; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MacMillan F, 1997, BIOCHEMISTRY-US, V36, P9297, DOI 10.1021/bi971097d; Muhiuddin IP, 2001, FEBS LETT, V503, P56, DOI 10.1016/S0014-5793(01)02696-5; MULLER KH, 1991, EUR BIOPHYS J, V19, P231; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; Ramesh VM, 2004, BIOCHEMISTRY-US, V43, P1369, DOI 10.1021/bi0354177; RAPPAPORT F, 2005, IN PRESS PHOTOSYSTEM, V1; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; ROGNER M, 1990, J BIOL CHEM, V265, P6189; ROMIJN JC, 1977, BIOCHIM BIOPHYS ACTA, V461, P327, DOI 10.1016/0005-2728(77)90223-7; SETIF P, 1993, BIOCHEMISTRY-US, V32, P7846, DOI 10.1021/bi00082a002; Setif P, 2002, BBA-BIOENERGETICS, V1555, P204, DOI 10.1016/S0005-2728(02)00279-7; Shen GZ, 2002, J BIOL CHEM, V277, P20355, DOI 10.1074/jbc.M201104200; SIEFERMANNHARMS D, 1987, PHYSIOL PLANTARUM, V69, P561, DOI 10.1111/j.1399-3054.1987.tb09240.x; TAKAHASHI Y, 1985, PHOTOSYNTH RES, V6, P183, DOI 10.1007/BF00032792; TANG XS, 1994, BIOCHEMISTRY-US, V33, P4594, DOI 10.1021/bi00181a021; Trebst A, 1997, FEBS LETT, V400, P359, DOI 10.1016/S0014-5793(96)01419-6; van der Est A, 2004, BIOCHEMISTRY-US, V43, P1264, DOI 10.1021/bi035431j; vanderEst A, 1997, J PHYS CHEM B, V101, P1437, DOI 10.1021/jp9622086; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; Xu W, 2003, J BIOL CHEM, V278, P27876, DOI 10.1074/jbc.M302965200; Yang F, 1998, J PHYS CHEM B, V102, P8288, DOI 10.1021/jp981952i; ZECHMASTER L, 1962, CIS T ISOMERIC CAROT; Zybailov B, 2000, J BIOL CHEM, V275, P8531, DOI 10.1074/jbc.275.12.8531	53	65	68	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20030	20041		10.1074/jbc.M500809200	http://dx.doi.org/10.1074/jbc.M500809200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15760840	hybrid			2022-12-25	WOS:000229113700073
J	Guo, XM; Razandi, M; Pedram, A; Kassab, G; Levin, ER				Guo, XM; Razandi, M; Pedram, A; Kassab, G; Levin, ER			Estrogen induces vascular wall dilation - Mediation through kinase signaling to nitric oxide and estrogen receptors alpha and beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; POSTMENOPAUSAL WOMEN; MYOCARDIAL-ISCHEMIA; PLASMA-MEMBRANE; BINDING SITES; ER-BETA; PATHWAY; INJURY; GENE; 17-BETA-ESTRADIOL	Estrogen has been shown to affect vascular cell and arterial function in vitro and in vivo. Here we examined the ability of estradiol (E-2) to cause rapid arterial dilation of elastic and muscular arteries in vivo and the mechanisms involved. E-2 administration caused a rapid increase in the outer wall diameter of both types of arteries in ovariectomized female mice. This resulted from estrogen receptor (ER)- mediated stimulation of nitric oxide production, demonstrated by preinjecting the mice arteries with a soluble inhibitor of nitric oxide ( monomethyl L-arginine) and by showing the absence of E-2 action in eNOS-/- mice. Rapid activation of both ERK/MAP kinase and phosphatidylinositol 3-kinase activity was found in the E-2-exposed arteries, and inhibiting either kinase prevented the vasodilatory action of E-2. Kinase activation and vasodilator responses to E-2 were absent in either ER alpha or ER beta knock-out mice, implicating both receptor subtypes as mediating this E-2 action. These results indicate that E-2 modulation of arterial tonus through plasma membrane ER and rapid signaling could underlie many previously observed actions of estrogen reported to occur in women.	Calif State Univ Long Beach, Vet Affairs Med Ctr, Med Serv, Div Endocrinol, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92717 USA	California State University System; California State University Long Beach; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine	Levin, ER (corresponding author), Calif State Univ Long Beach, Vet Affairs Med Ctr, Med Serv, Div Endocrinol, 5901 E 7th St, Long Beach, CA 90822 USA.	ellis.levin@med.va.gov	Levin, Ellis/J-5402-2013		NHLBI NIH HHS [HL055554-06, HL59890] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055554, R29HL055554, R01HL059890] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Benten WPM, 2001, ENDOCRINOLOGY, V142, P1669, DOI 10.1210/en.142.4.1669; Chambliss KL, 2002, ENDOCR REV, V23, P665, DOI 10.1210/er.2001-0045; Chambliss KL, 2002, MOL ENDOCRINOL, V16, P938, DOI 10.1210/me.16.5.938; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Cho MM, 1999, AM J PHYSIOL-CELL PH, V276, pC337; COLBURN P, 1978, SCIENCE, V201, P817, DOI 10.1126/science.684408; COLLINS P, 1995, CIRCULATION, V92, P24, DOI 10.1161/01.CIR.92.1.24; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; HERRINGTON DM, 1994, AM J CARDIOL, V73, P951, DOI 10.1016/0002-9149(94)90136-8; KARRAS RH, 1994, CIRCULATION, V89, P1943; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Konidala S, 2004, PROG CARDIOVASC DIS, V46, P349, DOI 10.1016/j.pcad.2003.10.001; Levin ER, 2001, J APPL PHYSIOL, V91, P1860, DOI 10.1152/jappl.2001.91.4.1860; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; McCrohon JA, 1997, J AM COLL CARDIOL, V29, P1432, DOI 10.1016/S0735-1097(97)00063-6; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Node K, 1997, CIRCULATION, V96, P1953, DOI 10.1161/01.CIR.96.6.1953; PAPPAS TC, 1994, ENDOCRINE, V2, P813; Pare G, 2002, CIRC RES, V90, P1087, DOI 10.1161/01.RES.0000021114.92282.FA; Pedram A, 2002, J BIOL CHEM, V277, P50768, DOI 10.1074/jbc.M210106200; Pedram A, 2002, J BIOL CHEM, V277, P44385, DOI 10.1074/jbc.M202391200; Razandi M, 2000, J BIOL CHEM, V275, P38540, DOI 10.1074/jbc.M007555200; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Razandi M, 2004, MOL ENDOCRINOL, V18, P2854, DOI 10.1210/me.2004-0115; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; ROSANO GMC, 1993, LANCET, V342, P133, DOI 10.1016/0140-6736(93)91343-K; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; Sanada M, 2003, J CLIN ENDOCR METAB, V88, P1303, DOI 10.1210/jc.2002-021147; Shlipak MG, 2001, CIRCULATION, V104, P2300, DOI 10.1161/hc4401.98414; Shughrue PJ, 2002, ENDOCRINOLOGY, V143, P1643, DOI 10.1210/en.143.5.1643; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Singer CA, 1999, J NEUROSCI, V19, P2455; TESARIK J, 1995, J CLIN ENDOCR METAB, V80, P1438, DOI 10.1210/jc.80.4.1438; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Wassmann S, 2001, CIRCULATION, V103, P435; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; Williams MRI, 2001, J CLIN ENDOCR METAB, V86, P5389, DOI 10.1210/jc.86.11.5389; Zhai PY, 2000, AM J PHYSIOL-HEART C, V278, pH1640, DOI 10.1152/ajpheart.2000.278.5.H1640; Zhu Y, 2002, SCIENCE, V295, P505, DOI 10.1126/science.1065250	43	134	139	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19704	19710		10.1074/jbc.M501244200	http://dx.doi.org/10.1074/jbc.M501244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15764600	hybrid			2022-12-25	WOS:000229113700036
J	Iancu, CV; Mukund, S; Fromm, HJ; Honzatko, RB				Iancu, CV; Mukund, S; Fromm, HJ; Honzatko, RB			R-state AMP complex reveals initial steps of the quaternary transition of fructose-1,6-bisphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-KIDNEY FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; LIVER FRUCTOSE-1,6-BISPHOSPHATASE; ALLOSTERIC INHIBITION; CRYSTAL-STRUCTURE; MECHANISM; SITE; INTERFACE; 1,6-BISPHOSPHATASE; FLUORESCENCE	AMP transforms fructose-1,6-bisphosphatase from its active R-state to its inactive T-state; however, the mechanism of that transformation is poorly understood. The mutation of Ala(54) to leucine destabilizes the T-state of fructose-1,6-bisphosphatase. The mutant enzyme retains wild-type levels of activity, but the concentration of AMP that causes 50% inhibition increases 50-fold. In the absence of AMP, the Leu(54) enzyme adopts an R-state conformation nearly identical to that of the wild-type enzyme. The mutant enzyme, however, grows in two crystal forms in the presence of saturating AMP. In one form, the AMP-bound tetramer is in a T-like conformation, whereas in the other form, the AMP-bound tetramer is in a R-like conformation. The latter reveals conformational changes in two helices due to the binding of AMP. Helix H1 moves toward the center of the tetramer and displaces Ile(10) from a hydrophobic pocket. The displacement of Ile(10) exposes a hydrophobic surface critical to interactions that stabilize the T-state. Helix H2 moves away from the center of the tetramer, breaking hydrogen bonds with a buried loop ( residues 187 195) in an adjacent subunit. The same hydrogen bonds reform but only after the quaternary transition to the T-state. Proposed here is a model that accounts for the quaternary transition and cooperativity in the inhibition of catalysis by AMP.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	honzatko@iastate.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546, R01 NS010546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carcamo JG, 2000, EUR J BIOCHEM, V267, P2242, DOI 10.1046/j.1432-1327.2000.01227.x; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Choe JY, 1998, BIOCHEMISTRY-US, V37, P11441, DOI 10.1021/bi981112u; Choe JY, 2003, J BIOL CHEM, V278, P51176, DOI 10.1074/jbc.M308396200; Choe JY, 2003, J BIOL CHEM, V278, P16008, DOI 10.1074/jbc.M212394200; Choe JY, 2003, J BIOL CHEM, V278, P16015, DOI 10.1074/jbc.M212395200; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; KE H, 1990, J MOL BIOL, V212, P513, DOI 10.1016/0022-2836(90)90329-K; KE HM, 1991, P NATL ACAD SCI USA, V88, P2989, DOI 10.1073/pnas.88.8.2989; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1991, J BIOL CHEM, V266, P11774; LIU F, 1990, J BIOL CHEM, V265, P7401; Lu GQ, 1996, PROTEIN SCI, V5, P2333, DOI 10.1002/pro.5560051120; Lu GQ, 1997, J BIOL CHEM, V272, P5076, DOI 10.1074/jbc.272.8.5076; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Nelson SW, 2002, J BIOL CHEM, V277, P15539, DOI 10.1074/jbc.M112304200; Nelson SW, 2001, J BIOL CHEM, V276, P6119, DOI 10.1074/jbc.M009485200; Nelson SW, 2001, FEBS LETT, V492, P254, DOI 10.1016/S0014-5793(01)02262-1; Nelson SW, 2000, BIOCHEMISTRY-US, V39, P11100, DOI 10.1021/bi000609c; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; Shyur LF, 1996, J BIOL CHEM, V271, P33301, DOI 10.1074/jbc.271.52.33301; Shyur LF, 1996, J BIOL CHEM, V271, P3005, DOI 10.1074/jbc.271.6.3005; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Van Schaftingen E., 1987, ADV ENZYMOL RELAT AR, V59, P45; Wen J, 2001, PHOTOCHEM PHOTOBIOL, V74, P679, DOI 10.1562/0031-8655(2001)074<0679:EOTIPF>2.0.CO;2; XUE YF, 1994, P NATL ACAD SCI USA, V91, P12482, DOI 10.1073/pnas.91.26.12482; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	38	21	22	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19737	19745		10.1074/jbc.M501011200	http://dx.doi.org/10.1074/jbc.M501011200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767255	hybrid			2022-12-25	WOS:000229113700040
J	Petrakis, TG; Sogaard, TMM; Erdjument-Bromage, H; Tempst, P; Svejstrup, JQ				Petrakis, TG; Sogaard, TMM; Erdjument-Bromage, H; Tempst, P; Svejstrup, JQ			Physical and functional interaction between Elongator and the chromatin-associated Kti12 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; KLUYVEROMYCES-LACTIS ZYMOCIN; SACCHAROMYCES-CEREVISIAE ELONGATOR; HISTONE ACETYLTRANSFERASE; SUBUNIT; HOLOENZYME; COMPLEX; TOXIN; GENES	Cells lacking KTI12 or Elongator (ELP) genes are insensitive to the toxin zymocin and also share more general phenotypes. Moreover, data from low stringency immunoprecipitation experiments suggest that Elongator and Kti12 may interact. However, the precise relationship between these factors has not been determined. Here we use a variety of approaches to investigate the possibility that Elongator and Kti12 functionally overlap. Native Kti12 purified to virtual homogeneity under stringent conditions is a single polypeptide, but depletion of Kti12 from a yeast extract results in co-depletion of Elongator, indicating that these factors do interact. Indeed, biochemical evidence suggests that Elongator and Kti12 form a fragile complex under physiological salt conditions. Purified Kti12 does not affect Elongator histone acetyltransferase activity in vitro. However, a variety of genetic experiments comparing the effects of mutation in ELP3 and KTI12 alone and in combination with other transcription factor mutations clearly demonstrate a significant functional overlap between Elongator and Kti12 in vivo. Intriguingly, chromatin immunoprecipitation experiments show that Kti12 is associated with chromatin throughout the genome, even in non-transcribed regions and in the absence of Elongator. Conversely, RNA-immunoprecipitation experiments indicate that Kti12 only plays a minor role for Elongator association with active genes. Together, these experiments indicate a close physical and functional relationship between Elongator and the highly conserved Kti12 protein.	Imperial Canc Res Fund, Clare Hall Labs, Canc Res UK London Res Inst, S Mimms EN6 3LD, Herts, England; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Cancer Research UK; Memorial Sloan Kettering Cancer Center	Svejstrup, JQ (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, Canc Res UK London Res Inst, Blanche Lane, S Mimms EN6 3LD, Herts, England.	J.svejstrup@cancer.org.uk		Svejstrup, Jesper/0000-0003-4964-6147; Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Sogaard, Teit Max Moscote/0000-0001-6224-4818				BUTLER AR, 1991, YEAST, V7, P617, DOI 10.1002/yea.320070610; Fellows J, 2000, J BIOL CHEM, V275, P12896, DOI 10.1074/jbc.275.17.12896; Fichtner L, 2003, MOL MICROBIOL, V49, P1297, DOI 10.1046/j.1365-2958.2003.03632.x; Fichtner L, 2002, MOL MICROBIOL, V45, P817, DOI 10.1046/j.1365-2958.2002.03055.x; Fichtner L, 2002, MOL MICROBIOL, V43, P783, DOI 10.1046/j.1365-2958.2002.02794.x; Frohloff F, 2003, J BIOL CHEM, V278, P956, DOI 10.1074/jbc.M210060200; Frohloff F, 2001, EMBO J, V20, P1993, DOI 10.1093/emboj/20.8.1993; Gilbert C, 2004, MOL CELL, V14, P457, DOI 10.1016/S1097-2765(04)00239-4; Gilbert CS, 2003, EMBO REP, V4, P953, DOI 10.1038/sj.embor.embor935; Jablonowski D, 2002, J BIOL CHEM, V277, P26276, DOI 10.1074/jbc.M203354200; Jablonowski D, 2001, MOL MICROBIOL, V42, P1095, DOI 10.1046/j.1365-2958.2001.02705.x; Kishida M, 1996, BIOSCI BIOTECH BIOCH, V60, P798, DOI 10.1271/bbb.60.798; Kitamoto HK, 2002, MOL GENET GENOMICS, V268, P49, DOI 10.1007/s00438-002-0720-3; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Petrakis TG, 2004, J BIOL CHEM, V279, P32087, DOI 10.1074/jbc.M403361200; STARK MJR, 1990, YEAST, V6, P1, DOI 10.1002/yea.320060102; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; Winkler GS, 2001, J BIOL CHEM, V276, P32743, DOI 10.1074/jbc.M105303200; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X	24	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19454	19460		10.1074/jbc.M413373200	http://dx.doi.org/10.1074/jbc.M413373200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772087	hybrid			2022-12-25	WOS:000229113700006
J	Price, MG; Davis, CF; Deng, F; Burgess, DL				Price, MG; Davis, CF; Deng, F; Burgess, DL			The alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate receptor trafficking regulator " stargazin" is related to the Claudin family of proteins by its ability to mediate cell-cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL MYELIN PROTEIN-22; CHANNEL GAMMA-SUBUNITS; CA2+ CHANNEL; TIGHT JUNCTIONS; AMPA RECEPTORS; BINDING-SITE; EXPRESSION; MUTANT; MOUSE; IDENTIFICATION	Mutations in the Cacng2 gene encoding the neuronal transmembrane protein stargazin result in recessively inherited epilepsy and ataxia in "stargazer" mice. Functional studies suggest a dual role for stargazin, both as a modulatory gamma subunit for voltage-dependent calcium channels and as a regulator of post- synaptic membrane targeting for alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate (AMPA)-type glutamate receptors. Co-immunoprecipitation experiments demonstrate that stargazin can bind proteins of either complex in vivo, but it remains unclear whether it can associate with both complexes simultaneously. Cacng2 is one of eight closely related genes (Cacng1-8) encoding proteins with four transmembrane segments, cytoplasmic termini, and molecular masses between 25 and 44 kDa. This group of Cacng genes constitutes only one branch of a larger monophyletic assembly dominated by over 20 genes encoding proteins known as claudins. Claudins regulate cell adhesion and paracellular permeability as fundamental components of non-neuronal tight junctions. Because stargazin is structurally similar to claudins, we hypothesized that it might also have retained claudin-like functions inherited from a common ancestor. Here, we report that expression of stargazin in mouse L-fibroblasts results in cell aggregation comparable with that produced by claudins, and present evidence that the interaction is heterotypic and calcium dependent. The data suggest that the cell adhesion function of stargazin preceded its current role in neurons as a regulator of either voltage-dependent calcium channels or AMPA receptors. We speculate these complexes may have co-opted the established presence of stargazin at sites of close cell-cell contact to facilitate their own evolving intercellular signaling functions.	Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA	Baylor College of Medicine	Burgess, DL (corresponding author), Baylor Coll Med, Dept Neurol, NB206,1 Baylor Plaza, Houston, TX 77030 USA.	dburgess@bcm.tmc.edu		Davis, Caleb/0000-0002-5125-0494	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042632] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS042632-01, NS042632, R01 NS042632-04, R01 NS042632, R01 NS042632-03, R01 NS042632-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adato A, 2002, EUR J HUM GENET, V10, P339, DOI 10.1038/sj.ejhg.5200831; Black JL, 2003, J BIOENERG BIOMEMBR, V35, P649, DOI 10.1023/B:JOBB.0000008029.22650.c5; Black JL, 1999, MAYO CLIN PROC, V74, P357, DOI 10.4065/74.4.357; Burgess DL, 2001, GENOMICS, V71, P339, DOI 10.1006/geno.2000.6440; Burgess DL, 1999, GENOME RES, V9, P1204, DOI 10.1101/gr.9.12.1204; CAMPBELL KP, 1989, ANN NY ACAD SCI, V560, P251, DOI 10.1111/j.1749-6632.1989.tb24102.x; Cereijido M, 2000, AM J PHYSIOL-GASTR L, V279, pG477, DOI 10.1152/ajpgi.2000.279.3.G477; Chen CL, 2004, J NEUROSCI, V24, P4030, DOI 10.1523/JNEUROSCI.4139-03.2004; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chen T, 2002, MOL VIS, V8, P372; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Chu PJ, 2001, GENE, V280, P37, DOI 10.1016/S0378-1119(01)00738-7; Cuadra AE, 2004, J NEUROSCI, V24, P7491, DOI 10.1523/JNEUROSCI.1255-04.2004; Davis TH, 2004, J BIOL CHEM, V279, P51424, DOI 10.1074/jbc.M410830200; DOHERTY P, 1995, J NEUROBIOL, V26, P437, DOI 10.1002/neu.480260315; Duguay D, 2003, DEV BIOL, V253, P309, DOI 10.1016/S0012-1606(02)00016-7; Fields RD, 1996, TRENDS NEUROSCI, V19, P473, DOI 10.1016/S0166-2236(96)30013-1; Force A, 1999, GENETICS, V151, P1531; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; GLOSSMANN H, 1987, BIOMED BIOCHIM ACTA, V46, pS351; Green PJ, 2001, J PHYSIOL-LONDON, V533, P467, DOI 10.1111/j.1469-7793.2001.0467a.x; Grey AC, 2003, EXP EYE RES, V77, P567, DOI 10.1016/S0014-4835(03)00192-1; Hansen JP, 2004, J MOL CELL CARDIOL, V37, P1147, DOI 10.1016/j.yjmcc.2004.08.005; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Isom LL, 2002, FRONT BIOSCI, V7, P12; Kang MG, 2003, J BIOL CHEM, V278, P21315, DOI 10.1074/jbc.R300004200; Kang MG, 2001, J BIOL CHEM, V276, P32917, DOI 10.1074/jbc.M100787200; Kious BM, 2002, DEV BIOL, V243, P249, DOI 10.1006/dbio.2001.0570; Kleene R, 2004, NAT REV NEUROSCI, V5, P195, DOI 10.1038/nrn1349; Klugbauer N, 2000, FEBS LETT, V470, P189, DOI 10.1016/S0014-5793(00)01306-5; Kobayashi J, 2002, HISTOCHEM CELL BIOL, V117, P29, DOI 10.1007/s00418-001-0359-x; Kubota K, 1999, CURR BIOL, V9, P1035, DOI 10.1016/S0960-9822(99)80452-7; LacazVieira F, 1997, J GEN PHYSIOL, V110, P727, DOI 10.1085/jgp.110.6.727; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Martin PT, 2003, J NEUROCYTOL, V32, P915, DOI 10.1023/B:NEUR.0000020632.41508.83; Mi RF, 2004, NEURON, V44, P335, DOI 10.1016/j.neuron.2004.09.029; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Moss FJ, 2002, EMBO J, V21, P1514, DOI 10.1093/emboj/21.7.1514; Nadeau JH, 1997, GENETICS, V147, P1259; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NOEBELS JL, 1990, EPILEPSY RES, V7, P129, DOI 10.1016/0920-1211(90)90098-G; Notterpek L, 2001, P NATL ACAD SCI USA, V98, P14404, DOI 10.1073/pnas.251548398; Ohno S., 1970, EVOLUTION GENE DUPLI; Prince VE, 2002, NAT REV GENET, V3, P827, DOI 10.1038/nrg928; Qiao XO, 1996, J NEUROSCI, V16, P640; Qiao XX, 1998, J NEUROSCI, V18, P6990; Richardson CA, 2005, J COMP NEUROL, V481, P145, DOI 10.1002/cne.20386; Richardson CA, 2002, J COMP NEUROL, V453, P85, DOI 10.1002/cne.10406; Rothen-Rutishauser B, 2002, J MEMBRANE BIOL, V188, P151, DOI 10.1007/s00232-001-0182-2; Rousset M, 2001, J PHYSIOL-LONDON, V532, P583, DOI 10.1111/j.1469-7793.2001.0583e.x; Sanders CR, 2001, BIOCHEMISTRY-US, V40, P9453, DOI 10.1021/bi010894f; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Sharp AH, 2001, NEUROSCIENCE, V105, P599, DOI 10.1016/S0306-4522(01)00220-2; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Spacek J, 1998, J COMP NEUROL, V393, P58, DOI 10.1002/(SICI)1096-9861(19980330)393:1<58::AID-CNE6>3.0.CO;2-P; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; Tomita S, 2003, J CELL BIOL, V161, P805, DOI 10.1083/jcb.200212116; Tomita S, 2004, SCIENCE, V303, P1508, DOI 10.1126/science.1090262; Tsukita S, 2000, ANN NY ACAD SCI, V915, P129, DOI 10.1111/j.1749-6632.2000.tb05235.x; Van Itallie CM, 2004, PHYSIOLOGY, V19, P331, DOI 10.1152/physiol.00027.2004; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Yamada A, 2003, GENES CELLS, V8, P985, DOI 10.1046/j.1356-9597.2003.00690.x; Yamagata M, 2003, CURR OPIN CELL BIOL, V15, P621, DOI 10.1016/S0955-0674(03)00107-8; Yamazaki M, 2004, NEUROSCI RES, V50, P369, DOI 10.1016/j.neures.2004.10.002; Zahraoui A, 2000, J CELL BIOL, V151, pF31, DOI 10.1083/jcb.151.5.F31; Zhang JZ, 2000, J MOL EVOL, V50, P56, DOI 10.1007/s002399910007	71	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19711	19720		10.1074/jbc.M500623200	http://dx.doi.org/10.1074/jbc.M500623200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15760900	Green Accepted, hybrid			2022-12-25	WOS:000229113700037
J	Covarrubias, AS; Larsson, AM; Hogbom, M; Lindberg, J; Bergfors, T; Bjorkelid, C; Mowbray, SL; Unge, T; Jones, TA				Covarrubias, AS; Larsson, AM; Hogbom, M; Lindberg, J; Bergfors, T; Bjorkelid, C; Mowbray, SL; Unge, T; Jones, TA			Structure and function of carbonic anhydrases from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MODEL; PARAMETERS; MECHANISM; MOTIFS; ENZYME; SITE	Carbonic anhydrases catalyze the reversible hydration of carbon dioxide to form bicarbonate. This activity is universally required for fatty acid biosynthesis as well as for the production of a number of small molecules, pH homeostasis, and other functions. At least three different carbonic anhydrase families are known to exist, of which the alpha-class found in humans has been studied in most detail. In the present work, we describe the structures of two of the three beta-class carbonic anhydrases that have been identified in Mycobacterium tuberculosis, i.e. Rv1284 and Rv3588c. Both structures were solved by molecular replacement and then refined to resolutions of 2.0 and 1.75 angstrom, respectively. The active site of Rv1284 is small and almost completely shielded from solvent, whereas that of Rv3588c is larger and quite open to solution. Differences in coordination of the active site metal are also observed. In Rv3588c, an aspartic acid side chain displaces a water molecule and coordinates directly to the zinc ion, thereby closing the zinc coordination sphere and breaking the salt link to a nearby arginine that is a feature of Rv1284. The two carbonic anhydrases thus exhibit both of the metal coordination geometries that have previously been observed for structures in this family. Activity studies demonstrate that Rv3588c is a completely functional carbonic anhydrase. The apparent lack of activity of Rv1284 in the present assay system is likely exacerbated by the observed depletion of zinc in the preparation.	Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden; Swedish Univ Agr Sci, Dept Mol Biol, S-75124 Uppsala, Sweden	Uppsala University; Swedish University of Agricultural Sciences	Jones, TA (corresponding author), Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, Box 596, S-75124 Uppsala, Sweden.	alwyn@xray.bmc.uu.se	Mowbray, Sherry L/D-2141-2013	Bjorkelid, Christofer/0000-0002-2780-7424; Hogbom, Martin/0000-0001-5574-9383				ARMSTRONG JM, 1966, J BIOL CHEM, V241, P5137; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Branden C., 1999, INTRO PROTEIN STRUCT; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cronk JD, 2001, PROTEIN SCI, V10, P911, DOI 10.1110/ps.46301; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; Kimber MS, 2000, EMBO J, V19, P1407, DOI 10.1093/emboj/19.7.1407; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; Kleywegt GJ, 1999, J MOL BIOL, V285, P1887, DOI 10.1006/jmbi.1998.2393; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; LINDSKOG S, 1993, CURR OPIN STRUC BIOL, V3, P915, DOI 10.1016/0959-440X(93)90156-F; Lindskog S, 1997, PHARMACOL THERAPEUT, V74, P1, DOI 10.1016/S0163-7258(96)00198-2; Maren T H, 1995, J Glaucoma, V4, P49; McPherson A, 1982, PREPARATION ANAL PRO; Merlin C, 2003, J BACTERIOL, V185, P6415, DOI 10.1128/JB.185.21.6415-6424.2003; Mitsuhashi S, 2000, J BIOL CHEM, V275, P5521, DOI 10.1074/jbc.275.8.5521; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALMBERG P, 1995, ARCH OPHTHALMOL-CHIC, V113, P985, DOI 10.1001/archopht.1995.01100080035025; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Rowlett RS, 2002, ARCH BIOCHEM BIOPHYS, V404, P197, DOI 10.1016/S0003-9861(02)00243-6; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Smith KS, 2002, J BACTERIOL, V184, P4240, DOI 10.1128/JB.184.15.4240-4245.2002; Smith KS, 1999, J BACTERIOL, V181, P6247, DOI 10.1128/JB.181.20.6247-6253.1999; Smith KS, 1999, P NATL ACAD SCI USA, V96, P15184, DOI 10.1073/pnas.96.26.15184; Strop P, 2001, J BIOL CHEM, V276, P10299, DOI 10.1074/jbc.M009182200; Supuran CT, 2003, MED RES REV, V23, P146, DOI 10.1002/med.10025; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	40	122	128	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18782	18789		10.1074/jbc.M414348200	http://dx.doi.org/10.1074/jbc.M414348200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753099	hybrid			2022-12-25	WOS:000228932300029
J	Rahuel-Clermont, S; Arutyunov, D; Marchal, S; Orlov, V; Muronetz, V; Branlant, G				Rahuel-Clermont, S; Arutyunov, D; Marchal, S; Orlov, V; Muronetz, V; Branlant, G			Thermal destabilization of non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase from Streptococcus mutans upon phosphate binding in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; DEPENDENT ALDEHYDE DEHYDROGENASE; D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; CATALYTIC MECHANISM; DENATURATION; SPECIFICITY; PROTEIN	Catalysis by the NADP-dependent non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPN) from Streptococcus mutans, a member of the aldehyde dehydrogenase (ALDH) family, relies on a local conformational reorganization of the active site. This rearrangement is promoted by the binding of NADP and is strongly kinetically favored by the formation of the ternary complex enzyme.NADP.substrate. Adiabatic differential scanning calorimetry was used to investigate the effect of ligands on the irreversible thermal denaturation of GAPN. We showed that phosphate binds to GAPN, resulting in the formation of a GAPN.phosphate binary complex characterized by a strongly decreased thermal stability, with a difference of at least 15 degrees C between the maximum temperatures of the thermal transition peaks. The kinetics of phosphate association and dissociation are slow, allowing both free and GAPN.phosphate complexes to be observed by differential scanning calorimetry and to be separated by native polyacrylamide electrophoresis run in phosphate buffer. Analysis of a set of mutants of GAPN strongly suggests that phosphate is bound to the substrate C-3 subsite. In addition, the substrate analog glycerol-3-phosphate has similar effects as does phosphate on the thermal behavior of GAPN. Based on the current knowledge on the catalytic mechanism of GAPN and other ALDHs, we propose that ligand-induced thermal destabilization is a mechanism that provides to ALDHs the required flexibility for an efficient catalysis.	Univ Nancy 1, Fac Sci, CNRS, UMR 7567, F-54506 Vandoeuvre Les Nancy, France; Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Moscow 119992, Russia	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Lomonosov Moscow State University	Branlant, G (corresponding author), Univ Nancy 1, Fac Sci, CNRS, UMR 7567, BP 239, F-54506 Vandoeuvre Les Nancy, France.	guy.branlant@maem.uhp-nancy.fr	Орлов, Виктор/AAH-3795-2019; Muronetz, Vladimir/C-8337-2012; MARCHAL, stéphane/M-4324-2017; Rahuel-Clermont, Sophie/AAB-3451-2020	Орлов, Виктор/0000-0001-5641-864X; MARCHAL, stéphane/0000-0002-1101-7890; Rahuel-Clermont, Sophie/0000-0001-5143-0105; Muronetz, Vladimir/0000-0001-7838-3089				BOYD DA, 1995, J BACTERIOL, V177, P2622, DOI 10.1128/jb.177.10.2622-2627.1995; Cobessi D, 1999, J MOL BIOL, V290, P161, DOI 10.1006/jmbi.1999.2853; Cobessi D, 2000, J MOL BIOL, V300, P141, DOI 10.1006/jmbi.2000.3824; Cogan EB, 1999, ANAL BIOCHEM, V271, P29, DOI 10.1006/abio.1999.4100; Habenicht A, 1997, BIOL CHEM, V378, P1413; Hammen PK, 2002, BIOCHEMISTRY-US, V41, P7156, DOI 10.1021/bi012197t; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Kurganov BI, 1997, BIOPHYS CHEM, V69, P125, DOI 10.1016/S0301-4622(97)80552-2; Levashov P, 1999, BBA-PROTEIN STRUCT M, V1433, P294, DOI 10.1016/S0167-4838(99)00132-6; Marchal S, 2002, J BIOL CHEM, V277, P39235, DOI 10.1074/jbc.M205633200; Marchal S, 2000, BIOCHEMISTRY-US, V39, P3327, DOI 10.1021/bi9914208; Marchal S, 1999, BIOCHEMISTRY-US, V38, P12950, DOI 10.1021/bi990453k; MARCHAL S, 2001, FS UFR SCI TECHNIQUE, P200; Perez-Miller SJ, 2003, BIOCHEMISTRY-US, V42, P7100, DOI 10.1021/bi034182w; Roitel O, 2002, BIOCHEMISTRY-US, V41, P7556, DOI 10.1021/bi012084+; SANCHEZRUIZ JM, 1992, BIOPHYS J, V61, P921, DOI 10.1016/S0006-3495(92)81899-4; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; Zhang L, 1999, BIOCHEMISTRY-US, V38, P11440, DOI 10.1021/bi991101g	20	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18590	18597		10.1074/jbc.M414110200	http://dx.doi.org/10.1074/jbc.M414110200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757901	hybrid, Green Published			2022-12-25	WOS:000228932300007
J	Shim, M; Eling, TE				Shim, M; Eling, TE			Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA SUPERFAMILY; NF-KAPPA-B; MACROPHAGE INHIBITORY CYTOKINE; ACTIVATED GENE NAG-1; GROWTH-FACTOR-BETA; CANCER CELLS; 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED APOPTOSIS; T-LYMPHOCYTES; FAS-LIGAND; MEMBER	NAG-1 (nonsteroidal anti-inflammatory drug-activated gene), a member of the transforming growth factor beta superfamily, is involved in cellular processes such as inflammation, apoptosis/survival, and tumorigenesis and is regulated by p53, Sp1, and Egr-1. In the current study, the regulation of NAG-1 expression in LNCaP human prostate carcinoma cells by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) was examined. TPA treatment increased NAG-1 protein and mRNA levels in a time- and concentration-dependent manner as well as NF-kappa B binding/transcriptional activity in LNCaP cells. Pretreatment with protein kinase C (PKC) inhibitor blocked the TPA-induced increase in NAG-1 protein levels and NF-kappa B binding/transcriptional activity, whereas an inhibition of p38, JNK, MEK activity had no effect on TPA-induced NAG-1 levels and NF-kappa B transcriptional activity. Expression of constitutively active PKCs induced an increase in NF-kappa B transcriptional activity and NAG-1 protein levels in LNCaP cells. The expression of NF-kappa B p65 induced NAG-1 promoter activity, and chromatin immunoprecipitation assay for p65 showed that NF-kappa B binds the NAG-1 promoter in LNCaP cells. Inhibition of TPA-induced NAG-1 expression by NAG-1 short interfering RNA blocked TPA-induced apoptosis in LNCaP cells, suggesting induction of NAG-1 negatively affects LNCaP cell survival. These results demonstrate that NAG-1 expression is up-regulated by TPA in LNCaP cells through a PKC-dependent pathway involving the activation of NF-kappa B.	NIEHS, Eicosanoids Biochem Sect, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Eling, TE (corresponding author), NIEHS, Eicosanoids Biochem Sect, Mol Carcinogenesis Lab, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	eling@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010016, ZIAES010016] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baek SJ, 2004, J BIOL CHEM, V279, P6883, DOI 10.1074/jbc.M305295200; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Bauskin AR, 2000, EMBO J, V19, P2212, DOI 10.1093/emboj/19.10.2212; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Engedal N, 2002, ONCOGENE, V21, P1017, DOI 10.1038/sj.onc.1205167; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Fujioka S, 2004, J BIOL CHEM, V279, P27549, DOI 10.1074/jbc.M313435200; Garcia-Bermejo ML, 2002, J BIOL CHEM, V277, P645, DOI 10.1074/jbc.M107639200; Garzotto M, 1998, CANCER RES, V58, P2260; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kimura K, 2002, CELL DEATH DIFFER, V9, P972, DOI 10.1038/sj.cdd.4401049; Lawton LN, 1997, GENE, V203, P17, DOI 10.1016/S0378-1119(97)00485-X; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Liu T, 2003, CANCER RES, V63, P5034; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Rameshwar P, 2000, J IMMUNOL, V165, P2271, DOI 10.4049/jimmunol.165.4.2271; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200; Spitaler M, 2004, NAT IMMUNOL, V5, P785, DOI 10.1038/ni1097; Strelau J, 2000, ADV RES NEURODEGENER, V8, P273; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Yamaguchi K, 2004, J BIOL CHEM, V279, P49617, DOI 10.1074/jbc.M408796200; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	40	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18636	18642		10.1074/jbc.M414613200	http://dx.doi.org/10.1074/jbc.M414613200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757899	hybrid			2022-12-25	WOS:000228932300013
J	Vogt, A; Tamewitz, A; Skoko, J; Sikorski, RP; Giuliano, KA; Lazo, JS				Vogt, A; Tamewitz, A; Skoko, J; Sikorski, RP; Giuliano, KA; Lazo, JS			The benzo[c] phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; KOLMOGOROV-SMIRNOV TEST; CATALYTIC ACTIVATION; DRUG DISCOVERY; APOPTOSIS; MKP-1; EXPRESSION; DEATH; PYST1; OVEREXPRESSION	Mitogen-activated protein kinase phosphatase-1 (MKP-1) is a dual specificity phosphatase that is overexpressed in many human tumors and can protect cells from apoptosis caused by DNA-damaging agents or cellular stress. Small molecule inhibitors of MKP-1 have not been reported, in part because of the lack of structural guidance for inhibitor design and definitive assays for MKP-1 inhibition in intact cells. Herein we have exploited a high content chemical complementation assay to analyze a diverse collection of pure natural products for cellular MKP-1 inhibition. Using two-dimensional Kolmogorov-Smirnov statistics, we identified sanguinarine, a plant alkaloid with known antibiotic and antitumor activity but no primary cellular target, as a potent and selective inhibitor of MKP-1. Sanguinarine inhibited cellular MKP-1 with an IC50 of 10 mu M and showed selectivity for MKP-1 over MKP-3. Sanguinarine also inhibited MKP-1 and the MKP-1 like phosphatase, MKP-L, in vitro with IC50 values of 17.3 and 12.5 mu M, respectively, and showed 5-10-fold selectivity for MKP-3 and MKP-1 over VH-1-related phosphatase, Cdc25B(2), or protein-tyrosine phosphatase 1B. In a human tumor cell line with high MKP-1 levels, sanguinarine caused enhanced ERK and JNK/SAPK phosphorylation. A close congener of sanguinarine, chelerythrine, also inhibited MKP-1 in vitro and in whole cells, and activated ERK and JNK/SAPK. In contrast, sanguinarine analogs lacking the benzophenanthridine scaffold did not inhibit MKP-1 in vitro or in cells nor did they cause ERK or JNK/SAPK phosphorylation. These data illustrate the utility of a chemical complementation assay linked with multiparameter high content cellular screening.	Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lazo, JS (corresponding author), Univ Pittsburgh, Dept Pharmacol, Hillman Canc Ctr G-27A, Pittsburgh, PA 15213 USA.	lazo@pitt.edu	Skoko, John/AAL-1885-2021	Skoko, John/0000-0002-1885-6929	NATIONAL CANCER INSTITUTE [U01CA052995, P01CA078039, U19CA052995] Funding Source: NIH RePORTER; NCI NIH HHS [CA78039, CA52995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhami VM, 2004, MOL CANCER THER, V3, P933; Bang YJ, 1998, BIOCHEM BIOPH RES CO, V250, P43, DOI 10.1006/bbrc.1998.9256; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Colombo ML, 1996, PHARMACOL RES, V33, P127, DOI 10.1006/phrs.1996.0019; COX C, 1988, CYTOMETRY, V9, P291, DOI 10.1002/cyto.990090404; Denkert C, 2002, INT J CANCER, V102, P507, DOI 10.1002/ijc.10746; Ding ZH, 2002, BIOCHEM PHARMACOL, V63, P1415, DOI 10.1016/S0006-2952(02)00902-4; Dowd S, 1998, J CELL SCI, V111, P3389; Eun JP, 2004, BIOCHEM BIOPH RES CO, V317, P618, DOI 10.1016/j.bbrc.2004.03.077; FASANO G, 1987, MON NOT R ASTRON SOC, V225, P155, DOI 10.1093/mnras/225.1.155; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Giuliano KA, 2004, J BIOMOL SCREEN, V9, P557, DOI 10.1177/1087057104265387; Giuliano KA, 1997, J BIOMOL SCREEN, V2, P249, DOI 10.1177/108705719700200410; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Houghton Janet A., 1999, Current Opinion in Oncology, V11, P475, DOI 10.1097/00001622-199911000-00008; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Lampariello F, 2000, CYTOMETRY, V39, P179, DOI 10.1002/(SICI)1097-0320(20000301)39:3<179::AID-CYTO2>3.0.CO;2-I; Lazo JS, 2001, J MED CHEM, V44, P4042, DOI 10.1021/jm0102046; Lee SS, 2001, PHYTOTHER RES, V15, P167, DOI 10.1002/ptr.703; Liao Q, 2003, GASTROENTEROLOGY, V124, P1830, DOI 10.1016/S0016-5085(03)00398-6; Loda M, 1996, AM J PATHOL, V149, P1553; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; MAJNO G, 1995, AM J PATHOL, V146, P3; PEACOCK JA, 1983, MON NOT R ASTRON SOC, V202, P615, DOI 10.1093/mnras/202.3.615; Press W. H., 1992, NUMERICAL RECIPES FO, P640; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Small GW, 2004, MOL PHARMACOL, V66, P1478, DOI 10.1124/mol.104.003400; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; Tanaka S, 2001, PLANTA MED, V67, P108, DOI 10.1055/s-2001-11514; Vogt A, 2003, CHEM BIOL, V10, P733, DOI 10.1016/S1074-5521(03)00170-4; Vogt A, 2001, J BIOL CHEM, V276, P20544, DOI 10.1074/jbc.M100078200; Wang BH, 1997, PLANTA MED, V63, P494, DOI 10.1055/s-2006-957749; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Watson JV, 2001, CYTOMETRY, V43, P55, DOI 10.1002/1097-0320(20010101)43:1<55::AID-CYTO1019>3.0.CO;2-T; WOLFF J, 1993, BIOCHEMISTRY-US, V32, P13334, DOI 10.1021/bi00211a047; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009; 2002, EUROPEAN PHARMACOPOE, V4, P2841	41	159	167	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19078	19086		10.1074/jbc.M501467200	http://dx.doi.org/10.1074/jbc.M501467200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753082	hybrid			2022-12-25	WOS:000228932300064
J	Dodge, JE; Okano, M; Dick, F; Tsujimoto, N; Chen, TP; Wang, SM; Ueda, Y; Dyson, N; Li, E				Dodge, JE; Okano, M; Dick, F; Tsujimoto, N; Chen, TP; Wang, SM; Ueda, Y; Dyson, N; Li, E			Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CANCER-CELLS; DE-NOVO METHYLATION; CPG METHYLATION; TUMOR-FORMATION; STEM-CELLS; LSH; METHYLTRANSFERASES; HETEROCHROMATIN; PROLIFERATION; PATTERNS	DNA hypomethylation is a hallmark of many types of solid tumors. However, it remains elusive how DNA hypomethylation may contribute to tumorigenesis. In this study, we have investigated how targeted disruption of the DNA methyltransferases Dnmt3a and Dnmt3b affects the growth of mouse embryonic fibroblasts (MEFs). Our studies led to the following observations. 1) Constitutive or conditional deletion of Dnmt3b, but not Dnmt3a, resulted in partial loss of DNA methylation throughout the genome, suggesting that Dnmt3b, in addition to the major maintenance methyltransferase Dnmt1, is required for maintaining DNA methylation in MEF cells. 2) Dnmt3b-deficient MEF cells showed aneuploidy and polyploidy, chromosomal breaks, and fusions. 3) Inactivation of Dnmt3b resulted in either premature senescence or spontaneous immortalization of MEF cells. 4) The G(1) to S-phase checkpoint was intact in primary and spontaneously immortalized Dnmt3b-deficient MEFs because the p53 protein was inducible by DNA damage. Interestingly, protein levels of the cyclin-dependent kinase inhibitor p21 were increased in immortalized Dnmt3b-deficient MEFs even in the absence of p53 induction. These results suggest that DNA hypomethylation may induce genomic instability, which in turn leads to spontaneous immortalization or premature senescence of Dnmt3b-deficient MEFs via a p53-independent mechanism.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Canc Res Ctr, Charlestown, MA 02129 USA; RIKEN, Ctr Dev Biol, Kobe, Hyogo 6500047, Japan	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; RIKEN	Li, E (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.	en.li@pharma.novartis.com	Ueda, Yoshihide/S-7620-2016	Ueda, Yoshihide/0000-0003-3196-3494	NCI NIH HHS [CA82389] Funding Source: Medline; NIGMS NIH HHS [GM52106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chen TP, 2004, CURR TOP DEV BIOL, V60, P55; Chen TP, 2004, MOL CELL BIOL, V24, P9048, DOI 10.1128/MCB.24.20.9048-9058.2004; Chen TP, 2002, J BIOL CHEM, V277, P38746, DOI 10.1074/jbc.M205312200; Dennis K, 2001, GENE DEV, V15, P2940, DOI 10.1101/gad.929101; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dodge JE, 1998, INT J CANCER, V78, P561, DOI 10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO;2-R; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Fan T, 2003, CANCER RES, V63, P4677; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Hernandez L, 2003, P NATL ACAD SCI USA, V100, P13344, DOI 10.1073/pnas.2234026100; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633; Lei H, 1996, DEVELOPMENT, V122, P3195; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Yan QS, 2003, MOL CELL BIOL, V23, P8416, DOI 10.1128/MCB.23.23.8416-8428.2003	26	192	202	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17986	17991		10.1074/jbc.M413246200	http://dx.doi.org/10.1074/jbc.M413246200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15757890	hybrid			2022-12-25	WOS:000228807200053
J	Kotoshiba, S; Kamura, T; Hara, T; Ishida, N; Nakayama, KI				Kotoshiba, S; Kamura, T; Hara, T; Ishida, N; Nakayama, KI			Molecular dissection of the interaction between p27 and Kip1 ubiquitylation-promoting complex, the ubiquitin ligase that regulates proteolysis of p27 in G(1) phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; BREAST-CANCER; P27(KIP1) GENE; MUTATIONAL ANALYSIS; MICE LACKING; CYCLIN-E; S-PHASE; DEGRADATION; PHOSPHORYLATION	The cyclin-dependent kinase (CDK) inhibitor p27 is degraded at the G(0)-G(1) transition of the cell cycle by the ubiquitin-proteasome pathway in a Skp2-independent manner. We recently identified a novel ubiquitin ligase, KPC (Kip1 ubiquitylation-promoting complex), consisting of KPC1 and KPC2, which regulates the ubiquitin-dependent degradation of p27 at G(1) phase. We have now investigated the structural requirements for the interactions of KPC1 with KPC2 and p27. The NH2-terminal region of KPC1 was found to be responsible for binding to KPC2 and to p27. KPC1 mutants that lack this region failed to mediate polyubiquitylation of p27 in vitro and expression of one such mutant delayed p27 degradation in vivo. We also generated a series of deletion mutants of p27 and found that KPC failed to polyubiquitylate a p27 mutant that lacks the CDK inhibitory domain. Interestingly, the cyclin E.CDK2 complex prevented both the interaction of KPC with p27 as well as KPC-mediated polyubiquitylation of p27. A complex of cyclin E with a kinase-negative mutant of CDK2 also exhibited these inhibitory effects, suggesting that cyclin E.CDK2 competes with KPC1 for access to the CDK inhibitory domain of p27. These results suggest that free p27 is recognized by the NH2-terminal region of KPC1, which also associates with KPC2, and that p27 is then polyubiquitylated by the COOH-terminal RING-finger domain of KPC1.	Kyushu Univ, Dept Mol & Cellular Biol, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawagoe, Saitama 3320012, Japan; Tohoku Univ, Dept Dev Biol, Ctr Translat & Adv Anim Res Human Dis, Aoba Ku,Grad Sch Med, Sendai, Miyagi 9808575, Japan	Kyushu University; Japan Science & Technology Agency (JST); Tohoku University	Nakayama, KI (corresponding author), Kyushu Univ, Dept Mol & Cellular Biol, Med Inst Bioregulat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	nakayak1@bioreg.kyushu-u.ac.jp						Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Ferrando AA, 1996, HUM GENET, V97, P91; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Kawamata N, 1996, CANCER, V77, P570; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kotake Y, 2005, J BIOL CHEM, V280, P1095, DOI 10.1074/jbc.M406117200; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Mikolajczyk M, 2003, BIOCHEM BIOPH RES CO, V310, P14, DOI 10.1016/j.bbrc.2003.08.116; Minamishima YA, 2002, CANCER RES, V62, P995; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Seriu T, 1996, LEUKEMIA, V10, P345; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Spirin KS, 1996, CANCER RES, V56, P2400; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stegmaier K, 1996, CANCER RES, V56, P1413; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tan P, 1997, CANCER RES, V57, P1259; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	54	72	79	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17694	17700		10.1074/jbc.M500866200	http://dx.doi.org/10.1074/jbc.M500866200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746103	hybrid			2022-12-25	WOS:000228807200018
J	Lin, H; Monaco, G; Sun, T; Ling, XY; Stephens, C; Xie, SH; Belmont, J; Arlinghaus, A				Lin, H; Monaco, G; Sun, T; Ling, XY; Stephens, C; Xie, SH; Belmont, J; Arlinghaus, A			Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia	ONCOGENE			English	Article						BCR-ABL; lipocalin 2; leukemia; hematopoiesis; apoptosis	NORMAL GRANULOPOIESIS INVITRO; HUMAN NEUTROPHIL GELATINASE; CHRONIC MYELOID-LEUKEMIA; INHIBITOR LAI; PROTEIN; LIPOCALIN; MOUSE; CELLS; FIBROBLASTS; INDUCTION	A variety of experimental evidence including findings in various mouse models indicates that the BCR-ABL oncogene is the cause of chronic myeloid leukemia (CML). Since normal hematopoietic cells in marrow and spleen are replaced with proliferating leukemic blasts, we determined whether this is an active process mediated by the leukemia cells. The lipocalin 24p3 was reported to be secreted by mouse hematopoietic cells deprived of IL-3, resulting in apoptosis induction in a variety of hematopoietic cells including bone marrow cells. Here, we show that BCR-ABL + mouse hematopoietic cells induced persistent expression and secretion of 24p3. Importantly, BCR-ABL + hematopoietic cells were resistant to the apoptotic effects of 24p3. The expression of the Bcr-Abl oncoprotein and its tyrosine kinase were required for induction of 24p3 expression. Co-culture studies showed that BCR-ABL + cells induced apoptosis in BCR-ABL negative cells. Antisense 24p3/siRNA expression reduced the level of 24p3 protein in both BCR-ABL + cells and in conditioned medium ( CM) obtained from these cells. CM from BCR-ABL + cells expressing antisense 24p3/siRNA had reduced apoptotic activity for target cells; 24p3 antibody also reduced the apoptotic activity of the CM. Leukemic mice induced by BCR-ABL + cells expressing either antisense 24p3 or 24p3 siRNA had increased levels of normal hematopoiesis and reduced invasion of leukemia cells in marrow and spleen tissues. These findings indicate that suppression of normal hematopoiesis in BCR-ABL-induced leukemia is an active process involving secretion of the cell death-inducing factor 24p3 by mouse leukemia cells, raising the possibility that similar factors are involved in BCR-ABL + CML.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, A (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rarlingh@mdanderson.org	Belmont, John W/AAI-2494-2019; Belmont, John/AAH-6084-2021	Belmont, John W/0000-0001-7409-3578; 	NCI NIH HHS [CA16672, CA49639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA049639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DAVIS TR, 1991, BIOCHIM BIOPHYS ACTA, V1095, P145, DOI 10.1016/0167-4889(91)90077-B; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Eaves C, 1998, LEUKEMIA RES, V22, P1085, DOI 10.1016/S0145-2126(98)00113-1; El Ouriaghli F, 2003, BLOOD, V102, P3786; FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Guo JQ, 2002, LEUKEMIA, V16, P2447, DOI 10.1038/sj.leu.2402730; Kjeldsen L, 2000, BBA-PROTEIN STRUCT M, V1482, P272, DOI 10.1016/S0167-4838(00)00152-7; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Lin F, 2001, ONCOGENE, V20, P1873, DOI 10.1038/sj.onc.1204409; Ling XY, 2003, CANCER RES, V63, P298; Liu QS, 1997, MOL REPROD DEV, V46, P507, DOI 10.1002/(SICI)1098-2795(199704)46:4&lt;507::AID-MRD9&gt;3.0.CO;2-S; MATULONIS UA, 1995, BLOOD, V85, P2507, DOI 10.1182/blood.V85.9.2507.bloodjournal8592507; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; OLOFSSON T, 1980, BLOOD, V55, P983; OLOFSSON T, 1980, BLOOD, V55, P975; Salomoni P, 2000, BLOOD, V96, P676; Skold S, 1999, BLOOD, V93, P849, DOI 10.1182/blood.V93.3.849.403k07_849_856; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942; Yousefi S, 2002, CELL DEATH DIFFER, V9, P595, DOI 10.1038/sj.cdd.4401037	23	45	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3246	3256		10.1038/sj.onc.1208500	http://dx.doi.org/10.1038/sj.onc.1208500			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735695				2022-12-25	WOS:000228881800003
J	Miralem, T; Hu, ZB; Torno, MD; Lelli, KM; Maines, MD				Miralem, T; Hu, ZB; Torno, MD; Lelli, KM; Maines, MD			Small interference RNA-mediated gene silencing of human biliverdin reductase, but not that of heme oxygenase-1, attenuates arsenite-mediated induction of the oxygenase and increases apoptosis in 293A kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; IX-ALPHA REDUCTASE; NF-KAPPA-B; CARBON-MONOXIDE; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; HYDROGEN-PEROXIDE; BETA REDUCTASE; MESSENGER-RNA; BILE-PIGMENTS	BVR reduces biliverdin, the HO-1 and HO-2 product, to bilirubin. Human biliverdin ( BVR) is a serine/threonine kinase activated by free radicals. It is a leucine zipper (bZip) DNA-binding protein and a regulatory factor for 8/7-bp AP-1-regulated genes, including HO-1 and ATF-2/CREB. Presently, small interference ( si) RNA constructs were used to investigate the role of human BVR in sodium arsenite (As)-mediated induction of HO-1 and in cytoprotection against apoptosis. Activation of BVR involved increased serine/threonine phosphorylation but not its protein or transcript levels. The peak activity at 1 h ( 4 -5-fold) after treatment of 293A cells with 5 mu M As preceded induction of HO-1 expression by 3 h. The following suggests BVR involvement in regulating oxidative stress response of HO-1: siBVR attenuated As-mediated increase in HO-1 expression; siBVR, but not siHO-1, inhibited As-dependent increased c-jun promoter activity; treatment of cells with As increased AP-1 binding of nuclear proteins; BVR was identified in the DNA-protein complex; and AP-1 binding of the in vitro translated BVR was phosphorylation-dependent and was attenuated by biliverdin. Most unexpectedly, cells transfected with siBVR, but not siHO-1, displayed a 4-fold increase in apoptotic cells when treated with 10 mu M As as detected by flow cytometry. The presence of BVR small interference RNA augmented the effect of As on levels of cytochrome c, TRAIL, and DR-5 mRNA and cleavage of poly( ADP-ribose) polymerase. The findings describe the function of BVR in HO-1 oxidative response and, demonstrate, for the first time, not only that BVR advances the role of HO-1 in cytoprotection but also affords cytoprotection independent of heme degradation.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14624 USA	University of Rochester	Maines, MD (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, 601 Elmwood Ave, Rochester, NY 14624 USA.	mahin_maines@urmc.rochester.edu	Miralem, Tihomir/F-7576-2013	Miralem, Tihomir/0000-0001-7705-0442	NIEHS NIH HHS [R01/ES12187, R01/ES04066] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004066, R01ES012187] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmad Z, 2002, J BIOL CHEM, V277, P9226, DOI 10.1074/jbc.M108239200; ALAM J, 1994, J BIOL CHEM, V269, P25049; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Barchowsky A, 1996, FREE RADICAL BIO MED, V21, P783, DOI 10.1016/0891-5849(96)00174-8; Bode AM, 2002, CRIT REV ONCOL HEMAT, V42, P5, DOI 10.1016/S1040-8428(01)00215-3; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen Nan-Yue, 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P297; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Chen YH, 2003, EXP BIOL MED, V228, P447, DOI 10.1177/15353702-0322805-03; CHIKUBA K, 1994, BIOCHEM BIOPH RES CO, V198, P1170, DOI 10.1006/bbrc.1994.1165; CHOI SY, 1996, J PARODONTOL IMPLANT, V15, P19; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Durante W, 1997, AM J PHYSIOL-HEART C, V273, pH317, DOI 10.1152/ajpheart.1997.273.1.H317; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; Falchuk KH, 2002, P NATL ACAD SCI USA, V99, P251, DOI 10.1073/pnas.012616099; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; Gong PF, 2002, ARCH BIOCHEM BIOPHYS, V405, P265, DOI 10.1016/S0003-9861(02)00404-6; Haga Y, 1996, BBA-MOL BASIS DIS, V1316, P29, DOI 10.1016/0925-4439(96)00004-X; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; Hansen TWR, 1996, PEDIATR RES, V39, P1072, DOI 10.1203/00006450-199606000-00023; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUANG TJ, 1989, J BIOL CHEM, V264, P7844; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Jung DK, 2003, EXP CELL RES, V290, P144, DOI 10.1016/S0014-4827(03)00320-3; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kietzmann T, 2003, J BIOL CHEM, V278, P17927, DOI 10.1074/jbc.M203929200; Kitamuro T, 2003, J BIOL CHEM, V278, P9125, DOI 10.1074/jbc.M209939200; Komuro A, 1996, BIOL PHARM BULL, V19, P796; Kravets A, 2004, J BIOL CHEM, V279, P19916, DOI 10.1074/jbc.M314251200; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; KUTTY RK, 1984, BIOCHEM BIOPH RES CO, V122, P40, DOI 10.1016/0006-291X(84)90436-4; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; Liao WT, 2004, J INVEST DERMATOL, V122, P125, DOI 10.1046/j.0022-202X.2003.22109.x; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; MAINES MD, 1993, ARCH BIOCHEM BIOPHYS, V300, P320, DOI 10.1006/abbi.1993.1044; Maines MD, 1996, EUR J BIOCHEM, V235, P372, DOI 10.1111/j.1432-1033.1996.00372.x; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Maines MD, 2003, TOXICOL SCI, V71, P9, DOI 10.1093/toxsci/71.1.9; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Maines MD, 2001, J PHARMACOL EXP THER, V296, P1091; MAINES MD, 1992, HEME OXYGENASE CLIN, P1; Miralem T, 2003, MOL CELL BIOL, V23, P579, DOI 10.1128/MCB.23.2.579-593.2003; Morse D, 2002, CRIT CARE MED, V30, pS12, DOI 10.1097/00003246-200201001-00002; Motterlini R, 2000, FREE RADICAL BIO MED, V28, P1303, DOI 10.1016/S0891-5849(00)00294-X; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; NAKAGAMI T, 1993, BIOCHIM BIOPHYS ACTA, V1158, P189, DOI 10.1016/0304-4165(93)90013-X; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Parry N, 1999, TRANSPLANTATION, V67, pS252, DOI 10.1097/00007890-199904150-01006; Phelan D, 1998, ARCH BIOCHEM BIOPHYS, V357, P155, DOI 10.1006/abbi.1998.0814; Qian Y, 2003, J INORG BIOCHEM, V96, P271, DOI 10.1016/S0162-0134(03)00235-6; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; Shalloe F, 1996, BIOCHEM J, V316, P385, DOI 10.1042/bj3160385; Shen ZY, 2002, WORLD J GASTROENTERO, V8, P40, DOI 10.3748/wjg.v8.i1.40; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; Sinal CJ, 1997, MOL PHARMACOL, V52, P590, DOI 10.1124/mol.52.4.590; SINGLETON JW, 1965, J BIOL CHEM, V240, P4780; Song RP, 2004, J IMMUNOL, V172, P1220, DOI 10.4049/jimmunol.172.2.1220; Stocker R, 2004, ANTIOXID REDOX SIGN, V6, P841, DOI 10.1089/1523086041797999; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; Wijayanti N, 2004, ANTIOXID REDOX SIGN, V6, P802, DOI 10.1089/1523086041798132; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; YAMAGUCHI T, 1994, J BIOL CHEM, V269, P24343; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; Zhang XC, 2004, J BIOL CHEM, V279, P10677, DOI 10.1074/jbc.M312941200	71	85	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17084	17092		10.1074/jbc.M413121200	http://dx.doi.org/10.1074/jbc.M413121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15741166	hybrid			2022-12-25	WOS:000228615500067
J	Hideshima, T; Chauhan, D; Ishitsuka, K; Yasui, H; Raje, N; Kumar, S; Podar, K; Mitsiades, C; Hideshima, H; Bonham, L; Munshi, NC; Richardson, PG; Singer, JW; Anderson, KC				Hideshima, T; Chauhan, D; Ishitsuka, K; Yasui, H; Raje, N; Kumar, S; Podar, K; Mitsiades, C; Hideshima, H; Bonham, L; Munshi, NC; Richardson, PG; Singer, JW; Anderson, KC			Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors	ONCOGENE			English	Article						lysophosphatidic acid acyltransferase-beta inhibitor; bortezomib; PS-341; caspase; necrosis; cell cycle	PROTEASOME INHIBITOR PS-341; MULTIPLE-MYELOMA CELLS; REFRACTORY HEMATOLOGIC MALIGNANCIES; ACID ACYLTRANSFERASE-BETA; DNA FRAGMENTATION FACTOR; HIGH-DOSE THERAPY; NF-KAPPA-B; LYSOPHOSPHATIDIC ACID; DRUG-RESISTANCE; CAM-DR	PS-341 (bortezomib, Velcade(TM)) is a promising novel agent for treatment of advanced multiple myeloma ( MM); however, 65% of patients with relapsed refractory disease in a phase II study do not respond to PS-341. We have previously shown that lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitor CT-32615 triggers caspase-dependent apoptosis, and can overcome resistance to conventional therapeutics (i.e., dexamethasone, doxorubicin, melphalan) in MM cells. In this study, we therefore determined whether CT-32615 could also overcome resistance to PS- 341. We first characterized molecular mechanisms of resistance to PS- 341 in DHL-4 cells. DHL-4 cells express low levels of caspase-3 and caspase-8; furthermore, no cleavage in caspase-8, caspase-9, caspase-3, poly ADP-ribose polymerase ( PARP), or DNA fragmentation factor 45 was triggered by PS- 341 treatment. We have previously shown that PS- 341 treatment triggers phosphorylation of c-Jun NH2-terminal kinase (JNK), which subsequently induces caspase-dependent apoptosis; conversely, JNK inhibition blocks PS- 341-induced apoptosis. We here show that phosphorylation of SEK-1, JNK, and c-Jun are not induced by PS-341 treatment, suggesting that PS- 341 does not trigger a stress response in DHL-4 cells. Importantly, CT-32615 inhibits growth of DHL-4 cells in a time-and dose-dependent fashion: a transient G2/M cell cycle arrest induced by CT-32615 is mediated via downregulation of cdc25c and cdc2. CT-32615 triggered swelling and lysis of DHL-4 cells, without caspase/PARP cleavage or TUNEL-positivity, suggesting a necrotic response. Our studies therefore demonstrate that LPAAT-beta inhibitor CT-32615 triggers necrosis, even in PS-341-resistant DHL-4 cells, providing the framework for its evaluation to overcome clinical PS- 341 resistance and improve patient outcome.	Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Cell Therapeut Inc, Seattle, WA 98119 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Mayer 557,44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Podar, Klaus/ABD-1112-2020; Munshi, Nikhil/ABE-2338-2021	Podar, Klaus/0000-0002-7414-3632; Yasui, Hiroshi/0000-0003-0905-6855; Singer, Jack/0000-0003-4001-4549	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [IP50 CA10070-01, R0-1 CA 50947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attal M, 2001, SEMIN HEMATOL, V38, P226, DOI 10.1053/shem.2001.26005; Bonham L, 2003, EXPERT OPIN THER TAR, V7, P643; Chauhan D, 2003, CANCER RES, V63, P6174; Coon M, 2003, MOL CANCER THER, V2, P1067; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Fermand JP, 1998, BLOOD, V92, P3131, DOI 10.1182/blood.V92.9.3131.421k30_3131_3136; GREGORY WM, 1992, J CLIN ONCOL, V10, P334, DOI 10.1200/JCO.1992.10.2.334; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2004, ONCOGENE, V23, P8766, DOI 10.1038/sj.onc.1208118; Hideshima T, 2003, CANCER RES, V63, P8428; Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170; Hideshima T, 2003, IMMUNOL REV, V194, P164, DOI 10.1034/j.1600-065X.2003.00053.x; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Koester SK, 1997, CYTOMETRY, V29, P306; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; LeBlanc R, 2002, CANCER RES, V62, P4996; Lenhoff S, 2000, BLOOD, V95, P7; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Orlowski RZ, 2003, BLOOD, V102, p449A; Pasquali S, 1998, J CLIN ONCOL, V16, P3832; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Yang F, 2003, CYTOGENET GENOME RES, V102, P235, DOI 10.1159/000075755	34	35	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3121	3129		10.1038/sj.onc.1208522	http://dx.doi.org/10.1038/sj.onc.1208522			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735676				2022-12-25	WOS:000228728100006
J	Qian, Y; Zhong, XS; Flynn, DC; Zheng, JZ; Qiao, M; Wu, CY; Dedhar, S; Shi, XL; Jiang, BH				Qian, Y; Zhong, XS; Flynn, DC; Zheng, JZ; Qiao, M; Wu, CY; Dedhar, S; Shi, XL; Jiang, BH			ILK mediates actinfilament rearrangements and cell migration and invasion through PI3K/Akt/Rac1 signaling	ONCOGENE			English	Article						ILK; PI3K; Akt; p70S6K1; Rac1; actin filaments	INTEGRIN-LINKED KINASE; ENDOTHELIAL GROWTH-FACTOR; ACTIN CYTOSKELETON; PROTEIN-KINASE; ALPHA-6-BETA-4 INTEGRIN; EXTRACELLULAR-MATRIX; PLASMA-MEMBRANE; FOCAL ADHESION; AKT; PHOSPHORYLATION	One of the hallmarks of integrin signaling is an increase in cell migration and invasion, both of which are associated with actin. lament rearrangements. Integrin-linked kinase ( ILK) is a cytoplasmic effector of integrin receptors. ILK is known to be involved in multiple cellular functions. However, the signaling pathways involved in ILK-mediated cellular structure and motility remain to be elucidated. Here, we have demonstrated that overexpression of ILK was sufficient to induce actin. lament rearrangements, to form cell motility structures, and to increase cell migration and invasion in a phosphatidylinositol 3-kinase (PI3K)-dependent manner. This corresponds with the activation of both Akt and p70 ribosomal protein S6 kinase (p70S6K1). Overexpression of dominant-negative mutants of Akt inhibited ILK-dependent activation of p70S6K1, indicating that Akt is upstream of p70S6K1 in response to ILK signaling. Overexpression of ILK was sufficient to induce Rac1 activation, which was abolish by a PI3K inhibitor, indicating that Rac1 activity is involved in ILK signaling in a PI3K dependent manner. Inhibition of Akt, Rac1, or p70S6K1 inhibited the effects of ILK on actin. laments and cell migration, suggesting a regulatory role of the PI3K/Akt/p70S6K1/Rac1 signaling pathway in response to ILK signaling. We have shown that overexpression of a dominant-negative ILK was sufficient to abolish fibronectin peptide (PHSRN)-induced rearrangements of actin. laments and cell migration and invasion. Taken together, our results identify a mechanism through which ILK can regulate both integrin-associated rearrangements of actin. laments and cell migration and invasion at the integrin receptor - proximal region.	NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26506 USA; W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Univ British Columbia, Vancouver, BC V6H 3Z6, Canada; British Columbia Canc Agcy, Vancouver, BC V6H 3Z6, Canada; Vancouver Hosp, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); West Virginia University; West Virginia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of British Columbia; British Columbia Cancer Agency; University of British Columbia	Qian, Y (corresponding author), NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26506 USA.	yaq2@cdc.gov; bhjiang@hsc.wvu.edu	Shi, Xianglin/B-8588-2012	Jiang, Bing-Hua/0000-0003-4526-2031; Dedhar, Shoukat/0000-0003-4355-1657	NATIONAL CANCER INSTITUTE [R01CA060731, R29CA060731] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016440] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065188] Funding Source: NIH RePORTER; NCI NIH HHS [CA60731] Funding Source: Medline; NCRR NIH HHS [RR16440] Funding Source: Medline; NIDDK NIH HHS [DK54639] Funding Source: Medline; NIGMS NIH HHS [GM65188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguiar RCT, 2000, BLOOD, V96, P4328, DOI 10.1182/blood.V96.13.4328.h8004328_4328_4334; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Cary LA, 1999, HISTOL HISTOPATHOL, V14, P1001, DOI 10.14670/HH-14.1001; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Defilippi P, 1999, MICROSC RES TECHNIQ, V47, P67, DOI 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.3.CO;2-G; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Liu YP, 2002, CELL SIGNAL, V14, P145, DOI 10.1016/S0898-6568(01)00246-7; Livant DL, 2000, CANCER RES, V60, P309; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2003, J BIOL CHEM, V278, P16189, DOI 10.1074/jbc.M207517200; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Stupack DG, 2000, IMMUNOL RES, V21, P83, DOI 10.1385/IR:21:2-3:83; Svoboda KKH, 1999, ANAT REC, V254, P348, DOI 10.1002/(SICI)1097-0185(19990301)254:3<348::AID-AR5>3.0.CO;2-5; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; VAN AL, 1997, GENE DEV, V11, P2295; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Yoganathan N, 2002, PHARMACOL THERAPEUT, V93, P233, DOI 10.1016/S0163-7258(02)00192-4; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	43	123	134	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3154	3165		10.1038/sj.onc.1208525	http://dx.doi.org/10.1038/sj.onc.1208525			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735674				2022-12-25	WOS:000228728100009
J	Wang, W; Huper, G; Guo, YQ; Murphy, SK; Olson, JA; Marks, JR				Wang, W; Huper, G; Guo, YQ; Murphy, SK; Olson, JA; Marks, JR			Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer	ONCOGENE			English	Article						GADD45a; methylation; breast cancer; expression array	MAMMARY EPITHELIAL-CELLS; DNA METHYLATION; PROMOTER HYPERMETHYLATION; CAVEOLIN-1 GENE; CPG ISLAND; EXPRESSION; GROWTH; BRCA1; INDUCTION; RECEPTOR	Treatment of the breast cancer cell line, MDAMB468 with the DNA methylation inhibitor, 5-azacytidine (5-AzaC) results in growth arrest, whereas the growth of the normal breast epithelial line DU99 ( telomerase immortalized) is relatively unaffected. Comparing gene expression profiles of these two lines after 5-AzaC treatment, we identified 36 genes that had relatively low basal levels in MDAMB468 cells compared to the DU99 line and were induced in the cancer cell line but not in the normal breast epithelial line. Of these genes, 33 have associated CpG islands greater than 300 bp in length but only three have been previously described as targets for aberrant methylation in human cancer. Northern blotting for five of these genes (alpha-Catenin, DTR, FYN, GADD45a, and Zyxin) verified the array results. Further analysis of one of these genes, GADD45a, showed that 5-AzaC induced expression in five additional breast cancer cell lines with little or no induction in three additional lines derived from normal breast epithelial cells. The CpG island associated with GADD45a was analysed by bisulfite sequencing, sampling over 100 CpG dinucleotides. We found that four CpG's, located approximately 700 bp upstream of the transcriptional start site are methylated in the majority of breast cancer cell lines and primary tumors but not in DNA from normal breast epithelia or matched lymphocytes from cancer patients. Therefore, this simple method of dynamic transcriptional pro. ling yielded a series of novel methylation-sensitive genes in breast cancer including the BRCA1 and p53 responsive gene, GADD45a.	Dept Surg, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA	Duke University	Marks, JR (corresponding author), Dept Surg, Med Ctr, Dept Surg, Box 3873,Med Sci Res Bldg, Durham, NC 27710 USA.	marks003@mc.duke.edu	Murphy, Susan/R-3903-2019	Murphy, Susan/0000-0001-8298-7272	NATIONAL CANCER INSTITUTE [U01CA084955] Funding Source: NIH RePORTER; NCI NIH HHS [CA84955] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Baylin Stephen B, 2004, Novartis Found Symp, V259, P226; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050; Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#; DAIRKEE SH, 1988, J NATL CANCER I, V80, P691, DOI 10.1093/jnci/80.9.691; Davis P, 1996, ONCOGENE, V13, P1315; Dobrovic A, 1997, CANCER RES, V57, P3347; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Dowell JE, 2004, J CLIN ONCOL, V22, P1353, DOI 10.1200/JCO.2004.01.947; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Evron E, 2001, CANCER RES, V61, P2782; Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Marks J, 1988, Prog Clin Biol Res, V284, P163; McPherson SJ, 1997, J ENDOCRINOL, V154, P535, DOI 10.1677/joe.0.1540535; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Muller HM, 2003, CANCER RES, V63, P7641; MURPHY SK, 2001, CANC HDB, P317; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; Oue N, 2003, ONCOLOGY-BASEL, V64, P423, DOI 10.1159/000070302; Parker BS, 2003, CANCER BIOL THER, V2, P259, DOI 10.4161/cbt.2.3.364; Paz MF, 2003, CANCER RES, V63, P1114; Pechoux C, 1999, DEV BIOL, V206, P88, DOI 10.1006/dbio.1998.9133; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tomlinson GE, 1998, CANCER RES, V58, P3237; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; van Noesel MM, 2003, GENE CHROMOSOME CANC, V38, P226, DOI 10.1002/gcc.10278; Wang W, 2004, MOL CANCER RES, V2, P442; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Woodcock DM, 1999, BRIT J CANCER, V79, P251, DOI 10.1038/sj.bjc.6690041; Zelent Arthur, 2004, Clin Cancer Res, V10, P4622, DOI 10.1158/1078-0432.CCR-1219-03; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	50	68	77	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2705	2714		10.1038/sj.onc.1208464	http://dx.doi.org/10.1038/sj.onc.1208464			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735726				2022-12-25	WOS:000228356700012
J	Guerrico, AMG; Jaffer, ZM; Page, RE; Braunewell, KH; Chernoff, J; Klein-Szanto, AJP				Guerrico, AMG; Jaffer, ZM; Page, RE; Braunewell, KH; Chernoff, J; Klein-Szanto, AJP			Visinin-like protein-1 is a potent inhibitor of cell adhesion and migration in squamous carcinoma cells	ONCOGENE			English	Article						visinin-like protein-1 (VILIP-1); squamous cell carcinoma (SCC); adhesion; migraition; integrins	INTEGRIN ALPHA-V-BETA-3; ALPHA-6-BETA-4 INTEGRIN; KINASE-A; EXTRACELLULAR-MATRIX; ALPHA(V) INTEGRINS; LAMELLAE FORMATION; TUMOR INVASION; GROWTH-FACTOR; IN-VITRO; EXPRESSION	Tumor cell invasion is a highly integrated and complex process comprising several biologically distinct functions such as cell adhesion, motility, proteolysis, etc. Visinin-like protein-1 (VILIP-1), a member of the neuronal EF-hand calcium-sensor protein family, plays a role in regulating tumor cell invasiveness of mouse squamous cell carcinoma (SCC). VILIP-1 enhances cyclic adenosine monophosphate levels through PKA induction. However, the mechanism by which VILIP-1 reduces cell invasiveness is not well understood. In this study, we show that VILIP-1 decreased cell adhesion and migration/invasiveness of highly invasive mouse SCC cells. Forced expression of VILIP-1 reduced cell adhesion to fibronectin in parallel to downregulating alpha v and alpha 5 integrin subunit levels. VILIP-1 overexpression also led to decreased migration ability. Conversely, short hairpin RNA-mediated VILIP-1 knock-down of SCC cells' characterized by little or no invasiveness, correlated with increased adhesion to fibro-nectin and enhanced expression of av and %5 integrin subunits together with increased cell migration. Function-blocking assays with inhibitory anti-alpha 5 and anti-alpha v integrin antibodies showed that both subunits contributed to cell adhesion, migration, and invasiveness of highly invasive SCC cell lines. These results point to a critical role of VILIP-1 in regulating cell adhesion and migration by downregulation of fibronectin receptor expression. Decreased or absent VILIP-1 expression in SCC cell subpopulations may lead to a more advanced malignant phenotype characterized by changes in adhesive ability and increased cell motility, suggestive of a tumor suppressor function.	Fox Chase Canc Ctr, Tumor Cell Biol Program, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; Humboldt Univ, Neurosci Res Ctr, Charite, Fac Med, D-10117 Berlin, Germany	Fox Chase Cancer Center; Fox Chase Cancer Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Klein-Szanto, AJP (corresponding author), Fox Chase Canc Ctr, Tumor Cell Biol Program, 333 Cottman Ave,Room C417, Philadelphia, PA 19111 USA.	aj_klein-szanto@fccc.edu	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; Bagutti C, 1998, J PATHOL, V186, P8, DOI 10.1002/(SICI)1096-9896(199809)186:1<8::AID-PATH156>3.0.CO;2-H; Felding-Habermann B, 2002, CLIN EXP METASTAS, V19, P427, DOI 10.1023/A:1016377114119; Gong JG, 1997, CELL GROWTH DIFFER, V8, P83; Haapasalmi K, 1996, J INVEST DERMATOL, V106, P42, DOI 10.1111/1523-1747.ep12327199; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Huang S, 2000, ONCOGENE, V19, P1915, DOI 10.1038/sj.onc.1203509; Hubbard FC, 1997, CANCER RES, V57, P5226; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Jones J, 1997, J ORAL PATHOL MED, V26, P63, DOI 10.1111/j.1600-0714.1997.tb00023.x; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Kerr JS, 2002, EXPERT OPIN INV DRUG, V11, P1765, DOI 10.1517/13543784.11.12.1765; Kikuchi M, 1997, J Gastrointest Surg, V1, P132, DOI 10.1016/S1091-255X(97)80100-X; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Koivisto L, 1999, CELL ADHES COMMUN, V7, P245, DOI 10.3109/15419069909010806; Koivisto L, 2000, EXP CELL RES, V255, P10, DOI 10.1006/excr.1999.4769; Koukoulis GK, 1997, HUM PATHOL, V28, P1018, DOI 10.1016/S0046-8177(97)90054-X; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; Li XW, 2001, J CELL SCI, V114, P2665; Ma TY, 1999, J LAB CLIN MED, V134, P363, DOI 10.1016/S0022-2143(99)90150-6; Mahloogi H, 2003, CANCER RES, V63, P4997; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Nagaoka K, 2003, J BIOL CHEM, V278, P29048, DOI 10.1074/jbc.M300470200; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Paddison Patrick J, 2004, Methods Mol Biol, V265, P85; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; Reinmuth N, 2003, CANCER RES, V63, P2079; Rolli M, 2003, P NATL ACAD SCI USA, V100, P9482, DOI 10.1073/pnas.1633689100; RUGGERI B, 1991, CANCER RES, V51, P6615; Santibanez JF, 2003, INT J CANCER, V107, P715, DOI 10.1002/ijc.11457; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; TAKAHASHI K, 1990, J IMMUNOL, V145, P4371; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; YASUDA M, 1995, INT IMMUNOL, V7, P251, DOI 10.1093/intimm/7.2.251; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	39	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2307	2316		10.1038/sj.onc.1208476	http://dx.doi.org/10.1038/sj.onc.1208476			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735716				2022-12-25	WOS:000227877400004
J	de Roos, B; Duivenvoorden, I; Rucklidge, G; Reid, M; Ross, K; Lamers, RJAN; Voshol, PJ; Havekes, LM; Teusink, B				de Roos, B; Duivenvoorden, I; Rucklidge, G; Reid, M; Ross, K; Lamers, RJAN; Voshol, PJ; Havekes, LM; Teusink, B			Response of apolipoprotein E*3-Leiden transgenic mice to dietary fatty acids: combining liver proteomics with physiological data	FASEB JOURNAL			English	Article						fish oil; CLA; elaidic acid; lipoprotein metabolism; glucose metabolism	CONJUGATED LINOLEIC-ACID; CHOLESTEROL LEVELS; LIPID-COMPOSITION; BODY-COMPOSITION; GENE-EXPRESSION; DOWN-REGULATION; SERUM-LIPIDS; ATHEROSCLEROSIS; LIPOPROTEINS; METABOLISM	Dietary fatty acids have a profound impact on atherosclerosis, but mechanisms are not fully understood. We studied the effects of a saturated fat diet supplemented with fish oil, trans10,cis12 conjugated linoleic acid (CLA), or elaidic acid on lipid and glucose metabolism and liver protein levels of APOE*3 Leiden transgenic mice, a model for lipid metabolism and atherosclerosis. Fish oil lowered plasma and liver cholesterol and triglycerides, plasma free fatty acids, and glucose but increased plasma insulin. CLA lowered plasma cholesterol but increased plasma and liver triglycerides, plasma beta-hydroxybutyrate, and insulin. Elaidic acid lowered plasma and liver cholesterol. Proteomics identified significant regulation of 65 cytosolic and 8-membrane proteins. Many of these proteins were related to lipid and glucose metabolism, and to oxidative stress. Principal component analysis revealed that fish oil had a major impact on cytosolic proteins, and elaidic acid on membrane proteins. Correlation analysis between physiological and protein data revealed novel clusters of correlated variables, among which a metabolic syndrome cluster. The combination of proteomics and physiology gave new insights in mechanisms by which these dietary fatty acids regulate lipid metabolism and related pathways, for example, by altering protein levels of long-chain acyl-CoA thioester hydrolase and adipophilin in the liver.	Rowett Res Inst, Aberdeen AB21 9SB, Scotland; TNO Prevent & Hlth, Gaubius Lab, Leiden, Netherlands; TNO Nutr & Food Res, Zeist, Netherlands; Leiden Univ, Med Ctr, Dept Endocrinol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Internal Med, Leiden, Netherlands; Wageningen Ctr Food Sci, NIZO Food Res, Ede, Netherlands	University of Aberdeen; Netherlands Organization Applied Science Research; Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; NIZO Food Research	de Roos, B (corresponding author), Rowett Res Inst, Greenburn Rd, Aberdeen AB21 9SB, Scotland.	b.deroos@rowett.ac.uk		Teusink, Bas/0000-0003-3929-0423				Aro A, 1997, AM J CLIN NUTR, V65, P1419, DOI 10.1093/ajcn/65.5.1419; Belury MA, 1997, LIPIDS, V32, P199, DOI 10.1007/s11745-997-0025-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cho HP, 1999, J BIOL CHEM, V274, P471, DOI 10.1074/jbc.274.1.471; Cho HP, 1999, J BIOL CHEM, V274, P37335, DOI 10.1074/jbc.274.52.37335; Clark PI, 2000, BRIT J CANCER, V83, P1; Clarke SD, 1999, AM J CLIN NUTR, V70, P566; Clement L, 2002, J LIPID RES, V43, P1400, DOI 10.1194/jlr.M20008-JLR200; Degrace P, 2003, FEBS LETT, V546, P335, DOI 10.1016/S0014-5793(03)00610-0; Delany JP, 1999, AM J PHYSIOL-REG I, V276, pR1172, DOI 10.1152/ajpregu.1999.276.4.R1172; den Boer M, 2004, ARTERIOSCL THROM VAS, V24, P644, DOI 10.1161/01.ATV.0000116217.57583.6e; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; FOLCH J, 1957, J BIOL CHEM, V226, P497; HAVEKES LM, 1987, BIOCHEM J, V247, P739, DOI 10.1042/bj2470739; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; HILL EG, 1982, P NATL ACAD SCI-BIOL, V79, P953, DOI 10.1073/pnas.79.4.953; Hu FB, 2002, JAMA-J AM MED ASSOC, V288, P2569, DOI 10.1001/jama.288.20.2569; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; KATAN MB, 1995, ANNU REV NUTR, V15, P473, DOI 10.1146/annurev.nutr.15.1.473; KINSELLA JE, 1981, AM J CLIN NUTR, V34, P2307, DOI 10.1093/ajcn/34.10.2307; LEE KN, 1994, ATHEROSCLEROSIS, V108, P19, DOI 10.1016/0021-9150(94)90034-5; Lee KN, 1998, BIOCHEM BIOPH RES CO, V248, P817, DOI 10.1006/bbrc.1998.8994; Lovejoy J C, 1999, Curr Atheroscler Rep, V1, P215, DOI 10.1007/s11883-999-0035-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; McManaman JL, 2003, J LIPID RES, V44, P668, DOI 10.1194/jlr.C200021-JLR200; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; Mori TA, 2001, CURR OPIN LIPIDOL, V12, P11, DOI 10.1097/00041433-200102000-00003; Moya-Camarena SY, 1999, J LIPID RES, V40, P1426; Munday JS, 1999, BRIT J NUTR, V81, P251, DOI 10.1017/S0007114599000458; Nicolosi RJ, 1997, ARTERY, V22, P266; Ohnuki K, 2001, BIOSCI BIOTECH BIOCH, V65, P2200, DOI 10.1271/bbb.65.2200; Park Y, 2000, BBA-MOL CELL BIOL L, V1486, P285, DOI 10.1016/S1388-1981(00)00074-3; Park Y, 1997, LIPIDS, V32, P853, DOI 10.1007/s11745-997-0109-x; Peters JM, 2001, BBA-MOL CELL BIOL L, V1533, P233, DOI 10.1016/S1388-1981(01)00155-X; Post SM, 1997, ARTERIOSCL THROM VAS, V17, P3064, DOI 10.1161/01.ATV.17.11.3064; Post SM, 2000, ARTERIOSCL THROM VAS, V20, P1551, DOI 10.1161/01.ATV.20.6.1551; Roche HM, 2002, DIABETES, V51, P2037, DOI 10.2337/diabetes.51.7.2037; Roche HM, 2001, NUTR RES REV, V14, P173, DOI [10.1079/095442201108729187, 10.1079/NRR200122]; Salmeron J, 2001, AM J CLIN NUTR, V73, P1019; Schuller-Levis GB, 2003, FEMS MICROBIOL LETT, V226, P195, DOI 10.1016/S0378-1097(03)00611-6; Sessler AM, 1998, J NUTR, V128, P923, DOI 10.1093/jn/128.6.923; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131; Takahashi Y, 2003, BBA-MOL CELL BIOL L, V1631, P265, DOI 10.1016/S1388-1981(03)00038-6; Toomey S, 2003, BIOCHEM SOC T, V31, P1075, DOI 10.1042/BST0311075; Tsuboyama-Kasaoka N, 2000, DIABETES, V49, P1534, DOI 10.2337/diabetes.49.9.1534; van Oostrom AJHHM, 2002, J ROY SOC MED, V95, P54; van Vlijmen BJM, 1998, J LIPID RES, V39, P1181; vanVlijmen BJM, 1996, J CLIN INVEST, V97, P1184, DOI 10.1172/JCI118532; VANVLIJMEN BJM, 1994, J CLIN INVEST, V93, P1403, DOI 10.1172/JCI117117; Volger OL, 2001, ATHEROSCLEROSIS, V157, P375, DOI 10.1016/S0021-9150(00)00750-4; Volger OL, 2001, ARTERIOSCL THROM VAS, V21, P1046, DOI 10.1161/01.ATV.21.6.1046; West DB, 1998, AM J PHYSIOL-REG I, V275, pR667; Wever RMF, 1998, CIRCULATION, V97, P108, DOI 10.1161/01.CIR.97.1.108; Yotsumoto H, 1998, FOOD RES INT, V31, P403, DOI 10.1016/S0963-9969(98)00103-3; ZAMBON A, 1993, J LIPID RES, V34, P1021	63	55	55	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					813	+		10.1096/fj.04-2974fje	http://dx.doi.org/10.1096/fj.04-2974fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15755870				2022-12-25	WOS:000227901300025
J	Fisher, I; Abraham, D; Bouri, K; Hoffman, EP; Muntoni, F; Morgan, J				Fisher, I; Abraham, D; Bouri, K; Hoffman, EP; Muntoni, F; Morgan, J			Prednisolone-induced changes in dystrophic skeletal muscle	FASEB JOURNAL			English	Article						muscular dystrophy; dystrophin; corticosteroids; microarrays; fiber type	DUCHENNE MUSCULAR-DYSTROPHY; DEFICIENT MDX MICE; LONG-TERM BENEFIT; GENE-EXPRESSION; IMMUNOPHILIN FKBP51; HINDLIMB MUSCLES; FIBER TYPES; MOUSE; CELLS; DIAPHRAGM	Although glucocorticoids delay the progression of Duchenne muscular dystrophy (DMD) their mechanism of action is unknown. Skeletal muscle gene expression profiles of mdx mice, an animal model of DMD, treated with prednisolone were compared with control mice at 1 and 6 wk. Of the 89 early differentially regulated genes and ESTs, delta-sarcoglycan, myosin Va, FK506-binding protein 51 (FKBP51), the potassium channel regulator potassium inwardly-rectifying channel Isk-like (IRK2) and ADAM 10 were overexpressed, whereas growth hormone-releasing hormone receptor (GHRHR) and Homer-2 were underexpressed. The 58 late differentially overexpressed genes included kallikreins ( 13, 16, and 26), FKBP51, PI3K alpha regulatory subunit, and IGFBP6, while underexpressed genes included NeuroD and nicotinic cholinergic receptor gamma. At both time points, overexpression of a cohort of genes relating to metabolism and proteolysis was apparent, alongside the differential expression of genes relating to calcium metabolism. Treatment did not increase muscle regeneration, reduce the number of infiltrating macrophages, or alter utrophin expression or localization. However, in the treated mdx soleus muscle, the percentage of slow fibers was significantly lower compared with untreated controls after 6 wk of treatment. These results show that glucocorticoids confer their benefit to dystrophic muscle in a complex fashion, culminating in a switch to a more normal muscle fiber type.	Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, Muscle Cell Biol Grp, London W12 0NN, England; UCL, Royal Free Hosp, Sch Med, Ctr Rheumatol, London NW3 2QG, England; Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Paediat, Dubowitz Neuromuscular Ctr, London W12 0NN, England	Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Children's National Health System; Imperial College London; University of London; University College London	Morgan, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, Muscle Cell Biol Grp, London W12 0NN, England.	jmorgan@csc.mrc.ac.uk	Morgan, Jennifer/C-6475-2008	Hoffman, Eric/0000-0001-6470-5139				AGARWAL DP, 1992, PHARMACOGENETICS, V2, P48, DOI 10.1097/00008571-199204000-00002; Anderson JE, 1996, MUSCLE NERVE, V19, P1576, DOI 10.1002/(SICI)1097-4598(199612)19:12<1576::AID-MUS7>3.0.CO;2-7; BORRIONE AC, 1989, EUR J BIOCHEM, V183, P413, DOI 10.1111/j.1432-1033.1989.tb14943.x; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; Chakkalakal JV, 2004, HUM MOL GENET, V13, P379, DOI 10.1093/hmg/ddh037; Chakkalakal JV, 2003, P NATL ACAD SCI USA, V100, P7791, DOI 10.1073/pnas.0932671100; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Collins CA, 2003, INT J EXP PATHOL, V84, P165, DOI 10.1046/j.1365-2613.2003.00354.x; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Connolly AM, 2002, J NEUROIMMUNOL, V127, P80, DOI 10.1016/S0165-5728(02)00104-2; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; Courdier-Fruh I, 2002, NEUROMUSCULAR DISORD, V12, pS95, DOI 10.1016/S0960-8966(02)00089-5; CURTIS A. S. G., 1960, MED AND BIOL, V10, P261; DANGAIN J, 1984, MUSCLE NERVE, V7, P700, DOI 10.1002/mus.880070903; De Luca A, 2003, J PHARMACOL EXP THER, V304, P453, DOI 10.1124/jpet.102.041343; DESILVA S, 1987, ARCH NEUROL-CHICAGO, V44, P818, DOI 10.1001/archneur.1987.00520200022012; Dubowitz V, 2002, Eur J Paediatr Neurol, V6, P153, DOI 10.1053/ejpn.2002.0583; Fang J, 2000, J CELL BIOCHEM, V79, P164, DOI 10.1002/1097-4644(2000)79:1<164::AID-JCB10>3.0.CO;2-D; Fenichel G, 1997, NEUROLOGY, V48, P1225, DOI 10.1212/WNL.48.5.1225; FENICHEL GM, 1991, NEUROLOGY, V41, P1874, DOI 10.1212/WNL.41.12.1874; FINK RHA, 1990, J PHYSIOL-LONDON, V420, P337, DOI 10.1113/jphysiol.1990.sp017916; Gaud A, 2004, NEUROMUSCULAR DISORD, V14, P365, DOI 10.1016/j.nmd.2004.02.011; Goldspink G, 1999, J ANAT, V194, P323, DOI 10.1046/j.1469-7580.1999.19430323.x; Granchelli JA, 2000, NEUROMUSCULAR DISORD, V10, P235, DOI 10.1016/S0960-8966(99)00126-1; Gross JG, 1999, MUSCLE NERVE, V22, P174, DOI 10.1002/(SICI)1097-4598(199902)22:2<174::AID-MUS5>3.0.CO;2-S; GUERRIERO V, 1980, ENDOCRINOLOGY, V106, P1198, DOI 10.1210/endo-106-4-1198; Hartel JV, 2001, MUSCLE NERVE, V24, P428, DOI 10.1002/1097-4598(200103)24:3<428::AID-MUS1018>3.3.CO;2-5; Horsley V, 2003, J CELL BIOL, V161, P111, DOI 10.1083/jcb.200208085; HUDECKI MS, 1993, RES COMMUN CHEM PATH, V79, P45; Jacobs SCJM, 1996, J NEUROL, V243, P410, DOI 10.1007/BF00869001; Jennische E, 2000, APMIS, V108, P747, DOI 10.1034/j.1600-0463.2000.d01-24.x; Jobling Andrew I, 2002, Clin Exp Optom, V85, P61; KISSEL JT, 1991, NEUROLOGY, V41, P667, DOI 10.1212/WNL.41.5.667; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Leijendekker WJ, 1996, BRIT J PHARMACOL, V118, P611, DOI 10.1111/j.1476-5381.1996.tb15445.x; Li TK, 2002, J CELL BIOCHEM, V84, P460, DOI 10.1002/jcb.10026.abs; Lim JH, 2004, MUSCLE NERVE, V30, P456, DOI 10.1002/mus.20139; LOCASCIO V, 1995, CALCIFIED TISSUE INT, V56, P109, DOI 10.1007/BF00296340; Mayfield RK, 1996, DIABETES, V45, pS20, DOI 10.2337/diab.45.1.S20; MCGEACHIE JK, 1993, J NEUROL SCI, V119, P169, DOI 10.1016/0022-510X(93)90130-Q; McKay LI, 1997, MUSCLE NERVE, V20, P1318, DOI 10.1002/(SICI)1097-4598(199710)20:10<1318::AID-MUS17>3.0.CO;2-Z; MENDELL JR, 1989, NEW ENGL J MED, V320, P1592, DOI 10.1056/NEJM198906153202405; Murgia M, 2000, NAT CELL BIOL, V2, P142, DOI 10.1038/35004013; Pagel CN, 1999, J NEUROL SCI, V164, P103, DOI 10.1016/S0022-510X(99)00061-1; PARSONS SA, 2004, J BIOL CHEM; PASQUINI F, 1995, NEUROMUSCULAR DISORD, V5, P105, DOI 10.1016/0960-8966(94)00042-8; PASSAQUIN AC, 1993, J NEUROSCI RES, V35, P363, DOI 10.1002/jnr.490350403; PASTORET C, 1993, NEUROMUSCULAR DISORD, V3, P471, DOI 10.1016/0960-8966(93)90099-6; Perkins KJ, 2002, NEUROMUSCULAR DISORD, V12, pS78, DOI 10.1016/S0960-8966(02)00087-1; Pette D, 2000, MICROSC RES TECHNIQ, V50, P500, DOI 10.1002/1097-0029(20000915)50:6<500::AID-JEMT7>3.0.CO;2-7; Porter JD, 2003, NEUROMUSCULAR DISORD, V13, P223, DOI 10.1016/S0960-8966(02)00242-0; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; RIFAI Z, 1995, AM J PHYSIOL-ENDOC M, V268, pE67, DOI 10.1152/ajpendo.1995.268.1.E67; Roberts RG, 1995, ADV GENET, V33, P177, DOI 10.1016/S0065-2660(08)60334-X; Roig M, 2004, ACTA NEUROPATHOL, V107, P27, DOI 10.1007/s00401-003-0773-3; Rouger K, 2002, AM J PHYSIOL-CELL PH, V283, pC773, DOI 10.1152/ajpcell.00112.2002; SALMONS S, 1994, INT J SPORTS MED, V15, P136, DOI 10.1055/s-2007-1021035; Scammell JG, 2001, GEN COMP ENDOCR, V124, P152, DOI 10.1006/gcen.2001.7696; Schiaffino S, 2002, TRENDS PHARMACOL SCI, V23, P569, DOI 10.1016/S0165-6147(02)02111-9; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; SHERRATT TG, 1992, BIOCHEM J, V287, P755, DOI 10.1042/bj2870755; St-Pierre SJG, 2004, FASEB J, V18, P1937, DOI 10.1096/fj.04-1859fje; Stevenson EJ, 2003, J PHYSIOL-LONDON, V551, P33, DOI 10.1113/jphysiol.2003.044701; Takagi A, 1998, Rinsho Shinkeigaku, V38, P724; Tkatchenko AV, 2000, BBA-MOL BASIS DIS, V1500, P17, DOI 10.1016/S0925-4439(99)00084-8; Tkatchenko AV, 2001, NEUROMUSCULAR DISORD, V11, P269, DOI 10.1016/S0960-8966(00)00198-X; Vandebrouck C, 1999, NEUROSCI LETT, V269, P110, DOI 10.1016/S0304-3940(99)00418-8; Ward CW, 2004, J BIOL CHEM, V279, P5781, DOI 10.1074/jbc.M311422200; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; Wehling-Henricks M, 2004, NEUROMUSCULAR DISORD, V14, P483, DOI 10.1016/j.nmd.2004.04.008; WELLER B, 1991, MUSCLE NERVE, V14, P771, DOI 10.1002/mus.880140812; Yang LY, 1998, MUSCLE NERVE, V21, P394, DOI 10.1002/(SICI)1097-4598(199803)21:3<394::AID-MUS14>3.0.CO;2-#; Yang YH, 2004, ARTHRITIS RHEUM-US, V50, P976, DOI 10.1002/art.20201; Zhao P, 2002, J BIOL CHEM, V277, P30091, DOI 10.1074/jbc.M202668200	75	55	59	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					834	+		10.1096/fj.04-2511fje	http://dx.doi.org/10.1096/fj.04-2511fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15734791				2022-12-25	WOS:000227591900004
J	Fukuen, S; Iwaki, M; Yasui, A; Makishima, M; Matsuda, M; Shimomura, I				Fukuen, S; Iwaki, M; Yasui, A; Makishima, M; Matsuda, M; Shimomura, I			Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS ADIPOCYTE DIFFERENTIATION; TYPE-2 DIABETIC SUBJECTS; PPAR-GAMMA; 3T3-L1 ADIPOCYTES; NUCLEAR RECEPTORS; GENE-EXPRESSION; INSULIN-RESISTANCE; X-RECEPTOR; LIGAND; IDENTIFICATION	Sulfonylurea (SU) agents, including glimepiride and glibenclamide, are the most widely used oral hypoglycemic drugs, which stimulate insulin secretion primarily by binding to the SU receptor on the plasma membrane of pancreatic beta-cells. Thiazolidinediones, such as pioglitazone and rosiglitazone, are other hypoglycemic agents that effectively improve peripheral insulin resistance through activation of peroxisome proliferator-activated receptor gamma( PPAR gamma). In the present study, we found that glimepiride specifically induced the transcriptional activity of PPAR gamma in luciferase reporter assays. Glimepiride enhanced the recruitment of coactivator DRIP205 and dissociation of corepressors such as nuclear receptor corepressor and silencing mediator for retinoid and thyroid hormone receptors. In addition, glimepride directly bound to PPAR delta in a manner competitive to rosiglitazone, which is a proven ligand for PPAR delta. Furthermore, in 3T3-L1 adipocytes, glimepiride stimulated the transcriptional activity of the gene promoter containing PPAR gamma responsive element and altered mRNA levels of PPAR gamma target genes including aP2, leptin, and adiponectin. Finally, glimepiride induced adipose differentiation in 3T3- F442A cells, which was known to differentiate into adipocytes in a PPAR gamma-dependent manner. Most effects observed with glimepiride were also seen with glibenclamide. These data strongly suggest that glimepiride and glibenclamide, both of which belong to SU agents, should have PPAR gamma agonist activity, whose potencies were 16-25% of the maximum level achieved by pioglitazone. Our observation that glimepiride and glibenclamide could act not only on SU receptor but also on PPAR gamma may give an important clue to the development of novel antidiabetic drugs, which can enhance both insulin secretion from pancreatic beta-cells and peripheral insulin sensitivity.	Osaka Univ, Grad Sch Forntier Biosci, Dept Med & Pathophysiol, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Mol sci, Suita, Osaka 5650871, Japan; Japan Sci & Technol agcy, PREST, Kawaguchi, Saitama 3320012, Japan; Japan Soc Promot Sci, Century COE Program 21, Tokyo, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST); Japan Society for the Promotion of Science	Matsuda, M (corresponding author), Osaka Univ, Grad Sch Forntier Biosci, Dept Med & Pathophysiol, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	mmatsuda@fbs.osaka-u.ac.jp		Yasui, Atsutaka/0000-0003-4903-7210				Adachi R, 2004, MOL ENDOCRINOL, V18, P43, DOI 10.1210/me.2003-0244; Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Glass CK, 2000, GENE DEV, V14, P121; Gribble FM, 2000, METABOLISM, V49, P3, DOI 10.1053/meta.2000.17822; Hsu MH, 2001, J BIOL CHEM, V276, P27950, DOI 10.1074/jbc.M100258200; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; JACOBS DB, 1985, J BIOL CHEM, V260, P2593; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kaneko E, 2003, J BIOL CHEM, V278, P36091, DOI 10.1074/jbc.M304153200; Kishida K, 2001, J BIOL CHEM, V276, P48572, DOI 10.1074/jbc.M108213200; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Lee G, 2002, J BIOL CHEM, V277, P19649, DOI 10.1074/jbc.M200743200; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Malerczyk V., 1994, Drug Metabolism and Drug Interactions, V11, P341; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; MILLER RE, 1986, BIOCHEM INT, V13, P313; MULLER G, 1995, DIABETES RES CLIN S, V28, P115; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nishizawa H, 2002, J BIOL CHEM, V277, P1586, DOI 10.1074/jbc.M104301200; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Perrey S, 2001, METABOLISM, V50, P36, DOI 10.1053/meta.2001.19505; Rangwala SM, 2004, TRENDS PHARMACOL SCI, V25, P331, DOI 10.1016/j.tips.2004.03.012; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Tamori Y, 2002, DIABETES, V51, P2045, DOI 10.2337/diabetes.51.7.2045; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tsunekawa T, 2003, DIABETES CARE, V26, P285, DOI 10.2337/diacare.26.2.285; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; Yang W, 2000, MOL CELL BIOL, V20, P8008, DOI 10.1128/MCB.20.21.8008-8017.2000; Yu JG, 2002, DIABETES, V51, P2968, DOI 10.2337/diabetes.51.10.2968; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	43	90	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23653	23659		10.1074/jbc.M412113200	http://dx.doi.org/10.1074/jbc.M412113200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15764598	hybrid			2022-12-25	WOS:000229880000032
J	Samuelson, AV; Narita, M; Chan, HM; Jin, JP; de Stanchina, E; McCurrach, ME; Narita, M; Fuchs, M; Livingston, DM; Lowe, SW				Samuelson, AV; Narita, M; Chan, HM; Jin, JP; de Stanchina, E; McCurrach, ME; Narita, M; Fuchs, M; Livingston, DM; Lowe, SW			p400 is required for E1A to promote apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARF TUMOR-SUPPRESSOR; REGULATES P53-DEPENDENT APOPTOSIS; HISTONE ACETYLASE COMPLEX; REGION 1A PROTEINS; ONCOGENIC TRANSFORMATION; DNA-DAMAGE; C-MYC; P53; P300; INDUCTION	The adenovirus E1A oncoprotein promotes proliferation and transformation by binding cellular proteins, including members of the retinoblastoma protein family, the p300/CREB-binding protein transcriptional coactivators, and the p400-TRRAP chromatin-remodeling complex. E1A also promotes apoptosis, in part, by engaging the ARF-p53 tumor suppressor pathway. We show that E1A induces ARF and p53 and promotes apoptosis in normal fibroblasts by physically associating with the retinoblastoma protein and a p400-TRRAP complex and that its interaction with p300 is largely dispensable for these effects. We further show that E1A increases p400 expression and, conversely, that suppression of p400 using stable RNA interference reduces the levels of ARF, p53, and apoptosis in E1A-expressing cells. Therefore, whereas E1A inactivates the retinoblastoma protein, it requires p400 to efficiently promote cell death. These results identify p400 as a regulator of the ARF-p53 pathway and a component of the cellular machinery that couples proliferation to cell death.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Cold Spring Harbor Laboratory; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Lowe, SW (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	lowe@cshl.org	Jin, Jianping/K-5002-2018	Jin, Jianping/0000-0003-4175-9104; Samuelson, Andrew/0000-0002-3071-5766; Narita, Masako/0000-0002-9774-4908; Narita, Masashi/0000-0001-7764-577X	NCI NIH HHS [CA 13106, P30 CA008748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Ben-Israel H, 2002, FRONT BIOSCI-LANDMRK, V7, pD1369, DOI 10.2741/ben; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Ceol CJ, 2004, DEV CELL, V6, P563, DOI 10.1016/S1534-5807(04)00065-6; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Chattopadhyay D, 2001, J VIROL, V75, P9844, DOI 10.1128/JVI.75.20.9844-9856.2001; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Deleu L, 2001, ONCOGENE, V20, P8270, DOI 10.1038/sj.onc.1205159; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kawamura T, 2004, BIOCHEM BIOPH RES CO, V315, P733, DOI 10.1016/j.bbrc.2004.01.105; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Nakajima T, 1998, P NATL ACAD SCI USA, V95, P10590, DOI 10.1073/pnas.95.18.10590; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; NEVINS JR, 1992, SCIENCE, V258, P424; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; Sandmoller A, 1996, MOL CELL BIOL, V16, P5846; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yageta M, 1999, ONCOGENE, V18, P4767, DOI 10.1038/sj.onc.1203063; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	66	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21915	21923		10.1074/jbc.M414564200	http://dx.doi.org/10.1074/jbc.M414564200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15741165	hybrid			2022-12-25	WOS:000229557900032
J	Szczepanowski, RH; Filipek, R; Bochtler, M				Szczepanowski, RH; Filipek, R; Bochtler, M			Crystal structure of a fragment of mouse ubiquitin-activating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME PATHWAY; PROTEIN-ACTIVATION; E1; SYSTEM; RECRUITMENT; CONJUGATION; MECHANISM; INSIGHTS; COMPLEX; NEDD8	Protein ubiquitination requires the sequential activity of three enzymes: a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2), and a ubiquitinligase (E3). The ubiquitin-transfer machinery is hierarchically organized; for every ubiquitin-activating enzyme, there are several ubiquitin-conjugating enzymes, and most ubiquitin-conjugating enzymes can in turn interact with multiple ubiquitin ligases. Despite the central role of ubiquitin-activating enzyme in this cascade, a crystal structure of a ubiquitin-activating enzyme is not available. The enzyme is thought to consist of an adenylation domain, a catalytic cysteine domain, a four-helix bundle, and possibly, a ubiquitin-like domain. Its adenylation domain can be modeled because it is clearly homologous to the structurally known adenylation domains of the activating enzymes for the small ubiquitinlike modifier ( SUMO) and for the protein encoded by the neuronal precursor cell-expressed, developmentally down-regulated gene 8 (NEDD8). Low sequence similarity and vastly different domain lengths make modeling difficult for the catalytic cysteine domain that results from the juxtaposition of two catalytic cysteine halfdomains. Here, we present a biochemical and crystallographic characterization of the two half-domains and the crystal structure of the larger, second catalytic cysteine half-domain of mouse ubiquitin-activating enzyme. We show that the domain is organized around a conserved folding motif that is also present in the NEDD8- and SUMO-activating enzymes, and we propose a tentative model for full-length ubiquitin-activating enzyme.	Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; Max Planck Inst Mol Cell Biol & Genet, D-01309 Dresden, Germany	Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Max Planck Society	Bochtler, M (corresponding author), Int Inst Mol & Cell Biol, Ul Trojdena 4, PL-02109 Warsaw, Poland.	MBochtler@iimcb.gov.pl	Bochtler, Matthias/A-4514-2010	Bochtler, Matthias/0000-0001-7884-4463				ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; HAAS AL, 1982, J BIOL CHEM, V257, P2543; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; Huang DT, 2005, MOL CELL, V17, P341, DOI 10.1016/j.molcel.2004.12.020; Huang DT, 2004, ONCOGENE, V23, P1958, DOI 10.1038/sj.onc.1207393; Huang DT, 2004, NAT STRUCT MOL BIOL, V11, P927, DOI 10.1038/nsmb826; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Lois LM, 2005, EMBO J, V24, P439, DOI 10.1038/sj.emboj.7600552; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; VanDemark AP, 2003, NAT STRUCT BIOL, V10, P244, DOI 10.1038/nsb0403-244; Walden H, 2003, MOL CELL, V12, P1427, DOI 10.1016/S1097-2765(03)00452-0; Walden H, 2003, NATURE, V422, P330, DOI 10.1038/nature01456	23	39	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22006	22011		10.1074/jbc.M502583200	http://dx.doi.org/10.1074/jbc.M502583200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15774460	hybrid			2022-12-25	WOS:000229557900043
J	Dudas, KC; Kreuzer, KN				Dudas, KC; Kreuzer, KN			Bacteriophage T4 helicase loader protein gp59 functions as gatekeeper in origin-dependent replication in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DNA-BINDING-PROTEIN; GENE 59; LEADING-STRAND; MINICIRCLE SUBSTRATE; LOADING PROTEIN; R-LOOPS; RECOMBINATION; MUTATIONS; PLASMIDS	Bacteriophage T4 initiates origin-dependent replication via an R-loop mechanism in vivo. During in vitro reactions, the phage-encoded gp59 stimulates loading of the replicative helicase, gp41, onto branched intermediates, including origin R-loops. However, although gp59 is essential for recombination-dependent replication from D-loops, it does not appear to be required for origin-dependent replication in vivo. In this study, we have analyzed the origin-replicative intermediates formed during infections that are deficient in gp59 and other phage replication proteins. During infections lacking gp59, the initial replication forks from two different T4 origins actively replicated both leading- and lagging-strands. However, the retrograde replication forks from both origins were abnormal in the gp59-deficient infections. The lagging-strand from the initial fork was elongated as a new leading- strand in the retrograde direction without lagging-strand synthesis, whereas in the wild-type, leading- and lagging-strand synthesis appeared to be coupled. These results imply that gp59 inhibits the polymerase holoenzyme in vivo until the helicase-primase (gp41-gp61) complex is loaded, and we thereby refer to gp59 as a gatekeeper. We also found that all origin-replicative intermediates were absent in infections deficient in the helicase gp41 or the single-strand-binding protein gp32, regardless of whether gp59 was present or absent. These results argue that replication from the origin in vivo is dependent on both the helicase and single-strand-binding protein and demonstrate that the strong replication defect of gene 41 and 32 single mutants is not caused by gp59 inhibition of the polymerase.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Kreuzer, KN (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	kenneth.kreuzer@duke.edu			NIGMS NIH HHS [GM34622, R01 GM034622, R37 GM034622] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034622, R01GM034622] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRY J, 1994, J BIOL CHEM, V269, P33049; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; Belanger KG, 1996, NUCLEIC ACIDS RES, V24, P2166, DOI 10.1093/nar/24.11.2166; Belanger KG, 1998, MOL CELL, V2, P693, DOI 10.1016/S1097-2765(00)80167-7; BENSON KH, 1992, J VIROL, V66, P6960, DOI 10.1128/JVI.66.12.6960-6968.1992; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; CarlesKinch K, 1997, J MOL BIOL, V266, P915, DOI 10.1006/jmbi.1996.0844; Chastain PD, 2003, J BIOL CHEM, V278, P21276, DOI 10.1074/jbc.M301573200; CUNNINGHAM RP, 1977, VIROLOGY, V80, P67, DOI 10.1016/0042-6822(77)90381-6; Doan PL, 2001, GENETICS, V157, P1077; Dudas KC, 2001, MOL CELL BIOL, V21, P2706, DOI 10.1128/MCB.21.8.2706-2715.2001; EDGAR RS, 1964, GENETICS, V49, P635; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; George JW, 1996, GENETICS, V143, P1507; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; Ishmael FT, 2003, J BIOL CHEM, V278, P3145, DOI 10.1074/jbc.M209858200; Ishmael FT, 2002, J BIOL CHEM, V277, P20555, DOI 10.1074/jbc.M111951200; Jones CE, 2004, J BIOL CHEM, V279, P25721, DOI 10.1074/jbc.M402128200; Jones CE, 2000, J BIOL CHEM, V275, P27145; KABACK DB, 1979, NUCLEIC ACIDS RES, V6, P2499, DOI 10.1093/nar/6.7.2499; Kadyrov FA, 2001, J BIOL CHEM, V276, P29559, DOI 10.1074/jbc.M101310200; KARAM JD, 1973, J VIROL, V11, P933, DOI 10.1128/JVI.11.6.933-945.1973; Kornberg A., 1992, DNA REPLICATION; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; KREUZER KN, 1995, J BACTERIOL, V177, P6844, DOI 10.1128/jb.177.23.6844-6853.1995; KREUZER KN, 1988, J BIOL CHEM, V263, P11366; KREUZER KN, 1986, J MOL BIOL, V188, P185, DOI 10.1016/0022-2836(86)90303-7; KREUZER KN, 1988, J BIOL CHEM, V263, P11348; KREUZER KN, 1994, MOL BIOL BACTERIOP T, V4, P452; KUES U, 1989, MICROBIOL REV, V53, P491; LANDGRAF R, 1995, NUCLEIC ACIDS RES, V23, P3516, DOI 10.1093/nar/23.17.3516; Lee DY, 1996, J BIOL CHEM, V271, P24262, DOI 10.1074/jbc.271.39.24262; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; LUDER A, 1982, P NATL ACAD SCI-BIOL, V79, P1101, DOI 10.1073/pnas.79.4.1101; Ma YJ, 2004, J BIOL CHEM, V279, P19035, DOI 10.1074/jbc.M311738200; MENKENS AE, 1988, J BIOL CHEM, V263, P11358; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; MOSIG G, 1995, FEMS MICROBIOL REV, V17, P83, DOI 10.1111/j.1574-6976.1995.tb00190.x; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; Nossal NG, 2001, MOL CELL, V7, P31, DOI 10.1016/S1097-2765(01)00152-6; Raney KD, 1996, J BIOL CHEM, V271, P14074, DOI 10.1074/jbc.271.24.14074; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; SELICK HE, 1988, J BIOL CHEM, V263, P11336; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; Tomso DJ, 2000, GENETICS, V155, P1493; Trakselis MA, 2003, J BIOL CHEM, V278, P49839, DOI 10.1074/jbc.M307405200; Trakselis MA, 2001, TRENDS BIOCHEM SCI, V26, P566, DOI 10.1016/S0968-0004(01)01929-6; WU JR, 1978, J VIROL, V27, P103, DOI 10.1128/JVI.27.1.103-117.1978; WU R, 1972, VIROLOGY, V47, P147, DOI 10.1016/0042-6822(72)90248-6; WU R, 1974, VIROLOGY, V59, P108, DOI 10.1016/0042-6822(74)90209-8; Xi J, 2005, BIOCHEMISTRY-US, V44, P2305, DOI 10.1021/bi0479508; Xu H, 2001, BIOCHEMISTRY-US, V40, P7651, DOI 10.1021/bi010116n; Yang JS, 2003, J BIOL CHEM, V278, P49828, DOI 10.1074/jbc.M307406200; YONESAKI T, 1994, J BIOL CHEM, V269, P1284	56	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21561	21569		10.1074/jbc.m502351200	http://dx.doi.org/10.1074/jbc.m502351200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15781450	hybrid, Green Accepted			2022-12-25	WOS:000229438800079
J	van Meeteren, LA; Ruurs, P; Christodoulou, E; Goding, JW; Takakusa, H; Kikuchi, K; Perrakis, A; Nagano, T; Moolenaar, WH				van Meeteren, LA; Ruurs, P; Christodoulou, E; Goding, JW; Takakusa, H; Kikuchi, K; Perrakis, A; Nagano, T; Moolenaar, WH			Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTILITY-STIMULATING PROTEIN; LYSOPHOSPHOLIPASE-D; NUCLEOTIDE PYROPHOSPHATASES/PHOSPHODIESTERASES; CATALYTIC SITE; PHOSPHODIESTERASE; PLASMA; SPHINGOSINE-1-PHOSPHATE; HYDROLYSIS; RECEPTORS; BLOOD	Autotaxin (ATX) or nucleotide pyrophosphatase/ phosphodiesterase 2 (NPP2) is an NPP family member that promotes tumor cell motility, experimental metastasis, and angiogenesis. ATX primarily functions as a lysophospholipase D, generating the lipid mediator lysophosphatidic acid (LPA) from lysophosphatidylcholine. ATX uses a single catalytic site for the hydrolysis of both lipid and non-lipid phosphodiesters, but its regulation is not well understood. Using a new fluorescence resonance energy transfer-based phosphodiesterase sensor that reports ATX activity with high sensitivity, we show here that ATX is potently and specifically inhibited by LPA and sphingosine 1-phosphate (S1P) in a mixed-type manner (K-i similar to 10(-7) M). The homologous ecto-phosphodiesterase NPP1, which lacks lysophospholipase D activity, is insensitive to LPA and S1P. Our results suggest that, by repressing ATX activity, LPA can regulate its own biosynthesis in the extracellular environment, and they reveal a novel role for S1P as an inhibitor of ATX, in addition to its well established role as a receptor ligand.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Monash Univ, Sch Med, Dept Pathol & Immunol, Melbourne, Vic 3181, Australia; Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo 1130033, Japan	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Monash University; University of Tokyo	Moolenaar, WH (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	moolenaar@nki.nl	van Meeteren, Laurens/A-9890-2008; Perrakis, Anastassis/E-8704-2013; Kikuchi, Kazuya/D-2370-2009; Van Meeteren, Laurens A./AGQ-6139-2022	van Meeteren, Laurens/0000-0001-9885-0668; Perrakis, Anastassis/0000-0002-1151-6227; Christodoulou, Evangelos/0000-0001-8464-1558				Bachner D, 1999, MECH DEVELOP, V84, P121, DOI 10.1016/S0925-4773(99)00048-9; Baker DL, 2002, JAMA-J AM MED ASSOC, V287, P3081, DOI 10.1001/jama.287.23.3081; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Clair T, 2003, CANCER RES, V63, P5446; Clair T, 1997, BIOCHEM BIOPH RES CO, V236, P449, DOI 10.1006/bbrc.1997.6982; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Fuss B, 1997, J NEUROSCI, V17, P9095; Gijsbers R, 2003, FEBS LETT, V538, P60, DOI 10.1016/S0014-5793(03)00133-9; Goding JW, 2003, BBA-MOL BASIS DIS, V1638, P1, DOI 10.1016/S0925-4439(03)00058-9; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; KELLY SJ, 1975, BIOCHEMISTRY-US, V14, P4983, DOI 10.1021/bi00693a030; Koh E, 2003, CANCER RES, V63, P2042; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; Liliom K, 2001, BIOCHEM J, V355, P189, DOI 10.1042/0264-6021:3550189; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; MURATA J, 1994, J BIOL CHEM, V269, P30479; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Nam SW, 2001, CANCER RES, V61, P6938; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Rudolph AE, 1999, J BIOL CHEM, V274, P11824, DOI 10.1074/jbc.274.17.11824; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Takakusa H, 2002, J AM CHEM SOC, V124, P1653, DOI 10.1021/ja011251q; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Meeteren LA, 2004, J BIOL CHEM, V279, P10833, DOI 10.1074/jbc.C300563200; Vollmayer P, 2003, EUR J BIOCHEM, V270, P2971, DOI 10.1046/j.1432-1033.2003.03674.x; Yang LB, 1999, BRIT J HAEMATOL, V107, P282, DOI 10.1046/j.1365-2141.1999.01697.x; Zambonelli C, 2003, J BIOL CHEM, V278, P52282, DOI 10.1074/jbc.M310252200	35	166	184	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21155	21161		10.1074/jbc.M413183200	http://dx.doi.org/10.1074/jbc.M413183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15769751	hybrid			2022-12-25	WOS:000229438800032
J	Cho, J; Melnick, M; Solidakis, GP; Tsichlis, PN				Cho, J; Melnick, M; Solidakis, GP; Tsichlis, PN			Tpl2 (tumor progression locus 2) phosphorylation at Thr(290) is induced by lipopolysaccharide via an I kappa-B kinase-beta-dependent pathway and is required for Tpl2 activation by external signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LINES; PROTEIN-KINASE; NF-KAPPA-B1 P105; COT KINASE; INDUCTION; ONCOPROTEIN; PROTEOLYSIS; EXPRESSION; STABILITY; DISEASE	The serine-threonine protein kinase encoded by the tumor progression locus 2 ( Tpl2) proto-oncogene transduces Toll-like receptor and death receptor signals in a variety of cell types. Here we show that Tpl2 undergoes phosphorylation at Thr(290) both in cells overexpressing Tpl2 and in cells stimulated with lipopolysaccharide (LPS) or tumor necrosis factor-alpha and that phosphorylation on this site parallels Tpl2 activation. Reconstitution of Tpl2(-/-) macrophages with wild type Tpl2 or Tpl2 T290D restored ERK activation by LPS, whereas reconstitution of the same cells with Tpl2 T290A did not, suggesting that phosphorylation at Thr290 is required for the physiological activation of Tpl2 by external signals. Both the wild type Tpl2 and the kinase-inactive mutant Tpl2 K167M undergo Thr290 phosphorylation, suggesting that Thr290 may be a site of trans-phosphorylation rather than auto-phosphorylation. Pretreatment of 293 cells and primary macrophages with the I kappa-B kinase-beta (IKK beta) inhibitor PS-1145 blocked Tpl2 phosphorylation at Thr290, suggesting that phosphorylation depends on IKK beta, an obligatory positive regulator of Tpl2. We conclude that Tpl2 phosphorylation at Thr290 is induced by LPS, depends on IKK beta, and is required for the physiological activation of Tpl2 by external signals.	Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; Tufts Canc Ctr, Boston, MA 02111 USA; Cell Signaling Technol Inc, Beverly, MA 01915 USA	Tufts Medical Center; Tufts University	Tsichlis, PN (corresponding author), Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, 750 Washington St,Box 5609, Boston, MA 02111 USA.	ptsichlis@tufts-nemc.org			NATIONAL CANCER INSTITUTE [R01CA038047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NCI NIH HHS [CA R01 38047] Funding Source: Medline; NIDDK NIH HHS [P30DK34928] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Cho JH, 2005, P NATL ACAD SCI USA, V102, P2350, DOI 10.1073/pnas.0409856102; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eliopoulos AG, 2003, EMBO J, V22, P3855, DOI 10.1093/emboj/cdg386; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Erny KM, 1996, ONCOGENE, V13, P2015; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; Gandara ML, 2003, MOL CELL BIOL, V23, P7377, DOI 10.1128/MCB.23.20.7377-7390.2003; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Kontoyiannis D, 2002, J EXP MED, V196, P1563, DOI 10.1084/jem.20020281; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Luciano BS, 2004, J BIOL CHEM, V279, P52117, DOI 10.1074/jbc.M403716200; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; Velasco-Sampayo A, 2001, J IMMUNOL, V166, P6084, DOI 10.4049/jimmunol.166.10.6084; Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040-6048.2004; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4	28	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20442	20448		10.1074/jbc.M413554200	http://dx.doi.org/10.1074/jbc.M413554200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15778223	hybrid			2022-12-25	WOS:000229242000036
J	Bao, JJ; Jana, SS; Adelstein, RS				Bao, JJ; Jana, SS; Adelstein, RS			Vertebrate nonmuscle myosin II Isoforms rescue small interfering RNA-induced defects in COS-7 cell cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ISOFORMS; CONTRACTILE RING; CULTURED-CELLS; GENE; LOCALIZATION; EXPRESSION; MECHANISM; ABLATION; IDENTIFICATION; DICTYOSTELIUM	RNA interference (RNAi) treatment of monkey COS-7 cells, a cell line that lacks nonmuscle myosin heavy chain II-A (NMHC II-A) but contains NMHC II-B and II-C, was used to investigate the participation of NMHC isoforms in cytokinesis. We specifically suppressed the expression of NMHC II-B or II-C using 21 nucleotide small interfering RNA (siRNA) duplexes. Down-regulation of NMHC II-B protein expression to 10.2 +/- 0.7% inhibited COS-7 cell proliferation by 50% in the RNAi-treated cells compared with control cells. Moreover, whereas 8.7 +/- 1.0% of control cells were multinucleated, 62.4 +/- 8.8% of the NMHC II-B RNAi-treated cells were multinucleated 72 h after transfection. The RNAi-treated cells had increased surface areas and, unlike control cells, lacked actin stress fibers. Treatment of the COS-7 cells with NMHC II-C siRNA decreased NMHC II-C expression to 5.2 +/- 0.1% compared with the endogenous content of II-C; however, down-regulation of NMHC II-C did not cause increased multinucleation. Immunoblot analysis using a pan-myosin antibody showed that the content of NMHC II-C was less than one-twentieth the amount of NMHC II-B, thereby explaining the lack of response to II-C siRNA. Introducing green fluorescent protein (GFP)-tagged NMHC II isoforms into II-B siRNA-treated cells resulted in reduction of multinucleation from 62.4 +/- 8.8% to 17.8 +/- 2.2% using GFP-NMHC II-B, to 29.8 +/- 7.4% using GFP-NMHC II-A, and to 34.1 +/- 8.6% using NMHC II-C- GFP. These studies have shown that expression of endogenous NMHC II-C in COS-7 cells is insufficient for normal cytokinesis and that exogenous NMHC II-A and NMHC II-C can, at least partially, rescue the defect in cytokinesis due to the loss of NMHC II-B.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Adelstein, RS (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202,10 Ctr Dr,MSC 1762, Bethesda, MD 20892 USA.	AdelsteR@NHLBI.NationalInstitutesofHealth.GOV		Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004216, ZIAHL004216] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Buxton DB, 2003, J BIOL CHEM, V278, P15449, DOI 10.1074/jbc.M210145200; Conti MA, 2004, J BIOL CHEM, V279, P41263, DOI 10.1074/jbc.C400352200; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; FUJIWARA K, 1978, J CELL BIOL, V79, P268, DOI 10.1083/jcb.79.1.268; FUKUI Y, 1991, CELL MOTIL CYTOSKEL, V18, P41, DOI 10.1002/cm.970180105; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; KIM K, 2005, J BIOL CHEM; Kolega J, 1998, J CELL SCI, V111, P2085; Kolega J, 2003, MOL BIOL CELL, V14, P4745, DOI 10.1091/mbc.E03-04-0205; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Leal A, 2003, GENE, V312, P165, DOI 10.1016/S0378-1119(03)00613-9; Lippincott J, 1998, J CELL BIOL, V140, P355, DOI 10.1083/jcb.140.2.355; Lo CM, 2004, MOL BIOL CELL, V15, P982, DOI 10.1091/mbc.E03-06-0359; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MAUPIN P, 1994, J CELL SCI, V107, P3077; Meshel AS, 2005, NAT CELL BIOL, V7, P157, DOI 10.1038/ncb1216; MURAKAMI N, 1993, DEV BIOL, V157, P19, DOI 10.1006/dbio.1993.1108; SCHROEDER TE, 1973, P NATL ACAD SCI USA, V70, P1688, DOI 10.1073/pnas.70.6.1688; Sellers J. R., 1999, MYOSINS; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; Straight AF, 2005, MOL BIOL CELL, V16, P193, DOI 10.1091/mbc.E04-08-0758; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; Takeda K, 2003, CIRC RES, V93, P330, DOI 10.1161/01.RES.0000089256.00309.CB; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; Tullio AN, 2001, J COMP NEUROL, V433, P62, DOI 10.1002/cne.1125; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wang YL, 2001, CELL STRUCT FUNCT, V26, P633, DOI 10.1247/csf.26.633; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29	34	92	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19594	19599		10.1074/jbc.M501573200	http://dx.doi.org/10.1074/jbc.M501573200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774463	hybrid			2022-12-25	WOS:000229113700022
J	Legiewicz, M; Yarus, M				Legiewicz, M; Yarus, M			A more complex isoleucine aptamer with a cognate triplet	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA APTAMERS; IN-VITRO; STRUCTURAL BASIS; GENETIC-CODE; AMINO-ACIDS; SELECTION; BINDING; ARGININE; RECOGNITION; EVOLUTION	The simplest RNA that can meet a column affinity selection for isoleucine was previously defined using selection amplification with decreasing numbers of randomized nucleotides. This simplest UAUU motif was a small asymmetric internal loop. Conserved positions of the loop include isoleucine codon and anticodon triplets (Lozupone C., Changayil, S., Majerfeld, I., and Yarus, M. (2003) RNA (N.Y.) 9, 1315-1322). Using new primer sequences, we now select a somewhat more complex isoleucine binding RNA, requiring 4.7 more bits of information to describe. The newly selected structure is a terminal or hairpin loop of 20 nucleotides, 15 being invariant. An information profile shows that the new binding site contains five short functional loop regions joined by less significant single nucleotide positions. Among the important nucleotides is a conserved isoleucine anticodon, supporting the escaped triplet theory, which posits a stereochemical genetic code originating in RNA amino acid binding sites.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Yarus, M (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	yarus@colorado.edu	Yarus, Michael/Q-9813-2019		NIGMS NIH HHS [GM 48080] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048080] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burgstaller P, 1995, NUCLEIC ACIDS RES, V23, P4769, DOI 10.1093/nar/23.23.4769; Carothers JM, 2004, J AM CHEM SOC, V126, P5130, DOI 10.1021/ja031504a; Ciesiolka J, 1996, METHOD ENZYMOL, V267, P315; Ciesiolka J, 1996, RNA, V2, P785; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; CONNELL GJ, 1994, SCIENCE, V264, P1137, DOI 10.1126/science.7513905; de Zwart I, 2005, HANDBOOK OF RNA BIOCHEMISTRY, P783, DOI 10.1002/9783527619504.ch47; Doudna JA, 2002, NATURE, V418, P222, DOI 10.1038/418222a; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; Geiger A, 1996, NUCLEIC ACIDS RES, V24, P1029, DOI 10.1093/nar/24.6.1029; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; Gorodkin J, 1997, COMPUT APPL BIOSCI, V13, P583; Illangasekare M, 2002, J MOL EVOL, V54, P298, DOI 10.1007/s00239-001-0045-6; Knight R, 2004, RNA, V10, P1323, DOI 10.1261/rna.5168504; Knight R, 2003, RNA, V9, P218, DOI 10.1261/rna.2138803; KNIGHT RD, 2000, NUCLEIC ACIDS RES, V31, pE30; KROL A, 1989, METHOD ENZYMOL, V180, P212; Lozupone C, 2003, RNA, V9, P1315, DOI 10.1261/rna.5114503; MAJERFELD I, 1994, NAT STRUCT BIOL, V1, P287, DOI 10.1038/nsb0594-287; Majerfeld I, 1998, RNA, V4, P471; Mandal M, 2004, NAT REV MOL CELL BIO, V5, P451, DOI 10.1038/nrm1403; Mannironi C, 2000, RNA, V6, P520, DOI 10.1017/S1355838200991763; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SCHNEIDER TD, 1986, J MOL BIOL, V188, P415, DOI 10.1016/0022-2836(86)90165-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WALTER AE, 1994, P NATL ACAD SCI USA, V91, P9218, DOI 10.1073/pnas.91.20.9218; Winkler WC, 2003, CHEMBIOCHEM, V4, P1024, DOI 10.1002/cbic.200300685; Yang YS, 1996, SCIENCE, V272, P1343, DOI 10.1126/science.272.5266.1343; Yarus M, 2005, ANNU REV BIOCHEM, V74, P179, DOI 10.1146/annurev.biochem.74.082803.133119; Yarus M, 1998, J MOL EVOL, V47, P109, DOI 10.1007/PL00006357; Yarus M, 2000, RNA, V6, P475, DOI 10.1017/S1355838200002569; Yarus M, 2004, MOL B INT U, P75	35	32	38	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19815	19822		10.1074/jbc.M502329200	http://dx.doi.org/10.1074/jbc.M502329200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772067	hybrid			2022-12-25	WOS:000229113700048
J	Zhang, Y; Lyver, ER; Knight, SAB; Lesuisse, E; Dancis, A				Zhang, Y; Lyver, ER; Knight, SAB; Lesuisse, E; Dancis, A			Frataxin and mitochondrial carrier proteins, Mrs3p and Mrs4p, cooperate in providing iron for heme synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; SULFUR CLUSTER BIOSYNTHESIS; FRIEDREICHS-ATAXIA; CRYSTAL-STRUCTURE; PRECURSOR FORM; HOMOLOG; FERROCHELATASE; ACCUMULATION; PURIFICATION; DEFICIENCY	Frataxin is a conserved mitochondrial protein implicated in cellular iron metabolism. Deletion of the yeast frataxin homolog (YFH1) was combined with deletions of MRS3 and MRS4, mitochondrial carrier proteins implicated in iron homeostasis. As previously reported, the Delta yfh1 mutant accumulated iron in mitochondria, whereas the triple mutant (Delta Delta Delta) did not. When wildtype, Delta mrs3/4, Delta yfh1, and Delta Delta Delta strains were incubated anaerobically, all strains were devoid of heme and protected from iron and oxygen toxicity. The cultures were then shifted to air for a short time (4-5 h) or a longer time ( 15 h), and the evolving mutant phenotypes were analyzed (heme-dependent growth, total heme, cytochromes, heme proteins, and iron levels). A picture emerges from these data of defective heme formation in the mutants, with a markedly more severe defect in the Delta Delta Delta than in the individual Delta mrs3/4 or Delta yfh1 mutants (a "synthetic" defect in the genetic sense). The defect(s) in heme formation could be traced to lack of iron. Using a real time assay of heme biosynthesis, porphyrin precursor and iron were presented to permeabilized cells, and the appearance and disappearance of fluorescent porphyrins were followed. The Mrs3/4p carriers were required for rapid iron transport into mitochondria for heme synthesis, whereas there was also evidence for an alternative slower system. A different role for Yfh1p was observed under conditions of low mitochondrial iron and aerobic growth (revealed in the Delta Delta Delta), acting to protect bioavailable iron within mitochondria and to facilitate its use for heme synthesis.	Univ Penn, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA; Univ Paris 06, Inst Jacques Monod, Dept Biol Genomes, Lab Ingn Prot & Controle Metab,UMR 7592,CNRS, F-75251 Paris, France; Univ Paris 07, Inst Jacques Monod, Dept Biol Genomes, Lab Ingn Prot & Controle Metab,UMR 7592,CNRS, F-75251 Paris, France	University of Pennsylvania; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Dancis, A (corresponding author), Univ Penn, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA.	adancis@mail.med.upenn.edu	Zhang, Yan/K-1638-2015	Zhang, Yan/0000-0003-2031-0631; Knight, Simon/0000-0001-7407-3390	NIDDK NIH HHS [DK53953] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK053953, R01DK053953] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHLEITNER G, 1995, J BIOL CHEM, V270, P29836; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Aloria K, 2004, EMBO REP, V5, P1096, DOI 10.1038/sj.embor.7400272; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Branda SS, 1999, HUM MOL GENET, V8, P1099, DOI 10.1093/hmg/8.6.1099; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CAMADRO JM, 1994, J BIOL CHEM, V269, P32085; CAMADRO JM, 1986, EUR J BIOCHEM, V156, P579, DOI 10.1111/j.1432-1033.1986.tb09617.x; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Chen XJ, 2005, SCIENCE, V307, P714, DOI 10.1126/science.1106391; Cho SJ, 2000, P NATL ACAD SCI USA, V97, P8932, DOI 10.1073/pnas.160270897; Dhe-Paganon S, 2000, J BIOL CHEM, V275, P30753, DOI 10.1074/jbc.C000407200; Farrelly E, 2001, ANAL BIOCHEM, V293, P269, DOI 10.1006/abio.2001.5139; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Gakh O, 2002, BIOCHEMISTRY-US, V41, P6798, DOI 10.1021/bi025566+; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Gordon DM, 2001, HUM MOL GENET, V10, P259, DOI 10.1093/hmg/10.3.259; HE YA, 2004, BIOCHEMISTRY-US, V51, P16254; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; Karthikeyan G, 2003, HUM MOL GENET, V12, P3331, DOI 10.1093/hmg/ddg349; Kastaniotis AJ, 2000, ADV EXP MED BIOL, V475, P185; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Labbe P, 1969, Bull Soc Chim Biol (Paris), V51, P1642; Labbe-Bois Rosine, 1994, V11, P413; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; Lesuisse E, 2005, GENETICS, V169, P107, DOI 10.1534/genetics.104.035873; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Lesuisse Emmanuel, 1994, V11, P149; Li LT, 2004, J BIOL CHEM, V279, P33653, DOI 10.1074/jbc.M403146200; Luk E, 2003, J BIOL INORG CHEM, V8, P803, DOI 10.1007/s00775-003-0482-3; Miranda CJ, 2004, FEBS LETT, V572, P281, DOI 10.1016/j.febslet.2004.07.022; Muhlenhoff U, 2003, J BIOL CHEM, V278, P40612, DOI 10.1074/jbc.M307847200; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Park S, 2003, J BIOL CHEM, V278, P31340, DOI 10.1074/jbc.M303158200; Petracek ME, 2002, METHOD ENZYMOL, V350, P445, DOI 10.1016/S0076-6879(02)50978-2; PON L, MOL CELLULAR BIOL YE, P333; PORRA RJ, 1963, BIOCHEM J, V87, P181, DOI 10.1042/bj0870181; Puccio H, 2002, CURR OPIN GENET DEV, V12, P272, DOI 10.1016/S0959-437X(02)00298-8; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Puig S, 2005, CELL, V120, P99, DOI 10.1016/j.cell.2004.11.032; Ramazzotti A, 2004, FEBS LETT, V557, P215, DOI 10.1016/S0014-5793(03)01498-4; ROGGENKAMP R, 1974, FEBS LETT, V41, P283, DOI 10.1016/0014-5793(74)81230-5; Rotig A, 2002, TRENDS MOL MED, V8, P221, DOI 10.1016/S1471-4914(02)02330-4; Santos R, 2004, MOL MICROBIOL, V54, P507, DOI 10.1111/j.1365-2958.2004.04281.x; Shi Z, 2003, ANAL BIOCHEM, V318, P18, DOI 10.1016/S0003-2697(03)00175-1; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; Yoon T, 2004, J BIOL CHEM, V279, P25943, DOI 10.1074/jbc.C400107200; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i; Zeth K, 2004, P NATL ACAD SCI USA, V101, P13780, DOI 10.1073/pnas.0401821101	57	98	98	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19794	19807		10.1074/jbc.M500397200	http://dx.doi.org/10.1074/jbc.M500397200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767258	hybrid			2022-12-25	WOS:000229113700046
J	Byrd, MP; Zamora, M; Lloyd, RE				Byrd, MP; Zamora, M; Lloyd, RE			Translation of eukaryotic translation initiation factor 4GI (eIF4GI) proceeds from multiple mRNAs containing a novel cap-dependent internal ribosome entry site (IRES) that is active during poliovirus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; POLY(A)-BINDING PROTEIN; BINDING-PROTEIN; C-MYC; PROTEOLYTIC CLEAVAGE; GENE-EXPRESSION; VIRUS; INHIBITION; ADENOVIRUS; APOPTOSIS	Eukaryotic translation initiation factor 4GI (eIF4GI) is an essential scaffolding protein required to recruit the 43 S complex to the 5'-end of mRNA during translation initiation. We have previously demonstrated that eIF4GI protein expression is translationally regulated. This regulation is mediated by cis-acting RNA elements, including an upstream open reading frame and an IRES that directs synthesis of five eIF4GI protein isoforms via alternative AUG initiation codon selection. Here, we further characterize eIF4GI IRES function and show that eIF4GI is expressed from several distinct mRNAs that vary via alternate promoter use and alternate splicing. Several mRNA variants contain the IRES element. We found that IRES activity mapped to multiple regions within the eIF4GI RNA sequence, but not within the 5'-UTR per se. However, the 5'-UTR enhanced IRES activity in vivo and played a role in initiation codon selection. The eIF4GI IRES was active when transfected into cells in an RNA form, and thus, does not require nuclear processing events for its function. However, IRES activity was found to be dependent upon the presence, in cis, of a 5' m(7)guanosine-cap. Despite this requirement, the eIF4GI IRES was activated by 2A protease cleavage of eIF4GI, in vitro, and retained the ability to promote translation during poliovirus-mediated inhibition of cap-dependent translation. These data indicate that intact eIF4GI protein is not required for the de novo synthesis of eIF4GI, suggesting its expression can continue under stress or infection conditions where eIF4GI is cleaved.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine	Lloyd, RE (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Rm 860E,1 Baylor Plaza, Houston, TX 77030 USA.	rlloyd@bcm.tmc.edu			NIAID NIH HHS [AI 50237, T32 AI07471] Funding Source: Medline; NIGMS NIH HHS [GM 59803] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI050237, R01AI050237, T32AI007471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059803] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali IK, 2001, J VIROL, V75, P7854, DOI 10.1128/JVI.75.17.7854-7863.2001; ALI N, 1995, J VIROL, V69, P6367, DOI 10.1128/JVI.69.10.6367-6375.1995; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; Bushell M, 2000, CELL DEATH DIFFER, V7, P628, DOI 10.1038/sj.cdd.4400699; Byrd MP, 2002, MOL CELL BIOL, V22, P4499, DOI 10.1128/MCB.22.13.4499-4511.2002; CASTRILLO JL, 1987, J BIOL CHEM, V262, P7328; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; De Gregorio E, 1999, EMBO J, V18, P4865, DOI 10.1093/emboj/18.17.4865; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; Dominguez DI, 1998, J BIOL CHEM, V273, P3669, DOI 10.1074/jbc.273.6.3669; ETCHISON D, 1985, J VIROL, V54, P634, DOI 10.1128/JVI.54.2.634-638.1985; Eu JY, 2001, LUMINESCENCE, V16, P57, DOI 10.1002/bio.612; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Honda M, 2000, GASTROENTEROLOGY, V118, P152, DOI 10.1016/S0016-5085(00)70424-0; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Joachims M, 1999, J VIROL, V73, P718, DOI 10.1128/JVI.73.1.718-727.1999; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kean KM, 2003, BIOL CELL, V95, P129, DOI 10.1016/S0248-4900(03)00030-3; Kozak M, 2003, GENE, V318, P1, DOI 10.1016/S0378-1119(03)00774-1; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kuyumcu-Martinez NM, 2004, MOL CELL BIOL, V24, P1779, DOI 10.1128/MCB.24.4.1779-1790.2004; Kuyumcu-Martinez NM, 2002, J VIROL, V76, P2062, DOI 10.1128/JVI.76.5.2062-2074.2002; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; MADER S, 1995, BIOCHIMIE, V77, P40, DOI 10.1016/0300-9084(96)88102-8; Marcotrigiano J, 2001, MOL CELL, V7, P193, DOI 10.1016/S1097-2765(01)00167-8; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Michel YM, 2000, J BIOL CHEM, V275, P32268, DOI 10.1074/jbc.M004304200; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Pudi R, 2003, J BIOL CHEM, V278, P12231, DOI 10.1074/jbc.M210287200; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; ROSE JK, 1978, P NATL ACAD SCI USA, V75, P2732, DOI 10.1073/pnas.75.6.2732; Schneider RJ, 2000, COLD SPRING HARBOR M, V39, P901; Sherrill KW, 2004, J BIOL CHEM, V279, P29066, DOI 10.1074/jbc.M402727200; SOMMERGRUBER W, 1994, VIROLOGY, V198, P741, DOI 10.1006/viro.1994.1089; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Van Eden ME, 2004, RNA, V10, P720, DOI 10.1261/rna.5225204; Van Eden ME, 2004, RNA, V10, P469, DOI 10.1261/rna.5156804; Ventoso I, 2001, P NATL ACAD SCI USA, V98, P12966, DOI 10.1073/pnas.231343498; YAN RQ, 1992, J BIOL CHEM, V267, P23226; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; Yueh A, 2000, GENE DEV, V14, P414; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; Zamora M, 2002, J VIROL, V76, P165, DOI 10.1128/JVI.76.1.165-177.2002	58	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18610	18622		10.1074/jbc.M414014200	http://dx.doi.org/10.1074/jbc.M414014200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755734	hybrid			2022-12-25	WOS:000228932300010
J	Fernandez, E; Torrents, D; Zorzano, A; Palacin, M; Chillaron, J				Fernandez, E; Torrents, D; Zorzano, A; Palacin, M; Chillaron, J			Identification and functional characterization of a novel low affinity aromatic-preferring amino acid transporter (arpAT) - One of the few proteins silenced during primate evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTINE/GLUTAMATE EXCHANGE TRANSPORTER; 4F2 HEAVY-CHAIN; MULTIPLE SEQUENCE ALIGNMENT; HUMAN JEJUNAL ENTEROCYTES; STRUCTURAL SIMILARITY; MEMBRANE-PROTEIN; SYSTEM X(C)(-); MESSENGER-RNA; LIGHT SUBUNIT; MOUSE-BRAIN	We have identified in silico arpAT, a gene encoding a new member of the LSHAT family, and cloned it from kidney. Co-expression of arpAT with the heavy subunits rBAT or 4F2hc elicited a sodium-independent alanine transport activity in HeLa cells. L-Tyrosine, L-3,4-dihydroxyphenylalanine (L-DOPA), L-glutamine, L-serine, L-cystine, and L-arginine were also transported. Kinetic and cis-inhibition studies showed a K-m = 1.59 +/- 0.24 mM for L-alanine or IC50 in the millimolar range for most amino acids, except L-proline, glycine, anionic and D-amino acids, which were not inhibitory. L-DOPA and L-tyrosine were the most effective competitive inhibitors of L-alanine transport, with IC50 values of 272.2 +/- 57.1 and 716.3 +/- 112.4 mu M, respectively. In the small intestine, arpAT mRNA was located at the enterocytes, in a decreasing gradient from the crypts to the tip of the villi. It was also expressed in neurons from different brain areas. Finally, we show that while the arpAT gene is conserved in rat, dog, and chicken, it has become silenced in humans and chimpanzee. Actually, it has been recently reported that it is one of the 33 recently inactivated genes in the human lineage. The evolutionary implications of the silencing process and the roles of arpAT in transport of L-DOPA in the brain and in aromatic amino acid absorption are discussed.	Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Univ Barcelona, Barcelona Sci Pk, E-08028 Barcelona, Spain; European Mol Biol Lab, D-69117 Heidelberg, Germany	University of Barcelona; University of Barcelona; European Molecular Biology Laboratory (EMBL)	Chillaron, J (corresponding author), Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, New Bldg,Av Diagonal 645, E-08028 Barcelona, Spain.	chillaro@worldonline.es	Zorzano, Antonio/R-5479-2018; Palacín, Manuel/G-9786-2015; Chillaron, Josep/ABF-7663-2021; Torrents, David/G-5785-2015	Chillaron, Josep/0000-0003-3068-7598; Palacin, Manuel/0000-0002-8670-293X; Torrents, David/0000-0002-6086-9037				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bauch C, 2003, J BIOL CHEM, V278, P1316, DOI 10.1074/jbc.M210449200; BAUMAN A, 1974, BRAIN RES, V66, P253, DOI 10.1016/0006-8993(74)90144-9; Birney E, 2004, GENOME RES, V14, P988, DOI 10.1101/gr.1865504; Boado RJ, 1999, P NATL ACAD SCI USA, V96, P12079, DOI 10.1073/pnas.96.21.12079; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; Broer A, 2004, J BIOL CHEM, V279, P24467, DOI 10.1074/jbc.M400904200; Broer A, 2000, BIOCHEM J, V349, P787, DOI 10.1042/bj3490787; Campbell WA, 2000, J BIOL CHEM, V275, P5347, DOI 10.1074/jbc.275.8.5347; Chairoungdua A, 2001, J BIOL CHEM, V276, P49390, DOI 10.1074/jbc.M107517200; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Dave MH, 2004, J PHYSIOL-LONDON, V558, P597, DOI 10.1113/jphysiol.2004.065037; Duelli R, 2000, J CEREBR BLOOD F MET, V20, P1557, DOI 10.1097/00004647-200011000-00005; Fernandez E, 2003, J AM SOC NEPHROL, V14, P837, DOI 10.1097/01.ASN.0000057852.35075.AC; Fernandez E, 2002, AM J PHYSIOL-RENAL, V283, pF540, DOI 10.1152/ajprenal.00071.2002; Font M, 2001, HUM MOL GENET, V10, P305, DOI 10.1093/hmg/10.4.305; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; GARCIASANCHO FJ, 1975, BIOCHIM BIOPHYS ACTA, V406, P538, DOI 10.1016/0005-2736(75)90031-0; Gasol E, 2004, J BIOL CHEM, V279, P31228, DOI 10.1074/jbc.M402428200; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Helboe L, 2003, EUR J NEUROSCI, V18, P2227, DOI 10.1046/j.1460-9568.2003.02966.x; Hisano S, 1996, BRAIN RES, V710, P299, DOI 10.1016/0006-8993(95)01442-X; Kageyama T, 2000, NEUROREPORT, V11, P3663, DOI 10.1097/00001756-200011270-00015; Kim DK, 2002, GENOMICS, V79, P95, DOI 10.1006/geno.2001.6678; Kim DK, 2001, J BIOL CHEM, V276, P17221, DOI 10.1074/jbc.M009462200; Kleta R, 2004, NAT GENET, V36, P999, DOI 10.1038/ng1405; Li W, 2000, J HISTOCHEM CYTOCHEM, V48, P89, DOI 10.1177/002215540004800109; Li W, 1998, GASTROENTEROLOGY, V115, P86, DOI 10.1016/S0016-5085(98)70368-3; LI WH, 1981, NATURE, V292, P237, DOI 10.1038/292237a0; Liu XM, 2004, FASEB J, V18, P768, DOI 10.1096/fj.03-0886fje; Matsuo H, 2002, J BIOL CHEM, V277, P21017, DOI 10.1074/jbc.M200019200; Meier C, 2002, EMBO J, V21, P580, DOI 10.1093/emboj/21.4.580; Misu Y, 2003, PHARMACOL THERAPEUT, V97, P117, DOI 10.1016/S0163-7258(02)00325-X; NIRENBERG MJ, 1995, J COMP NEUROL, V356, P505, DOI 10.1002/cne.903560403; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Palacin M, 2004, PFLUG ARCH EUR J PHY, V447, P490, DOI 10.1007/s00424-003-1062-7; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Pineda M, 2004, KIDNEY INT, V66, P1453, DOI 10.1111/j.1523-1755.2004.00908.x; Pineda M, 2004, BIOCHEM J, V377, P665, DOI 10.1042/BJ20030956; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Rajan DP, 2000, J BIOL CHEM, V275, P14331, DOI 10.1074/jbc.275.19.14331; Reig N, 2002, EMBO J, V21, P4906, DOI 10.1093/emboj/cdf500; Rome S, 2002, J NUTR, V132, P1009, DOI 10.1093/jn/132.5.1009; Sasaki H, 2002, J BIOL CHEM, V277, P44765, DOI 10.1074/jbc.M208704200; Sato H, 2002, J NEUROSCI, V22, P8028; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Seow HF, 2004, NAT GENET, V36, P1003, DOI 10.1038/ng1406; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tome D, 2004, BRIT J NUTR, V92, pS27, DOI 10.1079/BJN20041138; Torrents D, 2003, GENOME RES, V13, P2559, DOI 10.1101/gr.1455503; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; Uchino H, 2002, MOL PHARMACOL, V61, P729, DOI 10.1124/mol.61.4.729; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Vieira-Coelho MA, 1998, LIFE SCI, V64, P69, DOI 10.1016/S0024-3205(98)00535-9; VieiraCoelho MA, 1997, CLIN EXP HYPERTENS, V19, P43, DOI 10.3109/10641969709080803; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; YAN N, 1992, P NATL ACAD SCI USA, V89, P9982, DOI 10.1073/pnas.89.21.9982; Yanagida O, 2001, BBA-BIOMEMBRANES, V1514, P291, DOI 10.1016/S0005-2736(01)00384-4; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555	64	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19364	19372		10.1074/jbc.M412516200	http://dx.doi.org/10.1074/jbc.M412516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757906	hybrid			2022-12-25	WOS:000228932300094
J	Harikumar, KG; Miller, LJ				Harikumar, KG; Miller, LJ			Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2) ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTOR; PEPTIDE AGONIST; CONFORMATIONAL-CHANGES; REFINEMENT; SITE	Changes in receptor conformation are believed to be key for ligand-induced regulation of cellular signaling cascades. However, little information exists about specific conformations of a receptor. We recently applied fluorescence resonance energy transfer to determine distances from distinct points distributed over the surface and within the helical bundle of the cholecystokinin receptor to the amino terminus of a full agonist CCK analogue (Harikumar, K. G., Pinon, D. I., Wessels, W. S., Dawson, E. S., Lybrand, T. P., Prendergast, F. G., and Miller, L. J. ( 2004) Mol. Pharmacol. 65, 28-35). Here, we apply the same experimental strategy to determine distances from the same receptor positions to an analogous point at the amino terminus of structurally related partial agonist (Alexa(488)-Gly-[(Nle(28,31))CCK-26-32]phenethyl ester) and antagonist (Alexa(488)-Gly-[(D-Trp(31), Nle(28,31)) CCK-26-32]phenethyl ester) ligands. A high degree of spectral overlap and fluorescence transfer was observed for ligand-occupied fluorescent-tagged receptors with no transfer observed for the ligand-occupied pseudo-wild type null cysteine-reactive mutant receptor (C94S). For the partial agonist, calculated distances to receptor positions 94, 102, 204, and 341, representing sites within the helical confluence, and the first, second, and third loops, were 21 +/- 0.4, 18 +/- 0.4, 25 +/- 1, and 17 +/- 1 angstrom, not different from those measured previously for the analogous full agonist. For the antagonist, the analogous distances were 21 +/- 2, 28 +/- 2, 15 +/- 1 and 21 +/- 1 angstrom. Distances to the first and third loops were longer and the distance to the second loop was shorter for the antagonist relative to both the full and partial agonist probes, whereas all three probes demonstrated similar distances to the intrahelical reference point. This supports the possibilities of changes in the conformation of the probe and/or the receptor induced by structurally similar ligands having distinct intrinsic biological activities.	Mayo Clin Scottsdale, Ctr Canc, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Miller, LJ (corresponding author), Mayo Clin Scottsdale, Ctr Canc, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	miller@mayo.edu			NIDDK NIH HHS [DK32878] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032878, R01DK032878] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arlander SJH, 2004, MOL PHARMACOL, V66, P545, DOI 10.1124/mol.104.001396; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Ding XQ, 2003, RECEPTOR CHANNEL, V9, P83, DOI 10.1080/10606820308249; Ding XQ, 2002, MOL PHARMACOL, V61, P1041, DOI 10.1124/mol.61.5.1041; Ding XQ, 2001, J BIOL CHEM, V276, P4236, DOI 10.1074/jbc.M003798200; Dong MQ, 1999, J BIOL CHEM, V274, P4778, DOI 10.1074/jbc.274.8.4778; Donnelly D, 1997, FEBS LETT, V409, P431, DOI 10.1016/S0014-5793(97)00546-2; GETHER U, 1995, J BIOL CHEM, V270, P28268; Hadac EM, 1999, J MED CHEM, V42, P2105, DOI 10.1021/jm980732q; Harikumar KG, 2004, MOL PHARMACOL, V65, P28, DOI 10.1124/mol.65.1.28; Harikumar KG, 2002, J BIOL CHEM, V277, P18552, DOI 10.1074/jbc.M201164200; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; LAKOWICZ JR, 1980, J BIOCHEM BIOPH METH, V2, P91, DOI 10.1016/0165-022X(80)90077-9; Lin SS, 1996, BIOCHEMISTRY-US, V35, P14445, DOI 10.1021/bi961619+; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719	17	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18631	18635		10.1074/jbc.M410834200	http://dx.doi.org/10.1074/jbc.M410834200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757907	hybrid			2022-12-25	WOS:000228932300012
J	Lussier, MP; Cayouette, S; Lepage, PK; Bernier, CL; Francoeur, N; St Hilaire, M; Pinard, M; Boulay, G				Lussier, MP; Cayouette, S; Lepage, PK; Bernier, CL; Francoeur, N; St Hilaire, M; Pinard, M; Boulay, G			MxA, a member of the dynamin superfamily, interacts with the ankyrin-like repeat domain of TRPC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; VIRUS NUCLEOCAPSID PROTEIN; PLASMA-MEMBRANE; CA2+ ENTRY; CALMODULIN-BINDING; POTENTIAL TRP; IP3 RECEPTOR; SH3 DOMAINS; GTPASE; FAMILY	Mammalian transient receptor potential canonical channels have been proposed as the molecular entities associated with calcium entry activity in nonexcitable cells. Amino acid sequence analyses of TRPCs revealed the presence of ankyrin-like repeat domains, one of the most common protein-protein interaction motifs. Using a yeast two-hybrid interaction assay, we found that the second ankyrin-like repeat domain of TRPC6 interacted with MxA, a member of the dynamin superfamily. Using a GST pull-down and co-immunoprecipitation assay, we showed that MxA interacted with TRPC1, -3, -4, -5, -6, and -7. Overexpression of MxA in HEK293T cells slightly increased endogenous calcium entry subsequent to stimulation of G(q) protein-coupled receptors or store depletion by thapsigargin. Co-expression of MxA with TRPC6 enhanced agonist-induced or OAG-induced calcium entry activity. GTP binding-defective MxA mutants had only a minor potentiating effect on OAG-induced TRPC6 activity. However, a MxA mutant that could bind GTP but that lacked GTPase activity produced the same effect as MxA on OAG-induced TRPC6 activity. These results indicated that MxA interacted specifically with the second ankyrin-like repeat domain of TRPCs and suggested that monomeric MxA regulated the activity of TRPC6 by a mechanism requiring GTP binding. Additional results showed that an increase in the endogenous expression of MxA, induced by a treatment with interferon alpha, regulated the activity of TRPC6. The study clearly identified MxA as a new regulatory protein involved in Ca2+ signaling.	Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Boulay, G (corresponding author), Univ Sherbrooke, Fac Med, Dept Pharmacol, 3001 12th Ave N, Sherbrooke, PQ J1H 5N4, Canada.	Guylain.Boulay@USherbrooke.ca	Boulay, Guylain/D-9773-2010	Lussier, Marc/0000-0001-5568-0072				Accola MA, 2002, J BIOL CHEM, V277, P21829, DOI 10.1074/jbc.M201641200; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson I, 2004, J VIROL, V78, P4323, DOI 10.1128/JVI.78.8.4323-4329.2004; AUSUBEL FM, 2002, CURRENT PROTOCOLS MO; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Boulay G, 2002, CELL CALCIUM, V32, P201, DOI 10.1016/S0143416002001550; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Burysek L, 2001, J VIROL, V75, P2345, DOI 10.1128/JVI.75.5.2345-2352.2001; Cayouette S, 2004, J BIOL CHEM, V279, P7241, DOI 10.1074/jbc.M312042200; Di Paolo C, 1999, J BIOL CHEM, V274, P32071, DOI 10.1074/jbc.274.45.32071; Engelhardt OG, 2001, EXP CELL RES, V271, P286, DOI 10.1006/excr.2001.5380; Estacion M, 2004, J BIOL CHEM, V279, P22047, DOI 10.1074/jbc.M402320200; Foord R, 1999, NAT STRUCT BIOL, V6, P157; FRESE M, 1995, J VIROL, V69, P3904, DOI 10.1128/JVI.69.6.3904-3909.1995; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Greka A, 2003, NAT NEUROSCI, V6, P837, DOI 10.1038/nn1092; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haller O, 2002, TRAFFIC, V3, P710, DOI 10.1034/j.1600-0854.2002.31003.x; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Janzen C, 2000, J VIROL, V74, P8202, DOI 10.1128/JVI.74.17.8202-8206.2000; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kochs G, 2002, J BIOL CHEM, V277, P14172, DOI 10.1074/jbc.M200244200; Kochs G, 2002, P NATL ACAD SCI USA, V99, P3153, DOI 10.1073/pnas.052430399; Lai MM, 2000, J BIOL CHEM, V275, P34017, DOI 10.1074/jbc.C000429200; Ma R, 2003, J BIOL CHEM, V278, P52763, DOI 10.1074/jbc.M309610200; Main ERG, 2003, CURR OPIN STRUC BIOL, V13, P482, DOI 10.1016/S0959-440X(03)00105-2; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; MELEN K, 1992, J BIOL CHEM, V267, P25898; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; Ponten A, 1997, J VIROL, V71, P2591, DOI 10.1128/JVI.71.4.2591-2599.1997; Reichelt M, 2004, TRAFFIC, V5, P772, DOI 10.1111/j.1600-0854.2004.00219.x; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Sambrook J, 2001, MOL CLONING LAB MANU; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Trost C, 2001, BIOCHEM J, V355, P663, DOI 10.1042/bj3550663; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Vennekens R, 2002, CELL CALCIUM, V31, P253, DOI 10.1016/S0143-4160(02)00055-6; Wedel BJ, 2003, J BIOL CHEM, V278, P25758, DOI 10.1074/jbc.M303890200; Yildirim E, 2003, P NATL ACAD SCI USA, V100, P2220, DOI 10.1073/pnas.0438036100; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; ZURCHER T, 1992, J VIROL, V66, P5059	71	51	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19393	19400		10.1074/jbc.M500391200	http://dx.doi.org/10.1074/jbc.M500391200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757897	hybrid			2022-12-25	WOS:000228932300097
J	Jiang, F; Caraway, NP; Li, RY; Katz, RL				Jiang, F; Caraway, NP; Li, RY; Katz, RL			RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells	ONCOGENE			English	Article						SKP2; small interfering RNAs; lung cancer; apoptosis; centrosome	F-BOX PROTEIN; CYCLIN-E; GENETIC INSTABILITY; SKP2 OVEREXPRESSION; REGULATE P27(KIP1); NUCLEAR EXPORT; EXPRESSION; P27; DEGRADATION; DUPLICATION	The S-phase kinase-associated protein-2 (SKP2) plays a keyrole in ubiquitin-mediated proteolysis, which results in the progression of cells from a quiescence to proliferative state. SKP2 is overexpressed in a variety of tumors. In this study, we used small interfering RNAs (siRNAs) to inhibit the SKP2 expression in lung cancer cells and thereby investigate the role of SKP2 in lung tumorigenesis. Three lung cancer cell lines were transfected with siRNAs targeted against SKP2. SKP2-siRNAs specifically and efficiently reduced the levels of the SKP2 protein by 90% 48 h after transfection in all cell lines. In the A549 and H1792 cells, p27 expression was increased and the increase was inversely proportional to the level of SKP2; cell proliferation was reduced to 12 and 28%, respectively; apoptosis was increased to 36 and 30%, respectively; 36 and 28% of cells accumulated in the sub-G1 phase, respectively; and the population of cells in the G1 phase was decreased to 37 and 41%, respectively. In addition, the SKP2-depleted A549 and H1792 cells showed decreased levels of cyclin E/CDK2. Correspondingly, only 4 and 6% of the treated A549 and H1792 cells had multiple centrosomes, respectively, compared with 43 and 46% of the control cells, respectively. These results imply that SKP2 plays an oncogenic role in lung cancer and that SKP2 silencing maybe useful in the treatment of lung cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Unit 53, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Jiang, F (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Unit 53, 1515 Holcombe Blvd, Houston, TX 77030 USA.	fjiang@mail.mdanderson.org						Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Brambilla E, 1999, J PATHOL, V188, P351, DOI 10.1002/(SICI)1096-9896(199908)188:4<351::AID-PATH385>3.0.CO;2-W; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chiarle R, 2002, AM J PATHOL, V160, P1457, DOI 10.1016/S0002-9440(10)62571-0; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Dao MA, 1998, P NATL ACAD SCI USA, V95, P13006, DOI 10.1073/pnas.95.22.13006; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Foster JS, 2003, J BIOL CHEM, V278, P41355, DOI 10.1074/jbc.M302830200; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Fukuse T, 2000, CANCER RES, V60, P242; Gstaiger M, 1999, EXP CELL RES, V247, P554, DOI 10.1006/excr.1999.4386; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Jiang F, 2003, INT J CANCER, V106, P661, DOI 10.1002/ijc.11251; Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9; Kaye FJ, 2002, ONCOGENE, V21, P6908, DOI 10.1038/sj.onc.1205834; Kudo Y, 2001, CANCER RES, V61, P7044; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Lim MS, 2002, BLOOD, V100, P2950, DOI 10.1182/blood.V100.8.2950; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Martinez LA, 2002, P NATL ACAD SCI USA, V99, P14849, DOI 10.1073/pnas.222406899; Masuda T, 2002, CANCER RES, V62, P3819; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Murphy TD, 2003, J CELL SCI, V116, P2321, DOI 10.1242/jcs.00463; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Oliveira AM, 2003, J CLIN ONCOL, V21, P722, DOI 10.1200/JCO.2003.05.112; Pagano M, 2004, MOL CELL, V14, P414, DOI 10.1016/S1097-2765(04)00268-0; Park KH, 2001, LUNG CANCER-J IASLC, V31, P149, DOI 10.1016/S0169-5002(00)00195-1; Pihan GA, 1998, CANCER RES, V58, P3974; Piva R, 2002, MOL CELL BIOL, V22, P8375, DOI 10.1128/MCB.22.23.8375-8387.2002; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Shigemasa K, 2003, CLIN CANCER RES, V9, P1756; Shim EH, 2003, CANCER RES, V63, P1583; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Thyrell L, 2002, ONCOGENE, V21, P1251, DOI 10.1038/sj.onc.1205179; Vidwans SJ, 1999, J CELL BIOL, V147, P1371, DOI 10.1083/jcb.147.7.1371; Volm M, 1998, INT J CANCER, V79, P294, DOI 10.1002/(SICI)1097-0215(19980619)79:3<294::AID-IJC15>3.3.CO;2-0; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yeh KH, 2001, BIOCHEM BIOPH RES CO, V281, P884, DOI 10.1006/bbrc.2001.4442; Yokoi S, 2003, CANCER SCI, V94, P344, DOI 10.1111/j.1349-7006.2003.tb01444.x; Yokoi S, 2002, AM J PATHOL, V161, P207, DOI 10.1016/S0002-9440(10)64172-7; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhu CQ, 2004, CLIN CANCER RES, V10, P1984, DOI 10.1158/1078-0432.CCR-03-0470	62	54	68	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3409	3418		10.1038/sj.onc.1208459	http://dx.doi.org/10.1038/sj.onc.1208459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735730				2022-12-25	WOS:000229038800003
J	Koch, A; Mancini, A; El Bounkari, O; Tamura, T				Koch, A; Mancini, A; El Bounkari, O; Tamura, T			The SH2-domian-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading	ONCOGENE			English	Article						SHIP-2; c-Met tyrosine kinase; lamellipodium formation; cell scattering; actin rearrangement	MULTIFUNCTIONAL DOCKING SITE; FACTOR-RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; POLYPHOSPHATE 5-PHOSPHATASE; PROTEIN; SHIP2; KINASE; IDENTIFICATION; ADHESION; 3-KINASE	Recently, evidence has been accumulating that inositol and phosphatidylinositol polyphosphate play important roles in a variety of signal transduction systems including membrane traffic, actin cytoskeleton rearrangement and cell motility. In this paper, we show for the first time that the SH2-domain-containing inositol 5-phosphatase (SHIP)-2 binds directly to the hepatocyte growth factor (HGF/SF) receptor, c-Met, via phosphotyrosine 1356. HGF induces the breakdown of cell junctions and the dispersion of colonies of epithelial cells including MDCK cells. Whereas only few lamellipodia are observed in MDCK cells 2 min after stimulation with HGF, both SHIP-2- and SHIP-1-overexpressing cells form large, broad lamellipodia. The number of lamellipodia is 2-4-fold greater than that of mock-transfected MDCK cells in the same time period and SHIP is found to colocalize with actin at the leading edge. Furthermore, overexpression of a catalytic inactive mutant of SHIP-2 suppresses HGF-potentiated cell scattering and cell spreading, although these mutant-expressing cells form enhanced number of lamellipodia 2 min after HGF stimulation. Interestingly, cells expressing a mutant lacking the proline-rich domain of SHIP-2 at the C-terminal form few lamellipodia, but still spread and scatter upon stimulation with HGF at a reduced rate. These data suggest that phosphatase activity is required for HGF-mediated cell spreading and scattering but not for alteration of lamellipodium formation, while the proline-rich region influences lamellipodium formation. Furthermore, treatment with 10 mu M of phosphatidylinositol 3(PI3) kinase inhibitor, LY294002, abrogates HGF-induced cell scattering of SHIP-2-overexpressing cells but not parental HEK293 cells, suggesting that a balance between PI3 kinase and SHIP is important for cell motility.	Hannover Med Sch, Inst Biochem, D-30623 Hannover, Germany	Hannover Medical School	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE 4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	tamura.teruko@mh-hannover.de						Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bouscary D, 2003, BLOOD, V101, P3436, DOI 10.1182/blood-2002-07-2332; Dyson JM, 2003, BLOOD, V102, P940, DOI 10.1182/blood-2002-09-2897; Dyson JM, 2001, J CELL BIOL, V155, P1065, DOI 10.1083/jcb.200104005; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Giuriato S, 2003, BIOCHEM J, V376, P199, DOI 10.1042/BJ20030581; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Kawamura K, 2004, J BIOL CHEM, V279, P54862, DOI 10.1074/jbc.M408057200; Khoury H, 2001, ONCOGENE, V20, P788, DOI 10.1038/sj.onc.1204166; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Koch A, 2000, FEBS LETT, V469, P72, DOI 10.1016/S0014-5793(00)01242-4; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Mancini A, 2002, ONCOGENE, V21, P1477, DOI 10.1038/sj.onc.1205224; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PELICCI G, 1995, ONCOGENE, V10, P1631; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Pesesse X, 2001, J BIOL CHEM, V276, P28348, DOI 10.1074/jbc.M103537200; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prasad N, 2002, J CELL SCI, V115, P3807, DOI 10.1242/jcs.00070; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Stefan M, 2001, J BIOL CHEM, V276, P3017, DOI 10.1074/jbc.M009333200; STOKER M, 1985, J CELL SCI, V77, P209; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Tsujishita Y, 2001, CELL, V105, P379, DOI 10.1016/S0092-8674(01)00326-9; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; Wang YJ, 2004, J IMMUNOL, V173, P6820, DOI 10.4049/jimmunol.173.11.6820; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720	36	49	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3436	3447		10.1038/sj.onc.1208558	http://dx.doi.org/10.1038/sj.onc.1208558			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735664				2022-12-25	WOS:000229038800006
J	Busschots, K; Vercammen, J; Emiliani, S; Benarous, R; Engelborghs, Y; Christ, F; Debyser, Z				Busschots, K; Vercammen, J; Emiliani, S; Benarous, R; Engelborghs, Y; Christ, F; Debyser, Z			The interaction of LEDGF/p75 with integrase is lentivirus-specific and promotes DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FLUORESCENCE CORRELATION SPECTROSCOPY; NUCLEAR-LOCALIZATION SIGNAL; GROWTH-FACTOR LEDGF/P75; HIV-1 INTEGRASE; TYPE-1 INTEGRASE; ESCHERICHIA-COLI; HUMAN-CELLS; IN-VITRO; PREINTEGRATION COMPLEXES	We have previously shown that the p75 isoform of the transcriptional co-activator lens epithelium-derived growth factor ( LEDGF) interacts tightly with human immunodeficiency virus (HIV)-1 integrase ( IN) and is essential for nuclear targeting of this protein in human cells (Cherepanov, P., Maertens, G., Proost, P., Devreese, B., Van Beeumen, J., Engelborghs, Y., De Clercq, E., and Debyser, Z. ( 2003) J. Biol. Chem. 278, 372 - 381; Maertens, G., Cherepanov, P., Pluymers, W., Busschots, K., De Clercq, E., Debyser, Z., and Engelborghs, Y. ( 2003) J. Biol. Chem. 278, 33528 - 33539). Here the interaction between recombinant LEDGF/p75 and HIV-1 IN was examined in a pull-down binding test. LEDGF/p75 was shown to increase the solubility of HIV-1 IN. Next, fluorescent correlation spectroscopy was used to measure the interaction of LEDGF/p75 or the complex of HIV-1 IN and LEDGF/p75 with a specific double-stranded DNA oligonucleotide. Whereas LEDGF/p75 displayed only a moderate affinity for DNA, it strongly promoted the binding of HIV-1 IN to DNA. This effect was specific for the p75 isoform of LEDGF and was not seen with p52. In the pull-down assay LEDGF/p75 interacted with HIV-1, HIV-2, and feline immunodeficiency virus IN, but not with the IN of human T-cell lymphotropic virus type 2, Moloney murine leukemia virus, or Rous sarcoma virus. These results strongly suggest that the interaction of LEDGF/p75 with IN is specific to lentiviridae. LEDGF/ p75 stimulated the binding of HIV-1 and HIV-2 IN, but not Moloney murine leukemia virus or Rous sarcoma virus IN, to an aspecific DNA. These results provide supporting evidence for our hypothesis that LEDGF/ p75 plays a role in the tethering of lentiviral IN to the chromosomal DNA.	Katholieke Univ Leuven, Lab Mol Virol & Gene Therapy, B-3000 Louvain, Flanders, Belgium; Katholieke Univ Leuven, Interdisciplinary Res Ctr, B-3000 Louvain, Flanders, Belgium; Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Louvain, Flanders, Belgium; Inst Cochin Genet Mol, Dept Infect Dis, CNRS, UMR8104,INSERM,U567, F-75104 Paris, France	KU Leuven; KU Leuven; KU Leuven; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Debyser, Z (corresponding author), Katholieke Univ Leuven, Lab Mol Virol & Gene Therapy, Kapucijnenvoer 33, B-3000 Louvain, Flanders, Belgium.	zeger.debyser@med.kuleuven.ac.be	Christ, Frauke/H-7513-2018	Christ, Frauke/0000-0001-9580-3874				Asante-Appiah E, 1999, ADV VIRUS RES, V52, P351, DOI 10.1016/S0065-3527(08)60306-1; Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; BROWN PO, 1997, CURR TOP MICROBIOL, V157, P19; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; Bushman FD, 2003, CELL, V115, P135, DOI 10.1016/S0092-8674(03)00760-8; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; Cherepanov P, 2000, FASEB J, V14, P1389, DOI 10.1096/fj.14.10.1389; Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200; Chiu R, 2003, J VIROL, V77, P6482, DOI 10.1128/JVI.77.11.6482-6492.2003; Coffin J. M., 1997, RETROVIRUSES, P1; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; Depienne C, 2000, EXP CELL RES, V260, P387, DOI 10.1006/excr.2000.5016; Depienne C, 2001, J BIOL CHEM, V276, P18102, DOI 10.1074/jbc.M009029200; Devroe E, 2003, J CELL SCI, V116, P4401, DOI 10.1242/jcs.00747; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Fatma N, 2001, J BIOL CHEM, V276, P48899, DOI 10.1074/jbc.M100733200; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; Ganapathy V, 2003, AUTOIMMUN REV, V2, P290, DOI 10.1016/S1568-9972(03)00063-6; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; JONSSON CB, 1993, J BIOL CHEM, V268, P1462; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Llano M, 2004, J VIROL, V78, P9524, DOI 10.1128/JVI.78.17.9524-9537.2004; Lutzke RAP, 1998, J VIROL, V72, P4841, DOI 10.1128/JVI.72.6.4841-4848.1998; Maertens G, 2004, J BIOL CHEM, V279, P33421, DOI 10.1074/jbc.M404700200; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; MILLER MD, 1995, CURR BIOL, V5, P368, DOI 10.1016/S0960-9822(95)00074-1; Mitchell RS, 2004, PLOS BIOL, V2, P1127, DOI 10.1371/journal.pbio.0020234; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; Nishizawa Y, 2001, CELL TISSUE RES, V305, P107, DOI 10.1007/s004410100398; PRUSS D, 1994, J BIOL CHEM, V269, P25031; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Singh DP, 2000, BIOCHEM BIOPH RES CO, V267, P373, DOI 10.1006/bbrc.1999.1979; Singh DP, 2000, GENE, V242, P265, DOI 10.1016/S0378-1119(99)00506-5; Singh DP, 2001, BIOCHEM BIOPH RES CO, V283, P943, DOI 10.1006/bbrc.2001.4887; Van Craenenbroeck E, 1999, BIOCHEMISTRY-US, V38, P5082, DOI 10.1021/bi9821925; Van Craenenbroeck  E, 2000, J MOL RECOGNIT, V13, P93, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<93::AID-JMR492>3.0.CO;2-6; Van Craenenbroeck E, 2001, BIOL CHEM, V382, P355; van den Ent FMI, 1999, J VIROL, V73, P3176, DOI 10.1128/JVI.73.4.3176-3183.1999; Vercammen J, 2002, J BIOL CHEM, V277, P38045, DOI 10.1074/jbc.M205842200; Villanueva RA, 2003, VIROLOGY, V316, P146, DOI 10.1016/S0042-6822(03)00559-2; VINK C, 1994, J VIROL, V68, P1468, DOI 10.1128/JVI.68.3.1468-1474.1994; Violot S, 2003, J VIROL, V77, P12507, DOI 10.1128/JVI.77.23.12507-12522.2003; Wang T, 2001, J BIOL CHEM, V276, P14710, DOI 10.1074/jbc.M007754200; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	56	164	178	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17841	17847		10.1074/jbc.M411681200	http://dx.doi.org/10.1074/jbc.M411681200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749713	hybrid			2022-12-25	WOS:000228807200036
J	Rangel, R; McKeller, MR; Sims-Mourtada, JC; Kashi, C; Cain, K; Wieder, ED; Molldrem, JJ; Pham, LV; Ford, RJ; Yotnda, P; Guret, C; Frances, V; Martinez-Valdez, H				Rangel, R; McKeller, MR; Sims-Mourtada, JC; Kashi, C; Cain, K; Wieder, ED; Molldrem, JJ; Pham, LV; Ford, RJ; Yotnda, P; Guret, C; Frances, V; Martinez-Valdez, H			Assembly of the kappa PreB receptor requires a V kappa-like protein encoded by a germline transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL DEVELOPMENT; ACUTE LYMPHOBLASTIC-LEUKEMIA; LIGHT-CHAIN EXPRESSION; MU-HEAVY-CHAIN; ACCESSIBILITY CONTROL; V(D)J RECOMBINATION; GENE-TRANSCRIPTION; ALLELIC EXCLUSION; VDJ RECOMBINATION; DEFICIENT MICE	By confining germline transcription as a byproduct of the mechanisms inherent to genetic rearrangements, the translation of respective mRNAs and their biological relevance might have been overlooked. Here we report the identification, cloning, and biochemical characterization of a human V kappa-like protein that is encoded by a germline transcript. This surrogate protein assembles with the immunoglobulin mu heavy chain at the surface of B cell progenitors and precursors to form a kappa-like antigen receptor. These findings support the notion that germline transcription is not futile and stress the flexibility in eukaryotic gene usage and expression. In addition, the present study confirms the co-existence of surrogate lambda and kappa receptors that are proposed to work in concert to promote B lymphocyte maturation.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77054 USA; Univ Texas, MD Anderson Canc Ctr, Sect Transplant Immunol, Dept Blood & Bone Marrow Transplantat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Schering Plough Corp, Lab Immunol Res, F-69571 Dardilly, France	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Merck & Company; Schering Plough Corporation	Martinez-Valdez, H (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Unit 902, 1515 Holcombe Blvd, Houston, TX 77030 USA.	hmartine@mail.mdanderson.org	Rangel, Roberto/AHE-6583-2022	Rangel, Roberto/0000-0002-9088-7957	NATIONAL CANCER INSTITUTE [T32CA009598] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009598-15] Funding Source: Medline; NIAID NIH HHS [AI 05625-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Bachl J, 1996, EUR J IMMUNOL, V26, P870, DOI 10.1002/eji.1830260422; BOSSY D, 1993, INT IMMUNOL, V5, P467, DOI 10.1093/intimm/5.5.467; BROUNS GS, 1993, EUR J IMMUNOL, V23, P1088, DOI 10.1002/eji.1830230517; Burrows PD, 2002, SEMIN IMMUNOL, V14, P343, DOI 10.1016/S1044-5323(02)00067-2; Casellas R, 2001, SCIENCE, V291, P1541, DOI 10.1126/science.1056600; CHANG H, 1986, J EXP MED, V163, P425, DOI 10.1084/jem.163.2.425; CHEN JZ, 1993, CURR OPIN IMMUNOL, V5, P194, DOI 10.1016/0952-7915(93)90004-C; Cocea L, 1999, J EXP MED, V189, P1443, DOI 10.1084/jem.189.9.1443; Erdmann VA, 2000, NUCLEIC ACIDS RES, V28, P197, DOI 10.1093/nar/28.1.197; FINDLEY HW, 1982, BLOOD, V60, P1305; FRANCES V, 1994, EMBO J, V13, P5937, DOI 10.1002/j.1460-2075.1994.tb06939.x; Gellert M, 1996, GENES CELLS, V1, P269, DOI 10.1046/j.1365-2443.1996.22023.x; Jolly CJ, 1997, IMMUNOL CELL BIOL, V75, P13, DOI 10.1038/icb.1997.3; KABAT EA, 1987, SEQUENCE PROTEINS IM; Kaplan D, 2000, CYTOMETRY, V40, P81, DOI 10.1002/(SICI)1097-0320(20000501)40:1<81::AID-CYTO11>3.0.CO;2-K; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KLOBECK HG, 1985, NUCLEIC ACIDS RES, V13, P6515, DOI 10.1093/nar/13.18.6515; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUNGBERG UK, 1993, MOL IMMUNOL, V30, P1279, DOI 10.1016/0161-5890(93)90044-C; Martensson A, 1999, INT IMMUNOL, V11, P453, DOI 10.1093/intimm/11.3.453; MARTIN D, 1991, J EXP MED, V173, P639, DOI 10.1084/jem.173.3.639; Meffre E, 1998, J EXP MED, V188, P765, DOI 10.1084/jem.188.4.765; Minegishi Y, 1998, J EXP MED, V187, P71, DOI 10.1084/jem.187.1.71; MISENER V, 1991, INT IMMUNOL, V3, P1129, DOI 10.1093/intimm/3.11.1129; Mundt C, 2001, J EXP MED, V193, P435, DOI 10.1084/jem.193.4.435; Oltz EM, 2001, IMMUNOL RES, V23, P121, DOI 10.1385/IR:23:2-3:121; PANDRAU D, 1993, LEUKEMIA, V7, P635; Pelanda R, 2002, J IMMUNOL, V169, P865, DOI 10.4049/jimmunol.169.2.865; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; Scherer DC, 1996, IMMUNITY, V5, P563, DOI 10.1016/S1074-7613(00)80271-X; Schlissel M S, 1997, Semin Immunol, V9, P161, DOI 10.1006/smim.1997.0066; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; Shimizu T, 2002, J IMMUNOL, V168, P6286, DOI 10.4049/jimmunol.168.12.6286; Sleckman BP, 1998, IMMUNOL REV, V165, P121, DOI 10.1111/j.1600-065X.1998.tb01235.x; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; Thompson A, 1998, IMMUNOGENETICS, V48, P305, DOI 10.1007/s002510050437; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Wang YH, 1998, J IMMUNOL, V161, P1132; Wang YH, 2002, BLOOD, V99, P2459, DOI 10.1182/blood.V99.7.2459; Weng WK, 1997, J IMMUNOL, V159, P5502; Yang XXO, 2003, BLOOD, V101, P4492, DOI 10.1182/blood-2002-08-2579	46	10	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17807	17814		10.1074/jbc.M409479200	http://dx.doi.org/10.1074/jbc.M409479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15757909	hybrid			2022-12-25	WOS:000228807200032
J	Tottene, A; Pivotto, F; Fellin, T; Cesetti, T; van den Maagdenberg, AMJM; Pietrobon, D				Tottene, A; Pivotto, F; Fellin, T; Cesetti, T; van den Maagdenberg, AMJM; Pietrobon, D			Specific kinetic alterations of human Ca(V)2.1 calcium channels produced by mutation S218L causing familial hemiplegic migraine and delayed cerebral edema and coma after minor head trauma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL SPREADING DEPRESSION; EPISODIC ATAXIA TYPE-2; CEREBELLAR-ATAXIA; FUNCTIONAL CONSEQUENCES; CENTRAL NEURONS; CA2+ CHANNELS; SUBUNIT; DEPOLARIZATION; MECHANISMS; MICE	Mutation S218L in the Ca(V)2.1 alpha(1) subunit of P/Q-type Ca2+ channels produces a severe clinical phenotype in which typical attacks of familial hemiplegic migraine (FHM) triggered by minor head trauma are followed, after a lucid interval, by deep (even fatal) coma and long lasting severe cerebral edema. We investigated the functional consequences of this mutation on human Ca(V)2.1 channels expressed in human embryonic kidney 293 cells and in neurons from Ca(V)2.1 alpha(-/-)(1) mice by combining single channel and whole cell patch clamp recordings. Mutation S218L produced a shift to lower voltages of the single channel activation curve and a consequent increase of both single channel and whole cell Ba2+ influx in both neurons and human embryonic kidney 293 cells. Compared with the other FHM-1 mutants, the S218L shows one of the largest gains of function, especially for small depolarizations, which are insufficient to open the wild-type channel. S218L channels open at voltages close to the resting potential of many neurons. Moreover, the S218L mutation has unique effects on the kinetics of inactivation of the channel because it introduces a large component of current that inactivates very slowly, and it increases the rate of recovery from inactivation. During long depolarizations at voltages that are attained during cortical spreading depression, the extent of inactivation of the S218L channel is considerably smaller than that of the wild-type channel. We discuss how the unique combination of a particularly slow inactivation during cortical spreading depression and a particularly low threshold of channel activation might lead to delayed severe cerebral edema and coma after minor head trauma.	Univ Padua, Dept Biomed Sci, CNR Inst Neurosci, I-35121 Padua, Italy; Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 AL Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RC Leiden, Netherlands	Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze (IN-CNR); University of Padua; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Pietrobon, D (corresponding author), Univ Padua, Dept Biomed Sci, CNR Inst Neurosci, Viale G Colombo 3, I-35121 Padua, Italy.	daniela.pietrobon@unipd.it	van den Maagdenberg, Arn M.J.M./AAE-9052-2019		Telethon [E.1297] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		Alonso I, 2004, CLIN GENET, V65, P70, DOI 10.1111/j..2004.00187.x; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Ayata C, 2000, NEUROSCIENCE, V95, P639; Bolay H, 2002, NAT MED, V8, P136, DOI 10.1038/nm0202-136; Bowyer SM, 2001, ANN NEUROL, V50, P582, DOI 10.1002/ana.1293; Cao YQ, 2004, NEURON, V43, P387, DOI 10.1016/j.neuron.2004.07.014; Ducros A, 2001, NEW ENGL J MED, V345, P17, DOI 10.1056/NEJM200107053450103; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; FITZSIMONS RB, 1985, BRAIN, V108, P555, DOI 10.1093/brain/108.3.555-a; Fletcher CF, 2001, FASEB J, V15, P1288, DOI 10.1096/fj.00-0562fje; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; Haan Joost, 2004, Curr Pain Headache Rep, V8, P238, DOI 10.1007/s11916-004-0058-0; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hans M, 1999, J NEUROSCI, V19, P1610; KAJA S, 2004, SOC NEUR 34 ANN M OC; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Kors EE, 2004, NEUROLOGY, V63, P1136, DOI 10.1212/01.WNL.0000138571.48593.FC; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; Kraus RL, 2000, J BIOL CHEM, V275, P9239, DOI 10.1074/jbc.275.13.9239; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Liang HY, 2003, NEURON, V39, P951, DOI 10.1016/S0896-6273(03)00560-9; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; Mullner C, 2004, J BIOL CHEM, V279, P51844, DOI 10.1074/jbc.M408756200; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Patil PG, 1998, NEURON, V20, P1027, DOI 10.1016/S0896-6273(00)80483-3; Pietrobon D, 2002, MOL NEUROBIOL, V25, P31, DOI 10.1385/MN:25:1:031; Pietrobon D, 2003, NAT REV NEUROSCI, V4, P386, DOI 10.1038/nrn1102; PIETROBON D, 2005, IN PRESS NEUROSCIENT; Pineda JC, 1998, J NEUROPHYSIOL, V79, P2522, DOI 10.1152/jn.1998.79.5.2522; SHAPOVALOVA M, 2004, SOC NEUR 34 ANN M OC; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; Thomsen LL, 2002, BRAIN, V125, P1379, DOI 10.1093/brain/awf132; Tottene A, 2002, P NATL ACAD SCI USA, V99, P13284, DOI 10.1073/pnas.192242399; van den Maagdenberg AMJM, 2004, NEURON, V41, P701, DOI 10.1016/S0896-6273(04)00085-6; Wappl E, 2002, J BIOL CHEM, V277, P6960, DOI 10.1074/jbc.M110948200; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403	42	104	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17678	17686		10.1074/jbc.M501110200	http://dx.doi.org/10.1074/jbc.M501110200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15743764	hybrid			2022-12-25	WOS:000228807200016
J	Lonskaya, I; Potaman, VN; Shlyakhtenko, LS; Oussatcheva, EA; Lyubchenko, YL; Soldatenkov, VA				Lonskaya, I; Potaman, VN; Shlyakhtenko, LS; Oussatcheva, EA; Lyubchenko, YL; Soldatenkov, VA			Regulation of poly(ADP-ribose) polymerase-1 by DNA structure-specific binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; ADP-RIBOSYLTRANSFERASE; CHROMATIN; PARP; PROMOTER; RIBOSYLATION; SEQUENCES; COMPLEX; ELEMENT; PROTEIN	Poly(ADP-ribose) polymerase-1 (PARP-1) is an intracellular sensor of DNA strand breaks and plays a critical role in cellular responses to DNA damage. In normally functioning cells, PARP-1 enzymatic activity has been linked to the alterations in chromatin structure associated with gene expression. However, the molecular determinants for PARP-1 recruitment to specific sites in chromatin in the absence of DNA strand breaks remain obscure. Using gel shift and enzymatic footprinting assays and atomic force microscopy, we show that PARP-1 recognizes distortions in the DNA helical backbone and that it binds to three- and four-way junctions as well as to stably unpaired regions in double-stranded DNA. PARP-1 interactions with non-B DNA structures are functional and lead to its catalytic activation. DNA hairpins, cruciforms, and stably unpaired regions are all effective co-activators of PARP-1 auto-modification and poly( ADP-ribosyl) ation of histone H1 in the absence of free DNA ends. Enzyme kinetic analyses revealed that the structural features of non-B form DNA co-factors are important for PARP-1 catalysis activated by undamaged DNA. K-0.5 constants for DNA co-factors, which are structurally different in the degree of base pairing and spatial DNA organization, follow the order: cruciform <= hairpin << loop. DNA structure also influenced the reaction rate; when a hairpin was substituted with a stably unpaired region, the maximum reaction velocity decreased almost 2-fold. These data suggest a link between PARP-1 binding to non-B DNA structures in genome and its function in the dynamics of local modulation of chromatin structure in the normal physiology of the cell.	Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Radiat Med, Washington, DC 20057 USA; Texas A&M Univ Syst Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA	Georgetown University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Nebraska System; University of Nebraska Medical Center	Soldatenkov, VA (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Radiat Med, 3970 Reservoir Rd NW,Res Bldg,Rm E-204A,Box 57148, Washington, DC 20057 USA.	soldates@georgetown.edu			NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062235] Funding Source: NIH RePORTER; NCI NIH HHS [CA74175-07] Funding Source: Medline; NIGMS NIH HHS [GM62235] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SL, 1993, P NATL ACAD SCI USA, V90, P11865, DOI 10.1073/pnas.90.24.11865; Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; BAUER PI, 1990, BIOCHEM J, V270, P17, DOI 10.1042/bj2700017; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; D'Silva I, 1999, BBA-PROTEIN STRUCT M, V1430, P119, DOI 10.1016/S0167-4838(98)00278-7; DEMURCIA G, 1986, J BIOL CHEM, V261, P7011; DESNOYERS S, 1995, BIOCHIMIE, V77, P433, DOI 10.1016/0300-9084(96)88156-9; FERRO AM, 1982, J BIOL CHEM, V257, P7808; GAAL JC, 1985, BIOCHEM J, V230, P1; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; GRADWOHL G, 1987, BIOCHEM BIOPH RES CO, V148, P913, DOI 10.1016/S0006-291X(87)80219-X; Kramer PR, 1999, J BIOL CHEM, V274, P28590, DOI 10.1074/jbc.274.40.28590; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Kun E, 2004, BIOCHEMISTRY-US, V43, P210, DOI 10.1021/bi0301791; Kun E, 2002, J BIOL CHEM, V277, P39066, DOI 10.1074/jbc.C200410200; LEONARD MW, 1991, MOL CELL BIOL, V11, P6128, DOI 10.1128/MCB.11.12.6128; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; LOETSCHER P, 1987, P NATL ACAD SCI USA, V84, P1286, DOI 10.1073/pnas.84.5.1286; MENDOZAALVAREZ H, 1993, J BIOL CHEM, V268, P22575; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OEI SL, 1994, MOL CELL BIOCHEM, V138, P99, DOI 10.1007/BF00928449; Oussatcheva EA, 1999, J MOL BIOL, V292, P75, DOI 10.1006/jmbi.1999.3043; Pion E, 2003, BIOCHEMISTRY-US, V42, P12409, DOI 10.1021/bi0344432; Pomerantz JL, 1998, BIOCHEMISTRY-US, V37, P965, DOI 10.1021/bi972464o; REALINI CA, 1992, J BIOL CHEM, V267, P18858; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; SASTRY SS, 1990, BIOCHEM BIOPH RES CO, V167, P842, DOI 10.1016/0006-291X(90)92102-6; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Shlyakhtenko LS, 2000, NUCLEIC ACIDS RES, V28, P3472, DOI 10.1093/nar/28.18.3472; SINDEN RR, 1994, DNA STRUCTURE FUNCTI, P138; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; Soldatenkov VA, 2004, CURR DRUG TARGETS, V5, P357, DOI 10.2174/1389450043345498; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Yoo S, 1999, J BIOL CHEM, V274, P20034, DOI 10.1074/jbc.274.28.20034; Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426; Zhang Z, 2002, VIROLOGY, V296, P107, DOI 10.1006/viro.2002.1385	40	145	150	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17076	17083		10.1074/jbc.M413483200	http://dx.doi.org/10.1074/jbc.M413483200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15737996	hybrid			2022-12-25	WOS:000228615500066
J	Matsushima, Y; Adan, C; Garesse, R; Kaguni, LS				Matsushima, Y; Adan, C; Garesse, R; Kaguni, LS			Drosophila mitochondrial transcription factor B1 modulates mitochondrial translation but not transcription or DNA copy number in Schneider cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA METHYLTRANSFERASE; DOUBLE-STRANDED-RNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; KASUGAMYCIN RESISTANCE; GENETIC INTERFERENCE; 3' END; PROMOTER; ADENINE; BINDING	We report the cloning and molecular analysis of Drosophila mitochondrial transcription factor (d-mtTF) B1. An RNA interference (RNAi) construct was designed that reduces expression of d-mtTFB1 to 5% of its normal level in Schneider cells. In striking contrast with our previous study on d-mtTFB2, we found that RNAi knockdown of d-mtTFB1 does not change the abundance of specific mitochondrial RNA transcripts, nor does it affect the copy number of mitochondrial DNA. In a corollary manner, overexpression of d-mtTFB1 did not increase either the abundance of mitochondrial RNA transcripts or mitochondrial DNA copy number. Our data suggest that, unlike d-mtTFB2, d-mtTFB1 does not have a critical role in either transcription or regulation of the copy number of mitochondrial DNA. Instead, because we found that RNAi knockdown of d-mtTFB1 reduces mitochondrial protein synthesis, we propose that it serves its primary role in modulating translation. Our work represents the first study to document the role of mtTFB1 in vivo and establishes clearly functional differences between mtTFB1 and mtTFB2.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Univ Autonoma Madrid, Dept Bioquim, Inst Invest Biomed Alberto Sols, Consejo Super Invest Cient,Fac Med, Madrid 28029, Spain	Michigan State University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Kaguni, LS (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	lskaguni@msu.edu	Garesse, Rafael/F-3836-2012	Garesse, Rafael/0000-0002-0338-2281	NIGMS NIH HHS [GM45295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam TI, 2003, NUCLEIC ACIDS RES, V31, P1640, DOI 10.1093/nar/gkg251; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baulcombe DC, 1999, CURR BIOL, V9, pR599, DOI 10.1016/S0960-9822(99)80383-2; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Bussiere DE, 1998, BIOCHEMISTRY-US, V37, P7103, DOI 10.1021/bi973113c; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; Gaspari M, 2004, BBA-BIOENERGETICS, V1659, P148, DOI 10.1016/j.bbabio.2004.10.003; Gaspari M, 2004, EMBO J, V23, P4606, DOI 10.1038/sj.emboj.7600465; GHIVIZZANI SC, 1994, MOL CELL BIOL, V14, P7717, DOI 10.1128/MCB.14.12.7717; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; HELSER TL, 1972, NATURE-NEW BIOL, V235, P6, DOI 10.1038/newbio235006a0; HELSER TL, 1971, NATURE-NEW BIOL, V233, P12, DOI 10.1038/newbio233012a0; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; IGARASHI K, 1981, EUR J BIOCHEM, V113, P587, DOI 10.1111/j.1432-1033.1981.tb05103.x; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KLOOTWIJK J, 1975, J MOL BIOL, V97, P337, DOI 10.1016/S0022-2836(75)80044-1; Lam G, 2000, CURR BIOL, V10, P957, DOI 10.1016/S0960-9822(00)00631-X; Lu Q, 1998, J BACTERIOL, V180, P5243, DOI 10.1128/JB.180.19.5243-5246.1998; Maravic G, 2003, J MOL BIOL, V332, P99, DOI 10.1016/S0022-2836(03)00863-5; Maravic G, 2003, NUCLEIC ACIDS RES, V31, P4941, DOI 10.1093/nar/gkg666; Matsushima Y, 2004, J BIOL CHEM, V279, P26900, DOI 10.1074/jbc.M401643200; McCulloch V, 2003, MOL CELL BIOL, V23, P5816, DOI 10.1128/MCB.23.16.5816-5824.2003; McCulloch V, 2002, MOL CELL BIOL, V22, P1116, DOI 10.1128/MCB.22.4.1116-1125.2002; O'Farrell HC, 2004, J MOL BIOL, V339, P337, DOI 10.1016/j.jmb.2004.02.068; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; POLDERMANS B, 1979, J BIOL CHEM, V254, P9094; Schluckebier G, 1999, J MOL BIOL, V289, P277, DOI 10.1006/jmbi.1999.2788; Schubot FD, 2001, PROTEIN SCI, V10, P1980, DOI 10.1110/ps.11201; Seidel-Rogol BL, 2003, NAT GENET, V33, P23, DOI 10.1038/ng1064; Shadel GS, 2004, TRENDS GENET, V20, P513, DOI 10.1016/j.tig.2004.08.005; Tavernarakis N, 2000, J NEUROGENET, V13, P257, DOI 10.3109/01677060009084497; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Knippenberg PH, 1986, STRUCTURE FUNCTION G, P412; VANBUUL CPJJ, 1984, FEBS LETT, V177, P119, DOI 10.1016/0014-5793(84)80994-1; VANKNIPPENBERG PH, 1984, NUCLEIC ACIDS RES, V12, P2595, DOI 10.1093/nar/12.6.2595	39	61	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16815	16820		10.1074/jbc.M500569200	http://dx.doi.org/10.1074/jbc.M500569200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15749697	hybrid			2022-12-25	WOS:000228615500034
J	Pennarun, G; Granotier, C; Gauthier, LR; Gomez, D; Hoffschir, F; Mandine, E; Riou, JF; Mergny, JL; Mailliet, P; Boussin, FD				Pennarun, G; Granotier, C; Gauthier, LR; Gomez, D; Hoffschir, F; Mandine, E; Riou, JF; Mergny, JL; Mailliet, P; Boussin, FD			Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands	ONCOGENE			English	Article						glioma; anticancer agent; G-quadruplex ligands; apoptosis	S-PHASE CHECKPOINT; LEUKEMIA-CELLS; INHIBITION; ARREST; GROWTH; RETINOBLASTOMA; TELOMESTATIN; PROGRESSION; SENESCENCE; INDUCTION	Telomerase represents a relevant target for cancer therapy. Molecules able to stabilize the G-quadruplex (G4), a structure adopted by the 3'-overhang of telomeres, are thought to inhibit telomerase by blocking its access to telomeres. We investigated the cellular effects of four new 2,6-pyridine-dicarboxamide derivatives displaying strong selectivity for G4 structures and strong inhibition of telomerase in in vitro assays. These compounds inhibited cell proliferation at very low concentrations and then induced a massive apoptosis within a few days in a dose-dependent manner in cultures of three telomerase-positive glioma cell lines, T98G, CB193 and U118-MG. They had also antiproliferative effects in SAOS-2, a cell line in which telomere maintenance involves an alternative lengthening of telomeres (ALT) mechanism. We show that apoptosis was preceded by multiple alterations of the cell cycle: activation of S-phase checkpoints, dramatic increase of metaphase duration and cytokinesis defects. These effects were not associated with telomere shortening, but they were directly related to telomere instability involving telomere end fusion and anaphase bridge formation. Pyridine-based G-quadruplex ligands are therefore promising agents for the treatment of various tumors including malignant gliomas.	CEA, DRR, DSV, Lab Radiopathol, 18 Route Panorama, F-92265 Fontenay Aux Roses, France; Univ Reims, JE 2428, Lab Oncopharmacol, F-51096 Reims, France; Aventis Pharma SA, Ctr Rech Paris, F-94403 Vitry Sur Seine, France; Museum Natl Hist Nat USM 503, Biophys Lab, CNRS, UMR 5153,INSERM,U565, F-75005 Paris, France	CEA; Universite de Reims Champagne-Ardenne; Sanofi-Aventis; Sanofi France; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN)	Boussin, FD (corresponding author), CEA, DRR, DSV, Lab Radiopathol, 18 Route Panorama, F-92265 Fontenay Aux Roses, France.	boussin@cea.fr	Pennarun, Gaelle/AAX-6579-2021; Gomez Zamorano, Dennis Gomez/AAX-5182-2021; Gauthier, Laurent/ABC-7614-2021; Mergny, Jean-Louis/E-2860-2013	Gomez Zamorano, Dennis Gomez/0000-0001-9942-1451; Gauthier, Laurent/0000-0003-4644-7660; Mergny, Jean-Louis/0000-0003-3043-8401; riou, jean-francois/0000-0002-0055-6506; Boussin, francois/0000-0003-3778-4403; GRANOTIER-BECKERS, Christine/0000-0003-1063-1159; Pennarun, Gaelle/0000-0001-9881-9345				Alonso M, 2003, MOL CANCER THER, V2, P139; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Cimino-Reale G, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e35; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dutrillaux B, 1981, PRATIQUE ANAL CHROMO; Dynek JN, 2004, SCIENCE, V304, P97, DOI 10.1126/science.1094754; Eller MS, 2003, FASEB J, V17, P152, DOI 10.1096/fj.02-0197com; Gomez D, 2004, J BIOL CHEM, V279, P41487, DOI 10.1074/jbc.M406123200; Gomez D, 2003, CANCER RES, V63, P6149; Gomez D, 2002, CANCER RES, V62, P3365; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Gowan SM, 2001, MOL PHARMACOL, V60, P981, DOI 10.1124/mol.60.5.981; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hakin-Smith V, 2003, LANCET, V361, P836, DOI 10.1016/S0140-6736(03)12681-5; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Kim MY, 2003, J MED CHEM, V46, P571, DOI 10.1021/jm0203377; Lemarteleur T, 2004, BIOCHEM BIOPH RES CO, V323, P802, DOI 10.1016/j.bbrc.2004.08.150; Li JL, 2001, BIOCHEMISTRY-US, V40, P15194, DOI 10.1021/bi011067h; MAILLIET P, 2003, 94 AACR M LB28 JUL 1; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; Nakajima A, 2003, LEUKEMIA, V17, P560, DOI 10.1038/sj.leu.2402825; Neidle S, 2003, CURR OPIN STRUC BIOL, V13, P275, DOI 10.1016/S0959-440X(03)00072-1; Neidle S, 2002, NAT REV DRUG DISCOV, V1, P383, DOI 10.1038/nrd793; Pommier JP, 1997, VIROLOGY, V231, P148, DOI 10.1006/viro.1997.8512; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Sampath D, 2002, MOL PHARMACOL, V62, P680, DOI 10.1124/mol.62.3.680; Shammas MA, 2003, MOL CANCER THER, V2, P825; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; Shi Z, 2001, CANCER RES, V61, P1065; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	45	201	210	2	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2917	2928		10.1038/sj.onc.1208468	http://dx.doi.org/10.1038/sj.onc.1208468			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735722				2022-12-25	WOS:000228649500001
J	Cao, C; Li, YP; Leng, YM; Li, P; Ma, QJ; Kufe, D				Cao, C; Li, YP; Leng, YM; Li, P; Ma, QJ; Kufe, D			Ubiquitination and degradation of the Arg tyrosine kinase is regulated by oxidative stress	ONCOGENE			English	Article						Arg; c-Abl; oxidative stress; phosphorylation; ubiquitination; proteosomal degradation	C-ABL; APOPTOTIC RESPONSE; CELLULAR-RESPONSE; ACTIVATION; DNA; NUCLEAR; AUTOINHIBITION; MITOCHONDRIA; BINDING; DAMAGE	The c-Abl and Arg nonreceptor tyrosine kinases are activated in the response of cells to oxidative stress. The present studies demonstrate that treatment of cells with 0.1mM H2O2 is associated with increased tyrosine phosphorylation of Arg and little effect on Arg levels. By contrast, exposure to 1.0mM H2O2 decreased Arg phosphorylation. Treatment with 1.0mM H2O2 was also associated with ubiquitination and degradation of Arg. The results show that Arg is stabilized in response to 0.1mM H2O2 by autophosphorylation of Y-261, consistent with involvement of the Arg kinase function in regulating Arg levels. The results further demonstrate that c-Abl-mediated phosphorylation of Arg on Y-261 similarly confers Arg stabilization. In concert with these results, phosphorylation of Arg on Y-261 blocked H2O2-induced ubiquitination and thereby Arg degradation and inactivation. These findings demonstrate that Arg phosphorylation and degradation are differentially regulated by the degree of oxidative stress, and that Arg stability is conferred by phosphorylation of Y-261.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Beijing Inst Biotechnol, Beijing 100850, Peoples R China	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NCI NIH HHS [CA42802, CA98628] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802, R01CA098628] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Cao C, 2003, J BIOL CHEM, V278, P39609, DOI 10.1074/jbc.M305770200; Cao C, 2003, J BIOL CHEM, V278, P29667, DOI 10.1074/jbc.M301292200; Cao C, 2003, J BIOL CHEM, V278, P12961, DOI 10.1074/jbc.M300058200; Cao C, 2001, J BIOL CHEM, V276, P11465, DOI 10.1074/jbc.C100050200; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648	31	20	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2433	2440		10.1038/sj.onc.1208454	http://dx.doi.org/10.1038/sj.onc.1208454			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735735				2022-12-25	WOS:000228180600001
J	Guo, XC; Schrader, KA; Xu, YX; Schrader, JW				Guo, XC; Schrader, KA; Xu, YX; Schrader, JW			Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated	ONCOGENE			English	Article						M-Ras; leukemia; mastocytosis; H-Ras dendritic cell	HEMATOPOIETIC GROWTH-FACTORS; COLONY-STIMULATING FACTOR; PROTEIN-KINASE PATHWAY; MESSENGER-RNA TURNOVER; ABL-INDUCED ACTIVATION; N-TERMINAL KINASE; H-RAS; PHOSPHATIDYLINOSITOL 3-KINASE; MAST-CELLS; V-ABL	Expression of constitutively activated M-Ras in normal murine bone-marrow cells was sufficient to induce the factor-independent, in vitro growth and differentiation of colonies of macrophages and neutrophils, and the generation of immortal lines of factor-independent mast cells, and, upon in vivo injection of the transduced cells, a fatal mastocytosis/mast-cell leukemia. In contrast, expression of constitutively activated H-Ras in bone-marrow cells resulted in the in vitro growth, in the absence of exogenous factors, of colonies that contained only macrophages and of lines of cells resembling dendritic cells, and, upon in vivo injection of the transduced cells, a fatal histiocytosis/monocytic leukemia. Macrophages generated by bone-marrow cells expressing activated M-Ras or activated H-Ras differed morphologically, the latter appearing more activated, a difference abrogated by an inhibitor of Erk activation. Inhibition of either Erk or PI3 kinase blocked the capacity of both activated M-Ras and activated H-Ras to support proliferation and viability. However, inhibition of p38 MAPK activity suppressed proliferation of bone-marrow cells expressing activated H-Ras, but enhanced that of bone-marrow cells expressing activated M-Ras. Thus, expression of either activated M-Ras or H-Ras in normal hematopoietic cells was sufficient for transformation but each resulted in the generation of distinct lineages of cells.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Schrader, JW (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	john@brc.ubc.ca		Schrader, Kasmintan/0000-0002-7413-4314				ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BASHEY A, 1992, BLOOD, V79, P981; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; Darley RL, 2002, BLOOD, V100, P4185, DOI 10.1182/blood-2002-05-1358; Darley RL, 1999, EXP HEMATOL, V27, P1599, DOI 10.1016/S0301-472X(99)00100-9; Darley RL, 1997, J EXP MED, V185, P1337, DOI 10.1084/jem.185.7.1337; DUNBAR CE, 1991, ONCOGENE RES, V6, P39; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; Ehrhardt A, 2004, MOL CELL BIOL, V24, P6311, DOI 10.1128/MCB.24.14.6311-6323.2004; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Ehrhardt GRA, 2001, ONCOGENE, V20, P188, DOI 10.1038/sj.onc.1204053; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Grill B, 2002, BLOOD, V100, P3183, DOI 10.1182/blood-2002-01-0154; Guo XC, 2003, J BIOL CHEM, V278, P22237, DOI 10.1074/jbc.M300847200; Gupta AK, 2003, CANCER BIOL THER, V2, P73; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; Hamad NM, 2002, ONCOGENE, V21, P7121, DOI 10.1038/sj.onc.1205860; HAWLEY RG, 1995, ONCOGENE, V11, P1113; HIBI S, 1993, BLOOD, V81, P1841; Ingram DA, 2000, J EXP MED, V191, P181, DOI 10.1084/jem.191.1.181; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; JIN DI, 1995, MOL CELL BIOL, V15, P693; Karlsson R, 2003, J LEUKOCYTE BIOL, V74, P923, DOI 10.1189/jlb.0403142; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530; Levings MK, 1999, BLOOD, V93, P3694, DOI 10.1182/blood.V93.11.3694.411a33_3694_3702; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; MacKenzie KL, 1999, BLOOD, V93, P2043, DOI 10.1182/blood.V93.6.2043.406k17_2043_2056; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MAHER J, 1994, EXP HEMATOL, V22, P8; Matsuguchi T, 1998, ONCOGENE, V17, P2701, DOI 10.1038/sj.onc.1202201; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; NAIR APK, 1992, ONCOGENE, V7, P1963; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Oki S, 2002, BLOOD, V100, P966, DOI 10.1182/blood.V100.3.966; OKUDA K, 1994, J BIOL CHEM, V269, P24602; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; PIERCE JH, 1982, J EXP MED, V156, P873, DOI 10.1084/jem.156.3.873; PIERCE JH, 1985, MOL CELL BIOL, V5, P667, DOI 10.1128/MCB.5.4.667; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SKORSKI T, 1992, J EXP MED, V175, P743, DOI 10.1084/jem.175.3.743; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; VONRUDEN T, 1992, BLOOD, V79, P3145; Ward KR, 2004, ONCOGENE, V23, P1187, DOI 10.1038/sj.onc.1207226; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Zhang KX, 2004, MOL CANCER RES, V2, P242; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	80	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2330	2342		10.1038/sj.onc.1208441	http://dx.doi.org/10.1038/sj.onc.1208441			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735740				2022-12-25	WOS:000227877400006
J	Zavros, Y; Eaton, KA; Kang, WQ; Rathinavelu, S; Katukuri, V; Kao, JY; Samuelson, LC; Merchant, JL				Zavros, Y; Eaton, KA; Kang, WQ; Rathinavelu, S; Katukuri, V; Kao, JY; Samuelson, LC; Merchant, JL			Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma	ONCOGENE			English	Article						gastric cancer; anchorage-independent assay; atrophy; somatostatin; RUNX3; villin; STAT3; STAT1	INTESTINAL METAPLASIA; MICE LACKING; CANCER; EXPRESSION; RUNX3; PROTEIN; VILLIN; STAT3; DIFFERENTIATION; ACTIVATION	The current study tests the hypothesis that chronic atrophic gastritis from hypochlorhydria in the gastrin-deficient mouse predisposes the stomach to gastric cancer. Gross morphology and histology of 12-month-old wildtype (WT), gastrin-deficient (G-/-) and somatostatin-deficient (SOM-/-) mice were examined. Parietal and G cells, Ki67, TUNEL, villin and MUC2 expression were analysed by immunohistochemistry. RUNX3 and STAT3 expression was analysed by Western blot. Anchorage-independent growth was determined by cell cluster formation in soft agar. Compared to the WT and SOM-/- mice, hypochlorhydric G-/- mice developed parietal cell atrophy, significant antral inflammation and intestinal metaplasia. Areas of metaplasia within the G-/- mouse stomach showed decreased RUNX3 expression with elevated MUC2 and villin expression. Cells isolated from the tumor grew in soft agar. However, the cells isolated from WT, nontransformed G-/- and SOM-/gastric tissue did not form colonies in soft agar. Consistent with elevated antral proliferation, tumor tissue isolated from the G-/- mice showed elevated phosphorylated STAT3 expression. We then examined the mechanism by which STAT3 was constitutively expressed in the tumor tissue of the G-/- mice. We found that IFN gamma expression was also significantly higher in the tumor tissue of G-/- mice compared to WT and SOM-/- animals. To determine whether STAT3 was regulated by IFN gamma, MKN45 cells were cocultured with IFN gamma or gastrin. IFN gamma significantly stimulated phosphorylation of STAT3 in the MKN45 cell line, but not gastrin. Therefore, we show here that in the hypochlorhydric mouse stomach, the chronic gastritis, atrophy, metaplasia, dysplasia paradigm can be recapitulated in mice. Moreover, neoplastic transformation of the antral gastric mucosa does not require gastrin.	Univ Michigan, Dept Gastroenterol, Ann Arbor, MI USA; Univ Michigan, Unit Lab Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Merchant, JL (corresponding author), 1150 W Med Dr,MSRB 1,3510, Ann Arbor, MI 48109 USA.	merchanj@umich.edu	Merchant, Juanita/AAF-8277-2019; Rathinavelu, Sivaprakash/AAT-2526-2021	Merchant, Juanita/0000-0002-6559-8184; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061410, P30DK041301, P01DK062041, P30DK034933, R37DK045729, R01DK045729] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK062041, DK45729, DK61410, DK34933, DK41301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACCHI CE, 1991, LAB INVEST, V64, P418; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; BARRETT NR, 1957, SURGERY, V41, P881; BLASER MJ, 1994, J CLIN INVEST, V94, P4, DOI 10.1172/JCI117336; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BRETSCHER A, 1979, P NATL ACAD SCI USA, V76, P2321, DOI 10.1073/pnas.76.5.2321; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CORREA P, 1992, CANCER RES, V52, P6735; Cover TL, 2003, CANCER RES, V63, P951; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Eaton KA, 1999, INFECT IMMUN, V67, P4594, DOI 10.1128/IAI.67.9.4594-4602.1999; Fox JG, 1998, GASTROENTEROLOGY, V114, P755, DOI 10.1016/S0016-5085(98)70589-X; Fox JG, 2003, CANCER RES, V63, P942; Friis-Hansen L, 1998, AM J PHYSIOL-GASTR L, V274, pG561, DOI 10.1152/ajpgi.1998.274.3.G561; Harigai M, 2004, ARTHRITIS RHEUM-US, V50, P2167, DOI 10.1002/art.20340; JOHNSON LR, 1977, GASTROENTEROLOGY, V72, P788; Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066; Kanda N, 2004, ONCOGENE, V23, P4921, DOI 10.1038/sj.onc.1207606; Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0; Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060; Koh TJ, 1997, GASTROENTEROLOGY, V113, P1015, DOI 10.1016/S0016-5085(97)70199-9; Ku JL, 2004, ONCOGENE, V23, P6736, DOI 10.1038/sj.onc.1207731; Kumble S, 1996, INT J CANCER, V66, P48, DOI 10.1002/(SICI)1097-0215(19960328)66:1<48::AID-IJC9>3.0.CO;2-Z; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; MOORE JH, 1994, INT J CANCER, V56, P487, DOI 10.1002/ijc.2910560406; Mora LB, 2002, CANCER RES, V62, P6659; Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825; OSBORN M, 1988, VIRCHOWS ARCH A, V413, P303, DOI 10.1007/BF00783022; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; Peek RM, 2002, J GASTROENTEROL, V37, P10, DOI 10.1007/BF02990093; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Semino-Mora C, 2003, J INFECT DIS, V187, P1165, DOI 10.1086/368133; Suter J, 2001, BIOL REPROD, V64, P1481, DOI 10.1095/biolreprod64.5.1481; Torquati A, 2004, SURGERY, V136, P310, DOI 10.1016/j.surg.2004.05.005; Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; WATSON S, 1989, BRIT J CANCER, V59, P554, DOI 10.1038/bjc.1989.112; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Zavros Y, 2003, P NATL ACAD SCI USA, V100, P12944, DOI 10.1073/pnas.2135193100; Zavros Y, 2002, GASTROENTEROLOGY, V122, P119, DOI 10.1053/gast.2002.30298; Zavros Y, 2002, AM J PHYSIOL-GASTR L, V282, pG175, DOI 10.1152/ajpgi.00287.2001	44	112	119	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2354	2366		10.1038/sj.onc.1208407	http://dx.doi.org/10.1038/sj.onc.1208407			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735748				2022-12-25	WOS:000227877400008
J	Darby, RAJ; Hine, AV				Darby, RAJ; Hine, AV			LacI-mediated sequence-specific affinity purification of plasmid DNA for therapeutic applications	FASEB JOURNAL			English	Article						lac repressor protein; protein-DNA interactions; gene therapy; DNA vaccines	HUMAN GENE-THERAPY; PERFORMANCE LIQUID-CHROMATOGRAPHY; REPRESSOR-OPERATOR INTERACTION; ANION-EXCHANGE CHROMATOGRAPHY; PREPARATIVE PURIFICATION; SCALE PRODUCTION; LACTOSE OPERON; ADSORPTION; EXPRESSION; COMPLEXES	Affinity purification of plasmid DNA is an attractive option for the biomanufacture of therapeutic plasmids, which are strictly controlled for levels of host protein, DNA, RNA, and endotoxin. Plasmid vectors are considered to be a safer alternative than viruses for gene therapy, but milligram quantities of DNA are required per dose. Previous affinity approaches have involved triplex DNA formation and a sequence-specific zinc finger protein. We present a more generically applicable protein-based approach, which exploits the lac operator, present in a wide diversity of plasmids, as a target sequence. We used a GFP/His-tagged Lacl protein, which is precomplexed with the plasmid, and the resulting complex was immobilized on a solid support (TALON resin). Ensuing elution gives plasmid DNA, in good yield (>80% based on recovered starting material, 35-50% overall process), free from detectable RNA and protein and with minimal genomic DNA contamination. Such an affinity-based process should enhance plasmid purity and ultimately, after appropriate development, may simplify the biomanufacturing process of therapeutic plasmids.	Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England	Aston University	Hine, AV (corresponding author), Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.	a.v.hine@aston.ac.uk		Hine, Anna/0000-0003-4065-831X				Anderson WF, 1998, NATURE, V392, P25; ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; Bell CE, 2001, J MOL BIOL, V312, P921, DOI 10.1006/jmbi.2001.5024; BETZ JL, 1976, J MOL BIOL, V105, P293, DOI 10.1016/0022-2836(76)90113-3; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CARTER BJ, 1999, BIOTECHNOLOGY, P395; CHANDRA G, 1992, ANAL BIOCHEM, V203, P169, DOI 10.1016/0003-2697(92)90060-K; COLOTE S, 1986, ANAL BIOCHEM, V154, P15, DOI 10.1016/0003-2697(86)90488-4; Durland RH, 1998, ADV DRUG DELIVER REV, V30, P33, DOI 10.1016/S0169-409X(97)00105-1; Ferreira GNM, 1999, BIOTECHNOL PROGR, V15, P725, DOI 10.1021/bp990065+; Ferreira GNM, 2000, BIOSEPARATION, V9, P1, DOI 10.1023/A:1008134822673; Fox JL, 1999, NAT BIOTECHNOL, V17, P1153, DOI 10.1038/70689; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GEISLER N, 1976, P NATL ACAD SCI USA, V73, P3103, DOI 10.1073/pnas.73.9.3103; GILBERT W, 1967, P NATL ACAD SCI USA, V58, P2415, DOI 10.1073/pnas.58.6.2415; Giovannini R, 2002, BIOTECHNOL BIOENG, V77, P445, DOI 10.1002/bit.10149; Green AP, 1997, BIOPHARM-APPL T BIO, V10, P52; Grunwald AG, 2001, ANAL BIOCHEM, V296, P138, DOI 10.1006/abio.2001.5197; HORN NA, 1995, HUM GENE THER, V6, P565, DOI 10.1089/hum.1995.6.5-565; Huber CG, 1998, J CHROMATOGR A, V806, P3, DOI 10.1016/S0021-9673(97)01124-2; JOBE A, 1972, J MOL BIOL, V69, P397, DOI 10.1016/0022-2836(72)90253-7; KANIA J, 1976, P NATL ACAD SCI USA, V73, P3529, DOI 10.1073/pnas.73.10.3529; Krisky DM, 1998, GENE THER, V5, P1593, DOI 10.1038/sj.gt.3300766; Leitner WW, 1999, VACCINE, V18, P765, DOI 10.1016/S0264-410X(99)00271-6; Lemmens R, 2003, J CHROMATOGR B, V784, P291, DOI 10.1016/S1570-0232(02)00805-X; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; Mountain A, 2000, TRENDS BIOTECHNOL, V18, P119, DOI 10.1016/S0167-7799(99)01416-X; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; NICK H, 1982, P NATL ACAD SCI-BIOL, V79, P218, DOI 10.1073/pnas.79.2.218; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; Oh J, 2002, J VIROL, V76, P1762, DOI 10.1128/JVI.76.4.1762-1768.2002; PFAHL M, 1979, J MOL BIOL, V127, P339, DOI 10.1016/0022-2836(79)90333-4; Prather KJ, 2003, ENZYME MICROB TECH, V33, P865, DOI 10.1016/S0141-0229(03)00205-9; Prazeres DMF, 2004, CHEM ENG PROCESS, V43, P609, DOI 10.1016/j.cep.2003.02.002; Prazeres DMF, 1998, J CHROMATOGR A, V806, P31, DOI 10.1016/S0021-9673(97)01254-5; Prazeres DMF, 1999, TRENDS BIOTECHNOL, V17, P169, DOI 10.1016/S0167-7799(98)01291-8; RENZNIKOFF WS, 1974, P NATL ACAD SCI USA, V71, P2314; Robbins PD, 1998, TRENDS BIOTECHNOL, V16, P35, DOI 10.1016/S0167-7799(97)01137-2; ROBINSON H, 2000, CLIN MICROBIOL NEWSL, V23, P17; Robinson HL, 1999, NAT MED, V5, P526, DOI 10.1038/8406; SADLER JR, 1983, P NATL ACAD SCI-BIOL, V80, P6785, DOI 10.1073/pnas.80.22.6785; SADLER JR, 1976, BIOCHEMISTRY-US, V15, P4353, DOI 10.1021/bi00665a001; Sanda MG, 1999, UROLOGY, V53, P260, DOI 10.1016/S0090-4295(98)00539-1; Sandberg LM, 2004, J BIOTECHNOL, V109, P193, DOI 10.1016/j.jbiotec.2003.10.036; Schluep T, 1998, NUCLEIC ACIDS RES, V26, P4524, DOI 10.1093/nar/26.19.4524; SOFER G, 1994, HDB PROCESS CHROMATO; Tighe H, 1998, IMMUNOL TODAY, V19, P89, DOI 10.1016/S0167-5699(97)01201-2; Varley DL, 1999, BIOSEPARATION, V8, P209, DOI 10.1023/A:1008015701773; Wils P, 1997, GENE THER, V4, P323, DOI 10.1038/sj.gt.3300388; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6948, DOI 10.1021/bi00527a029; Winters MA, 2003, BIOTECHNOL PROGR, V19, P440, DOI 10.1021/bp020043e; Woodgate J, 2002, BIOTECHNOL BIOENG, V79, P450, DOI 10.1002/bit.10296	53	23	24	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					801	+		10.1096/fj.04-2812fje	http://dx.doi.org/10.1096/fj.04-2812fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15760969				2022-12-25	WOS:000227901300020
J	Sainson, RCA; Aoto, J; Nakatsu, MN; Holderfield, M; Conn, E; Koller, E; Hughes, CCW				Sainson, RCA; Aoto, J; Nakatsu, MN; Holderfield, M; Conn, E; Koller, E; Hughes, CCW			Cell-autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis	FASEB JOURNAL			English	Article						angiogenesis; sprouts; EC	3-DIMENSIONAL FIBRIN MATRICES; TRANSCRIPTION FACTOR; IN-VITRO; GROWTH-FACTOR; MESENCHYMAL TRANSITION; TUMOR ANGIOGENESIS; ACTIVATED NOTCH4; TUBE FORMATION; CYCLE ARREST; MICE LACKING	The requirement for notch signaling during vascular development is well-documented but poorly understood. Embryonic and adult endothelial cells (EC) express notch and notch ligands; however, the necessity for cell-autonomous notch signaling during angiogenesis has not been determined. During angiogenesis, EC display plasticity, whereby a subset of previously quiescent cells loses polarity and becomes migratory. To investigate the role of notch in EC, we have used a three-dimensional in vitro system that models all of the early steps of angiogenesis. We find that newly forming sprouts are composed of specialized tip cells that guide the sprout and trunk cells that proliferate and rearrange to form intercellular lumens. Furthermore, we find that notch acts cell-autonomously to suppress EC proliferation, thereby regulating tube diameter. In addition, when notch signaling is blocked, tip cells divide, and both daughter cells take on a tip cell phenotype, resulting in increased branching through vessel bifurcation. In contrast, notch signaling is not required for re-establishment of EC polarity or for lumen formation. Thus, notch is used reiteratively and cell-autonomously by EC to regulate vessel diameter, to limit branching at the tip of sprouts, and to establish a mature, quiescent phenotype.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92612 USA; ISIS Pharmaceut Inc, Carlsbad, CA USA	University of California System; University of California Irvine; Isis Pharmaceuticals Inc	Hughes, CCW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92612 USA.	cchughes@uci.edu	Hughes, Christopher/F-7510-2010	Nakatsu, Martin/0000-0001-9808-5230; Holderfield, Matthew/0000-0001-8474-3220; Aoto, Jason/0000-0003-0568-634X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060067] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL60067] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aitkenhead M, 2002, MICROVASC RES, V63, P159, DOI 10.1006/mvre.2001.2380; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Bayless KJ, 2000, AM J PATHOL, V156, P1673, DOI 10.1016/S0002-9440(10)65038-9; Bell SE, 2001, J CELL SCI, V114, P2755; Dor Y, 2003, TRENDS CELL BIOL, V13, P131, DOI 10.1016/S0962-8924(03)00022-9; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004; Fischer A, 2003, TRENDS CARDIOVAS MED, V13, P221, DOI 10.1016/S1050-1738(03)00082-3; FOLKMAN J, 1975, ANN INTERN MED, V82, P96, DOI 10.7326/0003-4819-82-1-96; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; Fruman DA, 2002, P NATL ACAD SCI USA, V99, P359, DOI 10.1073/pnas.012605099; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Gessler M, 2002, CURR BIOL, V12, P1601, DOI 10.1016/S0960-9822(02)01150-8; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; Hogan BLM, 2002, NAT REV GENET, V3, P513, DOI 10.1038/nrg840; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kopan R, 2002, J CELL SCI, V115, P1095; Krebs LT, 2000, GENE DEV, V14, P1343; Lawson ND, 2002, DEV CELL, V3, P127, DOI 10.1016/S1534-5807(02)00198-3; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Lewis J, 1998, SEMIN CELL DEV BIOL, V9, P583, DOI 10.1006/scdb.1998.0266; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Lubarsky B, 2003, CELL, V112, P19, DOI 10.1016/S0092-8674(02)01283-7; Markwald R, 1996, ACTA ANAT, V156, P173; Minoguchi S, 1997, MOL CELL BIOL, V17, P2679, DOI 10.1128/MCB.17.5.2679; Nakajima M, 2003, MECH DEVELOP, V120, P657, DOI 10.1016/S0925-4773(03)00064-9; Nakatsu MN, 2003, LAB INVEST, V83, P1873, DOI 10.1097/01.LAB.0000107160.81875.33; Nakatsu MN, 2003, MICROVASC RES, V66, P102, DOI 10.1016/S0026-2862(03)00045-1; NEHLS V, 1995, HISTOCHEM CELL BIOL, V104, P459, DOI 10.1007/BF01464336; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Noseda M, 2004, CIRC RES, V94, P910, DOI 10.1161/01.RES.0000124300.76171.C9; Noseda M, 2004, MOL CELL BIOL, V24, P8813, DOI 10.1128/MCB.24.20.8813-8822.2004; Parker LH, 2004, NATURE, V428, P754, DOI 10.1038/nature02416; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Shawber CJ, 2003, ANN NY ACAD SCI, V995, P162, DOI 10.1111/j.1749-6632.2003.tb03219.x; Shutter JR, 2000, GENE DEV, V14, P1313; Simian M, 2001, DEVELOPMENT, V128, P3117; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sriuranpong V, 2001, CANCER RES, V61, P3200; Sweeney C, 2004, FASEB J, V18, P1421, DOI 10.1096/fj.04-1700fje; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Taylor KL, 2002, MICROVASC RES, V64, P372, DOI 10.1006/mvre.2002.2443; Timmerman LA, 2004, GENE DEV, V18, P99, DOI 10.1101/gad.276304; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Weijzen S, 2002, J IMMUNOL, V169, P4273, DOI 10.4049/jimmunol.169.8.4273; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599	57	172	185	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					1027	+		10.1096/fj.04-3172fje	http://dx.doi.org/10.1096/fj.04-3172fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15774577				2022-12-25	WOS:000227901300012
J	Krymskaya, VP; Goncharova, EA; Ammit, AJ; Lim, PN; Goncharov, DA; Eszterhas, A; Panettieri, RA				Krymskaya, VP; Goncharova, EA; Ammit, AJ; Lim, PN; Goncharov, DA; Eszterhas, A; Panettieri, RA			Src is necessary and sufficient for human airway smooth muscle cell proliferation and migration	FASEB JOURNAL			English	Article						asthma; airway remodeling; COPD	PROTEIN-KINASE PATHWAY; TYROSINE KINASE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; C-SRC; ACTIVATION; FAMILY; STIMULATION; HOMEOSTASIS; MECHANISMS	Airway smooth muscle (ASM) hypertrophy and hyperplasia, important pathological features in chronic severe asthma, likely contribute to irreversible airflow obstruction. Despite considerable research effort, the precise cellular mechanisms that modulate ASM growth remain unknown. Src, a nonreceptor tyrosine kinase proto-oncogene, reportedly modulates cell proliferative responses to growth factors, contractile agonists, and inflammatory mediators. Here, we show that Src activation is required for human ASM mitogenesis and motility. Platelet-derived growth factor ( PDGF), epidermal growth factor (EGF), and thrombin induce rapid activation of Src, and inhibition of Src induces a concentration-dependent abrogation of PDGF-, EGF-, and thrombin-induced ASM cell proliferation. Src immunoprecipitates had associated phosphatidylinositol 3-kinase, or PI3K, activation in response to PDGF and thrombin but not EGF. Further, Src activation is both necessary and sufficient for the stimulation of DNA synthesis as demonstrated by dominant negative Src inhibition of PDGF-, EGF-, and thrombin-induced DNA synthesis. Human ASM cell migration was also attenuated by transfection of cells with dominant negative Src. Further, expression of constitutively active Src promoted cell migration. Collectively, these data demonstrate that Src modulates human ASM cell proliferation and migration, suggesting that Src may play an important role in promoting ASM cell growth and migration that occur in airway remodeling found in asthma and chronic obstructive pulmonary disease, or COPD.	Univ Penn, Pulm Allergy & Crit Care Div, Dept Med, Philadelphia, PA 19104 USA; Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia	University of Pennsylvania; University of Sydney	Krymskaya, VP (corresponding author), Univ Penn, Pulm Allergy & Crit Care Div, Dept Med, 421 Curie Blvd,BRB II III, Philadelphia, PA 19104 USA.	krymskay@mail.med.upenn.edu	panettieri, reynold/AAG-9485-2019	Ammit, Alaina/0000-0003-0555-2544	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067663, R01HL064063, R01HL055301, R01HL071106, P50HL067663] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071106, HL55301, HL67663, HL071106, R01 HL064063, R01 HL055301, P01 HL067663, P50 HL067663, HL64063] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ammit AJ, 1999, AM J RESP CELL MOL, V21, P719, DOI 10.1165/ajrcmb.21.6.3731; Ammit AJ, 2001, J APPL PHYSIOL, V91, P1431, DOI 10.1152/jappl.2001.91.3.1431; Amrani Y, 1997, AM J PHYSIOL-LUNG C, V273, pL1020, DOI 10.1152/ajplung.1997.273.5.L1020; Billington CK, 2003, RESP RES, V4; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Condliffe A M, 2000, Respir Res, V1, P24, DOI 10.1186/rr8; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Goncharova EA, 2003, AM J RESP CELL MOL, V29, P19, DOI 10.1165/rcmb.2002-0254OC; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hershenson MB, 1999, AM J RESP CELL MOL, V21, P651, DOI 10.1165/ajrcmb.21.6.f168; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Krymskaya VP, 1997, AM J PHYSIOL-LUNG C, V273, pL1220, DOI 10.1152/ajplung.1997.273.6.L1220; Krymskaya VP, 2000, AM J RESP CELL MOL, V23, P546, DOI 10.1165/ajrcmb.23.4.4115; Krymskaya VP, 1999, AM J PHYSIOL-LUNG C, V277, pL65; Krymskaya VP, 2001, AM J PHYSIOL-LUNG C, V280, pL1009, DOI 10.1152/ajplung.2001.280.5.L1009; Krymskaya VP, 1999, AM J PHYSIOL-LUNG C, V276, pL246, DOI 10.1152/ajplung.1999.276.2.L246; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MURRAY RK, 1993, AM J PHYSIOL, V264, pC485, DOI 10.1152/ajpcell.1993.264.2.C485; Orsini MJ, 1999, AM J PHYSIOL-LUNG C, V277, pL479, DOI 10.1152/ajplung.1999.277.3.L479; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; Sayeski PP, 2003, EXP CELL RES, V287, P339, DOI 10.1016/S0014-4827(03)00154-X; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tsang F, 2002, BIOCHEM BIOPH RES CO, V293, P72, DOI 10.1016/S0006-291X(02)00170-5; Weber DS, 2004, CIRC RES, V94, P1219, DOI 10.1161/01.RES.0000126848.54740.4A; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75; Yamboliev IA, 2001, AM J PHYSIOL-CELL PH, V281, pC709, DOI 10.1152/ajpcell.2001.281.2.C709	36	70	76	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					428	+		10.1096/fj.04-2869fje	http://dx.doi.org/10.1096/fj.04-2869fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15746183				2022-12-25	WOS:000226091000009
J	Hemmati, PG; Normand, G; Verdoodt, B; von Haefen, C; Hasenjager, A; Guner, D; Wendt, J; Dorken, B; Daniel, PT				Hemmati, PG; Normand, G; Verdoodt, B; von Haefen, C; Hasenjager, A; Guner, D; Wendt, J; Dorken, B; Daniel, PT			Loss of p21 disrupts p14(ARF)-induced G1 cell cycle arrest but augments p14(ARF)-induced apoptosis in human carcinoma cells	ONCOGENE			English	Article						p14(ARF); p53; p21; cell cycle; apoptosis	P19(ARF) TUMOR-SUPPRESSOR; HUMAN CANCER-CELLS; P53-DEPENDENT APOPTOSIS; GROWTH ARREST; G(2) ARREST; P53; ARF; PATHWAYS; P16(INK4A); LOCUS	The human INK4a locus encodes two structurally unrelated tumor suppressor proteins, p16(INK4a) and p14(ARF) (p19(ARF) in the mouse), which are frequently inactivated in human cancer. Both the proapoptotic and cell cycle-regulatory functions of p14ARF were initially proposed to be strictly dependent on a functional p53/mdm-2 tumor suppressor pathway. However, a number of recent reports have implicated p53-independent mechanisms in the regulation of cell cycle arrest and apoptosis induction by p14ARF. Here, we show that the G1 cell cycle arrest induced by p14ARF entirely depends on both p53 and p21 in human HCT116 and DU145 carcinoma cells. In contrast, neither loss of p53 nor p21 impaired apoptosis induction by p14ARF as evidenced by nuclear DNA fragmentation, phosphatidyl serine exposure, and caspase activation, which included caspase-3/7- and caspase-9-like activities. However, lack of functional p21 resulted in the accumulation of cells in G2/Mphase of the cell cycle and markedly enhanced p14(ARF)-induced apoptosis that was, nevertheless, efficiently inhibited by the cell permeable broad-spectrum caspase inhibitor zVAD-fmk (valyl-alanyl-aspartyl( O)-methyl)-fluoromethylketone). Thus, loss of cell cycle restriction point control in the absence of p21 may interfere with p14(ARF)-induced apoptosis. Finally, these data indicate that the signaling events required for G1 cell cycle arrest and apoptosis induction by p14ARF dissociate upstream of p53.	Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Daniel, PT (corresponding author), Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Normand, Guillaume/A-1975-2010	Normand, Guillaume/0000-0003-1228-3813				Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Cleveland JL, 2004, CANCER CELL, V6, P309, DOI 10.1016/j.ccr.2004.09.020; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; DURO D, 1995, ONCOGENE, V11, P21; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Fotedar R, 1999, ONCOGENE, V18, P3652, DOI 10.1038/sj.onc.1202693; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Groth A, 2000, J BIOL CHEM, V275, P27473; Guner Dilek, 2003, Curr Med Chem Anticancer Agents, V3, P319, DOI 10.2174/1568011033482369; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Kuo ML, 2003, CANCER RES, V63, P1046; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; MAO L, 1995, CANCER RES, V55, P2995; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Mason SL, 2002, ONCOGENE, V21, P4220, DOI 10.1038/sj.onc.1205524; Modestou M, 2001, CANCER RES, V61, P3145; NORMAND G, 2004, J BIOL CHEM     1206; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pennington KN, 2001, MOL CELL BIOL, V21, P1930, DOI 10.1128/MCB.21.6.1930-1941.2001; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rau B, 2003, J CLIN ONCOL, V21, P3391, DOI 10.1200/JCO.2003.07.077; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Scholz C, 2002, GENE THER, V9, P1438, DOI 10.1038/sj.gt.3301796; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; WALDMAN T, 1995, CANCER RES, V55, P5187; Weber HO, 2002, ONCOGENE, V21, P3207, DOI 10.1038/sj.onc.1205429; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Yarbrough WG, 2002, CANCER RES, V62, P1171; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426; Zhu JH, 1998, CANCER RES, V58, P5061; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	49	30	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4114	4128		10.1038/sj.onc.1208579	http://dx.doi.org/10.1038/sj.onc.1208579			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15750619				2022-12-25	WOS:000229680300010
J	Mishra, V; Bilgrami, S; Sharma, RS; Kaur, P; Yadav, S; Krauspenhaar, R; Betzel, C; Voelter, W; Babu, CR; Singh, TP				Mishra, V; Bilgrami, S; Sharma, RS; Kaur, P; Yadav, S; Krauspenhaar, R; Betzel, C; Voelter, W; Babu, CR; Singh, TP			Crystal structure of Himalayan mistletoe ribosome-inactivating protein reveals the presence of a natural inhibitor and a new functionally active sugar-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN A-CHAIN; POKEWEED ANTIVIRAL PROTEIN; RNA N-GLYCOSIDASE; VISCUM-ALBUM; B-CHAIN; SUBSTRATE-ANALOGS; GALACTOSE-BINDING; LECTIN-I; MECHANISM; IDENTIFICATION	Ribosome-inactivating proteins (RIPs) are toxins involved in plant defense. How the plant prevents autotoxicity is not yet fully understood. The present study is the first structural evidence of a naturally inhibited form of RIP from a plant. Himalayan mistletoe RIP (HmRIP) was purified from Viscum album leaves and crystallized with lactose. The structure was determined by the molecular replacement method and refined at 2.8-angstrom resolution. The crystal structure revealed the presence of high quality non-protein electron density at the active site, into which a pteridine derivative (2-amino 4-isopropyl 6-carboxyl pteridine) was modeled. The carboxyl group of the ligand binds strongly with the key active site residue Arg(162), nullifies the positive charge required for catalysis, and thereby acts as a natural inhibitor. Lectin subunits of RIPs have two active sugar-binding sites present in 1 alpha- and 2 gamma-subdomains. A third functionally active site has been identified in the 1 beta-subdomain of HmRIP. The 1 beta-site is active despite the absence of conserved polar sugar-binding residues. Loss of these residues is compensated by the following: (i) the presence of an extended site where the penultimate sugar also interacts with the protein; (ii) the interactions of galactose with the protein main chain carbonyl and amide nitrogen atoms; (iii) the presence of a well defined pocket encircled by four walls; and (iv) a favorable stacking of the galactose ring with Tyr(66) besides the conserved Phe(75). The mode of sugar binding is also distinct at the 1 alpha and 2 gamma sugar-binding sites.	All India Inst Med Sci, Dept Biophys, New Delhi 110029, India; Univ Delhi, Dept Bot, Delhi 100007, India; Univ Delhi, Ctr Environm Management Degraded Ecosyst, Sch Environm Sci, Delhi 100007, India; Inst Med Biochem & Mol Biol, D-22603 Hamburg, Germany; Univ Tubingen, Inst Physiol Chem, D-72076 Tubingen, Germany	All India Institute of Medical Sciences (AIIMS) New Delhi; University of Delhi; University of Delhi; Eberhard Karls University of Tubingen	Singh, TP (corresponding author), All India Inst Med Sci, Dept Biophys, New Delhi 110029, India.	tps@aiims.aiims.ac.in	Betzel, Christian/G-8105-2018	Betzel, Christian/0000-0002-3879-5019				Bagga S, 2003, J BIOL CHEM, V278, P4813, DOI 10.1074/jbc.M207389200; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; Bolognesi A, 2004, MINI-REV MED CHEM, V4, P563, DOI 10.2174/1389557043403864; Bussing A., 2000, MISTLETOE GENUS VISC; Day PJ, 1996, BIOCHEMISTRY-US, V35, P11098, DOI 10.1021/bi960880n; Desvoyes B, 1997, FEBS LETT, V410, P303, DOI 10.1016/S0014-5793(97)00648-0; Elhaggar S, 1993, Arch AIDS Res, V7, P120; ELPIDINA EN, 1991, PLANTA, V185, P46, DOI 10.1007/BF00194513; ENDO Y, 1988, J BIOL CHEM, V263, P8735; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Frankel A, 1996, PROTEIN ENG, V9, P371, DOI 10.1093/protein/9.4.371; Frigerio L, 1998, J EXP BOT, V49, P1473, DOI 10.1093/jexbot/49.326.1473; Gabius H.-J., 1991, LECTINS CANC; Gu YJ, 2000, PROTEINS, V39, P37, DOI 10.1002/(SICI)1097-0134(20000401)39:1<37::AID-PROT4>3.3.CO;2-7; HAJTO T, 1989, CANCER RES, V49, P4803; HARLEY SM, 1982, P NATL ACAD SCI-BIOL, V79, P5935, DOI 10.1073/pnas.79.19.5935; HARTLEY MR, 1996, TRENDS PLANT SCI, V1, P260; Heiny BM, 1998, ANTICANCER RES, V18, P583; HOUSTON LL, 1982, J BIOL CHEM, V257, P4147; HUANG QC, 1995, BIOCHEM J, V309, P285, DOI 10.1042/bj3090285; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kovacs E, 2000, BIOMED PHARMACOTHER, V54, P305, DOI 10.1016/S0753-3322(00)80052-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krauspenhaar R, 1999, BIOCHEM BIOPH RES CO, V257, P418, DOI 10.1006/bbrc.1999.0470; Kurinov IV, 1999, PROTEIN SCI, V8, P1765, DOI 10.1110/ps.8.9.1765; Lam SK, 2001, ARCH BIOCHEM BIOPHYS, V393, P271, DOI 10.1006/abbi.2001.2506; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE RT, 1994, CARBOHYD RES, V254, P269, DOI 10.1016/0008-6215(94)84259-0; LEE RT, 1992, J BIOL CHEM, V267, P23722; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mishra V, 2005, PLANT SCI, V168, P615, DOI 10.1016/j.plantsci.2004.09.024; Mishra V, 2004, ACTA CRYSTALLOGR D, V60, P2295, DOI 10.1107/S0907444904023534; Mishra V, 2004, ARCH BIOCHEM BIOPHYS, V423, P288, DOI 10.1016/j.abb.2003.12.033; MISHRA V, 1908, THESIS U DELHI DELHI; MONZINGO AF, 1992, J MOL BIOL, V227, P1136, DOI 10.1016/0022-2836(92)90526-P; Motto M, 2004, MINI-REV MED CHEM, V4, P493, DOI 10.2174/1389557043403873; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nielsen K, 2001, ANNU REV PLANT PHYS, V52, P785, DOI 10.1146/annurev.arplant.52.1.785; Niwa H, 2003, EUR J BIOCHEM, V270, P2739, DOI 10.1046/j.1432-1033.2003.03646.x; Oettl K, 1999, BBA-PROTEIN STRUCT M, V1430, P387, DOI 10.1016/S0167-4838(99)00023-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parikh BA, 2004, MINI-REV MED CHEM, V4, P523, DOI 10.2174/1389557043403800; Park SW, 2002, PLANTA, V216, P227, DOI 10.1007/s00425-002-0851-0; Park SW, 2004, PLANTA, V219, P1093, DOI 10.1007/s00425-004-1357-8; Pascal JM, 2001, PROTEINS, V43, P319, DOI 10.1002/prot.1043; Peumans WJ, 2001, FASEB J, V15, P1493, DOI 10.1096/fj.00-0751rev; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; READY MP, 1991, PROTEINS, V10, P270, DOI 10.1002/prot.340100311; REINBOTHE S, 1994, P NATL ACAD SCI USA, V91, P7012, DOI 10.1073/pnas.91.15.7012; REN JS, 1994, STRUCTURE, V2, P7, DOI 10.1016/S0969-2126(00)00004-6; Robertus JD, 1996, TOXICON, V34, P1325, DOI 10.1016/S0041-0101(96)00103-1; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; RUTENBER E, 1991, PROTEINS, V10, P241; Schlick JL, 1999, PLANT SCI, V140, P1, DOI 10.1016/S0168-9452(98)00208-8; Steeves RM, 1999, BIOCHEMISTRY-US, V38, P11677, DOI 10.1021/bi990493o; TAHIROV TH, 1995, J MOL BIOL, V250, P354, DOI 10.1006/jmbi.1995.0382; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yan XJ, 1998, PROTEINS, V31, P33, DOI 10.1002/(SICI)1097-0134(19980401)31:1<33::AID-PROT4>3.0.CO;2-I; Yan XJ, 1997, J MOL BIOL, V266, P1043, DOI 10.1006/jmbi.1996.0865; YOULE RJ, 1981, CELL, V23, P551, DOI 10.1016/0092-8674(81)90151-3; ZISKA P, 1993, LECTINS BIOL BIOCH C, V8, P10	64	27	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20712	20721		10.1074/jbc.M500735200	http://dx.doi.org/10.1074/jbc.M500735200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15774467	hybrid			2022-12-25	WOS:000229242000069
J	Kumar, S; Chen, CS; Waxman, DJ; Halpert, JR				Kumar, S; Chen, CS; Waxman, DJ; Halpert, JR			Directed evolution of mammalian cytochrome P4502B1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; LABORATORY EVOLUTION; ENZYMES; MUTAGENESIS; ACTIVATION; RESIDUES; MUTANTS; CYCLOPHOSPHAMIDE; IDENTIFICATION; AGGREGATION	Cytochrome P450 2B1 has been subjected to directed evolution to investigate the role of amino acid residues outside of the active site and to engineer novel, more active P450 catalysts. A high throughput screening system was developed to measure H2O2-supported oxidation of the marker fluorogenic substrate 7-ethoxy-4-trifluoromethylcoumarin (7-EFC). Random mutagenesis by error-prone polymerase chain reaction and activity screening were optimized using the L209A mutant of P450 2B1 in an N-terminally modified construct with a C-terminal His tag (P450 2B1dH). Two rounds of mutagenesis and screening and one subcloning step yielded the P450 2B1 quadruple mutant V183L/F202L/L209A/S334P, which demonstrated a 6-fold higher k(cat) than L209A. Further random or site-directed mutagenesis did not improve the activity. When assayed in an NADPH-supported reconstituted system, V183L/L209A demonstrated lower 7-EFC oxidation than L209A. Therefore, F202L/L209A/S334P was generated, which showed a 2.5-fold higher k(cat)/K-m for NADPH-dependent 7-EFC oxidation than L209A. F202L/L209A/S334P also showed enhanced catalytic efficiency with 7-benzyloxyresorufin, benzphetamine, and testosterone, and a 10-fold increase in stereoselectivity for testosterone 16 alpha- versus 16 beta-hydroxylation compared with 2B1dH. Enhanced catalytic efficiency of F202L/L209A/S334P was also retained in the full-length P450 2B1 background with 7-EFC and testosterone as substrates. Finally, the individual mutants were tested for metabolism of the anti-cancer prodrugs cyclophosphamide and ifosfamide. Several of the mutants showed increased metabolism via the therapeutically beneficial 4-hydroxylation pathway, with L209A/S334P showing 2.8-fold enhancement of k(cat)/K-m with cyclophosphamide and V183L/L209A showing 3.5-fold enhancement with ifosfamide. Directed evolution can thus be used to enhance P450 2B1 catalytic efficiency across a panel of substrates and to identify functionally important residues distant from the active site.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Boston Univ, Dept Biol, Boston, MA 02215 USA	University of Texas System; University of Texas Medical Branch Galveston; Boston University	Kumar, S (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, 301 Univ Blvd, Galveston, TX 77555 USA.	sakumar@utmb.edu		Waxman, David/0000-0001-7982-9206	NATIONAL CANCER INSTITUTE [R01CA049248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, P42ES007381, R01ES003619] Funding Source: NIH RePORTER; NCI NIH HHS [CA49248] Funding Source: Medline; NIEHS NIH HHS [ES03619, ES06676, 5 P42 ES07381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CHANG TKH, 1993, CANCER RES, V53, P5629; Chen CS, 2004, MOL PHARMACOL, V65, P1278, DOI 10.1124/mol.65.5.1278; Chen L, 2002, CURR PHARM DESIGN, V8, P1405, DOI 10.2174/1381612023394566; Cherry JR, 2003, CURR OPIN BIOTECH, V14, P438, DOI 10.1016/S0958-1669(03)00099-5; Cirino Patrick C, 2003, Methods Mol Biol, V231, P3; Cosme J, 2000, J BIOL CHEM, V275, P2545, DOI 10.1074/jbc.275.4.2545; Domanski TL, 2001, CURR DRUG METAB, V2, P117, DOI 10.2174/1389200013338612; Farinas ET, 2001, ADV SYNTH CATAL, V343, P601, DOI 10.1002/1615-4169(200108)343:6/7<601::AID-ADSC601>3.0.CO;2-9; Glieder A, 2002, NAT BIOTECHNOL, V20, P1135, DOI 10.1038/nbt744; Harlow GR, 1997, BBA-PROTEIN STRUCT M, V1338, P259, DOI 10.1016/S0167-4838(96)00209-9; He YQ, 1996, ARCH BIOCHEM BIOPHYS, V335, P152, DOI 10.1006/abbi.1996.0493; Hilser V J, 2001, Methods Mol Biol, V168, P93; Hilser VJ, 1998, P NATL ACAD SCI USA, V95, P9903, DOI 10.1073/pnas.95.17.9903; Hult K, 2003, CURR OPIN BIOTECH, V14, P395, DOI 10.1016/S0958-1669(03)00095-8; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; Jounaidi Y, 2004, CANCER RES, V64, P292, DOI 10.1158/0008-5472.CAN-03-1798; Khan KK, 2002, CHEM RES TOXICOL, V15, P806, DOI 10.1021/tx0200010; Kim D, 2004, BIOCHEMISTRY-US, V43, P981, DOI 10.1021/bi035593f; Kim D, 2004, ARCH BIOCHEM BIOPHYS, V432, P102, DOI 10.1016/j.abb.2004.09.001; Kirk O, 2002, CURR OPIN BIOTECH, V13, P345, DOI 10.1016/S0958-1669(02)00328-2; Kumar S, 2003, J BIOL CHEM, V278, P17178, DOI 10.1074/jbc.M212515200; Salazar Oriana, 2003, V230, P85; Schmid A, 2001, NATURE, V409, P258, DOI 10.1038/35051736; Schoemaker HE, 2003, SCIENCE, V299, P1694, DOI 10.1126/science.1079237; Scott EE, 2004, ARCH BIOCHEM BIOPHYS, V423, P266, DOI 10.1016/j.abb.2003.12.035; Scott EE, 2001, ARCH BIOCHEM BIOPHYS, V395, P57, DOI 10.1006/abbi.2001.2574; Scott EE, 2002, CHEM RES TOXICOL, V15, P1407, DOI 10.1021/tx020057u; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200; Spatzenegger M, 2001, MOL PHARMACOL, V59, P475, DOI 10.1124/mol.59.3.475; Strobel SM, 1997, BIOCHEMISTRY-US, V36, P11697, DOI 10.1021/bi9710176; Tobias Alexander V, 2003, Methods Mol Biol, V231, P11; Turner NJ, 2003, TRENDS BIOTECHNOL, V21, P474, DOI 10.1016/j.tibtech.2003.09.001; Waller SC, 1999, CHEM RES TOXICOL, V12, P690, DOI 10.1021/tx990030j; Williams D, 2000, PERFORM RES, V5, P131; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200	37	78	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19569	19575		10.1074/jbc.M500158200	http://dx.doi.org/10.1074/jbc.M500158200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774478	hybrid			2022-12-25	WOS:000229113700019
J	Lu, D; Zhang, HF; Koo, H; Tonra, J; Balderes, P; Prewett, M; Corcoran, E; Mangalampalli, V; Bassi, R; Anselma, D; Patel, D; Kang, XQ; Ludwig, DL; Hicklin, DJ; Bohlen, P; Witte, L; Zhu, ZP				Lu, D; Zhang, HF; Koo, H; Tonra, J; Balderes, P; Prewett, M; Corcoran, E; Mangalampalli, V; Bassi, R; Anselma, D; Patel, D; Kang, XQ; Ludwig, DL; Hicklin, DJ; Bohlen, P; Witte, L; Zhu, ZP			A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; BREAST-CANCER CELLS; MONOCLONAL-ANTIBODY; SIGNALING PATHWAYS; COLORECTAL-CANCER; EGF RECEPTOR; COLON-CANCER; THERAPY; DESIGN; CHEMOTHERAPY	Both the epidermal growth factor receptor ( EGFR) and the insulin-like growth factor receptor (IGFR) have been implicated in the tumorigenesis of a variety of cancers. Here we propose that simultaneous targeting of both receptors with a bispecific antibody would lead to enhanced antitumor activity. To this end, we produced a recombinant human IgG-like bispecific antibody, a Di-diabody, using the variable regions from two antagonistic antibodies: IMC-11F8 to EGFR and IMC-A12 to IGFR. The Di-diabody binds to both EGFR and IGFR and effectively blocked both EGF- and IGF-stimulated receptor activation and tumor cell proliferation. The Di-diabody also inherited the biological properties from both of its parent antibodies; it triggers rapid and significant IGFR internalization and degradation and mediates effective antibody-dependent cellular cytotoxicity in a variety of tumor cells. Finally, the Di-diabody strongly inhibited the growth of two different human tumor xenografts in vivo. Our results underscore the benefits of simultaneous targeting of two tumor targets with bispecific antibodies.	ImClone Syst Inc, Dept Antibody Technol, New York, NY 10014 USA; ImClone Syst Inc, Dept Mol & Cell Biol, New York, NY 10014 USA; ImClone Syst Inc, Dept Expt Therapeut, New York, NY 10014 USA; ImClone Syst Inc, Dept Prot Sci, New York, NY 10014 USA; ImClone Syst Inc, Res Dept, New York, NY 10014 USA	Eli Lilly; Eli Lilly; Eli Lilly; Eli Lilly; Eli Lilly	Zhu, ZP (corresponding author), ImClone Syst Inc, Dept Antibody Technol, 180 Varick St, New York, NY 10014 USA.	Zhenping@imclone.com						Alt M, 1999, FEBS LETT, V454, P90, DOI 10.1016/S0014-5793(99)00782-6; Arteaga C, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00185-4; Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Baselga J, 2001, ONCOLOGY-BASEL, V61, P14, DOI 10.1159/000055397; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Benini S, 2001, CLIN CANCER RES, V7, P1790; Bonner JA, 2004, J CLIN ONCOL, V22, p489S; Boylan M, 1998, ANN ONCOL, V9, P205, DOI 10.1023/A:1008241804078; Burtrum D, 2003, CANCER RES, V63, P8912; Cao Y, 2003, ADV DRUG DELIVER REV, V55, P171, DOI 10.1016/S0169-409X(02)00178-3; Carter P, 1995, J Hematother, V4, P463, DOI 10.1089/scd.1.1995.4.463; Carter P, 2001, J IMMUNOL METHODS, V248, P7, DOI 10.1016/S0022-1759(00)00339-2; Chakravarti A, 2002, CANCER RES, V62, P200; Clark AS, 2002, MOL CANCER THER, V1, P707; Coloma MJ, 1997, NAT BIOTECHNOL, V15, P159, DOI 10.1038/nbt0297-159; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Khalil Mazen Y, 2003, Expert Rev Anticancer Ther, V3, P367, DOI 10.1586/14737140.3.3.367; Kufer P, 2004, TRENDS BIOTECHNOL, V22, P238, DOI 10.1016/j.tibtech.2004.03.006; Lee CT, 1996, CANCER RES, V56, P3038; Lenz HJ, 2004, J CLIN ONCOL, V22, p247S; Lu D, 2004, J BIOL CHEM, V279, P2856, DOI 10.1074/jbc.M310132200; Lu D, 2004, BIOCHEM BIOPH RES CO, V318, P507, DOI 10.1016/j.bbrc.2004.04.060; Lu D, 2003, J BIOL CHEM, V278, P43496, DOI 10.1074/jbc.M307742200; Lu D, 2003, J IMMUNOL METHODS, V279, P219, DOI 10.1016/S0022-1759(03)00251-5; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Mendelsohn J, 2003, CANCER IMMUNOL IMMUN, V52, P342, DOI 10.1007/s00262-002-0354-7; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677; Perer ES, 2000, J SURG RES, V94, P1, DOI 10.1006/jsre.2000.5923; Pluckthun A, 1997, IMMUNOTECHNOLOGY, V3, P83, DOI 10.1016/S1380-2933(97)00067-5; Prewett M, 2004, P AM ASS CANC RES, V45; Reinmuth N, 2002, CLIN CANCER RES, V8, P3259; Ross JS, 2003, AM J CLIN PATHOL, V119, P472, DOI 10.1309/Y6LPC0LR726L9DX9; RUBIN R, 1995, LAB INVEST, V73, P311; Sachdev D, 2003, CANCER RES, V63, P627; Todorovska A, 2001, J IMMUNOL METHODS, V248, P47, DOI 10.1016/S0022-1759(00)00342-2; Turner BC, 1997, CANCER RES, V57, P3079; van Spriel AB, 2000, IMMUNOL TODAY, V21, P391, DOI 10.1016/S0167-5699(00)01659-5; vandenBerg HW, 1996, BRIT J CANCER, V73, P477, DOI 10.1038/bjc.1996.84; Waksal HW, 1999, CANCER METAST REV, V18, P427, DOI 10.1023/A:1006302101468; Wang YL, 2002, CURR CANCER DRUG TAR, V2, P191, DOI 10.2174/1568009023333863; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Yarden Y, 2001, EUR J CANCER, V37, pS3; ZHU ZP, 1995, INT J CANCER, V62, P319, DOI 10.1002/ijc.2910620315; Zhu ZP, 1997, PROTEIN SCI, V6, P781; ZHUANG Z, 2000, PROTEIN ENG, V13, P361; Zia F, 1996, J CELL BIOCHEM, P269	51	153	284	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19665	19672		10.1074/jbc.M500815200	http://dx.doi.org/10.1074/jbc.M500815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15757893	hybrid			2022-12-25	WOS:000229113700031
J	Riewald, M; Ruf, W				Riewald, M; Ruf, W			Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BRAIN ENDOTHELIUM; FACTOR XA; APOPTOSIS; P53; COAGULATION; PAR2; IDENTIFICATION; ANGIOGENESIS; INFLAMMATION; MECHANISMS	Activated protein C (APC) has anti-inflammatory and vascular protective effects independent of anticoagulation. We previously identified the prototypical thrombin receptor, protease-activated receptor-1 (PAR1), as part of a novel APC-endothelial cell protein C receptor ( EPCR) signaling pathway in endothelial cells. Experiments in wild-type and PAR1(-/-) mice demonstrated that intravenous injection of APC leads to PAR1-dependent gene induction in the lung. The vascular endothelium undergoes profound changes in severe sepsis, the approved therapeutic indication for APC. Similar to PAR1, APC activated PAR2 through canonical cleavage. Although PAR2 was up-regulated in cytokine-stimulated endothelial cells, APC signaling remained PAR1-dependent. Large scale gene expression profiling documented marked differences in both up- and down-regulated genes between APC and thrombin signaling in cytokine-stimulated cells. APC down-regulated transcripts for proapoptotic proteins including p53 and thrombospondin-1, but p53 was unchanged, and thrombospondin was even upregulated by thrombin. Concordant PAR1-dependent effects on protein levels were found. Thus, by signaling through the same receptor PAR1, APC, and thrombin can exert distinct biological effects in perturbed endothelium. These data may explain how APC can be therapeutically protective through the EPCR-PAR1 signaling despite ongoing thrombin generation due to disseminated intravascular coagulopathy.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Riewald, M (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd,VB-4, La Jolla, CA 92037 USA.	riewald@scripps.edu			NHLBI NIH HHS [HL 48752, HL 78614] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048752, R01HL078614] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bono F, 2000, ARTERIOSCL THROM VAS, V20, pE107, DOI 10.1161/01.ATV.20.11.e107; Camerer E, 2002, J BIOL CHEM, V277, P16081, DOI 10.1074/jbc.M108555200; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Cunningham MA, 2000, J EXP MED, V191, P455, DOI 10.1084/jem.191.3.455; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; Darrow AL, 1996, THROMB HAEMOSTASIS, V76, P860; Domotor E, 2003, BLOOD, V101, P4797, DOI 10.1182/blood-2002-12-3680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Esmon CT, 1999, THROMB HAEMOSTASIS, V82, P251; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Esmon CT, 2001, THROMB HAEMOSTASIS, V86, P51; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Fernandez JA, 2003, BLOOD CELL MOL DIS, V30, P271, DOI 10.1016/S1079-9796(03)00034-2; Franscini N, 2004, CIRCULATION, V110, P2903, DOI 10.1161/01.CIR.0000146344.49689.BB; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; Hotchkiss RS, 2002, CRIT CARE MED, V30, pS225, DOI 10.1097/00003246-200205001-00009; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Kataoka H, 2003, BLOOD, V102, P3224, DOI 10.1182/blood-2003-04-1130; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; Liaw PCY, 2001, J BIOL CHEM, V276, P8364, DOI 10.1074/jbc.M010572200; Mosnier LO, 2004, BLOOD, V104, P1740, DOI 10.1182/blood-2004-01-0110; Mosnier LO, 2003, BIOCHEM J, V373, P65, DOI 10.1042/BJ20030341; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pawlinski R, 2004, BLOOD, V103, P1342, DOI 10.1182/blood-2003-09-3051; Perez-Casal M, 2005, BLOOD, V105, P1515, DOI 10.1182/blood-2004-05-1896; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; Riewald M, 2001, BLOOD, V97, P3109, DOI 10.1182/blood.V97.10.3109; Shi XL, 2004, MOL CANCER RES, V2, P395; Uchiba M, 2004, CIRC RES, V95, P34, DOI 10.1161/01.RES.0000133680.87668.FA; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Xu J, 1999, THROMB HAEMOSTASIS, P695; Ye XF, 1999, BIOCHEM BIOPH RES CO, V259, P671, DOI 10.1006/bbrc.1999.0846; Yoon H, 2002, P NATL ACAD SCI USA, V99, P15632, DOI 10.1073/pnas.242597299; Zhang HC, 2001, J MED CHEM, V44, P1021, DOI 10.1021/jm000506s	46	171	184	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19808	19814		10.1074/jbc.M500747200	http://dx.doi.org/10.1074/jbc.M500747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769747	hybrid			2022-12-25	WOS:000229113700047
J	Salaun, C; Gould, GW; Chamberlain, LH				Salaun, C; Gould, GW; Chamberlain, LH			Lipid raft association of SNARE proteins regulates exocytosis in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM NEUROTOXIN E; MEMBRANE-FUSION; PLASMA-MEMBRANE; GLUT4 TRANSLOCATION; SNAP-25; VESICLE; PALMITOYLATION	SNAP25 and SNAP23 are plasma membrane SNARE proteins essential for regulated exocytosis in diverse cell types. Several recent studies have shown that these proteins are partly localized in lipid rafts, domains of the plasma membrane enriched in sphingolipids, and cholesterol. Here, we have employed cysteine mutants of SNAP25/SNAP23, which have modified affinities for raft domains, to examine whether raft association of these proteins is important for the regulation of exocytosis. PC12 cells were engineered that express the light chain of botulinum neurotoxin; in these cells all of the SNAP25 was cleaved to a lower molecular weight form, and regulated exocytosis was essentially absent. Exocytosis was rescued by expressing toxin-resistant SNAP25 or wildtype SNAP23, which is naturally toxin-resistant. Remarkably, a mutant SNAP25 protein with an increased affinity for rafts displayed a reduced ability to support exocytosis, whereas SNAP23 mutants with a decreased affinity for rafts displayed an enhancement of exocytosis when compared with wild-type SNAP23. The effects of the mutant proteins on exocytosis were dependent upon the integrity of the plasma membrane and lipid rafts. These results provide the first direct evidence that rafts regulate SNARE function and exocytosis and identify the central cysteine-rich region of SNAP25/23 as an important regulatory domain.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Henry Wellcome Lab Cell Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Chamberlain, LH (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Henry Wellcome Lab Cell Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	l.chamberlain@bio.gla.ac.uk	Taylor, Graham/A-4027-2012; Gould, Gwyn/AAF-6721-2019	Gould, Gwyn/0000-0001-6571-2875; Salaun, Christine/0000-0003-3002-6810	Biotechnology and Biological Sciences Research Council [C16435] Funding Source: Medline; Wellcome Trust [070835] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Bark C, 2004, J NEUROSCI, V24, P8796, DOI 10.1523/JNEUROSCI.1940-04.2004; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Chamberlain LH, 2004, FEBS LETT, V559, P1, DOI 10.1016/S0014-5793(04)00050-X; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; Gonzalo S, 1999, J BIOL CHEM, V274, P21313, DOI 10.1074/jbc.274.30.21313; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; Graham ME, 2002, ANN NY ACAD SCI, V971, P210, DOI 10.1111/j.1749-6632.2002.tb04465.x; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Koticha DK, 2002, J CELL SCI, V115, P3341; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Liu P, 2004, AM J PHYSIOL-CELL PH, V286, pC317, DOI 10.1152/ajpcell.00073.2003; Macaulay SL, 1997, BIOCHEM BIOPH RES CO, V237, P388, DOI 10.1006/bbrc.1997.7143; Pombo I, 2003, FEBS LETT, V550, P144, DOI 10.1016/S0014-5793(03)00864-0; Sadoul K, 1997, J BIOL CHEM, V272, P33023, DOI 10.1074/jbc.272.52.33023; Salaun C, 2004, TRAFFIC, V5, P255, DOI 10.1111/j.1600-0854.2004.0162.x; Salaun C, 2005, J BIOL CHEM, V280, P1236, DOI 10.1074/jbc.M410674200; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sorensen JB, 2003, CELL, V114, P75, DOI 10.1016/S0092-8674(03)00477-X; Taverna E, 2004, J BIOL CHEM, V279, P5127, DOI 10.1074/jbc.M308798200; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Washbourne P, 1999, J NEUROCHEM, V73, P2424, DOI 10.1046/j.1471-4159.1999.0732424.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xia FZ, 2004, J BIOL CHEM, V279, P24685, DOI 10.1074/jbc.M314314200	32	106	108	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19449	19453		10.1074/jbc.M501923200	http://dx.doi.org/10.1074/jbc.M501923200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769746	Green Accepted, hybrid			2022-12-25	WOS:000229113700005
J	Gioia, U; Laneve, P; Dlakic, M; Arceci, M; Bozzoni, I; Caffarelli, E				Gioia, U; Laneve, P; Dlakic, M; Arceci, M; Bozzoni, I; Caffarelli, E			Functional characterization of XendoU, the endoribonuclease involved in small nucleolar RNA biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRON-ENCODED U16; XENOPUS-LAEVIS; DNA-REPAIR; SNORNA; RECOGNITION; CLEAVAGE; CLONING; MARKER; ENZYME	XendoU is the endoribonuclease involved in the biosynthesis of a specific subclass of Xenopus laevis intron-encoded small nucleolar RNAs. XendoU has no homology to any known cellular RNase, although it has sequence similarity with proteins tentatively annotated as serine proteases. It has been recently shown that XendoU represents the cellular counterpart of a nidovirus replicative endoribonuclease (NendoU), which plays a critical role in viral replication and transcription. In this paper, we combined prediction and experimental data to define the amino acid residues directly involved in XendoU catalysis. Specifically, we find that XendoU residues Glu-161, Glu-167, His-162, His-178, and Lys-224 are essential for RNA cleavage, which occurs in the presence of manganese ions. Furthermore, we identified the RNA sequence required for XendoU binding and showed that the formation of XendoU-RNA complex is Mn2+-independent.	Univ Roma La Sapienza, Dept Genet & Mol Biol, Fdn Cenci Bolognetti, Inst Pasteur, I-00185 Rome, Italy; CNR, Inst Mol Biol & Pathol, I-00185 Rome, Italy; Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA	Fondazione Cenci Bolognetti; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Montana State University System; Montana State University Bozeman	Caffarelli, E (corresponding author), Univ Roma La Sapienza, Dept Genet & Mol Biol, Inst Mol Biol & Pathol, Ple A Moro 5, I-00185 Rome, Italy.	elisa.caffarelli@uniroma1.it	Gioia, Ubaldo/O-1660-2014; Dlakic, Mensur/S-2702-2019; Gioia, Ubaldo/GZL-7436-2022; laneve, pietro/ABD-1633-2020; laneve, pietro/M-3386-2014	Gioia, Ubaldo/0000-0002-4993-5283; Dlakic, Mensur/0000-0003-4315-1514; Gioia, Ubaldo/0000-0002-4993-5283; bozzoni, irene/0000-0002-3485-8537; laneve, pietro/0000-0002-8865-4038	NCRR NIH HHS [P20 RR16455] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016455] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Caffarelli E, 1996, EMBO J, V15, P1121, DOI 10.1002/j.1460-2075.1996.tb00450.x; CAFFARELLI E, 1994, MOL CELL BIOL, V14, P2966, DOI 10.1128/MCB.14.5.2966; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; Dlakic M, 2000, TRENDS BIOCHEM SCI, V25, P272, DOI 10.1016/S0968-0004(00)01582-6; Edgar RC, 2004, BIOINFORMATICS, V20, P1309, DOI 10.1093/bioinformatics/bth091; Fatica A, 2004, RNA, V10, P1698, DOI 10.1261/rna.7123504; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; FRAGAPANE P, 1993, EMBO J, V12, P2921, DOI 10.1002/j.1460-2075.1993.tb05954.x; Giorgi C, 2001, EMBO J, V20, P6856, DOI 10.1093/emboj/20.23.6856; Goodstadt L, 2001, BIOINFORMATICS, V17, P845, DOI 10.1093/bioinformatics/17.9.845; GRUNDMANN U, 1990, DNA CELL BIOL, V9, P243, DOI 10.1089/dna.1990.9.243; Irie M, 1997, J BIOCHEM-TOKYO, V121, P849; Ivanov KA, 2004, P NATL ACAD SCI USA, V101, P12694, DOI 10.1073/pnas.0403127101; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Laneve P, 2003, J BIOL CHEM, V278, P13026, DOI 10.1074/jbc.M211937200; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Mol CD, 1999, ANNU REV BIOPH BIOM, V28, P101, DOI 10.1146/annurev.biophys.28.1.101; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; NISHIKAWA S, 1987, BIOCHEMISTRY-US, V26, P8620, DOI 10.1021/bi00400a019; PRISLEI S, 1995, GENE, V163, P221, DOI 10.1016/0378-1119(95)00344-6; Saida F, 2003, NUCLEIC ACIDS RES, V31, P2751, DOI 10.1093/nar/gkg377; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; STEYAERT J, 1990, BIOCHEMISTRY-US, V29, P9064, DOI 10.1021/bi00490a025; Suck D, 1997, BIOPOLYMERS, V44, P405, DOI 10.1002/(SICI)1097-0282(1997)44:4<405::AID-BIP5>3.0.CO;2-L; THOMPSON JE, 1994, BIOCHEMISTRY-US, V33, P7408, DOI 10.1021/bi00189a047; Tsujishita Y, 2001, CELL, V105, P379, DOI 10.1016/S0092-8674(01)00326-9	30	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18996	19002		10.1074/jbc.M501160200	http://dx.doi.org/10.1074/jbc.M501160200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755742	hybrid			2022-12-25	WOS:000228932300054
J	Larsen, R; Kok, J; Kuipers, OP				Larsen, R; Kok, J; Kuipers, OP			Interaction between ArgR and AhrC controls regulation of arginine metabolism in Lactococcus lactis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; DNA-BINDING; BACILLUS-STEAROTHERMOPHILUS; OPERATOR INTERACTIONS; REPRESSOR; GENE; PROTEIN; EXPRESSION; SEQUENCE; PLASMID	The expression of arginine metabolism in Lactococcus lactis is controlled by the two homologous transcriptional regulators ArgR and AhrC. Genome sequence analyses have shown that the occurrence of multiple homologues of the ArgR family of transcriptional regulators is a common feature of many low-G + C Gram-positive bacteria. Detailed studies of ArgR type regulators have previously only been carried out in bacteria containing single regulators. Here, we present a first characterization of the two L. lactis arginine regulators by means of gel retardation and DNase I footprinting. ArgR of L. lactis was shown to bind to the promoter regions of both the arginine biosynthetic argCJDBF operon and the arginine catabolic arcABD1C1C2TD2yvaD operon, but in an arginine-independent manner. Surprisingly, AhrC alone was unable to bind to DNA. Arginine-dependent DNA binding was obtained by mixing the two regulators in gel retardation assays. With both regulators present, the addition of arginine led to increased binding of ArgR-AhrC to the biosynthetic argC promoter but also to diminished binding to the catabolic arcA promoter. Footprinting showed ArgR-AhrC protection of regions containing ARG box operator sequences preceding argC. In the absence of AhrC, ArgR protected sites in the arcA promoter region with similarity to ARG box half-sites, here called ARC boxes. We propose a model for repression of arginine biosynthesis and activation of catabolism by anti-repression, involving arginine-dependent interaction between the two L. lactis regulator proteins, ArgR and AhrC.	Univ Groningen, Dept Mol Genet, NL-9751 NN Haren, Netherlands	University of Groningen	Kuipers, OP (corresponding author), Univ Groningen, Dept Mol Genet, Kerklaan 30, NL-9751 NN Haren, Netherlands.	O.P.Kuipers@rug.nl	Larsen, Rasmus/I-9204-2012; Kok, Jan/C-9972-2012; Kuipers, Oscar/B-6752-2009	Kuipers, Oscar/0000-0001-5596-7735				Archibald RM, 1944, J BIOL CHEM, V156, P121; Barcelona-Andres B, 2002, J BACTERIOL, V184, P6289, DOI 10.1128/JB.184.22.6289-6300.2002; Belitsky, 2001, BACILLUS SUBTILIS IT, P203; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE M, 1994, MOL MICROBIOL, V13, P609, DOI 10.1111/j.1365-2958.1994.tb00455.x; CHARLIER D, 1992, J MOL BIOL, V226, P367, DOI 10.1016/0022-2836(92)90953-H; Chen SH, 1997, MOL MICROBIOL, V24, P1143, DOI 10.1046/j.1365-2958.1997.4301791.x; CZAPLEWSKI LG, 1992, MOL MICROBIOL, V6, P267, DOI 10.1111/j.1365-2958.1992.tb02008.x; Dennis CA, 2002, ACTA CRYSTALLOGR D, V58, P421, DOI 10.1107/S0907444901021692; Dimova D, 2000, MOL GEN GENET, V263, P119, DOI 10.1007/PL00008670; Dion M, 1997, MOL MICROBIOL, V25, P385, DOI 10.1046/j.1365-2958.1997.4781845.x; EBBOLE DJ, 1989, J BIOL CHEM, V264, P3553; GARDAN R, 1995, J MOL BIOL, V249, P843, DOI 10.1006/jmbi.1995.0342; GASSON MJ, 1983, J BACTERIOL, V154, P1; Hamoen LW, 1998, GENE DEV, V12, P1539, DOI 10.1101/gad.12.10.1539; Holo H, 1995, Methods Mol Biol, V47, P195; JOHANSEN E, 1992, PLASMID, V27, P200, DOI 10.1016/0147-619X(92)90022-3; Kleerebezem M, 2003, CURR OPIN BIOTECH, V14, P232, DOI 10.1016/S0958-1669(03)00033-8; KLINGEL U, 1995, MOL GEN GENET, V248, P329, DOI 10.1007/BF02191600; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; Kunji ERS, 1996, MOL MICROBIOL, V21, P123, DOI 10.1046/j.1365-2958.1996.6231339.x; Larsen R, 2004, J BACTERIOL, V186, P1147, DOI 10.1128/JB.186.4.1147-1157.2004; Leenhouts K, 1998, APPL MICROBIOL BIOT, V49, P417, DOI 10.1007/s002530051192; LIM D, 1987, P NATL ACAD SCI USA, V84, P6697, DOI 10.1073/pnas.84.19.6697; LU CD, 1992, J MOL BIOL, V225, P11, DOI 10.1016/0022-2836(92)91022-H; MAAS WK, 1994, MICROBIOL REV, V58, P631, DOI 10.1128/MMBR.58.4.631-640.1994; MAGUIN E, 1992, J BACTERIOL, V174, P5633, DOI 10.1128/JB.174.17.5633-5638.1992; Makarova KS, 2001, GENOME BIOL, V2; Miller CM, 1997, MOL MICROBIOL, V26, P37, DOI 10.1046/j.1365-2958.1997.5441907.x; Morin A, 2003, J MOL BIOL, V332, P537, DOI 10.1016/S0022-2836(03)00951-3; Ni JP, 1999, NAT STRUCT BIOL, V6, P427; Nicoloff H, 2004, J BACTERIOL, V186, P6059, DOI 10.1128/JB.186.18.6059-6069.2004; RodriguezGarcia A, 1997, MOL MICROBIOL, V25, P219, DOI 10.1046/j.1365-2958.1997.4511815.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Song H, 2002, J MOL BIOL, V315, P255, DOI 10.1006/jmbi.2001.5236; Sunnerhagen M, 1997, NAT STRUCT BIOL, V4, P819, DOI 10.1038/nsb1097-819; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; TIAN GL, 1994, MOL MICROBIOL, V13, P599, DOI 10.1111/j.1365-2958.1994.tb00454.x; TIAN GL, 1992, J MOL BIOL, V226, P387, DOI 10.1016/0022-2836(92)90954-I; VanDuyne GD, 1996, J MOL BIOL, V256, P377, DOI 10.1006/jmbi.1996.0093; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	43	36	38	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19319	19330		10.1074/jbc.M413983200	http://dx.doi.org/10.1074/jbc.M413983200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15749710	Green Published, hybrid			2022-12-25	WOS:000228932300089
J	Roux, J; Kawakatsu, H; Gartland, B; Pespeni, M; Sheppard, D; Matthay, MA; Canessa, CM; Pittet, JF				Roux, J; Kawakatsu, H; Gartland, B; Pespeni, M; Sheppard, D; Matthay, MA; Canessa, CM; Pittet, JF			Interleukin-1 beta decreases expression of the epithelial sodium channel alpha-subunit in alveolar epithelial cells via a p38 MAPK-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS-SYNDROME; ACTIVATED PROTEIN-KINASE; SENSITIVE NA+ CHANNEL; LUNG LIQUID CLEARANCE; COLLECTING DUCT CELLS; NECROSIS-FACTOR-ALPHA; FLUID TRANSPORT; II CELLS; MESSENGER-RNA; IN-VITRO	Acute lung injury (ALI) is a devastating syndrome characterized by diffuse alveolar damage, elevated airspace levels of pro-inflammatory cytokines, and flooding of the alveolar spaces with protein-rich edema fluid. Interleukin-1 beta (IL-1 beta) is one of the most biologically active cytokines in the distal airspaces of patients with ALI. IL-1 beta has been shown to increase lung epithelial and endothelial permeability. In this study, we hypothesized that IL-1 beta would decrease vectorial ion and water transport across the distal lung epithelium. Therefore, we measured the effects of IL-1 beta on transepithelial current, resistance, and sodium transport in primary cultures of alveolar epithelial type II (ATII) cells. IL-1 beta significantly reduced the amiloride-sensitive fraction of the transepithelial current and sodium transport across rat ATII cell monolayers. Moreover, IL-1 beta decreased basal and dexamethasone-induced epithelial sodium channel alpha-subunit (alpha ENaC) mRNA levels and total and cell-surface protein expression. The inhibitory effect of IL-1 beta on alpha ENaC expression was mediated by the activation of p38 MAPK in both rat and human ATII cells and was independent of the activation of alpha v beta 6 integrin and transforming growth factor-beta. These results indicate that IL-1 beta may contribute to alveolar edema in ALI by reducing distal lung epithelial sodium absorption. This reduction in ion and water transport across the lung epithelium is in large part due to a decrease in alpha ENaC expression through p38 MAPK-dependent inhibition of alpha ENaC promoter activity and to an alteration in ENaC trafficking to the apical membrane of ATII cells.	Univ Calif San Francisco, Surg Res Lab, San Francisco, CA 94110 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94110 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Yale University	Pittet, JF (corresponding author), San Francisco Gen Hosp, Dept Anesthesia, Rm 3C-38,1001 Potrero Ave, San Francisco, CA 94110 USA.	pittetj@anesthesia.ucsf.edu	Roux, Jeremie/A-9746-2013	Roux, Jeremie/0000-0001-5712-8660	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051854, P50HL074005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062188] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51854, P50HL074005] Funding Source: Medline; NIGMS NIH HHS [R01GM62188] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adir Y, 2003, AM J RESP CRIT CARE, V168, P1445, DOI 10.1164/rccm.200207-702OC; Baines DL, 2000, J PHYSIOL-LONDON, V522, P147, DOI 10.1111/j.1469-7793.2000.t01-2-00147.xm; Barker PM, 1998, J CLIN INVEST, V102, P1634, DOI 10.1172/JCI3971; Barmeyer C, 2004, BIOCHEM BIOPH RES CO, V317, P500, DOI 10.1016/j.bbrc.2004.03.072; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; Benito E, 1998, MOL CELL BIOCHEM, V189, P169, DOI 10.1023/A:1006997731607; Blazer-Yost BL, 1998, AM J PHYSIOL-CELL PH, V274, pC1373, DOI 10.1152/ajpcell.1998.274.5.C1373; BREUSS JM, 1995, J CELL SCI, V108, P2241; BREUSS JM, 1993, J HISTOCHEM CYTOCHEM, V41, P1521, DOI 10.1177/41.10.8245410; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Chen XJ, 2002, AM J PHYSIOL-LUNG C, V282, pL609, DOI 10.1152/ajplung.00356.2001; Cui CH, 2002, AM J RESP CELL MOL, V27, P329, DOI 10.1165/rcmb.4762; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Dagenais A, 2001, AM J PHYSIOL-LUNG C, V281, pL217, DOI 10.1152/ajplung.2001.281.1.L217; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; DOBBS LG, 1990, AM J PHYSIOL, V258, pL134, DOI 10.1152/ajplung.1990.258.4.L134; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; Fang XH, 2004, AM J PHYSIOL-LUNG C, V287, pL104, DOI 10.1152/ajplung.00176.2003; Frank J, 2003, J BIOL CHEM, V278, P43939, DOI 10.1074/jbc.M304882200; Furuichi S, 2002, RESPIROLOGY, V7, P193, DOI 10.1046/j.1440-1843.2002.00401.x; Galietta LJV, 2002, J IMMUNOL, V168, P839, DOI 10.4049/jimmunol.168.2.839; Geiser T, 2000, AM J PHYSIOL-LUNG C, V279, pL1184, DOI 10.1152/ajplung.2000.279.6.L1184; Gray T, 2004, AM J PHYSIOL-LUNG C, V286, pL320, DOI 10.1152/ajplung.00440.2002; Hashimoto S, 1999, AM J RESP CRIT CARE, V159, P634, DOI 10.1164/ajrccm.159.2.9712090; Huang XZ, 1998, J CELL SCI, V111, P2189; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Hybertson BM, 2000, INFLAMMATION, V24, P289, DOI 10.1023/A:1007092529261; Itani OA, 2003, AM J PHYSIOL-RENAL, V284, pF778, DOI 10.1152/ajprenal.00088.2002; Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646, DOI 10.1152/ajplung.2001.280.4.L646; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Laffon M, 1999, AM J PHYSIOL-LUNG C, V277, pL760, DOI 10.1152/ajplung.1999.277.4.L760; Lee YM, 2000, AM J PHYSIOL-LUNG C, V279, pL75, DOI 10.1152/ajplung.2000.279.1.L75; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; Mairbaurl H, 1997, AM J PHYSIOL-LUNG C, V273, pL797, DOI 10.1152/ajplung.1997.273.4.L797; MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250; McDonald FJ, 1999, P NATL ACAD SCI USA, V96, P1727, DOI 10.1073/pnas.96.4.1727; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Norlin A, 1999, J PHYSIOL-LONDON, V519, P261, DOI 10.1111/j.1469-7793.1999.0261o.x; Olman MA, 2004, J IMMUNOL, V172, P2668, DOI 10.4049/jimmunol.172.4.2668; Otulakowski G, 1999, AM J RESP CELL MOL, V20, P1028, DOI 10.1165/ajrcmb.20.5.3382; Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963; Pittet JF, 2001, J IMMUNOL, V166, P6301, DOI 10.4049/jimmunol.166.10.6301; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Pugin J, 1996, AM J RESP CRIT CARE, V153, P1850, DOI 10.1164/ajrccm.153.6.8665045; Pugin J, 1999, CRIT CARE MED, V27, P304, DOI 10.1097/00003246-199902000-00036; RENARD S, 1995, PFLUG ARCH EUR J PHY, V430, P299, DOI 10.1007/BF00373903; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; Stokes JB, 1998, AM J PHYSIOL-CELL PH, V274, pC1699, DOI 10.1152/ajpcell.1998.274.6.C1699; SUZUKI S, 1995, AM J PHYSIOL-LUNG C, V268, pL983, DOI 10.1152/ajplung.1995.268.6.L983; TCHEPICHEV S, 1995, AM J PHYSIOL, V269, P805; TIBALLI RN, 1995, J CLIN MICROBIOL, V33, P915, DOI 10.1128/JCM.33.4.915-917.1995; Towne JE, 2004, J BIOL CHEM, V279, P13677, DOI 10.1074/jbc.M400117200; Wang X, 2004, MOL PSYCHIATR, V9, P65, DOI 10.1038/sj.mp.4001339; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Ware LB, 2002, LANCET, V360, P619, DOI 10.1016/S0140-6736(02)09774-X; Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035; Webster JC, 2001, P NATL ACAD SCI USA, V98, P6865, DOI 10.1073/pnas.121455098; WEINACKER A, 1995, AM J RESP CELL MOL, V12, P547, DOI 10.1165/ajrcmb.12.5.7537970; ZEIDEL ML, 1991, AM J PHYSIOL, V261, pF1013, DOI 10.1152/ajprenal.1991.261.6.F1013	61	141	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18579	18589		10.1074/jbc.M410561200	http://dx.doi.org/10.1074/jbc.M410561200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755725	hybrid			2022-12-25	WOS:000228932300006
J	Gemmill, RM; Lee, JP; Chamovitz, DA; Segal, D; Hooper, JE; Drabkin, HA				Gemmill, RM; Lee, JP; Chamovitz, DA; Segal, D; Hooper, JE; Drabkin, HA			Growth suppression induced by the TRC8 hereditary kidney cancer gene is dependent upon JAB1/CSN5	ONCOGENE			English	Article						TRC8; CSN5; CSN6; CSN7; VHL; Cul-1; NEDD8; COP9 signalosome; Drosophila	MODULATE AP-1 ACTIVITY; COP9 SIGNALOSOME; CELL-CYCLE; DROSOPHILA-MELANOGASTER; TRANSLOCATION; CARCINOMA; DEGRADATION; SUBCOMPLEX; P27(KIP1); CLEAVAGE	TRC8 encodes an E3-ubiquitin ligase disrupted in a family with hereditary renal cell carcinoma (RCC). We previously reported that Drosophila Trc8 (DTrc8) overexpression inhibits growth and that human and fly proteins interact with with the COP9 signalosome (CSN) subunit JAB1/CSN5. However, further mechanistic evidence linking DTrc8 growth suppression to CSN5 was lacking. Here, we show that haploinsufficiency of CSN5, or a T100I point mutation (CSN5(3)), relieved growth suppression by DTrc8, whereas CSN5(1) (E160V) and CSN5(2) (G147D) mutations had no effect. The strength of yeast two-hybrid interactions between DTrc8 and CSN5 were in complete agreement with the observed phenotypes. DTrc8 overexpression resulted in elevated levels of CSN5 and CSN7, but had no effect on NEDD8-modified Cul-1. In contrast to CSN5, heterozygosity for CSN4(null) had no effect on the DTrc8 phenotype. We also looked for genetic interactions between DTrc8 and other MPN domain proteins in the CSN and 26S proteasome lid. CSN6 haploinsufficiency restored growth, whereas reduction of proteasome subunits RPN8 or RPN11 had no effect. DTrc8 expression increased the level of digitonin-extractable CSN complex, consistent with elevated levels of CSN5 and 7. Our genetic results confirm that DTrc8-induced growth suppression is CSN5 (and CSN6) dependent. While there was no obvious influence on CSN deneddylation activity, the increase in CSN subunits and holocomplex suggests that TRC8 modulates signalosome levels or compartmentalization.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Aurora, CO 80010 USA; Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel; Univ Colorado, Hlth Sci Ctr, Dept Cellular & Dev Biol, Aurora, CO 80010 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Tel Aviv University; Tel Aviv University; University of Colorado System; University of Colorado Anschutz Medical Campus	Gemmill, RM (corresponding author), Univ Colorado, Fitzsimons Army Med Ctr, Hlth Sci Ctr, MailStop 8117,POB 6511,12801 E 17th Ave, Aurora, CO 80045 USA.	robert.gemmill@uchsc.edu	Chamovitz, Daniel/S-5021-2019	Chamovitz, Daniel/0000-0002-2815-2909; Segal, Daniel/0000-0002-6777-505X	NATIONAL CANCER INSTITUTE [R01CA076035] Funding Source: NIH RePORTER; NCI NIH HHS [CA76035] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Chamovitz DA, 2002, CURR BIOL, V12, pR232, DOI 10.1016/S0960-9822(02)00775-3; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Freilich S, 1999, CURR BIOL, V9, P1187, DOI 10.1016/S0960-9822(00)80023-8; Gemmill RM, 2002, ONCOGENE, V21, P3507, DOI 10.1038/sj.onc.1205437; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; Mundt KE, 2002, MOL BIOL CELL, V13, P493, DOI 10.1091/mbc.01-10-0521; Oron E, 2002, DEVELOPMENT, V129, P4399; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Suh GSB, 2002, NEURON, V33, P35, DOI 10.1016/S0896-6273(01)00576-1; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tomoda K, 2005, BLOOD, V105, P775, DOI 10.1182/blood-2004-04-1242; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449	23	10	12	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 12	2005	24	21					3503	3511		10.1038/sj.onc.1208509	http://dx.doi.org/10.1038/sj.onc.1208509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735686				2022-12-25	WOS:000229038800012
J	Fuzesi, M; Gottschalk, KE; Lindzen, M; Shainskaya, A; Kuster, B; Garty, H; Karlish, SJD				Fuzesi, M; Gottschalk, KE; Lindzen, M; Shainskaya, A; Kuster, B; Garty, H; Karlish, SJD			Covalent cross-links between the gamma subunit (FXYD2) and alpha and beta subunits of Na,K-ATPase - Modeling the alpha-gamma interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL NA,K-ATPASE; FUNCTIONAL INTERACTION; STRUCTURE PREDICTION; CALCIUM-PUMP; NA/K-ATPASE; PROTEIN; CLEAVAGE; TRANSPORT; SITES; NA+,K+-ATPASE	This study describes specific intramolecular covalent cross-linking of the gamma to alpha and gamma to beta subunits of pig kidney Na,K-ATPase and rat gamma to alpha co-expressed in HeLa cells. For this purpose pig gamma a and gamma b sequences were determined by cloning and mass spectrometry. Three bifunctional reagents were used: N-hydroxysuccinimidyl-4-azidosalicylic acid (NHS-ASA), disuccinimidyl tartrate (DST), and 1-ethyl-3-[3dimethylaminopropyl]carbodiimide (EDC). NHS-ASA induced alpha-gamma, DST induced alpha-gamma and beta-gamma, and EDC induced primarily beta-gamma cross-links. Specific proteolytic and Fe2+-catalyzed cleavages located NHS-ASA- and DST-induced alpha-gamma cross- links on the cytoplasmic surface of the alpha subunit, downstream of His(283) and upstream of Val(440). Additional considerations indicated that the DST-induced and NHS-ASA-induced cross-links involve either Lys(347) or Lys(352) in the S4 stalk segment. Mutational analysis of the rat gamma subunit expressed in HeLa cells showed that the DST-induced cross-link involves Lys(55) and Lys(56) in the cytoplasmic segment. DST and EDC induced two beta-gamma cross-links, a major one at the extracellular surface within the segment Gly(143)-Ser(302) of the beta subunit and another within Ala(1)-Arg(142). Based on the cross- linking and other data on alpha-gamma proximities, we modeled interactions of the transmembrane alpha-helix and an unstructured cytoplasmic segment SKRLRCG-GKKHR of gamma with a homology model of the pig alpha 1 subunit. According to the model, the transmembrane segment fits in a groove between M2, M6, and M9, and the cytoplasmic segment interacts with loops L6/7 and L8/9 and stalk S5.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Biol Mass Spectrometry Facil, IL-76100 Rehovot, Israel; Univ So Denmark, Prot Interact Lab, DK-5230 Odense, Denmark	Weizmann Institute of Science; Weizmann Institute of Science; University of Southern Denmark	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	steven.karlish@weizmann.ac.il	Gottschalk, Kay/D-6503-2012; Kuster, Bernhard/Q-6031-2016	Gottschalk, Kay/0000-0002-7951-0972; Kuster, Bernhard/0000-0002-9094-1677				Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Arystarkhova E, 2002, J BIOL CHEM, V277, P10162, DOI 10.1074/jbc.M111552200; Arystarkhova E, 2002, AM J PHYSIOL-RENAL, V282, pF393, DOI 10.1152/ajprenal.00146.2001; Asahi M, 2001, P NATL ACAD SCI USA, V98, P10061, DOI 10.1073/pnas.181348298; Bar Shimon M, 1998, J BIOL CHEM, V273, P34190, DOI 10.1074/jbc.273.51.34190; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; Cornelius F, 2003, NEWS PHYSIOL SCI, V18, P119, DOI 10.1152/nips.01434.2003; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; CRAMBERT G, 2003, SCI STKE, pRE1; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; Eswar N, 2003, NUCLEIC ACIDS RES, V31, P3375, DOI 10.1093/nar/gkg543; Feschenko MS, 2003, J NEUROSCI, V23, P2161; Garty H, 2003, ANN NY ACAD SCI, V986, P395, DOI 10.1111/j.1749-6632.2003.tb07220.x; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; GARTY H, 2005, IN PRESS SEMIN NEPHR; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; Gottschalk KE, 2004, J MOL GRAPH MODEL, V23, P99, DOI 10.1016/j.jmgm.2004.02.002; Gottschalk KE, 2004, BIOPHYS J, V86, P3335, DOI 10.1529/biophysj.103.034546; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; Karlish SJD, 2003, ANN NY ACAD SCI, V986, P39, DOI 10.1111/j.1749-6632.2003.tb07137.x; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; Li CM, 2004, J BIOL CHEM, V279, P38895, DOI 10.1074/jbc.M406697200; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lindzen M, 2003, ANN NY ACAD SCI, V986, P530, DOI 10.1111/j.1749-6632.2003.tb07242.x; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; Montigny C, 2004, J BIOL CHEM, V279, P43971, DOI 10.1074/jbc.M407142200; Or E, 1996, BIOCHEMISTRY-US, V35, P6853, DOI 10.1021/bi960093q; Or E, 1998, BIOCHEMISTRY-US, V37, P8197, DOI 10.1021/bi9730442; PARK LS, 1986, J BIOL CHEM, V261, P205; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; van Gunsteren W. F., 1998, ENCY COMPUTATIONAL C, V2, P1211, DOI DOI 10.1002/0470845015.CGA011; VANDERHORST GTJ, 1990, J BIOL CHEM, V265, P10801; Wang SG, 1998, J BIOL CHEM, V273, P29400, DOI 10.1074/jbc.273.45.29400; Zouzoulas A, 2003, J BIOL CHEM, V278, P40437, DOI 10.1074/jbc.M308610200	57	27	28	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18291	18301		10.1074/jbc.M500080200	http://dx.doi.org/10.1074/jbc.M500080200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15743768	hybrid			2022-12-25	WOS:000228807200088
J	Meigs, TE; Juneja, J; DeMarco, CT; Stemmle, LN; Kaplan, DD; Casey, PJ				Meigs, TE; Juneja, J; DeMarco, CT; Stemmle, LN; Kaplan, DD; Casey, PJ			Selective uncoupling of G alpha(12) from rho-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS FIBER FORMATION; LEUKEMIA-ASSOCIATED RHOGEF; HETEROTRIMERIC G-PROTEINS; SERUM RESPONSE ELEMENT; ALPHA-SUBUNIT; CYTOPLASMIC DOMAIN; POINT MUTATION; P115 RHOGEF; ACTIVATION; EXCHANGE	The heterotrimeric G protein G(12) has been implicated in such cellular regulatory processes as cytoskeletal rearrangement, cell-cell adhesion, and oncogenic transformation. Although the activated alpha-subunit of G(12) has been shown to interact directly with a number of protein effectors, the roles of many of these protein-protein interactions in G(12)-mediated cell physiology are poorly understood. To begin dissecting the specific cellular pathways engaged upon G(12) activation, we produced a series of substitution mutants in the regions of G alpha(12) predicted to play a role in effector binding. Here we report the identification and characterization of an altered form of G alpha(12) that is functionally uncoupled from signaling through the monomeric G protein Rho, a protein known to propagate several G alpha(12)-mediated signals. This mutant of G alpha(12) fails to bind the Rho-specific guanine nucleotide exchange factors p115RhoGEF and LARG (leukemia-associated RhoGEF), fails to stimulate Rho-dependent transcriptional activation, and fails to trigger activation of RhoA and the Rho-mediated cellular responses of cell rounding and c-jun N-terminal kinase activation. Importantly, this mutant of G alpha(12) retains coupling to the effector protein E-cadherin, as evidenced by its ability both to bind E-cadherin in vitro and to disrupt E-cadherin-mediated cell-cell adhesion. Furthermore, this mutant retains the ability to trigger beta-catenin release from the cytoplasmic domain of cadherin. This identification of a variant of G alpha(12) that is selectively uncoupled from one signaling pathway while retaining signaling capacity through a separate pathway will facilitate investigations into the mechanisms through which G(12) proteins mediate diverse biological responses.	Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol, Box 3813, Durham, NC 27710 USA.	casey006@mc.duke.edu		Casey, Patrick/0000-0002-7366-9309; Kaplan, Daniel/0000-0001-8297-560X	NCI NIH HHS [CA100869] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100869] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; Barnes WG, 2005, J BIOL CHEM, V280, P8041, DOI 10.1074/jbc.M412924200; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Dermott JM, 2001, J CELL BIOCHEM, V81, P1; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Kaplan DD, 2001, J BIOL CHEM, V276, P44037, DOI 10.1074/jbc.M106121200; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Meigs TE, 2002, J BIOL CHEM, V277, P24594, DOI 10.1074/jbc.M201984200; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Meyer TN, 2002, J BIOL CHEM, V277, P24855, DOI 10.1074/jbc.C200240200; Nakamura S, 2004, MOL PHARMACOL, V66, P1029, DOI 10.1124/mol.104.002287; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WILSON IA, 1985, P NATL ACAD SCI USA, V82, P5255, DOI 10.1073/pnas.82.16.5255; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	38	28	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18049	18055		10.1074/jbc.M500445200	http://dx.doi.org/10.1074/jbc.M500445200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746095	hybrid			2022-12-25	WOS:000228807200061
J	Moss, CX; Matthews, SP; Lamont, DJ; Watts, C				Moss, CX; Matthews, SP; Lamont, DJ; Watts, C			Asparagine deamidation perturbs antigen presentation on class II major histocompatibility complex molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; T-CELL RECOGNITION; TETANUS TOXIN; TISSUE TRANSGLUTAMINASE; CELIAC-DISEASE; H-C; ENDOPEPTIDASE; PEPTIDES; FRAGMENT; BINDING	Post-translational protein modifications can be recognized by B and T lymphocytes and can potentially make "self"-proteins appear foreign to the immune system. Such modifications may directly affect major histocompatibility complex-restricted T cell recognition of processed peptides or may perturb the processing events that generate such peptides. Using the tetanus toxin C fragment protein as a test case, we show that spontaneous deamidation of asparagine residues interferes with processing by the enzyme asparagine endopeptidase (AEP) and contributes to diminished antigen presentation. Deamidation inhibits AEP action either directly, when asparagine residues targeted by AEP are modified, or indirectly, when adjacent Asn residues are deamidated. Thus, deamidation of long-lived self-proteins may qualitatively or quantitatively affect the spectrum of self-peptides displayed to T cells and may thereby contribute to the onset or exacerbation of autoimmune disease.	Univ Dundee, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland; Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Watts, C (corresponding author), Univ Dundee, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland.	c.watts@dundee.ac.uk		Watts, Colin/0000-0001-6183-2087; Matthews, Stephen/0000-0003-3556-962X				Antoniou AN, 2000, IMMUNITY, V12, P391, DOI 10.1016/S1074-7613(00)80191-0; Arentz-Hansen H, 2000, J EXP MED, V191, P603, DOI 10.1084/jem.191.4.603; Beck H, 2001, EUR J IMMUNOL, V31, P3726, DOI 10.1002/1521-4141(200112)31:12<3726::AID-IMMU3726>3.0.CO;2-O; Casciola-Rosen L, 1999, J EXP MED, V190, P815, DOI 10.1084/jem.190.6.815; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Chen WS, 1996, J IMMUNOL, V157, P1000; Cirrito TP, 2001, J EXP MED, V194, P1165, DOI 10.1084/jem.194.8.1165; Dando PM, 1999, BIOCHEM J, V339, P743, DOI 10.1042/0264-6021:3390743; DAUMY GO, 1991, FEBS LETT, V278, P98, DOI 10.1016/0014-5793(91)80093-I; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Doyle HA, 2001, TRENDS IMMUNOL, V22, P443, DOI 10.1016/S1471-4906(01)01976-7; Emsley P, 2000, J BIOL CHEM, V275, P8889, DOI 10.1074/jbc.275.12.8889; Fotinou C, 2001, J BIOL CHEM, V276, P32274, DOI 10.1074/jbc.M103285200; GEIGER T, 1987, J BIOL CHEM, V262, P785; HALLAHAN TW, 1992, BIOCHEMISTRY-US, V31, P8022, DOI 10.1021/bi00149a036; Herreros J, 2000, BIOCHEM J, V347, P199, DOI 10.1042/0264-6021:3470199; Hewitt EW, 1997, J IMMUNOL, V159, P4693; Mamula MJ, 1999, J BIOL CHEM, V274, P22321, DOI 10.1074/jbc.274.32.22321; Manoury B, 2003, IMMUNITY, V18, P489, DOI 10.1016/S1074-7613(03)00085-2; Manoury B, 2002, NAT IMMUNOL, V3, P169, DOI 10.1038/ni754; Manoury B, 1998, NATURE, V396, P695, DOI 10.1038/25379; McAdam SN, 2001, J EXP MED, V193, P1239, DOI 10.1084/jem.193.11.1239; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Ni DTN, 2003, J BIOL CHEM, V278, P38980, DOI 10.1074/jbc.M305930200; Robinson NE, 2004, J PEPT RES, V63, P426, DOI 10.1111/j.1399-3011.2004.00151.x; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P4367, DOI 10.1073/pnas.071066498; Saric T, 2001, J BIOL CHEM, V276, P36474, DOI 10.1074/jbc.M105517200; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; TESHIMA G, 1991, BIOCHEMISTRY-US, V30, P3916, DOI 10.1021/bi00230a016; Umland TC, 1997, NAT STRUCT BIOL, V4, P788, DOI 10.1038/nsb1097-788; Watts C, 2004, NAT IMMUNOL, V5, P685, DOI 10.1038/ni1088; Watts C, 2003, ANN NY ACAD SCI, V987, P9, DOI 10.1111/j.1749-6632.2003.tb06028.x; West MA, 2004, SCIENCE, V305, P1153, DOI 10.1126/science.1099153; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	34	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18498	18503		10.1074/jbc.M501241200	http://dx.doi.org/10.1074/jbc.M501241200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749706	hybrid			2022-12-25	WOS:000228807200113
J	Gomez, MD; Nasi, E				Gomez, MD; Nasi, E			A direct signaling role for phosphatidylinositol 4,5-bisphosphate (PIP2) in the visual excitation process of microvillar receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMULUS VENTRAL PHOTORECEPTORS; LIGHT-SENSITIVE CHANNELS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; PDZ-DOMAIN PROTEIN; K-ATP CHANNELS; DROSOPHILA PHOTORECEPTORS; INVERTEBRATE PHOTORECEPTORS; RHABDOMERIC PHOTORECEPTORS; INTRACELLULAR INJECTION; POTASSIUM CHANNELS	In microvillar photoreceptors the pivotal role of phospholipase C in light transduction is undisputed, but previous attempts to account for the photoresponse solely in terms of downstream products of phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis have proved wanting. In other systems PIP2 has been shown to possess signaling functions of its own, rather than simply serving as a precursor molecule. Because illumination of microvillar photoreceptors cells leads to PIP2 breakdown, a potential role for this phospholipid in phototransduction would be to help maintain some element(s) of the transduction cascade in the inactive state. We tested the effect of intracellular dialysis of PIP2 on voltage-clamped molluscan photoreceptors and found a marked reduction in the amplitude of the photocurrent; by contrast, depolarization-activated calcium and potassium currents were unaffected, thus supporting the notion of a specific effect on light signaling. In the dark, PIP2 caused a gradual outward shift of the holding current; this change was due to a decrease in membrane conductance and may reflect the suppression of basal openings of the light-sensitive conductance. The consequences of depleting PIP2 were examined in patches of light-sensitive microvillar membrane screened for the exclusive presence of light-activated ion channels. After excision, superfusion with anti-PIP2 antibodies induced the appearance of single-channel currents. Replenishment of PIP2 by exogenous application reverted the effect. These data support the notion that PIP2, in addition to being the source of inositol trisphosphate and diacylglycerol, two messengers of visual excitation, may also participate in a direct fashion in the control of the light-sensitive conductance.	Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Marine Biol Lab, Woods Hole, MA 02543 USA	Boston University; Marine Biological Laboratory - Woods Hole	Gomez, MD (corresponding author), Boston Univ, Sch Med, Dept Physiol & Biophys, 715 Albany St, Boston, MA 02118 USA.	mpgomez@bu.edu			NEI NIH HHS [EY07559] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007559] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; BAER KM, 1988, J BIOL CHEM, V263, P17; Bahner M, 2002, NEURON, V34, P83, DOI 10.1016/S0896-6273(02)00630-X; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BAYLOR DA, 1987, INVEST OPHTH VIS SCI, V28, P34; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOLSOVER SR, 1985, J PHYSIOL-LONDON, V364, P381, DOI 10.1113/jphysiol.1985.sp015751; BROWN HM, 1971, FED PROC, V30, P69; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; BROWN JE, 1974, J GEN PHYSIOL, V64, P643, DOI 10.1085/jgp.64.6.643; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Cook B, 1999, CELL CALCIUM, V25, P161, DOI 10.1054/ceca.1998.0018; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DEVARY O, 1987, P NATL ACAD SCI USA, V84, P6939, DOI 10.1073/pnas.84.19.6939; Estacion M, 2001, J PHYSIOL-LONDON, V530, P1, DOI 10.1111/j.1469-7793.2001.0001m.x; FADDIS MN, 1993, J GEN PHYSIOL, V101, P909, DOI 10.1085/jgp.101.6.909; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FEIN A, 1984, NATURE, V311, P157, DOI 10.1038/311157a0; Fein A, 2000, VISUAL NEUROSCI, V17, P911, DOI 10.1017/S0952523800176102; FRANK TM, 1991, J GEN PHYSIOL, V97, P697, DOI 10.1085/jgp.97.4.697; Gomez MD, 1998, J NEUROSCI, V18, P5253, DOI 10.1523/JNEUROSCI.18-14-05253.1998; Gomez MD, 2001, BIOPHYS J, V80, p606A; Gomez MD, 1996, J GEN PHYSIOL, V107, P715, DOI 10.1085/jgp.107.6.715; Hardie RC, 2004, J BIOL CHEM, V279, P47773, DOI 10.1074/jbc.M407525200; HARDIE RC, 1995, J NEUROSCI, V15, P889; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; Hardie RC, 2001, NEURON, V30, P149, DOI 10.1016/S0896-6273(01)00269-0; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Irvine R, 2004, CURR BIOL, V14, pR308, DOI 10.1016/j.cub.2004.03.051; Kaznacheyeva E, 2000, J BIOL CHEM, V275, P4561, DOI 10.1074/jbc.275.7.4561; Lee SJ, 2004, P NATL ACAD SCI USA, V101, P11874, DOI 10.1073/pnas.0402205101; LISMAN JE, 1975, J GEN PHYSIOL, V66, P489, DOI 10.1085/jgp.66.4.489; Lupu VD, 1998, J BIOL CHEM, V273, P14067, DOI 10.1074/jbc.273.23.14067; MCKAY RR, 1995, J BIOL CHEM, V270, P13271, DOI 10.1074/jbc.270.22.13271; NASI E, 1991, J GEN PHYSIOL, V97, P35, DOI 10.1085/jgp.97.1.35; NASI E, 1992, J GEN PHYSIOL, V99, P747, DOI 10.1085/jgp.99.5.747; NASI E, 1991, J GEN PHYSIOL, V97, P17, DOI 10.1085/jgp.97.1.17; NASI E, 2000, HDB BIOL PHYS, V0003, P00389; PAK WL, 1969, NATURE, V222, P351, DOI 10.1038/222351a0; PAYNE R, 1986, J GEN PHYSIOL, V88, P107, DOI 10.1085/jgp.88.1.107; PAYNE R, 1986, J GEN PHYSIOL, V87, P243, DOI 10.1085/jgp.87.2.243; PAYNE R, 1986, J GEN PHYSIOL, V88, P127, DOI 10.1085/jgp.88.1.127; Piccoli G, 2002, J PHYSIOL-LONDON, V543, P481, DOI 10.1113/jphysiol.2002.022772; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Raghu P, 2000, MOL CELL NEUROSCI, V15, P429, DOI 10.1006/mcne.2000.0846; RANGANATHAN R, 1994, NEURON, V13, P837, DOI 10.1016/0896-6273(94)90250-X; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SHIN JH, 1993, NEURON, V11, P845, DOI 10.1016/0896-6273(93)90114-7; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; SZUTS EZ, 1993, VISUAL NEUROSCI, V10, P921, DOI 10.1017/S0952523800006131; SZUTS EZ, 1986, BIOCHEM J, V240, P929, DOI 10.1042/bj2400929; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Womack KB, 2000, J NEUROSCI, V20, P2792; Xu XZS, 1998, J BIOL CHEM, V273, P31297, DOI 10.1074/jbc.273.47.31297; Zhainazarov AB, 1999, J NEUROSCI, V19, P2929	59	11	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16784	16789		10.1074/jbc.M414538200	http://dx.doi.org/10.1074/jbc.M414538200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15741162	hybrid, Green Published			2022-12-25	WOS:000228615500030
J	Valabrega, G; Montemurro, F; Sarotto, I; Petrelli, A; Rubini, P; Tacchetti, C; Aglietta, M; Comoglio, PM; Giordano, S				Valabrega, G; Montemurro, F; Sarotto, I; Petrelli, A; Rubini, P; Tacchetti, C; Aglietta, M; Comoglio, PM; Giordano, S			TGF alpha expression impairs trastuzumab-induced HER2 downregulation	ONCOGENE			English	Article						HER2; Cbl ubiquitin ligase; TGF alpha; receptor degradation	METASTATIC BREAST-CANCER; EPIDERMAL-GROWTH-FACTOR; MONOCLONAL-ANTIBODY; C-CBL; PROTOONCOGENE PRODUCT; ERBB RECEPTORS; LUNG-CANCER; CELL; UBIQUITINATION; CHEMOTHERAPY	The HER2 gene encodes a tyrosine kinase receptor overexpressed in 25-30% of human breast cancers. Clinical trials have shown the efficacy of the anti-HER2 monoclonal antibody Trastuzumab in metastatic breast cancer patients. Nevertheless, 70% of patients are unresponsive from start of treatment and nearly all become unresponsive during treatment. Possible mechanisms for these failures could depend on impairment of the machinery responsible for receptor downregulation. To test this hypothesis, we analysed the genomic sequences encoding regions known to be critical for HER2 downregulation, of both HER2 and of the ubiquitin ligase Cbl. We investigated 63 breast cancers, and found no mutations in these regions. We thus considered alternative mechanisms - such as TGF alpha production - possibly interfering with HER2 downregulation. In selected cases, by comparing breast cancer neoplastic tissue before and after Trastuzumab treatment, we found induction of TGF alpha expression. Moreover, by in vitro expression of exogenous TGF alpha in breast cancer cells, we observed a dramatic reduction in Trastuzumab-induced HER2 endocytosis, downregulation and cell growth inhibition. Our results suggest that unresponsiveness to Trastuzumab may not be due to intrinsic defects in the machinery responsible for HER2 downregulation, but can be associated with a TGF alpha-related mechanism of escape to HER2 downregulation.	Univ Turin, Sch Med, IRCC, Div Mol Oncol, I-10060 Candiolo, Italy; Univ Turin, Sch Med, IRCC, Div Med Oncol, I-10060 Candiolo, Italy; Univ Turin, Sch Med, IRCC, Dept Pathol, I-10060 Candiolo, Italy; Univ Genoa, Anat Sect, FIRC Inst Mol Oncol, Dept Expt Med, I-16132 Genoa, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IFOM - FIRC Institute of Molecular Oncology; University of Genoa	Giordano, S (corresponding author), Univ Turin, Sch Med, IRCC, Div Mol Oncol, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.	silvia.giordano@ircc.it	Montemurro, Filippo/AAC-1957-2019; Valabrega, Giorgio/J-7313-2018; sarotto, ivana/AAB-7797-2020; Giordano, Silvia/J-9858-2018	Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; Montemurro, Filippo/0000-0003-4231-2291; AGLIETTA, Massimo/0000-0002-2255-7972; VALABREGA, Giorgio/0000-0001-5444-6305; TACCHETTI, CARLO/0000-0003-4602-000X				Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cooley S, 1999, EXP HEMATOL, V27, P1533, DOI 10.1016/S0301-472X(99)00089-2; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Johannes L, 2002, TRAFFIC, V3, P443, DOI 10.1034/j.1600-0854.2002.30701.x; Klapper LN, 2000, CANCER RES, V60, P3384; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1996, ONCOGENE, V12, P1117; Leyland-Jones B, 2002, LANCET ONCOL, V3, P137, DOI 10.1016/S1470-2045(02)00676-9; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Molina MA, 2001, CANCER RES, V61, P4744; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Normanno N, 2002, ANN ONCOL, V13, P65, DOI 10.1093/annonc/mdf020; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Rabouille C, 1999, METH MOL B, V117, P125; Shah NP, 2003, ONCOGENE, V22, P7389, DOI 10.1038/sj.onc.1206942; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; TACCHETTI C, 1987, J CELL BIOL, V105, P999, DOI 10.1083/jcb.105.2.999; Tubbs RR, 2001, J CLIN ONCOL, V19, P2714, DOI 10.1200/JCO.2001.19.10.2714; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; zum Buschenfelde CM, 2002, CANCER RES, V62, P2244	32	107	109	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3002	3010		10.1038/sj.onc.1208478	http://dx.doi.org/10.1038/sj.onc.1208478			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735715				2022-12-25	WOS:000228649500009
J	Basoni, C; Nobles, M; Grimshaw, A; Desgranges, C; Davies, D; Perretti, M; Kramer, IM; Genot, E				Basoni, C; Nobles, M; Grimshaw, A; Desgranges, C; Davies, D; Perretti, M; Kramer, IM; Genot, E			Inhibitory control of TGF-beta 1 on the activation of Rap1, CD11b, and transendothelial migration of leukocytes	FASEB JOURNAL			English	Article						monocytes; endothelium; integrins; Epac; atherosclerosis	GROWTH-FACTOR-BETA; CELL-LINE U-937; VASCULAR ENDOTHELIUM; ADHESION MOLECULE-1; MAC-1 CD11B/CD18; HUMAN PLATELETS; HUMAN MONOCYTES; INTEGRIN MAC-1; LIPID LESIONS; SMALL GTPASE	beta 2-Integrins are a family of dimeric adhesion molecules expressed on leukocytes. Their capacity to bind ligand is regulated by their state of activation. CD11b, an alpha M beta 2 integrin, is implicated in a number of physiological and pathological events such as inflammation, thrombosis, or atherosclerosis. The GTPase Rap1 is essential for its activation and could therefore play a strategic role in the regulation of leukocyte functioning. Because low levels of circulating TGF-beta have been linked with severe atherosclerosis, we have assessed the role of this cytokine in the regulation of Rap1 and CD11b activation in differentiated U937 cells and in human peripheral blood monocytes. TGF-beta 1 caused a significant reduction in the expression of CD11b but not in the expression of other integrins tested. More importantly, TGF-beta 1 greatly reduced the capacity of PMA or chemokines to activate CD11b and Rap 1, a phenomenon paralleled by a loss of the Epac transcript and a reduction in 8-pCPT-2'-O-Me-cAMP-mediated activation of Rap1. This inhibition diminished the capacity of monocytes to migrate across a monolayer of endothelial cells. The inhibitory effect of TGF-beta 1 on Rap1 activity may exert a general protective influence against aberrant transendothelial migration, thereby holding inflammatory responses in check.	INSERM, U441, F-33600 Pessac, France; European Inst Chem & Biol, Mol & Cellular Biol Sect, F-33600 Pessac, France; UCL, Rayne Inst, Dept Med, London WC1E 6BT, England; Univ London Imperial Coll Sci & Technol, Kennedy Inst, London W8 8LH, England; Canc Res UK, London WC2A 3PX, England; Barts & London Queen Marys Sch Med & Dent, Dept Biochem Pharmacol, London E1 2AD, England	Institut National de la Sante et de la Recherche Medicale (Inserm); University of London; King's College London; University College London; Imperial College London; University of Oxford; Cancer Research UK; University of London; Queen Mary University London	Kramer, IM (corresponding author), Univ Bordeaux 1, INSERM, European Inst Chem & Biol, U441, Ave Fac, F-33405 Talence, France.	i.kramer@iecb.u-bordeaux.fr	Genot, Elisabeth/G-8031-2014	Davies, Derek/0000-0002-6977-4181				ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fantuzzi L, 1999, BLOOD, V94, P875, DOI 10.1182/blood.V94.3.875.415k28_875_883; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GAMBLE JR, 1993, J IMMUNOL, V150, P4494; GOMPERTS BD, 2002, SIGNAL TRANSDUCTION; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195-74; Grainger DJ, 2000, J CELL SCI, V113, P2355; GRAINGER DJ, 1995, NAT MED, V1, P1067, DOI 10.1038/nm1095-1067; GRAINGER DJ, 1995, CLIN CHIM ACTA, V235, P11, DOI 10.1016/0009-8981(94)05995-4; Grainger DJ, 2000, CYTOKINE GROWTH F R, V11, P133, DOI 10.1016/S1359-6101(99)00037-4; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; KELSEY SM, 1992, LEUKEMIA RES, V16, P427, DOI 10.1016/0145-2126(92)90167-6; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; LUSCINSKAS FW, 1994, J CELL BIOL, V125, P1417, DOI 10.1083/jcb.125.6.1417; Lutgens E, 2002, ARTERIOSCL THROM VAS, V22, P975, DOI 10.1161/01.ATV.0000019729.39500.2F; Mallat Z, 2001, CIRC RES, V89, P930, DOI 10.1161/hh2201.099415; MEERSCHAERT J, 1995, J IMMUNOL, V154, P4099; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; OLSSON I, 1983, CANCER RES, V43, P5862; OLSSON IL, 1982, CANCER RES, V42, P3928; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Smith WB, 1996, J IMMUNOL, V157, P360; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Tachimoto H, 2000, J IMMUNOL, V165, P2748, DOI 10.4049/jimmunol.165.5.2748; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; Wheller SK, 1997, EUR J PHARMACOL, V331, P65, DOI 10.1016/S0014-2999(97)01015-7; WRIGHT SD, 1989, J EXP MED, V169, P175, DOI 10.1084/jem.169.1.175; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; Zicha D, 1999, J CELL SCI, V112, P447	54	32	33	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					822	+		10.1096/fj.04-3085fje	http://dx.doi.org/10.1096/fj.04-3085fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746186				2022-12-25	WOS:000227901300027
J	Reid, B; Song, B; McCaig, CD; Zhao, M				Reid, B; Song, B; McCaig, CD; Zhao, M			Wound healing in rat cornea: the role of electric currents	FASEB JOURNAL			English	Article						cornea epithelium; vibrating probe; electric field	CHLORIDE TRANSPORT; DIRECTED MIGRATION; EPITHELIAL-CELLS; FROG CORNEA; FIELDS; STIMULATION; SODIUM; REGENERATION; ORIENTATION; INHIBITION	Human corneal epithelial cells respond rapidly following injury to restore the integrity of the ocular surface. What stimulates and guides cells to move into the wound to heal? One candidate is the wound-induced electric field. Using vibrating probe techniques, we provide detailed temporal and spatial mapping of endogenous electric currents at rat corneal wounds. We find Cl- and Na+ are the major components of electric currents in rat corneal wounds. Na+ is the major component of ionic transport in the resting (nonwounded) rat cornea and of the wound center leakage current, whereas Cl- is a more important component of the endogenous electrical current at the wound edges. Enhancing or decreasing Cl- flow with clinically approved pharmacological agents such as aminophylline, ascorbic acid, or furosemide increased or decreased endogenous wound electric currents, respectively. These changes in wound currents correlated directly with the rate of wound healing in vivo. Thus, pharmacologically enhancing or decreasing wound-induced electric currents increased and decreased wound healing rate, respectively. This may have wide-reaching and novel therapeutic potential in the management of wound healing and may help explain some mechanistic aspects of the effects of some clinically used agents.	Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Zhao, M (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland.	m.zhao@abdn.ac.uk	McCaig, Colin/B-1774-2010; Song, Bing/AAB-4755-2021	Song, Bing/0000-0001-9356-2333	Wellcome Trust [068012] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altizer AM, 2002, J EXP ZOOL, V293, P467, DOI 10.1002/jez.10141; BECKER RO, 1972, NATURE, V235, P109, DOI 10.1038/235109a0; BORGENS RB, 1977, P NATL ACAD SCI USA, V74, P4528, DOI 10.1073/pnas.74.10.4528; BORGENS RB, 1984, J EXP ZOOL, V231, P249, DOI 10.1002/jez.1402310209; CANDIA OA, 1968, BIOCHIM BIOPHYS ACTA, V163, P262, DOI 10.1016/0005-2736(68)90105-3; CHIANG M, 1991, DEV BIOL, V146, P377, DOI 10.1016/0012-1606(91)90239-Y; CHIANG MC, 1992, EXP EYE RES, V54, P999, DOI 10.1016/0014-4835(92)90164-N; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; FOULDS IS, 1983, BRIT J DERMATOL, V109, P515, DOI 10.1111/j.1365-2133.1983.tb07673.x; HINKLE L, 1981, J PHYSIOL-LONDON, V314, P121, DOI 10.1113/jphysiol.1981.sp013695; Illingworth C. M., 1980, Clinical Physics and Physiological Measurement, V1, P87, DOI 10.1088/0143-0815/1/1/007; JAFFE LF, 1979, J EXP ZOOL, V209, P115, DOI 10.1002/jez.1402090114; KLYCE SD, 1972, J PHYSIOL-LONDON, V226, P407, DOI 10.1113/jphysiol.1972.sp009991; KLYCE SD, 1977, J PHYSIOL-LONDON, V266, P777, DOI 10.1113/jphysiol.1977.sp011793; KLYCE SD, 1975, AM J PHYSIOL, V228, P1446, DOI 10.1152/ajplegacy.1975.228.5.1446; MAURICE DM, 1967, EXP EYE RES, V6, P138, DOI 10.1016/S0014-4835(67)80065-4; McCaig CD, 1997, BIOESSAYS, V19, P819, DOI 10.1002/bies.950190912; MCGAHAN MC, 1982, BIOCHIM BIOPHYS ACTA, V689, P385, DOI 10.1016/0005-2736(82)90273-5; Nishimura KY, 1996, J CELL SCI, V109, P199; Nuccitelli R, 2003, CURR TOP DEV BIOL, V58, P1, DOI 10.1016/S0070-2153(03)58001-2; Nuccitelli R., 1988, ADV CELL BIOL, V2, P213, DOI DOI 10.1016/S1569-2558(08)60435-X; Ojingwa JC, 2003, J INVEST DERMATOL, V121, P1, DOI 10.1046/j.1523-1747.2003.12454.x; PATARCA R, 1983, AM J PHYSIOL, V245, pF660, DOI 10.1152/ajprenal.1983.245.6.F660; Robinson KR, 2003, BIOESSAYS, V25, P759, DOI 10.1002/bies.10307; ROBINSON KR, 1985, J CELL BIOL, V101, P2023, DOI 10.1083/jcb.101.6.2023; Song B, 2002, P NATL ACAD SCI USA, V99, P13577, DOI 10.1073/pnas.202235299; SOONG HK, 1990, INVEST OPHTH VIS SCI, V31, P2278; Sta Iglesia Drina D., 1998, Wound Repair and Regeneration, V6, P531; VANDERHEYDEN C, 1975, EXP EYE RES, V20, P89, DOI 10.1016/0014-4835(75)90111-6; WIGHAM CG, 1994, PFLUG ARCH EUR J PHY, V428, P577, DOI 10.1007/BF00374580; WOLOSIN JM, 1991, AM J PHYSIOL, V261, pC857, DOI 10.1152/ajpcell.1991.261.5.C857; ZADUNAISKY JA, 1973, EXP EYE RES, V15, P577, DOI 10.1016/0014-4835(73)90069-9; ZADUNAISKY JA, 1966, AM J PHYSIOL, V211, P506, DOI 10.1152/ajplegacy.1966.211.2.506; Zhao M, 1996, J CELL SCI, V109, P1405; Zhao M, 1996, INVEST OPHTH VIS SCI, V37, P2548; Zhao M, 1999, P NATL ACAD SCI USA, V96, P4942, DOI 10.1073/pnas.96.9.4942	36	128	135	2	47	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					379	386		10.1096/fj.04-2325com	http://dx.doi.org/10.1096/fj.04-2325com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746181	Green Accepted			2022-12-25	WOS:000227901300038
J	Wang, Q; Woltjer, RL; Cimino, PJ; Pan, C; Montine, KS; Zhang, J; Montine, TJ				Wang, Q; Woltjer, RL; Cimino, PJ; Pan, C; Montine, KS; Zhang, J; Montine, TJ			Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein	FASEB JOURNAL			English	Article						neurodegeneration; laser capture microdissection; liquid chromatography mass spectrometry	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ALPHA-SYNUCLEIN; LESIONS	We performed proteomic analysis of neurofibrillary tangles (NFTs) obtained by laser capture microdissection from pyramidal neurons in hippocampal sector CA1 in patients with Alzheimer disease (AD) using liquid chromatography (LC)-mass spectrometry (MS)/MS. We discovered a total of 155 proteins in laser captured NFT's, 72 of which were identified by multiple unique peptides. Of these 72 proteins, 63 had previously unknown association with NFTs; one of these was glyceraldehyde-3-phosphate dehydrogenase (GAPDH). We validated by immunohistochemistry that GAPDH colocalized with the majority of NFTs as well as plaque-like structures in AD brain and was coimmunoprecipitated by antibodies to abnormal forms of tau in AD, but not tau from AD temporal cortex. Characterization of GAPDH showed that it, along with phosphorylated tau and A beta peptides, was present in detergent-insoluble fractions from AD temporal cortex but not from age-matched controls. These data are the first proteomic investigation of NFTs. Moreover, our results validate this approach by demonstrating that GAPDH, a glycolytic and microtubule binding protein, not only co-localized to NFTs and immunoprecipitated with PHF-tau, but also is one of the few proteins known to undergo conversion to a detergent-insoluble form in AD.	Univ Washington, Harborview Med Ctr, Sch Med,Dept Pathol, Div Neuropathol, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle	Montine, TJ (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med,Dept Pathol, Div Neuropathol, Box 359660, Seattle, WA 98104 USA.	tmontine@u.washington.edu		Cimino, P.J./0000-0003-0441-4502; Montine, Kathleen/0000-0003-2110-8363	NIA NIH HHS [AG22040, AG05144, AG05136, AG24011] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005136, P50AG005144, K01AG022040, R01AG024011] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Caligiuri G, 1999, ATHEROSCLEROSIS, V145, P301, DOI 10.1016/S0021-9150(99)00081-7; Fend F, 1999, AM J PATHOL, V154, P61, DOI 10.1016/S0002-9440(10)65251-0; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; Levy-Lahad E, 1998, J GERIATR PSYCH NEUR, V11, P42, DOI 10.1177/089198879801100202; Lia LJ, 2004, J BIOL CHEM, V279, P37061, DOI 10.1074/jbc.M403672200; LOWE JS, 2002, GREENFIELDS NEUROPAT, V2, P325; Mazzola JL, 2003, J NEUROSCI RES, V71, P279, DOI 10.1002/jnr.10484; Mazzola JL, 2002, NEUROTOXICOLOGY, V23, P603, DOI 10.1016/S0161-813X(02)00062-1; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Trojanowski JQ, 1995, FASEB J, V9, P1570, DOI 10.1096/fasebj.9.15.8529836; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; ZHANG J, IN PRESS NEUROBIOL A; Zhou Y, 2004, J BIOL CHEM, V279, P39155, DOI 10.1074/jbc.M405456200	16	152	160	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					869	+		10.1096/fj.04-3210fje	http://dx.doi.org/10.1096/fj.04-3210fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746184				2022-12-25	WOS:000227901300030
J	Morel, C; Ibarz, G; Oiry, C; Carnazzi, E; Berge, G; Gagne, D; Galleyrand, JC; Martinez, J				Morel, C; Ibarz, G; Oiry, C; Carnazzi, E; Berge, G; Gagne, D; Galleyrand, JC; Martinez, J			Cross-interactions of two p38 mitogen-activated protein (MAP) kinase inhibitors and two cholecystokinin (CCK) receptor antagonists with the CCK1 receptor and p38 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PANCREATIC ACINI; NUCLEOSIDE TRANSPORT; SB 203580; IN-VITRO; PATHWAYS; POTENT; CELLS; IDENTIFICATION; DETERMINANTS; ISOFORMS	Although SB202190 and SB203580 are described as specific p38 MAP kinase inhibitors, several reports have indicated that other enzymes are also sensitive to SB203580. Using a pharmacological approach, we report for the first time that compounds SB202190 and SB203580 were able to directly and selectively interact with a G-protein-coupled receptor, namely the cholecystokinin receptor subtype CCK1, but not with the CCK2 receptor. We demonstrated that these compounds were non-competitive antagonists of the CCK1 receptor at concentrations typically used to inhibit protein kinases. By chimeric construction of the CCK2 receptor, we determined the involvement of two CCK1 receptor intracellular loops in the binding of SB202190 and SB203580. We also showed that two CCK antagonists, L364,718 and L365,260, were able to regulate p38 mitogen-activated protein ( MAP) kinase activity. Using a reporter gene strategy and immunoblotting experiments, we demonstrated that both CCK antagonists inhibited selectively the enzymatic activity of p38 MAP kinase. Kinase assays suggested that this inhibition resulted from a direct interaction with both CCK antagonists. Molecular modeling simulations suggested that this interaction occurs in the ATP binding pocket of p38 MAP kinase. These results suggest that SB202190 and SB203580 bind to the CCK1 receptor and, as such, these compounds should be used with caution in models that express this receptor. We also found that L364,718 and L365,260, two CCK receptor antagonists, directly interacted with p38 MAP kinase and inhibited its activity. These findings suggest that the CCK1 receptor shares structural analogies with the p38 MAP kinase ATP binding site. They open the way to potential design of either a new family of MAP kinase inhibitors from CCK1 receptor ligand structures or new CCK1 receptor ligands based on p38 MAP kinase inhibitor structures.	CNRS, Lab Aminoacides Peptides & Prot, UMI & UMII, UFR Pharm,UMR 5810, F-34093 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Galleyrand, JC (corresponding author), CNRS, Lab Aminoacides Peptides & Prot, UMI & UMII, UFR Pharm,UMR 5810, 15 Ave Charles Flahault, F-34093 Montpellier, France.	jean-claude.galleyrand@univ-montp1.fr	Martinez, Jean/R-9421-2019	Martinez, Jean/0000-0002-9267-4621				BATTEY J, 1991, TRENDS NEUROSCI, V14, P524, DOI 10.1016/0166-2236(91)90005-F; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; CHANG RSL, 1986, P NATL ACAD SCI USA, V83, P4923, DOI 10.1073/pnas.83.13.4923; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CRAWLEY JN, 1994, PEPTIDES, V15, P731, DOI 10.1016/0196-9781(94)90104-X; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUAN RD, 1995, AM J PHYSIOL-GASTR L, V268, pG1060, DOI 10.1152/ajpgi.1995.268.6.G1060; DUAN RD, 1994, AM J PHYSIOL, V267, pG401, DOI 10.1152/ajpgi.1994.267.3.G401; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; EVANS BE, 1986, P NATL ACAD SCI USA, V83, P4918, DOI 10.1073/pnas.83.13.4918; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; Han JH, 1997, FEBS LETT, V403, P19, DOI 10.1016/S0014-5793(97)00021-5; Huang M, 2003, J PHARMACOL EXP THER, V304, P753, DOI 10.1124/jpet.102.044214; Huang M, 2002, J BIOL CHEM, V277, P28364, DOI 10.1074/jbc.C200321200; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LOTTI VJ, 1989, EUR J PHARMACOL, V162, P273, DOI 10.1016/0014-2999(89)90290-2; Mas JS, 2002, EUR J BIOCHEM, V269, P6133, DOI 10.1046/j.1432-1033.2002.03329.x; Noble F, 1999, PHARMACOL REV, V51, P745; Oiry C, 1997, MOL PHARMACOL, V52, P292, DOI 10.1124/mol.52.2.292; Oiry C, 1995, EUR J PHARMACOL, V294, P511, DOI 10.1016/0014-2999(95)00574-9; Piiper A, 1997, AM J PHYSIOL-GASTR L, V272, pG135, DOI 10.1152/ajpgi.1997.272.1.G135; PONTKINGDON G, 1994, BIOTECHNIQUES, V16, P1010; POOTSI R, 2000, MOL PHARMACOL, V58, P1381; QIAN JM, 1993, AM J PHYSIOL, V264, P718; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sambrook J., 2002, MOL CLONING LAB MANU; SANKARAN H, 1979, J BIOL CHEM, V254, P9349; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; Szewczyk JR, 2003, CURR TOP MED CHEM, V3, P837, DOI 10.2174/1568026033452258; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Williams John A., 1993, P167	45	16	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21384	21393		10.1074/jbc.M408851200	http://dx.doi.org/10.1074/jbc.M408851200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15772081	hybrid, Green Published			2022-12-25	WOS:000229438800058
J	Cui, QQ; Lim, SK; Zhao, B; Hoffmann, FM				Cui, QQ; Lim, SK; Zhao, B; Hoffmann, FM			Selective inhibition of TGF-beta responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP	ONCOGENE			English	Article						TGF-beta; peptide aptamer; Smad; FoxH1; Lef1	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; SYNERGISTIC COOPERATION; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; INTERACTION MOTIF; SKI ONCOPROTEIN; WNT PATHWAYS; PROLINE-RICH	Transforming growth factor beta (TGF-beta) stimulation results in the assembly of Smad-containing protein complexes that mediate activation or repression of TGF-beta responsive genes. To determine if disruption of specific Smad protein-protein interactions would selectively inhibit responses to TGF-beta or generally interfere with Smad-dependent signaling, we developed three Smad-binding peptide aptamers by introducing Smad interaction motifs from Smad-binding proteins CBP, FoxH1 and Lef1. into the scaffold protein E. coli thioredoxin A (Trx). All three classes of aptamers bound to Smads by GST pulldown assays and co-immunoprecipitation from mammalian cells. Expression of the aptamers in HepG2 cells did not generally inhibit Smad-dependent signaling as evaluated using seven TGF-beta responsive luciferase reporter genes. The Trx-xFoxH1b aptamer inhibited TGF-beta-induced expression from a reporter dependent on the Smad-FoxH1 interaction, A3-lux, by 50%. Trx-xFoxH1b also partially inhibited two reporters not dependent on a Smad-FoxH1 interaction, 3TP-lux and Twntop, and endogenous PAI-1 expression. Trx-Lef1 aptamer only inhibited expression of the Smad-Lef1 responsive reporter gene TwnTop. The Trx-CBP aptamer had no significant effect on reporter gene expression. The results suggest that Smad-binding peptide aptamers can be developed to selectively inhibit TGF-beta-induced gene expression.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Hoffmann, FM (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	fmhoffma@wisc.edu		Hoffmann, F. Michael/0000-0002-2770-9656	NATIONAL CANCER INSTITUTE [R01CA090875, T32CA009135, P30CA014520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK064336] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 014520, T32 CA 09135, R01 CA 090875] Funding Source: Medline; NIDDK NIH HHS [R21 DK 064336] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Buerger C, 2003, J BIOL CHEM, V278, P37610, DOI 10.1074/jbc.M301629200; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Chong PA, 2004, J BIOL CHEM, V279, P40707, DOI 10.1074/jbc.M404375200; Colas P, 2000, P NATL ACAD SCI USA, V97, P13720, DOI 10.1073/pnas.97.25.13720; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Crease DJ, 1998, P NATL ACAD SCI USA, V95, P4398, DOI 10.1073/pnas.95.8.4398; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DiChiara MR, 2000, J EXP MED, V192, P695, DOI 10.1084/jem.192.5.695; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Germain S, 2000, GENE DEV, V14, P435; Geyer CR, 1999, P NATL ACAD SCI USA, V96, P8567, DOI 10.1073/pnas.96.15.8567; Goodman RH, 2000, GENE DEV, V14, P1553; Howell M, 2002, DEVELOPMENT, V129, P2823; Hu MC, 2003, DEVELOPMENT, V130, P2753, DOI 10.1242/dev.00478; Hua XX, 2000, J BIOL CHEM, V275, P33205, DOI 10.1074/jbc.C000568200; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inman GJ, 2002, J BIOL CHEM, V277, P51008, DOI 10.1074/jbc.M208532200; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kennedy G, 2003, MOL CELL BIOL, V23, P6901, DOI 10.1128/MCB.23.19.6901-6908.2003; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Long JY, 2004, P NATL ACAD SCI USA, V101, P99, DOI 10.1073/pnas.0307598100; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Nagel-Wolfrum K, 2004, MOL CANCER RES, V2, P170; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Randall RA, 2004, MOL CELL BIOL, V24, P1106, DOI 10.1128/MCB.24.3.1106-1121.2004; Randall RA, 2002, EMBO J, V21, P145, DOI 10.1093/emboj/21.1.145; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Theil T, 2002, DEVELOPMENT, V129, P3045; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317	67	48	60	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3864	3874		10.1038/sj.onc.1208556	http://dx.doi.org/10.1038/sj.onc.1208556			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15750622				2022-12-25	WOS:000229435300002
J	Davidson, D; Blanc, A; Filion, D; Wang, HF; Plut, P; Pfeffer, G; Buschmann, MD; Henderson, JE				Davidson, D; Blanc, A; Filion, D; Wang, HF; Plut, P; Pfeffer, G; Buschmann, MD; Henderson, JE			Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL PROGENITOR DIFFERENTIATION; CARTILAGE REPAIR; IN-VITRO; CHONDROCYTES; LIMB; PROLIFERATION; MOUSE; INTEGRIN; CELLS; MICE	Signaling by fibroblast growth factor (FGF) 18 and FGF receptor 3 (FGFR3) have been shown to regulate proliferation, differentiation, and matrix production of articular and growth plate chondrocytes in vivo and in vitro. Notably, the congenital absence of either FGF18 or FGFR3 resulted in similar expansion of the growth plates of fetal mice and the addition of FGF18 to human articular chondrocytes in culture enhanced proliferation and matrix production. Based on these and other experiments it has been proposed that FGF18 signals through FGFR3 to promote cartilage production by chondrocytes. Its role in chondrogenesis remains to be defined. In the current work we used the limb buds of FGFR3(+/+) and FGFR3(-/-) embryonic mice as a source of mesenchymal cells to determine how FGF18 signaling affects chondrogenesis. Confocal laser-scanning microscopy demonstrated impaired cartilage nodule formation in the FGFR3(-/-) cultures. Potential contributing factors to the phenotype were identified as impaired mitogenic response to FGF18, decreased production of type II collagen and proteoglycan in response to FGF18 stimulation, impaired interactions with the extracellular matrix resulting from altered integrin receptor expression, and altered expression of FGFR1 and FGFR2. The data identified FGF18 as a selective ligand for FGFR3 in limb bud mesenchymal cells, which suppressed proliferation and promoted their differentiation and production of cartilage matrix. This work, thus, identifies FGF18 and FGFR3 as potential molecular targets for intervention in tissue engineering aimed at cartilage repair and regeneration of damaged cartilage.	McGill Univ, Ctr Bone & Periodontal Res, Dept Med, Montreal, PQ H3A 1A4, Canada; Ecole Polytech, Dept Chem Engn, Montreal, PQ H3C 3A7, Canada	McGill University; Universite de Montreal; Polytechnique Montreal	Henderson, JE (corresponding author), McGill Univ, Ctr Bone & Periodontal Res, Dept Med, 740 Ave Dr Penfield Rm 2203, Montreal, PQ H3A 1A4, Canada.	janet.henderson@mcgill.ca		Pfeffer, Gerald/0000-0002-7657-7098; Blanc, Antoine/0000-0002-8305-2513; Buschmann, Michael/0000-0002-2242-6198				Aarts MM, 2001, J BIOL CHEM, V276, P37934; Amizuka N, 2004, BONE, V34, P13, DOI 10.1016/j.bone.2003.08.009; Baird Andrew, 2000, P167; Barbero A, 2004, OSTEOARTHR CARTILAGE, V12, P476, DOI 10.1016/j.joca.2004.02.010; Barbieri O, 2003, AM J PHYSIOL-CELL PH, V285, pC1504, DOI 10.1152/ajpcell.00579.2002; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; CUEVAS P, 1988, BIOCHEM BIOPH RES CO, V156, P611, DOI 10.1016/S0006-291X(88)80887-8; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Dowthwaite GP, 2004, J CELL SCI, V117, P889, DOI 10.1242/jcs.00912; Ekholm E, 2002, AM J PATHOL, V160, P1779, DOI 10.1016/S0002-9440(10)61124-8; Ellsworth JL, 2002, OSTEOARTHR CARTILAGE, V10, P308, DOI 10.1053/joca.2002.0514; EnomotoIwamoto M, 1997, J BONE MINER RES, V12, P1124, DOI 10.1359/jbmr.1997.12.7.1124; Henderson JE, 2000, J BONE MINER RES, V15, P155, DOI 10.1359/jbmr.2000.15.1.155; Hickey Derrick G, 2003, Am J Orthop (Belle Mead NJ), V32, P70; Hunziker EB, 2002, OSTEOARTHR CARTILAGE, V10, P432, DOI 10.1053/joca.2002.0801; JONES KL, 1975, ENDOCRINOLOGY, V97, P359, DOI 10.1210/endo-97-2-359; KAPLOWITZ PB, 1982, J CELL PHYSIOL, V112, P353, DOI 10.1002/jcp.1041120307; Knezevic V, 1997, DEVELOPMENT, V124, P4523; Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361; Laplantine E, 2002, J CELL BIOL, V158, P741, DOI 10.1083/jcb.200205025; Legeai-Mallet L, 2004, BONE, V34, P26, DOI 10.1016/j.bone.2003.09.002; Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602; Loeser RF, 2000, OSTEOARTHR CARTILAGE, V8, P96, DOI 10.1053/joca.1999.0277; Miao DS, 2004, EXP CELL RES, V294, P210, DOI 10.1016/j.yexcr.2003.10.021; Minina E, 2002, DEV CELL, V3, P439, DOI 10.1016/S1534-5807(02)00261-7; Murakami S, 2004, GENE DEV, V18, P290, DOI 10.1101/gad.1179104; Naski MC, 1998, DEVELOPMENT, V125, P4977; Neubert R, 1995, LIFE SCI, V58, P295, DOI 10.1016/0024-3205(95)02290-2; O'Connor WJ, 2000, ORTHOP CLIN N AM, V31, P399, DOI 10.1016/S0030-5898(05)70159-0; O'Driscoll SW, 2001, CLIN ORTHOP S, V391, P190; Ochi M, 2004, ARTIF ORGANS, V28, P28, DOI 10.1111/j.1525-1594.2004.07317.x; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PETERS KG, 1992, DEVELOPMENT, V114, P233; Pizette S, 2000, DEV BIOL, V219, P237, DOI 10.1006/dbio.2000.9610; Sass JO, 1997, ARCH TOXICOL, V71, P142, DOI 10.1007/s002040050368; Shakibaei M, 1998, EXP CELL RES, V240, P95, DOI 10.1006/excr.1998.3933; Solchaga LA, 2001, CLIN ORTHOP RELAT R, pS161; Valverde-Franco G, 2004, HUM MOL GENET, V13, P271, DOI 10.1093/hmg/ddh034; van den Berg WB, 2001, CLIN ORTHOP RELAT R, pS244; van der Kraan PM, 2002, OSTEOARTHR CARTILAGE, V10, P631, DOI 10.1053/joca.2002.0806; Wang DS, 2001, J BIOL CHEM, V276, P33995, DOI 10.1074/jbc.M007757200; Wang O, 2001, DEVELOPMENT, V128, P3867; Weston AD, 2000, J CELL BIOL, V148, P679, DOI 10.1083/jcb.148.4.679; Weston AD, 2002, J CELL BIOL, V158, P39, DOI 10.1083/jcb.200112029; Yasoda A, 2004, NAT MED, V10, P80, DOI 10.1038/nm971; ZANETTI NC, 1984, J CELL BIOL, V99, P115, DOI 10.1083/jcb.99.1.115	50	188	209	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20509	20515		10.1074/jbc.M410148200	http://dx.doi.org/10.1074/jbc.M410148200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781473	hybrid			2022-12-25	WOS:000229242000044
J	Essex-Fraser, PA; Steele, SL; Bernier, NJ; Murray, BW; Stevens, ED; Wright, PA				Essex-Fraser, PA; Steele, SL; Bernier, NJ; Murray, BW; Stevens, ED; Wright, PA			Expression of four glutamine synthetase genes in the early stages of development of rainbow trout (Oncorhynchus mykiss) in relationship to nitrogen excretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UREA CYCLE ENZYMES; EARLY-LIFE STAGES; RESPIRATORY GAS-EXCHANGE; GULF TOADFISH; MOLECULAR CHARACTERIZATION; POTENTIAL IMPORTANCE; BRANCHIAL SURFACES; AMMONIA; TELEOST; LIVER	The incorporation of ammonia into glutamine, catalyzed by glutamine synthetase, is thought to be important in the detoxification of ammonia in animals. During early fish development, ammonia is continuously formed as yolk proteins and amino acids are catabolized. We followed the changes in ammonia and ureanitrogen content, ammonia and urea-nitrogen excretion, glutamine synthetase activity, and mRNA expression of four genes coding for glutamine synthetase (Onmy-GS01-GS04) over 3-80 days post fertilization and in adult liver and skeletal muscle of the rainbow trout ( Oncorhynchus mykiss). Both ammonia and urea-nitrogen accumulate before hatching, although the rate of ammonia excretion is considerably higher relative to urea-nitrogen excretion. All four genes were expressed during early development, but only Onmy-GS01 and -GS02 were expressed at appreciable levels in adult liver, and expression was very low in muscle tissue. The high level of expression of Onmy-GS01 and -GS03 prior to hatching corresponded to a linear increase in glutamine synthetase activity. We propose that the induction of glutamine synthetase genes early in development and the subsequent formation of the active protein are preparatory for the increased capacity of the embryo to convert the toxic nitrogen end product, ammonia, into glutamine, which may then be utilized in the ornithineurea cycle or other pathways.	Univ Guelph, Dept Zool, Guelph, ON N1G 2W1, Canada	University of Guelph	Wright, PA (corresponding author), Univ Guelph, Dept Zool, 50 Stone Rd, Guelph, ON N1G 2W1, Canada.	patwrigh@uoguelph.ca	Murray, Brent/F-5031-2012; stevens, don/AAI-6983-2021; Stevens, Ernest/G-9569-2014	Stevens, Ernest/0000-0002-3113-1543				Allendorf F.W., 1984, P1; ANDERSON PM, 1984, J BIOL CHEM, V259, P456; BALLARD WW, 1973, J EXP ZOOL, V184, P7, DOI 10.1002/jez.1401840103; Barimo JF, 2004, J EXP BIOL, V207, P2011, DOI 10.1242/jeb.00956; Billiau AD, 2001, TRANSPLANTATION, V71, P292, DOI 10.1097/00007890-200101270-00022; CAGGESE C, 1994, GENETICA, V94, P275, DOI 10.1007/BF01443441; Chadwick TD, 1999, J EXP BIOL, V202, P2653; COOPER AJL, 1987, PHYSIOL REV, V67, P440, DOI 10.1152/physrev.1987.67.2.440; DEPECHE J, 1979, COMP BIOCHEM PHYS A, V63, P51, DOI 10.1016/0300-9629(79)90626-1; FUCCI L, 1995, GENE, V152, P205, DOI 10.1016/0378-1119(94)00719-9; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; GRIFFITH RW, 1991, ENVIRON BIOL FISH, V32, P199, DOI 10.1007/BF00007454; Ip Y.K., 2001, Fish Physiology, V20, P109; Kelly SP, 2001, J EXP BIOL, V204, P4115; Korsgaard B., 1995, NITROGEN METABOLISM, P259; Korte JJ, 1997, J BIOL CHEM, V272, P6270, DOI 10.1074/jbc.272.10.6270; LAUD PR, 1994, J MOL EVOL, V39, P93; MEAROW KM, 1989, MOL BRAIN RES, V6, P223, DOI 10.1016/0169-328X(89)90068-5; Mistry AC, 2001, AM J PHYSIOL-REG I, V281, pR1594, DOI 10.1152/ajpregu.2001.281.5.R1594; Mommsen TP, 2003, J COMP PHYSIOL B, V173, P419, DOI 10.1007/s00360-003-0350-z; Murray BW, 2003, J EXP BIOL, V206, P1511, DOI 10.1242/jeb.00283; Nagler JJ, 2000, FISH PHYSIOL BIOCHEM, V22, P61, DOI 10.1023/A:1007825013917; Part P, 1998, COMP BIOCHEM PHYS A, V119, P117, DOI 10.1016/S1095-6433(97)00400-5; Pilley CM, 2000, J EXP BIOL, V203, P3199; RahamanNoronha E, 1996, J EXP BIOL, V199, P2713; RAHMATULLAH M, 1980, CLIN CHIM ACTA, V107, P3, DOI 10.1016/0009-8981(80)90407-6; Randall D. J., 2002, Marine Pollution Bulletin, V45, P17, DOI 10.1016/S0025-326X(02)00227-8; Rice S.D., 1974, P325; ROMBOUGH PJ, 1990, J EXP BIOL, V154, P1; Rombough PJ, 1997, J EXP BIOL, V200, P2459; Sakamoto T, 2000, GENETICS, V155, P1331; SHANKAR RA, 1985, ARCH BIOCHEM BIOPHYS, V239, P248, DOI 10.1016/0003-9861(85)90833-1; Smirnov AV, 2000, CLIN CHIM ACTA, V292, P1, DOI 10.1016/S0009-8981(99)00180-1; SMITH S, 1957, METABOLISM, P323; Steele SL, 2001, J EXP BIOL, V204, P2145; Terjesen BF, 1997, FISH PHYSIOL BIOCHEM, V16, P311, DOI 10.1023/A:1007719618473; Terjesen BF, 2001, J EXP BIOL, V204, P2155; Terjesen BF, 2000, COMP BIOCHEM PHYS B, V126, P521, DOI 10.1016/S0305-0491(00)00221-2; Todgham AE, 2001, COMP BIOCHEM PHYS A, V129, P527, DOI 10.1016/S1095-6433(01)00290-2; VERDOUW H, 1978, WATER RES, V12, P399, DOI 10.1016/0043-1354(78)90107-0; Walsh PJ, 2000, J EXP BIOL, V203, P2357; Walsh PJ, 1999, COMP BIOCHEM PHYS B, V124, P251, DOI 10.1016/S0305-0491(99)00105-4; Walsh PJ, 2001, J EXP BIOL, V204, P509; Walsh PJ, 2003, J EXP BIOL, V206, P1523, DOI 10.1242/jeb.00251; Wood Chris M., 1993, P379; Wright P.A., 2001, Fish Physiology, V20, P149; WRIGHT PA, 1995, J EXP BIOL, V198, P127	47	64	66	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20268	20273		10.1074/jbc.M412338200	http://dx.doi.org/10.1074/jbc.M412338200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781468	hybrid			2022-12-25	WOS:000229242000015
J	Martens, GA; Cai, Y; Hinke, S; Stange, G; Van de Casteele, M; Pipeleers, D				Martens, GA; Cai, Y; Hinke, S; Stange, G; Van de Casteele, M; Pipeleers, D			Glucose suppresses superoxide generation in metabolically responsive pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; B-CELLS; MITOCHONDRIAL SUPEROXIDE; UNCOUPLING PROTEINS; INSULIN-SECRETION; ISLET CELLS; TOXICITY; ACTIVATION; EXPRESSION; OXYGEN	High rates of glucose metabolism and mitochondrial electron transport have been associated with increased mitochondrial production of reactive oxygen species (ROS). This mechanism was also proposed as a possible cause for dysfunction and death of pancreatic beta cells exposed to high glucose levels. We examined whether high rates of glucose metabolism increase ROS production in purified rat beta cells. Glucose up to 20 mM did not stimulate H2O2 or superoxide production, whereas it dose-dependently increased cellular NAD(P)H and FADH(2) levels with an EC50 around 8 mM. On the contrary, glucose concentration-dependently suppressed H2O2 and superoxide formation, with a major effect between 0 and 5 mM, parallel to an increase in cellular NAD(P)H levels. This suppressive effect was more marked in beta cells with higher NAD(P)H responsiveness to glucose; it was not observed in glucagon-containing alpha cells, which lacked a glucose-induced increase in NAD(P)H. Suppression was also induced by the mitochondrial substrates leucine and succinate. Experiments with electron transport chain inhibitors indicate a role of respiratory complex I in ROS production at low mitochondrial activity and low NADH levels. Superoxide production at low glucose is potentially cytotoxic, because scavenging by the superoxide dismutase mimetic agent manganese(III)tetrakis(4-benzoic acid) porphyrin was found to reduce the rate of beta cell apoptosis. Analysis of islets cultured at 20 mM glucose confirmed that this condition does not induce ROS production in beta cells as a result of their increased rates of glucose metabolism. Our study indicates the need of beta cells for basal nutrients maintaining mitochondrial NADH production at levels that suppress ROS accumulation from an inadequate respiratory complex I activity and thus inhibit a potential apoptotic pathway.	Free Univ Brussels, VUB, Diabet Res Ctr, B-1090 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Pipeleers, D (corresponding author), Free Univ Brussels, VUB, Diabet Res Ctr, Laarbeeklaan 103, B-1090 Brussels, Belgium.	Daniel.Pipeleers@vub.ac.be	stange, geert m/C-1092-2009; Hinke, Simon/R-7120-2019; Martens, Geert/ABA-6297-2020; Martens, Geert A./F-6920-2015	stange, geert m/0000-0003-3148-1372; Martens, Geert/0000-0003-1208-6289; Martens, Geert A./0000-0003-1208-6289; Van De Casteele, mark/0000-0002-8594-9260; Pipeleers, Daniel/0000-0002-6440-2485				Bennett BD, 1996, J BIOL CHEM, V271, P3647; Bindokas VP, 2003, J BIOL CHEM, V278, P9796, DOI 10.1074/jbc.M206913200; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; CHANCE B, 1967, P NATL ACAD SCI USA, V57, P1498, DOI 10.1073/pnas.57.5.1498; Du YP, 2003, FREE RADICAL BIO MED, V35, P1491, DOI 10.1016/j.freeradbiomed.2003.08.018; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; Fahien LA, 2002, DIABETES, V51, P2669, DOI 10.2337/diabetes.51.9.2669; Fridlyand LE, 2004, DIABETES, V53, P1942, DOI 10.2337/diabetes.53.8.1942; GRANKVIST K, 1981, BIOCHEM J, V199, P393, DOI 10.1042/bj1990393; HATEFI Y, 1968, P NATL ACAD SCI USA, V60, P733, DOI 10.1073/pnas.60.2.733; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; IMLAY JA, 1995, J BIOL CHEM, V270, P19767; Jonas JC, 2003, DIABETOLOGIA, V46, P1234, DOI 10.1007/s00125-003-1174-9; Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398; KIEKENS R, 1992, J CLIN INVEST, V89, P117, DOI 10.1172/JCI115551; Kilpatrick ED, 1998, DIABETES, V47, P606, DOI 10.2337/diabetes.47.4.606; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Krauss S, 2003, J CLIN INVEST, V112, P1831, DOI 10.1172/JCI200319774; Kubisch HM, 1997, DIABETES, V46, P1563, DOI 10.2337/diabetes.46.10.1563; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Laybutt DR, 2002, DIABETES, V51, P413, DOI 10.2337/diabetes.51.2.413; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Ling ZD, 1996, DIABETES, V45, P1774, DOI 10.2337/diabetes.45.12.1774; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; MASSEY V, 1994, J BIOL CHEM, V269, P22459; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; PIPELEERS D, 1986, P NATL ACAD SCI USA, V83, P5267, DOI 10.1073/pnas.83.14.5267; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; Robertson RP, 2004, DIABETES, V53, pS119, DOI 10.2337/diabetes.53.2007.S119; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; Schuit F, 1999, J BIOL CHEM, V274, P32803, DOI 10.1074/jbc.274.46.32803; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; Van de Casteele M, 2002, ENDOCRINOLOGY, V143, P320, DOI 10.1210/en.143.1.320; VANDEWINKEL M, 1983, BIOCHEM BIOPH RES CO, V114, P835, DOI 10.1016/0006-291X(83)90857-4; VANDEWINKEL M, 1982, BIOCHEM BIOPH RES CO, V107, P525, DOI 10.1016/0006-291X(82)91523-6; Vincent AM, 2004, DIABETES, V53, P726, DOI 10.2337/diabetes.53.3.726; Wang HY, 1997, J BIOL CHEM, V272, P25731, DOI 10.1074/jbc.272.41.25731; Wu L, 2004, J BIOL CHEM, V279, P12126, DOI 10.1074/jbc.M307097200; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4	47	100	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20389	20396		10.1074/jbc.M411869200	http://dx.doi.org/10.1074/jbc.M411869200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15774474	hybrid			2022-12-25	WOS:000229242000030
J	Shi, WW; Mersfelder, J; Hille, R				Shi, WW; Mersfelder, J; Hille, R			The interaction of trimethylamine dehydrogenase and electron-transferring flavoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND COENZYME; AMINO-ACID OXIDASE; METHYLOPHILUS-METHYLOTROPHUS; BACTERIUM W3A1; 3-DIMENSIONAL STRUCTURE; OXIDATION-REDUCTION; TRANSFER COMPLEX; IDENTIFICATION; SULFUR; IRON	The interaction between the physiological electron transfer partners trimethylamine dehydrogenase (TMADH) and electron-transferring flavoprotein (ETF) from Methylophilus methylotrophus has been examined with particular regard to the proposal that the former protein "imprints" a conformational change on the latter. The results indicate that the absorbance change previously attributed to changes in the environment of the FAD of ETF upon binding to TMADH is instead caused by electron transfer from partially reduced, as-isolated TMADH to ETF. Prior treatment of the as-isolated enzyme with the oxidant ferricenium essentially abolishes the observed spectral change. Further, when the semiquinone form of ETF is used instead of the oxidized form, the mirror image of the spectral change seen with as-isolated TMADH and oxidized ETF is observed. This is attributable to a small amount of electron transfer in the reverse of the physiological direction. Kinetic determination of the dissociation constant and limiting rate constant for electron transfer within the complex of (reduced) TMADH with (oxidized) ETF is reconfirmed and discussed in the context of a recently proposed model for the interaction between the two proteins that involves "structural imprinting" of ETF.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	Ohio State University	Hille, R (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	hille.1@osu.edu			NIGMS NIH HHS [GM 52322] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052322] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; Basran J, 2000, BIOCHEMISTRY-US, V39, P9188, DOI 10.1021/bi0006868; Basran J, 2001, J BIOL CHEM, V276, P42887, DOI 10.1074/jbc.M108296200; Beinert H, 1978, Methods Enzymol, V54, P111; BEVINGTON RR, 1996, DATA REDUCTION ERROR, P235; DAVIDSON VL, 1986, J BACTERIOL, V166, P812, DOI 10.1128/jb.166.3.812-817.1986; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; FOUST GP, 1969, ANAL BIOCHEM, V27, P530, DOI 10.1016/0003-2697(69)90066-9; GHISLA S, 1979, J BIOL CHEM, V254, P662; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; HILLE R, 1984, J BIOL CHEM, V259, P1570; HUSAIN M, 1990, METHOD ENZYMOL, V188, P309; Jang MH, 2000, J BIOL CHEM, V275, P12546, DOI 10.1074/jbc.275.17.12546; Jones M, 2000, J BIOL CHEM, V275, P21349, DOI 10.1074/jbc.M001564200; Jones M, 2002, J BIOL CHEM, V277, P8457, DOI 10.1074/jbc.M111105200; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; Leys D, 2003, NAT STRUCT BIOL, V10, P219, DOI 10.1038/nsb894; LIM LW, 1988, J BIOL CHEM, V263, P3075; LIM LW, 1986, J BIOL CHEM, V261, P5140; MASSEY V, 1965, BIOCHEMISTRY-US, V4, P1161, DOI 10.1021/bi00882a027; MCINTIRE WS, 1990, METHOD ENZYMOL, V188, P250; NAGY J, 1979, J BIOL CHEM, V254, P2684; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; QUAY S, 1977, BIOCHEMISTRY-US, V16, P3348, DOI 10.1021/bi00634a010; Roberts DL, 1996, P NATL ACAD SCI USA, V93, P14355, DOI 10.1073/pnas.93.25.14355; ROHLFS RJ, 1995, J BIOL CHEM, V270, P22196, DOI 10.1074/jbc.270.38.22196; STEENKAMP DJ, 1976, BIOCHEM BIOPH RES CO, V71, P1289, DOI 10.1016/0006-291X(76)90794-4; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2812; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; Wills PR, 1996, BIOPOLYMERS, V38, P119, DOI 10.1002/(SICI)1097-0282(199601)38:1<119::AID-BIP10>3.0.CO;2-C; Wilson EK, 1997, EUR J BIOCHEM, V243, P393, DOI 10.1111/j.1432-1033.1997.0393a.x; Wilson EK, 1997, BIOCHEMISTRY-US, V36, P41, DOI 10.1021/bi961224q	37	5	6	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20239	20246		10.1074/jbc.M500582200	http://dx.doi.org/10.1074/jbc.M500582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15760891	hybrid			2022-12-25	WOS:000229242000011
J	Xu, HP; Kurihara, H; Ito, T; Kikuchi, H; Yoshida, K; Yamanokuchi, H; Asari, A				Xu, HP; Kurihara, H; Ito, T; Kikuchi, H; Yoshida, K; Yamanokuchi, H; Asari, A			The keratan sulfate disaccharide gal(6S03) beta 1,4-GlcNAc(6S03) modulates interleukin 12 production by macrophages in murine Thy-1 type autoimmune disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACULAR CORNEAL-DYSTROPHY; NECROSIS-FACTOR-ALPHA; CYSTEINE-RICH DOMAIN; MRL-LPR/LPR MICE; MANNOSE RECEPTOR; T-CELLS; IN-VIVO; PROTEIN-KINASE; P40 HOMODIMER; IL-12	It has been reported that disaccharides of the glyco-saminoglycans (GAGs), heparin, or heparan sulfate suppress the production of cytokines. Therefore, we examined the effects of GAGs (keratan sulfate, hyaluronan, chondroitin, chondroitin sulfate, and heparin sulfate) disaccharides on production of interleukin (IL)-12, a pivotal cytokine in the Th-1 type immune system. Among the GAG disaccharides, only a keratan sulfate disaccharide, Gal(6SO(3))- GlcNAc(6-SO3) (L4), suppressed IL-12 production in macrophages stimulated with lipopolysaccharides and interferon-gamma. Neither keratan sulfate chains nor keratan sulfate tetrasaccharides elicited any change in the IL-12 production. N-Acetyl-lactosamine, Gal-GlcNAc ( LacNAc), also did not change IL-12 production. These results indicated that a certain size, i.e. disaccharide and sulfate, are essential to suppress IL-12 production. L4 was then applied to MRL-lpr/lpr mice, a Th-1 type autoimmune disease model. The treatment of MRL-lpr/lpr mice with L41) decreased in serum IL-12, 2) induced apoptosis in T cells in lymph nodes thereby suppressing lymphoaccumulation, and 3) suppressed hypergammaglobulinemia and glomerulonephritis. We showed previously that IL-12 suppresses cell death of T cells, thereby enhancing the lymphoaccumulation in MRL-lpr/lpr mice. Moreover, it has been reported that IL-12 deficiency in MRL-lpr/lpr mice diminishes lymphoaccumulation and delays glomerulonephritis. The treatment with L4 suppressed phosphoprotein kinase C and phosphoinositide 3-kinase expression in macrophages, suggesting that L4 suppresses IL-12 production by inhibiting phosphoprotein kinase C and phosphoinositide 3-kinase pathways.	Seikagaku Corp, Chuo Ku, Tokyo 1030023, Japan; Univ Aberdeen, Sch Med, Dept Ophthalmol, Aberdeen AB25 2ZD, Scotland; Mizutani Fdn Glycosci, Chuo Ku, Tokyo 1030023, Japan	Seikagaku Corporation; University of Aberdeen	Asari, A (corresponding author), Seikagaku Corp, Chuo Ku, 1-5,Nihonbashi Honcho 2 Chome, Tokyo 1030023, Japan.	aaquira@hotmail.com	Xu, Heping/A-4430-2008	Xu, Heping/0000-0003-4000-931X				Aksoy E, 2002, EUR J IMMUNOL, V32, P3040, DOI 10.1002/1521-4141(200211)32:11<3040::AID-IMMU3040>3.0.CO;2-M; Cahalon L, 1997, INT IMMUNOL, V9, P1517, DOI 10.1093/intimm/9.10.1517; Chowers Y, 2001, GASTROENTEROLOGY, V120, P449, DOI 10.1053/gast.2001.21202; COHEN GM, 1993, PROGRAMMED CELL DEAT, P123; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; FABIO R, 2001, J BIOL CHEM, V276, P37692; FLESCH IEA, 1995, J EXP MED, V181, P1615, DOI 10.1084/jem.181.5.1615; Funderburgh JL, 2000, GLYCOBIOLOGY, V10, P951, DOI 10.1093/glycob/10.10.951; GATELY MK, 1991, J IMMUNOL, V147, P874; Gately MK, 1996, ANN NY ACAD SCI, V795, P1, DOI 10.1111/j.1749-6632.1996.tb52650.x; GATELY MK, 1994, INT IMMUNOL, V6, P157, DOI 10.1093/intimm/6.1.157; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Ha SJ, 1999, J IMMUNOL, V163, P2902; Hascall V C, 1982, Prog Clin Biol Res, V110 Pt B, P3; Hasegawa N, 2000, INVEST OPHTH VIS SCI, V41, P3670; Kaposzta R, 1999, J CELL SCI, V112, P3237; Kato K, 1996, P NATL ACAD SCI USA, V93, P9085, DOI 10.1073/pnas.93.17.9085; Kikawada E, 2003, J IMMUNOL, V170, P3915, DOI 10.4049/jimmunol.170.7.3915; Kubota M, 2000, EUR J MASS SPECTROM, V6, P193, DOI 10.1255/ejms.338; Leteux C, 2000, J EXP MED, V191, P1117, DOI 10.1084/jem.191.7.1117; Lewis D, 2000, GLYCOBIOLOGY, V10, P305, DOI 10.1093/glycob/10.3.305; Linehan SA, 2001, EUR J IMMUNOL, V31, P1857, DOI 10.1002/1521-4141(200106)31:6<1857::AID-IMMU1857>3.0.CO;2-D; Liu TF, 1998, CYTOKINE, V10, P140, DOI 10.1006/cyto.1997.0268; Liu Y, 2000, J EXP MED, V191, P1105, DOI 10.1084/jem.191.7.1105; Martinez-Pomares L, 2001, IMMUNOBIOLOGY, V204, P527, DOI 10.1078/0171-2985-00089; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; Mehal WZ, 1998, J IMMUNOL, V161, P1686; Neumann A, 1999, FEBS LETT, V453, P283, DOI 10.1016/S0014-5793(99)00731-0; NIEDUSZYNSKI IA, 1990, BIOCHEM SOC T, V18, P792, DOI 10.1042/bst0180792; Piccotti JR, 1997, J IMMUNOL, V158, P643; Quantock AJ, 2001, INVEST OPHTH VIS SCI, V42, P1750; Rempel JD, 1997, J IMMUNOL, V159, P1490; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; WU JG, 1994, P NATL ACAD SCI USA, V91, P2344, DOI 10.1073/pnas.91.6.2344; Xu HP, 2001, J AUTOIMMUN, V16, P87, DOI 10.1006/jaut.2000.0468; Xu HP, 2002, J BIOL CHEM, V277, P17308, DOI 10.1074/jbc.M112371200; Yoo JK, 2002, J IMMUNOL, V169, P3637, DOI 10.4049/jimmunol.169.7.3637; Yu QG, 2004, J IMMUNOL, V172, P6047, DOI 10.4049/jimmunol.172.10.6047	38	17	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20879	20886		10.1074/jbc.M411954200	http://dx.doi.org/10.1074/jbc.M411954200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15749717	hybrid			2022-12-25	WOS:000229242000086
J	Paltoglou, SM; Roberts, BJ				Paltoglou, SM; Roberts, BJ			Role of the von Hippel-Lindau tumour suppressor protein in the regulation of HIF-1 alpha and its oxygen-regulated transactivation domains at high cell density	ONCOGENE			English	Article						HIF-1 alpha; VHL; RCC	HIF-ALPHA; CYTOPLASMIC LOCALIZATION; PROLYL HYDROXYLATION/; HYPOXIA; VHL; NUCLEAR; BINDING; UBIQUITYLATION; TRANSCRIPTION; DESTRUCTION	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) induction and associated transcription were investigated during high cell density, focusing on the negative regulator of HIF-1 alpha expression, the von Hippel-Lindau (VHL) protein. In 293T and HeLa cells, HIF-1 alpha protein levels and associated transcription were induced as cells approached confluence. To determine whether these changes were due to a deficit in nuclear VHL-mediated ubiquitination of HIF-1 alpha at confluence, cells were stably transfected with VHL. Overexpression of VHL in 293T cells had no demonstrable effect on the induction and nuclear accumulation of HIF-1 alpha during high cell density or associated transcription. Moreover, RCC cells stably transfected with full-length VHL failed to exhibit the cell-density-dependent induction of HIF-1 alpha noted in other cell lines. Investigation of both N-terminal and C-terminal (aa 727 826) oxygen-regulated proline and asparagine hydroxylation of HIF-1 alpha revealed that both are inhibited during high cell density, as determined by impaired capture of HIF-1 alpha by VHL and enhanced C-terminal transactivation. Finally, cell-density-mediated induction of HIF-1 alpha and GLUT1 in RCC cells could be completely reconstituted by mutations in VHL binding affinity, suggesting that cell-density dependent induction of HIF-1 alpha and transactivation may underpin some of the deregulated gene expression observed in VHL disease.	Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Adelaide, SA 5000, Australia	University of South Australia	Roberts, BJ (corresponding author), Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Reid Bldg,Frome Rd, Adelaide, SA 5000, Australia.	Ben.Roberts@unisa.edu.au						Bemis L, 2004, GENE DEV, V18, P739, DOI 10.1101/gad.1180104; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Ekblom P, 1996, CURR OPIN CELL BIOL, V8, P599, DOI 10.1016/S0955-0674(96)80099-8; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee S, 1999, MOL CELL BIOL, V19, P1486; Lewis MD, 2004, ONCOGENE, V23, P2315, DOI 10.1038/sj.onc.1207384; Lewis MD, 2003, ONCOGENE, V22, P3992, DOI 10.1038/sj.onc.1206683; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; Mekhail K, 2004, NAT CELL BIOL, V6, P642, DOI 10.1038/ncb1144; Mukhopadhyay D, 1998, GENE EXPRESSION, V7, P53; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Peles E, 1998, TRENDS BIOCHEM SCI, V23, P121, DOI 10.1016/S0968-0004(98)01195-5; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	28	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3830	3835		10.1038/sj.onc.1208531	http://dx.doi.org/10.1038/sj.onc.1208531			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15750626				2022-12-25	WOS:000229346300013
J	Mulrooney, EF; Poon, KKH; McNally, DJ; Brisson, JR; Lam, JS				Mulrooney, EF; Poon, KKH; McNally, DJ; Brisson, JR; Lam, JS			Biosynthesis of UDP-N-acetyl-L-fucosamine, a precursor to the biosynthesis of lipopolysaccharide in Pseudomonas aeruginosa serotype O11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR SOMATIC ANTIGENS; ACETYLGLUCOSAMINE 2-EPIMERASE; O-ANTIGEN; STAPHYLOCOCCUS-AUREUS; CAPSULAR POLYSACCHARIDE; ENZYMATIC-SYNTHESIS; ESCHERICHIA-COLI; D-GLUCOSAMINE; MECHANISM; BACTERIA	UDP-N-acetyl-L-fucosamine is a precursor to L-fucosamine in the lipopolysaccharide of Pseudomonas aeruginosa serotype O11 and the capsule of Staphylococcus aureus type 5. We have demonstrated previously the involvement of three enzymes, WbjB, WbjC, and WbjD, in the biosynthesis of UDP-2-acetamido-2,6-dideoxy-L-galactose or UDP-N-acetyl-L-fucosamine (UDP-L-FucNAc). An intermediate compound from the coupled-reaction of WbjB-WbjC with the initial substrate UDP-2-acetamido-2deoxy-beta-D-glucose or UDP-N-acetyl-D-glucosamine (UDPGlcNAc) was purified, and the structure was determined by NMR spectroscopy to be UDP-2-acetamido-2,6-dideoxy-L-talose (UDP-L-PneNAc). WbjD could then convert this intermediate into a new product with the same mass, consistent with a C-2 epimerization reaction. Those results led us to propose a pathway for the biosynthesis of UDP-L-FucNAc; however, the exact enzymatic activity of each of these proteins has not been defined. Here, we describe a fast protein liquid chromatography (FPLC)-based anion-exchange procedure, which allowed the separation and purification of the products of C-2 epimerization due to WbjD. Also, the application of a cryogenically cooled probe in NMR spectrometry offers the greatest sensitivity for determining the structures of minute quantities of materials, allowing the identification of the final product of the pathway. Our results showed that WbjB is bifunctional, catalyzing firstly C-4, C-6 dehydration and secondly C-5 epimerization in the reaction with the substrate UDP-D-GlcNAc, producing two intermediates. WbjC is also bifunctional, catalyzing C-3 epimerization of the second intermediate followed by reduction at C-4. The FPLC-based procedure provided good resolution of the final product of WbjD reaction from its epimer/substrate UDP-L-PneNAc, and the use of the cryogenically cooled probe in NMR revealed unequivocally that the final product is UDP-L-FucNAc.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Lam, JS (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.	jlam@uoguelph.ca						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISSON JR, 2002, NMR SPECTROSCOPY GLY, P59; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P14993, DOI 10.1021/bi001627x; Chen HW, 2000, P NATL ACAD SCI USA, V97, P11942, DOI 10.1073/pnas.210395097; Chou WK, 2003, J AM CHEM SOC, V125, P2455, DOI 10.1021/ja021309g; Creuzenet C, 2002, J BIOL CHEM, V277, P26769, DOI 10.1074/jbc.M202882200; CRYZ SJ, 1984, INFECT IMMUN, V44, P508, DOI 10.1128/IAI.44.2.508-513.1984; DASGUPTA T, 1994, INFECT IMMUN, V62, P809, DOI 10.1128/IAI.62.3.809-817.1994; Dong CJ, 2003, STRUCTURE, V11, P715, DOI 10.1016/S0969-2126(03)00098-4; ENGELS W, 1985, INFECT IMMUN, V49, P182, DOI 10.1128/IAI.49.1.182-189.1985; Field RA, 2003, BIOCHEMISTRY-US, V42, P7637, DOI 10.1021/bi0345079; FOURNIER JM, 1984, INFECT IMMUN, V45, P87, DOI 10.1128/IAI.45.1.87-93.1984; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; JONES C, 1991, CARBOHYD RES, V221, P95, DOI 10.1016/0008-6215(91)80051-N; Jornvall H, 1999, FEBS LETT, V445, P261, DOI 10.1016/S0014-5793(99)00130-1; KAWAMURA T, 1979, J BIOL CHEM, V254, P8457; Kirkpatrick PN, 2000, CHEM COMMUN, P1565, DOI 10.1039/b004463f; Kneidinger B, 2003, BIOCHEM J, V371, P989, DOI 10.1042/BJ20030099; Kneidinger B, 2003, J BIOL CHEM, V278, P3615, DOI 10.1074/jbc.M203867200; KNIREL YA, 1994, BIOCHEMISTRY-MOSCOW+, V59, P1325; Koplin R, 1997, J BIOL CHEM, V272, P4121, DOI 10.1074/jbc.272.7.4121; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU PHV, 1990, J CLIN MICROBIOL, V28, P922, DOI 10.1128/JCM.28.5.922-925.1990; LIU PV, 1983, INT J SYST BACTERIOL, V33, P256, DOI 10.1099/00207713-33-2-256; Manca MC, 1996, CARBOHYD RES, V281, P155, DOI 10.1016/0008-6215(95)00333-9; Merkel AB, 2004, J BIOL CHEM, V279, P32684, DOI 10.1074/jbc.M404091200; Miller WL, 2004, J BIOL CHEM, V279, P37551, DOI 10.1074/jbc.M404749200; MOREAU M, 1990, CARBOHYD RES, V201, P285, DOI 10.1016/0008-6215(90)84244-O; Morgan PM, 1997, J AM CHEM SOC, V119, P10269, DOI 10.1021/ja971718q; Murkin AS, 2004, BIOCHEMISTRY-US, V43, P14290, DOI 10.1021/bi048606d; PITT TL, 1988, EUR J CLIN MICROBIOL, V7, P238, DOI 10.1007/BF01963095; PRIHAR HS, 1980, BIOCHEMISTRY-US, V19, P495, DOI 10.1021/bi00544a016; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Rocchetta HL, 1999, MICROBIOL MOL BIOL R, V63, P523, DOI 10.1128/MMBR.63.3.523-553.1999; Sala RF, 1996, J AM CHEM SOC, V118, P3033, DOI 10.1021/ja960266z; SALO WL, 1976, BIOCHIM BIOPHYS ACTA, V452, P625, DOI 10.1016/0005-2744(76)90216-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SOMPOLINSKY D, 1985, J CLIN MICROBIOL, V22, P828, DOI 10.1128/JCM.22.5.828-834.1985	39	30	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19535	19542		10.1074/jbc.M500612200	http://dx.doi.org/10.1074/jbc.M500612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778500	hybrid			2022-12-25	WOS:000229113700015
J	Picard, D; Kao, CC; Hudak, KA				Picard, D; Kao, CC; Hudak, KA			Pokeweed antiviral protein inhibits brome mosaic virus replication in plant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; RIBOSOME-INACTIVATING PROTEINS; TERMINAL DELETION MUTANT; N-GLYCOSIDASE ACTIVITY; EUKARYOTIC RIBOSOMES; SARCIN/RICIN LOOP; MESSENGER-RNA; IN-VIVO; INFECTION; INITIATION	Pokeweed antiviral protein ( PAP) is a ribosome-inactivating protein isolated from the pokeweed plant ( Phytolacca americana) that inhibits the proliferation of several plant and animal viruses. We have shown previously that PAP and nontoxic mutants of PAP can directly depurinate brome mosaic virus (BMV) RNA in vitro, resulting in reduced viral protein translation. Here we expand on these initial studies and, using a barley protoplast system, demonstrate that recombinant PAP and nontoxic mutants isolated from E. coli are able to reduce the accumulation of BMV RNAs in vivo. Pretreatment of only BMV RNA3 with PAP prior to transfection of barley protoplasts reduced the accumulation of all BMV RNAs, with a more severe effect on subgenomic RNA4 levels. Using in vitro RNA synthesis assays, we show that a depurinated template causes the BMV replicase to stall at the template nucleotide adjacent to the missing base. These results provide new insight into the antiviral mechanism of PAP, namely that PAP depurination of BMV RNA impedes both RNA replication and subgenomic RNA transcription. These novel activities are distinct from the PAP-induced reduction of viral RNA translation and represent new targets for the inhibition of viral infection.	York Univ, Dept Biol, Toronto, ON M3J 1P3, Canada; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	York University - Canada; Texas A&M University System; Texas A&M University College Station	Hudak, KA (corresponding author), York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	hudak@yorku.ca						Adkins S, 1998, RNA, V4, P455; Ahlquist P, 1992, CURR OPIN GENET DEV, V2, P71, DOI 10.1016/S0959-437X(05)80325-9; Ahola T, 2000, J VIROL, V74, P8803, DOI 10.1128/JVI.74.19.8803-8811.2000; ALLISON R, 1990, P NATL ACAD SCI USA, V87, P1820, DOI 10.1073/pnas.87.5.1820; ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; Bhardwaj K, 2004, J VIROL, V78, P12218, DOI 10.1128/JVI.78.22.12218-12224.2004; Bolognesi A, 2002, J BIOL CHEM, V277, P13709, DOI 10.1074/jbc.M111514200; CHAUDHRY B, 1994, PLANT J, V6, P815, DOI 10.1046/j.1365-313X.1994.6060815.x; DUGGAR B. M., 1925, Ann. Mo. Bot. Gdn., V12, P359, DOI 10.2307/2394061; EADY MP, 1986, P NATL ACAD SCI USA, V84, P5053; ENDO Y, 1988, BIOCHEM BIOPH RES CO, V150, P1032, DOI 10.1016/0006-291X(88)90733-4; ENDO Y, 1987, J BIOL CHEM, V262, P8128; FRENCH R, 1986, SCIENCE, V231, P1294, DOI 10.1126/science.231.4743.1294; FRENCH R, 1987, J VIROL, V61, P1457, DOI 10.1128/JVI.61.5.1457-1465.1987; Hema M, 2004, J VIROL, V78, P1169, DOI 10.1128/JVI.78.3.1169-1180.2004; Hogg M, 2004, EMBO J, V23, P1483, DOI 10.1038/sj.emboj.7600150; Honjo E, 1999, BIOSCI BIOTECH BIOCH, V63, P1291, DOI 10.1271/bbb.63.1291; Hudak KA, 2000, RNA, V6, P369, DOI 10.1017/S1355838200991337; Hudak KA, 2001, VIROLOGY, V279, P292, DOI 10.1006/viro.2000.0647; HUR Y, 1995, P NATL ACAD SCI USA, V92, P8448, DOI 10.1073/pnas.92.18.8448; Kao CC, 2000, MOL PLANT PATHOL, V1, P91, DOI 10.1046/j.1364-3703.2000.00017.x; Kim CH, 2000, NAT STRUCT BIOL, V7, P415, DOI 10.1038/75202; Kong F, 1999, VIROLOGY, V259, P200, DOI 10.1006/viro.1999.9763; KRONER P, 1989, J VIROL, V63, P5302, DOI 10.1128/JVI.63.12.5302-5309.1989; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MARSH LE, 1991, VIROLOGY, V182, P76, DOI 10.1016/0042-6822(91)90650-Z; MILLER WA, 1985, NATURE, V313, P68, DOI 10.1038/313068a0; Nicolas E, 1998, J BIOL CHEM, V273, P17216, DOI 10.1074/jbc.273.27.17216; Parikh BA, 2002, J BIOL CHEM, V277, P41428, DOI 10.1074/jbc.M205463200; Rajamohan F, 1999, PROTEIN EXPRES PURIF, V16, P359, DOI 10.1006/prep.1999.1084; Rajamohan F, 1999, BIOCHEM BIOPH RES CO, V260, P453, DOI 10.1006/bbrc.1999.0922; Schmitz I, 1996, VIROLOGY, V226, P281, DOI 10.1006/viro.1996.0656; Sivakumaran K, 2004, J VIROL, V78, P6091, DOI 10.1128/JVI.78.12.6091-6101.2004; SMIRNYAGINA E, 1994, VIROLOGY, V198, P427, DOI 10.1006/viro.1994.1054; STIRPE F, 1988, NUCLEIC ACIDS RES, V16, P405; Sun JH, 1997, VIROLOGY, V236, P348, DOI 10.1006/viro.1997.8742; Sun JH, 1997, VIROLOGY, V233, P63, DOI 10.1006/viro.1997.8583; Sun JH, 1996, VIROLOGY, V226, P1, DOI 10.1006/viro.1996.0622; TAYLOR S, 1994, PLANT J, V5, P827, DOI 10.1046/j.1365-313X.1994.5060827.x; TOMLINSON JA, 1974, J GEN VIROL, V22, P225, DOI 10.1099/0022-1317-22-2-225; Toulme F, 2000, EMBO J, V19, P6853, DOI 10.1093/emboj/19.24.6853; Tumer NE, 1999, CURR TOP MICROBIOL, V240, P139; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; USSERY MA, 1977, ANN NY ACAD SCI, V284, P431, DOI 10.1111/j.1749-6632.1977.tb21979.x; Wang ML, 2003, GENET ENG P, V25, P143; Wang P, 1999, NUCLEIC ACIDS RES, V27, P1900, DOI 10.1093/nar/27.8.1900; Watanabe K, 1997, BIOSCI BIOTECH BIOCH, V61, P994, DOI 10.1271/bbb.61.994; ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0; Zoubenko O, 2000, PLANT MOL BIOL, V44, P219, DOI 10.1023/A:1006443626864	49	37	44	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20069	20075		10.1074/jbc.M413452200	http://dx.doi.org/10.1074/jbc.M413452200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15764597	hybrid			2022-12-25	WOS:000229113700077
J	Gingerich, DJ; Gagne, JM; Salter, DW; Hellmann, H; Estelle, M; Ma, LG; Vierstra, RD				Gingerich, DJ; Gagne, JM; Salter, DW; Hellmann, H; Estelle, M; Ma, LG; Vierstra, RD			Cullins 3a and 3b assemble with members of the broad complex/tramtrack/bric-a-brac (BTB) protein family to form essential ubiquitin-protein ligases (E3s) in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RESPONSIVE GENE-EXPRESSION; POZ-DOMAIN; INTERACTING PROTEIN; INTERACTION MOTIF; BOX PROTEIN; S-PHASE; SCF; COMPLEX; DEGRADATION	Selective modification of proteins by ubiquitination is directed by diverse families of ubiquitin-protein ligases (or E3s). A large collection of E3s use Cullins (CULs) as scaffolds to form multisubunit E3 complexes in which the CUL binds a target recognition subcomplex and the RBX1 docking protein, which delivers the activated ubiquitin moiety. Arabidopsis and rice contain a large collection of CUL isoforms, indicating that multiple CUL-based E3s exist in plants. Here we show that Arabidopsis CUL3a and CUL3b associate with RBX1 and members of the broad complex/tramtrack/bric-a-brac (BTB) protein family to form BTB E3s. Eighty genes encoding BTB domain-containing proteins were identified in the Arabidopsis genome, indicating that a diverse array of BTB E3s is possible. In addition to the BTB domain, the encoded proteins also contain various other interaction motifs that likely serve as target recognition elements. DNA microarray analyses show that BTB genes are expressed widely in the plant and that tissue-specific and isoform-specific patterns exist. Arabidopsis defective in both CUL3a and CUL3b are embryo-lethal, indicating that BTB E3s are essential for plant development.	Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Free Univ Berlin, Inst Biol & Appl Genet, D-14195 Berlin, Germany; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	University of Wisconsin System; University of Wisconsin Madison; Indiana University System; Indiana University Bloomington; Free University of Berlin; Yale University	Vierstra, RD (corresponding author), Univ Wisconsin, Dept Genet, 425-G Henry Mall, Madison, WI 53706 USA.	vierstra@wisc.edu	Gagne, Jennifer M/B-2866-2009	Gagne, Jennifer M/0000-0003-2563-087X; Gingerich, Derek/0000-0003-3553-1613	NIGMS NIH HHS [F32-GM68361] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM068361] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; Azevedo C, 2001, TRENDS PLANT SCI, V6, P354, DOI 10.1016/S1360-1385(01)01960-4; Banno H, 2000, PLANT CELL PHYSIOL, V41, P617, DOI 10.1093/pcp/41.5.617; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Capron A, 2003, PLANT CELL, V15, P2370, DOI 10.1105/tpc.013847; Capron A, 2003, TRENDS PLANT SCI, V8, P83, DOI 10.1016/S1360-1385(02)00028-6; Cheung AY, 2004, PLANT CELL, V16, P257, DOI 10.1105/tpc.016550; Chiba T, 2004, CURR PROTEIN PEPT SC, V5, P177, DOI 10.2174/1389203043379783; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dias DC, 2002, P NATL ACAD SCI USA, V99, P16601, DOI 10.1073/pnas.252646399; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Dong XN, 2004, CURR OPIN PLANT BIOL, V7, P547, DOI 10.1016/j.pbi.2004.07.005; Downes BP, 2003, PLANT J, V35, P729, DOI 10.1046/j.1365-313X.2003.01844.x; Du LQ, 2004, PLANT MOL BIOL, V54, P549, DOI 10.1023/B:PLAN.0000038269.98972.bb; Duttweiler HM, 1996, TRENDS GENET, V12, P340, DOI 10.1016/S0168-9525(96)80008-4; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; Farras R, 2001, EMBO J, V20, P2742, DOI 10.1093/emboj/20.11.2742; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Furukawa M, 2002, J BIOL CHEM, V277, P15758, DOI 10.1074/jbc.M108565200; Gagne JM, 2002, P NATL ACAD SCI USA, V99, P11519, DOI 10.1073/pnas.162339999; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Gray WM, 1999, GENE DEV, V13, P1678, DOI 10.1101/gad.13.13.1678; Gray WM, 2002, PLANT CELL, V14, P2137, DOI 10.1105/tpc.003178; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; Ha CM, 2004, PLANT CELL PHYSIOL, V45, P1361, DOI 10.1093/pcp/pch201; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Inada S, 2004, PLANT CELL, V16, P887, DOI 10.1105/tpc.019901; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kim S, 2004, PLANT PHYSIOL, V136, P3639, DOI 10.1104/pp.104.049189; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kominami K, 1998, GENES CELLS, V3, P721, DOI 10.1046/j.1365-2443.1998.00225.x; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Laux T, 1997, PLANT CELL, V9, P989, DOI 10.1105/tpc.9.7.989; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MA L, 2005, IN PRESS PLANT PHYSL; Meyers BC, 2004, PLANT PHYSIOL, V135, P801, DOI 10.1104/pp.104.039495; Michel JJ, 2003, J BIOL CHEM, V278, P22828, DOI 10.1074/jbc.M210358200; Motchoulski A, 1999, SCIENCE, V286, P961, DOI 10.1126/science.286.5441.961; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nayak S, 2002, CURR BIOL, V12, P277, DOI 10.1016/S0960-9822(02)00682-6; Nemeth K, 1998, GENE DEV, V12, P3059, DOI 10.1101/gad.12.19.3059; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Risseeuw EP, 2003, PLANT J, V34, P753, DOI 10.1046/j.1365-313X.2003.01768.x; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Shen WH, 2002, MOL BIOL CELL, V13, P1916, DOI 10.1091/mbc.E02-02-0077; Shiu SH, 2003, PLANT PHYSIOL, V132, P530, DOI 10.1104/pp.103.021964; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Smalle J, 2004, ANNU REV PLANT BIOL, V55, P555, DOI 10.1146/annurev.arplant.55.031903.141801; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Thelander M, 2002, PLANT MOL BIOL, V49, P69, DOI 10.1023/A:1014440531842; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wang KLC, 2004, NATURE, V428, P945, DOI 10.1038/nature02516; Weber H, 2005, PLANT PHYSIOL, V137, P83, DOI 10.1104/pp.104.052654; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Woodger FJ, 2004, PLANT CELL PHYSIOL, V45, P945, DOI 10.1093/pcp/pch100; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	73	118	204	3	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18810	18821		10.1074/jbc.M413247200	http://dx.doi.org/10.1074/jbc.M413247200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15749712	hybrid			2022-12-25	WOS:000228932300033
J	Gabai, VL; Budagova, KR; Sherman, MY				Gabai, VL; Budagova, KR; Sherman, MY			Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents	ONCOGENE			English	Article						Hsp72; prostate cancer; chemoresistance; apoptosis; signal transduction	NF-KAPPA-B; INDUCED APOPTOSIS; TERMINAL KINASE; ENHANCED RADIOSENSITIVITY; PROTEASOME INHIBITORS; BREAST-CANCER; ACTIVATION; DEATH; PATHWAY; HEAT-SHOCK-PROTEIN-72	The major heat shock protein Hsp72 is expressed at high levels in various types of cancer. Here we attempt to clarify the role of Hsp72 in prostate cancer cells by studying the effects of specific downregulation of this protein using siRNA and antisense RNA approaches. Contrary to previous reports, specific depletion of Hsp72 did not reduce viability of the prostate carcinoma cell lines PC-3 and DU-145. However, even short-term downregulation of Hsp72 in these cells made them more sensitive to hyperthermia, inhibitors of proteasome and Hsp90, and tumor necrosis factor. Interestingly, prolonged downregulation of Hsp72 in PC-3 cells over 3 weeks aggravated these effects, as well as enhanced the sensitivity of cells to oxidative stress, radiation, cis-platinum, vinblastin and taxol. The increased sensitivity to the anticancer agents was due to increased apoptosis, as well as other types of cell death, which resulted in the loss of clonogenic survival. Prolonged downregulation of Hsp72 led to severe suppression of the major survival pathways, ERK and NF-kappa B, which may be responsible for enhanced sensitivity of prostate carcinoma cells to a variety of anticancer treatments, as well as reduction of the cell's capability of forming colonies in soft agar.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Med Radiol Res Ctr, Obninsk 249020, Russia	Boston University	Sherman, MY (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	Sherman@biochem.bumc.bu.edu	Gabai, Vladimir L/I-1650-2013	Gabai, Vladimir L/0000-0003-4505-4718; Sherman, Michael/0000-0003-3345-073X				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2002, CURR OPIN CHEM BIOL, V6, P493, DOI 10.1016/S1367-5931(02)00343-5; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Costa MJM, 1997, ONCOL REP, V4, P1113; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Ekedahl J, 2003, CANCER BIOL THER, V2, P663; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Gabai VL, 2000, MOL CELL BIOL, V20, P6826, DOI 10.1128/MCB.20.18.6826-6836.2000; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gasparian AV, 2002, J CELL SCI, V115, P141; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hostein I, 2001, CANCER RES, V61, P4003; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Hwang TS, 2003, J GASTROEN HEPATOL, V18, P690, DOI 10.1046/j.1440-1746.2003.03011.x; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Musch MW, 2001, CELL GROWTH DIFFER, V12, P419; Nanbu K, 1998, CANCER DETECT PREV, V22, P549, DOI 10.1046/j.1525-1500.1998.00069.x; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nylandsted J, 2002, CANCER RES, V62, P7139; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Orlowski RZ, 2002, J BIOL CHEM, V277, P27864, DOI 10.1074/jbc.M201519200; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Roninson IB, 2003, CANCER RES, V63, P2705; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; VargasRoig LM, 1997, CANCER DETECT PREV, V21, P441; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Volm M, 2002, CLIN EXP METASTAS, V19, P385, DOI 10.1023/A:1016361924216; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yaglom J, 2003, MOL CELL BIOL, V23, P3813, DOI 10.1128/MCB.23.11.3813-3824.2003; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374	50	112	114	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3328	3338		10.1038/sj.onc.1208495	http://dx.doi.org/10.1038/sj.onc.1208495			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735699				2022-12-25	WOS:000228881800011
J	Nijjar, T; Bassett, E; Garbe, J; Takenaka, Y; Stampfer, MR; Gilley, D; Yaswen, P				Nijjar, T; Bassett, E; Garbe, J; Takenaka, Y; Stampfer, MR; Gilley, D; Yaswen, P			Accumulation and altered localization of telomere-associated protein TRF2 in immortally transformed and tumor-derived human breast cells	ONCOGENE			English	Article						telomeres; senescence; immortalization	MAMMARY EPITHELIAL-CELLS; MAMMALIAN TELOMERES; IMMORTALIZATION; SENESCENCE; EXPRESSION; P53; CONVERSION; ARREST; CANCER; LINES	We have used cultured human mammary epithelial cells (HMEC) and breast tumor-derived lines to gain information on defects that occur during breast cancer progression. HMEC immortalized by a variety of agents ( the chemical carcinogen benzo( a) pyrene, oncogenes c-myc and ZNF217, and/or dominant negative p53 genetic suppressor element GSE22) displayed marked upregulation (10-15 fold) of the telomere-binding protein, TRF2. Upregulation of TRF2 protein was apparently due to differences in post-transcriptional regulation, as mRNA levels remained comparable infinite lifespan and immortal HMEC. TRF2 protein was not upregulated by the oncogenic agents alone in the absence of immortalization, nor by expression of exogenously introduced hTERT genes. We found TRF2 levels to be at least twofold higher than in control cells in 11/15 breast tumor cell lines, suggesting that elevated TRF2 levels are a frequent occurrence during the transformation of breast tumor cells in vivo. The dispersed distribution of TRF2 throughout the nuclei in some immortalized and tumor-derived cells indicated that not all the TRF2 was associated with telomeres in these cells. The process responsible for accumulation of TRF2 in immortalized HMEC and breast tumor-derived cell lines may promote tumorigenesis by contributing to the cells' ability to maintain an indefinite lifespan.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Indiana University System; Indiana University-Purdue University Indianapolis	Gilley, D (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Bldg 70A1118,1 Cyclotron Rd, Berkeley, CA 94720 USA.	dpgilley@iupui.edu; P_Yaswen@lbl.gov			NATIONAL CANCER INSTITUTE [R37CA024844, F32CA108480, R01CA024844] Funding Source: NIH RePORTER; NCI NIH HHS [CA-108480, CA-24844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Feldser DM, 2003, NAT REV CANCER, V3, P623, DOI 10.1038/nrc1142; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Klapper W, 2003, LEUKEMIA, V17, P2007, DOI 10.1038/sj.leu.2403086; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakagami Yoshihiro, 2002, Radiat Med, V20, P121; Nijjar T, 1999, CANCER RES, V59, P5112; Nonet GH, 2001, CANCER RES, V61, P1250; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667; Stampfer MR, 2003, CANCER LETT, V194, P199, DOI 10.1016/S0304-3835(02)00707-3; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3; Yaswen P, 2002, INT J BIOCHEM CELL B, V34, P1382, DOI 10.1016/S1357-2725(02)00047-X; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	29	30	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 5	2005	24	20					3369	3376		10.1038/sj.onc.1208482	http://dx.doi.org/10.1038/sj.onc.1208482			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735711	Green Submitted			2022-12-25	WOS:000228881800015
J	Hansen, AM; Gu, YJ; Li, M; Andrykovitch, M; Waugh, DS; Jin, DJ; Ji, XH				Hansen, AM; Gu, YJ; Li, M; Andrykovitch, M; Waugh, DS; Jin, DJ; Ji, XH			Structural basis for the function of stringent starvation protein A as a transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; RNA-POLYMERASE; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; ACID TOLERANCE; NULL MUTATION; LENS; EXPRESSION; EVOLUTION; REFINEMENT	Stringent starvation protein A ( SspA) of Escherichia coli is an RNA polymerase-associated transcriptional activator for the lytic development of phage P1 and is essential for stationary phase-induced acid tolerance of E. coli. We report the crystal structure of Yersinia pestis SspA, which is 83% identical to E. coli SspA in amino acid sequence and is functionally complementary in supporting the lytic growth of phage P1 and acid resistance of an E. coli sspA mutant. The structure reveals that SspA assumes the characteristic fold of glutathione S-transferase (GST). However, SspA lacks GST activity and does not bind glutathione. Three regions of SspA are flexible, the N and C termini and the alpha 2-helix. The structure also reveals a conserved surface-exposed pocket composed of residues from a loop between helices alpha 3 and alpha 4. The functional roles of these structural features were investigated by assessing the ability of deletion and site-directed mutants to confer acid resistance of E. coli and to activate transcription from a phage P1 late promoter, thereby supporting the lytic growth of phage P1. The results indicate that the flexible regions are not critical for SspA function, whereas the surface pocket is important for both transcriptional activation of the phage P1 late promoter and acid resistance of E. coli. The size, shape, and property of the pocket suggest that it mediates protein-protein interactions. SspA orthologs from Y. pestis, Vibrio cholerae, and Pseudomonas aeruginosa are all functional in acid resistance of E. coli, whereas only Y. pestis SspA supports phage P1 growth.	NCI, Transcript Control Sect, Gene Regulat & Chromosome Biol Lab, NIH, Frederick, MD 21702 USA; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark; NCI, Macromol Crystallog Lab, NIH, Frederick, MD 21702 USA; SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Southern Denmark; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Jin, DJ (corresponding author), NCI, Transcript Control Sect, Gene Regulat & Chromosome Biol Lab, NIH, 1050 Boyles St,Bldg 469,Rm 127, Frederick, MD 21702 USA.	djjin@helix.nih.gov; jix@ncifcrf.gov	Gu, Yijun/B-6017-2012; Ji, Xinhua/C-9664-2012	Ji, Xinhua/0000-0001-6942-1514	NCI NIH HHS [N01-CO-24000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010632, Z01BC010326] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Andrykovitch M, 2003, ACTA CRYSTALLOGR D, V59, P881, DOI 10.1107/S0907444903005699; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Atlung T, 1997, MOL MICROBIOL, V24, P7, DOI 10.1046/j.1365-2958.1997.3151679.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baron GS, 1998, MOL MICROBIOL, V29, P247, DOI 10.1046/j.1365-2958.1998.00926.x; Bearson S, 1997, FEMS MICROBIOL LETT, V147, P173, DOI 10.1016/S0378-1097(96)00503-4; Bousset L, 2001, BIOCHEMISTRY-US, V40, P13564, DOI 10.1021/bi011007b; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; Brunger AT, 1997, METHOD ENZYMOL, V277, P243, DOI 10.1016/S0076-6879(97)77015-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgess R.R., 1987, RNA POLYM REGULATION, P3; Choi JH, 1998, J BIOL CHEM, V273, P29915, DOI 10.1074/jbc.273.45.29915; Chuang CC, 1999, BIOPHYS J, V76, P679, DOI 10.1016/S0006-3495(99)77235-8; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeReuse H, 1997, RES MICROBIOL, V148, P289, DOI 10.1016/S0923-2508(97)81585-9; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Dixon DP, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews3004; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hansen AM, 2005, MOL MICROBIOL, V56, P719, DOI 10.1111/j.1365-2958.2005.04567.x; Hansen AM, 2003, MOL MICROBIOL, V48, P1621, DOI 10.1046/j.1365-2958.2003.03533.x; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hommais F, 2001, MOL MICROBIOL, V40, P20, DOI 10.1046/j.1365-2958.2001.02358.x; ISHIHAMA A, 1979, J MOL BIOL, V129, P517, DOI 10.1016/0022-2836(79)90466-2; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kulkarni AA, 2001, J BIOL CHEM, V276, P32136, DOI 10.1074/jbc.M104580200; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lauriano CM, 2004, P NATL ACAD SCI USA, V101, P4246, DOI 10.1073/pnas.0307690101; LIN JS, 1995, J BACTERIOL, V177, P4097, DOI 10.1128/jb.177.14.4097-4104.1995; Merrell DS, 2002, CURR OPIN MICROBIOL, V5, P51, DOI 10.1016/S1369-5274(02)00285-0; Merrell DS, 2002, MOL MICROBIOL, V43, P1471, DOI 10.1046/j.1365-2958.2002.02857.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mooney RA, 1998, J BACTERIOL, V180, P3265, DOI 10.1128/JB.180.13.3265-3275.1998; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishida M, 1998, J MOL BIOL, V281, P135, DOI 10.1006/jmbi.1998.1927; Nudler E, 2002, GENES CELLS, V7, P755, DOI 10.1046/j.1365-2443.2002.00563.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; Rife CL, 2003, PROTEINS, V53, P777, DOI 10.1002/prot.10452; ROSNER JL, 1972, VIROLOGY, V48, P679, DOI 10.1016/0042-6822(72)90152-3; Rossjohn J, 1998, STRUCT FOLD DES, V6, P721, DOI 10.1016/S0969-2126(98)00074-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Sukhodolets MV, 1998, J BIOL CHEM, V273, P7018, DOI 10.1074/jbc.273.12.7018; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMAREV SI, 1988, NATURE, V336, P86, DOI 10.1038/336086a0; TOMAREV SI, 1991, J BIOL CHEM, V266, P24226; Tomarev SI, 1995, J MOL EVOL, V41, P1048; TOUNG YPS, 1992, BIOCHEM BIOPH RES CO, V182, P355, DOI 10.1016/S0006-291X(05)80152-4; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; WILLIAMS MD, 1994, MOL MICROBIOL, V11, P1029, DOI 10.1111/j.1365-2958.1994.tb00381.x; WILLIAMS MD, 1991, GENE, V109, P21, DOI 10.1016/0378-1119(91)90584-X; Xu Q, 2003, P NATL ACAD SCI USA, V100, P1286, DOI 10.1073/pnas.0337479100; YARMOLINSKY MB, 1988, BACTERIOPHAGES, V1, P291; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	68	44	45	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17380	17391		10.1074/jbc.M501444200	http://dx.doi.org/10.1074/jbc.M501444200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15735307	hybrid			2022-12-25	WOS:000228615500103
J	Miyake, I; Hakomori, Y; Misu, Y; Nakadate, H; Matsuura, N; Sakamoto, M; Sakai, R				Miyake, I; Hakomori, Y; Misu, Y; Nakadate, H; Matsuura, N; Sakamoto, M; Sakai, R			Domain-specific function of ShcC docking protein in neuroblastoma cells	ONCOGENE			English	Article						ShcC; neuroblastoma; dominant-negative form; SH2 domain; Src family kinase	RECEPTOR TYROSINE KINASE; ADAPTER PROTEIN; CYCLE PROGRESSION; HEMATOPOIETIC-CELLS; SH3 DOMAINS; GROWTH; SRC; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION	ShcC is a family member of the Shc docking proteins that possess two different phosphotyrosine-binding motifs and conduct signals as Grb2-binding substrates of various receptor tyrosine kinases. We have recently shown that some neuroblastoma cell lines, such as NB-39-nu cells, express a protein complex of hyperphosphorylated ShcC and anaplastic lymphoma kinase (ALK), which is self-activated by gene amplification. Here, we demonstrate that the expression of a mutant ShcC lacking Grb2-binding sites, 3YF-ShcC, significantly impaired the survival, differentiation and motility of NB-39-nu cells by blocking the ERK and Akt pathways. On the other hand, cells overexpressing ShcC or 3YF-ShcC, but not a mutant ShcC that lacks SH2, showed decreased anchorage independency and in vivo tumorigenicity, suggesting a novel ShcC-specific suppressive effect through its SH2 domain on cell transformation. Notably, overexpression of ShcC suppressed the sustained phosphorylation of Src family kinase after cell detachment, which might be independent of phosphorylation of Grb2-binding site. It was indicated that the Src/Fyn-Cas pathway is modulated as a target of these suppressive effects by ShcC. Reciprocal change of ShcC expression and phosphorylation observed in malignant neuroblastoma cell lines might be explained by these phosphotyrosine-dependent and - independent functions of ShcC.	Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan; Kitasato Univ, Sch Med, Dept Pediat, Sagamihara, Kanagawa 2288555, Japan; Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1608582, Japan	National Cancer Center - Japan; Kitasato University; Keio University	Sakai, R (corresponding author), Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	rsakai@gan2.res.ncc.go.jp		Sakai, Ryuichi/0000-0001-6833-1103				Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Collins LR, 1999, J CELL BIOL, V147, P1561, DOI 10.1083/jcb.147.7.1561; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; MCNEIL PL, 1985, J CELL BIOL, V101, P372, DOI 10.1083/jcb.101.2.372; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Nakamura T, 1996, ONCOGENE, V13, P1111; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OBryan JP, 1996, J BIOL CHEM, V271, P11787, DOI 10.1074/jbc.271.20.11787; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Pelicci G, 1996, ONCOGENE, V13, P633; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; Stevenson LE, 1999, CELL GROWTH DIFFER, V10, P61; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Wang YJ, 2002, J CELL BIOCHEM, V87, P424, DOI 10.1002/jcb.10321; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei L, 2002, J CELL BIOCHEM, V87, P439, DOI 10.1002/jcb.10322; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989	38	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3206	3215		10.1038/sj.onc.1208523	http://dx.doi.org/10.1038/sj.onc.1208523			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735675				2022-12-25	WOS:000228728100014
J	Kobayashi, S; Nantz, R; Kitamura, T; Higashikubo, R; Horikoshi, N				Kobayashi, S; Nantz, R; Kitamura, T; Higashikubo, R; Horikoshi, N			Combined inhibition of extracellular signal-regulated kinases and HSP90 sensitizes human colon carcinoma cells to ionizing radiation	ONCOGENE			English	Article						nonsteroidal anti-inflammatory drug; MAP kinase; HSP90; radiosensitization	GROWTH-FACTOR RECEPTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TUMOR-CELLS; CYCLIN D1; ACTIVATION; CYCLOOXYGENASE-2; GELDANAMYCIN; RAS; PHOSPHORYLATION; RESVERATROL	Indomethacin, a common nonsteroidal anti-inflammatory drug, has been shown to enhance radiation-mediated cell-killing effect through the activation of p38 mitogen-activated protein kinase ( MAPK). We found that indomethacin strongly reduced the basal level of extracellular signal-regulated kinases 1 and 2 (ERK1/2) in HT-29 human colon carcinoma cells. The inhibition of ERK1/2 by indomethacin was only observed in cells with high basal activities of ERK1/2 such as HT-29 cells, but not in cells with low basal activities, such as HeLa. Cell cycle analysis of HT-29 cells exposed with indomethacin showed a partial G1/S arrest and slow DNA synthesis. However, the treatment with NS398, a specific COX-1/2 inhibitor, failed to show any effect on cell cycle, indicating that the inhibition of COX-1/2 is not responsible for cell cycle arrest. Since U0126, a specific inhibitor for MEK1/2, also induced a partial G1/S arrest, the G1/S arrest induced by indomethacin is, at least in part, caused by the inhibition of ERK1/2. Cell proliferation of HT-29 was inhibited by the treatment of U0126 but not in HeLa cells, and the treatment of HT-29 cells with U0126 enhanced radiation sensitivity possibly due to the accumulation of cells in G1 phase. We found that 17-allylamino-17-demethoxygeldanamycin, a geldanamycin delivative, radiosensitized HT-29 cells at a relatively low dose of irradiation, and indomethacin and U0126 further enhanced this effect. Therefore, tumor cells with elevated ERK1/2 activity can be effectively sensitized to radiation treatment by a combinational inhibition of HSP90 and MAPK activity.	Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Dept Radiat Oncol, St Louis, MO 63108 USA	Washington University (WUSTL)	Horikoshi, N (corresponding author), Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Dept Radiat Oncol, 4511 Forest Pk Blvd, St Louis, MO 65108 USA.	horikoshi@radonc.wustl.edu	Horikoshi, Nobuo/Y-8245-2019	Horikoshi, Nobuo/0000-0001-8464-8178	NATIONAL CANCER INSTITUTE [R01CA098666, P01CA104457] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA104457, R01CA98666] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1997, CANCER CHEMOTH PHARM, V40, P60, DOI 10.1007/s002800050626; Barnard J, 2001, GASTROENTEROLOGY, V120, P1872, DOI 10.1053/gast.2001.25297; Bisht KS, 2003, CANCER RES, V63, P8984; Bradbury CM, 2001, CANCER RES, V61, P7689; Brooks P, 1999, RHEUMATOLOGY, V38, P779, DOI 10.1093/rheumatology/38.8.779; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; Gerosa M, 2003, CURR OPIN ONCOL, V15, P188, DOI 10.1097/00001622-200305000-00002; Gupta AK, 2001, CANCER RES, V61, P4278; Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2; Joe AK, 2002, CLIN CANCER RES, V8, P893; Jones MK, 1999, NAT MED, V5, P1418; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Machida H, 2003, INT J RADIAT BIOL, V79, P973, DOI 10.1080/09553000310001626135; Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3; MARNETT LJ, 1995, PREV MED, V24, P103, DOI 10.1006/pmed.1995.1017; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Maurizi M, 1996, BRIT J CANCER, V74, P1253, DOI 10.1038/bjc.1996.525; Menon SG, 2003, CANCER RES, V63, P2109; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Munster PN, 2001, CANCER RES, V61, P2945; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; O'Dwyer PJ, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.35643; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; Purdy JA, 2002, SEMIN RADIAT ONCOL, V12, P199, DOI 10.1053/srao.2002.32432; Rice PL, 2003, CANCER RES, V63, P616; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Roberts RB, 2002, P NATL ACAD SCI USA, V99, P1521, DOI 10.1073/pnas.032678499; Russell JS, 2003, CLIN CANCER RES, V9, P3749; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sheng HM, 2001, CANCER RES, V61, P2670; Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stivala LA, 2001, J BIOL CHEM, V276, P22586, DOI 10.1074/jbc.M101846200; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wolter F, 2001, J NUTR, V131, P2197, DOI 10.1093/jn/131.8.2197; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhong H, 2004, INT J CANCER, V112, P585, DOI 10.1002/ijc.20438; Zhu A, 1996, INT J RADIAT ONCOL, V34, P809, DOI 10.1016/0360-3016(95)02184-1	50	24	27	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3011	3019		10.1038/sj.onc.1208508	http://dx.doi.org/10.1038/sj.onc.1208508			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735687				2022-12-25	WOS:000228649500010
J	Wang, L; Dai, W; Lu, L				Wang, L; Dai, W; Lu, L			Ultraviolet irradiation-induced K+ channel activity involving p53 activation in corneal epithelial cells	ONCOGENE			English	Article						gene expression; Kv channel blocker; DNA damage; apoptosis	DNA-DAMAGE CHECKPOINT; MOLECULAR EPIDEMIOLOGY; SIGNALING PATHWAYS; GENOMIC STABILITY; LEUKEMIA-CELLS; SKIN TUMORS; APOPTOSIS; KINASE; CARCINOGENESIS; ATM	Recent studies from our lab found that ultraviolet (UV) irradiation induces a voltage-gated potassium (Kv) channel activation and subsequently activates JNK signaling pathway resulting in apoptosis. The present study in rabbit corneal epithelial (RCE) cells is to investigate mechanisms of UV irradiation-induced Kv channel activity involving p53 activation in parallel to DNA damage-induced signaling pathway. UV irradiation-induced signaling events were characterized by measurements of JNK activation and further downstream p53 phosphorylation. UV irradiation elicited an early response in the cell membrane through activation of Kv channels to activate the JNK signaling pathway and p53 phosphorylation. Exposure of RCE cells to UV irradiation within a few min resulted in JNK and p53 activations that were markedly inhibited by suppression of Kv channel activity. However, suppression of Kv channel activity failed to prevent p53 activation induced by extended DNA damages through prolonging UV exposure time ( more than 15 min). In addition, caffeine inhibited UV-induced activation of SEK, an upstream MAPK kinase of JNK, resulting in suppression of both Kv channel-involved and DNA damage-induced p53 activation. Our results indicate in these cells that UV irradiation induces earlier and later intracellular events that link to activation of JNK and p53. The early event in response to UV irradiation is initiated by activating Kv channels in the cell membrane, and the later event is predominated by UV irradiation-caused DNA damage.	Univ Calif Los Angeles, Sch Med, Harbor UCLA Med Ctr, Div Mol Med, Torrance, CA 90502 USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; New York Medical College	Lu, L (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Dept Med,Div Mol Med, 1124 W Carson St,C-2, Torrance, CA 90502 USA.	lluou@ucla.edu		Dai, Wei/0000-0003-0169-8327	NCI NIH HHS [R01 CA074229, CA 79229] Funding Source: Medline; NEI NIH HHS [R01 EY012953, EY12953, R01 EY015281, EY15282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074229] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY015281, R01EY012953] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABRAHAMS PJ, 1995, MUTAT RES-DNA REPAIR, V336, P169, DOI 10.1016/0921-8777(94)00049-C; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Blaise R, 2001, LEUKEMIA LYMPHOMA, V42, P1173, DOI 10.3109/10428190109097742; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Cross JV, 2004, BIOCHEM J, V381, P675, DOI 10.1042/BJ20040591; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gentiletti F, 2002, ONCOGENE, V21, P867, DOI 10.1038/sj.onc.1205137; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Goodarzi Aaron A, 2003, Prog Cell Cycle Res, V5, P393; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Hofseth LJ, 2004, CHEST, V125, p83S, DOI 10.1378/chest.125.5_suppl.83S-a; Hussain SP, 2000, P NATL ACAD SCI USA, V97, P12770, DOI 10.1073/pnas.220416097; Hussain SP, 1998, CANCER RES, V58, P4023; Irarrazabal CE, 2004, P NATL ACAD SCI USA, V101, P8809, DOI 10.1073/pnas.0403062101; Ito K, 2003, J CELL PHYSIOL, V196, P276, DOI 10.1002/jcp.10289; Kastan MB, 2004, BIOMED PHARMACOTHER, V58, P72, DOI 10.1016/S0753-3322(03)00045-3; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kwan R, 2001, MOL CELL BIOL, V21, P7183, DOI 10.1128/MCB.21.21.7183-7190.2001; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lieber JG, 2004, BLOOD, V103, P852, DOI 10.1182/blood-2003-04-1030; Lu L, 2003, INVEST OPHTH VIS SCI, V44, P5102, DOI 10.1167/iovs.03-0591; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Medina D, 2002, ENVIRON MOL MUTAGEN, V39, P178, DOI 10.1002/em.10064; Melnikova VO, 2003, ONCOGENE, V22, P5958, DOI 10.1038/sj.onc.1206595; Nishikawa T, 2003, CANCER LETT, V194, P45, DOI 10.1016/S0304-3835(03)00057-0; Pluquet O, 2003, J BIOL CHEM, V278, P11879, DOI 10.1074/jbc.M207396200; Ringvold A, 1998, ACTA OPHTHALMOL SCAN, V76, P149, DOI 10.1034/j.1600-0420.1998.760205.x; Roderick C, 2003, J MEMBRANE BIOL, V196, P41, DOI 10.1007/s00232-003-0623-1; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Shirai N, 2002, CARCINOGENESIS, V23, P1541, DOI 10.1093/carcin/23.9.1541; Smirnova IS, 2001, CELL BIOL INT, V25, P1101, DOI 10.1006/cbir.2001.0709; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Tang Zhong-Hui, 2003, Ai Zheng, V22, P1057; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; VANKRANEN HJ, 1995, CARCINOGENESIS, V16, P1141; Wang L, 2004, INVEST OPHTH VIS SCI, V45, P1796, DOI 10.1167/iovs.03-1056; Wang L, 2003, INVEST OPHTH VIS SCI, V44, P5095, DOI 10.1167/iovs.03-0590; Wang L, 1999, J BIOL CHEM, V274, P3678, DOI 10.1074/jbc.274.6.3678; Wang LD, 1998, WORLD J GASTROENTERO, V4, P287, DOI 10.3748/wjg.v4.i4.287; Wang XW, 1999, ANTICANCER RES, V19, P4759; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Xu DZ, 1999, BLOOD, V94, P139, DOI 10.1182/blood.V94.1.139.413k11_139_145; Yang L, 2004, WORLD J GASTROENTERO, V10, P155; Ye RQ, 2001, J BIOL CHEM, V276, P4828, DOI 10.1074/jbc.M004894200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Ziegler A, 1996, PHOTOCHEM PHOTOBIOL, V63, P432, DOI 10.1111/j.1751-1097.1996.tb03064.x	56	25	25	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3020	3027		10.1038/sj.onc.1208547	http://dx.doi.org/10.1038/sj.onc.1208547			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15750624	Green Accepted			2022-12-25	WOS:000228649500011
J	Andrique, T; Ayrault, O; Larsen, CJ; Seite, P				Andrique, T; Ayrault, O; Larsen, CJ; Seite, P			In vitro and in vivo analysis of the interaction between 5.8S rRNA and ARF protein reveal a new difference between murine p19(ARF) and human p14(ARF)	ONCOGENE			English	Article						p14(ARF); p19(ARF); 5.8s; chip-RNA	TUMOR-SUPPRESSOR; B23	Both human and murine ARF proteins have been recently reported to impair rRNA maturation and ribosomes biogenesis through a p53-independent pathway. A specific interaction has been established between 5.8S rRNA and the murine p19(ARF) specie. We report here, by use of both in vitro and ChIP-RNA assays, the absence of any interaction between the human p14(ARF) and the homologous 5.8S rRNA. Our data are not consistent with the involvement of a 5.8S-p14(ARF) complex in ribosome biogenesis in man. Rather they suggest that the human protein does not require such an interaction to achieve a similar function. This result is a new argument in favour of functional differences between human and murine ARF proteins.	Oncol Mol Lab, EA 3805, Pole Biol Sante, F-86022 Poitiers, France	Universite de Poitiers	Seite, P (corresponding author), Oncol Mol Lab, EA 3805, Pole Biol Sante, 40 Ave Recteur Pineau, F-86022 Poitiers, France.	paule.seite@univ-poitiers.fr		Seite, Paule/0000-0002-7809-7610; Andrique, Laetitia/0000-0001-7840-8135				Ayrault O, 2004, ONCOGENE, V23, P8097, DOI 10.1038/sj.onc.1207968; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Olivier A, 2003, ONCOGENE, V22, P1945, DOI 10.1038/sj.onc.1206214; QUELLE DE, 1995, CELL, V83, P993; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Wadhwa R, 2002, J BIOL CHEM, V277, P36665, DOI 10.1074/jbc.M203222200; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300	16	5	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2580	2584		10.1038/sj/onc.1208457	http://dx.doi.org/10.1038/sj/onc.1208457			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735732				2022-12-25	WOS:000228180600016
J	Chamboredon, S; Castellazzi, M				Chamboredon, S; Castellazzi, M			v-Jun downregulates the alpha 2(I) collagen target gene indirectly through Sp1/3	ONCOGENE			English	Article						v-Jun; Sp1; Sp3; alpha 2 (I) collagen; cell transformation; primary chick embryo fibroblasts	EXTRACELLULAR-MATRIX PROTEIN; CHICK-EMBRYO FIBROBLASTS; C-JUN; TRANSCRIPTION FACTORS; PROMOTER ACTIVITY; BINDING PROTEINS; CELL-LINES; IN-VIVO; EXPRESSION; SPARC	Transformation of chick embryo fibroblasts (CEFs) by the v-Jun oncoprotein correlates with a downregulation of the alpha 2 (I) collagen gene. To investigate whether this gene constitutes a direct target of v-Jun, an analysis of a large proximal fragment of the promoter, extending from position -1080 to +109, was performed. Transient transfections with -1080/+109 and deleted derivatives revealed that a short proximal fragment, -433/-11, is the target for repression by v-Jun. Extensive analysis, conducted in CEFs and in Sp1/3-deficient Drosophila SL2 cells, further showed that (i) high constitutive activity of -433/-11 requires a direct binding of the ubiquitous Sp1 and/or Sp3 transcription factors acting on two distinct motifs, that is, a proximal TCC-rich region and an upstream GC box, and that (ii) repression by v-Jun does not require any direct binding of the oncoprotein to the DNA, but an indirect binding within a v-Jun-Sp1/3-DNA chromatin-associated complex. This situation is reminiscent of a situation previously reported with the tata-less, SPARC ( secreted protein, acidic, and rich in cysteine) target promoter that regulates the expression of another extracellular matrix component in the same model of cell transformation. Taken together, these data reinforce the view that, at least in CEFs, v-Jun downregulates a family of direct target genes by binding to the DNA indirectly through Sp1/3.	Ecole Normale Super, INSERM, U412, Unite Virol Humaine,IFR128 BioSci Lyon Gerland, F-69364 Lyon, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Castellazzi, M (corresponding author), Ecole Normale Super, INSERM, U412, Unite Virol Humaine,IFR128 BioSci Lyon Gerland, 46 Allee Italie, F-69364 Lyon, France.	marc.castellazzi@ens-lyon.fr						Andreu T, 1998, J BIOL CHEM, V273, P13848, DOI 10.1074/jbc.273.22.13848; Basso J, 2000, ONCOGENE, V19, P4876, DOI 10.1038/sj.onc.1203863; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BOEDTKER H, 1985, ANN NY ACAD SCI, V460, P85, DOI 10.1111/j.1749-6632.1985.tb51159.x; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken RA, 2000, MATRIX BIOL, V19, P569, DOI 10.1016/S0945-053X(00)00105-0; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Chamboredon S, 2003, ONCOGENE, V22, P4047, DOI 10.1038/sj.onc.1206713; Chlenski A, 2002, CANCER RES, V62, P7357; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Du W, 1999, CANCER RES, V59, P2059; Gao MH, 1996, CANCER RES, V56, P4229; Hartl M, 2003, CURR CANCER DRUG TAR, V3, P41, DOI 10.2174/1568009033333781; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; JURDIC P, 1995, ONCOGENE, V11, P1699; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kassel O, 2004, GENE DEV, V18, P2518, DOI 10.1101/gad.322404; Kilbey A, 1996, ONCOGENE, V12, P2409; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; MIKAELIAN I, 1993, J VIROL, V67, P734; Mok SC, 1996, ONCOGENE, V12, P1895; Oberst C, 1999, VIROLOGY, V253, P193, DOI 10.1006/viro.1998.9499; Pallante KM, 1996, J BIOL CHEM, V271, P25233, DOI 10.1074/jbc.271.41.25233; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Sengupta PK, 2003, CANCER RES, V63, P1789; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; Travers H, 1996, CELL GROWTH DIFFER, V7, P1353; Trojanowska M, 1998, J MOL MED, V76, P266, DOI 10.1007/s001090050216; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; VOGELI G, 1981, P NATL ACAD SCI-BIOL, V78, P5334, DOI 10.1073/pnas.78.9.5334; Vogt PK, 1999, CELL GROWTH DIFFER, V10, P777; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wu YZ, 2003, ONCOGENE, V22, P8891, DOI 10.1038/sj.onc.1206898	51	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2547	2557		10.1038/sj.onc.1208489	http://dx.doi.org/10.1038/sj.onc.1208489			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735704				2022-12-25	WOS:000228180600012
J	Steiner, FA; Hong, JA; Fischette, MR; Beer, DG; Guo, ZS; Chen, GA; Weiser, TS; Kassis, ES; Nguyen, DM; Lee, S; Trepel, JB; Schrump, DS				Steiner, FA; Hong, JA; Fischette, MR; Beer, DG; Guo, ZS; Chen, GA; Weiser, TS; Kassis, ES; Nguyen, DM; Lee, S; Trepel, JB; Schrump, DS			Sequential 5-Aza 2 '-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells	ONCOGENE			English	Article						TFPI-2; 5-aza 2 '-deoxycytidine; depsipeptide FK228; lung cancer; esophageal cancer	HISTONE DEACETYLASE INHIBITORS; SERINE-PROTEASE INHIBITOR; HUMAN GLIOMA-CELLS; FACTOR VIIA; DNA METHYLATION; IN-VITRO; DEMETHYLASE ACTIVITY; CARCINOMA-CELLS; UP-REGULATION; GENE	cDNA arrays were used to examine gene induction in CALU-6 and H460 lung cancer cells mediated by sequential 5-aza 2-deoxycytidine (DAC)/depsipeptide FK228 (DP) exposure in order to identify translational end points for clinical trials evaluating these agents. In both cell lines, sequential DAC/DP treatment induced expression of tissue factor pathway inhibitor-2 (TFPI-2), an inhibitor of Factor VII: tissue factor signal transduetion known to diminish the malignant phenotype of cancer cells. TFPI-2 expression was diminished or absent in 16 of 32 cell lines established from thoracic malignancies. Sequential DAC/DP treatment induced TFPI-2 in cancer cells deficient for TFPI-2 expression in the basal state. Promoter methylation coincided with loss of TFPI-2 expression in a number of cancer tines. TFPI-2 promoter methylation was observed in one of five pulmonary adenocarcinomas, and seven of seven esophageal adenocarcinomas, but not corresponding normal tissues. DP enhanced acetylation of TFPI-2-associated histones in CALU-6 cells. DP or PDBU, alone, induced TFPI-2 expression in cancer cells deficient for TFPI-2 expression in the absence of promoter methylation. In these cells, DP-mediated TFPI-2 induction was abrogated by calphostin. Induction of TFPI-2 by distinct, yet cooperative mechanisms involving chromatin remodeling and PKC signaling strengthens the preclinical rationale for sequential administration of DNA demethylating agents and HDAC inhibitors in cancer patients. Furthermore, induction of TFPI-2 may be a useful surrogate marker of treatment response in individuals receiving sequential DAC/DP infusions.	NCI, Thorac Oncol Sect, Surg Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; Univ Michigan, Ctr Med, Thorac Surg Sect, Ann Arbor, MI USA; NCI, Med Oncol Clin Res Unit, Ctr Canc Res, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schrump, DS (corresponding author), NCI, Thorac Oncol Sect, Surg Branch, Ctr Canc Res,NIH, Bldg 10,Room 4-3942,10 Ctr Dr MSC1201, Bethesda, MD 20892 USA.	david_schrump@nih.gov	Chen, Guoan/J-9140-2018; Guo, Zong Sheng/H-3098-2019	Chen, Guoan/0000-0001-5608-6761; Guo, Zong Sheng/0000-0002-4624-9907	NATIONAL CANCER INSTITUTE [Z01SC010093, Z01BC010519, ZIASC010093, Z01SC006743, ZICSC006743] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 1999, P NATL ACAD SCI USA, V96, P8663, DOI 10.1073/pnas.96.15.8663; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Attwood JT, 2002, CELL MOL LIFE SCI, V59, P241, DOI 10.1007/s00018-002-8420-z; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Bender CM, 1998, CANCER RES, V58, P95; Brinkmann H, 2001, J BIOL CHEM, V276, P22491, DOI 10.1074/jbc.M100206200; Bromberg ME, 1999, THROMB HAEMOSTASIS, V82, P88; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Chand HS, 2004, BLOOD, V103, P1069, DOI 10.1182/blood-2003-06-1930; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; Detich N, 2003, J BIOL CHEM, V278, P27586, DOI 10.1074/jbc.M303740200; Fahrner JA, 2002, CANCER RES, V62, P7213; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herman MP, 2001, J CLIN INVEST, V107, P1117, DOI 10.1172/JCI10403; Hjortoe GM, 2004, BLOOD, V103, P3029, DOI 10.1182/blood-2003-10-3417; Izumi H, 2000, FEBS LETT, V481, P31, DOI 10.1016/S0014-5793(00)01902-5; Jin MS, 2001, GYNECOL ONCOL, V83, P325, DOI 10.1006/gyno.2001.6394; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kamei S, 2001, BBA-GENE STRUCT EXPR, V1517, P430, DOI 10.1016/S0167-4781(00)00298-0; Kast C, 2003, J BIOL CHEM, V278, P6787, DOI 10.1074/jbc.M210935200; Kazama Y, 2000, THROMB HAEMOSTASIS, V83, P141; Kim YB, 2000, J ANTIBIOT, V53, P1191, DOI 10.7164/antibiotics.53.1191; Konduri SD, 2003, ONCOGENE, V22, P4509, DOI 10.1038/sj.onc.1206695; Konduri SD, 2003, INT J ONCOL, V22, P1277; Konduri SD, 2002, ONCOGENE, V21, P921, DOI 10.1038/sj.onc.1204983; Konduri SD, 2001, INT J ONCOL, V18, P127; Konduri SD, 2000, CLIN EXP METASTAS, V18, P303, DOI 10.1023/A:1011085820250; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; LEHMAN TA, 1991, CANCER RES, V51, P4090; Liu YY, 1999, ARCH BIOCHEM BIOPHYS, V370, P112, DOI 10.1006/abbi.1999.1371; Markl IDC, 2001, CANCER RES, V61, P5875; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Neaud V, 2000, J BIOL CHEM, V275, P35565, DOI 10.1074/jbc.M006101200; Nguyen DM, 2004, CLIN CANCER RES, V10, P1813, DOI 10.1158/1078-0432.CCR-0901-3; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Rao CN, 2000, BIOCHEM BIOPH RES CO, V276, P1286, DOI 10.1006/bbrc.2000.3611; Rao CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P82, DOI 10.1006/abbi.1996.0484; Rao CN, 2003, INT J ONCOL, V22, P843; Rao CN, 1999, BIOCHEM BIOPH RES CO, V255, P94, DOI 10.1006/bbrc.1999.0153; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; Rao CN, 2001, CLIN CANCER RES, V7, P570; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581; SHAPIRO GI, 1995, CANCER RES, V55, P6200; Shinoda E, 1999, J BIOL CHEM, V274, P5379, DOI 10.1074/jbc.274.9.5379; Siegbahn A, 2000, BLOOD, V96, P3452, DOI 10.1182/blood.V96.10.3452.h8003452_3452_3458; Sorensen BB, 1999, J BIOL CHEM, V274, P21349, DOI 10.1074/jbc.274.30.21349; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tasiou A, 2001, INT J ONCOL, V19, P591; Ueki T, 2002, ONCOGENE, V21, P2114, DOI 10.1038/sj.onc.1205275; Vairapandi M, 2004, J CELL BIOCHEM, V91, P572, DOI 10.1002/jcb.10749; Versteeg HH, 2000, J BIOL CHEM, V275, P28750, DOI 10.1074/jbc.M907635199; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Weiser TS, 2001, ANN THORAC SURG, V71, P295, DOI 10.1016/S0003-4975(00)02421-8; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010; Wojtukiewicz MZ, 2003, THROMB HAEMOSTASIS, V90, P140; Yu XD, 2002, J NATL CANCER I, V94, P504; ZACHARSKI LR, 1987, CANCER, V60, P2675, DOI 10.1002/1097-0142(19871201)60:11<2675::AID-CNCR2820601117>3.0.CO;2-C; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697; Zhu WG, 2001, CANCER RES, V61, P1327	75	38	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 31	2005	24	14					2386	2397		10.1038/sj.onc.1208376	http://dx.doi.org/10.1038/sj.onc.1208376			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735751				2022-12-25	WOS:000227877400011
J	Linke, T; Dawson, H; Harrison, EH				Linke, T; Dawson, H; Harrison, EH			Isolation and characterization of a microsomal acid retinyl ester hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CARBOXYLESTERASES; BILE-SALT; ENDOPLASMIC-RETICULUM; BINDING-PROTEIN; STELLATE CELLS; HEPATIC-UPTAKE; HYDROLYSIS; METABOLISM; PURIFICATION; EXPRESSION	Previous work demonstrated both acid and neutral, bile salt-independent retinyl ester hydrolase activities in rat liver homogenates. Here we present the purification, identification, and characterization of an acid retinyl ester hydrolase activity from solubilized rat liver microsomes. Purification to homogeneity was achieved by sequential chromatography using SP-Sepharose cation exchange, phenyl-Sepharose hydrophobic interaction, concanavalin A- Sepharose affinity and Superose 12 gel filtration chromatography. The isolated protein had a monomer molecular mass of similar to 62 kDa, as measured by mass spectrometry. Gel filtration chromatography of the purified protein revealed a native molecular mass of similar to 176 kDa, indicating that the protein exists as a homotrimeric complex in solution. The purified protein was identified as carboxylesterase ES-10 (EC 3.1.1.1) by N-terminal Edman sequencing and extensive LC-MS/MS sequence analysis and cross-reaction with an anti-ES-10 antibody. Glycosylation analysis revealed that only one of two potential N-linked glycosylation sites is occupied by a high mannose-type carbohydrate structure. Using retinyl palmitate in a micellar assay system the enzyme was active over a broad pH range and displayed Michaelis-Menten kinetics with a K-m of 86 mu M. Substrate specificity studies showed that ES-10 is also able to catalyze hydrolysis of triolein. Cholesteryl oleate was not a substrate for ES-10 under these assay conditions. Real time reverse transcriptase-PCR and Western blot analysis revealed that ES-10 is highly expressed in liver and lung. Lower levels of ES-10 mRNA were also found in kidney, testis, and heart. A comparison of mRNA expression levels in liver demonstrated that ES-10, ES-4,and ES-3 were expressed at significantly higher levels than ES-2, an enzyme previously thought to play a major role in retinyl ester metabolism in liver. Taken together these data indicate that carboxylesterase ES-10 plays a major role in the hydrolysis of newly-endocytosed, chylomicron retinyl esters in both neutral and acidic membrane compartments of liver cells.	USDA ARS, Lab Phytonutrients, Beltsville, MD 20705 USA; USDA ARS, Lab Nutrients Requirements & Funct, Beltsville, MD 20705 USA	United States Department of Agriculture (USDA); United States Department of Agriculture (USDA)	Harrison, EH (corresponding author), USDA ARS, Lab Phytonutrients, BARC E,Bldg 307C, Beltsville, MD 20705 USA.	harrisoe@ba.ars.usda.gov	Harrison, Earl H/AAN-5378-2021; Dawson, Harry/ABG-2734-2021; Dawson, Harry/H-8242-2013	Dawson, Harry/0000-0002-7648-9952; 	NIDDK NIH HHS [DK044498, R01 DK044498] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044498] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AzaisBraesco V, 1995, BBA-LIPID LIPID MET, V1259, P271, DOI 10.1016/0005-2760(95)00173-5; BLANER WS, 1994, RETINOIDS BIOL CHEM, P299; BLOMHOFF R, 1985, J BIOL CHEM, V260, P3566; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; Cooper AD, 1997, J LIPID RES, V38, P2173; DIFALUSY MA, 1999, BIOCHIM BIOPHYS ACTA, V1439, P40; Fazio S, 2000, TRENDS CARDIOVAS MED, V10, P23, DOI 10.1016/S1050-1738(00)00033-5; GAD MZ, 1991, J LIPID RES, V32, P685; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P8487; Hagen E, 1999, J LIPID RES, V40, P309; Harrison EH, 1998, ANNU REV NUTR, V18, P259, DOI 10.1146/annurev.nutr.18.1.259; HARRISON EH, 1995, J LIPID RES, V36, P1498; HARRISON EH, 1990, METHOD ENZYMOL, V189, P459; Harrison EH, 1997, BBA-LIPID LIPID MET, V1347, P177, DOI 10.1016/S0005-2760(97)00052-0; HARRISON EH, 1989, J BIOL CHEM, V264, P17142; Hosokawa M, 2001, ARCH BIOCHEM BIOPHYS, V389, P245, DOI 10.1006/abbi.2001.2346; Kristensen DB, 2000, HEPATOLOGY, V32, P268; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MEDDA S, 1992, EUR J BIOCHEM, V206, P801, DOI 10.1111/j.1432-1033.1992.tb16987.x; MENTLEIN R, 1987, BIOCHIM BIOPHYS ACTA, V913, P27, DOI 10.1016/0167-4838(87)90228-7; MENTLEIN R, 1987, BIOCHEM J, V245, P863, DOI 10.1042/bj2450863; MERCIER M, 1994, BBA-LIPID LIPID MET, V1212, P176, DOI 10.1016/0005-2760(94)90251-8; Molotkov A, 2004, BIOCHEM J, V383, P295, DOI 10.1042/BJ20040621; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; NAPOLI JL, 1989, ARCH BIOCHEM BIOPHYS, V274, P192, DOI 10.1016/0003-9861(89)90430-X; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RIGTRUP KM, 1994, AM J CLIN NUTR, V60, P111, DOI 10.1093/ajcn/60.1.111; RIGTRUP KM, 1992, BIOCHEMISTRY-US, V31, P2920, DOI 10.1021/bi00126a011; Sanghani SP, 2002, EUR J BIOCHEM, V269, P4387, DOI 10.1046/j.1432-1033.2002.03121.x; Satoh T, 1998, ANNU REV PHARMACOL, V38, P257, DOI 10.1146/annurev.pharmtox.38.1.257; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schindler R, 1998, EUR J BIOCHEM, V251, P863, DOI 10.1046/j.1432-1327.1998.2510863.x; Silveira ER, 1998, J NUTR BIOCHEM, V9, P446, DOI 10.1016/S0955-2863(98)00040-0; Sun GS, 1997, J BIOL CHEM, V272, P24488, DOI 10.1074/jbc.272.39.24488; van Bennekum AM, 2000, BIOCHEMISTRY-US, V39, P4900, DOI 10.1021/bi9927235; YAN BF, 1995, J BIOL CHEM, V270, P19128, DOI 10.1074/jbc.270.32.19128	40	22	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23287	23294		10.1074/jbc.M413585200	http://dx.doi.org/10.1074/jbc.M413585200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15767260	hybrid			2022-12-25	WOS:000229741800087
J	Ferdinandusse, S; Denis, S; Overmars, H; Van Eeckhoudt, L; Van Veldhoven, PP; Duran, M; Wanders, RJA; Baes, M				Ferdinandusse, S; Denis, S; Overmars, H; Van Eeckhoudt, L; Van Veldhoven, PP; Duran, M; Wanders, RJA; Baes, M			Developmental changes of bile acid composition and conjugation in L- and D-bifunctional protein single and double knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL BETA-OXIDATION; CHROMATOGRAPHY-MASS SPECTROMETRY; FARNESOID-X RECEPTOR; ACYL-COA OXIDASE; ZELLWEGER-SYNDROME; N-ACYLTRANSFERASE; RAT-LIVER; 25-HYDROXYLATION PATHWAY; ONTOGENIC REGULATION; BINDING-PROTEIN	Peroxisomal beta-oxidation is an essential step in bile acid synthesis, since it is required for shortening of C27-bile acid intermediates to produce mature C24-bile acids. D-Bifunctional protein (DBP) is responsible for the second and third step of this beta-oxidation process. However, both patients and mice with a DBP deficiency still produce C24-bile acids, although C27-intermediates accumulate. An alternative pathway for bile acid biosynthesis involving the peroxisomal L-bifunctional protein (LBP) has been proposed. We investigated the role of LBP and DBP in bile acid synthesis by analyzing bile acids in bile, liver, and plasma from LBP, DBP, and LBP: DBP double knock-out mice. Bile acid biosynthesis, estimated by the ratio of C27/C24-bile acids, was more severely affected in double knock-out mice as compared with DBP-/- mice but was normal in LBP-/- mice. Unexpectedly, trihydroxycholestanoyl-CoA oxidase was inactive in double knock-out mice due to a peroxisomal import defect, preventing us from drawing any firm conclusion about the potential role of LBP in an alternative bile acid biosynthesis pathway. Interestingly, the immature C27-bile acids in DBP and double knock-out mice remained unconjugated in juvenile mice, whereas they occurred as taurine conjugates after weaning, probably contributing to the minimal weight gain of the mice during the lactation period. This correlated with a marked induction of bile acyl-CoA:amino acid N-acyltransferase expression and enzyme activity between postnatal days 10 and 21, whereas the bile acyl-CoA synthetases increased gradually with age. The nuclear receptors hepatocyte nuclear factor-4 alpha, farnesoid X receptor, and peroxisome proliferator receptor alpha did not appear to be involved in the up-regulation of the transferase.	Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands; Katholieke Univ Leuven, Clin Chem Lab, B-3000 Louvain, Belgium; Dept Pharmacol, B-3000 Louvain, Belgium	University of Amsterdam; Academic Medical Center Amsterdam; KU Leuven	Ferdinandusse, S (corresponding author), Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, F0-224,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	S.Ferdinandusse@amc.uva.nl	, Van Veldhoven Paul/U-6359-2019	, Van Veldhoven Paul/0000-0002-4478-2564; Baes, Myriam/0000-0002-2525-2269; Ferdinandusse, Sacha/0000-0002-7738-5709				Baes M, 2000, J BIOL CHEM, V275, P16329, DOI 10.1074/jbc.M001994200; Baes M, 2002, J NEUROPATH EXP NEUR, V61, P368, DOI 10.1093/jnen/61.4.368; Balasubramaniyan N, 2005, AM J PHYSIOL-GASTR L, V288, pG251, DOI 10.1152/ajpgi.00351.2004; Baumgart E, 1996, P NATL ACAD SCI USA, V93, P13748, DOI 10.1073/pnas.93.24.13748; Bjorkhem I, 2001, J BIOL CHEM, V276, P37004, DOI 10.1074/jbc.M103828200; Bootsma AH, 1999, J INHERIT METAB DIS, V22, P307, DOI 10.1023/A:1005543802724; Bove KE, 2000, PEDIATR DEVEL PATHOL, V3, P1, DOI 10.1007/s100240050001; CLAYTON PT, 1988, J INHERIT METAB DIS, V11, P165, DOI 10.1007/BF01804226; Cuebas DA, 2002, BIOCHEM J, V363, P801, DOI 10.1042/0264-6021:3630801; CZUBA B, 1982, J BIOL CHEM, V257, P8761; DUANE WC, 1988, J CLIN INVEST, V82, P82, DOI 10.1172/JCI113605; DUANE WC, 1988, HEPATOLOGY, V8, P613, DOI 10.1002/hep.1840080329; Falany CN, 1997, J LIPID RES, V38, P1139; Ferdinandusse S, 2003, MOL GENET METAB, V79, P281, DOI 10.1016/S1096-7192(03)00108-2; Gao B, 2004, J HEPATOL, V41, P201, DOI 10.1016/j.jhep.2004.04.029; Honda A, 2000, J LIPID RES, V41, P442; Huyghe S, 2001, BIOCHEM J, V353, P673, DOI 10.1042/0264-6021:3530673; Hwang ST, 2001, EXP BIOL MED, V226, P674, DOI 10.1177/153537020222600713; Hwang ST, 2002, GASTROENTEROLOGY, V122, P1483, DOI 10.1053/gast.2002.32982; Inoue Y, 2004, J BIOL CHEM, V279, P2480, DOI 10.1074/jbc.M311015200; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Jia YZ, 2003, J BIOL CHEM, V278, P47232, DOI 10.1074/jbc.M306363200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mihalik SJ, 2002, J BIOL CHEM, V277, P24771, DOI 10.1074/jbc.M203295200; O'Byrne J, 2003, J BIOL CHEM, V278, P34237, DOI 10.1074/jbc.M300987200; Pircher PC, 2003, J BIOL CHEM, V278, P27703, DOI 10.1074/jbc.M302128200; Qi C, 1999, J BIOL CHEM, V274, P15775, DOI 10.1074/jbc.274.22.15775; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Solaas K, 2004, J LIPID RES, V45, P1051, DOI 10.1194/jlr.M300291-JLR200; SUCHY FJ, 1985, PEDIATR RES, V19, P97, DOI 10.1203/00006450-198501000-00026; Une M, 1997, J BIOCHEM-TOKYO, V122, P655; VANVELDHOVEN PP, 1987, J BIOL CHEM, V262, P4310; Vreken P, 1998, J LIPID RES, V39, P2452; Wanders R.J., 2001, METABOLIC MOL BASES, P3219; WANDERS RJA, 1993, J BIOCHEM-TOKYO, V113, P577; Wanders RJA, 2001, BIOCHEM SOC T, V29, P250, DOI 10.1042/0300-5127:0290250; Xu RF, 1996, BIOCHEM BIOPH RES CO, V221, P271, DOI 10.1006/bbrc.1996.0585	38	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18658	18666		10.1074/jbc.M414311200	http://dx.doi.org/10.1074/jbc.M414311200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15769750	hybrid			2022-12-25	WOS:000228932300016
J	Hua, SM; Xu, C; Ma, HL; Inesi, G				Hua, SM; Xu, C; Ma, HL; Inesi, G			Interference with phosphoenzyme isomerization and inhibition of the sarco-endoplasmic reticulum Ca2+ ATPase by 1,3-dibromo-2,4,6-tris(methylisothiouronium) benzene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-PUMP; CRYSTAL-STRUCTURE; PROTEINASE-K; CA2+-ATPASE; THAPSIGARGIN; MECHANISM; PHOSPHATE	ATP hydrolysis and Ca2+ transport by the sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) are inhibited by 1,3-dibromo-2,4,6-tris(methylisothiouronium) benzene (Br-2-TITU) in the micromolar range (Berman, M. C., and Karlish, S. J. (2003) Biochemistry 42, 3556-3566). In a study of the mechanism of inhibition, we found that Br-2-TITU allows the enzyme to bind Ca2+ and undergo phosphorylation by ATP. The level of ADP-sensitive phosphoenzyme (i.e. E1P-2Ca(2+)) observed in the transient state following addition of ATP is much higher in the presence than in the absence of the inhibitor. Br-2-TITU does not interfere with enzyme phosphorylation by Pi in the reverse direction of the cycle (i.e. E2P) and produces only a slight inhibition of its hydrolytic cleavage. The inhibitory effect of Br-2-TITU on steady state ATPase velocity is attributed to interference with the E1P-2Ca(2+) to E2P-2Ca(2+) transition. In fact, experiments on conformation-dependent protection from proteolytic digestion suggest that, in the presence of Br-2-TITU, the loops connecting the "A" domain to the ATPase transmembrane region undergo greater fluctuation than expected in the E2 and E2P states. Optimal stability of the gathered headpiece domains is thereby prevented. These effects are opposite to those of thapsigargin, in which the mechanism of inhibition is related to stabilization of a highly compact ATPase conformation and interference with Ca2+ binding and phosphoenzyme formation. Our experiments with Br-2-TITU provide the first demonstration of a kinetic limit posed by an inhibitor on the wild-type enzyme.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Inesi, G (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.	ginesi@umaryland.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069830] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL69830] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berman MC, 2003, BIOCHEMISTRY-US, V42, P3556, DOI 10.1021/bi026071n; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; TAL DM, 1995, TETRAHEDRON, V51, P3823, DOI 10.1016/0040-4020(95)00105-H; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944	17	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17579	17583		10.1074/jbc.M500472200	http://dx.doi.org/10.1074/jbc.M500472200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746094	hybrid			2022-12-25	WOS:000228807200003
J	Sun, JZ; Blaskovich, MA; Jove, R; Livingston, SK; Coppola, D; Sebti, SDM				Sun, JZ; Blaskovich, MA; Jove, R; Livingston, SK; Coppola, D; Sebti, SDM			Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity	ONCOGENE			English	Article						STAT3; apoptosis; antitumor activity; cucurbitacins; JAK2	SIGNALING INDUCES APOPTOSIS; BREAST-CARCINOMA CELLS; DNA-BINDING ACTIVITY; CONSTITUTIVE ACTIVATION; SRC ONCOPROTEIN; MYELOMA CELLS; CANCER-CELLS; EXPRESSION; TRANSDUCER; GROWTH	Constitutive activation of the JAK/STAT3 pathway is a major contributor to oncogenesis. In the present study, structure-activity relationship (SAR) studies with five cucurbitacin (Cuc) analogs, A, B, E, I, and Q, led to the discovery of Cuc Q, which inhibits the activation of STAT3 but not JAK2; Cuc A which inhibits JAK2 but not STAT3 activation; and Cuc B, E, and I, which inhibit the activation of both. Further more, these SAR studies demonstrated that conversion of the C3 carbonyl of the cucurbitacins to a hydroxyl results in loss of anti-JAK2 activity, whereas addition of a hydroxyl group to C11 of the cucurbitacins results in loss of anti-STAT3 activity. Cuc Q inhibits selectively the activation of STAT3 and induces apoptosis without inhibition of JAK2, Src, Akt, Erk, or JNK activation. Furthermore, Cuc Q induces apoptosis more potently in human and murine tumors that contain constitutively activated STAT3 (i.e., A549, MDA-MB-435, and v-Src/NIH 3T3) as compared to those that do not (i.e., H-Ras/NIH 3T3, MDA-MB-453, and NIH 3T3 cells). Finally, in a nude mouse tumor xenograft model, Cuc Q, but not Cuc A, suppresses tumor growth indicating that JAK2 inhibition is not sufficient to inhibit tumor growth and suggesting that the ability of Cuc Q to inhibit tumor growth is related to its anti-STAT3 activity. These studies further validate STAT3 as a drug discovery target and provide evidence that pharmacological agents that can selectively reduce the P-STAT3 levels in human cancer cells result in tumor apoptosis and growth inhibition.	Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Sebti, SDM (corresponding author), Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, MRC DRDIS, 12902 Magnolia Dr, Tampa, FL 33612 USA.	sebti@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [P01CA078038] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Berclaz G, 2001, INT J ONCOL, V19, P1155; Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863; Blaskovich MA, 2003, CANCER RES, V63, P1270; Bowman, 1999, Cancer Control, V6, P615; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Konnikova L, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-23; Lefebvre DC, 2003, BBA-PROTEINS PROTEOM, V1650, P40, DOI 10.1016/S1570-9639(03)00190-0; Lehmann U, 2003, J BIOL CHEM, V278, P661, DOI 10.1074/jbc.M210552200; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Mora LB, 2002, CANCER RES, V62, P6659; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 1999, CANCER RES, V59, P5059; Paner GP, 2003, ANTICANCER RES, V23, P2253; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shuai K, 1996, ONCOGENE, V13, P247; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Spiekermann K, 2002, EXP HEMATOL, V30, P262, DOI 10.1016/S0301-472X(01)00787-1; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Turkson J, 2004, MOL CANCER THER, V3, P261; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang T, 2003, BIOCHEM J, V376, P457, DOI 10.1042/BJ20030668	38	214	234	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3236	3245		10.1038/sj.onc.1208470	http://dx.doi.org/10.1038/sj.onc.1208470			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735720				2022-12-25	WOS:000228881800002
J	Holden, P; Keene, DR; Lunstrum, GP; Bachinger, HP; Horton, WA				Holden, P; Keene, DR; Lunstrum, GP; Bachinger, HP; Horton, WA			Secretion of cartilage oligomeric matrix protein is affected by the signal peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; 5-STRANDED COILED-COIL; EGF-LIKE MOTIF; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; CALCIUM-BINDING; PSEUDOACHONDROPLASIA; COMP; MUTATION; DOMAIN	Cartilage oligomeric matrix protein ( COMP) is a secreted glycoprotein found in the extracellular matrices of skeletal tissues. Mutations associated with two human skeletal dysplasias, pseudoachondroplasia and multiple epiphyseal dysplasia, disturb COMP secretion leading to intracellular accumulation of mutant COMP, especially in chondrocytes. Here we show that the manifestation of this secretory defect is dramatically influenced by the signal peptide that targets COMP for secretion. The comparison of wild type and mutant COMP secretion directed by the COMP or BM40 signal peptide in HEK-293 cells and rat chondrosarcoma cells revealed that the BM40 signal peptide substantially enhances secretion of mutant COMP that accumulates in endoplasmic reticulum-like structures when targeted by its own signal peptide. Additionally, we demonstrate that mutant COMP forms mixed pentamers with wild type COMP. Our findings suggest that the secretory defect in pseudoachondroplasia and multiple epiphyseal dysplasia is not specific for chondrocytes, nor does it require interaction of mutant COMP with other matrix proteins prior to transport from the cell. They also imply a previously unappreciated role for the signal peptide in the regulation of protein secretion beyond targeting to the endoplasmic reticulum.	Shriners Hosp Children, Res Ctr, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Horton, WA (corresponding author), Shriners Hosp Children, Res Ctr, 3101 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	wah@shcc.org						BIRD P, 1990, J BIOL CHEM, V265, P8420; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; Briggs MD, 2002, HUM MUTAT, V19, P465, DOI 10.1002/humu.10066; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Brostrom MA, 2003, CELL CALCIUM, V34, P345, DOI 10.1016/S0143-4160(03)00127-1; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; Cho JY, 2001, AM J MED GENET, V106, P251, DOI 10.1002/ajmg.10230; Delot E, 1998, J BIOL CHEM, V273, P26692, DOI 10.1074/jbc.273.41.26692; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; Dinser R, 2002, J CLIN INVEST, V110, P505, DOI 10.1172/JCI200214386; Duke J, 2003, APOPTOSIS, V8, P191, DOI 10.1023/A:1022926811397; Froeschke M, 2003, J BIOL CHEM, V278, P41914, DOI 10.1074/jbc.M302343200; Guo Y, 1998, EMBO J, V17, P5265, DOI 10.1093/emboj/17.18.5265; Hashimoto Y, 2003, AM J PATHOL, V163, P101, DOI 10.1016/S0002-9440(10)63634-6; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; Hecht JT, 2001, MATRIX BIOL, V20, P251, DOI 10.1016/S0945-053X(01)00136-6; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; Hou J, 2000, CELL CALCIUM, V27, P309, DOI 10.1054/ceca.2000.0125; Kim SJ, 2002, DEV CELL, V2, P207, DOI 10.1016/S1534-5807(01)00120-4; KOSFELD MD, 1992, J BIOL CHEM, V267, P16230; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Li Y, 1996, P NATL ACAD SCI USA, V93, P9606, DOI 10.1073/pnas.93.18.9606; LOHMANDER LS, 1994, ANN RHEUM DIS, V53, P8, DOI 10.1136/ard.53.1.8; Loughlin J, 1998, HUM MUTAT, pS10; LYKO F, 1995, J BIOL CHEM, V270, P19873, DOI 10.1074/jbc.270.34.19873; Mabuchi A, 2003, HUM GENET, V112, P84, DOI 10.1007/s00439-002-0845-9; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; Maddox BK, 2000, J BIOL CHEM, V275, P11412, DOI 10.1074/jbc.275.15.11412; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; Martoglio B, 2003, BIOCHEM SOC T, V31, P1243; Martoglio B, 1997, EMBO J, V16, P6636, DOI 10.1093/emboj/16.22.6636; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; MAYER U, 1995, FEBS LETT, V365, P129, DOI 10.1016/0014-5793(95)00438-F; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; Muller G, 1998, CONNECT TISSUE RES, V39, P233, DOI 10.3109/03008209809021499; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; Ozbek S, 2002, EMBO J, V21, P5960, DOI 10.1093/emboj/cdf628; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; Riessen R, 2001, ARTERIOSCL THROM VAS, V21, P47, DOI 10.1161/01.ATV.21.1.47; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; Rutkowski DT, 2003, J BIOL CHEM, V278, P30365, DOI 10.1074/jbc.M302117200; Rutkowski DT, 2001, P NATL ACAD SCI USA, V98, P7823, DOI 10.1073/pnas.141125098; Smith RKW, 2002, EQUINE VET J, V34, P726, DOI 10.2746/042516402776250423; Spitznagel L, 2004, BIOCHEM J, V377, P479, DOI 10.1042/BJ20031179; Svensson L, 2002, MOL CELL BIOL, V22, P4366, DOI 10.1128/MCB.22.12.4366-4371.2002; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; Unger S, 2001, AM J MED GENET, V106, P244, DOI 10.1002/ajmg.10234; VERTEL BM, 1989, J CELL BIOL, V109, P1827, DOI 10.1083/jcb.109.4.1827; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Zheng T, 1999, J BIOL CHEM, V274, P36623, DOI 10.1074/jbc.274.51.36623	56	24	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17172	17179		10.1074/jbc.M411716200	http://dx.doi.org/10.1074/jbc.M411716200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15749701	hybrid			2022-12-25	WOS:000228615500078
J	Jackson, D; Zheng, Y; Lyo, DG; Shen, YJ; Nakayama, K; Nakayama, KI; Humphries, MJ; Reyland, ME; Foster, DA				Jackson, D; Zheng, Y; Lyo, DG; Shen, YJ; Nakayama, K; Nakayama, KI; Humphries, MJ; Reyland, ME; Foster, DA			Suppression of cell migration by protein kinase C delta	ONCOGENE			English	Article						protein kinase C delta; cell migration; metastasis; breast cancer cells	GROWTH-FACTOR RECEPTOR; TUMOR PROMOTION; PLASMINOGEN-ACTIVATOR; DOWN-REGULATION; NIH 3T3-CELLS; CANCER; TUMORIGENICITY; BRYOSTATIN-1; MOTILITY; EPSILON	The ability of cancer cells to migrate is strongly correlated with malignant progression and metastasis. Survival signals that suppress apoptosis have also been linked to increased cell motility. We previously reported that suppression of protein kinase C delta (PKC delta) provided survival signals in a rat fibroblast model system. These studies have been extended to human breast cancer cells with differential cell motilities and PKC delta levels. BT-549 cells, which lack detectable expression of PKC delta, migrate very efficiently, whereas MCF-7 cells, which express high levels of PKC delta, migrate very poorly. Ectopic expression of PKC delta suppressed cell migration in the BT-549 cells, and downregulation of PKC delta enhanced cell migration in the MCF-7 cells. Downregulation of PKC delta in the MCF-7 cells also led to increased secretion of the matrix metalloprotease MMP-9. The migration of mouse embryo fibroblasts (MEFs) from wild type and PKC delta knockout mice was also examined and MEFs from PKC delta knockout mice had a five-fold increase in cell migration relative to the wild-type MEFs. These data provide evidence that PKC delta suppresses cell migration in both human breast cancer cells and in primary mouse fibroblasts, and indicate that the loss of PKC delta in human cancers could contribute to both cell survival and metastasis.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Fukuoka 8128582, Japan; Univ Colorado, Sch Dent, Dept Craniofacial Biol, Denver, CO 80262 USA	City University of New York (CUNY) System; Hunter College (CUNY); Kyushu University; University of Colorado System; University of Colorado Denver	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu			NCI NIH HHS [R01-CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [SO6-GM60654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas T, 2004, J BIOL CHEM, V279, P9970, DOI 10.1074/jbc.M306979200; Acs P, 1997, J BIOL CHEM, V272, P28793, DOI 10.1074/jbc.272.45.28793; Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Bartucci M, 2001, CANCER RES, V61, P6747; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Clamp A, 2002, ANTI-CANCER DRUG, V13, P673, DOI 10.1097/00001813-200208000-00001; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; HATA A, 1993, J BIOL CHEM, V268, P9122; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; Hornia A, 1999, MOL CELL BIOL, V19, P7672; HUPPI K, 1994, GENOMICS, V19, P161, DOI 10.1006/geno.1994.1028; Jackson DN, 2004, FASEB J, V18, P627, DOI 10.1096/fj.03-0979rev; Johnson MD, 1999, EXP CELL RES, V247, P105, DOI 10.1006/excr.1998.4336; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; Kruger JS, 2003, MOL CANCER RES, V1, P801; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Marshall JL, 2002, CANCER BIOL THER, V1, P409, DOI 10.4161/cbt.1.4.17; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; OHNO S, 1994, J BIOL CHEM, V269, P17495; Reddig PJ, 1999, CANCER RES, V59, P5710; Sevignani C, 2003, CANCER RES, V63, P1183; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; YANG Q, 2000, J HUM GENET, V47, P453; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zhong MH, 2002, ONCOGENE, V21, P1071, DOI 10.1038/sj/onc/1205165; Zhong MH, 2001, CELL GROWTH DIFFER, V12, P187	36	45	48	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3067	3072		10.1038/sj.onc.1208465	http://dx.doi.org/10.1038/sj.onc.1208465			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735725				2022-12-25	WOS:000228649500018
J	Zhang, BY; Srirangam, A; Potter, DA; Roman, A				Zhang, BY; Srirangam, A; Potter, DA; Roman, A			HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes	ONCOGENE			English	Article						human papillomavirus; ubiquitination; epidermal growth factor receptor; c-Cbl; human foreskin keratinocytes	HUMAN-PAPILLOMAVIRUS TYPE-16; GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR; E7; GENE; ONCOPROTEIN; ONCOGENE; E6; DEGRADATION; AUTOPHOSPHORYLATION	The E5 protein of human papillomavirus type 16 (HPV16) is a small hydrophobic protein, which localizes to the cell membrane, Golgi apparatus and endosomes. HPV16 E5 enhances the activation of the epidermal growth factor (EGFR). The activated EGFR is downregulated through the endocytic pathway, where E5 has been shown to inhibit endosomal acidification and trafficking. Ubiquitination of the activated EGFR plays a role in this downregulation. c-Cbl is a ubiquitin ligase that associates with the activated EGFR and targets it for degradation. Since E5 has been shown to form a complex with the EGFR, we tested the hypothesis that E5 affects the interaction of c-Cbl with the EGFR. We found a significant decrease of c-Cbl bound to the EGFR and of ubiquitinated EGFR in the presence of E5. E5 did not affect c-Cbl steady-state level, phosphorylation or translocation to the membrane. This novel result suggests that HPV16 E5 may, at least in part, upregulate EGFR-mediated signal transduction by inhibiting the interaction of c-Cbl with the EGFR, thereby decreasing c-Cbl-mediated degradation of the EGFR.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46204 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46204 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46204 USA; Walther Canc Inst, Indianapolis, IN USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Roman, A (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, 635 Barnhill Dr,Med Sci Bldg,Room 420, Indianapolis, IN 46202 USA.	aroman@iupui.edu			NCI NIH HHS [R56 CA113570, R56 CA113570-01] Funding Source: Medline; NIGMS NIH HHS [1P20-GM66402, P20 GM066402] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM066402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akerman GS, 2001, CANCER RES, V61, P3837; Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; de Melker AA, 2001, J CELL SCI, V114, P2167; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; Genther SM, 2003, J VIROL, V77, P2832, DOI 10.1128/JVI.77.5.2832-2842.2003; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hubbard SR, 1999, PROG BIOPHYS MOL BIO, V71, P343, DOI 10.1016/S0079-6107(98)00047-9; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1996, ONCOGENE, V12, P1117; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Mantovani F, 1999, SEMIN CANCER BIOL, V9, P387, DOI 10.1006/scbi.1999.0142; Mathur SP, 2001, AM J REPROD IMMUNOL, V46, P280, DOI 10.1034/j.1600-0897.2001.d01-14.x; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1992, CANCER SURV, V12, P197; PIM D, 1992, ONCOGENE, V7, P27; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Ravid T, 2004, J BIOL CHEM, V279, P37153, DOI 10.1074/jbc.M403210200; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SORKIN A, 1991, J BIOL CHEM, V266, P8355; Stoppler MC, 1996, VIROLOGY, V223, P251, DOI 10.1006/viro.1996.0475; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; VALLE GF, 1995, J GEN VIROL, V76, P1239, DOI 10.1099/0022-1317-76-5-1239; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zhang BY, 2002, J VIROL, V76, P220, DOI 10.1128/JVI.76.1.220-231.2002; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	46	62	67	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2585	2588		10.1038/sj.onc.1208453	http://dx.doi.org/10.1038/sj.onc.1208453			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735736	Green Accepted			2022-12-25	WOS:000228180600017
J	Camps, J; Ponsa, I; Ribas, M; Prat, E; Egozcue, J; Peinado, MA; Miro, R				Camps, J; Ponsa, I; Ribas, M; Prat, E; Egozcue, J; Peinado, MA; Miro, R			Comprehensive measurement of chromosomal instability in cancer cells: combination of fluorescence in situ hybridization and cytokinesis-block micronucleus assay	FASEB JOURNAL			English	Article						colorectal cancer; genetic instability; aneuploidy; nondisjunction; chromosomal rearrangements	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN-LYMPHOCYTES; CYTOGENETIC CHARACTERIZATION; NUCLEOPLASMIC BRIDGES; EVOLUTION; TUMORS; LINES	Most tumors show abnormal karyotypes involving either chromosome rearrangements and/or aneuploidies. The aim of our study is to measure the rate of both structural and numerical chromosome instability in two colorectal cancer cell lines: HCT116, and SW480 and its single subclones. To determine structural instability, we measured the nonclonal chromosome alterations of the last cell division by means of multicolor-fluorescence in situ hybridization (FISH). To quantify numerical instability, we used centromere-specific DNA probes to simultaneously detect chromosome loss and nondisjunctional events in binucleated cells obtained by cytokinesis-block micronucleus assay (CBMN). After clonal episodes, the structural chromosome instability rate increased significantly, confirming the large contribution of structural rearrangements to the heterogeneity of cancer cells. On the other hand, the aneuploidy rate was high and conserved in both the parental SW480 cell line and its subclones. The ability to differentiate chromosome loss and nondisjunction by the CBMN assay allowed us to conclude that no significant differences were detected among these events. Analysis of nucleoplasmic bridges, micronuclei, and nuclear blebs also demonstrated the differences among the structural instability rates of the parental cell line and its subclones. Overall, our results demonstrate the prevalence of structural over numerical chromosome instability in the subclones when comparing them with their parental cell line, confirming the contribution of ongoing chromosomal reorganizations in the generation of tumor cell heterogeneity.	Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Lab Citogenet, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Dept Biol Cellular Fisiol & Immunol, E-08193 Barcelona, Spain; Hosp Duran & Reynals, Inst Rec Oncol, IDIBELL, Barcelona, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals	Camps, J (corresponding author), Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Lab Citogenet, E-08193 Barcelona, Spain.	Jordi.Camps@uab.es	Peinado, Miguel A./A-5591-2008; Camps, Jordi/AAG-3080-2020	Peinado, Miguel A./0000-0002-4090-793X; Camps, Jordi/0000-0002-3165-3640; Ponsa, Immaculada/0000-0003-3436-1907; miro, rosa/0000-0003-2508-5074				Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Beheshti B, 2001, NEOPLASIA, V3, P62, DOI 10.1038/sj.neo.7900125; Camps J, 2004, ONCOL REP, V11, P1215; Duesberg P, 2003, CELL CYCLE, V2, P202, DOI 10.4161/cc.2.3.382; Fabarius A, 2003, CANCER GENET CYTOGEN, V143, P59, DOI 10.1016/S0165-4608(03)00003-7; Fenech M, 2002, DRUG DISCOV TODAY, V7, P1128, DOI 10.1016/S1359-6446(02)02502-3; FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Fenech M, 2003, MUTAT RES-GEN TOX EN, V534, P65, DOI 10.1016/S1383-5718(02)00249-8; Fenech M, 2002, MUTAT RES-FUND MOL M, V504, P131, DOI 10.1016/S0027-5107(02)00086-6; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Gutierrez Norma C, 2003, Hematol J, V4, P67, DOI 10.1038/sj.thj.6200226; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LOEB LA, 1991, CANCER RES, V51, P3075; LOEB LA, 1974, CANCER RES, V34, P2311; Masramon L, 2000, CANCER GENET CYTOGEN, V121, P17, DOI 10.1016/S0165-4608(00)00219-3; Mitelman F, 1995, INT SYSTEM HUMAN CYT; NORPPA H, 1993, MUTAGENESIS, V8, P519, DOI 10.1093/mutage/8.6.519; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ponsa I, 2001, RADIAT RES, V155, P424, DOI 10.1667/0033-7587(2001)155[0424:NDACLI]2.0.CO;2; Prat E, 2001, UROLOGY, V57, P986, DOI 10.1016/S0090-4295(01)00909-8; Ribas M, 2002, FASEB J, V16, P289, DOI 10.1096/fj.02-0425fje; Roschke AV, 2002, NEOPLASIA, V4, P19, DOI 10.1038/sj.neo.7900197; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Thomas P, 2003, MUTAGENESIS, V18, P187, DOI 10.1093/mutage/18.2.187; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; WEIER HUG, 1991, HUM GENET, V87, P489	30	38	39	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					828	+		10.1096/fj.04-2276fje	http://dx.doi.org/10.1096/fj.04-2276fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15760839				2022-12-25	WOS:000227901300021
J	Castino, R; Isidoro, C; Murphy, D				Castino, R; Isidoro, C; Murphy, D			Autophagy-dependent cell survival and cell death in an autosomal dominant familial neurohypophyseal diabetes insipidus in vitro model	FASEB JOURNAL			English	Article						vasopressin; apoptosis; dopamine; adFNDI	ENDOSOMAL-LYSOSOMAL SYSTEM; HYPOTHALAMIC NEURONS; APOPTOSIS; INHIBITION; HEREDITARY; MECHANISMS; RELEASE; GENE; POLYGLUTAMINE; EXPANSIONS	Mutations in the human gene encoding the antidiuretic hormone vasopressin (VP) cause autosomal dominant familial neurohypophyseal diabetes insipidus (adFNDI), a rare inherited disorder that presents as polydipsia and polyuria as a consequence of a loss of secretion of VP from posterior pituitary nerve terminals. Work from our laboratories has shown that adFNDI, like other neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's, is associated with autophagy. We have recently shown that the activation of autophagy in mouse neuroblastoma Neuro2a cells after adenoviral vector-mediated delivery of an adFNDI mutant VP transgene (Cys67stop) is a cell survival mechanism; its inhibition induces apoptosis. We now show that expression of Cys67stop sensitizes Neuro2a cells to the lethal effects of dopamine. This mode of cell death exhibits features typically associated with classical apoptosis. Yet inhibition of autophagy reversed these effects and rescued cell viability. We propose that autophagy-mediated cell death is a "two-hit" process: Following the cellular stress of the accumulation of a misfolded mutant protein, autophagy is prosurvival. However, a second insult triggers an autophagy-dependent apoptosis.	Henry Wellcome Labs Integrat Neurosci & Endocrino, Mol Neuroendocrinol Res Grp, Bristol BS1 3NY, Avon, England; Amedeo Avogadro Univ, Dept Med Sci, Lab Mol Pathol, Novara, Italy	University of Bristol; University of Eastern Piedmont Amedeo Avogadro	Murphy, D (corresponding author), Henry Wellcome Labs Integrat Neurosci & Endocrino, Mol Neuroendocrinol Res Grp, Dorothy Hodgkin Bldg,Whitson St, Bristol BS1 3NY, Avon, England.	d.murphy@bristol.ac.uk	Murphy, David/C-3967-2012; Isidoro, Ciro/J-6063-2016	Murphy, David/0000-0003-2946-0353; Isidoro, Ciro/0000-0002-5494-3034	Biotechnology and Biological Sciences Research Council [S18346] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Adamec E, 2000, NEUROSCIENCE, V100, P663, DOI 10.1016/S0306-4522(00)00281-5; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; BRAVERMAN LE, 1965, ANN INTERN MED, V63, P503, DOI 10.7326/0003-4819-63-3-503; BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132; Burbach JPH, 2001, PHYSIOL REV, V81, P1197, DOI 10.1152/physrev.2001.81.3.1197; Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x; Castino R, 2002, INT J CANCER, V97, P775, DOI 10.1002/ijc.10139; CASTINO R, 2005, FASEB J EXPRESS, DOI DOI 10.1096/F4.04-3162FJE; Cataldo AM, 1996, J NEUROSCI, V16, P186; Chen C, 2000, BIOCHEM BIOPH RES CO, V270, P816, DOI 10.1006/bbrc.2000.2520; Chen Quan, 2001, ScientificWorldJournal, V1, P142, DOI 10.1100/tsw.2001.233; Christensen JH, 2004, CLIN ENDOCRINOL, V60, P125, DOI 10.1111/j.1365-2265.2004.01953.x; Christensen JH, 2004, EUR J HUM GENET, V12, P44, DOI 10.1038/sj.ejhg.5201086; Christensen JH, 2003, APMIS, V111, P92; CUEVO AM, 2004, TRENDS CELL BIOL, V14, P70; Davies J, 2002, J NEUROENDOCRINOL, V14, P629, DOI 10.1046/j.1365-2826.2002.00822.x; de Bree FM, 2000, FEBS LETT, V475, P175, DOI 10.1016/S0014-5793(00)01623-9; Demoz M, 2002, BIOL CHEM, V383, P1237, DOI 10.1515/BC.2002.137; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GREEN JR, 1967, BRAIN, V90, P707, DOI 10.1093/brain/90.3.707; Harding TC, 1997, J NEUROCHEM, V69, P2620; HOYVIK H, 1991, J CELL BIOL, V113, P1305, DOI 10.1083/jcb.113.6.1305; Jellinger K. A., 2000, Journal of Neural Transmission Supplement, V60, P21; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; Jellinger KA, 2000, J NEURAL TRANSM-SUPP, P95; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Lim MLR, 2002, J BIOMED SCI, V9, P488, DOI 10.1159/000064722; Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Martin DN, 2004, DEVELOPMENT, V131, P275, DOI 10.1242/dev.00933; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Munafo DB, 2001, J CELL SCI, V114, P3619; NAGAI I, 1984, ACTA ENDOCRINOL-COP, V105, P318, DOI 10.1530/acta.0.1050318; NAGASAKI H, 1995, J CLIN ENDOCR METAB, V80, P1352, DOI 10.1210/jc.80.4.1352; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; REEVES WB, 1992, WILLIAMS TXB ENDOCRI, P311; Russell TA, 2003, J CLIN INVEST, V112, P1697, DOI 10.1172/JCI200318616; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Sharman G, 2004, PROG BIOPHYS MOL BIO, V84, P151, DOI 10.1016/j.pbiomolbio.2003.11.005; Si-Hoe SL, 2000, FASEB J, V14, P1680; Waller S, 1996, ENDOCRINOLOGY, V137, P5068, DOI 10.1210/en.137.11.5068; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9	49	43	45	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					1024	+		10.1096/fj.04-3163fje	http://dx.doi.org/10.1096/fj.04-3163fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15781608				2022-12-25	WOS:000227901300010
J	Carriere, V; Le Gall, M; Saumande, FG; Schmoll, D; Brot-Laroche, E; Chauffeton, V; Chambaz, J; Rousset, M				Carriere, V; Le Gall, M; Saumande, FG; Schmoll, D; Brot-Laroche, E; Chauffeton, V; Chambaz, J; Rousset, M			Intestinal glucose-dependent expression of glucose-6-phosphatase - Involvement of the aryl receptor nuclear translocator transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; BINDING PROTEIN CHREBP; RAT SMALL-INTESTINE; CELL-LINE CACO-2; GENE-EXPRESSION; RESPONSE ELEMENT; DIFFERENTIAL EXPRESSION; SUCRASE-ISOMALTASE; CATALYTIC SUBUNIT; DIABETIC-RATS	Glucose-6-phosphatase (G6Pase) catalyzes the release of glucose from glucose 6-phosphate. This enzyme was mainly studied in the liver, but while detected in the small intestine little is known about the regulation of its intestinal expression. This study describes the mechanisms of the glucose-dependent regulation of G6Pase expression in intestinal cells. Results obtained in vivo and in Caco-2/TC7 enterocytes showed that glucose increases the G6Pase mRNA level. In Caco-2/TC7 cells, glucose stabilized G6Pase mRNA and activated the transcription of the gene, meaning that glucose-dependent G6Pase expression involved both transcriptional and post-transcriptional mechanisms. Reporter-gene studies showed that, although the -299/+57 region of the human G6Pase promoter was sufficient to trigger the glucose response in the hepatoma cell line HepG2, the -1157/+1133 fragment was required for maximal activation of glucose-6-phosphatase gene transcription in Caco-2/TC7 cells. This fragment binds the aryl receptor nuclear translocator ( ARNT), cAMP-responsive element-binding protein, and upstream stimulatory factor transcription factors. The DNA binding activity of these transcription factors was increased in nuclear extracts of differentiated cells from the intestinal villus of mice fed sugar-rich diets as compared with mice fed a no-sugar diet. A direct implication of ARNT in the activation of G6Pase gene transcription by glucose has been observed in Caco-2/TC7 cells using RNA interference experiments. These results support a physiological role for G6Pase in the control of nutrient absorption in the small intestine.	Univ Paris 06, INSERM, UMR 505, F-75006 Paris, France; Sanofi Aventis Pharma, DG Metab Dis, D-65926 Frankfurt, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Sanofi-Aventis	Carriere, V (corresponding author), Ctr Rech Biomed Cordeliers, UMR 505, 15 Rue Ecole Med, F-75006 Paris, France.	veronique.carriere-u505@bhdc.jussieu.fr	Carrière, Véronique/AAQ-5027-2021; Le Gall, Maude/W-2593-2019; Le Gall, Maude/C-3917-2017	Carrière, Véronique/0000-0002-6263-0847; Le Gall, Maude/0000-0002-5372-4585; Le Gall, Maude/0000-0002-5372-4585; Schmoll, Dieter/0000-0003-2578-3366				Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; Bandsma RHJ, 2002, EUR J PEDIATR, V161, pS65, DOI 10.1007/s00431-002-1007-8; Bandsma RHJ, 2001, DIABETES, V50, P2591, DOI 10.2337/diabetes.50.11.2591; Bissonnette P, 1996, AM J PHYSIOL-GASTR L, V270, pG153, DOI 10.1152/ajpgi.1996.270.1.G153; Bizeau ME, 2001, J APPL PHYSIOL, V91, P2041, DOI 10.1152/jappl.2001.91.5.2041; Brahimi-Horn C, 2001, TRENDS CELL BIOL, V11, pS32, DOI 10.1016/S0962-8924(01)02126-2; Carriere V, 1998, AM J PHYSIOL-GASTR L, V274, pG1101, DOI 10.1152/ajpgi.1998.274.6.G1101; CHANTRET I, 1994, J CELL SCI, V107, P213; Chatelain F, 1998, DIABETES, V47, P882, DOI 10.2337/diabetes.47.6.882; Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798; Collier JJ, 2003, J BIOL CHEM, V278, P6588, DOI 10.1074/jbc.M208011200; Croset M, 2001, DIABETES, V50, P740, DOI 10.2337/diabetes.50.4.740; Delie F, 1997, CRIT REV THER DRUG, V14, P221; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Gouyon F, 2003, J PHYSIOL-LONDON, V552, P823, DOI 10.1113/jphysiol.2003.049247; HORD NG, 1994, MOL PHARMACOL, V46, P618; HUGON JS, 1973, J HISTOCHEM CYTOCHEM, V21, P426, DOI 10.1177/21.5.426; Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101; Kellett GL, 2001, J PHYSIOL-LONDON, V531, P585, DOI 10.1111/j.1469-7793.2001.0585h.x; KORIEH A, 1991, ARCH INT PHYSIOL BIO, V99, P455; Krones A, 2001, ENDOCRINOLOGY, V142, P2707, DOI 10.1210/en.142.6.2707; Li YZ, 1999, J BIOL CHEM, V274, P33866, DOI 10.1074/jbc.274.48.33866; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Massillon D, 2003, J BIOL CHEM, V278, P40694, DOI 10.1074/jbc.M303182200; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; Massillon D, 2001, J BIOL CHEM, V276, P4055, DOI 10.1074/jbc.M007939200; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mithieux G, 2004, AM J PHYSIOL-ENDOC M, V286, pE370, DOI 10.1152/ajpendo.00299.2003; OCKERMAN PA, 1965, BIOCHIM BIOPHYS ACTA, V105, P22; PINTO M, 1983, BIOL CELL, V47, P323; Rajas F, 1999, GASTROENTEROLOGY, V117, P132, DOI 10.1016/S0016-5085(99)70559-7; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; Rodolosse A, 1998, BIOCHEM J, V336, P115, DOI 10.1042/bj3360115; Santer R, 2003, GASTROENTEROLOGY, V124, P34, DOI 10.1053/gast.2003.50009; Sauvaget D, 2002, J BIOL CHEM, V277, P34540, DOI 10.1074/jbc.M206074200; Schmoll D, 1999, BIOCHEM J, V338, P457, DOI 10.1042/0264-6021:3380457; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Stumpel F, 2001, P NATL ACAD SCI USA, V98, P11330, DOI 10.1073/pnas.211357698; Swanson HI, 2002, CHEM-BIOL INTERACT, V141, P63, DOI 10.1016/S0009-2797(02)00066-2; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; Uyeda K, 2002, BIOCHEM PHARMACOL, V63, P2075, DOI 10.1016/S0006-2952(02)01012-2; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	46	13	14	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20094	20101		10.1074/jbc.M502192200	http://dx.doi.org/10.1074/jbc.M502192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767253	hybrid			2022-12-25	WOS:000229113700080
J	Dugast, M; Toussaint, LN; Dousset, C; Benaroch, P				Dugast, M; Toussaint, LN; Dousset, C; Benaroch, P			AP2 clathrin adaptor complex, but not AP1, controls the access of the major histocompatibility complex (MHC) class II to endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVARIANT CHAIN COMPLEXES; ANTIGEN-PRESENTING CELLS; SORTING SIGNALS; HLA-DR; MEDIATED ENDOCYTOSIS; PROTEIN ANTIGENS; CYTOPLASMIC TAIL; MOLECULES; TRAFFICKING; PEPTIDE	Newly synthesized MHC II alpha- and beta-chains associated with the invariant chain chaperone (Ii) enter the endocytic pathway for Ii degradation and loading with peptides before transport to the cell surface. It is unclear how alpha beta Ii complexes are sorted from the Golgi apparatus and directed to endosomes. However, indirect evidence tends to support direct transport involving the AP1 clathrin adaptor complex. Surprisingly, we show here that knocking down the production of AP1 by RNA interference did not affect the trafficking of alpha beta Ii complexes. In contrast, AP2 depletion led to a large increase in surface levels of alpha beta Ii complexes, inhibited their rapid internalization, and strongly delayed the appearance of mature MHC II in intracellular compartments. Thus, in the cell systems studied here, rapid internalization of alpha beta Ii complexes via an AP2-dependent pathway represents a key step for MHC II delivery to endosomes and lysosomes.	INSERM, Inst Curie, Sect Rech, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Benaroch, P (corresponding author), INSERM, Inst Curie, U520, 26 Rue Ulm, F-75248 Paris, France.	benaroch@curie.fr		Benaroch, Philippe/0000-0002-2655-0129				ADAMS TE, 1983, IMMUNOLOGY, V50, P613; ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; BANIA J, 2003, P NATL ACAD SCI USA; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BIJLMAKERS MJJE, 1994, EMBO J, V13, P2699, DOI 10.1002/j.1460-2075.1994.tb06560.x; Brachet V, 1999, MOL BIOL CELL, V10, P2891, DOI 10.1091/mbc.10.9.2891; BREMNES B, 1994, J CELL SCI, V107, P2021; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Caplan S, 2000, IMMUNOL LETT, V72, P113, DOI 10.1016/S0165-2478(00)00176-0; CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2; Davidson HW, 1999, J BIOL CHEM, V274, P27315, DOI 10.1074/jbc.274.38.27315; Driessen C, 1999, J CELL BIOL, V147, P775, DOI 10.1083/jcb.147.4.775; FUTTER CE, 1995, J BIOL CHEM, V270, P10999, DOI 10.1074/jbc.270.18.10999; Glickman JN, 1996, J CELL BIOL, V132, P769, DOI 10.1083/jcb.132.5.769; Griffin JP, 1997, J IMMUNOL, V158, P1523; HACKETT CJ, 1991, J IMMUNOL, V146, P2944; Hansen HJ, 1996, BIOCHEM J, V320, P293, DOI 10.1042/bj3200293; Hiltbold EM, 2002, CURR OPIN IMMUNOL, V14, P30, DOI 10.1016/S0952-7915(01)00295-3; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; KONGSVIK TL, 2002, J BIOL CHEM; LAMB CA, 1992, J IMMUNOL, V148, P3478; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; Lennon-Dumenil AM, 2002, J EXP MED, V196, P529, DOI 10.1084/jem.20020327; Liu SH, 1998, J CELL BIOL, V140, P1023, DOI 10.1083/jcb.140.5.1023; Meyer C, 2001, J CELL SCI, V114, P4469; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; PARHAM P, 1979, J IMMUNOL, V123, P342; PIETERS J, 1993, J CELL SCI, V106, P831; Pond L, 1999, J BIOL CHEM, V274, P18049, DOI 10.1074/jbc.274.25.18049; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Saint-Pol A, 2004, DEV CELL, V6, P525, DOI 10.1016/S1534-5807(04)00100-5; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Saudrais C, 1998, J IMMUNOL, V160, P2597; Sevilla LM, 2001, CELL IMMUNOL, V210, P143, DOI 10.1006/cimm.2001.1817; SHAW S, 1985, HUM IMMUNOL, V12, P191, DOI 10.1016/0198-8859(85)90336-2; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001; STPIERRE Y, 1990, J IMMUNOL, V145, P812; Stumptner-Cuvelette P, 2001, P NATL ACAD SCI USA, V98, P12144, DOI 10.1073/pnas.221256498; Stumptner-Cuvelette P, 2003, MOL BIOL CELL, V14, P4857, DOI 10.1091/mbc.E03-04-0211; Stumptner-Cuvelette P, 2002, BBA-MOL CELL RES, V1542, P1, DOI 10.1016/S0167-4889(01)00166-5; Wang K, 1997, J BIOL CHEM, V272, P17055, DOI 10.1074/jbc.272.27.17055; Watts C, 2004, NAT IMMUNOL, V5, P685, DOI 10.1038/ni1088; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787	59	86	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19656	19664		10.1074/jbc.M501357200	http://dx.doi.org/10.1074/jbc.M501357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15749704	hybrid			2022-12-25	WOS:000229113700030
J	Kambacheld, M; Augustin, S; Tatsuta, T; Muller, S; Langer, T				Kambacheld, M; Augustin, S; Tatsuta, T; Muller, S; Langer, T			Role of the novel metallopeptidase MoP112 and saccharolysin for the complete degradation of proteins residing in different subcompartments of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-AAA PROTEASE; YEAST SACCHAROMYCES-CEREVISIAE; CHAPERONE-LIKE ACTIVITY; INNER MEMBRANE; THIMET OLIGOPEPTIDASE; OXIDATIVE STRESS; ATP; YME1; PROHIBITINS; PEPTIDES	Mitochondria harbor a conserved proteolytic system that mediates the complete degradation of organellar proteins. ATP-dependent proteases, like a Lon protease in the matrix space and m- and i-AAA proteases in the inner membrane, degrade malfolded proteins within mitochondria and thereby protect the cell against mitochondrial damage. Proteolytic breakdown products include peptides and free amino acids, which are constantly released from mitochondria. It remained unclear, however, whether the turnover of malfolded proteins involves only ATP-dependent proteases or also oligopeptidases within mitochondria. Here we describe the identification of Mop112, a novel metallopeptidase of the pitrilysin family M16 localized in the intermembrane space of yeast mitochondria. This peptidase exerts important functions for the maintenance of the respiratory competence of the cells that overlap with the i-AAA protease. Deletion of MOP112 did not affect the stability of misfolded proteins in mitochondria, but resulted in an increased release from the organelle of peptides, generated upon proteolysis of mitochondrial proteins. We find that the previously described metallopeptidase saccharolysin ( or Prd1) exerts a similar function in the intermembrane space. The identification of peptides released from peptidase-deficient mitochondria by mass spectrometry indicates a dual function of Mop112 and saccharolysin: they degrade peptides generated upon proteolysis of proteins both in the intermembrane and matrix space and presequence peptides cleaved off by specific processing peptidases in both compartments. These results suggest that the turnover of mitochondrial proteins is mediated by the sequential action of ATP-dependent proteases and oligopeptidases, some of them localized in the intermembrane space.	Univ Cologne, Inst Genet, D-50674 Cologne, Germany; Univ Cologne, ZMMK, D-50674 Cologne, Germany	University of Cologne; University of Cologne	Langer, T (corresponding author), Univ Cologne, Inst Genet, Zulpicher Str 47, D-50674 Cologne, Germany.	Thomas.Langer@uni-koeln.de		Langer, Thomas/0000-0003-1250-1462				Arlt H, 1998, EMBO J, V17, P4837, DOI 10.1093/emboj/17.16.4837; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Atorino L, 2003, J CELL BIOL, V163, P777, DOI 10.1083/jcb.200304112; Augustin S, 2005, J BIOL CHEM, V280, P2691, DOI 10.1074/jbc.M410609200; BARRETT AJ, 2004, HDB PROTEOLYTIC ENZY, V1, P1112; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; Bota DA, 2001, MITOCHONDRION, V1, P33, DOI 10.1016/S1567-7249(01)00005-8; BUCHLER M, 1994, EUR J BIOCHEM, V219, P627, DOI 10.1111/j.1432-1033.1994.tb19978.x; DENFERT C, 2004, HDB PROTEOLYTIC ENZY, V1, P1115; DESAUTELS M, 1982, P NATL ACAD SCI-BIOL, V79, P1869, DOI 10.1073/pnas.79.6.1869; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; Ferreirinha F, 2004, J CLIN INVEST, V113, P231, DOI 10.1172/JCI200420138; Gakh E, 2002, BBA-MOL CELL RES, V1592, P63, DOI 10.1016/S0167-4889(02)00265-3; GARCIAALVAREZ N, 1987, EUR J BIOCHEM, V163, P339, DOI 10.1111/j.1432-1033.1987.tb10805.x; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Kaser M, 2003, J BIOL CHEM, V278, P46414, DOI 10.1074/jbc.M305584200; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Langer T, 1995, METHOD ENZYMOL, V260, P495, DOI 10.1016/0076-6879(95)60161-9; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; Leonhard K, 2000, MOL CELL, V5, P629, DOI 10.1016/S1097-2765(00)80242-7; Leonhard K, 1999, NATURE, V398, P348, DOI 10.1038/18704; LIPSKY NG, 1981, J BIOL CHEM, V256, P8652; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Meisinger C, 2000, ANAL BIOCHEM, V287, P339, DOI 10.1006/abio.2000.4868; Moberg P, 2003, PLANT J, V36, P616, DOI 10.1046/j.1365-313X.2003.01904.x; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Oliveira V, 2002, EUR J BIOCHEM, V269, P4326, DOI 10.1046/j.1432-1033.2002.03129.x; Shah ZH, 2000, FEBS LETT, V478, P267, DOI 10.1016/S0014-5793(00)01859-7; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Steglich G, 1999, MOL CELL BIOL, V19, P3435; Tatsuta T, 2005, MOL BIOL CELL, V16, P248, DOI 10.1091/mbc.e04-09-0807; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; Van Dyck L, 1999, CELL MOL LIFE SCI, V56, P825, DOI 10.1007/s000180050029; WALKER JH, 1978, BIOCHEM J, V176, P927, DOI 10.1042/bj1760927; Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957	38	69	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20132	20139		10.1074/jbc.M500398200	http://dx.doi.org/10.1074/jbc.M500398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772085	hybrid			2022-12-25	WOS:000229113700085
J	Li, S; Whorton, AR				Li, S; Whorton, AR			Identification of stereoselective transporters for s-nitroso-L-cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; NITRIC-OXIDE; HEAVY-CHAIN; SYSTEM L; PROTEIN; SUBSTRATE; CELLS; NITROSOCYSTEINE; MECHANISM; RAT	Many of the biological effects of nitric oxide are mediated by S-nitrosothiols. However, the mechanisms by which S-nitrosothiols transduce their activity across cell membranes are unclear. We show that the pathway responsible for the cellular effects of S-nitrosothiols is specific for S-nitrosocysteine (CSNO), is stereoselective, and requires direct uptake of intact L-CSNO. Transport is independent of extracellular sodium, competitively inhibited by leucine, and blocked by 2-aminobicyclo[2.2.1] heptane-2-carboxylic acid, a specific inhibitor of the system L amino acid transporter family. Other nitrosothiols such as S-nitrosoglutathione are not substrates for transport and require reaction with L-cysteine for activity. To show that system L family members mediate uptake, we expressed two members, LAT1 and LAT2, in Xenopus oocytes. Both LAT1 and LAT2, when co-expressed with 4F2 heavy chain, were found to efficiently transport L-CSNO. Mammalian cells were shown to express LAT1 and LAT2. A431 cells express both proteins, whereas T24 cells express only LAT1. Overexpression of LAT1 in T24 cells using recombinant adenoviruses led to increased uptake of L-CSNO, whereas knockdown using a specific small interfering RNA led to decreased uptake. These data definitively identify LAT1 and LAT2 as members of system L that mediate transmembrane movement of L-CSNO and suggest that system L family members are involved in the cellular activity of small molecular weight nitrosothiols.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Whorton, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, C138B LSRC,Box 3813, Durham, NC 27710 USA.	awho@duke.edu						Davisson RL, 1996, CIRC RES, V79, P256, DOI 10.1161/01.RES.79.2.256; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Fraga S, 2002, J NUTR, V132, P733, DOI 10.1093/jn/132.4.733; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gow AJ, 2004, AM J PHYSIOL-LUNG C, V287, pL262, DOI 10.1152/ajplung.00295.2003; Grossi L, 2002, J ORG CHEM, V67, P8625, DOI 10.1021/jo026154+; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Hogg N, 1997, BIOCHEM J, V323, P477, DOI 10.1042/bj3230477; Hogg N, 2002, ANNU REV PHARMACOL, V42, P585, DOI 10.1146/annurev.pharmtox.42.092501.104328; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Josch C, 2003, BIOL CHEM, V384, P213, DOI 10.1515/BC.2003.023; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kim D, 2002, BBA-BIOMEMBRANES, V1565, P112, DOI 10.1016/S0005-2736(02)00516-3; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Li S, 2003, ARCH BIOCHEM BIOPHYS, V410, P269, DOI 10.1016/S0003-9861(02)00696-3; Lipton AJ, 2001, NATURE, V413, P171, DOI 10.1038/35093117; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Mallis RJ, 2000, ARCH BIOCHEM BIOPHYS, V383, P60, DOI 10.1006/abbi.2000.2048; MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529; McMahon TJ, 2003, BLOOD, V102, P410, DOI 10.1182/blood-2003-04-1058; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; Nemoto T, 2003, EUR J PHARMACOL, V458, P17, DOI 10.1016/S0014-2999(02)02699-7; Padgett C. M., 1995, AM J PHYSIOL, V269, pC739; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Ramachandran N, 2001, P NATL ACAD SCI USA, V98, P9539, DOI 10.1073/pnas.171180998; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; Satoh S, 1997, J NEUROCHEM, V69, P2197; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Simmons-Willis TA, 2002, BIOCHEM J, V367, P239, DOI 10.1042/BJ20020841; Stamler JS, 2002, CURR OPIN CHEM BIOL, V6, P779, DOI 10.1016/S1367-5931(02)00383-6; Travis MD, 1997, AM J PHYSIOL-HEART C, V273, pH1493, DOI 10.1152/ajpheart.1997.273.3.H1493; Tsikas D, 1999, ANAL BIOCHEM, V270, P231, DOI 10.1006/abio.1999.4084; Uchino H, 2002, MOL PHARMACOL, V61, P729, DOI 10.1124/mol.61.4.729; Verrey F, 2003, PFLUG ARCH EUR J PHY, V445, P529, DOI 10.1007/S00424-002-0973-Z; Yanagida O, 2001, BBA-BIOMEMBRANES, V1514, P291, DOI 10.1016/S0005-2736(01)00384-4; Zai A, 1999, J CLIN INVEST, V103, P393, DOI 10.1172/JCI4890; Zhang YH, 2004, P NATL ACAD SCI USA, V101, P7891, DOI 10.1073/pnas.0401167101	38	66	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20102	20110		10.1074/jbc.M413164200	http://dx.doi.org/10.1074/jbc.M413164200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769744	hybrid			2022-12-25	WOS:000229113700081
J	Tonazzi, A; Giangregorio, N; Indiveri, C; Palmieri, F				Tonazzi, A; Giangregorio, N; Indiveri, C; Palmieri, F			Identification by site-directed mutagenesis and chemical modification of three vicinal cysteine residues in rat mitochondrial carnitine/acylcarnitine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED CARNITINE CARRIER; LIVER MITOCHONDRIA; ESCHERICHIA-COLI; SWISS-MODEL; ARSA ATPASE; PROTEIN; PURIFICATION; METALLOACTIVATION; COMPLEX; GENE	The proximity of the Cys residues present in the mitochondrial rat carnitine/acylcarnitine carrier (CAC) primary structure was studied by using site-directed mutagenesis in combination with chemical modification. CAC mutants, in which one or more Cys residues had been replaced with Ser, were overexpressed in Escherichia coli and reconstituted into liposomes. The effect of SH oxidizing, cross-linking, and coordinating reagents was evaluated on the carnitine/carnitine exchange catalyzed by the recombinant reconstituted CAC proteins. All the tested reagents efficiently inhibited the wild-type CAC. The inhibitory effect of diamide, Cu2+-phenanthroline, or phenylarsine oxide was largely reduced or abolished by the double substitutions C136S/C155S, C58S/C136S, and C58S/C155S. The decrease in sensitivity to these reagents was much lower in double mutants in which Cys(23) was substituted with Cys(136) or Cys(155). No decrease in inhibition was found when Cys(89) and/or Cys(283) were replaced with Ser. Sb3+, which coordinates three cysteines, inhibited only the Cys replacement mutants containing cysteines 58, 136, and 155 of the six native cysteines. In addition, the mutant C23S/C89S/C155S/C283S, in which double tandem fXa recognition sites were inserted in positions 65-72, i.e. between Cys(58) and Cys(136), was not cleaved into two fragments by fXa protease after treatment with diamide. These results are interpreted in light of the homology model of CAC based on the available x-ray structure of the ADP/ATP carrier. They indicate that Cys(58), Cys(136), and Cys(155) become close in the tertiary structure of the CAC during its catalytic cycle.	Univ Bari, Dipartimento Farmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy; CNR, Inst Biomembranes & Bioenerget, I-70125 Bari, Italy; Univ Calabria, Dept Cellular Biol, I-87030 Cosenza, Italy	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); University of Calabria	Palmieri, F (corresponding author), Univ Bari, Dipartimento Farmacobiol, Biochem & Mol Biol Lab, Via E Orabona 4, I-70125 Bari, Italy.	fpalm@farmbiol.uniba.it	tonazzi, annamaria/G-9799-2012	Indiveri, Cesare/0000-0001-9818-6621				Bhattacharjee H, 1996, J BIOL CHEM, V271, P24465, DOI 10.1074/jbc.271.40.24465; BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; De Lucas JR, 1999, ARCH MICROBIOL, V171, P386, DOI 10.1007/s002030050725; Fiermonte G, 1998, J BIOL CHEM, V273, P22782, DOI 10.1074/jbc.273.35.22782; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iacobazzi V, 1998, BIOCHEM BIOPH RES CO, V252, P770, DOI 10.1006/bbrc.1998.9738; IDELLWENGER JA, 1981, J BIOL CHEM, V256, P5579; Indiveri C, 1998, BIOCHEM BIOPH RES CO, V249, P589, DOI 10.1006/bbrc.1998.9197; INDIVERI C, 1990, BIOCHIM BIOPHYS ACTA, V1020, P81, DOI 10.1016/0005-2728(90)90096-M; Indiveri C, 2002, BIOCHEMISTRY-US, V41, P8649, DOI 10.1021/bi012183n; Indiveri C, 1997, BIOCHEM J, V321, P713, DOI 10.1042/bj3210713; INDIVERI C, 1995, EUR J BIOCHEM, V228, P271; INDIVERI C, 1994, BBA-BIOMEMBRANES, V1189, P65, DOI 10.1016/0005-2736(94)90281-X; KALEF E, 1994, METHOD ENZYMOL, V233, P395; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Krumer R., 1992, MOL MECHANISMS BIOEN, P359, DOI DOI 10.1016/50167-7306(08)60184-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Nagano N, 1999, FEBS LETT, V458, P69, DOI 10.1016/S0014-5793(99)01122-9; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; Palmieri F, 2004, ENCY BIOL CHEM, V2, P725; Palmieri L, 1999, FEBS LETT, V462, P472, DOI 10.1016/S0014-5793(99)01555-0; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Phelps A, 1996, BIOCHEMISTRY-US, V35, P10757, DOI 10.1021/bi961052x; Raso SW, 2001, J MOL BIOL, V307, P899, DOI 10.1006/jmbi.2001.4476; SAHINTOTH M, 1995, BIOCHEMISTRY-US, V34, P1107, DOI 10.1021/bi00004a001; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520	30	40	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19607	19612		10.1074/jbc.M411181200	http://dx.doi.org/10.1074/jbc.M411181200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15757911	hybrid			2022-12-25	WOS:000229113700024
J	Tsui, C; Raguraj, A; Pickart, CM				Tsui, C; Raguraj, A; Pickart, CM			Ubiquitin binding site of the ubiquitin E2 variant (UEV) protein Mms2 is required for DNA damage tolerance in the yeast RAD6 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATING ENZYME COMPLEX; POSTREPLICATION REPAIR; POLYUBIQUITIN CHAINS; CRYSTAL-STRUCTURE; LYSINE; PCNA; RECOGNITION; DOMAINS; DEGRADATION; SPECIFICITY	Different ubiquitin modifications to proliferating cell nuclear antigen ( PCNA) signal distinct modes of lesion bypass in the RAD6 pathway of DNA damage tolerance. The modification of PCNA with monoubiquitin signals an error-prone bypass, whereas the extension of this modification into a Lys-63-linked polyubiquitin chain promotes error-free bypass. Chain formation is catalyzed by the Mms2/Ubc13 conjugating enzyme variant/conjugating enzyme (UEV center dot E2) complex together with the Rad5 ubiquitin ligase. In vitro studies of this UEV center dot E2 complex have identified a ubiquitin binding site that is mainly localized on Mms2. However, the role of this site in DNA damage tolerance and the molecular features of the ubiquitin/Mms2 interaction are poorly understood. Here we identify two molecular determinants, the side chains of Mms2-Ile-57 and ubiquitin-Ile-44, that are required for chain assembly in vitro and error-free lesion bypass in vivo. Mutating either of these side chains to alanine elicits a severe 10-20-fold inhibition of chain synthesis that is caused by compromised binding of the acceptor ubiquitin to Mms2. These results suggest that the ubiquitin binding site of Mms2 is necessary for error-free lesion bypass in the RAD6 pathway and provide new insights into ubiquitin recognition by UEV proteins.	Johns Hopkins Univ, Dept Biochem & Mol Biol, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Pickart, CM (corresponding author), Johns Hopkins Univ, Dept Biochem & Mol Biol, Bloomberg Sch Publ Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.	cpickart@jhmi.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060372] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60372] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; Bernstein CN, 2002, INFLAMM BOWEL DIS, V8, P356, DOI 10.1097/00054725-200209000-00007; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; HAAS AL, 1982, J BIOL CHEM, V257, P329; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; HALDEMAN MT, 1981, BIOCHEMISTRY-US, V266, P9235; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Haracska L, 2004, MOL CELL BIOL, V24, P4267, DOI 10.1128/MCB.24.10.4267-4274.2004; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; McKenna S, 2003, BIOCHEMISTRY-US, V42, P7922, DOI 10.1021/bi034480t; McKenna S, 2003, J BIOL CHEM, V278, P13151, DOI 10.1074/jbc.M212353200; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; Mueller TD, 2004, J BIOL CHEM, V279, P11926, DOI 10.1074/jbc.M312865200; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Sundquist WI, 2004, MOL CELL, V13, P783, DOI 10.1016/S1097-2765(04)00129-7; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Torres-Ramos CA, 2002, MOL CELL BIOL, V22, P2419, DOI 10.1128/MCB.22.7.2419-2426.2002; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Ulrich HD, 2003, J BIOL CHEM, V278, P7051, DOI 10.1074/jbc.M212195200; Ulrich HD, 2002, EUKARYOT CELL, V1, P1, DOI 10.1128/EC.1.1.1-10.2002; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Varadan R, 2004, J BIOL CHEM, V279, P7055, DOI 10.1074/jbc.M309184200; Verma R, 2004, SCIENCE, V306, P117, DOI 10.1126/science.1100946; Wang QH, 2003, BIOCHEMISTRY-US, V42, P13529, DOI 10.1021/bi035391j; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; WILKINSON KD, 1981, J BIOL CHEM, V256, P9235; Xiao W, 2000, GENETICS, V155, P1633; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01	66	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19829	19835		10.1074/jbc.M414060200	http://dx.doi.org/10.1074/jbc.M414060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772086	hybrid			2022-12-25	WOS:000229113700050
J	Ariyoshi, W; Takahashi, T; Kanno, T; Ichimiya, H; Takano, H; Koseki, T; Nishihara, T				Ariyoshi, W; Takahashi, T; Kanno, T; Ichimiya, H; Takano, H; Koseki, T; Nishihara, T			Mechanisms involved in enhancement of osteoclast formation and function by low molecular weight hyaluronic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EXPRESS HIGH-LEVELS; NF-KAPPA-B; RHEUMATOID-ARTHRITIS; RECEPTOR ACTIVATOR; SIGNALING PATHWAY; BONE-RESORPTION; SYNOVIAL-FLUID; MAP KINASE; PC12 CELLS	Hyaluronic acid ( HA) is a component of the extracellular matrix that has been shown to play an important role in bone formation, resorption, and mineralization both in vivo and in vitro. We examined the effects of HA at several molecular weights on osteoclast formation and function induced by RANKL ( receptor activator of NF-kappa B ligand) in a mouse monocyte cell line (RAW 264.7). HA atM(r) < 8,000 (low molecular weight HA (LMW-HA)) enhanced tartrate-resistant acid phosphatase-positive multinucleated cell formation and tartrate-resistant acid phosphatase activity induced by RANKL in a dose-dependent manner, whereas HA at M-r > 900,000 ( high molecular weight HA (HMW-HA)) showed no effect on osteoclast differentiation. LMW-HA enhanced pit formation induced by RAW 264.7 cells, whereas HMW-HA did not, and LMW-HA stimulated the expression of RANK (receptor activator of NF-kappa B) protein in RAW 264.7 cells. In addition, we found that LMW-HA enhanced the levels of c-Src protein and phosphorylation of ERKs and p38 MAPK in RAW 264.7 cells stimulated with RANKL, whereas the p38 MAPK inhibitor SB203580 inhibited RANKL-induced osteoclast differentiation. This enhancement of c-Src and RANK proteins induced by LMW-HA was inhibited by CD44 function-blocking monoclonal antibody. These results indicate that LMW-HA plays an important role in osteoclast differentiation and function through the interaction of RANKL and RANK.	Kyushu Dent Coll, Sch Dent, Dept Oral Microbiol, Kitakyushu, Fukuoka 8038580, Japan; Kyushu Dent Coll, Sch Dent, Dept Oral & Maxillofacial Surg 2, Kitakyushu, Fukuoka 8038580, Japan; Tohoku Univ, Grad Sch Dent, Dept Lifelong Oral Hlth Sci, Div Prevent Dent, Sendai, Miyagi 9808575, Japan	Kyushu Dental University; Kyushu Dental University; Tohoku University	Nishihara, T (corresponding author), Kyushu Dent Coll, Sch Dent, Dept Oral Microbiol, Kitakyushu, Fukuoka 8038580, Japan.	tatsujin@kyu-dent.ac.jp		Nishihara, Tatsuji/0000-0001-7075-9678				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Brun P, 1999, J BIOMED MATER RES, V46, P337, DOI 10.1002/(SICI)1097-4636(19990905)46:3<337::AID-JBM5>3.0.CO;2-Q; Cao JJ, 2005, J BONE MINER RES, V20, P30, DOI 10.1359/JBMR.041014; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CULTY M, 1994, J LEUKOCYTE BIOL, V56, P605, DOI 10.1002/jlb.56.5.605; DAHL LB, 1985, ANN RHEUM DIS, V44, P817, DOI 10.1136/ard.44.12.817; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Fukuda K, 1996, J PHARMACOL EXP THER, V277, P1672; FULLER K, 1994, J BONE MINER RES, V9, P17; Homandberg GA, 1997, OSTEOARTHR CARTILAGE, V5, P309, DOI 10.1016/S1063-4584(97)80035-0; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Iwasaki S, 1996, J BIOL CHEM, V271, P17360, DOI 10.1074/jbc.271.29.17360; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Kawasaki K, 1999, J CELL PHYSIOL, V179, P142, DOI 10.1002/(SICI)1097-4652(199905)179:2<142::AID-JCP4>3.0.CO;2-Q; KIND PRN, 1954, J CLIN PATHOL, V7, P322, DOI 10.1136/jcp.7.4.322; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; Knudson W, 1996, EXP CELL RES, V228, P216, DOI 10.1006/excr.1996.0320; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Kumar S, 2001, J CELL PHYSIOL, V187, P294, DOI 10.1002/jcp.1082; LARSEN NE, 1992, J ORTHOPAED RES, V10, P23, DOI 10.1002/jor.1100100104; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Okahashi N, 1997, J BONE MINER RES, V12, P1116, DOI 10.1359/jbmr.1997.12.7.1116; Prince CW, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471-2474-5-12; SAKAMOTO T, 1984, ORTHOPEDIC RES SCI, V11, P264; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; SHIMAZU A, 1993, ARTHRITIS RHEUM, V36, P247, DOI 10.1002/art.1780360217; SMITH MM, 1987, RHEUMATOL INT, V7, P113, DOI 10.1007/BF00270463; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Suzuki K, 2002, J BONE MINER RES, V17, P1486, DOI 10.1359/jbmr.2002.17.8.1486; Takahashi T, 2004, J ORAL PATHOL MED, V33, P224, DOI 10.1111/j.0904-2512.2004.00024.x; TANAKA S, 1992, FEBS LETT, V313, P85, DOI 10.1016/0014-5793(92)81190-W; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; UNDERHILL C, 1992, J CELL SCI, V103, P293; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; YASUI T, 1992, BIOMED RES-TOKYO, V13, P343, DOI 10.2220/biomedres.13.343	44	56	58	2	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18967	18972		10.1074/jbc.M412740200	http://dx.doi.org/10.1074/jbc.M412740200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757905	hybrid			2022-12-25	WOS:000228932300050
J	Imagawa, T; Yamamoto, T; Kaya, S; Sakaguchi, K; Taniguchi, K				Imagawa, T; Yamamoto, T; Kaya, S; Sakaguchi, K; Taniguchi, K			Thr-774 (transmembrane segment M5), Val-920 (M8), and Glu-954 (M9) are involved in Na+ transport, and Gln-923 (m8) is essential for Na,K-ATPaseActivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY NA+,K+-ATPASE; SITE-DIRECTED MUTAGENESIS; INDUCED CONFORMATIONAL-CHANGES; AMINO-ACID SUBSTITUTIONS; CATION-BINDING POCKET; SHEEP ALPHA-1 ISOFORM; SARCOPLASMIC-RETICULUM; FUNCTIONAL CONSEQUENCES; RENAL NA,K-ATPASE; ACTIVE-TRANSPORT	The highly conserved amino acids of rat Na,K-ATPase, Thr-774 in the transmembrane helices M5, Val-920 and Gln-923 in M8, and Glu-953 and Glu-954 in M9, the side chains of which appear to be in close proximity, were mutated, and the resulting proteins, T774A, E953A/K, and E954A/K, V920E and Q923N/E/D/L, were expressed in HeLa cells. Ouabain-resistant cell lines were obtained from T774A, V920E, E953A, and E954A, whereas Q923N/E/D/L, E953K, and E954K could only be transiently expressed as fusion proteins with an enhanced green fluorescent protein. The apparent K-0.5 values for Na+, as estimated by the Na+-dependent phosphoenzyme formation (K-0.5(Na,EP)) or Na, K-ATPase activity (K-0.5(Na,ATPase)), were increased by around 2 similar to 8- fold in the case of T774A, V920E, and E954A. The apparent K-0.5 values for K+, as estimated by the Na,K-ATPase (K-0.5(K,ATPase)) or p-nitrophenylphosphatase activity (K-0.5(K,pNPPase)), were affected only slightly by the 3 mutations, except that V920E showed a 1.7-fold increase in the K-0.5(K,ATPase). The apparent K-0.5 values for ATP (K-0.5(EP)), as estimated by phosphorylation ( a high affinity ATP effect), were increased by 1.6 similar to 2.6-fold in the case of T774A, V920E, and E954A. Those estimated by Na, K-ATPase activity (K-0.5(ATPase)) and ATP-induced inhibition (K-i,0.5(pNPPase)) of K-pNPPase activity (low affinity ATP effects) were, respectively, increased by 1.8-fold and unchanged in the case of T774A but decreased by 2- and 4.8-fold in the case of V920E and were slightly changed and increased by 1.7-fold in the case of E954A. The E953A showed little significant change in the apparent affinities. These results suggest that Gln-923 in M8 is crucial for the active transport of Na+ and/or K+ across membranes and that the side chain oxygen atom of Thr-774 in M5, the methyl group(s) of Val-920 in M8, and the carboxyl oxygen(s) of Glu-954 in M9 mainly play some role in the transport of Na+ and also in the high and low affinity ATP effects rather than the transport of K+.	Hokkaido Univ, Grad Sch Sci, Div Chem, Kita Ku, Sapporo, Hokkaido 0600810, Japan	Hokkaido University	Imagawa, T (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Chem, Kita Ku, Kita 10 Nishi 8, Sapporo, Hokkaido 0600810, Japan.	toshi@sci.hokudai.ac.jp	Imagawa, Toshiaki/A-4255-2012					ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; Arguello JM, 1999, ARCH BIOCHEM BIOPHYS, V367, P341, DOI 10.1006/abbi.1999.1278; Arguello JM, 1999, ARCH BIOCHEM BIOPHYS, V364, P254, DOI 10.1006/abbi.1999.1124; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Arguello JM, 1996, J BIOL CHEM, V271, P24610, DOI 10.1074/jbc.271.40.24610; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; Blostein R, 1999, BIOCHEM CELL BIOL, V77, P1, DOI 10.1139/bcb-77-1-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; Domaszewicz W, 1999, FEBS LETT, V458, P241, DOI 10.1016/S0014-5793(99)01162-X; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; Hilge M, 2003, NAT STRUCT BIOL, V10, P468, DOI 10.1038/nsb924; Imagawa T, 2003, J BIOL CHEM, V278, P50283, DOI 10.1074/jbc.M309833200; Imagawa T, 1998, JPN J PHARMACOL, V76, P415, DOI 10.1254/jjp.76.415; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JOHNSON CL, 1995, BIOCHEM J, V309, P187, DOI 10.1042/bj3090187; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; Jorgensen PL, 1998, ACTA PHYSIOL SCAND, V163, P79; Jorgensen PL, 1998, BBA-BIOENERGETICS, V1365, P65, DOI 10.1016/S0005-2728(98)00043-7; Jorgensen PL, 2001, BBA-BIOENERGETICS, V1505, P57, DOI 10.1016/S0005-2728(00)00277-2; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Koenderink JB, 2000, BIOCHEMISTRY-US, V39, P9959, DOI 10.1021/bi0001168; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P2993, DOI 10.1074/jbc.270.7.2993; Lingrel JB, 1998, ACTA PHYSIOL SCAND, V163, P69; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MAEDA M, 1988, BIOCHEM BIOPH RES CO, V157, P203, DOI 10.1016/S0006-291X(88)80033-0; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; Mense M, 2000, J BIOL CHEM, V275, P1749, DOI 10.1074/jbc.275.3.1749; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; POST RL, 1972, J BIOL CHEM, V247, P6530; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Segall L, 2002, J BIOL CHEM, V277, P35202, DOI 10.1074/jbc.M206115200; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Taniguchi K, 2001, J BIOCHEM, V129, P335, DOI 10.1093/oxfordjournals.jbchem.a002862; Tao Bernard Y., 1994, P69; Tepperman K, 1997, AM J PHYSIOL-CELL PH, V273, pC2065, DOI 10.1152/ajpcell.1997.273.6.C2065; Teramachi S, 2002, J BIOL CHEM, V277, P37394, DOI 10.1074/jbc.M204772200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; VANHUYSSE JW, 1993, CELL MOL BIOL RES, V39, P497; VanHuysse JW, 1996, FEBS LETT, V389, P179, DOI 10.1016/0014-5793(96)00578-9; Vasilets LA, 1998, BBA-BIOMEMBRANES, V1368, P137, DOI 10.1016/S0005-2736(97)00195-8; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; VILSEN B, 1995, FEBS LETT, V363, P179, DOI 10.1016/0014-5793(95)00313-X; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; VILSEN B, 1993, FEBS LETT, V333, P44, DOI 10.1016/0014-5793(93)80372-2; WEBER K, 1969, J BIOL CHEM, V244, P4406	65	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18736	18744		10.1074/jbc.M500137200	http://dx.doi.org/10.1074/jbc.M500137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15764602	hybrid			2022-12-25	WOS:000228932300025
J	Wong, CF; Barnes, LM; Dahler, AL; Smith, L; Popa, C; Serewko-Auret, MM; Saunders, NA				Wong, CF; Barnes, LM; Dahler, AL; Smith, L; Popa, C; Serewko-Auret, MM; Saunders, NA			E2F suppression and Sp1 overexpression are sufficient to induce the differentiation-specific marker, transglutaminase type 1, in a squamous cell carcinoma cell line	ONCOGENE			English	Article						squamous cell carcinoma; differentiation therapy; keratinocytes; E2F; Sp1	HUMAN EPIDERMAL-KERATINOCYTES; TRANSCRIPTION FACTOR E2F; SKIN TUMOR-DEVELOPMENT; EPITHELIAL-CELLS; GENE-EXPRESSION; CULTURED-CELLS; RETINOIC ACID; IN-VITRO; PROMOTER; BINDING	Recently, E2F function has expanded to include the regulation of differentiation in human epidermal keratinocytes (HEKs). We extend these findings to report that in HEKs, Sp1 is a differentiation-specific activator and a downstream target of E2F-mediated suppression of the differentiation-specific marker, transglutaminase type 1 (TG-1). Deletion of elements between -0.084 to -0.034 kb of the TG-1 promoter disabled E2F1-induced suppression of promoter activity. Electrophoretic mobility shift assays (EMSAs) demonstrated that Sp1 and Sp3 bound this region. Protein expression analysis suggested that squamous differentiation was accompanied by increased Sp1/Sp3 ratio. Cotransfection of proliferating HEKs or the squamous cell carcinoma (SCC) cell line, KJD-1/SV40, with an E2F inhibitor (E2Fd/n) and Sp1 expression plasmid was sufficient to activate the TG-1 promoter. The suppression of Sp1 activity by E2F in differentiated cells appeared to be indirect since we found no evidence of an Sp1/E2F coassociation on the TG-1 promoter fragment. Moreover, E2F inhibition in the presence of a differentiation stimulus induced Sp1 protein. These data demonstrate that (i) Sp1 can act as a differentiation stimulus, (ii) E2F-mediated suppression of differentiation-specific markers is indirect via Sp1 inhibition and (iii) a combination of E2F inhibition and Sp1 activation could form the basis of a differentiation therapy for SCCs.	Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Programme,Epithelial Pathobiol Grp, Woolloongabba, Qld 4102, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4067, Australia	University of Queensland; University of Queensland	Saunders, NA (corresponding author), Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Programme,Epithelial Pathobiol Grp, 4th Floor,Bldg 1,R Wing,Ipswich Rd, Woolloongabba, Qld 4102, Australia.	nsaunders@circ.uq.edu.au	saunders, nicholas/AAJ-6101-2020; McTaggart, Jill/G-4696-2010	saunders, nicholas/0000-0002-2478-3420; McTaggart, Jill/0000-0002-9000-8529				ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; Dahler AL, 1998, J CELL PHYSIOL, V177, P474, DOI 10.1002/(SICI)1097-4652(199812)177:3<474::AID-JCP10>3.3.CO;2-D; Dahler AL, 2001, J INVEST DERMATOL, V116, P266, DOI 10.1046/j.1523-1747.2001.01243.x; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dicker AJ, 2000, EXP CELL RES, V258, P352, DOI 10.1006/excr.2000.4944; Dicker AJ, 2000, ONCOGENE, V19, P2887, DOI 10.1038/sj.onc.1203610; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Guo CS, 2003, J BIOL CHEM, V278, P22615, DOI 10.1074/jbc.M301943200; Guy CT, 1996, MOL CELL BIOL, V16, P685; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Jang SI, 2002, J BIOL CHEM, V277, P42268, DOI 10.1074/jbc.M205593200; Jessen BA, 2000, J INVEST DERMATOL, V115, P113, DOI 10.1046/j.1523-1747.2000.00027.x; Johnson-Pais T, 2001, P NATL ACAD SCI USA, V98, P2211, DOI 10.1073/pnas.051415898; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KHANNA KK, 1995, ONCOGENE, V11, P609; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LANE EB, 1985, ANN NY ACAD SCI, V455, P241, DOI 10.1111/j.1749-6632.1985.tb50415.x; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lee JH, 1996, J BIOL CHEM, V271, P4561; Medvedev A, 1999, J BIOL CHEM, V274, P3887, DOI 10.1074/jbc.274.6.3887; Park GT, 1999, J BIOL CHEM, V274, P26599, DOI 10.1074/jbc.274.37.26599; Phillips Marjorie A, 2004, BMC Dermatol, V4, P2, DOI 10.1186/1471-5945-4-2; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Popa C, 2004, DIFFERENTIATION, V72, P185, DOI 10.1111/j.1432-0436.2004.07205001.x; Popa C, 1999, BRIT J DERMATOL, V141, P460; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SAUNDERS NA, 1993, BIOCHEM BIOPH RES CO, V197, P46, DOI 10.1006/bbrc.1993.2439; Serewko MM, 2002, CANCER RES, V62, P3759; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wong CF, 2004, BIOCHEM BIOPH RES CO, V324, P497, DOI 10.1016/j.bbrc.2004.09.084; Wong CF, 2003, J BIOL CHEM, V278, P28516, DOI 10.1074/jbc.M301246200; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; WU RL, 1994, J BIOL CHEM, V269, P28450	45	28	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3525	3534		10.1038/sj.onc.1208372	http://dx.doi.org/10.1038/sj.onc.1208372			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735752				2022-12-25	WOS:000229038800014
J	Keith, N; Parodi, AJ; Caramelo, JJ				Keith, N; Parodi, AJ; Caramelo, JJ			Glycoprotein tertiary and quaternary structures are monitored by the same quality control mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSYLTRANSFERASE RECOGNIZES; SOYBEAN AGGLUTININ; CALNEXIN; LECTINS	Folding of glycoproteins entering the secretory pathway is strictly surveyed in the endoplasmic reticulum by a quality control system. Folding intermediates and proteins irreparably misfolded are marked via glucosylation by the UDPglucose: glycoprotein glucosyltransferase, an enzyme that acts as a folding sensor by exclusively labeling glycoproteins not displaying their native structures. Here we show that this sensing mechanism also applies to the oligomerization of protein complexes, as the glucosyltransferase appeared to be able to glucosylate folded complex subunits lacking the full complement of oligomer components.	Fdn Inst Leloir, Lab Glycobiol, RA-1405 Buenos Aires, DF, Argentina	Leloir Institute	Caramelo, JJ (corresponding author), Fdn Inst Leloir, Lab Glycobiol, Avenida Patricias Argentinas 435, RA-1405 Buenos Aires, DF, Argentina.	jcaramelo@leloir.org.ar			NIGMS NIH HHS [GM44500] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN HJ, 1976, CARBOHYD RES, V50, P121; Caramelo JJ, 2004, J BIOL CHEM, V279, P46280, DOI 10.1074/jbc.M408404200; Caramelo JJ, 2003, P NATL ACAD SCI USA, V100, P86, DOI 10.1073/pnas.262661199; Chatterjee M, 2003, BIOCHEMISTRY-US, V42, P12217, DOI 10.1021/bi034642l; Gardner TG, 1999, J BIOL CHEM, V274, P14094, DOI 10.1074/jbc.274.20.14094; Ghosh M, 2001, INT J BIOL MACROMOL, V29, P273, DOI 10.1016/S0141-8130(01)00175-1; GOREVIC PD, 1986, P NATL ACAD SCI USA, V83, P7908, DOI 10.1073/pnas.83.20.7908; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Jones S, 2003, J MOL BIOL, V325, P249, DOI 10.1016/S0022-2836(02)01227-5; Lewis JW, 1998, CURR BIOL, V8, P717, DOI 10.1016/S0960-9822(98)70280-5; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061	18	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18138	18141		10.1074/jbc.M501710200	http://dx.doi.org/10.1074/jbc.M501710200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746090	Green Published, hybrid			2022-12-25	WOS:000228807200071
J	Kobayashi, T; Takematsu, H; Yamaji, T; Hiramoto, S; Kozutsumi, Y				Kobayashi, T; Takematsu, H; Yamaji, T; Hiramoto, S; Kozutsumi, Y			Disturbance of sphingolipid biosynthesis abrogates the signaling of Mss4, phosphatidylinositol-4-phosphate 5-kinase, in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; CELL-GROWTH; ACTIN CYTOSKELETON; SERINE PALMITOYLTRANSFERASE; PHOSPHATIDIC-ACID; BASE SYNTHESIS; LIPID RAFTS	The functional relationships between phosphoinositides and sphingolipids have not been well characterized to date. ISP-1/myriocin is a potent inhibitor of sphingolipid biosynthesis and induces severe growth defects in eukaryotic cells because of the sphingolipid deprivation. We characterized a novel multicopy suppressor gene of ISP-1-mediated cell death in yeast, MSS4. MSS4 encodes a phosphatidylinositol-4-phosphate5-kinase that synthesizes phosphatidylinositol ( 4,5)-bisphosphate (PI4,5P(2)). We demonstrate here that ISP-1 treatment of yeast causes defects both in the activity and subcellular localization of Mss4. The effect of the Mss4 defect on the downstream signaling was examined, because interaction between the Mss4 product, PI4,5P2, and the pleckstrin-homology domain of Rom2 mediates recruitment of Rom2 to the membrane, which is the crucial step for subsequent Rho1/2 activation. Indeed, failure of Rom2 recruitment was observed in ISP-1-treated cells as well as in csg2-deleted cells, which have reduced mannosylated inositolphosphorylceramide. These data suggested that proper sphingolipids are required for the signaling pathway involving Mss4.	RIKEN, Suprabiomol Syst Res Grp, Frontier Res Syst, Kawaguchi, Saitama 3320012, Japan; Kyoto Univ, Grad Sch Biostudies, Lab Membrane Biochem & Biophys, Sakyo Ku, Kyoto 6068501, Japan; JST, CREST, Kawaguchi, Saitama 3320012, Japan	RIKEN; Kyoto University; Japan Science & Technology Agency (JST)	Kozutsumi, Y (corresponding author), RIKEN, Suprabiomol Syst Res Grp, Frontier Res Syst, Kawaguchi, Saitama 3320012, Japan.	yasu@pharm.kyoto-u.ac.jp	Kobayashi, Toshihide/B-6298-2015	Kobayashi, Toshihide/0000-0002-4811-7270				Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; Audhya A, 2002, DEV CELL, V2, P593, DOI 10.1016/S1534-5807(02)00168-5; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chung JH, 2003, J BIOL CHEM, V278, P28872, DOI 10.1074/jbc.M300943200; Cockcroft S, 2001, J MEMBRANE BIOL, V180, P187, DOI 10.1007/s002320010069; Cowart LA, 2003, J BIOL CHEM, V278, P30328, DOI 10.1074/jbc.M300656200; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; deHart AKA, 2002, J CELL BIOL, V156, P241, DOI 10.1083/jcb.200107135; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Friant S, 2001, EMBO J, V20, P6783, DOI 10.1093/emboj/20.23.6783; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; Hearn JD, 2003, J BIOL CHEM, V278, P3679, DOI 10.1074/jbc.M209170200; Helliwell SB, 1998, GENETICS, V148, P99; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Inagaki M, 1999, MOL CELL BIOL, V19, P8344; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Karpova TS, 1998, J CELL BIOL, V142, P1501, DOI 10.1083/jcb.142.6.1501; Kozutsumi Y, 2002, BBA-MOL CELL BIOL L, V1582, P138, DOI 10.1016/S1388-1981(02)00148-8; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Marcoux N, 2000, GENETICS, V156, P579; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; Momoi M, 2004, BIOCHEM J, V381, P321, DOI 10.1042/BJ20040108; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Nakamura S, 1996, J BIOL CHEM, V271, P1255, DOI 10.1074/jbc.271.3.1255; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; Roelants FM, 2004, MICROBIOL-SGM, V150, P3289, DOI 10.1099/mic.0.27286-0; Roelants FM, 2002, MOL BIOL CELL, V13, P3005, DOI 10.1091/mbc.E02-04-0201; Schmelzle T, 2002, MOL CELL BIOL, V22, P1329, DOI 10.1128/MCB.22.5.1329-1339.2002; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sun YD, 2000, MOL CELL BIOL, V20, P4411, DOI 10.1128/MCB.20.12.4411-4419.2000; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Uemura S, 2003, J BIOL CHEM, V278, P45049, DOI 10.1074/jbc.M305498200; Umebayashi K, 2003, J CELL BIOL, V161, P1117, DOI 10.1083/jcb.200303088; Wang QQ, 2002, P NATL ACAD SCI USA, V99, P12853, DOI 10.1073/pnas.202115499; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; ZHAO C, 1994, J BIOL CHEM, V269, P21480	55	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18087	18094		10.1074/jbc.M414138200	http://dx.doi.org/10.1074/jbc.M414138200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15741172	hybrid			2022-12-25	WOS:000228807200066
J	Lee, JE; Singh, V; Evans, GB; Tyler, PC; Furneaux, RH; Cornell, KA; Riscoe, MK; Schramm, VL; Howell, PL				Lee, JE; Singh, V; Evans, GB; Tyler, PC; Furneaux, RH; Cornell, KA; Riscoe, MK; Schramm, VL; Howell, PL			Structural rationale for the affinity of pico- and femtomolar transition state analogues of Escherichia coli 5 '-methylthioadenosine/S-adenosylhomocysteine nucleosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARRIER HYDROGEN-BONDS; QUORUM-SENSING SIGNAL; CATALYTIC MECHANISM; MYCOBACTERIUM-TUBERCULOSIS; PLASMODIUM-FALCIPARUM; ENZYMATIC CATALYSIS; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; IMMUCILLIN-H; DRUG DESIGN	Immucillin and DADMe-Immucillin inhibitors are tight binding transition state mimics of purine nucleoside phosphorylases (PNP). 5'-Methylthioadenosine/S-adenosylhomocysteine nucleosidase (MTAN) is proposed to form a similar transition state structure as PNP. The companion paper describes modifications of the Immucillin and DADMe-Immucillin inhibitors to better match transition state features of MTAN and have led to 5'-thio aromatic substitutions that extend the inhibition constants to the femtomolar range (Singh, V., Evans, G. B., Lenz, D. H., Mason, J., Clinch, K., Mee, S., Painter, G. F., Tyler, P. C., Furneaux, R. H., Lee, J. E., Howell, P. L., and Schramm, V. L. (2005) J. Biol. Chem. 280, 18265-18273). 5'-Methylthio-Immucillin A (MT-ImmA) and 5'-methylthio-DADMe-Immucillin A (MT-DADMe-ImmA) exhibit slow-onset inhibition with K-i* of 77 and 2 pM, respectively, and were selected for structural analysis as the parent compounds of each class of transition state analogue. The crystal structures of Escherichia coli MTAN complexed with MT-ImmA and MT-DADMe-ImmA were determined to 2.2 angstrom resolution and compared with the existing MTAN inhibitor complexes. These MTAN-transition state complexes are among the tightest binding enzyme-ligand complexes ever described and analysis of their mode of binding provides extraordinary insight into the structural basis for their affinity. The MTAN-MT-ImmA complex reveals the presence of a new ion pair between the 4'-iminoribitol atom and the nucleophilic water (WAT3) that captures key features of the transition state. Similarly, in the MTAN-MT-DADMe-ImmA complex a favorable hydrogen bond or ion pair interaction between the cationic 1'-pyrrolidine atom and WAT3 is crucial for tight affinity. Distance analysis of the nucleophile and leaving group show that MT-ImmA is a mimic of an early transition state, while MT-DADMe-ImmA is a better mimic of the highly dissociated transition state of E. coli MTAN.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Fac Med, Toronto, ON M5S 1A8, Canada; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Ind Res Ltd, Carbohydrate Chem Team, Lower Hutt, New Zealand; Boise State Univ, Dept Chem, Boise, ID 83725 USA; Vet Affairs Med Ctr, Med Res Serv, Portland, OR 97021 USA; Portland State Univ, Dept Chem, Portland, OR 97207 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Yeshiva University; Albert Einstein College of Medicine; Callaghan Innovation; Idaho; Boise State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland State University	Howell, PL (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	howell@sickkids.ca	Evans, Gary/B-8343-2011; Evans, Gary/I-4123-2019; Furneaux, Richard Hubert/B-4157-2015	Evans, Gary/0000-0002-6973-2002; Evans, Gary/0000-0002-6973-2002; Furneaux, Richard Hubert/0000-0003-0973-2606				Allart B, 1999, NUCLEOS NUCLEOT NUCL, V18, P861, DOI 10.1080/15257779908041582; Allart B, 1998, EUR J BIOCHEM, V256, P155, DOI 10.1046/j.1432-1327.1998.2560155.x; Appleby TC, 1999, STRUCTURE, V7, P629, DOI 10.1016/S0969-2126(99)80084-7; Basso LA, 2001, BIOCHEMISTRY-US, V40, P8196, DOI 10.1021/bi010584x; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Berti PJ, 2002, ADV PHYS ORG CHEM, V37, P239, DOI 10.1016/S0065-3160(02)37004-7; Blessing R. H., 1987, CRYSTALLOGR REV, V1, P3; BORCHARDT RT, 1986, BIOL METHYLATION DRU, P227; BORKAKOTI N, 1978, ACTA CRYSTALLOGR B, V34, P867, DOI 10.1107/S0567740878004215; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; Cleland WW, 2000, ARCH BIOCHEM BIOPHYS, V382, P1, DOI 10.1006/abbi.2000.2011; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; Cornell KA, 1996, BIOCHEM BIOPH RES CO, V228, P724, DOI 10.1006/bbrc.1996.1723; DELAHABA G, 1959, J BIOL CHEM, V234, P603; DUERRE JA, 1962, J BIOL CHEM, V237, P3737; Erion MD, 1997, BIOCHEMISTRY-US, V36, P11735, DOI 10.1021/bi961970v; Evans GB, 2004, J MED CHEM, V47, P3275, DOI 10.1021/jm0306475; Evans GB, 2003, J MED CHEM, V46, P5271, DOI 10.1021/jm030305z; Evans GB, 2003, J MED CHEM, V46, P3412, DOI 10.1021/jm030145r; Evans GB, 2003, J MED CHEM, V46, P155, DOI 10.1021/jm0203332; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kaplan W, 2001, Brief Bioinform, V2, P195, DOI 10.1093/bib/2.2.195; Kicska GA, 2002, BIOCHEMISTRY-US, V41, P14489, DOI 10.1021/bi026636f; Kicska GA, 2002, J BIOL CHEM, V277, P3226, DOI 10.1074/jbc.M105906200; Kicska GA, 2002, J BIOL CHEM, V277, P3219, DOI 10.1074/jbc.M105905200; Kleywegt G. J., 1995, CCP4 ESF EACBM NEWSL, V31, P45; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KLINE PC, 1993, BIOCHEMISTRY-US, V32, P13212, DOI 10.1021/bi00211a033; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JE, 2004, BIOCHEMISTRY-US, V43, P5159, DOI 10.1021/bi035492h; Lee JE, 2003, J BIOL CHEM, V278, P8761, DOI 10.1074/jbc.M210836200; Lee JE, 2001, STRUCTURE, V9, P941, DOI 10.1016/S0969-2126(01)00656-6; Lee JE, 2001, ACTA CRYSTALLOGR D, V57, P150, DOI 10.1107/S0907444900014669; Lewandowicz A, 2004, BIOCHEMISTRY-US, V43, P1458, DOI 10.1021/bi0359123; Lewandowicz A, 2003, J BIOL CHEM, V278, P31465, DOI 10.1074/jbc.C300259200; Lewandowicz A, 2003, BIOCHEMISTRY-US, V42, P6057, DOI 10.1021/bi0343830; MARKERT M L, 1991, Immunodeficiency Reviews, V3, P45; Markham GD, 2002, BIOCHEMISTRY-US, V41, P7636, DOI 10.1021/bi025682c; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miles RW, 1999, BIOCHEMISTRY-US, V38, P13147, DOI 10.1021/bi990829u; Miles RW, 1998, BIOCHEMISTRY-US, V37, P8615, DOI 10.1021/bi980658d; MONTGOMERY JA, 1993, MED RES REV, V13, P209, DOI 10.1002/med.2610130302; PAJULA RL, 1979, FEBS LETT, V99, P343, DOI 10.1016/0014-5793(79)80988-6; PEGG AE, 1969, J BIOL CHEM, V244, P682; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Pugmire MJ, 2002, BIOCHEM J, V361, P1, DOI 10.1042/0264-6021:3610001; RAINA A, 1982, BIOCHEM J, V204, P697, DOI 10.1042/bj2040697; RISCOE MK, 1989, PARASITOL TODAY, V5, P330, DOI 10.1016/0169-4758(89)90128-2; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P5694, DOI 10.1021/bi034003a; Schauder S, 2001, MOL MICROBIOL, V41, P463, DOI 10.1046/j.1365-2958.2001.02532.x; Shi WX, 2001, BIOCHEMISTRY-US, V40, P8204, DOI 10.1021/bi010585p; Singh V, 2005, J BIOL CHEM, V280, P18265, DOI 10.1074/jbc.M414472200; Singh V, 2004, BIOCHEMISTRY-US, V43, P9, DOI 10.1021/bi0358420; SUFRIN JR, 1995, ANTIMICROB AGENTS CH, V39, P2511, DOI 10.1128/AAC.39.11.2511	62	68	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18274	18282		10.1074/jbc.M414471200	http://dx.doi.org/10.1074/jbc.M414471200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746096	hybrid			2022-12-25	WOS:000228807200086
J	Calamita, G; Ferri, D; Gena, P; Liquori, GE; Cavalier, A; Thomas, D; Svelto, M				Calamita, G; Ferri, D; Gena, P; Liquori, GE; Cavalier, A; Thomas, D; Svelto, M			The inner mitochondrial membrane has aquaporin-8 water channels and is highly permeable to water	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; BRAIN MITOCHONDRIA; LIGHT-SCATTERING; TRANSITION; VOLUME; IMMUNOLOCALIZATION; EXPRESSION; APOPTOSIS; CLONING; FAMILY	Mitochondria are remarkably plastic organelles constantly changing their shape to fulfil their various functional activities. Although the osmotic movement of water into and out of the mitochondrion is central for its morphology and activity, the molecular mechanisms and the pathways for water transport across the inner mitochondrial membrane (IMM), the main barrier for molecules moving into and out of the organelle, are completely unknown. Here, we show the presence of a member of the aquaporin family of water channels, AQP8, and demonstrate the strikingly high water permeability (P-f) characterizing the rat liver IMM. Immunoblotting, electron microscopy, and biophysical studies show that the largest mitochondria feature the highest AQP8 expression and IMM Pf. AQP8 was also found in the mitochondria of other organs, whereas no other known aquaporins were seen. The osmotic water transport of liver IMM was partially inhibited by the aquaporin blocker Hg2+, while the related activation energy remained low, suggesting the presence of a Hg2+-insensitive facilitated pathway in addition to AQP8. It is suggested that AQP8-mediated water transport may be particularly important for rapid expansions of mitochondrial volume such as those occurring during active oxidative phosphorylation and those following apoptotic signals.	Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Univ Bari, Dipartimento Zool, Lab Istol & Anat Comparata, I-70126 Bari, Italy; Univ Rennes 1, CNRS, URA 256, Rennes, France	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Calamita, G (corresponding author), Univ Bari, Dipartimento Fisiol Gen & Ambientale, Via Amendola 165-A, I-70126 Bari, Italy.	calamita@biologia.uniba.it	THOMAS, Danniel/AAJ-5033-2020; Gena, patrizia/AAC-3396-2022; Svelto, Maria/P-6186-2014	THOMAS, Danniel/0000-0002-9650-0434; Svelto, Maria/0000-0002-5584-9541; Calamita, Giuseppe/0000-0003-4666-9546				Agre P, 2003, FEBS LETT, V555, P72, DOI 10.1016/S0014-5793(03)01083-4; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; Bereiter-Hahn J., 1990, International Review of Cytology, V122, P1, DOI 10.1016/S0074-7696(08)61205-X; Calamita G, 2001, EUR J CELL BIOL, V80, P711, DOI 10.1078/0171-9335-00210; Calamita G, 1999, CYTOGENET CELL GENET, V85, P237, DOI 10.1159/000015300; Colombini M, 2004, MOL CELL BIOCHEM, V256, P107, DOI 10.1023/B:MCBI.0000009862.17396.8d; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Elkjaer ML, 2000, BIOCHEM BIOPH RES CO, V276, P1118, DOI 10.1006/bbrc.2000.3505; Ferri D, 2003, HEPATOLOGY, V38, P947, DOI 10.1053/jhep.2003.50397; Fujii F, 2004, BRAIN RES, V999, P29, DOI 10.1016/j.brainres.2003.11.017; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; GARLID KD, 1988, MITOCHONDRIAL VOLUME, P259; Gradilone SA, 2003, HEPATOLOGY, V37, P1435, DOI 10.1053/jhep.2003.50241; Guerrieri F, 2002, EUR J BIOCHEM, V269, P3304, DOI 10.1046/j.1432-1033.2002.03010.x; ICHAS F, 1994, FEBS LETT, V348, P211, DOI 10.1016/0014-5793(94)00615-6; Ishibashi K, 1997, BIOCHEM BIOPH RES CO, V237, P714, DOI 10.1006/bbrc.1997.7219; Jablonski EM, 2004, AM J PHYSIOL-CELL PH, V286, pC975, DOI 10.1152/ajpcell.00180.2003; Kristian T, 2000, J NEUROCHEM, V74, P1999, DOI 10.1046/j.1471-4159.2000.0741999.x; Lanni A, 1996, INT J BIOCHEM CELL B, V28, P337, DOI 10.1016/1357-2725(95)00137-9; Lee WK, 2005, AM J PHYSIOL-RENAL, V288, pF27, DOI 10.1152/ajprenal.00224.2004; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Portincasa P, 2003, J HEPATOL, V39, P864, DOI 10.1016/S0168-8278(03)00294-0; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VANHEESWIJK MPE, 1986, J MEMBRANE BIOL, V92, P183, DOI 10.1007/BF01870707; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68; Zardoya R, 2001, J MOL EVOL, V52, P391, DOI 10.1007/s002390010169; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	28	166	176	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17149	17153		10.1074/jbc.C400595200	http://dx.doi.org/10.1074/jbc.C400595200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15749715	hybrid			2022-12-25	WOS:000228615500075
J	Wang, XM; Tang, XL; Li, MT; Marshall, J; Mao, ZX				Wang, XM; Tang, XL; Li, MT; Marshall, J; Mao, ZX			Regulation of neuroprotective activity of myocyte-enhancer factor 2 by cAMP-protein kinase A signaling pathway in neuronal survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; GROWTH-FACTOR-I; CYCLASE-ACTIVATING POLYPEPTIDE; TRANSCRIPTION FACTOR MEF2; CENTRAL-NERVOUS-SYSTEM; DNA-BINDING ACTIVITY; CYCLIC-AMP; PHOSPHATIDYLINOSITOL 3-KINASE; NEURITE-OUTGROWTH; INDUCED APOPTOSIS	The transcription factor myocyte-enhancer factor 2 (MEF2) has been shown to be required for the survival of different types of neurons. However, the death- or survival-inducing second messenger pathways that regulate MEF2 activity remain to be fully elucidated. Membrane depolarization by KCl induces neuronal survival that is dependent upon MEF2-mediated gene transactivation. Here we report that membrane depolarization-induced activation of MEF2 requires the cAMP-protein kinase A (PKA) pathway. Inhibition of the activity of cAMP-PKA pathway attenuates membrane depolarization-induced activation of MEF2 activity and neuronal survival, whereas enhancing the activity of this pathway prevents KCl withdrawal-induced inhibition of MEF2 and neuronal apoptosis. Moreover, PKA directly phosphorylates MEF2 at Thr-20 in vitro to increase MEF2 DNA binding activity. A mutation of Thr-20 to Ala renders MEF2 resistant to PKA phosphorylation in vitro and reduces its DNA binding activity. Transfection of this T20A mutant blocks survival and induces apoptosis in cultured cortical and cerebellar granule neurons. This study identifies the transcription factor MEF2 as a target of cAMP-PKA pathway and demonstrates that PKA phosphorylation of MEF2 is a key step in modulating its DNA binding activity and ability to promote neuronal survival.	Brown Univ, Sch Med, Dept Med, Providence, RI 02903 USA; Rhode Isl Hosp, Providence, RI 02903 USA; Sun Yat Sen Univ, Zhongshan med Coll, Dept Pharmacol, Guangzhou 510080, Peoples R China; Brown Univ, Sch Med, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Sun Yat Sen University; Brown University	Mao, ZX (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.	zmao@pharm.emory.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039446] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039063] Funding Source: NIH RePORTER; NICHD NIH HHS [HD39446] Funding Source: Medline; NINDS NIH HHS [NS39063] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bhave SV, 2004, J NEUROCHEM, V88, P359, DOI 10.1046/j.1471-4159.2003.02167.x; Blair LAC, 1999, J NEUROSCI, V19, P1940; Borodinsky LN, 2002, J NEUROCHEM, V80, P1062, DOI 10.1046/j.1471-4159.2002.00795.x; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; Cordenonsi M, 1999, EUR J BIOCHEM, V264, P374, DOI 10.1046/j.1432-1327.1999.00616.x; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Facci L, 2003, NEUROPHARMACOLOGY, V45, P623, DOI 10.1016/S0028-3908(03)00211-9; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Franke B, 2000, EXP NEUROL, V165, P125, DOI 10.1006/exnr.2000.7453; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Hanson MG, 1998, J NEUROSCI, V18, P7361; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hashiguchi M, 2002, J BIOL CHEM, V277, P44525, DOI 10.1074/jbc.M207426200; Heidenreich KA, 2004, MOL NEUROBIOL, V29, P155, DOI 10.1385/MN:29:2:155; Huang K, 2000, EMBO J, V19, P2615, DOI 10.1093/emboj/19.11.2615; IKESHIMA H, 1995, NEUROSCI LETT, V200, P117, DOI 10.1016/0304-3940(95)12092-I; Jaworski J, 2003, J NEUROSCI, V23, P4519; Jiang XY, 2003, ANN NY ACAD SCI, V993, P134, DOI 10.1111/j.1749-6632.2003.tb07522.x; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Koulich E, 2001, J NEUROCHEM, V76, P1188, DOI 10.1046/j.1471-4159.2001.00134.x; Lee HT, 2003, INVEST OPHTH VIS SCI, V44, P3816, DOI 10.1167/iovs.03-0147; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Linseman DA, 2003, J NEUROCHEM, V85, P1488, DOI 10.1046/j.1471-4159.2003.09799.x; Liu LD, 2003, P NATL ACAD SCI USA, V100, P8532, DOI 10.1073/pnas.1332804100; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Mei YA, 2004, EUR J NEUROSCI, V19, P1446, DOI 10.1111/j.1460-9568.2004.03227.x; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; Miller TM, 1997, J BIOL CHEM, V272, P9847; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; Nara M, 1998, J BIOL CHEM, V273, P14920, DOI 10.1074/jbc.273.24.14920; Nguyen PV, 2003, PROG NEUROBIOL, V71, P401, DOI 10.1016/j.pneurobio.2003.12.003; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Poser S, 2003, J NEUROSCI, V23, P4420; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; Shalizi A, 2003, J NEUROSCI, V23, P7326; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Vaudry D, 2003, SCIENCE, V300, P1532, DOI 10.1126/science.1085260; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963	57	55	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16705	16713		10.1074/jbc.M501819200	http://dx.doi.org/10.1074/jbc.M501819200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15735306	hybrid			2022-12-25	WOS:000228615500022
J	Belaidouni, N; Peuchmaur, M; Perret, C; Florentin, A; Benarous, R; Besnard-Guerin, C				Belaidouni, N; Peuchmaur, M; Perret, C; Florentin, A; Benarous, R; Besnard-Guerin, C			Overexpression of human beta TrCP1 deleted of its F box induces tumorigenesis in transgenic mice	ONCOGENE			English	Article						beta TrCP; beta-catenin; transgenic mice; tumors	PROTEIN BETA-TRCP; I-KAPPA-B; CATENIN GENE; DEGRADATION; LIVER; PROGRESSION; EXPRESSION; PATHWAY; COMPLEX; CANCER	Genetic alterations affecting beta-catenin, adenomatous polyposis coli or axin proteins are associated with the pathogenesis of numerous human tumors. All these mutations result in the synthesis of unphosphorylated beta-catenin that escapes recognition by the beta transducin repeat protein (beta TrCP1), the receptor of an ubiquitin. The stabilized beta-catenin translocates to the nucleus and activates the transcription of genes crucial for tumorigenesis. Recent evidence implicates mutations and overexpresssion of bTrCP1 in human prostate and colon tumors, respectively, suggesting that deregulated bTrCP1 may be involved in tumorigenesis. To explore this possibility further, we generated transgenic mice that specifically express a dominant-negative mutant of beta TrCP1 (Delta F beta TrCP1) or full-length beta TrCP1 in intestine, liver and kidney. We found that 46% (16/35) of the transgenic mice that overexpressed the transgenes developed either intestinal adenomas (10/35) or hepatic (4/35) or urothelial (2/35) tumors. Immunohistological analysis of the tumors revealed that upregulation of cyclin D1, glutamine synthetase and chemotaxin 2 was associated with nuclear accumulation of beta-catenin. These results show that the overexpression of DFbTrCP1 or bTrCP1 in vivo induce tumors through beta-catenin activation.	Univ Paris 05, CNRS, UMR 8104, Dept INSERM U567,Dept Infect Dis,Inst Cochin, F-75014 Paris, France; Hop Robert Debre, Serv Anatomapathol, F-75019 Paris, France; Univ Paris 05, CNRS, UMR 8104, Inst Cochin,U567,Dept INSERM,Dept Genet Dev & Mol, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Benarous, R (corresponding author), Univ Paris 05, CNRS, UMR 8104, Dept INSERM U567,Dept Infect Dis,Inst Cochin, 27,Rue Faubourg St Jacques, F-75014 Paris, France.	benarous@cochin.inserm.fr; besnard-guerin@cochin.inserm.fr	Perret-Mayeux, Christine/L-3297-2017; Besnard-Guerin, Corinne/J-3985-2017	perret, christine/0000-0003-4710-7051				Besnard-Guerin C, 2004, J BIOL CHEM, V279, P788, DOI 10.1074/jbc.M308068200; Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118; Cadoret A, 2001, CANCER RES, V61, P3245; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Harada N, 2002, CANCER RES, V62, P1971; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Nakayama K, 2003, P NATL ACAD SCI USA, V100, P8752, DOI 10.1073/pnas.1133216100; Ovejero C, 2004, HEPATOLOGY, V40, P167, DOI 10.1002/hep.20286; Polakis P, 2000, GENE DEV, V14, P1837; Romagnolo B, 1999, CANCER RES, V59, P3875; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5	21	37	38	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2271	2276		10.1038/sj.onc.1208418	http://dx.doi.org/10.1038/sj.onc.1208418			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735746				2022-12-25	WOS:000227857900014
J	Lawrence, KM; Kabir, AMN; Bellahcene, M; Davidson, S; Mesquita, RS; Cao, XB; McCormick, J; Carroll, CJ; Chanalaris, A; Townsend, PA; Hubank, M; Stephanou, A; Knight, RA; Marber, MS; Latchman, DS				Lawrence, KM; Kabir, AMN; Bellahcene, M; Davidson, S; Mesquita, RS; Cao, XB; McCormick, J; Carroll, CJ; Chanalaris, A; Townsend, PA; Hubank, M; Stephanou, A; Knight, RA; Marber, MS; Latchman, DS			Cardioprotection mediated by urocortin is dependent upon PKCF epsilon activation	FASEB JOURNAL			English	Article						ischemia; protein kinase C epsilon; apoptosis; mitochondria	PROTEIN-KINASE-C; CARDIAC MYOCYTES; REPERFUSION INJURY; GENE-EXPRESSION; ISCHEMIC-INJURY; MOUSE HEARTS; DELTA-PKC; LOCALIZATION; PEPTIDES; PROTECTION	Urocortin (Ucn) is an endogenous cardioprotective agent that protects against the damaging effects of ischemia and reperfusion injury in vitro and in vivo. We have found that the mechanism of action of Ucn involves both acute activation of specific target molecules, and using Affymetrix (Santa Clara, CA) gene chip technology, altered gene expression of different end effector molecules. Here, from our gene chip data, we show that after a 24 h exposure to Ucn, there was a specific increase in mRNA and protein levels of the protein kinase C epsilon (PKC epsilon) isozyme in primary rat cardiomyocytes compared with untreated cells and in the Langendorff perfused ex vivo heart. Furthermore, a short 10 min exposure of these cells to Ucn caused a specific translocation/activation of PKC epsilon, in vitro and in the Langendorff perfused ex vivo heart. The importance of the PKC epsilon, isozyme in cardioprotection and its relationship to cardioprotection produced by Ucn was assessed using PKC epsilon-specific inhibitor peptides. The inhibitor peptide, when introduced into cardiomyocytes, caused an increase in apoptotic cell death compared with control peptide after ischemia and reperfusion. When the inhibitor peptide was present with Ucn, the cardioprotective effect of Ucn was lost. This loss of cardioprotection by Ucn was also seen in whole hearts from PKC epsilon, knockout mice. These findings indicate that the cardioprotective effect of Ucn is dependent upon PKC epsilon.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England; St Thomas Hosp, Rayne Inst, London SE1 7EH, England; Royal Brompton Hosp, Natl Heart & Lung Inst, London SW3 6LY, England	University of London; University College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Imperial College London; Royal Brompton Hospital	Lawrence, KM (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.	k.lawrence@ich.ucl.ac.uk	Carroll, Christopher/AAV-8023-2021; Carroll, Christopher/AAJ-6185-2021; Kabir, Arif Md. Rashedul/ABZ-1320-2022; Townsend, Paul/AAF-8234-2020; Hubank, Michael JF/C-1837-2008; marber, michael/AAW-7916-2021; Davidson, Sean M/F-5275-2010; Chanalaris, Anastasios/A-5620-2008	Carroll, Christopher/0000-0002-2814-6955; Kabir, Arif Md. Rashedul/0000-0001-6367-7690; Hubank, Michael JF/0000-0002-2901-0742; Davidson, Sean M/0000-0001-5182-4980; Marber, Michael/0000-0002-3463-7128; Townsend, Paul/0000-0001-8956-9508; Chanalaris, Anastasios/0000-0002-8884-6750				Baines CP, 2003, CIRC RES, V92, P873, DOI 10.1161/01.RES.0000069215.36389.8D; Brar BK, 2000, J BIOL CHEM, V275, P8508, DOI 10.1074/jbc.275.12.8508; Brar BK, 2002, J MOL CELL CARDIOL, V34, P483, DOI 10.1006/jmcc.2002.1529; Brar BK, 1999, MOL CELL ENDOCRINOL, V158, P55, DOI 10.1016/S0303-7207(99)00183-5; Chen L, 2001, CHEM BIOL, V8, P1123, DOI 10.1016/S1074-5521(01)00076-X; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Cross HR, 2002, J MOL CELL CARDIOL, V34, P361, DOI 10.1006/jmcc.2001.1518; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Jin ZQ, 2002, AM J PHYSIOL-HEART C, V282, pH1970, DOI 10.1152/ajpheart.01029.2001; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Latchman DS, 2002, INT J BIOCHEM CELL B, V34, P907, DOI 10.1016/S1357-2725(02)00011-0; Latchman DS, 2001, TRENDS CARDIOVAS MED, V11, P167, DOI 10.1016/S1050-1738(01)00093-7; Lawrence KM, 2003, FASEB J, V17, P2313, DOI 10.1096/fj.02-0832fje; Lawrence KM, 2002, CIRCULATION, V106, P1556, DOI 10.1161/01.CIR.0000028424.02525.AE; Liu GS, 1999, J MOL CELL CARDIOL, V31, P1937, DOI 10.1006/jmcc.1999.1026; Mackay K, 2001, J MOL CELL CARDIOL, V33, P1301, DOI 10.1006/jmcc.2001.1400; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Murriel CL, 2003, ARCH BIOCHEM BIOPHYS, V420, P246, DOI 10.1016/j.abb.2003.08.038; Naruse K, 2000, CIRC RES, V86, P1104; Ohnuma Y, 2002, AM J PHYSIOL-HEART C, V283, pH440, DOI 10.1152/ajpheart.00434.2001; Okosi A, 1998, NEUROPEPTIDES, V32, P167, DOI 10.1016/S0143-4179(98)90033-6; Oldenburg O, 2002, CARDIOVASC RES, V55, P429, DOI 10.1016/S0008-6363(02)00439-X; Ping PP, 2001, CIRC RES, V88, P59, DOI 10.1161/01.RES.88.1.59; PRZYKLENK K, 1995, CIRCULATION, V92, P1546, DOI 10.1161/01.CIR.92.6.1546; SARGENT CA, 1992, J CARDIOVASC PHARM, V20, P251, DOI 10.1097/00005344-199208000-00010; Sato T, 1998, CIRC RES, V83, P110, DOI 10.1161/01.RES.83.1.110; Saurin AT, 2002, CARDIOVASC RES, V55, P672, DOI 10.1016/S0008-6363(02)00325-5; Schulman D, 2002, AM J PHYSIOL-HEART C, V283, pH1481, DOI 10.1152/ajpheart.01089.2001; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Wang YG, 1999, CIRC RES, V84, P1156, DOI 10.1161/01.RES.84.10.1156; Williams SD, 2002, BIOCHEM J, V362, P23, DOI 10.1042/bj3620023	31	44	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					831	+		10.1096/fj.04-2506fje	http://dx.doi.org/10.1096/fj.04-2506fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15764590				2022-12-25	WOS:000227901300019
J	Rotoli, BM; Bussolati, O; Sala, R; Gazzola, GC; Dall'Asta, V				Rotoli, BM; Bussolati, O; Sala, R; Gazzola, GC; Dall'Asta, V			The transport of cationic amino acids in human airway cells: expression of system y(+)L activity and transepithelial delivery of NOS inhibitors	FASEB JOURNAL			English	Article						arginine; cationic amino acid transport; system B-0,B-+; nitric oxide; lysinuric protein intolerance	NITRIC-OXIDE SYNTHASE; L-ARGININE; FUNCTIONAL EXPRESSION; HUMAN ERYTHROCYTES; PROTEIN; IDENTIFICATION; MEMBRANE; LUNG; EPITHELIUM; CLONING	The transport of arginine has been characterized in human airway Calu-3 cells. As assessed with RT-PCR, Calu-3 cells express the genes for several transporters, such as the system y(+)-related SLC7A1, SLC7A2, and SLC7A4; the system y(+)L-related SLC7A6, SLC7A7, and SLC3A2; and the system B-0,B-+-related SLC6A14. In polarized Calu-3 cell monolayers, apical arginine influx has a leucine-sensitive, sodium-dependent component and a leucine- and lysine-resistant sodium-independent fraction. At the basolateral membrane, arginine transport was fully sodium-independent and partially inhibited by leucine provided that sodium was present in the extracellular medium. Moreover, extracellular leucine trans-stimulated arginine efflux from the basolateral membrane in the presence, but not in the absence, of sodium. The transepithelial, apical to basolateral, arginine transport strictly depended on the presence of sodium and was markedly inhibited by apical leucine, but significantly trans-stimulated by the neutral amino acid added at the basolateral side. When added at the apical side, the NOS-inhibitors NMMA and NIL, CAA analogs with a free carboxyl group, markedly inhibited the apical arginine influx and the transepithelial flux of the cationic amino acid. The same compounds trans-stimulated basolateral arginine efflux. None of these effects were observed in the presence of the methyl ester analog NAME. The basolateral medium of Calu-3 cell monolayers, obtained after incubation in the presence of the three inhibitors at the apical side, inhibited the production of NO by activated murine macrophages. The inhibitory effect of the Calu-3 cell conditioned medium was time-dependent and markedly higher with NMMA and NIL than with NAME. Moreover, the NOS-inhibitory effect of the medium was significantly enhanced if NMMA and NIL, at the apical side, and basolateral leucine were simultaneously present during the conditioning procedure. These results indicate that 1) human airway epithelial cells express a functional system y(+)L at the basolateral membrane; 2) in this model, transepithelial arginine transport involves apical influx through system B-0,B-+ and basolateral efflux through system y+L, and 3) the same transporters also perform an efficient transepithelial transport of amino acid-like NOS inhibitors.	Univ Parma, Dipartimento Med Sperimentale, Sez Patol Gen & Clin, I-43100 Parma, Italy	University of Parma	Dall'Asta, V (corresponding author), Univ Parma, Dipartimento Med Sperimentale, Sez Patol Gen & Clin, Via Volturno 39, I-43100 Parma, Italy.	valeria.dallasta@unipr.it	Bussolati, Ovidio/B-7589-2013; Sala, Roberto/B-9736-2013; Dall'Asta, Valeria/M-6698-2015	Bussolati, Ovidio/0000-0002-4301-2939; Sala, Roberto/0000-0002-9167-0020; Dall'Asta, Valeria/0000-0001-8540-0916				BARNES PJ, 1995, ANN MED, V27, P389, DOI 10.3109/07853899509002592; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; BAYDOUN AR, 1994, BIOCHEM BIOPH RES CO, V200, P726, DOI 10.1006/bbrc.1994.1511; BOGLE RG, 1992, BRIT J PHARMACOL, V105, P768, DOI 10.1111/j.1476-5381.1992.tb09053.x; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; Broer A, 2000, BIOCHEM J, V349, P787, DOI 10.1042/bj3490787; Dall'Asta V, 2000, AM J PHYSIOL-CELL PH, V279, pC1829, DOI 10.1152/ajpcell.2000.279.6.C1829; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Donnelly LE, 2002, AM J RESP CELL MOL, V26, P144, DOI 10.1165/ajrcmb.26.1.4477; Edwards RM, 1998, J PHARMACOL EXP THER, V285, P1019; Eynott PR, 2002, EUR J PHARMACOL, V452, P123, DOI 10.1016/S0014-2999(02)02237-9; FINKBEINER WE, 1993, AM J RESP CELL MOL, V9, P547, DOI 10.1165/ajrcmb/9.5.547; Florea BI, 2003, J CONTROL RELEASE, V87, P131, DOI 10.1016/S0168-3659(02)00356-5; Forray MI, 1995, BIOCHEM PHARMACOL, V50, P1963, DOI 10.1016/0006-2952(95)02090-X; Foster KA, 2000, INT J PHARMACEUT, V208, P1, DOI 10.1016/S0378-5173(00)00452-X; Galietta LJV, 1998, AM J PHYSIOL-LUNG C, V275, pL917, DOI 10.1152/ajplung.1998.275.5.L917; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; Gomez FP, 1998, EUR RESPIR J, V12, P865, DOI 10.1183/09031936.98.12040865; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; Guo FH, 2000, J IMMUNOL, V164, P5970, DOI 10.4049/jimmunol.164.11.5970; Hansel TT, 2003, FASEB J, V17, P1298, DOI 10.1096/fj.02-0633fje; Hatanaka T, 2001, J CLIN INVEST, V107, P1035, DOI 10.1172/JCI12060; Karadag B, 1999, EUR RESPIR J, V13, P1402, DOI 10.1034/j.1399-3003.1999.13f28.x; KHARITONOV SA, 1995, CLIN SCI, V88, P135, DOI 10.1042/cs0880135; KHARITONOV SA, 1995, CHEST, V107, pS156, DOI 10.1378/chest.107.3_Supplement.156S; Kharitonov SA, 1997, THORAX, V52, P1051, DOI 10.1136/thx.52.12.1051; Kizaki T, 2002, P NATL ACAD SCI USA, V99, P9392, DOI 10.1073/pnas.142206299; LYONS CR, 1992, J BIOL CHEM, V267, P6370; Mathias NR, 2002, J DRUG TARGET, V10, P31, DOI 10.1080/10611860290007504; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Morris CR, 2004, AM J RESP CRIT CARE, V170, P148, DOI 10.1164/rccm.200309-1304OC; Paredi P, 1999, CHEST, V115, P1352, DOI 10.1378/chest.115.5.1352; PARTO K, 1993, CHEST, V104, P1176, DOI 10.1378/chest.104.4.1176; Ribeiro ACM, 1997, CLIN SCI, V93, P57, DOI 10.1042/cs0930057; Rotoli BM, 2004, FEBS LETT, V571, P177, DOI 10.1016/j.febslet.2004.06.086; Sala R, 2002, AM J PHYSIOL-CELL PH, V282, pC134, DOI 10.1152/ajpcell.2002.282.1.C134; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Sapienza MA, 1998, THORAX, V53, P172, DOI 10.1136/thx.53.3.172; Sloan JL, 1999, J BIOL CHEM, V274, P23740, DOI 10.1074/jbc.274.34.23740; Sloan JL, 2003, AM J PHYSIOL-LUNG C, V284, pL39, DOI 10.1152/ajplung.00164.2002; Taylor DA, 1998, AM J RESP CRIT CARE, V158, P99, DOI 10.1164/ajrccm.158.1.9709091; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; Trapnell BC, 2003, NEW ENGL J MED, V349, P2527, DOI 10.1056/NEJMra023226; Uetani K, 2001, AM J RESP CELL MOL, V24, P720, DOI 10.1165/ajrcmb.24.6.4297; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892, DOI 10.1164/ajrccm.152.3.7663801; Zhuang JC, 1997, P NATL ACAD SCI USA, V94, P11875, DOI 10.1073/pnas.94.22.11875	49	23	25	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					810	+		10.1096/fj.04-2924fje	http://dx.doi.org/10.1096/fj.04-2924fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746185				2022-12-25	WOS:000227901300031
J	Kashkar, H; Wiegmann, K; Yazdanpanah, B; Haubert, D; Kronke, M				Kashkar, H; Wiegmann, K; Yazdanpanah, B; Haubert, D; Kronke, M			Acid sphingomyelinase is indispensable for UV light-induced bax conformational change at the mitochondrial membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; ENDOPLASMIC-RETICULUM; CASPASE ACTIVATION; HELA-CELLS; APOPTOSIS; CERAMIDE; INDUCTION; AGENTS; PERMEABILITY; FIBROBLASTS	Ultraviolet light-induced apoptosis can be caused by DNA damage but also involves immediate-early cell death cascades characteristic of death receptor signaling. Here we show that the UV light-induced apoptotic signaling pathway is unique, targeting Bax activation at the mitochondrial membrane independent of caspase-8 or cathepsin D activity. Cells deficient in acid sphingomyelinase (ASMase) do not show UV light-induced Bax activation, cytochrome c release, or apoptosis. In ASMase-deficient cells, the apoptotic UV light response is restored by stable or transient expression of human ASMase. Bax conformational change in ASMase(-/-) cells is also caused by synthetic C-16-ceramide acting on intact cells or isolated mitochondria. The results suggest that UV light-triggered ASMase activation is essentially required for Bax conformational change leading to mitochondrial release of pro-apoptotic factors like cytochrome c and Smac.	Univ Cologne, Inst Med Microbiol Immunol & Hyg, D-50935 Cologne, Germany; Univ Cologne, Ctr Mol Med Cologne, D-50935 Cologne, Germany	University of Cologne; University of Cologne	Kronke, M (corresponding author), Univ Cologne, Inst Med Microbiol Immunol & Hyg, Goldenfelsstr 19-21, D-50935 Cologne, Germany.	Martin.Kroenke@medizin.uni-koeln.de						Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Ardail D, 2003, BIOCHEM J, V371, P1013, DOI 10.1042/BJ20021834; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Dai Q, 2004, ONCOGENE, V23, P3650, DOI 10.1038/sj.onc.1207430; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; FERLINZ K, 1991, BIOCHEM BIOPH RES CO, V179, P1187, DOI 10.1016/0006-291X(91)91697-B; Gniadecki R, 1997, J INVEST DERMATOL, V109, P163, DOI 10.1111/1523-1747.ep12319216; Gniadecki R, 2000, J CELL BIOCHEM, V80, P216; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Herrlich P, 1997, BIOL CHEM, V378, P1217; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; Johansson AC, 2003, CELL DEATH DIFFER, V10, P1253, DOI 10.1038/sj.cdd.4401290; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kashkar H, 2002, CELL DEATH DIFFER, V9, P750, DOI 10.1038/sj.cdd.4401024; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Komatsu M, 2001, BBA-MOL CELL BIOL L, V1533, P47, DOI 10.1016/S1388-1981(01)00139-1; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; Lin T, 2000, J BIOL CHEM, V275, P8657, DOI 10.1074/jbc.275.12.8657; Lips J, 2001, CARCINOGENESIS, V22, P579, DOI 10.1093/carcin/22.4.579; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tafani M, 2001, CANCER RES, V61, P2459; van Meer G, 2000, BBA-MOL CELL BIOL L, V1486, P145, DOI 10.1016/S1388-1981(00)00054-8; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yamaguchi H, 2002, CANCER RES, V62, P466; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	50	108	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20804	20813		10.1074/jbc.M410869200	http://dx.doi.org/10.1074/jbc.M410869200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15743760	hybrid			2022-12-25	WOS:000229242000078
J	Naumann, B; Stauber, EJ; Busch, A; Sommer, F; Hippler, M				Naumann, B; Stauber, EJ; Busch, A; Sommer, F; Hippler, M			N-terminal processing of Lhca3 is a key step in remodeling of the photosystem I-light-harvesting complex under iron deficiency in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-PROTEIN COMPLEX; PHOTO-CHEMICAL CAPACITY; LIMITING FACTORS; PSI-LHCI; PROTEOMICS; STRESS; PHOTOSYNTHESIS; CYANOBACTERIA/; EXPRESSION; SELECTION	Iron deficiency induces a remodeling of the photosynthetic apparatus in Chlamydomonas reinhardtii. In this study we showed that a key mechanistic event in the remodeling process of photosystem I (PSI) and its associated light-harvesting proteins (LHCI) is the N-terminal processing of Lhca3. N-terminal processing of Lhca3 is documented independently by two-dimensional gel electrophoresis and tandem mass spectrometric (MS/MS) analysis as well as by quantitative comparative MS/MS peptide profiling using isotopic labeling of proteins. Dynamic remodeling of the LHCI complex under iron deficiency is further exemplified by depletion of Lhca5 and up-regulation of Lhca4 and Lhca9 polypeptides in respect to photosystem I. Most importantly, the induction of N-terminal processing of Lhca3 by progression of iron deficiency correlates with the functional drop in excitation energy transfer efficiency between LHCI and PSI as assessed by low temperature fluorescence emission spectroscopy. Using an RNA interference (RNAi) strategy, we showed that the truncated form of Lhca3 is essential for the structural stability of LHCI. Depletion of Lhca3 by RNAi strongly impacted the efficiency of excitation energy transfer between PSI and LHCI, as is the case for iron deficiency. However, in contrast to iron deficiency, comparative MS/MS peptide profiling using isotopic labeling of proteins demonstrated that RNAi depletion of Lhca3 caused strong reduction of almost all Lhca proteins in isolated PSI particles.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA; Univ Jena, Lehrstuhl Pflanzenphysiol, D-07743 Jena, Germany	University of Pennsylvania; Friedrich Schiller University of Jena	Hippler, M (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA.	mhippler@sas.upenn.edu						Asamizu E, 1999, DNA Res, V6, P369, DOI 10.1093/dnares/6.6.369; BASSI R, 1992, J BIOL CHEM, V267, P25714; Behrenfeld MJ, 1999, SCIENCE, V283, P840, DOI 10.1126/science.283.5403.840; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Bibby TS, 2001, NATURE, V412, P743, DOI 10.1038/35089098; Boekema EJ, 2001, NATURE, V412, P745, DOI 10.1038/35089104; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNAP RL, 1993, PLANT PHYSIOL, V103, P893, DOI 10.1104/pp.103.3.893; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; Croce R, 1998, BIOCHEMISTRY-US, V37, P17355, DOI 10.1021/bi9813227; Ganeteg U, 2004, PLANT MOL BIOL, V54, P641, DOI 10.1023/B:PLAN.0000040813.05224.94; Ganeteg U, 2001, PLANT PHYSIOL, V127, P150, DOI 10.1104/pp.127.1.150; GUIKEMA JA, 1984, PLANT PHYSIOL, V74, P90, DOI 10.1104/pp.74.1.90; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Harris EH, 2001, ANNU REV PLANT PHYS, V52, P363, DOI 10.1146/annurev.arplant.52.1.363; Hippler M, 1997, BIOCHEMISTRY-US, V36, P6343, DOI 10.1021/bi970082c; Hippler M, 2002, PROTIST, V153, P197, DOI 10.1078/1434-4610-00098; Hippler M, 2001, PLANT J, V28, P595, DOI 10.1046/j.1365-313X.2001.01175.x; Jennings RC, 2003, BBA-BIOENERGETICS, V1557, P91, DOI 10.1016/S0005-2728(02)00399-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDENBACH DE, 1988, J BACTERIOL, V170, P5018, DOI 10.1128/jb.170.11.5018-5026.1988; Morosinotto T, 2003, J BIOL CHEM, V278, P49223, DOI 10.1074/jbc.M309203200; Moseley JL, 2002, EMBO J, V21, P6709, DOI 10.1093/emboj/cdf666; Nield J, 2004, EUKARYOT CELL, V3, P1370, DOI 10.1128/EC.3.6.1370-1380.2004; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Ranish JA, 2003, NAT GENET, V33, P349, DOI 10.1038/ng1101; Regnier FE, 2002, J MASS SPECTROM, V37, P133, DOI 10.1002/jms.290; Rochaix JD, 2002, FEBS LETT, V529, P34, DOI 10.1016/S0014-5793(02)03181-2; Rohr J, 2004, PLANT J, V40, P611, DOI 10.1111/j.1365-313X.2004.02227.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmid VHR, 2002, J BIOL CHEM, V277, P37307, DOI 10.1074/jbc.M205889200; Shrager J, 2003, PLANT PHYSIOL, V131, P401, DOI 10.1104/pp.016899; SPILLER S, 1980, PLANT PHYSIOL, V65, P121, DOI 10.1104/pp.65.1.121; Stauber EJ, 2004, PLANT PHYSIOL BIOCH, V42, P989, DOI 10.1016/j.plaphy.2004.09.008; Stauber EJ, 2003, EUKARYOT CELL, V2, P978, DOI 10.1128/EC.2.5.978-994.2003; Steen H, 2002, TRENDS BIOTECHNOL, V20, P361, DOI 10.1016/S0167-7799(02)02009-7; STRAUS NA, 1994, MOL BIOL CYANOBACTER; Takahashi Y, 2004, BIOCHEMISTRY-US, V43, P7816, DOI 10.1021/bi035988z; TERRY N, 1980, PLANT PHYSIOL, V65, P114, DOI 10.1104/pp.65.1.114; Wehner A, 2004, J BIOL CHEM, V279, P26823, DOI 10.1074/jbc.M402399200; WOLLMAN FA, 1982, BIOCHIM BIOPHYS ACTA, V680, P352, DOI 10.1016/0005-2728(82)90149-9; Yamaguchi K, 2002, PLANT CELL, V14, P2957, DOI 10.1105/tpc.004341	43	109	111	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20431	20441		10.1074/jbc.M414486200	http://dx.doi.org/10.1074/jbc.M414486200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15774469	hybrid			2022-12-25	WOS:000229242000035
J	Ahlers, BA; Zhang, XQ; Moorman, JR; Rothblum, LI; Carl, LL; Song, JL; Wang, JF; Geddis, LM; Tucker, AL; Mounsey, JP; Cheung, JY				Ahlers, BA; Zhang, XQ; Moorman, JR; Rothblum, LI; Carl, LL; Song, JL; Wang, JF; Geddis, LM; Tucker, AL; Mounsey, JP; Cheung, JY			Identification of an endogenous inhibitor of the cardiac Na+/Ca2+ exchanger, phospholemman	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ALTERS CONTRACTILITY; DEPENDENT REGULATION; SARCOLEMMAL PROTEIN; NA+-CA2+ EXCHANGE; DOWN-REGULATION; PHOSPHORYLATION; TRANSIENTS; CHANNELS; RELEASE	Rapid and precise control of Na+/Ca2+ exchanger (NCX1) activity is essential in the maintenance of beat-to-beat Ca2+ homeostasis in cardiac myocytes. Here, we show that phospholemman (PLM), a 15-kDa integral sarcolemmal phosphoprotein, is a novel endogenous protein inhibitor of cardiac NCX1. Using a heterologous expression system that is devoid of both endogenous PLM and NCX1, we first demonstrated by confocal immunofluorescence studies that both exogenous PLM and NCX1 co-localized at the plasma membrane. Reciprocal co-immunoprecipitation studies revealed specific protein-protein interaction between PLM and NCX1. The functional consequences of direct association of PLM with NCX1 was the inhibition of NCX1 activity, as demonstrated by whole-cell patch clamp studies to measure NCX1 current density and radiotracer flux assays to assess Na+-dependent Ca-45(2+) uptake. Inhibition of NCX1 by PLM was specific, because a single mutation of serine 68 to alanine in PLM resulted in a complete loss of inhibition of NCX1 current, although association of the PLM mutant with NCX1 was unaltered. In native adult cardiac myocytes, PLM co-immunoprecipitated with NCX1. We conclude that PLM, a member of the FXYD family of small ion transport regulators known to modulate Na+-K+-ATPase, also regulates Na+/Ca2+ exchange in the heart.	Penn State Univ, Milton S Hershey Med Ctr, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Med, Hershey, PA 17033 USA; Geisinger Med Ctr, Weis Ctr Res, Danville, PA 17822 USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Cardiovasc, Charlottesville, VA 22908 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Geisinger Medical Center; University of Virginia	Cheung, JY (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Dept Cellular & Mol Physiol, MC-H166, Hershey, PA 17033 USA.	jyc1@psu.edu	Moorman, J Randall/ABG-9946-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058672, R01HL070548, R01HL069074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064640] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-58672, HL-69074, HL-70548] Funding Source: Medline; NIDDK NIH HHS [DK-46678] Funding Source: Medline; NIGMS NIH HHS [GM-64640] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; CRAMBERT G, 2003, SCI STKE 2003 RE1; Davis CE, 2004, NEUROCHEM RES, V29, P177, DOI 10.1023/B:NERE.0000010447.24128.ac; DIXON IMC, 1992, AM J PHYSIOL, V262, pH1387, DOI 10.1152/ajpheart.1992.262.5.H1387; Dong H, 2002, BIOPHYS J, V82, P1943, DOI 10.1016/S0006-3495(02)75543-4; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hilgemann DW, 2004, AM J PHYSIOL-CELL PH, V287, pC1167, DOI 10.1152/ajpcell.00288.2004; Hinata M, 2002, J PHYSIOL-LONDON, V545, P453, DOI 10.1113/jphysiol.2002.025866; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Kang TM, 2004, NATURE, V427, P544, DOI 10.1038/nature02271; Kowdley GC, 1997, BIOPHYS J, V72, P141, DOI 10.1016/S0006-3495(97)78653-3; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LINDEMANN JP, 1986, J BIOL CHEM, V261, P4860; Mirza MA, 2004, AM J PHYSIOL-HEART C, V286, pH1322, DOI 10.1152/ajpheart.00997.2003; MOORMAN JR, 1995, NATURE, V377, P737, DOI 10.1038/377737a0; NUSS HB, 1992, AM J PHYSIOL, V263, pH1161, DOI 10.1152/ajpheart.1992.263.4.H1161; Ottolia M, 2004, BIOPHYS J, V87, P899, DOI 10.1529/biophysj.104.043471; Pan Y, 2000, AM J PHYSIOL-CELL PH, V279, pC393, DOI 10.1152/ajpcell.2000.279.2.C393; PRESTI CF, 1985, J BIOL CHEM, V260, P3879; PRESTI CF, 1985, J BIOL CHEM, V260, P3860; Scriven DRL, 2000, BIOPHYS J, V79, P2682, DOI 10.1016/S0006-3495(00)76506-4; Sehl PD, 2000, CIRCULATION, V101, P1990, DOI 10.1161/01.CIR.101.16.1990; Shigekawa M, 2001, CIRC RES, V88, P864, DOI 10.1161/hh0901.090298; Shimbo K, 1995, BIOPHYS J, V69, P1819, DOI 10.1016/S0006-3495(95)80052-4; Sogaard R, 2001, AM J PHYSIOL-CELL PH, V280, pC859; Song JL, 2002, AM J PHYSIOL-HEART C, V283, pH576, DOI 10.1152/ajpheart.00197.2002; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Tadros GM, 2002, AM J PHYSIOL-HEART C, V283, pH1616, DOI 10.1152/ajpheart.00186.2002; Tong JF, 1999, J BIOL CHEM, V274, P693, DOI 10.1074/jbc.274.2.693; VORNANEN M, 1994, AM J PHYSIOL, V267, pC623, DOI 10.1152/ajpcell.1994.267.2.C623; WALAAS SI, 1994, BIOCHEM J, V304, P635, DOI 10.1042/bj3040635; Zhang XQ, 2003, AM J PHYSIOL-HEART C, V284, pH225, DOI 10.1152/ajpheart.00698.2002; Zhang XQ, 2001, J APPL PHYSIOL, V90, P1720, DOI 10.1152/jappl.2001.90.5.1720; Zhang XQ, 2001, AM J PHYSIOL-HEART C, V281, pH2079, DOI 10.1152/ajpheart.2001.281.5.H2079	36	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19875	19882		10.1074/jbc.M414703200	http://dx.doi.org/10.1074/jbc.M414703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774479	hybrid			2022-12-25	WOS:000229113700056
J	Humrich, J; Bermel, C; Bunemann, MB; Harmark, LH; Frost, RJA; Quitterer, U; Lohse, MJ				Humrich, J; Bermel, C; Bunemann, MB; Harmark, LH; Frost, RJA; Quitterer, U; Lohse, MJ			Phosducin-like protein regulates G-protein beta gamma folding by interaction with tailless complex polypeptide-1 alpha - Dephosphorylation or splicing of PhLP turns the switch toward regulation of G beta gamma folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; SUBUNIT; PHOSPHORYLATION; EXPRESSION; CHANNELS; CELLS; IDENTIFICATION; INHIBITION; GENES; BRAIN	Phosducin-like protein ( PhLP) exists in two splice variants PhLPLONG (PhLPL) and PhLPSHORT (PhLPS). Whereas PhLPL directly inhibits G beta gamma-stimulated signaling, the G beta gamma-inhibitory mechanism of PhLPS is not understood. We report here that inhibition of G beta gamma signaling in intact HEK cells by PhLPS was independent of direct G beta gamma binding; however, PhLPS caused down-regulation of G beta and G gamma proteins. The down-regulation was partially suppressed by lactacystine, indicating the involvement of proteasomal degradation. N-terminal fusion of G beta or G gamma with a dye-labeling protein resulted in their stabilization against down-regulation by PhLPS but did not lead to a functional rescue. Moreover, in the presence of PhLPS, stabilized G gamma subunits did not coprecipitate with stabilized G beta subunits, suggesting that PhLPS might interfere with G beta gamma folding. PhLPS and several truncated mutants of PhLPS interacted with the subunit tailless complex polypeptide-1 alpha (TCP-1 alpha) of the CCT chaperonin complex, which is involved in protein folding. Knock-down of TCP-1 alpha in HEK cells by small interfering RNA also led to down-regulation of G beta gamma. We therefore conclude that the strong inhibitory action of PhLPS on G beta gamma signaling is the result of a previously unrecognized mechanism of G beta gamma-regulation, inhibition of G beta gamma-folding by interference with TCP-1 alpha.	Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany	University of Wurzburg	Lohse, MJ (corresponding author), Univ Wurzburg, Inst Pharmacol & Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany.		Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; Bluml K, 1997, EMBO J, V16, P4908, DOI 10.1093/emboj/16.16.4908; Bunemann M, 1998, J BIOL CHEM, V273, P31186, DOI 10.1074/jbc.273.47.31186; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Garcia-Higuera I, 1998, J BIOL CHEM, V273, P9041, DOI 10.1074/jbc.273.15.9041; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gensse M, 2000, FEBS LETT, V480, P184, DOI 10.1016/S0014-5793(00)01926-8; Hamilton MH, 2003, P NATL ACAD SCI USA, V100, P5081, DOI 10.1073/pnas.0831228100; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Hommers LG, 2003, J BIOL CHEM, V278, P1037, DOI 10.1074/jbc.M205325200; Humrich J, 2003, J BIOL CHEM, V278, P4474, DOI 10.1074/jbc.M206347200; ITO H, 1994, J PHYSIOL-LONDON, V476, P55; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Keppler A, 2003, NAT BIOTECHNOL, V21, P86, DOI 10.1038/nbt765; LEE RH, 1990, J BIOL CHEM, V265, P15860; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; McLaughlin JN, 2002, P NATL ACAD SCI USA, V99, P7962, DOI 10.1073/pnas.112075699; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; NEER EJ, 1984, J BIOL CHEM, V259, P4222; Ruiz-Gomez A, 2000, J BIOL CHEM, V275, P29724, DOI 10.1074/jbc.M001864200; Savage JR, 2000, J BIOL CHEM, V275, P30399, DOI 10.1074/jbc.M005120200; Schroder S, 2000, N-S ARCH PHARMACOL, V362, P435, DOI 10.1007/s002100000298; Schroder S, 1997, FEBS LETT, V401, P243, DOI 10.1016/S0014-5793(96)01483-4; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Thibault C, 1999, BBA-GENE STRUCT EXPR, V1444, P346, DOI 10.1016/S0167-4781(99)00006-8; Thibault C, 1997, J BIOL CHEM, V272, P12253, DOI 10.1074/jbc.272.19.12253; Thulin CD, 2001, J BIOL CHEM, V276, P23805, DOI 10.1074/jbc.M101482200; Valpuesta JM, 2002, FEBS LETT, V529, P11, DOI 10.1016/S0014-5793(02)03180-0; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	32	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20042	20050		10.1074/jbc.M409233200	http://dx.doi.org/10.1074/jbc.M409233200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15745879	hybrid			2022-12-25	WOS:000229113700074
J	Hurbin, A; Coll, JL; Dubrez-Daloz, L; Mari, B; Auberger, P; Brambilla, C; Favrot, MC				Hurbin, A; Coll, JL; Dubrez-Daloz, L; Mari, B; Auberger, P; Brambilla, C; Favrot, MC			Cooperation of amphiregulin and insulin-like growth factor-1 inhibits bax- and bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGE; SIGNALING PATHWAYS; FACTOR RECEPTOR; PKC-ZETA; SURVIVAL; PHOSPHORYLATION; DELTA; DEATH; ACTIVATION; AKT	Amphiregulin (AR) and insulin-like growth factor-1 (IGF1) are growth factors known to promote non-small cell lung cancer (NSCLC) survival. We have previously published that 1) AR and IGF1, secreted by H358 NSCLC cells, cooperate to protect those cells and H322 NSCLC cells from serum-starved apoptosis; 2) H358 cells resist Bax-induced apoptosis through an inhibition of Bax conformational change. We show here that the antiapoptotic activity of the AR/IGF1 combination is specifically abolished by the PKC inhibitors calphostin C and staurosporine, but not by the MAPK and phosphatidylinositol 3-kinase inhibitors PD98059 and wortmannin, suggesting the involvement of a PKC-dependent and MAPK- and phosphatidylinositol 3-kinase-independent survival pathway. The PKC delta inhibitor rottlerin restores apoptosis induced by serum deprivation. In addition, phosphorylation of PKC delta and PKC zeta/lambda, but not of PKC alpha/beta(II), increases in serum-starved H358 cells and in H322 cells treated with an AR/IGF1 combination and is blocked by calphostin C. The combination of AR and IGF1 increases p90(rsk) and Bad phosphorylation as well as inhibiting the conformational change of Bax by a PKC-dependent mechanism. Finally, PKC delta, PKC zeta, or p90(rsk) small interfering RNAs block the antiapoptotic activity of AR/IGF1 combination but have no effect on partial apoptosis inhibition observed with each factor used alone. Constitutively active PKC expression inhibits serum deprivation-induced apoptosis, whereas a catalytically inactive form of p90(rsk) restores it. Thus, AR and IGF1 cooperate to prevent apoptosis by activating a specific PKC-p90(rsk)-dependent pathway, which leads to Bad and Bax inactivation. This signaling pathway is different to that used by single factor.	INSERM, Inst Albert Bonniot, U578, Grp Rech Canc Poumon, F-38706 La Tronche, France; INSERM, U517, Fac Med Pharm, F-21033 Dijon, France; INSERM, Fac Med Pasteur, U526, F-06107 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Favrot, MC (corresponding author), INSERM, Inst Albert Bonniot, U578, Grp Rech Canc Poumon, F-38706 La Tronche, France.	MCFavrot@chu-grenoble.fr	Coll, Jean-Luc/G-2520-2013; Dubrez, Laurence/I-4971-2016; AUBERGER, Patrick/G-1491-2013; Mari, Bernard P/GVS-3100-2022; Mari, Bernard P/F-8960-2013; Mari, Bernard/Q-5832-2019; Laurence, Dubrez/P-9472-2019; Mari, Bernard P/D-7445-2015; Hurbin, Amandine/M-2693-2013	Coll, Jean-Luc/0000-0002-2453-3552; Dubrez, Laurence/0000-0002-7030-2181; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Laurence, Dubrez/0000-0002-7030-2181; Mari, Bernard P/0000-0002-0422-9182; Hurbin, Amandine/0000-0003-0535-1945				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Andre F, 1999, GASTROENTEROLOGY, V116, P64, DOI 10.1016/S0016-5085(99)70230-1; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Barr LF, 1997, CELL GROWTH DIFFER, V8, P381; Basu A, 2003, J CELL MOL MED, V7, P341, DOI 10.1111/j.1582-4934.2003.tb00237.x; Basu A, 1999, BIOCHEMISTRY-US, V38, P4245, DOI 10.1021/bi982854q; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brognard J, 2002, CELL DEATH DIFFER, V9, P893, DOI 10.1038/sj.cdd.4401054; Brognard J, 2001, CANCER RES, V61, P3986; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; Cheng HL, 2000, MOL CELL ENDOCRINOL, V170, P211, DOI 10.1016/S0303-7207(00)00324-5; Clark AS, 2003, CANCER RES, V63, P780; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dubrez L, 2001, J BIOL CHEM, V276, P38980, DOI 10.1074/jbc.M102683200; Fernandes AM, 1999, CANCER LETT, V142, P55, DOI 10.1016/S0304-3835(99)00166-4; Fontanini G, 1998, CLIN CANCER RES, V4, P241; Gagnon A, 2001, ENDOCRINOLOGY, V142, P205, DOI 10.1210/en.142.1.205; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hennige AM, 2002, BIOCHEM BIOPH RES CO, V290, P85, DOI 10.1006/bbrc.2001.6144; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; Hofmann J, 2001, REV PHYSIOL BIOCH P, V142, P1, DOI 10.1007/BFb0117491; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hurbin A, 2002, J BIOL CHEM, V277, P49127, DOI 10.1074/jbc.M207584200; Ikeo S, 2001, AM J PHYSIOL-CELL PH, V280, pC1255, DOI 10.1152/ajpcell.2001.280.5.C1255; Irie N, 2002, BIOCHEM BIOPH RES CO, V298, P738, DOI 10.1016/S0006-291X(02)02531-7; Iwabu A, 2004, J BIOL CHEM, V279, P14551, DOI 10.1074/jbc.M311981200; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; McJilton MA, 2003, ONCOGENE, V22, P7958, DOI 10.1038/sj.onc.1206795; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rozengurt Enrique, 1999, Current Opinion in Oncology, V11, P116; RUSCH V, 1995, CANCER RES, V55, P1365; Rusch V, 1997, CLIN CANCER RES, V3, P515; Shen L, 1999, MOL PHARMACOL, V55, P396, DOI 10.1124/mol.55.2.396; Shen S, 2001, DIABETES, V50, P255, DOI 10.2337/diabetes.50.2.255; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; TATEISHI M, 1990, CANCER RES, V50, P7077; Valverde AM, 1996, ENDOCRINOLOGY, V137, P3832, DOI 10.1210/en.137.9.3832; WELSH JB, 1991, J CELL BIOL, V114, P533, DOI 10.1083/jcb.114.3.533; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yano KJ, 1999, ENDOCRINOLOGY, V140, P4622, DOI 10.1210/en.140.10.4622; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	57	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19757	19767		10.1074/jbc.M413516200	http://dx.doi.org/10.1074/jbc.M413516200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767261	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000229113700042
J	Villafuerte, BC; Kaytor, EN				Villafuerte, BC; Kaytor, EN			An insulin-response element-binding protein that ameliorates hyperglycemia in diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-B; MALONYL-COA; GLUCOSE; EXPRESSION; LIVER; METABOLISM; GLUT4; DIFFERENTIATION; TRANSLOCATION; ADIPONUTRIN	Insulin modulates glucose homeostasis, but the role of insulin-responsive transcription factors in such actions is not well understood. Recently, we have identified the insulin-response element-binding protein-1 (IRE-BP1) as a transcription factor that appears to mediate insulin action on multiple target genes. To examine the possibility that IRE-BP1 is an insulin-responsive glucoregulatory factor involved in the metabolic actions of insulin, we investigated the effect of adenoviral overexpression of hepatic IRE-BP1 on the glycemic control of insulin-resistant diabetic rats. Adenoviral IRE-BP1 lowered both fasting and postprandial glucose levels, and microarray of hepatic RNA revealed modulation of the expression of genes involved in gluconeogenesis, lipogenesis, and fatty acid oxidation. The insulin mimetic effects of IRE-BP1 were also confirmed in L6 myocytes; stable constitutive expressions of IRE-BP1 enhanced glucose transporter expression, glucose uptake, and glycogen accumulation in these cells. These findings showed physiologic sufficiency of IRE-BP1 as the transcriptional mediator of the metabolic action of insulin. Understanding IRE-BP1 action should constitute a useful probe into the mechanisms of metabolic regulation and an important target to develop therapeutic agents that mimic or enhance insulin action.	Univ Louisville, Sch Med, Dept Med, Div Endocrinol, Louisville, KY 40202 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA	University of Louisville; Emory University	Villafuerte, BC (corresponding author), Univ Louisville, Sch Med, Dept Med, Div Endocrinol, 570 S Preston St,Donald Baxter Bldg,Rm 221E, Louisville, KY 40202 USA.	bcvill01@louisville.edu	Core, Vector/CAF-4832-2022					Altomonte J, 2003, AM J PHYSIOL-ENDOC M, V285, pE718, DOI 10.1152/ajpendo.00156.2003; Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003; Baulande S, 2001, J BIOL CHEM, V276, P33336, DOI 10.1074/jbc.M105193200; Beck-Nielsen H, 2003, BEST PRACT RES CL EN, V17, P445, DOI 10.1016/S1521-690X(03)00041-1; Boden G, 2002, CURR OPIN CLIN NUTR, V5, P545, DOI 10.1097/00075197-200209000-00014; CARNAC G, 1993, ENDOCRINOLOGY, V133, P2171, DOI 10.1210/en.133.5.2171; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; Fronhoffs S, 2002, MOL CELL PROBE, V16, P99, DOI 10.1006/mcpr.2002.0405; Green A, 2003, DIABETES-METAB RES, V19, P3, DOI 10.1002/dmrr.340; Hall Robert K., 1999, Journal of Basic and Clinical Physiology and Pharmacology, V10, P119; Hermsdorf T, 1998, CELL SIGNAL, V10, P629, DOI 10.1016/S0898-6568(98)00003-5; Kaytor EN, 2001, ENDOCRINOLOGY, V142, P1041, DOI 10.1210/en.142.3.1041; Kido Y, 2001, J CLIN ENDOCR METAB, V86, P972, DOI 10.1210/jc.86.3.972; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS516; Kruszynska YT, 1996, J INVEST MED, V44, P413; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE863, DOI 10.1152/ajpendo.00033.2003; Louet JF, 2001, BIOCHEM SOC T, V29, P310, DOI 10.1042/0300-5127:0290310; Lu HG, 2002, J BIOL CHEM, V277, P46687, DOI 10.1074/jbc.M209643200; Manganiello VC, 1996, CURR TOP CELL REGUL, V34, P63, DOI 10.1016/S0070-2137(96)80003-3; MARCHMONT RJ, 1980, NATURE, V286, P904, DOI 10.1038/286904a0; Mead JR, 2002, J MOL MED, V80, P753, DOI 10.1007/s00109-002-0384-9; Monzillo LU, 2003, NUTR REV, V61, P397, DOI 10.1301/nr.2003.dec.397-412; Nakamura MT, 2002, BIOCHEM SOC T, V30, P1076, DOI 10.1042/BST0301076; Niu WY, 2003, J BIOL CHEM, V278, P17953, DOI 10.1074/jbc.M211136200; O'Doherty RM, 1999, AM J PHYSIOL-ENDOC M, V277, pE544, DOI 10.1152/ajpendo.1999.277.3.E544; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Peterson R.G., 1990, ILAR NEWS, V32, P16, DOI [10.1093/ilar.32.3.16, DOI 10.1093/ILAR.32.3.16, DOI 10.1093/ILAR.32.3.16)]; Poirier M, 2002, AM J PHYSIOL-HEART C, V283, pH1379, DOI 10.1152/ajpheart.00244.2002; Polson DA, 2003, BIOCHEM BIOPH RES CO, V301, P261, DOI 10.1016/S0006-291X(02)03027-9; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Shah Pankaj, 2003, Curr Diab Rep, V3, P214, DOI 10.1007/s11892-003-0066-1; SHIN Y, 2001, DIABETES-METAB RES, V50, P1093; Shintani M, 2001, DIABETES, V50, P2296, DOI 10.2337/diabetes.50.10.2296; Song S, 2002, DIABETES-METAB RES, V18, P5, DOI 10.1002/dmrr.260; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; Totzke G, 1996, MOL CELL PROBE, V10, P427, DOI 10.1006/mcpr.1996.0059; TURO KA, 1982, AM J PHYSIOL, V243, pC278, DOI 10.1152/ajpcell.1982.243.5.C278; VANDERLAARSE WJ, 1992, BIOTECH HISTOCHEM, V67, P303, DOI 10.3109/10520299209110039; Villafuerte BC, 1996, MOL ENDOCRINOL, V10, P622, DOI 10.1210/me.10.6.622; Villafuerte BC, 2004, J BIOL CHEM, V279, P36650, DOI 10.1074/jbc.M404349200; VILLAFUERTE BC, 1994, ENDOCRINOLOGY, V134, P2044, DOI 10.1210/en.134.5.2044; VILLAFUERTE BC, 1991, DIABETES, V40, P837, DOI 10.2337/diabetes.40.7.837; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Yamatani K, 2001, REGUL PEPTIDES, V99, P45, DOI 10.1016/S0167-0115(01)00228-2; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505; Zhu JL, 1999, ENDOCRINOLOGY, V140, P4761, DOI 10.1210/en.140.10.4761	52	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20010	20020		10.1074/jbc.M410817200	http://dx.doi.org/10.1074/jbc.M410817200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15753094	hybrid			2022-12-25	WOS:000229113700071
J	Wing, LYC; Chen, HM; Chuang, PC; Wu, MH; Tsai, SJ				Wing, LYC; Chen, HM; Chuang, PC; Wu, MH; Tsai, SJ			The mammalian target of rapamycin-p70 ribosomal S6 kinase but not phosphatidylinositol 3-kinase-Akt signaling is responsible for fibroblast growth factor-9-induced cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR-1; PHOSPHOINOSITIDE 3-KINASE; AMINO-ACIDS; MAP KINASE; FACTOR FGF; PROTEIN; ACTIVATION; EXPRESSION; MTOR; PHOSPHORYLATION	Fibroblast growth factor-9 (FGF9) is a potent mitogen that stimulates normal and cancer cell proliferation though the signaling mechanism is not fully understood. In this study, we aimed to unravel the signaling cascades mediate FGF9 actions in human uterine endometrial stromal cell. Our results demonstrate that the mitogenic effect of FGF9 is transduced via two parallel but additive signaling pathways involving mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase. Activation of mTOR by FGF9 induces p70 ribosomal S6 kinase (S6K1) phosphorylation, cyclin expression, and cell proliferation, which are independent of phosphatidylinositol 3-kinase and Akt. Coimmuno-precipitation analysis demonstrates that mTOR physically associates with S6K1 upon FGF9 treatment, whereas ablation of mTOR activity using RNA interference or pharmacological inhibitor blocks S6K1 phosphorylation and cell proliferation induced by FGF9. Further study demonstrates that activation of mTOR is regulated by a phospholipase C gamma-controlled calcium signaling pathway. These studies provide evidence to demonstrate, for the first time, that a novel signaling cascade involving phospholipase C gamma, calcium, mTOR, and S6K1 is activated by FGF9 in a receptor-specific manner.	Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Obstet & Gynecol, Tainan 70101, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Wing, LYC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 70101, Taiwan.	wing@mail.ncku.edu.tw; seantsai@mail.ncku.edu.tw	Tsai, Shaw-Jenq/AAG-6569-2019	TSAI, SHAW-JENQ/0000-0002-3569-5813				AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; Ballou LM, 2003, FEBS LETT, V550, P51, DOI 10.1016/S0014-5793(03)00816-0; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Cailliau K, 2001, BBA-MOL CELL RES, V1538, P228, DOI 10.1016/S0167-4889(01)00074-X; Carballada R, 2001, DEVELOPMENT, V128, P35; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Chen Y, 2000, ONCOGENE, V19, P3750, DOI 10.1038/sj.onc.1203726; Cohen RI, 2000, J NEUROSCI RES, V61, P273, DOI 10.1002/1097-4547(20000801)61:3<273::AID-JNR5>3.0.CO;2-I; Colvin JS, 2001, DEVELOPMENT, V128, P2095; Debiais F, 2004, EXP CELL RES, V297, P235, DOI 10.1016/j.yexcr.2004.03.032; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garces A, 2000, J NEUROSCI RES, V60, P1, DOI 10.1002/(SICI)1097-4547(20000401)60:1<1::AID-JNR1>3.0.CO;2-P; Giri D, 1999, J CELL PHYSIOL, V180, P53, DOI 10.1002/(SICI)1097-4652(199907)180:1<53::AID-JCP6>3.0.CO;2-P; Goncharova EA, 2002, AM J PHYSIOL-LUNG C, V283, pL354, DOI 10.1152/ajplung.00010.2002; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hinault C, 2004, FASEB J, V18, P1894, DOI 10.1096/fj.03-1409fje; Hinsby AM, 2003, MOL CELL PROTEOMICS, V2, P29, DOI 10.1074/mcp.M200075-MCP200; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Kam Y, 2004, FASEB J, V18, P311, DOI 10.1096/fj.03-0731com; Kanda T, 2000, BRAIN RES, V876, P22, DOI 10.1016/S0006-8993(00)02563-4; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Larsson H, 1999, J BIOL CHEM, V274, P25726, DOI 10.1074/jbc.274.36.25726; Lovicu FJ, 1998, DEVELOPMENT, V125, P3365; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mochizuki Y, 2002, ONCOGENE, V21, P7027, DOI 10.1038/sj.onc.1205736; Mothe-Satney I, 2004, J BIOL CHEM, V279, P42628, DOI 10.1074/jbc.M405173200; Nauc V, 2004, J ANDROL, V25, P573; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; Ozeki M, 2004, MOL CELL BIOCHEM, V259, P169, DOI 10.1023/B:MCBI.0000021369.17958.f4; Pham PTT, 2000, J CELL BIOCHEM, V79, P427, DOI 10.1002/1097-4644(20001201)79:3<427::AID-JCB80>3.0.CO;2-0; Pirvola U, 2004, DEV BIOL, V273, P350, DOI 10.1016/j.ydbio.2004.06.010; Portnoy J, 2004, AM J RESP CELL MOL, V30, P901, DOI 10.1165/rcmb.2003-0406OC; Reuss B, 2000, GLIA, V30, P231, DOI 10.1002/(SICI)1098-1136(200005)30:3<231::AID-GLIA3>3.3.CO;2-T; Saitoh M, 2002, J BIOL CHEM, V277, P20104, DOI 10.1074/jbc.M201745200; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Todo T, 1998, NEUROSURGERY, V43, P337, DOI 10.1097/00006123-199808000-00098; Tsai SJ, 2002, ENDOCRINOLOGY, V143, P2715, DOI 10.1210/en.143.7.2715; Tsai SJ, 2001, J CLIN ENDOCR METAB, V86, P5765, DOI 10.1210/jc.86.12.5765; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; Wing LYC, 2003, J CLIN ENDOCR METAB, V88, P5547, DOI 10.1210/jc.2003-030597; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Wu MH, 2002, MOL HUM REPROD, V8, P456, DOI 10.1093/molehr/8.5.456; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200	66	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19937	19947		10.1074/jbc.M411865200	http://dx.doi.org/10.1074/jbc.M411865200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15760907	hybrid			2022-12-25	WOS:000229113700063
J	Schleiermacher, G; Bourdeaut, F; Combaret, V; Picrron, G; Raynal, V; Aurias, A; Ribeiro, A; Janoueix-Lerosey, I; Delattre, O				Schleiermacher, G; Bourdeaut, F; Combaret, V; Picrron, G; Raynal, V; Aurias, A; Ribeiro, A; Janoueix-Lerosey, I; Delattre, O			Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain	ONCOGENE			English	Article						neuroblastoma; chromosome 17; translocation breakpoint; molecular cloning; interstitial telomere	ARM 17Q; PATIENT; REGION; BREAKPOINT; 5-KINASE; FAMILY; DOMAIN; TUMORS; GENES	In neuroblastoma, the most frequent genetic alterations are unbalanced translocations involving chromosome 17. To gain insights into these rearrangements, we have characterized a previously identified der(1)t(1;17) of the CLB-Bar cell line. The 17q breakpoint was mapped by FISH. Subsequently, a rearranged fragment was identified by Southern analysis, cloned in a lambda vector and sequenced. The chromosome rearrangement is more complex than expected due to the presence of an interstitial 4p telomeric sequence between chromosome 1p and 17q. Three different genes, which may play a role in neuroblastoma development, are disrupted by the translocation breakpoints. Indeed, the 3'UTR of the PIP5K2B gene on chromosome 17q is directly fused to the (TTAGGG)n repeat of the chromosome 4p telomere, and the ( 1; 4) fusion disrupts the MACF1 (microtubule-actin crosslinking factor 1) and POLN genes, respectively. Interestingly, the ( 1; 4) fusion was present at diagnosis and at relapse, whereas the ( 4; 17) fusion was detected at relapse only, leading to a secondary 17q gain confirmed by array CGH therefore indicating that 17q gain may not be a primary event in neuroblastoma. Finally, screening of a panel of neuroblastoma cell lines identified interstitial telomeric sequences in three other cases, suggesting that this may be a recurrent mechanism leading to unbalanced translocations in neuroblastoma.	Inst Curie, INSERM, Lab Pathol Mol Canc, Unite 509, F-75248 Paris, France; Ctr Leon Berard, Biol Cellulaire Lab, F-69373 Lyon, France; Inst Curie, Unite Genet Somat, F-75248 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Delattre, O (corresponding author), Inst Curie, INSERM, Lab Pathol Mol Canc, Unite 509, 26 Rue Ulm, F-75248 Paris, France.	delattre@curie.fr	Janoueix-Lerosey, Isabelle/G-1758-2018; , Bourdeaut/AAG-8494-2019	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; delattre, olivier/0000-0002-8730-2276				Bown N, 2001, J CLIN PATHOL, V54, P897, DOI 10.1136/jcp.54.12.897; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; CARON H, 1994, AM J HUM GENET, V55, P341; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; CHRISTIANSEN H, 1987, CANCER GENET CYTOGEN, V26, P235, DOI 10.1016/0165-4608(87)90057-4; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Gong TWL, 2001, MAMM GENOME, V12, P852, DOI 10.1007/s00335-001-3037-3; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Lastowska M, 2002, GENE CHROMOSOME CANC, V34, P428, DOI 10.1002/gcc.10089; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; Marini F, 2003, J BIOL CHEM, V278, P32014, DOI 10.1074/jbc.M305646200; Meddeb M, 1996, GENE CHROMOSOME CANC, V17, P156, DOI 10.1002/(SICI)1098-2264(199611)17:3<156::AID-GCC3>3.0.CO;2-3; Perri P, 2002, ONCOGENE, V21, P8356, DOI 10.1038/sj.onc.1206009; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; SAMBROOK J, 2000, MOL CLONING LAB MANU; Schleiermacher G, 2004, GENE CHROMOSOME CANC, V39, P143, DOI 10.1002/gcc.10313; Schleiermacher G, 2003, CANCER GENET CYTOGEN, V141, P32, DOI 10.1016/S0165-4608(02)00644-1; Sossey-Alaoui K, 2002, ONCOGENE, V21, P5967, DOI 10.1038/sj.onc.1205734; Spitz R, 2003, CLIN CANCER RES, V9, P4835; Trakhtenbrot L, 2002, CANCER GENET CYTOGEN, V137, P95, DOI 10.1016/S0165-4608(02)00553-8; Van Roy N, 2002, GENE CHROMOSOME CANC, V35, P113, DOI 10.1002/gcc.10034; Yamazaki M, 2002, J BIOL CHEM, V277, P17226, DOI 10.1074/jbc.M109795200; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	24	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3377	3384		10.1038/sj.onc.1208486	http://dx.doi.org/10.1038/sj.onc.1208486			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735707	Bronze			2022-12-25	WOS:000228881800016
J	Naishiro, Y; Yamada, T; Idogawa, M; Honda, K; Takada, M; Kondo, T; Imai, K; Hirohashi, S				Naishiro, Y; Yamada, T; Idogawa, M; Honda, K; Takada, M; Kondo, T; Imai, K; Hirohashi, S			Morphological and transcriptional responses of untransformed intestinal epithelial cells to an oncogenic beta-catenin protein	ONCOGENE			English	Article						IEC6; beta-catenin; colorectal carcinogenesis; IGFBP2; clusterin	FACTOR-BINDING PROTEIN-2; COLORECTAL-CANCER; GENE-EXPRESSION; TUMOR-FORMATION; IGF-I; GROWTH; MICE; POLYPOSIS; DIFFERENTIATION; NEOPLASIA	Aberrant transactivation of a certain set of target genes by the beta-catenin and T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factor complexes has been implicated in the process of intestinal epithelial cells entering early colorectal carcinogenesis. A rat intestinal epithelial cell line IEC6 became elongated, extended protrusions at cell periphery, and increased stress fibers and focal contacts upon the induction of beta-catenin protein stabilized by deletion of the N-terminal glycogen synthase kinase-3 beta (GSK beta) phosphorylation sites (beta-catenin Delta N89). We used the GeneChip(TM) oligonucleotide microarray system to examine approximately 24 000 genes and identified 13 genes whose expression was altered during the course of this morphological transformation. Those genes included known negative regulators of the Wnt signaling pathway, Sfrp4 and Axin2; extracellular matrix and related molecule, Hxb and Crtl1; cell adhesion and cytoskeletal proteins, Podxl, Igaf4, and Itab6; and molecules involved in the insulin and insulin-like growth factor (IGF) signaling pathways, Enpp1, Igfbp2, and Sgk. We report the finding that insulin-like growth factor-binding protein-2 (IGFBP2) is a direct target gene of the beta-catenin and TCF/LEF complexes. The IGFBP2 protein interacts with integrins. Disruption of the multigene network system regulating cell adhesion and cytoskeleton may be crucial in the initiation of colorectal carcinogenesis.	Natl Canc Ctr, Res Inst, Chemotherapy Div, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Canc Proteom Project, Chuo Ku, Tokyo 1040045, Japan; Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Sapporo Medical University	Yamada, T (corresponding author), Natl Canc Ctr, Res Inst, Chemotherapy Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tyamada@ncc.go.jp	Idogawa, Masashi/B-5208-2008; Kondo, Tadashi/I-4819-2019	Idogawa, Masashi/0000-0002-8507-1726; Kondo, Tadashi/0000-0001-6405-7792				Barbara PD, 2003, CELL MOL LIFE SCI, V60, P1322, DOI 10.1007/s00018-003-2289-3; BROWN AL, 1990, MOL ENDOCRINOL, V4, P2039, DOI 10.1210/mend-4-12-2039; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Chen XD, 2003, P NATL ACAD SCI USA, V100, P9530, DOI 10.1073/pnas.1233633100; CORKINS MR, 1995, BIOCHEM BIOPH RES CO, V211, P707, DOI 10.1006/bbrc.1995.1870; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Fuller GN, 1999, CANCER RES, V59, P4228; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1997, BIOESSAYS, V19, P551, DOI 10.1002/bies.950190705; Hoeflich A, 2001, CANCER RES, V61, P8601; Inomata M, 1996, CANCER RES, V56, P2213; Kayahara T, 2003, FEBS LETT, V535, P131, DOI 10.1016/S0014-5793(02)03896-6; KEDINGER M, 1986, DEV BIOL, V113, P474, DOI 10.1016/0012-1606(86)90183-1; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Maiti S, 2000, CANCER RES, V60, P6288; Miraki-Moud F, 2001, CLIN ENDOCRINOL, V54, P499, DOI 10.1046/j.1365-2265.2001.01221.x; Mishra L, 1998, GROWTH HORM IGF RES, V8, P473, DOI 10.1016/S1096-6374(98)80300-6; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Oshima H, 1997, CANCER RES, V57, P1644; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; Polakis P, 1999, ADV EXP MED BIOL, V470, P23; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Schwartz DR, 2002, CANCER RES, V62, P4722; Seike M, 2003, CANCER RES, V63, P4641; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Soubeyran P, 2001, ONCOGENE, V20, P4180, DOI 10.1038/sj.onc.1204551; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Suh ER, 2001, AM J PHYSIOL-GASTR L, V280, pG149, DOI 10.1152/ajpgi.2001.280.1.G149; Suzuki Y, 2004, NUCLEIC ACIDS RES, V32, pD78, DOI 10.1093/nar/gkh076; Takeda T, 2001, J CLIN INVEST, V108, P289, DOI 10.1172/JCI12539; Theodosiou NA, 2003, DEV BIOL, V259, P258, DOI 10.1016/S0012-1606(03)00185-4; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wang H, 2003, CANCER RES, V63, P4315; Yamada T, 2003, CANCER RES, V63, P895; Yamada T, 2000, CANCER RES, V60, P4761; ZHANG Y, 1995, AM J PHYSIOL-ENDOC M, V269, pE804, DOI 10.1152/ajpendo.1995.269.5.E804	47	38	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 28	2005	24	19					3141	3153		10.1038/sj.onc.1208517	http://dx.doi.org/10.1038/sj.onc.1208517			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735679				2022-12-25	WOS:000228728100008
J	He, GG; Siddik, ZH; Huang, ZF; Wang, RN; Koomen, J; Kobayashi, R; Khokhar, AR; Kuang, J				He, GG; Siddik, ZH; Huang, ZF; Wang, RN; Koomen, J; Kobayashi, R; Khokhar, AR; Kuang, J			Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities	ONCOGENE			English	Article						p21 functions; Cdk inhibition; cisplatin analog; DNA-damaging agents; G(1)-phase checkpoint	CYCLIN-DEPENDENT KINASES; P53-MEDIATED G(1) ARREST; S-PHASE CHECKPOINTS; HUMAN CELL-CYCLE; TYROSINE PHOSPHORYLATION; IONIZING-RADIATION; PROTEIN-KINASE; CANCER-CELLS; ULTRAVIOLET-IRRADIATION; PLATINUM(IV) COMPLEXES	DNA damage often activates the p53-p21 pathway and causes G(1)-phase arrest in mammalian cells. Although there is ample evidence that p21 induction by p53 leads to Cdk2 inhibition, it is unclear whether this checkpoint event also leads to Cdk4 inhibition. Diaminocyclohexane(trans-diacetato)(dichloro) platinum(IV) (DAP), a platinum-based coordination complex, is a DNA-damaging agent that is effective against a variety of tumor cells resistant to the parental drug cisplatin. Our previous studies established that treatment of human cancer cells with low effective concentrations of DAP specifically activates the G(1)-phase checkpoint and simultaneously inhibit Cdk4 and Cdk2 activities. Here we demonstrate that DAP treatment of human cancer cells activates the p53-p21 pathway without activating other known mechanisms that inhibit Cdk4 and Cdk2 activities. The induced p21 binds to both the Cdk4/cyclin D and Cdk2/cyclin E complexes and inhibits both of their kinase activities. Conversely, inhibition of p21 induction by cycloheximide or by p21 gene deletion prevents DAP-induced inhibition of Cdk4 and Cdk2 activities. Attenuated p53 expression and p21 induction also eliminates DAP-induced G(1)-phase arrest and inhibition of Cdk4 and Cdk2 activities. Together, these findings establish that activation of the p53-p21 pathway is responsible for the DAP-induced G(1)-phase checkpoint response and provide the first solid evidence that p21 induction by p53 during a DNA damage-induced G(1)-phase checkpoint response inhibits both Cdk4 and Cdk2 activities.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kuang, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Box 019,1515 Holcombe Blvd, Houston, TX 77030 USA.	jkuang@mdanderson.org	Wang, Ruoning/C-1683-2014; Koomen, John/D-1844-2013		NCI NIH HHS [CA-77332, CA-82361, CA-93941] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082361, R01CA093941, R01CA077332] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Agami R, 2002, CANCER LETT, V177, P111, DOI 10.1016/S0304-3835(01)00785-6; Attardi LD, 2004, ONCOGENE, V23, P973, DOI 10.1038/sj.onc.1207026; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Boulaire J, 2000, PATHOL BIOL, V48, P190; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Burger H, 1998, BRIT J CANCER, V77, P1562, DOI 10.1038/bjc.1998.257; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Che SL, 1999, J BIOL CHEM, V274, P5522, DOI 10.1074/jbc.274.9.5522; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eastman A, 2002, MOL CANCER THER, V1, P1067; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Goldwasser F, 1996, CLIN CANCER RES, V2, P687; GONG JP, 1995, CELL GROWTH DIFFER, V6, P1485; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hagopian GS, 1999, CLIN CANCER RES, V5, P655; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Khokhar AR, 1997, J MED CHEM, V40, P112, DOI 10.1021/jm960587l; KIDO Y, 1993, CANCER RES, V53, P4567; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kuang J, 2001, CLIN CANCER RES, V7, P3629; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lenferink AEG, 2001, CANCER RES, V61, P6583; LI Y, 1994, ONCOGENE, V9, P2261; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Miyakawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P71, DOI 10.1006/bbrc.2001.4950; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUSCHEL RJ, 1992, RADIAT RES, V132, P153, DOI 10.2307/3578520; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; Nahum A, 2001, ONCOGENE, V20, P3428, DOI 10.1038/sj.onc.1204452; OConnor PM, 1997, CANCER SURV, V29, P151; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Perdiguero E, 2003, EMBO J, V22, P5746, DOI 10.1093/emboj/cdg559; Pestell KE, 2000, MOL PHARMACOL, V57, P503, DOI 10.1124/mol.57.3.503; Petrocelli T, 1996, ONCOGENE, V12, P1387; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Shapiro GI, 2000, CELL BIOCHEM BIOPHYS, V33, P189, DOI 10.1385/CBB:33:2:189; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SIDDIK ZH, 1994, ANTI-CANCER DRUG DES, V9, P139; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Ye XS, 1997, EMBO J, V16, P182, DOI 10.1093/emboj/16.1.182; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	76	192	199	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2929	2943		10.1038/sj.onc.1208474	http://dx.doi.org/10.1038/sj.onc.1208474			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735718				2022-12-25	WOS:000228649500002
J	Nilsen, H; An, Q; Lindahl, T				Nilsen, H; An, Q; Lindahl, T			Mutation frequencies and AID activation state in B-cell lymphomas from Ung-deficient mice	ONCOGENE			English	Article						Ung; Aid; c-myc; bcl-6	CLASS-SWITCH RECOMBINATION; CYTIDINE DEAMINASE AID; SOMATIC HYPERMUTATION; EXPRESSION; ENZYME; GENES	B-cell lymphomas arising in lymph nodes and spleen of aging mice deficient in the Ung DNA glycosylase were recovered, dispersed, grown in short-term culture, and CD19-positive B-cells retrieved and analysed. Several tumors as well as controls only expressed detectable amounts of the Aid deaminase after mitogenic stimulation, as estimated by real-time PCR of transcripts. However, one unusually large lymph node tumor expressed a high level of Aid constitutively. This particular tumor also showed a substantially increased mutation frequency in the Aid gene itself as well as in the bcl-6 and c-myc genes, but not in the p53 gene, consistent with aberrant somatic hypermutation. Other B-cell lymphomas from Ung(-/-) mice exhibited a modest increase in mutation frequency.	CR UK London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England		Lindahl, T (corresponding author), CR UK London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	tomas.lindahl@cancer.org.uk	Nilsen, Hilde/F-6432-2014	Nilsen, Hilde/0000-0003-2115-2663				Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Coleman AE, 2000, GENE CHROMOSOME CANC, V29, P70, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1009>3.0.CO;2-C; Gearhart PJ, 2003, ONCOGENE, V22, P5379, DOI 10.1038/sj.onc.1206874; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Martin A, 2002, P NATL ACAD SCI USA, V99, P12304, DOI 10.1073/pnas.192442899; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Nilsen H, 2003, ONCOGENE, V22, P5381, DOI 10.1038/sj.onc.1206860; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Pasqualucci L, 2004, BLOOD, V104, P3318, DOI 10.1182/blood-2004-04-1558; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Rada C, 2004, MOL CELL, V16, P163, DOI 10.1016/j.molcel.2004.10.011; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L	15	18	19	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3063	3066		10.1038/sj.onc.1208480	http://dx.doi.org/10.1038/sj.onc.1208480			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735713				2022-12-25	WOS:000228649500017
J	Berton, TR; Mitchell, DL; Guo, RF; Johnson, DG				Berton, TR; Mitchell, DL; Guo, RF; Johnson, DG			Regulation of epidermal apoptosis and DNA repair by E2F1 in response to ultraviolet B radiation	ONCOGENE			English	Article						E2F1; UV radiation; apoptosis; DNA repair; p53	NUCLEOTIDE EXCISION-REPAIR; TRANSCRIPTION-COUPLED REPAIR; MOUSE SKIN CARCINOGENESIS; GLOBAL GENOMIC REPAIR; TUMOR-SUPPRESSOR P53; XERODERMA-PIGMENTOSUM; CELL-CYCLE; IN-VIVO; MICE LACKING; S-PHASE	The E2F1 transcription factor regulates the expression of genes involved in cell proliferation, apoptosis and DNA repair. Following DNA damage, E2F1 is phosphorylated and stabilized, but the physiological role of E2F1 in the response to DNA damage is unclear. We find that mice lacking E2F1 have increased levels of epidermal apoptosis compared to wild-type mice following exposure to ultraviolet B (UVB) radiation. Moreover, transgenic overexpression of E2F1 in basal layer keratinocytes suppresses apoptosis induced by UVB. Inhibition of UVB-induced apoptosis by E2F1 is unexpected given that most studies have demonstrated a proapoptotic function for E2F1. E2F1-mediated suppression of apoptosis does not involve alterations in mitogen-activated protein kinase activation or Bcl-2 downregulation in response to UVB and is independent of p53. Instead, inhibition of UVB-induced apoptosis by E2F1 correlates with a stimulation of DNA repair. Mice lacking E2F1 are impaired for the removal of DNA photoproducts, while E2F1 transgenic mice repair UVB-induced DNA damage at an accelerated rate compared to wild-type mice. These findings suggest that E2F1 participates in the response to UVB by promoting DNA repair and suppressing apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389,1808 Pk Rd 1C, Smithville, TX 78957 USA.	djohnson@mdanderson.org	Guo, Ruifeng/D-1270-2010	Johnson, David/0000-0002-6223-1790	NCI NIH HHS [U01CA105345, CA79648, CA09480, CA16672] Funding Source: Medline; NIEHS NIH HHS [U01ES11047, ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079648, P30CA016672, T32CA009480, U01CA105345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011047, P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Amundson SA, 2002, CANCER BIOL THER, V1, P145, DOI 10.4161/cbt.59; BERG RJW, 1993, CANCER RES, V53, P4212; Berg RJW, 2000, CANCER RES, V60, P2858; Berton TP, 2001, J INVEST DERMATOL, V117, P1171, DOI 10.1046/j.0022-202x.2001.01536.x; Berton TR, 1998, MOL CARCINOGEN, V23, P175, DOI 10.1002/(SICI)1098-2744(199811)23:3<175::AID-MC6>3.0.CO;2-B; Berton TR, 1997, J INVEST DERMATOL, V109, P340, DOI 10.1111/1523-1747.ep12335984; Blattner C, 1999, MOL CELL BIOL, V19, P3704; BODE AM, 2003, SCI STKE, pRE2; Brash DE, 2001, J INVEST DERMATOL, V117, P1234, DOI 10.1046/j.0022-202x.2001.01554.x; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Cleaver JE, 2000, J DERMATOL SCI, V23, P1, DOI 10.1016/S0923-1811(99)00088-2; Croxton R, 2002, ONCOGENE, V21, P1563, DOI 10.1038/sj.onc.1205232; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Eckert RL, 2003, J INVEST DERMATOL, V120, P823, DOI 10.1046/j.1523-1747.2003.12120.x; Fitch ME, 2003, DNA REPAIR, V2, P819, DOI 10.1016/S1568-7864(03)00066-1; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Huang YY, 1997, CANCER RES, V57, P3640; IANAI A, 2004, J BIOL CHEM, V279, P30380; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Isoherranen K, 1999, ARCH DERMATOL RES, V291, P212, DOI 10.1007/s004030050396; KANJILAL S, 1993, CANCER RES, V53, P2961; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lin WC, 2001, GENE DEV, V15, P1833; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; Meira LB, 2002, DNA REPAIR, V1, P929, DOI 10.1016/S1568-7864(02)00143-X; Meng RD, 1999, INT J ONCOL, V14, P5; Mitchell DL, 1999, CANCER RES, V59, P2875; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; Nichols AF, 2003, NUCLEIC ACIDS RES, V31, P562, DOI 10.1093/nar/gkg152; Nip J, 2001, ONCOGENE, V20, P910, DOI 10.1038/sj.onc.1204171; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Powers JT, 2004, MOL CANCER RES, V2, P203; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rounbehler RJ, 2002, CANCER RES, V62, P3276; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Takimoto R, 2002, CANCER BIOL THER, V1, P177, DOI 10.4161/cbt.65; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; van Oosten M, 2000, P NATL ACAD SCI USA, V97, P11268, DOI 10.1073/pnas.200226697; van Steeg H, 1999, MOL MED TODAY, V5, P86, DOI 10.1016/S1357-4310(98)01394-X; Vorburger SA, 2002, ONCOGENE, V21, P6278, DOI 10.1038/sj.onc.1205761; Wang AJ, 1999, NUCLEIC ACIDS RES, V27, P4609, DOI 10.1093/nar/27.23.4609; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Wang QE, 2003, DNA REPAIR, V2, P483, DOI 10.1016/S1568-7864(03)00002-8; Washio F, 1999, BRIT J DERMATOL, V140, P1031; Wikonkal NM, 2003, NAT CELL BIOL, V5, P655, DOI 10.1038/ncb1001; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Young LC, 2003, J INVEST DERMATOL, V121, P435, DOI 10.1046/j.1523-1747.2003.12450.x; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	89	50	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2449	2460		10.1038/sj.onc.1208462	http://dx.doi.org/10.1038/sj.onc.1208462			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735727				2022-12-25	WOS:000228180600003
J	Zancai, P; Dal Col, J; Piccinin, S; Guidoboni, M; Cariati, R; Rizzo, S; Boiocchi, M; Maestro, R; Dolcetti, R				Zancai, P; Dal Col, J; Piccinin, S; Guidoboni, M; Cariati, R; Rizzo, S; Boiocchi, M; Maestro, R; Dolcetti, R			Retinoic acid stabilizes p27(Kip1) in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45(Skp2) and Cks1 proteins	ONCOGENE			English	Article						retinoic acid; p27(Kip1); p45(Skp2); Cks1; EBV; B lymphocytes; proteasome	CDK INHIBITOR P27; MEDIATED GROWTH ARREST; S-PHASE KINASE; NUCLEAR EXPORT; CYCLIN D1; UP-REGULATION; LEPTOMYCIN B; LUNG-CANCER; HUMAN CUL-1; C-MYC	Retinoic acid (RA) arrests the growth of EBV-immortalized lymphoblastoid B cell lines (LCLs) by upregulating the cyclin-dependent kinase inhibitor p27(Kip1). Here, we show that in LCLs, RA inhibits ubiquitination and proteasomedependent degradation of p27Kip1, a phenomenon that is associated with downregulation of Thr187 phosphorylation of the protein, whereas the phosphorylation on Ser10 is unaffected. Furthermore, we demonstrate that RA downregulates the expression of the p45(Skp2) and Cks1 proteins, two essential components of the SCFSkp2 ubiquitin ligase complex that target p27(Kip1) for degradation. Downregulation of p45(Skp2) and Cks1 occurs before the onset of growth arrest and is due to enhanced proteasome-mediated proteolysis of these proteins. Moreover, overexpression of p45(Skp2) in DG75 cells prevents p27(Kip1) protein accumulation and promotes resistance to the antiproliferative effects of RA. Treatment with Leptomycin B (LMB) blocked the translocation of p27(Kip1) to the cytoplasm and prevented its degradation, indicating that CRM1-dependent nuclear export is required for p27(Kip1) degradation. The shuttle protein p38(Jab1), however, does not accumulate in the nucleus upon LMB treatment, nor does it interact with p27(Kip1). Conversely, p45(Skp2) is associated with p27(Kip1) both in the nucleus and in the cytoplasm, accumulating within the nuclei after exposure to LMB and co-localizing with the exportin CRM1, suggesting a possible involvement of p45(Skp2) in CRM1-dependent nuclear export of p27(Kip1). These results indicate that downregulation of p45(Skp2) is a key element underlying RA-induced p27(Kip1) stabilization in B cells, resulting in an impaired targeting of the protein to the ubiquitin-proteasome pathway and probably contributing to the nuclear accumulation of p27(Kip1).	Natl Canc Inst, IRCCS, Ctr Riferimento Oncol, Dept Preclin & Epidemiol Res,Immunovirol & Biothe, I-33081 Aviano, PN, Italy; Natl Canc Inst, IRCCS, Ctr Riferimento Oncol, Mechanisms Neoplast Progress Unit, I-33081 Aviano, PN, Italy	IRCCS Aviano (CRO); IRCCS Aviano (CRO)	Dolcetti, R (corresponding author), Natl Canc Inst, IRCCS, Ctr Riferimento Oncol, Dept Preclin & Epidemiol Res,Immunovirol & Biothe, Via Pedemontana Occidentale 12, I-33081 Aviano, PN, Italy.	rdolcetti@cro.it	, Dal Col Jessica/AAC-4852-2020; Dal Col, Jessica/ABD-9479-2020; PICCININ, SARA/AAZ-2679-2020; Dolcetti, Riccardo/O-3832-2015; Maestro, Roberta/P-9748-2019; Guidoboni, Massimo/A-5322-2010; Maestro, Roberta/M-1846-2015; Rizzo, Silvana/AAW-1132-2020	Dal Col, Jessica/0000-0002-0042-2161; PICCININ, SARA/0000-0002-7987-4020; Dolcetti, Riccardo/0000-0003-1625-9853; Maestro, Roberta/0000-0002-6642-5592; Maestro, Roberta/0000-0002-6642-5592; Rizzo, Silvana/0000-0002-7156-1783; Guidoboni, Massimo/0000-0001-7703-790X				Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; Cariati R, 2000, INT J CANCER, V86, P375, DOI 10.1002/(SICI)1097-0215(20000501)86:3<375::AID-IJC12>3.0.CO;2-Z; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chiarle R, 2002, AM J PATHOL, V160, P1457, DOI 10.1016/S0002-9440(10)62571-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; de Vos S, 2003, DIAGN MOL PATHOL, V12, P35, DOI 10.1097/00019606-200303000-00005; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Esposito V, 1997, CANCER RES, V57, P3381; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; Hattori T, 2003, GENES CELLS, V8, P889, DOI 10.1046/j.1365-2443.2003.00684.x; Hsu SL, 2000, EXP CELL RES, V258, P322, DOI 10.1006/excr.2000.4933; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Lim MS, 2002, BLOOD, V100, P2950, DOI 10.1182/blood.V100.8.2950; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nakamura M, 2003, CELL DEATH DIFFER, V10, P230, DOI 10.1038/sj.cdd.4401125; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pomponi F, 1996, BLOOD, V88, P3147, DOI 10.1182/blood.V88.8.3147.bloodjournal8883147; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Suzui M, 2002, CANCER RES, V62, P3997; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Zancai P, 1998, ONCOGENE, V17, P1827, DOI 10.1038/sj.onc.1202089; Zhang DM, 2001, ONCOGENE, V20, P7935, DOI 10.1038/sj.onc.1204971; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	51	16	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2483	2494		10.1038/sj.onc.1208458	http://dx.doi.org/10.1038/sj.onc.1208458			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735731				2022-12-25	WOS:000228180600006
J	McKie, AB; Douglas, DA; Olijslagers, S; Graham, J; Omar, MM; Heer, R; Gnanapragasam, VJ; Robson, CN; Leung, HY				McKie, AB; Douglas, DA; Olijslagers, S; Graham, J; Omar, MM; Heer, R; Gnanapragasam, VJ; Robson, CN; Leung, HY			Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer	ONCOGENE			English	Article						hypermethylation; CpG; island; sprouty ( modulator); prostate cancer; tumour suppressor	GROWTH-FACTORS; CPG-ISLANDS; EXPRESSION; METHYLATION; ANTAGONIST; INHIBITOR; RECEPTORS	Abnormal signalling events mediated by receptor tyrosine kinases (RTKs) contribute to human carcinogenesis. Sprouty2 (Spry2) is a key antagonistic regulator of RTK signalling and suppression of its expression or function may facilitate proliferation and angiogenesis. Using prostate cancer (CaP) as a model, we investigated the significance of Spry2 in human malignancy. We observed downregulated Spry2 expression in invasive CaP cell lines and high-grade clinical CaP ( compared to benign prostatic hyperplasia (BPH) and well-differentiated tumours, P = 0.041). A large CpG island is associated with hSPRY2, and extensive hypermethylation of this CpG island was observed in 76 - 82% of high-grade CaP, while control BPH tissues were predominantly unmethylated (P = 0.0005). Furthermore, suppressed Spry2 expression correlated with methylation of the CpG region in clinical samples (P = 0.004) and treatment with 5-aza-2'-deoxycytidine reactivated Spry2 expression in LNCaP and PC-3M cells. hSPRY2 maps to the long arm of chromosome 13 (13q31.1), where loss of heterozygosity (LOH) has been reported. We found no evidence of mutation; however, we demonstrated 27 - 40% LOH using flanking markers to hSPRY2. Hence, while biallelic epigenetic inactivation of hSPRY2 represents the main genetic event in prostate carcinogenesis, the observed 27 - 40% LOH presents evidence of hemizygous deletion with the remaining allele hypermethylated. We therefore propose hSPRY2 as a potential tumour suppressor locus in CaP.	Univ Newcastle, Sch Med, No Inst Canc Res, Urol Res Grp, Newcastle Upon Tyne NE2 4AD, Tyne & Wear, England	Newcastle University - UK	Leung, HY (corresponding author), Univ Newcastle, Sch Med, No Inst Canc Res, Urol Res Grp, Paul O Gorman Bldg,N Terrace, Newcastle Upon Tyne NE2 4AD, Tyne & Wear, England.	h.y.leung@ncl.ac.uk		Leung, Hing Y./0000-0002-3933-3975	MRC [G0100100] Funding Source: UKRI; Medical Research Council [G0100100] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Ding W, 2003, GENE, V322, P175, DOI 10.1016/j.gene.2003.09.004; Djakiew D, 2000, PROSTATE, V42, P150, DOI 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H; Dong JT, 2001, PROSTATE, V49, P166, DOI 10.1002/pros.1131; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Lim J, 2002, MOL CELL BIOL, V22, P7953, DOI 10.1128/MCB.22.22.7953-7966.2002; Maegawa S, 2001, MOL CARCINOGEN, V31, P1, DOI 10.1002/mc.1034; McKie AB, 2001, HUM MOL GENET, V10, P1555, DOI 10.1093/hmg/10.15.1555; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Reich A, 1999, DEVELOPMENT, V126, P4139; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	24	104	107	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2166	2174		10.1038/sj.onc.1208371	http://dx.doi.org/10.1038/sj.onc.1208371			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735753				2022-12-25	WOS:000227857900004
J	Wang, ET; Reid, B; Lois, N; Forrester, JV; McCaig, CD; Zhao, M				Wang, ET; Reid, B; Lois, N; Forrester, JV; McCaig, CD; Zhao, M			Electrical inhibition of lens epithelial cell proliferation: an additional factor in secondary cataract?	FASEB JOURNAL			English	Article						posterior capsule opacification; electric fields; lens epithelium; cell cycle	POSTERIOR CAPSULE OPACIFICATION; DIRECTED MIGRATION; SURFACE-CHARGE; FIELDS; GROWTH; CURRENTS; REGENERATION; ORIENTATION; FREQUENCY; CORNEAL	Cataract is the most common cause of blindness but is at least curable by surgery. Unfortunately, many patients gradually develop the complication of posterior capsule opacification (PCO) or secondary cataract. This arises from stimulated cell growth within the lens capsule and can greatly impair vision. It is not fully understood why residual lens epithelial cell growth occurs after surgery. We propose and show that cataract surgery might remove an important inhibitory factor for lens cell growth, namely electric fields. The lens generates a unique pattern of electric currents constantly flowing out from the equator and entering the anterior and posterior poles. We show here that cutting and removing part of the anterior capsule as in cataract surgery significantly decreases the equatorial outward electric currents. Application of electric fields in culture inhibits proliferation of human lens epithelial cells. This inhibitory effect is likely to be mediated through a cell cycle control mechanism that decreases entry of cells into S phase from G1 phase by decreasing the G1-specific cell cycle protein cyclin E and increasing the cyclin-Cdk complex inhibitor p27(kip1). Capsulorrhexis in vivo, which reduced endogenous lens electric fields, significantly increased LEC growth. This, together with our previous findings that electric fields have significant effects on the direction of lens cell migration, points to a controlling mechanism for the aberrant cell growth in posterior capsule opacification. A novel approach to control growth of lens epithelial cells using electric fields combined with other controlling mechanisms may be more effective in the prevention and treatment of this common complication of cataract surgery.	Univ Aberdeen, Sch Med Sci, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Dept Ophthalmol, Aberdeen AB25 2ZD, Scotland	University of Aberdeen; University of Aberdeen	Zhao, M (corresponding author), Univ Aberdeen, Sch Med Sci, Aberdeen AB25 2ZD, Scotland.	m.zhao@abdn.ac.uk	McCaig, Colin/B-1774-2010		Wellcome Trust [068012] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APPLE DJ, 1992, SURV OPHTHALMOL, V37, P73, DOI 10.1016/0039-6257(92)90073-3; Apple DJ, 2001, OPHTHALMOLOGY, V108, P505, DOI 10.1016/S0161-6420(00)00589-3; AZADNIV M, 1993, RADIAT ENVIRON BIOPH, V32, P73, DOI 10.1007/BF01213133; Bertelmann E, 2001, CURR OPIN OPHTHALMOL, V12, P35, DOI 10.1097/00055735-200102000-00007; Binhi VN, 2000, BBA-GEN SUBJECTS, V1474, P147, DOI 10.1016/S0304-4165(00)00002-7; BRENT TP, 1967, NATURE, V215, P92, DOI 10.1038/215092a0; Candia OA, 2004, EXP EYE RES, V78, P527, DOI 10.1016/j.exer.2003.08.015; Candia OA, 2002, AM J PHYSIOL-CELL PH, V282, pC252, DOI 10.1152/ajpcell.00360.2001; CHU ZW, 1991, ACTA PHARM SINIC, V12, P285; Clark D S, 2000, Curr Opin Ophthalmol, V11, P56, DOI 10.1097/00055735-200002000-00009; Cuzick J, 1998, LANCET, V352, P359, DOI 10.1016/S0140-6736(97)10002-2; ELUL R, 1975, NATURE, V258, P616, DOI 10.1038/258616a0; FITZSIMMONS RJ, 1992, J CELL PHYSIOL, V150, P84, DOI 10.1002/jcp.1041500112; Goldman R, 1996, BIOELECTROMAGNETICS, V17, P450, DOI 10.1002/(SICI)1521-186X(1996)17:6<450::AID-BEM4>3.0.CO;2-2; Ibaraki N, 1998, EXP EYE RES, V67, P577, DOI 10.1006/exer.1998.0551; Ibaraki N, 1997, NAT MED, V3, P958, DOI 10.1038/nm0997-958; INOUE M, 1985, BIOELECTROMAGNETICS, V6, P293, DOI 10.1002/bem.2250060309; KnightNanan D, 1996, J CATARACT REFR SURG, V22, P730, DOI 10.1016/S0886-3350(96)80312-9; Lois N, 2003, INVEST OPHTH VIS SCI, V44, P3450, DOI 10.1167/iovs.02-1293; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; Mathias RT, 1997, PHYSIOL REV, V77, P21, DOI 10.1152/physrev.1997.77.1.21; McCaig CD, 1997, BIOESSAYS, V19, P819, DOI 10.1002/bies.950190912; McCaig CD, 2002, TRENDS NEUROSCI, V25, P354, DOI 10.1016/S0166-2236(02)02174-4; MOISSEIEV J, 1989, J CATARACT REFR SURG, V15, P531, DOI 10.1016/S0886-3350(89)80110-5; NAEGELE RJ, 1991, CANCER BIOCHEM BIOPH, V12, P95; Nuccitelli R, 2003, CURR TOP DEV BIOL, V58, P1, DOI 10.1016/S0070-2153(03)58001-2; Nuccitelli R, 2003, RADIAT PROT DOSIM, V106, P375, DOI 10.1093/oxfordjournals.rpd.a006375; Nuccitelli R., 1988, ADV CELL BIOL, V2, P213, DOI DOI 10.1016/S1569-2558(08)60435-X; PARMELEE JT, 1985, INVEST OPHTH VIS SCI, V26, P1343; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rakic JM, 1997, EXP EYE RES, V64, P67, DOI 10.1006/exer.1996.0179; Ranta P, 1998, OPHTHALMOLOGY, V105, P2127, DOI 10.1016/S0161-6420(98)91138-1; ROBERTSON D, 1981, RADIAT ENVIRON BIOPH, V19, P227, DOI 10.1007/BF01324190; ROBINSON KR, 1983, CURR EYE RES, V2, P843, DOI 10.3109/02713688209020020; Schaumberg DA, 1998, OPHTHALMOLOGY, V105, P1213, DOI 10.1016/S0161-6420(98)97023-3; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Song B, 2004, J CELL SCI, V117, P4681, DOI 10.1242/jcs.01341; Song B, 2002, P NATL ACAD SCI USA, V99, P13577, DOI 10.1073/pnas.202235299; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; Wang E, 2000, EXP EYE RES, V71, P91, DOI 10.1006/exer.2000.0858; Wang ET, 2003, EXP EYE RES, V76, P29, DOI 10.1016/S0014-4835(02)00257-9; Wang ET, 2003, FASEB J, V17, P458, DOI 10.1096/fj.02-0510fje; Wang ET, 2003, INVEST OPHTH VIS SCI, V44, P244, DOI 10.1167/iovs.02-0456; WIND BE, 1988, EXP EYE RES, V46, P117, DOI 10.1016/S0014-4835(88)80070-8; Wormstone IM, 2002, EXP EYE RES, V74, P337, DOI 10.1006/exer.2001.1153; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; Zhao M, 1996, J CELL SCI, V109, P1405; Zhao M, 1999, P NATL ACAD SCI USA, V96, P4942, DOI 10.1073/pnas.96.9.4942	48	28	31	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					842	+		10.1096/fj.04-2733fje	http://dx.doi.org/10.1096/fj.04-2733fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15764648	Green Accepted			2022-12-25	WOS:000227901300018
J	Okhrimenko, H; Lu, W; Xiang, CL; Ju, DH; Blumberg, PM; Gomel, R; Kazimirsky, G; Brodie, C				Okhrimenko, H; Lu, W; Xiang, CL; Ju, DH; Blumberg, PM; Gomel, R; Kazimirsky, G; Brodie, C			Roles of tyrosine phosphorylation and cleavage of protein kinase C delta in its protective effect against tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; RADIATION-INDUCED APOPTOSIS; DAMAGE-INDUCED APOPTOSIS; PROSTATE-CANCER CELLS; PROTEOLYTIC ACTIVATION; HUMAN KERATINOCYTES; GROWTH-FACTOR; DNA-DAMAGE; PKC-DELTA; ENDOPLASMIC-RETICULUM	Protein kinase C delta (PKC delta) regulates cell apoptosis in a cell- and stimulus-specific manner. Here, we studied the role of PKC delta in the apoptotic effect of TRAIL in glioma cells. We found that transfection of the cells with a PKC delta kinase-dead mutant (K376R) or with a small interfering RNA targeting the PKC delta mRNA increased the apoptotic effect of tumor necrosis factor-related apoptosis inducing ligand ( TRAIL), whereas overexpression of PKC delta decreased it. PKC delta acted downstream of caspase 8 and upstream of cytochrome c release from the mitochondria. TRAIL induced cleavage of PKC delta within 2-3 h of treatment, which was abolished by caspase 3, 8, and 9 inhibitors. The cleavage of PKC delta was essential for its protective effect because overexpression of a caspase-resistant mutant (PKC delta D327A) did not protect glioma cells from TRAIL-induced apoptosis but rather increased it. TRAIL induced translocation of PKC delta to the perinuclear region and the endoplasmic reticulum and phosphorylation of PKC delta on tyrosine 155. Using a PKC delta Y155F mutant, we found that the phosphorylation of PKC delta on tyrosine 155 was essential for the cleavage of PKC delta in response to TRAIL and for its translocation to the endoplasmic reticulum. In addition, phosphorylation of PKC delta on tyrosine 155 was necessary for the activation of AKT in response to TRAIL. Our results indicate that PKC delta protects glioma cells from the apoptosis induced by TRAIL and implicate the phosphorylation of PKC delta on tyrosine 155 and its cleavage as essential factors in the anti-apoptotic effect of PKC delta.	Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, Detroit, MI 48202 USA; NCI, Lab Cellular Carcinogenesis & Tumor Promot, NIH, Bethesda, MD 20892 USA; Bar Ilan Univ, Fac Life Sci, Gonda Goldschmied Med Diagnosis Res Ctr, IL-52900 Ramat Gan, Israel	Henry Ford Health System; Henry Ford Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Bar Ilan University	Brodie, C (corresponding author), Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, Detroit, MI 48202 USA.	chaya@mail.biu.ac.il			NATIONAL CANCER INSTITUTE [ZIABC005270, Z01BC005270] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Basu A, 2003, J CELL MOL MED, V7, P341, DOI 10.1111/j.1582-4934.2003.tb00237.x; Basu A, 2002, J BIOL CHEM, V277, P41850, DOI 10.1074/jbc.M205997200; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Brodie C, 1998, J BIOL CHEM, V273, P30713, DOI 10.1074/jbc.273.46.30713; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chawla-Sarkar M, 2003, J BIOL CHEM, V278, P39461, DOI 10.1074/jbc.M306111200; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chen YR, 2000, INT J ONCOL, V16, P651; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Deutsch E, 2004, J VIROL, V78, P10187, DOI 10.1128/JVI.78.18.10187-10192.2004; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Harper N, 2003, J BIOL CHEM, V278, P44338, DOI 10.1074/jbc.M307376200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jun CD, 1999, J IMMUNOL, V162, P3395; Kajimoto T, 2004, J BIOL CHEM, V279, P12668, DOI 10.1074/jbc.M312350200; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kim KM, 2005, ONCOGENE, V24, P355, DOI 10.1038/sj.onc.1208213; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; Leverrier S, 2002, BIOCHEM J, V368, P905, DOI 10.1042/BJ20021253; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lynch K, 2000, ENDOCRINOLOGY, V141, P4209, DOI 10.1210/en.141.11.4209; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Milani D, 2003, J NEUROCHEM, V86, P126, DOI 10.1046/j.1471-4159.2003.01805.x; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schultz A, 2003, CELL DEATH DIFFER, V10, P662, DOI 10.1038/sj.cdd.4401235; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; Song JH, 2003, BRAIN PATHOL, V13, P539; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175; White WO, 2002, J CELL BIOCHEM, V85, P42, DOI 10.1002/jcb.10101; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zrachia A, 2002, J BIOL CHEM, V277, P23693, DOI 10.1074/jbc.M111658200	71	52	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23643	23652		10.1074/jbc.M501374200	http://dx.doi.org/10.1074/jbc.M501374200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15774464	hybrid			2022-12-25	WOS:000229880000031
J	Drosopoulos, KG; Roberts, ML; Cermak, L; Sasazuki, T; Shirasawa, S; Andera, L; Pintzas, A				Drosopoulos, KG; Roberts, ML; Cermak, L; Sasazuki, T; Shirasawa, S; Andera, L; Pintzas, A			Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LIGAND-INDUCED APOPTOSIS; TUMORICIDAL ACTIVITY; CARCINOMA-CELLS; CANCER-CELLS; ACTIVATION; ERK; CASPASE-8; FADD; TNF	RAS oncogenes play a major role in cancer development by activating an array of signaling pathways, most notably mitogen-activated protein kinases, resulting in aberrant proliferation and inhibition of apoptotic signaling cascades, rendering transformed cells resistant to extrinsic death stimuli. However, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is able to kill specific tumor cells through the engagement of its receptors, death receptor 4 (DR4) and death receptor 5 (DR5), and the activation of apoptotic pathways, providing promising targets for anticancer therapies. In this study, we show that TRAIL induces cell death in human colon adenocarcinoma cells in a MEK-dependent manner. We also report a prolonged MEK-dependent activation of ERK1/2 and increased c-FOS expression induced by TRAIL in this system. Our study reveals that transformation of the colon cell line Caco-2 by Ki- and mainly by Ha-ras oncogenes sensitizes these cells to TRAIL-induced apoptosis by causing specific MEK-dependent up-regulation of DR4 and DR5. These observations taken together reveal that RAS-MEK-ERK1/2 signaling pathway can sensitize cells to TRAIL-induced apoptosis by up-regulating DR4 and DR5 and overall imply that TRAIL-based therapeutic strategies using TRAIL agonists could be used in cases of human colon cancers bearing RAS mutations.	Natl Hellen Res Fdn, Lab Signal Mediated Gene Express, Inst Biol Res & Biotechnol, Athens 11635, Greece; Acad Sci Czech Republ, Inst Mol Genet, Lab Cell Signaling Apoptosis, CZ-14220 Prague, Czech Republic; Int Med Ctr Japan, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan; Univ Patras, Dept Pharm, Rion 26500, Greece	National Hellenic Research Foundation; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; National Center for Global Health & Medicine - Japan; University of Patras	Pintzas, A (corresponding author), Natl Hellen Res Fdn, Lab Signal Mediated Gene Express, Inst Biol Res & Biotechnol, 48 Vasileos Konstantinou Ave, Athens 11635, Greece.	apint@eie.gr	Andera, Ladislav/ABA-3403-2020; Cermak, Lukas/N-2254-2016; Andera, Ladislav/A-4536-2011	Cermak, Lukas/0000-0002-8777-3692; Roberts, Michael/0000-0001-7387-1155				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BOS JL, 1989, CANCER RES, V49, P4682; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Guan BX, 2002, ONCOGENE, V21, P3121, DOI 10.1038/sj.onc.1205430; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Koornstra JJ, 2003, J PATHOL, V200, P327, DOI 10.1002/path.1364; LE LH, 2004, J CLIN ONCOL S, V22; Li WQ, 2004, J BIOL CHEM, V279, P37398, DOI 10.1074/jbc.M405730200; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Mizutani Y, 2002, EUR J CANCER, V38, P167, DOI 10.1016/S0959-8049(01)00339-2; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Nesterov A, 2004, CANCER RES, V64, P3922, DOI 10.1158/0008-5472.CAN-03-2219; Nimmanapalli R, 2001, CANCER RES, V61, P759; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Plattner R, 1999, ONCOGENE, V18, P1807, DOI 10.1038/sj.onc.1202482; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Secchiero P, 2003, CIRCULATION, V107, P2250, DOI 10.1161/01.CIR.0000062702.60708.C4; Shetty S, 2002, APOPTOSIS, V7, P413, DOI 10.1023/A:1020031023947; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Siegmund D, 2001, J BIOL CHEM, V276, P32585, DOI 10.1074/jbc.M100444200; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; TOLCHER AW, 2004, J CLIN ONCOL S, V22; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WORKMAN P, 2002, TRENDS MOL MED, V8, P1	43	74	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22856	22867		10.1074/jbc.M412483200	http://dx.doi.org/10.1074/jbc.M412483200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15757891	hybrid			2022-12-25	WOS:000229741800038
J	Weber, CC; Cai, H; Ehrbar, M; Kubota, H; Martiny-Baron, G; Weber, W; Djonov, V; Weber, E; Mallik, AS; Fussenegger, M; Frei, K; Hubbell, JA; Zisch, AH				Weber, CC; Cai, H; Ehrbar, M; Kubota, H; Martiny-Baron, G; Weber, W; Djonov, V; Weber, E; Mallik, AS; Fussenegger, M; Frei, K; Hubbell, JA; Zisch, AH			Effects of protein and gene transfer of the angiopoietin-1 fibrinogen-like receptor-binding domain on endothelial and vessel organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; IN-VITRO; OVEREXPRESSING ANGIOPOIETIN-1; TYROSINE KINASES; BLOOD-VESSELS; CELLS; ANGIOGENESIS; EXPRESSION; VEGF; PERMEABILITY	The vessel-stabilizing effect of angiopoietin-1 (Ang1)/ Tie2 receptor signaling is a potential target for pro-angiogenic therapies as well as anti-angiogenic inhibition of tumor growth. We explored the endothelial and vascular specific activities of the Ang1 monomer, i.e. dissociated from its state as an oligomer. A truncated monomeric Ang1 variant (i.e. Delta Ang1) containing the isolated fibrinogen-like receptor-binding domain of Ang1 was created and recombinantly produced in insect cells. Delta Ang1 ligated the Tie2 receptor without triggering its phosphorylation. Moreover, monomeric Delta Ang1 was observed to bind alpha(5)beta(1) integrin with similar affinity compared with Tie2. Unexpectedly, in vitro treatment of endothelial cells with Delta Ang1 showed some of the known effects of full-length Ang1, including inhibition of basal endothelial cell permeability and stimulation of cell adhesion as well as activation of MAPKs. Local treatment of the microvasculature of the developing chicken chorioallantoic membrane with the Delta Ang1 protein led to profound reduction of the mean vascular length density, thinning of vessels, and reduction of the number of vessel branching points. Similar effects were observed in side-by-side experiments with the recombinant full-length Ang1 protein. These effects of simplification of the vessel branching pattern were confirmed through local gene transfer with lentiviral particles encoding Delta Ang1 or full- length Ang1. Together, our findings suggest a potential use for exogenous Ang1 in reducing rather than increasing vascular density. Furthermore, we show that the isolated receptor-binding domain of Ang1 is capable of mediating some effects of full- length Ang1 independently of Tie2 phosphorylation, possibly through integrin ligation.	Univ Zurich Hosp, Dept Obstet, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland; Swiss Fed Inst Technol, Dept Mat Sci, CH-8044 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Biomed Engn, CH-8044 Zurich, Switzerland; Univ Zurich, CH-8044 Zurich, Switzerland; Novartis Pharma AG, CH-4002 Basel, Switzerland; Swiss Fed Inst Technol, Inst Biotechnol, CH-8093 Zurich, Switzerland; Univ Bern, Inst Anat, CH-3000 Bern, Switzerland; German Canc Res Ctr, Dept Biostat, D-69210 Heidelberg, Germany	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Novartis; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Bern; Helmholtz Association; German Cancer Research Center (DKFZ)	Zisch, AH (corresponding author), Univ Zurich Hosp, Dept Obstet, Frauenklinstr 10, CH-8091 Zurich, Switzerland.	andreas.zisch@usz.ch	Ehrbar, Martin/F-4578-2012; Hubbell, Jeffrey A/A-9266-2008; Weber, Wilfried/B-4732-2012	Ehrbar, Martin/0000-0003-2707-4870; Hubbell, Jeffrey A/0000-0003-0276-5456; Weber, Wilfried/0000-0003-4340-4446; Djonov, Valentin/0000-0002-5062-1169				ABT K, 1987, METHOD INFORM MED, V26, P77; AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Arsic N, 2003, MOL THER, V7, P450, DOI 10.1016/S1525-0016(03)00034-0; AUERBACH R, 1974, DEV BIOL, V41, P391, DOI 10.1016/0012-1606(74)90316-9; AUSUBEL FM, 1995, SHORT PROTOCOLS MOL, P11; BATSCHELET E, 1980, EINFUHRUNG MATH BIOL; Birgbauer E, 2000, DEVELOPMENT, V127, P1231; Carlson TR, 2001, J BIOL CHEM, V276, P26516, DOI 10.1074/jbc.M100282200; Cho CH, 2004, P NATL ACAD SCI USA, V101, P5547, DOI 10.1073/pnas.0307574101; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Davis S, 2003, NAT STRUCT BIOL, V10, P38, DOI 10.1038/nsb880; Djonov V, 2000, CIRC RES, V86, P286, DOI 10.1161/01.RES.86.3.286; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Ehrbar M, 2005, J CONTROL RELEASE, V101, P93, DOI 10.1016/j.jconrel.2004.07.018; Ehrbar M, 2004, CIRC RES, V94, P1124, DOI 10.1161/01.RES.0000126411.29641.08; Ellis LM, 2002, ONCOLOGY-NY, V16, P31; Fiedler U, 2003, J BIOL CHEM, V278, P1721, DOI 10.1074/jbc.M208550200; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Gloor SM, 1997, BIOCHEM BIOPH RES CO, V239, P804, DOI 10.1006/bbrc.1997.7557; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Harfouche R, 2002, MICROVASC RES, V64, P135, DOI 10.1006/mvre.2002.2421; Hayes AJ, 2000, BRIT J CANCER, V83, P1154, DOI 10.1054/bjoc.2000.1437; Hori S, 2004, J NEUROCHEM, V89, P503, DOI 10.1111/j.1471-4159.2004.02343.x; Joussen AM, 2002, AM J PATHOL, V160, P1683, DOI 10.1016/S0002-9440(10)61115-7; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 2001, CIRC RES, V89, P477, DOI 10.1161/hh1801.097034; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mitta B, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf112; Pizurki L, 2003, BRIT J PHARMACOL, V139, P329, DOI 10.1038/sj.bjp.0705259; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; Sakiyama-Elbert SE, 2001, FASEB J, V15, P1300, DOI 10.1096/fj.00-0564fje; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schense JC, 1999, BIOCONJUGATE CHEM, V10, P75, DOI 10.1021/bc9800769; Schmoekel HG, 2005, BIOTECHNOL BIOENG, V89, P253, DOI 10.1002/bit.20168; Shyu KG, 2003, LIFE SCI, V73, P563, DOI 10.1016/S0024-3205(03)00318-7; Stoeltzing O, 2003, CANCER RES, V63, P3370; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 2003, CELL TISSUE RES, V314, P61, DOI 10.1007/s00441-003-0749-6; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Uemura A, 2002, J CLIN INVEST, V110, P1619, DOI 10.1172/JCI200215621; Ward NL, 2002, SEMIN CELL DEV BIOL, V13, P19, DOI 10.1006/scdb.2001.0288; WEBER E, 1985, STAT AUSWERTUNG BIOM; Weber W, 2002, CYTOTECHNOLOGY, V38, P77, DOI 10.1023/A:1021102015070; Weibel E.R., 1967, QUANTITATIVE METHODS, P89, DOI 10.1007/978-3-642-50130-2_7; Xu Y, 2001, J BIOL CHEM, V276, P34990, DOI 10.1074/jbc.M103661200; Yamauchi A, 2003, J GENE MED, V5, P994, DOI 10.1002/jgm.439; Zhou DP, 2000, ARCH BIOCHEM BIOPHYS, V374, P3, DOI 10.1006/abbi.1999.1622	53	30	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22445	22453		10.1074/jbc.M410367200	http://dx.doi.org/10.1074/jbc.M410367200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15781448	hybrid			2022-12-25	WOS:000229557900090
J	Coffey, JC; Wang, JH; Smith, MJF; Laing, A; Bouchier-Hayes, D; Cotter, TG; Redmond, HP				Coffey, JC; Wang, JH; Smith, MJF; Laing, A; Bouchier-Hayes, D; Cotter, TG; Redmond, HP			Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UP-REGULATION; IN-VITRO; CANCER; SURGERY; CELLS; ANGIOGENESIS; ANGIOSTATIN; LAPAROSCOPY; LAPAROTOMY; CARCINOMA	Tumor removal remains the principal treatment modality in the management of solid tumors. The process of tumor removal may potentiate the resurgent growth of residual neoplastic tissue. Herein, we describe a novel murine model in which flank tumor cytoreduction is followed by accelerated local tumor recurrence. This model held for primary and recurrent tumors generated using a panel of human and murine (LS174T, DU145, SW480, SW640, and 3LL) cell lines and replicated accelerated tumor growth following excisional surgery. In investigating this further, epithelial cells were purified from LS174T primary and corresponding recurrent tumors for comparison. Baseline as well as tumor necrosis factor apoptosis-inducing ligand ( TRAIL)-induced apoptosis were significantly reduced in recurrent tumor epithelia. Primary and recurrent tumor gene expression profiles were then compared. This identified an increase and reduction in the expression of p110g and p85a class Ia phosphoinositide 3-kinase (PI3K) subunits in recurrent tumor epithelia. These changes were further confirmed at the protein level. The targeting of PI3K ex vivo, using LY294002, restored sensitivity to TRAIL in recurrent tumor epithelia. In vivo, adjuvant LY294002 prolonged survival and significantly attenuated recurrent tumor growth by greatly enhancing apoptosis levels. Hence, PI3K plays a role in generating the antiapoptotic and chemoresistant phenotype associated with accelerated local tumor recurrence.	Cork Univ Hosp, Dept Surg, Cork, Munster, Ireland; Cork Univ Hosp, Dept Tumor Biol, Cork, Munster, Ireland; Cork Univ Hosp, Dept Biochem, Cork, Munster, Ireland; Beaumont Hosp, Dept Surg, Dublin 9, Ireland; Royal Coll Surgeons Ireland, Dublin 2, Ireland	University College Cork; University College Cork; University College Cork; Royal College of Surgeons - Ireland	Coffey, JC (corresponding author), Cork Univ Hosp, Dept Surg, Cork, Munster, Ireland.	calvincoffey@hotmail.com	Smith, Myles JF/B-7803-2009	Smith, Myles JF/0000-0002-3254-4817; Cotter, Thomas/0000-0003-4626-5613				Abramovitch R, 1999, BRIT J CANCER, V79, P1392, DOI 10.1038/sj.bjc.6690223; Baum M, 1999, EUR J CANCER, V35, P886, DOI 10.1016/S0959-8049(99)00067-2; BAUM M, 1994, DOES SURG INFLUENCE; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cao YH, 1998, J CLIN INVEST, V101, P1055, DOI 10.1172/JCI1558; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coffey JC, 2003, LANCET ONCOL, V4, P760, DOI 10.1016/S1470-2045(03)01282-8; Coffey JC, 2002, ANN SURG ONCOL, V9, pS37; Coffey JC, 2001, J SURG RES, V98, P27, DOI 10.1006/jsre.2001.6129; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Da Costa ML, 1998, BRIT J SURG, V85, P1439; Da Costa ML, 1998, SURGERY, V124, P516, DOI 10.1067/msy.1998.89410; Da Costa ML, 2001, J SURG RES, V101, P111, DOI 10.1006/jsre.2001.6250; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Demicheli R, 2001, BRIT J CANCER, V85, P490, DOI 10.1054/bjoc.2001.1969; Demicheli R, 2000, J NATL CANCER I, V92, P347, DOI 10.1093/jnci/92.4.347; Ellis Harold, 2001, HIST SURG; GIAVAZZI R, 1986, CANCER RES, V46, P1928; Hofer SOP, 1998, ARCH SURG-CHICAGO, V133, P383, DOI 10.1001/archsurg.133.4.383; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; HOSKINS WJ, 1989, BAILLIERE CLIN OB GY, V3, P59, DOI 10.1016/S0950-3552(89)80042-2; Hu LM, 2002, CANCER RES, V62, P1087; Hu LM, 2000, CLIN CANCER RES, V6, P880; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Kandasamy K, 2002, CANCER RES, V62, P4929; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Krasilnikov M, 2003, ONCOGENE, V22, P4092, DOI 10.1038/sj.onc.1206598; Lacy AM, 2002, LANCET, V359, P2224, DOI 10.1016/S0140-6736(02)09290-5; LANGE PH, 1980, CANCER-AM CANCER SOC, V45, P1498, DOI 10.1002/1097-0142(19800315)45:6<1498::AID-CNCR2820450633>3.0.CO;2-7; Lee SW, 2000, SURG ENDOSC, V14, P490, DOI 10.1007/s004640020061; LEE YTN, 1977, J SURG ONCOL, V9, P425, DOI 10.1002/jso.2930090503; Li TS, 2001, EUR J CANCER, V37, P2283, DOI 10.1016/S0959-8049(01)00281-7; Mauvais-Jarvis F, 2002, J CLIN INVEST, V109, P141, DOI 10.1172/JCI200213305; MOORE GE, 1980, SURG GYNECOL OBSTET, V150, P395; Nam SY, 2003, CANCER SCI, V94, P1066, DOI 10.1111/j.1349-7006.2003.tb01402.x; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Patel H, 2002, ANN SURG, V235, P226, DOI 10.1097/00000658-200202000-00010; Pidgeon GP, 1999, BRIT J CANCER, V81, P1311, DOI 10.1038/sj.bjc.6694369; Pidgeon GP, 2001, BRIT J CANCER, V85, P273, DOI 10.1054/bjoc.2001.1876; Qadri SSA, 2005, ANN THORAC SURG, V79, P990, DOI 10.1016/j.athoracsur.2004.07.042; ROUSSEAU DL, 2003, MD ANDERSON SURG ONC, V1, P215; Spigel DR, 2003, LANCET, V362, P502, DOI 10.1016/S0140-6736(03)14147-5; Tagliabue E, 2003, LANCET, V362, P527, DOI 10.1016/S0140-6736(03)14112-8; Tyzzer EE, 1913, J MED RES, V28, P309; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang JH, 2003, J IMMUNOL, V170, P795, DOI 10.4049/jimmunol.170.2.795; Weaver SA, 2001, TRENDS MOL MED, V7, P455, DOI 10.1016/S1471-4914(01)02107-4; WONG RJ, 1990, SURG GYNECOL OBSTET, V170, P276; Zhang B, 2003, CLIN CANCER RES, V9, P3073; Zhang RL, 2003, GLIA, V42, P194, DOI 10.1002/glia.10222	53	31	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20968	20977		10.1074/jbc.M414696200	http://dx.doi.org/10.1074/jbc.M414696200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15741161	hybrid			2022-12-25	WOS:000229438800010
J	Dammermann, W; Guse, AH				Dammermann, W; Guse, AH			Functional ryanodine receptor expression is required for NAADP-mediated local Ca2+ signaling in T-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; ADENINE-DINUCLEOTIDE PHOSPHATE; PANCREATIC ACINAR-CELLS; INOSITOL TRISPHOSPHATE; CALCIUM-RELEASE; MOBILIZES CA2+; ENTRY; PROPAGATION; STORE	Nicotinic acid adenine dinucleotide phosphate (NAADP) is a potent Ca2+-mobilizing nucleotide involved in T cell Ca2+ signaling ( Berg, I., Potter, B. V. L., Mayr, G. W., and Guse, A. H. (2000) J. Cell Biol. 150, 581-588). The objective of this study was to analyze whether the first subcellular Ca2+ signals obtained upon NAADP stimulation of T-lymphocytes depend on the functional expression of ryanodine receptors. Using combined microinjection and high resolution confocal calcium imaging, we demonstrate here that subcellular Ca2+ signals, characterized by amplitudes between similar to 30 and 100 nM and diameters of similar to 0.5 mu m, preceded global Ca2+ signals. Co-injection of the ryanodine receptor antagonists ruthenium red and ryanodine together with NAADP abolished the effects of NAADP, whereas the D-myo-inositol 1,4,5- trisphosphate antagonist heparin and the Ca2+ entry blocker SKF& 96365 were without effect. This pharmacological approach was confirmed by a molecular knock-down approach. Jurkat T cell clones with largely reduced expression of ryanodine receptors did not respond to microinjections of NAADP. Taken together, our data suggest that the Ca2+ release channel sensitive to NAADP in T- lymphocytes is the ryanodine receptor.	Univ Hamburg, Hosp Eppendorf, Ctr Med Expt, Inst Biochem & Mol Biol Cellular Signal Transduct, D-20246 Hamburg, Germany	University of Hamburg	Guse, AH (corresponding author), Univ Hamburg, Hosp Eppendorf, Ctr Med Expt, Inst Biochem & Mol Biol Cellular Signal Transduct, Martinistr 52, D-20246 Hamburg, Germany.	guse@uke.uni-hamburg.de	Dammermann, Werner/G-5811-2016; Dammermann, Werner/GZN-1268-2022	Dammermann, Werner/0000-0001-6847-3769; 				Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; BEZPROZVANNY IB, 1993, MOL BIOL CELL, V4, P347, DOI 10.1091/mbc.4.3.347; Brailoiu E, 2005, J BIOL CHEM, V280, P5646, DOI 10.1074/jbc.M408746200; Bruzzone S, 2003, J CELL BIOL, V163, P837, DOI 10.1083/jcb.200307016; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Gerasimenko JV, 2003, J CELL BIOL, V163, P271, DOI 10.1083/jcb.200306134; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; Guse AH, 1997, J BIOL CHEM, V272, P8546, DOI 10.1074/jbc.272.13.8546; Hohenegger M, 2002, BIOCHEM J, V367, P423, DOI 10.1042/BJ20020584; Kunerth S, 2004, J CELL SCI, V117, P2141, DOI 10.1242/jcs.01063; Kunerth S, 2003, CELL SIGNAL, V15, P783, DOI 10.1016/S0898-6568(03)00015-9; Langhorst MF, 2004, CELL SIGNAL, V16, P1283, DOI 10.1016/j.cellsig.2004.03.013; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 2000, J CELL SCI, V113, P4413; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lipp P, 1996, J PHYSIOL-LONDON, V492, P31, DOI 10.1113/jphysiol.1996.sp021286; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Mojzisova A, 2001, PFLUG ARCH EUR J PHY, V441, P674, DOI 10.1007/s004240000465; Schwarzmann N, 2002, J BIOL CHEM, V277, P50636, DOI 10.1074/jbc.M209061200; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200	24	92	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21394	21399		10.1074/jbc.M413085200	http://dx.doi.org/10.1074/jbc.M413085200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15774471	hybrid			2022-12-25	WOS:000229438800059
J	Wu, PP; Ma, DD; Pierzchala, M; Wu, J; Yang, LC; Mai, XP; Chang, XY; Schmidt-Glenewinkel, TS				Wu, PP; Ma, DD; Pierzchala, M; Wu, J; Yang, LC; Mai, XP; Chang, XY; Schmidt-Glenewinkel, TS			The Drosophila acetylcholine receptor subunit D alpha 5 is part of an alpha-bungarotoxin binding acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; CHOLINERGIC RECEPTOR; NICOTINIC RECEPTOR; DETERGENT BINDING; CROSS-LINKING; CO-ASSEMBLE; PROTEIN; MELANOGASTER; COMPLEX; EXPRESSION	The central nervous system of Drosophila melanogaster contains an alpha-bungarotoxin-binding protein with the properties expected of a nicotinic acetylcholine receptor. This protein was purified 5800-fold from membranes prepared from Drosophila heads. The protein was solubilized with 1 % Triton X-100 and 0.5 M sodium chloride and then purified using an alpha-cobratoxin column followed by a lentil lectin affinity column. The purified protein had a specific activity of 3.9 mu mol of I-125- bungarotoxin binding sites/g of protein. The subunit composition of the purified receptor was determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis. This subunit profile was identical with that revealed by in situ labeling of the membrane-bound protein using the photolyzable methyl-4-azidobenzoimidate derivative of I-125-alpha-bungarotoxin. The purified receptor reveals two different protein bands with molecular masses of 42 and 57 kDa. From sedimentation analysis of the purified protein complex in H2O and D2O and gel filtration, a mass of 270 kDa was calculated. The receptor has a s(20),omega of 9.4 and a Stoke's radius of 7.4 nm. The frictional coefficient was calculated to be 1.7 indicating a highly asymmetric protein complex compatible with a transmembrane protein forming an ion channel. The sequence of a peptide obtained after tryptic digestion of the 42-kDa protein allowed the specific identification of the Drosophila D alpha 5 subunit by sequence comparison. A peptide-specific antibody raised against the D alpha 5 subunit provides further evidence that this subunit is a component of an alpha-bungarotoxin binding nicotinic acetylcholine receptor from the central nervous system of Drosophila.	CUNY Hunter Coll, Ctr Study Gene Struct & Funct, Dept Sci Biol, New York, NY 10021 USA; CUNY Hunter Coll, Grad Ctr, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY)	Schmidt-Glenewinkel, TS (corresponding author), CUNY Hunter Coll, Ctr Study Gene Struct & Funct, Dept Sci Biol, 695 Pk Ave, New York, NY 10021 USA.	thomas@genectr.hunter.cuny.edu	Pierzchala, Mariusz/G-1052-2013; Ma, Diane/AAR-6749-2021	Pierzchala, Mariusz/0000-0001-7001-1336; Ma, Diane/0000-0001-7125-9587	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [SC3GM086323, S06GM060654] Funding Source: NIH RePORTER; NCRR NIH HHS [G12 RR003037, RR-03037] Funding Source: Medline; NIGMS NIH HHS [SC3 GM086323, 1SO6 GM 60654, S06 GM060654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BLANCHARD SG, 1979, BIOCHEMISTRY-US, V18, P1875, DOI 10.1021/bi00577a005; BOSSY B, 1988, EMBO J, V7, P611, DOI 10.1002/j.1460-2075.1988.tb02854.x; Chamaon K, 2000, FEBS LETT, V482, P189, DOI 10.1016/S0014-5793(00)02057-3; Chamaon K, 2002, J NEUROCHEM, V80, P149, DOI 10.1046/j.0022-3042.2001.00685.x; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Changeux JP, 2001, CURR OPIN NEUROBIOL, V11, P369, DOI 10.1016/S0959-4388(00)00221-X; CLARKE S, 1975, J BIOL CHEM, V250, P5459; CONTITRONCONI BM, 1982, ANNU REV BIOCHEM, V51, P491, DOI 10.1146/annurev.bi.51.070182.002423; COOPER D, 1972, J BIOL CHEM, V247, P3008; DUDAI Y, 1978, BIOCHIM BIOPHYS ACTA, V539, P505, DOI 10.1016/0304-4165(78)90084-3; Grauso M, 2002, GENETICS, V160, P1519; HAYMAN MJ, 1972, BIOCHEM BIOPH RES CO, V47, P923, DOI 10.1016/0006-291X(72)90581-5; HERMANSBORGMEYER I, 1986, EMBO J, V5, P1503, DOI 10.1002/j.1460-2075.1986.tb04389.x; JI I, 1985, ANAL BIOCHEM, V151, P348, DOI 10.1016/0003-2697(85)90186-1; JI TH, 1977, J BIOL CHEM, V252, P1566; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lansdell SJ, 2004, J NEUROCHEM, V90, P479, DOI 10.1111/j.1471-4159.2004.02499.x; Lansdell SJ, 1997, J NEUROCHEM, V68, P1812; Lansdell SJ, 2002, J NEUROCHEM, V80, P1009, DOI 10.1046/j.0022-3042.2002.00789.x; Leech C.A., 1993, Experientia Supplementum (Basel), V63, P81; Lewis E.B., 1960, DROS INFORM SERV, V34, P117, DOI DOI 10.1101/PDB.REC081414; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; MA D, 2001, 31 ANN M SOC NEUR SA; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MEUNIER JC, 1972, FEBS LETT, V24, P63, DOI 10.1016/0014-5793(72)80827-5; NATHANSON NM, 1980, J BIOL CHEM, V255, P1698; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PINNOCK RD, 1988, BRAIN RES, V458, P45, DOI 10.1016/0006-8993(88)90494-5; REYNOLDS JA, 1976, P NATL ACAD SCI USA, V73, P4467, DOI 10.1073/pnas.73.12.4467; Role L W, 1992, Curr Opin Neurobiol, V2, P254, DOI 10.1016/0959-4388(92)90112-X; RUDLOFF E, 1978, EXP CELL RES, V111, P185, DOI 10.1016/0014-4827(78)90248-3; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SAWRUK E, 1990, EMBO J, V9, P2671, DOI 10.1002/j.1460-2075.1990.tb07452.x; SAWRUK E, 1990, FEBS LETT, V273, P177, DOI 10.1016/0014-5793(90)81078-3; SCHLOSS P, 1988, EMBO J, V7, P2889, DOI 10.1002/j.1460-2075.1988.tb03146.x; SCHLOSS P, 1992, NEUROSCI LETT, V145, P63, DOI 10.1016/0304-3940(92)90204-K; SCHMIDTNIELSEN BK, 1977, J NEUROCHEM, V29, P1013, DOI 10.1111/j.1471-4159.1977.tb06505.x; Schulz R, 2000, J NEUROCHEM, V74, P2537, DOI 10.1046/j.1471-4159.2000.0742537.x; Schulz R, 1998, J NEUROCHEM, V71, P853; SIEGEL LM, 1965, BIOCHEM BIOPH RES CO, V19, P494, DOI 10.1016/0006-291X(65)90152-X; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; Tomizawa M, 1997, NEUROSCI LETT, V237, P61, DOI 10.1016/S0304-3940(97)00811-2; Tomizawa M, 1996, J NEUROCHEM, V67, P1669; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	49	12	15	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20987	20994		10.1074/jbc.M409639200	http://dx.doi.org/10.1074/jbc.M409639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15781463	Green Accepted, hybrid			2022-12-25	WOS:000229438800012
J	Kurata, A; Kurihara, T; Kamachi, H; Esaki, N				Kurata, A; Kurihara, T; Kamachi, H; Esaki, N			2-Haloacrylate reductase, a novel enzyme of the medium chain dehydrogenase/reductase superfamily that catalyzes the reduction of a carbon-carbon double bond of unsaturated organohalogen compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINONE OXIDOREDUCTASE; L-2-HALOACID DEHALOGENASE; REACTION-MECHANISM; ACID DEHALOGENASE; ZETA-CRYSTALLIN; IDENTIFICATION; DEGRADATION; DIVERSITY; EVOLUTION; INSIGHT	A soil bacterium, Burkholderia sp. WS, grows on 2-chloroacrylate as the sole carbon source. To identify the enzymes metabolizing 2-chloroacrylate, we carried out comparative two-dimensional gel electrophoresis of the proteins from 2-chloroacrylate- and lactate-grown bacterial cells. As a result, we found that a protein named CAA43 was inducibly synthesized when the cells were grown on 2-chloroacrylate. The CAA43 gene was cloned and shown to encode a protein of 333 amino acid residues (M-r 35,788) that shared a significant sequence similarity with NADPH-dependent quinone oxidoreductase from Escherichia coli (38.2% identity). CAA43 was overproduced in E. coli and purified to homogeneity. The purified protein catalyzed the NADPH-dependent reduction of the carbon-carbon double bond of 2-chloroacrylate to produce (S)-2-chloropropionate, which is probably further metabolized to (R)-lactate by (S)-2-haloacid dehalogenase in Burkholderia sp. WS. NADH did not serve as a reductant. Despite the sequence similarity to quinone oxidoreductases, CAA43 did not act on 1,4-benzoquinone and 1,4-naphthoquinone. 2-Chloroacrylate analogs, such as acrylate and methacrylate, were also inert as the substrates. In contrast, 2-bromoacrylate served as the substrate. Thus, we named this novel enzyme 2-haloacrylate reductase. This study revealed a new pathway for the degradation of unsaturated organohalogen compounds. It is also notable that the enzyme is useful for the production of (S)-2-chloropropionate, which is used for the industrial production of aryloxyphenoxypropionic acid herbicides.	Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan; Showa Denko Co Ltd, Corp R&D Ctr, Chiba 2670056, Japan	Kyoto University; Showa Denko K.K.	Kurihara, T (corresponding author), Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan.	kurihara@mbc.kuicr.kyoto-u.ac.jp; esaki@scl.kyoto-u.ac.jp						Banerjee R, 2003, ANNU REV BIOCHEM, V72, P209, DOI 10.1146/annurev.biochem.72.121801.161828; Bossi RT, 2002, BIOCHEMISTRY-US, V41, P3018, DOI 10.1021/bi015939r; Breuer M, 2004, ANGEW CHEM INT EDIT, V43, P788, DOI 10.1002/anie.200300599; Copley SD, 1998, CURR OPIN CHEM BIOL, V2, P613, DOI 10.1016/S1367-5931(98)80092-6; de Jong RM, 2003, EMBO J, V22, P4933, DOI 10.1093/emboj/cdg479; de Jong RM, 2004, J BIOL CHEM, V279, P11546, DOI 10.1074/jbc.M311966200; de Jong RM, 2003, CURR OPIN STRUC BIOL, V13, P722, DOI 10.1016/j.sbi.2003.10.009; Edwards KJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P173, DOI 10.1006/abbi.1996.0158; Furukawa K, 2000, J GEN APPL MICROBIOL, V46, P283, DOI 10.2323/jgam.46.283; Gribble GW, 2003, CHEMOSPHERE, V52, P289, DOI 10.1016/S0045-6535(03)00207-8; Haga T, 1998, W S AGROCHEM PLANT, P175; HASAN AKMQ, 1994, BIOSCI BIOTECH BIOCH, V58, P1599, DOI 10.1271/bbb.58.1599; Janssen DB, 2004, CURR OPIN CHEM BIOL, V8, P150, DOI 10.1016/j.cbpa.2004.02.012; Janssen DB, 2001, CURR OPIN BIOTECH, V12, P254, DOI 10.1016/S0958-1669(00)00208-1; Kurata A, 2004, TETRAHEDRON-ASYMMETR, V15, P2837, DOI 10.1016/j.tetasy.2004.06.035; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; LeBrun LA, 2004, BIOCHEMISTRY-US, V43, P3014, DOI 10.1021/bi036103m; Li YF, 1998, J BIOL CHEM, V273, P15035, DOI 10.1074/jbc.273.24.15035; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; LIU JQ, 1994, APPL ENVIRON MICROB, V60, P2389, DOI 10.1128/AEM.60.7.2389-2393.1994; Liu JQ, 1998, J BIOL CHEM, V273, P30897, DOI 10.1074/jbc.273.47.30897; MARSDEN PJ, 1982, J AGR FOOD CHEM, V30, P627, DOI 10.1021/jf00112a002; Nardi-Dei V, 1999, J BIOL CHEM, V274, P20977, DOI 10.1074/jbc.274.30.20977; Poelarends GJ, 2004, BIOORG CHEM, V32, P376, DOI 10.1016/j.bioorg.2004.05.006; Poelarends GJ, 2004, BIOCHEMISTRY-US, V43, P759, DOI 10.1021/bi0355948; RAO PV, 1992, J BIOL CHEM, V267, P96; Riveros-Rosas H, 2003, EUR J BIOCHEM, V270, P3309, DOI 10.1046/j.1432-1033.2003.03704.x; Shimomura Y, 2002, ACTA CRYSTALLOGR D, V58, P1365, DOI 10.1107/S090744490201003X; Swanson PE, 1999, CURR OPIN BIOTECH, V10, P365, DOI 10.1016/S0958-1669(99)80066-4; THORN JM, 1995, J MOL BIOL, V249, P785, DOI 10.1006/jmbi.1995.0337; VANDERWAARDE JJ, 1993, APPL ENVIRON MICROB, V59, P528, DOI 10.1128/AEM.59.2.528-535.1993; WOODLARD FX, 1979, PHYTOCHEMISTRY, V18, P617; Xu DG, 2004, J AM CHEM SOC, V126, P13649, DOI 10.1021/ja0460211	33	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20286	20291		10.1074/jbc.M414605200	http://dx.doi.org/10.1074/jbc.M414605200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781461	hybrid			2022-12-25	WOS:000229242000017
J	Liu, HY; MacDonald, JIS; Hryciw, T; Li, CH; Meakin, SO				Liu, HY; MacDonald, JIS; Hryciw, T; Li, CH; Meakin, SO			Human tumorous imaginal disc 1 (TID1) associates with Trk receptor tyrosine kinases and regulates neurite outgrowth in nnr5-TrkA cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ACTIVATION LOOP TYROSINES; HUMAN DNAJ PROTEIN; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; ACIDIC SUBSTITUTION; NEUROTROPHIC FACTOR; HUMAN HOMOLOG; RAT TRKA; DROSOPHILA	The human tumorous imaginal disc 1 (TID1) proteins including TID1(L) and TID1(S), members of the DnaJ domain protein family, are involved in multiple intracellular signaling pathways such as apoptosis induction, cell proliferation, and survival. Here we report that TID1 associates with the Trk receptor tyrosine kinases and regulates nerve growth factor (NGF)-induced neurite outgrowth in PC12-derived nnr5 cells. Binding assays and transfection studies showed that the carboxyl-terminal end of TID1 (residues 224-429) bound to Trk at the activation loop (Tyr(P)(683)-Tyr(684)(P) 684 in rat TrkA) and that TID1 was tyrosine phosphorylated by Trk both in yeast and in transfected cells. Moreover endogenous TID1 was also tyrosine phosphorylated by and co-immunoprecipitated with Trk in neurotrophin-stimulated primary rat hippocampal neurons. Overexpression studies showed that both TID1L and TID1S significantly facilitated NGF-induced neurite outgrowth in TrkA-expressing nnr5 cells possibly through a mechanism involving increased activation of mitogen-activated protein kinase. Consistently knockdown of endogenous TID1, mediated with specific short hairpin RNA, significantly reduced NGF-induced neurite growth in nnr5-TrkA cells. These data provide the first evidence that TID1 is a novel intracellular adaptor that interacts with the Trk receptor tyrosine kinases in an activity-dependent manner to facilitate Trk-dependent intracellular signaling.	John P Robarts Res Inst, Cell Biol Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Meakin, SO (corresponding author), John P Robarts Res Inst, Cell Biol Grp, POB 5015, London, ON N6A 5K8, Canada.		Meakin, Susan/K-8823-2013	Meakin, Susan/0000-0003-2469-6615				Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; BERG MM, 1992, J BIOL CHEM, V267, P13; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Brewer GJ, 1997, J NEUROSCI METH, V71, P143, DOI 10.1016/S0165-0270(96)00136-7; Cheng H, 2002, J BIOL CHEM, V277, P20605, DOI 10.1074/jbc.M201204200; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; Gentry JJ, 2004, PROG BRAIN RES, V146, P25, DOI 10.1016/S0079-6123(03)46002-0; GOSILIN K, 1998, CULTURING NERVE CELL, V386, P339; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; Gryz EA, 2003, ONCOGENE, V22, P8774, DOI 10.1038/sj.onc.1206890; Gryz EA, 2000, ONCOGENE, V19, P417, DOI 10.1038/sj.onc.1203330; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KURZIKDUMKE U, 1992, DIFFERENTIATION, V51, P91, DOI 10.1111/j.1432-0436.1992.tb00685.x; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; Liu HY, 2002, J BIOL CHEM, V277, P26046, DOI 10.1074/jbc.M111659200; Liu HY, 2001, J NEUROCHEM, V78, P325, DOI 10.1046/j.1471-4159.2001.00422.x; Lo JF, 2004, MOL CELL BIOL, V24, P2226, DOI 10.1128/MCB.24.6.2226-2236.2004; MacDonald JIS, 2004, J CELL BIOL, V164, P851, DOI 10.1083/jcb.200309081; MacDonald JIS, 1999, J MOL NEUROSCI, V13, P141, DOI 10.1385/JMN:13:1-2:141; MacDonald JIS, 2000, J BIOL CHEM, V275, P18225, DOI 10.1074/jbc.M001862200; Meakin SO, 1997, J NEUROCHEM, V69, P954; Meakin SO, 2000, REC RES DEV NEUROCH, V3, P75; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; Muragaki Y, 1997, J NEUROSCI, V17, P530; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Nakamura T, 2002, MOL CELL BIOL, V22, P8721, DOI 10.1128/MCB.22.24.8721-8734.2002; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OTTEN U, 1980, NATURE, V287, P158, DOI 10.1038/287158a0; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Robinson KN, 2005, J BIOL CHEM, V280, P225, DOI 10.1074/jbc.M410454200; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Schaaf CP, 2004, FASEB J, V18, P267, DOI 10.1096/fj.04-1558fje; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Syken J, 2003, ONCOGENE, V22, P4636, DOI 10.1038/sj.onc.1206569; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; TAPLEY P, 1992, ONCOGENE, V7, P371; Tarunina M, 2004, MOL CELL BIOL, V24, P10792, DOI 10.1128/MCB.24.24.10792-10801.2004; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; Watson FL, 1999, J NEUROBIOL, V39, P323, DOI 10.1002/(SICI)1097-4695(199905)39:2<323::AID-NEU15>3.0.CO;2-4; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; Yin X, 2001, GENE, V278, P201, DOI 10.1016/S0378-1119(01)00720-X	59	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19461	19471		10.1074/jbc.M500313200	http://dx.doi.org/10.1074/jbc.M500313200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15753086	hybrid			2022-12-25	WOS:000229113700007
J	Patton, JR; Bykhovskaya, Y; Mengesha, E; Bertolotto, C; Fischel-Ghodsian, N				Patton, JR; Bykhovskaya, Y; Mengesha, E; Bertolotto, C; Fischel-Ghodsian, N			Mitochondrial myopathy and sideroblastic anemia (MLASA) - Missense mutation in the pseudouridine synthase 1 (PUS1) gene is associated with the loss of tRNA pseudouridylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							U2 SNRNA; DYSKERATOSIS-CONGENITA; RIBOSOMAL-RNA; IN-VIVO; CONSERVED PSEUDOURIDINE; ANTICODON LOOP; CHAIN-REACTION; DNA INVITRO; BIOGENESIS; STABILIZATION	A missense mutation in the PUS1 gene affecting a highly conserved amino acid has been associated with mitochondrial myopathy and sideroblastic anemia (MLASA), a rare autosomal recessive oxidative phosphorylation disorder. The PUS1 gene encodes the enzyme pseudouridine synthase 1 (Pus1p) that is known to pseudouridylate tRNAs in other species. Total RNA was isolated from lymphoblastoid cell lines established from patients, parents, unaffected siblings, and unrelated controls, and the tRNAs were assayed for the presence of pseudouridine (Psi) at the expected positions. Mitochondrial and cytoplasmic tRNAs from MLASA patients are lacking modification at sites normally modified by Pus1p, whereas tRNAs from controls, unaffected siblings, or parents all have Psi at these positions. In addition, there was no Pus1p activity in an extract made from a cell line derived from a patient with MLASA. Immunohistochemical staining of Pus1p in cell lines showed nuclear, cytoplasmic, and mitochondrial distribution of the protein, and there is no difference in staining between patients and unaffected family members. MLASA is thus associated with absent or greatly reduced tRNA pseudouridylation at specific sites, implicating this pathway in its molecular pathogenesis.	Univ S Carolina, Sch Med, Dept Pathol & Microbiol, Columbia, SC 29209 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Inst Med Genet,David Geffen Sch Med, Ahmanson Dept Pediat,Steven Spielberg Pediat Res, Los Angeles, CA 90048 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Fischel-Ghodsian, N (corresponding author), Cedars Sinai Med Ctr, Dept Pediat, 8700 Beverly Blvd,Ste 1165 WT, Los Angeles, CA 90048 USA.	nathan.fischel@cshs.org	Alu, Andrea/A-1328-2007; Chen, Pai-Yen/AAR-3291-2020	Alu, Andrea/0000-0002-4297-5274; Chen, Pai-Yen/0000-0002-8112-8457; Mengesha, Emebet/0000-0001-7830-1557	NIDCD NIH HHS [R01DC01402] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001402] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Ansmant I, 2000, NUCLEIC ACIDS RES, V28, P1941, DOI 10.1093/nar/28.9.1941; Auffinger P, 1998, Modification and Editing of RNA, P103, DOI [10.1128/9781555818296.ch6, DOI 10.1128/9781555818296.CH6]; Auffinger P, 1998, MODIFICATION EDITING, P569; Bakin AV, 1998, METH MOL B, V77, P297; Baumstark T, 2001, RNA, V7, P1652; Becker HF, 1997, NUCLEIC ACIDS RES, V25, P4493, DOI 10.1093/nar/25.22.4493; Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530; Casas KA, 2004, AM J MED GENET A, V125A, P201, DOI 10.1002/ajmg.a.20368; Chen JG, 2000, BIOCHEMISTRY-US, V39, P12723, DOI 10.1021/bi001109m; Chen JG, 1999, RNA, V5, P409, DOI 10.1017/S1355838299981591; Davis DR, 1995, NUCLEIC ACIDS RES, V23, P5020, DOI 10.1093/nar/23.24.5020; Davis DR, 1998, J BIOMOL STRUCT DYN, V15, P1121, DOI 10.1080/07391102.1998.10509006; DAVIS DR, 1991, BIOCHEMISTRY-US, V30, P4223, DOI 10.1021/bi00231a017; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Donmez G, 2004, RNA, V10, P1925, DOI 10.1261/rna.7186504; GRIFFEY RH, 1985, J BIOL CHEM, V260, P9734; Grosshans H, 2001, J BIOL CHEM, V276, P46333, DOI 10.1074/jbc.M107141200; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Hellmuth K, 2000, NUCLEIC ACIDS RES, V28, P4604, DOI 10.1093/nar/28.23.4604; Helm M, 2004, J MOL BIOL, V337, P545, DOI 10.1016/j.jmb.2004.01.036; Huang LX, 1998, BIOCHEMISTRY-US, V37, P344, DOI 10.1021/bi971874+; Lecointe F, 1998, J BIOL CHEM, V273, P1316, DOI 10.1074/jbc.273.3.1316; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Motorin Y, 1998, RNA, V4, P856, DOI 10.1017/S1355838298980396; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Newby MI, 2002, NAT STRUCT BIOL, V9, P958, DOI 10.1038/nsb873; Newby MI, 2001, RNA, V7, P833, DOI 10.1017/S1355838201002308; Nishimura S, 1972, Prog Nucleic Acid Res Mol Biol, V12, P49; Patton JR, 2003, BIOCHEM J, V372, P595, DOI 10.1042/BJ20021938; Ramamurthy V, 1999, J BIOL CHEM, V274, P22225, DOI 10.1074/jbc.274.32.22225; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; SAMBROOK J, 2001, MOL CLONING LAB MANU, P776; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656; WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589; Yu YT, 1998, EMBO J, V17, P5783, DOI 10.1093/emboj/17.19.5783; Zebarjadian Y, 1999, MOL CELL BIOL, V19, P7461; Zhao XL, 2004, RNA, V10, P681, DOI 10.1261/rna.5159504; Zhao XS, 2004, MOL CELL, V15, P549, DOI 10.1016/j.molcel.2004.06.044	43	95	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19823	19828		10.1074/jbc.M500216200	http://dx.doi.org/10.1074/jbc.M500216200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772074	hybrid			2022-12-25	WOS:000229113700049
J	Hu, JJ; Hubbard, SR				Hu, JJ; Hubbard, SR			Structural characterization of a novel Cbl phosphotyrosine recognition motif in the APS family of adapter proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN BINDING; C-CBL; TYROSINE PHOSPHORYLATION; GLUT4 TRANSLOCATION; GLUCOSE-TRANSPORT; INSULIN-RECEPTOR; KINASE; ACTIVATION; SITE; CAP	The Cbl adapter proteins typically function to down-regulate activated protein tyrosine kinases and other signaling proteins by coupling them to the ubiquitination machinery for degradation by the proteasome. Cbl proteins bind to specific tyrosine-phosphorylated sequences in target proteins via the tyrosine kinase-binding (TKB) domain, which comprises a four-helix bundle, an EF-hand calcium-binding domain, and a non-conventional Src homology-2 domain. The previously derived consensus sequence for phosphotyrosine recognition by the Cbl TKB domain is NXpY(S/T)XXP (X denotes lesser residue preference), wherein specificity is conferred primarily by residues C-terminal to the phosphotyrosine. Cbl is recruited to and phosphorylated by the insulin receptor in adipose cells through the adapter protein APS. APS is phosphorylated by the insulin receptor on a C-terminal tyrosine residue, which then serves as a binding site for the Cbl TKB domain. Using x-ray crystallography, site-directed mutagenesis, and calorimetric studies, we have characterized the interaction between the Cbl TKB domain and the Cbl recruitment site in APS, which contains a sequence motif, RA(V/I)XNQpY(S/T), that is conserved in the related adapter proteins SH2-B and Lnk. These studies reveal a novel mode of phosphopeptide interaction with the Cbl TKB domain, in which N-terminal residues distal to the phosphotyrosine directly contact residues of the four-helix bundle of the TKB domain.	NYU, Sch Med, Skirball Inst Biomol Med, Struct Biol Program, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	New York University; New York University	Hubbard, SR (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Struct Biol Program, New York, NY 10016 USA.	hubbard@saturn.med.nyu.edu	Hu, Junjie/F-9713-2013	Hubbard, Stevan/0000-0002-2707-9383				Ahmed Z, 2001, BIOCHEM SOC T, V29, P529, DOI 10.1042/BST0290529; Ahn MY, 2004, J BIOL CHEM, V279, P21526, DOI 10.1074/jbc.M307740200; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Betancourt MR, 2004, J MOL BIOL, V342, P635, DOI 10.1016/j.jmb.2004.06.091; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; Hu JJ, 2003, MOL CELL, V12, P1379, DOI 10.1016/S1097-2765(03)00487-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kobayashi S, 2004, FASEB J, V18, P929, DOI 10.1096/fj.03-0767fje; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu J, 2003, J BIOL CHEM, V278, P36754, DOI 10.1074/jbc.M300664200; Liu J, 2002, MOL CELL BIOL, V22, P3599, DOI 10.1128/MCB.22.11.3599-3609.2002; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Minami A, 2003, DIABETES, V52, P2657, DOI 10.2337/diabetes.52.11.2657; Mitra P, 2004, J BIOL CHEM, V279, P37431, DOI 10.1074/jbc.C400180200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohrt T, 2004, CELL SIGNAL, V16, P1291, DOI 10.1016/j.cellsig.2004.03.017; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; SANJAY A, 2001, SCI STKE, pPE40; Standaert ML, 2004, BIOCHEMISTRY-US, V43, P15494, DOI 10.1021/bi049222q; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yasuda T, 2002, J EXP MED, V196, P51, DOI 10.1084/jem.20020068; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Yoon CH, 2000, MOL BIOL CELL, V11, P4019, DOI 10.1091/mbc.11.11.4019	37	59	60	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18943	18949		10.1074/jbc.M414157200	http://dx.doi.org/10.1074/jbc.M414157200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15737992	hybrid			2022-12-25	WOS:000228932300047
J	Auperin, TC; Bolduc, GR; Baron, MJ; Heroux, A; Filman, DJ; Madoff, LC; Hogle, JM				Auperin, TC; Bolduc, GR; Baron, MJ; Heroux, A; Filman, DJ; Madoff, LC; Hogle, JM			Crystal structure of the n-terminal domain of the group B Streptococcus alpha C protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOTUBERCULOSIS INVASIN PROTEIN; HETERODIMERIC DISINTEGRIN; INTEGRIN ALPHA(5)BETA(1); ANTIGEN GENE; BINDING; HEPARIN; IDENTIFICATION; FIBRONECTIN; ADHERENCE; DISEASE	Group B Streptococcus (GBS) is the leading cause of bacterial pneumonia, sepsis, and meningitis among neonates and an important cause of morbidity among pregnant women and immunocompromised adults. Invasive diseases due to GBS are attributed to the ability of the pathogen to translocate across human epithelial surfaces. The alpha C protein (ACP) has been identified as an invasin that plays a role in internalization and translocation of GBS across epithelial cells. The soluble N-terminal domain of ACP (NtACP) blocks the internalization of GBS. We determined the 1.86-angstrom resolution crystal structure of NtACP comprising residues Ser(52) through Leu(225) of the full-length ACP. NtACP has two domains, an N-terminal beta-sandwich and a C-terminal three-helix bundle. Structural and topological alignments reveal that the beta-sandwich shares structural elements with the type III fibronectin fold (FnIII), but includes structural elaborations that make it unique. We have identified a potential integrin-binding motif consisting of Lys-Thr-Asp(146), Arg(110), and Asp(118). A similar arrangement of charged residues has been described in other invasins. ACP shows a heparin binding activity that requires NtACP. We propose a possible heparin-binding site, including one surface of the three-helix bundle, and nearby portions of the sandwich and repeat domains. We have validated this prediction using assays of the heparin binding and cell-adhesion properties of engineered fragments of ACP. This is the first crystal structure of a member of the highly conserved Gram-positive surface alpha-like protein family, and it will enable the internalization mechanism of GBS to be dissected at the atomic level.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab,Dept Med, Boston, MA 02115 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; United States Department of Energy (DOE); Brookhaven National Laboratory	Hogle, JM (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	jhogle@hms.harvard.edu	Hogle, James/HIG-9121-2022	Hogle, James/0000-0002-3655-1504; filman, david/0000-0002-8714-1644	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI038424, R01AI038424, R21AI038424] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38424] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altroff H, 2001, J BIOL CHEM, V276, P38885, DOI 10.1074/jbc.M105868200; Baker C., 1995, INFECT DIS FETUS NEW, V4th ed., P980; Baron MJ, 2004, J BIOL CHEM, V279, P24714, DOI 10.1074/jbc.M402164200; Bisig D, 1999, ACTA CRYSTALLOGR D, V55, P1069, DOI 10.1107/S090744499900284X; Bliss SJ, 2002, CLIN INFECT DIS, V34, P184, DOI 10.1086/338258; Bolduc GR, 2002, CELL MICROBIOL, V4, P751, DOI 10.1046/j.1462-5822.2002.00227.x; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BULGAKOVA TN, 1986, FOLIA MICROBIOL, V31, P394, DOI 10.1007/BF02936605; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P473; Creti R, 2004, J CLIN MICROBIOL, V42, P1326, DOI 10.1128/JCM.42.3.1326-1329.2004; Dahl Mats S., 2003, International Journal of Infectious Diseases, V7, P113, DOI 10.1016/S1201-9712(03)90006-3; Delacoux F, 1998, J BIOL CHEM, V273, P15069, DOI 10.1074/jbc.273.24.15069; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FLORES TP, 1994, PROTEIN ENG, V7, P31, DOI 10.1093/protein/7.1.31; Freissler E, 2000, CELL MICROBIOL, V2, P69, DOI 10.1046/j.1462-5822.2000.00036.x; Gravekamp C, 1998, INFECT IMMUN, V66, P4347; Gravekamp C, 1996, INFECT IMMUN, V64, P3576, DOI 10.1128/IAI.64.9.3576-3583.1996; Gravekamp C, 1997, INFECT IMMUN, V65, P5216, DOI 10.1128/IAI.65.12.5216-5221.1997; Hamburger ZA, 1999, SCIENCE, V286, P291, DOI 10.1126/science.286.5438.291; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HULSE ML, 1993, INFECT IMMUN, V61, P4835, DOI 10.1128/IAI.61.11.4835-4841.1993; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isberg RR, 2000, MICROBES INFECT, V2, P793, DOI 10.1016/S1286-4579(00)90364-2; JACKSON LA, 1995, ANN INTERN MED, V123, P415, DOI 10.7326/0003-4819-123-6-199509150-00003; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kling DE, 1997, INFECT IMMUN, V65, P1462, DOI 10.1128/IAI.65.4.1462-1467.1997; Lachenauer CS, 2000, P NATL ACAD SCI USA, V97, P9630, DOI 10.1073/pnas.97.17.9630; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEONG JM, 1993, J BIOL CHEM, V268, P20524; LEONG JM, 1991, INFECT IMMUN, V59, P3424, DOI 10.1128/IAI.59.10.3424-3433.1991; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LEONG JM, 1995, EMBO J, V14, P422, DOI 10.1002/j.1460-2075.1995.tb07018.x; Li J, 1997, P NATL ACAD SCI USA, V94, P13251, DOI 10.1073/pnas.94.24.13251; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; Marcinkiewicz C, 1999, BIOCHEMISTRY-US, V38, P13302, DOI 10.1021/bi9906930; Marcinkiewicz C, 1999, J BIOL CHEM, V274, P12468, DOI 10.1074/jbc.274.18.12468; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; Menozzi FD, 1996, J EXP MED, V184, P993, DOI 10.1084/jem.184.3.993; MENOZZI FD, 1994, INFECT IMMUN, V62, P769, DOI 10.1128/IAI.62.3.769-778.1994; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MICHEL JL, 1992, P NATL ACAD SCI USA, V89, P10060, DOI 10.1073/pnas.89.21.10060; Monleon D, 2003, J BIOL CHEM, V278, P45570, DOI 10.1074/jbc.M307030200; Moreno-Murciano MP, 2003, PROTEIN SCI, V12, P366, DOI 10.1110/ps.0230203; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nykvist P, 2001, J BIOL CHEM, V276, P38673, DOI 10.1074/jbc.M102589200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; RUBENS CE, 1992, INFECT IMMUN, V60, P5157, DOI 10.1128/IAI.60.12.5157-5163.1992; Schrag SJ, 2000, NEW ENGL J MED, V342, P15, DOI 10.1056/NEJM200001063420103; Shankar N, 2001, INFECT IMMUN, V69, P4366, DOI 10.1128/IAI.69.7.4366-4372.2001; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Shimazaki K, 1998, J DAIRY SCI, V81, P2841, DOI 10.3168/jds.S0022-0302(98)75843-6; Smith SA, 2000, J VIROL, V74, P5659, DOI 10.1128/JVI.74.12.5659-5666.2000; Stalhammar-Carlemalm M, 1999, MOL MICROBIOL, V33, P208, DOI 10.1046/j.1365-2958.1999.01470.x; Stebbins CE, 2001, NATURE, V412, P701, DOI 10.1038/35089000; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; TAMURA GS, 1994, INFECT IMMUN, V62, P2450, DOI 10.1128/IAI.62.6.2450-2458.1994; Tan K, 1998, STRUCTURE, V6, P793, DOI 10.1016/S0969-2126(98)00080-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tyrrell GJ, 2000, J INFECT DIS, V182, P168, DOI 10.1086/315699; ValentinWeigand P, 1997, FEMS MICROBIOL LETT, V147, P69, DOI 10.1016/S0378-1097(96)00506-X; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wastfelt M, 1996, J BIOL CHEM, V271, P18892, DOI 10.1074/jbc.271.31.18892; Zangwill Kenneth M., 1992, Morbidity and Mortality Weekly Report, V41, P25; ZAWANEH SM, 1979, INFECT IMMUN, V26, P441, DOI 10.1128/IAI.26.2.441-447.1979	71	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18245	18252		10.1074/jbc.M412391200	http://dx.doi.org/10.1074/jbc.M412391200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15753100	hybrid			2022-12-25	WOS:000228807200083
J	Eyster, CA; Duggins, QS; Olson, AL				Eyster, CA; Duggins, QS; Olson, AL			Expression of constitutively active Akt/protein kinase B signals GLUT4 translocation in the absence of an intact actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; CELL-SURFACE; SUBCELLULAR TRAFFICKING; INSULIN INCREASES; SKELETAL-MUSCLE; STIMULATION; ENDOCYTOSIS	The actin cytoskeleton has been shown to be required for insulin-dependent GLUT4 translocation; however, the role that the actin network plays is unknown. Actin may play a role in formation of an active signaling complex, or actin may be required for movement of vesicles to the plasma membrane surface. To distinguish between these possibilities, we examined the ability of myr-Akt, a constitutively active form of Akt that signals GLUT4 translocation to the plasma membrane in the absence of insulin, to signal translocation of an HA-GLUT4-GFP reporter protein in the presence or absence of an intact cytoskeleton in 3T3-L1 adipocytes. Expression of myr-Akt signaled the redistribution of the GLUT4 reporter protein to the cell surface in the absence or presence of 10 mu M latrunculin B, a concentration sufficient to completely inhibit insulin-dependent redistribution of the GLUT4 reporter to the cell surface. These data suggest that the actin network plays a primary role in organization of the insulin-signaling complex. To further support this conclusion, we measured the activation of known signaling proteins using a saturating concentration of insulin in cells pretreated without or with 10 mu M latrunculin B. We found that latrunculin treatment did not affect insulin-dependent tyrosine phosphorylation of the insulin receptor beta-subunit and IRS-1 but completely inhibited activation of Akt/PKB enzymatic activity. Phosphorylation of Akt/ PKB at Ser-473 and Thr-308 was inhibited by latrunculin B treatment, indicating that the defect in signaling lies prior to Akt/ PKB activation. In summary, our data support the hypothesis that the actin network plays a role in organization of the insulin-signaling complex but is not required for vesicle trafficking and/or fusion.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Olson, AL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, POB 26901,Rm 853-BMSB, Oklahoma City, OK 73190 USA.	ann-olson@ouhsc.edu			NIDDK NIH HHS [DK68438, DK62341, R01 DK068438] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068438, R01DK062341] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Hasani H, 1998, J BIOL CHEM, V273, P17504, DOI 10.1074/jbc.273.28.17504; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bose A, 2004, MOL CELL BIOL, V24, P5447, DOI 10.1128/MCB.24.12.5447-5458.2004; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Cenni V, 2003, CELL MOL LIFE SCI, V60, P2710, DOI 10.1007/s00018-003-3349-4; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Coffer PJ, 1998, BIOCHEM J, V335, P1; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Govers R, 2004, MOL CELL BIOL, V24, P6456, DOI 10.1128/MCB.24.14.6456-6466.2004; Guilherme A, 2004, J BIOL CHEM, V279, P10593, DOI 10.1074/jbc.M307702200; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; Hresko RC, 2003, J BIOL CHEM, V278, P21615, DOI 10.1074/jbc.M302937200; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kanzaki M, 2004, J BIOL CHEM, V279, P30622, DOI 10.1074/jbc.M401443200; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; Khayat ZA, 2000, J CELL SCI, V113, P279; Knight JB, 2000, ENDOCRINOLOGY, V141, P208, DOI 10.1210/en.141.1.208; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kupriyanova TA, 2002, J BIOL CHEM, V277, P9133, DOI 10.1074/jbc.M106999200; Lampson MA, 2001, MOL BIOL CELL, V12, P3489, DOI 10.1091/mbc.12.11.3489; Lampson MA, 2000, J CELL SCI, V113, P4065; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Millar CA, 2000, TRAFFIC, V1, P141, DOI 10.1034/j.1600-0854.2000.010206.x; Olson AL, 2001, J BIOL CHEM, V276, P10706, DOI 10.1074/jbc.M007610200; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; Patel N, 2003, MOL CELL BIOL, V23, P4611, DOI 10.1128/MCB.23.13.4611-4626.2003; Peyrollier K, 2000, BIOCHEM J, V352, P617, DOI 10.1042/0264-6021:3520617; QUON MJ, 1994, J BIOL CHEM, V269, P27920; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROTHMAN DL, 1995, P NATL ACAD SCI USA, V92, P983, DOI 10.1073/pnas.92.4.983; Rudich A, 2003, ACTA PHYSIOL SCAND, V178, P297, DOI 10.1046/j.1365-201X.2003.01163.x; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Semiz S, 2003, EMBO J, V22, P2387, DOI 10.1093/emboj/cdg237; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; TSAKIRIDIS T, 1995, BIOCHEM J, V309, P1; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; YANG J, 1993, J BIOL CHEM, V268, P4600; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071; Zeigerer A, 2004, MOL BIOL CELL, V15, P4406, DOI 10.1091/mbc.e04-04-0333	57	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17978	17985		10.1074/jbc.M409806200	http://dx.doi.org/10.1074/jbc.M409806200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15738003	hybrid			2022-12-25	WOS:000228807200052
J	Rodrigue, CM; Porteu, F; Navarro, N; Bruyneel, E; Bracke, M; Romeo, PH; Gespach, C; Garel, MC				Rodrigue, CM; Porteu, F; Navarro, N; Bruyneel, E; Bracke, M; Romeo, PH; Gespach, C; Garel, MC			The cancer chemopreventive agent resveratrol induces tensin, a cell-matrix adhesion protein with signaling and antitumor activities	ONCOGENE			English	Article						focal adhesions; stress fibers; bronectin; cancer cell invasion; resveratrol; K562 and MCF7 cells	RAS-INDUCED CANCERS; THYMOSIN BETA-10; INDUCED APOPTOSIS; TUMOR-CELLS; IN-VITRO; ACTIN; EXPRESSION; CYTOSKELETON; PRODUCT; GRAPES	During a search to identify resveratrol (3,5,4'-trihydroxy-trans-stilbene, RV) target genes in the human erythroleukemic K562 cell line, we show here that the tensin gene and protein levels are remarkably induced by this dietary polyphenol. Tensin, a cell-matrix adhesion protein binding the integrins and cytoskeletal actin. laments also interacts with PI3-kinase and JNK signaling pathways. Tensin induction by RV is associated with increased K562 cell adhesion to fibronectin, cell spreading and actin polymerization. The same responses were observed in the tensin-deficient MCF7 human breast cancer cell line. In K562 and MCF7 cells treated by RV, tensin was found in punctate and intracytoplasmic areas. in MCF7 epithelial cells, induction of tensin is not exclusively associated with plasma membrane-bound vinculin, suggesting a dual localization of tensin in both focal and fibrillar adhesions. pharmacological blockade of PI3-kinase and Rho GTPases/Rho-kinase resulted in selective depletion of focal adhesions, disorganization of tensin localization and disruption of stress fibers. RV increased cell motility and attachment to fibronectin in MCF7 cells submitted to mechanical laminar flow stress, and abrogated estrogen-induced MCF7 cancer cell invasion. Our data support the conclusion that induction of tensin by RV contributes to the chemopreventive and anti-invasive activity of this natural dietary compound in tensin-negative and-deficient leukemic cells or epithelioid cancers.	Hop St Antoine, INSERM, U673, F-75571 Paris, France; Univ Paris 05, Inst Cochin, INSERM,U567, UMR,8104,Dept Hematol, F-75014 Paris, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ghent University; Ghent University Hospital	Gespach, C (corresponding author), Hop St Antoine, INSERM, U673, 184 Rue Faubourg St Antoine, F-75571 Paris, France.	gespach@st-antoine.inserm.fr	PORTEU, Françoise/I-8445-2016; Romeo, Paul-Henri/L-5989-2017	PORTEU, Françoise/0000-0002-2403-4163; Romeo, Paul-Henri/0000-0002-8294-0367				ADLERCREUTZ H, 1992, J STEROID BIOCHEM, V41, P331, DOI 10.1016/0960-0760(92)90359-Q; Ahmad N, 2001, CLIN CANCER RES, V7, P1466; Auger KR, 1996, J BIOL CHEM, V271, P23452, DOI 10.1074/jbc.271.38.23452; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; Cavailles V, 2002, J MOL ENDOCRINOL, V28, P165, DOI 10.1677/jme.0.0280165; Chen HY, 2000, BIOCHEM J, V351, P403, DOI 10.1042/0264-6021:3510403; Chen HY, 2002, P NATL ACAD SCI USA, V99, P733, DOI 10.1073/pnas.022518699; Clement MV, 1998, BLOOD, V92, P996; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; Dong ZG, 2003, MUTAT RES-FUND MOL M, V523, P145, DOI 10.1016/S0027-5107(02)00330-5; Dorrie J, 2001, CANCER RES, V61, P4731; Drexler HG, 1999, LEUKEMIA RES, V23, P207; Entschladen F, 2000, J CANCER RES CLIN, V126, P671, DOI 10.1007/s004320000143; Ferry-Dumazet H, 2002, CARCINOGENESIS, V23, P1327, DOI 10.1093/carcin/23.8.1327; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Golla R, 1997, CELL MOTIL CYTOSKEL, V38, P187, DOI 10.1002/(SICI)1097-0169(1997)38:2<187::AID-CM7>3.0.CO;2-4; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; HALL AK, 1991, J NEUROCHEM, V56, P462, DOI 10.1111/j.1471-4159.1991.tb08173.x; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Levesque JP, 1999, EXP HEMATOL, V27, P579, DOI 10.1016/S0301-472X(98)00069-1; Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516; Maxwell PJ, 2003, CANCER RES, V63, P4602; Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404; Otto AM, 2002, J CANCER RES CLIN, V128, P247, DOI 10.1007/s00432-002-0332-7; Park JW, 2001, CARCINOGENESIS, V22, P1633, DOI 10.1093/carcin/22.10.1633; POKORNA E, 1994, CELL MOTIL CYTOSKEL, V28, P25, DOI 10.1002/cm.970280103; Pozo-Guisado E, 2002, BIOCHEM PHARMACOL, V64, P1375, DOI 10.1016/S0006-2952(02)01296-0; Rodrigue CM, 2001, BRIT J HAEMATOL, V113, P500, DOI 10.1046/j.1365-2141.2001.02746.x; Salesse S, 2002, ONCOGENE, V21, P8605, DOI 10.1038/sj.onc.1206088; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; Schneider Y, 2000, CANCER LETT, V158, P85, DOI 10.1016/S0304-3835(00)00511-5; SHIMAMURA R, 1990, BLOOD, V76, P977; Sun HQ, 1996, J BIOL CHEM, V271, P9223, DOI 10.1074/jbc.271.16.9223; Sun NJ, 1998, J NAT PROD, V61, P362, DOI 10.1021/np970488q; Tikoo A, 2000, CANCER J, V6, P162; Tikoo A, 1999, CANCER J SCI AM, V5, P293; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Torgler CN, 2004, DEV CELL, V6, P357, DOI 10.1016/S1534-5807(04)00055-3; Uenobe F, 1997, MUTAT RES-FUND MOL M, V373, P197, DOI 10.1016/S0027-5107(96)00191-1; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang MF, 1999, J AGR FOOD CHEM, V47, P3974, DOI 10.1021/jf990382w; YU FX, 1993, J BIOL CHEM, V268, P502; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zamir E, 2001, J CELL SCI, V114, P3583; Zamir E, 1999, J CELL SCI, V112, P1655	50	22	25	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3274	3284		10.1038/sj.onc.1208485	http://dx.doi.org/10.1038/sj.onc.1208485			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735708				2022-12-25	WOS:000228881800006
J	Li, AM; Harris, DA				Li, AM; Harris, DA			Mammalian prion protein suppresses Bax-induced cell death in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRP; EXPRESSION; BCL-2; MUTATIONS; ATAXIA; ALTER; LINE	Several lines of evidence suggest that PrPC, the noninfectious form of the prion protein, may function to protect neurons and other cells from stress or toxicity. In this paper, we report on the use of the yeast Saccharomyces cerevisiae as a model system to assay the cytoprotective activity of PrPC. The mammalian pro-apoptotic protein, Bax, confers a lethal phenotype when expressed in yeast. Since overexpression of PrPC has been found to prevent Bax-mediated cell death in cultured human neurons, we explored whether PrP could also suppress Bax-induced cell death in yeast. We utilized a form of mouse PrP containing a modified signal peptide that we had previously shown is efficiently targeted to the secretory pathway in yeast. We found that this PrP potently suppressed the death of yeast cells expressing mammalian Bax under control of a galactose-inducible promoter. In contrast, cytosolic PrP-( 23 231) failed to rescue growth of Bax-expressing yeast, indicating that protective activity requires targeting of PrP to the secretory pathway. Deletion of the octapeptide repeat region did not affect the rescuing activity of PrP, but deletion of a charged region encompassing residues 23 - 31 partially eliminated activity. We also tested several PrP mutants associated with human familial prion diseases and found that only a mutant containing nine extra octapeptide repeats failed to suppress Bax-induced cell death. These findings establish a simple and genetically tractable system for assaying a putative biological activity of PrPC.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Harris, DA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	dharris@cellbiology.wustl.edu		Harris, David/0000-0002-6985-5790	NINDS NIH HHS [NS40061] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040061] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Ausubel F. M., 2001, CURRENT PROTOCOLS MO; BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Brown DR, 2002, J NEUROSCI RES, V67, P211, DOI 10.1002/jnr.10118; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; Chiesa R, 2005, P NATL ACAD SCI USA, V102, P238, DOI 10.1073/pnas.0406173102; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Diarra-Mehrpour M, 2004, CANCER RES, V64, P719, DOI 10.1158/0008-5472.CAN-03-1735; Drisaldi B, 2004, J BIOL CHEM, V279, P55443, DOI 10.1074/jbc.M404794200; Greenhalf W, 1999, YEAST, V15, P1307, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1307::AID-YEA455>3.3.CO;2-V; Hoshino S, 2003, ACT NEUR S, V86, P297; Jin C, 2002, NAT REV MOL CELL BIO, V3, P453, DOI 10.1038/nrm832; Kong Qingzhong, 2004, VVolume 41, P673; KURSCHNER C, 1995, MOL BRAIN RES, V30, P165, DOI 10.1016/0169-328X(95)00013-I; Kurschner C, 1996, MOL BRAIN RES, V37, P249, DOI 10.1016/0169-328X(95)00323-K; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; Li AM, 2004, J BIOL CHEM, V279, P29469, DOI 10.1074/jbc.M402517200; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Mange A, 2002, FEBS LETT, V514, P159, DOI 10.1016/S0014-5793(02)02338-4; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Prusiner SB, 2004, PRION BIOL DIS; Rossi D, 2001, EMBO J, V20, P694, DOI 10.1093/emboj/20.4.694; Roucou X, 2004, J NEUROSCI RES, V75, P153, DOI 10.1002/jnr.10864; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	35	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17430	17434		10.1074/jbc.C500058200	http://dx.doi.org/10.1074/jbc.C500058200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15753097	hybrid			2022-12-25	WOS:000228615500109
J	Starai, VJ; Thorngren, N; Fratti, RA; Wickner, W				Starai, VJ; Thorngren, N; Fratti, RA; Wickner, W			Ion regulation of homotypic vacuole fusion in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-COMPLEX FORMATION; VERTEX RING DOMAIN; MEMBRANE-FUSION; SNARE COMPLEX; IN-VITRO; INFLUENZA HEMAGGLUTININ; LYSOPHOSPHATIDIC ACID; PHOSPHATIDIC-ACID; DIVALENT-CATIONS; GOLGI MEMBRANES	Biological membrane fusion employs divalent cations as protein cofactors or as signaling ligands. For example, Mg2+ is a cofactor for the N-ethylmaleimide-sensitive factor (NSF) ATPase, and the Ca2+ signal from neuronal membrane depolarization is required for synaptotagmin activation. Divalent cations also regulate liposome fusion, but the role of such ion interactions with lipid bilayers in Rab- and soluble NSF attachment protein receptor ( SNARE)-dependent biological membrane fusion is less clear. Yeast vacuole fusion requires Mg2+ for Sec18p ATPase activity, and vacuole docking triggers an efflux of luminal Ca2+. We now report distinct reaction conditions where divalent or monovalent ions interchangeably regulate Rab- and SNARE-dependent vacuole fusion. In reactions with 5 mM Mg2+, other free divalent ions are not needed. Reactions containing low Mg2+ concentrations are strongly inhibited by the rapid Ca2+ chelator BAPTA. However, addition of the soluble SNARE Vam7p relieves BAPTA inhibition as effectively as Ca2+ or Mg2+, suggesting that Ca2+ does not perform a unique signaling function. When the need for Mg2+, ATP, and Sec18p for fusion is bypassed through the addition of Vam7p, vacuole fusion does not require any appreciable free divalent cations and can even be stimulated by their chelators. The similarity of these findings to those with liposomes, and the higher ion specificity of the regulation of proteins, suggests a working model in which ion interactions with bilayer lipids permit Rab- and SNARE-dependent membrane fusion.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	Bill.Wickner@Dartmouth.edu						Aballay A, 1995, BIOCHEM J, V312, P919, DOI 10.1042/bj3120919; ALLAN D, 1978, NATURE, V276, P289, DOI 10.1038/276289a0; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; Bayer MJ, 2003, J CELL BIOL, V162, P211, DOI 10.1083/jcb.200212004; BENTZ J, 1985, BIOCHEMISTRY-US, V24, P5436, DOI 10.1021/bi00341a023; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; CHIANCONE E, 1986, J BIOL CHEM, V261, P6306; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; DUNN T, 1994, J BIOL CHEM, V269, P7273; DUZGUNES N, 1981, J MEMBRANE BIOL, V59, P115, DOI 10.1007/BF01875709; Eitzen G, 2000, EMBO J, V19, P6713, DOI 10.1093/emboj/19.24.6713; Eitzen G, 2001, EMBO J, V20, P5650, DOI 10.1093/emboj/20.20.5650; Fratti RA, 2004, J CELL BIOL, V167, P1087, DOI 10.1083/jcb.200409068; GARRETT MD, 1995, METHOD ENZYMOL, V257, P232; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; Gietz RD, 2001, BIOTECHNIQUES, V30, P816, DOI 10.2144/01304rv02; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Grote E, 2000, J CELL BIOL, V151, P453, DOI 10.1083/jcb.151.2.453; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; Hofmann MW, 2004, P NATL ACAD SCI USA, V101, P14776, DOI 10.1073/pnas.0405175101; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Jones EW, 2002, METHOD ENZYMOL, V351, P127; Jun Y, 2004, J BIOL CHEM, V279, P53186, DOI 10.1074/jbc.M411363200; Kooijman EE, 2003, TRAFFIC, V4, P162, DOI 10.1034/j.1600-0854.2003.00086.x; Leikina E, 2000, MOL BIOL CELL, V11, P2359, DOI 10.1091/mbc.11.7.2359; LEVENTIS R, 1986, BIOCHEMISTRY-US, V25, P6978, DOI 10.1021/bi00370a600; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; LUAN Y, 1987, J BIOCHEM-TOKYO, V102, P1531, DOI 10.1093/oxfordjournals.jbchem.a122201; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; Melikyan GB, 2000, MOL BIOL CELL, V11, P3765, DOI 10.1091/mbc.11.11.3765; Merz AJ, 2004, J CELL BIOL, V164, P195, DOI 10.1083/jcb.200310105; Moser NJ, 1996, MOL CELL BIOL, V16, P4824; Muller O, 2002, EMBO J, V21, P259, DOI 10.1093/emboj/21.3.259; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; PERIN MS, 1991, J BIOL CHEM, V266, P623; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; PLANKERT U, 1991, EUR J BIOCHEM, V196, P191, DOI 10.1111/j.1432-1033.1991.tb15803.x; Rousset M, 2004, FEBS LETT, V576, P41, DOI 10.1016/j.febslet.2004.08.058; Saoudi Y, 2004, EUR J BIOCHEM, V271, P3255, DOI 10.1111/j.1432-1033.2004.04259.x; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Slusarewicz P, 1997, P NATL ACAD SCI USA, V94, P5582, DOI 10.1073/pnas.94.11.5582; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005; Subramaniam VN, 1997, J BIOL CHEM, V272, P25441, DOI 10.1074/jbc.272.41.25441; Takeda Y, 2002, J BIOL CHEM, V277, P47756, DOI 10.1074/jbc.M209199200; Thorngren N, 2004, EMBO J, V23, P2765, DOI 10.1038/sj.emboj.7600286; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Tucker WC, 2004, SCIENCE, V304, P435, DOI 10.1126/science.1097196; Ungermann C, 1999, P NATL ACAD SCI USA, V96, P11194, DOI 10.1073/pnas.96.20.11194; Wang JY, 2001, J BIOL CHEM, V276, P5012, DOI 10.1074/jbc.M008355200; Wang L, 2003, J CELL BIOL, V160, P365, DOI 10.1083/jcb.200209095; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Wickner W, 2002, EMBO J, V21, P1241, DOI 10.1093/emboj/21.6.1241	64	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16754	16762		10.1074/jbc.M500421200	http://dx.doi.org/10.1074/jbc.M500421200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15737991	hybrid			2022-12-25	WOS:000228615500027
J	Nabha, SM; Glaros, S; Hong, M; Lykkesfeldt, AE; Schiff, R; Osborne, K; Reddy, KB				Nabha, SM; Glaros, S; Hong, M; Lykkesfeldt, AE; Schiff, R; Osborne, K; Reddy, KB			Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells	ONCOGENE			English	Article						tamoxifen resistance; PKC-delta; MAPK; AKT; breast cancer	PROTEIN-KINASE-C; HUMAN-BREAST-CANCER; ESTROGEN-RECEPTOR-ALPHA; GROWTH-FACTOR RECEPTOR; FACTOR CROSS-TALK; TAMOXIFEN RESISTANCE; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; CARCINOMA CELLS; STEROID-HORMONE	Acquired resistance to tamoxifen (Tam) in breast cancer patients is a serious therapeutic problem. We have previously reported that protein kinase C-delta (PKC-delta) plays a major role in estrogen (E2)-mediated cell proliferation. To determine if PKC-delta is one of the major alternate signaling pathways that supports cell growth in the presence of Tam, we determined the levels of PKC isoforms in four different models of antiestrogen-resistant cells. Three out of four antiestrogen resistance cell lines (Tam/MCF-7, ICI/MCF-7 and HER-2/MCF-7) expressed significantly high levels of both total and activated PKC-delta levels compared to sensitive cells. Estrogen receptor ( ER) alpha content and function are maintained in all the antiestrogen-resistant cell lines. Overexpressing active PKC-delta in Tam-sensitive MCF-7 cells (PKC-delta/ MCF-7) led to Tam resistance both in vitro and in vivo. Inhibition of PKC-delta by rottlerin ( a relatively specific inhibitor of PKC-delta) or siRNA significantly inhibited estrogen- and Tam-induced growth in antiestrogen-resistant cells. PKC-delta levels are significantly higher in Tam-resistant tumors compared to Tam-sensitive tumors in xenograft model (P<0.05). Taken together, these data suggest that PKC-delta plays a major role in antiestrogen resistance in breast tumor cells and thus provides a new target for treatment.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Danish Canc Soc, Inst Canc Biol, Dept Tumor Endocrinol, DK-2100 Copenhagen, Denmark; Baylor Coll Med, Ctr Brest, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA	Wayne State University; Danish Cancer Society; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston	Reddy, KB (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.	kreddy@med.wayne.edu			NCI NIH HHS [R01 CA 83964] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083964] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atanaskova N, 2002, ONCOGENE, V21, P4000, DOI 10.1038/sj.onc.1205506; BALTUCH GH, 1995, J NEURO-ONCOL, V24, P241, DOI 10.1007/BF01052840; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; Berstein LM, 2003, ENDOCR-RELAT CANCER, V10, P267, DOI 10.1677/erc.0.0100267; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BRUNNER N, 1993, CANCER RES, V53, P3229; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cartee L, 2000, CANCER INVEST, V18, P731, DOI 10.3109/07357900009012205; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Cerda SR, 2001, GASTROENTEROLOGY, V120, P1700, DOI 10.1053/gast.2001.24843; Chisamore MJ, 2001, CLIN CANCER RES, V7, P3156; Clarke R, 2001, PHARMACOL REV, V53, P25; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEL PL, 1997, SCIENCE, V278, P687; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; FUQUA SAW, 1993, J CELL BIOCHEM, V51, P135, DOI 10.1002/jcb.240510204; Goekjian PG, 1999, CURR MED CHEM, V6, P877; GOUBIN F, 1995, ONCOGENE, V10, P2281; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HORWITZ KB, 1995, ENDOCRINOLOGY, V136, P821, DOI 10.1210/en.136.3.821; JARVIS WD, 1994, CANCER RES, V54, P1707; Johnston SRD, 2003, CLIN CANCER RES, V9, p524S; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Kruger JS, 2003, MOL CANCER RES, V1, P801; Kurokawa H, 2000, CANCER RES, V60, P5887; LEE SA, 1992, CANCER RES, V52, P3750; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; LYKKESFELDT AE, 1995, INT J CANCER, V61, P529, DOI 10.1002/ijc.2910610417; LYKKESFELDT AE, 1986, BRIT J CANCER, V53, P29, DOI 10.1038/bjc.1986.5; MacGregor JI, 1998, PHARMACOL REV, V50, P151; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; McCracken MA, 2003, MOL CANCER THER, V2, P273; McKeage K, 2002, DRUGS, V62, P209, DOI 10.2165/00003495-200262010-00008; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nicholson RI, 2000, BRIT J CANCER, V82, P501; Nicholson RI, 1999, ENDOCR-RELAT CANCER, V6, P373, DOI 10.1677/erc.0.0060373; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBRIAN CA, 1989, CANCER RES, V49, P3215; OSBORNE CK, 1994, BREAST CANCER RES TR, V32, P49, DOI 10.1007/BF00666205; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; OSBORNE CK, 1987, EUR J CANCER CLIN ON, V23, P1189; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; RAPP UR, 1991, ONCOGENE, V6, P495; Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W; REDDY KB, 1992, CANCER RES, V52, P3636; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Santen RJ, 1996, J CLIN ENDOCR METAB, V81, P2027, DOI 10.1210/jc.81.6.2027; Schiff R, 2004, CLIN CANCER RES, V10, p331S, DOI 10.1158/1078-0432.CCR-031212; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; SELINA G, 2004, P AACR 2004 ANN M OR; Shanmugam M, 1999, MOL CELL ENDOCRINOL, V148, P109, DOI 10.1016/S0303-7207(98)00229-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Sun M, 2001, CANCER RES, V61, P5985; Takimoto GS, 1999, J STEROID BIOCHEM, V69, P45, DOI 10.1016/S0960-0760(98)00148-4; Tolcher AW, 2002, CLIN CANCER RES, V8, P2530; Tonetti DA, 2003, BRIT J CANCER, V88, P1400, DOI 10.1038/sj.bjc.6600923; Tonetti DA, 2000, BRIT J CANCER, V83, P782, DOI 10.1054/bjoc.2000.1326; Tortora G, 2003, SEMIN ONCOL, V30, P26, DOI 10.1016/S0093-7754(03)00282-3; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	81	71	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3166	3176		10.1038/sj.onc.1208502	http://dx.doi.org/10.1038/sj.onc.1208502			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735693				2022-12-25	WOS:000228728100010
J	Perri, P; Bachetti, T; Longo, L; Matera, I; Seri, M; Tonini, GP; Ceccherini, I				Perri, P; Bachetti, T; Longo, L; Matera, I; Seri, M; Tonini, GP; Ceccherini, I			PHOX2B mutations and genetic predisposition to neuroblastoma	ONCOGENE			English	Article						familial neuroblastoma; PHOX2B; cancer predisposition; oligogenic model	CENTRAL HYPOVENTILATION SYNDROME; CRITERIA; LINKAGE	Neuroblastoma ( NB) is a childhood malignancy originating from neural crest cells, which seldom occurs in association with other neurocristopathies. Owing to the rarity of familial NB cases, only a few linkage data are available and no mutations in candidate genes have been demonstrated up till now. Germline mutations in a small proportion of NB patients have been recently reported in the paired-like homeobox 2B (PHOX2B) gene, suggesting its role in NB predisposition. On the basis of this indication, we screened three Italian families with recurrence of NB and one family with occurrence of ganglioneuroblastoma and isolated Hirschsprung disease for PHOX2B defects. Our analysis did not show any mutation, excluding PHOX2B as the NB susceptibility gene in the families we analysed. Our findings combined with those derived from other PHOX2B mutation screenings and from genome-wide linkage analysis support a remarkable genetic heterogeneity of NB and suggest an oligogenic model of disease transmission. Furthermore, as PHOX2B mutations were mainly observed in some NB families with multifocal and syndromic NB, features that are missing in the families we have studied, we suggest they represent second-site modi. cations responsible for a specific phenotype rather than causal mutations of a major locus.	CBA, Fdn Italiana Lotta Neuroblastoma, Lab Neuroblastoma Res, I-16132 Genoa, Italy; G Gaslini Inst Children, Mol Genet Lab, Genoa, Italy; Natl Inst Canc Res, Lab Neuroblastoma, Genoa, Italy; Univ Bologna, Dept Internal Med Cardioangiol & Hepatol, Bologna, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS AOU San Martino IST; University of Bologna	Perri, P (corresponding author), CBA, Fdn Italiana Lotta Neuroblastoma, Lab Neuroblastoma Res, Lgo R Benzi 10, I-16132 Genoa, Italy.	perri@cba.unige.it	Perri, Patrizia/I-8124-2018; Perri, Patrizia/AFV-5794-2022; Ceccherini, Isabella/P-8195-2014; Bachetti, Tiziana/AAB-4516-2021; Bachetti, Tiziana/K-6405-2016; Longo, Luca/K-6156-2018; Seri, Marco/A-4339-2014	Perri, Patrizia/0000-0003-2538-8278; Perri, Patrizia/0000-0003-2538-8278; Ceccherini, Isabella/0000-0001-8732-1955; Bachetti, Tiziana/0000-0002-9456-8945; Longo, Luca/0000-0002-5153-4243; Seri, Marco/0000-0003-2425-2176	Telethon [GGP04257] Funding Source: Medline	Telethon(Fondazione Telethon)		Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Croaker GDH, 1998, ARCH DIS CHILD, V78, P316, DOI 10.1136/adc.78.4.316; GRISERI P, 2000, GENE FUNCT DIS, V1, P184; Katsanis N, 2004, HUM MOL GENET, V13, pR65, DOI 10.1093/hmg/ddh092; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; Maris JM, 2002, CANCER RES, V62, P6651; Matera I, 2004, J MED GENET, V41, P373, DOI 10.1136/jmg.2003.015412; Ming JE, 2002, AM J HUM GENET, V71, P1017, DOI 10.1086/344412; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; Origone P, 2003, AM J MED GENET A, V118A, P309, DOI 10.1002/ajmg.a.10167; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Perri P, 2002, ANN NY ACAD SCI, V963, P74; Perri P, 2002, ONCOGENE, V21, P8356, DOI 10.1038/sj.onc.1206009; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Tonini GP, 2003, CANCER LETT, V197, P41, DOI 10.1016/S0304-3835(03)00080-6; Trochet D, 2004, AM J HUM GENET, V74, P761, DOI 10.1086/383253; van Limpt V, 2004, ONCOGENE, V23, P9280, DOI 10.1038/sj.onc.1208157; Weese-Mayer DE, 2003, AM J MED GENET A, V123A, P267, DOI 10.1002/ajmg.a.20527	19	35	36	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3050	3053		10.1038/sj.onc.1208532	http://dx.doi.org/10.1038/sj.onc.1208532			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735672	Bronze			2022-12-25	WOS:000228649500014
J	Brunn, GJ; Bungum, MK; Johnson, GB; Platt, JL				Brunn, GJ; Bungum, MK; Johnson, GB; Platt, JL			Conditional signaling by Toll-like receptor 4	FASEB JOURNAL			English	Article						sepsis; inflammatory response syndrome; extracellular matrix; heparan sulfate	INFLAMMATORY RESPONSE SYNDROME; NF-KAPPA-B; HEPARAN-SULFATE; ENDOTHELIAL-CELLS; IMMUNE-SYSTEM; DENDRITIC CELLS; DROSOPHILA TOLL; ACTIVATION; EXPRESSION; OLIGOSACCHARIDES	Signaling through Toll-like receptor 4 (TLR4) is thought to initiate innate and adaptive immune responses. Signaling of TLR4 is usually studied using isolated cells, which are activated by subnanomolar concentrations of lipopolysaccharide (LPS). However, in normal tissues, cells bearing TLR4 reside in microenvironments containing large amounts of endogenous substances that can stimulate the receptor. We developed an in vitro model system using the human cell line HEK 293 and an in vivo model using mice that have normal or that lack TLR4 receptors to study how TLR4 functions in such microenvironments. Here we report that signaling through TLR4 is strongly inhibited by intact extracellular matrix and that inhibition is abrogated and endogenous agonist(s) are liberated when the matrix is degraded. Thus, release from inhibition rather than direct stimulation by agonists such as LPS is the critical first event by which TLR4 initiates immune responses.	Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Surg, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Pediat, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Platt, JL (corresponding author), Mayo Clin, Coll Med, Dept Immunol, 200 1st St SW,2-66 Med Sci Bldg, Rochester, MN 55905 USA.	platt.jeffrey@mayo.edu	Johnson, Geoffrey B/AAG-2729-2021; Eckhardt, Erik/G-1567-2010; Platt, Jeffrey/AHB-0480-2022	Johnson, Geoffrey B/0000-0002-4866-1401; Platt, Jeffrey/0000-0002-4915-0419; Johnson, Geoffrey/0000-0002-9781-4072	NHLBI NIH HHS [HL46810] Funding Source: Medline; NIAID NIH HHS [AI53733] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053733] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; BONIFACINO JS, 1998, CURRENT PROTOCOLS CE, pCH10; Boulday G, 2001, CIRC RES, V88, P430; Conrad H E, 2001, Methods Mol Biol, V171, P347; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; Dunn D L, 2000, Surg Infect (Larchmt), V1, P227, DOI 10.1089/109629600750018150; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; Ihrcke NS, 1996, J CELL PHYSIOL, V168, P625, DOI 10.1002/(SICI)1097-4652(199609)168:3<625::AID-JCP15>3.3.CO;2-A; IHRCKE NS, 1993, IMMUNOL TODAY, V14, P500, DOI 10.1016/0167-5699(93)90265-M; Ihrcke NS, 1998, J CELL PHYSIOL, V175, P255, DOI 10.1002/(SICI)1097-4652(199806)175:3<255::AID-JCP3>3.0.CO;2-N; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Johnson GB, 2004, J IMMUNOL, V172, P20, DOI 10.4049/jimmunol.172.1.20; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; Kaisho T, 2002, BBA-MOL CELL RES, V1589, P1, DOI 10.1016/S0167-4889(01)00182-3; Kishore SP, 2005, FEBS LETT, V579, P699, DOI 10.1016/j.febslet.2004.12.047; Magor BG, 2001, DEV COMP IMMUNOL, V25, P651, DOI 10.1016/S0145-305X(01)00029-5; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Okada Y, 2002, J BIOL CHEM, V277, P42488, DOI 10.1074/jbc.M206510200; Paterson RL, 2000, J ROY COLL SURG EDIN, V45, P178; PAYA CV, 1992, P NATL ACAD SCI USA, V89, P7826, DOI 10.1073/pnas.89.16.7826; PLATT JL, 1990, J EXP MED, V171, P1363, DOI 10.1084/jem.171.4.1363; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Saadi S, 2002, FASEB J, V16, DOI 10.1096/fj.01-0690hyp; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863	30	97	110	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					872	+		10.1096/fj.04-3211fje	http://dx.doi.org/10.1096/fj.04-3211fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15738005				2022-12-25	WOS:000227591900001
